ID   5HT2A_HUMAN             Reviewed;         471 AA.
AC   P28223; B2RAC5; B4DZ79; F5GWE8; Q5T8C0;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 2.
DT   07-OCT-2020, entry version 208.
DE   RecName: Full=5-hydroxytryptamine receptor 2A;
DE            Short=5-HT-2;
DE            Short=5-HT-2A;
DE   AltName: Full=Serotonin receptor 2A;
GN   Name=HTR2A; Synonyms=HTR2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain stem;
RX   PubMed=1722404; DOI=10.1016/0006-291x(91)92105-s;
RA   Saltzman A.G., Morse B., Whitman M.M., Ivanshchenko Y., Jaye M., Felder S.;
RT   "Cloning of the human serotonin 5-HT2 and 5-HT1C receptor subtypes.";
RL   Biochem. Biophys. Res. Commun. 181:1469-1478(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1323014; DOI=10.1016/0169-328x(92)90005-v;
RA   Chen K., Yang W., Grimsby J., Shih J.C.;
RT   "The human 5-HT2 receptor is encoded by a multiple intron-exon gene.";
RL   Brain Res. Mol. Brain Res. 14:20-26(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Platelet;
RX   PubMed=8035173; DOI=10.1046/j.1471-4159.1994.63020465.x;
RA   Cook E.H. Jr., Fletcher K.E., Wainwright M., Marks N., Yan S.Y.,
RA   Leventhal B.L.;
RT   "Primary structure of the human platelet serotonin 5-HT2A receptor:
RT   identify with frontal cortex serotonin 5-HT2A receptor.";
RL   J. Neurochem. 63:465-469(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Testis, and Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S.,
RA   Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C.,
RA   Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P.,
RA   Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L.,
RA   Frankish A.G., Frankland J., French L., Garner P., Garnett J.,
RA   Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M.,
RA   Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D.,
RA   Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D.,
RA   Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S.,
RA   Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R.,
RA   Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W.,
RA   Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L.,
RA   Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R.,
RA   Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 9-464 (ISOFORM 1).
RC   TISSUE=Brain;
RA   Tritch R.J., Robinson D.L., Sahagan B.G., Horlick R.A.;
RT   "Cloning and nucleotide sequence of the human(5HT) type 2 receptor.";
RL   Submitted (MAY-1992) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 105-218, FUNCTION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=1330647; DOI=10.1016/0922-4106(92)90123-d;
RA   Stam N.J., van Huizen F., van Alebeek C., Brands J., Dijkema R.,
RA   Tonnaer J.A., Olijve W.;
RT   "Genomic organization, coding sequence and functional expression of human
RT   5-HT2 and 5-HT1A receptor genes.";
RL   Eur. J. Pharmacol. 227:153-162(1992).
RN   [11]
RP   INTERACTION WITH MPDZ.
RX   PubMed=11150294; DOI=10.1074/jbc.m008089200;
RA   Becamel C., Figge A., Poliak S., Dumuis A., Peles E., Bockaert J.,
RA   Luebbert H., Ullmer C.;
RT   "Interaction of serotonin 5-hydroxytryptamine type 2C receptors with PDZ10
RT   of the multi-PDZ domain protein MUPP1.";
RL   J. Biol. Chem. 276:12974-12982(2001).
RN   [12]
RP   INTERACTION WITH PATJ; MPP3; PRDX6; DLG4; DLG1; CASK; APBA1 AND MAGI2, AND
RP   MUTAGENESIS OF GLY-463; ASN-465; CYS-470 AND VAL-471.
RX   PubMed=14988405; DOI=10.1074/jbc.m312106200;
RA   Becamel C., Gavarini S., Chanrion B., Alonso G., Galeotti N., Dumuis A.,
RA   Bockaert J., Marin P.;
RT   "The serotonin 5-HT2A and 5-HT2C receptors interact with specific sets of
RT   PDZ proteins.";
RL   J. Biol. Chem. 279:20257-20266(2004).
RN   [13]
RP   REVIEW.
RX   PubMed=18476671; DOI=10.1021/cr078224o;
RA   Nichols D.E., Nichols C.D.;
RT   "Serotonin receptors.";
RL   Chem. Rev. 108:1614-1641(2008).
RN   [14]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=18703043; DOI=10.1016/j.ejphar.2008.07.040;
RA   Cussac D., Boutet-Robinet E., Ailhaud M.C., Newman-Tancredi A.,
RA   Martel J.C., Danty N., Rauly-Lestienne I.;
RT   "Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and
RT   5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in
RT   CHO cells.";
RL   Eur. J. Pharmacol. 594:32-38(2008).
RN   [15]
RP   INTERACTION WITH GRM2, FUNCTION, TISSUE SPECIFICITY, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=18297054; DOI=10.1038/nature06612;
RA   Gonzalez-Maeso J., Ang R.L., Yuen T., Chan P., Weisstaub N.V.,
RA   Lopez-Gimenez J.F., Zhou M., Okawa Y., Callado L.F., Milligan G.,
RA   Gingrich J.A., Filizola M., Meana J.J., Sealfon S.C.;
RT   "Identification of a serotonin/glutamate receptor complex implicated in
RT   psychosis.";
RL   Nature 452:93-97(2008).
RN   [16]
RP   FUNCTION.
RX   PubMed=19057895; DOI=10.1007/s00210-008-0378-4;
RA   Knauer C.S., Campbell J.E., Chio C.L., Fitzgerald L.W.;
RT   "Pharmacological characterization of mitogen-activated protein kinase
RT   activation by recombinant human 5-HT2C, 5-HT2A, and 5-HT2B receptors.";
RL   Naunyn Schmiedebergs Arch. Pharmacol. 379:461-471(2009).
RN   [17]
RP   INTERACTION WITH DRD2, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=21645528; DOI=10.1016/j.neuropharm.2011.05.023;
RA   Albizu L., Holloway T., Gonzalez-Maeso J., Sealfon S.C.;
RT   "Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine
RT   D2 receptors.";
RL   Neuropharmacology 61:770-777(2011).
RN   [18]
RP   REVIEW.
RX   PubMed=20945968; DOI=10.33549/physiolres.931903;
RA   Pytliak M., Vargova V., Mechirova V., Felsoci M.;
RT   "Serotonin receptors - from molecular biology to clinical applications.";
RL   Physiol. Res. 60:15-25(2011).
RN   [19]
RP   INTERACTION WITH GRM2, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=22300836; DOI=10.1016/j.neuropharm.2012.01.010;
RA   Delille H.K., Becker J.M., Burkhardt S., Bleher B., Terstappen G.C.,
RA   Schmidt M., Meyer A.H., Unger L., Marek G.J., Mezler M.;
RT   "Heterocomplex formation of 5-HT2A-mGlu2 and its relevance for cellular
RT   signaling cascades.";
RL   Neuropharmacology 62:2184-2191(2012).
RN   [20]
RP   PHOSPHORYLATION AT SER-280, AND MUTAGENESIS OF SER-280.
RX   PubMed=24637012; DOI=10.1074/mcp.m113.036558;
RA   Karaki S., Becamel C., Murat S., Mannoury la Cour C., Millan M.J.,
RA   Prezeau L., Bockaert J., Marin P., Vandermoere F.;
RT   "Quantitative phosphoproteomics unravels biased phosphorylation of
RT   serotonin 2A receptor at Ser280 by hallucinogenic versus nonhallucinogenic
RT   agonists.";
RL   Mol. Cell. Proteomics 13:1273-1285(2014).
RN   [21]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=24089568; DOI=10.1128/jvi.02252-13;
RA   Assetta B., Maginnis M.S., Gracia Ahufinger I., Haley S.A., Gee G.V.,
RA   Nelson C.D., O'Hara B.A., Allen Ramdial S.A., Atwood W.J.;
RT   "5-HT2 receptors facilitate JC polyomavirus entry.";
RL   J. Virol. 87:13490-13498(2013).
RN   [22]
RP   FUNCTION, AND MUTAGENESIS OF LEU-229.
RX   PubMed=28129538; DOI=10.1016/j.cell.2016.12.033;
RA   Wacker D., Wang S., McCorvy J.D., Betz R.M., Venkatakrishnan A.J.,
RA   Levit A., Lansu K., Schools Z.L., Che T., Nichols D.E., Shoichet B.K.,
RA   Dror R.O., Roth B.L.;
RT   "Crystal structure of an LSD-bound human serotonin receptor.";
RL   Cell 168:377-389(2017).
RN   [23]
RP   VARIANTS ASN-25 AND TYR-452.
RX   PubMed=8655141; DOI=10.1007/bf02281871;
RA   Erdmann J., Shimron-Abarbanell D., Rietschel M., Albus M., Maier W.,
RA   Koerner J., Bondy B., Chen K., Shih J.C., Knapp M., Propping P.,
RA   Noethen M.M.;
RT   "Systematic screening for mutations in the human serotonin-2A (5-HT2A)
RT   receptor gene: identification of two naturally occurring receptor variants
RT   and association analysis in schizophrenia.";
RL   Hum. Genet. 97:614-619(1996).
RN   [24]
RP   VARIANTS ASN-25 AND TYR-452.
RX   PubMed=10581480;
RX   DOI=10.1002/(sici)1096-8628(19991215)88:6<621::aid-ajmg9>3.0.co;2-h;
RA   Marshall S.E., Bird T.G., Hart K., Welsh K.I.;
RT   "Unified approach to the analysis of genetic variation in serotonergic
RT   pathways.";
RL   Am. J. Med. Genet. 88:621-627(1999).
RN   [25]
RP   VARIANTS VAL-197; VAL-447 AND TYR-452.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions of
RT   human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [26]
RP   ERRATUM OF PUBMED:10391209.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
CC   -!- FUNCTION: G-protein coupled receptor for 5-hydroxytryptamine
CC       (serotonin) (PubMed:1330647, PubMed:18703043, PubMed:19057895). Also
CC       functions as a receptor for various drugs and psychoactive substances,
CC       including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-
CC       aminopropane (DOI) and lysergic acid diethylamide (LSD)
CC       (PubMed:28129538). Ligand binding causes a conformation change that
CC       triggers signaling via guanine nucleotide-binding proteins (G proteins)
CC       and modulates the activity of down-stream effectors (PubMed:28129538).
CC       Beta-arrestin family members inhibit signaling via G proteins and
CC       mediate activation of alternative signaling pathways (PubMed:28129538).
CC       Signaling activates phospholipase C and a phosphatidylinositol-calcium
CC       second messenger system that modulates the activity of
CC       phosphatidylinositol 3-kinase and promotes the release of Ca(2+) ions
CC       from intracellular stores (PubMed:18703043, PubMed:28129538). Affects
CC       neural activity, perception, cognition and mood (PubMed:18297054).
CC       Plays a role in the regulation of behavior, including responses to
CC       anxiogenic situations and psychoactive substances. Plays a role in
CC       intestinal smooth muscle contraction, and may play a role in arterial
CC       vasoconstriction. {ECO:0000269|PubMed:1330647,
CC       ECO:0000269|PubMed:18297054, ECO:0000269|PubMed:18703043,
CC       ECO:0000269|PubMed:19057895, ECO:0000269|PubMed:21645528,
CC       ECO:0000269|PubMed:22300836, ECO:0000269|PubMed:28129538}.
CC   -!- FUNCTION: (Microbial infection) Acts as a receptor for human JC
CC       polyomavirus/JCPyV. {ECO:0000269|PubMed:24089568}.
CC   -!- SUBUNIT: Interacts (via C-terminus) with MPDZ and PATJ
CC       (PubMed:11150294, PubMed:14988405). May interact (via C-terminus) with
CC       MPP3, PRDX6, DLG4, DLG1, CASK, APBA1 and MAGI2 (PubMed:14988405).
CC       Interacts with GRM2 and DRD2; this may affect signaling
CC       (PubMed:18297054, PubMed:21645528, PubMed:22300836).
CC       {ECO:0000269|PubMed:11150294, ECO:0000269|PubMed:14988405,
CC       ECO:0000269|PubMed:18297054, ECO:0000269|PubMed:21645528,
CC       ECO:0000269|PubMed:22300836}.
CC   -!- INTERACTION:
CC       P28223; P08908: HTR1A; NbExp=3; IntAct=EBI-6656333, EBI-6570214;
CC       P28223; P28223: HTR2A; NbExp=3; IntAct=EBI-6656333, EBI-6656333;
CC       P28223; P41595: HTR2B; NbExp=3; IntAct=EBI-6656333, EBI-7474947;
CC       P28223; P28335: HTR2C; NbExp=5; IntAct=EBI-6656333, EBI-994141;
CC       P28223-1; P21554: CNR1; NbExp=2; IntAct=EBI-15573967, EBI-2909859;
CC       P28223-1; Q14416: GRM2; NbExp=4; IntAct=EBI-15573967, EBI-10232876;
CC       P28223-1; P28335-1: HTR2C; NbExp=3; IntAct=EBI-15573967, EBI-21299643;
CC       P28223-1; P18654: Rps6ka3; Xeno; NbExp=2; IntAct=EBI-15573967, EBI-397744;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:28129538};
CC       Multi-pass membrane protein {ECO:0000305}. Cell projection, dendrite
CC       {ECO:0000250|UniProtKB:P35363}. Cell projection, axon
CC       {ECO:0000250|UniProtKB:P14842}. Cytoplasmic vesicle
CC       {ECO:0000250|UniProtKB:P14842}. Membrane, caveola
CC       {ECO:0000250|UniProtKB:P14842}. Cell junction, synapse, presynapse
CC       {ECO:0000250|UniProtKB:P14842}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P28223-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P28223-2; Sequence=VSP_046663;
CC   -!- TISSUE SPECIFICITY: Detected in brain cortex (at protein level).
CC       Detected in blood platelets. {ECO:0000269|PubMed:18297054}.
CC   -!- DOMAIN: The PDZ domain-binding motif is involved in the interaction
CC       with PATJ, CASK, APBA1, DLG1 and DLG4. {ECO:0000269|PubMed:11150294,
CC       ECO:0000269|PubMed:14988405}.
CC   -!- MISCELLANEOUS: Binds lysergic acid diethylamine (LSD) in the
CC       orthosteric pocket (Probable). Bound LSD dissociates extremely slowly,
CC       with a residence time of about 221 minutes at 37 degrees Celsius.
CC       {ECO:0000269|PubMed:28129538}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=HTR2A";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X57830; CAA40963.1; -; mRNA.
DR   EMBL; S42168; AAB22791.2; -; Genomic_DNA.
DR   EMBL; S42165; AAB22791.2; JOINED; Genomic_DNA.
DR   EMBL; S42167; AAB22791.2; JOINED; Genomic_DNA.
DR   EMBL; S71229; AAB31320.1; -; mRNA.
DR   EMBL; AF498982; AAM21129.1; -; mRNA.
DR   EMBL; AK302787; BAG63991.1; -; mRNA.
DR   EMBL; AK314132; BAG36822.1; -; mRNA.
DR   EMBL; AL160397; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL136958; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471075; EAX08770.1; -; Genomic_DNA.
DR   EMBL; BC069356; AAH69356.1; -; mRNA.
DR   EMBL; BC069576; AAH69576.1; -; mRNA.
DR   EMBL; BC074848; AAH74848.1; -; mRNA.
DR   EMBL; BC074849; AAH74849.1; -; mRNA.
DR   EMBL; BC096839; AAH96839.1; -; mRNA.
DR   EMBL; M86841; AAA58354.1; -; mRNA.
DR   EMBL; S50130; AAB24166.2; -; Genomic_DNA.
DR   EMBL; S49737; AAB24166.2; JOINED; Genomic_DNA.
DR   EMBL; S50113; AAB24166.2; JOINED; Genomic_DNA.
DR   CCDS; CCDS9405.1; -. [P28223-1]
DR   PIR; A43956; A43956.
DR   RefSeq; NP_000612.1; NM_000621.4. [P28223-1]
DR   RefSeq; NP_001159419.1; NM_001165947.2.
DR   PDB; 6A93; X-ray; 3.00 A; A/B=70-265, A/B=313-403.
DR   PDB; 6A94; X-ray; 2.90 A; A/B=70-265, A/B=313-403.
DR   PDBsum; 6A93; -.
DR   PDBsum; 6A94; -.
DR   SMR; P28223; -.
DR   BioGRID; 109588; 7.
DR   DIP; DIP-41844N; -.
DR   IntAct; P28223; 21.
DR   MINT; P28223; -.
DR   STRING; 9606.ENSP00000437737; -.
DR   ChEMBL; CHEMBL224; -.
DR   DrugBank; DB13940; 2,5-Dimethoxy-4-ethylthioamphetamine.
DR   DrugBank; DB01537; 4-Bromo-2,5-dimethoxyphenethylamine.
DR   DrugBank; DB14010; 5-methoxy-N,N-dimethyltryptamine.
DR   DrugBank; DB01614; Acepromazine.
DR   DrugBank; DB06288; Amisulpride.
DR   DrugBank; DB00321; Amitriptyline.
DR   DrugBank; DB00543; Amoxapine.
DR   DrugBank; DB08927; Amperozide.
DR   DrugBank; DB04599; Aniracetam.
DR   DrugBank; DB05227; APD791.
DR   DrugBank; DB00714; Apomorphine.
DR   DrugBank; DB01238; Aripiprazole.
DR   DrugBank; DB14185; Aripiprazole lauroxil.
DR   DrugBank; DB06216; Asenapine.
DR   DrugBank; DB05687; BL-1020.
DR   DrugBank; DB09223; Blonanserin.
DR   DrugBank; DB09128; Brexpiprazole.
DR   DrugBank; DB01200; Bromocriptine.
DR   DrugBank; DB09016; Butriptyline.
DR   DrugBank; DB00248; Cabergoline.
DR   DrugBank; DB09061; Cannabidiol.
DR   DrugBank; DB06016; Cariprazine.
DR   DrugBank; DB00477; Chlorpromazine.
DR   DrugBank; DB01239; Chlorprothixene.
DR   DrugBank; DB08810; Cinitapride.
DR   DrugBank; DB00604; Cisapride.
DR   DrugBank; DB01242; Clomipramine.
DR   DrugBank; DB00363; Clozapine.
DR   DrugBank; DB00924; Cyclobenzaprine.
DR   DrugBank; DB00434; Cyproheptadine.
DR   DrugBank; DB06512; Deramciclane.
DR   DrugBank; DB01151; Desipramine.
DR   DrugBank; DB11273; Dihydroergocornine.
DR   DrugBank; DB13345; Dihydroergocristine.
DR   DrugBank; DB01488; Dimethyltryptamine.
DR   DrugBank; DB00843; Donepezil.
DR   DrugBank; DB09167; Dosulepin.
DR   DrugBank; DB06446; Dotarizine.
DR   DrugBank; DB01142; Doxepin.
DR   DrugBank; DB05492; Epicept NP-1.
DR   DrugBank; DB00751; Epinastine.
DR   DrugBank; DB12177; Eplivanserin.
DR   DrugBank; DB01049; Ergoloid mesylate.
DR   DrugBank; DB00696; Ergotamine.
DR   DrugBank; DB01175; Escitalopram.
DR   DrugBank; DB06678; Esmirtazapine.
DR   DrugBank; DB09194; Etoperidone.
DR   DrugBank; DB00574; Fenfluramine.
DR   DrugBank; DB04908; Flibanserin.
DR   DrugBank; DB00875; Flupentixol.
DR   DrugBank; DB00623; Fluphenazine.
DR   DrugBank; DB04842; Fluspirilene.
DR   DrugBank; DB12141; Gilteritinib.
DR   DrugBank; DB00502; Haloperidol.
DR   DrugBank; DB05079; HY10275.
DR   DrugBank; DB04946; Iloperidone.
DR   DrugBank; DB00458; Imipramine.
DR   DrugBank; DB01221; Ketamine.
DR   DrugBank; DB12465; Ketanserin.
DR   DrugBank; DB00555; Lamotrigine.
DR   DrugBank; DB00589; Lisuride.
DR   DrugBank; DB09195; Lorpiprazole.
DR   DrugBank; DB00408; Loxapine.
DR   DrugBank; DB06077; Lumateperone.
DR   DrugBank; DB08815; Lurasidone.
DR   DrugBank; DB00934; Maprotiline.
DR   DrugBank; DB14009; Medical Cannabis.
DR   DrugBank; DB00933; Mesoridazine.
DR   DrugBank; DB01403; Methotrimeprazine.
DR   DrugBank; DB00247; Methysergide.
DR   DrugBank; DB06148; Mianserin.
DR   DrugBank; DB01454; Midomafetamine.
DR   DrugBank; DB00805; Minaprine.
DR   DrugBank; DB00370; Mirtazapine.
DR   DrugBank; DB01442; MMDA.
DR   DrugBank; DB01618; Molindone.
DR   DrugBank; DB13948; N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.
DR   DrugBank; DB14011; Nabiximols.
DR   DrugBank; DB01149; Nefazodone.
DR   DrugBank; DB12555; Nelotanserin.
DR   DrugBank; DB00540; Nortriptyline.
DR   DrugBank; DB06229; Ocaperidone.
DR   DrugBank; DB00334; Olanzapine.
DR   DrugBank; DB01267; Paliperidone.
DR   DrugBank; DB00715; Paroxetine.
DR   DrugBank; DB01186; Pergolide.
DR   DrugBank; DB08922; Perospirone.
DR   DrugBank; DB05316; Pimavanserin.
DR   DrugBank; DB09286; Pipamperone.
DR   DrugBank; DB01621; Pipotiazine.
DR   DrugBank; DB06153; Pizotifen.
DR   DrugBank; DB00420; Promazine.
DR   DrugBank; DB00777; Propiomazine.
DR   DrugBank; DB01224; Quetiapine.
DR   DrugBank; DB00409; Remoxipride.
DR   DrugBank; DB00734; Risperidone.
DR   DrugBank; DB12693; Ritanserin.
DR   DrugBank; DB12163; Sarpogrelate.
DR   DrugBank; DB08839; Serotonin.
DR   DrugBank; DB06144; Sertindole.
DR   DrugBank; DB09304; Setiptiline.
DR   DrugBank; DB01079; Tegaserod.
DR   DrugBank; DB01622; Thioproperazine.
DR   DrugBank; DB00679; Thioridazine.
DR   DrugBank; DB01623; Thiothixene.
DR   DrugBank; DB13025; Tiapride.
DR   DrugBank; DB00656; Trazodone.
DR   DrugBank; DB00726; Trimipramine.
DR   DrugBank; DB06109; YKP-1358.
DR   DrugBank; DB01392; Yohimbine.
DR   DrugBank; DB00246; Ziprasidone.
DR   DrugBank; DB09225; Zotepine.
DR   DrugBank; DB01624; Zuclopenthixol.
DR   DrugCentral; P28223; -.
DR   GuidetoPHARMACOLOGY; 6; -.
DR   GlyGen; P28223; 5 sites.
DR   iPTMnet; P28223; -.
DR   PhosphoSitePlus; P28223; -.
DR   BioMuta; HTR2A; -.
DR   DMDM; 543727; -.
DR   MassIVE; P28223; -.
DR   PaxDb; P28223; -.
DR   PeptideAtlas; P28223; -.
DR   PRIDE; P28223; -.
DR   ProteomicsDB; 24094; -.
DR   ProteomicsDB; 54453; -. [P28223-1]
DR   Antibodypedia; 2927; 360 antibodies.
DR   Ensembl; ENST00000378688; ENSP00000367959; ENSG00000102468. [P28223-1]
DR   Ensembl; ENST00000542664; ENSP00000437737; ENSG00000102468. [P28223-1]
DR   Ensembl; ENST00000543956; ENSP00000441861; ENSG00000102468. [P28223-2]
DR   GeneID; 3356; -.
DR   KEGG; hsa:3356; -.
DR   UCSC; uc001vbr.5; human. [P28223-1]
DR   CTD; 3356; -.
DR   DisGeNET; 3356; -.
DR   EuPathDB; HostDB:ENSG00000102468.10; -.
DR   GeneCards; HTR2A; -.
DR   HGNC; HGNC:5293; HTR2A.
DR   HPA; ENSG00000102468; Tissue enriched (brain).
DR   MalaCards; HTR2A; -.
DR   MIM; 182135; gene.
DR   neXtProt; NX_P28223; -.
DR   OpenTargets; ENSG00000102468; -.
DR   PharmGKB; PA193; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00960000186619; -.
DR   HOGENOM; CLU_009579_11_3_1; -.
DR   InParanoid; P28223; -.
DR   KO; K04157; -.
DR   OMA; RLYNNDF; -.
DR   OrthoDB; 962038at2759; -.
DR   PhylomeDB; P28223; -.
DR   TreeFam; TF316350; -.
DR   PathwayCommons; P28223; -.
DR   Reactome; R-HSA-390666; Serotonin receptors.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   SignaLink; P28223; -.
DR   SIGNOR; P28223; -.
DR   BioGRID-ORCS; 3356; 2 hits in 871 CRISPR screens.
DR   GeneWiki; 5-HT2A_receptor; -.
DR   GenomeRNAi; 3356; -.
DR   Pharos; P28223; Tclin.
DR   PRO; PR:P28223; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   RNAct; P28223; protein.
DR   Bgee; ENSG00000102468; Expressed in dorsolateral prefrontal cortex and 158 other tissues.
DR   ExpressionAtlas; P28223; baseline and differential.
DR   Genevisible; P28223; HS.
DR   GO; GO:0030424; C:axon; IEA:UniProtKB-SubCell.
DR   GO; GO:0005901; C:caveola; IEA:UniProtKB-SubCell.
DR   GO; GO:0070852; C:cell body fiber; IEA:Ensembl.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IEA:UniProtKB-KW.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0030425; C:dendrite; IBA:GO_Central.
DR   GO; GO:0043198; C:dendritic shaft; IEA:Ensembl.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0099056; C:integral component of presynaptic membrane; IEA:Ensembl.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0071886; F:1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding; IDA:UniProtKB.
DR   GO; GO:0008144; F:drug binding; IDA:UniProtKB.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0004993; F:G protein-coupled serotonin receptor activity; IDA:UniProtKB.
DR   GO; GO:0001965; F:G-protein alpha-subunit binding; IEA:Ensembl.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0030594; F:neurotransmitter receptor activity; IBA:GO_Central.
DR   GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl.
DR   GO; GO:0051378; F:serotonin binding; IDA:UniProtKB.
DR   GO; GO:0001618; F:virus receptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0007202; P:activation of phospholipase C activity; IDA:UniProtKB.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0014824; P:artery smooth muscle contraction; IEA:Ensembl.
DR   GO; GO:0048148; P:behavioral response to cocaine; IEA:Ensembl.
DR   GO; GO:0008219; P:cell death; IEA:Ensembl.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IDA:UniProtKB.
DR   GO; GO:0007268; P:chemical synaptic transmission; IBA:GO_Central.
DR   GO; GO:0050966; P:detection of mechanical stimulus involved in sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0050965; P:detection of temperature stimulus involved in sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007187; P:G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; IBA:GO_Central.
DR   GO; GO:0007613; P:memory; IEA:Ensembl.
DR   GO; GO:0043267; P:negative regulation of potassium ion transport; IEA:Ensembl.
DR   GO; GO:0051967; P:negative regulation of synaptic transmission, glutamatergic; IEA:Ensembl.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; IDA:UniProtKB.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007208; P:phospholipase C-activating serotonin receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0045600; P:positive regulation of fat cell differentiation; IEA:Ensembl.
DR   GO; GO:0045821; P:positive regulation of glycolytic process; IEA:Ensembl.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IEA:Ensembl.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IEA:Ensembl.
DR   GO; GO:0010513; P:positive regulation of phosphatidylinositol biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; IEA:Ensembl.
DR   GO; GO:0044380; P:protein localization to cytoskeleton; IEA:Ensembl.
DR   GO; GO:0014059; P:regulation of dopamine secretion; IEA:Ensembl.
DR   GO; GO:2000300; P:regulation of synaptic vesicle exocytosis; IEA:Ensembl.
DR   GO; GO:0051209; P:release of sequestered calcium ion into cytosol; IDA:UniProtKB.
DR   GO; GO:0042493; P:response to drug; IDA:UniProtKB.
DR   GO; GO:0007210; P:serotonin receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0030431; P:sleep; IEA:Ensembl.
DR   GO; GO:0001659; P:temperature homeostasis; IEA:Ensembl.
DR   GO; GO:0014832; P:urinary bladder smooth muscle contraction; IEA:Ensembl.
DR   InterPro; IPR000455; 5HT2A_rcpt.
DR   InterPro; IPR002231; 5HT_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   PANTHER; PTHR24247:SF30; PTHR24247:SF30; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00516; 5HT2ARECEPTR.
DR   PRINTS; PR01101; 5HTRECEPTOR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Behavior; Cell junction; Cell membrane;
KW   Cell projection; Cytoplasmic vesicle; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein;
KW   Host cell receptor for virus entry; Host-virus interaction; Membrane;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome; Synapse;
KW   Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..471
FT                   /note="5-hydroxytryptamine receptor 2A"
FT                   /id="PRO_0000068946"
FT   TOPO_DOM        1..75
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        76..99
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        100..110
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        111..132
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        133..148
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        149..171
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        172..191
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        192..215
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        216..233
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        234..254
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        255..324
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        325..346
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        347..362
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        363..384
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        385..471
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   REGION          155..160
FT                   /note="Agonist binding"
FT                   /evidence="ECO:0000250|UniProtKB:P41595"
FT   REGION          336..340
FT                   /note="Agonist binding"
FT                   /evidence="ECO:0000250|UniProtKB:P41595"
FT   MOTIF           172..174
FT                   /note="DRY motif; important for ligand-induced conformation
FT                   changes"
FT                   /evidence="ECO:0000250|UniProtKB:P41595"
FT   MOTIF           376..380
FT                   /note="NPxxY motif; important for ligand-induced
FT                   conformation changes and signaling"
FT                   /evidence="ECO:0000250|UniProtKB:P41595"
FT   MOTIF           469..471
FT                   /note="PDZ-binding"
FT                   /evidence="ECO:0000269|PubMed:11150294,
FT                   ECO:0000269|PubMed:14988405"
FT   SITE            229
FT                   /note="Hydrophobic barrier that decreases the speed of
FT                   ligand binding and dissociation"
FT                   /evidence="ECO:0000269|PubMed:28129538"
FT   MOD_RES         280
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:24637012"
FT   CARBOHYD        8
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        38
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        44
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        51
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        54
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        148..227
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   DISULFID        349..353
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VAR_SEQ         1..138
FT                   /note="MDILCEENTSLSSTTNSLMQLNDDTRLYSNDFNSGEANTSDAFNWTVDSENR
FT                   TNLSCEGCLSPSCLSLLHLQEKNWSALLTAVVIILTIAGNILVIMAVSLEKKLQNATNY
FT                   FLMSLAIADMLLGFLVMPVSMLTILYG -> MQFLKSAKQKPNYYHIMLVEDQEEGTLH
FT                   QFNYCERCSESQNNKCISCVDPEDKW (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_046663"
FT   VARIANT         25
FT                   /note="T -> N (in dbSNP:rs1805055)"
FT                   /evidence="ECO:0000269|PubMed:10581480,
FT                   ECO:0000269|PubMed:8655141"
FT                   /id="VAR_003448"
FT   VARIANT         197
FT                   /note="I -> V (in dbSNP:rs6304)"
FT                   /evidence="ECO:0000269|PubMed:10391209"
FT                   /id="VAR_013901"
FT   VARIANT         447
FT                   /note="A -> V (in dbSNP:rs6308)"
FT                   /evidence="ECO:0000269|PubMed:10391209"
FT                   /id="VAR_013902"
FT   VARIANT         452
FT                   /note="H -> Y (in dbSNP:rs6314)"
FT                   /evidence="ECO:0000269|PubMed:10391209,
FT                   ECO:0000269|PubMed:10581480, ECO:0000269|PubMed:8655141"
FT                   /id="VAR_003449"
FT   MUTAGEN         229
FT                   /note="L->A: Strongly increases dissociation of bound
FT                   lysergic acid diethylamine, without affecting binding
FT                   affinity. Reduces signaling via arrestins, but has no
FT                   effect on signaling via the phosphatidylinositol-calcium
FT                   second messenger system."
FT                   /evidence="ECO:0000269|PubMed:28129538"
FT   MUTAGEN         280
FT                   /note="S->A: Increased ability of hallucinogens to
FT                   desensitize the receptor."
FT                   /evidence="ECO:0000269|PubMed:24637012"
FT   MUTAGEN         280
FT                   /note="S->D: Reduced receptor desensitization by
FT                   nonhallucinogenic agonists."
FT                   /evidence="ECO:0000269|PubMed:24637012"
FT   MUTAGEN         463
FT                   /note="G->V: Loss of interaction with PATJ."
FT                   /evidence="ECO:0000269|PubMed:14988405"
FT   MUTAGEN         465
FT                   /note="N->S: No effect on interaction with PATJ. Acquires
FT                   the binding properties of HTR2C; when associated with S-
FT                   470."
FT                   /evidence="ECO:0000269|PubMed:14988405"
FT   MUTAGEN         470
FT                   /note="C->S: No effect on interaction with PATJ. Acquires
FT                   the binding properties of HTR2C; when associated with S-
FT                   465."
FT                   /evidence="ECO:0000269|PubMed:14988405"
FT   MUTAGEN         471
FT                   /note="V->A: Loss of interaction with PATJ, CASK, APBA1,
FT                   DLG1 and DLG4."
FT                   /evidence="ECO:0000269|PubMed:14988405"
FT   HELIX           70..101
FT                   /evidence="ECO:0000244|PDB:6A94"
FT   HELIX           103..105
FT                   /evidence="ECO:0000244|PDB:6A94"
FT   HELIX           108..126
FT                   /evidence="ECO:0000244|PDB:6A94"
FT   HELIX           128..136
FT                   /evidence="ECO:0000244|PDB:6A94"
FT   TURN            137..139
FT                   /evidence="ECO:0000244|PDB:6A94"
FT   HELIX           146..177
FT                   /evidence="ECO:0000244|PDB:6A94"
FT   TURN            180..183
FT                   /evidence="ECO:0000244|PDB:6A94"
FT   HELIX           189..207
FT                   /evidence="ECO:0000244|PDB:6A94"
FT   HELIX           209..216
FT                   /evidence="ECO:0000244|PDB:6A94"
FT   TURN            219..221
FT                   /evidence="ECO:0000244|PDB:6A94"
FT   STRAND          226..228
FT                   /evidence="ECO:0000244|PDB:6A94"
FT   HELIX           232..242
FT                   /evidence="ECO:0000244|PDB:6A94"
FT   HELIX           244..265
FT                   /evidence="ECO:0000244|PDB:6A94"
FT   HELIX           313..348
FT                   /evidence="ECO:0000244|PDB:6A94"
FT   TURN            350..352
FT                   /evidence="ECO:0000244|PDB:6A94"
FT   HELIX           355..383
FT                   /evidence="ECO:0000244|PDB:6A94"
FT   HELIX           385..395
FT                   /evidence="ECO:0000244|PDB:6A94"
FT   CONFLICT        P28223-2:49
FT                   /note="D -> N (in Ref. 5; BAG63991)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   471 AA;  52603 MW;  EF8AAC0BC5379DA2 CRC64;
     MDILCEENTS LSSTTNSLMQ LNDDTRLYSN DFNSGEANTS DAFNWTVDSE NRTNLSCEGC
     LSPSCLSLLH LQEKNWSALL TAVVIILTIA GNILVIMAVS LEKKLQNATN YFLMSLAIAD
     MLLGFLVMPV SMLTILYGYR WPLPSKLCAV WIYLDVLFST ASIMHLCAIS LDRYVAIQNP
     IHHSRFNSRT KAFLKIIAVW TISVGISMPI PVFGLQDDSK VFKEGSCLLA DDNFVLIGSF
     VSFFIPLTIM VITYFLTIKS LQKEATLCVS DLGTRAKLAS FSFLPQSSLS SEKLFQRSIH
     REPGSYTGRR TMQSISNEQK ACKVLGIVFF LFVVMWCPFF ITNIMAVICK ESCNEDVIGA
     LLNVFVWIGY LSSAVNPLVY TLFNKTYRSA FSRYIQCQYK ENKKPLQLIL VNTIPALAYK
     SSQLQMGQKK NSKQDAKTTD NDCSMVALGK QHSEEASKDN SDGVNEKVSC V
//
ID   APJ_HUMAN               Reviewed;         380 AA.
AC   P35414;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   07-OCT-2020, entry version 181.
DE   RecName: Full=Apelin receptor;
DE   AltName: Full=Angiotensin receptor-like 1;
DE   AltName: Full=G-protein coupled receptor APJ;
DE   AltName: Full=G-protein coupled receptor HG11;
GN   Name=APLNR; Synonyms=AGTRL1, APJ;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND TISSUE SPECIFICITY.
RX   PubMed=8294032; DOI=10.1016/0378-1119(93)90495-o;
RA   O'Dowd B.F., Heiber M., Chan A., Heng H.H.Q., Tsui L.-C., Kennedy J.L.,
RA   Shi X., Petronis A., George S.R., Nguyen T.;
RT   "A human gene that shows identity with the gene encoding the angiotensin
RT   receptor is located on chromosome 11.";
RL   Gene 136:355-360(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Eggerickx D., Schurmans S., Vassart G., Parmentier M.;
RT   "Molecular cloning and tissue distribution of a human orphan receptor
RT   belonging to the G protein coupled receptors family.";
RL   Submitted (JUN-1995) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   FUNCTION, AND FUNCTION (MICROBIAL INFECTION).
RX   PubMed=11090199; DOI=10.1128/jvi.74.24.11972-11976.2000;
RA   Cayabyab M., Hinuma S., Farzan M., Choe H., Fukusumi S., Kitada C.,
RA   Nishizawa N., Hosoya M., Nishimura O., Messele T., Pollakis G.,
RA   Goudsmit J., Fujino M., Sodroski J.;
RT   "Apelin, the natural ligand of the orphan seven-transmembrane receptor APJ,
RT   inhibits human immunodeficiency virus type 1 entry.";
RL   J. Virol. 74:11972-11976(2000).
RN   [5]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=25639753; DOI=10.1038/srep08170;
RA   Wang Z., Yu D., Wang M., Wang Q., Kouznetsova J., Yang R., Qian K., Wu W.,
RA   Shuldiner A., Sztalryd C., Zou M., Zheng W., Gong D.W.;
RT   "Elabela-apelin receptor signaling pathway is functional in mammalian
RT   systems.";
RL   Sci. Rep. 5:8170-8170(2015).
RN   [6]
RP   FUNCTION.
RX   PubMed=28137936; DOI=10.1161/circulationaha.116.023218;
RA   Yang P., Read C., Kuc R.E., Buonincontri G., Southwood M., Torella R.,
RA   Upton P.D., Crosby A., Sawiak S.J., Carpenter T.A., Glen R.C.,
RA   Morrell N.W., Maguire J.J., Davenport A.P.;
RT   "Elabela/Toddler is an endogenous agonist of the apelin APJ receptor in the
RT   adult cardiovascular system, and exogenous administration of the peptide
RT   compensates for the downregulation of its expression in pulmonary arterial
RT   hypertension.";
RL   Circulation 135:1160-1173(2017).
CC   -!- FUNCTION: Receptor for apelin receptor early endogenous ligand (APELA)
CC       and apelin (APLN) hormones coupled to G proteins that inhibit adenylate
CC       cyclase activity (PubMed:11090199, PubMed:25639753, PubMed:28137936).
CC       Plays a key role in early development such as gastrulation, blood
CC       vessels formation and heart morphogenesis by acting as a receptor for
CC       APELA hormone (By similarity). May promote angioblast migration toward
CC       the embryonic midline, i.e. the position of the future vessel
CC       formation, during vasculogenesis (By similarity). Promotes sinus
CC       venosus (SV)-derived endothelial cells migration into the developing
CC       heart to promote coronary blood vessel development (By similarity).
CC       Plays also a role in various processes in adults such as regulation of
CC       blood vessel formation, blood pressure, heart contractility and heart
CC       failure (PubMed:25639753, PubMed:28137936).
CC       {ECO:0000250|UniProtKB:P79960, ECO:0000250|UniProtKB:Q7SZP9,
CC       ECO:0000250|UniProtKB:Q9WV08, ECO:0000269|PubMed:11090199,
CC       ECO:0000269|PubMed:25639753, ECO:0000269|PubMed:28137936}.
CC   -!- FUNCTION: (Microbial infection) Alternative coreceptor with CD4 for
CC       HIV-1 infection; may be involved in the development of AIDS dementia
CC       (PubMed:11090199). {ECO:0000269|PubMed:11090199}.
CC   -!- INTERACTION:
CC       P35414; P30556: AGTR1; NbExp=14; IntAct=EBI-2875891, EBI-6623016;
CC       P35414; P29033: GJB2; NbExp=3; IntAct=EBI-2875891, EBI-3905204;
CC       P35414; P41145: OPRK1; NbExp=3; IntAct=EBI-2875891, EBI-925028;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:25639753}.
CC       Note=After exposure to apelin (APLN), internalized from the cell
CC       surface into an endosomal recycling compartment, from where it is
CC       recycled to the cell membrane (By similarity). After exposure to apelin
CC       receptor early endogenous ligand (APELA), internalized from the cell
CC       surface into an endosomal recycling compartment, from where it is
CC       recycled to the cell membrane (PubMed:25639753).
CC       {ECO:0000250|UniProtKB:Q9JHG3, ECO:0000269|PubMed:25639753}.
CC   -!- TISSUE SPECIFICITY: Expressed in heart, brain, kidney, stomach, spleen,
CC       thymus, lung, ovary, small intestine and colon, adipose tissues and
CC       pancreas (PubMed:8294032, PubMed:25639753). Expressed in glial cells,
CC       astrocytes and neuronal subpopulations (PubMed:8294032). Expressed in
CC       embryonic (ESCs) and induced (iPSCs) pluripotent stem cells
CC       (PubMed:25639753). {ECO:0000269|PubMed:25639753,
CC       ECO:0000269|PubMed:8294032}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/APLNRID44364ch11q12.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U03642; AAA18954.1; -; Genomic_DNA.
DR   EMBL; X89271; CAA61546.1; -; mRNA.
DR   EMBL; BC032688; AAH32688.1; -; mRNA.
DR   CCDS; CCDS7950.1; -.
DR   PIR; I38435; I38435.
DR   RefSeq; NP_005152.1; NM_005161.4.
DR   PDB; 2LOT; NMR; -; A=1-55.
DR   PDB; 2LOU; NMR; -; A=1-55.
DR   PDB; 2LOV; NMR; -; A=1-55.
DR   PDB; 2LOW; NMR; -; A=1-55.
DR   PDB; 5VBL; X-ray; 2.60 A; B=7-229, B=243-330.
DR   PDB; 6KNM; X-ray; 3.20 A; B=7-229, B=243-330.
DR   PDBsum; 2LOT; -.
DR   PDBsum; 2LOU; -.
DR   PDBsum; 2LOV; -.
DR   PDBsum; 2LOW; -.
DR   PDBsum; 5VBL; -.
DR   PDBsum; 6KNM; -.
DR   BMRB; P35414; -.
DR   SMR; P35414; -.
DR   BioGRID; 106693; 119.
DR   IntAct; P35414; 109.
DR   MINT; P35414; -.
DR   STRING; 9606.ENSP00000475344; -.
DR   BindingDB; P35414; -.
DR   ChEMBL; CHEMBL1628481; -.
DR   GuidetoPHARMACOLOGY; 36; -.
DR   TCDB; 9.A.14.13.10; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; P35414; 2 sites.
DR   iPTMnet; P35414; -.
DR   PhosphoSitePlus; P35414; -.
DR   BioMuta; APLNR; -.
DR   DMDM; 543823; -.
DR   jPOST; P35414; -.
DR   MassIVE; P35414; -.
DR   PaxDb; P35414; -.
DR   PeptideAtlas; P35414; -.
DR   PRIDE; P35414; -.
DR   ProteomicsDB; 55061; -.
DR   ABCD; P35414; 2 sequenced antibodies.
DR   Antibodypedia; 14066; 540 antibodies.
DR   DNASU; 187; -.
DR   Ensembl; ENST00000257254; ENSP00000257254; ENSG00000134817.
DR   Ensembl; ENST00000606794; ENSP00000475344; ENSG00000134817.
DR   Ensembl; ENST00000611099; ENSP00000477818; ENSG00000134817.
DR   GeneID; 187; -.
DR   KEGG; hsa:187; -.
DR   UCSC; uc001njo.4; human.
DR   CTD; 187; -.
DR   DisGeNET; 187; -.
DR   EuPathDB; HostDB:ENSG00000134817.10; -.
DR   GeneCards; APLNR; -.
DR   HGNC; HGNC:339; APLNR.
DR   HPA; ENSG00000134817; Group enriched (brain, lymphoid tissue, placenta).
DR   MIM; 600052; gene.
DR   neXtProt; NX_P35414; -.
DR   OpenTargets; ENSG00000134817; -.
DR   PharmGKB; PA162376687; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT01000000214406; -.
DR   HOGENOM; CLU_009579_8_1_1; -.
DR   InParanoid; P35414; -.
DR   KO; K04174; -.
DR   OMA; TVMLTCY; -.
DR   OrthoDB; 788659at2759; -.
DR   PhylomeDB; P35414; -.
DR   TreeFam; TF330024; -.
DR   PathwayCommons; P35414; -.
DR   Reactome; R-HSA-375276; Peptide ligand-binding receptors.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   SIGNOR; P35414; -.
DR   BioGRID-ORCS; 187; 4 hits in 873 CRISPR screens.
DR   ChiTaRS; APLNR; human.
DR   GeneWiki; Apelin_receptor; -.
DR   GenomeRNAi; 187; -.
DR   Pharos; P35414; Tchem.
DR   PRO; PR:P35414; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; P35414; protein.
DR   Bgee; ENSG00000134817; Expressed in spinal cord and 213 other tissues.
DR   Genevisible; P35414; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0060182; F:apelin receptor activity; IBA:GO_Central.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0038023; F:signaling receptor activity; TAS:ProtInc.
DR   GO; GO:0007512; P:adult heart development; IEA:Ensembl.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0001568; P:blood vessel development; IBA:GO_Central.
DR   GO; GO:0060976; P:coronary vasculature development; ISS:UniProtKB.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0007369; P:gastrulation; IEA:UniProtKB-KW.
DR   GO; GO:0007507; P:heart development; ISS:UniProtKB.
DR   GO; GO:0043951; P:negative regulation of cAMP-mediated signaling; IMP:UniProtKB.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IMP:UniProtKB.
DR   GO; GO:1903589; P:positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis; ISS:UniProtKB.
DR   GO; GO:1904325; P:positive regulation of inhibitory G protein-coupled receptor phosphorylation; IMP:UniProtKB.
DR   GO; GO:0051281; P:positive regulation of release of sequestered calcium ion into cytosol; IMP:UniProtKB.
DR   GO; GO:0050878; P:regulation of body fluid levels; IEA:Ensembl.
DR   GO; GO:0001570; P:vasculogenesis; ISS:UniProtKB.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   InterPro; IPR003904; APJ_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01416; APJRECEPTOR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Angiogenesis; Cell membrane; Developmental protein;
KW   G-protein coupled receptor; Gastrulation; Glycoprotein;
KW   Host-virus interaction; Membrane; Polymorphism; Receptor;
KW   Reference proteome; Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..380
FT                   /note="Apelin receptor"
FT                   /id="PRO_0000069173"
FT   TOPO_DOM        1..26
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        27..51
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        52..66
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        67..91
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        92..100
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        101..125
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        126..144
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        145..166
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        167..200
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        201..221
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        222..244
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        245..271
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        272..284
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        285..308
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        309..380
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        15
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        175
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VARIANT         300
FT                   /note="V -> I (in dbSNP:rs7943508)"
FT                   /id="VAR_049375"
FT   STRAND          9..12
FT                   /evidence="ECO:0000244|PDB:2LOV"
FT   HELIX           13..16
FT                   /evidence="ECO:0000244|PDB:2LOU"
FT   STRAND          18..20
FT                   /evidence="ECO:0000244|PDB:2LOT"
FT   TURN            21..23
FT                   /evidence="ECO:0000244|PDB:2LOT"
FT   HELIX           24..27
FT                   /evidence="ECO:0000244|PDB:2LOT"
FT   HELIX           30..55
FT                   /evidence="ECO:0000244|PDB:5VBL"
FT   HELIX           58..60
FT                   /evidence="ECO:0000244|PDB:5VBL"
FT   HELIX           65..79
FT                   /evidence="ECO:0000244|PDB:5VBL"
FT   HELIX           82..90
FT                   /evidence="ECO:0000244|PDB:5VBL"
FT   HELIX           98..131
FT                   /evidence="ECO:0000244|PDB:5VBL"
FT   HELIX           137..140
FT                   /evidence="ECO:0000244|PDB:5VBL"
FT   HELIX           142..160
FT                   /evidence="ECO:0000244|PDB:5VBL"
FT   HELIX           162..167
FT                   /evidence="ECO:0000244|PDB:5VBL"
FT   STRAND          168..171
FT                   /evidence="ECO:0000244|PDB:5VBL"
FT   STRAND          174..177
FT                   /evidence="ECO:0000244|PDB:6KNM"
FT   STRAND          180..183
FT                   /evidence="ECO:0000244|PDB:5VBL"
FT   TURN            186..188
FT                   /evidence="ECO:0000244|PDB:5VBL"
FT   TURN            191..193
FT                   /evidence="ECO:0000244|PDB:6KNM"
FT   HELIX           194..209
FT                   /evidence="ECO:0000244|PDB:5VBL"
FT   HELIX           211..228
FT                   /evidence="ECO:0000244|PDB:5VBL"
FT   HELIX           245..275
FT                   /evidence="ECO:0000244|PDB:5VBL"
FT   TURN            276..278
FT                   /evidence="ECO:0000244|PDB:5VBL"
FT   HELIX           281..312
FT                   /evidence="ECO:0000244|PDB:5VBL"
FT   HELIX           314..325
FT                   /evidence="ECO:0000244|PDB:5VBL"
FT   TURN            326..329
FT                   /evidence="ECO:0000244|PDB:5VBL"
SQ   SEQUENCE   380 AA;  42660 MW;  78DB18BEA6D2B2E4 CRC64;
     MEEGGDFDNY YGADNQSECE YTDWKSSGAL IPAIYMLVFL LGTTGNGLVL WTVFRSSREK
     RRSADIFIAS LAVADLTFVV TLPLWATYTY RDYDWPFGTF FCKLSSYLIF VNMYASVFCL
     TGLSFDRYLA IVRPVANARL RLRVSGAVAT AVLWVLAALL AMPVMVLRTT GDLENTTKVQ
     CYMDYSMVAT VSSEWAWEVG LGVSSTTVGF VVPFTIMLTC YFFIAQTIAG HFRKERIEGL
     RKRRRLLSII VVLVVTFALC WMPYHLVKTL YMLGSLLHWP CDFDLFLMNI FPYCTCISYV
     NSCLNPFLYA FFDPRFRQAC TSMLCCGQSR CAGTSHSSSG EKSASYSSGH SQGPGPNMGK
     GGEQMHEKSI PYSQETLVVD
//
ID   CCR7_HUMAN              Reviewed;         378 AA.
AC   P32248;
DT   01-OCT-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 2.
DT   07-OCT-2020, entry version 188.
DE   RecName: Full=C-C chemokine receptor type 7;
DE            Short=C-C CKR-7;
DE            Short=CC-CKR-7;
DE            Short=CCR-7;
DE   AltName: Full=BLR2;
DE   AltName: Full=CDw197;
DE   AltName: Full=Epstein-Barr virus-induced G-protein coupled receptor 1;
DE            Short=EBI1;
DE            Short=EBV-induced G-protein coupled receptor 1;
DE   AltName: Full=MIP-3 beta receptor;
DE   AltName: CD_antigen=CD197;
DE   Flags: Precursor;
GN   Name=CCR7; Synonyms=CMKBR7, EBI1, EVI1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8383238;
RA   Birkenbach M.P., Josefsen K., Yalamanchili R.R., Lenoir G.M., Kieff E.;
RT   "Epstein-Barr virus-induced genes: first lymphocyte-specific G protein-
RT   coupled peptide receptors.";
RL   J. Virol. 67:2209-2220(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RC   TISSUE=Placenta;
RX   PubMed=7851893; DOI=10.1006/geno.1994.1553;
RA   Schweickart V.L., Raport C.J., Godiska R., Byers M.G., Eddy R.L. Jr.,
RA   Shows T.B., Gray P.W.;
RT   "Cloning of human and mouse EBI1, a lymphoid-specific G-protein-coupled
RT   receptor encoded on human chromosome 17q12-q21.2.";
RL   Genomics 23:643-650(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (APR-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- FUNCTION: Receptor for the MIP-3-beta chemokine. Probable mediator of
CC       EBV effects on B-lymphocytes or of normal lymphocyte functions.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Expressed in various lymphoid tissues and activated
CC       B- and T-lymphocytes, strongly up-regulated in B-cells infected with
CC       Epstein-Barr virus and T-cells infected with herpesvirus 6 or 7.
CC   -!- INDUCTION: By Epstein-Barr virus (EBV).
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=CC chemokine receptors entry;
CC       URL="https://en.wikipedia.org/wiki/CC_chemokine_receptors";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L08176; AAA58615.1; -; mRNA.
DR   EMBL; L31584; AAA74230.1; -; Genomic_DNA.
DR   EMBL; L31582; AAA74230.1; JOINED; Genomic_DNA.
DR   EMBL; L31583; AAA74230.1; JOINED; Genomic_DNA.
DR   EMBL; L31581; AAA74231.1; -; mRNA.
DR   EMBL; AY587876; AAT52232.1; -; mRNA.
DR   EMBL; BC035343; AAH35343.1; -; mRNA.
DR   CCDS; CCDS11369.1; -.
DR   PIR; A45680; A45680.
DR   PIR; B55735; B55735.
DR   RefSeq; NP_001288643.1; NM_001301714.1.
DR   RefSeq; NP_001288645.1; NM_001301716.1.
DR   RefSeq; NP_001288646.1; NM_001301717.1.
DR   RefSeq; NP_001288647.1; NM_001301718.1.
DR   RefSeq; NP_001829.1; NM_001838.3.
DR   PDB; 6QZH; X-ray; 2.10 A; A=46-247.
DR   PDBsum; 6QZH; -.
DR   SMR; P32248; -.
DR   BioGRID; 107641; 2.
DR   DIP; DIP-5855N; -.
DR   IntAct; P32248; 4.
DR   MINT; P32248; -.
DR   STRING; 9606.ENSP00000246657; -.
DR   BindingDB; P32248; -.
DR   ChEMBL; CHEMBL4594; -.
DR   GuidetoPHARMACOLOGY; 64; -.
DR   GlyGen; P32248; 1 site.
DR   iPTMnet; P32248; -.
DR   PhosphoSitePlus; P32248; -.
DR   BioMuta; CCR7; -.
DR   DMDM; 1352335; -.
DR   MassIVE; P32248; -.
DR   MaxQB; P32248; -.
DR   PaxDb; P32248; -.
DR   PeptideAtlas; P32248; -.
DR   PRIDE; P32248; -.
DR   ProteomicsDB; 54856; -.
DR   Antibodypedia; 3533; 1041 antibodies.
DR   DNASU; 1236; -.
DR   Ensembl; ENST00000246657; ENSP00000246657; ENSG00000126353.
DR   GeneID; 1236; -.
DR   KEGG; hsa:1236; -.
DR   UCSC; uc002huw.4; human.
DR   CTD; 1236; -.
DR   DisGeNET; 1236; -.
DR   EuPathDB; HostDB:ENSG00000126353.3; -.
DR   GeneCards; CCR7; -.
DR   HGNC; HGNC:1608; CCR7.
DR   HPA; ENSG00000126353; Group enriched (blood, lymphoid tissue).
DR   MIM; 600242; gene.
DR   neXtProt; NX_P32248; -.
DR   OpenTargets; ENSG00000126353; -.
DR   PharmGKB; PA26172; -.
DR   eggNOG; ENOG502QUZ9; Eukaryota.
DR   GeneTree; ENSGT00950000182749; -.
DR   InParanoid; P32248; -.
DR   KO; K04182; -.
DR   OMA; TLACFRC; -.
DR   OrthoDB; 715251at2759; -.
DR   PhylomeDB; P32248; -.
DR   TreeFam; TF330966; -.
DR   PathwayCommons; P32248; -.
DR   Reactome; R-HSA-380108; Chemokine receptors bind chemokines.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   SIGNOR; P32248; -.
DR   BioGRID-ORCS; 1236; 4 hits in 875 CRISPR screens.
DR   GeneWiki; C-C_chemokine_receptor_type_7; -.
DR   GenomeRNAi; 1236; -.
DR   Pharos; P32248; Tbio.
DR   PRO; PR:P32248; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; P32248; protein.
DR   Bgee; ENSG00000126353; Expressed in blood and 136 other tissues.
DR   ExpressionAtlas; P32248; baseline and differential.
DR   Genevisible; P32248; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0009897; C:external side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005739; C:mitochondrion; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0019957; F:C-C chemokine binding; IBA:GO_Central.
DR   GO; GO:0016493; F:C-C chemokine receptor activity; ISS:BHF-UCL.
DR   GO; GO:0038117; F:C-C motif chemokine 19 receptor activity; IDA:UniProtKB.
DR   GO; GO:0038121; F:C-C motif chemokine 21 receptor activity; IDA:UniProtKB.
DR   GO; GO:0035757; F:chemokine (C-C motif) ligand 19 binding; IPI:BHF-UCL.
DR   GO; GO:0035758; F:chemokine (C-C motif) ligand 21 binding; IPI:BHF-UCL.
DR   GO; GO:0019956; F:chemokine binding; IBA:GO_Central.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; TAS:BHF-UCL.
DR   GO; GO:0090630; P:activation of GTPase activity; IC:BHF-UCL.
DR   GO; GO:0019722; P:calcium-mediated signaling; IBA:GO_Central.
DR   GO; GO:0060326; P:cell chemotaxis; IBA:GO_Central.
DR   GO; GO:0071345; P:cellular response to cytokine stimulus; IDA:BHF-UCL.
DR   GO; GO:0006935; P:chemotaxis; IBA:GO_Central.
DR   GO; GO:0002407; P:dendritic cell chemotaxis; IC:BHF-UCL.
DR   GO; GO:0001768; P:establishment of T cell polarity; IC:BHF-UCL.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:BHF-UCL.
DR   GO; GO:0048872; P:homeostasis of number of cells; IEA:Ensembl.
DR   GO; GO:0006955; P:immune response; IBA:GO_Central.
DR   GO; GO:0006954; P:inflammatory response; NAS:BHF-UCL.
DR   GO; GO:0097022; P:lymphocyte migration into lymph node; TAS:BHF-UCL.
DR   GO; GO:0097029; P:mature conventional dendritic cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0002408; P:myeloid dendritic cell chemotaxis; IDA:BHF-UCL.
DR   GO; GO:2000669; P:negative regulation of dendritic cell apoptotic process; IC:BHF-UCL.
DR   GO; GO:0032695; P:negative regulation of interleukin-12 production; ISS:BHF-UCL.
DR   GO; GO:0045060; P:negative thymic T cell selection; IEA:Ensembl.
DR   GO; GO:0030838; P:positive regulation of actin filament polymerization; IC:BHF-UCL.
DR   GO; GO:0045785; P:positive regulation of cell adhesion; IC:BHF-UCL.
DR   GO; GO:2000147; P:positive regulation of cell motility; IC:BHF-UCL.
DR   GO; GO:0001954; P:positive regulation of cell-matrix adhesion; IC:BHF-UCL.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IBA:GO_Central.
DR   GO; GO:0002606; P:positive regulation of dendritic cell antigen processing and presentation; ISS:BHF-UCL.
DR   GO; GO:2000510; P:positive regulation of dendritic cell chemotaxis; ISS:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IC:BHF-UCL.
DR   GO; GO:0051491; P:positive regulation of filopodium assembly; IC:BHF-UCL.
DR   GO; GO:2000526; P:positive regulation of glycoprotein biosynthetic process involved in immunological synapse formation; ISS:BHF-UCL.
DR   GO; GO:0002922; P:positive regulation of humoral immune response; ISS:BHF-UCL.
DR   GO; GO:0002885; P:positive regulation of hypersensitivity; ISS:BHF-UCL.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IC:BHF-UCL.
DR   GO; GO:2000522; P:positive regulation of immunological synapse formation; ISS:BHF-UCL.
DR   GO; GO:0032735; P:positive regulation of interleukin-12 production; ISS:BHF-UCL.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IC:BHF-UCL.
DR   GO; GO:0090023; P:positive regulation of neutrophil chemotaxis; IDA:BHF-UCL.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; IC:BHF-UCL.
DR   GO; GO:0045860; P:positive regulation of protein kinase activity; IC:BHF-UCL.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IC:BHF-UCL.
DR   GO; GO:0031274; P:positive regulation of pseudopodium assembly; IC:BHF-UCL.
DR   GO; GO:2000525; P:positive regulation of T cell costimulation; ISS:BHF-UCL.
DR   GO; GO:0050862; P:positive regulation of T cell receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:2000547; P:regulation of dendritic cell dendrite assembly; ISS:BHF-UCL.
DR   GO; GO:0032649; P:regulation of interferon-gamma production; ISS:BHF-UCL.
DR   GO; GO:0032651; P:regulation of interleukin-1 beta production; ISS:BHF-UCL.
DR   GO; GO:0051209; P:release of sequestered calcium ion into cytosol; IC:BHF-UCL.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0071731; P:response to nitric oxide; IC:BHF-UCL.
DR   GO; GO:0034695; P:response to prostaglandin E; IC:BHF-UCL.
DR   GO; GO:0031529; P:ruffle organization; IC:BHF-UCL.
DR   InterPro; IPR001718; Chemokine_CCR7.
DR   InterPro; IPR000355; Chemokine_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00657; CCCHEMOKINER.
DR   PRINTS; PR00641; CHEMOKINER7.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Membrane; Polymorphism; Receptor; Reference proteome; Signal;
KW   Transducer; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..24
FT                   /evidence="ECO:0000255"
FT   CHAIN           25..378
FT                   /note="C-C chemokine receptor type 7"
FT                   /id="PRO_0000012735"
FT   TOPO_DOM        25..59
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        60..86
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        87..95
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        96..116
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        117..130
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        131..152
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        153..170
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        171..191
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        192..219
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        220..247
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        248..263
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        264..289
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        290..313
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        314..331
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        332..378
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        36
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        129..210
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VARIANT         7
FT                   /note="M -> V (in dbSNP:rs2228015)"
FT                   /id="VAR_049383"
FT   CONFLICT        182..183
FT                   /note="IW -> SA (in Ref. 1; AAA58615)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        337
FT                   /note="L -> I (in Ref. 1; AAA58615)"
FT                   /evidence="ECO:0000305"
FT   HELIX           56..84
FT                   /evidence="ECO:0000244|PDB:6QZH"
FT   HELIX           85..89
FT                   /evidence="ECO:0000244|PDB:6QZH"
FT   HELIX           92..108
FT                   /evidence="ECO:0000244|PDB:6QZH"
FT   HELIX           111..119
FT                   /evidence="ECO:0000244|PDB:6QZH"
FT   HELIX           125..157
FT                   /evidence="ECO:0000244|PDB:6QZH"
FT   HELIX           168..171
FT                   /evidence="ECO:0000244|PDB:6QZH"
FT   HELIX           173..190
FT                   /evidence="ECO:0000244|PDB:6QZH"
FT   HELIX           191..195
FT                   /evidence="ECO:0000244|PDB:6QZH"
FT   STRAND          196..200
FT                   /evidence="ECO:0000244|PDB:6QZH"
FT   STRAND          209..212
FT                   /evidence="ECO:0000244|PDB:6QZH"
FT   HELIX           221..231
FT                   /evidence="ECO:0000244|PDB:6QZH"
FT   HELIX           233..247
FT                   /evidence="ECO:0000244|PDB:6QZH"
SQ   SEQUENCE   378 AA;  42874 MW;  D4CB4213841A1BD4 CRC64;
     MDLGKPMKSV LVVALLVIFQ VCLCQDEVTD DYIGDNTTVD YTLFESLCSK KDVRNFKAWF
     LPIMYSIICF VGLLGNGLVV LTYIYFKRLK TMTDTYLLNL AVADILFLLT LPFWAYSAAK
     SWVFGVHFCK LIFAIYKMSF FSGMLLLLCI SIDRYVAIVQ AVSAHRHRAR VLLISKLSCV
     GIWILATVLS IPELLYSDLQ RSSSEQAMRC SLITEHVEAF ITIQVAQMVI GFLVPLLAMS
     FCYLVIIRTL LQARNFERNK AIKVIIAVVV VFIVFQLPYN GVVLAQTVAN FNITSSTCEL
     SKQLNIAYDV TYSLACVRCC VNPFLYAFIG VKFRNDLFKL FKDLGCLSQE QLRQWSSCRH
     IRRSSMSVEA ETTTTFSP
//
ID   AA2AR_HUMAN             Reviewed;         412 AA.
AC   P29274; B2R7E0;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 2.
DT   07-OCT-2020, entry version 215.
DE   RecName: Full=Adenosine receptor A2a;
GN   Name=ADORA2A; Synonyms=ADORA2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Tiffany H.L., Murphy P.M.;
RL   Submitted (JUL-1992) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RA   Salvatore C.A., Luneau C.J., Johnson R.G., Jacobson M.;
RL   Submitted (SEP-1992) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Hippocampus;
RX   PubMed=1331670; DOI=10.1016/0169-328x(92)90152-2;
RA   Furlong T.J., Pierce K.D., Selbie L.A., Shine J.;
RT   "Molecular characterization of a human brain adenosine A2 receptor.";
RL   Brain Res. Mol. Brain Res. 15:62-66(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8670304; DOI=10.1006/bbrc.1996.0916;
RA   Le F., Townsend-Nicholson A., Baker E., Sutherland G.R., Schofield P.R.;
RT   "Characterization and chromosomal localization of the human A2a adenosine
RT   receptor gene: ADORA2A.";
RL   Biochem. Biophys. Res. Commun. 223:461-467(1996).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15461802; DOI=10.1186/gb-2004-5-10-r84;
RA   Collins J.E., Wright C.L., Edwards C.A., Davis M.P., Grinham J.A.,
RA   Cole C.G., Goward M.E., Aguado B., Mallya M., Mokrab Y., Huckle E.J.,
RA   Beare D.M., Dunham I.;
RT   "A genome annotation-driven approach to cloning the human ORFeome.";
RL   Genome Biol. 5:R84.1-R84.11(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Thymus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   INTERACTION WITH NECAB2.
RX   PubMed=17689978; DOI=10.1016/j.mcn.2007.05.007;
RA   Canela L., Lujan R., Lluis C., Burgueno J., Mallol J., Canela E.I.,
RA   Franco R., Ciruela F.;
RT   "The neuronal Ca(2+) -binding protein 2 (NECAB2) interacts with the
RT   adenosine A(2A) receptor and modulates the cell surface expression and
RT   function of the receptor.";
RL   Mol. Cell. Neurosci. 36:1-12(2007).
RN   [12]
RP   POSSIBLE INTERACTION WITH DRD4.
RX   PubMed=20836733; DOI=10.3109/10799893.2010.513842;
RA   Woods A.S.;
RT   "The dopamine D(4) receptor, the ultimate disordered protein.";
RL   J. Recept. Signal Transduct. 30:331-336(2010).
RN   [13]
RP   3D-STRUCTURE MODELING OF TRANSMEMBRANE DOMAINS.
RX   PubMed=7775460; DOI=10.1074/jbc.270.23.13987;
RA   Kim J., Wess J., van Rhee A.M., Schoneberg T., Jacobson K.A.;
RT   "Site-directed mutagenesis identifies residues involved in ligand
RT   recognition in the human A2a adenosine receptor.";
RL   J. Biol. Chem. 270:13987-13997(1995).
RN   [14]
RP   INTERACTION WITH USP4, UBIQUITINATION, AND DEUBIQUITINATION BY USP4.
RX   PubMed=16339847; DOI=10.1124/mol.105.015818;
RA   Milojevic T., Reiterer V., Stefan E., Korkhov V.M., Dorostkar M.M.,
RA   Ducza E., Ogris E., Boehm S., Freissmuth M., Nanoff C.;
RT   "The ubiquitin-specific protease Usp4 regulates the cell surface level of
RT   the A2A receptor.";
RL   Mol. Pharmacol. 69:1083-1094(2006).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 2-316 IN COMPLEX WITH ANTAGONIST,
RP   TOPOLOGY, AND DISULFIDE BONDS.
RX   PubMed=18832607; DOI=10.1126/science.1164772;
RA   Jaakola V.-P., Griffith M.T., Hanson M.A., Cherezov V., Chien E.Y.T.,
RA   Lane J.R., Ijzerman A.P., Stevens R.C.;
RT   "The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound
RT   to an antagonist.";
RL   Science 322:1211-1217(2008).
RN   [16]
RP   VARIANT VAL-50.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions of
RT   human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [17]
RP   ERRATUM OF PUBMED:10391209.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
CC   -!- FUNCTION: Receptor for adenosine (By similarity). The activity of this
CC       receptor is mediated by G proteins which activate adenylyl cyclase (By
CC       similarity). {ECO:0000250|UniProtKB:P11617}.
CC   -!- SUBUNIT: Interacts (via cytoplasmic C-terminal domain) with USP4; the
CC       interaction is direct (PubMed:16339847). May interact with DRD4
CC       (PubMed:18832607). Interacts with NECAB2 (PubMed:17689978). Interacts
CC       (via cytoplasmic C-terminal domain) with GAS2L2; interaction enhances
CC       receptor-mediated adenylyl cyclase activity (By similarity).
CC       {ECO:0000250|UniProtKB:P30543, ECO:0000269|PubMed:16339847,
CC       ECO:0000269|PubMed:17689978, ECO:0000269|PubMed:18832607}.
CC   -!- INTERACTION:
CC       P29274; P30542: ADORA1; NbExp=4; IntAct=EBI-2902702, EBI-2903663;
CC       P29274; P29274: ADORA2A; NbExp=8; IntAct=EBI-2902702, EBI-2902702;
CC       P29274; P29275: ADORA2B; NbExp=5; IntAct=EBI-2902702, EBI-3904751;
CC       P29274; O15155: BET1; NbExp=3; IntAct=EBI-2902702, EBI-749204;
CC       P29274; P0DP25: CALM3; NbExp=3; IntAct=EBI-2902702, EBI-397435;
CC       P29274; P21554: CNR1; NbExp=8; IntAct=EBI-2902702, EBI-2909859;
CC       P29274; Q99418: CYTH2; NbExp=6; IntAct=EBI-2902702, EBI-448974;
CC       P29274; P14416: DRD2; NbExp=4; IntAct=EBI-2902702, EBI-2928178;
CC       P29274; O15354: GPR37; NbExp=3; IntAct=EBI-2902702, EBI-15639515;
CC       P29274; Q7Z6G3: NECAB2; NbExp=6; IntAct=EBI-2902702, EBI-950070;
CC       P29274; O43759-2: SYNGR1; NbExp=3; IntAct=EBI-2902702, EBI-12187159;
CC       P29274; Q13107: USP4; NbExp=4; IntAct=EBI-2902702, EBI-723290;
CC       P29274; Q5T9L3-1: WLS; NbExp=3; IntAct=EBI-2902702, EBI-22114623;
CC       P29274; P31424-1: Grm5; Xeno; NbExp=3; IntAct=EBI-2902702, EBI-2902778;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:P30543};
CC       Multi-pass membrane protein {ECO:0000250|UniProtKB:P30543}.
CC       Note=Colocalizes with GAS2L2 at neuronal processes.
CC       {ECO:0000250|UniProtKB:P30543}.
CC   -!- DOMAIN: The cytoplasmic C-terminal domain is necessary for targeting
CC       the non-ubiquitinated form of this protein to the cell surface.
CC   -!- PTM: Ubiquitinated. Deubiquitinated by USP4; leading to stabilization
CC       and expression at the cell surface. {ECO:0000269|PubMed:16339847}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA58356.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M97370; AAA58356.1; ALT_INIT; mRNA.
DR   EMBL; X68486; CAA48504.1; -; mRNA.
DR   EMBL; S46950; AAB23956.1; -; mRNA.
DR   EMBL; U40771; AAA83270.1; -; Genomic_DNA.
DR   EMBL; U40770; AAA83270.1; JOINED; Genomic_DNA.
DR   EMBL; AY136747; AAN01273.1; -; mRNA.
DR   EMBL; CR456367; CAG30253.1; -; mRNA.
DR   EMBL; BT006999; AAP35645.1; -; mRNA.
DR   EMBL; AK312946; BAG35787.1; -; mRNA.
DR   EMBL; CH471095; EAW59658.1; -; Genomic_DNA.
DR   EMBL; BC013780; AAH13780.1; -; mRNA.
DR   CCDS; CCDS13826.1; -.
DR   PIR; A48978; A48978.
DR   RefSeq; NP_000666.2; NM_000675.5.
DR   RefSeq; NP_001265426.1; NM_001278497.1.
DR   RefSeq; NP_001265427.1; NM_001278498.1.
DR   RefSeq; NP_001265428.1; NM_001278499.1.
DR   RefSeq; NP_001265429.1; NM_001278500.1.
DR   PDB; 1MMH; Model; -; 1=6-36, 2=42-69, 3=78-102, 4=117-143, 5=175-203, 6=233-260, 7=264-296.
DR   PDB; 1UPE; Model; -; A=1-304.
DR   PDB; 2YDO; X-ray; 3.00 A; A=1-317.
DR   PDB; 2YDV; X-ray; 2.60 A; A=1-317.
DR   PDB; 3EML; X-ray; 2.60 A; A=2-208, A=222-316.
DR   PDB; 3PWH; X-ray; 3.30 A; A=1-317.
DR   PDB; 3QAK; X-ray; 2.71 A; A=2-208, A=222-316.
DR   PDB; 3REY; X-ray; 3.31 A; A=1-317.
DR   PDB; 3RFM; X-ray; 3.60 A; A=1-317.
DR   PDB; 3UZA; X-ray; 3.27 A; A=1-317.
DR   PDB; 3UZC; X-ray; 3.34 A; A=1-317.
DR   PDB; 3VG9; X-ray; 2.70 A; A=1-316.
DR   PDB; 3VGA; X-ray; 3.10 A; A=1-316.
DR   PDB; 4EIY; X-ray; 1.80 A; A=2-208, A=219-316.
DR   PDB; 4UG2; X-ray; 2.60 A; A/B=1-317.
DR   PDB; 4UHR; X-ray; 2.60 A; A=1-317.
DR   PDB; 5G53; X-ray; 3.40 A; A/B=1-308.
DR   PDB; 5IU4; X-ray; 1.72 A; A=2-208, A=219-318.
DR   PDB; 5IU7; X-ray; 1.90 A; A=2-208, A=219-315.
DR   PDB; 5IU8; X-ray; 2.00 A; A=2-208, A=219-315.
DR   PDB; 5IUA; X-ray; 2.20 A; A=2-208, A=219-315.
DR   PDB; 5IUB; X-ray; 2.10 A; A=2-208, A=219-315.
DR   PDB; 5JTB; X-ray; 2.80 A; A=2-212, A=219-316.
DR   PDB; 5K2A; X-ray; 2.50 A; A=2-208, A=219-316.
DR   PDB; 5K2B; X-ray; 2.50 A; A=2-208, A=219-316.
DR   PDB; 5K2C; X-ray; 1.90 A; A=2-208, A=219-316.
DR   PDB; 5K2D; X-ray; 1.90 A; A=2-208, A=219-316.
DR   PDB; 5MZJ; X-ray; 2.00 A; A=2-208, A=219-318.
DR   PDB; 5MZP; X-ray; 2.10 A; A=2-208, A=219-317.
DR   PDB; 5N2R; X-ray; 2.80 A; A=2-208, A=219-318.
DR   PDB; 5NLX; X-ray; 2.14 A; A=2-317.
DR   PDB; 5NM2; X-ray; 1.95 A; A=2-317.
DR   PDB; 5NM4; X-ray; 1.70 A; A=2-317.
DR   PDB; 5OLG; X-ray; 1.87 A; A=2-208, A=219-317.
DR   PDB; 5OLH; X-ray; 2.60 A; A=2-208, A=219-317.
DR   PDB; 5OLO; X-ray; 3.10 A; A=2-208, A=219-318.
DR   PDB; 5OLV; X-ray; 2.00 A; A=2-208, A=219-317.
DR   PDB; 5OLZ; X-ray; 1.90 A; A=2-208, A=219-317.
DR   PDB; 5OM1; X-ray; 2.10 A; A=2-208, A=219-317.
DR   PDB; 5OM4; X-ray; 2.00 A; A=2-208, A=219-317.
DR   PDB; 5UIG; X-ray; 3.50 A; A=1-191, A=219-316.
DR   PDB; 5UVI; X-ray; 3.20 A; A=2-212, A=219-316.
DR   PDB; 5VRA; X-ray; 2.35 A; A=2-208, A=219-316.
DR   PDB; 5WF5; X-ray; 2.60 A; A=2-208, A=222-316.
DR   PDB; 5WF6; X-ray; 2.90 A; A=2-208, A=222-316.
DR   PDB; 6AQF; X-ray; 2.51 A; A=2-208, A=219-316.
DR   PDB; 6GDG; EM; 4.11 A; A=8-316.
DR   PDB; 6GT3; X-ray; 2.00 A; A=2-208, A=219-317.
DR   PDB; 6JZH; X-ray; 2.25 A; A=2-208, A=219-316.
DR   PDB; 6MH8; X-ray; 4.20 A; A=2-208, A=219-316.
DR   PDB; 6PS7; X-ray; 1.85 A; A=2-208, A=219-316.
DR   PDB; 6S0Q; X-ray; 2.65 A; A=2-208, A=219-317.
DR   PDBsum; 1MMH; -.
DR   PDBsum; 1UPE; -.
DR   PDBsum; 2YDO; -.
DR   PDBsum; 2YDV; -.
DR   PDBsum; 3EML; -.
DR   PDBsum; 3PWH; -.
DR   PDBsum; 3QAK; -.
DR   PDBsum; 3REY; -.
DR   PDBsum; 3RFM; -.
DR   PDBsum; 3UZA; -.
DR   PDBsum; 3UZC; -.
DR   PDBsum; 3VG9; -.
DR   PDBsum; 3VGA; -.
DR   PDBsum; 4EIY; -.
DR   PDBsum; 4UG2; -.
DR   PDBsum; 4UHR; -.
DR   PDBsum; 5G53; -.
DR   PDBsum; 5IU4; -.
DR   PDBsum; 5IU7; -.
DR   PDBsum; 5IU8; -.
DR   PDBsum; 5IUA; -.
DR   PDBsum; 5IUB; -.
DR   PDBsum; 5JTB; -.
DR   PDBsum; 5K2A; -.
DR   PDBsum; 5K2B; -.
DR   PDBsum; 5K2C; -.
DR   PDBsum; 5K2D; -.
DR   PDBsum; 5MZJ; -.
DR   PDBsum; 5MZP; -.
DR   PDBsum; 5N2R; -.
DR   PDBsum; 5NLX; -.
DR   PDBsum; 5NM2; -.
DR   PDBsum; 5NM4; -.
DR   PDBsum; 5OLG; -.
DR   PDBsum; 5OLH; -.
DR   PDBsum; 5OLO; -.
DR   PDBsum; 5OLV; -.
DR   PDBsum; 5OLZ; -.
DR   PDBsum; 5OM1; -.
DR   PDBsum; 5OM4; -.
DR   PDBsum; 5UIG; -.
DR   PDBsum; 5UVI; -.
DR   PDBsum; 5VRA; -.
DR   PDBsum; 5WF5; -.
DR   PDBsum; 5WF6; -.
DR   PDBsum; 6AQF; -.
DR   PDBsum; 6GDG; -.
DR   PDBsum; 6GT3; -.
DR   PDBsum; 6JZH; -.
DR   PDBsum; 6MH8; -.
DR   PDBsum; 6PS7; -.
DR   PDBsum; 6S0Q; -.
DR   SMR; P29274; -.
DR   BioGRID; 106647; 14.
DR   IntAct; P29274; 23.
DR   MINT; P29274; -.
DR   STRING; 9606.ENSP00000480012; -.
DR   BindingDB; P29274; -.
DR   ChEMBL; CHEMBL251; -.
DR   DrugBank; DB08770; 4-{2-[(7-amino-2-furan-2-yl[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino]ethyl}phenol.
DR   DrugBank; DB14132; 8-chlorotheophylline.
DR   DrugBank; DB00640; Adenosine.
DR   DrugBank; DB05009; Apadenoson.
DR   DrugBank; DB05191; Atl146e.
DR   DrugBank; DB04853; Binodenoson.
DR   DrugBank; DB00201; Caffeine.
DR   DrugBank; DB04932; Defibrotide.
DR   DrugBank; DB09273; Doxofylline.
DR   DrugBank; DB00651; Dyphylline.
DR   DrugBank; DB00824; Enprofylline.
DR   DrugBank; DB11757; Istradefylline.
DR   DrugBank; DB00555; Lamotrigine.
DR   DrugBank; DB00358; Mefloquine.
DR   DrugBank; DB01303; Oxtriphylline.
DR   DrugBank; DB00806; Pentoxifylline.
DR   DrugBank; DB06213; Regadenoson.
DR   DrugBank; DB01412; Theobromine.
DR   DrugBank; DB00277; Theophylline.
DR   DrugCentral; P29274; -.
DR   GuidetoPHARMACOLOGY; 19; -.
DR   TCDB; 9.A.14.3.8; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; P29274; 1 site.
DR   iPTMnet; P29274; -.
DR   PhosphoSitePlus; P29274; -.
DR   BioMuta; ADORA2A; -.
DR   DMDM; 543740; -.
DR   MassIVE; P29274; -.
DR   PaxDb; P29274; -.
DR   PeptideAtlas; P29274; -.
DR   PRIDE; P29274; -.
DR   ProteomicsDB; 54531; -.
DR   ABCD; P29274; 3 sequenced antibodies.
DR   Antibodypedia; 9718; 410 antibodies.
DR   DNASU; 135; -.
DR   Ensembl; ENST00000337539; ENSP00000336630; ENSG00000128271.
DR   Ensembl; ENST00000610595; ENSP00000480012; ENSG00000128271.
DR   Ensembl; ENST00000611543; ENSP00000483102; ENSG00000128271.
DR   Ensembl; ENST00000618076; ENSP00000481552; ENSG00000128271.
DR   GeneID; 135; -.
DR   KEGG; hsa:135; -.
DR   CTD; 135; -.
DR   DisGeNET; 135; -.
DR   EuPathDB; HostDB:ENSG00000128271.20; -.
DR   EuPathDB; HostDB:ENSG00000258555.5; -.
DR   GeneCards; ADORA2A; -.
DR   HGNC; HGNC:263; ADORA2A.
DR   HPA; ENSG00000128271; Group enriched (blood, bone marrow, brain, lymphoid tissue).
DR   MalaCards; ADORA2A; -.
DR   MIM; 102776; gene.
DR   neXtProt; NX_P29274; -.
DR   OpenTargets; ENSG00000128271; -.
DR   Orphanet; 363549; Acute encephalopathy with biphasic seizures and late reduced diffusion.
DR   PharmGKB; PA24584; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00990000203617; -.
DR   InParanoid; P29274; -.
DR   KO; K04266; -.
DR   OMA; IHRDPEK; -.
DR   OrthoDB; 550297at2759; -.
DR   TreeFam; TF325296; -.
DR   PathwayCommons; P29274; -.
DR   Reactome; R-HSA-187024; NGF-independant TRKA activation.
DR   Reactome; R-HSA-417973; Adenosine P1 receptors.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-5683826; Surfactant metabolism.
DR   Reactome; R-HSA-9660821; ADORA2B mediated anti-inflammatory cytokines production.
DR   SIGNOR; P29274; -.
DR   BioGRID-ORCS; 135; 7 hits in 872 CRISPR screens.
DR   EvolutionaryTrace; P29274; -.
DR   GeneWiki; Adenosine_A2A_receptor; -.
DR   GenomeRNAi; 135; -.
DR   Pharos; P29274; Tclin.
DR   PRO; PR:P29274; -.
DR   Proteomes; UP000005640; Chromosome 22.
DR   RNAct; P29274; protein.
DR   Bgee; ENSG00000128271; Expressed in cerebellum and 114 other tissues.
DR   ExpressionAtlas; P29274; baseline and differential.
DR   Genevisible; P29274; HS.
DR   GO; GO:0030673; C:axolemma; IEA:Ensembl.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; IMP:UniProtKB.
DR   GO; GO:0099055; C:integral component of postsynaptic membrane; IEA:Ensembl.
DR   GO; GO:0099056; C:integral component of presynaptic membrane; IEA:Ensembl.
DR   GO; GO:0005882; C:intermediate filament; IEA:Ensembl.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0014069; C:postsynaptic density; IEA:Ensembl.
DR   GO; GO:0048786; C:presynaptic active zone; IEA:Ensembl.
DR   GO; GO:0051393; F:alpha-actinin binding; IEA:Ensembl.
DR   GO; GO:0019899; F:enzyme binding; IPI:UniProtKB.
DR   GO; GO:0001609; F:G protein-coupled adenosine receptor activity; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl.
DR   GO; GO:0031802; F:type 5 metabotropic glutamate receptor binding; IEA:Ensembl.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007188; P:adenylate cyclase-modulating G protein-coupled receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0006915; P:apoptotic process; TAS:ProtInc.
DR   GO; GO:0048143; P:astrocyte activation; IEA:Ensembl.
DR   GO; GO:0008015; P:blood circulation; TAS:ProtInc.
DR   GO; GO:0007596; P:blood coagulation; TAS:ProtInc.
DR   GO; GO:0007267; P:cell-cell signaling; TAS:ProtInc.
DR   GO; GO:0006968; P:cellular defense response; TAS:ProtInc.
DR   GO; GO:0044267; P:cellular protein metabolic process; TAS:Reactome.
DR   GO; GO:0007417; P:central nervous system development; TAS:ProtInc.
DR   GO; GO:0042755; P:eating behavior; IEA:Ensembl.
DR   GO; GO:0060079; P:excitatory postsynaptic potential; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006954; P:inflammatory response; TAS:ProtInc.
DR   GO; GO:0060080; P:inhibitory postsynaptic potential; IEA:Ensembl.
DR   GO; GO:0007626; P:locomotory behavior; IEA:Ensembl.
DR   GO; GO:0051899; P:membrane depolarization; IEA:Ensembl.
DR   GO; GO:0046636; P:negative regulation of alpha-beta T cell activation; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0043154; P:negative regulation of cysteine-type endopeptidase activity involved in apoptotic process; IEA:Ensembl.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IEA:Ensembl.
DR   GO; GO:0040013; P:negative regulation of locomotion; IEA:Ensembl.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; IEA:Ensembl.
DR   GO; GO:0043116; P:negative regulation of vascular permeability; IEA:Ensembl.
DR   GO; GO:0048812; P:neuron projection morphogenesis; IEA:Ensembl.
DR   GO; GO:0006909; P:phagocytosis; TAS:ProtInc.
DR   GO; GO:0014057; P:positive regulation of acetylcholine secretion, neurotransmission; IEA:Ensembl.
DR   GO; GO:2001235; P:positive regulation of apoptotic signaling pathway; IEA:Ensembl.
DR   GO; GO:0045938; P:positive regulation of circadian sleep/wake cycle, sleep; IEA:Ensembl.
DR   GO; GO:0014049; P:positive regulation of glutamate secretion; IEA:Ensembl.
DR   GO; GO:1900273; P:positive regulation of long-term synaptic potentiation; IEA:Ensembl.
DR   GO; GO:0050714; P:positive regulation of protein secretion; IEA:Ensembl.
DR   GO; GO:0035815; P:positive regulation of renal sodium excretion; IEA:Ensembl.
DR   GO; GO:0032230; P:positive regulation of synaptic transmission, GABAergic; IEA:Ensembl.
DR   GO; GO:0051968; P:positive regulation of synaptic transmission, glutamatergic; IEA:Ensembl.
DR   GO; GO:0035810; P:positive regulation of urine volume; IEA:Ensembl.
DR   GO; GO:0060134; P:prepulse inhibition; IEA:Ensembl.
DR   GO; GO:0007205; P:protein kinase C-activating G protein-coupled receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0051924; P:regulation of calcium ion transport; IEA:Ensembl.
DR   GO; GO:0051881; P:regulation of mitochondrial membrane potential; IEA:Ensembl.
DR   GO; GO:0014061; P:regulation of norepinephrine secretion; IEA:Ensembl.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:Ensembl.
DR   GO; GO:0001975; P:response to amphetamine; IEA:Ensembl.
DR   GO; GO:0031000; P:response to caffeine; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0007600; P:sensory perception; TAS:ProtInc.
DR   GO; GO:0007271; P:synaptic transmission, cholinergic; IEA:Ensembl.
DR   GO; GO:0001963; P:synaptic transmission, dopaminergic; IEA:Ensembl.
DR   GO; GO:0035249; P:synaptic transmission, glutamatergic; IEA:Ensembl.
DR   GO; GO:0042311; P:vasodilation; IEA:Ensembl.
DR   DisProt; DP01547; -.
DR   InterPro; IPR001513; Adeno_A2A_rcpt.
DR   InterPro; IPR001634; Adenosn_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00553; ADENOSINA2AR.
DR   PRINTS; PR00424; ADENOSINER.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Membrane; Polymorphism; Receptor; Reference proteome;
KW   Transducer; Transmembrane; Transmembrane helix; Ubl conjugation.
FT   CHAIN           1..412
FT                   /note="Adenosine receptor A2a"
FT                   /id="PRO_0000068999"
FT   TOPO_DOM        1..7
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:18832607"
FT   TRANSMEM        8..32
FT                   /note="Helical; Name=1"
FT   TOPO_DOM        33..42
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:18832607"
FT   TRANSMEM        43..66
FT                   /note="Helical; Name=2"
FT   TOPO_DOM        67..77
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:18832607"
FT   TRANSMEM        78..100
FT                   /note="Helical; Name=3"
FT   TOPO_DOM        101..120
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:18832607"
FT   TRANSMEM        121..143
FT                   /note="Helical; Name=4"
FT   TOPO_DOM        144..173
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:18832607"
FT   TRANSMEM        174..198
FT                   /note="Helical; Name=5"
FT   TOPO_DOM        199..234
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:18832607"
FT   TRANSMEM        235..258
FT                   /note="Helical; Name=6"
FT   TOPO_DOM        259..266
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:18832607"
FT   TRANSMEM        267..290
FT                   /note="Helical; Name=7"
FT   TOPO_DOM        291..412
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:18832607"
FT   REGION          168..177
FT                   /note="Agonist binding"
FT   REGION          246..253
FT                   /note="Agonist binding"
FT   REGION          264..274
FT                   /note="Agonist binding"
FT   CARBOHYD        154
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        71..159
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521,
FT                   ECO:0000269|PubMed:18832607"
FT   DISULFID        74..146
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521,
FT                   ECO:0000269|PubMed:18832607"
FT   DISULFID        77..166
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521,
FT                   ECO:0000269|PubMed:18832607"
FT   DISULFID        259..262
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521,
FT                   ECO:0000269|PubMed:18832607"
FT   VARIANT         50
FT                   /note="A -> V (in dbSNP:rs4530)"
FT                   /evidence="ECO:0000269|PubMed:10391209"
FT                   /id="VAR_011835"
FT   VARIANT         300
FT                   /note="R -> H (in dbSNP:rs4990)"
FT                   /id="VAR_011836"
FT   VARIANT         392
FT                   /note="G -> R (in dbSNP:rs1277013918)"
FT                   /id="VAR_003451"
FT   HELIX           2..33
FT                   /evidence="ECO:0000244|PDB:5NM4"
FT   HELIX           35..37
FT                   /evidence="ECO:0000244|PDB:5NM4"
FT   HELIX           40..57
FT                   /evidence="ECO:0000244|PDB:5NM4"
FT   HELIX           59..67
FT                   /evidence="ECO:0000244|PDB:5NM4"
FT   STRAND          71..73
FT                   /evidence="ECO:0000244|PDB:5NM4"
FT   HELIX           74..107
FT                   /evidence="ECO:0000244|PDB:5NM4"
FT   HELIX           109..115
FT                   /evidence="ECO:0000244|PDB:5NM4"
FT   HELIX           118..136
FT                   /evidence="ECO:0000244|PDB:5NM4"
FT   HELIX           138..141
FT                   /evidence="ECO:0000244|PDB:5NM4"
FT   STRAND          144..148
FT                   /evidence="ECO:0000244|PDB:5JTB"
FT   HELIX           151..157
FT                   /evidence="ECO:0000244|PDB:5NM4"
FT   STRAND          163..165
FT                   /evidence="ECO:0000244|PDB:5NM4"
FT   HELIX           168..171
FT                   /evidence="ECO:0000244|PDB:5NM4"
FT   HELIX           174..179
FT                   /evidence="ECO:0000244|PDB:5NM4"
FT   HELIX           182..185
FT                   /evidence="ECO:0000244|PDB:5NM4"
FT   HELIX           187..208
FT                   /evidence="ECO:0000244|PDB:5NM4"
FT   STRAND          213..216
FT                   /evidence="ECO:0000244|PDB:3VGA"
FT   HELIX           219..258
FT                   /evidence="ECO:0000244|PDB:5NM4"
FT   STRAND          260..262
FT                   /evidence="ECO:0000244|PDB:2YDV"
FT   HELIX           267..291
FT                   /evidence="ECO:0000244|PDB:5NM4"
FT   HELIX           293..303
FT                   /evidence="ECO:0000244|PDB:5NM4"
FT   TURN            304..307
FT                   /evidence="ECO:0000244|PDB:3QAK"
FT   TURN            308..310
FT                   /evidence="ECO:0000244|PDB:2YDV"
FT   HELIX           312..317
FT                   /evidence="ECO:0000244|PDB:2YDV"
SQ   SEQUENCE   412 AA;  44707 MW;  9438E9D64A6BE61B CRC64;
     MPIMGSSVYI TVELAIAVLA ILGNVLVCWA VWLNSNLQNV TNYFVVSLAA ADIAVGVLAI
     PFAITISTGF CAACHGCLFI ACFVLVLTQS SIFSLLAIAI DRYIAIRIPL RYNGLVTGTR
     AKGIIAICWV LSFAIGLTPM LGWNNCGQPK EGKNHSQGCG EGQVACLFED VVPMNYMVYF
     NFFACVLVPL LLMLGVYLRI FLAARRQLKQ MESQPLPGER ARSTLQKEVH AAKSLAIIVG
     LFALCWLPLH IINCFTFFCP DCSHAPLWLM YLAIVLSHTN SVVNPFIYAY RIREFRQTFR
     KIIRSHVLRQ QEPFKAAGTS ARVLAAHGSD GEQVSLRLNG HPPGVWANGS APHPERRPNG
     YALGLVSGGS AQESQGNTGL PDVELLSHEL KGVCPEPPGL DDPLAQDGAG VS
//
ID   P2RY4_HUMAN             Reviewed;         365 AA.
AC   P51582; Q4VBB7; Q4VBB8; Q502W2; Q5JT22;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   07-OCT-2020, entry version 169.
DE   RecName: Full=P2Y purinoceptor 4;
DE            Short=P2Y4;
DE   AltName: Full=P2P;
DE   AltName: Full=Uridine nucleotide receptor;
DE            Short=UNR;
GN   Name=P2RY4; Synonyms=NRU;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8537336; DOI=10.1074/jbc.270.52.30849;
RA   Communi D., Pirotton S., Parmentier M., Boeynaems J.-M.;
RT   "Cloning and functional expression of a human uridine nucleotide
RT   receptor.";
RL   J. Biol. Chem. 270:30849-30852(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS THR-178 AND ALA-234.
RX   PubMed=8537335; DOI=10.1074/jbc.270.52.30845;
RA   Nguyen T., Erb L., Weisman G.A., Marchese A., Heng H.H.Q., Garrad R.C.,
RA   George S.R., Turner J.T., O'Dowd B.F.;
RT   "Cloning, expression, and chromosomal localization of the human uridine
RT   nucleotide receptor gene.";
RL   J. Biol. Chem. 270:30845-30848(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Pancreas;
RX   PubMed=8617367; DOI=10.1016/0014-5793(96)00321-3;
RA   Stam N.J., Klomp J., van der Heuvel M., Olijve W.;
RT   "Molecular cloning and characterization of a novel orphan receptor (P2P)
RT   expressed in human pancreas that shows high structural homology to the P2U
RT   purinoceptor.";
RL   FEBS Lett. 384:260-264(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT THR-178.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   PHOSPHORYLATION AT SER-333 AND SER-334, AND MUTAGENESIS OF SER-243;
RP   SER-333; SER-334 AND SER-339.
RX   PubMed=11114308; DOI=10.1074/jbc.m009909200;
RA   Brinson A.E., Harden T.K.;
RT   "Differential regulation of the uridine nucleotide-activated P2Y4 and P2Y6
RT   receptors. Ser-333 and Ser-334 in the carboxyl terminus are involved in
RT   agonist-dependent phosphorylation desensitization and internalization of
RT   the P2Y4 receptor.";
RL   J. Biol. Chem. 276:11939-11948(2001).
CC   -!- FUNCTION: Receptor for UTP and UDP coupled to G-proteins that activate
CC       a phosphatidylinositol-calcium second messenger system. Not activated
CC       by ATP or ADP.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Pancreas.
CC   -!- PTM: Phosphorylation of Ser-333 and Ser-334 is a key step in agonist-
CC       dependent desensitization and loss of surface P2RY4. This
CC       phosphorylation does not involve PKC, nor other calcium activated
CC       kinases. {ECO:0000269|PubMed:11114308}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X91852; CAA62963.1; -; Genomic_DNA.
DR   EMBL; U40223; AAC50347.1; -; Genomic_DNA.
DR   EMBL; X96597; CAA65415.1; -; Genomic_DNA.
DR   EMBL; AL357752; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC095503; AAH95503.1; -; mRNA.
DR   EMBL; BC096067; AAH96067.1; -; mRNA.
DR   EMBL; BC096068; AAH96068.1; -; mRNA.
DR   EMBL; BC096069; AAH96069.1; -; mRNA.
DR   EMBL; BC096070; AAH96070.1; -; mRNA.
DR   CCDS; CCDS14398.1; -.
DR   PIR; S68679; S68679.
DR   RefSeq; NP_002556.1; NM_002565.3.
DR   PDB; 2B6Q; Model; -; A=1-365.
DR   PDBsum; 2B6Q; -.
DR   IntAct; P51582; 1.
DR   STRING; 9606.ENSP00000363643; -.
DR   BindingDB; P51582; -.
DR   ChEMBL; CHEMBL2123; -.
DR   DrugBank; DB01069; Promethazine.
DR   DrugCentral; P51582; -.
DR   GuidetoPHARMACOLOGY; 325; -.
DR   iPTMnet; P51582; -.
DR   PhosphoSitePlus; P51582; -.
DR   BioMuta; P2RY4; -.
DR   DMDM; 1709524; -.
DR   PaxDb; P51582; -.
DR   PeptideAtlas; P51582; -.
DR   PRIDE; P51582; -.
DR   ProteomicsDB; 56339; -.
DR   Antibodypedia; 13260; 274 antibodies.
DR   Ensembl; ENST00000374519; ENSP00000363643; ENSG00000186912.
DR   GeneID; 5030; -.
DR   KEGG; hsa:5030; -.
DR   UCSC; uc004dxz.2; human.
DR   CTD; 5030; -.
DR   DisGeNET; 5030; -.
DR   EuPathDB; HostDB:ENSG00000186912.6; -.
DR   GeneCards; P2RY4; -.
DR   HGNC; HGNC:8542; P2RY4.
DR   HPA; ENSG00000186912; Tissue enriched (intestine).
DR   MIM; 300038; gene.
DR   neXtProt; NX_P51582; -.
DR   OpenTargets; ENSG00000186912; -.
DR   PharmGKB; PA32871; -.
DR   eggNOG; ENOG502QSTF; Eukaryota.
DR   GeneTree; ENSGT00960000186584; -.
DR   HOGENOM; CLU_009579_8_2_1; -.
DR   InParanoid; P51582; -.
DR   KO; K04271; -.
DR   OMA; TLCHDTT; -.
DR   OrthoDB; 1077455at2759; -.
DR   PhylomeDB; P51582; -.
DR   TreeFam; TF350009; -.
DR   PathwayCommons; P51582; -.
DR   Reactome; R-HSA-417957; P2Y receptors.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   SIGNOR; P51582; -.
DR   BioGRID-ORCS; 5030; 3 hits in 493 CRISPR screens.
DR   GeneWiki; P2RY4; -.
DR   GenomeRNAi; 5030; -.
DR   Pharos; P51582; Tchem.
DR   PRO; PR:P51582; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; P51582; protein.
DR   Bgee; ENSG00000186912; Expressed in small intestine and 41 other tissues.
DR   Genevisible; P51582; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0016323; C:basolateral plasma membrane; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0099059; C:integral component of presynaptic active zone membrane; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:Ensembl.
DR   GO; GO:0045028; F:G protein-coupled purinergic nucleotide receptor activity; IEA:InterPro.
DR   GO; GO:0045030; F:G protein-coupled UTP receptor activity; TAS:GO_Central.
DR   GO; GO:0071318; P:cellular response to ATP; TAS:ARUK-UCL.
DR   GO; GO:0071380; P:cellular response to prostaglandin E stimulus; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; TAS:ProtInc.
DR   GO; GO:0030321; P:transepithelial chloride transport; IEA:Ensembl.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR000018; P2Y4.
DR   PANTHER; PTHR24231:SF21; PTHR24231:SF21; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01066; P2Y4PRNOCPTR.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Membrane; Phosphoprotein; Polymorphism; Receptor; Reference proteome;
KW   Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..365
FT                   /note="P2Y purinoceptor 4"
FT                   /id="PRO_0000070020"
FT   TOPO_DOM        1..34
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        35..61
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        62..72
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        73..95
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        96..112
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        113..131
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        132..154
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        155..174
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        175..196
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        197..222
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        223..246
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        247..269
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        270..287
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        288..309
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        310..365
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         333
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000305|PubMed:11114308"
FT   MOD_RES         334
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000305|PubMed:11114308"
FT   DISULFID        108..185
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VARIANT         168
FT                   /note="V -> M (in dbSNP:rs1152186)"
FT                   /id="VAR_011854"
FT   VARIANT         178
FT                   /note="N -> T (in dbSNP:rs1152187)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:8537335"
FT                   /id="VAR_011855"
FT   VARIANT         191
FT                   /note="P -> L (in dbSNP:rs1152188)"
FT                   /id="VAR_011856"
FT   VARIANT         234
FT                   /note="S -> A (in dbSNP:rs3829709)"
FT                   /evidence="ECO:0000269|PubMed:8537335"
FT                   /id="VAR_049429"
FT   MUTAGEN         243
FT                   /note="S->A: No effect."
FT                   /evidence="ECO:0000269|PubMed:11114308"
FT   MUTAGEN         333..365
FT                   /note="Missing: Abolishes agonist-induced phosphorylation.
FT                   Prevents agonist-induced desensitization and loss of cell
FT                   surface receptors."
FT   MUTAGEN         333..359
FT                   /note="SSLALVSLPEDSSCRWAATPQDSSCST->AALALVALPEDAACRWAAAPQDA
FT                   ACAA: Greatly reduces agonist-induced desensitization and
FT                   loss of cell surface receptors."
FT   MUTAGEN         333
FT                   /note="S->A: Greatly reduces agonist-induced
FT                   desensitization and loss of cell surface receptors; when
FT                   associated with A-334 and A-339."
FT                   /evidence="ECO:0000269|PubMed:11114308"
FT   MUTAGEN         334
FT                   /note="S->A: Greatly reduces agonist-induced
FT                   desensitization and loss of cell surface receptors; when
FT                   associated with A-333 and A-339."
FT                   /evidence="ECO:0000269|PubMed:11114308"
FT   MUTAGEN         339
FT                   /note="S->A: Greatly reduces agonist-induced
FT                   desensitization and loss of cell surface receptors; when
FT                   associated with A-333 and A-334."
FT                   /evidence="ECO:0000269|PubMed:11114308"
FT   MUTAGEN         344..365
FT                   /note="Missing: No effect on agonist-induced
FT                   phosphorylation, no functional effect."
FT   MUTAGEN         356..365
FT                   /note="Missing: No functional effect."
FT   CONFLICT        86
FT                   /note="L -> V (in Ref. 2; AAC50347)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        121
FT                   /note="C -> S (in Ref. 5; AAH96068)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        247
FT                   /note="I -> V (in Ref. 5; AAH96069)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        352
FT                   /note="P -> T (in Ref. 5; AAH96069)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   365 AA;  40963 MW;  23E0AFED3B7BDEED CRC64;
     MASTESSLLR SLGLSPGPGS SEVELDCWFD EDFKFILLPV SYAVVFVLGL GLNAPTLWLF
     IFRLRPWDAT ATYMFHLALS DTLYVLSLPT LIYYYAAHNH WPFGTEICKF VRFLFYWNLY
     CSVLFLTCIS VHRYLGICHP LRALRWGRPR LAGLLCLAVW LVVAGCLVPN LFFVTTSNKG
     TTVLCHDTTR PEEFDHYVHF SSAVMGLLFG VPCLVTLVCY GLMARRLYQP LPGSAQSSSR
     LRSLRTIAVV LTVFAVCFVP FHITRTIYYL ARLLEADCRV LNIVNVVYKV TRPLASANSC
     LDPVLYLLTG DKYRRQLRQL CGGGKPQPRT AASSLALVSL PEDSSCRWAA TPQDSSCSTP
     RADRL
//
ID   S1PR1_HUMAN             Reviewed;         382 AA.
AC   P21453; D3DT66; Q9BYY4; Q9NYN8;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   02-SEP-2008, sequence version 2.
DT   07-OCT-2020, entry version 200.
DE   RecName: Full=Sphingosine 1-phosphate receptor 1;
DE            Short=S1P receptor 1;
DE            Short=S1P1;
DE   AltName: Full=Endothelial differentiation G-protein coupled receptor 1;
DE   AltName: Full=Sphingosine 1-phosphate receptor Edg-1;
DE            Short=S1P receptor Edg-1;
DE   AltName: CD_antigen=CD363;
GN   Name=S1PR1; Synonyms=CHEDG1, EDG1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Umbilical vein endothelial cell;
RX   PubMed=2160972;
RA   Hla T., Maciag T.;
RT   "An abundant transcript induced in differentiating human endothelial cells
RT   encodes a polypeptide with structural similarities to G-protein-coupled
RT   receptors.";
RL   J. Biol. Chem. 265:9308-9313(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lung;
RX   PubMed=9409733; DOI=10.1016/s0014-5793(97)01301-x;
RA   An S., Bleu T., Huang W., Hallmark O.G., Coughlin S.R., Goetzl E.J.;
RT   "Identification of cDNAs encoding two G protein-coupled receptors for
RT   lysosphingolipids.";
RL   FEBS Lett. 417:279-282(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS
RP   OF ARG-120; GLU-121 AND ARG-292.
RX   PubMed=10982820; DOI=10.1074/jbc.m007680200;
RA   Parrill A.L., Wang D., Bautista D.L., Van Brocklyn J.R., Lorincz Z.,
RA   Fischer D.J., Baker D.L., Liliom K., Spiegel S., Tigyi G.;
RT   "Identification of Edg1 receptor residues that recognize sphingosine 1-
RT   phosphate.";
RL   J. Biol. Chem. 275:39379-39384(2000).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Substantia nigra;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S., Neubert P.,
RA   Kstrang K., Schatten R., Shen B., Henze S., Mar W., Korn B., Zuo D., Hu Y.,
RA   LaBaer J.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH GNAI1 AND GNAI3.
RX   PubMed=8626678; DOI=10.1074/jbc.271.19.11272;
RA   Lee M.-J., Evans M., Hla T.;
RT   "The inducible G protein-coupled receptor edg-1 signals via the
RT   G(i)/mitogen-activated protein kinase pathway.";
RL   J. Biol. Chem. 271:11272-11279(1996).
RN   [10]
RP   FUNCTION.
RX   PubMed=9488656; DOI=10.1126/science.279.5356.1552;
RA   Lee M.-J., Van Brocklyn J.R., Thangada S., Liu C.H., Hand A.R.,
RA   Menzeleev R., Spiegel S., Hla T.;
RT   "Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor
RT   EDG-1.";
RL   Science 279:1552-1555(1998).
RN   [11]
RP   PHARMACOLOGICAL CHARACTERIZATION.
RX   PubMed=10383399; DOI=10.1074/jbc.274.27.18997;
RA   Ancellin N., Hla T.;
RT   "Differential pharmacological properties and signal transduction of the
RT   sphingosine 1-phosphate receptors EDG-1, EDG-3, and EDG-5.";
RL   J. Biol. Chem. 274:18997-19002(1999).
RN   [12]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=11604399; DOI=10.1074/jbc.m107301200;
RA   Wang D.A., Lorincz Z., Bautista D.L., Liliom K., Tigyi G., Parrill A.L.;
RT   "A single amino acid determines lysophospholipid specificity of the S1P1
RT   (EDG1) and LPA1 (EDG2) phospholipid growth factor receptors.";
RL   J. Biol. Chem. 276:49213-49220(2001).
RN   [13]
RP   FUNCTION IN CHEMOTAXIS, PHOSPHORYLATION AT THR-236, AND MUTAGENESIS OF
RP   THR-236.
RX   PubMed=11583630; DOI=10.1016/s1097-2765(01)00324-0;
RA   Lee M.-J., Thangada S., Paik J.-H., Sapkota G.P., Ancellin N., Chae S.-S.,
RA   Wu M., Morales-Ruiz M., Sessa W.C., Alessi D.R., Hla T.;
RT   "Akt-mediated phosphorylation of the G protein-coupled receptor EDG-1 is
RT   required for endothelial cell chemotaxis.";
RL   Mol. Cell 8:693-704(2001).
RN   [14]
RP   FUNCTION.
RX   PubMed=11230698; DOI=10.1126/science.1057559;
RA   Hobson J.P., Rosenfeldt H.M., Barak L.S., Olivera A., Poulton S.,
RA   Caron M.G., Milstien S., Spiegel S.;
RT   "Role of the sphingosine-1-phosphate receptor EDG-1 in PDGF-induced cell
RT   motility.";
RL   Science 291:1800-1803(2001).
RN   [15]
RP   SUBCELLULAR LOCATION, TOPOLOGY, AND GLYCOSYLATION AT ASN-30.
RX   PubMed=15750791; DOI=10.1007/s10719-004-5540-8;
RA   Kohno T., Igarashi Y.;
RT   "Roles for N-glycosylation in the dynamics of Edg-1/S1P1 in sphingosine 1-
RT   phosphate-stimulated cells.";
RL   Glycoconj. J. 21:497-501(2004).
RN   [16]
RP   FUNCTION, PHOSPHORYLATION, AND SUBCELLULAR LOCATION.
RX   PubMed=19286607; DOI=10.1161/circresaha.108.193367;
RA   Singleton P.A., Chatchavalvanich S., Fu P., Xing J., Birukova A.A.,
RA   Fortune J.A., Klibanov A.M., Garcia J.G., Birukov K.G.;
RT   "Akt-mediated transactivation of the S1P1 receptor in caveolin-enriched
RT   microdomains regulates endothelial barrier enhancement by oxidized
RT   phospholipids.";
RL   Circ. Res. 104:978-986(2009).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 2-326 IN COMPLEX WITH SPHINGOLIPID
RP   ANALOG, FUNCTION, SUBCELLULAR LOCATION, MEMBRANE TOPOLOGY, MUTAGENESIS OF
RP   PHE-210; PHE-265 AND TRP-269, GLYCOSYLATION AT ASN-30, AND DISULFIDE BONDS.
RX   PubMed=22344443; DOI=10.1126/science.1215904;
RA   Hanson M.A., Roth C.B., Jo E., Griffith M.T., Scott F.L., Reinhart G.,
RA   Desale H., Clemons B., Cahalan S.M., Schuerer S.C., Sanna M.G., Han G.W.,
RA   Kuhn P., Rosen H., Stevens R.C.;
RT   "Crystal structure of a lipid G protein-coupled receptor.";
RL   Science 335:851-855(2012).
CC   -!- FUNCTION: G-protein coupled receptor for the bioactive lysosphingolipid
CC       sphingosine 1-phosphate (S1P) that seems to be coupled to the G(i)
CC       subclass of heteromeric G proteins. Signaling leads to the activation
CC       of RAC1, SRC, PTK2/FAK1 and MAP kinases. Plays an important role in
CC       cell migration, probably via its role in the reorganization of the
CC       actin cytoskeleton and the formation of lamellipodia in response to
CC       stimuli that increase the activity of the sphingosine kinase SPHK1.
CC       Required for normal chemotaxis toward sphingosine 1-phosphate. Required
CC       for normal embryonic heart development and normal cardiac
CC       morphogenesis. Plays an important role in the regulation of sprouting
CC       angiogenesis and vascular maturation. Inhibits sprouting angiogenesis
CC       to prevent excessive sprouting during blood vessel development.
CC       Required for normal egress of mature T-cells from the thymus into the
CC       blood stream and into peripheral lymphoid organs. Plays a role in the
CC       migration of osteoclast precursor cells, the regulation of bone
CC       mineralization and bone homeostasis (By similarity). Plays a role in
CC       responses to oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-
CC       phosphocholine by pulmonary endothelial cells and in the protection
CC       against ventilator-induced lung injury. {ECO:0000250,
CC       ECO:0000269|PubMed:10982820, ECO:0000269|PubMed:11230698,
CC       ECO:0000269|PubMed:11583630, ECO:0000269|PubMed:11604399,
CC       ECO:0000269|PubMed:19286607, ECO:0000269|PubMed:22344443,
CC       ECO:0000269|PubMed:8626678, ECO:0000269|PubMed:9488656}.
CC   -!- SUBUNIT: Interacts with GNAI1 and GNAI3. {ECO:0000269|PubMed:22344443,
CC       ECO:0000269|PubMed:8626678}.
CC   -!- INTERACTION:
CC       P21453; Q07108: CD69; NbExp=2; IntAct=EBI-2681920, EBI-2836595;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC       Endosome. Membrane raft. Note=Recruited to caveolin-enriched plasma
CC       membrane microdomains in response to oxidized 1-palmitoyl-2-
CC       arachidonoyl-sn-glycero-3-phosphocholine. Ligand binding leads to
CC       receptor internalization.
CC   -!- TISSUE SPECIFICITY: Endothelial cells, and to a lesser extent, in
CC       vascular smooth muscle cells, fibroblasts, melanocytes, and cells of
CC       epithelioid origin.
CC   -!- INDUCTION: By the tumor promoter phorbol 12-myristate 13-acetate (PMA)
CC       in the presence of cycloheximide.
CC   -!- PTM: S1P-induced endothelial cell migration requires the PKB/AKT1-
CC       mediated phosphorylation of the third intracellular loop at the Thr-236
CC       residue. {ECO:0000269|PubMed:11583630, ECO:0000269|PubMed:19286607}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M31210; AAA52336.1; -; mRNA.
DR   EMBL; AF022137; AAC51905.1; -; mRNA.
DR   EMBL; AF233365; AAF43420.1; -; mRNA.
DR   EMBL; AK312493; BAG35395.1; -; mRNA.
DR   EMBL; CR541786; CAG46585.1; -; mRNA.
DR   EMBL; CR542269; CAG47065.1; -; mRNA.
DR   EMBL; AL109741; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471097; EAW72927.1; -; Genomic_DNA.
DR   EMBL; CH471097; EAW72928.1; -; Genomic_DNA.
DR   EMBL; BC018650; AAH18650.1; -; mRNA.
DR   CCDS; CCDS777.1; -.
DR   PIR; A35300; A35300.
DR   RefSeq; NP_001307659.1; NM_001320730.1.
DR   RefSeq; NP_001391.2; NM_001400.4.
DR   PDB; 3V2W; X-ray; 3.35 A; A=2-231, A=244-326.
DR   PDB; 3V2Y; X-ray; 2.80 A; A=2-231, A=244-326.
DR   PDBsum; 3V2W; -.
DR   PDBsum; 3V2Y; -.
DR   SMR; P21453; -.
DR   BioGRID; 108225; 30.
DR   CORUM; P21453; -.
DR   DIP; DIP-60427N; -.
DR   IntAct; P21453; 23.
DR   STRING; 9606.ENSP00000305416; -.
DR   BindingDB; P21453; -.
DR   ChEMBL; CHEMBL4333; -.
DR   DrugBank; DB09105; Asfotase alfa.
DR   DrugBank; DB08868; Fingolimod.
DR   DrugBank; DB12612; Ozanimod.
DR   DrugBank; DB12371; Siponimod.
DR   DrugCentral; P21453; -.
DR   GuidetoPHARMACOLOGY; 275; -.
DR   TCDB; 9.A.14.2.1; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; P21453; 2 sites.
DR   iPTMnet; P21453; -.
DR   PhosphoSitePlus; P21453; -.
DR   SwissPalm; P21453; -.
DR   BioMuta; S1PR1; -.
DR   DMDM; 205371820; -.
DR   EPD; P21453; -.
DR   jPOST; P21453; -.
DR   MassIVE; P21453; -.
DR   PaxDb; P21453; -.
DR   PeptideAtlas; P21453; -.
DR   PRIDE; P21453; -.
DR   ProteomicsDB; 53871; -.
DR   Antibodypedia; 4111; 731 antibodies.
DR   DNASU; 1901; -.
DR   Ensembl; ENST00000305352; ENSP00000305416; ENSG00000170989.
DR   Ensembl; ENST00000475289; ENSP00000498038; ENSG00000170989.
DR   Ensembl; ENST00000648480; ENSP00000497478; ENSG00000170989.
DR   Ensembl; ENST00000649383; ENSP00000497175; ENSG00000170989.
DR   GeneID; 1901; -.
DR   KEGG; hsa:1901; -.
DR   UCSC; uc001dud.3; human.
DR   CTD; 1901; -.
DR   DisGeNET; 1901; -.
DR   EuPathDB; HostDB:ENSG00000170989.8; -.
DR   GeneCards; S1PR1; -.
DR   HGNC; HGNC:3165; S1PR1.
DR   HPA; ENSG00000170989; Tissue enhanced (blood).
DR   MIM; 601974; gene.
DR   neXtProt; NX_P21453; -.
DR   OpenTargets; ENSG00000170989; -.
DR   PharmGKB; PA162402344; -.
DR   eggNOG; ENOG502QSFG; Eukaryota.
DR   GeneTree; ENSGT00970000193365; -.
DR   HOGENOM; CLU_047979_1_0_1; -.
DR   InParanoid; P21453; -.
DR   KO; K04288; -.
DR   OMA; CFIACWA; -.
DR   OrthoDB; 981486at2759; -.
DR   PhylomeDB; P21453; -.
DR   TreeFam; TF330052; -.
DR   PathwayCommons; P21453; -.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-419408; Lysosphingolipid and LPA receptors.
DR   Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling.
DR   Reactome; R-HSA-9679191; Potential therapeutics for SARS.
DR   SignaLink; P21453; -.
DR   SIGNOR; P21453; -.
DR   BioGRID-ORCS; 1901; 4 hits in 873 CRISPR screens.
DR   ChiTaRS; S1PR1; human.
DR   GeneWiki; S1PR1; -.
DR   GenomeRNAi; 1901; -.
DR   Pharos; P21453; Tclin.
DR   PRO; PR:P21453; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P21453; protein.
DR   Bgee; ENSG00000170989; Expressed in right lung and 200 other tissues.
DR   ExpressionAtlas; P21453; baseline and differential.
DR   Genevisible; P21453; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005768; C:endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0031226; C:intrinsic component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0001664; F:G protein-coupled receptor binding; IPI:UniProtKB.
DR   GO; GO:0046625; F:sphingolipid binding; IEA:Ensembl.
DR   GO; GO:0038036; F:sphingosine-1-phosphate receptor activity; IDA:UniProtKB.
DR   GO; GO:0031532; P:actin cytoskeleton reorganization; ISS:UniProtKB.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007193; P:adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0001525; P:angiogenesis; IBA:GO_Central.
DR   GO; GO:0001955; P:blood vessel maturation; ISS:UniProtKB.
DR   GO; GO:0007420; P:brain development; IEA:Ensembl.
DR   GO; GO:0003245; P:cardiac muscle tissue growth involved in heart morphogenesis; ISS:UniProtKB.
DR   GO; GO:0007155; P:cell adhesion; TAS:ProtInc.
DR   GO; GO:0016477; P:cell migration; ISS:UniProtKB.
DR   GO; GO:0006935; P:chemotaxis; ISS:UniProtKB.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0045446; P:endothelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0061384; P:heart trabecula morphogenesis; ISS:UniProtKB.
DR   GO; GO:0030032; P:lamellipodium assembly; ISS:UniProtKB.
DR   GO; GO:0030595; P:leukocyte chemotaxis; IEA:Ensembl.
DR   GO; GO:0051497; P:negative regulation of stress fiber assembly; IEA:Ensembl.
DR   GO; GO:0030182; P:neuron differentiation; IEA:Ensembl.
DR   GO; GO:0030335; P:positive regulation of cell migration; IEA:Ensembl.
DR   GO; GO:0051482; P:positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway; IEA:Ensembl.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; IEA:Ensembl.
DR   GO; GO:0050927; P:positive regulation of positive chemotaxis; IEA:Ensembl.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0030500; P:regulation of bone mineralization; ISS:UniProtKB.
DR   GO; GO:0045124; P:regulation of bone resorption; ISS:UniProtKB.
DR   GO; GO:0030155; P:regulation of cell adhesion; IEA:Ensembl.
DR   GO; GO:0019222; P:regulation of metabolic process; IBA:GO_Central.
DR   GO; GO:0003376; P:sphingosine-1-phosphate receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0072678; P:T cell migration; ISS:UniProtKB.
DR   GO; GO:0019226; P:transmission of nerve impulse; IEA:Ensembl.
DR   InterPro; IPR000987; EDG1_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR004061; S1P_rcpt.
DR   PANTHER; PTHR22750:SF16; PTHR22750:SF16; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01523; S1PRECEPTOR.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Angiogenesis; Cell membrane; Chemotaxis;
KW   Disulfide bond; Endosome; G-protein coupled receptor; Glycoprotein;
KW   Lipoprotein; Membrane; Palmitate; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..382
FT                   /note="Sphingosine 1-phosphate receptor 1"
FT                   /id="PRO_0000069412"
FT   TOPO_DOM        1..46
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:15750791"
FT   TRANSMEM        47..68
FT                   /note="Helical; Name=1"
FT   TOPO_DOM        69..82
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:15750791"
FT   TRANSMEM        83..104
FT                   /note="Helical; Name=2"
FT   TOPO_DOM        105..116
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:15750791"
FT   TRANSMEM        117..138
FT                   /note="Helical; Name=3"
FT   TOPO_DOM        139..160
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:15750791"
FT   TRANSMEM        161..182
FT                   /note="Helical; Name=4"
FT   TOPO_DOM        183..196
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:15750791"
FT   TRANSMEM        197..224
FT                   /note="Helical; Name=5"
FT   TOPO_DOM        225..257
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:15750791"
FT   TRANSMEM        258..278
FT                   /note="Helical; Name=6"
FT   TOPO_DOM        279..289
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:15750791"
FT   TRANSMEM        290..310
FT                   /note="Helical; Name=7"
FT   TOPO_DOM        311..382
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:15750791"
FT   REGION          120..121
FT                   /note="Sphingosine 1-phosphate binding"
FT   REGION          265..269
FT                   /note="Sphingosine 1-phosphate binding"
FT   MOD_RES         10
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:O08530"
FT   MOD_RES         236
FT                   /note="Phosphothreonine; by PKB/AKT1"
FT                   /evidence="ECO:0000269|PubMed:11583630"
FT   MOD_RES         351
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O08530"
FT   MOD_RES         353
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000255"
FT   LIPID           328
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        30
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:15750791,
FT                   ECO:0000269|PubMed:22344443"
FT   CARBOHYD        36
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        184..191
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521,
FT                   ECO:0000269|PubMed:22344443"
FT   DISULFID        282..287
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521,
FT                   ECO:0000269|PubMed:22344443"
FT   VARIANT         15
FT                   /note="S -> L (in dbSNP:rs4987250)"
FT                   /id="VAR_046158"
FT   VARIANT         115
FT                   /note="A -> T (in dbSNP:rs11542632)"
FT                   /id="VAR_046159"
FT   VARIANT         332
FT                   /note="P -> R (in dbSNP:rs7549921)"
FT                   /id="VAR_046160"
FT   MUTAGEN         120
FT                   /note="R->A: Drastically reduced affinity for sphingosine
FT                   1-phosphate."
FT                   /evidence="ECO:0000269|PubMed:10982820"
FT   MUTAGEN         121
FT                   /note="E->A: Drastically reduced affinity for sphingosine
FT                   1-phosphate."
FT                   /evidence="ECO:0000269|PubMed:10982820"
FT   MUTAGEN         121
FT                   /note="E->Q: Slight activation of the receptor at maximal
FT                   ligand concentration."
FT                   /evidence="ECO:0000269|PubMed:10982820"
FT   MUTAGEN         210
FT                   /note="F->L: Impairs sphingosine 1-phosphate binding and
FT                   signaling."
FT                   /evidence="ECO:0000269|PubMed:22344443"
FT   MUTAGEN         236
FT                   /note="T->A: Acts as a dominant negative GPCR and inhibits
FT                   S1P-induced Rac activation, chemotaxis, and angiogenesis."
FT                   /evidence="ECO:0000269|PubMed:11583630"
FT   MUTAGEN         265
FT                   /note="F->L: Impairs sphingosine 1-phosphate binding and
FT                   signaling."
FT                   /evidence="ECO:0000269|PubMed:22344443"
FT   MUTAGEN         269
FT                   /note="W->F,L: Impairs sphingosine 1-phosphate binding and
FT                   signaling."
FT                   /evidence="ECO:0000269|PubMed:22344443"
FT   MUTAGEN         292
FT                   /note="R->A,V: Drastically reduced affinity for sphingosine
FT                   1-phosphate."
FT                   /evidence="ECO:0000269|PubMed:10982820"
FT   CONFLICT        250..252
FT                   /note="KSL -> NV (in Ref. 1; AAA52336 and 2; AAC51905)"
FT                   /evidence="ECO:0000305"
FT   HELIX           23..31
FT                   /evidence="ECO:0000244|PDB:3V2Y"
FT   HELIX           36..39
FT                   /evidence="ECO:0000244|PDB:3V2Y"
FT   HELIX           42..72
FT                   /evidence="ECO:0000244|PDB:3V2Y"
FT   HELIX           74..76
FT                   /evidence="ECO:0000244|PDB:3V2W"
FT   HELIX           79..104
FT                   /evidence="ECO:0000244|PDB:3V2Y"
FT   HELIX           106..109
FT                   /evidence="ECO:0000244|PDB:3V2Y"
FT   HELIX           114..146
FT                   /evidence="ECO:0000244|PDB:3V2Y"
FT   HELIX           158..176
FT                   /evidence="ECO:0000244|PDB:3V2Y"
FT   TURN            177..181
FT                   /evidence="ECO:0000244|PDB:3V2Y"
FT   HELIX           188..190
FT                   /evidence="ECO:0000244|PDB:3V2Y"
FT   STRAND          193..195
FT                   /evidence="ECO:0000244|PDB:3V2Y"
FT   HELIX           200..231
FT                   /evidence="ECO:0000244|PDB:3V2Y"
FT   TURN            247..249
FT                   /evidence="ECO:0000244|PDB:3V2Y"
FT   HELIX           251..280
FT                   /evidence="ECO:0000244|PDB:3V2Y"
FT   TURN            284..286
FT                   /evidence="ECO:0000244|PDB:3V2Y"
FT   TURN            289..291
FT                   /evidence="ECO:0000244|PDB:3V2Y"
FT   HELIX           294..302
FT                   /evidence="ECO:0000244|PDB:3V2Y"
FT   HELIX           303..305
FT                   /evidence="ECO:0000244|PDB:3V2Y"
FT   HELIX           307..314
FT                   /evidence="ECO:0000244|PDB:3V2Y"
FT   HELIX           316..323
FT                   /evidence="ECO:0000244|PDB:3V2Y"
SQ   SEQUENCE   382 AA;  42811 MW;  0CCE8685A5E1BAD2 CRC64;
     MGPTSVPLVK AHRSSVSDYV NYDIIVRHYN YTGKLNISAD KENSIKLTSV VFILICCFII
     LENIFVLLTI WKTKKFHRPM YYFIGNLALS DLLAGVAYTA NLLLSGATTY KLTPAQWFLR
     EGSMFVALSA SVFSLLAIAI ERYITMLKMK LHNGSNNFRL FLLISACWVI SLILGGLPIM
     GWNCISALSS CSTVLPLYHK HYILFCTTVF TLLLLSIVIL YCRIYSLVRT RSRRLTFRKN
     ISKASRSSEK SLALLKTVII VLSVFIACWA PLFILLLLDV GCKVKTCDIL FRAEYFLVLA
     VLNSGTNPII YTLTNKEMRR AFIRIMSCCK CPSGDSAGKF KRPIIAGMEF SRSKSDNSSH
     PQKDEGDNPE TIMSSGNVNS SS
//
ID   PE2R4_HUMAN             Reviewed;         488 AA.
AC   P35408; Q3MJ87;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   12-AUG-2020, entry version 186.
DE   RecName: Full=Prostaglandin E2 receptor EP4 subtype;
DE            Short=PGE receptor EP4 subtype;
DE            Short=PGE2 receptor EP4 subtype;
DE   AltName: Full=Prostanoid EP4 receptor;
GN   Name=PTGER4; Synonyms=PTGER2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lung;
RX   PubMed=8163486;
RA   Bastien L., Sawyer N., Grygorczyk R., Metters K.M., Adam M.;
RT   "Cloning, functional expression, and characterization of the human
RT   prostaglandin E2 receptor EP2 subtype.";
RL   J. Biol. Chem. 269:11873-11877(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lung;
RX   PubMed=8250933; DOI=10.1006/bbrc.1993.2470;
RA   An S., Yang J., Xia M., Goetzl E.J.;
RT   "Cloning and expression of the EP2 subtype of human receptors for
RT   prostaglandin E2.";
RL   Biochem. Biophys. Res. Commun. 197:263-270(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8661119; DOI=10.1006/geno.1996.0337;
RA   Foord S.M., Marks B., Stolz M., Bufflier E., Fraser N.J., Lee M.G.;
RT   "The structure of the prostaglandin EP4 receptor gene and related
RT   pseudogenes.";
RL   Genomics 35:182-188(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lung;
RX   PubMed=8862514; DOI=10.1007/bf00207510;
RA   Mori K., Tanaka I., Kotani M., Miyaoka F., Sando T., Muro S., Sasaki Y.,
RA   Nakagawa O., Ogawa Y., Usui T., Ozaki S., Ichikawa A., Narumiya S.,
RA   Nakao K.;
RT   "Gene expression of the human prostaglandin E receptor EP4 subtype:
RT   differential regulation in monocytoid and lymphoid lineage cells by phorbol
RT   ester.";
RL   J. Mol. Med. 74:333-336(1996).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   SeattleSNPs variation discovery resource;
RL   Submitted (FEB-2006) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PHOSPHORYLATION.
RX   PubMed=11597569; DOI=10.1016/s0006-2952(01)00742-0;
RA   Slipetz D., Buchanan S., Mackereth C., Brewer N., Pellow V., Hao C.,
RA   Adam M., Abramovitz M., Metters K.M.;
RT   "Sequestration and phosphorylation of the prostaglandin E2 EP4 receptor:
RT   dependence on the C-terminal tail.";
RL   Biochem. Pharmacol. 62:997-1012(2001).
RN   [9]
RP   PHOSPHORYLATION AT SER-374; SER-377; SER-379 AND SER-382.
RX   PubMed=14709160; DOI=10.1042/bj20031820;
RA   Neuschafer-Rube F., Hermosilla R., Rehwald M., Ronnstrand L., Schulein R.,
RA   Wernstedt C., Puschel G.P.;
RT   "Identification of a Ser/Thr cluster in the C-terminal domain of the human
RT   prostaglandin receptor EP4 that is essential for agonist-induced beta-
RT   arrestin1 recruitment but differs from the apparent principal
RT   phosphorylation site.";
RL   Biochem. J. 379:573-585(2004).
RN   [10]
RP   INTERACTION WITH FEM1A.
RX   PubMed=16424369; DOI=10.1161/01.res.0000204451.88147.96;
RA   Takayama K., Sukhova G.K., Chin M.T., Libby P.;
RT   "A novel prostaglandin E receptor 4-associated protein participates in
RT   antiinflammatory signaling.";
RL   Circ. Res. 98:499-504(2006).
CC   -!- FUNCTION: Receptor for prostaglandin E2 (PGE2). The activity of this
CC       receptor is mediated by G(s) proteins that stimulate adenylate cyclase.
CC       Has a relaxing effect on smooth muscle. May play an important role in
CC       regulating renal hemodynamics, intestinal epithelial transport, adrenal
CC       aldosterone secretion, and uterine function.
CC   -!- SUBUNIT: Interacts with FEM1A. {ECO:0000269|PubMed:16424369}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: High in intestine and in peripheral blood
CC       mononuclear cells; low in lung, kidney, thymus, uterus, vasculature and
CC       brain. Not found in liver, heart, retina oe skeletal muscle.
CC   -!- PTM: Phosphorylation mediates agonist-mediated desensitization by
CC       promoting cytoplasmic retention. {ECO:0000269|PubMed:11597569,
CC       ECO:0000269|PubMed:14709160}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- CAUTION: Was originally designated as the EP2 subtype. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/ptger4/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L28175; AAA36434.1; -; mRNA.
DR   EMBL; L25124; AAA36438.1; -; mRNA.
DR   EMBL; X97873; CAA66463.1; -; Genomic_DNA.
DR   EMBL; X97874; CAA66463.1; JOINED; Genomic_DNA.
DR   EMBL; D28472; BAA05834.1; -; mRNA.
DR   EMBL; AY429109; AAR07904.1; -; mRNA.
DR   EMBL; DQ400918; ABD48960.1; -; Genomic_DNA.
DR   EMBL; BC101534; AAI01535.1; -; mRNA.
DR   EMBL; BC113523; AAI13524.1; -; mRNA.
DR   CCDS; CCDS3930.1; -.
DR   PIR; A53572; A53572.
DR   RefSeq; NP_000949.1; NM_000958.2.
DR   PDB; 5YHL; X-ray; 4.20 A; A=4-366.
DR   PDB; 5YWY; X-ray; 3.20 A; A=4-366.
DR   PDBsum; 5YHL; -.
DR   PDBsum; 5YWY; -.
DR   SMR; P35408; -.
DR   BioGRID; 111706; 6.
DR   DIP; DIP-61099N; -.
DR   IntAct; P35408; 43.
DR   MINT; P35408; -.
DR   STRING; 9606.ENSP00000302846; -.
DR   BindingDB; P35408; -.
DR   ChEMBL; CHEMBL1836; -.
DR   DrugBank; DB11113; Castor oil.
DR   DrugBank; DB00917; Dinoprostone.
DR   DrugBank; DB12836; Grapiprant.
DR   DrugBank; DB09211; Limaprost.
DR   DrugBank; DB00929; Misoprostol.
DR   DrugCentral; P35408; -.
DR   GuidetoPHARMACOLOGY; 343; -.
DR   GlyGen; P35408; 1 site.
DR   iPTMnet; P35408; -.
DR   PhosphoSitePlus; P35408; -.
DR   BioMuta; PTGER4; -.
DR   DMDM; 548476; -.
DR   jPOST; P35408; -.
DR   MassIVE; P35408; -.
DR   MaxQB; P35408; -.
DR   PaxDb; P35408; -.
DR   PeptideAtlas; P35408; -.
DR   PRIDE; P35408; -.
DR   ProteomicsDB; 55059; -.
DR   Antibodypedia; 2762; 354 antibodies.
DR   DNASU; 5734; -.
DR   Ensembl; ENST00000302472; ENSP00000302846; ENSG00000171522.
DR   GeneID; 5734; -.
DR   KEGG; hsa:5734; -.
DR   UCSC; uc003jlz.5; human.
DR   CTD; 5734; -.
DR   DisGeNET; 5734; -.
DR   EuPathDB; HostDB:ENSG00000171522.5; -.
DR   GeneCards; PTGER4; -.
DR   HGNC; HGNC:9596; PTGER4.
DR   HPA; ENSG00000171522; Tissue enhanced (pancreas).
DR   MIM; 601586; gene.
DR   neXtProt; NX_P35408; -.
DR   OpenTargets; ENSG00000171522; -.
DR   PharmGKB; PA289; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT01000000214437; -.
DR   HOGENOM; CLU_045991_0_2_1; -.
DR   InParanoid; P35408; -.
DR   KO; K04261; -.
DR   OMA; LLYMPDL; -.
DR   OrthoDB; 972015at2759; -.
DR   PhylomeDB; P35408; -.
DR   TreeFam; TF324982; -.
DR   PathwayCommons; P35408; -.
DR   Reactome; R-HSA-391908; Prostanoid ligand receptors.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-9660821; ADORA2B mediated anti-inflammatory cytokines production.
DR   SABIO-RK; P35408; -.
DR   SIGNOR; P35408; -.
DR   BioGRID-ORCS; 5734; 2 hits in 876 CRISPR screens.
DR   ChiTaRS; PTGER4; human.
DR   GeneWiki; EP4_receptor; -.
DR   GenomeRNAi; 5734; -.
DR   Pharos; P35408; Tclin.
DR   PRO; PR:P35408; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; P35408; protein.
DR   Bgee; ENSG00000171522; Expressed in metanephric glomerulus and 222 other tissues.
DR   Genevisible; P35408; HS.
DR   GO; GO:0016021; C:integral component of membrane; NAS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0004957; F:prostaglandin E receptor activity; IDA:UniProtKB.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007188; P:adenylate cyclase-modulating G protein-coupled receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0060348; P:bone development; ISS:UniProtKB.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; ISS:UniProtKB.
DR   GO; GO:0071380; P:cellular response to prostaglandin E stimulus; IBA:GO_Central.
DR   GO; GO:0070371; P:ERK1 and ERK2 cascade; ISS:UniProtKB.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006955; P:immune response; IEP:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; IBA:GO_Central.
DR   GO; GO:0007254; P:JNK cascade; ISS:UniProtKB.
DR   GO; GO:0050710; P:negative regulation of cytokine secretion; ISS:UniProtKB.
DR   GO; GO:2000420; P:negative regulation of eosinophil extravasation; IDA:UniProtKB.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IDA:UniProtKB.
DR   GO; GO:0033624; P:negative regulation of integrin activation; IDA:UniProtKB.
DR   GO; GO:0050715; P:positive regulation of cytokine secretion; ISS:UniProtKB.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IBA:GO_Central.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; ISS:UniProtKB.
DR   GO; GO:0030278; P:regulation of ossification; IEA:Ensembl.
DR   GO; GO:0051492; P:regulation of stress fiber assembly; ISS:UniProtKB.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0009612; P:response to mechanical stimulus; IEP:UniProtKB.
DR   GO; GO:0042093; P:T-helper cell differentiation; ISS:UniProtKB.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR001758; Prost_EP4_rcpt.
DR   InterPro; IPR008365; Prostanoid_rcpt.
DR   InterPro; IPR001244; Prostglndn_DP_rcpt.
DR   PANTHER; PTHR11866; PTHR11866; 1.
DR   PANTHER; PTHR11866:SF6; PTHR11866:SF6; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00428; PROSTAGLNDNR.
DR   PRINTS; PR01788; PROSTANOIDR.
DR   PRINTS; PR00586; PRSTNOIDEP4R.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Membrane; Phosphoprotein; Receptor; Reference proteome;
KW   Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..488
FT                   /note="Prostaglandin E2 receptor EP4 subtype"
FT                   /id="PRO_0000070064"
FT   TOPO_DOM        1..19
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        20..43
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        44..55
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        56..79
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        80..96
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        97..115
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        116..135
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        136..160
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        161..184
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        185..211
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        212..267
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        268..295
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        296..312
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        313..332
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        333..488
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        230..234
FT                   /note="Poly-Ala"
FT   MOD_RES         374
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:14709160"
FT   MOD_RES         377
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:14709160"
FT   MOD_RES         379
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:14709160"
FT   MOD_RES         382
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:14709160"
FT   CARBOHYD        7
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        92..170
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   CONFLICT        464..466
FT                   /note="GPA -> WAC (in Ref. 2; AAA36438)"
FT                   /evidence="ECO:0000305"
FT   HELIX           19..41
FT                   /evidence="ECO:0000244|PDB:5YWY"
FT   STRAND          44..46
FT                   /evidence="ECO:0000244|PDB:5YWY"
FT   HELIX           52..82
FT                   /evidence="ECO:0000244|PDB:5YWY"
FT   HELIX           89..122
FT                   /evidence="ECO:0000244|PDB:5YWY"
FT   HELIX           125..128
FT                   /evidence="ECO:0000244|PDB:5YWY"
FT   HELIX           134..152
FT                   /evidence="ECO:0000244|PDB:5YWY"
FT   TURN            153..156
FT                   /evidence="ECO:0000244|PDB:5YWY"
FT   STRAND          161..163
FT                   /evidence="ECO:0000244|PDB:5YWY"
FT   TURN            165..167
FT                   /evidence="ECO:0000244|PDB:5YWY"
FT   STRAND          170..172
FT                   /evidence="ECO:0000244|PDB:5YWY"
FT   HELIX           179..213
FT                   /evidence="ECO:0000244|PDB:5YWY"
FT   HELIX           267..283
FT                   /evidence="ECO:0000244|PDB:5YWY"
FT   HELIX           286..297
FT                   /evidence="ECO:0000244|PDB:5YWY"
FT   TURN            306..308
FT                   /evidence="ECO:0000244|PDB:5YWY"
FT   HELIX           310..319
FT                   /evidence="ECO:0000244|PDB:5YWY"
FT   HELIX           321..331
FT                   /evidence="ECO:0000244|PDB:5YWY"
FT   HELIX           334..343
FT                   /evidence="ECO:0000244|PDB:5YWY"
SQ   SEQUENCE   488 AA;  53119 MW;  D028478CD72C85EE CRC64;
     MSTPGVNSSA SLSPDRLNSP VTIPAVMFIF GVVGNLVAIV VLCKSRKEQK ETTFYTLVCG
     LAVTDLLGTL LVSPVTIATY MKGQWPGGQP LCEYSTFILL FFSLSGLSII CAMSVERYLA
     INHAYFYSHY VDKRLAGLTL FAVYASNVLF CALPNMGLGS SRLQYPDTWC FIDWTTNVTA
     HAAYSYMYAG FSSFLILATV LCNVLVCGAL LRMHRQFMRR TSLGTEQHHA AAAASVASRG
     HPAASPALPR LSDFRRRRSF RRIAGAEIQM VILLIATSLV VLICSIPLVV RVFVNQLYQP
     SLEREVSKNP DLQAIRIASV NPILDPWIYI LLRKTVLSKA IEKIKCLFCR IGGSRRERSG
     QHCSDSQRTS SAMSGHSRSF ISRELKEISS TSQTLLPDLS LPDLSENGLG GRNLLPGVPG
     MGLAQEDTTS LRTLRISETS DSSQGQDSES VLLVDEAGGS GRAGPAPKGS SLQVTFPSET
     LNLSEKCI
//
ID   AGRB3_HUMAN             Reviewed;        1522 AA.
AC   O60242; B7Z1K0; O60297; Q2NKN6; Q5VY37; Q9BX54;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   02-NOV-2010, sequence version 2.
DT   07-OCT-2020, entry version 181.
DE   RecName: Full=Adhesion G protein-coupled receptor B3 {ECO:0000303|PubMed:25713288};
DE   AltName: Full=Brain-specific angiogenesis inhibitor 3;
DE   Flags: Precursor;
GN   Name=ADGRB3 {ECO:0000312|HGNC:HGNC:945}; Synonyms=BAI3, KIAA0550;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT SER-503, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Fetal brain;
RX   PubMed=9533023; DOI=10.1159/000134693;
RA   Shiratsuchi T., Nishimori H., Ichise H., Nakamura Y., Tokino T.;
RT   "Cloning and characterization of BAI2 and BAI3, novel genes homologous to
RT   brain-specific angiogenesis inhibitor 1 (BAI1).";
RL   Cytogenet. Cell Genet. 79:103-108(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT SER-503.
RC   TISSUE=Brain;
RX   PubMed=9628581; DOI=10.1093/dnares/5.1.31;
RA   Nagase T., Ishikawa K., Miyajima N., Tanaka A., Kotani H., Nomura N.,
RA   Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. IX. The
RT   complete sequences of 100 new cDNA clones from brain which can code for
RT   large proteins in vitro.";
RL   DNA Res. 5:31-39(1998).
RN   [3]
RP   SEQUENCE REVISION TO 643-665 AND C-TERMINUS.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Cerebellum;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT SER-503.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-619, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [9]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH C1QL1; C1QL2; C1QL3 AND C1QL4.
RX   PubMed=21262840; DOI=10.1073/pnas.1019577108;
RA   Bolliger M.F., Martinelli D.C., Sudhof T.C.;
RT   "The cell-adhesion G protein-coupled receptor BAI3 is a high-affinity
RT   receptor for C1q-like proteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:2534-2539(2011).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH ELMO1; ELMO2 AND ELMO3.
RX   PubMed=24567399; DOI=10.1073/pnas.1313886111;
RA   Hamoud N., Tran V., Croteau L.P., Kania A., Cote J.F.;
RT   "G-protein coupled receptor BAI3 promotes myoblast fusion in vertebrates.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:3745-3750(2014).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS) OF 498-868, PROTEOLYTIC PROCESSING,
RP   GLYCOSYLATION AT ASN-540 AND ASN-625, DISULFIDE BONDS, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=22333914; DOI=10.1038/emboj.2012.26;
RA   Arac D., Boucard A.A., Bolliger M.F., Nguyen J., Soltis S.M., Sudhof T.C.,
RA   Brunger A.T.;
RT   "A novel evolutionarily conserved domain of cell-adhesion GPCRs mediates
RT   autoproteolysis.";
RL   EMBO J. 31:1364-1378(2012).
RN   [12]
RP   NOMENCLATURE.
RX   PubMed=25713288; DOI=10.1124/pr.114.009647;
RA   Hamann J., Aust G., Arac D., Engel F.B., Formstone C., Fredriksson R.,
RA   Hall R.A., Harty B.L., Kirchhoff C., Knapp B., Krishnan A., Liebscher I.,
RA   Lin H.H., Martinelli D.C., Monk K.R., Peeters M.C., Piao X., Promel S.,
RA   Schoneberg T., Schwartz T.W., Singer K., Stacey M., Ushkaryov Y.A.,
RA   Vallon M., Wolfrum U., Wright M.W., Xu L., Langenhan T., Schioth H.B.;
RT   "International union of basic and clinical pharmacology. XCIV. Adhesion G
RT   protein-coupled receptors.";
RL   Pharmacol. Rev. 67:338-367(2015).
CC   -!- FUNCTION: Receptor that plays a role in the regulation of
CC       synaptogenesis and dendritic spine formation at least partly via
CC       interaction with ELMO1 and RAC1 activity (By similarity). Promotes
CC       myoblast fusion through ELMO/DOCK1 (PubMed:24567399).
CC       {ECO:0000250|UniProtKB:Q80ZF8, ECO:0000269|PubMed:24567399}.
CC   -!- SUBUNIT: Forms a heterodimer, consisting of a large extracellular
CC       region non-covalently linked to a seven-transmembrane moiety. Interacts
CC       (via TSP N-terminal domains) with C1QL1, C1QL2, C1QL3 and C1QL4
CC       (PubMed:21262840). Interacts with ELMO1, ELMO2 AND ELMO3
CC       (PubMed:24567399). {ECO:0000269|PubMed:21262840,
CC       ECO:0000269|PubMed:24567399}.
CC   -!- INTERACTION:
CC       O60242; Q8N954: GPATCH11; NbExp=3; IntAct=EBI-2682765, EBI-2555378;
CC       O60242; O60883: GPR37L1; NbExp=3; IntAct=EBI-2682765, EBI-2927498;
CC       O60242; P15941-11: MUC1; NbExp=3; IntAct=EBI-2682765, EBI-17263240;
CC       O60242; P30825: SLC7A1; NbExp=3; IntAct=EBI-2682765, EBI-4289564;
CC       O60242; Q96MV1: TLCD4; NbExp=3; IntAct=EBI-2682765, EBI-12947623;
CC       O60242; Q9ESN4: C1ql3; Xeno; NbExp=4; IntAct=EBI-2682765, EBI-15907894;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:21262840,
CC       ECO:0000269|PubMed:22333914}; Multi-pass membrane protein
CC       {ECO:0000255}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O60242-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O60242-2; Sequence=VSP_056939;
CC   -!- TISSUE SPECIFICITY: Strongly expressed in brain. Also detected in
CC       heart. Reduced expression in some glioblastoma cell lines.
CC       {ECO:0000269|PubMed:9533023}.
CC   -!- PTM: The endogenous protein is proteolytically cleaved into 2 subunits,
CC       an extracellular subunit and a seven-transmembrane subunit.
CC       {ECO:0000269|PubMed:22333914}.
CC   -!- MISCELLANEOUS: Autoproteolysis appears to be cell specific, does not
CC       readily undergo proteolytic cleavage in HEK293T cells.
CC       {ECO:0000269|PubMed:25713288}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 2 family.
CC       Adhesion G-protein coupled receptor (ADGR) subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA25476.2; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB005299; BAA25363.1; -; mRNA.
DR   EMBL; AB011122; BAA25476.2; ALT_INIT; mRNA.
DR   EMBL; AK293560; BAH11536.1; -; mRNA.
DR   EMBL; AL035469; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL078598; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL589875; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL133378; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL158051; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL160401; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL356117; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL359714; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL391807; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471051; EAW48837.1; -; Genomic_DNA.
DR   EMBL; BC111720; AAI11721.1; -; mRNA.
DR   CCDS; CCDS4968.1; -. [O60242-1]
DR   PIR; T00028; T00028.
DR   PIR; T00326; T00326.
DR   RefSeq; NP_001695.1; NM_001704.2. [O60242-1]
DR   RefSeq; XP_005248809.1; XM_005248752.2.
DR   PDB; 4DLO; X-ray; 2.30 A; A/B=498-868.
DR   PDBsum; 4DLO; -.
DR   SMR; O60242; -.
DR   BioGRID; 107053; 7.
DR   DIP; DIP-56121N; -.
DR   IntAct; O60242; 9.
DR   STRING; 9606.ENSP00000359630; -.
DR   MEROPS; P02.027; -.
DR   TCDB; 9.A.14.6.7; the g-protein-coupled receptor (gpcr) family.
DR   GlyConnect; 2016; 1 N-Linked glycan (1 site).
DR   GlyGen; O60242; 14 sites, 1 N-linked glycan (1 site).
DR   iPTMnet; O60242; -.
DR   PhosphoSitePlus; O60242; -.
DR   BioMuta; ADGRB3; -.
DR   MassIVE; O60242; -.
DR   PaxDb; O60242; -.
DR   PeptideAtlas; O60242; -.
DR   PRIDE; O60242; -.
DR   ProteomicsDB; 49275; -. [O60242-1]
DR   ProteomicsDB; 6341; -.
DR   Antibodypedia; 2938; 231 antibodies.
DR   Ensembl; ENST00000370598; ENSP00000359630; ENSG00000135298. [O60242-1]
DR   Ensembl; ENST00000546190; ENSP00000441821; ENSG00000135298. [O60242-1]
DR   GeneID; 577; -.
DR   KEGG; hsa:577; -.
DR   UCSC; uc003pev.5; human. [O60242-1]
DR   CTD; 577; -.
DR   DisGeNET; 577; -.
DR   EuPathDB; HostDB:ENSG00000135298.13; -.
DR   GeneCards; ADGRB3; -.
DR   HGNC; HGNC:945; ADGRB3.
DR   HPA; ENSG00000135298; Group enriched (brain, pituitary gland).
DR   MIM; 602684; gene.
DR   neXtProt; NX_O60242; -.
DR   OpenTargets; ENSG00000135298; -.
DR   PharmGKB; PA25249; -.
DR   eggNOG; ENOG502QRKJ; Eukaryota.
DR   GeneTree; ENSGT00940000155081; -.
DR   HOGENOM; CLU_003751_1_0_1; -.
DR   InParanoid; O60242; -.
DR   KO; K04598; -.
DR   OMA; LWDDSRT; -.
DR   OrthoDB; 27621at2759; -.
DR   PhylomeDB; O60242; -.
DR   TreeFam; TF331634; -.
DR   PathwayCommons; O60242; -.
DR   BioGRID-ORCS; 577; 6 hits in 869 CRISPR screens.
DR   ChiTaRS; ADGRB3; human.
DR   GeneWiki; Brain-specific_angiogenesis_inhibitor_3; -.
DR   GenomeRNAi; 577; -.
DR   Pharos; O60242; Tbio.
DR   PRO; PR:O60242; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; O60242; protein.
DR   Bgee; ENSG00000135298; Expressed in middle temporal gyrus and 156 other tissues.
DR   ExpressionAtlas; O60242; baseline and differential.
DR   Genevisible; O60242; HS.
DR   GO; GO:0016021; C:integral component of membrane; TAS:GDB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IPI:UniProtKB.
DR   GO; GO:0098794; C:postsynapse; IBA:GO_Central.
DR   GO; GO:0043083; C:synaptic cleft; IBA:GO_Central.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0005096; F:GTPase activator activity; ISS:UniProtKB.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IEA:InterPro.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:GDB.
DR   GO; GO:0099558; P:maintenance of synapse structure; IEA:Ensembl.
DR   GO; GO:0061743; P:motor learning; IEA:Ensembl.
DR   GO; GO:0007520; P:myoblast fusion; IDA:UniProtKB.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IEA:InterPro.
DR   GO; GO:0016322; P:neuron remodeling; IBA:GO_Central.
DR   GO; GO:0051965; P:positive regulation of synapse assembly; IEA:Ensembl.
DR   GO; GO:0048814; P:regulation of dendrite morphogenesis; ISS:UniProtKB.
DR   Gene3D; 2.20.100.10; -; 4.
DR   Gene3D; 4.10.1240.10; -; 1.
DR   InterPro; IPR000859; CUB_dom.
DR   InterPro; IPR032471; GAIN_dom_N.
DR   InterPro; IPR017981; GPCR_2-like.
DR   InterPro; IPR008077; GPCR_2_brain_angio_inhib.
DR   InterPro; IPR036445; GPCR_2_extracell_dom_sf.
DR   InterPro; IPR001879; GPCR_2_extracellular_dom.
DR   InterPro; IPR000832; GPCR_2_secretin-like.
DR   InterPro; IPR017983; GPCR_2_secretin-like_CS.
DR   InterPro; IPR000203; GPS.
DR   InterPro; IPR000884; TSP1_rpt.
DR   InterPro; IPR036383; TSP1_rpt_sf.
DR   Pfam; PF00002; 7tm_2; 1.
DR   Pfam; PF16489; GAIN; 1.
DR   Pfam; PF01825; GPS; 1.
DR   Pfam; PF02793; HRM; 1.
DR   Pfam; PF00090; TSP_1; 4.
DR   PRINTS; PR01694; BAIPRECURSOR.
DR   PRINTS; PR00249; GPCRSECRETIN.
DR   SMART; SM00303; GPS; 1.
DR   SMART; SM00008; HormR; 1.
DR   SMART; SM00209; TSP1; 4.
DR   SUPFAM; SSF82895; SSF82895; 4.
DR   PROSITE; PS01180; CUB; 1.
DR   PROSITE; PS00650; G_PROTEIN_RECEP_F2_2; 1.
DR   PROSITE; PS50227; G_PROTEIN_RECEP_F2_3; 1.
DR   PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1.
DR   PROSITE; PS50221; GPS; 1.
DR   PROSITE; PS50092; TSP1; 4.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Phosphoprotein;
KW   Polymorphism; Receptor; Reference proteome; Repeat; Signal; Transducer;
KW   Transmembrane; Transmembrane helix.
FT   SIGNAL          1..24
FT                   /evidence="ECO:0000255"
FT   CHAIN           25..1522
FT                   /note="Adhesion G protein-coupled receptor B3"
FT                   /id="PRO_0000012865"
FT   TOPO_DOM        25..880
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        881..901
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        902..910
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        911..931
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        932..939
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        940..960
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        961..981
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        982..1002
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        1003..1023
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1024..1044
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        1045..1098
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1099..1119
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        1120..1125
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        1126..1146
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        1147..1522
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   DOMAIN          30..159
FT                   /note="CUB"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00059"
FT   DOMAIN          291..343
FT                   /note="TSP type-1 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DOMAIN          345..398
FT                   /note="TSP type-1 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DOMAIN          400..453
FT                   /note="TSP type-1 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DOMAIN          455..508
FT                   /note="TSP type-1 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DOMAIN          816..868
FT                   /note="GPS"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00098"
FT   COMPBIAS        942..945
FT                   /note="Poly-Thr"
FT   COMPBIAS        1173..1176
FT                   /note="Poly-Ser"
FT   MOD_RES         619
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         1220
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80ZF8"
FT   MOD_RES         1411
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80ZF8"
FT   CARBOHYD        51
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        54
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        82
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        105
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        241
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        337
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        418
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        540
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:22333914"
FT   CARBOHYD        625
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:22333914"
FT   CARBOHYD        779
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        812
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        828
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        937
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        30..55
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00059"
FT   DISULFID        303..336
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        307..342
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        318..326
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        357..392
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        361..397
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        372..382
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        412..447
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        416..452
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        427..437
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        467..502
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        471..507
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        482..492
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DISULFID        514..549
FT                   /evidence="ECO:0000269|PubMed:22333914"
FT   DISULFID        537..567
FT                   /evidence="ECO:0000269|PubMed:22333914"
FT   DISULFID        819..851
FT                   /evidence="ECO:0000269|PubMed:22333914"
FT   DISULFID        839..853
FT                   /evidence="ECO:0000269|PubMed:22333914"
FT   VAR_SEQ         1..1036
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056939"
FT   VARIANT         503
FT                   /note="N -> S (in dbSNP:rs1932618)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:9533023, ECO:0000269|PubMed:9628581"
FT                   /id="VAR_046525"
FT   TURN            502..504
FT                   /evidence="ECO:0000244|PDB:4DLO"
FT   TURN            519..521
FT                   /evidence="ECO:0000244|PDB:4DLO"
FT   STRAND          532..535
FT                   /evidence="ECO:0000244|PDB:4DLO"
FT   STRAND          541..551
FT                   /evidence="ECO:0000244|PDB:4DLO"
FT   STRAND          557..559
FT                   /evidence="ECO:0000244|PDB:4DLO"
FT   STRAND          563..569
FT                   /evidence="ECO:0000244|PDB:4DLO"
FT   HELIX           570..583
FT                   /evidence="ECO:0000244|PDB:4DLO"
FT   HELIX           589..608
FT                   /evidence="ECO:0000244|PDB:4DLO"
FT   HELIX           613..632
FT                   /evidence="ECO:0000244|PDB:4DLO"
FT   HELIX           639..652
FT                   /evidence="ECO:0000244|PDB:4DLO"
FT   HELIX           655..657
FT                   /evidence="ECO:0000244|PDB:4DLO"
FT   HELIX           658..664
FT                   /evidence="ECO:0000244|PDB:4DLO"
FT   TURN            665..667
FT                   /evidence="ECO:0000244|PDB:4DLO"
FT   HELIX           670..687
FT                   /evidence="ECO:0000244|PDB:4DLO"
FT   STRAND          694..698
FT                   /evidence="ECO:0000244|PDB:4DLO"
FT   STRAND          700..710
FT                   /evidence="ECO:0000244|PDB:4DLO"
FT   STRAND          718..721
FT                   /evidence="ECO:0000244|PDB:4DLO"
FT   HELIX           730..734
FT                   /evidence="ECO:0000244|PDB:4DLO"
FT   STRAND          738..741
FT                   /evidence="ECO:0000244|PDB:4DLO"
FT   HELIX           743..746
FT                   /evidence="ECO:0000244|PDB:4DLO"
FT   STRAND          759..769
FT                   /evidence="ECO:0000244|PDB:4DLO"
FT   HELIX           770..772
FT                   /evidence="ECO:0000244|PDB:4DLO"
FT   STRAND          781..783
FT                   /evidence="ECO:0000244|PDB:4DLO"
FT   STRAND          787..794
FT                   /evidence="ECO:0000244|PDB:4DLO"
FT   STRAND          803..808
FT                   /evidence="ECO:0000244|PDB:4DLO"
FT   STRAND          815..823
FT                   /evidence="ECO:0000244|PDB:4DLO"
FT   STRAND          833..835
FT                   /evidence="ECO:0000244|PDB:4DLO"
FT   STRAND          839..845
FT                   /evidence="ECO:0000244|PDB:4DLO"
FT   STRAND          848..855
FT                   /evidence="ECO:0000244|PDB:4DLO"
FT   STRAND          857..864
FT                   /evidence="ECO:0000244|PDB:4DLO"
SQ   SEQUENCE   1522 AA;  171518 MW;  D22D0A5CF59E811F CRC64;
     MKAVRNLLIY IFSTYLLVMF GFNAAQDFWC STLVKGVIYG SYSVSEMFPK NFTNCTWTLE
     NPDPTKYSIY LKFSKKDLSC SNFSLLAYQF DHFSHEKIKD LLRKNHSIMQ LCNSKNAFVF
     LQYDKNFIQI RRVFPTNFPG LQKKGEEDQK SFFEFLVLNK VSPSQFGCHV LCTWLESCLK
     SENGRTESCG IMYTKCTCPQ HLGEWGIDDQ SLILLNNVVL PLNEQTEGCL TQELQTTQVC
     NLTREAKRPP KEEFGMMGDH TIKSQRPRSV HEKRVPQEQA DAAKFMAQTG ESGVEEWSQW
     STCSVTCGQG SQVRTRTCVS PYGTHCSGPL RESRVCNNTA LCPVHGVWEE WSPWSLCSFT
     CGRGQRTRTR SCTPPQYGGR PCEGPETHHK PCNIALCPVD GQWQEWSSWS QCSVTCSNGT
     QQRSRQCTAA AHGGSECRGP WAESRECYNP ECTANGQWNQ WGHWSGCSKS CDGGWERRIR
     TCQGAVITGQ QCEGTGEEVR RCNEQRCPAP YEICPEDYLM SMVWKRTPAG DLAFNQCPLN
     ATGTTSRRCS LSLHGVAFWE QPSFARCISN EYRHLQHSIK EHLAKGQRML AGDGMSQVTK
     TLLDLTQRKN FYAGDLLMSV EILRNVTDTF KRASYIPASD GVQNFFQIVS NLLDEENKEK
     WEDAQQIYPG SIELMQVIED FIHIVGMGMM DFQNSYLMTG NVVASIQKLP AASVLTDINF
     PMKGRKGMVD WARNSEDRVV IPKSIFTPVS SKELDESSVF VLGAVLYKNL DLILPTLRNY
     TVINSKIIVV TIRPEPKTTD SFLEIELAHL ANGTLNPYCV LWDDSKTNES LGTWSTQGCK
     TVLTDASHTK CLCDRLSTFA ILAQQPREII MESSGTPSVT LIVGSGLSCL ALITLAVVYA
     ALWRYIRSER SIILINFCLS IISSNILILV GQTQTHNKSI CTTTTAFLHF FFLASFCWVL
     TEAWQSYMAV TGKIRTRLIR KRFLCLGWGL PALVVATSVG FTRTKGYGTD HYCWLSLEGG
     LLYAFVGPAA AVVLVNMVIG ILVFNKLVSR DGILDKKLKH RAGQMSEPHS GLTLKCAKCG
     VVSTTALSAT TASNAMASLW SSCVVLPLLA LTWMSAVLAM TDKRSILFQI LFAVFDSLQG
     FVIVMVHCIL RREVQDAFRC RLRNCQDPIN ADSSSSFPNG HAQIMTDFEK DVDIACRSVL
     HKDIGPCRAA TITGTLSRIS LNDDEEEKGT NPEGLSYSTL PGNVISKVII QQPTGLHMPM
     SMNELSNPCL KKENSELRRT VYLCTDDNLR GADMDIVHPQ ERMMESDYIV MPRSSVNNQP
     SMKEESKMNI GMETLPHERL LHYKVNPEFN MNPPVMDQFN MNLEQHLAPQ EHMQNLPFEP
     RTAVKNFMAS ELDDNAGLSR SETGSTISMS SLERRKSRYS DLDFEKVMHT RKRHMELFQE
     LNQKFQTLDR FRDIPNTSSM ENPAPNKNPW DTFKNPSEYP HYTTINVLDT EAKDALELRP
     AEWEKCLNLP LDVQEGDFQT EV
//
ID   CRFR2_HUMAN             Reviewed;         411 AA.
AC   Q13324; B2R967; B3SXS6; B3SXS7; B3SXS8; B3SXT0; F8WA81; O43461; Q4QRJ4;
AC   Q99431;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   30-MAY-2000, sequence version 2.
DT   07-OCT-2020, entry version 170.
DE   RecName: Full=Corticotropin-releasing factor receptor 2;
DE            Short=CRF-R-2;
DE            Short=CRF-R2;
DE            Short=CRFR-2;
DE   AltName: Full=Corticotropin-releasing hormone receptor 2;
DE            Short=CRH-R-2;
DE            Short=CRH-R2;
GN   Name=CRHR2; Synonyms=CRF2R, CRH2R;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM CRF2-ALPHA).
RX   PubMed=8536644; DOI=10.1210/endo.137.1.8536644;
RA   Liaw C.W., Lovenberg T.W., Barry G., Oltersdorf T., Grigoriadis D.E.,
RA   de Souza E.B.;
RT   "Cloning and characterization of the human corticotropin-releasing factor-2
RT   receptor complementary deoxyribonucleic acid.";
RL   Endocrinology 137:72-77(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM CRF2-BETA).
RC   TISSUE=Amygdala;
RA   Kostich W.A., Chen A., Sperle K., Horlick R.A., Patterson J., Hyde T.M.,
RA   Largent B.L.;
RT   "Molecular cloning of the human CRH2B receptor isoform: divergence from the
RT   rodent isoform in sequence and expression pattern.";
RL   Submitted (JUN-1997) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM CRF2-GAMMA).
RC   TISSUE=Amygdala;
RX   PubMed=9717834; DOI=10.1210/mend.12.8.0145;
RA   Kostich W.A., Chen A., Sperle K., Largent B.L.;
RT   "Molecular identification and analysis of a novel human corticotropin-
RT   releasing factor (CRF) receptor: the CRF2gamma receptor.";
RL   Mol. Endocrinol. 12:1077-1085(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM CRF2-ALPHA).
RA   Suwa M., Sato T., Okouchi I., Arita M., Futami K., Matsumoto S.,
RA   Tsutsumi S., Aburatani H., Asai K., Akiyama Y.;
RT   "Genome-wide discovery and analysis of human seven transmembrane helix
RT   receptor genes.";
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM CRF2-ALPHA).
RC   TISSUE=Brain;
RA   King M.M., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS D; E; F AND DESQ), AND ALTERNATIVE
RP   SPLICING.
RA   Wu S.V., Yuan P.-Q., Lai J., Tache Y.;
RT   "Identification and characterization of novel CRF receptor type 2 isoforms
RT   in human.";
RL   Submitted (JUL-2007) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM CRF2-ALPHA).
RC   TISSUE=Amygdala;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM CRF2-ALPHA).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-88 (ISOFORM CRF2-BETA).
RC   TISSUE=Skeletal muscle;
RX   PubMed=9199241; DOI=10.1016/s0167-4781(97)00047-x;
RA   Valdenaire O., Giller T., Breu V., Gottowik J., Kilpatrick G.;
RT   "A new functional isoform of the human CRF2 receptor for corticotropin-
RT   releasing factor.";
RL   Biochim. Biophys. Acta 1352:129-132(1997).
RN   [11]
RP   SUBUNIT, SUBCELLULAR LOCATION, AND NON-CLEAVABLE SIGNAL SEQUENCE.
RX   PubMed=22689579; DOI=10.1074/jbc.m112.360594;
RA   Teichmann A., Rutz C., Kreuchwig A., Krause G., Wiesner B., Schulein R.;
RT   "The Pseudo signal peptide of the corticotropin-releasing factor receptor
RT   type 2A prevents receptor oligomerization.";
RL   J. Biol. Chem. 287:27265-27274(2012).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 3-104 IN COMPLEXES WITH UCN; UCN2
RP   AND UCN3, INTERACTION WITH CRF; UCN; UCN2 AND UCN3, AND DISULFIDE BONDS.
RX   PubMed=20966082; DOI=10.1074/jbc.m110.186072;
RA   Pal K., Swaminathan K., Xu H.E., Pioszak A.A.;
RT   "Structural basis for hormone recognition by the Human CRFR2{alpha} G
RT   protein-coupled receptor.";
RL   J. Biol. Chem. 285:40351-40361(2010).
CC   -!- FUNCTION: G-protein coupled receptor for CRH (corticotropin-releasing
CC       factor), UCN (urocortin), UCN2 and UCN3. Has high affinity for UCN.
CC       Ligand binding causes a conformation change that triggers signaling via
CC       guanine nucleotide-binding proteins (G proteins) and down-stream
CC       effectors, such as adenylate cyclase. Promotes the activation of
CC       adenylate cyclase, leading to increased intracellular cAMP levels.
CC   -!- SUBUNIT: Monomer. Interacts (via N-terminal extracellular domain) with
CC       CRF, UCN, UCN2 and UCN3. Has highest affinity for UCN, and considerably
CC       lower affinity for CRF, UNC2 and UCN3. {ECO:0000269|PubMed:20966082,
CC       ECO:0000269|PubMed:22689579}.
CC   -!- INTERACTION:
CC       Q13324-2; Q13021: MALL; NbExp=3; IntAct=EBI-23865243, EBI-750078;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:22689579};
CC       Multi-pass membrane protein {ECO:0000269|PubMed:22689579}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=7;
CC       Name=CRF2-alpha;
CC         IsoId=Q13324-1; Sequence=Displayed;
CC       Name=CRF2-beta;
CC         IsoId=Q13324-2; Sequence=VSP_001999;
CC       Name=CRF2-gamma;
CC         IsoId=Q13324-3; Sequence=VSP_002000;
CC       Name=D;
CC         IsoId=Q13324-4; Sequence=VSP_053565;
CC       Name=E;
CC         IsoId=Q13324-5; Sequence=VSP_053566;
CC       Name=F;
CC         IsoId=Q13324-6; Sequence=VSP_053567;
CC       Name=desQ;
CC         IsoId=Q13324-7; Sequence=VSP_053564;
CC   -!- DOMAIN: The transmembrane domain is composed of seven transmembrane
CC       helices that are arranged in V-shape. Transmembrane helix 7 assumes a
CC       sharply kinked structure (By similarity). {ECO:0000250}.
CC   -!- DOMAIN: The uncleaved pseudo signal peptide prevents receptor's
CC       oligomerization and coupling to G(i) subunits. It is also responsible
CC       for the rather low receptor localization at the plasma membrane
CC       (PubMed:22689579). {ECO:0000269|PubMed:22689579}.
CC   -!- PTM: A N-glycosylation site within the signal peptide impedes its
CC       proper cleavage and function. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 2 family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U34587; AAA91320.1; -; mRNA.
DR   EMBL; AF011406; AAB94503.1; -; mRNA.
DR   EMBL; AF019381; AAB94562.1; -; mRNA.
DR   EMBL; AB065699; BAC05922.1; -; Genomic_DNA.
DR   EMBL; AY449734; AAR18078.1; -; mRNA.
DR   EMBL; EU012439; ABV59313.1; -; mRNA.
DR   EMBL; EU012440; ABV59314.1; -; mRNA.
DR   EMBL; EU012441; ABV59315.1; -; mRNA.
DR   EMBL; EU012443; ABV59317.1; -; mRNA.
DR   EMBL; AK313661; BAG36414.1; -; mRNA.
DR   EMBL; AC004976; AAC71653.1; -; Genomic_DNA.
DR   EMBL; AC004976; AAC71654.1; -; Genomic_DNA.
DR   EMBL; BC096830; AAH96830.1; -; mRNA.
DR   EMBL; Y10151; CAA71235.1; -; mRNA.
DR   CCDS; CCDS5429.1; -. [Q13324-1]
DR   CCDS; CCDS56477.1; -. [Q13324-3]
DR   CCDS; CCDS56478.1; -. [Q13324-2]
DR   CCDS; CCDS75576.1; -. [Q13324-4]
DR   RefSeq; NP_001189404.1; NM_001202475.1. [Q13324-2]
DR   RefSeq; NP_001189410.1; NM_001202481.1. [Q13324-3]
DR   RefSeq; NP_001189411.1; NM_001202482.1. [Q13324-7]
DR   RefSeq; NP_001189412.1; NM_001202483.1. [Q13324-4]
DR   RefSeq; NP_001874.2; NM_001883.4. [Q13324-1]
DR   RefSeq; XP_011513430.1; XM_011515128.2.
DR   RefSeq; XP_011513431.1; XM_011515129.2.
DR   RefSeq; XP_016867241.1; XM_017011752.1. [Q13324-3]
DR   PDB; 3N93; X-ray; 2.50 A; A/B=3-104.
DR   PDB; 3N95; X-ray; 2.72 A; A/B/C/D=3-104.
DR   PDB; 3N96; X-ray; 2.75 A; A/B/C/D=3-104.
DR   PDB; 6PB1; EM; 2.80 A; P=2-388.
DR   PDBsum; 3N93; -.
DR   PDBsum; 3N95; -.
DR   PDBsum; 3N96; -.
DR   PDBsum; 6PB1; -.
DR   SMR; Q13324; -.
DR   BioGRID; 107785; 3.
DR   IntAct; Q13324; 2.
DR   MINT; Q13324; -.
DR   STRING; 9606.ENSP00000340943; -.
DR   BindingDB; Q13324; -.
DR   ChEMBL; CHEMBL4069; -.
DR   DrugCentral; Q13324; -.
DR   GuidetoPHARMACOLOGY; 213; -.
DR   GlyGen; Q13324; 5 sites.
DR   PhosphoSitePlus; Q13324; -.
DR   BioMuta; CRHR2; -.
DR   DMDM; 6226847; -.
DR   PaxDb; Q13324; -.
DR   PeptideAtlas; Q13324; -.
DR   PRIDE; Q13324; -.
DR   ProteomicsDB; 30449; -.
DR   ProteomicsDB; 59312; -. [Q13324-1]
DR   ProteomicsDB; 59313; -. [Q13324-2]
DR   ProteomicsDB; 59314; -. [Q13324-3]
DR   Antibodypedia; 12618; 622 antibodies.
DR   Ensembl; ENST00000341843; ENSP00000344304; ENSG00000106113. [Q13324-3]
DR   Ensembl; ENST00000348438; ENSP00000340943; ENSG00000106113. [Q13324-2]
DR   Ensembl; ENST00000471646; ENSP00000418722; ENSG00000106113. [Q13324-1]
DR   Ensembl; ENST00000506074; ENSP00000426498; ENSG00000106113. [Q13324-4]
DR   GeneID; 1395; -.
DR   KEGG; hsa:1395; -.
DR   UCSC; uc003tbn.4; human. [Q13324-1]
DR   CTD; 1395; -.
DR   DisGeNET; 1395; -.
DR   EuPathDB; HostDB:ENSG00000106113.18; -.
DR   GeneCards; CRHR2; -.
DR   HGNC; HGNC:2358; CRHR2.
DR   HPA; ENSG00000106113; Tissue enhanced (brain).
DR   MIM; 602034; gene.
DR   neXtProt; NX_Q13324; -.
DR   OpenTargets; ENSG00000106113; -.
DR   PharmGKB; PA26875; -.
DR   eggNOG; KOG4564; Eukaryota.
DR   GeneTree; ENSGT00940000156795; -.
DR   HOGENOM; CLU_002753_4_1_1; -.
DR   InParanoid; Q13324; -.
DR   KO; K04579; -.
DR   OMA; EFDVNCS; -.
DR   OrthoDB; 1163977at2759; -.
DR   PhylomeDB; Q13324; -.
DR   TreeFam; TF315710; -.
DR   PathwayCommons; Q13324; -.
DR   Reactome; R-HSA-373080; Class B/2 (Secretin family receptors).
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-422085; Synthesis, secretion, and deacylation of Ghrelin.
DR   Reactome; R-HSA-9660821; ADORA2B mediated anti-inflammatory cytokines production.
DR   BioGRID-ORCS; 1395; 3 hits in 864 CRISPR screens.
DR   ChiTaRS; CRHR2; human.
DR   EvolutionaryTrace; Q13324; -.
DR   GeneWiki; Corticotropin_releasing_hormone_receptor_2; -.
DR   GenomeRNAi; 1395; -.
DR   Pharos; Q13324; Tbio.
DR   PRO; PR:Q13324; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; Q13324; protein.
DR   Bgee; ENSG00000106113; Expressed in frontal cortex and 107 other tissues.
DR   ExpressionAtlas; Q13324; baseline and differential.
DR   Genevisible; Q13324; HS.
DR   GO; GO:0043679; C:axon terminus; IBA:GO_Central.
DR   GO; GO:0030425; C:dendrite; IBA:GO_Central.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0015056; F:corticotrophin-releasing factor receptor activity; IBA:GO_Central.
DR   GO; GO:0043404; F:corticotropin-releasing hormone receptor activity; IBA:GO_Central.
DR   GO; GO:0008528; F:G protein-coupled peptide receptor activity; IBA:GO_Central.
DR   GO; GO:0017046; F:peptide hormone binding; IBA:GO_Central.
DR   GO; GO:0007188; P:adenylate cyclase-modulating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IEA:InterPro.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0060291; P:long-term synaptic potentiation; IBA:GO_Central.
DR   Gene3D; 4.10.1240.10; -; 1.
DR   InterPro; IPR017981; GPCR_2-like.
DR   InterPro; IPR003053; GPCR_2_CRF2_rcpt.
DR   InterPro; IPR003051; GPCR_2_CRF_rcpt.
DR   InterPro; IPR036445; GPCR_2_extracell_dom_sf.
DR   InterPro; IPR001879; GPCR_2_extracellular_dom.
DR   InterPro; IPR000832; GPCR_2_secretin-like.
DR   InterPro; IPR017983; GPCR_2_secretin-like_CS.
DR   Pfam; PF00002; 7tm_2; 1.
DR   Pfam; PF02793; HRM; 1.
DR   PRINTS; PR01279; CRFRECEPTOR.
DR   PRINTS; PR01281; CRFRECEPTOR2.
DR   PRINTS; PR00249; GPCRSECRETIN.
DR   SMART; SM00008; HormR; 1.
DR   SUPFAM; SSF111418; SSF111418; 1.
DR   PROSITE; PS00649; G_PROTEIN_RECEP_F2_1; 1.
DR   PROSITE; PS00650; G_PROTEIN_RECEP_F2_2; 1.
DR   PROSITE; PS50227; G_PROTEIN_RECEP_F2_3; 1.
DR   PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Polymorphism; Receptor;
KW   Reference proteome; Signal; Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..411
FT                   /note="Corticotropin-releasing factor receptor 2"
FT                   /id="PRO_0000012820"
FT   SIGNAL          1..19
FT                   /note="Not cleaved"
FT   TOPO_DOM        1..108
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        109..139
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        140..146
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        147..171
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        172..185
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        186..214
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        215..221
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        222..249
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        250..265
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        266..291
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        292..302
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        303..327
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        328..334
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        335..364
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        365..411
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        13
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        41
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        74
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        86
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        94
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        14..50
FT                   /evidence="ECO:0000269|PubMed:20966082"
FT   DISULFID        40..83
FT                   /evidence="ECO:0000269|PubMed:20966082"
FT   DISULFID        64..98
FT                   /evidence="ECO:0000269|PubMed:20966082"
FT   DISULFID        184..254
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         1..34
FT                   /note="MDAALLHSLLEANCSLALAEELLLDGWGPPLDPE -> MRGPSGPPGLLYVP
FT                   HLLLCLLCLLPPPLQYAAGQSQMPKDQPLWALLEQYCHTIMTLTNLS (in isoform
FT                   CRF2-beta)"
FT                   /evidence="ECO:0000303|PubMed:9199241, ECO:0000303|Ref.2"
FT                   /id="VSP_001999"
FT   VAR_SEQ         1..34
FT                   /note="MDAALLHSLLEANCSLALAEELLLDGWGPPLDPE -> MGREPWPEDRDLGF
FT                   PQLFCQ (in isoform CRF2-gamma)"
FT                   /evidence="ECO:0000303|PubMed:9717834"
FT                   /id="VSP_002000"
FT   VAR_SEQ         106
FT                   /note="Missing (in isoform desQ)"
FT                   /evidence="ECO:0000303|Ref.6"
FT                   /id="VSP_053564"
FT   VAR_SEQ         366..411
FT                   /note="VRSAVRKRWHRWQDHHSLRVPMARAMSIPTSPTRISFHSIKQTAAV -> SW
FT                   VSKEAQAAGPHGREKPEQRW (in isoform D)"
FT                   /evidence="ECO:0000303|Ref.6"
FT                   /id="VSP_053565"
FT   VAR_SEQ         366..411
FT                   /note="VRSAVRKRWHRWQDHHSLRVPMARAMSIPTSPTRISFHSIKQTAAV -> GL
FT                   EPV (in isoform E)"
FT                   /evidence="ECO:0000303|Ref.6"
FT                   /id="VSP_053566"
FT   VAR_SEQ         367..411
FT                   /note="Missing (in isoform F)"
FT                   /evidence="ECO:0000303|Ref.6"
FT                   /id="VSP_053567"
FT   VARIANT         220
FT                   /note="E -> D (in dbSNP:rs34625936)"
FT                   /id="VAR_049455"
FT   CONFLICT        185
FT                   /note="R -> H (in Ref. 1; AAA91320 and 6; ABV59313/
FT                   ABV59314/ABV59315/ABV59317)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        374
FT                   /note="W -> R (in Ref. 7; BAG36414)"
FT                   /evidence="ECO:0000305"
FT   HELIX           111..140
FT                   /evidence="ECO:0000244|PDB:6PB1"
FT   HELIX           147..170
FT                   /evidence="ECO:0000244|PDB:6PB1"
FT   HELIX           174..178
FT                   /evidence="ECO:0000244|PDB:6PB1"
FT   HELIX           182..213
FT                   /evidence="ECO:0000244|PDB:6PB1"
FT   HELIX           219..221
FT                   /evidence="ECO:0000244|PDB:6PB1"
FT   HELIX           224..231
FT                   /evidence="ECO:0000244|PDB:6PB1"
FT   TURN            232..236
FT                   /evidence="ECO:0000244|PDB:6PB1"
FT   HELIX           237..247
FT                   /evidence="ECO:0000244|PDB:6PB1"
FT   HELIX           253..255
FT                   /evidence="ECO:0000244|PDB:6PB1"
FT   HELIX           266..297
FT                   /evidence="ECO:0000244|PDB:6PB1"
FT   HELIX           301..315
FT                   /evidence="ECO:0000244|PDB:6PB1"
FT   TURN            316..320
FT                   /evidence="ECO:0000244|PDB:6PB1"
FT   HELIX           321..324
FT                   /evidence="ECO:0000244|PDB:6PB1"
FT   HELIX           334..349
FT                   /evidence="ECO:0000244|PDB:6PB1"
FT   HELIX           351..360
FT                   /evidence="ECO:0000244|PDB:6PB1"
FT   HELIX           364..381
FT                   /evidence="ECO:0000244|PDB:6PB1"
FT   DISULFID        Q13324-2:51..77
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   411 AA;  47688 MW;  96B99A93594CF07F CRC64;
     MDAALLHSLL EANCSLALAE ELLLDGWGPP LDPEGPYSYC NTTLDQIGTC WPRSAAGALV
     ERPCPEYFNG VKYNTTRNAY RECLENGTWA SKINYSQCEP ILDDKQRKYD LHYRIALVVN
     YLGHCVSVAA LVAAFLLFLA LRSIRCLRNV IHWNLITTFI LRNVMWFLLQ LVDHEVHESN
     EVWCRCITTI FNYFVVTNFF WMFVEGCYLH TAIVMTYSTE RLRKCLFLFI GWCIPFPIIV
     AWAIGKLYYE NEQCWFGKEP GDLVDYIYQG PIILVLLINF VFLFNIVRIL MTKLRASTTS
     ETIQYRKAVK ATLVLLPLLG ITYMLFFVNP GEDDLSQIMF IYFNSFLQSF QGFFVSVFYC
     FFNGEVRSAV RKRWHRWQDH HSLRVPMARA MSIPTSPTRI SFHSIKQTAA V
//
ID   CRFR1_HUMAN             Reviewed;         444 AA.
AC   P34998; B4DIE9; Q13008; Q4QRJ1; Q9UK64;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1994, sequence version 1.
DT   12-AUG-2020, entry version 203.
DE   RecName: Full=Corticotropin-releasing factor receptor 1;
DE            Short=CRF-R-1;
DE            Short=CRF-R1;
DE            Short=CRFR-1;
DE   AltName: Full=Corticotropin-releasing hormone receptor 1;
DE            Short=CRH-R-1;
DE            Short=CRH-R1;
DE   Flags: Precursor;
GN   Name=CRHR1; Synonyms=CRFR, CRFR1, CRHR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS CRF-R1 AND CRF-R2).
RC   TISSUE=Pituitary;
RX   PubMed=7692441; DOI=10.1073/pnas.90.19.8967;
RA   Chen R., Lewis K.A., Perrin M.H., Vale W.W.;
RT   "Expression cloning of a human corticotropin-releasing-factor receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:8967-8971(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM CRF-R2), AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=8243652; DOI=10.1016/0014-5793(93)80427-v;
RA   Vita N., Laurent P., Lefort S., Chalon P., Lelias J.-M., Kaghad M.,
RA   le Fur G., Caput D., Ferrara P.;
RT   "Primary structure and functional expression of mouse pituitary and human
RT   brain corticotrophin releasing factor receptors.";
RL   FEBS Lett. 335:1-5(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9757017; DOI=10.1016/s0378-1119(98)00322-9;
RA   Sakai K., Yamada M., Horiba N., Wakui M., Demura H., Suda T.;
RT   "The genomic organization of the human corticotropin-releasing factor type-
RT   1 receptor.";
RL   Gene 219:125-130(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM CRF-R3).
RC   TISSUE=Hippocampus;
RX   PubMed=7811272; DOI=10.1006/bbrc.1994.2884;
RA   Ross P.C., Kostas C.M., Ramabhadran T.V.;
RT   "A variant of the human corticotropin-releasing factor (CRF) receptor:
RT   cloning, expression and pharmacology.";
RL   Biochem. Biophys. Res. Commun. 205:1836-1842(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM CRF-R4).
RX   PubMed=10598591; DOI=10.1210/mend.13.12.0391;
RA   Grammatopoulos D.K., Dai Y., Randeva H.S., Levine M.A., Karteris E.,
RA   Easton A.J., Hillhouse E.W.;
RT   "A novel spliced variant of the type 1 corticotropin-releasing hormone
RT   receptor with a deletion in the seventh transmembrane domain present in the
RT   human pregnant term myometrium and fetal membranes.";
RL   Mol. Endocrinol. 13:2189-2202(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5).
RA   Sherrin T., Murthy S.R., Spiess J.;
RT   "A novel CRF1 splice isoform involved in neurodegenerative and stress
RT   disorders.";
RL   Submitted (DEC-2008) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM CRF-R2).
RC   TISSUE=Brain;
RA   King M.M., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (NOV-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM CRF-R2).
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y.,
RA   Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A.,
RA   Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y.,
RA   Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T.,
RA   Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y.,
RA   Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S.,
RA   Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in vitro-
RT   expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5).
RC   TISSUE=Hippocampus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM CRF-R2).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   PROTEIN SEQUENCE OF 24-31, AND DISULFIDE BONDS.
RX   PubMed=11425856; DOI=10.1074/jbc.m101838200;
RA   Perrin M.H., Fischer W.H., Kunitake K.S., Craig A.G., Koerber S.C.,
RA   Cervini L.A., Rivier J.E., Groppe J.C., Greenwald J., Moller Nielsen S.,
RA   Vale W.W.;
RT   "Expression, purification, and characterization of a soluble form of the
RT   first extracellular domain of the human type 1 corticotropin releasing
RT   factor receptor.";
RL   J. Biol. Chem. 276:31528-31534(2001).
RN   [14]
RP   PHOSPHORYLATION AT SER-330.
RX   PubMed=14657255; DOI=10.1210/me.2003-0365;
RA   Papadopoulou N., Chen J., Randeva H.S., Levine M.A., Hillhouse E.W.,
RA   Grammatopoulos D.K.;
RT   "Protein kinase A-induced negative regulation of the corticotropin-
RT   releasing hormone R1alpha receptor-extracellularly regulated kinase signal
RT   transduction pathway: the critical role of Ser301 for signaling switch and
RT   selectivity.";
RL   Mol. Endocrinol. 18:624-639(2004).
RN   [15]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=18292205; DOI=10.1124/mol.107.043612;
RA   Tao J., Hildebrand M.E., Liao P., Liang M.C., Tan G., Li S., Snutch T.P.,
RA   Soong T.W.;
RT   "Activation of corticotropin-releasing factor receptor 1 selectively
RT   inhibits CaV3.2 T-type calcium channels.";
RL   Mol. Pharmacol. 73:1596-1609(2008).
RN   [16]
RP   INTERACTION WITH CRF AND UCN.
RX   PubMed=20966082; DOI=10.1074/jbc.m110.186072;
RA   Pal K., Swaminathan K., Xu H.E., Pioszak A.A.;
RT   "Structural basis for hormone recognition by the Human CRFR2{alpha} G
RT   protein-coupled receptor.";
RL   J. Biol. Chem. 285:40351-40361(2010).
RN   [17]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH DLG1.
RX   PubMed=23576434; DOI=10.1074/jbc.m113.473660;
RA   Dunn H.A., Walther C., Godin C.M., Hall R.A., Ferguson S.S.;
RT   "Role of SAP97 protein in the regulation of corticotropin-releasing factor
RT   receptor 1 endocytosis and extracellular signal-regulated kinase 1/2
RT   signaling.";
RL   J. Biol. Chem. 288:15023-15034(2013).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (1.96 ANGSTROMS) OF 24-119 IN COMPLEX WITH CRH,
RP   FUNCTION, AND DISULFIDE BONDS.
RX   PubMed=18801728; DOI=10.1074/jbc.m805749200;
RA   Pioszak A.A., Parker N.R., Suino-Powell K., Xu H.E.;
RT   "Molecular recognition of corticotropin-releasing factor by its G-protein-
RT   coupled receptor CRFR1.";
RL   J. Biol. Chem. 283:32900-32912(2008).
RN   [19]
RP   STRUCTURE BY NMR OF 25-109 IN COMPLEX WITH SYNTHETIC CRH ANALOG.
RX   PubMed=20843795; DOI=10.1074/jbc.m110.121897;
RA   Grace C.R., Perrin M.H., Gulyas J., Rivier J.E., Vale W.W., Riek R.;
RT   "NMR structure of the first extracellular domain of corticotropin-releasing
RT   factor receptor 1 (ECD1-CRF-R1) complexed with a high affinity agonist.";
RL   J. Biol. Chem. 285:38580-38589(2010).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.98 ANGSTROMS) OF 104-373 IN COMPLEX WITH THE
RP   SYNTHETIC ANTAGONIST CP-376395, FUNCTION, SUBCELLULAR LOCATION, MEMBRANE
RP   TOPOLOGY, DISULFIDE BOND, ANTAGONIST BINDING SITES, AND MUTAGENESIS OF
RP   PHE-232; MET-235; LEU-309; ASN-312; PHE-313; LEU-316; ILE-319; TYR-356 AND
RP   GLN-384.
RX   PubMed=23863939; DOI=10.1038/nature12357;
RA   Hollenstein K., Kean J., Bortolato A., Cheng R.K., Dore A.S., Jazayeri A.,
RA   Cooke R.M., Weir M., Marshall F.H.;
RT   "Structure of class B GPCR corticotropin-releasing factor receptor 1.";
RL   Nature 499:438-443(2013).
CC   -!- FUNCTION: G-protein coupled receptor for CRH (corticotropin-releasing
CC       factor) and UCN (urocortin). Has high affinity for CRH and UCN. Ligand
CC       binding causes a conformation change that triggers signaling via
CC       guanine nucleotide-binding proteins (G proteins) and down-stream
CC       effectors, such as adenylate cyclase. Promotes the activation of
CC       adenylate cyclase, leading to increased intracellular cAMP levels.
CC       Inhibits the activity of the calcium channel CACNA1H. Required for
CC       normal embryonic development of the adrenal gland and for normal
CC       hormonal responses to stress. Plays a role in the response to
CC       anxiogenic stimuli. {ECO:0000269|PubMed:18292205,
CC       ECO:0000269|PubMed:18801728, ECO:0000269|PubMed:23576434,
CC       ECO:0000269|PubMed:23863939}.
CC   -!- SUBUNIT: Heterodimer; heterodimerizes with GPER1 (By similarity).
CC       Interacts (via N-terminal extracellular domain) with CRH and UCN.
CC       Interacts with DLG1; this inhibits endocytosis of CRHR1 after agonist
CC       binding. {ECO:0000250, ECO:0000269|PubMed:18801728,
CC       ECO:0000269|PubMed:20843795, ECO:0000269|PubMed:20966082,
CC       ECO:0000269|PubMed:23576434, ECO:0000269|PubMed:23863939}.
CC   -!- INTERACTION:
CC       P34998; P06850: CRH; NbExp=2; IntAct=EBI-3870393, EBI-3870390;
CC       P34998; Q12959: DLG1; NbExp=2; IntAct=EBI-3870393, EBI-357481;
CC       P34998; Q14160: SCRIB; NbExp=3; IntAct=EBI-3870393, EBI-357345;
CC       P34998; Q63622: Dlg2; Xeno; NbExp=2; IntAct=EBI-3870393, EBI-396947;
CC       P34998; O88382: Magi2; Xeno; NbExp=2; IntAct=EBI-3870393, EBI-696179;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC       Endosome. Note=Agonist-binding promotes endocytosis.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=CRF-R1;
CC         IsoId=P34998-1; Sequence=Displayed;
CC       Name=CRF-R2;
CC         IsoId=P34998-2; Sequence=VSP_001997;
CC       Name=CRF-R3;
CC         IsoId=P34998-3; Sequence=VSP_001996, VSP_001997;
CC       Name=CRF-R4; Synonyms=1D;
CC         IsoId=P34998-4; Sequence=VSP_001997, VSP_001998;
CC       Name=5;
CC         IsoId=P34998-5; Sequence=VSP_045434;
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in the cerebellum,
CC       pituitary, cerebral cortex and olfactory lobe.
CC       {ECO:0000269|PubMed:8243652}.
CC   -!- DOMAIN: The transmembrane domain is composed of seven transmembrane
CC       helices that are arranged in V-shape. Transmembrane helix 7 assumes a
CC       sharply kinked structure. The antagonist CP-376395 binds at an
CC       allosteric site, far from the presumed binding site for the
CC       physiological peptide ligand.
CC   -!- PTM: C-terminal Ser or Thr residues may be phosphorylated.
CC       {ECO:0000269|PubMed:14657255}.
CC   -!- PTM: Phosphorylation at Ser-330 by PKA prevents maximal coupling to Gq-
CC       protein, and thereby negatively regulates downstream signaling.
CC       {ECO:0000269|PubMed:14657255}.
CC   -!- MISCELLANEOUS: [Isoform CRF-R2]: Major isoform. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform CRF-R3]: Does not bind to CRF with high
CC       affinity. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 2 family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L23333; AAA35719.1; -; mRNA.
DR   EMBL; L23332; AAA35718.1; -; mRNA.
DR   EMBL; X72304; CAA51052.1; -; mRNA.
DR   EMBL; AF039523; AAC69993.1; -; Genomic_DNA.
DR   EMBL; AF039510; AAC69993.1; JOINED; Genomic_DNA.
DR   EMBL; AF039511; AAC69993.1; JOINED; Genomic_DNA.
DR   EMBL; AF039512; AAC69993.1; JOINED; Genomic_DNA.
DR   EMBL; AF039513; AAC69993.1; JOINED; Genomic_DNA.
DR   EMBL; AF039514; AAC69993.1; JOINED; Genomic_DNA.
DR   EMBL; AF039515; AAC69993.1; JOINED; Genomic_DNA.
DR   EMBL; AF039516; AAC69993.1; JOINED; Genomic_DNA.
DR   EMBL; AF039517; AAC69993.1; JOINED; Genomic_DNA.
DR   EMBL; AF039518; AAC69993.1; JOINED; Genomic_DNA.
DR   EMBL; AF039519; AAC69993.1; JOINED; Genomic_DNA.
DR   EMBL; AF039520; AAC69993.1; JOINED; Genomic_DNA.
DR   EMBL; AF039521; AAC69993.1; JOINED; Genomic_DNA.
DR   EMBL; AF039522; AAC69993.1; JOINED; Genomic_DNA.
DR   EMBL; U16273; AAC50073.1; -; mRNA.
DR   EMBL; AF180301; AAD52688.1; -; mRNA.
DR   EMBL; FJ543100; ACU68591.1; -; mRNA.
DR   EMBL; AY457172; AAR19768.1; -; mRNA.
DR   EMBL; AB451466; BAG70280.1; -; mRNA.
DR   EMBL; AK295559; BAG58461.1; -; mRNA.
DR   EMBL; AC126544; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC217770; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC217771; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC217774; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC225613; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471233; EAW93557.1; -; Genomic_DNA.
DR   EMBL; BC096836; AAH96836.1; -; mRNA.
DR   CCDS; CCDS42350.1; -. [P34998-2]
DR   CCDS; CCDS45712.1; -. [P34998-1]
DR   CCDS; CCDS45713.1; -. [P34998-4]
DR   CCDS; CCDS45714.1; -. [P34998-3]
DR   CCDS; CCDS58556.1; -. [P34998-5]
DR   PIR; I38879; I38879.
DR   PIR; I60975; A48260.
DR   RefSeq; NP_001138618.1; NM_001145146.1. [P34998-1]
DR   RefSeq; NP_001138619.1; NM_001145147.1. [P34998-3]
DR   RefSeq; NP_001138620.1; NM_001145148.1. [P34998-4]
DR   RefSeq; NP_001243228.1; NM_001256299.2. [P34998-5]
DR   RefSeq; NP_001289945.1; NM_001303016.1.
DR   RefSeq; NP_001289947.1; NM_001303018.1. [P34998-5]
DR   RefSeq; NP_004373.2; NM_004382.4. [P34998-2]
DR   PDB; 2L27; NMR; -; A=25-108.
DR   PDB; 3EHS; X-ray; 2.76 A; A=24-119.
DR   PDB; 3EHT; X-ray; 3.40 A; A=24-119.
DR   PDB; 3EHU; X-ray; 1.96 A; A/B=24-119.
DR   PDB; 4K5Y; X-ray; 2.98 A; A/B/C=104-373.
DR   PDB; 4Z9G; X-ray; 3.18 A; A/B/C=104-249, A/B/C=252-401.
DR   PDB; 6P9X; EM; 2.91 A; R=23-444.
DR   PDB; 6PB0; EM; 3.00 A; R=24-427.
DR   PDBsum; 2L27; -.
DR   PDBsum; 3EHS; -.
DR   PDBsum; 3EHT; -.
DR   PDBsum; 3EHU; -.
DR   PDBsum; 4K5Y; -.
DR   PDBsum; 4Z9G; -.
DR   PDBsum; 6P9X; -.
DR   PDBsum; 6PB0; -.
DR   SMR; P34998; -.
DR   BioGRID; 107784; 18.
DR   IntAct; P34998; 7.
DR   MINT; P34998; -.
DR   STRING; 9606.ENSP00000381333; -.
DR   BindingDB; P34998; -.
DR   ChEMBL; CHEMBL1800; -.
DR   DrugBank; DB09067; Corticorelin ovine triflutate.
DR   DrugCentral; P34998; -.
DR   GuidetoPHARMACOLOGY; 212; -.
DR   TCDB; 9.A.14.4.3; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; P34998; 5 sites.
DR   iPTMnet; P34998; -.
DR   PhosphoSitePlus; P34998; -.
DR   BioMuta; CRHR1; -.
DR   DMDM; 461836; -.
DR   PaxDb; P34998; -.
DR   PeptideAtlas; P34998; -.
DR   PRIDE; P34998; -.
DR   ProteomicsDB; 4300; -.
DR   ProteomicsDB; 54968; -. [P34998-1]
DR   ProteomicsDB; 54969; -. [P34998-2]
DR   ProteomicsDB; 54970; -. [P34998-3]
DR   ProteomicsDB; 54971; -. [P34998-4]
DR   Antibodypedia; 8417; 369 antibodies.
DR   DNASU; 1394; -.
DR   Ensembl; ENST00000314537; ENSP00000326060; ENSG00000120088. [P34998-2]
DR   Ensembl; ENST00000352855; ENSP00000344068; ENSG00000120088. [P34998-3]
DR   Ensembl; ENST00000398285; ENSP00000381333; ENSG00000120088. [P34998-1]
DR   Ensembl; ENST00000577353; ENSP00000462016; ENSG00000120088. [P34998-4]
DR   Ensembl; ENST00000616274; ENSP00000480396; ENSG00000276191. [P34998-1]
DR   Ensembl; ENST00000616748; ENSP00000478177; ENSG00000276191. [P34998-3]
DR   Ensembl; ENST00000617905; ENSP00000483802; ENSG00000276191. [P34998-2]
DR   Ensembl; ENST00000633723; ENSP00000488342; ENSG00000276191. [P34998-4]
DR   GeneID; 104909134; -.
DR   GeneID; 1394; -.
DR   KEGG; hsa:104909134; -.
DR   KEGG; hsa:1394; -.
DR   UCSC; uc002ijm.4; human. [P34998-1]
DR   CTD; 104909134; -.
DR   CTD; 1394; -.
DR   DisGeNET; 104909134; -.
DR   DisGeNET; 1394; -.
DR   EuPathDB; HostDB:ENSG00000120088.14; -.
DR   GeneCards; CRHR1; -.
DR   HGNC; HGNC:2357; CRHR1.
DR   HPA; ENSG00000120088; Group enriched (brain, pituitary gland).
DR   MIM; 122561; gene.
DR   neXtProt; NX_P34998; -.
DR   OpenTargets; ENSG00000120088; -.
DR   OpenTargets; ENSG00000263715; -.
DR   PharmGKB; PA26874; -.
DR   eggNOG; KOG4564; Eukaryota.
DR   GeneTree; ENSGT00940000158410; -.
DR   InParanoid; P34998; -.
DR   KO; K04578; -.
DR   OMA; VHYHIAV; -.
DR   OrthoDB; 1163977at2759; -.
DR   PhylomeDB; P34998; -.
DR   TreeFam; TF315710; -.
DR   PathwayCommons; P34998; -.
DR   Reactome; R-HSA-373080; Class B/2 (Secretin family receptors).
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-9660821; ADORA2B mediated anti-inflammatory cytokines production.
DR   SIGNOR; P34998; -.
DR   BioGRID-ORCS; 104909134; 1 hit in 14 CRISPR screens.
DR   BioGRID-ORCS; 1394; 4 hits in 863 CRISPR screens.
DR   EvolutionaryTrace; P34998; -.
DR   GeneWiki; Corticotropin_releasing_hormone_receptor_1; -.
DR   Pharos; P34998; Tclin.
DR   PRO; PR:P34998; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; P34998; protein.
DR   Bgee; ENSG00000120088; Expressed in pituitary gland and 86 other tissues.
DR   ExpressionAtlas; P34998; baseline and differential.
DR   Genevisible; P34998; HS.
DR   GO; GO:0005768; C:endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0031226; C:intrinsic component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0015056; F:corticotrophin-releasing factor receptor activity; IDA:UniProtKB.
DR   GO; GO:0051424; F:corticotropin-releasing hormone binding; IBA:GO_Central.
DR   GO; GO:0043404; F:corticotropin-releasing hormone receptor activity; IBA:GO_Central.
DR   GO; GO:0008528; F:G protein-coupled peptide receptor activity; IBA:GO_Central.
DR   GO; GO:0017046; F:peptide hormone binding; IBA:GO_Central.
DR   GO; GO:0007190; P:activation of adenylate cyclase activity; TAS:ProtInc.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007188; P:adenylate cyclase-modulating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IEA:InterPro.
DR   GO; GO:0071376; P:cellular response to corticotropin-releasing hormone stimulus; IDA:UniProtKB.
DR   GO; GO:0051458; P:corticotropin secretion; ISS:UniProtKB.
DR   GO; GO:0007565; P:female pregnancy; NAS:ProtInc.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006955; P:immune response; TAS:ProtInc.
DR   GO; GO:1901386; P:negative regulation of voltage-gated calcium channel activity; IDA:UniProtKB.
DR   GO; GO:0007567; P:parturition; TAS:ProtInc.
DR   GO; GO:0010578; P:regulation of adenylate cyclase activity involved in G protein-coupled receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:2000852; P:regulation of corticosterone secretion; ISS:UniProtKB.
DR   Gene3D; 4.10.1240.10; -; 1.
DR   InterPro; IPR017981; GPCR_2-like.
DR   InterPro; IPR003052; GPCR_2_CRF1_rcpt.
DR   InterPro; IPR003051; GPCR_2_CRF_rcpt.
DR   InterPro; IPR036445; GPCR_2_extracell_dom_sf.
DR   InterPro; IPR001879; GPCR_2_extracellular_dom.
DR   InterPro; IPR000832; GPCR_2_secretin-like.
DR   InterPro; IPR017983; GPCR_2_secretin-like_CS.
DR   Pfam; PF00002; 7tm_2; 1.
DR   Pfam; PF02793; HRM; 1.
DR   PRINTS; PR01279; CRFRECEPTOR.
DR   PRINTS; PR01280; CRFRECEPTOR1.
DR   PRINTS; PR00249; GPCRSECRETIN.
DR   SMART; SM00008; HormR; 1.
DR   SUPFAM; SSF111418; SSF111418; 1.
DR   PROSITE; PS00649; G_PROTEIN_RECEP_F2_1; 1.
DR   PROSITE; PS00650; G_PROTEIN_RECEP_F2_2; 1.
DR   PROSITE; PS50227; G_PROTEIN_RECEP_F2_3; 1.
DR   PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane;
KW   Direct protein sequencing; Disulfide bond; Endosome;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Phosphoprotein;
KW   Receptor; Reference proteome; Signal; Transducer; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL          1..23
FT                   /evidence="ECO:0000269|PubMed:11425856"
FT   CHAIN           24..444
FT                   /note="Corticotropin-releasing factor receptor 1"
FT                   /id="PRO_0000012814"
FT   TOPO_DOM        24..111
FT                   /note="Extracellular"
FT   TRANSMEM        112..142
FT                   /note="Helical; Name=1"
FT   TOPO_DOM        143..178
FT                   /note="Cytoplasmic"
FT   TRANSMEM        179..203
FT                   /note="Helical; Name=2"
FT   TOPO_DOM        204..218
FT                   /note="Extracellular"
FT   TRANSMEM        219..247
FT                   /note="Helical; Name=3"
FT   TOPO_DOM        248..254
FT                   /note="Cytoplasmic"
FT   TRANSMEM        255..282
FT                   /note="Helical; Name=4"
FT   TOPO_DOM        283..298
FT                   /note="Extracellular"
FT   TRANSMEM        299..324
FT                   /note="Helical; Name=5"
FT   TOPO_DOM        325..335
FT                   /note="Cytoplasmic"
FT   TRANSMEM        336..360
FT                   /note="Helical; Name=6"
FT   TOPO_DOM        361..367
FT                   /note="Extracellular"
FT   TRANSMEM        368..397
FT                   /note="Helical; Name=7"
FT   TOPO_DOM        398..444
FT                   /note="Cytoplasmic"
FT   REGION          99..108
FT                   /note="Important for peptide agonist binding"
FT   REGION          309..319
FT                   /note="Important for antagonist binding"
FT   MOD_RES         330
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:14657255"
FT   CARBOHYD        38
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        45
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        78
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        90
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        98
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        30..54
FT   DISULFID        44..87
FT   DISULFID        68..102
FT   DISULFID        217..287
FT   VAR_SEQ         1..204
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:14702039, ECO:0000303|Ref.6"
FT                   /id="VSP_045434"
FT   VAR_SEQ         41..81
FT                   /note="GLQCNASVDLIGTCWPRSPAGQLVVRPCPAFFYGVRYNTTN -> D (in
FT                   isoform CRF-R3)"
FT                   /evidence="ECO:0000303|PubMed:7811272"
FT                   /id="VSP_001996"
FT   VAR_SEQ         146..174
FT                   /note="Missing (in isoform CRF-R2, isoform CRF-R3 and
FT                   isoform CRF-R4)"
FT                   /evidence="ECO:0000303|PubMed:10598591,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:19054851,
FT                   ECO:0000303|PubMed:7692441, ECO:0000303|PubMed:7811272,
FT                   ECO:0000303|PubMed:8243652, ECO:0000303|Ref.7"
FT                   /id="VSP_001997"
FT   VAR_SEQ         385..398
FT                   /note="Missing (in isoform CRF-R4)"
FT                   /evidence="ECO:0000303|PubMed:10598591"
FT                   /id="VSP_001998"
FT   MUTAGEN         232
FT                   /note="F->A: Nearly abolishes antagonist binding."
FT                   /evidence="ECO:0000269|PubMed:23863939"
FT   MUTAGEN         235
FT                   /note="M->A: Strongly reduces antagonist binding."
FT                   /evidence="ECO:0000269|PubMed:23863939"
FT   MUTAGEN         309
FT                   /note="L->A: Nearly abolishes antagonist binding."
FT                   /evidence="ECO:0000269|PubMed:23863939"
FT   MUTAGEN         312
FT                   /note="N->A: Nearly abolishes antagonist binding."
FT                   /evidence="ECO:0000269|PubMed:23863939"
FT   MUTAGEN         313
FT                   /note="F->A: Slightly reduces antagonist binding."
FT                   /evidence="ECO:0000269|PubMed:23863939"
FT   MUTAGEN         316
FT                   /note="L->A: Strongly reduces antagonist binding."
FT                   /evidence="ECO:0000269|PubMed:23863939"
FT   MUTAGEN         319
FT                   /note="I->A: Strongly reduces antagonist binding."
FT                   /evidence="ECO:0000269|PubMed:23863939"
FT   MUTAGEN         356
FT                   /note="Y->A: Strongly reduces antagonist binding."
FT                   /evidence="ECO:0000269|PubMed:23863939"
FT   MUTAGEN         384
FT                   /note="Q->A: Increases antagonist binding."
FT                   /evidence="ECO:0000269|PubMed:23863939"
FT   TURN            25..27
FT                   /evidence="ECO:0000244|PDB:3EHT"
FT   HELIX           28..32
FT                   /evidence="ECO:0000244|PDB:3EHU"
FT   STRAND          49..52
FT                   /evidence="ECO:0000244|PDB:2L27"
FT   STRAND          62..67
FT                   /evidence="ECO:0000244|PDB:3EHU"
FT   STRAND          70..74
FT                   /evidence="ECO:0000244|PDB:3EHU"
FT   STRAND          81..87
FT                   /evidence="ECO:0000244|PDB:3EHU"
FT   TURN            89..91
FT                   /evidence="ECO:0000244|PDB:2L27"
FT   STRAND          93..98
FT                   /evidence="ECO:0000244|PDB:3EHS"
FT   HELIX           99..101
FT                   /evidence="ECO:0000244|PDB:2L27"
FT   HELIX           103..107
FT                   /evidence="ECO:0000244|PDB:3EHS"
FT   HELIX           114..143
FT                   /evidence="ECO:0000244|PDB:6P9X"
FT   HELIX           175..177
FT                   /evidence="ECO:0000244|PDB:4K5Y"
FT   HELIX           179..203
FT                   /evidence="ECO:0000244|PDB:6P9X"
FT   HELIX           207..212
FT                   /evidence="ECO:0000244|PDB:6P9X"
FT   HELIX           215..235
FT                   /evidence="ECO:0000244|PDB:6P9X"
FT   HELIX           237..247
FT                   /evidence="ECO:0000244|PDB:6P9X"
FT   STRAND          249..252
FT                   /evidence="ECO:0000244|PDB:6P9X"
FT   HELIX           257..264
FT                   /evidence="ECO:0000244|PDB:6P9X"
FT   TURN            265..267
FT                   /evidence="ECO:0000244|PDB:6P9X"
FT   HELIX           268..281
FT                   /evidence="ECO:0000244|PDB:6P9X"
FT   HELIX           286..288
FT                   /evidence="ECO:0000244|PDB:6P9X"
FT   HELIX           299..330
FT                   /evidence="ECO:0000244|PDB:6P9X"
FT   HELIX           334..347
FT                   /evidence="ECO:0000244|PDB:6P9X"
FT   HELIX           349..352
FT                   /evidence="ECO:0000244|PDB:6P9X"
FT   HELIX           355..358
FT                   /evidence="ECO:0000244|PDB:6P9X"
FT   HELIX           367..382
FT                   /evidence="ECO:0000244|PDB:6P9X"
FT   HELIX           384..392
FT                   /evidence="ECO:0000244|PDB:6P9X"
FT   HELIX           397..408
FT                   /evidence="ECO:0000244|PDB:6P9X"
SQ   SEQUENCE   444 AA;  50719 MW;  7221AEFB0E7AA8ED CRC64;
     MGGHPQLRLV KALLLLGLNP VSASLQDQHC ESLSLASNIS GLQCNASVDL IGTCWPRSPA
     GQLVVRPCPA FFYGVRYNTT NNGYRECLAN GSWAARVNYS ECQEILNEEK KSKVHYHVAV
     IINYLGHCIS LVALLVAFVL FLRLRPGCTH WGDQADGALE VGAPWSGAPF QVRRSIRCLR
     NIIHWNLISA FILRNATWFV VQLTMSPEVH QSNVGWCRLV TAAYNYFHVT NFFWMFGEGC
     YLHTAIVLTY STDRLRKWMF ICIGWGVPFP IIVAWAIGKL YYDNEKCWFG KRPGVYTDYI
     YQGPMILVLL INFIFLFNIV RILMTKLRAS TTSETIQYRK AVKATLVLLP LLGITYMLFF
     VNPGEDEVSR VVFIYFNSFL ESFQGFFVSV FYCFLNSEVR SAIRKRWHRW QDKHSIRARV
     ARAMSIPTSP TRVSFHSIKQ STAV
//
ID   CALCR_HUMAN             Reviewed;         474 AA.
AC   P30988; A4D1G6; F5H605; O14585; Q13941; Q5ZGL8; Q659U6; Q6DJU8; Q6T712;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   03-JUL-2019, sequence version 3.
DT   07-OCT-2020, entry version 207.
DE   RecName: Full=Calcitonin receptor;
DE            Short=CT-R;
DE   Flags: Precursor;
GN   Name=CALCR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Ovarian carcinoma;
RX   PubMed=1331173; DOI=10.1172/jci116046;
RA   Gorn A.H., Lin H.Y., Yamin M., Auron P.E., Flannery M.R., Tapp D.R.,
RA   Manning C.A., Lodish H.F., Krane S.M., Goldring S.R.;
RT   "Cloning, characterization, and expression of a human calcitonin receptor
RT   from an ovarian carcinoma cell line.";
RL   J. Clin. Invest. 90:1726-1735(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT LEU-447.
RX   PubMed=8078488;
RA   Kuestner R.E., Elrod R.D., Grant F.J., Hagen F.S., Kuijper J.L.,
RA   Mathewes S.L., O'Hara P.J., Sheppard P.O., Stroop S.D., Thompson D.L.,
RA   Whitmore T.E., Findlays D.M., Houssamis S., Sexton P.M., Moore E.E.;
RT   "Cloning and characterization of an abundant subtype of the human
RT   calcitonin receptor.";
RL   Mol. Pharmacol. 46:246-255(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3), ALTERNATIVE SPLICING, AND
RP   VARIANT LEU-447.
RC   TISSUE=Mammary carcinoma;
RX   PubMed=7588285; DOI=10.1210/endo.136.12.7588285;
RA   Albrandt K., Brady E.M.G., Moore C.X., Mull E., Sierzega M.E., Beaumont K.;
RT   "Molecular cloning and functional expression of a third isoform of the
RT   human calcitonin receptor and partial characterization of the calcitonin
RT   receptor gene.";
RL   Endocrinology 136:5377-5384(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT LEU-447.
RX   PubMed=8143880; DOI=10.1016/0014-5793(94)80503-2;
RA   Frendo J.L., Pichaud F., Delage-Mourroux R., Bouizar Z., Segond N.,
RA   Moukhtar M.S., Jullienne A.;
RT   "An isoform of the human calcitonin receptor is expressed in TT cells and
RT   in medullary carcinoma of the thyroid.";
RL   FEBS Lett. 342:214-216(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Mammary carcinoma;
RX   PubMed=10570950; DOI=10.1016/s0014-5793(99)01176-x;
RA   Nishikawa T., Ishikawa H., Yamamoto S., Koshihara Y.;
RT   "A novel calcitonin receptor gene in human osteoclasts from normal bone
RT   marrow.";
RL   FEBS Lett. 458:409-414(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5 AND 6).
RX   PubMed=15563840; DOI=10.1016/j.gene.2004.08.019;
RA   Beaudreuil J., Balasubramanian S., Chenais J., Taboulet J., Frenkian M.,
RA   Orcel P., Jullienne A., Horne W., de Vernejoul M.C., Cressent M.;
RT   "Molecular characterization of two novel isoforms of the human calcitonin
RT   receptor.";
RL   Gene 343:143-151(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT LEU-447.
RC   TISSUE=Cartilage;
RA   Bonnefond C.;
RT   "Identification of the human calcitonin receptor expressed in
RT   osteoarthritis chondrocytes.";
RL   Submitted (JUN-2010) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT LEU-447.
RC   TISSUE=Kidney;
RA   King M.M., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT LEU-447.
RC   TISSUE=Amygdala;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT LEU-447.
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT LEU-447.
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D.,
RA   Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S.,
RA   Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R.,
RA   Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N.,
RA   Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E.,
RA   Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R.,
RA   Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T.,
RA   Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W.,
RA   Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A.,
RA   Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X.,
RA   Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E.,
RA   Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J.,
RA   Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT LEU-447.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT LEU-447.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [14]
RP   PROTEIN SEQUENCE OF 25-39.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally verified
RT   cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [15]
RP   ALTERNATIVE SPLICING.
RC   TISSUE=Placenta;
RX   PubMed=7720653; DOI=10.1210/endo.136.5.7720653;
RA   Nussenzveig D.R., Mathew S., Gershengorn M.C.;
RT   "Alternative splicing of a 48-nucleotide exon generates two isoforms of the
RT   human calcitonin receptor.";
RL   Endocrinology 136:2047-2051(1995).
RN   [16]
RP   ALTERNATIVE SPLICING.
RX   PubMed=7733946; DOI=10.1006/bbrc.1995.1562;
RA   Nakamura M., Hashimoto T., Nakajima T., Ichii S., Furuyama J., Ishihara Y.,
RA   Kakudo K.;
RT   "A new type of human calcitonin receptor isoform generated by alternative
RT   splicing.";
RL   Biochem. Biophys. Res. Commun. 209:744-751(1995).
RN   [17]
RP   ALTERNATIVE SPLICING, AND FUNCTION.
RX   PubMed=7476993; DOI=10.1210/mend.9.8.7476993;
RA   Moore E.E., Kuestner R.E., Stroop S.D., Grant F.J., Matthewes S.L.,
RA   Brady C.L., Sexton P.M., Findlay D.M.;
RT   "Functionally different isoforms of the human calcitonin receptor result
RT   from alternative splicing of the gene transcript.";
RL   Mol. Endocrinol. 9:959-968(1995).
RN   [18]
RP   ALTERNATIVE PROMOTER USAGE.
RX   PubMed=10860825; DOI=10.1006/bbrc.2000.2842;
RA   Hebden C., Smalt R., Chambers T., Pondel M.D.;
RT   "Multiple promoters regulate human calcitonin receptor gene expression.";
RL   Biochem. Biophys. Res. Commun. 272:738-743(2000).
RN   [19]
RP   INTERACTION WITH GPRASP2.
RX   PubMed=15086532; DOI=10.1111/j.1471-4159.2004.02411.x;
RA   Simonin F., Karcher P., Boeuf J.J.-M., Matifas A., Kieffer B.L.;
RT   "Identification of a novel family of G protein-coupled receptor associated
RT   sorting proteins.";
RL   J. Neurochem. 89:766-775(2004).
RN   [20]
RP   INVOLVEMENT IN LUMBAR BMD.
RX   PubMed=9675109; DOI=10.1006/bbrc.1998.8880;
RA   Masi L., Becherini L., Colli E., Gennari L., Mansani R., Falchetti A.,
RA   Becorpi A.M., Cepollaro C., Gonnelli S., Tanini A., Brandi M.L.;
RT   "Polymorphisms of the calcitonin receptor gene are associated with bone
RT   mineral density in postmenopausal Italian women.";
RL   Biochem. Biophys. Res. Commun. 248:190-195(1998).
RN   [21]
RP   ALTERNATIVE SPLICING (ISOFORM 4).
RX   PubMed=22946511; DOI=10.1111/j.1476-5381.2012.02197.x;
RA   Qi T., Dong M., Watkins H.A., Wootten D., Miller L.J., Hay D.L.;
RT   "Receptor activity-modifying protein-dependent impairment of calcitonin
RT   receptor splice variant Delta(1-47)hCT((a)) function.";
RL   Br. J. Pharmacol. 168:644-657(2013).
RN   [22]
RP   ASSOCIATION OF VARIANT LEU-447 WITH LOWER LUMBAR BMD.
RX   PubMed=9571205; DOI=10.1006/bbrc.1998.8445;
RA   Masi L., Becherini L., Gennari L., Colli E., Mansani R., Falchetti A.,
RA   Cepollaro C., Gonnelli S., Tanini A., Brandi M.L.;
RT   "Allelic variants of human calcitonin receptor: distribution and
RT   association with bone mass in postmenopausal Italian women.";
RL   Biochem. Biophys. Res. Commun. 245:622-626(1998).
RN   [23]
RP   VARIANT LEU-447.
RX   PubMed=9817931; DOI=10.1093/hmg/7.13.2129;
RA   Taboulet J., Frenkian M., Frendo J.L., Feingold N., Jullienne A.,
RA   de Vernejoul M.-C.;
RT   "Calcitonin receptor polymorphism is associated with a decreased fracture
RT   risk in post-menopausal women.";
RL   Hum. Mol. Genet. 7:2129-2133(1998).
CC   -!- FUNCTION: This is a receptor for calcitonin. The activity of this
CC       receptor is mediated by G proteins which activate adenylyl cyclase. The
CC       calcitonin receptor is thought to couple to the heterotrimeric
CC       guanosine triphosphate-binding protein that is sensitive to cholera
CC       toxin.
CC   -!- FUNCTION: [Isoform 2]: Receptor for calcitonin but is unable to couple
CC       to G proteins and activate adenylyl cyclase (PubMed:7476993). Does not
CC       undergo receptor internalization following ligand binding
CC       (PubMed:7476993). {ECO:0000269|PubMed:7476993}.
CC   -!- SUBUNIT: Interacts with GPRASP2. {ECO:0000269|PubMed:15086532}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage, Alternative splicing; Named isoforms=6;
CC       Name=1;
CC         IsoId=P30988-2; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P30988-1; Sequence=VSP_060210, VSP_060211;
CC       Name=3;
CC         IsoId=P30988-3; Sequence=VSP_060209;
CC       Name=4; Synonyms=Delta(1-47)hCT((a));
CC         IsoId=P30988-4; Sequence=VSP_060209, VSP_060211;
CC       Name=5; Synonyms=HCTR-5;
CC         IsoId=P30988-5; Sequence=VSP_060212, VSP_060213;
CC       Name=6; Synonyms=HCTR-6;
CC         IsoId=P30988-6; Sequence=VSP_060211, VSP_060212, VSP_060213;
CC   -!- POLYMORPHISM: Genetic variations in CALCR may be correlated with bone
CC       mineral density (BMD). Low BMD is a risk factor for osteoporotic
CC       fracture. Osteoporosis is characterized by reduced bone mineral
CC       density, disruption of bone microarchitecture, and the alteration of
CC       the amount and variety of non-collagenous proteins in bone.
CC       Osteoporotic bones are more at risk of fracture.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 2 family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA35640.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L00587; AAA35640.1; ALT_INIT; mRNA.
DR   EMBL; X69920; CAA49541.1; -; mRNA.
DR   EMBL; U26553; AAC50300.1; -; mRNA.
DR   EMBL; U26554; AAC50301.1; -; mRNA.
DR   EMBL; X82466; CAA57849.1; -; mRNA.
DR   EMBL; S77876; AAD14268.1; -; Genomic_DNA.
DR   EMBL; S77875; AAD14268.1; JOINED; Genomic_DNA.
DR   EMBL; AB022177; BAA86929.1; -; mRNA.
DR   EMBL; AB022178; BAA86928.1; -; mRNA.
DR   EMBL; AJ831406; CAH40796.1; -; mRNA.
DR   EMBL; AJ831407; CAH40797.1; -; mRNA.
DR   EMBL; FN994995; CBN80567.1; -; mRNA.
DR   EMBL; FN994996; CBN80568.1; -; mRNA.
DR   EMBL; AY430048; AAR06949.1; -; mRNA.
DR   EMBL; AK313996; BAG36708.1; -; mRNA.
DR   EMBL; AC003078; AAB83945.1; -; Genomic_DNA.
DR   EMBL; AC005024; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH236949; EAL24142.1; -; Genomic_DNA.
DR   EMBL; CH471091; EAW76814.1; -; Genomic_DNA.
DR   EMBL; BC069611; AAH69611.1; -; mRNA.
DR   EMBL; BC075028; AAH75028.2; -; mRNA.
DR   CCDS; CCDS5631.1; -. [P30988-2]
DR   PIR; I37217; I37217.
DR   PIR; S34486; S34486.
DR   RefSeq; NP_001158209.1; NM_001164737.1.
DR   RefSeq; NP_001158210.1; NM_001164738.1.
DR   RefSeq; NP_001733.1; NM_001742.3.
DR   PDB; 5II0; X-ray; 2.10 A; A/B/C=25-144.
DR   PDB; 5UZ7; EM; 4.10 A; R=25-474.
DR   PDB; 6NIY; EM; 3.34 A; R=1-474.
DR   PDB; 6PFO; X-ray; 1.78 A; A/B=38-141.
DR   PDB; 6PGQ; X-ray; 2.85 A; A=39-141.
DR   PDBsum; 5II0; -.
DR   PDBsum; 5UZ7; -.
DR   PDBsum; 6NIY; -.
DR   PDBsum; 6PFO; -.
DR   PDBsum; 6PGQ; -.
DR   SMR; P30988; -.
DR   BioGRID; 107250; 6.
DR   ComplexPortal; CPX-2173; Amylin receptor 1 complex.
DR   ComplexPortal; CPX-3186; Amylin receptor 2 complex.
DR   ComplexPortal; CPX-3187; Amylin receptor 3 complex.
DR   IntAct; P30988; 8.
DR   MINT; P30988; -.
DR   STRING; 9606.ENSP00000352561; -.
DR   ChEMBL; CHEMBL1832; -.
DR   DrugBank; DB01278; Pramlintide.
DR   DrugBank; DB00017; Salmon calcitonin.
DR   DrugCentral; P30988; -.
DR   GuidetoPHARMACOLOGY; 43; -.
DR   TCDB; 9.A.14.4.1; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; P30988; 4 sites.
DR   iPTMnet; P30988; -.
DR   PhosphoSitePlus; P30988; -.
DR   BioMuta; CALCR; -.
DR   DMDM; 550544247; -.
DR   PaxDb; P30988; -.
DR   PeptideAtlas; P30988; -.
DR   PRIDE; P30988; -.
DR   ProteomicsDB; 27039; -.
DR   ProteomicsDB; 54752; -. [P30988-1]
DR   ProteomicsDB; 54753; -. [P30988-2]
DR   ProteomicsDB; 54754; -. [P30988-3]
DR   ProteomicsDB; 620; -.
DR   ProteomicsDB; 65864; -.
DR   ProteomicsDB; 65945; -.
DR   Ensembl; ENST00000415529; ENSP00000413179; ENSG00000004948. [P30988-5]
DR   Ensembl; ENST00000423724; ENSP00000391369; ENSG00000004948. [P30988-6]
DR   GeneID; 799; -.
DR   KEGG; hsa:799; -.
DR   UCSC; uc003umw.3; human. [P30988-2]
DR   CTD; 799; -.
DR   DisGeNET; 799; -.
DR   EuPathDB; HostDB:ENSG00000004948.13; -.
DR   GeneCards; CALCR; -.
DR   HGNC; HGNC:1440; CALCR.
DR   MalaCards; CALCR; -.
DR   MIM; 114131; gene.
DR   neXtProt; NX_P30988; -.
DR   OpenTargets; ENSG00000004948; -.
DR   PharmGKB; PA26032; -.
DR   eggNOG; KOG4564; Eukaryota.
DR   GeneTree; ENSGT00940000155380; -.
DR   HOGENOM; CLU_002753_4_6_1; -.
DR   InParanoid; P30988; -.
DR   KO; K04576; -.
DR   OrthoDB; 1005634at2759; -.
DR   TreeFam; TF315710; -.
DR   PathwayCommons; P30988; -.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-419812; Calcitonin-like ligand receptors.
DR   Reactome; R-HSA-9660821; ADORA2B mediated anti-inflammatory cytokines production.
DR   BioGRID-ORCS; 799; 3 hits in 867 CRISPR screens.
DR   GeneWiki; Calcitonin_receptor; -.
DR   GenomeRNAi; 799; -.
DR   Pharos; P30988; Tclin.
DR   PRO; PR:P30988; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; P30988; protein.
DR   Bgee; ENSG00000004948; Expressed in tibia and 69 other tissues.
DR   ExpressionAtlas; P30988; baseline and differential.
DR   Genevisible; P30988; HS.
DR   GO; GO:0150056; C:amylin receptor complex 1; IDA:ARUK-UCL.
DR   GO; GO:0150057; C:amylin receptor complex 2; IDA:ARUK-UCL.
DR   GO; GO:0150058; C:amylin receptor complex 3; IDA:ARUK-UCL.
DR   GO; GO:0030424; C:axon; IBA:GO_Central.
DR   GO; GO:0005887; C:integral component of plasma membrane; NAS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0097643; F:amylin receptor activity; IPI:UniProtKB.
DR   GO; GO:0001540; F:amyloid-beta binding; IC:ARUK-UCL.
DR   GO; GO:0032841; F:calcitonin binding; IDA:UniProtKB.
DR   GO; GO:0001635; F:calcitonin gene-related peptide receptor activity; IPI:UniProtKB.
DR   GO; GO:0004948; F:calcitonin receptor activity; IDA:UniProtKB.
DR   GO; GO:0008528; F:G protein-coupled peptide receptor activity; IBA:GO_Central.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007188; P:adenylate cyclase-modulating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0097647; P:amylin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IEA:InterPro.
DR   GO; GO:0038041; P:cross-receptor inhibition within G protein-coupled receptor heterodimer; IPI:UniProtKB.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0045762; P:positive regulation of adenylate cyclase activity; IDA:UniProtKB.
DR   GO; GO:1905665; P:positive regulation of calcium ion import across plasma membrane; IGI:ARUK-UCL.
DR   GO; GO:0010942; P:positive regulation of cell death; IGI:ARUK-UCL.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IDA:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IGI:ARUK-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IGI:ARUK-UCL.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IGI:ARUK-UCL.
DR   GO; GO:0010739; P:positive regulation of protein kinase A signaling; IGI:ARUK-UCL.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IGI:ARUK-UCL.
DR   GO; GO:1904645; P:response to amyloid-beta; IGI:ARUK-UCL.
DR   GO; GO:0051384; P:response to glucocorticoid; IDA:UniProtKB.
DR   Gene3D; 4.10.1240.10; -; 1.
DR   InterPro; IPR003287; GCPR_2_calcitonin_rcpt_fam.
DR   InterPro; IPR017981; GPCR_2-like.
DR   InterPro; IPR001688; GPCR_2_calcitonin_rcpt.
DR   InterPro; IPR036445; GPCR_2_extracell_dom_sf.
DR   InterPro; IPR001879; GPCR_2_extracellular_dom.
DR   InterPro; IPR000832; GPCR_2_secretin-like.
DR   InterPro; IPR017983; GPCR_2_secretin-like_CS.
DR   PANTHER; PTHR45620:SF8; PTHR45620:SF8; 1.
DR   Pfam; PF00002; 7tm_2; 1.
DR   Pfam; PF02793; HRM; 1.
DR   PRINTS; PR00361; CALCITONINR.
DR   PRINTS; PR01350; CTRFAMILY.
DR   PRINTS; PR00249; GPCRSECRETIN.
DR   SMART; SM00008; HormR; 1.
DR   SUPFAM; SSF111418; SSF111418; 1.
DR   PROSITE; PS00649; G_PROTEIN_RECEP_F2_1; 1.
DR   PROSITE; PS00650; G_PROTEIN_RECEP_F2_2; 1.
DR   PROSITE; PS50227; G_PROTEIN_RECEP_F2_3; 1.
DR   PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative promoter usage; Alternative splicing;
KW   Cell membrane; Direct protein sequencing; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Polymorphism; Receptor;
KW   Reference proteome; Signal; Transducer; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..24
FT                   /evidence="ECO:0000269|PubMed:15340161"
FT   CHAIN           25..474
FT                   /note="Calcitonin receptor"
FT                   /id="PRO_0000447620"
FT   TOPO_DOM        25..152
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        153..173
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        174..186
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        187..207
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        208..233
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        234..254
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        255..258
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        259..279
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        280..296
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        297..317
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        318..340
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        341..361
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        362..373
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        374..394
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        395..474
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   CARBOHYD        28
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        73
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        125
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        130
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        55..81
FT                   /evidence="ECO:0000250"
FT   DISULFID        72..112
FT                   /evidence="ECO:0000250"
FT   DISULFID        95..134
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         1..47
FT                   /note="Missing (in isoform 3 and isoform 4)"
FT                   /id="VSP_060209"
FT   VAR_SEQ         1
FT                   /note="M -> MQFSGEKISGQRDLQKSKM (in isoform 2)"
FT                   /id="VSP_060210"
FT   VAR_SEQ         174
FT                   /note="R -> RKLTTIFPLNWKYRKAL (in isoform 2, isoform 4 and
FT                   isoform 6)"
FT                   /id="VSP_060211"
FT   VAR_SEQ         268..274
FT                   /note="GFPLVPT -> APAFHRD (in isoform 5 and isoform 6)"
FT                   /id="VSP_060212"
FT   VAR_SEQ         275..474
FT                   /note="Missing (in isoform 5 and isoform 6)"
FT                   /id="VSP_060213"
FT   VARIANT         447
FT                   /note="P -> L (may be correlated with low bone mineral
FT                   density (BMD); dbSNP:rs1801197)"
FT                   /evidence="ECO:0000269|PubMed:12690205,
FT                   ECO:0000269|PubMed:12853948, ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:7588285,
FT                   ECO:0000269|PubMed:8078488, ECO:0000269|PubMed:8143880,
FT                   ECO:0000269|PubMed:9817931, ECO:0000269|Ref.12,
FT                   ECO:0000269|Ref.7, ECO:0000269|Ref.8"
FT                   /id="VAR_003580"
FT   CONFLICT        347
FT                   /note="I -> T (in Ref. 3; AAC50301)"
FT                   /evidence="ECO:0000305"
FT   HELIX           41..61
FT                   /evidence="ECO:0000244|PDB:5II0"
FT   STRAND          67..69
FT                   /evidence="ECO:0000244|PDB:5II0"
FT   STRAND          90..94
FT                   /evidence="ECO:0000244|PDB:5II0"
FT   STRAND          97..99
FT                   /evidence="ECO:0000244|PDB:5II0"
FT   STRAND          106..112
FT                   /evidence="ECO:0000244|PDB:5II0"
FT   TURN            122..125
FT                   /evidence="ECO:0000244|PDB:5II0"
FT   HELIX           132..134
FT                   /evidence="ECO:0000244|PDB:5II0"
FT   HELIX           139..172
FT                   /evidence="ECO:0000244|PDB:6NIY"
FT   HELIX           174..176
FT                   /evidence="ECO:0000244|PDB:6NIY"
FT   HELIX           179..204
FT                   /evidence="ECO:0000244|PDB:6NIY"
FT   HELIX           218..248
FT                   /evidence="ECO:0000244|PDB:6NIY"
FT   HELIX           259..266
FT                   /evidence="ECO:0000244|PDB:6NIY"
FT   TURN            267..270
FT                   /evidence="ECO:0000244|PDB:6NIY"
FT   HELIX           271..284
FT                   /evidence="ECO:0000244|PDB:6NIY"
FT   HELIX           296..298
FT                   /evidence="ECO:0000244|PDB:6NIY"
FT   HELIX           299..329
FT                   /evidence="ECO:0000244|PDB:6NIY"
FT   HELIX           337..352
FT                   /evidence="ECO:0000244|PDB:6NIY"
FT   HELIX           355..358
FT                   /evidence="ECO:0000244|PDB:6NIY"
FT   HELIX           366..381
FT                   /evidence="ECO:0000244|PDB:6NIY"
FT   HELIX           383..392
FT                   /evidence="ECO:0000244|PDB:6NIY"
FT   HELIX           396..411
FT                   /evidence="ECO:0000244|PDB:6NIY"
SQ   SEQUENCE   474 AA;  55329 MW;  0D9FA80FF16E82D9 CRC64;
     MRFTFTSRCL ALFLLLNHPT PILPAFSNQT YPTIEPKPFL YVVGRKKMMD AQYKCYDRMQ
     QLPAYQGEGP YCNRTWDGWL CWDDTPAGVL SYQFCPDYFP DFDPSEKVTK YCDEKGVWFK
     HPENNRTWSN YTMCNAFTPE KLKNAYVLYY LAIVGHSLSI FTLVISLGIF VFFRSLGCQR
     VTLHKNMFLT YILNSMIIII HLVEVVPNGE LVRRDPVSCK ILHFFHQYMM ACNYFWMLCE
     GIYLHTLIVV AVFTEKQRLR WYYLLGWGFP LVPTTIHAIT RAVYFNDNCW LSVETHLLYI
     IHGPVMAALV VNFFFLLNIV RVLVTKMRET HEAESHMYLK AVKATMILVP LLGIQFVVFP
     WRPSNKMLGK IYDYVMHSLI HFQGFFVATI YCFCNNEVQT TVKRQWAQFK IQWNQRWGRR
     PSNRSARAAA AAAEAGDIPI YICHQEPRNE PANNQGEESA EIIPLNIIEQ ESSA
//
ID   ACM1_HUMAN              Reviewed;         460 AA.
AC   P11229; Q96RH1;
DT   01-JUL-1989, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1990, sequence version 2.
DT   07-OCT-2020, entry version 207.
DE   RecName: Full=Muscarinic acetylcholine receptor M1;
GN   Name=CHRM1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3697105; DOI=10.1093/nar/15.24.10604;
RA   Allard W.J., Sigal I.S., Dixon R.A.F.;
RT   "Sequence of the gene encoding the human M1 muscarinic acetylcholine
RT   receptor.";
RL   Nucleic Acids Res. 15:10604-10604(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2336407; DOI=10.1093/nar/18.8.2191;
RA   Chapman C.G., Browne M.J.;
RT   "Isolation of the human ml (Hml) muscarinic acetylcholine receptor gene by
RT   PCR amplification.";
RL   Nucleic Acids Res. 18:2191-2191(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3443095; DOI=10.1002/j.1460-2075.1987.tb02733.x;
RA   Peralta E.G., Ashkenazi A., Winslow J.W., Smith D.H., Ramachandran J.,
RA   Capon D.J.;
RT   "Distinct primary structures, ligand-binding properties and tissue-specific
RT   expression of four human muscarinic acetylcholine receptors.";
RL   EMBO J. 6:3923-3929(1987).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Arredondo J., Grando S.A.;
RT   "Cloning Cholinergic Receptors in Human Keratinocytes.";
RL   Submitted (MAY-2001) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   MUTAGENESIS.
RX   PubMed=1445347; DOI=10.1016/0006-291x(92)91346-r;
RA   Arden J.R., Nagata O., Shockley M.S., Philip M., Lameh J., Sadee W.;
RT   "Mutational analysis of third cytoplasmic loop domains in G-protein
RT   coupling of the HM1 muscarinic receptor.";
RL   Biochem. Biophys. Res. Commun. 188:1111-1115(1992).
RN   [9]
RP   INTERACTION WITH GPRASP2.
RX   PubMed=15086532; DOI=10.1111/j.1471-4159.2004.02411.x;
RA   Simonin F., Karcher P., Boeuf J.J.-M., Matifas A., Kieffer B.L.;
RT   "Identification of a novel family of G protein-coupled receptor associated
RT   sorting proteins.";
RL   J. Neurochem. 89:766-775(2004).
RN   [10]
RP   INTERACTION WITH TMEM147.
RX   PubMed=21056967; DOI=10.1124/mol.110.067363;
RA   Rosemond E., Rossi M., McMillin S.M., Scarselli M., Donaldson J.G.,
RA   Wess J.;
RT   "Regulation of M(3) muscarinic receptor expression and function by
RT   transmembrane protein 147.";
RL   Mol. Pharmacol. 79:251-261(2011).
CC   -!- FUNCTION: The muscarinic acetylcholine receptor mediates various
CC       cellular responses, including inhibition of adenylate cyclase,
CC       breakdown of phosphoinositides and modulation of potassium channels
CC       through the action of G proteins. Primary transducing effect is Pi
CC       turnover.
CC   -!- SUBUNIT: Interacts with GPRASP2 (PubMed:15086532). Interacts with
CC       TMEM147 (PubMed:21056967). {ECO:0000269|PubMed:15086532,
CC       ECO:0000269|PubMed:21056967}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein. Cell
CC       junction, synapse, postsynaptic cell membrane; Multi-pass membrane
CC       protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P11229-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P11229-2; Sequence=VSP_056651;
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       Muscarinic acetylcholine receptor subfamily. CHRM1 sub-subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Y00508; CAA68560.1; -; Genomic_DNA.
DR   EMBL; X52068; CAA36291.1; -; Genomic_DNA.
DR   EMBL; X15263; CAA33334.1; -; Genomic_DNA.
DR   EMBL; AF385587; AAK68112.1; -; mRNA.
DR   EMBL; AF498915; AAM18938.1; -; mRNA.
DR   EMBL; AP000438; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC007740; AAH07740.1; -; mRNA.
DR   EMBL; BC022984; AAH22984.1; -; mRNA.
DR   CCDS; CCDS8040.1; -. [P11229-1]
DR   PIR; S09508; S09508.
DR   RefSeq; NP_000729.2; NM_000738.2. [P11229-1]
DR   RefSeq; XP_011543044.1; XM_011544742.2. [P11229-1]
DR   PDB; 5CXV; X-ray; 2.70 A; A=2-218, A=355-460.
DR   PDB; 6OIJ; EM; 3.30 A; R=2-460.
DR   PDB; 6WJC; X-ray; 2.55 A; A=2-218, A=355-460.
DR   PDBsum; 5CXV; -.
DR   PDBsum; 6OIJ; -.
DR   PDBsum; 6WJC; -.
DR   SMR; P11229; -.
DR   BioGRID; 107550; 4.
DR   IntAct; P11229; 5.
DR   MINT; P11229; -.
DR   STRING; 9606.ENSP00000306490; -.
DR   BindingDB; P11229; -.
DR   ChEMBL; CHEMBL216; -.
DR   DrugBank; DB03128; Acetylcholine.
DR   DrugBank; DB08897; Aclidinium.
DR   DrugBank; DB05766; ACP-104.
DR   DrugBank; DB05752; ALKS 27.
DR   DrugBank; DB00321; Amitriptyline.
DR   DrugBank; DB00543; Amoxapine.
DR   DrugBank; DB00517; Anisotropine methylbromide.
DR   DrugBank; DB04365; Arecoline.
DR   DrugBank; DB01238; Aripiprazole.
DR   DrugBank; DB14185; Aripiprazole lauroxil.
DR   DrugBank; DB00572; Atropine.
DR   DrugBank; DB00245; Benzatropine.
DR   DrugBank; DB00767; Benzquinamide.
DR   DrugBank; DB01019; Bethanechol.
DR   DrugBank; DB00810; Biperiden.
DR   DrugBank; DB00835; Brompheniramine.
DR   DrugBank; DB00354; Buclizine.
DR   DrugBank; DB00411; Carbamoylcholine.
DR   DrugBank; DB00185; Cevimeline.
DR   DrugBank; DB00477; Chlorpromazine.
DR   DrugBank; DB01239; Chlorprothixene.
DR   DrugBank; DB00568; Cinnarizine.
DR   DrugBank; DB00771; Clidinium.
DR   DrugBank; DB00363; Clozapine.
DR   DrugBank; DB00907; Cocaine.
DR   DrugBank; DB00785; Cryptenamine.
DR   DrugBank; DB00979; Cyclopentolate.
DR   DrugBank; DB00942; Cycrimine.
DR   DrugBank; DB00434; Cyproheptadine.
DR   DrugBank; DB00496; Darifenacin.
DR   DrugBank; DB01151; Desipramine.
DR   DrugBank; DB00804; Dicyclomine.
DR   DrugBank; DB01231; Diphenidol.
DR   DrugBank; DB00280; Disopyramide.
DR   DrugBank; DB09167; Dosulepin.
DR   DrugBank; DB01142; Doxepin.
DR   DrugBank; DB00366; Doxylamine.
DR   DrugBank; DB01175; Escitalopram.
DR   DrugBank; DB09194; Etoperidone.
DR   DrugBank; DB06702; Fesoterodine.
DR   DrugBank; DB01148; Flavoxate.
DR   DrugBank; DB00875; Flupentixol.
DR   DrugBank; DB00483; Gallamine triethiodide.
DR   DrugBank; DB00986; Glycopyrronium.
DR   DrugBank; DB06787; Hexocyclium.
DR   DrugBank; DB11181; Homatropine.
DR   DrugBank; DB00725; Homatropine methylbromide.
DR   DrugBank; DB00424; Hyoscyamine.
DR   DrugBank; DB09262; Imidafenacin.
DR   DrugBank; DB00458; Imipramine.
DR   DrugBank; DB00332; Ipratropium.
DR   DrugBank; DB01221; Ketamine.
DR   DrugBank; DB00408; Loxapine.
DR   DrugBank; DB00934; Maprotiline.
DR   DrugBank; DB04843; Mepenzolate.
DR   DrugBank; DB00454; Meperidine.
DR   DrugBank; DB00940; Methantheline.
DR   DrugBank; DB01403; Methotrimeprazine.
DR   DrugBank; DB00462; Methscopolamine bromide.
DR   DrugBank; DB00340; Metixene.
DR   DrugBank; DB01233; Metoclopramide.
DR   DrugBank; DB00805; Minaprine.
DR   DrugBank; DB01618; Molindone.
DR   DrugBank; DB05152; NGX267.
DR   DrugBank; DB00622; Nicardipine.
DR   DrugBank; DB00540; Nortriptyline.
DR   DrugBank; DB00334; Olanzapine.
DR   DrugBank; DB01062; Oxybutynin.
DR   DrugBank; DB00383; Oxyphencyclimine.
DR   DrugBank; DB00219; Oxyphenonium.
DR   DrugBank; DB00715; Paroxetine.
DR   DrugBank; DB01085; Pilocarpine.
DR   DrugBank; DB00670; Pirenzepine.
DR   DrugBank; DB06153; Pizotifen.
DR   DrugBank; DB00387; Procyclidine.
DR   DrugBank; DB00392; Profenamine.
DR   DrugBank; DB00420; Promazine.
DR   DrugBank; DB01069; Promethazine.
DR   DrugBank; DB00782; Propantheline.
DR   DrugBank; DB00777; Propiomazine.
DR   DrugBank; DB12278; Propiverine.
DR   DrugBank; DB11156; Pyrantel.
DR   DrugBank; DB01224; Quetiapine.
DR   DrugBank; DB11855; Revefenacin.
DR   DrugBank; DB13581; Rociverine.
DR   DrugBank; DB00747; Scopolamine.
DR   DrugBank; DB01591; Solifenacin.
DR   DrugBank; DB02010; Staurosporine.
DR   DrugBank; DB00202; Succinylcholine.
DR   DrugBank; DB00342; Terfenadine.
DR   DrugBank; DB11235; Thonzylamine.
DR   DrugBank; DB01409; Tiotropium.
DR   DrugBank; DB01036; Tolterodine.
DR   DrugBank; DB00193; Tramadol.
DR   DrugBank; DB00505; Tridihexethyl.
DR   DrugBank; DB00508; Triflupromazine.
DR   DrugBank; DB00376; Trihexyphenidyl.
DR   DrugBank; DB09089; Trimebutine.
DR   DrugBank; DB00726; Trimipramine.
DR   DrugBank; DB00809; Tropicamide.
DR   DrugBank; DB00209; Trospium.
DR   DrugBank; DB09076; Umeclidinium.
DR   DrugBank; DB00246; Ziprasidone.
DR   DrugCentral; P11229; -.
DR   GuidetoPHARMACOLOGY; 13; -.
DR   GlyGen; P11229; 2 sites.
DR   iPTMnet; P11229; -.
DR   PhosphoSitePlus; P11229; -.
DR   BioMuta; CHRM1; -.
DR   DMDM; 113118; -.
DR   MassIVE; P11229; -.
DR   PaxDb; P11229; -.
DR   PeptideAtlas; P11229; -.
DR   PRIDE; P11229; -.
DR   ProteomicsDB; 52724; -. [P11229-1]
DR   ProteomicsDB; 77961; -.
DR   ABCD; P11229; 12 sequenced antibodies.
DR   Antibodypedia; 2948; 307 antibodies.
DR   DNASU; 1128; -.
DR   Ensembl; ENST00000306960; ENSP00000306490; ENSG00000168539. [P11229-1]
DR   Ensembl; ENST00000543973; ENSP00000441188; ENSG00000168539. [P11229-2]
DR   GeneID; 1128; -.
DR   KEGG; hsa:1128; -.
DR   UCSC; uc058cqg.1; human. [P11229-1]
DR   CTD; 1128; -.
DR   DisGeNET; 1128; -.
DR   EuPathDB; HostDB:ENSG00000168539.3; -.
DR   GeneCards; CHRM1; -.
DR   HGNC; HGNC:1950; CHRM1.
DR   HPA; ENSG00000168539; Group enriched (brain, prostate, salivary gland).
DR   MIM; 118510; gene.
DR   neXtProt; NX_P11229; -.
DR   OpenTargets; ENSG00000168539; -.
DR   PharmGKB; PA26484; -.
DR   eggNOG; KOG4220; Eukaryota.
DR   GeneTree; ENSGT00940000162301; -.
DR   HOGENOM; CLU_009579_11_2_1; -.
DR   InParanoid; P11229; -.
DR   KO; K04129; -.
DR   OMA; RCCRTPR; -.
DR   PhylomeDB; P11229; -.
DR   TreeFam; TF320495; -.
DR   PathwayCommons; P11229; -.
DR   Reactome; R-HSA-390648; Muscarinic acetylcholine receptors.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   SIGNOR; P11229; -.
DR   BioGRID-ORCS; 1128; 10 hits in 873 CRISPR screens.
DR   ChiTaRS; CHRM1; human.
DR   GeneWiki; Muscarinic_acetylcholine_receptor_M1; -.
DR   GenomeRNAi; 1128; -.
DR   Pharos; P11229; Tclin.
DR   PRO; PR:P11229; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; P11229; protein.
DR   Bgee; ENSG00000168539; Expressed in anterior cingulate cortex and 100 other tissues.
DR   ExpressionAtlas; P11229; baseline and differential.
DR   Genevisible; P11229; HS.
DR   GO; GO:0043679; C:axon terminus; IEA:Ensembl.
DR   GO; GO:0030425; C:dendrite; IBA:GO_Central.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0099056; C:integral component of presynaptic membrane; IEA:Ensembl.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0014069; C:postsynaptic density; IEA:Ensembl.
DR   GO; GO:0045211; C:postsynaptic membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0098685; C:Schaffer collateral - CA1 synapse; IEA:Ensembl.
DR   GO; GO:0045202; C:synapse; IBA:GO_Central.
DR   GO; GO:0016907; F:G protein-coupled acetylcholine receptor activity; IBA:GO_Central.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0004993; F:G protein-coupled serotonin receptor activity; IBA:GO_Central.
DR   GO; GO:0030594; F:neurotransmitter receptor activity; IBA:GO_Central.
DR   GO; GO:0099529; F:neurotransmitter receptor activity involved in regulation of postsynaptic membrane potential; IEA:Ensembl.
DR   GO; GO:0004435; F:phosphatidylinositol phospholipase C activity; TAS:ProtInc.
DR   GO; GO:0007197; P:adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007268; P:chemical synaptic transmission; IBA:GO_Central.
DR   GO; GO:0050890; P:cognition; IEA:InterPro.
DR   GO; GO:0007213; P:G protein-coupled acetylcholine receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007187; P:G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; IBA:GO_Central.
DR   GO; GO:0007399; P:nervous system development; TAS:ProtInc.
DR   GO; GO:0007274; P:neuromuscular synaptic transmission; IEA:Ensembl.
DR   GO; GO:0007207; P:phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0090316; P:positive regulation of intracellular protein transport; IEA:Ensembl.
DR   GO; GO:0043270; P:positive regulation of ion transport; IGI:MGI.
DR   GO; GO:0007205; P:protein kinase C-activating G protein-coupled receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0060251; P:regulation of glial cell proliferation; TAS:GO_Central.
DR   GO; GO:0040012; P:regulation of locomotion; IEA:Ensembl.
DR   GO; GO:0046541; P:saliva secretion; IEA:InterPro.
DR   GO; GO:0007165; P:signal transduction; TAS:GO_Central.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR002228; Musac_Ach_M1_rcpt.
DR   InterPro; IPR000995; Musac_Ach_rcpt.
DR   PANTHER; PTHR24248:SF155; PTHR24248:SF155; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00243; MUSCARINICR.
DR   PRINTS; PR00538; MUSCRINICM1R.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell junction; Cell membrane;
KW   Disulfide bond; G-protein coupled receptor; Glycoprotein; Membrane;
KW   Phosphoprotein; Postsynaptic cell membrane; Receptor; Reference proteome;
KW   Synapse; Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..460
FT                   /note="Muscarinic acetylcholine receptor M1"
FT                   /id="PRO_0000069015"
FT   TOPO_DOM        1..24
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        25..47
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        48..61
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        62..82
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        83..99
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        100..121
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        122..141
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        142..164
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        165..186
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        187..209
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        210..366
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        367..387
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        388..401
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        402..421
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        422..460
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         230
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P12657"
FT   MOD_RES         428
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         451
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         455
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         457
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        2
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000305"
FT   CARBOHYD        12
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000305"
FT   DISULFID        98..178
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VAR_SEQ         455..460
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.4"
FT                   /id="VSP_056651"
FT   CONFLICT        173
FT                   /note="V -> M (in Ref. 3; CAA33334)"
FT                   /evidence="ECO:0000305"
FT   HELIX           22..52
FT                   /evidence="ECO:0000244|PDB:5CXV"
FT   HELIX           54..56
FT                   /evidence="ECO:0000244|PDB:5CXV"
FT   HELIX           59..76
FT                   /evidence="ECO:0000244|PDB:5CXV"
FT   HELIX           78..88
FT                   /evidence="ECO:0000244|PDB:5CXV"
FT   HELIX           95..128
FT                   /evidence="ECO:0000244|PDB:5CXV"
FT   TURN            130..133
FT                   /evidence="ECO:0000244|PDB:5CXV"
FT   HELIX           134..136
FT                   /evidence="ECO:0000244|PDB:5CXV"
FT   HELIX           139..168
FT                   /evidence="ECO:0000244|PDB:5CXV"
FT   HELIX           181..184
FT                   /evidence="ECO:0000244|PDB:6OIJ"
FT   HELIX           186..196
FT                   /evidence="ECO:0000244|PDB:5CXV"
FT   HELIX           198..212
FT                   /evidence="ECO:0000244|PDB:5CXV"
FT   HELIX           215..218
FT                   /evidence="ECO:0000244|PDB:5CXV"
FT   HELIX           358..390
FT                   /evidence="ECO:0000244|PDB:5CXV"
FT   STRAND          391..393
FT                   /evidence="ECO:0000244|PDB:5CXV"
FT   HELIX           397..406
FT                   /evidence="ECO:0000244|PDB:5CXV"
FT   HELIX           409..421
FT                   /evidence="ECO:0000244|PDB:5CXV"
FT   HELIX           425..433
FT                   /evidence="ECO:0000244|PDB:5CXV"
FT   HELIX           439..441
FT                   /evidence="ECO:0000244|PDB:6OIJ"
SQ   SEQUENCE   460 AA;  51421 MW;  567C20F63541C8D0 CRC64;
     MNTSAPPAVS PNITVLAPGK GPWQVAFIGI TTGLLSLATV TGNLLVLISF KVNTELKTVN
     NYFLLSLACA DLIIGTFSMN LYTTYLLMGH WALGTLACDL WLALDYVASN ASVMNLLLIS
     FDRYFSVTRP LSYRAKRTPR RAALMIGLAW LVSFVLWAPA ILFWQYLVGE RTVLAGQCYI
     QFLSQPIITF GTAMAAFYLP VTVMCTLYWR IYRETENRAR ELAALQGSET PGKGGGSSSS
     SERSQPGAEG SPETPPGRCC RCCRAPRLLQ AYSWKEEEEE DEGSMESLTS SEGEEPGSEV
     VIKMPMVDPE AQAPTKQPPR SSPNTVKRPT KKGRDRAGKG QKPRGKEQLA KRKTFSLVKE
     KKAARTLSAI LLAFILTWTP YNIMVLVSTF CKDCVPETLW ELGYWLCYVN STINPMCYAL
     CNKAFRDTFR LLLLCRWDKR RWRKIPKRPG SVHRTPSRQC
//
ID   CASR_HUMAN              Reviewed;        1078 AA.
AC   P41180; Q13912; Q16108; Q16109; Q16110; Q16379; Q2M1T0; Q4PJ19;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   10-MAY-2017, sequence version 3.
DT   12-AUG-2020, entry version 211.
DE   RecName: Full=Extracellular calcium-sensing receptor {ECO:0000305};
DE            Short=CaR {ECO:0000303|PubMed:7759551, ECO:0000303|PubMed:8813042};
DE            Short=CaSR;
DE            Short=hCasR {ECO:0000303|PubMed:27386547};
DE   AltName: Full=Parathyroid cell calcium-sensing receptor 1 {ECO:0000303|PubMed:8698326};
DE            Short=PCaR1 {ECO:0000303|PubMed:8698326};
DE   Flags: Precursor;
GN   Name=CASR {ECO:0000312|HGNC:HGNC:1514};
GN   Synonyms=GPRC2A, PCAR1 {ECO:0000303|PubMed:8698326};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANTS HYPOC1 LYS-118; LEU-128;
RP   MET-151; LYS-191 AND SER-612, AND CHARACTERIZATION OF VARIANTS HYPOC1
RP   LEU-128; MET-151 AND LYS-191.
RX   PubMed=8813042; DOI=10.1056/nejm199610103351505;
RA   Pearce S.H.S., Williamson C., Kifor O., Bai M., Coulthard M.G., Davies M.,
RA   Lewis-Barned N., McCredie D., Powell H., Kendall-Taylor P., Brown E.M.,
RA   Thakker R.V.;
RT   "A familial syndrome of hypocalcemia with hypercalciuria due to mutations
RT   in the calcium-sensing receptor.";
RL   N. Engl. J. Med. 335:1115-1122(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, AND VARIANT
RP   GLY-990.
RC   TISSUE=Parathyroid;
RX   PubMed=7759551; DOI=10.1074/jbc.270.21.12919;
RA   Garrett J.E., Capuano I.V., Hammerland L.G., Hung B.C., Brown E.M.,
RA   Hebert S.C., Nemeth E.F., Fuller F.;
RT   "Molecular cloning and functional expression of human parathyroid calcium
RT   receptor cDNAs.";
RL   J. Biol. Chem. 270:12919-12925(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Kidney;
RX   PubMed=7677761; DOI=10.1006/bbrc.1995.2318;
RA   Aida K., Koishi S., Tawata M., Onaya T.;
RT   "Molecular cloning of a putative Ca(2+)-sensing receptor cDNA from human
RT   kidney.";
RL   Biochem. Biophys. Res. Commun. 214:524-529(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=8756555; DOI=10.1210/endo.137.9.8756555;
RA   Freichel M., Zink-Lorenz A., Holloschi A., Hafner M., Flockerzi V.,
RA   Raue F.;
RT   "Expression of a calcium-sensing receptor in a human medullary thyroid
RT   carcinoma cell line and its contribution to calcitonin secretion.";
RL   Endocrinology 137:3842-3848(1996).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-986; GLY-990 AND
RP   GLN-1011.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUN-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-61, AND VARIANT HHC1 ALA-39.
RX   PubMed=7673400; DOI=10.1210/jcem.80.9.7673400;
RA   Aida K., Koishi S., Inoue M., Nakazato M., Tawata M., Onaya T.;
RT   "Familial hypocalciuric hypercalcemia associated with mutation in the human
RT   Ca(2+)-sensing receptor gene.";
RL   J. Clin. Endocrinol. Metab. 80:2594-2598(1995).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 643-908.
RX   PubMed=8613532; DOI=10.1172/jci118501;
RA   Bikle D.D., Ratnam A., Mauro T., Harris J., Pillai S.;
RT   "Changes in calcium responsiveness and handling during keratinocyte
RT   differentiation. Potential role of the calcium receptor.";
RL   J. Clin. Invest. 97:1085-1093(1996).
RN   [9]
RP   INTERACTION WITH VCP AND RNF19A, GLYCOSYLATION, AND UBIQUITINATION.
RX   PubMed=16513638; DOI=10.1074/jbc.m513552200;
RA   Huang Y., Niwa J., Sobue G., Breitwieser G.E.;
RT   "Calcium-sensing receptor ubiquitination and degradation mediated by the E3
RT   ubiquitin ligase dorfin.";
RL   J. Biol. Chem. 281:11610-11617(2006).
RN   [10]
RP   DOMAIN.
RX   PubMed=17360426; DOI=10.1073/pnas.0611577104;
RA   Muto T., Tsuchiya D., Morikawa K., Jingami H.;
RT   "Structures of the extracellular regions of the group II/III metabotropic
RT   glutamate receptors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:3759-3764(2007).
RN   [11]
RP   SUBCELLULAR LOCATION, AND GLYCOSYLATION.
RX   PubMed=20861236; DOI=10.1210/en.2010-0422;
RA   Zhuang X., Adipietro K.A., Datta S., Northup J.K., Ray K.;
RT   "Rab1 small GTP-binding protein regulates cell surface trafficking of the
RT   human calcium-sensing receptor.";
RL   Endocrinology 151:5114-5123(2010).
RN   [12]
RP   ACTIVITY REGULATION, AND MUTAGENESIS OF CYS-482.
RX   PubMed=26290606; DOI=10.1124/mol.115.098392;
RA   Alexander S.T., Hunter T., Walter S., Dong J., Maclean D., Baruch A.,
RA   Subramanian R., Tomlinson J.;
RT   "Critical cysteine residues in both the calcium-sensing receptor and the
RT   allosteric activator AMG 416 underlie the mechanism of action.";
RL   Mol. Pharmacol. 88:853-865(2015).
RN   [13] {ECO:0000244|PDB:5K5S, ECO:0000244|PDB:5K5T}
RP   X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 20-607 IN COMPLEX WITH CALCIUM;
RP   ANION AND TRYPTOPHAN, FUNCTION, ACTIVITY REGULATION, DOMAIN, DISULFIDE
RP   BONDS, GLYCOSYLATION AT ASN-261; ASN-287; ASN-446; ASN-468; ASN-488;
RP   ASN-541 AND ASN-594, MUTAGENESIS OF ARG-69; ASN-102; THR-145; SER-147;
RP   SER-170; TYR-218; SER-417 AND TRP-458, CHARACTERIZATION OF VARIANTS NSHPT
RP   ILE-100; LEU-227 AND LYS-551, AND CHARACTERIZATION OF VARIANTS HHC1 HIS-66;
RP   MET-81; PRO-159; GLY-172; GLY-215; LYS-297 AND GLU-557.
RX   PubMed=27434672; DOI=10.7554/elife.13662;
RA   Geng Y., Mosyak L., Kurinov I., Zuo H., Sturchler E., Cheng T.C.,
RA   Subramanyam P., Brown A.P., Brennan S.C., Mun H.C., Bush M., Chen Y.,
RA   Nguyen T.X., Cao B., Chang D.D., Quick M., Conigrave A.D., Colecraft H.M.,
RA   McDonald P., Fan Q.R.;
RT   "Structural mechanism of ligand activation in human calcium-sensing
RT   receptor.";
RL   Elife 5:0-0(2016).
RN   [14] {ECO:0000244|PDB:5FBH, ECO:0000244|PDB:5FBK}
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 20-541 IN COMPLEX WITH MAGNESIUM
RP   AND TRYPTOPHAN, FUNCTION, ACTIVITY REGULATION, DOMAIN, DISULFIDE BONDS, AND
RP   MUTAGENESIS OF GLU-297.
RX   PubMed=27386547; DOI=10.1126/sciadv.1600241;
RA   Zhang C., Zhang T., Zou J., Miller C.L., Gorkhali R., Yang J.Y.,
RA   Schilmiller A., Wang S., Huang K., Brown E.M., Moremen K.W., Hu J.,
RA   Yang J.J.;
RT   "Structural basis for regulation of human calcium-sensing receptor by
RT   magnesium ions and an unexpected tryptophan derivative co-agonist.";
RL   Sci. Adv. 2:E1600241-E1600241(2016).
RN   [15]
RP   VARIANTS HHC1 GLN-185; LYS-297 AND TRP-795.
RX   PubMed=7916660; DOI=10.1016/0092-8674(93)90617-y;
RA   Pollak M.R., Brown E.M., Chou Y.-H.W., Hebert S.C., Marx S.J.,
RA   Steinmann B., Levi T., Seidman C.E., Seidman J.G.;
RT   "Mutations in the human Ca(2+)-sensing receptor gene cause familial
RT   hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism.";
RL   Cell 75:1297-1303(1993).
RN   [16]
RP   VARIANT HYPOC1 ALA-127.
RX   PubMed=7874174; DOI=10.1038/ng1194-303;
RA   Pollak M.R., Brown E.M., Estep H.L., McLaine P.N., Kifor O., Park J.,
RA   Hebert S.C., Seidman C.E., Seidman J.G.;
RT   "Autosomal dominant hypocalcaemia caused by a Ca(2+)-sensing receptor gene
RT   mutation.";
RL   Nat. Genet. 8:303-307(1994).
RN   [17]
RP   VARIANTS HHC1 MET-62; CYS-66; MET-138; GLU-143 AND GLN-227.
RX   PubMed=7726161;
RA   Chou Y.-H.W., Pollak M.R., Brandi M.L., Toss G., Arnqvist H.,
RA   Atkinson A.B., Papapoulos S.E., Marx S., Brown E.M., Seidman J.G.,
RA   Seidman C.E.;
RT   "Mutations in the human Ca(2+)-sensing-receptor gene that cause familial
RT   hypocalciuric hypercalcemia.";
RL   Am. J. Hum. Genet. 56:1075-1079(1995).
RN   [18]
RP   VARIANTS NSHPT LEU-227 AND TYR-582.
RX   PubMed=8675635; DOI=10.1172/jci118335;
RA   Pearce S.H.S., Trump D., Wooding C., Besser G.M., Chew S.L., Grant D.B.,
RA   Heath D.A., Hughes I.A., Paterson C.R., Whyte M.P., Thakker R.V.;
RT   "Calcium-sensing receptor mutations in familial benign hypercalcemia and
RT   neonatal hyperparathyroidism.";
RL   J. Clin. Invest. 96:2683-2692(1995).
RN   [19]
RP   VARIANT FIH MET-151.
RX   PubMed=8698326; DOI=10.1007/s004390050174;
RA   Lovlie R., Eiken H.G., Sorheim J.I., Boman H.;
RT   "The Ca(2+)-sensing receptor gene (PCAR1) mutation T151M in isolated
RT   autosomal dominant hypoparathyroidism.";
RL   Hum. Genet. 98:129-133(1996).
RN   [20]
RP   VARIANTS HYPOC1 THR-116; HIS-681 AND SER-806, AND VARIANT SER-851.
RX   PubMed=8733126; DOI=10.1093/hmg/5.5.601;
RA   Baron J., Winer K.K., Yanovski J.A., Cunningham A.W., Laue L.,
RA   Zimmerman D., Cutler G.B. Jr.;
RT   "Mutations in the Ca(2+)-sensing receptor gene cause autosomal dominant and
RT   sporadic hypoparathyroidism.";
RL   Hum. Mol. Genet. 5:601-606(1996).
RN   [21]
RP   VARIANTS HHC1 MET-62; CYS-66; MET-138; GLU-143; GLN-185; LYS-297 AND
RP   TRP-795, VARIANT HYPOC1 ALA-127, FUNCTION, SUBCELLULAR LOCATION,
RP   GLYCOSYLATION, CHARACTERIZATION OF VARIANTS HHC1 MET-62; CYS-66; MET-138;
RP   GLU-143; GLN-185; LYS-297 AND TRP-795, AND CHARACTERIZATION OF VARIANT
RP   HYPOC1 ALA-127.
RX   PubMed=8702647; DOI=10.1074/jbc.271.32.19537;
RA   Bai M., Quinn S., Trivedi S., Kifor O., Pearce S.H.S., Pollak M.R.,
RA   Krapcho K., Hebert S.C., Brown E.M.;
RT   "Expression and characterization of inactivating and activating mutations
RT   in the human Ca2+o-sensing receptor.";
RL   J. Biol. Chem. 271:19537-19545(1996).
RN   [22]
RP   VARIANTS HHC1 PRO-53; LEU-55; GLN-185; GLY-215; TYR-657 AND ARG-748,
RP   VARIANTS SER-986; GLY-990 AND GLN-1011, AND CHARACTERIZATION OF VARIANTS
RP   HHC1 PRO-53; LEU-55 AND GLY-215.
RX   PubMed=8636323; DOI=10.1210/jcem.81.4.8636323;
RA   Heath H. III, Odelberg S., Jackson C.E., Teh B.T., Hayward N., Larsson C.,
RA   Buist N.R., Krapcho K.J., Hung B.C., Capuano I.V., Garrett J.E.,
RA   Leppert M.F.;
RT   "Clustered inactivating mutations and benign polymorphisms of the calcium
RT   receptor gene in familial benign hypocalciuric hypercalcemia suggest
RT   receptor functional domains.";
RL   J. Clin. Endocrinol. Metab. 81:1312-1317(1996).
RN   [23]
RP   VARIANTS HHC1 LEU-55; ASP-178; SER-221 AND ILE-817, VARIANTS HYPOC1
RP   LEU-128; MET-151 AND LYS-191, VARIANT NSHPT LEU-227, CHARACTERIZATION OF
RP   VARIANTS HHC1 LEU-55; ASP-178; SER-221 AND ILE-817, FUNCTION,
RP   CHARACTERIZATION OF VARIANTS HYPOC1 LEU-128; MET-151 AND LYS-191, AND
RP   CHARACTERIZATION OF VARIANT NSHPT LEU-227.
RX   PubMed=8878438; DOI=10.1172/jci118987;
RA   Pearce S.H.S., Bai M., Quinn S.J., Kifor O., Brown E.M., Thakker R.V.;
RT   "Functional characterization of calcium-sensing receptor mutations
RT   expressed in human embryonic kidney cells.";
RL   J. Clin. Invest. 98:1860-1866(1996).
RN   [24]
RP   VARIANT HHC1 ARG-174.
RX   PubMed=9298824;
RX   DOI=10.1002/(sici)1098-1004(1997)10:3<233::aid-humu9>3.0.co;2-j;
RA   Ward B.K., Stuckey B.G.A., Gutteridge D.H., Laing N.G., Pullan P.T.,
RA   Ratajczak T.;
RT   "A novel mutation (L174R) in the Ca2+-sensing receptor gene associated with
RT   familial hypocalciuric hypercalcemia.";
RL   Hum. Mutat. 10:233-235(1997).
RN   [25]
RP   VARIANTS HYPOC1 LYS-118; ARG-773 AND SER-806, AND CHARACTERIZATION OF
RP   VARIANTS HYPOC1 LYS-118; ARG-773 AND SER-806.
RX   PubMed=9253358; DOI=10.1210/jcem.82.8.4166;
RA   De Luca F., Ray K., Mancilla E.E., Fan G.-F., Winer K.K., Gore P.,
RA   Spiegel A.M., Baron J.;
RT   "Sporadic hypoparathyroidism caused by de Novo gain-of-function mutations
RT   of the Ca(2+)-sensing receptor.";
RL   J. Clin. Endocrinol. Metab. 82:2710-2715(1997).
RN   [26]
RP   VARIANT NSHPT GLU-670.
RX   PubMed=9253359; DOI=10.1210/jcem.82.8.4135;
RA   Kobayashi M., Tanaka H., Tsuzuki K., Tsuyuki M., Igaki H., Ichinose Y.,
RA   Aya K., Nishioka N., Seino Y.;
RT   "Two novel missense mutations in calcium-sensing receptor gene associated
RT   with neonatal severe hyperparathyroidism.";
RL   J. Clin. Endocrinol. Metab. 82:2716-2719(1997).
RN   [27]
RP   VARIANT HYPOC1 CYS-788, AND CHARACTERIZATION OF VARIANT HYPOC1 CYS-788.
RX   PubMed=9661634; DOI=10.1210/jcem.83.7.4920;
RA   Watanabe T., Bai M., Lane C.R., Matsumoto S., Minamitani K., Minagawa M.,
RA   Niimi H., Brown E.M., Yasuda T.;
RT   "Familial hypoparathyroidism: identification of a novel gain of function
RT   mutation in transmembrane domain 5 of the calcium-sensing receptor.";
RL   J. Clin. Endocrinol. Metab. 83:2497-2502(1998).
RN   [28]
RP   VARIANT ARG-27, CHARACTERIZATION OF VARIANT ARG-27, AND INVOLVEMENT IN
RP   PRIMARY HYPERPARATHYROIDISM.
RX   PubMed=10468915; DOI=10.1046/j.1365-2265.1999.00729.x;
RA   Chikatsu N., Fukumoto S., Suzawa M., Tanaka Y., Takeuchi Y., Takeda S.,
RA   Tamura Y., Matsumoto T., Fujita T.;
RT   "An adult patient with severe hypercalcaemia and hypocalciuria due to a
RT   novel homozygous inactivating mutation of calcium-sensing receptor.";
RL   Clin. Endocrinol. (Oxf.) 50:537-543(1999).
RN   [29]
RP   VARIANT HYPOC1 ASN-47, AND CHARACTERIZATION OF VARIANT HYPOC1 ASN-47.
RX   PubMed=9920108; DOI=10.1210/jcem.84.1.5385;
RA   Okazaki R., Chikatsu N., Nakatsu M., Takeuchi Y., Ajima M., Miki J.,
RA   Fujita T., Arai M., Totsuka Y., Tanaka K., Fukumoto S.;
RT   "A novel activating mutation in calcium-sensing receptor gene associated
RT   with a family of autosomal dominant hypocalcemia.";
RL   J. Clin. Endocrinol. Metab. 84:363-366(1999).
RN   [30]
RP   VARIANT HYPOC1 VAL-616, AND CHARACTERIZATION OF VARIANT HYPOC1 VAL-616.
RX   PubMed=10487661; DOI=10.1210/jcem.84.9.5977;
RA   Stock J.L., Brown R.S., Baron J., Coderre J.A., Mancilla E., De Luca F.,
RA   Ray K., Mericq M.V.;
RT   "Autosomal dominant hypoparathyroidism associated with short stature and
RT   premature osteoarthritis.";
RL   J. Clin. Endocrinol. Metab. 84:3036-3040(1999).
RN   [31]
RP   VARIANT SER-986, AND ASSOCIATION WITH SERUM LEVEL OF CALCIUM.
RX   PubMed=10023897; DOI=10.1016/s0140-6736(98)06434-4;
RA   Cole D.E.C., Peltekova V.D., Rubin L.A., Hawker G.A., Vieth R., Liew C.C.,
RA   Hwang D.M., Evrovski J., Hendy G.N.;
RT   "A986S polymorphism of the calcium-sensing receptor and circulating calcium
RT   concentrations.";
RL   Lancet 353:112-115(1999).
RN   [32]
RP   VARIANT HYPERCALCIURIC HYPERCALCEMIA LEU-881, AND CHARACTERIZATION OF
RP   VARIANT HYPERCALCIURIC HYPERCALCEMIA LEU-881.
RX   PubMed=10843194; DOI=10.1210/jcem.85.5.6477;
RA   Carling T., Szabo E., Bai M., Ridefelt P., Westin G., Gustavsson P.,
RA   Trivedi S., Hellman P., Brown E.M., Dahl N., Rastad J.;
RT   "Familial hypercalcemia and hypercalciuria caused by a novel mutation in
RT   the cytoplasmic tail of the calcium receptor.";
RL   J. Clin. Endocrinol. Metab. 85:2042-2047(2000).
RN   [33]
RP   VARIANT HHC1 GLU-557.
RX   PubMed=11762699; DOI=10.1385/endo:15:3:277;
RA   Nakayama T., Minato M., Nakagawa M., Soma M., Tobe H., Aoi N., Kosuge K.,
RA   Sato M., Ozawa Y., Kanmatsuse K., Kokubun S.;
RT   "A novel mutation in Ca2+-sensing receptor gene in familial hypocalciuric
RT   hypercalcemia.";
RL   Endocrine 15:277-282(2001).
RN   [34]
RP   VARIANT SER-986, ASSOCIATION WITH SERUM LEVEL OF CALCIUM, AND PREDISPOSING
RP   FACTOR IN DISORDERS OF BONE AND MINERAL METABOLISM.
RX   PubMed=11161843; DOI=10.1006/mgme.2000.3126;
RA   Cole D.E.C., Vieth R., Trang H.M., Wong B.Y.-L., Hendy G.N., Rubin L.A.;
RT   "Association between total serum calcium and the A986S polymorphism of the
RT   calcium-sensing receptor gene.";
RL   Mol. Genet. Metab. 72:168-174(2001).
RN   [35]
RP   VARIANT HYPOC1 PHE-820, CHARACTERIZATION OF VARIANT HYPOC1 PHE-820, AND
RP   VARIANT GLY-990.
RX   PubMed=12050233; DOI=10.1210/jcem.87.6.8531;
RA   Nagase T., Murakami T., Tsukada T., Kitamura R., Chikatsu N., Takeo H.,
RA   Takata N., Yasuda H., Fukumoto S., Tanaka Y., Nagata N., Yamaguchi K.,
RA   Akatsu T., Yamamoto M.;
RT   "A family of autosomal dominant hypocalcemia with a positive correlation
RT   between serum calcium and magnesium: identification of a novel gain of
RT   function mutation (Ser(820)Phe) in the calcium-sensing receptor.";
RL   J. Clin. Endocrinol. Metab. 87:2681-2687(2002).
RN   [36]
RP   VARIANTS HYPOC1 PRO-125 AND GLU-843, AND CHARACTERIZATION OF VARIANTS
RP   HYPOC1 PRO-125 AND GLU-843.
RX   PubMed=12107202; DOI=10.1210/jcem.87.7.8639;
RA   Sato K., Hasegawa Y., Nakae J., Nanao K., Takahashi I., Tajima T.,
RA   Shinohara N., Fujieda K.;
RT   "Hydrochlorothiazide effectively reduces urinary calcium excretion in two
RT   Japanese patients with gain-of-function mutations of the calcium-sensing
RT   receptor gene.";
RL   J. Clin. Endocrinol. Metab. 87:3068-3073(2002).
RN   [37]
RP   VARIANTS HYPOC1 TRP-131 AND GLU-843.
RX   PubMed=12241879; DOI=10.1016/s0140-6736(02)09842-2;
RA   Watanabe S., Fukumoto S., Chang H., Takeuchi Y., Hasegawa Y., Okazaki R.,
RA   Chikatsu N., Fujita T.;
RT   "Association between activating mutations of calcium-sensing receptor and
RT   Bartter's syndrome.";
RL   Lancet 360:692-694(2002).
RN   [38]
RP   VARIANT HYPOC1 LYS-604, AND CHARACTERIZATION OF VARIANT HYPOC1 LYS-604.
RX   PubMed=12574188; DOI=10.1210/jc.2002-020081;
RA   Tan Y.M., Cardinal J., Franks A.H., Mun H.-C., Lewis N., Harris L.B.,
RA   Prins J.B., Conigrave A.D.;
RT   "Autosomal dominant hypocalcemia: a novel activating mutation (E604K) in
RT   the cysteine-rich domain of the calcium-sensing receptor.";
RL   J. Clin. Endocrinol. Metab. 88:605-610(2003).
RN   [39]
RP   VARIANT HYPOC1 LEU-788, AND CHARACTERIZATION OF VARIANT HYPOC1 LEU-788.
RX   PubMed=12915654; DOI=10.1210/jc.2003-030409;
RA   Hendy G.N., Minutti C., Canaff L., Pidasheva S., Yang B., Nouhi Z.,
RA   Zimmerman D., Wei C., Cole D.E.C.;
RT   "Recurrent familial hypocalcemia due to germline mosaicism for an
RT   activating mutation of the calcium-sensing receptor gene.";
RL   J. Clin. Endocrinol. Metab. 88:3674-3681(2003).
RN   [40]
RP   VARIANTS SER-986; GLY-990 AND GLN-1011, AND ASSOCIATION WITH SERUM LEVEL OF
RP   CALCIUM.
RX   PubMed=15531522; DOI=10.1210/jc.2004-0129;
RA   Scillitani A., Guarnieri V., De Geronimo S., Muscarella L.A., Battista C.,
RA   D'Agruma L., Bertoldo F., Florio C., Minisola S., Hendy G.N., Cole D.E.C.;
RT   "Blood ionized calcium is associated with clustered polymorphisms in the
RT   carboxyl-terminal tail of the calcium-sensing receptor.";
RL   J. Clin. Endocrinol. Metab. 89:5634-5638(2004).
RN   [41]
RP   VARIANT HHC1 PRO-13, AND CHARACTERIZATION OF VARIANT HHC1 PRO-13.
RX   PubMed=15579740; DOI=10.1210/jc.2004-1046;
RA   Miyashiro K., Kunii I., Manna T.D., de Menezes Filho H.C., Damiani D.,
RA   Setian N., Hauache O.M.;
RT   "Severe hypercalcemia in a 9-year-old Brazilian girl due to a novel
RT   inactivating mutation of the calcium-sensing receptor.";
RL   J. Clin. Endocrinol. Metab. 89:5936-5941(2004).
RN   [42]
RP   VARIANTS NSHPT ILE-100; LYS-336 DEL; PRO-650 AND MET-689, AND VARIANTS
RP   SER-986; GLY-990 AND GLN-1011.
RX   PubMed=14985373; DOI=10.1136/jmg.2003.016725;
RA   Warner J., Epstein M., Sweet A., Singh D., Burgess J., Stranks S., Hill P.,
RA   Perry-Keene D., Learoyd D., Robinson B., Birdsey P., Mackenzie E.,
RA   Teh B.T., Prins J.B., Cardinal J.;
RT   "Genetic testing in familial isolated hyperparathyroidism: unexpected
RT   results and their implications.";
RL   J. Med. Genet. 41:155-160(2004).
RN   [43]
RP   VARIANT HYPOC1 LYS-767, AND VARIANT GLY-990.
RX   PubMed=15551332; DOI=10.1002/ajmg.a.30403;
RA   Uckun-Kitapci A., Underwood L.E., Zhang J., Moats-Staats B.;
RT   "A novel mutation (E767K) in the second extracellular loop of the calcium
RT   sensing receptor in a family with autosomal dominant hypocalcemia.";
RL   Am. J. Med. Genet. A 132:125-129(2005).
RN   [44]
RP   VARIANTS HHC1 SER-11 AND PRO-13, VARIANT ALA-14, CHARACTERIZATION OF
RP   VARIANTS HHC1 SER-11 AND PRO-13, AND CHARACTERIZATION OF VARIANT ALA-14.
RX   PubMed=15879434; DOI=10.1093/hmg/ddi176;
RA   Pidasheva S., Canaff L., Simonds W.F., Marx S.J., Hendy G.N.;
RT   "Impaired cotranslational processing of the calcium-sensing receptor due to
RT   signal peptide missense mutations in familial hypocalciuric
RT   hypercalcemia.";
RL   Hum. Mol. Genet. 14:1679-1690(2005).
RN   [45]
RP   VARIANT HHC1 GLN-227, SUBCELLULAR LOCATION, CHARACTERIZATION OF VARIANT
RP   NSHPT LEU-227, AND CHARACTERIZATION OF VARIANT HHC1 GLN-227.
RX   PubMed=15572418; DOI=10.1210/jc.2004-1791;
RA   Wystrychowski A., Pidasheva S., Canaff L., Chudek J., Kokot F., Wiecek A.,
RA   Hendy G.N.;
RT   "Functional characterization of calcium-sensing receptor codon 227
RT   mutations presenting as either familial (benign) hypocalciuric
RT   hypercalcemia or neonatal hyperparathyroidism.";
RL   J. Clin. Endocrinol. Metab. 90:864-870(2005).
RN   [46]
RP   VARIANT HHC1 GLN-465, CHARACTERIZATION OF VARIANT HHC1 GLN-465, AND VARIANT
RP   SER-986.
RX   PubMed=16598859; DOI=10.1016/j.bbrc.2006.02.018;
RA   Leech C., Lohse P., Stanojevic V., Lechner A., Goeke B., Spitzweg C.;
RT   "Identification of a novel inactivating R465Q mutation of the calcium-
RT   sensing receptor.";
RL   Biochem. Biophys. Res. Commun. 342:996-1002(2006).
RN   [47]
RP   VARIANTS HHC1 CYS-66; HIS-66 AND 583-ASN--SER-1078 DEL, SUBCELLULAR
RP   LOCATION, SUBUNIT, GLYCOSYLATION, AND CHARACTERIZATION OF VARIANTS CYS-66;
RP   HIS-66 AND 583-ASN--SER-1078 DEL.
RX   PubMed=16740594; DOI=10.1093/hmg/ddl145;
RA   Pidasheva S., Grant M., Canaff L., Ercan O., Kumar U., Hendy G.N.;
RT   "Calcium-sensing receptor dimerizes in the endoplasmic reticulum:
RT   biochemical and biophysical characterization of CASR mutants retained
RT   intracellularly.";
RL   Hum. Mol. Genet. 15:2200-2209(2006).
RN   [48]
RP   VARIANT HYPOC1 GLN-727, AND CHARACTERIZATION OF VARIANT HYPOC1 GLN-727.
RX   PubMed=16608894; DOI=10.1210/jc.2005-2605;
RA   Mittelman S.D., Hendy G.N., Fefferman R.A., Canaff L., Mosesova I.,
RA   Cole D.E., Burkett L., Geffner M.E.;
RT   "A hypocalcemic child with a novel activating mutation of the calcium-
RT   sensing receptor gene: successful treatment with recombinant human
RT   parathyroid hormone.";
RL   J. Clin. Endocrinol. Metab. 91:2474-2479(2006).
RN   [49]
RP   VARIANT HHC1 CYS-180, AND CHARACTERIZATION OF VARIANT HHC1 CYS-180.
RX   PubMed=17473068; DOI=10.1210/jc.2007-0123;
RA   Zajickova K., Vrbikova J., Canaff L., Pawelek P.D., Goltzman D.,
RA   Hendy G.N.;
RT   "Identification and functional characterization of a novel mutation in the
RT   calcium-sensing receptor gene in familial hypocalciuric hypercalcemia:
RT   modulation of clinical severity by vitamin D status.";
RL   J. Clin. Endocrinol. Metab. 92:2616-2623(2007).
RN   [50]
RP   VARIANT NSHPT LYS-551, VARIANT SER-986, FUNCTION, SUBCELLULAR LOCATION, AND
RP   CHARACTERIZATION OF VARIANT NSHPT LYS-551.
RX   PubMed=17555508; DOI=10.1111/j.1365-2265.2007.02896.x;
RA   Toke J., Czirjak G., Patocs A., Enyedi B., Gergics P., Csakvary V.,
RA   Enyedi P., Toth M.;
RT   "Neonatal severe hyperparathyroidism associated with a novel de novo
RT   heterozygous R551K inactivating mutation and a heterozygous A986S
RT   polymorphism of the calcium-sensing receptor gene.";
RL   Clin. Endocrinol. (Oxf.) 67:385-392(2007).
RN   [51]
RP   VARIANTS HHC1 ARG-21; ASN-171; GLN-221; THR-225; PHE-271; ARG-397; ARG-509;
RP   ARG-553; VAL-555; TYR-562; PHE-582; TYR-582; ASP-623; ARG-670; PHE-728;
RP   ARG-742 AND TRP-886, AND VARIANTS LYS-250; SER-986; GLY-990 AND GLN-1011.
RX   PubMed=17698911; DOI=10.1210/jc.2007-0322;
RA   Nissen P.H., Christensen S.E., Heickendorff L., Brixen K., Mosekilde L.;
RT   "Molecular genetic analysis of the calcium sensing receptor gene in
RT   patients clinically suspected to have familial hypocalciuric hypercalcemia:
RT   phenotypic variation and mutation spectrum in a Danish population.";
RL   J. Clin. Endocrinol. Metab. 92:4373-4379(2007).
RN   [52]
RP   VARIANTS EIG8 ALA-354; VAL-686; GLN-898; VAL-988 AND GLY-988, VARIANTS
RP   SER-986 AND GLY-990, AND TISSUE SPECIFICITY.
RX   PubMed=18756473; DOI=10.1002/ana.21428;
RA   Kapoor A., Satishchandra P., Ratnapriya R., Reddy R., Kadandale J.,
RA   Shankar S.K., Anand A.;
RT   "An idiopathic epilepsy syndrome linked to 3q13.3-q21 and missense
RT   mutations in the extracellular calcium sensing receptor gene.";
RL   Ann. Neurol. 64:158-167(2008).
RN   [53]
RP   VARIANT HHC1 ARG-459, VARIANTS SER-986 AND GLN-1011, FUNCTION, AND
RP   CHARACTERIZATION OF VARIANT HHC1 ARG-459.
RX   PubMed=19789209; DOI=10.1210/jc.2008-2484;
RA   Lietman S.A., Tenenbaum-Rakover Y., Jap T.S., Yi-Chi W., De-Ming Y.,
RA   Ding C., Kussiny N., Levine M.A.;
RT   "A novel loss-of-function mutation, Gln459Arg, of the calcium-sensing
RT   receptor gene associated with apparent autosomal recessive inheritance of
RT   familial hypocalciuric hypercalcemia.";
RL   J. Clin. Endocrinol. Metab. 94:4372-4379(2009).
RN   [54]
RP   VARIANTS HHC1 SER-42; LEU-55; HIS-66; MET-81; MET-138; ARG-143; ARG-158;
RP   GLY-166; TRP-220; ARG-549; TYR-562; GLY-565; TYR-582; 583-ASN--SER-1078
RP   DEL; TYR-661; HIS-680; ILE-761 DEL AND TRP-795, AND VARIANTS HYPOC1
RP   LYS-118; PHE-125; ARG-129; LYS-228; LYS-604; ILE-802; SER-830; LEU-832 AND
RP   SER-832.
RX   PubMed=19179454; DOI=10.1677/jme-08-0164;
RA   Cole D.E., Yun F.H., Wong B.Y., Shuen A.Y., Booth R.A., Scillitani A.,
RA   Pidasheva S., Zhou X., Canaff L., Hendy G.N.;
RT   "Calcium-sensing receptor mutations and denaturing high performance liquid
RT   chromatography.";
RL   J. Mol. Endocrinol. 42:331-339(2009).
RN   [55]
RP   VARIANT THR-339, CHARACTERIZATION OF VARIANT THR-339, AND INVOLVEMENT IN
RP   PRIMARY HYPERPARATHYROIDISM.
RX   PubMed=20846291; DOI=10.1111/j.1365-2265.2010.03870.x;
RA   Hannan F.M., Nesbit M.A., Christie P.T., Lissens W., Van der Schueren B.,
RA   Bex M., Bouillon R., Thakker R.V.;
RT   "A homozygous inactivating calcium-sensing receptor mutation, Pro339Thr, is
RT   associated with isolated primary hyperparathyroidism: correlation between
RT   location of mutations and severity of hypercalcaemia.";
RL   Clin. Endocrinol. (Oxf.) 73:715-722(2010).
RN   [56]
RP   VARIANT HHC1 ILE-550, FUNCTION, AND CHARACTERIZATION OF VARIANT HHC1
RP   ILE-550.
RX   PubMed=21566075; DOI=10.1530/eje-11-0141;
RA   Al-Salameh A., Cetani F., Pardi E., Vulpoi C., Pierre P., de Calan L.,
RA   Guyetant S., Jeunemaitre X., Lecomte P.;
RT   "A novel mutation in the calcium-sensing receptor in a French family with
RT   familial hypocalciuric hypercalcaemia.";
RL   Eur. J. Endocrinol. 165:359-363(2011).
RN   [57]
RP   VARIANTS HHC1 PRO-159 AND TRP-795, FUNCTION, SUBCELLULAR LOCATION, AND
RP   CHARACTERIZATION OF VARIANTS HHC1 PRO-159 AND TRP-795.
RX   PubMed=22114145; DOI=10.1126/scisignal.2002208;
RA   Grant M.P., Stepanchick A., Cavanaugh A., Breitwieser G.E.;
RT   "Agonist-driven maturation and plasma membrane insertion of calcium-sensing
RT   receptors dynamically control signal amplitude.";
RL   Sci. Signal. 4:RA78-RA78(2011).
RN   [58]
RP   VARIANT HHC1 MET-697.
RX   PubMed=21643651; DOI=10.1007/s00431-011-1504-8;
RA   Aparicio Lopez C., Anton-Martin P., Gil-Fournier B., Ramiro-Leon S.,
RA   Perez-Nanclares G., Perez de Nanclares G., Martinez Menendez B.,
RA   Castano L.;
RT   "Familial hypocalciuric hypercalcemia: new mutation in the CASR gene
RT   converting valine 697 to methionine.";
RL   Eur. J. Pediatr. 171:147-150(2012).
RN   [59]
RP   VARIANTS HHC1 THR-110 AND GLY-172, VARIANTS HYPOC1 CYS-122; HIS-569 AND
RP   THR-839, FUNCTION, CHARACTERIZATION OF VARIANTS HHC1 THR-110 AND GLY-172,
RP   AND CHARACTERIZATION OF VARIANTS HYPOC1 CYS-122; HIS-569 AND THR-839.
RX   PubMed=23966241; DOI=10.1210/jc.2013-1974;
RA   Nakamura A., Hotsubo T., Kobayashi K., Mochizuki H., Ishizu K., Tajima T.;
RT   "Loss-of-function and gain-of-function mutations of calcium-sensing
RT   receptor: functional analysis and the effect of allosteric modulators NPS
RT   R-568 and NPS 2143.";
RL   J. Clin. Endocrinol. Metab. 98:E1692-E1701(2013).
RN   [60]
RP   VARIANT HHC1 SER-802, AND VARIANT HYPOC1 ILE-802.
RX   PubMed=23169696; DOI=10.1530/eje-12-0714;
RA   Lia-Baldini A.S., Magdelaine C., Nizou A., Airault C., Salles J.P.,
RA   Moulin P., Delemer B., Aitouares M., Funalot B., Sturtz F.,
RA   Lienhardt-Roussie A.;
RT   "Two novel mutations of the calcium-sensing receptor gene affecting the
RT   same amino acid position lead to opposite phenotypes and reveal the
RT   importance of p.N802 on receptor activity.";
RL   Eur. J. Endocrinol. 168:K27-K34(2013).
RN   [61]
RP   VARIANT HHC1 MET-972, FUNCTION, AND CHARACTERIZATION OF VARIANT HHC1
RP   MET-972.
RX   PubMed=25292184; DOI=10.1186/1472-6823-14-81;
RA   Mastromatteo E., Lamacchia O., Campo M.R., Conserva A., Baorda F.,
RA   Cinque L., Guarnieri V., Scillitani A., Cignarelli M.;
RT   "A novel mutation in calcium-sensing receptor gene associated to
RT   hypercalcemia and hypercalciuria.";
RL   BMC Endocr. Disord. 14:81-81(2014).
RN   [62]
RP   VARIANTS HHC1 VAL-707 AND SER-774, FUNCTION, SUBCELLULAR LOCATION, AND
RP   CHARACTERIZATION OF VARIANTS HHC1 VAL-707 AND SER-774.
RX   PubMed=25104082; DOI=10.1093/ndt/gfu065;
RA   Stratta P., Merlotti G., Musetti C., Quaglia M., Pagani A., Izzo C.,
RA   Radin E., Airoldi A., Baorda F., Palladino T., Leone M.P., Guarnieri V.;
RT   "Calcium-sensing-related gene mutations in hypercalcaemic hypocalciuric
RT   patients as differential diagnosis from primary hyperparathyroidism:
RT   detection of two novel inactivating mutations in an Italian population.";
RL   Nephrol. Dial. Transplant. 29:1902-1909(2014).
RN   [63]
RP   VARIANT HHC1 TRP-571, FUNCTION, SUBCELLULAR LOCATION, AND CHARACTERIZATION
RP   OF VARIANT HHC1 TRP-571.
RX   PubMed=26386835; DOI=10.1007/s00774-015-0713-z;
RA   Kim E.S., Kim S.Y., Lee J.Y., Han J.H., Sohn T.S., Son H.S., Moon S.D.;
RT   "Identification and functional analysis of a novel CaSR mutation in a
RT   family with familial hypocalciuric hypercalcemia.";
RL   J. Bone Miner. Metab. 34:662-667(2016).
RN   [64]
RP   VARIANT HYPOC1 LEU-136, FUNCTION, SUBCELLULAR LOCATION, AND
RP   CHARACTERIZATION OF VARIANT HYPOC1 LEU-136.
RX   PubMed=25766501; DOI=10.1016/j.mce.2015.02.021;
RA   Baran N., ter Braak M., Saffrich R., Woelfle J., Schmitz U.;
RT   "Novel activating mutation of human calcium-sensing receptor in a family
RT   with autosomal dominant hypocalcaemia.";
RL   Mol. Cell. Endocrinol. 407:18-25(2015).
RN   [65]
RP   VARIANTS HYPOC1 LEU-221; ARG-681 AND GLN-727, FUNCTION, SUBCELLULAR
RP   LOCATION, AND CHARACTERIZATION OF VARIANTS HYPOC1 ARG-681 AND GLN-727.
RX   PubMed=22789683; DOI=10.1016/j.ymgme.2012.06.012;
RA   Guarnieri V., Valentina D'Elia A., Baorda F., Pazienza V., Benegiamo G.,
RA   Stanziale P., Copetti M., Battista C., Grimaldi F., Damante G.,
RA   Pellegrini F., D'Agruma L., Zelante L., Carella M., Scillitani A.;
RT   "CASR gene activating mutations in two families with autosomal dominant
RT   hypocalcemia.";
RL   Mol. Genet. Metab. 107:548-552(2012).
CC   -!- FUNCTION: G-protein-coupled receptor that senses changes in the
CC       extracellular concentration of calcium ions and plays a key role in
CC       maintaining calcium homeostasis (PubMed:7759551, PubMed:8702647,
CC       PubMed:8636323, PubMed:8878438, PubMed:17555508, PubMed:19789209,
CC       PubMed:21566075, PubMed:22114145, PubMed:23966241, PubMed:25292184,
CC       PubMed:25104082, PubMed:26386835, PubMed:25766501, PubMed:22789683).
CC       Senses fluctuations in the circulating calcium concentration and
CC       modulates the production of parathyroid hormone (PTH) in parathyroid
CC       glands (By similarity). The activity of this receptor is mediated by a
CC       G-protein that activates a phosphatidylinositol-calcium second
CC       messenger system (PubMed:7759551). The G-protein-coupled receptor
CC       activity is activated by a co-agonist mechanism: aromatic amino acids,
CC       such as Trp or Phe, act concertedly with divalent cations, such as
CC       calcium or magnesium, to achieve full receptor activation
CC       (PubMed:27434672, PubMed:27386547). {ECO:0000250|UniProtKB:Q9QY96,
CC       ECO:0000269|PubMed:17555508, ECO:0000269|PubMed:19789209,
CC       ECO:0000269|PubMed:21566075, ECO:0000269|PubMed:22114145,
CC       ECO:0000269|PubMed:22789683, ECO:0000269|PubMed:23966241,
CC       ECO:0000269|PubMed:25104082, ECO:0000269|PubMed:25292184,
CC       ECO:0000269|PubMed:25766501, ECO:0000269|PubMed:26386835,
CC       ECO:0000269|PubMed:27386547, ECO:0000269|PubMed:27434672,
CC       ECO:0000269|PubMed:7759551, ECO:0000269|PubMed:8636323,
CC       ECO:0000269|PubMed:8702647, ECO:0000269|PubMed:8878438}.
CC   -!- ACTIVITY REGULATION: In resting state, adopts an open conformation,
CC       anion-binding promoting the inactive configuration (PubMed:27434672).
CC       Upon aromatic amino acid-binding, the groove in the extracellular venus
CC       flytrap module is closed, thereby inducing the formation of a novel
CC       homodimer interface between subunits (PubMed:27434672,
CC       PubMed:27386547). Calcium ions stabilize the active state by enhancing
CC       homodimer interactions between membrane-proximal domains to fully
CC       activate the receptor (PubMed:27434672, PubMed:27386547). Activated by
CC       AMG 416, a D-amino acid-containing peptide agonist that is being
CC       evaluated for the treatment of secondary hyperparathyroidism in chronic
CC       kidney disease patients receiving hemodialysis (PubMed:26290606). AMG
CC       416 agonist acts by forming a disulfide bond with Cys-482
CC       (PubMed:26290606). {ECO:0000269|PubMed:26290606,
CC       ECO:0000269|PubMed:27386547, ECO:0000269|PubMed:27434672}.
CC   -!- SUBUNIT: Homodimer; disulfide-linked (PubMed:27434672, PubMed:27386547,
CC       PubMed:16740594). Interacts with VCP and RNF19A (PubMed:16513638).
CC       Interacts with ARRB1 (By similarity). {ECO:0000250|UniProtKB:P48442,
CC       ECO:0000269|PubMed:16513638, ECO:0000269|PubMed:16740594,
CC       ECO:0000269|PubMed:27386547, ECO:0000269|PubMed:27434672}.
CC   -!- INTERACTION:
CC       P41180; Q15363: TMED2; NbExp=3; IntAct=EBI-4400127, EBI-998485;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:15572418,
CC       ECO:0000269|PubMed:16740594, ECO:0000269|PubMed:17555508,
CC       ECO:0000269|PubMed:19789209, ECO:0000269|PubMed:20861236,
CC       ECO:0000269|PubMed:22114145, ECO:0000269|PubMed:22789683,
CC       ECO:0000269|PubMed:25104082, ECO:0000269|PubMed:25766501,
CC       ECO:0000269|PubMed:26386835, ECO:0000269|PubMed:8702647}; Multi-pass
CC       membrane protein {ECO:0000269|PubMed:20861236}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P41180-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P41180-2; Sequence=VSP_002035;
CC   -!- TISSUE SPECIFICITY: Expressed in the temporal lobe, frontal lobe,
CC       parietal lobe, hippocampus, and cerebellum. Also found in kidney, lung,
CC       liver, heart, skeletal muscle, placenta. {ECO:0000269|PubMed:18756473}.
CC   -!- DOMAIN: The extracellular regions of the homodimer interact in a side-
CC       by-side fashion while facing opposite directions (PubMed:27434672,
CC       PubMed:27386547). Each extracellular region consists of three domains,
CC       LB1 (ligand-binding 1), LB2 and CR (cysteine-rich) (PubMed:17360426).
CC       The two lobe-shaped domains LB1 and LB2 form a venus flytrap module
CC       (PubMed:27434672, PubMed:27386547). In the inactive configuration, the
CC       venus flytrap modules of both protomers are in the open conformation
CC       associated with the resting state (open-open) and the interdomain cleft
CC       is empty (PubMed:27434672). In addition, each protomer contains three
CC       anions, which reinforce the inactive conformation, and one calcium ion
CC       (PubMed:27434672). In the active configuration, both protomers of
CC       extracellular regions have the closed conformation associated with
CC       agonist-binding (closed-closed) (PubMed:27434672, PubMed:27386547). The
CC       ligand-binding cleft of each protomer is solely occupied by an aromatic
CC       amino-acid (PubMed:27434672, PubMed:27386547). Calcium is bound at four
CC       novel sites, including one at the homodimer interface (PubMed:27434672,
CC       PubMed:27386547). Agonist-binding induces large conformational changes
CC       within the extracellular region homodimer: first, the venus flytrap
CC       module of each protomer undergoes domain closure (PubMed:27434672,
CC       PubMed:27386547). Second, the LB2 regions of the two protomers approach
CC       each other, resulting in an expansion of the homodimer interactions
CC       involving LB2 domains (PubMed:27434672, PubMed:27386547). Third, the CR
CC       regions of the two subunits interact to form a large homodimer
CC       interface that is unique to the active state (PubMed:27434672,
CC       PubMed:27386547). The CR regions are brought into close contact by the
CC       motion involving LB2 since the two domains are rigidly associated
CC       within each subunit (PubMed:27434672, PubMed:27386547).
CC       {ECO:0000269|PubMed:27386547, ECO:0000269|PubMed:27434672,
CC       ECO:0000303|PubMed:17360426}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:16513638,
CC       ECO:0000269|PubMed:16740594, ECO:0000269|PubMed:20861236,
CC       ECO:0000269|PubMed:27434672, ECO:0000269|PubMed:8702647}.
CC   -!- PTM: Ubiquitinated by RNF19A; which induces proteasomal degradation.
CC       {ECO:0000269|PubMed:16513638}.
CC   -!- DISEASE: Hypocalciuric hypercalcemia, familial 1 (HHC1) [MIM:145980]: A
CC       form of hypocalciuric hypercalcemia, a disorder of mineral homeostasis
CC       that is transmitted as an autosomal dominant trait with a high degree
CC       of penetrance. It is characterized biochemically by lifelong elevation
CC       of serum calcium concentrations and is associated with inappropriately
CC       low urinary calcium excretion and a normal or mildly elevated
CC       circulating parathyroid hormone level. Hypermagnesemia is typically
CC       present. Affected individuals are usually asymptomatic and the disorder
CC       is considered benign. However, chondrocalcinosis and pancreatitis occur
CC       in some adults. {ECO:0000269|PubMed:11762699,
CC       ECO:0000269|PubMed:15572418, ECO:0000269|PubMed:15579740,
CC       ECO:0000269|PubMed:15879434, ECO:0000269|PubMed:16598859,
CC       ECO:0000269|PubMed:16740594, ECO:0000269|PubMed:17473068,
CC       ECO:0000269|PubMed:17698911, ECO:0000269|PubMed:19179454,
CC       ECO:0000269|PubMed:19789209, ECO:0000269|PubMed:21566075,
CC       ECO:0000269|PubMed:21643651, ECO:0000269|PubMed:22114145,
CC       ECO:0000269|PubMed:23169696, ECO:0000269|PubMed:23966241,
CC       ECO:0000269|PubMed:25104082, ECO:0000269|PubMed:25292184,
CC       ECO:0000269|PubMed:26386835, ECO:0000269|PubMed:27434672,
CC       ECO:0000269|PubMed:7673400, ECO:0000269|PubMed:7726161,
CC       ECO:0000269|PubMed:7916660, ECO:0000269|PubMed:8636323,
CC       ECO:0000269|PubMed:8702647, ECO:0000269|PubMed:8878438,
CC       ECO:0000269|PubMed:9298824}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Hyperparathyroidism, neonatal severe (NSHPT) [MIM:239200]: A
CC       disorder characterized by severe hypercalcemia, bone demineralization,
CC       and failure to thrive usually manifesting in the first 6 months of
CC       life. If untreated, NSHPT can be a devastating neurodevelopmental
CC       disorder, which in some cases is lethal without parathyroidectomy.
CC       {ECO:0000269|PubMed:14985373, ECO:0000269|PubMed:15572418,
CC       ECO:0000269|PubMed:17555508, ECO:0000269|PubMed:27434672,
CC       ECO:0000269|PubMed:8675635, ECO:0000269|PubMed:8878438,
CC       ECO:0000269|PubMed:9253359}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Hypocalcemia, autosomal dominant 1 (HYPOC1) [MIM:601198]: A
CC       disorder of mineral homeostasis characterized by blood calcium levels
CC       below normal, and low or normal serum parathyroid hormone
CC       concentrations. Disease manifestations include mild or asymptomatic
CC       hypocalcemia, paresthesias, carpopedal spasm, seizures, hypercalciuria
CC       with nephrocalcinosis or kidney stones, and ectopic and basal ganglia
CC       calcifications. Few patients manifest hypocalcemia and features of
CC       Bartter syndrome, including hypomagnesemia, hypokalemia, metabolic
CC       alkalosis, hyperreninemia, and hyperaldosteronemia.
CC       {ECO:0000269|PubMed:10487661, ECO:0000269|PubMed:12050233,
CC       ECO:0000269|PubMed:12107202, ECO:0000269|PubMed:12241879,
CC       ECO:0000269|PubMed:12574188, ECO:0000269|PubMed:12915654,
CC       ECO:0000269|PubMed:15551332, ECO:0000269|PubMed:16608894,
CC       ECO:0000269|PubMed:19179454, ECO:0000269|PubMed:22789683,
CC       ECO:0000269|PubMed:23169696, ECO:0000269|PubMed:23966241,
CC       ECO:0000269|PubMed:25766501, ECO:0000269|PubMed:7874174,
CC       ECO:0000269|PubMed:8702647, ECO:0000269|PubMed:8733126,
CC       ECO:0000269|PubMed:8813042, ECO:0000269|PubMed:8878438,
CC       ECO:0000269|PubMed:9253358, ECO:0000269|PubMed:9661634,
CC       ECO:0000269|PubMed:9920108}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Epilepsy, idiopathic generalized 8 (EIG8) [MIM:612899]: A
CC       disorder characterized by recurring generalized seizures in the absence
CC       of detectable brain lesions and/or metabolic abnormalities. Seizure
CC       types are variable, but include myoclonic seizures, absence seizures,
CC       febrile seizures, complex partial seizures, and generalized tonic-
CC       clonic seizures. {ECO:0000269|PubMed:18756473}. Note=Disease
CC       susceptibility is associated with variations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 3 family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB29413.2; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/casr/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X81086; CAA56990.1; -; Genomic_DNA.
DR   EMBL; U20759; AAA86503.1; -; mRNA.
DR   EMBL; U20760; AAA86504.1; -; mRNA.
DR   EMBL; D50855; BAA09453.1; -; mRNA.
DR   EMBL; S83176; AAB46873.1; -; mRNA.
DR   EMBL; S79217; AAB35262.2; -; mRNA.
DR   EMBL; S81755; AAD14370.1; -; mRNA.
DR   EMBL; S68032; AAB29413.2; ALT_SEQ; Genomic_DNA.
DR   EMBL; S68033; AAB29414.1; -; Genomic_DNA.
DR   EMBL; S68036; AAB29415.1; -; Genomic_DNA.
DR   EMBL; DQ088967; AAY68221.1; -; Genomic_DNA.
DR   EMBL; BC104999; AAI05000.1; -; mRNA.
DR   EMBL; BC112236; AAI12237.1; -; mRNA.
DR   CCDS; CCDS3010.1; -. [P41180-1]
DR   CCDS; CCDS54632.1; -. [P41180-2]
DR   PIR; A56715; A56715.
DR   PIR; B56715; B56715.
DR   RefSeq; NP_000379.2; NM_000388.3. [P41180-1]
DR   RefSeq; NP_001171536.1; NM_001178065.1. [P41180-2]
DR   RefSeq; XP_006713852.1; XM_006713789.3. [P41180-1]
DR   RefSeq; XP_016862813.1; XM_017007324.1. [P41180-1]
DR   RefSeq; XP_016862814.1; XM_017007325.1. [P41180-1]
DR   PDB; 5FBH; X-ray; 2.70 A; A/B=20-541.
DR   PDB; 5FBK; X-ray; 2.10 A; A/B=20-541.
DR   PDB; 5K5S; X-ray; 2.60 A; A/B=20-607.
DR   PDB; 5K5T; X-ray; 3.10 A; A=20-607.
DR   PDBsum; 5FBH; -.
DR   PDBsum; 5FBK; -.
DR   PDBsum; 5K5S; -.
DR   PDBsum; 5K5T; -.
DR   SMR; P41180; -.
DR   BioGRID; 107296; 19.
DR   DIP; DIP-5975N; -.
DR   ELM; P41180; -.
DR   IntAct; P41180; 1.
DR   STRING; 9606.ENSP00000420194; -.
DR   BindingDB; P41180; -.
DR   ChEMBL; CHEMBL1878; -.
DR   DrugBank; DB11093; Calcium citrate.
DR   DrugBank; DB11348; Calcium Phosphate.
DR   DrugBank; DB14481; Calcium phosphate dihydrate.
DR   DrugBank; DB01012; Cinacalcet.
DR   DrugBank; DB12865; Etelcalcetide.
DR   DrugBank; DB00994; Neomycin.
DR   DrugBank; DB05695; NPS-2143.
DR   DrugBank; DB05255; Ronacaleret.
DR   DrugBank; DB00127; Spermine.
DR   DrugCentral; P41180; -.
DR   GuidetoPHARMACOLOGY; 54; -.
DR   TCDB; 9.A.14.7.2; the g-protein-coupled receptor (gpcr) family.
DR   GlyConnect; 1227; 2 N-Linked glycans (1 site).
DR   GlyGen; P41180; 11 sites.
DR   iPTMnet; P41180; -.
DR   PhosphoSitePlus; P41180; -.
DR   BioMuta; CASR; -.
DR   DMDM; 1168781; -.
DR   MassIVE; P41180; -.
DR   PaxDb; P41180; -.
DR   PeptideAtlas; P41180; -.
DR   PRIDE; P41180; -.
DR   ProteomicsDB; 55410; -. [P41180-1]
DR   ProteomicsDB; 55411; -. [P41180-2]
DR   Antibodypedia; 16753; 663 antibodies.
DR   Ensembl; ENST00000498619; ENSP00000420194; ENSG00000036828. [P41180-2]
DR   Ensembl; ENST00000638421; ENSP00000492190; ENSG00000036828. [P41180-1]
DR   Ensembl; ENST00000639785; ENSP00000491584; ENSG00000036828. [P41180-1]
DR   GeneID; 846; -.
DR   KEGG; hsa:846; -.
DR   UCSC; uc003eev.5; human. [P41180-1]
DR   CTD; 846; -.
DR   DisGeNET; 846; -.
DR   EuPathDB; HostDB:ENSG00000036828.13; -.
DR   GeneCards; CASR; -.
DR   GeneReviews; CASR; -.
DR   HGNC; HGNC:1514; CASR.
DR   HPA; ENSG00000036828; Tissue enriched (parathyroid).
DR   MalaCards; CASR; -.
DR   MIM; 145980; phenotype.
DR   MIM; 239200; phenotype.
DR   MIM; 601198; phenotype.
DR   MIM; 601199; gene.
DR   MIM; 612899; phenotype.
DR   neXtProt; NX_P41180; -.
DR   OpenTargets; ENSG00000036828; -.
DR   Orphanet; 428; Autosomal dominant hypocalcemia.
DR   Orphanet; 93372; Familial hypocalciuric hypercalcemia type 1.
DR   Orphanet; 676; Hereditary chronic pancreatitis.
DR   Orphanet; 417; Neonatal severe primary hyperparathyroidism.
DR   PharmGKB; PA26097; -.
DR   eggNOG; KOG1056; Eukaryota.
DR   GeneTree; ENSGT00940000157596; -.
DR   HOGENOM; CLU_005389_0_0_1; -.
DR   InParanoid; P41180; -.
DR   KO; K04612; -.
DR   OMA; KKILWSG; -.
DR   OrthoDB; 327938at2759; -.
DR   PhylomeDB; P41180; -.
DR   PathwayCommons; P41180; -.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-420499; Class C/3 (Metabotropic glutamate/pheromone receptors).
DR   SIGNOR; P41180; -.
DR   BioGRID-ORCS; 846; 24 hits in 873 CRISPR screens.
DR   ChiTaRS; CASR; human.
DR   GeneWiki; Calcium-sensing_receptor; -.
DR   GenomeRNAi; 846; -.
DR   Pharos; P41180; Tclin.
DR   PRO; PR:P41180; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; P41180; protein.
DR   Bgee; ENSG00000036828; Expressed in islet of Langerhans and 99 other tissues.
DR   ExpressionAtlas; P41180; baseline and differential.
DR   Genevisible; P41180; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0043679; C:axon terminus; IEA:Ensembl.
DR   GO; GO:0016323; C:basolateral plasma membrane; IEA:Ensembl.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0016597; F:amino acid binding; IDA:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IDA:UniProtKB.
DR   GO; GO:0005178; F:integrin binding; IEA:Ensembl.
DR   GO; GO:0044325; F:ion channel binding; IEA:Ensembl.
DR   GO; GO:0004435; F:phosphatidylinositol phospholipase C activity; TAS:ProtInc.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IEA:Ensembl.
DR   GO; GO:0038023; F:signaling receptor activity; IBA:GO_Central.
DR   GO; GO:0007193; P:adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0009653; P:anatomical structure morphogenesis; TAS:ProtInc.
DR   GO; GO:0006915; P:apoptotic process; IEA:Ensembl.
DR   GO; GO:0032782; P:bile acid secretion; IEA:Ensembl.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; IEA:Ensembl.
DR   GO; GO:0070509; P:calcium ion import; IDA:UniProtKB.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IDA:UniProtKB.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; IEA:Ensembl.
DR   GO; GO:0035729; P:cellular response to hepatocyte growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:0071404; P:cellular response to low-density lipoprotein particle stimulus; IEA:Ensembl.
DR   GO; GO:1901653; P:cellular response to peptide; IEA:Ensembl.
DR   GO; GO:0071305; P:cellular response to vitamin D; IEA:Ensembl.
DR   GO; GO:0007635; P:chemosensory behavior; TAS:ProtInc.
DR   GO; GO:1902476; P:chloride transmembrane transport; IEA:Ensembl.
DR   GO; GO:0005513; P:detection of calcium ion; IDA:UniProtKB.
DR   GO; GO:0060613; P:fat pad development; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007254; P:JNK cascade; IEA:Ensembl.
DR   GO; GO:0001503; P:ossification; TAS:ProtInc.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0032781; P:positive regulation of ATPase activity; IEA:Ensembl.
DR   GO; GO:0090280; P:positive regulation of calcium ion import; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0032024; P:positive regulation of insulin secretion; IEA:Ensembl.
DR   GO; GO:0050927; P:positive regulation of positive chemotaxis; IEA:Ensembl.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; IEA:Ensembl.
DR   GO; GO:0051924; P:regulation of calcium ion transport; IBA:GO_Central.
DR   GO; GO:0071774; P:response to fibroblast growth factor; IEA:Ensembl.
DR   GO; GO:0002931; P:response to ischemia; IEA:Ensembl.
DR   GO; GO:0042311; P:vasodilation; IEA:Ensembl.
DR   Gene3D; 2.10.50.30; -; 1.
DR   InterPro; IPR001828; ANF_lig-bd_rcpt.
DR   InterPro; IPR000337; GPCR_3.
DR   InterPro; IPR011500; GPCR_3_9-Cys_dom.
DR   InterPro; IPR038550; GPCR_3_9-Cys_sf.
DR   InterPro; IPR017978; GPCR_3_C.
DR   InterPro; IPR000068; GPCR_3_Ca_sens_rcpt-rel.
DR   InterPro; IPR017979; GPCR_3_CS.
DR   InterPro; IPR028082; Peripla_BP_I.
DR   PANTHER; PTHR24061; PTHR24061; 1.
DR   Pfam; PF00003; 7tm_3; 1.
DR   Pfam; PF01094; ANF_receptor; 1.
DR   Pfam; PF07562; NCD3G; 1.
DR   PRINTS; PR00592; CASENSINGR.
DR   PRINTS; PR00248; GPCRMGR.
DR   SUPFAM; SSF53822; SSF53822; 1.
DR   PROSITE; PS00979; G_PROTEIN_RECEP_F3_1; 1.
DR   PROSITE; PS00980; G_PROTEIN_RECEP_F3_2; 1.
DR   PROSITE; PS00981; G_PROTEIN_RECEP_F3_3; 1.
DR   PROSITE; PS50259; G_PROTEIN_RECEP_F3_4; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Cell membrane;
KW   Disease mutation; Disulfide bond; Epilepsy; G-protein coupled receptor;
KW   Glycoprotein; Membrane; Metal-binding; Phosphoprotein; Polymorphism;
KW   Receptor; Reference proteome; Signal; Transducer; Transmembrane;
KW   Transmembrane helix; Ubl conjugation.
FT   SIGNAL          1..19
FT                   /evidence="ECO:0000255"
FT   CHAIN           20..1078
FT                   /note="Extracellular calcium-sensing receptor"
FT                   /id="PRO_0000012946"
FT   TOPO_DOM        20..612
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        613..635
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        636..649
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        650..670
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        671..681
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        682..700
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        701..724
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        725..745
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        746..769
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        770..792
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        793..805
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        806..828
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        829..836
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        837..862
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        863..1078
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REGION          22..188
FT                   /note="Ligand-binding 1 (LB1)"
FT                   /evidence="ECO:0000303|PubMed:17360426"
FT   REGION          66..70
FT                   /note="Anion binding"
FT                   /evidence="ECO:0000244|PDB:5K5S, ECO:0000244|PDB:5K5T,
FT                   ECO:0000269|PubMed:27434672"
FT   REGION          189..324
FT                   /note="Ligand-binding 2 (LB2)"
FT                   /evidence="ECO:0000303|PubMed:17360426"
FT   REGION          415..417
FT                   /note="Anion binding"
FT                   /evidence="ECO:0000244|PDB:5K5S, ECO:0000244|PDB:5K5T,
FT                   ECO:0000269|PubMed:27434672"
FT   REGION          542..612
FT                   /note="Cysteine-rich (CR)"
FT                   /evidence="ECO:0000303|PubMed:17360426"
FT   REGION          880..900
FT                   /note="Interaction with RNF19A"
FT                   /evidence="ECO:0000269|PubMed:16513638"
FT   METAL           81
FT                   /note="Calcium; via carbonyl oxygen"
FT                   /evidence="ECO:0000244|PDB:5FBH, ECO:0000244|PDB:5FBK,
FT                   ECO:0000244|PDB:5K5S, ECO:0000269|PubMed:27434672,
FT                   ECO:0000305|PubMed:27386547"
FT   METAL           84
FT                   /note="Calcium"
FT                   /evidence="ECO:0000244|PDB:5FBK, ECO:0000244|PDB:5K5S,
FT                   ECO:0000269|PubMed:27434672, ECO:0000305|PubMed:27386547"
FT   METAL           87
FT                   /note="Calcium; via carbonyl oxygen"
FT                   /evidence="ECO:0000244|PDB:5FBH, ECO:0000244|PDB:5FBK,
FT                   ECO:0000244|PDB:5K5S, ECO:0000269|PubMed:27434672,
FT                   ECO:0000305|PubMed:27386547"
FT   METAL           88
FT                   /note="Calcium; via carbonyl oxygen"
FT                   /evidence="ECO:0000244|PDB:5FBH, ECO:0000244|PDB:5FBK,
FT                   ECO:0000244|PDB:5K5S, ECO:0000269|PubMed:27434672,
FT                   ECO:0000305|PubMed:27386547"
FT   METAL           100
FT                   /note="Calcium"
FT                   /evidence="ECO:0000244|PDB:5K5S, ECO:0000244|PDB:5K5T,
FT                   ECO:0000269|PubMed:27434672"
FT   METAL           145
FT                   /note="Calcium"
FT                   /evidence="ECO:0000244|PDB:5K5S,
FT                   ECO:0000269|PubMed:27434672"
FT   METAL           231
FT                   /note="Calcium"
FT                   /evidence="ECO:0000244|PDB:5K5S,
FT                   ECO:0000269|PubMed:27434672"
FT   METAL           234
FT                   /note="Calcium"
FT                   /evidence="ECO:0000244|PDB:5K5S,
FT                   ECO:0000269|PubMed:27434672"
FT   METAL           557
FT                   /note="Calcium; via carbonyl oxygen"
FT                   /evidence="ECO:0000244|PDB:5K5S,
FT                   ECO:0000269|PubMed:27434672"
FT   BINDING         147
FT                   /note="Aromatic amino acid"
FT                   /evidence="ECO:0000244|PDB:5FBH, ECO:0000244|PDB:5FBK,
FT                   ECO:0000244|PDB:5K5S, ECO:0000269|PubMed:27386547,
FT                   ECO:0000269|PubMed:27434672"
FT   BINDING         168
FT                   /note="Aromatic amino acid; via carbonyl oxygen"
FT                   /evidence="ECO:0000244|PDB:5FBH, ECO:0000244|PDB:5FBK,
FT                   ECO:0000244|PDB:5K5S, ECO:0000269|PubMed:27386547,
FT                   ECO:0000269|PubMed:27434672"
FT   BINDING         170
FT                   /note="Aromatic amino acid"
FT                   /evidence="ECO:0000244|PDB:5FBH, ECO:0000244|PDB:5FBK,
FT                   ECO:0000244|PDB:5K5S, ECO:0000269|PubMed:27386547,
FT                   ECO:0000269|PubMed:27434672"
FT   BINDING         297
FT                   /note="Aromatic amino acid"
FT                   /evidence="ECO:0000244|PDB:5FBH, ECO:0000244|PDB:5FBK,
FT                   ECO:0000244|PDB:5K5S, ECO:0000269|PubMed:27386547,
FT                   ECO:0000269|PubMed:27434672"
FT   SITE            482
FT                   /note="Important for ability of agonist AMG 416 to activate
FT                   G-protein-coupled receptor activity"
FT                   /evidence="ECO:0000269|PubMed:26290606"
FT   MOD_RES         920
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QY96"
FT   MOD_RES         1061
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9QY96"
FT   CARBOHYD        90
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        130
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        261
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255, ECO:0000269|PubMed:27434672"
FT   CARBOHYD        287
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255, ECO:0000269|PubMed:27434672"
FT   CARBOHYD        386
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        400
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        446
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255, ECO:0000269|PubMed:27434672"
FT   CARBOHYD        468
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255, ECO:0000269|PubMed:27434672"
FT   CARBOHYD        488
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255, ECO:0000269|PubMed:27434672"
FT   CARBOHYD        541
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255, ECO:0000269|PubMed:27434672"
FT   CARBOHYD        594
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255, ECO:0000269|PubMed:27434672"
FT   DISULFID        60..101
FT                   /evidence="ECO:0000244|PDB:5FBH, ECO:0000244|PDB:5FBK,
FT                   ECO:0000244|PDB:5K5S, ECO:0000269|PubMed:27386547,
FT                   ECO:0000269|PubMed:27434672"
FT   DISULFID        129
FT                   /note="Interchain"
FT                   /evidence="ECO:0000269|PubMed:27434672,
FT                   ECO:0000305|PubMed:27386547"
FT   DISULFID        131
FT                   /note="Interchain"
FT                   /evidence="ECO:0000269|PubMed:27434672,
FT                   ECO:0000305|PubMed:27386547"
FT   DISULFID        236..561
FT                   /evidence="ECO:0000269|PubMed:27434672"
FT   DISULFID        358..395
FT                   /evidence="ECO:0000244|PDB:5FBH, ECO:0000244|PDB:5FBK,
FT                   ECO:0000244|PDB:5K5S, ECO:0000269|PubMed:27386547,
FT                   ECO:0000269|PubMed:27434672"
FT   DISULFID        437..449
FT                   /evidence="ECO:0000244|PDB:5FBH, ECO:0000244|PDB:5FBK,
FT                   ECO:0000244|PDB:5K5S, ECO:0000269|PubMed:27386547,
FT                   ECO:0000269|PubMed:27434672"
FT   DISULFID        542..562
FT                   /evidence="ECO:0000269|PubMed:27434672"
FT   DISULFID        546..565
FT                   /evidence="ECO:0000269|PubMed:27434672"
FT   DISULFID        568..582
FT                   /evidence="ECO:0000269|PubMed:27434672"
FT   DISULFID        585..598
FT                   /evidence="ECO:0000269|PubMed:27434672"
FT   VAR_SEQ         536
FT                   /note="E -> EPLTFVLSVLQ (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:7759551"
FT                   /id="VSP_002035"
FT   VARIANT         11
FT                   /note="L -> S (in HHC1; demonstrates reduced intracellular
FT                   and plasma membrane expression and signaling to the MAPK
FT                   pathway in response to extracellular calcium relative to
FT                   wild-type; fails to be inserted in the microsomes and does
FT                   not undergo proper glycosylation; dbSNP:rs200673016)"
FT                   /evidence="ECO:0000269|PubMed:15879434"
FT                   /id="VAR_058046"
FT   VARIANT         13
FT                   /note="L -> P (in HHC1; has a dose-response curve shifted
FT                   to the right relative to that of wild-type; demonstrates
FT                   reduced intracellular and plasma membrane expression and
FT                   signaling to the MAPK pathway in response to extracellular
FT                   calcium relative to wild-type; fails to be inserted in the
FT                   microsomes and does not undergo proper glycosylation;
FT                   dbSNP:rs104893717)"
FT                   /evidence="ECO:0000269|PubMed:15579740,
FT                   ECO:0000269|PubMed:15879434"
FT                   /id="VAR_058047"
FT   VARIANT         14
FT                   /note="T -> A (does not demonstrate reduced intracellular
FT                   and plasma membrane expression and signaling to the MAPK
FT                   pathway in response to extracellular calcium relative to
FT                   wild-type; does not fail to be inserted in the microsomes
FT                   and does undergo proper glycosylation; dbSNP:rs199515839)"
FT                   /evidence="ECO:0000269|PubMed:15879434"
FT                   /id="VAR_058048"
FT   VARIANT         21
FT                   /note="G -> R (in HHC1; dbSNP:rs1064794290)"
FT                   /evidence="ECO:0000269|PubMed:17698911"
FT                   /id="VAR_058049"
FT   VARIANT         27
FT                   /note="Q -> R (found in a patient with primary
FT                   hyperparathyroidism detected at adulthood; mutant CASR is
FT                   activated by a higher calcium concentrations than the wild-
FT                   type)"
FT                   /evidence="ECO:0000269|PubMed:10468915"
FT                   /id="VAR_065198"
FT   VARIANT         39
FT                   /note="P -> A (in HHC1; dbSNP:rs121909262)"
FT                   /evidence="ECO:0000269|PubMed:7673400"
FT                   /id="VAR_003585"
FT   VARIANT         42
FT                   /note="F -> S (in HHC1; dbSNP:rs1553765909)"
FT                   /evidence="ECO:0000269|PubMed:19179454"
FT                   /id="VAR_078139"
FT   VARIANT         47
FT                   /note="K -> N (in HYPOC1; the EC(50) of the mutant is
FT                   significantly lower than that of wild-type;
FT                   dbSNP:rs104893702)"
FT                   /evidence="ECO:0000269|PubMed:9920108"
FT                   /id="VAR_058050"
FT   VARIANT         53
FT                   /note="S -> P (in HHC1; decreased G-protein coupled
FT                   receptor signaling pathway)"
FT                   /evidence="ECO:0000269|PubMed:8636323"
FT                   /id="VAR_078140"
FT   VARIANT         55
FT                   /note="P -> L (in HHC1; decreased G-protein coupled
FT                   receptor signaling pathway; dbSNP:rs886041154)"
FT                   /evidence="ECO:0000269|PubMed:19179454,
FT                   ECO:0000269|PubMed:8636323, ECO:0000269|PubMed:8878438"
FT                   /id="VAR_078141"
FT   VARIANT         62
FT                   /note="R -> M (in HHC1; mild; decreased G-protein coupled
FT                   receptor signaling pathway; dbSNP:rs121909265)"
FT                   /evidence="ECO:0000269|PubMed:7726161,
FT                   ECO:0000269|PubMed:8702647"
FT                   /id="VAR_003586"
FT   VARIANT         66
FT                   /note="R -> C (in HHC1; does not affect homodimerization;
FT                   impaired N-glycosylation; impaired cell membrane
FT                   localization; decreased G-protein coupled receptor
FT                   signaling pathway; dbSNP:rs121909266)"
FT                   /evidence="ECO:0000269|PubMed:16740594,
FT                   ECO:0000269|PubMed:7726161, ECO:0000269|PubMed:8702647"
FT                   /id="VAR_003587"
FT   VARIANT         66
FT                   /note="R -> H (in HHC1; does not affect homodimerization;
FT                   impaired N-glycosylation; impaired cell membrane
FT                   localization; decreased G-protein coupled receptor
FT                   signaling pathway; dbSNP:rs1276839362)"
FT                   /evidence="ECO:0000269|PubMed:16740594,
FT                   ECO:0000269|PubMed:19179454, ECO:0000269|PubMed:27434672"
FT                   /id="VAR_078142"
FT   VARIANT         81
FT                   /note="I -> M (in HHC1; decreased G-protein coupled
FT                   receptor signaling pathway)"
FT                   /evidence="ECO:0000269|PubMed:19179454,
FT                   ECO:0000269|PubMed:27434672"
FT                   /id="VAR_078143"
FT   VARIANT         100
FT                   /note="T -> I (in NSHPT; Abolished G-protein coupled
FT                   receptor activity)"
FT                   /evidence="ECO:0000269|PubMed:14985373,
FT                   ECO:0000269|PubMed:27434672"
FT                   /id="VAR_065199"
FT   VARIANT         110
FT                   /note="A -> T (in HHC1; decreased G-protein coupled
FT                   receptor signaling pathway)"
FT                   /evidence="ECO:0000269|PubMed:23966241"
FT                   /id="VAR_078144"
FT   VARIANT         116
FT                   /note="A -> T (in HYPOC1; dbSNP:rs104893691)"
FT                   /evidence="ECO:0000269|PubMed:8733126"
FT                   /id="VAR_003588"
FT   VARIANT         118
FT                   /note="N -> K (in HYPOC1; the mutation shifts the
FT                   concentration-response curve to the left and increases
FT                   maximal activity; dbSNP:rs104893695)"
FT                   /evidence="ECO:0000269|PubMed:19179454,
FT                   ECO:0000269|PubMed:8813042, ECO:0000269|PubMed:9253358"
FT                   /id="VAR_058051"
FT   VARIANT         122
FT                   /note="S -> C (in HYPOC1; increased G-protein coupled
FT                   receptor signaling pathway)"
FT                   /evidence="ECO:0000269|PubMed:23966241"
FT                   /id="VAR_078145"
FT   VARIANT         125
FT                   /note="L -> F (in HYPOC1)"
FT                   /evidence="ECO:0000269|PubMed:19179454"
FT                   /id="VAR_078146"
FT   VARIANT         125
FT                   /note="L -> P (in HYPOC1; shifts the concentration-response
FT                   curve of calcium ions to the left; dbSNP:rs104893708)"
FT                   /evidence="ECO:0000269|PubMed:12107202"
FT                   /id="VAR_058052"
FT   VARIANT         127
FT                   /note="E -> A (in HYPOC1; increased G-protein coupled
FT                   receptor signaling pathway; dbSNP:rs121909260)"
FT                   /evidence="ECO:0000269|PubMed:7874174,
FT                   ECO:0000269|PubMed:8702647"
FT                   /id="VAR_003589"
FT   VARIANT         128
FT                   /note="F -> L (in HYPOC1; increased G-protein coupled
FT                   receptor signaling pathway; dbSNP:rs104893696)"
FT                   /evidence="ECO:0000269|PubMed:8813042,
FT                   ECO:0000269|PubMed:8878438"
FT                   /id="VAR_058053"
FT   VARIANT         129
FT                   /note="C -> R (in HYPOC1)"
FT                   /evidence="ECO:0000269|PubMed:19179454"
FT                   /id="VAR_078147"
FT   VARIANT         131
FT                   /note="C -> W (in HYPOC1; associated with clinical features
FT                   of Bartter syndrome; dbSNP:rs121909267)"
FT                   /evidence="ECO:0000269|PubMed:12241879"
FT                   /id="VAR_058054"
FT   VARIANT         136
FT                   /note="P -> L (in HYPOC1; increased G-protein coupled
FT                   receptor signaling pathway; does not affect cell membrane
FT                   localization)"
FT                   /evidence="ECO:0000269|PubMed:25766501"
FT                   /id="VAR_078148"
FT   VARIANT         138
FT                   /note="T -> M (in HHC1; decreased G-protein coupled
FT                   receptor signaling pathway; dbSNP:rs121909263)"
FT                   /evidence="ECO:0000269|PubMed:19179454,
FT                   ECO:0000269|PubMed:7726161, ECO:0000269|PubMed:8702647"
FT                   /id="VAR_003590"
FT   VARIANT         143
FT                   /note="G -> E (in HHC1; decreased G-protein coupled
FT                   receptor signaling pathway; dbSNP:rs121909264)"
FT                   /evidence="ECO:0000269|PubMed:7726161,
FT                   ECO:0000269|PubMed:8702647"
FT                   /id="VAR_003591"
FT   VARIANT         143
FT                   /note="G -> R (in HHC1; dbSNP:rs769256610)"
FT                   /evidence="ECO:0000269|PubMed:19179454"
FT                   /id="VAR_078149"
FT   VARIANT         151
FT                   /note="T -> M (in HYPOC1; increased G-protein coupled
FT                   receptor signaling pathway; dbSNP:rs104893694)"
FT                   /evidence="ECO:0000269|PubMed:8698326,
FT                   ECO:0000269|PubMed:8813042, ECO:0000269|PubMed:8878438"
FT                   /id="VAR_058055"
FT   VARIANT         158
FT                   /note="G -> R (in HHC1)"
FT                   /evidence="ECO:0000269|PubMed:19179454"
FT                   /id="VAR_078150"
FT   VARIANT         159
FT                   /note="L -> P (in HHC1; decreased G-protein coupled
FT                   receptor signaling pathway)"
FT                   /evidence="ECO:0000269|PubMed:22114145,
FT                   ECO:0000269|PubMed:27434672"
FT                   /id="VAR_078151"
FT   VARIANT         166
FT                   /note="S -> G (in HHC1; dbSNP:rs193922441)"
FT                   /evidence="ECO:0000269|PubMed:19179454"
FT                   /id="VAR_078152"
FT   VARIANT         171
FT                   /note="S -> N (in HHC1)"
FT                   /evidence="ECO:0000269|PubMed:17698911"
FT                   /id="VAR_058056"
FT   VARIANT         172
FT                   /note="R -> G (in HHC1; decreased G-protein coupled
FT                   receptor signaling pathway; dbSNP:rs201851934)"
FT                   /evidence="ECO:0000269|PubMed:23966241,
FT                   ECO:0000269|PubMed:27434672"
FT                   /id="VAR_078153"
FT   VARIANT         174
FT                   /note="L -> R (in HHC1)"
FT                   /evidence="ECO:0000269|PubMed:9298824"
FT                   /id="VAR_003592"
FT   VARIANT         178
FT                   /note="N -> D (in HHC1; decreased G-protein coupled
FT                   receptor signaling pathway; dbSNP:rs1060502855)"
FT                   /evidence="ECO:0000269|PubMed:8878438"
FT                   /id="VAR_078154"
FT   VARIANT         180
FT                   /note="F -> C (in HHC1; although the mutant receptor is
FT                   expressed normally at the cell surface it is unresponsive
FT                   with respect to intracellular signaling (MAPK activation)
FT                   to increases in extracellular calcium concentrations;
FT                   dbSNP:rs121909268)"
FT                   /evidence="ECO:0000269|PubMed:17473068"
FT                   /id="VAR_058057"
FT   VARIANT         185
FT                   /note="R -> Q (in HHC1; decreased G-protein coupled
FT                   receptor signaling pathway; dbSNP:rs104893689)"
FT                   /evidence="ECO:0000269|PubMed:7916660,
FT                   ECO:0000269|PubMed:8636323, ECO:0000269|PubMed:8702647"
FT                   /id="VAR_003593"
FT   VARIANT         191
FT                   /note="E -> K (in HYPOC1; increased G-protein coupled
FT                   receptor signaling pathway; dbSNP:rs104893697)"
FT                   /evidence="ECO:0000269|PubMed:8813042,
FT                   ECO:0000269|PubMed:8878438"
FT                   /id="VAR_058058"
FT   VARIANT         215
FT                   /note="D -> G (in HHC1; decreased G-protein coupled
FT                   receptor signaling pathway)"
FT                   /evidence="ECO:0000269|PubMed:27434672,
FT                   ECO:0000269|PubMed:8636323"
FT                   /id="VAR_078155"
FT   VARIANT         220
FT                   /note="R -> W (in HHC1; dbSNP:rs1482119762)"
FT                   /evidence="ECO:0000269|PubMed:19179454"
FT                   /id="VAR_078156"
FT   VARIANT         221
FT                   /note="P -> L (in HYPOC1; dbSNP:rs397514728)"
FT                   /evidence="ECO:0000269|PubMed:22789683"
FT                   /id="VAR_078157"
FT   VARIANT         221
FT                   /note="P -> Q (in HHC1; dbSNP:rs397514728)"
FT                   /evidence="ECO:0000269|PubMed:17698911"
FT                   /id="VAR_058059"
FT   VARIANT         221
FT                   /note="P -> S (in HHC1; decreased G-protein coupled
FT                   receptor signaling pathway)"
FT                   /evidence="ECO:0000269|PubMed:8878438"
FT                   /id="VAR_078158"
FT   VARIANT         225
FT                   /note="K -> T (in HHC1)"
FT                   /evidence="ECO:0000269|PubMed:17698911"
FT                   /id="VAR_058060"
FT   VARIANT         227
FT                   /note="R -> L (in NSHPT; decreased G-protein coupled
FT                   receptor signaling pathway; does not affect cell membrane
FT                   localization; dbSNP:rs28936684)"
FT                   /evidence="ECO:0000269|PubMed:15572418,
FT                   ECO:0000269|PubMed:27434672, ECO:0000269|PubMed:8675635,
FT                   ECO:0000269|PubMed:8878438"
FT                   /id="VAR_003594"
FT   VARIANT         227
FT                   /note="R -> Q (in HHC1; G-protein coupled receptor
FT                   signaling pathway; less markedly impaired relative to wild-
FT                   type than L-227; does not affect cell membrane
FT                   localization; dbSNP:rs28936684)"
FT                   /evidence="ECO:0000269|PubMed:15572418,
FT                   ECO:0000269|PubMed:7726161"
FT                   /id="VAR_003595"
FT   VARIANT         228
FT                   /note="E -> K (in HYPOC1)"
FT                   /evidence="ECO:0000269|PubMed:19179454"
FT                   /id="VAR_078159"
FT   VARIANT         250
FT                   /note="E -> K (in dbSNP:rs62269092)"
FT                   /evidence="ECO:0000269|PubMed:17698911"
FT                   /id="VAR_058061"
FT   VARIANT         271
FT                   /note="S -> F (in HHC1)"
FT                   /evidence="ECO:0000269|PubMed:17698911"
FT                   /id="VAR_058062"
FT   VARIANT         297
FT                   /note="E -> K (in HHC1; decreased G-protein coupled
FT                   receptor signaling pathway; dbSNP:rs121909259)"
FT                   /evidence="ECO:0000269|PubMed:27434672,
FT                   ECO:0000269|PubMed:7916660, ECO:0000269|PubMed:8702647"
FT                   /id="VAR_003596"
FT   VARIANT         336
FT                   /note="Missing (in NSHPT)"
FT                   /evidence="ECO:0000269|PubMed:14985373"
FT                   /id="VAR_065200"
FT   VARIANT         339
FT                   /note="P -> T (mutation found in a patient with primary
FT                   hyperparathyroidism detected at adulthood; inactivating
FT                   mutation; mutant CASR is activated by a higher calcium
FT                   concentrations than the wild-type)"
FT                   /evidence="ECO:0000269|PubMed:20846291"
FT                   /id="VAR_065201"
FT   VARIANT         354
FT                   /note="E -> A (in EIG8; patients present juvenile myoclonus
FT                   epilepsy)"
FT                   /evidence="ECO:0000269|PubMed:18756473"
FT                   /id="VAR_060206"
FT   VARIANT         397
FT                   /note="G -> R (in HHC1; dbSNP:rs1064794291)"
FT                   /evidence="ECO:0000269|PubMed:17698911"
FT                   /id="VAR_058063"
FT   VARIANT         459
FT                   /note="Q -> R (in HHC1; decreased G-protein coupled
FT                   receptor signaling pathway; does not affect cell membrane
FT                   localization)"
FT                   /evidence="ECO:0000269|PubMed:19789209"
FT                   /id="VAR_078160"
FT   VARIANT         465
FT                   /note="R -> Q (in HHC1; loss-of-function mutation; the
FT                   quantity of the mutant receptor is higher than that of the
FT                   wild-type receptor; dose-response curves show that the
FT                   mutation significantly reduces the sensitivity of the
FT                   receptor to extracellular calcium concentrations;
FT                   dbSNP:rs104893716)"
FT                   /evidence="ECO:0000269|PubMed:16598859"
FT                   /id="VAR_058064"
FT   VARIANT         509
FT                   /note="G -> R (in HHC1; dbSNP:rs193922423)"
FT                   /evidence="ECO:0000269|PubMed:17698911"
FT                   /id="VAR_058065"
FT   VARIANT         549
FT                   /note="G -> R (in HHC1)"
FT                   /evidence="ECO:0000269|PubMed:19179454"
FT                   /id="VAR_078161"
FT   VARIANT         550
FT                   /note="T -> I (in HHC1; decreased G-protein coupled
FT                   receptor signaling pathway)"
FT                   /evidence="ECO:0000269|PubMed:21566075"
FT                   /id="VAR_078162"
FT   VARIANT         551
FT                   /note="R -> K (in NSHPT; decreased G-protein coupled
FT                   receptor signaling pathway; does not affect cell membrane
FT                   localization; dbSNP:rs1060502861)"
FT                   /evidence="ECO:0000269|PubMed:17555508,
FT                   ECO:0000269|PubMed:27434672"
FT                   /id="VAR_078163"
FT   VARIANT         553
FT                   /note="G -> R (in HHC1; dbSNP:rs104893719)"
FT                   /evidence="ECO:0000269|PubMed:17698911"
FT                   /id="VAR_058066"
FT   VARIANT         555
FT                   /note="I -> V (in HHC1; dbSNP:rs777646067)"
FT                   /evidence="ECO:0000269|PubMed:17698911"
FT                   /id="VAR_058067"
FT   VARIANT         557
FT                   /note="G -> E (in HHC1; Abolished G-protein coupled
FT                   receptor activity)"
FT                   /evidence="ECO:0000269|PubMed:11762699,
FT                   ECO:0000269|PubMed:27434672"
FT                   /id="VAR_012649"
FT   VARIANT         562
FT                   /note="C -> Y (in HHC1)"
FT                   /evidence="ECO:0000269|PubMed:17698911,
FT                   ECO:0000269|PubMed:19179454"
FT                   /id="VAR_058068"
FT   VARIANT         565
FT                   /note="C -> G (in HHC1)"
FT                   /evidence="ECO:0000269|PubMed:19179454"
FT                   /id="VAR_078164"
FT   VARIANT         569
FT                   /note="P -> H (in HYPOC1; increased G-protein coupled
FT                   receptor signaling pathway)"
FT                   /evidence="ECO:0000269|PubMed:23966241"
FT                   /id="VAR_078165"
FT   VARIANT         571
FT                   /note="G -> W (in HHC1; decreased G-protein coupled
FT                   receptor signaling pathway; does not affect cell membrane
FT                   localization)"
FT                   /evidence="ECO:0000269|PubMed:26386835"
FT                   /id="VAR_078166"
FT   VARIANT         582
FT                   /note="C -> F (in HHC1; dbSNP:rs104893690)"
FT                   /evidence="ECO:0000269|PubMed:17698911"
FT                   /id="VAR_058069"
FT   VARIANT         582
FT                   /note="C -> Y (in NSHPT and HHC1; dbSNP:rs104893690)"
FT                   /evidence="ECO:0000269|PubMed:17698911,
FT                   ECO:0000269|PubMed:19179454, ECO:0000269|PubMed:8675635"
FT                   /id="VAR_003597"
FT   VARIANT         583..1078
FT                   /note="Missing (in HHC1; impaired homodimerization;
FT                   impaired cell membrane localization)"
FT                   /evidence="ECO:0000269|PubMed:16740594,
FT                   ECO:0000269|PubMed:19179454"
FT                   /id="VAR_078167"
FT   VARIANT         604
FT                   /note="E -> K (in HYPOC1; there is a significant leftward
FT                   shift in the concentration response curves for the effects
FT                   of extracellular calcium on both intracellular calcium
FT                   mobilization and MAPK activity; dbSNP:rs104893712)"
FT                   /evidence="ECO:0000269|PubMed:12574188,
FT                   ECO:0000269|PubMed:19179454"
FT                   /id="VAR_058070"
FT   VARIANT         612
FT                   /note="F -> S (in HYPOC1; dbSNP:rs104893698)"
FT                   /evidence="ECO:0000269|PubMed:8813042"
FT                   /id="VAR_058071"
FT   VARIANT         616
FT                   /note="L -> V (in HYPOC1; does not affect the total
FT                   accumulation of inositol phosphates as a function of
FT                   extracellular calcium concentrations in transfected cells;
FT                   dbSNP:rs104893703)"
FT                   /evidence="ECO:0000269|PubMed:10487661"
FT                   /id="VAR_015414"
FT   VARIANT         623
FT                   /note="G -> D (in HHC1)"
FT                   /evidence="ECO:0000269|PubMed:17698911"
FT                   /id="VAR_058072"
FT   VARIANT         650
FT                   /note="L -> P (in NSHPT)"
FT                   /evidence="ECO:0000269|PubMed:14985373"
FT                   /id="VAR_065202"
FT   VARIANT         657
FT                   /note="S -> Y (in HHC1)"
FT                   /evidence="ECO:0000269|PubMed:8636323"
FT                   /id="VAR_078168"
FT   VARIANT         661
FT                   /note="C -> Y (in HHC1)"
FT                   /evidence="ECO:0000269|PubMed:19179454"
FT                   /id="VAR_078169"
FT   VARIANT         670
FT                   /note="G -> E (in NSHPT; dbSNP:rs104893700)"
FT                   /evidence="ECO:0000269|PubMed:9253359"
FT                   /id="VAR_058073"
FT   VARIANT         670
FT                   /note="G -> R (in HHC1)"
FT                   /evidence="ECO:0000269|PubMed:17698911"
FT                   /id="VAR_058074"
FT   VARIANT         680
FT                   /note="R -> H (in HHC1; dbSNP:rs773146939)"
FT                   /evidence="ECO:0000269|PubMed:19179454"
FT                   /id="VAR_078170"
FT   VARIANT         681
FT                   /note="Q -> H (in HYPOC1; dbSNP:rs121909261)"
FT                   /evidence="ECO:0000269|PubMed:8733126"
FT                   /id="VAR_003598"
FT   VARIANT         681
FT                   /note="Q -> R (in HYPOC1; increased G-protein coupled
FT                   receptor signaling pathway; does not affect cell membrane
FT                   localization)"
FT                   /evidence="ECO:0000269|PubMed:22789683"
FT                   /id="VAR_078171"
FT   VARIANT         686
FT                   /note="I -> V (in EIG8; patients present juvenile myoclonus
FT                   epilepsy; dbSNP:rs753013993)"
FT                   /evidence="ECO:0000269|PubMed:18756473"
FT                   /id="VAR_060207"
FT   VARIANT         689
FT                   /note="V -> M (in NSHPT)"
FT                   /evidence="ECO:0000269|PubMed:14985373"
FT                   /id="VAR_065203"
FT   VARIANT         697
FT                   /note="V -> M (in HHC1)"
FT                   /evidence="ECO:0000269|PubMed:21643651"
FT                   /id="VAR_065494"
FT   VARIANT         707
FT                   /note="E -> V (in HHC1; decreased protein level)"
FT                   /evidence="ECO:0000269|PubMed:25104082"
FT                   /id="VAR_078172"
FT   VARIANT         727
FT                   /note="L -> Q (in HYPOC1; increased G-protein coupled
FT                   receptor signaling pathway; does not affect cell membrane
FT                   localization; dbSNP:rs104893718)"
FT                   /evidence="ECO:0000269|PubMed:16608894,
FT                   ECO:0000269|PubMed:22789683"
FT                   /id="VAR_058075"
FT   VARIANT         728
FT                   /note="V -> F (in HHC1)"
FT                   /evidence="ECO:0000269|PubMed:17698911"
FT                   /id="VAR_058076"
FT   VARIANT         742
FT                   /note="W -> R (in HHC1)"
FT                   /evidence="ECO:0000269|PubMed:17698911"
FT                   /id="VAR_058077"
FT   VARIANT         748
FT                   /note="P -> R (in HHC1)"
FT                   /evidence="ECO:0000269|PubMed:8636323"
FT                   /id="VAR_078173"
FT   VARIANT         761
FT                   /note="Missing (in HHC1)"
FT                   /evidence="ECO:0000269|PubMed:19179454"
FT                   /id="VAR_078174"
FT   VARIANT         767
FT                   /note="E -> K (in HYPOC1)"
FT                   /evidence="ECO:0000269|PubMed:15551332"
FT                   /id="VAR_021019"
FT   VARIANT         773
FT                   /note="L -> R (in HYPOC1; the mutation shifts the
FT                   concentration-response curve to the left and increases
FT                   maximal activity; dbSNP:rs104893699)"
FT                   /evidence="ECO:0000269|PubMed:9253358"
FT                   /id="VAR_058078"
FT   VARIANT         774
FT                   /note="G -> S (in HHC1; decreased G-protein coupled
FT                   receptor signaling pathway; does not affect cell membrane
FT                   localization)"
FT                   /evidence="ECO:0000269|PubMed:25104082"
FT                   /id="VAR_078175"
FT   VARIANT         788
FT                   /note="F -> C (in HYPOC1; leftward shift in the
FT                   concentration-response curve for the mutant receptor; cells
FT                   cotransfected with both the wild-type and the mutant
FT                   receptor show an EC(50) similar to the mutant; a gain-of-
FT                   function mutation rendering the receptor more sensitive
FT                   than normal to activation; dbSNP:rs104893701)"
FT                   /evidence="ECO:0000269|PubMed:9661634"
FT                   /id="VAR_058079"
FT   VARIANT         788
FT                   /note="F -> L (in HYPOC1; induces a significant shift to
FT                   the left relative to the wild-type protein in the MAPK
FT                   response to increasing extracellular calcium
FT                   concentrations; dbSNP:rs886041537 and dbSNP:rs104893711)"
FT                   /evidence="ECO:0000269|PubMed:12915654"
FT                   /id="VAR_058080"
FT   VARIANT         795
FT                   /note="R -> W (in HHC1; decreased G-protein coupled
FT                   receptor signaling pathway; dbSNP:rs121909258)"
FT                   /evidence="ECO:0000269|PubMed:19179454,
FT                   ECO:0000269|PubMed:22114145, ECO:0000269|PubMed:7916660,
FT                   ECO:0000269|PubMed:8702647"
FT                   /id="VAR_003599"
FT   VARIANT         802
FT                   /note="N -> I (in HYPOC1; increased G-protein coupled
FT                   receptor signaling pathway)"
FT                   /evidence="ECO:0000269|PubMed:19179454,
FT                   ECO:0000269|PubMed:23169696"
FT                   /id="VAR_078176"
FT   VARIANT         802
FT                   /note="N -> S (in HHC1; decreased G-protein coupled
FT                   receptor signaling pathway; dbSNP:rs140022350)"
FT                   /evidence="ECO:0000269|PubMed:23169696"
FT                   /id="VAR_078177"
FT   VARIANT         806
FT                   /note="F -> S (in HYPOC1; does not produce a significant
FT                   activating effect; decreased cell surface receptor
FT                   expression; dbSNP:rs104893693)"
FT                   /evidence="ECO:0000269|PubMed:8733126,
FT                   ECO:0000269|PubMed:9253358"
FT                   /id="VAR_003600"
FT   VARIANT         817
FT                   /note="V -> I (in HHC1; decreased G-protein coupled
FT                   receptor signaling pathway; dbSNP:rs1057518933)"
FT                   /evidence="ECO:0000269|PubMed:8878438"
FT                   /id="VAR_078178"
FT   VARIANT         820
FT                   /note="S -> F (in HYPOC1; the concentration-response curve
FT                   of the mutant receptor is left-shifted and its EC(50) is
FT                   significantly lower than that of the wild-type;
FT                   dbSNP:rs104893710)"
FT                   /evidence="ECO:0000269|PubMed:12050233"
FT                   /id="VAR_058081"
FT   VARIANT         830
FT                   /note="G -> S (in HYPOC1)"
FT                   /evidence="ECO:0000269|PubMed:19179454"
FT                   /id="VAR_078179"
FT   VARIANT         832
FT                   /note="F -> L (in HYPOC1)"
FT                   /evidence="ECO:0000269|PubMed:19179454"
FT                   /id="VAR_078180"
FT   VARIANT         832
FT                   /note="F -> S (in HYPOC1)"
FT                   /evidence="ECO:0000269|PubMed:19179454"
FT                   /id="VAR_078181"
FT   VARIANT         839
FT                   /note="I -> T (in HYPOC1; increased G-protein coupled
FT                   receptor signaling pathway)"
FT                   /evidence="ECO:0000269|PubMed:23966241"
FT                   /id="VAR_078182"
FT   VARIANT         843
FT                   /note="A -> E (in HYPOC1; also in HYPOC1 associated with
FT                   clinical features of Bartter syndrome; shifts the
FT                   concentration-response curve of calcium ions to the left;
FT                   dbSNP:rs104893706)"
FT                   /evidence="ECO:0000269|PubMed:12107202,
FT                   ECO:0000269|PubMed:12241879"
FT                   /id="VAR_058082"
FT   VARIANT         851
FT                   /note="C -> S (in dbSNP:rs200777304)"
FT                   /evidence="ECO:0000269|PubMed:8733126"
FT                   /id="VAR_003601"
FT   VARIANT         881
FT                   /note="F -> L (probable disease-associated variant found in
FT                   a patient with hypercalciuric hypercalcemia; mutant CASR
FT                   has a right-shifted dose-response to extracellular calcium
FT                   concentrations; activated by a higher calcium
FT                   concentrations than the wild-type; dbSNP:rs104893704)"
FT                   /evidence="ECO:0000269|PubMed:10843194"
FT                   /id="VAR_058083"
FT   VARIANT         886
FT                   /note="R -> W (in HHC1)"
FT                   /evidence="ECO:0000269|PubMed:17698911"
FT                   /id="VAR_058084"
FT   VARIANT         898
FT                   /note="R -> Q (in EIG8; dbSNP:rs121909269)"
FT                   /evidence="ECO:0000269|PubMed:18756473"
FT                   /id="VAR_060208"
FT   VARIANT         951
FT                   /note="P -> T (in dbSNP:rs4987051)"
FT                   /id="VAR_020220"
FT   VARIANT         972
FT                   /note="T -> M (in HHC1; decreased G-protein coupled
FT                   receptor signaling pathway; dbSNP:rs200620134)"
FT                   /evidence="ECO:0000269|PubMed:25292184"
FT                   /id="VAR_078183"
FT   VARIANT         986
FT                   /note="A -> S (common polymorphism associated with high
FT                   serum level of calcium; is also a potential predisposing
FT                   factor in disorders of bone and mineral metabolism;
FT                   dbSNP:rs1801725)"
FT                   /evidence="ECO:0000269|PubMed:10023897,
FT                   ECO:0000269|PubMed:11161843, ECO:0000269|PubMed:14985373,
FT                   ECO:0000269|PubMed:15531522, ECO:0000269|PubMed:16598859,
FT                   ECO:0000269|PubMed:17555508, ECO:0000269|PubMed:17698911,
FT                   ECO:0000269|PubMed:18756473, ECO:0000269|PubMed:19789209,
FT                   ECO:0000269|PubMed:8636323, ECO:0000269|Ref.5"
FT                   /id="VAR_014450"
FT   VARIANT         988
FT                   /note="A -> G (in EIG8; patients present juvenile myoclonus
FT                   epilepsy)"
FT                   /evidence="ECO:0000269|PubMed:18756473"
FT                   /id="VAR_060209"
FT   VARIANT         988
FT                   /note="A -> V (in EIG8; patients present juvenile myoclonus
FT                   epilepsy; dbSNP:rs759027000)"
FT                   /evidence="ECO:0000269|PubMed:18756473"
FT                   /id="VAR_060210"
FT   VARIANT         990
FT                   /note="R -> G (common polymorphism associated with low
FT                   serum level of calcium; dbSNP:rs1042636)"
FT                   /evidence="ECO:0000269|PubMed:12050233,
FT                   ECO:0000269|PubMed:14985373, ECO:0000269|PubMed:15531522,
FT                   ECO:0000269|PubMed:15551332, ECO:0000269|PubMed:17698911,
FT                   ECO:0000269|PubMed:18756473, ECO:0000269|PubMed:7759551,
FT                   ECO:0000269|PubMed:8636323, ECO:0000269|Ref.5"
FT                   /id="VAR_020221"
FT   VARIANT         1011
FT                   /note="E -> Q (common polymorphism; dbSNP:rs1801726)"
FT                   /evidence="ECO:0000269|PubMed:14985373,
FT                   ECO:0000269|PubMed:15531522, ECO:0000269|PubMed:17698911,
FT                   ECO:0000269|PubMed:19789209, ECO:0000269|PubMed:8636323,
FT                   ECO:0000269|Ref.5"
FT                   /id="VAR_014451"
FT   MUTAGEN         69
FT                   /note="R->E: Abolishes G-protein coupled receptor signaling
FT                   pathway."
FT                   /evidence="ECO:0000269|PubMed:27434672"
FT   MUTAGEN         102
FT                   /note="N->I: Abolishes G-protein coupled receptor
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:27434672"
FT   MUTAGEN         145
FT                   /note="T->A: Abolishes G-protein coupled receptor
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:27434672"
FT   MUTAGEN         147
FT                   /note="S->A: Nearly abolished G-protein coupled receptor
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:27434672"
FT   MUTAGEN         170
FT                   /note="S->A: Abolishes G-protein coupled receptor
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:27434672"
FT   MUTAGEN         218
FT                   /note="Y->S: Abolishes G-protein coupled receptor
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:27434672"
FT   MUTAGEN         297
FT                   /note="E->I: Abolishes ability to sense calcium or
FT                   magnesium levels."
FT                   /evidence="ECO:0000269|PubMed:27386547"
FT   MUTAGEN         417
FT                   /note="S->L: Abolishes G-protein coupled receptor signaling
FT                   pathway."
FT                   /evidence="ECO:0000269|PubMed:27434672"
FT   MUTAGEN         458
FT                   /note="W->A: Decreased G-protein coupled receptor signaling
FT                   pathway."
FT                   /evidence="ECO:0000269|PubMed:27434672"
FT   MUTAGEN         482
FT                   /note="C->S,Y: Abolishes ability of agonist AMG 416 to
FT                   activate G-protein-coupled receptor activity."
FT                   /evidence="ECO:0000269|PubMed:26290606"
FT   CONFLICT        857
FT                   /note="I -> T (in Ref. 3; BAA09453)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        878
FT                   /note="A -> R (in Ref. 3; BAA09453)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        926
FT                   /note="Q -> R (in Ref. 2; AAA86503)"
FT                   /evidence="ECO:0000305"
FT   STRAND          26..28
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   STRAND          31..38
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   STRAND          40..44
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   STRAND          60..63
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   HELIX           65..82
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   STRAND          85..90
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   STRAND          93..99
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   HELIX           104..114
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   HELIX           116..123
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   HELIX           125..128
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   STRAND          138..142
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   HELIX           147..159
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   STRAND          164..168
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   HELIX           172..175
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   TURN            177..179
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   STRAND          183..187
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   HELIX           191..203
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   STRAND          208..216
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   HELIX           219..232
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   STRAND          237..243
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   HELIX           249..261
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   STRAND          266..270
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   HELIX           273..285
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   STRAND          292..295
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   HELIX           297..300
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   TURN            303..305
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   HELIX           308..310
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   HELIX           311..314
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   STRAND          318..322
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   HELIX           330..335
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   TURN            339..341
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   STRAND          343..345
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   HELIX           348..356
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   STRAND          358..360
FT                   /evidence="ECO:0000244|PDB:5K5T"
FT   HELIX           374..378
FT                   /evidence="ECO:0000244|PDB:5K5T"
FT   STRAND          384..386
FT                   /evidence="ECO:0000244|PDB:5K5T"
FT   HELIX           387..389
FT                   /evidence="ECO:0000244|PDB:5K5T"
FT   HELIX           401..403
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   TURN            407..409
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   HELIX           416..435
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   STRAND          441..444
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   HELIX           445..447
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   HELIX           452..454
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   HELIX           457..465
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   STRAND          468..470
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   STRAND          476..478
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   STRAND          481..485
FT                   /evidence="ECO:0000244|PDB:5K5T"
FT   STRAND          489..496
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   TURN            498..500
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   STRAND          502..511
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   STRAND          513..515
FT                   /evidence="ECO:0000244|PDB:5FBH"
FT   STRAND          519..523
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   HELIX           525..527
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   TURN            531..533
FT                   /evidence="ECO:0000244|PDB:5FBK"
FT   STRAND          550..554
FT                   /evidence="ECO:0000244|PDB:5K5S"
FT   STRAND          556..558
FT                   /evidence="ECO:0000244|PDB:5K5T"
FT   STRAND          563..567
FT                   /evidence="ECO:0000244|PDB:5K5S"
FT   STRAND          576..578
FT                   /evidence="ECO:0000244|PDB:5K5T"
FT   STRAND          589..591
FT                   /evidence="ECO:0000244|PDB:5K5T"
FT   STRAND          595..600
FT                   /evidence="ECO:0000244|PDB:5K5T"
SQ   SEQUENCE   1078 AA;  120675 MW;  D60C57C6C743FC06 CRC64;
     MAFYSCCWVL LALTWHTSAY GPDQRAQKKG DIILGGLFPI HFGVAAKDQD LKSRPESVEC
     IRYNFRGFRW LQAMIFAIEE INSSPALLPN LTLGYRIFDT CNTVSKALEA TLSFVAQNKI
     DSLNLDEFCN CSEHIPSTIA VVGATGSGVS TAVANLLGLF YIPQVSYASS SRLLSNKNQF
     KSFLRTIPND EHQATAMADI IEYFRWNWVG TIAADDDYGR PGIEKFREEA EERDICIDFS
     ELISQYSDEE EIQHVVEVIQ NSTAKVIVVF SSGPDLEPLI KEIVRRNITG KIWLASEAWA
     SSSLIAMPQY FHVVGGTIGF ALKAGQIPGF REFLKKVHPR KSVHNGFAKE FWEETFNCHL
     QEGAKGPLPV DTFLRGHEES GDRFSNSSTA FRPLCTGDEN ISSVETPYID YTHLRISYNV
     YLAVYSIAHA LQDIYTCLPG RGLFTNGSCA DIKKVEAWQV LKHLRHLNFT NNMGEQVTFD
     ECGDLVGNYS IINWHLSPED GSIVFKEVGY YNVYAKKGER LFINEEKILW SGFSREVPFS
     NCSRDCLAGT RKGIIEGEPT CCFECVECPD GEYSDETDAS ACNKCPDDFW SNENHTSCIA
     KEIEFLSWTE PFGIALTLFA VLGIFLTAFV LGVFIKFRNT PIVKATNREL SYLLLFSLLC
     CFSSSLFFIG EPQDWTCRLR QPAFGISFVL CISCILVKTN RVLLVFEAKI PTSFHRKWWG
     LNLQFLLVFL CTFMQIVICV IWLYTAPPSS YRNQELEDEI IFITCHEGSL MALGFLIGYT
     CLLAAICFFF AFKSRKLPEN FNEAKFITFS MLIFFIVWIS FIPAYASTYG KFVSAVEVIA
     ILAASFGLLA CIFFNKIYII LFKPSRNTIE EVRCSTAAHA FKVAARATLR RSNVSRKRSS
     SLGGSTGSTP SSSISSKSNS EDPFPQPERQ KQQQPLALTQ QEQQQQPLTL PQQQRSQQQP
     RCKQKVIFGS GTVTFSLSFD EPQKNAMAHR NSTHQNSLEA QKSSDTLTRH EPLLPLQCGE
     TDLDLTVQET GLQGPVGGDQ RPEVEDPEEL SPALVVSSSQ SFVISGGGST VTENVVNS
//
ID   ADA2B_HUMAN             Reviewed;         450 AA.
AC   P18089; A2RUS0; Q4TUH9; Q53RF2; Q9BZK0;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   15-MAR-2017, sequence version 4.
DT   07-OCT-2020, entry version 203.
DE   RecName: Full=Alpha-2B adrenergic receptor;
DE   AltName: Full=Alpha-2 adrenergic receptor subtype C2;
DE   AltName: Full=Alpha-2B adrenoreceptor;
DE            Short=Alpha-2B adrenoceptor;
DE            Short=Alpha-2BAR;
GN   Name=ADRA2B; Synonyms=ADRA2L1, ADRA2RL1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2164221; DOI=10.1073/pnas.87.13.5094;
RA   Lomasney J.W., Lorenz W., Allen L.F., King K., Regan J.W., Yang-Feng T.L.,
RA   Caron M.G., Lefkowitz R.J.;
RT   "Expansion of the alpha 2-adrenergic receptor family: cloning and
RT   characterization of a human alpha 2-adrenergic receptor subtype, the gene
RT   for which is located on chromosome 2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:5094-5098(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2172775;
RA   Weinshank R.L., Zgombick J.M., Macchi M., Adham N., Lichtblau H.,
RA   Branchek T.A., Hartig P.R.;
RT   "Cloning, expression, and pharmacological characterization of a human alpha
RT   2B-adrenergic receptor.";
RL   Mol. Pharmacol. 38:681-688(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT 301-GLU--GLU-303 DEL.
RX   PubMed=11056163; DOI=10.1074/jbc.m008118200;
RA   Small K.M., Brown K.M., Forbes S.L., Liggett S.B.;
RT   "Polymorphic deletion of three intracellular acidic residues of the alpha
RT   2B-adrenergic receptor decreases G protein-coupled receptor kinase-mediated
RT   phosphorylation and desensitization.";
RL   J. Biol. Chem. 276:4917-4922(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=15037199; DOI=10.1016/j.bcp.2003.09.029;
RA   Cayla C., Heinonen P., Viikari L., Schaak S., Snapir A., Bouloumie A.,
RA   Karvonen M.K., Pesonen U., Scheinin M., Paris H.;
RT   "Cloning, characterisation and identification of several polymorphisms in
RT   the promoter region of the human alpha2B-adrenergic receptor gene.";
RL   Biochem. Pharmacol. 67:469-478(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "Isolation of complete coding sequence for adrenergic receptor alpha 2B
RT   (ADRA2B).";
RL   Submitted (FEB-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], VARIANTS ALA-211 AND GLY-379, AND
RP   FRAMESHIFT POLYMORPHISM.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT 301-GLU--GLU-303
RP   DEL.
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 95-389.
RX   PubMed=2173582; DOI=10.1016/0006-291x(90)90748-c;
RA   Chang A.C., Ho T.F., Chang N.-C.A.;
RT   "In vitro amplification by polymerase chain reaction of a partial gene
RT   encoding the third subtype of alpha-2 adrenergic receptor in humans.";
RL   Biochem. Biophys. Res. Commun. 172:817-823(1990).
RN   [11]
RP   FUNCTION, INTERACTION WITH RAB26, AND SUBCELLULAR LOCATION.
RX   PubMed=23105096; DOI=10.1074/jbc.m112.410936;
RA   Li C., Fan Y., Lan T.H., Lambert N.A., Wu G.;
RT   "Rab26 modulates the cell surface transport of alpha2-adrenergic receptors
RT   from the Golgi.";
RL   J. Biol. Chem. 287:42784-42794(2012).
RN   [12]
RP   INTERACTION WITH PPP1R9B, INVOLVEMENT IN FAME2, VARIANT FAME2
RP   225-HIS--LEU-229 DELINS GLN-PHE-GLY-ARG, AND CHARACTERIZATION OF VARIANT
RP   FAME2 225-HIS--LEU-229 DELINS GLN-PHE-GLY-ARG.
RX   PubMed=24114805; DOI=10.1002/ana.24028;
RA   De Fusco M., Vago R., Striano P., Di Bonaventura C., Zara F., Mei D.,
RA   Kim M.S., Muallem S., Chen Y., Wang Q., Guerrini R., Casari G.;
RT   "The alpha2B-adrenergic receptor is mutant in cortical myoclonus and
RT   epilepsy.";
RL   Ann. Neurol. 75:77-87(2014).
RN   [13]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH GGA1 AND GGA2.
RX   PubMed=27901063; DOI=10.1038/srep37921;
RA   Zhang M., Huang W., Gao J., Terry A.V., Wu G.;
RT   "Regulation of alpha2B-Adrenergic Receptor Cell Surface Transport by GGA1
RT   and GGA2.";
RL   Sci. Rep. 6:37921-37921(2016).
RN   [14]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH GGA3.
RX   PubMed=26811329; DOI=10.1128/mcb.00009-16;
RA   Zhang M., Davis J.E., Li C., Gao J., Huang W., Lambert N.A.,
RA   Terry A.V. Jr., Wu G.;
RT   "GGA3 Interacts with a G Protein-Coupled Receptor and Modulates Its Cell
RT   Surface Export.";
RL   Mol. Cell. Biol. 36:1152-1163(2016).
CC   -!- FUNCTION: Alpha-2 adrenergic receptors mediate the catecholamine-
CC       induced inhibition of adenylate cyclase through the action of G
CC       proteins. The rank order of potency for agonists of this receptor is
CC       clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine >
CC       p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine.
CC       For antagonists, the rank order is yohimbine > chlorpromazine >
CC       phentolamine > mianserine > spiperone > prazosin > alprenolol >
CC       propanolol > pindolol. {ECO:0000269|PubMed:23105096}.
CC   -!- SUBUNIT: Interacts with RAB26 (PubMed:23105096). Interacts with PPP1R9B
CC       (PubMed:24114805). Interacts with GGA1, GGA2 and GGA3 (PubMed:27901063,
CC       PubMed:26811329). {ECO:0000269|PubMed:23105096,
CC       ECO:0000269|PubMed:24114805, ECO:0000269|PubMed:26811329,
CC       ECO:0000269|PubMed:27901063}.
CC   -!- INTERACTION:
CC       P18089; P25106: ACKR3; NbExp=2; IntAct=EBI-9077302, EBI-1965291;
CC       P18089; Q9ULW5: RAB26; NbExp=4; IntAct=EBI-9077302, EBI-958239;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:23105096,
CC       ECO:0000269|PubMed:26811329, ECO:0000269|PubMed:27901063}; Multi-pass
CC       membrane protein {ECO:0000269|PubMed:23105096}. Note=Interaction with
CC       RAB26, GGA1, GGA2 and GGA3 mediates transport from the Golgi to the
CC       cell membrane. {ECO:0000269|PubMed:23105096,
CC       ECO:0000269|PubMed:26811329, ECO:0000269|PubMed:27901063}.
CC   -!- POLYMORPHISM: A rare polymorphic frameshift in position 451 produces a
CC       protein of 545 residues. {ECO:0000269|Ref.6}.
CC   -!- DISEASE: Epilepsy, familial adult myoclonic, 2 (FAME2) [MIM:607876]: A
CC       form of familial myoclonic epilepsy, a neurologic disorder
CC       characterized by cortical hand tremors, myoclonic jerks and occasional
CC       generalized or focal seizures with a non-progressive or very slowly
CC       progressive disease course. Usually, myoclonic tremor is the presenting
CC       symptom, characterized by tremulous finger movements and myoclonic
CC       jerks of the limbs increased by action and posture. In a minority of
CC       patients, seizures are the presenting symptom. Some patients exhibit
CC       mild cognitive impairment. FAME2 inheritance is autosomal dominant.
CC       {ECO:0000269|PubMed:24114805}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       Adrenergic receptor subfamily. ADRA2B sub-subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/adra2b/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M34041; AAA51666.1; -; Genomic_DNA.
DR   EMBL; AF316895; AAK01635.1; -; Genomic_DNA.
DR   EMBL; AF005900; AAB62558.1; -; Genomic_DNA.
DR   EMBL; AY548167; AAS55646.1; -; Genomic_DNA.
DR   EMBL; DQ057076; AAY43127.1; -; Genomic_DNA.
DR   EMBL; EU332847; ABY87536.1; -; Genomic_DNA.
DR   EMBL; AC092603; AAX93218.1; -; Genomic_DNA.
DR   EMBL; KF573706; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471207; EAW71390.1; -; Genomic_DNA.
DR   EMBL; BC133021; AAI33022.1; -; mRNA.
DR   EMBL; BC136537; AAI36538.1; -; mRNA.
DR   EMBL; M38742; AAA62823.1; -; Genomic_DNA.
DR   CCDS; CCDS56129.1; -.
DR   PIR; A37223; A37223.
DR   RefSeq; NP_000673.2; NM_000682.6.
DR   PDB; 2CVA; Model; -; A=97-128.
DR   PDB; 6K41; EM; 2.90 A; R=9-450.
DR   PDB; 6K42; EM; 4.10 A; R=7-450.
DR   PDBsum; 2CVA; -.
DR   PDBsum; 6K41; -.
DR   PDBsum; 6K42; -.
DR   SMR; P18089; -.
DR   BioGRID; 106660; 7.
DR   DIP; DIP-61453N; -.
DR   IntAct; P18089; 5.
DR   STRING; 9606.ENSP00000480573; -.
DR   BindingDB; P18089; -.
DR   ChEMBL; CHEMBL1942; -.
DR   DrugBank; DB00543; Amoxapine.
DR   DrugBank; DB00182; Amphetamine.
DR   DrugBank; DB00714; Apomorphine.
DR   DrugBank; DB00964; Apraclonidine.
DR   DrugBank; DB09229; Aranidipine.
DR   DrugBank; DB01238; Aripiprazole.
DR   DrugBank; DB14185; Aripiprazole lauroxil.
DR   DrugBank; DB06216; Asenapine.
DR   DrugBank; DB00217; Bethanidine.
DR   DrugBank; DB00484; Brimonidine.
DR   DrugBank; DB01200; Bromocriptine.
DR   DrugBank; DB00248; Cabergoline.
DR   DrugBank; DB01136; Carvedilol.
DR   DrugBank; DB04846; Celiprolol.
DR   DrugBank; DB00477; Chlorpromazine.
DR   DrugBank; DB09202; Cirazoline.
DR   DrugBank; DB00575; Clonidine.
DR   DrugBank; DB00363; Clozapine.
DR   DrugBank; DB01151; Desipramine.
DR   DrugBank; DB11273; Dihydroergocornine.
DR   DrugBank; DB13345; Dihydroergocristine.
DR   DrugBank; DB11278; DL-Methylephedrine.
DR   DrugBank; DB09167; Dosulepin.
DR   DrugBank; DB04855; Dronedarone.
DR   DrugBank; DB06262; Droxidopa.
DR   DrugBank; DB01363; Ephedra sinica root.
DR   DrugBank; DB05492; Epicept NP-1.
DR   DrugBank; DB00668; Epinephrine.
DR   DrugBank; DB01049; Ergoloid mesylate.
DR   DrugBank; DB00696; Ergotamine.
DR   DrugBank; DB01175; Escitalopram.
DR   DrugBank; DB06678; Esmirtazapine.
DR   DrugBank; DB00292; Etomidate.
DR   DrugBank; DB09194; Etoperidone.
DR   DrugBank; DB00800; Fenoldopam.
DR   DrugBank; DB00629; Guanabenz.
DR   DrugBank; DB01018; Guanfacine.
DR   DrugBank; DB00502; Haloperidol.
DR   DrugBank; DB11577; Indigotindisulfonic acid.
DR   DrugBank; DB06707; Levonordefrin.
DR   DrugBank; DB00589; Lisuride.
DR   DrugBank; DB09195; Lorpiprazole.
DR   DrugBank; DB00408; Loxapine.
DR   DrugBank; DB00934; Maprotiline.
DR   DrugBank; DB01365; Mephentermine.
DR   DrugBank; DB01577; Metamfetamine.
DR   DrugBank; DB01403; Methotrimeprazine.
DR   DrugBank; DB06148; Mianserin.
DR   DrugBank; DB09205; Moxisylyte.
DR   DrugBank; DB00368; Norepinephrine.
DR   DrugBank; DB00540; Nortriptyline.
DR   DrugBank; DB06229; Ocaperidone.
DR   DrugBank; DB05461; OPC-28326.
DR   DrugBank; DB00935; Oxymetazoline.
DR   DrugBank; DB01267; Paliperidone.
DR   DrugBank; DB00715; Paroxetine.
DR   DrugBank; DB01186; Pergolide.
DR   DrugBank; DB00925; Phenoxybenzamine.
DR   DrugBank; DB00397; Phenylpropanolamine.
DR   DrugBank; DB06153; Pizotifen.
DR   DrugBank; DB00457; Prazosin.
DR   DrugBank; DB00433; Prochlorperazine.
DR   DrugBank; DB01069; Promethazine.
DR   DrugBank; DB01224; Quetiapine.
DR   DrugBank; DB11124; Racepinephrine.
DR   DrugBank; DB00734; Risperidone.
DR   DrugBank; DB00268; Ropinirole.
DR   DrugBank; DB05271; Rotigotine.
DR   DrugBank; DB09304; Setiptiline.
DR   DrugBank; DB13025; Tiapride.
DR   DrugBank; DB00697; Tizanidine.
DR   DrugBank; DB00797; Tolazoline.
DR   DrugBank; DB00193; Tramadol.
DR   DrugBank; DB00726; Trimipramine.
DR   DrugBank; DB11477; Xylazine.
DR   DrugBank; DB06694; Xylometazoline.
DR   DrugBank; DB01392; Yohimbine.
DR   DrugBank; DB00246; Ziprasidone.
DR   DrugCentral; P18089; -.
DR   GuidetoPHARMACOLOGY; 26; -.
DR   PhosphoSitePlus; P18089; -.
DR   BioMuta; ADRA2B; -.
DR   DMDM; 27151763; -.
DR   PaxDb; P18089; -.
DR   PeptideAtlas; P18089; -.
DR   PRIDE; P18089; -.
DR   ProteomicsDB; 53548; -.
DR   Antibodypedia; 72874; 112 antibodies.
DR   DNASU; 151; -.
DR   Ensembl; ENST00000620793; ENSP00000480573; ENSG00000274286.
DR   GeneID; 151; -.
DR   KEGG; hsa:151; -.
DR   UCSC; uc032nvj.2; human.
DR   CTD; 151; -.
DR   DisGeNET; 151; -.
DR   EuPathDB; HostDB:ENSG00000274286.1; -.
DR   GeneCards; ADRA2B; -.
DR   HGNC; HGNC:282; ADRA2B.
DR   HPA; ENSG00000274286; Low tissue specificity.
DR   MalaCards; ADRA2B; -.
DR   MIM; 104260; gene.
DR   MIM; 607876; phenotype.
DR   neXtProt; NX_P18089; -.
DR   OpenTargets; ENSG00000274286; -.
DR   Orphanet; 86814; Benign adult familial myoclonic epilepsy.
DR   PharmGKB; PA36; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00940000161915; -.
DR   InParanoid; P18089; -.
DR   KO; K04139; -.
DR   OMA; NSGQGQK; -.
DR   OrthoDB; 737211at2759; -.
DR   PhylomeDB; P18089; -.
DR   TreeFam; TF316350; -.
DR   PathwayCommons; P18089; -.
DR   Reactome; R-HSA-390696; Adrenoceptors.
DR   Reactome; R-HSA-392023; Adrenaline signalling through Alpha-2 adrenergic receptor.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-418597; G alpha (z) signalling events.
DR   SignaLink; P18089; -.
DR   SIGNOR; P18089; -.
DR   BioGRID-ORCS; 151; 3 hits in 874 CRISPR screens.
DR   ChiTaRS; ADRA2B; human.
DR   GeneWiki; Alpha-2B_adrenergic_receptor; -.
DR   GenomeRNAi; 151; -.
DR   Pharos; P18089; Tclin.
DR   PRO; PR:P18089; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; P18089; protein.
DR   Bgee; ENSG00000274286; Expressed in apex of heart and 101 other tissues.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0004938; F:alpha2-adrenergic receptor activity; IDA:BHF-UCL.
DR   GO; GO:0051379; F:epinephrine binding; IDA:BHF-UCL.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0000187; P:activation of MAPK activity; IEA:Ensembl.
DR   GO; GO:0032148; P:activation of protein kinase B activity; IDA:BHF-UCL.
DR   GO; GO:0071880; P:adenylate cyclase-activating adrenergic receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007188; P:adenylate cyclase-modulating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0071875; P:adrenergic receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0007267; P:cell-cell signaling; TAS:ProtInc.
DR   GO; GO:0007565; P:female pregnancy; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0032811; P:negative regulation of epinephrine secretion; NAS:BHF-UCL.
DR   GO; GO:0010700; P:negative regulation of norepinephrine secretion; TAS:BHF-UCL.
DR   GO; GO:0030168; P:platelet activation; IEA:InterPro.
DR   GO; GO:0045777; P:positive regulation of blood pressure; IEA:Ensembl.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:BHF-UCL.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; IDA:BHF-UCL.
DR   GO; GO:0070474; P:positive regulation of uterine smooth muscle contraction; IEA:Ensembl.
DR   GO; GO:0035624; P:receptor transactivation; IDA:BHF-UCL.
DR   GO; GO:0003056; P:regulation of vascular associated smooth muscle contraction; IEA:Ensembl.
DR   InterPro; IPR002233; ADR_fam.
DR   InterPro; IPR000207; ADRA2B_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01103; ADRENERGICR.
DR   PRINTS; PR00559; ADRENRGCA2BR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; Epilepsy;
KW   G-protein coupled receptor; Lipoprotein; Membrane; Palmitate; Polymorphism;
KW   Receptor; Reference proteome; Transducer; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..450
FT                   /note="Alpha-2B adrenergic receptor"
FT                   /id="PRO_0000069094"
FT   TOPO_DOM        1..12
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        13..38
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        39..48
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        49..69
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        70..86
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        87..107
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        108..128
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        129..149
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        150..172
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        173..193
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        194..368
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        369..389
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        390..405
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        406..426
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        427..450
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        294..311
FT                   /note="Asp/Glu-rich (acidic)"
FT   SITE            92
FT                   /note="Implicated in ligand binding"
FT                   /evidence="ECO:0000250"
FT   SITE            176
FT                   /note="Implicated in catechol agonist binding"
FT                   /evidence="ECO:0000250"
FT   SITE            180
FT                   /note="Implicated in catechol agonist binding"
FT                   /evidence="ECO:0000250"
FT   LIPID           442
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        85..164
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VARIANT         211
FT                   /note="G -> A (in dbSNP:rs9333568)"
FT                   /evidence="ECO:0000269|Ref.6"
FT                   /id="VAR_025099"
FT   VARIANT         225..229
FT                   /note="HGGAL -> QFGR (in FAME2; gain of function; decreases
FT                   interaction with PPP1R9B upon activation by
FT                   neurotransmitter)"
FT                   /evidence="ECO:0000269|PubMed:24114805"
FT                   /id="VAR_073953"
FT   VARIANT         301..303
FT                   /note="Missing (polymorphism; found with a frequency of
FT                   0.31 in Caucasians and 0.12 in African-Americans; exhibits
FT                   impaired phosphorylation and desensitization by G protein-
FT                   coupled receptor kinases; does not affect ligand-binding)"
FT                   /evidence="ECO:0000269|PubMed:11056163,
FT                   ECO:0000269|PubMed:15815621"
FT                   /id="VAR_070775"
FT   VARIANT         376
FT                   /note="V -> I (in dbSNP:rs1431850417)"
FT                   /id="VAR_033462"
FT   VARIANT         379
FT                   /note="V -> G (in dbSNP:rs527655811)"
FT                   /evidence="ECO:0000269|Ref.6"
FT                   /id="VAR_025100"
FT   VARIANT         379
FT                   /note="V -> I (in dbSNP:rs29000569)"
FT                   /id="VAR_033463"
FT   CONFLICT        362..363
FT                   /note="QL -> HV (in Ref. 1; AAA51666 and 2; no nucleotide
FT                   entry)"
FT                   /evidence="ECO:0000305"
FT   HELIX           12..38
FT                   /evidence="ECO:0000244|PDB:6K41"
FT   TURN            46..48
FT                   /evidence="ECO:0000244|PDB:6K41"
FT   HELIX           49..73
FT                   /evidence="ECO:0000244|PDB:6K41"
FT   HELIX           86..115
FT                   /evidence="ECO:0000244|PDB:6K41"
FT   HELIX           117..121
FT                   /evidence="ECO:0000244|PDB:6K41"
FT   HELIX           126..144
FT                   /evidence="ECO:0000244|PDB:6K41"
FT   TURN            146..148
FT                   /evidence="ECO:0000244|PDB:6K41"
FT   HELIX           171..180
FT                   /evidence="ECO:0000244|PDB:6K41"
FT   HELIX           182..202
FT                   /evidence="ECO:0000244|PDB:6K41"
FT   HELIX           363..392
FT                   /evidence="ECO:0000244|PDB:6K41"
FT   HELIX           407..427
FT                   /evidence="ECO:0000244|PDB:6K41"
FT   HELIX           431..441
FT                   /evidence="ECO:0000244|PDB:6K41"
SQ   SEQUENCE   450 AA;  49954 MW;  06E43857152A68ED CRC64;
     MDHQDPYSVQ ATAAIAAAIT FLILFTIFGN ALVILAVLTS RSLRAPQNLF LVSLAAADIL
     VATLIIPFSL ANELLGYWYF RRTWCEVYLA LDVLFCTSSI VHLCAISLDR YWAVSRALEY
     NSKRTPRRIK CIILTVWLIA AVISLPPLIY KGDQGPQPRG RPQCKLNQEA WYILASSIGS
     FFAPCLIMIL VYLRIYLIAK RSNRRGPRAK GGPGQGESKQ PRPDHGGALA SAKLPALASV
     ASAREVNGHS KSTGEKEEGE TPEDTGTRAL PPSWAALPNS GQGQKEGVCG ASPEDEAEEE
     EEEEEEEEEC EPQAVPVSPA SACSPPLQQP QGSRVLATLR GQVLLGRGVG AIGGQWWRRR
     AQLTREKRFT FVLAVVIGVF VLCWFPFFFS YSLGAICPKH CKVPHGLFQF FFWIGYCNSS
     LNPVIYTIFN QDFRRAFRRI LCRPWTQTAW
//
ID   LGR5_HUMAN              Reviewed;         907 AA.
AC   O75473; D8MCT0; Q4VAM0; Q4VAM2; Q9UP75;
DT   20-JUN-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1998, sequence version 1.
DT   12-AUG-2020, entry version 182.
DE   RecName: Full=Leucine-rich repeat-containing G-protein coupled receptor 5;
DE   AltName: Full=G-protein coupled receptor 49;
DE   AltName: Full=G-protein coupled receptor 67;
DE   AltName: Full=G-protein coupled receptor HG38;
DE   Flags: Precursor;
GN   Name=LGR5; Synonyms=GPR49, GPR67;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9642114; DOI=10.1006/bbrc.1998.8774;
RA   McDonald T., Wang R., Bailey W., Xie G., Chen F., Caskey C.T., Liu Q.;
RT   "Identification and cloning of an orphan G protein-coupled receptor of the
RT   glycoprotein hormone receptor subfamily.";
RL   Biochem. Biophys. Res. Commun. 247:266-270(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=9849958; DOI=10.1210/mend.12.12.0211;
RA   Hsu S.Y., Liang S.-G., Hsueh A.J.W.;
RT   "Characterization of two LGR genes homologous to gonadotropin and
RT   thyrotropin receptors with extracellular leucine-rich repeats and a G
RT   protein-coupled, seven-transmembrane region.";
RL   Mol. Endocrinol. 12:1830-1845(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RA   Rot S., Taubert H., Bache M., Vordermark D., Kappler M.;
RT   "Alternatively spliced transcript of the GPR49-mRNA occur in different
RT   tumor cell lines and soft tissue sarcoma.";
RL   Submitted (APR-2010) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C.,
RA   Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R.,
RA   Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E.,
RA   Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y.,
RA   Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G.,
RA   Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H.,
RA   Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S.,
RA   Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M.,
RA   Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H.,
RA   Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q.,
RA   Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V.,
RA   Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E.,
RA   Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R.,
RA   David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E.,
RA   D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N.,
RA   Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N.,
RA   Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R.,
RA   Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S.,
RA   LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H.,
RA   Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P.,
RA   Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G.,
RA   Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E.,
RA   Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S.,
RA   Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O.,
RA   Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y.,
RA   Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A.,
RA   Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F.,
RA   Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L.,
RA   Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G.,
RA   Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT
RP   ALA-666.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   TISSUE SPECIFICITY.
RX   PubMed=12601349; DOI=10.1053/jhep.2003.50029;
RA   Yamamoto Y., Sakamoto M., Fujii G., Tsuiji H., Kenetaka K., Asaka M.,
RA   Hirohashi S.;
RT   "Overexpression of orphan G-protein-coupled receptor, Gpr49, in human
RT   hepatocellular carcinomas with beta-catenin mutations.";
RL   Hepatology 37:528-533(2003).
RN   [7]
RP   TISSUE SPECIFICITY.
RX   PubMed=16575208; DOI=10.4161/cbt.5.4.2521;
RA   McClanahan T., Koseoglu S., Smith K., Grein J., Gustafson E., Black S.,
RA   Kirschmeier P., Samatar A.A.;
RT   "Identification of overexpression of orphan G protein-coupled receptor
RT   GPR49 in human colon and ovarian primary tumors.";
RL   Cancer Biol. Ther. 5:419-426(2006).
RN   [8]
RP   TISSUE SPECIFICITY.
RX   PubMed=19030762; DOI=10.1100/tsw.2008.148;
RA   Becker L., Huang Q., Mashimo H.;
RT   "Immunostaining of Lgr5, an intestinal stem cell marker, in normal and
RT   premalignant human gastrointestinal tissue.";
RL   ScientificWorldJournal 8:1168-1176(2008).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH RSPO1; RSPO2; RSPO3 AND RSPO4.
RX   PubMed=21909076; DOI=10.1038/embor.2011.175;
RA   Glinka A., Dolde C., Kirsch N., Huang Y.L., Kazanskaya O., Ingelfinger D.,
RA   Boutros M., Cruciat C.M., Niehrs C.;
RT   "LGR4 and LGR5 are R-spondin receptors mediating Wnt/beta-catenin and
RT   Wnt/PCP signalling.";
RL   EMBO Rep. 12:1055-1061(2011).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH RSPO1; RSPO2; RSPO3 AND RSPO4.
RX   PubMed=21727895; DOI=10.1038/nature10337;
RA   de Lau W., Barker N., Low T.Y., Koo B.K., Li V.S., Teunissen H., Kujala P.,
RA   Haegebarth A., Peters P.J., van de Wetering M., Stange D.E., van Es J.E.,
RA   Guardavaccaro D., Schasfoort R.B., Mohri Y., Nishimori K., Mohammed S.,
RA   Heck A.J., Clevers H.;
RT   "Lgr5 homologues associate with Wnt receptors and mediate R-spondin
RT   signalling.";
RL   Nature 476:293-297(2011).
RN   [11]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH RSPO1; RSPO2; RSPO3
RP   AND RSPO4.
RX   PubMed=21693646; DOI=10.1073/pnas.1106083108;
RA   Carmon K.S., Gong X., Lin Q., Thomas A., Liu Q.;
RT   "R-spondins function as ligands of the orphan receptors LGR4 and LGR5 to
RT   regulate Wnt/beta-catenin signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:11452-11457(2011).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH RSPO1.
RX   PubMed=22815884; DOI=10.1371/journal.pone.0040976;
RA   Ruffner H., Sprunger J., Charlat O., Leighton-Davies J., Grosshans B.,
RA   Salathe A., Zietzling S., Beck V., Therier M., Isken A., Xie Y., Zhang Y.,
RA   Hao H., Shi X., Liu D., Song Q., Clay I., Hintzen G., Tchorz J.,
RA   Bouchez L.C., Michaud G., Finan P., Myer V.E., Bouwmeester T., Porter J.,
RA   Hild M., Bassilana F., Parker C.N., Cong F.;
RT   "R-Spondin potentiates Wnt/beta-catenin signaling through orphan receptors
RT   LGR4 and LGR5.";
RL   PLoS ONE 7:E40976-E40976(2012).
RN   [13]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF SER-861 AND SER-864.
RX   PubMed=23439653; DOI=10.1074/jbc.m112.447540;
RA   Snyder J.C., Rochelle L.K., Lyerly H.K., Caron M.G., Barak L.S.;
RT   "Constitutive Internalization of the Leucine-rich G Protein-coupled
RT   Receptor-5 (LGR5) to the Trans-Golgi Network.";
RL   J. Biol. Chem. 288:10286-10297(2013).
RN   [14]
RP   INTERACTION WITH RSPO2.
RX   PubMed=29769720; DOI=10.1038/s41586-018-0118-y;
RA   Szenker-Ravi E., Altunoglu U., Leushacke M., Bosso-Lefevre C., Khatoo M.,
RA   Thi Tran H., Naert T., Noelanders R., Hajamohideen A., Beneteau C.,
RA   de Sousa S.B., Karaman B., Latypova X., Basaran S., Yuecel E.B., Tan T.T.,
RA   Vlaminck L., Nayak S.S., Shukla A., Girisha K.M., Le Caignec C.,
RA   Soshnikova N., Uyguner Z.O., Vleminckx K., Barker N., Kayserili H.,
RA   Reversade B.;
RT   "RSPO2 inhibition of RNF43 and ZNRF3 governs limb development independently
RT   of LGR4/5/6.";
RL   Nature 557:564-569(2018).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 22-543 IN COMPLEX WITH RSPO1,
RP   FUNCTION, MUTAGENESIS OF ASP-146; ASP-170 AND ALA-190, AND DISULFIDE BONDS.
RX   PubMed=23809763; DOI=10.1016/j.celrep.2013.06.009;
RA   Peng W.C., de Lau W., Forneris F., Granneman J.C., Huch M., Clevers H.,
RA   Gros P.;
RT   "Structure of stem cell growth factor R-spondin 1 in complex with the
RT   ectodomain of its receptor LGR5.";
RL   Cell Rep. 3:1885-1892(2013).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 32-557 IN COMPLEX WITH RNF43 AND
RP   RSPO1, SUBUNIT, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-208.
RX   PubMed=23756651; DOI=10.1101/gad.219915.113;
RA   Chen P.H., Chen X., Lin Z., Fang D., He X.;
RT   "The structural basis of R-spondin recognition by LGR5 and RNF43.";
RL   Genes Dev. 27:1345-1350(2013).
CC   -!- FUNCTION: Receptor for R-spondins that potentiates the canonical Wnt
CC       signaling pathway and acts as a stem cell marker of the intestinal
CC       epithelium and the hair follicle. Upon binding to R-spondins (RSPO1,
CC       RSPO2, RSPO3 or RSPO4), associates with phosphorylated LRP6 and
CC       frizzled receptors that are activated by extracellular Wnt receptors,
CC       triggering the canonical Wnt signaling pathway to increase expression
CC       of target genes. In contrast to classical G-protein coupled receptors,
CC       does not activate heterotrimeric G-proteins to transduce the signal.
CC       Involved in the development and/or maintenance of the adult intestinal
CC       stem cells during postembryonic development.
CC       {ECO:0000269|PubMed:21693646, ECO:0000269|PubMed:21727895,
CC       ECO:0000269|PubMed:21909076, ECO:0000269|PubMed:22815884,
CC       ECO:0000269|PubMed:23809763}.
CC   -!- SUBUNIT: Identified in a complex composed of RNF43, LGR5 and RSPO1
CC       (PubMed:21909076, PubMed:21727895, PubMed:21693646, PubMed:22815884,
CC       PubMed:23809763, PubMed:23756651). Also interacts with other R-spondin
CC       ligands, including RSPO2, RSPO3 and RSPO4 (PubMed:21909076,
CC       PubMed:21727895, PubMed:21693646, PubMed:29769720).
CC       {ECO:0000269|PubMed:21693646, ECO:0000269|PubMed:21727895,
CC       ECO:0000269|PubMed:21909076, ECO:0000269|PubMed:22815884,
CC       ECO:0000269|PubMed:23756651, ECO:0000269|PubMed:23809763,
CC       ECO:0000269|PubMed:29769720}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein. Golgi
CC       apparatus, trans-Golgi network membrane; Multi-pass membrane protein.
CC       Note=Rapidly and constitutively internalized to the trans-Golgi network
CC       at steady state. Internalization to the trans-Golgi network may be the
CC       result of phosphorylation at Ser-861 and Ser-864; however, the
CC       phosphorylation event has not been proven (PubMed:23439653).
CC       {ECO:0000269|PubMed:23439653}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=O75473-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O75473-2; Sequence=VSP_037746;
CC       Name=3;
CC         IsoId=O75473-3; Sequence=VSP_054782;
CC   -!- TISSUE SPECIFICITY: Expressed in skeletal muscle, placenta, spinal
CC       cord, and various region of brain. Expressed at the base of crypts in
CC       colonic and small mucosa stem cells. In premalignant cancer expression
CC       is not restricted to the cript base. Overexpressed in cancers of the
CC       ovary, colon and liver. {ECO:0000269|PubMed:12601349,
CC       ECO:0000269|PubMed:16575208, ECO:0000269|PubMed:19030762}.
CC   -!- MISCELLANEOUS: LGR5 is used as a marker of adult tissue stem cells in
CC       the intestine, stomach, hair follicle, and mammary epithelium.
CC       {ECO:0000305|PubMed:19030762}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF062006; AAC28019.1; -; mRNA.
DR   EMBL; AF061444; AAC77911.1; -; mRNA.
DR   EMBL; FN820440; CBL95002.2; -; mRNA.
DR   EMBL; AC078860; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC090116; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC096324; AAH96324.1; -; mRNA.
DR   EMBL; BC096325; AAH96325.1; -; mRNA.
DR   EMBL; BC096326; AAH96326.1; -; mRNA.
DR   EMBL; BC099650; AAH99650.1; -; mRNA.
DR   CCDS; CCDS61194.1; -. [O75473-2]
DR   CCDS; CCDS61195.1; -. [O75473-3]
DR   CCDS; CCDS9000.1; -. [O75473-1]
DR   PIR; JE0176; JE0176.
DR   RefSeq; NP_001264155.1; NM_001277226.1. [O75473-2]
DR   RefSeq; NP_001264156.1; NM_001277227.1. [O75473-3]
DR   RefSeq; NP_003658.1; NM_003667.3. [O75473-1]
DR   PDB; 4BSR; X-ray; 3.20 A; A/B=22-543.
DR   PDB; 4BSS; X-ray; 3.20 A; A/B/E/F=22-543.
DR   PDB; 4BST; X-ray; 4.30 A; A/B=22-543.
DR   PDB; 4BSU; X-ray; 3.20 A; A/B/E/F=22-543.
DR   PDB; 4KNG; X-ray; 2.50 A; A/B=32-557.
DR   PDB; 4UFR; X-ray; 2.20 A; A/C=32-486, A/C=538-544.
DR   PDB; 4UFS; X-ray; 4.80 A; A=32-486, A=538-544.
DR   PDBsum; 4BSR; -.
DR   PDBsum; 4BSS; -.
DR   PDBsum; 4BST; -.
DR   PDBsum; 4BSU; -.
DR   PDBsum; 4KNG; -.
DR   PDBsum; 4UFR; -.
DR   PDBsum; 4UFS; -.
DR   SMR; O75473; -.
DR   BioGRID; 114119; 9.
DR   CORUM; O75473; -.
DR   IntAct; O75473; 2.
DR   STRING; 9606.ENSP00000266674; -.
DR   GuidetoPHARMACOLOGY; 148; -.
DR   GlyGen; O75473; 6 sites.
DR   iPTMnet; O75473; -.
DR   PhosphoSitePlus; O75473; -.
DR   BioMuta; LGR5; -.
DR   jPOST; O75473; -.
DR   MassIVE; O75473; -.
DR   MaxQB; O75473; -.
DR   PaxDb; O75473; -.
DR   PeptideAtlas; O75473; -.
DR   PRIDE; O75473; -.
DR   ProteomicsDB; 15173; -.
DR   ProteomicsDB; 50034; -. [O75473-1]
DR   ProteomicsDB; 50035; -. [O75473-2]
DR   ABCD; O75473; 15 sequenced antibodies.
DR   Antibodypedia; 1987; 862 antibodies.
DR   Ensembl; ENST00000266674; ENSP00000266674; ENSG00000139292. [O75473-1]
DR   Ensembl; ENST00000536515; ENSP00000443033; ENSG00000139292. [O75473-3]
DR   Ensembl; ENST00000540815; ENSP00000441035; ENSG00000139292. [O75473-2]
DR   GeneID; 8549; -.
DR   KEGG; hsa:8549; -.
DR   UCSC; uc001swl.5; human. [O75473-1]
DR   CTD; 8549; -.
DR   DisGeNET; 8549; -.
DR   EuPathDB; HostDB:ENSG00000139292.12; -.
DR   GeneCards; LGR5; -.
DR   HGNC; HGNC:4504; LGR5.
DR   HPA; ENSG00000139292; Tissue enhanced (brain, fallopian tube, placenta, skeletal muscle).
DR   MIM; 606667; gene.
DR   neXtProt; NX_O75473; -.
DR   OpenTargets; ENSG00000139292; -.
DR   PharmGKB; PA28894; -.
DR   eggNOG; KOG0619; Eukaryota.
DR   eggNOG; KOG2087; Eukaryota.
DR   GeneTree; ENSGT00940000160214; -.
DR   HOGENOM; CLU_006843_0_0_1; -.
DR   InParanoid; O75473; -.
DR   KO; K04308; -.
DR   OMA; LHHNEIY; -.
DR   PhylomeDB; O75473; -.
DR   TreeFam; TF316814; -.
DR   PathwayCommons; O75473; -.
DR   Reactome; R-HSA-4641263; Regulation of FZD by ubiquitination.
DR   SIGNOR; O75473; -.
DR   BioGRID-ORCS; 8549; 4 hits in 866 CRISPR screens.
DR   ChiTaRS; LGR5; human.
DR   GeneWiki; LGR5; -.
DR   GenomeRNAi; 8549; -.
DR   Pharos; O75473; Tbio.
DR   PRO; PR:O75473; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; O75473; protein.
DR   Bgee; ENSG00000139292; Expressed in endometrium and 178 other tissues.
DR   ExpressionAtlas; O75473; baseline and differential.
DR   Genevisible; O75473; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0032588; C:trans-Golgi network membrane; IDA:UniProtKB.
DR   GO; GO:0008528; F:G protein-coupled peptide receptor activity; IBA:GO_Central.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; TAS:ProtInc.
DR   GO; GO:0016500; F:protein-hormone receptor activity; IEA:InterPro.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; IDA:UniProtKB.
DR   GO; GO:0007190; P:activation of adenylate cyclase activity; IBA:GO_Central.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:2001013; P:epithelial cell proliferation involved in renal tubule morphogenesis; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0001942; P:hair follicle development; IEA:Ensembl.
DR   GO; GO:0009755; P:hormone-mediated signaling pathway; IBA:GO_Central.
DR   GO; GO:0048839; P:inner ear development; IEA:Ensembl.
DR   GO; GO:0009994; P:oocyte differentiation; IEA:Ensembl.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IDA:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell population proliferation; IEA:Ensembl.
DR   Gene3D; 3.80.10.10; -; 1.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR002131; Gphrmn_rcpt_fam.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR003591; Leu-rich_rpt_typical-subtyp.
DR   InterPro; IPR032675; LRR_dom_sf.
DR   InterPro; IPR000372; LRRNT.
DR   Pfam; PF00560; LRR_1; 1.
DR   Pfam; PF13855; LRR_8; 4.
DR   Pfam; PF01462; LRRNT; 1.
DR   PRINTS; PR00373; GLYCHORMONER.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM00369; LRR_TYP; 15.
DR   SMART; SM00013; LRRNT; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
DR   PROSITE; PS51450; LRR; 15.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Golgi apparatus;
KW   Leucine-rich repeat; Membrane; Polymorphism; Receptor; Reference proteome;
KW   Repeat; Signal; Transducer; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..21
FT                   /evidence="ECO:0000255"
FT   CHAIN           22..907
FT                   /note="Leucine-rich repeat-containing G-protein coupled
FT                   receptor 5"
FT                   /id="PRO_0000012794"
FT   TOPO_DOM        22..561
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        562..582
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        583..593
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        594..614
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        615..638
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        639..659
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        660..682
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        683..703
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        704..722
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        723..743
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        744..767
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        768..788
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        789..802
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        803..823
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        824..907
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          25..66
FT                   /note="LRRNT"
FT   REPEAT          67..90
FT                   /note="LRR 1"
FT   REPEAT          91..112
FT                   /note="LRR 2"
FT   REPEAT          115..136
FT                   /note="LRR 3"
FT   REPEAT          139..160
FT                   /note="LRR 4"
FT   REPEAT          163..184
FT                   /note="LRR 5"
FT   REPEAT          187..208
FT                   /note="LRR 6"
FT   REPEAT          211..232
FT                   /note="LRR 7"
FT   REPEAT          235..256
FT                   /note="LRR 8"
FT   REPEAT          258..279
FT                   /note="LRR 9"
FT   REPEAT          282..303
FT                   /note="LRR 10"
FT   REPEAT          306..328
FT                   /note="LRR 11"
FT   REPEAT          329..350
FT                   /note="LRR 12"
FT   REPEAT          353..374
FT                   /note="LRR 13"
FT   REPEAT          375..396
FT                   /note="LRR 14"
FT   REPEAT          399..420
FT                   /note="LRR 15"
FT   REPEAT          423..446
FT                   /note="LRR 16"
FT   CARBOHYD        63
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        77
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        208
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:23756651"
FT   CARBOHYD        500
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        792
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        34..40
FT   DISULFID        38..52
FT   DISULFID        348..373
FT   DISULFID        479..541
FT   DISULFID        637..712
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VAR_SEQ         143..214
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.3"
FT                   /id="VSP_054782"
FT   VAR_SEQ         263..286
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_037746"
FT   VARIANT         383
FT                   /note="H -> R (in dbSNP:rs12303775)"
FT                   /id="VAR_049411"
FT   VARIANT         666
FT                   /note="V -> A (in dbSNP:rs17109924)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_049412"
FT   MUTAGEN         146
FT                   /note="D->F: Abolishes activation of Wnt signaling."
FT                   /evidence="ECO:0000269|PubMed:23809763"
FT   MUTAGEN         170
FT                   /note="D->F: Abolishes activation of Wnt signaling."
FT                   /evidence="ECO:0000269|PubMed:23809763"
FT   MUTAGEN         190
FT                   /note="A->D: Abolishes activation of Wnt signaling."
FT                   /evidence="ECO:0000269|PubMed:23809763"
FT   MUTAGEN         861
FT                   /note="S->A: Impaired internalization to the trans-Golgi
FT                   network; when associated with A-864."
FT                   /evidence="ECO:0000269|PubMed:23439653"
FT   MUTAGEN         864
FT                   /note="S->A: Impaired internalization to the trans-Golgi
FT                   network; when associated with A-861."
FT                   /evidence="ECO:0000269|PubMed:23439653"
FT   CONFLICT        90
FT                   /note="R -> H (in Ref. 2; AAC77911)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        212
FT                   /note="L -> W (in Ref. 2; AAC77911)"
FT                   /evidence="ECO:0000305"
FT   STRAND          39..42
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   TURN            44..46
FT                   /evidence="ECO:0000244|PDB:4KNG"
FT   STRAND          48..51
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   STRAND          68..72
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   HELIX           86..88
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   STRAND          94..96
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   TURN            107..112
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   STRAND          118..120
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   TURN            133..136
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   STRAND          142..144
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   TURN            155..160
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   STRAND          166..168
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   HELIX           181..183
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   STRAND          190..192
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   TURN            203..208
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   STRAND          214..216
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   TURN            227..232
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   STRAND          238..240
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   HELIX           251..255
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   STRAND          261..263
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   TURN            274..279
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   STRAND          285..287
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   TURN            298..303
FT                   /evidence="ECO:0000244|PDB:4KNG"
FT   STRAND          309..314
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   STRAND          331..338
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   HELIX           347..350
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   STRAND          356..358
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   STRAND          378..380
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   TURN            391..396
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   STRAND          402..404
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   TURN            415..420
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   STRAND          426..428
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   STRAND          446..449
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   TURN            462..464
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   STRAND          470..472
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   HELIX           476..482
FT                   /evidence="ECO:0000244|PDB:4UFR"
FT   HELIX           523..533
FT                   /evidence="ECO:0000244|PDB:4BSR"
FT   STRAND          534..536
FT                   /evidence="ECO:0000244|PDB:4BSR"
FT   STRAND          540..542
FT                   /evidence="ECO:0000244|PDB:4BSR"
SQ   SEQUENCE   907 AA;  99998 MW;  822D5C5E6F0D9092 CRC64;
     MDTSRLGVLL SLPVLLQLAT GGSSPRSGVL LRGCPTHCHC EPDGRMLLRV DCSDLGLSEL
     PSNLSVFTSY LDLSMNNISQ LLPNPLPSLR FLEELRLAGN ALTYIPKGAF TGLYSLKVLM
     LQNNQLRHVP TEALQNLRSL QSLRLDANHI SYVPPSCFSG LHSLRHLWLD DNALTEIPVQ
     AFRSLSALQA MTLALNKIHH IPDYAFGNLS SLVVLHLHNN RIHSLGKKCF DGLHSLETLD
     LNYNNLDEFP TAIRTLSNLK ELGFHSNNIR SIPEKAFVGN PSLITIHFYD NPIQFVGRSA
     FQHLPELRTL TLNGASQITE FPDLTGTANL ESLTLTGAQI SSLPQTVCNQ LPNLQVLDLS
     YNLLEDLPSF SVCQKLQKID LRHNEIYEIK VDTFQQLLSL RSLNLAWNKI AIIHPNAFST
     LPSLIKLDLS SNLLSSFPIT GLHGLTHLKL TGNHALQSLI SSENFPELKV IEMPYAYQCC
     AFGVCENAYK ISNQWNKGDN SSMDDLHKKD AGMFQAQDER DLEDFLLDFE EDLKALHSVQ
     CSPSPGPFKP CEHLLDGWLI RIGVWTIAVL ALTCNALVTS TVFRSPLYIS PIKLLIGVIA
     AVNMLTGVSS AVLAGVDAFT FGSFARHGAW WENGVGCHVI GFLSIFASES SVFLLTLAAL
     ERGFSVKYSA KFETKAPFSS LKVIILLCAL LALTMAAVPL LGGSKYGASP LCLPLPFGEP
     STMGYMVALI LLNSLCFLMM TIAYTKLYCN LDKGDLENIW DCSMVKHIAL LLFTNCILNC
     PVAFLSFSSL INLTFISPEV IKFILLVVVP LPACLNPLLY ILFNPHFKED LVSLRKQTYV
     WTRSKHPSLM SINSDDVEKQ SCDSTQALVT FTSSSITYDL PPSSVPSPAY PVTESCHLSS
     VAFVPCL
//
ID   GRM1_HUMAN              Reviewed;        1194 AA.
AC   Q13255; B9EG79; F8W805; Q13256; Q14757; Q14758; Q5VTF7; Q5VTF8; Q9NU10;
AC   Q9UGS9; Q9UGT0;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   02-NOV-2010, sequence version 3.
DT   07-OCT-2020, entry version 191.
DE   RecName: Full=Metabotropic glutamate receptor 1;
DE            Short=mGluR1;
DE   Flags: Precursor;
GN   Name=GRM1; Synonyms=GPRC1A, MGLUR1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA AND BETA), FUNCTION, AND
RP   VARIANTS PRO-593 AND PRO-993.
RX   PubMed=7476890;
RA   Desai M.A., Burnett J.P., Mayne N.G., Schoepp D.D.;
RT   "Cloning and expression of a human metabotropic glutamate receptor 1 alpha:
RT   enhanced coupling on co-transfection with a glutamate transporter.";
RL   Mol. Pharmacol. 48:648-657(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS ALPHA AND BETA), AND VARIANT PRO-993.
RX   PubMed=9076744; DOI=10.1016/s0028-3908(96)00108-6;
RA   Stephan D., Bon C., Holzwarth J.A., Galvan M., Pruss R.M.;
RT   "Human metabotropic glutamate receptor 1: mRNA distribution, chromosome
RT   localization and functional expression of two splice variants.";
RL   Neuropharmacology 35:1649-1660(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS ALPHA AND 3).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INVOLVEMENT IN SCAR13.
RX   PubMed=22901947; DOI=10.1016/j.ajhg.2012.07.019;
RA   Guergueltcheva V., Azmanov D.N., Angelicheva D., Smith K.R., Chamova T.,
RA   Florez L., Bynevelt M., Nguyen T., Cherninkova S., Bojinova V.,
RA   Kaprelyan A., Angelova L., Morar B., Chandler D., Kaneva R., Bahlo M.,
RA   Tournev I., Kalaydjieva L.;
RT   "Autosomal-recessive congenital cerebellar ataxia is caused by mutations in
RT   metabotropic glutamate receptor 1.";
RL   Am. J. Hum. Genet. 91:553-564(2012).
RN   [6]
RP   FUNCTION, INVOLVEMENT IN SCA44, VARIANTS SCA44 CYS-262 AND CYS-792, AND
RP   CHARACTERIZATION OF VARIANTS SCA44 CYS-262 AND CYS-792.
RX   PubMed=28886343; DOI=10.1016/j.ajhg.2017.08.005;
RA   Watson L.M., Bamber E., Schnekenberg R.P., Williams J., Bettencourt C.,
RA   Lickiss J., Jayawant S., Fawcett K., Clokie S., Wallis Y., Clouston P.,
RA   Sims D., Houlden H., Becker E.B.E., Nemeth A.H.;
RT   "Dominant Mutations in GRM1 Cause Spinocerebellar Ataxia Type 44.";
RL   Am. J. Hum. Genet. 101:451-458(2017).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 28-518 IN COMPLEX WITH ANTAGONIST
RP   LY341495, GLYCOSYLATION AT ASN-223, AND DISULFIDE BONDS.
RG   Structural genomics consortium (SGC);
RT   "Metabotropic glutamate receptor mGluR1 complexed with LY341495
RT   antagonist.";
RL   Submitted (JUL-2011) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 581-860 IN COMPLEX WITH ALLOSTERIC
RP   ANTAGONIST, FUNCTION, SUBCELLULAR LOCATION, TOPOLOGY, SUBUNIT, DISULFIDE
RP   BOND, AND ACTIVITY REGULATION.
RX   PubMed=24603153; DOI=10.1126/science.1249489;
RA   Wu H., Wang C., Gregory K.J., Han G.W., Cho H.P., Xia Y., Niswender C.M.,
RA   Katritch V., Meiler J., Cherezov V., Conn P.J., Stevens R.C.;
RT   "Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an
RT   allosteric modulator.";
RL   Science 344:58-64(2014).
RN   [9]
RP   VARIANT [LARGE SCALE ANALYSIS] TRP-696.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [10]
RP   VARIANT SCAR13 PHE-454.
RX   PubMed=26308914; DOI=10.1371/journal.pone.0129631;
RA   Davarniya B., Hu H., Kahrizi K., Musante L., Fattahi Z., Hosseini M.,
RA   Maqsoud F., Farajollahi R., Wienker T.F., Ropers H.H., Najmabadi H.;
RT   "The role of a novel TRMT1 gene mutation and rare grm1 gene defect in
RT   intellectual disability in two azeri families.";
RL   PLoS ONE 10:E0129631-E0129631(2015).
CC   -!- FUNCTION: G-protein coupled receptor for glutamate. Ligand binding
CC       causes a conformation change that triggers signaling via guanine
CC       nucleotide-binding proteins (G proteins) and modulates the activity of
CC       down-stream effectors. Signaling activates a phosphatidylinositol-
CC       calcium second messenger system. May participate in the central action
CC       of glutamate in the CNS, such as long-term potentiation in the
CC       hippocampus and long-term depression in the cerebellum
CC       (PubMed:24603153, PubMed:28886343, PubMed:7476890). May function in the
CC       light response in the retina (By similarity).
CC       {ECO:0000250|UniProtKB:P97772, ECO:0000269|PubMed:24603153,
CC       ECO:0000269|PubMed:28886343, ECO:0000269|PubMed:7476890}.
CC   -!- ACTIVITY REGULATION: Signaling is inhibited by the antagonist LY341495.
CC       The LY341495 binding site partially overlaps with the glutamate binding
CC       site. Signaling is also inhibited by synthetic allosteric regulators,
CC       such as FITM (4-fluoro-N-(4-(6-(isopropylamino)pyrimidin-4-yl)thiazol-
CC       2-yl)-N-methylbenzamide) that bind in a pocket between the
CC       transmembrane helices. {ECO:0000269|PubMed:24603153}.
CC   -!- SUBUNIT: Homodimer; disulfide-linked. The PPXXF motif binds HOMER1,
CC       HOMER2 and HOMER3. Interacts with SIAH1, RYR1, RYR2, ITPR1, SHANK1,
CC       SHANK3 and TAMALIN (By similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       Q13255; P52294: KPNA1; NbExp=2; IntAct=EBI-8527352, EBI-358383;
CC       Q13255-1; Q13255-1: GRM1; NbExp=2; IntAct=EBI-15564598, EBI-15564598;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:24603153};
CC       Multi-pass membrane protein {ECO:0000269|PubMed:24603153}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=Alpha;
CC         IsoId=Q13255-1; Sequence=Displayed;
CC       Name=Beta;
CC         IsoId=Q13255-2; Sequence=VSP_002024, VSP_002025;
CC       Name=3;
CC         IsoId=Q13255-3; Sequence=VSP_055127, VSP_055128;
CC   -!- TISSUE SPECIFICITY: Detected in brain.
CC   -!- DISEASE: Spinocerebellar ataxia, autosomal recessive, 13 (SCAR13)
CC       [MIM:614831]: A form of spinocerebellar ataxia, a clinically and
CC       genetically heterogeneous group of cerebellar disorders. Patients show
CC       progressive incoordination of gait and often poor coordination of
CC       hands, speech and eye movements, due to degeneration of the cerebellum
CC       with variable involvement of the brainstem and spinal cord. SCAR13 is
CC       characterized by delayed psychomotor development beginning in infancy.
CC       Affected individuals show mild to profound mental retardation with poor
CC       or absent speech as well as gait and stance ataxia and hyperreflexia.
CC       {ECO:0000269|PubMed:22901947, ECO:0000269|PubMed:26308914}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Spinocerebellar ataxia 44 (SCA44) [MIM:617691]: A form of
CC       spinocerebellar ataxia, a clinically and genetically heterogeneous
CC       group of cerebellar disorders. Patients show progressive incoordination
CC       of gait and often poor coordination of hands, speech and eye movements,
CC       due to degeneration of the cerebellum with variable involvement of the
CC       brainstem and spinal cord. SCA44 is a slowly progressive, autosomal
CC       dominant form. {ECO:0000269|PubMed:28886343}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 3 family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U31215; AAA87843.1; -; mRNA.
DR   EMBL; U31216; AAA87844.1; -; mRNA.
DR   EMBL; L76627; AAB05337.1; -; mRNA.
DR   EMBL; L76631; AAB05338.1; -; mRNA.
DR   EMBL; AL031769; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL592423; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL096867; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL035698; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC136280; AAI36281.1; -; mRNA.
DR   EMBL; BC143779; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS47497.1; -. [Q13255-2]
DR   CCDS; CCDS5209.1; -. [Q13255-1]
DR   CCDS; CCDS64548.1; -. [Q13255-3]
DR   RefSeq; NP_001264993.1; NM_001278064.1. [Q13255-1]
DR   RefSeq; NP_001264994.1; NM_001278065.1. [Q13255-2]
DR   RefSeq; NP_001264995.1; NM_001278066.1. [Q13255-2]
DR   RefSeq; NP_001264996.1; NM_001278067.1. [Q13255-3]
DR   RefSeq; XP_011534084.1; XM_011535782.1. [Q13255-1]
DR   RefSeq; XP_016866272.1; XM_017010783.1. [Q13255-1]
DR   RefSeq; XP_016866273.1; XM_017010784.1. [Q13255-1]
DR   RefSeq; XP_016866274.1; XM_017010785.1. [Q13255-2]
DR   RefSeq; XP_016866275.1; XM_017010786.1. [Q13255-2]
DR   RefSeq; XP_016866276.1; XM_017010787.1. [Q13255-2]
DR   PDB; 3KS9; X-ray; 1.90 A; A/B=28-518.
DR   PDB; 4OR2; X-ray; 2.80 A; A/B=581-860.
DR   PDBsum; 3KS9; -.
DR   PDBsum; 4OR2; -.
DR   SMR; Q13255; -.
DR   BioGRID; 109168; 39.
DR   CORUM; Q13255; -.
DR   DIP; DIP-57522N; -.
DR   ELM; Q13255; -.
DR   IntAct; Q13255; 4.
DR   MINT; Q13255; -.
DR   STRING; 9606.ENSP00000354896; -.
DR   BindingDB; Q13255; -.
DR   ChEMBL; CHEMBL3772; -.
DR   DrugBank; DB04256; (S)-alpha-methyl-4-carboxyphenylglycine.
DR   DrugBank; DB00142; Glutamic acid.
DR   DrugCentral; Q13255; -.
DR   GuidetoPHARMACOLOGY; 289; -.
DR   TCDB; 9.A.14.7.1; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; Q13255; 4 sites.
DR   iPTMnet; Q13255; -.
DR   PhosphoSitePlus; Q13255; -.
DR   BioMuta; GRM1; -.
DR   DMDM; 311033443; -.
DR   jPOST; Q13255; -.
DR   MassIVE; Q13255; -.
DR   MaxQB; Q13255; -.
DR   PaxDb; Q13255; -.
DR   PeptideAtlas; Q13255; -.
DR   PRIDE; Q13255; -.
DR   ProteomicsDB; 30048; -.
DR   ProteomicsDB; 59254; -. [Q13255-1]
DR   ProteomicsDB; 59255; -. [Q13255-2]
DR   Antibodypedia; 2943; 687 antibodies.
DR   DNASU; 2911; -.
DR   Ensembl; ENST00000282753; ENSP00000282753; ENSG00000152822. [Q13255-1]
DR   Ensembl; ENST00000355289; ENSP00000347437; ENSG00000152822. [Q13255-3]
DR   Ensembl; ENST00000361719; ENSP00000354896; ENSG00000152822. [Q13255-1]
DR   Ensembl; ENST00000492807; ENSP00000424095; ENSG00000152822. [Q13255-2]
DR   Ensembl; ENST00000507907; ENSP00000425599; ENSG00000152822. [Q13255-2]
DR   GeneID; 2911; -.
DR   KEGG; hsa:2911; -.
DR   UCSC; uc003qll.4; human. [Q13255-1]
DR   CTD; 2911; -.
DR   DisGeNET; 2911; -.
DR   EuPathDB; HostDB:ENSG00000152822.13; -.
DR   GeneCards; GRM1; -.
DR   HGNC; HGNC:4593; GRM1.
DR   HPA; ENSG00000152822; Tissue enriched (brain).
DR   MalaCards; GRM1; -.
DR   MIM; 604473; gene.
DR   MIM; 614831; phenotype.
DR   MIM; 617691; phenotype.
DR   neXtProt; NX_Q13255; -.
DR   OpenTargets; ENSG00000152822; -.
DR   Orphanet; 324262; Autosomal recessive congenital cerebellar ataxia due to MGLUR1 deficiency.
DR   Orphanet; 404507; Chondromyxoid fibroma.
DR   PharmGKB; PA28990; -.
DR   eggNOG; KOG1056; Eukaryota.
DR   GeneTree; ENSGT00950000182807; -.
DR   HOGENOM; CLU_005389_0_1_1; -.
DR   InParanoid; Q13255; -.
DR   KO; K04603; -.
DR   OMA; EIMNFQH; -.
DR   OrthoDB; 107675at2759; -.
DR   PhylomeDB; Q13255; -.
DR   TreeFam; TF313240; -.
DR   PathwayCommons; Q13255; -.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-420499; Class C/3 (Metabotropic glutamate/pheromone receptors).
DR   Reactome; R-HSA-6794361; Neurexins and neuroligins.
DR   SignaLink; Q13255; -.
DR   SIGNOR; Q13255; -.
DR   BioGRID-ORCS; 2911; 4 hits in 871 CRISPR screens.
DR   ChiTaRS; GRM1; human.
DR   EvolutionaryTrace; Q13255; -.
DR   GeneWiki; Metabotropic_glutamate_receptor_1; -.
DR   GenomeRNAi; 2911; -.
DR   Pharos; Q13255; Tchem.
DR   PRO; PR:Q13255; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; Q13255; protein.
DR   Bgee; ENSG00000152822; Expressed in cerebellum and 86 other tissues.
DR   Genevisible; Q13255; HS.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0038037; C:G protein-coupled receptor dimeric complex; IDA:UniProtKB.
DR   GO; GO:0038038; C:G protein-coupled receptor homodimeric complex; IPI:FlyBase.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; IMP:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0098839; C:postsynaptic density membrane; IBA:GO_Central.
DR   GO; GO:0098685; C:Schaffer collateral - CA1 synapse; IEA:Ensembl.
DR   GO; GO:0098872; F:G protein-coupled neurotransmitter receptor activity involved in regulation of postsynaptic cytosolic calcium ion concentration; IEA:Ensembl.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; TAS:UniProtKB.
DR   GO; GO:0099530; F:G protein-coupled receptor activity involved in regulation of postsynaptic membrane potential; IBA:GO_Central.
DR   GO; GO:0008066; F:glutamate receptor activity; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0099583; F:neurotransmitter receptor activity involved in regulation of postsynaptic cytosolic calcium ion concentration; IBA:GO_Central.
DR   GO; GO:0000187; P:activation of MAPK activity; IEA:Ensembl.
DR   GO; GO:0000186; P:activation of MAPKK activity; IEA:Ensembl.
DR   GO; GO:0071257; P:cellular response to electrical stimulus; IEA:Ensembl.
DR   GO; GO:0007268; P:chemical synaptic transmission; TAS:ProtInc.
DR   GO; GO:0007216; P:G protein-coupled glutamate receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007626; P:locomotory behavior; IEA:Ensembl.
DR   GO; GO:0051482; P:positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway; IMP:UniProtKB.
DR   GO; GO:0051930; P:regulation of sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0051966; P:regulation of synaptic transmission, glutamatergic; IBA:GO_Central.
DR   GO; GO:0019233; P:sensory perception of pain; IEA:Ensembl.
DR   Gene3D; 2.10.50.30; -; 1.
DR   InterPro; IPR001828; ANF_lig-bd_rcpt.
DR   InterPro; IPR000337; GPCR_3.
DR   InterPro; IPR011500; GPCR_3_9-Cys_dom.
DR   InterPro; IPR038550; GPCR_3_9-Cys_sf.
DR   InterPro; IPR017978; GPCR_3_C.
DR   InterPro; IPR017979; GPCR_3_CS.
DR   InterPro; IPR000162; GPCR_3_mtglu_rcpt.
DR   InterPro; IPR001256; GPCR_3_mtglu_rcpt_1.
DR   InterPro; IPR019588; Metabotropic_Glu_rcpt_Homer-bd.
DR   InterPro; IPR028082; Peripla_BP_I.
DR   Pfam; PF00003; 7tm_3; 1.
DR   Pfam; PF01094; ANF_receptor; 1.
DR   Pfam; PF10606; GluR_Homer-bdg; 1.
DR   Pfam; PF07562; NCD3G; 1.
DR   PRINTS; PR00248; GPCRMGR.
DR   PRINTS; PR01051; MTABOTROPC1R.
DR   PRINTS; PR00593; MTABOTROPICR.
DR   SMART; SM01229; GluR_Homer-bdg; 1.
DR   SUPFAM; SSF53822; SSF53822; 1.
DR   PROSITE; PS00979; G_PROTEIN_RECEP_F3_1; 1.
DR   PROSITE; PS00980; G_PROTEIN_RECEP_F3_2; 1.
DR   PROSITE; PS00981; G_PROTEIN_RECEP_F3_3; 1.
DR   PROSITE; PS50259; G_PROTEIN_RECEP_F3_4; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Disease mutation;
KW   Disulfide bond; G-protein coupled receptor; Glycoprotein; Membrane;
KW   Neurodegeneration; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Signal; Spinocerebellar ataxia; Transducer;
KW   Transmembrane; Transmembrane helix.
FT   SIGNAL          1..18
FT                   /evidence="ECO:0000255"
FT   CHAIN           19..1194
FT                   /note="Metabotropic glutamate receptor 1"
FT                   /id="PRO_0000012922"
FT   TOPO_DOM        19..592
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:24603153"
FT   TRANSMEM        593..615
FT                   /note="Helical; Name=1"
FT   TOPO_DOM        616..629
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:24603153"
FT   TRANSMEM        630..650
FT                   /note="Helical; Name=2"
FT   TOPO_DOM        651..658
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:24603153"
FT   TRANSMEM        659..680
FT                   /note="Helical; Name=3"
FT   TOPO_DOM        681..703
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:24603153"
FT   TRANSMEM        704..727
FT                   /note="Helical; Name=4"
FT   TOPO_DOM        728..750
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:24603153"
FT   TRANSMEM        751..772
FT                   /note="Helical; Name=5"
FT   TOPO_DOM        773..785
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:24603153"
FT   TRANSMEM        786..807
FT                   /note="Helical; Name=6"
FT   TOPO_DOM        808..815
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:24603153"
FT   TRANSMEM        816..840
FT                   /note="Helical; Name=7"
FT   TOPO_DOM        841..1194
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:24603153"
FT   REGION          186..188
FT                   /note="Glutamate binding"
FT                   /evidence="ECO:0000305"
FT   COMPBIAS        1014..1035
FT                   /note="Gln/Pro-rich"
FT   COMPBIAS        1067..1081
FT                   /note="Gln/Pro-rich"
FT   COMPBIAS        1095..1130
FT                   /note="Asp/Glu-rich (acidic)"
FT   COMPBIAS        1142..1194
FT                   /note="Ser-rich"
FT   BINDING         74
FT                   /note="Glutamate"
FT                   /evidence="ECO:0000305"
FT   BINDING         165
FT                   /note="Glutamate"
FT                   /evidence="ECO:0000305"
FT   BINDING         236
FT                   /note="Glutamate"
FT                   /evidence="ECO:0000250"
FT   BINDING         318
FT                   /note="Glutamate"
FT                   /evidence="ECO:0000250"
FT   BINDING         409
FT                   /note="Glutamate"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         853
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P97772"
FT   MOD_RES         871
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P97772"
FT   MOD_RES         894
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P23385"
FT   MOD_RES         969
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P97772"
FT   MOD_RES         1091
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P97772"
FT   MOD_RES         1142
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P97772"
FT   MOD_RES         1146
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P23385"
FT   MOD_RES         1149
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P97772"
FT   CARBOHYD        98
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        223
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|Ref.7"
FT   CARBOHYD        397
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        515
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        67..109
FT   DISULFID        140
FT                   /note="Interchain"
FT   DISULFID        289..291
FT                   /evidence="ECO:0000250"
FT   DISULFID        378..394
FT   DISULFID        432..439
FT   DISULFID        657..746
FT   VAR_SEQ         887..908
FT                   /note="NSNGKSVSWSEPGGGQVPKGQH -> KWRTGAQGTAYVAPPLCAREDQ (in
FT                   isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_055127"
FT   VAR_SEQ         887..906
FT                   /note="NSNGKSVSWSEPGGGQVPKG -> KKRQPEFSPTSQCPSAHVQL (in
FT                   isoform Beta)"
FT                   /evidence="ECO:0000303|PubMed:7476890,
FT                   ECO:0000303|PubMed:9076744"
FT                   /id="VSP_002024"
FT   VAR_SEQ         907..1194
FT                   /note="Missing (in isoform Beta)"
FT                   /evidence="ECO:0000303|PubMed:7476890,
FT                   ECO:0000303|PubMed:9076744"
FT                   /id="VSP_002025"
FT   VAR_SEQ         909..1194
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_055128"
FT   VARIANT         34
FT                   /note="S -> Y (in dbSNP:rs12190109)"
FT                   /id="VAR_028184"
FT   VARIANT         262
FT                   /note="Y -> C (in SCA44; enhances G-protein coupled
FT                   glutamate receptor signaling pathway; dbSNP:rs1554274719)"
FT                   /evidence="ECO:0000269|PubMed:28886343"
FT                   /id="VAR_080186"
FT   VARIANT         285
FT                   /note="R -> K (in dbSNP:rs7760248)"
FT                   /id="VAR_028185"
FT   VARIANT         454
FT                   /note="L -> F (in SCAR13)"
FT                   /evidence="ECO:0000269|PubMed:26308914"
FT                   /id="VAR_081782"
FT   VARIANT         593
FT                   /note="S -> P (in dbSNP:rs1047005)"
FT                   /evidence="ECO:0000269|PubMed:7476890"
FT                   /id="VAR_055875"
FT   VARIANT         696
FT                   /note="R -> W (in a colorectal cancer sample; somatic
FT                   mutation; dbSNP:rs1450433570)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036194"
FT   VARIANT         741
FT                   /note="E -> D (in dbSNP:rs3025919)"
FT                   /id="VAR_028186"
FT   VARIANT         792
FT                   /note="Y -> C (in SCA44; enhances G-protein coupled
FT                   glutamate receptor signaling pathway; dbSNP:rs1554308513)"
FT                   /evidence="ECO:0000269|PubMed:28886343"
FT                   /id="VAR_080187"
FT   VARIANT         884
FT                   /note="G -> E (in dbSNP:rs362936)"
FT                   /id="VAR_028187"
FT   VARIANT         929
FT                   /note="V -> I (in dbSNP:rs2941)"
FT                   /id="VAR_024482"
FT   VARIANT         993
FT                   /note="S -> P (in dbSNP:rs6923492)"
FT                   /evidence="ECO:0000269|PubMed:7476890,
FT                   ECO:0000269|PubMed:9076744"
FT                   /id="VAR_028188"
FT   STRAND          39..41
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   STRAND          44..51
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   HELIX           59..61
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   TURN            62..65
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   TURN            72..75
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   HELIX           76..90
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   STRAND          93..96
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   STRAND          101..107
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   HELIX           112..123
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   STRAND          156..160
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   HELIX           165..175
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   HELIX           176..178
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   STRAND          182..186
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   HELIX           190..193
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   TURN            195..197
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   STRAND          201..205
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   HELIX           209..221
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   STRAND          226..234
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   HELIX           235..250
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   STRAND          254..261
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   HELIX           267..278
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   TURN            279..284
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   STRAND          286..290
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   HELIX           293..306
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   STRAND          313..316
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   TURN            318..322
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   HELIX           324..327
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   HELIX           331..334
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   STRAND          338..342
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   HELIX           348..354
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   TURN            359..361
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   HELIX           368..375
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   STRAND          391..393
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   TURN            400..403
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   HELIX           410..431
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   HELIX           440..442
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   HELIX           447..455
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   STRAND          458..460
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   STRAND          466..468
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   STRAND          478..486
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   STRAND          492..501
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   STRAND          504..507
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   TURN            509..511
FT                   /evidence="ECO:0000244|PDB:3KS9"
FT   HELIX           591..616
FT                   /evidence="ECO:0000244|PDB:4OR2"
FT   STRAND          618..620
FT                   /evidence="ECO:0000244|PDB:4OR2"
FT   HELIX           621..624
FT                   /evidence="ECO:0000244|PDB:4OR2"
FT   HELIX           628..649
FT                   /evidence="ECO:0000244|PDB:4OR2"
FT   HELIX           654..685
FT                   /evidence="ECO:0000244|PDB:4OR2"
FT   HELIX           703..727
FT                   /evidence="ECO:0000244|PDB:4OR2"
FT   STRAND          732..735
FT                   /evidence="ECO:0000244|PDB:4OR2"
FT   STRAND          738..740
FT                   /evidence="ECO:0000244|PDB:4OR2"
FT   STRAND          742..746
FT                   /evidence="ECO:0000244|PDB:4OR2"
FT   HELIX           750..773
FT                   /evidence="ECO:0000244|PDB:4OR2"
FT   TURN            774..776
FT                   /evidence="ECO:0000244|PDB:4OR2"
FT   HELIX           779..807
FT                   /evidence="ECO:0000244|PDB:4OR2"
FT   HELIX           811..839
FT                   /evidence="ECO:0000244|PDB:4OR2"
FT   CONFLICT        Q13255-2:896
FT                   /note="T -> S (in Ref. 1; AAA87844)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        Q13255-2:904
FT                   /note="V -> A (in Ref. 1; AAA87844)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1194 AA;  132357 MW;  0A633505F6D51909 CRC64;
     MVGLLLFFFP AIFLEVSLLP RSPGRKVLLA GASSQRSVAR MDGDVIIGAL FSVHHQPPAE
     KVPERKCGEI REQYGIQRVE AMFHTLDKIN ADPVLLPNIT LGSEIRDSCW HSSVALEQSI
     EFIRDSLISI RDEKDGINRC LPDGQSLPPG RTKKPIAGVI GPGSSSVAIQ VQNLLQLFDI
     PQIAYSATSI DLSDKTLYKY FLRVVPSDTL QARAMLDIVK RYNWTYVSAV HTEGNYGESG
     MDAFKELAAQ EGLCIAHSDK IYSNAGEKSF DRLLRKLRER LPKARVVVCF CEGMTVRGLL
     SAMRRLGVVG EFSLIGSDGW ADRDEVIEGY EVEANGGITI KLQSPEVRSF DDYFLKLRLD
     TNTRNPWFPE FWQHRFQCRL PGHLLENPNF KRICTGNESL EENYVQDSKM GFVINAIYAM
     AHGLQNMHHA LCPGHVGLCD AMKPIDGSKL LDFLIKSSFI GVSGEEVWFD EKGDAPGRYD
     IMNLQYTEAN RYDYVHVGTW HEGVLNIDDY KIQMNKSGVV RSVCSEPCLK GQIKVIRKGE
     VSCCWICTAC KENEYVQDEF TCKACDLGWW PNADLTGCEP IPVRYLEWSN IESIIAIAFS
     CLGILVTLFV TLIFVLYRDT PVVKSSSREL CYIILAGIFL GYVCPFTLIA KPTTTSCYLQ
     RLLVGLSSAM CYSALVTKTN RIARILAGSK KKICTRKPRF MSAWAQVIIA SILISVQLTL
     VVTLIIMEPP MPILSYPSIK EVYLICNTSN LGVVAPLGYN GLLIMSCTYY AFKTRNVPAN
     FNEAKYIAFT MYTTCIIWLA FVPIYFGSNY KIITTCFAVS LSVTVALGCM FTPKMYIIIA
     KPERNVRSAF TTSDVVRMHV GDGKLPCRSN TFLNIFRRKK AGAGNANSNG KSVSWSEPGG
     GQVPKGQHMW HRLSVHVKTN ETACNQTAVI KPLTKSYQGS GKSLTFSDTS TKTLYNVEEE
     EDAQPIRFSP PGSPSMVVHR RVPSAATTPP LPSHLTAEET PLFLAEPALP KGLPPPLQQQ
     QQPPPQQKSL MDQLQGVVSN FSTAIPDFHA VLAGPGGPGN GLRSLYPPPP PPQHLQMLPL
     QLSTFGEELV SPPADDDDDS ERFKLLQEYV YEHEREGNTE EDELEEEEED LQAASKLTPD
     DSPALTPPSP FRDSVASGSS VPSSPVSESV LCTPPNVSYA SVILRDYKQS SSTL
//
ID   LPAR2_HUMAN             Reviewed;         351 AA.
AC   Q9HBW0; O00543; O43431;
DT   06-DEC-2002, integrated into UniProtKB/Swiss-Prot.
DT   06-DEC-2002, sequence version 2.
DT   12-AUG-2020, entry version 163.
DE   RecName: Full=Lysophosphatidic acid receptor 2;
DE            Short=LPA receptor 2;
DE            Short=LPA-2;
DE   AltName: Full=Lysophosphatidic acid receptor Edg-4;
GN   Name=LPAR2; Synonyms=EDG4, LPA2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Ovarian carcinoma;
RX   PubMed=9525886; DOI=10.1074/jbc.273.14.7906;
RA   An S., Bleu T., Hallmark O.G., Goetzl E.J.;
RT   "Characterization of a novel subtype of human G protein-coupled receptor
RT   for lysophosphatidic acid.";
RL   J. Biol. Chem. 273:7906-7910(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=10922489; DOI=10.1016/s0014-5793(00)01827-5;
RA   Bandoh K., Aoki J., Taira A., Tsujimoto M., Arai H., Inoue K.;
RT   "Lysophosphatidic acid (LPA) receptors of the EDG family are differentially
RT   activated by LPA species. Structure-activity relationship of cloned LPA
RT   receptors.";
RL   FEBS Lett. 478:159-165(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Colon cancer;
RA   An S.;
RT   "Human Edg4 lysophosphatidic acid receptor cDNA encoding a putative protein
RT   with COOH-terminus different from the previously-reported Edg4.";
RL   Submitted (OCT-1999) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kopatz S.A., King M.M., Cismowski M.J., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   REVIEW.
RX   PubMed=11093753; DOI=10.1124/mol.58.6.1188;
RA   Contos J.J.A., Ishii I., Chun J.;
RT   "Lysophosphatidic acid receptors.";
RL   Mol. Pharmacol. 58:1188-1196(2000).
RN   [8]
RP   IDENTIFICATION OF A PROBABLE FRAMESHIFT MUTATION.
RX   PubMed=10729222; DOI=10.1006/geno.2000.6122;
RA   Contos J.J.A., Chun J.;
RT   "Genomic characterization of the lysophosphatidic acid receptor gene,
RT   lp(A2)/Edg4, and identification of a frameshift mutation in a previously
RT   characterized cDNA.";
RL   Genomics 64:155-169(2000).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH SLC9A3R2/NHERF2 AND PLCB3.
RX   PubMed=15143197; DOI=10.1128/mcb.24.11.5069-5079.2004;
RA   Oh Y.-S., Jo N.W., Choi J.W., Kim H.S., Seo S.-W., Kang K.-O., Hwang J.-I.,
RA   Heo K., Kim S.-H., Kim Y.-H., Kim I.-H., Kim J.H., Banno Y., Ryu S.H.,
RA   Suh P.-G.;
RT   "NHERF2 specifically interacts with LPA2 receptor and defines the
RT   specificity and efficiency of receptor-mediated phospholipase C-beta3
RT   activation.";
RL   Mol. Cell. Biol. 24:5069-5079(2004).
RN   [10]
RP   INTERACTION WITH MAGI3, AND MUTAGENESIS OF ASP-348; SER-349; THR-350 AND
RP   LEU-351.
RX   PubMed=16904289; DOI=10.1016/j.cellsig.2006.06.008;
RA   Zhang H., Wang D., Sun H., Hall R.A., Yun C.C.;
RT   "MAGI-3 regulates LPA-induced activation of Erk and RhoA.";
RL   Cell. Signal. 19:261-268(2007).
RN   [11]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH RALA AND GRK2.
RX   PubMed=19306925; DOI=10.1016/j.cellsig.2009.03.011;
RA   Aziziyeh A.I., Li T.T., Pape C., Pampillo M., Chidiac P., Possmayer F.,
RA   Babwah A.V., Bhattacharya M.;
RT   "Dual regulation of lysophosphatidic acid (LPA1) receptor signalling by Ral
RT   and GRK.";
RL   Cell. Signal. 21:1207-1217(2009).
CC   -!- FUNCTION: Receptor for lysophosphatidic acid (LPA), a mediator of
CC       diverse cellular activities. Seems to be coupled to the G(i)/G(o),
CC       G(12)/G(13), and G(q) families of heteromeric G proteins. Plays a key
CC       role in phospholipase C-beta (PLC-beta) signaling pathway. Stimulates
CC       phospholipase C (PLC) activity in a manner that is independent of RALA
CC       activation. {ECO:0000269|PubMed:15143197, ECO:0000269|PubMed:19306925}.
CC   -!- SUBUNIT: Interacts with SLC9A3R2/NHERF2, MAGI3 and PLCB3. Interacts
CC       with RALA and GRK2. {ECO:0000269|PubMed:15143197,
CC       ECO:0000269|PubMed:16904289, ECO:0000269|PubMed:19306925}.
CC   -!- INTERACTION:
CC       Q9HBW0; P13569: CFTR; NbExp=4; IntAct=EBI-765995, EBI-349854;
CC       Q9HBW0; Q15599: SLC9A3R2; NbExp=2; IntAct=EBI-765995, EBI-1149760;
CC   -!- SUBCELLULAR LOCATION: Cell surface {ECO:0000269|PubMed:19306925}. Cell
CC       membrane {ECO:0000269|PubMed:19306925}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:19306925}. Note=Prior to LPA treatment found
CC       predominantly at the cell surface but in the presence of LPA
CC       colocalizes with RALA in the endocytic vesicles.
CC   -!- TISSUE SPECIFICITY: Expressed most abundantly in testes and peripheral
CC       blood leukocytes with less expression in pancreas, spleen, thymus and
CC       prostate. Little or no expression in heart, brain, placenta, lung,
CC       liver, skeletal muscle, kidney, ovary, small intestine, or colon.
CC   -!- MISCELLANEOUS: PubMed:9525886 cDNA clone has a guanine nucleotide
CC       deletion that causes a frameshift near its C-terminal coding region.
CC       This likely reflects a somatic mutation in the ovary tumor cells from
CC       which the cDNA was isolated and may have altered the function of the
CC       encoded receptor, and contributed to transformation of the original
CC       ovary cells that formed a tumor.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC27728.1; Type=Frameshift; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/LPAR2ID40406ch19p13.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF011466; AAC27728.1; ALT_FRAME; mRNA.
DR   EMBL; AF233092; AAF43409.1; -; mRNA.
DR   EMBL; AF197929; AAG28521.1; -; mRNA.
DR   EMBL; AY322548; AAP84361.1; -; mRNA.
DR   EMBL; AC002306; AAB61528.1; -; Genomic_DNA.
DR   EMBL; BC025695; AAH25695.1; -; mRNA.
DR   CCDS; CCDS12407.1; -.
DR   RefSeq; NP_004711.2; NM_004720.5.
DR   RefSeq; XP_011526723.1; XM_011528421.2.
DR   RefSeq; XP_016882957.1; XM_017027468.1.
DR   RefSeq; XP_016882958.1; XM_017027469.1.
DR   PDB; 4P0C; X-ray; 1.34 A; A=347-351.
DR   PDBsum; 4P0C; -.
DR   BioGRID; 114611; 10.
DR   CORUM; Q9HBW0; -.
DR   IntAct; Q9HBW0; 6.
DR   STRING; 9606.ENSP00000443256; -.
DR   BindingDB; Q9HBW0; -.
DR   ChEMBL; CHEMBL3724; -.
DR   GuidetoPHARMACOLOGY; 273; -.
DR   SwissLipids; SLP:000001569; -.
DR   TCDB; 9.A.14.2.5; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; Q9HBW0; 2 sites.
DR   iPTMnet; Q9HBW0; -.
DR   PhosphoSitePlus; Q9HBW0; -.
DR   BioMuta; LPAR2; -.
DR   DMDM; 26393399; -.
DR   EPD; Q9HBW0; -.
DR   jPOST; Q9HBW0; -.
DR   MassIVE; Q9HBW0; -.
DR   MaxQB; Q9HBW0; -.
DR   PaxDb; Q9HBW0; -.
DR   PeptideAtlas; Q9HBW0; -.
DR   PRIDE; Q9HBW0; -.
DR   ProteomicsDB; 81600; -.
DR   Antibodypedia; 15391; 327 antibodies.
DR   DNASU; 9170; -.
DR   Ensembl; ENST00000407877; ENSP00000384665; ENSG00000064547.
DR   Ensembl; ENST00000542587; ENSP00000443256; ENSG00000064547.
DR   Ensembl; ENST00000586703; ENSP00000465280; ENSG00000064547.
DR   GeneID; 9170; -.
DR   KEGG; hsa:9170; -.
DR   UCSC; uc002nna.6; human.
DR   CTD; 9170; -.
DR   DisGeNET; 9170; -.
DR   EuPathDB; HostDB:ENSG00000064547.13; -.
DR   GeneCards; LPAR2; -.
DR   HGNC; HGNC:3168; LPAR2.
DR   HPA; ENSG00000064547; Tissue enhanced (testis).
DR   MIM; 605110; gene.
DR   neXtProt; NX_Q9HBW0; -.
DR   OpenTargets; ENSG00000064547; -.
DR   PharmGKB; PA162394202; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT01000000214362; -.
DR   HOGENOM; CLU_047979_0_0_1; -.
DR   InParanoid; Q9HBW0; -.
DR   KO; K04291; -.
DR   OMA; NCSTMAP; -.
DR   OrthoDB; 1366218at2759; -.
DR   PhylomeDB; Q9HBW0; -.
DR   PathwayCommons; Q9HBW0; -.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-419408; Lysosphingolipid and LPA receptors.
DR   SIGNOR; Q9HBW0; -.
DR   BioGRID-ORCS; 9170; 26 hits in 874 CRISPR screens.
DR   ChiTaRS; LPAR2; human.
DR   GeneWiki; LPAR2; -.
DR   GenomeRNAi; 9170; -.
DR   Pharos; Q9HBW0; Tchem.
DR   PRO; PR:Q9HBW0; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; Q9HBW0; protein.
DR   Bgee; ENSG00000064547; Expressed in blood and 180 other tissues.
DR   ExpressionAtlas; Q9HBW0; baseline and differential.
DR   Genevisible; Q9HBW0; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0008289; F:lipid binding; TAS:ProtInc.
DR   GO; GO:0070915; F:lysophosphatidic acid receptor activity; IEA:InterPro.
DR   GO; GO:0007202; P:activation of phospholipase C activity; TAS:ProtInc.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; TAS:ProtInc.
DR   GO; GO:0019222; P:regulation of metabolic process; IBA:GO_Central.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR004065; LPA_rcpt.
DR   InterPro; IPR004066; LPA_rcpt_EDG4.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01528; EDG4RECEPTOR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01527; LPARECEPTOR.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; G-protein coupled receptor; Glycoprotein;
KW   Lipoprotein; Membrane; Palmitate; Receptor; Reference proteome; Transducer;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..351
FT                   /note="Lysophosphatidic acid receptor 2"
FT                   /id="PRO_0000069424"
FT   TOPO_DOM        1..33
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        34..54
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        55..69
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        70..90
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        91..103
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        104..126
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        127..146
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        147..167
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        168..188
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        189..209
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        210..242
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        243..263
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        264..279
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        280..297
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        298..351
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   MOTIF           348..351
FT                   /note="PDZ-binding"
FT   LIPID           311
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        10
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        18
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   MUTAGEN         348
FT                   /note="D->A: Abolishes interaction with MAGI3."
FT                   /evidence="ECO:0000269|PubMed:16904289"
FT   MUTAGEN         349
FT                   /note="S->A: Abolishes interaction with MAGI3."
FT                   /evidence="ECO:0000269|PubMed:16904289"
FT   MUTAGEN         350
FT                   /note="T->A: Does not affect interaction with MAGI3."
FT                   /evidence="ECO:0000269|PubMed:16904289"
FT   MUTAGEN         351
FT                   /note="L->A: Abolishes interaction with MAGI3."
FT                   /evidence="ECO:0000269|PubMed:16904289"
FT   CONFLICT        221
FT                   /note="R -> S (in Ref. 3; AAG28521)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   351 AA;  39084 MW;  DE225B0B3E9351B8 CRC64;
     MVIMGQCYYN ETIGFFYNNS GKELSSHWRP KDVVVVALGL TVSVLVLLTN LLVIAAIASN
     RRFHQPIYYL LGNLAAADLF AGVAYLFLMF HTGPRTARLS LEGWFLRQGL LDTSLTASVA
     TLLAIAVERH RSVMAVQLHS RLPRGRVVML IVGVWVAALG LGLLPAHSWH CLCALDRCSR
     MAPLLSRSYL AVWALSSLLV FLLMVAVYTR IFFYVRRRVQ RMAEHVSCHP RYRETTLSLV
     KTVVIILGAF VVCWTPGQVV LLLDGLGCES CNVLAVEKYF LLLAEANSLV NAAVYSCRDA
     EMRRTFRRLL CCACLRQSTR ESVHYTSSAQ GGASTRIMLP ENGHPLMDST L
//
ID   MC4R_HUMAN              Reviewed;         332 AA.
AC   P32245; B2RAC3; Q16317; Q3MIJ6;
DT   01-OCT-1993, integrated into UniProtKB/Swiss-Prot.
DT   25-OCT-2004, sequence version 2.
DT   07-OCT-2020, entry version 201.
DE   RecName: Full=Melanocortin receptor 4;
DE            Short=MC4-R;
GN   Name=MC4R;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ILE-103.
RX   PubMed=8392067;
RA   Gantz I., Miwa H., Konda Y., Shimoto Y., Tashiro T., Waston S.J.,
RA   Delvalle J.;
RT   "Molecular cloning, expression, and gene localization of a fourth
RT   melanocortin receptor.";
RL   J. Biol. Chem. 268:15174-15179(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ILE-103.
RX   PubMed=7854347; DOI=10.1210/mend.8.10.7854347;
RA   Mountjoy K.G., Mortrud M.T., Low M.J., Simerly R.B., Cone R.D.;
RT   "Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and
RT   autonomic control circuits in the brain.";
RL   Mol. Endocrinol. 8:1298-1308(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Subthalamic nucleus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   INTERACTION WITH MRAP AND MRAP2.
RX   PubMed=19329486; DOI=10.1073/pnas.0809918106;
RA   Chan L.F., Webb T.R., Chung T.T., Meimaridou E., Cooray S.N., Guasti L.,
RA   Chapple J.P., Egertova M., Elphick M.R., Cheetham M.E., Metherell L.A.,
RA   Clark A.J.;
RT   "MRAP and MRAP2 are bidirectional regulators of the melanocortin receptor
RT   family.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:6146-6151(2009).
RN   [8]
RP   INTERACTION WITH MGRN1.
RX   PubMed=19737927; DOI=10.1074/jbc.m109.028100;
RA   Perez-Oliva A.B., Olivares C., Jimenez-Cervantes C., Garcia-Borron J.C.;
RT   "Mahogunin ring finger-1 (MGRN1) E3 ubiquitin ligase inhibits signaling
RT   from melanocortin receptor by competition with Galphas.";
RL   J. Biol. Chem. 284:31714-31725(2009).
RN   [9]
RP   INTERCHAIN DISULFIDE BOND, AND SUBUNIT.
RX   PubMed=23088915; DOI=10.1016/j.bbamem.2012.10.011;
RA   Chapman K.L., Findlay J.B.;
RT   "The melanocortin 4 receptor: oligomer formation, interaction sites and
RT   functional significance.";
RL   Biochim. Biophys. Acta 1828:535-542(2013).
RN   [10]
RP   VARIANTS OBESITY PHE-30; VAL-37; LEU-78; TRP-165; SER-252 AND THR-317, AND
RP   VARIANTS MET-112 AND LEU-251.
RX   PubMed=10199800; DOI=10.1210/jcem.84.4.5728;
RA   Hinney A., Schmidt A., Nottebom K., Heibult O., Becker I., Ziegler A.,
RA   Gerber G., Sina M., Gorg T., Mayer H., Siegfried W., Fichter M.,
RA   Remschmidt H., Hebebrand J.;
RT   "Several mutations in the melanocortin-4 receptor gene including a nonsense
RT   and a frameshift mutation associated with dominantly inherited obesity in
RT   humans.";
RL   J. Clin. Endocrinol. Metab. 84:1483-1486(1999).
RN   [11]
RP   VARIANT OBESITY SER-274.
RX   PubMed=11443223; DOI=10.1210/jcem.86.7.7809;
RA   Mergen M., Mergen H., Ozata M., Oner R., Oner C.;
RT   "A novel melanocortin 4 receptor (MC4R) gene mutation associated with
RT   morbid obesity.";
RL   J. Clin. Endocrinol. Metab. 86:3448-3448(2001).
RN   [12]
RP   VARIANTS OBESITY MET-50; CYS-58; SER-102 AND VAL-170, AND VARIANTS ILE-103
RP   AND LEU-251.
RX   PubMed=11487744; DOI=10.1067/mpd.2001.116284;
RA   Dubern B., Clement K., Pelloux V., Froguel P., Girardet J.-P.,
RA   Guy-Grand B., Tounian P.;
RT   "Mutational analysis of melanocortin-4 receptor, agouti-related protein,
RT   and alpha-melanocyte-stimulating hormone genes in severely obese
RT   children.";
RL   J. Pediatr. 139:204-209(2001).
RN   [13]
RP   VARIANTS OBESITY SER-62; ASP-97; PRO-106; LYS-125; GLN-165; THR-175;
RP   ILE-253; TYR-271 AND SER-316, AND CHARACTERIZATION OF VARIANTS OBESITY
RP   SER-62; ASP-97; PRO-106; LYS-125; GLN-165; THR-175; ILE-253; TYR-271 AND
RP   SER-316.
RX   PubMed=12588803; DOI=10.1093/hmg/ddg057;
RA   Yeo G.S.H., Lank E.J., Farooqi I.S., Keogh J., Challis B.G., O'Rahilly S.;
RT   "Mutations in the human melanocortin-4 receptor gene associated with severe
RT   familial obesity disrupts receptor function through multiple molecular
RT   mechanisms.";
RL   Hum. Mol. Genet. 12:561-574(2003).
RN   [14]
RP   VARIANT OBESITY 88-VAL--LEU-92 DEL, AND CHARACTERIZATION OF VARIANT OBESITY
RP   88-VAL--LEU-92 DEL.
RX   PubMed=14671178; DOI=10.1210/jc.2003-030903;
RA   Donohoue P.A., Tao Y.-X., Collins M., Yeo G.S.H., O'Rahilly S.,
RA   Segaloff D.L.;
RT   "Deletion of codons 88-92 of the melanocortin-4 receptor gene: a novel
RT   deleterious mutation in an obese female.";
RL   J. Clin. Endocrinol. Metab. 88:5841-5845(2003).
RN   [15]
RP   VARIANTS OBESITY ALA-11; SER-62; ASP-97; LYS-125; GLN-165; THR-175;
RP   TYR-271; ARG-271 AND SER-316, VARIANTS ILE-103; MET-112 AND LEU-251,
RP   CHARACTERIZATION OF VARIANTS OBESITY ALA-11; SER-62; ASP-97; LYS-125;
RP   GLN-165; THR-175; TYR-271 AND SER-316, CHARACTERIZATION OF VARIANTS
RP   ILE-103; MET-112 AND LEU-251, AND FUNCTION.
RX   PubMed=12646665; DOI=10.1056/nejmoa022050;
RA   Farooqi I.S., Keogh J.M., Yeo G.S.H., Lank E.J., Cheetham T., O'Rahilly S.;
RT   "Clinical spectrum of obesity and mutations in the melanocortin 4 receptor
RT   gene.";
RL   N. Engl. J. Med. 348:1085-1095(2003).
RN   [16]
RP   VARIANT OBESITY LEU-127, VARIANTS ILE-103; MET-112; THR-226 AND LEU-251,
RP   CHARACTERIZATION OF VARIANT OBESITY LEU-127, AND CHARACTERIZATION OF
RP   VARIANTS MET-112 AND THR-226.
RX   PubMed=14764818; DOI=10.1210/jc.2003-031182;
RA   Valli-Jaakola K., Lipsanen-Nyman M., Oksanen L., Hollenberg A.N.,
RA   Kontula K., Bjoerbaek C., Schalin-Jaentti C.;
RT   "Identification and characterization of melanocortin-4 receptor gene
RT   mutations in morbidly obese Finnish children and adults.";
RL   J. Clin. Endocrinol. Metab. 89:940-945(2004).
RN   [17]
RP   VARIANTS OBESITY TYR-36; THR-102; GLN-165; THR-175; ASP-181; VAL-219 AND
RP   PHE-325, VARIANTS ILE-103; MET-112 AND LEU-251, AND CHARACTERIZATION OF
RP   VARIANTS OBESITY TYR-36; THR-102; GLN-165; ASP-181; VAL-219 AND PHE-325.
RX   PubMed=15486053; DOI=10.1210/jc.2004-0497;
RA   Larsen L.H., Echwald S.M., Soerensen T.I.A., Andersen T., Wulff B.S.,
RA   Pedersen O.;
RT   "Prevalence of mutations and functional analyses of melanocortin 4 receptor
RT   variants identified among 750 men with juvenile-onset obesity.";
RL   J. Clin. Endocrinol. Metab. 90:219-224(2005).
RN   [18]
RP   VARIANT OBESITY LYS-72, CHARACTERIZATION OF VARIANT OBESITY LYS-72,
RP   INVOLVEMENT IN EARLY ONSET OBESITY AND HYPERPHAGIA, FUNCTION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=25163632; DOI=10.1007/s11033-014-3691-7;
RA   Delhanty P.J., Bouw E., Huisman M., Vervenne R.M., Themmen A.P.,
RA   van der Lely A.J., van den Akker E.L.;
RT   "Functional characterization of a new human melanocortin-4 receptor
RT   homozygous mutation (N72K) that is associated with early-onset obesity.";
RL   Mol. Biol. Rep. 41:7967-7972(2014).
RN   [19]
RP   POLYMORPHISM, AND CHARACTERIZATION OF VARIANT ILE-103.
RX   PubMed=31002796; DOI=10.1016/j.cell.2019.03.044;
RA   Lotta L.A., Mokrosinski J., Mendes de Oliveira E., Li C., Sharp S.J.,
RA   Luan J., Brouwers B., Ayinampudi V., Bowker N., Kerrison N., Kaimakis V.,
RA   Hoult D., Stewart I.D., Wheeler E., Day F.R., Perry J.R.B., Langenberg C.,
RA   Wareham N.J., Farooqi I.S.;
RT   "Human gain-of-function MC4R variants show signaling bias and protect
RT   against obesity.";
RL   Cell 177:597-607(2019).
CC   -!- FUNCTION: Receptor specific to the heptapeptide core common to
CC       adrenocorticotropic hormone and alpha-, beta-, and gamma-MSH. Plays a
CC       central role in energy homeostasis and somatic growth. This receptor is
CC       mediated by G proteins that stimulate adenylate cyclase (cAMP).
CC       {ECO:0000269|PubMed:12646665, ECO:0000269|PubMed:25163632}.
CC   -!- SUBUNIT: Interacts with ATRNL1 (By similarity). Homodimer; disulfide-
CC       linked, also forms higher order oligomers. Interacts with MGRN1, but
CC       does not undergo MGRN1-mediated ubiquitination; this interaction
CC       competes with GNAS-binding and thus inhibits agonist-induced cAMP
CC       production. Interacts with MRAP and MRAP2; these associated factors
CC       increase ligand-sensitivity and generation of cAMP. {ECO:0000250,
CC       ECO:0000269|PubMed:19329486, ECO:0000269|PubMed:19737927,
CC       ECO:0000269|PubMed:23088915}.
CC   -!- INTERACTION:
CC       P32245; Q8TCY5: MRAP; NbExp=2; IntAct=EBI-3910694, EBI-9538727;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:25163632};
CC       Multi-pass membrane protein {ECO:0000255}.
CC   -!- TISSUE SPECIFICITY: Brain, placental, and gut tissues.
CC   -!- POLYMORPHISM: Genetic variations in MC4R define the body mass index
CC       quantitative trait locus 20 (BMIQ20) [MIM:618406]. MC4R loss-of-
CC       function variants are associated with higher body mass index, obesity,
CC       type 2 diabetes, and coronary artery disease. Gain-of-function variants
CC       have been reported to be associated with lower body mass index and
CC       resistance to obesity. {ECO:0000269|PubMed:31002796}.
CC   -!- DISEASE: Obesity (OBESITY) [MIM:601665]: A condition characterized by
CC       an increase of body weight beyond the limitation of skeletal and
CC       physical requirements, as the result of excessive accumulation of body
CC       fat. {ECO:0000269|PubMed:10199800, ECO:0000269|PubMed:11443223,
CC       ECO:0000269|PubMed:11487744, ECO:0000269|PubMed:12588803,
CC       ECO:0000269|PubMed:12646665, ECO:0000269|PubMed:14671178,
CC       ECO:0000269|PubMed:14764818, ECO:0000269|PubMed:15486053,
CC       ECO:0000269|PubMed:25163632}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Melanocortin receptor entry;
CC       URL="https://en.wikipedia.org/wiki/Melanocortin_receptor";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L08603; AAA35791.1; -; Genomic_DNA.
DR   EMBL; S77415; AAB33341.1; -; Genomic_DNA.
DR   EMBL; AY236539; AAO92061.1; -; Genomic_DNA.
DR   EMBL; AK314130; BAG36820.1; -; mRNA.
DR   EMBL; CH471096; EAW63105.1; -; Genomic_DNA.
DR   EMBL; BC069172; AAH69172.1; -; mRNA.
DR   EMBL; BC101802; AAI01803.1; -; mRNA.
DR   EMBL; BC111992; AAI11993.1; -; mRNA.
DR   CCDS; CCDS11976.1; -.
DR   PIR; A57055; A57055.
DR   RefSeq; NP_005903.2; NM_005912.2.
DR   PDB; 2IQP; Model; -; A=29-321.
DR   PDB; 2IQR; Model; -; A=28-321.
DR   PDB; 2IQS; Model; -; A=28-321.
DR   PDB; 2IQU; Model; -; A=28-321.
DR   PDB; 2IQV; Model; -; A=40-321.
DR   PDB; 2IQW; Model; -; A=40-321.
DR   PDB; 6W25; X-ray; 2.75 A; A=16-222, A=236-320.
DR   PDBsum; 2IQP; -.
DR   PDBsum; 2IQR; -.
DR   PDBsum; 2IQS; -.
DR   PDBsum; 2IQU; -.
DR   PDBsum; 2IQV; -.
DR   PDBsum; 2IQW; -.
DR   PDBsum; 6W25; -.
DR   SMR; P32245; -.
DR   BioGRID; 110330; 7.
DR   DIP; DIP-48791N; -.
DR   IntAct; P32245; 14.
DR   MINT; P32245; -.
DR   STRING; 9606.ENSP00000299766; -.
DR   BindingDB; P32245; -.
DR   ChEMBL; CHEMBL259; -.
DR   DrugBank; DB11653; Bremelanotide.
DR   DrugCentral; P32245; -.
DR   GuidetoPHARMACOLOGY; 285; -.
DR   TCDB; 9.A.14.2.3; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; P32245; 3 sites.
DR   iPTMnet; P32245; -.
DR   PhosphoSitePlus; P32245; -.
DR   BioMuta; MC4R; -.
DR   DMDM; 60392672; -.
DR   PaxDb; P32245; -.
DR   PeptideAtlas; P32245; -.
DR   PRIDE; P32245; -.
DR   ProteomicsDB; 54853; -.
DR   ABCD; P32245; 7 sequenced antibodies.
DR   Antibodypedia; 2947; 342 antibodies.
DR   Ensembl; ENST00000299766; ENSP00000299766; ENSG00000166603.
DR   GeneID; 4160; -.
DR   KEGG; hsa:4160; -.
DR   UCSC; uc002lie.2; human.
DR   CTD; 4160; -.
DR   DisGeNET; 4160; -.
DR   EuPathDB; HostDB:ENSG00000166603.4; -.
DR   GeneCards; MC4R; -.
DR   HGNC; HGNC:6932; MC4R.
DR   HPA; ENSG00000166603; Tissue enhanced (brain, fallopian tube).
DR   MalaCards; MC4R; -.
DR   MIM; 155541; gene.
DR   MIM; 601665; phenotype.
DR   neXtProt; NX_P32245; -.
DR   OpenTargets; ENSG00000166603; -.
DR   Orphanet; 71529; Obesity due to melanocortin 4 receptor deficiency.
DR   PharmGKB; PA30676; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00960000186617; -.
DR   HOGENOM; CLU_009579_13_0_1; -.
DR   InParanoid; P32245; -.
DR   KO; K04202; -.
DR   OMA; YCTCFMS; -.
DR   OrthoDB; 869396at2759; -.
DR   PhylomeDB; P32245; -.
DR   TreeFam; TF332646; -.
DR   PathwayCommons; P32245; -.
DR   Reactome; R-HSA-375276; Peptide ligand-binding receptors.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-9660821; ADORA2B mediated anti-inflammatory cytokines production.
DR   SIGNOR; P32245; -.
DR   BioGRID-ORCS; 4160; 2 hits in 865 CRISPR screens.
DR   GeneWiki; Melanocortin_4_receptor; -.
DR   GenomeRNAi; 4160; -.
DR   Pharos; P32245; Tchem.
DR   PRO; PR:P32245; -.
DR   Proteomes; UP000005640; Chromosome 18.
DR   RNAct; P32245; protein.
DR   Bgee; ENSG00000166603; Expressed in caudate nucleus and 52 other tissues.
DR   Genevisible; P32245; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0016021; C:integral component of membrane; TAS:ProtInc.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0004977; F:melanocortin receptor activity; TAS:ProtInc.
DR   GO; GO:0004980; F:melanocyte-stimulating hormone receptor activity; IDA:UniProtKB.
DR   GO; GO:0042923; F:neuropeptide binding; IMP:UniProtKB.
DR   GO; GO:0017046; F:peptide hormone binding; IEA:Ensembl.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0007188; P:adenylate cyclase-modulating G protein-coupled receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0002024; P:diet induced thermogenesis; IEA:Ensembl.
DR   GO; GO:0006112; P:energy reserve metabolic process; IEA:Ensembl.
DR   GO; GO:0007631; P:feeding behavior; TAS:ProtInc.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0030073; P:insulin secretion; IEA:Ensembl.
DR   GO; GO:2000252; P:negative regulation of feeding behavior; IEA:Ensembl.
DR   GO; GO:0045780; P:positive regulation of bone resorption; IMP:HGNC-UCL.
DR   GO; GO:2000821; P:regulation of grooming behavior; IEA:Ensembl.
DR   GO; GO:0019222; P:regulation of metabolic process; IBA:GO_Central.
DR   GO; GO:0032868; P:response to insulin; IEA:Ensembl.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR000155; Mcort_rcpt_4.
DR   InterPro; IPR001908; Melancort_rcpt.
DR   InterPro; IPR001671; Melcrt_ACTH_rcpt.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00534; MCRFAMILY.
DR   PRINTS; PR00535; MELNOCORTINR.
DR   PRINTS; PR01062; MELNOCORTN4R.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disease mutation; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane; Obesity;
KW   Palmitate; Polymorphism; Receptor; Reference proteome; Transducer;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..332
FT                   /note="Melanocortin receptor 4"
FT                   /id="PRO_0000069722"
FT   TOPO_DOM        1..43
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        44..69
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        70..81
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        82..106
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        107..123
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        124..145
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        146..165
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        166..186
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        187..191
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        192..215
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        216..248
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        249..271
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        272..280
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        281..304
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        305..332
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   LIPID           318
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        3
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        17
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        26
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        84
FT                   /note="Interchain"
FT   VARIANT         11
FT                   /note="T -> A (in obesity; partial activity;
FT                   dbSNP:rs372794914)"
FT                   /evidence="ECO:0000269|PubMed:12646665"
FT                   /id="VAR_038632"
FT   VARIANT         30
FT                   /note="S -> F (in obesity; dbSNP:rs13447323)"
FT                   /evidence="ECO:0000269|PubMed:10199800"
FT                   /id="VAR_010704"
FT   VARIANT         36
FT                   /note="S -> Y (in obesity; shows the same affinity as the
FT                   wild-type but significant impairment of cAMP-induced
FT                   activity in response to melanotan II compared with the
FT                   wild-type receptor)"
FT                   /evidence="ECO:0000269|PubMed:15486053"
FT                   /id="VAR_038633"
FT   VARIANT         37
FT                   /note="D -> V (in obesity; dbSNP:rs13447325)"
FT                   /evidence="ECO:0000269|PubMed:10199800"
FT                   /id="VAR_010705"
FT   VARIANT         50
FT                   /note="V -> M (in obesity; dbSNP:rs121913557)"
FT                   /evidence="ECO:0000269|PubMed:11487744"
FT                   /id="VAR_038634"
FT   VARIANT         58
FT                   /note="S -> C (in obesity; dbSNP:rs121913558)"
FT                   /evidence="ECO:0000269|PubMed:11487744"
FT                   /id="VAR_038635"
FT   VARIANT         62
FT                   /note="N -> S (in obesity; shows a partial cAMP response to
FT                   alpha-MSH; dbSNP:rs121913566)"
FT                   /evidence="ECO:0000269|PubMed:12588803,
FT                   ECO:0000269|PubMed:12646665"
FT                   /id="VAR_038636"
FT   VARIANT         72
FT                   /note="N -> K (in obesity; loss of plasma membrane
FT                   localization; loss of receptor function)"
FT                   /evidence="ECO:0000269|PubMed:25163632"
FT                   /id="VAR_077570"
FT   VARIANT         78
FT                   /note="P -> L (in obesity; dbSNP:rs13447326)"
FT                   /evidence="ECO:0000269|PubMed:10199800"
FT                   /id="VAR_010706"
FT   VARIANT         88..92
FT                   /note="Missing (in obesity; the mutant receptor is
FT                   expressed well on the cell surface but is completely devoid
FT                   of ligand binding and cAMP generation in response to
FT                   agonist stimulation)"
FT                   /evidence="ECO:0000269|PubMed:14671178"
FT                   /id="VAR_038637"
FT   VARIANT         97
FT                   /note="N -> D (in obesity; completely unable to generate
FT                   cAMP in response to ligand; shows evidence of impaired cell
FT                   surface expression; dbSNP:rs121913565)"
FT                   /evidence="ECO:0000269|PubMed:12588803,
FT                   ECO:0000269|PubMed:12646665"
FT                   /id="VAR_038638"
FT   VARIANT         102
FT                   /note="I -> S (in obesity; shows the same affinity as the
FT                   wild-type but significant impairment of cAMP-induced
FT                   activity in response to melanotan II compared with the
FT                   wild-type receptor; dbSNP:rs121913559)"
FT                   /evidence="ECO:0000269|PubMed:11487744"
FT                   /id="VAR_038639"
FT   VARIANT         102
FT                   /note="I -> T (in obesity; dbSNP:rs121913559)"
FT                   /evidence="ECO:0000269|PubMed:15486053"
FT                   /id="VAR_038640"
FT   VARIANT         103
FT                   /note="V -> I (common variant associated with lower body
FT                   mass index and obesity risk; also associated with lower
FT                   risk for type 2 diabetes and coronary artery disease;
FT                   increased MC4R signaling; increased surface expression;
FT                   dbSNP:rs2229616)"
FT                   /evidence="ECO:0000269|PubMed:11487744,
FT                   ECO:0000269|PubMed:12646665, ECO:0000269|PubMed:14764818,
FT                   ECO:0000269|PubMed:15486053, ECO:0000269|PubMed:31002796,
FT                   ECO:0000269|PubMed:7854347, ECO:0000269|PubMed:8392067"
FT                   /id="VAR_010707"
FT   VARIANT         106
FT                   /note="L -> P (in obesity; decreased MC4R signaling; shows
FT                   evidence of impaired cell surface expression)"
FT                   /evidence="ECO:0000269|PubMed:12588803"
FT                   /id="VAR_038641"
FT   VARIANT         112
FT                   /note="T -> M (polymorphism; no effect on MC4R signaling;
FT                   dbSNP:rs13447329)"
FT                   /evidence="ECO:0000269|PubMed:10199800,
FT                   ECO:0000269|PubMed:12646665, ECO:0000269|PubMed:14764818,
FT                   ECO:0000269|PubMed:15486053"
FT                   /id="VAR_010708"
FT   VARIANT         125
FT                   /note="I -> K (in obesity; completely unable to generate
FT                   cAMP in response to ligand; shows evidence of impaired cell
FT                   surface expression)"
FT                   /evidence="ECO:0000269|PubMed:12588803,
FT                   ECO:0000269|PubMed:12646665"
FT                   /id="VAR_038642"
FT   VARIANT         127
FT                   /note="S -> L (in obesity; signaling properties in response
FT                   to alpha-MSH, beta-MSH and gamma-1-MSH are impaired;
FT                   dbSNP:rs13447331)"
FT                   /evidence="ECO:0000269|PubMed:14764818"
FT                   /id="VAR_038643"
FT   VARIANT         165
FT                   /note="R -> Q (in obesity; shows a partial cAMP response to
FT                   alpha-MSH; dbSNP:rs13447332)"
FT                   /evidence="ECO:0000269|PubMed:12588803,
FT                   ECO:0000269|PubMed:12646665, ECO:0000269|PubMed:15486053"
FT                   /id="VAR_038644"
FT   VARIANT         165
FT                   /note="R -> W (in obesity; dbSNP:rs13447332)"
FT                   /evidence="ECO:0000269|PubMed:10199800"
FT                   /id="VAR_010709"
FT   VARIANT         170
FT                   /note="I -> V (in obesity; dbSNP:rs121913560)"
FT                   /evidence="ECO:0000269|PubMed:11487744"
FT                   /id="VAR_038645"
FT   VARIANT         175
FT                   /note="A -> T (in obesity; shows a partial cAMP response to
FT                   alpha-MSH; dbSNP:rs121913563)"
FT                   /evidence="ECO:0000269|PubMed:12588803,
FT                   ECO:0000269|PubMed:12646665, ECO:0000269|PubMed:15486053"
FT                   /id="VAR_038646"
FT   VARIANT         181
FT                   /note="G -> D (in obesity; does not bind alpha-MSH;
FT                   dbSNP:rs13447333)"
FT                   /evidence="ECO:0000269|PubMed:15486053"
FT                   /id="VAR_038647"
FT   VARIANT         219
FT                   /note="A -> V (in obesity; shows significantly impairment
FT                   of cAMP-induced activity in response to melanotan II
FT                   compared with the wild-type receptor; dbSNP:rs121913567)"
FT                   /evidence="ECO:0000269|PubMed:15486053"
FT                   /id="VAR_038648"
FT   VARIANT         226
FT                   /note="I -> T (in dbSNP:rs193922686)"
FT                   /evidence="ECO:0000269|PubMed:14764818"
FT                   /id="VAR_038649"
FT   VARIANT         251
FT                   /note="I -> L (in dbSNP:rs52820871)"
FT                   /evidence="ECO:0000269|PubMed:10199800,
FT                   ECO:0000269|PubMed:11487744, ECO:0000269|PubMed:12646665,
FT                   ECO:0000269|PubMed:14764818, ECO:0000269|PubMed:15486053"
FT                   /id="VAR_010710"
FT   VARIANT         252
FT                   /note="G -> S (in obesity; dbSNP:rs13447336)"
FT                   /evidence="ECO:0000269|PubMed:10199800"
FT                   /id="VAR_010711"
FT   VARIANT         253
FT                   /note="V -> I (in obesity; shows a partial cAMP response to
FT                   alpha-MSH; dbSNP:rs187152753)"
FT                   /evidence="ECO:0000269|PubMed:12588803"
FT                   /id="VAR_038650"
FT   VARIANT         271
FT                   /note="C -> R (in obesity; completely unable to generate
FT                   cAMP in response to ligand; shows impaired cell surface
FT                   expression; dbSNP:rs1057517991)"
FT                   /evidence="ECO:0000269|PubMed:12646665"
FT                   /id="VAR_038651"
FT   VARIANT         271
FT                   /note="C -> Y (in obesity; no activity; dbSNP:rs121913562)"
FT                   /evidence="ECO:0000269|PubMed:12588803,
FT                   ECO:0000269|PubMed:12646665"
FT                   /id="VAR_038652"
FT   VARIANT         274
FT                   /note="N -> S (in obesity; dbSNP:rs121913561)"
FT                   /evidence="ECO:0000269|PubMed:11443223"
FT                   /id="VAR_015357"
FT   VARIANT         316
FT                   /note="I -> S (in obesity; shows reduced cAMP response to
FT                   alpha-MSH; retains normal affinity for the antagonist AGRP;
FT                   dbSNP:rs121913564)"
FT                   /evidence="ECO:0000269|PubMed:12588803,
FT                   ECO:0000269|PubMed:12646665"
FT                   /id="VAR_038653"
FT   VARIANT         317
FT                   /note="I -> T (in obesity; dbSNP:rs13447337)"
FT                   /evidence="ECO:0000269|PubMed:10199800"
FT                   /id="VAR_010712"
FT   VARIANT         325
FT                   /note="L -> F (in obesity; does not bind alpha-MSH)"
FT                   /evidence="ECO:0000269|PubMed:15486053"
FT                   /id="VAR_038654"
FT   CONFLICT        169
FT                   /note="I -> S (in Ref. 2; AAB33341)"
FT                   /evidence="ECO:0000305"
FT   HELIX           48..71
FT                   /evidence="ECO:0000244|PDB:6W25"
FT   HELIX           73..75
FT                   /evidence="ECO:0000244|PDB:6W25"
FT   HELIX           78..109
FT                   /evidence="ECO:0000244|PDB:6W25"
FT   HELIX           116..152
FT                   /evidence="ECO:0000244|PDB:6W25"
FT   HELIX           154..160
FT                   /evidence="ECO:0000244|PDB:6W25"
FT   HELIX           163..186
FT                   /evidence="ECO:0000244|PDB:6W25"
FT   TURN            187..189
FT                   /evidence="ECO:0000244|PDB:6W25"
FT   HELIX           191..215
FT                   /evidence="ECO:0000244|PDB:6W25"
FT   HELIX           219..222
FT                   /evidence="ECO:0000244|PDB:6W25"
FT   HELIX           239..270
FT                   /evidence="ECO:0000244|PDB:6W25"
FT   HELIX           275..281
FT                   /evidence="ECO:0000244|PDB:6W25"
FT   HELIX           284..305
FT                   /evidence="ECO:0000244|PDB:6W25"
FT   HELIX           307..320
FT                   /evidence="ECO:0000244|PDB:6W25"
SQ   SEQUENCE   332 AA;  36943 MW;  E80010BAADBED2B4 CRC64;
     MVNSTHRGMH TSLHLWNRSS YRLHSNASES LGKGYSDGGC YEQLFVSPEV FVTLGVISLL
     ENILVIVAIA KNKNLHSPMY FFICSLAVAD MLVSVSNGSE TIVITLLNST DTDAQSFTVN
     IDNVIDSVIC SSLLASICSL LSIAVDRYFT IFYALQYHNI MTVKRVGIII SCIWAACTVS
     GILFIIYSDS SAVIICLITM FFTMLALMAS LYVHMFLMAR LHIKRIAVLP GTGAIRQGAN
     MKGAITLTIL IGVFVVCWAP FFLHLIFYIS CPQNPYCVCF MSHFNLYLIL IMCNSIIDPL
     IYALRSQELR KTFKEIICCY PLGGLCDLSS RY
//
ID   DRD1_HUMAN              Reviewed;         446 AA.
AC   P21728; B2RA44; Q4QRJ0;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1991, sequence version 1.
DT   07-OCT-2020, entry version 207.
DE   RecName: Full=D(1A) dopamine receptor;
DE   AltName: Full=Dopamine D1 receptor;
GN   Name=DRD1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND TISSUE SPECIFICITY.
RX   PubMed=2144334; DOI=10.1038/347072a0;
RA   Dearry A., Gingrich J.A., Falardeau P., Fremeau R.T. Jr., Bates M.D.,
RA   Caron M.G.;
RT   "Molecular cloning and expression of the gene for a human D1 dopamine
RT   receptor.";
RL   Nature 347:72-76(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2168520; DOI=10.1038/347076a0;
RA   Zhou Q.-Y., Grandy D.K., Thambi L., Kushner J.A., van Tol H.H.M., Cone R.,
RA   Pribnow D., Salon J., Bunzow J.R., Civelli O.;
RT   "Cloning and expression of human and rat D1 dopamine receptors.";
RL   Nature 347:76-80(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1975640; DOI=10.1038/347080a0;
RA   Sunahara R.K., Niznik H.B., Weiner D.M., Stormann T.M., Brann M.R.,
RA   Kennedy J.L., Gelernter J.E., Rozmahel R., Yang Y., Israel Y., Seeman P.,
RA   O'Dowd B.F.;
RT   "Human dopamine D1 receptor encoded by an intronless gene on chromosome
RT   5.";
RL   Nature 347:80-83(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Brain;
RX   PubMed=8471124; DOI=10.1038/npp.1993.14;
RA   Ohara K., Ulpian C., Seeman P., Sunahara R.K., van Tol H.H.M., Niznik H.B.;
RT   "Schizophrenia: dopamine D1 receptor sequence is normal, but has DNA
RT   polymorphisms.";
RL   Neuropsychopharmacology 8:131-135(1993).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Suwa M., Sato T., Okouchi I., Arita M., Futami K., Matsumoto S.,
RA   Tsutsumi S., Aburatani H., Asai K., Akiyama Y.;
RT   "Genome-wide discovery and analysis of human seven transmembrane helix
RT   receptor genes.";
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   PALMITOYLATION AT CYS-347 AND CYS-351.
RX   PubMed=10618483; DOI=10.1016/s0014-2999(99)00727-x;
RA   Jin H., Xie Z., George S.R., O'Dowd B.F.;
RT   "Palmitoylation occurs at cysteine 347 and cysteine 351 of the dopamine
RT   D(1) receptor.";
RL   Eur. J. Pharmacol. 386:305-312(1999).
RN   [11]
RP   VARIANTS ARG-81 AND TYR-259.
RX   PubMed=21179162; DOI=10.1038/nature09629;
RA   Bevilacqua L., Doly S., Kaprio J., Yuan Q., Tikkanen R., Paunio T.,
RA   Zhou Z., Wedenoja J., Maroteaux L., Diaz S., Belmer A., Hodgkinson C.A.,
RA   Dell'osso L., Suvisaari J., Coccaro E., Rose R.J., Peltonen L.,
RA   Virkkunen M., Goldman D.;
RT   "A population-specific HTR2B stop codon predisposes to severe
RT   impulsivity.";
RL   Nature 468:1061-1066(2010).
CC   -!- FUNCTION: Dopamine receptor whose activity is mediated by G proteins
CC       which activate adenylyl cyclase.
CC   -!- SUBUNIT: Interacts with DNAJC14 via its C-terminus (By similarity).
CC       Interacts with DRD2 (By similarity). {ECO:0000250|UniProtKB:P18901,
CC       ECO:0000250|UniProtKB:Q61616}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:P18901};
CC       Multi-pass membrane protein {ECO:0000250|UniProtKB:P18901}. Endoplasmic
CC       reticulum membrane {ECO:0000250|UniProtKB:P18901}; Multi-pass membrane
CC       protein {ECO:0000250|UniProtKB:P18901}. Cell projection, dendrite
CC       {ECO:0000250|UniProtKB:Q61616}. Cell projection, dendritic spine
CC       {ECO:0000250|UniProtKB:Q61616}. Note=Transport from the endoplasmic
CC       reticulum to the cell surface is regulated by interaction with DNAJC14.
CC       {ECO:0000250|UniProtKB:P18901}.
CC   -!- TISSUE SPECIFICITY: Detected in caudate, nucleus accumbens and in the
CC       olfactory tubercle. {ECO:0000269|PubMed:2144334}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X55760; CAA39286.1; -; Genomic_DNA.
DR   EMBL; X58987; CAA41734.1; -; mRNA.
DR   EMBL; X55758; CAA39284.1; -; Genomic_DNA.
DR   EMBL; S58541; AAB26273.1; -; Genomic_DNA.
DR   EMBL; AB065677; BAC05902.1; -; Genomic_DNA.
DR   EMBL; AF498961; AAM18131.1; -; mRNA.
DR   EMBL; AK314031; BAG36741.1; -; mRNA.
DR   EMBL; CH471062; EAW61377.1; -; Genomic_DNA.
DR   EMBL; BC074978; AAH74978.1; -; mRNA.
DR   EMBL; BC074979; AAH74979.1; -; mRNA.
DR   EMBL; BC096837; AAH96837.1; -; mRNA.
DR   CCDS; CCDS4393.1; -.
DR   PIR; S11377; DYHUD1.
DR   RefSeq; NP_000785.1; NM_000794.3.
DR   PDB; 1OZ5; Model; -; A=1-446.
DR   PDBsum; 1OZ5; -.
DR   SMR; P21728; -.
DR   BioGRID; 108146; 12.
DR   IntAct; P21728; 2.
DR   STRING; 9606.ENSP00000377353; -.
DR   BindingDB; P21728; -.
DR   ChEMBL; CHEMBL2056; -.
DR   DrugBank; DB01614; Acepromazine.
DR   DrugBank; DB01063; Acetophenazine.
DR   DrugBank; DB00543; Amoxapine.
DR   DrugBank; DB00714; Apomorphine.
DR   DrugBank; DB01238; Aripiprazole.
DR   DrugBank; DB14185; Aripiprazole lauroxil.
DR   DrugBank; DB06216; Asenapine.
DR   DrugBank; DB01200; Bromocriptine.
DR   DrugBank; DB00248; Cabergoline.
DR   DrugBank; DB01038; Carphenazine.
DR   DrugBank; DB00477; Chlorpromazine.
DR   DrugBank; DB01239; Chlorprothixene.
DR   DrugBank; DB00568; Cinnarizine.
DR   DrugBank; DB00363; Clozapine.
DR   DrugBank; DB12890; Dihydrexidine.
DR   DrugBank; DB11274; Dihydro-alpha-ergocryptine.
DR   DrugBank; DB13345; Dihydroergocristine.
DR   DrugBank; DB00988; Dopamine.
DR   DrugBank; DB11275; Epicriptine.
DR   DrugBank; DB01049; Ergoloid mesylate.
DR   DrugBank; DB00696; Ergotamine.
DR   DrugBank; DB00800; Fenoldopam.
DR   DrugBank; DB00875; Flupentixol.
DR   DrugBank; DB00623; Fluphenazine.
DR   DrugBank; DB00502; Haloperidol.
DR   DrugBank; DB04946; Iloperidone.
DR   DrugBank; DB00458; Imipramine.
DR   DrugBank; DB00555; Lamotrigine.
DR   DrugBank; DB01235; Levodopa.
DR   DrugBank; DB00589; Lisuride.
DR   DrugBank; DB00408; Loxapine.
DR   DrugBank; DB06077; Lumateperone.
DR   DrugBank; DB01403; Methotrimeprazine.
DR   DrugBank; DB00353; Methylergometrine.
DR   DrugBank; DB06148; Mianserin.
DR   DrugBank; DB00805; Minaprine.
DR   DrugBank; DB00334; Olanzapine.
DR   DrugBank; DB01267; Paliperidone.
DR   DrugBank; DB00715; Paroxetine.
DR   DrugBank; DB01186; Pergolide.
DR   DrugBank; DB01608; Periciazine.
DR   DrugBank; DB00850; Perphenazine.
DR   DrugBank; DB00397; Phenylpropanolamine.
DR   DrugBank; DB09286; Pipamperone.
DR   DrugBank; DB01621; Pipotiazine.
DR   DrugBank; DB11584; Pipradrol.
DR   DrugBank; DB00420; Promazine.
DR   DrugBank; DB00777; Propiomazine.
DR   DrugBank; DB01224; Quetiapine.
DR   DrugBank; DB09097; Quinagolide.
DR   DrugBank; DB00734; Risperidone.
DR   DrugBank; DB05271; Rotigotine.
DR   DrugBank; DB12093; Tetrahydropalmatine.
DR   DrugBank; DB00372; Thiethylperazine.
DR   DrugBank; DB01622; Thioproperazine.
DR   DrugBank; DB00679; Thioridazine.
DR   DrugBank; DB01623; Thiothixene.
DR   DrugBank; DB00508; Triflupromazine.
DR   DrugBank; DB00726; Trimipramine.
DR   DrugBank; DB00246; Ziprasidone.
DR   DrugBank; DB09225; Zotepine.
DR   DrugBank; DB01624; Zuclopenthixol.
DR   DrugCentral; P21728; -.
DR   GuidetoPHARMACOLOGY; 214; -.
DR   GlyGen; P21728; 1 site.
DR   iPTMnet; P21728; -.
DR   PhosphoSitePlus; P21728; -.
DR   SwissPalm; P21728; -.
DR   BioMuta; DRD1; -.
DR   DMDM; 118228; -.
DR   PaxDb; P21728; -.
DR   PeptideAtlas; P21728; -.
DR   PRIDE; P21728; -.
DR   ProteomicsDB; 53892; -.
DR   Antibodypedia; 2811; 639 antibodies.
DR   DNASU; 1812; -.
DR   Ensembl; ENST00000393752; ENSP00000377353; ENSG00000184845.
DR   GeneID; 1812; -.
DR   KEGG; hsa:1812; -.
DR   UCSC; uc003mcz.4; human.
DR   CTD; 1812; -.
DR   DisGeNET; 1812; -.
DR   EuPathDB; HostDB:ENSG00000184845.3; -.
DR   GeneCards; DRD1; -.
DR   HGNC; HGNC:3020; DRD1.
DR   HPA; ENSG00000184845; Tissue enriched (brain).
DR   MIM; 126449; gene.
DR   neXtProt; NX_P21728; -.
DR   OpenTargets; ENSG00000184845; -.
DR   PharmGKB; PA147; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00940000155857; -.
DR   HOGENOM; CLU_009579_11_0_1; -.
DR   InParanoid; P21728; -.
DR   KO; K04144; -.
DR   OMA; SLNRMYA; -.
DR   OrthoDB; 1045889at2759; -.
DR   PhylomeDB; P21728; -.
DR   TreeFam; TF325181; -.
DR   PathwayCommons; P21728; -.
DR   Reactome; R-HSA-390651; Dopamine receptors.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-9660821; ADORA2B mediated anti-inflammatory cytokines production.
DR   SIGNOR; P21728; -.
DR   BioGRID-ORCS; 1812; 2 hits in 874 CRISPR screens.
DR   GeneWiki; Dopamine_receptor_D1; -.
DR   GenomeRNAi; 1812; -.
DR   Pharos; P21728; Tclin.
DR   PRO; PR:P21728; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; P21728; protein.
DR   Bgee; ENSG00000184845; Expressed in caudate nucleus and 95 other tissues.
DR   Genevisible; P21728; HS.
DR   GO; GO:0060170; C:ciliary membrane; IDA:SYSCILIA_CCNET.
DR   GO; GO:0005929; C:cilium; IDA:MGI.
DR   GO; GO:0043197; C:dendritic spine; ISS:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0097730; C:non-motile cilium; IDA:SYSCILIA_CCNET.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0035240; F:dopamine binding; IMP:BHF-UCL.
DR   GO; GO:0004952; F:dopamine neurotransmitter receptor activity; IDA:MGI.
DR   GO; GO:0001588; F:dopamine neurotransmitter receptor activity, coupled via Gs; IDA:BHF-UCL.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0007190; P:activation of adenylate cyclase activity; IDA:BHF-UCL.
DR   GO; GO:0071880; P:adenylate cyclase-activating adrenergic receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007191; P:adenylate cyclase-activating dopamine receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007188; P:adenylate cyclase-modulating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007628; P:adult walking behavior; ISS:BHF-UCL.
DR   GO; GO:0014002; P:astrocyte development; IEA:Ensembl.
DR   GO; GO:0001662; P:behavioral fear response; IEA:Ensembl.
DR   GO; GO:0048148; P:behavioral response to cocaine; IEA:Ensembl.
DR   GO; GO:0071870; P:cellular response to catecholamine stimulus; IDA:BHF-UCL.
DR   GO; GO:1903351; P:cellular response to dopamine; IMP:CAFA.
DR   GO; GO:0021853; P:cerebral cortex GABAergic interneuron migration; ISS:BHF-UCL.
DR   GO; GO:0001661; P:conditioned taste aversion; IEA:Ensembl.
DR   GO; GO:0021542; P:dentate gyrus development; IEA:Ensembl.
DR   GO; GO:0042417; P:dopamine metabolic process; IC:BHF-UCL.
DR   GO; GO:0007212; P:dopamine receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0015872; P:dopamine transport; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007187; P:G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; IDA:BHF-UCL.
DR   GO; GO:0046323; P:glucose import; IEA:Ensembl.
DR   GO; GO:0007625; P:grooming behavior; IEA:Ensembl.
DR   GO; GO:0046959; P:habituation; IEA:Ensembl.
DR   GO; GO:0043987; P:histone H3-S10 phosphorylation; IEA:Ensembl.
DR   GO; GO:0060292; P:long-term synaptic depression; IEA:Ensembl.
DR   GO; GO:0060291; P:long-term synaptic potentiation; IEA:Ensembl.
DR   GO; GO:0042711; P:maternal behavior; IEA:Ensembl.
DR   GO; GO:0007617; P:mating behavior; ISS:BHF-UCL.
DR   GO; GO:0007613; P:memory; IEA:Ensembl.
DR   GO; GO:0019228; P:neuronal action potential; IEA:Ensembl.
DR   GO; GO:0035106; P:operant conditioning; IEA:Ensembl.
DR   GO; GO:0030432; P:peristalsis; IEA:Ensembl.
DR   GO; GO:0060158; P:phospholipase C-activating dopamine receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; ISS:BHF-UCL.
DR   GO; GO:0051482; P:positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:CAFA.
DR   GO; GO:0043268; P:positive regulation of potassium ion transport; ISS:BHF-UCL.
DR   GO; GO:0051281; P:positive regulation of release of sequestered calcium ion into cytosol; IDA:BHF-UCL.
DR   GO; GO:0051968; P:positive regulation of synaptic transmission, glutamatergic; ISS:BHF-UCL.
DR   GO; GO:0060134; P:prepulse inhibition; ISS:BHF-UCL.
DR   GO; GO:0006606; P:protein import into nucleus; IEA:Ensembl.
DR   GO; GO:0042053; P:regulation of dopamine metabolic process; IEA:Ensembl.
DR   GO; GO:0051584; P:regulation of dopamine uptake involved in synaptic transmission; IC:BHF-UCL.
DR   GO; GO:0001932; P:regulation of protein phosphorylation; IEA:Ensembl.
DR   GO; GO:2000300; P:regulation of synaptic vesicle exocytosis; IEA:Ensembl.
DR   GO; GO:0001975; P:response to amphetamine; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; ISS:BHF-UCL.
DR   GO; GO:0046960; P:sensitization; IEA:Ensembl.
DR   GO; GO:0021756; P:striatum development; IEA:Ensembl.
DR   GO; GO:0007416; P:synapse assembly; ISS:BHF-UCL.
DR   GO; GO:0001659; P:temperature homeostasis; IEA:Ensembl.
DR   GO; GO:0019226; P:transmission of nerve impulse; ISS:BHF-UCL.
DR   GO; GO:0042311; P:vasodilation; IEA:InterPro.
DR   GO; GO:0008542; P:visual learning; ISS:BHF-UCL.
DR   InterPro; IPR001413; Dopamine_D1_rcpt.
DR   InterPro; IPR000929; Dopamine_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   PANTHER; PTHR24248:SF139; PTHR24248:SF139; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00565; DOPAMINED1AR.
DR   PRINTS; PR00242; DOPAMINER.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell junction; Cell membrane; Cell projection;
KW   Disulfide bond; Endoplasmic reticulum; G-protein coupled receptor;
KW   Glycoprotein; Lipoprotein; Membrane; Palmitate; Polymorphism; Receptor;
KW   Reference proteome; Synapse; Transducer; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..446
FT                   /note="D(1A) dopamine receptor"
FT                   /id="PRO_0000069373"
FT   TOPO_DOM        1..23
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        24..49
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        50..60
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        61..87
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        88..96
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        97..119
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        120..138
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        139..163
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        164..192
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        193..218
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        219..272
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        273..299
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        300..312
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        313..337
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        338..446
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   LIPID           347
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:10618483"
FT   LIPID           351
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:10618483"
FT   CARBOHYD        5
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        96..186
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VARIANT         37
FT                   /note="T -> P (in dbSNP:rs5327)"
FT                   /id="VAR_014670"
FT   VARIANT         37
FT                   /note="T -> R (in dbSNP:rs879844008)"
FT                   /id="VAR_014671"
FT   VARIANT         50
FT                   /note="R -> S (in dbSNP:rs5330)"
FT                   /id="VAR_014672"
FT   VARIANT         81
FT                   /note="K -> R"
FT                   /evidence="ECO:0000269|PubMed:21179162"
FT                   /id="VAR_064577"
FT   VARIANT         199
FT                   /note="S -> A (in dbSNP:rs5331)"
FT                   /id="VAR_014673"
FT   VARIANT         259
FT                   /note="S -> Y (in dbSNP:rs74414188)"
FT                   /evidence="ECO:0000269|PubMed:21179162"
FT                   /id="VAR_064578"
FT   CONFLICT        438
FT                   /note="I -> M (in Ref. 2; CAA41734)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   446 AA;  49293 MW;  64E062D765D0DBA7 CRC64;
     MRTLNTSAMD GTGLVVERDF SVRILTACFL SLLILSTLLG NTLVCAAVIR FRHLRSKVTN
     FFVISLAVSD LLVAVLVMPW KAVAEIAGFW PFGSFCNIWV AFDIMCSTAS ILNLCVISVD
     RYWAISSPFR YERKMTPKAA FILISVAWTL SVLISFIPVQ LSWHKAKPTS PSDGNATSLA
     ETIDNCDSSL SRTYAISSSV ISFYIPVAIM IVTYTRIYRI AQKQIRRIAA LERAAVHAKN
     CQTTTGNGKP VECSQPESSF KMSFKRETKV LKTLSVIMGV FVCCWLPFFI LNCILPFCGS
     GETQPFCIDS NTFDVFVWFG WANSSLNPII YAFNADFRKA FSTLLGCYRL CPATNNAIET
     VSINNNGAAM FSSHHEPRGS ISKECNLVYL IPHAVGSSED LKKEEAAGIA RPLEKLSPAL
     SVILDYDTDV SLEKIQPITQ NGQHPT
//
ID   GHRHR_HUMAN             Reviewed;         423 AA.
AC   Q02643; Q99863;
DT   01-OCT-1993, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1998, sequence version 2.
DT   12-AUG-2020, entry version 183.
DE   RecName: Full=Growth hormone-releasing hormone receptor;
DE            Short=GHRH receptor;
DE   AltName: Full=Growth hormone-releasing factor receptor;
DE            Short=GRF receptor;
DE            Short=GRFR;
DE   Flags: Precursor;
GN   Name=GHRHR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Pituitary;
RX   PubMed=1333056; DOI=10.1210/mend.6.10.1333056;
RA   Mayo K.E.;
RT   "Molecular cloning and expression of a pituitary-specific receptor for
RT   growth hormone-releasing hormone.";
RL   Mol. Endocrinol. 6:1734-1744(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Pituitary;
RX   PubMed=7680413; DOI=10.1210/mend.7.1.7680413;
RA   Gaylinn B.D., Harrison J.K., Zysk J.R., Lyons C.E. Jr., Lynch K.R.,
RA   Thorner M.O.;
RT   "Molecular cloning and expression of a human anterior pituitary receptor
RT   for growth hormone-releasing hormone.";
RL   Mol. Endocrinol. 7:77-84(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Suwa M., Sato T., Okouchi I., Arita M., Futami K., Matsumoto S.,
RA   Tsutsumi S., Aburatani H., Asai K., Akiyama Y.;
RT   "Genome-wide discovery and analysis of human seven transmembrane helix
RT   receptor genes.";
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Pituitary;
RA   King M.M., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (FEB-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 37-271.
RA   Tang J., Collu R.;
RT   "The structure of the gene coding for human growth hormone releasing
RT   hormone.";
RL   Submitted (DEC-1996) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   INVOLVEMENT IN IGHD4, AND VARIANT IGHD4 72-GLU--CYS-423 DEL.
RX   PubMed=8528260; DOI=10.1038/ng0196-88;
RA   Wajnrajch M.P., Gertner J.M., Harbison M.D., Chua S.C. Jr., Leibel R.L.;
RT   "Nonsense mutation in the human growth hormone-releasing hormone receptor
RT   causes growth failure analogous to the little (lit) mouse.";
RL   Nat. Genet. 12:88-90(1996).
RN   [8]
RP   INVOLVEMENT IN IGHD4, AND VARIANT IGHD4 72-GLU--CYS-423 DEL.
RX   PubMed=9467553; DOI=10.1210/jcem.83.2.4528;
RA   Netchine I., Talon P., Dastot F., Vitaux F., Goossens M., Amselem S.;
RT   "Extensive phenotypic analysis of a family with growth hormone (GH)
RT   deficiency caused by a mutation in the GH-releasing hormone receptor
RT   gene.";
RL   J. Clin. Endocrinol. Metab. 83:432-436(1998).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 34-123, AND DISULFIDE BONDS.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of the extracellular domain of human growth hormone
RT   releasing hormone receptor.";
RL   Submitted (JUN-2010) to the PDB data bank.
RN   [10]
RP   VARIANTS IGHD4 HIS-144; GLU-222 AND CYS-242.
RX   PubMed=11232012; DOI=10.1210/jcem.86.1.7156;
RA   Salvatori R., Fan X., Phillips J.A. III, Espigares-Martin R.,
RA   Martin De Lara I., Freeman K.L., Plotnick L., Al-Ashwal A., Levine M.A.;
RT   "Three new mutations in the gene for the growth hormone (GH)-releasing
RT   hormone receptor in familial isolated GH deficiency type IB.";
RL   J. Clin. Endocrinol. Metab. 86:273-279(2001).
RN   [11]
RP   VARIANT IGHD4 GLU-329.
RX   PubMed=10084571; DOI=10.1210/jcem.84.3.5599;
RA   Salvatori R., Hayashida C.Y., Aguiar-Oliveira M.H., Phillips J.A. III,
RA   Souza A.H., Gondo R.G., Toledo S.P., Conceicao M.M., Prince M.,
RA   Maheshwari H.G., Baumann G., Levine M.A.;
RT   "Familial dwarfism due to a novel mutation of the growth hormone-releasing
RT   hormone receptor gene.";
RL   J. Clin. Endocrinol. Metab. 84:917-923(1999).
RN   [12]
RP   VARIANT IGHD4 VAL-176.
RX   PubMed=12534354; DOI=10.1530/eje.0.1480025;
RA   Carakushansky M., Whatmore A.J., Clayton P.E., Shalet S.M., Gleeson H.K.,
RA   Price D.A., Levine M.A., Salvatori R.;
RT   "A new missense mutation in the growth hormone-releasing hormone receptor
RT   gene in familial isolated GH deficiency.";
RL   Eur. J. Endocrinol. 148:25-30(2003).
RN   [13]
RP   VARIANT [LARGE SCALE ANALYSIS] THR-45.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Receptor for GRF, coupled to G proteins which activate
CC       adenylyl cyclase. Stimulates somatotroph cell growth, growth hormone
CC       gene transcription and growth hormone secretion.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Pituitary gland.
CC   -!- DISEASE: Growth hormone deficiency, isolated, 4 (IGHD4) [MIM:618157]:
CC       An autosomal recessive deficiency of growth hormone leading to early
CC       and severe growth failure and short stature. Patients have low but
CC       detectable levels of growth hormone, significantly retarded bone age,
CC       and a positive response and immunologic tolerance to growth hormone
CC       therapy. {ECO:0000269|PubMed:10084571, ECO:0000269|PubMed:11232012,
CC       ECO:0000269|PubMed:12534354, ECO:0000269|PubMed:8528260,
CC       ECO:0000269|PubMed:9467553}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 2 family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L01406; AAA35890.1; -; mRNA.
DR   EMBL; L09237; AAA58619.1; -; mRNA.
DR   EMBL; AB065701; BAC05924.1; -; Genomic_DNA.
DR   EMBL; AY557192; AAS59864.1; -; mRNA.
DR   EMBL; AC005155; AAC23789.1; -; Genomic_DNA.
DR   EMBL; U42225; AAB37758.1; -; Genomic_DNA.
DR   EMBL; U42222; AAB37758.1; JOINED; Genomic_DNA.
DR   EMBL; U42223; AAB37758.1; JOINED; Genomic_DNA.
DR   EMBL; U42224; AAB37758.1; JOINED; Genomic_DNA.
DR   CCDS; CCDS5432.1; -.
DR   PIR; A45363; A45363.
DR   RefSeq; NP_000814.2; NM_000823.3.
DR   PDB; 2XDG; X-ray; 1.95 A; A/B=34-123.
DR   PDBsum; 2XDG; -.
DR   SMR; Q02643; -.
DR   BioGRID; 108959; 2.
DR   STRING; 9606.ENSP00000320180; -.
DR   BindingDB; Q02643; -.
DR   ChEMBL; CHEMBL2032; -.
DR   DrugBank; DB00010; Sermorelin.
DR   DrugBank; DB08869; Tesamorelin.
DR   DrugCentral; Q02643; -.
DR   GuidetoPHARMACOLOGY; 247; -.
DR   TCDB; 9.A.14.4.7; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; Q02643; 1 site.
DR   PhosphoSitePlus; Q02643; -.
DR   BioMuta; GHRHR; -.
DR   DMDM; 3041685; -.
DR   PaxDb; Q02643; -.
DR   PeptideAtlas; Q02643; -.
DR   PRIDE; Q02643; -.
DR   ProteomicsDB; 58116; -.
DR   Antibodypedia; 3360; 302 antibodies.
DR   DNASU; 2692; -.
DR   Ensembl; ENST00000326139; ENSP00000320180; ENSG00000106128.
DR   GeneID; 2692; -.
DR   KEGG; hsa:2692; -.
DR   UCSC; uc003tbx.4; human.
DR   CTD; 2692; -.
DR   DisGeNET; 2692; -.
DR   EuPathDB; HostDB:ENSG00000106128.18; -.
DR   GeneCards; GHRHR; -.
DR   HGNC; HGNC:4266; GHRHR.
DR   HPA; ENSG00000106128; Tissue enriched (pituitary).
DR   MalaCards; GHRHR; -.
DR   MIM; 139191; gene.
DR   MIM; 618157; phenotype.
DR   neXtProt; NX_Q02643; -.
DR   OpenTargets; ENSG00000106128; -.
DR   Orphanet; 231671; Isolated growth hormone deficiency type IB.
DR   PharmGKB; PA28676; -.
DR   eggNOG; KOG4564; Eukaryota.
DR   GeneTree; ENSGT00940000159858; -.
DR   InParanoid; Q02643; -.
DR   KO; K04584; -.
DR   OMA; WLRWQER; -.
DR   OrthoDB; 651627at2759; -.
DR   PhylomeDB; Q02643; -.
DR   TreeFam; TF315710; -.
DR   PathwayCommons; Q02643; -.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-420092; Glucagon-type ligand receptors.
DR   Reactome; R-HSA-9660821; ADORA2B mediated anti-inflammatory cytokines production.
DR   BioGRID-ORCS; 2692; 3 hits in 876 CRISPR screens.
DR   ChiTaRS; GHRHR; human.
DR   EvolutionaryTrace; Q02643; -.
DR   GeneWiki; Growth-hormone-releasing_hormone_receptor; -.
DR   GeneWiki; Growth_hormone-releasing_hormone_receptor; -.
DR   GenomeRNAi; 2692; -.
DR   Pharos; Q02643; Tclin.
DR   PRO; PR:Q02643; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; Q02643; protein.
DR   Bgee; ENSG00000106128; Expressed in adenohypophysis and 96 other tissues.
DR   ExpressionAtlas; Q02643; baseline and differential.
DR   Genevisible; Q02643; HS.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0016021; C:integral component of membrane; IDA:BHF-UCL.
DR   GO; GO:0005637; C:nuclear inner membrane; IDA:BHF-UCL.
DR   GO; GO:0016363; C:nuclear matrix; IDA:BHF-UCL.
DR   GO; GO:0005640; C:nuclear outer membrane; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0042383; C:sarcolemma; IEA:Ensembl.
DR   GO; GO:0030141; C:secretory granule; IDA:BHF-UCL.
DR   GO; GO:0008528; F:G protein-coupled peptide receptor activity; IBA:GO_Central.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IC:BHF-UCL.
DR   GO; GO:0019838; F:growth factor binding; IPI:BHF-UCL.
DR   GO; GO:0016520; F:growth hormone-releasing hormone receptor activity; IMP:BHF-UCL.
DR   GO; GO:0017046; F:peptide hormone binding; IPI:BHF-UCL.
DR   GO; GO:0007190; P:activation of adenylate cyclase activity; IEA:Ensembl.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0007188; P:adenylate cyclase-modulating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0019933; P:cAMP-mediated signaling; IMP:BHF-UCL.
DR   GO; GO:0048469; P:cell maturation; IEA:Ensembl.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IEA:InterPro.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; IEA:Ensembl.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IEA:Ensembl.
DR   GO; GO:0008340; P:determination of adult lifespan; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0042445; P:hormone metabolic process; IEA:Ensembl.
DR   GO; GO:0007595; P:lactation; IEA:Ensembl.
DR   GO; GO:0048609; P:multicellular organismal reproductive process; NAS:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:BHF-UCL.
DR   GO; GO:0046010; P:positive regulation of circadian sleep/wake cycle, non-REM sleep; IEA:Ensembl.
DR   GO; GO:0060124; P:positive regulation of growth hormone secretion; NAS:BHF-UCL.
DR   GO; GO:0043568; P:positive regulation of insulin-like growth factor receptor signaling pathway; NAS:BHF-UCL.
DR   GO; GO:0040018; P:positive regulation of multicellular organism growth; IMP:BHF-UCL.
DR   GO; GO:0033143; P:regulation of intracellular steroid hormone receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0051246; P:regulation of protein metabolic process; IEA:Ensembl.
DR   GO; GO:0043627; P:response to estrogen; IDA:BHF-UCL.
DR   GO; GO:0051384; P:response to glucocorticoid; IDA:BHF-UCL.
DR   GO; GO:0032868; P:response to insulin; IMP:BHF-UCL.
DR   GO; GO:0060133; P:somatotropin secreting cell development; IEA:Ensembl.
DR   GO; GO:0030104; P:water homeostasis; IEA:Ensembl.
DR   Gene3D; 4.10.1240.10; -; 1.
DR   InterPro; IPR017981; GPCR_2-like.
DR   InterPro; IPR036445; GPCR_2_extracell_dom_sf.
DR   InterPro; IPR001879; GPCR_2_extracellular_dom.
DR   InterPro; IPR003288; GPCR_2_GHRH_rcpt.
DR   InterPro; IPR000832; GPCR_2_secretin-like.
DR   InterPro; IPR017983; GPCR_2_secretin-like_CS.
DR   PANTHER; PTHR45620:SF14; PTHR45620:SF14; 1.
DR   Pfam; PF00002; 7tm_2; 1.
DR   Pfam; PF02793; HRM; 1.
DR   PRINTS; PR01352; GHRHRECEPTOR.
DR   PRINTS; PR00249; GPCRSECRETIN.
DR   SMART; SM00008; HormR; 1.
DR   SUPFAM; SSF111418; SSF111418; 1.
DR   PROSITE; PS00649; G_PROTEIN_RECEP_F2_1; 1.
DR   PROSITE; PS00650; G_PROTEIN_RECEP_F2_2; 1.
DR   PROSITE; PS50227; G_PROTEIN_RECEP_F2_3; 1.
DR   PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disease mutation; Disulfide bond; Dwarfism;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Polymorphism; Receptor;
KW   Reference proteome; Signal; Transducer; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..22
FT                   /evidence="ECO:0000255"
FT   CHAIN           23..423
FT                   /note="Growth hormone-releasing hormone receptor"
FT                   /id="PRO_0000012828"
FT   TOPO_DOM        23..132
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        133..152
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        153..162
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        163..181
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        182..204
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        205..227
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        228..240
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        241..262
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        263..280
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        281..304
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        305..329
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        330..348
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        349..361
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        362..381
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        382..423
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        50
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        41..64
FT                   /evidence="ECO:0000269|Ref.9"
FT   DISULFID        55..96
FT                   /evidence="ECO:0000269|Ref.9"
FT   DISULFID        78..112
FT                   /evidence="ECO:0000269|Ref.9"
FT   VARIANT         45
FT                   /note="A -> T (in a colorectal cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036223"
FT   VARIANT         57
FT                   /note="A -> T (in dbSNP:rs4988496)"
FT                   /id="VAR_033962"
FT   VARIANT         72..423
FT                   /note="Missing (in IGHD4)"
FT                   /evidence="ECO:0000269|PubMed:8528260,
FT                   ECO:0000269|PubMed:9467553"
FT                   /id="VAR_081172"
FT   VARIANT         121
FT                   /note="E -> D (in dbSNP:rs4988498)"
FT                   /id="VAR_033963"
FT   VARIANT         144
FT                   /note="L -> H (in IGHD4; dbSNP:rs121918118)"
FT                   /evidence="ECO:0000269|PubMed:11232012"
FT                   /id="VAR_015796"
FT   VARIANT         176
FT                   /note="A -> V (in IGHD4; reduced cAMP response to GHRH;
FT                   dbSNP:rs774281185)"
FT                   /evidence="ECO:0000269|PubMed:12534354"
FT                   /id="VAR_015797"
FT   VARIANT         222
FT                   /note="A -> E (in IGHD4; dbSNP:rs121918120)"
FT                   /evidence="ECO:0000269|PubMed:11232012"
FT                   /id="VAR_015798"
FT   VARIANT         225
FT                   /note="V -> I (in dbSNP:rs28371560)"
FT                   /id="VAR_033964"
FT   VARIANT         242
FT                   /note="F -> C (in IGHD4; dbSNP:rs121918119)"
FT                   /evidence="ECO:0000269|PubMed:11232012"
FT                   /id="VAR_015799"
FT   VARIANT         329
FT                   /note="K -> E (in IGHD4; dbSNP:rs121918121)"
FT                   /evidence="ECO:0000269|PubMed:10084571"
FT                   /id="VAR_015800"
FT   VARIANT         422
FT                   /note="M -> T (in dbSNP:rs2228078)"
FT                   /id="VAR_033965"
FT   CONFLICT        178
FT                   /note="A -> R (in Ref. 1; AAA35890)"
FT                   /evidence="ECO:0000305"
FT   HELIX           34..45
FT                   /evidence="ECO:0000244|PDB:2XDG"
FT   STRAND          53..55
FT                   /evidence="ECO:0000244|PDB:2XDG"
FT   STRAND          72..76
FT                   /evidence="ECO:0000244|PDB:2XDG"
FT   HELIX           80..84
FT                   /evidence="ECO:0000244|PDB:2XDG"
FT   STRAND          92..97
FT                   /evidence="ECO:0000244|PDB:2XDG"
FT   HELIX           108..111
FT                   /evidence="ECO:0000244|PDB:2XDG"
FT   HELIX           116..119
FT                   /evidence="ECO:0000244|PDB:2XDG"
SQ   SEQUENCE   423 AA;  47402 MW;  C9C5E2E7D6649E06 CRC64;
     MDRRMWGAHV FCVLSPLPTV LGHMHPECDF ITQLREDESA CLQAAEEMPN TTLGCPATWD
     GLLCWPTAGS GEWVTLPCPD FFSHFSSESG AVKRDCTITG WSEPFPPYPV ACPVPLELLA
     EEESYFSTVK IIYTVGHSIS IVALFVAITI LVALRRLHCP RNYVHTQLFT TFILKAGAVF
     LKDAALFHSD DTDHCSFSTV LCKVSVAASH FATMTNFSWL LAEAVYLNCL LASTSPSSRR
     AFWWLVLAGW GLPVLFTGTW VSCKLAFEDI ACWDLDDTSP YWWIIKGPIV LSVGVNFGLF
     LNIIRILVRK LEPAQGSLHT QSQYWRLSKS TLFLIPLFGI HYIIFNFLPD NAGLGIRLPL
     ELGLGSFQGF IVAILYCFLN QEVRTEISRK WHGHDPELLP AWRTRAKWTT PSRSAAKVLT
     SMC
//
ID   ACM3_HUMAN              Reviewed;         590 AA.
AC   P20309; Q0VAJ8; Q4QRI3; Q5VXY2; Q9HB60;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1991, sequence version 1.
DT   07-OCT-2020, entry version 201.
DE   RecName: Full=Muscarinic acetylcholine receptor M3;
GN   Name=CHRM3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3443095; DOI=10.1002/j.1460-2075.1987.tb02733.x;
RA   Peralta E.G., Ashkenazi A., Winslow J.W., Smith D.H., Ramachandran J.,
RA   Capon D.J.;
RT   "Distinct primary structures, ligand-binding properties and tissue-specific
RT   expression of four human muscarinic acetylcholine receptors.";
RL   EMBO J. 6:3923-3929(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3272174; DOI=10.1016/0896-6273(88)90190-0;
RA   Bonner T.I., Young A.C., Brann M.R., Buckley N.J.;
RT   "Cloning and expression of the human and rat m5 muscarinic acetylcholine
RT   receptor genes.";
RL   Neuron 1:403-410(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=15014171; DOI=10.1093/molbev/msh100;
RA   Kitano T., Liu Y.-H., Ueda S., Saitou N.;
RT   "Human-specific amino acid changes found in 103 protein-coding genes.";
RL   Mol. Biol. Evol. 21:936-944(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-384.
RC   TISSUE=Teratocarcinoma;
RX   PubMed=11238933; DOI=10.1128/mcb.21.6.1973-1985.2001;
RA   Speek M.;
RT   "Antisense promoter of human L1 retrotransposon drives transcription of
RT   adjacent cellular genes.";
RL   Mol. Cell. Biol. 21:1973-1985(2001).
RN   [8]
RP   FUNCTION.
RX   PubMed=7565628;
RA   Yang J., Williams J.A., Yule D.I., Logsdon C.D.;
RT   "Mutation of carboxyl-terminal threonine residues in human M3 muscarinic
RT   acetylcholine receptor modulates the extent of sequestration and
RT   desensitization.";
RL   Mol. Pharmacol. 48:477-485(1995).
RN   [9]
RP   INVOLVEMENT IN PBS.
RX   PubMed=22077972; DOI=10.1016/j.ajhg.2011.10.007;
RA   Weber S., Thiele H., Mir S., Toliat M.R., Sozeri B., Reutter H.,
RA   Draaken M., Ludwig M., Altmuller J., Frommolt P., Stuart H.M., Ranjzad P.,
RA   Hanley N.A., Jennings R., Newman W.G., Wilcox D.T., Thiel U.,
RA   Schlingmann K.P., Beetz R., Hoyer P.F., Konrad M., Schaefer F.,
RA   Nurnberg P., Woolf A.S.;
RT   "Muscarinic acetylcholine receptor M3 mutation causes urinary bladder
RT   disease and a prune-belly-like syndrome.";
RL   Am. J. Hum. Genet. 89:668-674(2011).
RN   [10]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH TMEM147.
RX   PubMed=21056967; DOI=10.1124/mol.110.067363;
RA   Rosemond E., Rossi M., McMillin S.M., Scarselli M., Donaldson J.G.,
RA   Wess J.;
RT   "Regulation of M(3) muscarinic receptor expression and function by
RT   transmembrane protein 147.";
RL   Mol. Pharmacol. 79:251-261(2011).
RN   [11]
RP   SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=23521066; DOI=10.1042/bj20121902;
RA   Patowary S., Alvarez-Curto E., Xu T.R., Holz J.D., Oliver J.A.,
RA   Milligan G., Raicu V.;
RT   "The muscarinic M3 acetylcholine receptor exists as two differently sized
RT   complexes at the plasma membrane.";
RL   Biochem. J. 452:303-312(2013).
RN   [12]
RP   STRUCTURE BY NMR OF 271-289, MUTAGENESIS OF GLU-276; PHE-280 AND VAL-281,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=15870063; DOI=10.1074/jbc.m501264200;
RA   Iverson H.A., Fox D. III, Nadler L.S., Klevit R.E., Nathanson N.M.;
RT   "Identification and structural determination of the M(3) muscarinic
RT   acetylcholine receptor basolateral sorting signal.";
RL   J. Biol. Chem. 280:24568-24575(2005).
CC   -!- FUNCTION: The muscarinic acetylcholine receptor mediates various
CC       cellular responses, including inhibition of adenylate cyclase,
CC       breakdown of phosphoinositides and modulation of potassium channels
CC       through the action of G proteins. Primary transducing effect is Pi
CC       turnover. {ECO:0000269|PubMed:7565628}.
CC   -!- SUBUNIT: Homodimer; the dimers can form tetramers (PubMed:23521066).
CC       Interacts with NALCN (By similarity). Interacts with TMEM147
CC       (PubMed:21056967). {ECO:0000250|UniProtKB:Q9ERZ3,
CC       ECO:0000269|PubMed:21056967, ECO:0000269|PubMed:23521066}.
CC   -!- INTERACTION:
CC       P20309; P08912: CHRM5; NbExp=7; IntAct=EBI-2687785, EBI-6655256;
CC       P20309; Q8IZF0: NALCN; NbExp=3; IntAct=EBI-2687785, EBI-7085333;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:21056967};
CC       Multi-pass membrane protein {ECO:0000255}. Cell junction, synapse,
CC       postsynaptic cell membrane; Multi-pass membrane protein {ECO:0000255}.
CC       Basolateral cell membrane {ECO:0000269|PubMed:15870063}; Multi-pass
CC       membrane protein {ECO:0000255}. Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:21056967}; Multi-pass membrane protein
CC       {ECO:0000255}. Note=Colocalizes with TMEM147 in the endoplasmic
CC       reticulum (ER) membrane. TMEM147 impairs its trafficking to the cell
CC       membrane leading to its retention in the ER membrane.
CC       {ECO:0000269|PubMed:21056967}.
CC   -!- DISEASE: Prune belly syndrome (PBS) [MIM:100100]: A syndrome
CC       characterized by thin abdominal musculature with overlying lax skin,
CC       cryptorchism, megacystis with disorganized detrusor muscle, and urinary
CC       tract abnormalities. {ECO:0000269|PubMed:22077972}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       Muscarinic acetylcholine receptor subfamily. CHRM3 sub-subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X15266; CAA33337.1; -; Genomic_DNA.
DR   EMBL; U29589; AAA70337.1; -; Genomic_DNA.
DR   EMBL; AB041395; BAA94480.1; -; Genomic_DNA.
DR   EMBL; AF498917; AAM18940.1; -; mRNA.
DR   EMBL; AL356361; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC096844; AAH96844.1; -; mRNA.
DR   EMBL; BC121026; AAI21027.1; -; mRNA.
DR   EMBL; AF279779; AAG30036.1; -; mRNA.
DR   CCDS; CCDS1616.1; -.
DR   PIR; S10128; S10128.
DR   RefSeq; NP_000731.1; NM_000740.3.
DR   RefSeq; NP_001334645.1; NM_001347716.1.
DR   RefSeq; XP_005273089.1; XM_005273032.3.
DR   RefSeq; XP_011542343.1; XM_011544041.2.
DR   RefSeq; XP_011542345.1; XM_011544043.2.
DR   RefSeq; XP_011542346.1; XM_011544044.2.
DR   RefSeq; XP_011542348.1; XM_011544046.2.
DR   RefSeq; XP_011542349.1; XM_011544047.2.
DR   RefSeq; XP_016855641.1; XM_017000152.1.
DR   RefSeq; XP_016855642.1; XM_017000153.1.
DR   RefSeq; XP_016855643.1; XM_017000154.1.
DR   RefSeq; XP_016855644.1; XM_017000155.1.
DR   RefSeq; XP_016855645.1; XM_017000156.1.
DR   RefSeq; XP_016855646.1; XM_017000157.1.
DR   RefSeq; XP_016855647.1; XM_017000158.1.
DR   RefSeq; XP_016855648.1; XM_017000159.1.
DR   RefSeq; XP_016855649.1; XM_017000160.1.
DR   RefSeq; XP_016855650.1; XM_017000161.1.
DR   RefSeq; XP_016855651.1; XM_017000162.1.
DR   RefSeq; XP_016855652.1; XM_017000163.1.
DR   PDB; 2CSA; NMR; -; A=271-289.
DR   PDBsum; 2CSA; -.
DR   SMR; P20309; -.
DR   BioGRID; 107553; 60.
DR   DIP; DIP-44291N; -.
DR   IntAct; P20309; 65.
DR   MINT; P20309; -.
DR   STRING; 9606.ENSP00000255380; -.
DR   BindingDB; P20309; -.
DR   ChEMBL; CHEMBL245; -.
DR   DrugBank; DB03128; Acetylcholine.
DR   DrugBank; DB08897; Aclidinium.
DR   DrugBank; DB05752; ALKS 27.
DR   DrugBank; DB00321; Amitriptyline.
DR   DrugBank; DB00543; Amoxapine.
DR   DrugBank; DB00517; Anisotropine methylbromide.
DR   DrugBank; DB04365; Arecoline.
DR   DrugBank; DB01238; Aripiprazole.
DR   DrugBank; DB14185; Aripiprazole lauroxil.
DR   DrugBank; DB00572; Atropine.
DR   DrugBank; DB00767; Benzquinamide.
DR   DrugBank; DB01019; Bethanechol.
DR   DrugBank; DB00835; Brompheniramine.
DR   DrugBank; DB09300; Butylscopolamine.
DR   DrugBank; DB00411; Carbamoylcholine.
DR   DrugBank; DB00185; Cevimeline.
DR   DrugBank; DB00477; Chlorpromazine.
DR   DrugBank; DB01239; Chlorprothixene.
DR   DrugBank; DB00568; Cinnarizine.
DR   DrugBank; DB00363; Clozapine.
DR   DrugBank; DB00785; Cryptenamine.
DR   DrugBank; DB00434; Cyproheptadine.
DR   DrugBank; DB00496; Darifenacin.
DR   DrugBank; DB01151; Desipramine.
DR   DrugBank; DB13720; Diphemanil.
DR   DrugBank; DB01231; Diphenidol.
DR   DrugBank; DB00280; Disopyramide.
DR   DrugBank; DB09167; Dosulepin.
DR   DrugBank; DB01142; Doxepin.
DR   DrugBank; DB09194; Etoperidone.
DR   DrugBank; DB06702; Fesoterodine.
DR   DrugBank; DB00986; Glycopyrronium.
DR   DrugBank; DB00502; Haloperidol.
DR   DrugBank; DB06787; Hexocyclium.
DR   DrugBank; DB11181; Homatropine.
DR   DrugBank; DB00725; Homatropine methylbromide.
DR   DrugBank; DB00424; Hyoscyamine.
DR   DrugBank; DB09262; Imidafenacin.
DR   DrugBank; DB00458; Imipramine.
DR   DrugBank; DB00332; Ipratropium.
DR   DrugBank; DB01625; Isopropamide.
DR   DrugBank; DB01221; Ketamine.
DR   DrugBank; DB00408; Loxapine.
DR   DrugBank; DB00934; Maprotiline.
DR   DrugBank; DB04843; Mepenzolate.
DR   DrugBank; DB00454; Meperidine.
DR   DrugBank; DB06709; Methacholine.
DR   DrugBank; DB01403; Methotrimeprazine.
DR   DrugBank; DB00462; Methscopolamine bromide.
DR   DrugBank; DB00340; Metixene.
DR   DrugBank; DB01226; Mivacurium.
DR   DrugBank; DB00622; Nicardipine.
DR   DrugBank; DB00540; Nortriptyline.
DR   DrugBank; DB00334; Olanzapine.
DR   DrugBank; DB01062; Oxybutynin.
DR   DrugBank; DB00383; Oxyphencyclimine.
DR   DrugBank; DB01337; Pancuronium.
DR   DrugBank; DB00715; Paroxetine.
DR   DrugBank; DB01085; Pilocarpine.
DR   DrugBank; DB01338; Pipecuronium.
DR   DrugBank; DB06153; Pizotifen.
DR   DrugBank; DB00387; Procyclidine.
DR   DrugBank; DB00420; Promazine.
DR   DrugBank; DB01069; Promethazine.
DR   DrugBank; DB00777; Propiomazine.
DR   DrugBank; DB12278; Propiverine.
DR   DrugBank; DB01224; Quetiapine.
DR   DrugBank; DB11855; Revefenacin.
DR   DrugBank; DB13581; Rociverine.
DR   DrugBank; DB00747; Scopolamine.
DR   DrugBank; DB01591; Solifenacin.
DR   DrugBank; DB00202; Succinylcholine.
DR   DrugBank; DB00342; Terfenadine.
DR   DrugBank; DB00599; Thiopental.
DR   DrugBank; DB11235; Thonzylamine.
DR   DrugBank; DB01409; Tiotropium.
DR   DrugBank; DB01036; Tolterodine.
DR   DrugBank; DB00193; Tramadol.
DR   DrugBank; DB00505; Tridihexethyl.
DR   DrugBank; DB00376; Trihexyphenidyl.
DR   DrugBank; DB09089; Trimebutine.
DR   DrugBank; DB00726; Trimipramine.
DR   DrugBank; DB00809; Tropicamide.
DR   DrugBank; DB09076; Umeclidinium.
DR   DrugBank; DB00246; Ziprasidone.
DR   DrugCentral; P20309; -.
DR   GuidetoPHARMACOLOGY; 15; -.
DR   GlyGen; P20309; 5 sites.
DR   iPTMnet; P20309; -.
DR   PhosphoSitePlus; P20309; -.
DR   BioMuta; CHRM3; -.
DR   DMDM; 113125; -.
DR   jPOST; P20309; -.
DR   MassIVE; P20309; -.
DR   MaxQB; P20309; -.
DR   PaxDb; P20309; -.
DR   PeptideAtlas; P20309; -.
DR   PRIDE; P20309; -.
DR   ProteomicsDB; 53745; -.
DR   Antibodypedia; 4169; 362 antibodies.
DR   DNASU; 1131; -.
DR   Ensembl; ENST00000255380; ENSP00000255380; ENSG00000133019.
DR   Ensembl; ENST00000615928; ENSP00000482377; ENSG00000133019.
DR   GeneID; 1131; -.
DR   KEGG; hsa:1131; -.
DR   UCSC; uc001hyp.4; human.
DR   CTD; 1131; -.
DR   DisGeNET; 1131; -.
DR   EuPathDB; HostDB:ENSG00000133019.11; -.
DR   GeneCards; CHRM3; -.
DR   HGNC; HGNC:1952; CHRM3.
DR   HPA; ENSG00000133019; Tissue enhanced (retina).
DR   MalaCards; CHRM3; -.
DR   MIM; 100100; phenotype.
DR   MIM; 118494; gene.
DR   neXtProt; NX_P20309; -.
DR   OpenTargets; ENSG00000133019; -.
DR   Orphanet; 2970; Prune belly syndrome.
DR   PharmGKB; PA112; -.
DR   eggNOG; KOG4220; Eukaryota.
DR   GeneTree; ENSGT00940000160084; -.
DR   HOGENOM; CLU_009579_11_2_1; -.
DR   InParanoid; P20309; -.
DR   KO; K04131; -.
DR   OMA; VIFHKRI; -.
DR   OrthoDB; 1245472at2759; -.
DR   PhylomeDB; P20309; -.
DR   TreeFam; TF320495; -.
DR   PathwayCommons; P20309; -.
DR   Reactome; R-HSA-390648; Muscarinic acetylcholine receptors.
DR   Reactome; R-HSA-399997; Acetylcholine regulates insulin secretion.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   SignaLink; P20309; -.
DR   SIGNOR; P20309; -.
DR   BioGRID-ORCS; 1131; 3 hits in 870 CRISPR screens.
DR   ChiTaRS; CHRM3; human.
DR   EvolutionaryTrace; P20309; -.
DR   GeneWiki; Muscarinic_acetylcholine_receptor_M3; -.
DR   GenomeRNAi; 1131; -.
DR   Pharos; P20309; Tclin.
DR   PRO; PR:P20309; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P20309; protein.
DR   Bgee; ENSG00000133019; Expressed in endothelial cell and 179 other tissues.
DR   ExpressionAtlas; P20309; baseline and differential.
DR   Genevisible; P20309; HS.
DR   GO; GO:0009925; C:basal plasma membrane; IDA:ARUK-UCL.
DR   GO; GO:0030425; C:dendrite; IBA:GO_Central.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005887; C:integral component of plasma membrane; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0045211; C:postsynaptic membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0045202; C:synapse; IBA:GO_Central.
DR   GO; GO:0042166; F:acetylcholine binding; ISS:UniProtKB.
DR   GO; GO:0016907; F:G protein-coupled acetylcholine receptor activity; ISS:UniProtKB.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0004993; F:G protein-coupled serotonin receptor activity; IBA:GO_Central.
DR   GO; GO:0030594; F:neurotransmitter receptor activity; IBA:GO_Central.
DR   GO; GO:0004435; F:phosphatidylinositol phospholipase C activity; TAS:ProtInc.
DR   GO; GO:0038023; F:signaling receptor activity; TAS:ProtInc.
DR   GO; GO:0095500; P:acetylcholine receptor signaling pathway; IDA:ARUK-UCL.
DR   GO; GO:0007197; P:adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0019722; P:calcium-mediated signaling; IDA:ARUK-UCL.
DR   GO; GO:0006464; P:cellular protein modification process; TAS:ProtInc.
DR   GO; GO:0007268; P:chemical synaptic transmission; IBA:GO_Central.
DR   GO; GO:0007213; P:G protein-coupled acetylcholine receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007187; P:G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; IBA:GO_Central.
DR   GO; GO:0007399; P:nervous system development; TAS:ProtInc.
DR   GO; GO:0045987; P:positive regulation of smooth muscle contraction; IEA:InterPro.
DR   GO; GO:0032412; P:regulation of ion transmembrane transporter activity; IDA:ARUK-UCL.
DR   GO; GO:0003056; P:regulation of vascular associated smooth muscle contraction; IBA:GO_Central.
DR   GO; GO:0046541; P:saliva secretion; IEA:InterPro.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR001183; Musac_Ach_M3_rcpt.
DR   InterPro; IPR000995; Musac_Ach_rcpt.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00243; MUSCARINICR.
DR   PRINTS; PR00540; MUSCRINICM3R.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell junction; Cell membrane; Disulfide bond;
KW   Endoplasmic reticulum; G-protein coupled receptor; Glycoprotein; Membrane;
KW   Phosphoprotein; Polymorphism; Postsynaptic cell membrane; Receptor;
KW   Reference proteome; Synapse; Transducer; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..590
FT                   /note="Muscarinic acetylcholine receptor M3"
FT                   /id="PRO_0000069029"
FT   TOPO_DOM        1..67
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        68..91
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        92..104
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        105..130
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        131..142
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        143..164
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        165..184
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        185..206
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        207..229
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        230..252
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        253..491
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        492..514
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        515..526
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        527..546
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        547..590
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   REGION          148..152
FT                   /note="Agonist binding"
FT                   /evidence="ECO:0000250"
FT   REGION          507..530
FT                   /note="Agonist binding"
FT                   /evidence="ECO:0000250"
FT   MOTIF           275..281
FT                   /note="Basolateral sorting signal"
FT   MOD_RES         385
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9ERZ3"
FT   CARBOHYD        5
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        6
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        15
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        41
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        48
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        141..221
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   DISULFID        517..520
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VARIANT         65
FT                   /note="V -> I (in dbSNP:rs2067481)"
FT                   /id="VAR_033461"
FT   VARIANT         431
FT                   /note="L -> P (in dbSNP:rs16839102)"
FT                   /id="VAR_049368"
FT   MUTAGEN         276
FT                   /note="E->A: Loss of basolateral sorting."
FT                   /evidence="ECO:0000269|PubMed:15870063"
FT   MUTAGEN         276
FT                   /note="E->D: Loss of basolateral sorting. No effect on
FT                   basolateral sorting; when associated with L-280 and L-281."
FT                   /evidence="ECO:0000269|PubMed:15870063"
FT   MUTAGEN         280
FT                   /note="F->A: Loss of basolateral sorting."
FT                   /evidence="ECO:0000269|PubMed:15870063"
FT   MUTAGEN         280
FT                   /note="F->L: No effect on basolateral sorting."
FT                   /evidence="ECO:0000269|PubMed:15870063"
FT   MUTAGEN         281
FT                   /note="V->A: Loss of basolateral sorting."
FT                   /evidence="ECO:0000269|PubMed:15870063"
FT   MUTAGEN         281
FT                   /note="V->L: No effect on basolateral sorting."
FT                   /evidence="ECO:0000269|PubMed:15870063"
FT   CONFLICT        382..384
FT                   /note="KLP -> RLS (in Ref. 7; AAG30036)"
FT                   /evidence="ECO:0000305"
FT   STRAND          280..283
FT                   /evidence="ECO:0000244|PDB:2CSA"
SQ   SEQUENCE   590 AA;  66128 MW;  5CB473C57B9526E9 CRC64;
     MTLHNNSTTS PLFPNISSSW IHSPSDAGLP PGTVTHFGSY NVSRAAGNFS SPDGTTDDPL
     GGHTVWQVVF IAFLTGILAL VTIIGNILVI VSFKVNKQLK TVNNYFLLSL ACADLIIGVI
     SMNLFTTYII MNRWALGNLA CDLWLAIDYV ASNASVMNLL VISFDRYFSI TRPLTYRAKR
     TTKRAGVMIG LAWVISFVLW APAILFWQYF VGKRTVPPGE CFIQFLSEPT ITFGTAIAAF
     YMPVTIMTIL YWRIYKETEK RTKELAGLQA SGTEAETENF VHPTGSSRSC SSYELQQQSM
     KRSNRRKYGR CHFWFTTKSW KPSSEQMDQD HSSSDSWNNN DAAASLENSA SSDEEDIGSE
     TRAIYSIVLK LPGHSTILNS TKLPSSDNLQ VPEEELGMVD LERKADKLQA QKSVDDGGSF
     PKSFSKLPIQ LESAVDTAKT SDVNSSVGKS TATLPLSFKE ATLAKRFALK TRSQITKRKR
     MSLVKEKKAA QTLSAILLAF IITWTPYNIM VLVNTFCDSC IPKTFWNLGY WLCYINSTVN
     PVCYALCNKT FRTTFKMLLL CQCDKKKRRK QQYQQRQSVI FHKRAPEQAL
//
ID   ADA2C_HUMAN             Reviewed;         462 AA.
AC   P18825; P35369; Q9HB49;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   11-FEB-2002, sequence version 2.
DT   07-OCT-2020, entry version 181.
DE   RecName: Full=Alpha-2C adrenergic receptor;
DE   AltName: Full=Alpha-2 adrenergic receptor subtype C4;
DE   AltName: Full=Alpha-2C adrenoreceptor;
DE            Short=Alpha-2C adrenoceptor;
DE            Short=Alpha-2CAR;
GN   Name=ADRA2C; Synonyms=ADRA2L2, ADRA2RL2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Kidney;
RX   PubMed=2842764; DOI=10.1073/pnas.85.17.6301;
RA   Regan J.W., Kobilka T.S., Yang-Feng T.L., Caron M.G., Lefkowitz R.J.,
RA   Kobilka B.K.;
RT   "Cloning and expression of a human kidney cDNA for an alpha 2-adrenergic
RT   receptor subtype.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:6301-6305(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Brain;
RX   PubMed=9371698; DOI=10.1042/bj3280431;
RA   Schaak S., Devedjian J.C., Cayla C., Sender Y., Paris H.;
RT   "Molecular cloning, sequencing and functional study of the promoter region
RT   of the human alpha2C4-adrenergic receptor gene.";
RL   Biochem. J. 328:431-438(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Yano K., Takeda M., Sugimoto E., Sagai H.;
RT   "Molecular cloning and expression of a novel human alpha2C-adrenerginc
RT   receptor, alpha2CII, gene.";
RL   Submitted (OCT-1992) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT 322-GLY--PRO-325 DEL.
RX   PubMed=10801795; DOI=10.1074/jbc.m000796200;
RA   Small K.M., Forbes S.L., Rahman F.F., Bridges K.M., Liggett S.B.;
RT   "A four amino acid deletion polymorphism in the third intracellular loop of
RT   the human alpha 2C-adrenergic receptor confers impaired coupling to
RT   multiple effectors.";
RL   J. Biol. Chem. 275:23059-23064(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT 322-GLY--PRO-325 DEL.
RX   PubMed=15319474; DOI=10.1073/pnas.0405074101;
RA   Small K.M., Mialet-Perez J., Seman C.A., Theiss C.T., Brown K.M.,
RA   Liggett S.B.;
RT   "Polymorphisms of cardiac presynaptic alpha2C adrenergic receptors: Diverse
RT   intragenic variability with haplotype-specific functional effects.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:13020-13025(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT 322-GLY--PRO-325 DEL.
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "Isolation of complete coding sequence for adrenergic receptor alpha 2C
RT   (ADRA2C).";
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 95-223.
RX   PubMed=1849485; DOI=10.1016/0014-5793(91)80301-i;
RA   Chhajlani V., Rangel N., Uhlen S., Wikberg J.E.S.;
RT   "Identification of an additional gene belonging to the alpha 2 adrenergic
RT   receptor family in the human genome by PCR.";
RL   FEBS Lett. 280:241-244(1991).
CC   -!- FUNCTION: Alpha-2 adrenergic receptors mediate the catecholamine-
CC       induced inhibition of adenylate cyclase through the action of G
CC       proteins.
CC   -!- INTERACTION:
CC       P18825; P08913: ADRA2A; NbExp=2; IntAct=EBI-12015266, EBI-6622671;
CC       P18825; P18825: ADRA2C; NbExp=2; IntAct=EBI-12015266, EBI-12015266;
CC       P18825; Q8N4L8: CCDC24; NbExp=3; IntAct=EBI-12015266, EBI-1104933;
CC       P18825; Q9Y6H1: CHCHD2; NbExp=3; IntAct=EBI-12015266, EBI-2321769;
CC       P18825; Q9Y2B0: CNPY2; NbExp=3; IntAct=EBI-12015266, EBI-1054195;
CC       P18825; O14964: HGS; NbExp=3; IntAct=EBI-12015266, EBI-740220;
CC       P18825; Q2WGJ6: KLHL38; NbExp=3; IntAct=EBI-12015266, EBI-6426443;
CC       P18825; O76011: KRT34; NbExp=3; IntAct=EBI-12015266, EBI-1047093;
CC       P18825; Q99750: MDFI; NbExp=3; IntAct=EBI-12015266, EBI-724076;
CC       P18825; O14770-4: MEIS2; NbExp=3; IntAct=EBI-12015266, EBI-8025850;
CC       P18825; Q13064: MKRN3; NbExp=3; IntAct=EBI-12015266, EBI-2340269;
CC       P18825; Q7Z4N8: P4HA3; NbExp=3; IntAct=EBI-12015266, EBI-10181968;
CC       P18825; Q9NZC7-5: WWOX; NbExp=3; IntAct=EBI-12015266, EBI-12040603;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- POLYMORPHISM: The Del322-325 variant has a significant loss of
CC       function. It is approximately 10 times more frequent in African-
CC       Americans compared with Caucasians (allele frequencies 0.381 versus
CC       0.040). {ECO:0000269|PubMed:10801795}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       Adrenergic receptor subfamily. ADRA2C sub-subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA35513.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=AAC78723.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; J03853; AAA35513.1; ALT_FRAME; mRNA.
DR   EMBL; U72648; AAC78723.1; ALT_FRAME; Genomic_DNA.
DR   EMBL; D13538; BAA02737.1; -; Genomic_DNA.
DR   EMBL; AF280399; AAG28076.1; -; Genomic_DNA.
DR   EMBL; AF280400; AAG28077.1; -; Genomic_DNA.
DR   EMBL; AY605898; AAT02221.1; -; Genomic_DNA.
DR   EMBL; AY455666; AAR18071.1; -; Genomic_DNA.
DR   EMBL; X59684; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS47004.1; -.
DR   PIR; A31237; A31237.
DR   RefSeq; NP_000674.2; NM_000683.3.
DR   PDB; 6KUW; X-ray; 2.80 A; A/B=29-241, A/B=372-458.
DR   PDBsum; 6KUW; -.
DR   SMR; P18825; -.
DR   BioGRID; 106661; 16.
DR   IntAct; P18825; 12.
DR   STRING; 9606.ENSP00000386069; -.
DR   BindingDB; P18825; -.
DR   ChEMBL; CHEMBL1916; -.
DR   DrugBank; DB08838; Agmatine.
DR   DrugBank; DB00543; Amoxapine.
DR   DrugBank; DB00182; Amphetamine.
DR   DrugBank; DB00714; Apomorphine.
DR   DrugBank; DB09229; Aranidipine.
DR   DrugBank; DB01238; Aripiprazole.
DR   DrugBank; DB14185; Aripiprazole lauroxil.
DR   DrugBank; DB06216; Asenapine.
DR   DrugBank; DB00217; Bethanidine.
DR   DrugBank; DB09128; Brexpiprazole.
DR   DrugBank; DB00484; Brimonidine.
DR   DrugBank; DB01200; Bromocriptine.
DR   DrugBank; DB00248; Cabergoline.
DR   DrugBank; DB01136; Carvedilol.
DR   DrugBank; DB04846; Celiprolol.
DR   DrugBank; DB00477; Chlorpromazine.
DR   DrugBank; DB09202; Cirazoline.
DR   DrugBank; DB00575; Clonidine.
DR   DrugBank; DB00363; Clozapine.
DR   DrugBank; DB01151; Desipramine.
DR   DrugBank; DB11273; Dihydroergocornine.
DR   DrugBank; DB13345; Dihydroergocristine.
DR   DrugBank; DB11278; DL-Methylephedrine.
DR   DrugBank; DB09167; Dosulepin.
DR   DrugBank; DB04855; Dronedarone.
DR   DrugBank; DB06262; Droxidopa.
DR   DrugBank; DB01363; Ephedra sinica root.
DR   DrugBank; DB05492; Epicept NP-1.
DR   DrugBank; DB01049; Ergoloid mesylate.
DR   DrugBank; DB01175; Escitalopram.
DR   DrugBank; DB06678; Esmirtazapine.
DR   DrugBank; DB09194; Etoperidone.
DR   DrugBank; DB00800; Fenoldopam.
DR   DrugBank; DB00502; Haloperidol.
DR   DrugBank; DB04946; Iloperidone.
DR   DrugBank; DB11577; Indigotindisulfonic acid.
DR   DrugBank; DB06707; Levonordefrin.
DR   DrugBank; DB00589; Lisuride.
DR   DrugBank; DB09195; Lorpiprazole.
DR   DrugBank; DB00408; Loxapine.
DR   DrugBank; DB08815; Lurasidone.
DR   DrugBank; DB00934; Maprotiline.
DR   DrugBank; DB01365; Mephentermine.
DR   DrugBank; DB01577; Metamfetamine.
DR   DrugBank; DB01403; Methotrimeprazine.
DR   DrugBank; DB06148; Mianserin.
DR   DrugBank; DB09205; Moxisylyte.
DR   DrugBank; DB00368; Norepinephrine.
DR   DrugBank; DB00540; Nortriptyline.
DR   DrugBank; DB06229; Ocaperidone.
DR   DrugBank; DB05461; OPC-28326.
DR   DrugBank; DB00935; Oxymetazoline.
DR   DrugBank; DB01267; Paliperidone.
DR   DrugBank; DB00715; Paroxetine.
DR   DrugBank; DB01186; Pergolide.
DR   DrugBank; DB00925; Phenoxybenzamine.
DR   DrugBank; DB00397; Phenylpropanolamine.
DR   DrugBank; DB06153; Pizotifen.
DR   DrugBank; DB00433; Prochlorperazine.
DR   DrugBank; DB01069; Promethazine.
DR   DrugBank; DB01224; Quetiapine.
DR   DrugBank; DB11124; Racepinephrine.
DR   DrugBank; DB00734; Risperidone.
DR   DrugBank; DB00268; Ropinirole.
DR   DrugBank; DB09304; Setiptiline.
DR   DrugBank; DB13025; Tiapride.
DR   DrugBank; DB00697; Tizanidine.
DR   DrugBank; DB00797; Tolazoline.
DR   DrugBank; DB00193; Tramadol.
DR   DrugBank; DB11477; Xylazine.
DR   DrugBank; DB06694; Xylometazoline.
DR   DrugBank; DB01392; Yohimbine.
DR   DrugBank; DB00246; Ziprasidone.
DR   DrugCentral; P18825; -.
DR   GuidetoPHARMACOLOGY; 27; -.
DR   GlyGen; P18825; 2 sites.
DR   iPTMnet; P18825; -.
DR   PhosphoSitePlus; P18825; -.
DR   BioMuta; ADRA2C; -.
DR   DMDM; 20141211; -.
DR   jPOST; P18825; -.
DR   MassIVE; P18825; -.
DR   PaxDb; P18825; -.
DR   PeptideAtlas; P18825; -.
DR   PRIDE; P18825; -.
DR   ProteomicsDB; 53608; -.
DR   Antibodypedia; 21167; 502 antibodies.
DR   Ensembl; ENST00000330055; ENSP00000386069; ENSG00000184160.
DR   GeneID; 152; -.
DR   KEGG; hsa:152; -.
DR   CTD; 152; -.
DR   DisGeNET; 152; -.
DR   EuPathDB; HostDB:ENSG00000184160.7; -.
DR   GeneCards; ADRA2C; -.
DR   HGNC; HGNC:283; ADRA2C.
DR   HPA; ENSG00000184160; Tissue enhanced (enhanced).
DR   MIM; 104250; gene.
DR   neXtProt; NX_P18825; -.
DR   OpenTargets; ENSG00000184160; -.
DR   PharmGKB; PA37; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00940000161707; -.
DR   HOGENOM; CLU_009579_11_1_1; -.
DR   InParanoid; P18825; -.
DR   KO; K04140; -.
DR   OMA; GHYSVHH; -.
DR   OrthoDB; 737211at2759; -.
DR   PhylomeDB; P18825; -.
DR   TreeFam; TF316350; -.
DR   PathwayCommons; P18825; -.
DR   Reactome; R-HSA-390696; Adrenoceptors.
DR   Reactome; R-HSA-392023; Adrenaline signalling through Alpha-2 adrenergic receptor.
DR   Reactome; R-HSA-400042; Adrenaline,noradrenaline inhibits insulin secretion.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-418597; G alpha (z) signalling events.
DR   Reactome; R-HSA-5683826; Surfactant metabolism.
DR   SignaLink; P18825; -.
DR   SIGNOR; P18825; -.
DR   BioGRID-ORCS; 152; 6 hits in 872 CRISPR screens.
DR   GeneWiki; Alpha-2C_adrenergic_receptor; -.
DR   GenomeRNAi; 152; -.
DR   Pharos; P18825; Tclin.
DR   PRO; PR:P18825; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; P18825; protein.
DR   Bgee; ENSG00000184160; Expressed in decidua and 224 other tissues.
DR   ExpressionAtlas; P18825; baseline and differential.
DR   Genevisible; P18825; HS.
DR   GO; GO:0043679; C:axon terminus; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005768; C:endosome; TAS:ProtInc.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0099055; C:integral component of postsynaptic membrane; IEA:Ensembl.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0031694; F:alpha-2A adrenergic receptor binding; IPI:BHF-UCL.
DR   GO; GO:0004938; F:alpha2-adrenergic receptor activity; IDA:BHF-UCL.
DR   GO; GO:0051379; F:epinephrine binding; IDA:BHF-UCL.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL.
DR   GO; GO:0032148; P:activation of protein kinase B activity; IDA:BHF-UCL.
DR   GO; GO:0071880; P:adenylate cyclase-activating adrenergic receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007188; P:adenylate cyclase-modulating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0071875; P:adrenergic receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0007267; P:cell-cell signaling; TAS:ProtInc.
DR   GO; GO:0007565; P:female pregnancy; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0032811; P:negative regulation of epinephrine secretion; NAS:BHF-UCL.
DR   GO; GO:0010700; P:negative regulation of norepinephrine secretion; TAS:BHF-UCL.
DR   GO; GO:0070473; P:negative regulation of uterine smooth muscle contraction; IEA:Ensembl.
DR   GO; GO:0030168; P:platelet activation; IEA:InterPro.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:BHF-UCL.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; IDA:BHF-UCL.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; IEA:Ensembl.
DR   GO; GO:0035624; P:receptor transactivation; IDA:BHF-UCL.
DR   GO; GO:0050796; P:regulation of insulin secretion; TAS:Reactome.
DR   GO; GO:0051930; P:regulation of sensory perception of pain; IEA:Ensembl.
DR   InterPro; IPR002233; ADR_fam.
DR   InterPro; IPR000735; ADRA2C_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   PANTHER; PTHR24248:SF25; PTHR24248:SF25; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01103; ADRENERGICR.
DR   PRINTS; PR00560; ADRENRGCA2CR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Membrane; Polymorphism; Receptor; Reference proteome;
KW   Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..462
FT                   /note="Alpha-2C adrenergic receptor"
FT                   /id="PRO_0000069105"
FT   TOPO_DOM        1..51
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        52..76
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        77..88
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        89..114
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        115..124
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        125..147
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        148..168
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        169..191
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        192..207
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        208..231
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        232..379
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        380..407
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        408..420
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        421..441
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        442..462
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        294..308
FT                   /note="Arg-rich (basic)"
FT   SITE            131
FT                   /note="Implicated in ligand binding"
FT                   /evidence="ECO:0000250"
FT   SITE            214
FT                   /note="Implicated in catechol agonist binding and receptor
FT                   activation"
FT                   /evidence="ECO:0000250"
FT   SITE            218
FT                   /note="Implicated in catechol agonist binding and receptor
FT                   activation"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        19
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        33
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        124..202
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VARIANT         322..325
FT                   /note="Missing"
FT                   /evidence="ECO:0000269|PubMed:10801795,
FT                   ECO:0000269|PubMed:15319474, ECO:0000269|Ref.6"
FT                   /id="VAR_012747"
FT   CONFLICT        239
FT                   /note="L -> R (in Ref. 1 and 2)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        329
FT                   /note="E -> Q (in Ref. 1 and 2)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        401
FT                   /note="S -> I (in Ref. 1 and 2)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        446
FT                   /note="R -> P (in Ref. 1 and 2)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   462 AA;  49522 MW;  E1EF9CA21E7F6EDA CRC64;
     MASPALAAAL AVAAAAGPNA SGAGERGSGG VANASGASWG PPRGQYSAGA VAGLAAVVGF
     LIVFTVVGNV LVVIAVLTSR ALRAPQNLFL VSLASADILV ATLVMPFSLA NELMAYWYFG
     QVWCGVYLAL DVLFCTSSIV HLCAISLDRY WSVTQAVEYN LKRTPRRVKA TIVAVWLISA
     VISFPPLVSL YRQPDGAAYP QCGLNDETWY ILSSCIGSFF APCLIMGLVY ARIYRVAKLR
     TRTLSEKRAP VGPDGASPTT ENGLGAAAGA GENGHCAPPP ADVEPDESSA AAERRRRRGA
     LRRGGRRRAG AEGGAGGADG QGAGPGAAES GALTASRSPG PGGRLSRASS RSVEFFLSRR
     RRARSSVCRR KVAQAREKRF TFVLAVVMGV FVLCWFPFFF SYSLYGICRE ACQVPGPLFK
     FFFWIGYCNS SLNPVIYTVF NQDFRRSFKH ILFRRRRRGF RQ
//
ID   GASR_HUMAN              Reviewed;         447 AA.
AC   P32239; A8K7P9; O75824; Q16144; Q92492; Q96LC6; Q9NYK7; Q9UBV1;
DT   01-OCT-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1993, sequence version 1.
DT   12-AUG-2020, entry version 203.
DE   RecName: Full=Gastrin/cholecystokinin type B receptor {ECO:0000303|PubMed:8415658};
DE            Short=CCK-B receptor {ECO:0000303|PubMed:8415658};
DE            Short=CCK-BR;
DE   AltName: Full=Cholecystokinin-2 receptor {ECO:0000303|PubMed:11926817};
DE            Short=CCK2-R;
GN   Name=CCKBR {ECO:0000312|HGNC:HGNC:1571}; Synonyms=CCKRB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=1280419; DOI=10.1016/0006-291x(92)91557-7;
RA   Pisegna J.R., de Weerth A., Huppi K., Wank S.A.;
RT   "Molecular cloning of the human brain and gastric cholecystokinin receptor:
RT   structure, functional expression and chromosomal localization.";
RL   Biochem. Biophys. Res. Commun. 189:296-303(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=7681836;
RA   Lee Y.-M., Beinborn M., McBride E.W., Lu M., Kolakowski L.F. Jr.,
RA   Kopin A.S.;
RT   "The human brain cholecystokinin-B/gastrin receptor. Cloning and
RT   characterization.";
RL   J. Biol. Chem. 268:8164-8169(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=8349705;
RA   Ito M., Matsui T., Taniguchi T., Tsukamoto T., Murayama T., Arima N.,
RA   Nakata H., Chiba T., Chihara K.;
RT   "Functional characterization of a human brain cholecystokinin-B receptor. A
RT   trophic effect of cholecystokinin and gastrin.";
RL   J. Biol. Chem. 268:18300-18305(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Placenta;
RX   PubMed=8415658; DOI=10.1073/pnas.90.19.9085;
RA   Song I., Brown D.R., Wiltshire R.N., Gantz I., Trent J.M., Yamada T.;
RT   "The human gastrin/cholecystokinin type B receptor gene: alternative splice
RT   donor site in exon 4 generates two variant mRNAs.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:9085-9089(1993).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND TISSUE SPECIFICITY.
RC   TISSUE=Fetal brain;
RX   PubMed=8185170; DOI=10.1111/j.1749-6632.1994.tb44076.x;
RA   Herget T., Sethi T., Wu S.V., Walsh J.H., Rozengurt E.;
RT   "Cholecystokinin stimulates Ca2+ mobilization and clonal growth in small
RT   cell lung cancer through CCKA and CCKB/gastrin receptors.";
RL   Ann. N. Y. Acad. Sci. 713:283-297(1994).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, ALTERNATIVE SPLICING, AND
RP   TISSUE SPECIFICITY.
RC   TISSUE=Lung fibroblast;
RX   PubMed=7848914;
RA   Ito M., Iwata N., Taniguchi T., Murayama T., Chihara K., Matsui T.;
RT   "Functional characterization of two cholecystokinin-B/gastrin receptor
RT   isoforms: a preferential splice donor site in the human receptor gene.";
RL   Cell Growth Differ. 5:1127-1135(1994).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND TISSUE SPECIFICITY.
RC   TISSUE=Stomach;
RX   PubMed=7887934; DOI=10.1006/bbrc.1995.1328;
RA   Miyake A.;
RT   "A truncated isoform of human CCK-B/gastrin receptor generated by
RT   alternative usage of a novel exon.";
RL   Biochem. Biophys. Res. Commun. 208:230-237(1995).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION (ISOFORM 2), AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Colon cancer;
RX   PubMed=10913157; DOI=10.1074/jbc.m005754200;
RA   Hellmich M.R., Rui X.-L., Hellmich H.L., Fleming R.Y.D., Evers B.M.,
RA   Townsend C.M. Jr.;
RT   "Human colorectal cancers express a constitutively active cholecystokinin-
RT   B/gastrin receptor that stimulates cell growth.";
RL   J. Biol. Chem. 275:32122-32128(2000).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, AND ALTERNATIVE SPLICING.
RC   TISSUE=Peripheral blood;
RX   PubMed=11495676; DOI=10.1016/s0167-0115(01)00281-6;
RA   Schmitz F., Schrader H., Otte J.-M., Schmitz H., Stueber E., Herzig K.-H.,
RA   Schmidt W.E.;
RT   "Identification of CCK-B/gastrin receptor splice variants in human
RT   peripheral blood mononuclear cells.";
RL   Regul. Pept. 101:25-33(2001).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND TISSUE SPECIFICITY.
RC   TISSUE=Pancreatic cancer;
RX   PubMed=12429993;
RA   Smith J.P., Verderame M.F., McLaughlin P., Martenis M., Ballard E.,
RA   Zagon I.S.;
RT   "Characterization of the CCK-C (cancer) receptor in human pancreatic
RT   cancer.";
RL   Int. J. Mol. Med. 10:689-694(2002).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Temporal cortex;
RA   Tate S.N., Gray J., Denyer J., Stolz M., Foord S., Lee M.G.;
RT   "Cloning and expression of the human temporal cortex cholecystokinin B
RT   receptor.";
RL   Submitted (MAR-1996) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Stomach;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 52-447.
RX   PubMed=9872672; DOI=10.1023/a:1009289625352;
RA   O'Briant K.C., Ali S.Y., Weier H.-U.G., Bepler G.;
RT   "An 84-kilobase physical map and repeat polymorphisms of the
RT   gastrin/cholecystokinin brain receptor region at the junction of chromosome
RT   segments 11p15.4 and 15.5.";
RL   Chromosome Res. 6:415-418(1998).
RN   [17]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 244-333 (ISOFORMS 1/3), AND FUNCTION.
RC   TISSUE=Fetal brain;
RX   PubMed=8221657;
RA   Sethi T., Herget T., Wu S.V., Walsh J.H., Rozengurt E.;
RT   "CCKA and CCKB receptors are expressed in small cell lung cancer lines and
RT   mediate Ca2+ mobilization and clonal growth.";
RL   Cancer Res. 53:5208-5213(1993).
RN   [18]
RP   CHROMOSOMAL LOCATION.
RX   PubMed=8222757; DOI=10.1159/000133628;
RA   Zimonjic D.B., Popescu N.C., Matsui T., Ito M., Chihara K.;
RT   "Localization of the human cholecystokinin-B/gastrin receptor gene (CCKBR)
RT   to chromosome 11p15.5-->p15.4 by fluorescence in situ hybridization.";
RL   Cytogenet. Cell Genet. 65:184-185(1994).
RN   [19]
RP   STRUCTURE BY NMR OF 352-379.
RX   PubMed=11926817; DOI=10.1021/bi0160009;
RA   Giragossian C., Mierke D.F.;
RT   "Intermolecular interactions between cholecystokinin-8 and the third
RT   extracellular loop of the cholecystokinin-2 receptor.";
RL   Biochemistry 41:4560-4566(2002).
CC   -!- FUNCTION: Receptor for gastrin and cholecystokinin. The CCK-B receptors
CC       occur throughout the central nervous system where they modulate
CC       anxiety, analgesia, arousal, and neuroleptic activity. This receptor
CC       mediates its action by association with G proteins that activate a
CC       phosphatidylinositol-calcium second messenger system.
CC   -!- FUNCTION: Isoform 2 is constitutively activated and may regulate cancer
CC       cell proliferation via a gastrin-independent mechanism.
CC   -!- INTERACTION:
CC       P32239; PRO_0000010542 [P06307]: CCK; NbExp=2; IntAct=EBI-1753137, EBI-6624436;
CC       P32239; Q9P121: NTM; NbExp=3; IntAct=EBI-1753137, EBI-4315078;
CC       P32239; Q06124: PTPN11; NbExp=5; IntAct=EBI-1753137, EBI-297779;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P32239-1; Sequence=Displayed;
CC       Name=2; Synonyms=CCK-C, CCK-BRi4sv;
CC         IsoId=P32239-2; Sequence=VSP_033445;
CC       Name=3; Synonyms=DeltaCCK-B;
CC         IsoId=P32239-3; Sequence=VSP_033444;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is expressed in brain, pancreas, stomach,
CC       the colon cancer cell line LoVo and the T-lymphoblastoma Jurkat, but
CC       not in heart, placenta, liver, lung, skeletal muscle, kidney or the
CC       stomach cancer cell line AGS. Expressed at high levels in the small
CC       cell lung cancer cell line NCI-H510, at lower levels in NCI-H345, NCI-
CC       H69 and GLC-28 cell lines, not expressed in GLC-19 cell line. Within
CC       the stomach, expressed at high levels in the mucosa of the gastric
CC       fundus and at low levels in the antrum and duodenum. Isoform 2 is
CC       present in pancreatic cancer cells and colorectal cancer cells, but not
CC       in normal pancreas or colonic mucosa. Isoform 3 is expressed in brain,
CC       pancreas, stomach, the stomach cancer cell line AGS and the colon
CC       cancer cell line LoVo. {ECO:0000269|PubMed:10913157,
CC       ECO:0000269|PubMed:12429993, ECO:0000269|PubMed:7848914,
CC       ECO:0000269|PubMed:7887934, ECO:0000269|PubMed:8185170,
CC       ECO:0000269|PubMed:8349705}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Cholecystokinin receptor entry;
CC       URL="https://en.wikipedia.org/wiki/Cholecystokinin_receptor";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L04473; AAA35660.1; -; mRNA.
DR   EMBL; L08112; AAA35657.1; -; mRNA.
DR   EMBL; D13305; BAA02564.1; -; mRNA.
DR   EMBL; L10822; AAC37528.1; -; Genomic_DNA.
DR   EMBL; S70057; AAB30766.2; -; mRNA.
DR   EMBL; D21219; BAA04759.2; -; Genomic_DNA.
DR   EMBL; AF239668; AAF67174.1; -; mRNA.
DR   EMBL; AY029770; AAK38351.1; -; mRNA.
DR   EMBL; AF441129; AAN32829.1; -; mRNA.
DR   EMBL; L07746; AAA91831.1; -; mRNA.
DR   EMBL; AK292064; BAF84753.1; -; mRNA.
DR   EMBL; AY322551; AAP84364.1; -; mRNA.
DR   EMBL; BT006789; AAP35435.1; -; mRNA.
DR   EMBL; BC000740; AAH00740.1; -; mRNA.
DR   EMBL; AH006311; AAC27510.1; -; Genomic_DNA.
DR   CCDS; CCDS7761.1; -. [P32239-1]
DR   CCDS; CCDS86175.1; -. [P32239-2]
DR   PIR; A47430; A47430.
DR   PIR; I65231; I65231.
DR   RefSeq; NP_001304958.1; NM_001318029.1.
DR   RefSeq; NP_795344.1; NM_176875.3. [P32239-1]
DR   RefSeq; XP_005253267.1; XM_005253210.1.
DR   RefSeq; XP_016874005.1; XM_017018516.1. [P32239-3]
DR   PDB; 1L4T; NMR; -; A=352-379.
DR   PDBsum; 1L4T; -.
DR   SMR; P32239; -.
DR   BioGRID; 107329; 13.
DR   DIP; DIP-229N; -.
DR   IntAct; P32239; 21.
DR   MINT; P32239; -.
DR   STRING; 9606.ENSP00000335544; -.
DR   BindingDB; P32239; -.
DR   ChEMBL; CHEMBL298; -.
DR   DrugBank; DB08862; Cholecystokinin.
DR   DrugBank; DB00183; Pentagastrin.
DR   DrugCentral; P32239; -.
DR   GuidetoPHARMACOLOGY; 77; -.
DR   GlyGen; P32239; 3 sites.
DR   iPTMnet; P32239; -.
DR   PhosphoSitePlus; P32239; -.
DR   BioMuta; CCKBR; -.
DR   DMDM; 417029; -.
DR   PaxDb; P32239; -.
DR   PeptideAtlas; P32239; -.
DR   PRIDE; P32239; -.
DR   ProteomicsDB; 54845; -. [P32239-1]
DR   ProteomicsDB; 54846; -. [P32239-2]
DR   ProteomicsDB; 54847; -. [P32239-3]
DR   Antibodypedia; 11193; 341 antibodies.
DR   DNASU; 887; -.
DR   Ensembl; ENST00000334619; ENSP00000335544; ENSG00000110148. [P32239-1]
DR   Ensembl; ENST00000525462; ENSP00000435534; ENSG00000110148. [P32239-2]
DR   GeneID; 887; -.
DR   KEGG; hsa:887; -.
DR   UCSC; uc001mcp.4; human. [P32239-1]
DR   CTD; 887; -.
DR   DisGeNET; 887; -.
DR   EuPathDB; HostDB:ENSG00000110148.9; -.
DR   GeneCards; CCKBR; -.
DR   HGNC; HGNC:1571; CCKBR.
DR   HPA; ENSG00000110148; Group enriched (brain, pancreas, stomach).
DR   MIM; 118445; gene.
DR   neXtProt; NX_P32239; -.
DR   OpenTargets; ENSG00000110148; -.
DR   PharmGKB; PA26143; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00990000203585; -.
DR   HOGENOM; CLU_009579_6_3_1; -.
DR   InParanoid; P32239; -.
DR   KO; K04195; -.
DR   OMA; QAEQTWY; -.
DR   OrthoDB; 1042780at2759; -.
DR   PhylomeDB; P32239; -.
DR   TreeFam; TF315303; -.
DR   PathwayCommons; P32239; -.
DR   Reactome; R-HSA-375276; Peptide ligand-binding receptors.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-881907; Gastrin-CREB signalling pathway via PKC and MAPK.
DR   SignaLink; P32239; -.
DR   SIGNOR; P32239; -.
DR   BioGRID-ORCS; 887; 4 hits in 867 CRISPR screens.
DR   EvolutionaryTrace; P32239; -.
DR   GeneWiki; Cholecystokinin_B_receptor; -.
DR   GenomeRNAi; 887; -.
DR   Pharos; P32239; Tclin.
DR   PRO; PR:P32239; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; P32239; protein.
DR   Bgee; ENSG00000110148; Expressed in body of stomach and 129 other tissues.
DR   ExpressionAtlas; P32239; baseline and differential.
DR   Genevisible; P32239; HS.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0046935; F:1-phosphatidylinositol-3-kinase regulator activity; TAS:ProtInc.
DR   GO; GO:0004951; F:cholecystokinin receptor activity; IDA:GO_Central.
DR   GO; GO:0015054; F:gastrin receptor activity; IDA:UniProtKB.
DR   GO; GO:0017046; F:peptide hormone binding; IPI:GO_Central.
DR   GO; GO:0031741; F:type B gastrin/cholecystokinin receptor binding; IDA:NTNU_SB.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; NAS:UniProtKB.
DR   GO; GO:0038188; P:cholecystokinin signaling pathway; IDA:GO_Central.
DR   GO; GO:0048565; P:digestive tract development; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0001696; P:gastric acid secretion; IEA:Ensembl.
DR   GO; GO:0048732; P:gland development; IEA:Ensembl.
DR   GO; GO:0045851; P:pH reduction; IEA:Ensembl.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; IDA:GO_Central.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IDA:UniProtKB.
DR   InterPro; IPR009126; Cholcskin_rcpt.
DR   InterPro; IPR000314; Gastrin_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01822; CCYSTOKININR.
DR   PRINTS; PR00527; GASTRINR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane; Palmitate;
KW   Polymorphism; Receptor; Reference proteome; Transducer; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..447
FT                   /note="Gastrin/cholecystokinin type B receptor"
FT                   /id="PRO_0000069474"
FT   TOPO_DOM        1..57
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        58..79
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        80..87
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        88..109
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        110..131
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        132..150
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        151..170
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        171..189
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        190..219
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        220..242
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        243..333
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        334..355
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        356..373
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        374..394
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        395..447
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   LIPID           408
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250|UniProtKB:P17124"
FT   CARBOHYD        7
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        30
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        36
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        127..205
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VAR_SEQ         1..66
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:7887934"
FT                   /id="VSP_033444"
FT   VAR_SEQ         271
FT                   /note="G -> GGAGPREQNLGEAELWRATGPAGVGGTEMKVRVRRKLEMELSWERRS
FT                   GGDWAGDWGDSPFSLTAHPLCSG (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10913157,
FT                   ECO:0000303|PubMed:11495676, ECO:0000303|PubMed:12429993"
FT                   /id="VSP_033445"
FT   VARIANT         37
FT                   /note="L -> F (in dbSNP:rs1805000)"
FT                   /id="VAR_014684"
FT   VARIANT         77
FT                   /note="V -> G (in dbSNP:rs35816985)"
FT                   /id="VAR_049388"
FT   VARIANT         125
FT                   /note="V -> I (in dbSNP:rs1805002)"
FT                   /id="VAR_014685"
FT   VARIANT         215
FT                   /note="R -> H (in dbSNP:rs1805004)"
FT                   /id="VAR_014686"
FT   VARIANT         319
FT                   /note="R -> Q (in dbSNP:rs1805001)"
FT                   /id="VAR_014687"
FT   CONFLICT        64
FT                   /note="I -> T (in Ref. 8; AAF67174)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        93
FT                   /note="L -> F (in Ref. 16; AAC27510)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        96
FT                   /note="L -> M (in Ref. 16; AAC27510)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        116
FT                   /note="L -> I (in Ref. 16; AAC27510)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        171
FT                   /note="A -> P (in Ref. 11; AAA91831)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        227
FT                   /note="F -> S (in Ref. 12; BAF84753)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        249
FT                   /note="L -> V (in Ref. 11; AAA91831)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        288
FT                   /note="E -> K (in Ref. 5; AAB30766)"
FT                   /evidence="ECO:0000305"
FT   HELIX           353..358
FT                   /evidence="ECO:0000244|PDB:1L4T"
FT   HELIX           363..368
FT                   /evidence="ECO:0000244|PDB:1L4T"
FT   HELIX           372..378
FT                   /evidence="ECO:0000244|PDB:1L4T"
SQ   SEQUENCE   447 AA;  48419 MW;  BAEEFAD4C1F85915 CRC64;
     MELLKLNRSV QGTGPGPGAS LCRPGAPLLN SSSVGNLSCE PPRIRGAGTR ELELAIRITL
     YAVIFLMSVG GNMLIIVVLG LSRRLRTVTN AFLLSLAVSD LLLAVACMPF TLLPNLMGTF
     IFGTVICKAV SYLMGVSVSV STLSLVAIAL ERYSAICRPL QARVWQTRSH AARVIVATWL
     LSGLLMVPYP VYTVVQPVGP RVLQCVHRWP SARVRQTWSV LLLLLLFFIP GVVMAVAYGL
     ISRELYLGLR FDGDSDSDSQ SRVRNQGGLP GAVHQNGRCR PETGAVGEDS DGCYVQLPRS
     RPALELTALT APGPGSGSRP TQAKLLAKKR VVRMLLVIVV LFFLCWLPVY SANTWRAFDG
     PGAHRALSGA PISFIHLLSY ASACVNPLVY CFMHRRFRQA CLETCARCCP RPPRARPRAL
     PDEDPPTPSI ASLSRLSYTT ISTLGPG
//
ID   GABR2_HUMAN             Reviewed;         941 AA.
AC   O75899; O75974; O75975; Q5VXZ2; Q8WX04; Q9P1R2; Q9UNR1; Q9UNS9;
DT   11-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1998, sequence version 1.
DT   07-OCT-2020, entry version 195.
DE   RecName: Full=Gamma-aminobutyric acid type B receptor subunit 2;
DE            Short=GABA-B receptor 2;
DE            Short=GABA-B-R2;
DE            Short=GABA-BR2;
DE            Short=GABABR2;
DE            Short=Gb2;
DE   AltName: Full=G-protein coupled receptor 51;
DE   AltName: Full=HG20;
DE   Flags: Precursor;
GN   Name=GABBR2; Synonyms=GPR51, GPRC3B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBUNIT, INTERACTION WITH GABBR1, AND
RP   SUBCELLULAR LOCATION.
RC   TISSUE=Cerebellum {ECO:0000303|PubMed:9872316};
RX   PubMed=9872316; DOI=10.1038/25354;
RA   White J.H., Wise A., Main M.J., Green A., Fraser N.J., Disney G.H.,
RA   Barnes A.A., Emson P., Foord S.M., Marshall F.H.;
RT   "Heterodimerization is required for the formation of a functional GABA(B)
RT   receptor.";
RL   Nature 396:679-682(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Fetal brain {ECO:0000303|PubMed:10087195};
RX   PubMed=10087195; DOI=10.1006/geno.1998.5706;
RA   Ng G.Y.K., McDonald T., Bonnert T., Rigby M., Heavens R., Whiting P.,
RA   Chateauneuf A., Coulombe N., Kargman S., Caskey T., Evans J.F.,
RA   O'Neill G.P., Liu Q.;
RT   "Cloning of a novel G-protein-coupled receptor GPR 51 resembling GABAB
RT   receptors expressed predominantly in nervous tissues and mapped proximal to
RT   the hereditary sensory neuropathy type 1 locus on chromosome 9.";
RL   Genomics 56:288-295(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, AND VARIANTS PHE-628 AND ALA-869.
RC   TISSUE=Brain {ECO:0000303|PubMed:10328880};
RX   PubMed=10328880; DOI=10.1006/mcne.1999.0741;
RA   Martin S.C., Russek S.J., Farb D.H.;
RT   "Molecular identification of the human GABABR2: cell surface expression and
RT   coupling to adenylyl cyclase in the absence of GABABR1.";
RL   Mol. Cell. Neurosci. 13:180-191(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Brain {ECO:0000303|PubMed:10727622};
RX   PubMed=10727622; DOI=10.1016/s0006-8993(00)01958-2;
RA   Clark J.A., Mezey E., Lam A.S., Bonner T.I.;
RT   "Distribution of the GABA(B) receptor subunit gb2 in rat CNS.";
RL   Brain Res. 860:41-52(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Liu M., Parker R., McCrea K., Watson J., Baker E., Sutherland G.,
RA   Herzog H.;
RT   "Cloning and characterization of a novel human GABA-B receptor subtype with
RT   high affinity for GABA and low affinity for baclofen.";
RL   Submitted (NOV-1998) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Hippocampus {ECO:0000303|Ref.6};
RA   Borowsky B., Laz T., Gerald C.;
RL   Submitted (JAN-1999) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 14-941.
RC   TISSUE=Hippocampus {ECO:0000303|PubMed:15489334};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   FUNCTION.
RX   PubMed=10075644; DOI=10.1074/jbc.274.12.7607;
RA   Ng G.Y.K., Clark J., Coulombe N., Ethier N., Hebert T.E., Sullivan R.,
RA   Kargman S., Chateauneuf A., Tsukamoto N., McDonald T., Whiting P.,
RA   Mezey E., Johnson M.P., Liu Q., Kolakowski L.F. Jr., Evans J.F.,
RA   Bonner T.I., O'Neill G.P.;
RT   "Identification of a GABAB receptor subunit, gb2, required for functional
RT   GABAB receptor activity.";
RL   J. Biol. Chem. 274:7607-7610(1999).
RN   [10]
RP   FUNCTION, INTERACTION WITH GABBR1, TISSUE SPECIFICITY, AND DOMAIN.
RX   PubMed=9872744; DOI=10.1126/science.283.5398.74;
RA   Kuner R., Koehr G., Gruenewald S., Eisenhardt G., Bach A., Kornau H.-C.;
RT   "Role of heteromer formation in GABAB receptor function.";
RL   Science 283:74-77(1999).
RN   [11]
RP   FUNCTION, AND INTERACTION WITH GABBR1.
RX   PubMed=10906333; DOI=10.1074/jbc.m005333200;
RA   Schwarz D.A., Barry G., Eliasof S.D., Petroski R.E., Conlon P.J.,
RA   Maki R.A.;
RT   "Characterization of gamma-aminobutyric acid receptor GABAB(1e), a GABAB(1)
RT   splice variant encoding a truncated receptor.";
RL   J. Biol. Chem. 275:32174-32181(2000).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH GABBR1.
RX   PubMed=10773016;
RA   Sullivan R., Chateauneuf A., Coulombe N., Kolakowski L.F. Jr.,
RA   Johnson M.P., Hebert T.E., Ethier N., Belley M., Metters K., Abramovitz M.,
RA   O'Neill G.P., Ng G.Y.K.;
RT   "Coexpression of full-length gamma-aminobutyric acid(B) (GABA(B)) receptors
RT   with truncated receptors and metabotropic glutamate receptor 4 supports the
RT   GABA(B) heterodimer as the functional receptor.";
RL   J. Pharmacol. Exp. Ther. 293:460-467(2000).
RN   [13]
RP   VARIANT NDPLHS THR-567.
RX   PubMed=26740508; DOI=10.1136/jmedgenet-2015-103568;
RA   Lopes F., Barbosa M., Ameur A., Soares G., de Sa J., Dias A.I.,
RA   Oliveira G., Cabral P., Temudo T., Calado E., Cruz I.F., Vieira J.P.,
RA   Oliveira R., Esteves S., Sauer S., Jonasson I., Syvaenen A.C.,
RA   Gyllensten U., Pinto D., Maciel P.;
RT   "Identification of novel genetic causes of Rett syndrome-like phenotypes.";
RL   J. Med. Genet. 53:190-199(2016).
RN   [14]
RP   FUNCTION, INTERACTION WITH GABBR1, SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=15617512; DOI=10.1042/bj20041435;
RA   Villemure J.F., Adam L., Bevan N.J., Gearing K., Chenier S., Bouvier M.;
RT   "Subcellular distribution of GABA(B) receptor homo- and hetero-dimers.";
RL   Biochem. J. 388:47-55(2005).
RN   [15]
RP   FUNCTION, SUBUNIT, AND INTERACTION WITH GABBR1.
RX   PubMed=18165688; DOI=10.1074/jbc.m705202200;
RA   Nomura R., Suzuki Y., Kakizuka A., Jingami H.;
RT   "Direct detection of the interaction between recombinant soluble
RT   extracellular regions in the heterodimeric metabotropic gamma-aminobutyric
RT   acid receptor.";
RL   J. Biol. Chem. 283:4665-4673(2008).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (2.38 ANGSTROMS) OF 42-466, PARTIAL PROTEIN SEQUENCE,
RP   FUNCTION, INTERACTION WITH GABBR1, MUTAGENESIS OF TYR-118, GLYCOSYLATION AT
RP   ASN-90; ASN-389; ASN-404 AND ASN-453, AND DISULFIDE BONDS.
RX   PubMed=22660477; DOI=10.1038/nn.3133;
RA   Geng Y., Xiong D., Mosyak L., Malito D.L., Kniazeff J., Chen Y.,
RA   Burmakina S., Quick M., Bush M., Javitch J.A., Pin J.P., Fan Q.R.;
RT   "Structure and functional interaction of the extracellular domain of human
RT   GABA(B) receptor GBR2.";
RL   Nat. Neurosci. 15:970-978(2012).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 42-466 IN COMPLEXES WITH GABBR1;
RP   AGONISTS AND ANTAGONISTS, FUNCTION, SUBUNIT, GLYCOSYLATION AT ASN-404, AND
RP   DISULFIDE BOND.
RX   PubMed=24305054; DOI=10.1038/nature12725;
RA   Geng Y., Bush M., Mosyak L., Wang F., Fan Q.R.;
RT   "Structural mechanism of ligand activation in human GABA(B) receptor.";
RL   Nature 504:254-259(2013).
RN   [18]
RP   INVOLVEMENT IN EIEE59, AND VARIANT EIEE59 TRP-693.
RX   PubMed=29100083; DOI=10.1016/j.ajhg.2017.09.008;
RG   Deciphering Developmental Disorders Study;
RA   Hamdan F.F., Myers C.T., Cossette P., Lemay P., Spiegelman D.,
RA   Laporte A.D., Nassif C., Diallo O., Monlong J., Cadieux-Dion M.,
RA   Dobrzeniecka S., Meloche C., Retterer K., Cho M.T., Rosenfeld J.A., Bi W.,
RA   Massicotte C., Miguet M., Brunga L., Regan B.M., Mo K., Tam C.,
RA   Schneider A., Hollingsworth G., FitzPatrick D.R., Donaldson A., Canham N.,
RA   Blair E., Kerr B., Fry A.E., Thomas R.H., Shelagh J., Hurst J.A.,
RA   Brittain H., Blyth M., Lebel R.R., Gerkes E.H., Davis-Keppen L., Stein Q.,
RA   Chung W.K., Dorison S.J., Benke P.J., Fassi E., Corsten-Janssen N.,
RA   Kamsteeg E.J., Mau-Them F.T., Bruel A.L., Verloes A., Ounap K.,
RA   Wojcik M.H., Albert D.V.F., Venkateswaran S., Ware T., Jones D., Liu Y.C.,
RA   Mohammad S.S., Bizargity P., Bacino C.A., Leuzzi V., Martinelli S.,
RA   Dallapiccola B., Tartaglia M., Blumkin L., Wierenga K.J., Purcarin G.,
RA   O'Byrne J.J., Stockler S., Lehman A., Keren B., Nougues M.C., Mignot C.,
RA   Auvin S., Nava C., Hiatt S.M., Bebin M., Shao Y., Scaglia F., Lalani S.R.,
RA   Frye R.E., Jarjour I.T., Jacques S., Boucher R.M., Riou E., Srour M.,
RA   Carmant L., Lortie A., Major P., Diadori P., Dubeau F., D'Anjou G.,
RA   Bourque G., Berkovic S.F., Sadleir L.G., Campeau P.M., Kibar Z.,
RA   Lafreniere R.G., Girard S.L., Mercimek-Mahmutoglu S., Boelman C.,
RA   Rouleau G.A., Scheffer I.E., Mefford H.C., Andrade D.M., Rossignol E.,
RA   Minassian B.A., Michaud J.L.;
RT   "High rate of recurrent de novo mutations in developmental and epileptic
RT   encephalopathies.";
RL   Am. J. Hum. Genet. 101:664-685(2017).
RN   [19]
RP   INVOLVEMENT IN NDPLHS, INVOLVEMENT IN EIEE59, VARIANT NDPLHS THR-567,
RP   VARIANTS EIEE59 ILE-695 AND ASN-705, CHARACTERIZATION OF VARIANT NDPLHS
RP   THR-567, AND CHARACTERIZATION OF VARIANTS EIEE59 ILE-695 AND ASN-705.
RX   PubMed=28856709; DOI=10.1002/ana.25032;
RA   Yoo Y., Jung J., Lee Y.N., Lee Y., Cho H., Na E., Hong J., Kim E.,
RA   Lee J.S., Lee J.S., Hong C., Park S.Y., Wie J., Miller K., Shur N.,
RA   Clow C., Ebel R.S., DeBrosse S.D., Henderson L.B., Willaert R.,
RA   Castaldi C., Tikhonova I., Bilguevar K., Mane S., Kim K.J., Hwang Y.S.,
RA   Lee S.G., So I., Lim B.C., Choi H.J., Seong J.Y., Shin Y.B., Jung H.,
RA   Chae J.H., Choi M.;
RT   "GABBR2 mutations determine phenotype in rett syndrome and epileptic
RT   encephalopathy.";
RL   Ann. Neurol. 82:466-478(2017).
RN   [20]
RP   INVOLVEMENT IN NDPLHS, VARIANT NDPLHS THR-707, CHARACTERIZATION OF VARIANTS
RP   NDPLHS THR-567 AND THR-707, AND CHARACTERIZATION OF VARIANTS EIEE59 ILE-695
RP   AND ASN-705.
RX   PubMed=29369404; DOI=10.1002/ana.25155;
RA   Vuillaume M.L., Jeanne M., Xue L., Blesson S., Denomme-Pichon A.S.,
RA   Alirol S., Brulard C., Colin E., Isidor B., Gilbert-Dussardier B.,
RA   Odent S., Parent P., Donnart A., Redon R., Bezieau S., Rondard P.,
RA   Laumonnier F., Toutain A.;
RT   "A novel mutation in the transmembrane 6 domain of GABBR2 leads to a Rett-
RT   like phenotype.";
RL   Ann. Neurol. 83:437-439(2018).
CC   -!- FUNCTION: Component of a heterodimeric G-protein coupled receptor for
CC       GABA, formed by GABBR1 and GABBR2 (PubMed:9872316, PubMed:9872744,
CC       PubMed:15617512, PubMed:18165688, PubMed:22660477, PubMed:24305054).
CC       Within the heterodimeric GABA receptor, only GABBR1 seems to bind
CC       agonists, while GABBR2 mediates coupling to G proteins
CC       (PubMed:18165688). Ligand binding causes a conformation change that
CC       triggers signaling via guanine nucleotide-binding proteins (G proteins)
CC       and modulates the activity of down-stream effectors, such as adenylate
CC       cyclase (PubMed:10075644, PubMed:10773016, PubMed:24305054). Signaling
CC       inhibits adenylate cyclase, stimulates phospholipase A2, activates
CC       potassium channels, inactivates voltage-dependent calcium-channels and
CC       modulates inositol phospholipid hydrolysis (PubMed:10075644,
CC       PubMed:9872744, PubMed:10906333, PubMed:10773016). Plays a critical
CC       role in the fine-tuning of inhibitory synaptic transmission
CC       (PubMed:9872744, PubMed:22660477). Pre-synaptic GABA receptor inhibits
CC       neurotransmitter release by down-regulating high-voltage activated
CC       calcium channels, whereas postsynaptic GABA receptor decreases neuronal
CC       excitability by activating a prominent inwardly rectifying potassium
CC       (Kir) conductance that underlies the late inhibitory postsynaptic
CC       potentials (PubMed:9872316, PubMed:10075644, PubMed:9872744,
CC       PubMed:22660477). Not only implicated in synaptic inhibition but also
CC       in hippocampal long-term potentiation, slow wave sleep, muscle
CC       relaxation and antinociception (Probable).
CC       {ECO:0000269|PubMed:10075644, ECO:0000269|PubMed:10328880,
CC       ECO:0000269|PubMed:15617512, ECO:0000269|PubMed:18165688,
CC       ECO:0000269|PubMed:22660477, ECO:0000269|PubMed:24305054,
CC       ECO:0000269|PubMed:9872316, ECO:0000269|PubMed:9872744, ECO:0000305}.
CC   -!- SUBUNIT: Heterodimer of GABBR1 and GABBR2 (PubMed:9872316,
CC       PubMed:9872744, PubMed:10906333, PubMed:10773016, PubMed:15617512,
CC       PubMed:18165688, PubMed:22660477, PubMed:24305054). Homodimers may
CC       form, but are inactive (PubMed:15617512). Interacts (via C-terminus)
CC       with ATF4 (via leucine zipper domain) (By similarity).
CC       {ECO:0000250|UniProtKB:Q9Z0U4, ECO:0000269|PubMed:10773016,
CC       ECO:0000269|PubMed:15617512, ECO:0000269|PubMed:18165688,
CC       ECO:0000269|PubMed:22660477, ECO:0000269|PubMed:24305054,
CC       ECO:0000269|PubMed:9872316, ECO:0000269|PubMed:9872744}.
CC   -!- INTERACTION:
CC       O75899; Q9UBS5: GABBR1; NbExp=2; IntAct=EBI-715469, EBI-724156;
CC       O75899; Q9UBS5-2: GABBR1; NbExp=3; IntAct=EBI-715469, EBI-16084001;
CC       O75899; P46459: NSF; NbExp=4; IntAct=EBI-715469, EBI-712251;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10328880,
CC       ECO:0000269|PubMed:15617512, ECO:0000269|PubMed:9872316}; Multi-pass
CC       membrane protein {ECO:0000305}. Cell junction, synapse, postsynaptic
CC       cell membrane {ECO:0000250|UniProtKB:O88871}; Multi-pass membrane
CC       protein {ECO:0000305}. Note=Coexpression of GABBR1 and GABBR2 is
CC       required for GABBR1 maturation and transport to the plasma membrane. In
CC       contrast, GABBR2 does not depend on GABBR1 for transport to the cell
CC       membrane. {ECO:0000269|PubMed:15617512}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in brain, especially in cerebral
CC       cortex, thalamus, hippocampus, frontal, occipital and temporal lobe,
CC       occipital pole and cerebellum, followed by corpus callosum, caudate
CC       nucleus, spinal cord, amygdala and medulla (PubMed:10087195,
CC       PubMed:10328880, PubMed:10727622, PubMed:9872744). Weakly expressed in
CC       heart, testis and skeletal muscle (PubMed:10087195, PubMed:10727622).
CC       {ECO:0000269|PubMed:10087195, ECO:0000269|PubMed:10328880,
CC       ECO:0000269|PubMed:10727622, ECO:0000269|PubMed:9872744}.
CC   -!- DOMAIN: Alpha-helical parts of the C-terminal intracellular region
CC       mediate heterodimeric interaction with GABBR1.
CC       {ECO:0000305|PubMed:9872744}.
CC   -!- DISEASE: Neurodevelopmental disorder with poor language and loss of
CC       hand skills (NDPLHS) [MIM:617903]: An autosomal dominant disorder
CC       characterized by psychomotor developmental stagnation or regression.
CC       NDPLHS manifest in the first years of life as loss of purposeful hand
CC       movements, loss of language, and intellectual disability.
CC       {ECO:0000269|PubMed:26740508, ECO:0000269|PubMed:28856709,
CC       ECO:0000269|PubMed:29369404}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Epileptic encephalopathy, early infantile, 59 (EIEE59)
CC       [MIM:617904]: A form of epileptic encephalopathy, a heterogeneous group
CC       of severe childhood onset epilepsies characterized by refractory
CC       seizures, neurodevelopmental impairment, and poor prognosis.
CC       Development is normal prior to seizure onset, after which cognitive and
CC       motor delays become apparent. EIEE59 is an autosomal dominant condition
CC       characterized by onset of refractory seizures in early infancy.
CC       {ECO:0000269|PubMed:28856709, ECO:0000269|PubMed:29100083,
CC       ECO:0000269|PubMed:29369404}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 3 family. GABA-B
CC       receptor subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH35071.2; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AJ012188; CAA09942.1; -; mRNA.
DR   EMBL; AF069755; AAC99345.1; -; mRNA.
DR   EMBL; AF099033; AAD45867.1; -; mRNA.
DR   EMBL; AF056085; AAC63228.1; -; mRNA.
DR   EMBL; AF095784; AAD30389.1; -; mRNA.
DR   EMBL; AF074483; AAD03336.1; -; mRNA.
DR   EMBL; AL445495; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL353782; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL356282; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL591502; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC035071; AAH35071.2; ALT_INIT; mRNA.
DR   CCDS; CCDS6736.1; -.
DR   RefSeq; NP_005449.5; NM_005458.7.
DR   PDB; 4F11; X-ray; 2.38 A; A=42-466.
DR   PDB; 4F12; X-ray; 3.02 A; A=42-466.
DR   PDB; 4MQE; X-ray; 2.35 A; B=42-466.
DR   PDB; 4MQF; X-ray; 2.22 A; B=42-466.
DR   PDB; 4MR7; X-ray; 2.15 A; B=42-466.
DR   PDB; 4MR8; X-ray; 2.15 A; B=42-466.
DR   PDB; 4MR9; X-ray; 2.35 A; B=42-466.
DR   PDB; 4MRM; X-ray; 2.86 A; B=42-466.
DR   PDB; 4MS1; X-ray; 2.25 A; B=42-466.
DR   PDB; 4MS3; X-ray; 2.50 A; B=42-466.
DR   PDB; 4MS4; X-ray; 1.90 A; B=42-466.
DR   PDB; 4PAS; X-ray; 1.62 A; B=779-819.
DR   PDB; 6M8R; X-ray; 3.20 A; K/L=876-913.
DR   PDB; 6OCP; X-ray; 2.35 A; P/Q/R=895-909.
DR   PDB; 6UO8; EM; 3.63 A; B=41-819.
DR   PDB; 6UO9; EM; 4.80 A; B=41-819.
DR   PDB; 6UOA; EM; 6.30 A; B=41-819.
DR   PDB; 6VJM; EM; 3.97 A; B=41-819.
DR   PDB; 6W2X; EM; 3.60 A; B=42-941.
DR   PDB; 6WIV; EM; 3.30 A; B=1-819.
DR   PDB; 7C7Q; EM; 3.00 A; B=41-780.
DR   PDB; 7C7S; EM; 2.90 A; B=41-819.
DR   PDBsum; 4F11; -.
DR   PDBsum; 4F12; -.
DR   PDBsum; 4MQE; -.
DR   PDBsum; 4MQF; -.
DR   PDBsum; 4MR7; -.
DR   PDBsum; 4MR8; -.
DR   PDBsum; 4MR9; -.
DR   PDBsum; 4MRM; -.
DR   PDBsum; 4MS1; -.
DR   PDBsum; 4MS3; -.
DR   PDBsum; 4MS4; -.
DR   PDBsum; 4PAS; -.
DR   PDBsum; 6M8R; -.
DR   PDBsum; 6OCP; -.
DR   PDBsum; 6UO8; -.
DR   PDBsum; 6UO9; -.
DR   PDBsum; 6UOA; -.
DR   PDBsum; 6VJM; -.
DR   PDBsum; 6W2X; -.
DR   PDBsum; 6WIV; -.
DR   PDBsum; 7C7Q; -.
DR   PDBsum; 7C7S; -.
DR   SMR; O75899; -.
DR   BioGRID; 114938; 7.
DR   ComplexPortal; CPX-2955; GABA-B receptor complex.
DR   CORUM; O75899; -.
DR   DIP; DIP-42851N; -.
DR   IntAct; O75899; 7.
DR   MINT; O75899; -.
DR   STRING; 9606.ENSP00000259455; -.
DR   BindingDB; O75899; -.
DR   ChEMBL; CHEMBL5034; -.
DR   DrugBank; DB08891; Arbaclofen.
DR   DrugBank; DB08892; Arbaclofen Placarbil.
DR   DrugBank; DB00181; Baclofen.
DR   DrugBank; DB02530; gamma-Aminobutyric acid.
DR   DrugBank; DB05010; SGS-742.
DR   DrugCentral; O75899; -.
DR   GuidetoPHARMACOLOGY; 241; -.
DR   TCDB; 9.A.14.15.1; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; O75899; 5 sites.
DR   iPTMnet; O75899; -.
DR   PhosphoSitePlus; O75899; -.
DR   BioMuta; GABBR2; -.
DR   EPD; O75899; -.
DR   MassIVE; O75899; -.
DR   PaxDb; O75899; -.
DR   PeptideAtlas; O75899; -.
DR   PRIDE; O75899; -.
DR   ProteomicsDB; 50252; -.
DR   ABCD; O75899; 1 sequenced antibody.
DR   Antibodypedia; 2939; 557 antibodies.
DR   DNASU; 9568; -.
DR   Ensembl; ENST00000259455; ENSP00000259455; ENSG00000136928.
DR   GeneID; 9568; -.
DR   KEGG; hsa:9568; -.
DR   UCSC; uc004ays.4; human.
DR   CTD; 9568; -.
DR   DisGeNET; 9568; -.
DR   EuPathDB; HostDB:ENSG00000136928.5; -.
DR   GeneCards; GABBR2; -.
DR   HGNC; HGNC:4507; GABBR2.
DR   HPA; ENSG00000136928; Tissue enriched (brain).
DR   MalaCards; GABBR2; -.
DR   MIM; 607340; gene.
DR   MIM; 617903; phenotype.
DR   MIM; 617904; phenotype.
DR   neXtProt; NX_O75899; -.
DR   OpenTargets; ENSG00000136928; -.
DR   Orphanet; 3095; Atypical Rett syndrome.
DR   PharmGKB; PA28896; -.
DR   eggNOG; KOG1055; Eukaryota.
DR   GeneTree; ENSGT00940000155783; -.
DR   HOGENOM; CLU_005240_0_0_1; -.
DR   InParanoid; O75899; -.
DR   KO; K04615; -.
DR   OMA; LLKHYHW; -.
DR   OrthoDB; 590810at2759; -.
DR   PhylomeDB; O75899; -.
DR   TreeFam; TF313965; -.
DR   PathwayCommons; O75899; -.
DR   Reactome; R-HSA-1296041; Activation of G protein gated Potassium channels.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-420499; Class C/3 (Metabotropic glutamate/pheromone receptors).
DR   Reactome; R-HSA-977444; GABA B receptor activation.
DR   Reactome; R-HSA-997272; Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits.
DR   BioGRID-ORCS; 9568; 2 hits in 870 CRISPR screens.
DR   ChiTaRS; GABBR2; human.
DR   GeneWiki; GABBR2; -.
DR   GenomeRNAi; 9568; -.
DR   Pharos; O75899; Tclin.
DR   PRO; PR:O75899; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; O75899; protein.
DR   Bgee; ENSG00000136928; Expressed in primary visual cortex and 171 other tissues.
DR   ExpressionAtlas; O75899; baseline and differential.
DR   Genevisible; O75899; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0038039; C:G protein-coupled receptor heterodimeric complex; IPI:UniProtKB.
DR   GO; GO:1902710; C:GABA receptor complex; IDA:CAFA.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0045211; C:postsynaptic membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004965; F:G protein-coupled GABA receptor activity; TAS:ProtInc.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:CAFA.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; IBA:GO_Central.
DR   GO; GO:0007268; P:chemical synaptic transmission; TAS:ProtInc.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007214; P:gamma-aminobutyric acid signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007194; P:negative regulation of adenylate cyclase activity; TAS:ProtInc.
DR   GO; GO:0150099; P:neuron-glial cell signaling; ISS:ARUK-UCL.
DR   InterPro; IPR001828; ANF_lig-bd_rcpt.
DR   InterPro; IPR041689; GBR2_CC.
DR   InterPro; IPR002455; GPCR3_GABA-B.
DR   InterPro; IPR000337; GPCR_3.
DR   InterPro; IPR017978; GPCR_3_C.
DR   InterPro; IPR017979; GPCR_3_CS.
DR   InterPro; IPR002457; GPCR_3_GABA_rcpt_B2.
DR   InterPro; IPR028082; Peripla_BP_I.
DR   PANTHER; PTHR10519; PTHR10519; 1.
DR   Pfam; PF00003; 7tm_3; 1.
DR   Pfam; PF01094; ANF_receptor; 1.
DR   Pfam; PF18455; GBR2_CC; 1.
DR   PRINTS; PR01178; GABAB2RECPTR.
DR   PRINTS; PR00248; GPCRMGR.
DR   SUPFAM; SSF53822; SSF53822; 1.
DR   PROSITE; PS00981; G_PROTEIN_RECEP_F3_3; 1.
DR   PROSITE; PS50259; G_PROTEIN_RECEP_F3_4; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell junction; Cell membrane; Coiled coil;
KW   Direct protein sequencing; Disease mutation; Disulfide bond; Epilepsy;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Mental retardation;
KW   Phosphoprotein; Polymorphism; Postsynaptic cell membrane; Receptor;
KW   Reference proteome; Signal; Synapse; Transducer; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL          1..41
FT                   /evidence="ECO:0000255"
FT   CHAIN           42..941
FT                   /note="Gamma-aminobutyric acid type B receptor subunit 2"
FT                   /id="PRO_0000012952"
FT   TOPO_DOM        42..483
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        484..504
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        505..522
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        523..543
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        544..551
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        552..572
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        573..597
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        598..618
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        619..654
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        655..675
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        676..691
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        692..712
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        713..720
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        721..741
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        742..941
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   COILED          781..819
FT                   /evidence="ECO:0000255"
FT   MOD_RES         776
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80T41"
FT   MOD_RES         779
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80T41"
FT   MOD_RES         819
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80T41"
FT   MOD_RES         884
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80T41"
FT   MOD_RES         893
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80T41"
FT   MOD_RES         913
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80T41"
FT   MOD_RES         916
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80T41"
FT   MOD_RES         920
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80T41"
FT   MOD_RES         924
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80T41"
FT   CARBOHYD        90
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:22660477"
FT   CARBOHYD        298
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        389
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:22660477"
FT   CARBOHYD        404
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:22660477,
FT                   ECO:0000269|PubMed:24305054"
FT   CARBOHYD        453
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:22660477"
FT   DISULFID        108..135
FT   DISULFID        237..266
FT   DISULFID        265..302
FT   VARIANT         163
FT                   /note="L -> P (in dbSNP:rs35449008)"
FT                   /id="VAR_049280"
FT   VARIANT         567
FT                   /note="A -> T (in NDPLHS; increased basal signaling
FT                   activity and only weak stimulation by GABA agonist; when
FT                   injected into Xenopus tadpoles, causes abnormal swimming
FT                   patterns and increased frequencies of seizure-like behavior
FT                   compared to wild-type-injected animals; no effect on cell
FT                   surface expression; dbSNP:rs922847767)"
FT                   /evidence="ECO:0000269|PubMed:26740508,
FT                   ECO:0000269|PubMed:28856709, ECO:0000269|PubMed:29369404"
FT                   /id="VAR_079029"
FT   VARIANT         628
FT                   /note="Y -> F"
FT                   /evidence="ECO:0000269|PubMed:10328880"
FT                   /id="VAR_010148"
FT   VARIANT         693
FT                   /note="G -> W (in EIEE59; unknown pathological
FT                   significance; dbSNP:rs1554689320)"
FT                   /evidence="ECO:0000269|PubMed:29100083"
FT                   /id="VAR_080569"
FT   VARIANT         695
FT                   /note="S -> I (in EIEE59; full signaling activity in the
FT                   absence of GABA agonist; when injected into Xenopus
FT                   tadpoles, causes abnormal swimming patterns and increased
FT                   frequencies of seizure-like behavior compared to wild-type-
FT                   injected animals; no effect on cell surface expression;
FT                   dbSNP:rs1554689319)"
FT                   /evidence="ECO:0000269|PubMed:28856709,
FT                   ECO:0000269|PubMed:29369404"
FT                   /id="VAR_080570"
FT   VARIANT         705
FT                   /note="I -> N (in EIEE59; increased basal signaling
FT                   activity and no stimulation by GABA agonist; when injected
FT                   into Xenopus tadpoles, causes abnormal swimming patterns
FT                   and increased frequencies of seizure-like behavior compared
FT                   to wild-type-injected animals; no effect on cell surface
FT                   expression; dbSNP:rs1554689315)"
FT                   /evidence="ECO:0000269|PubMed:28856709,
FT                   ECO:0000269|PubMed:29369404"
FT                   /id="VAR_080571"
FT   VARIANT         707
FT                   /note="A -> T (in NDPLHS; increased basal signaling
FT                   activity and only weak stimulation by GABA agonist; no
FT                   effect on cell surface expression; dbSNP:rs1554689313)"
FT                   /evidence="ECO:0000269|PubMed:29369404"
FT                   /id="VAR_080572"
FT   VARIANT         869
FT                   /note="T -> A (in dbSNP:rs10985765)"
FT                   /evidence="ECO:0000269|PubMed:10328880"
FT                   /id="VAR_010149"
FT   MUTAGEN         118
FT                   /note="Y->A: Impairs interaction with GABBR1. Decreases
FT                   signaling via G-proteins."
FT                   /evidence="ECO:0000269|PubMed:22660477"
FT   CONFLICT        6
FT                   /note="S -> R (in Ref. 2; AAC99345)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        12
FT                   /note="P -> R (in Ref. 2; AAC99345)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        424
FT                   /note="G -> E (in Ref. 5; AAD30389)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        797
FT                   /note="R -> H (in Ref. 8; AAH35071)"
FT                   /evidence="ECO:0000305"
FT   STRAND          55..62
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          66..68
FT                   /evidence="ECO:0000244|PDB:4MQE"
FT   HELIX           71..90
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   TURN            91..96
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          98..105
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           110..123
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          128..132
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           136..145
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           146..149
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          152..157
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           161..164
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   TURN            166..168
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          172..176
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           179..181
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           182..192
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          197..205
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           206..219
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   TURN            220..223
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          225..234
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           237..245
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          250..254
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           257..269
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          278..283
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   TURN            287..290
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           304..311
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          315..319
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           335..345
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   TURN            346..348
FT                   /evidence="ECO:0000244|PDB:4MR7"
FT   HELIX           355..372
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           378..387
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           393..404
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          407..410
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          413..418
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          421..423
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          425..431
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          436..443
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   TURN            444..447
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          448..451
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   TURN            453..455
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          459..462
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           780..816
FT                   /evidence="ECO:0000244|PDB:4PAS"
FT   HELIX           885..890
FT                   /evidence="ECO:0000244|PDB:6M8R"
FT   HELIX           899..902
FT                   /evidence="ECO:0000244|PDB:6OCP"
FT   STRAND          908..911
FT                   /evidence="ECO:0000244|PDB:6M8R"
SQ   SEQUENCE   941 AA;  105821 MW;  09F1773DB0673C5D CRC64;
     MASPRSSGQP GPPPPPPPPP ARLLLLLLLP LLLPLAPGAW GWARGAPRPP PSSPPLSIMG
     LMPLTKEVAK GSIGRGVLPA VELAIEQIRN ESLLRPYFLD LRLYDTECDN AKGLKAFYDA
     IKYGPNHLMV FGGVCPSVTS IIAESLQGWN LVQLSFAATT PVLADKKKYP YFFRTVPSDN
     AVNPAILKLL KHYQWKRVGT LTQDVQRFSE VRNDLTGVLY GEDIEISDTE SFSNDPCTSV
     KKLKGNDVRI ILGQFDQNMA AKVFCCAYEE NMYGSKYQWI IPGWYEPSWW EQVHTEANSS
     RCLRKNLLAA MEGYIGVDFE PLSSKQIKTI SGKTPQQYER EYNNKRSGVG PSKFHGYAYD
     GIWVIAKTLQ RAMETLHASS RHQRIQDFNY TDHTLGRIIL NAMNETNFFG VTGQVVFRNG
     ERMGTIKFTQ FQDSREVKVG EYNAVADTLE IINDTIRFQG SEPPKDKTII LEQLRKISLP
     LYSILSALTI LGMIMASAFL FFNIKNRNQK LIKMSSPYMN NLIILGGMLS YASIFLFGLD
     GSFVSEKTFE TLCTVRTWIL TVGYTTAFGA MFAKTWRVHA IFKNVKMKKK IIKDQKLLVI
     VGGMLLIDLC ILICWQAVDP LRRTVEKYSM EPDPAGRDIS IRPLLEHCEN THMTIWLGIV
     YAYKGLLMLF GCFLAWETRN VSIPALNDSK YIGMSVYNVG IMCIIGAAVS FLTRDQPNVQ
     FCIVALVIIF CSTITLCLVF VPKLITLRTN PDAATQNRRF QFTQNQKKED SKTSTSVTSV
     NQASTSRLEG LQSENHRLRM KITELDKDLE EVTMQLQDTP EKTTYIKQNH YQELNDILNL
     GNFTESTDGG KAILKNHLDQ NPQLQWNTTE PSRTCKDPIE DINSPEHIQR RLSLQLPILH
     HAYLPSIGGV DASCVSPCVS PTASPRHRHV PPSFRVMVSG L
//
ID   FZD5_HUMAN              Reviewed;         585 AA.
AC   Q13467; A8K2X1; B2RCZ1; Q53R22;
DT   05-DEC-2001, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   07-OCT-2020, entry version 195.
DE   RecName: Full=Frizzled-5;
DE            Short=Fz-5;
DE            Short=hFz5;
DE   AltName: Full=FzE5;
DE   Flags: Precursor;
GN   Name=FZD5; Synonyms=C2orf31;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Retina;
RX   PubMed=8626800; DOI=10.1074/jbc.271.8.4468;
RA   Wang Y., Macke J.P., Abella B.S., Andreasson K., Worley P., Gilbert D.J.,
RA   Copeland N.G., Jenkins N.A., Nathans J.;
RT   "A large family of putative transmembrane receptors homologous to the
RT   product of the Drosophila tissue polarity gene frizzled.";
RL   J. Biol. Chem. 271:4468-4476(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=11408929; DOI=10.3892/ijo.19.1.105;
RA   Saitoh T., Hirai M., Katoh M.;
RT   "Molecular cloning and characterization of human Frizzled-5 gene on
RT   chromosome 2q33.3-q34 region.";
RL   Int. J. Oncol. 19:105-110(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Spleen, and Umbilical cord blood;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 273-331.
RC   TISSUE=Esophageal carcinoma;
RX   PubMed=9707618; DOI=10.1073/pnas.95.17.10164;
RA   Tanaka S., Akiyoshi T., Mori M., Wands J.R., Sugimachi K.;
RT   "A novel frizzled gene identified in human esophageal carcinoma mediates
RT   APC/beta-catenin signals.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:10164-10169(1998).
RN   [6]
RP   FUNCTION, AND COUPLING TO BETA-CATENIN PATHWAY.
RX   PubMed=9054360; DOI=10.1126/science.275.5306.1652;
RA   He X., Saint-Jeannet J.P., Wang Y., Nathans J., Dawid I., Varmus H.;
RT   "A member of the Frizzled protein family mediating axis induction by Wnt-
RT   5A.";
RL   Science 275:1652-1654(1997).
RN   [7]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=10097073; DOI=10.1073/pnas.96.7.3546;
RA   Hsieh J.C., Rattner A., Smallwood P.M., Nathans J.;
RT   "Biochemical characterization of Wnt-frizzled interactions using a soluble,
RT   biologically active vertebrate Wnt protein.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:3546-3551(1999).
RN   [8]
RP   INTERACTION WITH WNT2B.
RX   PubMed=12490564; DOI=10.1242/dev.00244;
RA   Kubo F., Takeichi M., Nakagawa S.;
RT   "Wnt2b controls retinal cell differentiation at the ciliary marginal
RT   zone.";
RL   Development 130:587-598(2003).
RN   [9]
RP   INTERACTION WITH WNT7A.
RX   PubMed=18230341; DOI=10.1016/j.bbrc.2008.01.088;
RA   Carmon K.S., Loose D.S.;
RT   "Wnt7a interaction with Fzd5 and detection of signaling activation using a
RT   split eGFP.";
RL   Biochem. Biophys. Res. Commun. 368:285-291(2008).
RN   [10]
RP   FUNCTION, AND INTERACTION WITH WNT7A.
RX   PubMed=20530549; DOI=10.1242/dev.046722;
RA   Sahores M., Gibb A., Salinas P.C.;
RT   "Frizzled-5, a receptor for the synaptic organizer Wnt7a, regulates
RT   activity-mediated synaptogenesis.";
RL   Development 137:2215-2225(2010).
RN   [11]
RP   UBIQUITINATION BY ZNRF3.
RX   PubMed=22575959; DOI=10.1038/nature11019;
RA   Hao H.X., Xie Y., Zhang Y., Charlat O., Oster E., Avello M., Lei H.,
RA   Mickanin C., Liu D., Ruffner H., Mao X., Ma Q., Zamponi R., Bouwmeester T.,
RA   Finan P.M., Kirschner M.W., Porter J.A., Serluca F.C., Cong F.;
RT   "ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner.";
RL   Nature 485:195-200(2012).
RN   [12]
RP   UBIQUITINATION BY RNF43.
RX   PubMed=22895187; DOI=10.1038/nature11308;
RA   Koo B.K., Spit M., Jordens I., Low T.Y., Stange D.E., van de Wetering M.,
RA   van Es J.H., Mohammed S., Heck A.J., Maurice M.M., Clevers H.;
RT   "Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis
RT   of Wnt receptors.";
RL   Nature 488:665-669(2012).
RN   [13] {ECO:0000244|PDB:5URY, ECO:0000244|PDB:5URZ}
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 28-155 IN COMPLEX WITH
RP   UNSATURATED FATTY ACID, SUBUNIT, GLYCOSYLATION AT ASN-47, AND DISULFIDE
RP   BONDS.
RX   PubMed=28377511; DOI=10.1073/pnas.1618293114;
RA   Nile A.H., Mukund S., Stanger K., Wang W., Hannoush R.N.;
RT   "Unsaturated fatty acyl recognition by Frizzled receptors mediates
RT   dimerization upon Wnt ligand binding.";
RL   Proc. Natl. Acad. Sci. U.S.A. 114:4147-4152(2017).
CC   -!- FUNCTION: Receptor for Wnt proteins (PubMed:9054360, PubMed:10097073,
CC       PubMed:20530549). Can activate WNT2, WNT10B, WNT5A, but not WNT2B or
CC       WNT4 (in vitro); the in vivo situation may be different since not all
CC       of these are known to be coexpressed (By similarity). In neurons,
CC       activation of WNT7A promotes formation of synapses (PubMed:20530549).
CC       Functions in the canonical Wnt/beta-catenin signaling pathway. The
CC       canonical Wnt/beta-catenin signaling pathway leads to the activation of
CC       disheveled proteins, inhibition of GSK-3 kinase, nuclear accumulation
CC       of beta-catenin and activation of Wnt target genes (By similarity). A
CC       second signaling pathway involving PKC and calcium fluxes has been seen
CC       for some family members, but it is not yet clear if it represents a
CC       distinct pathway or if it can be integrated in the canonical pathway,
CC       as PKC seems to be required for Wnt-mediated inactivation of GSK-3
CC       kinase. Both pathways seem to involve interactions with G-proteins. May
CC       be involved in transduction and intercellular transmission of polarity
CC       information during tissue morphogenesis and/or in differentiated
CC       tissues (Probable). Plays a role in yolk sac angiogenesis and in
CC       placental vascularization (By similarity).
CC       {ECO:0000250|UniProtKB:Q9EQD0, ECO:0000269|PubMed:10097073,
CC       ECO:0000269|PubMed:20530549, ECO:0000269|PubMed:9054360, ECO:0000305}.
CC   -!- SUBUNIT: Binding of unsaturated fatty acid molecules (via FZ domain)
CC       promotes homodimerization (PubMed:28377511). Interacts with WNT2B
CC       (PubMed:12490564). Interacts with WNT7A (PubMed:18230341,
CC       PubMed:20530549). Interacts with GOPC (By similarity).
CC       {ECO:0000250|UniProtKB:Q9EQD0, ECO:0000269|PubMed:12490564,
CC       ECO:0000269|PubMed:18230341, ECO:0000269|PubMed:20530549,
CC       ECO:0000269|PubMed:28377511}.
CC   -!- INTERACTION:
CC       Q13467; Q6P3W7: SCYL2; NbExp=4; IntAct=EBI-3913027, EBI-1046810;
CC       Q13467; P78383: SLC35B1; NbExp=3; IntAct=EBI-3913027, EBI-12147661;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:Q8CHL0};
CC       Multi-pass membrane protein {ECO:0000250|UniProtKB:Q8CHL0}. Golgi
CC       apparatus membrane {ECO:0000250|UniProtKB:Q9EQD0}; Multi-pass membrane
CC       protein {ECO:0000250|UniProtKB:Q9EQD0}. Cell junction, synapse
CC       {ECO:0000250|UniProtKB:Q8CHL0}. Perikaryon
CC       {ECO:0000250|UniProtKB:Q8CHL0}. Cell projection, dendrite
CC       {ECO:0000250|UniProtKB:Q8CHL0}. Cell projection, axon
CC       {ECO:0000250|UniProtKB:Q8CHL0}. Note=Localized at the plasma membrane
CC       and also found at the Golgi. {ECO:0000250|UniProtKB:Q9EQD0}.
CC   -!- DOMAIN: The PDZ-binding motif mediates interaction with GOPC.
CC       {ECO:0000250}.
CC   -!- DOMAIN: Lys-Thr-X-X-X-Trp motif interacts with the PDZ domain of Dvl
CC       (Disheveled) family members and is involved in the activation of the
CC       Wnt/beta-catenin signaling pathway. {ECO:0000250}.
CC   -!- DOMAIN: The FZ domain is involved in binding with Wnt ligands.
CC       {ECO:0000250}.
CC   -!- PTM: Ubiquitinated by RNF43 and ZNRF3, leading to its degradation by
CC       the proteasome. {ECO:0000269|PubMed:22575959,
CC       ECO:0000269|PubMed:22895187}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor Fz/Smo family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U43318; AAC50385.1; -; mRNA.
DR   EMBL; AB043702; BAB60959.1; -; mRNA.
DR   EMBL; AK290386; BAF83075.1; -; mRNA.
DR   EMBL; AK315338; BAG37738.1; -; mRNA.
DR   EMBL; AC096772; AAY24058.1; -; Genomic_DNA.
DR   CCDS; CCDS33366.1; -.
DR   RefSeq; NP_003459.2; NM_003468.3.
DR   PDB; 5URY; X-ray; 2.10 A; A/B=28-155.
DR   PDB; 5URZ; X-ray; 2.20 A; A/B=28-155.
DR   PDB; 6O39; X-ray; 1.80 A; C=28-150.
DR   PDBsum; 5URY; -.
DR   PDBsum; 5URZ; -.
DR   PDBsum; 6O39; -.
DR   SMR; Q13467; -.
DR   BioGRID; 113609; 15.
DR   CORUM; Q13467; -.
DR   IntAct; Q13467; 14.
DR   MINT; Q13467; -.
DR   STRING; 9606.ENSP00000354607; -.
DR   ChEMBL; CHEMBL3559687; -.
DR   GuidetoPHARMACOLOGY; 233; -.
DR   GlyGen; Q13467; 3 sites, 1 O-linked glycan (1 site).
DR   iPTMnet; Q13467; -.
DR   PhosphoSitePlus; Q13467; -.
DR   BioMuta; FZD5; -.
DR   DMDM; 116242481; -.
DR   EPD; Q13467; -.
DR   jPOST; Q13467; -.
DR   MassIVE; Q13467; -.
DR   MaxQB; Q13467; -.
DR   PaxDb; Q13467; -.
DR   PeptideAtlas; Q13467; -.
DR   PRIDE; Q13467; -.
DR   ProteomicsDB; 59463; -.
DR   TopDownProteomics; Q13467; -.
DR   ABCD; Q13467; 61 sequenced antibodies.
DR   Antibodypedia; 19996; 414 antibodies.
DR   DNASU; 7855; -.
DR   Ensembl; ENST00000295417; ENSP00000354607; ENSG00000163251.
DR   GeneID; 7855; -.
DR   KEGG; hsa:7855; -.
DR   UCSC; uc002vcj.4; human.
DR   CTD; 7855; -.
DR   DisGeNET; 7855; -.
DR   EuPathDB; HostDB:ENSG00000163251.3; -.
DR   GeneCards; FZD5; -.
DR   HGNC; HGNC:4043; FZD5.
DR   HPA; ENSG00000163251; Tissue enhanced (intestine, liver).
DR   MalaCards; FZD5; -.
DR   MIM; 601723; gene.
DR   neXtProt; NX_Q13467; -.
DR   OpenTargets; ENSG00000163251; -.
DR   Orphanet; 98942; Coloboma of choroid and retina.
DR   Orphanet; 98943; Coloboma of eye lens.
DR   Orphanet; 98946; Coloboma of eyelid.
DR   Orphanet; 98944; Coloboma of iris.
DR   Orphanet; 98945; Coloboma of macula.
DR   Orphanet; 98947; Coloboma of optic disc.
DR   PharmGKB; PA28460; -.
DR   eggNOG; KOG3577; Eukaryota.
DR   GeneTree; ENSGT00940000162639; -.
DR   HOGENOM; CLU_007873_2_0_1; -.
DR   InParanoid; Q13467; -.
DR   KO; K02375; -.
DR   OMA; CRADGPQ; -.
DR   OrthoDB; 509772at2759; -.
DR   PhylomeDB; Q13467; -.
DR   TreeFam; TF317907; -.
DR   PathwayCommons; Q13467; -.
DR   Reactome; R-HSA-373080; Class B/2 (Secretin family receptors).
DR   Reactome; R-HSA-4086398; Ca2+ pathway.
DR   Reactome; R-HSA-4608870; Asymmetric localization of PCP proteins.
DR   Reactome; R-HSA-4641262; Disassembly of the destruction complex and recruitment of AXIN to the membrane.
DR   Reactome; R-HSA-4641263; Regulation of FZD by ubiquitination.
DR   Reactome; R-HSA-5140745; WNT5A-dependent internalization of FZD2, FZD5 and ROR2.
DR   Reactome; R-HSA-5340588; RNF mutants show enhanced WNT signaling and proliferation.
DR   SignaLink; Q13467; -.
DR   SIGNOR; Q13467; -.
DR   BioGRID-ORCS; 7855; 17 hits in 872 CRISPR screens.
DR   ChiTaRS; FZD5; human.
DR   GeneWiki; FZD5; -.
DR   GenomeRNAi; 7855; -.
DR   Pharos; Q13467; Tbio.
DR   PRO; PR:Q13467; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q13467; protein.
DR   Bgee; ENSG00000163251; Expressed in colonic mucosa and 205 other tissues.
DR   Genevisible; Q13467; HS.
DR   GO; GO:0030424; C:axon; IEA:UniProtKB-SubCell.
DR   GO; GO:0005923; C:bicellular tight junction; IEA:Ensembl.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0030669; C:clathrin-coated endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0030425; C:dendrite; IEA:UniProtKB-SubCell.
DR   GO; GO:0031901; C:early endosome membrane; TAS:Reactome.
DR   GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IBA:GO_Central.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:FlyBase.
DR   GO; GO:0043204; C:perikaryon; IEA:UniProtKB-SubCell.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0045202; C:synapse; IEA:UniProtKB-SubCell.
DR   GO; GO:0001540; F:amyloid-beta binding; IPI:ARUK-UCL.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0008289; F:lipid binding; IEA:UniProtKB-KW.
DR   GO; GO:0019901; F:protein kinase binding; IPI:BHF-UCL.
DR   GO; GO:0044877; F:protein-containing complex binding; IPI:ARUK-UCL.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0042813; F:Wnt-activated receptor activity; IDA:FlyBase.
DR   GO; GO:0017147; F:Wnt-protein binding; IPI:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; IEA:Ensembl.
DR   GO; GO:0008595; P:anterior/posterior axis specification, embryo; IDA:BHF-UCL.
DR   GO; GO:0060561; P:apoptotic process involved in morphogenesis; IEA:Ensembl.
DR   GO; GO:1904886; P:beta-catenin destruction complex disassembly; TAS:Reactome.
DR   GO; GO:0060670; P:branching involved in labyrinthine layer morphogenesis; IEA:Ensembl.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0048469; P:cell maturation; IEA:Ensembl.
DR   GO; GO:0071219; P:cellular response to molecule of bacterial origin; IDA:BHF-UCL.
DR   GO; GO:0060718; P:chorionic trophoblast cell differentiation; IEA:Ensembl.
DR   GO; GO:0000578; P:embryonic axis specification; IDA:BHF-UCL.
DR   GO; GO:0048596; P:embryonic camera-type eye morphogenesis; IEA:Ensembl.
DR   GO; GO:0060716; P:labyrinthine layer blood vessel development; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0030182; P:neuron differentiation; ISS:UniProtKB.
DR   GO; GO:0032729; P:positive regulation of interferon-gamma production; IMP:BHF-UCL.
DR   GO; GO:0032731; P:positive regulation of interleukin-1 beta production; ISS:ARUK-UCL.
DR   GO; GO:0043507; P:positive regulation of JUN kinase activity; IEA:Ensembl.
DR   GO; GO:1903955; P:positive regulation of protein targeting to mitochondrion; HMP:ParkinsonsUK-UCL.
DR   GO; GO:0002726; P:positive regulation of T cell cytokine production; IDA:CACAO.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:1904469; P:positive regulation of tumor necrosis factor secretion; ISS:ARUK-UCL.
DR   GO; GO:0031077; P:post-embryonic camera-type eye development; IEA:Ensembl.
DR   GO; GO:1903146; P:regulation of autophagy of mitochondrion; HMP:ParkinsonsUK-UCL.
DR   GO; GO:2000810; P:regulation of bicellular tight junction assembly; IEA:Ensembl.
DR   GO; GO:1901382; P:regulation of chorionic trophoblast cell proliferation; IEA:Ensembl.
DR   GO; GO:0060061; P:Spemann organizer formation; IDA:BHF-UCL.
DR   GO; GO:0007416; P:synapse assembly; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0060715; P:syncytiotrophoblast cell differentiation involved in labyrinthine layer development; IEA:Ensembl.
DR   GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl.
DR   GO; GO:0007223; P:Wnt signaling pathway, calcium modulating pathway; TAS:Reactome.
DR   GO; GO:0060071; P:Wnt signaling pathway, planar cell polarity pathway; TAS:Reactome.
DR   CDD; cd07460; CRD_FZ5; 1.
DR   Gene3D; 1.10.2000.10; -; 1.
DR   InterPro; IPR015526; Frizzled/SFRP.
DR   InterPro; IPR000539; Frizzled/Smoothened_TM.
DR   InterPro; IPR020067; Frizzled_dom.
DR   InterPro; IPR036790; Frizzled_dom_sf.
DR   InterPro; IPR037441; FZ5_CRD.
DR   InterPro; IPR017981; GPCR_2-like.
DR   PANTHER; PTHR11309; PTHR11309; 1.
DR   Pfam; PF01534; Frizzled; 1.
DR   Pfam; PF01392; Fz; 1.
DR   PRINTS; PR00489; FRIZZLED.
DR   SMART; SM00063; FRI; 1.
DR   SMART; SM01330; Frizzled; 1.
DR   SUPFAM; SSF63501; SSF63501; 1.
DR   PROSITE; PS50038; FZ; 1.
DR   PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell junction; Cell membrane; Cell projection;
KW   Developmental protein; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Golgi apparatus; Lipid-binding; Membrane; Polymorphism;
KW   Receptor; Reference proteome; Signal; Synapse; Transducer; Transmembrane;
KW   Transmembrane helix; Ubl conjugation; Wnt signaling pathway.
FT   SIGNAL          1..26
FT                   /evidence="ECO:0000255"
FT   CHAIN           27..585
FT                   /note="Frizzled-5"
FT                   /id="PRO_0000012990"
FT   TOPO_DOM        27..238
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        239..259
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        260..270
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        271..291
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        292..315
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        316..336
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        337..358
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        359..379
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        380..402
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        403..423
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        424..449
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        450..470
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        471..500
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        501..521
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        522..585
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          28..150
FT                   /note="FZ"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00090"
FT   MOTIF           525..530
FT                   /note="Lys-Thr-X-X-X-Trp motif, mediates interaction with
FT                   the PDZ domain of Dvl family members"
FT                   /evidence="ECO:0000250"
FT   MOTIF           583..585
FT                   /note="PDZ-binding"
FT   CARBOHYD        47
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000244|PDB:5URY, ECO:0000244|PDB:5URZ,
FT                   ECO:0000269|PubMed:28377511"
FT   CARBOHYD        151
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        33..94
FT                   /evidence="ECO:0000244|PDB:5URY, ECO:0000244|PDB:5URZ,
FT                   ECO:0000255|PROSITE-ProRule:PRU00090,
FT                   ECO:0000269|PubMed:28377511"
FT   DISULFID        41..87
FT                   /evidence="ECO:0000244|PDB:5URY, ECO:0000244|PDB:5URZ,
FT                   ECO:0000255|PROSITE-ProRule:PRU00090,
FT                   ECO:0000269|PubMed:28377511"
FT   DISULFID        78..116
FT                   /evidence="ECO:0000244|PDB:5URY, ECO:0000244|PDB:5URZ,
FT                   ECO:0000255|PROSITE-ProRule:PRU00090,
FT                   ECO:0000269|PubMed:28377511"
FT   DISULFID        105..147
FT                   /evidence="ECO:0000244|PDB:5URY, ECO:0000244|PDB:5URZ,
FT                   ECO:0000255|PROSITE-ProRule:PRU00090,
FT                   ECO:0000269|PubMed:28377511"
FT   DISULFID        109..133
FT                   /evidence="ECO:0000244|PDB:5URY, ECO:0000244|PDB:5URZ,
FT                   ECO:0000255|PROSITE-ProRule:PRU00090,
FT                   ECO:0000269|PubMed:28377511"
FT   VARIANT         216
FT                   /note="P -> L (in dbSNP:rs35994626)"
FT                   /id="VAR_049291"
FT   CONFLICT        88
FT                   /note="S -> T (in Ref. 1; AAC50385)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        262..263
FT                   /note="ER -> DT (in Ref. 1; AAC50385)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        345
FT                   /note="G -> A (in Ref. 1; AAC50385)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        357
FT                   /note="A -> G (in Ref. 1; AAC50385)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        384
FT                   /note="D -> G (in Ref. 4; BAF83075)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        402
FT                   /note="G -> R (in Ref. 1; AAC50385)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        504
FT                   /note="M -> V (in Ref. 4; BAG37738)"
FT                   /evidence="ECO:0000305"
FT   HELIX           39..41
FT                   /evidence="ECO:0000244|PDB:6O39"
FT   HELIX           60..67
FT                   /evidence="ECO:0000244|PDB:6O39"
FT   HELIX           68..70
FT                   /evidence="ECO:0000244|PDB:6O39"
FT   HELIX           71..76
FT                   /evidence="ECO:0000244|PDB:6O39"
FT   HELIX           82..90
FT                   /evidence="ECO:0000244|PDB:6O39"
FT   HELIX           106..122
FT                   /evidence="ECO:0000244|PDB:6O39"
FT   HELIX           129..131
FT                   /evidence="ECO:0000244|PDB:6O39"
FT   HELIX           133..135
FT                   /evidence="ECO:0000244|PDB:6O39"
FT   TURN            139..141
FT                   /evidence="ECO:0000244|PDB:6O39"
FT   STRAND          143..145
FT                   /evidence="ECO:0000244|PDB:6O39"
SQ   SEQUENCE   585 AA;  64507 MW;  AC3AB2CD912C1B0A CRC64;
     MARPDPSAPP SLLLLLLAQL VGRAAAASKA PVCQEITVPM CRGIGYNLTH MPNQFNHDTQ
     DEAGLEVHQF WPLVEIQCSP DLRFFLCSMY TPICLPDYHK PLPPCRSVCE RAKAGCSPLM
     RQYGFAWPER MSCDRLPVLG RDAEVLCMDY NRSEATTAPP RPFPAKPTLP GPPGAPASGG
     ECPAGGPFVC KCREPFVPIL KESHPLYNKV RTGQVPNCAV PCYQPSFSAD ERTFATFWIG
     LWSVLCFIST STTVATFLID MERFRYPERP IIFLSACYLC VSLGFLVRLV VGHASVACSR
     EHNHIHYETT GPALCTIVFL LVYFFGMASS IWWVILSLTW FLAAGMKWGN EAIAGYAQYF
     HLAAWLIPSV KSITALALSS VDGDPVAGIC YVGNQNLNSL RGFVLGPLVL YLLVGTLFLL
     AGFVSLFRIR SVIKQGGTKT DKLEKLMIRI GIFTLLYTVP ASIVVACYLY EQHYRESWEA
     ALTCACPGHD TGQPRAKPEY WVLMLKYFMC LVVGITSGVW IWSGKTVESW RRFTSRCCCR
     PRRGHKSGGA MAAGDYPEAS AALTGRTGPP GPAATYHKQV SLSHV
//
ID   GRM8_HUMAN              Reviewed;         908 AA.
AC   O00222; A4D0Y3; B0FZ74; B0M0L0; O15493; O95945; O95946; Q3MIV9; Q52M02;
AC   Q6J165;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-2000, sequence version 2.
DT   12-AUG-2020, entry version 184.
DE   RecName: Full=Metabotropic glutamate receptor 8;
DE            Short=mGluR8;
DE   Flags: Precursor;
GN   Name=GRM8; Synonyms=GPRC1H, MGLUR8;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A).
RX   PubMed=9299241; DOI=10.1006/geno.1997.4842;
RA   Scherer S.W., Soder S., Duvoisin R.M., Huizenga J.J., Tsui L.-C.;
RT   "The human metabotropic glutamate receptor 8 (GRM8) gene: a
RT   disproportionately large gene located at 7q31.3-q32.1.";
RL   Genomics 44:232-236(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A), FUNCTION, AND VARIANT ASN-768.
RX   PubMed=9473604; DOI=10.1016/s0169-328x(97)00277-5;
RA   Wu S., Wright R.A., Rockey P.K., Burgett S.G., Arnold J.S.,
RA   Rosteck P.R. Jr., Johnson B.G., Schoepp D.D., Belagaje R.M.;
RT   "Group III human metabotropic glutamate receptors 4, 7 and 8: molecular
RT   cloning, functional expression, and comparison of pharmacological
RT   properties in RGT cells.";
RL   Brain Res. Mol. Brain Res. 53:88-97(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS B AND C).
RC   TISSUE=Fetal brain;
RX   PubMed=10216218; DOI=10.1016/s0169-328x(99)00050-9;
RA   Malherbe P., Kratzeisen C., Lundstrom K., Richards J.G., Faull R.L.M.,
RA   Mutel V.;
RT   "Cloning and functional expression of alternative spliced variants of the
RT   human metabotropic glutamate receptor 8.";
RL   Brain Res. Mol. Brain Res. 67:201-210(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM B).
RA   Stormann T.M., Simin R.T., Hammerland L.G., Fuller F.H.;
RT   "Homo sapiens metabotropic glutamate receptor.";
RL   Submitted (APR-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A).
RC   TISSUE=Brain;
RA   Kaighin V.A., Martin A.L., Aronstam R.S.;
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS CYS-10; THR-265; TYR-362;
RP   ASP-368 AND PHE-430.
RG   NIEHS SNPs program;
RL   Submitted (JAN-2008) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (ISOFORM A), AND VARIANT
RP   GLN-343.
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM A).
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- FUNCTION: G-protein coupled receptor for glutamate. Ligand binding
CC       causes a conformation change that triggers signaling via guanine
CC       nucleotide-binding proteins (G proteins) and modulates the activity of
CC       down-stream effectors, such as adenylate cyclase. Signaling inhibits
CC       adenylate cyclase activity. {ECO:0000269|PubMed:9473604}.
CC   -!- SUBUNIT: Interacts with PICK1. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=A; Synonyms=mGluR8a;
CC         IsoId=O00222-1; Sequence=Displayed;
CC       Name=B; Synonyms=mGluR8b;
CC         IsoId=O00222-2; Sequence=VSP_002032;
CC       Name=C; Synonyms=mGluR8c;
CC         IsoId=O00222-3; Sequence=VSP_002033, VSP_002034;
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 3 family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/grm8/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U95025; AAB72040.1; -; mRNA.
DR   EMBL; U92459; AAB51764.1; -; mRNA.
DR   EMBL; AJ236921; CAB36968.1; -; mRNA.
DR   EMBL; AJ236922; CAB36969.1; -; mRNA.
DR   EMBL; AY608335; AAT37959.1; -; mRNA.
DR   EMBL; EU432125; ABY87924.1; -; mRNA.
DR   EMBL; EU368948; ABY59657.1; -; Genomic_DNA.
DR   EMBL; CH236947; EAL24322.1; -; Genomic_DNA.
DR   EMBL; BC093725; AAH93725.1; -; mRNA.
DR   EMBL; BC101675; AAI01676.1; -; mRNA.
DR   CCDS; CCDS47696.1; -. [O00222-2]
DR   CCDS; CCDS5794.1; -. [O00222-1]
DR   RefSeq; NP_000836.2; NM_000845.2. [O00222-1]
DR   RefSeq; NP_001120795.1; NM_001127323.1. [O00222-2]
DR   RefSeq; XP_006716001.1; XM_006715938.3.
DR   RefSeq; XP_011514393.1; XM_011516091.1.
DR   RefSeq; XP_011514394.1; XM_011516092.2.
DR   RefSeq; XP_016867563.1; XM_017012074.1.
DR   PDB; 6BSZ; X-ray; 2.65 A; A/B=37-514.
DR   PDB; 6BT5; X-ray; 2.92 A; A/B=37-514.
DR   PDB; 6E5V; X-ray; 2.95 A; A/B=2-508.
DR   PDBsum; 6BSZ; -.
DR   PDBsum; 6BT5; -.
DR   PDBsum; 6E5V; -.
DR   SMR; O00222; -.
DR   BioGRID; 109175; 1.
DR   CORUM; O00222; -.
DR   IntAct; O00222; 1.
DR   STRING; 9606.ENSP00000344173; -.
DR   BindingDB; O00222; -.
DR   ChEMBL; CHEMBL3228; -.
DR   DrugBank; DB00142; Glutamic acid.
DR   DrugCentral; O00222; -.
DR   GuidetoPHARMACOLOGY; 296; -.
DR   GlyGen; O00222; 5 sites.
DR   iPTMnet; O00222; -.
DR   PhosphoSitePlus; O00222; -.
DR   BioMuta; GRM8; -.
DR   PaxDb; O00222; -.
DR   PeptideAtlas; O00222; -.
DR   PRIDE; O00222; -.
DR   ProteomicsDB; 47792; -. [O00222-1]
DR   ProteomicsDB; 47793; -. [O00222-2]
DR   ProteomicsDB; 47794; -. [O00222-3]
DR   Antibodypedia; 17706; 364 antibodies.
DR   Ensembl; ENST00000339582; ENSP00000344173; ENSG00000179603. [O00222-1]
DR   Ensembl; ENST00000341617; ENSP00000345747; ENSG00000179603. [O00222-3]
DR   Ensembl; ENST00000358373; ENSP00000351142; ENSG00000179603. [O00222-2]
DR   Ensembl; ENST00000472701; ENSP00000419832; ENSG00000179603. [O00222-2]
DR   GeneID; 2918; -.
DR   KEGG; hsa:2918; -.
DR   UCSC; uc003vlr.3; human. [O00222-1]
DR   CTD; 2918; -.
DR   DisGeNET; 2918; -.
DR   EuPathDB; HostDB:ENSG00000179603.17; -.
DR   GeneCards; GRM8; -.
DR   HGNC; HGNC:4600; GRM8.
DR   HPA; ENSG00000179603; Tissue enhanced (brain, liver).
DR   MIM; 601116; gene.
DR   neXtProt; NX_O00222; -.
DR   OpenTargets; ENSG00000179603; -.
DR   PharmGKB; PA28997; -.
DR   eggNOG; KOG1056; Eukaryota.
DR   GeneTree; ENSGT01000000214532; -.
DR   HOGENOM; CLU_005389_0_0_1; -.
DR   InParanoid; O00222; -.
DR   KO; K04610; -.
DR   OMA; TQKGNDR; -.
DR   OrthoDB; 483746at2759; -.
DR   PhylomeDB; O00222; -.
DR   TreeFam; TF313240; -.
DR   PathwayCommons; O00222; -.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-420499; Class C/3 (Metabotropic glutamate/pheromone receptors).
DR   BioGRID-ORCS; 2918; 6 hits in 867 CRISPR screens.
DR   ChiTaRS; GRM8; human.
DR   GeneWiki; Metabotropic_glutamate_receptor_8; -.
DR   GenomeRNAi; 2918; -.
DR   Pharos; O00222; Tchem.
DR   PRO; PR:O00222; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; O00222; protein.
DR   Bgee; ENSG00000179603; Expressed in anterior cingulate cortex and 167 other tissues.
DR   ExpressionAtlas; O00222; baseline and differential.
DR   Genevisible; O00222; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IMP:UniProtKB.
DR   GO; GO:0008066; F:glutamate receptor activity; IMP:UniProtKB.
DR   GO; GO:0001642; F:group III metabotropic glutamate receptor activity; IBA:GO_Central.
DR   GO; GO:0007196; P:adenylate cyclase-inhibiting G protein-coupled glutamate receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0007193; P:adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007216; P:G protein-coupled glutamate receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0051966; P:regulation of synaptic transmission, glutamatergic; IBA:GO_Central.
DR   GO; GO:0007601; P:visual perception; TAS:ProtInc.
DR   Gene3D; 2.10.50.30; -; 1.
DR   InterPro; IPR001828; ANF_lig-bd_rcpt.
DR   InterPro; IPR000337; GPCR_3.
DR   InterPro; IPR011500; GPCR_3_9-Cys_dom.
DR   InterPro; IPR038550; GPCR_3_9-Cys_sf.
DR   InterPro; IPR017978; GPCR_3_C.
DR   InterPro; IPR017979; GPCR_3_CS.
DR   InterPro; IPR000162; GPCR_3_mtglu_rcpt.
DR   InterPro; IPR000144; GPCR_3_mtglu_rcpt_8.
DR   InterPro; IPR028082; Peripla_BP_I.
DR   Pfam; PF00003; 7tm_3; 1.
DR   Pfam; PF01094; ANF_receptor; 1.
DR   Pfam; PF07562; NCD3G; 1.
DR   PRINTS; PR00248; GPCRMGR.
DR   PRINTS; PR01058; MTABOTROPC8R.
DR   PRINTS; PR00593; MTABOTROPICR.
DR   SUPFAM; SSF53822; SSF53822; 1.
DR   PROSITE; PS00979; G_PROTEIN_RECEP_F3_1; 1.
DR   PROSITE; PS00980; G_PROTEIN_RECEP_F3_2; 1.
DR   PROSITE; PS00981; G_PROTEIN_RECEP_F3_3; 1.
DR   PROSITE; PS50259; G_PROTEIN_RECEP_F3_4; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Isopeptide bond; Membrane;
KW   Polymorphism; Receptor; Reference proteome; Sensory transduction; Signal;
KW   Transducer; Transmembrane; Transmembrane helix; Ubl conjugation.
FT   SIGNAL          1..33
FT                   /evidence="ECO:0000255"
FT   CHAIN           34..908
FT                   /note="Metabotropic glutamate receptor 8"
FT                   /id="PRO_0000012941"
FT   TOPO_DOM        34..583
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        584..608
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        609..620
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        621..641
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        642..647
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        648..668
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        669..695
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        696..716
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        717..746
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        747..768
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        769..781
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        782..803
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        804..818
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        819..843
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        844..908
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REGION          177..179
FT                   /note="Glutamate binding"
FT                   /evidence="ECO:0000250"
FT   BINDING         156
FT                   /note="Glutamate"
FT                   /evidence="ECO:0000250"
FT   BINDING         227
FT                   /note="Glutamate"
FT                   /evidence="ECO:0000250"
FT   BINDING         309
FT                   /note="Glutamate"
FT                   /evidence="ECO:0000250"
FT   BINDING         401
FT                   /note="Glutamate"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        95
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        298
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        452
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        480
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        565
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        64..106
FT                   /evidence="ECO:0000250"
FT   DISULFID        246..534
FT                   /evidence="ECO:0000250"
FT   DISULFID        369..384
FT                   /evidence="ECO:0000250"
FT   DISULFID        424..431
FT                   /evidence="ECO:0000250"
FT   DISULFID        516..535
FT                   /evidence="ECO:0000250"
FT   DISULFID        520..538
FT                   /evidence="ECO:0000250"
FT   DISULFID        541..553
FT                   /evidence="ECO:0000250"
FT   DISULFID        556..569
FT                   /evidence="ECO:0000250"
FT   CROSSLNK        882
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1)"
FT                   /evidence="ECO:0000250|UniProtKB:P47743"
FT   VAR_SEQ         454..501
FT                   /note="SAGTPVTFNENGDAPGRYDIFQYQITNKSTEYKVIGHWTNQLHLKVED ->
FT                   CRRGIQMSLPWPTLFTPSFSSSWAVLALLSLLMKTEMLLDVMISSSIK (in
FT                   isoform C)"
FT                   /evidence="ECO:0000303|PubMed:10216218"
FT                   /id="VSP_002033"
FT   VAR_SEQ         502..908
FT                   /note="Missing (in isoform C)"
FT                   /evidence="ECO:0000303|PubMed:10216218"
FT                   /id="VSP_002034"
FT   VAR_SEQ         893..908
FT                   /note="TSSTKTTYISYSNHSI -> SKSSVEFPMVKSGSTS (in isoform B)"
FT                   /evidence="ECO:0000303|PubMed:10216218, ECO:0000303|Ref.4"
FT                   /id="VSP_002032"
FT   VARIANT         10
FT                   /note="S -> C (in dbSNP:rs769194)"
FT                   /evidence="ECO:0000269|Ref.6"
FT                   /id="VAR_014446"
FT   VARIANT         21
FT                   /note="F -> C (in dbSNP:rs769202)"
FT                   /id="VAR_014447"
FT   VARIANT         265
FT                   /note="I -> T (in dbSNP:rs17150343)"
FT                   /evidence="ECO:0000269|Ref.6"
FT                   /id="VAR_049278"
FT   VARIANT         343
FT                   /note="R -> Q (in dbSNP:rs13309334)"
FT                   /evidence="ECO:0000269|PubMed:12853948"
FT                   /id="VAR_054752"
FT   VARIANT         362
FT                   /note="F -> Y (in dbSNP:rs78124913)"
FT                   /evidence="ECO:0000269|Ref.6"
FT                   /id="VAR_054477"
FT   VARIANT         368
FT                   /note="G -> D (in dbSNP:rs78947184)"
FT                   /evidence="ECO:0000269|Ref.6"
FT                   /id="VAR_054478"
FT   VARIANT         392
FT                   /note="R -> Q (in dbSNP:rs2234947)"
FT                   /id="VAR_014448"
FT   VARIANT         430
FT                   /note="L -> F (in dbSNP:rs75863532)"
FT                   /evidence="ECO:0000269|Ref.6"
FT                   /id="VAR_054479"
FT   VARIANT         548
FT                   /note="V -> G (in dbSNP:rs2234948)"
FT                   /id="VAR_014449"
FT   VARIANT         768
FT                   /note="I -> N (in dbSNP:rs1051433)"
FT                   /evidence="ECO:0000269|PubMed:9473604"
FT                   /id="VAR_054753"
FT   VARIANT         902
FT                   /note="S -> I (in dbSNP:rs10225567)"
FT                   /id="VAR_054754"
FT   CONFLICT        194
FT                   /note="R -> A (in Ref. 1; AAB72040)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        460
FT                   /note="T -> I (in Ref. 1; AAB72040)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        591
FT                   /note="A -> V (in Ref. 5; ABY87924)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        642
FT                   /note="A -> G (in Ref. 1; AAB72040)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        904
FT                   /note="S -> T (in Ref. 1; AAB72040)"
FT                   /evidence="ECO:0000305"
FT   STRAND          39..42
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   STRAND          45..52
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   STRAND          55..57
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   STRAND          63..67
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   TURN            69..72
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   HELIX           73..88
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   TURN            92..95
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   STRAND          98..104
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   HELIX           109..116
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   HELIX           117..119
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   STRAND          147..151
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   HELIX           156..166
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   TURN            167..170
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   STRAND          173..177
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   HELIX           181..184
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   TURN            186..188
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   STRAND          192..196
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   HELIX           199..213
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   STRAND          217..225
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   HELIX           226..241
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   STRAND          242..244
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   STRAND          246..253
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   HELIX           261..269
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   STRAND          277..281
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   HELIX           284..296
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   TURN            300..302
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   STRAND          304..307
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   TURN            309..313
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   TURN            316..320
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   TURN            322..327
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   STRAND          329..334
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   HELIX           339..346
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   TURN            350..352
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   HELIX           359..367
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   TURN            390..392
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   HELIX           402..423
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   STRAND          424..426
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   HELIX           432..434
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   HELIX           439..448
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   STRAND          450..452
FT                   /evidence="ECO:0000244|PDB:6BT5"
FT   TURN            454..456
FT                   /evidence="ECO:0000244|PDB:6E5V"
FT   STRAND          458..460
FT                   /evidence="ECO:0000244|PDB:6BT5"
FT   STRAND          463..465
FT                   /evidence="ECO:0000244|PDB:6BT5"
FT   STRAND          470..478
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   STRAND          483..497
FT                   /evidence="ECO:0000244|PDB:6BSZ"
FT   HELIX           499..501
FT                   /evidence="ECO:0000244|PDB:6BSZ"
SQ   SEQUENCE   908 AA;  101741 MW;  95C2D5883DAF6FDE CRC64;
     MVCEGKRSAS CPCFFLLTAK FYWILTMMQR THSQEYAHSI RVDGDIILGG LFPVHAKGER
     GVPCGELKKE KGIHRLEAML YAIDQINKDP DLLSNITLGV RILDTCSRDT YALEQSLTFV
     QALIEKDASD VKCANGDPPI FTKPDKISGV IGAAASSVSI MVANILRLFK IPQISYASTA
     PELSDNTRYD FFSRVVPPDS YQAQAMVDIV TALGWNYVST LASEGNYGES GVEAFTQISR
     EIGGVCIAQS QKIPREPRPG EFEKIIKRLL ETPNARAVIM FANEDDIRRI LEAAKKLNQS
     GHFLWIGSDS WGSKIAPVYQ QEEIAEGAVT ILPKRASIDG FDRYFRSRTL ANNRRNVWFA
     EFWEENFGCK LGSHGKRNSH IKKCTGLERI ARDSSYEQEG KVQFVIDAVY SMAYALHNMH
     KDLCPGYIGL CPRMSTIDGK ELLGYIRAVN FNGSAGTPVT FNENGDAPGR YDIFQYQITN
     KSTEYKVIGH WTNQLHLKVE DMQWAHREHT HPASVCSLPC KPGERKKTVK GVPCCWHCER
     CEGYNYQVDE LSCELCPLDQ RPNMNRTGCQ LIPIIKLEWH SPWAVVPVFV AILGIIATTF
     VIVTFVRYND TPIVRASGRE LSYVLLTGIF LCYSITFLMI AAPDTIICSF RRVFLGLGMC
     FSYAALLTKT NRIHRIFEQG KKSVTAPKFI SPASQLVITF SLISVQLLGV FVWFVVDPPH
     IIIDYGEQRT LDPEKARGVL KCDISDLSLI CSLGYSILLM VTCTVYAIKT RGVPETFNEA
     KPIGFTMYTT CIIWLAFIPI FFGTAQSAEK MYIQTTTLTV SMSLSASVSL GMLYMPKVYI
     IIFHPEQNVQ KRKRSFKAVV TAATMQSKLI QKGNDRPNGE VKSELCESLE TNTSSTKTTY
     ISYSNHSI
//
ID   MTR1A_HUMAN             Reviewed;         350 AA.
AC   P48039; A0AVC5; B0M0L2;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 1.
DT   07-OCT-2020, entry version 175.
DE   RecName: Full=Melatonin receptor type 1A;
DE            Short=Mel-1A-R;
DE            Short=Mel1a receptor;
GN   Name=MTNR1A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7946354; DOI=10.1016/0896-6273(94)90055-8;
RA   Reppert S.M., Weaver D.R., Ebisawa T.;
RT   "Cloning and characterization of a mammalian melatonin receptor that
RT   mediates reproductive and circadian responses.";
RL   Neuron 13:1177-1185(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS TRP-54 AND VAL-157.
RC   TISSUE=Leukocyte;
RX   PubMed=10471411; DOI=10.1006/bbrc.1999.1308;
RA   Ebisawa T., Kajimura N., Uchiyama M., Katoh M., Sekimoto M., Watanabe T.,
RA   Ozeki Y., Ikeda M., Jodoi T., Sugishita M., Iwase T., Kamei Y., Kim K.,
RA   Shibui K., Kudo Y., Yamada N., Toyoshima R., Okawa M., Takahashi K.,
RA   Yamauchi T.;
RT   "Alleic variants of human melatonin 1a receptor: function and prevalence in
RT   subjects with circadian rhythm sleep disorders.";
RL   Biochem. Biophys. Res. Commun. 262:832-837(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Hippocampus;
RA   Huang Y.-H., Kaighin V.A., Martin A.L., Aronstam R.S.;
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 12-325 IN COMPLEX WITH MELATONIN
RP   ANALOG, AND DISULFIDE BOND.
RX   PubMed=31019306; DOI=10.1038/s41586-019-1141-3;
RA   Stauch B., Johansson L.C., McCorvy J.D., Patel N., Han G.W., Huang X.P.,
RA   Gati C., Batyuk A., Slocum S.T., Ishchenko A., Brehm W., White T.A.,
RA   Michaelian N., Madsen C., Zhu L., Grant T.D., Grandner J.M., Shiriaeva A.,
RA   Olsen R.H.J., Tribo A.R., Yous S., Stevens R.C., Weierstall U.,
RA   Katritch V., Roth B.L., Liu W., Cherezov V.;
RT   "Structural basis of ligand recognition at the human MT1 melatonin
RT   receptor.";
RL   Nature 569:284-288(2019).
CC   -!- FUNCTION: High affinity receptor for melatonin. Likely to mediate the
CC       reproductive and circadian actions of melatonin. The activity of this
CC       receptor is mediated by pertussis toxin sensitive G proteins that
CC       inhibit adenylate cyclase activity.
CC   -!- INTERACTION:
CC       P48039; P27797: CALR; NbExp=3; IntAct=EBI-1188238, EBI-1049597;
CC       P48039; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-1188238, EBI-3867333;
CC       P48039; P28335: HTR2C; NbExp=2; IntAct=EBI-1188238, EBI-994141;
CC       P48039; P49286: MTNR1B; NbExp=2; IntAct=EBI-1188238, EBI-1188341;
CC       P48039; O76081: RGS20; NbExp=6; IntAct=EBI-1188238, EBI-1052678;
CC       P48039; P57088: TMEM33; NbExp=3; IntAct=EBI-1188238, EBI-1048629;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Expressed in hypophyseal pars tuberalis and
CC       hypothalamic suprachiasmatic nuclei (SCN). Hippocampus.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Melatonin receptor entry;
CC       URL="https://en.wikipedia.org/wiki/Melatonin_receptor";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U14108; AAB17720.1; -; mRNA.
DR   EMBL; AB029933; BAA85303.1; -; Genomic_DNA.
DR   EMBL; EU432127; ABY87926.1; -; mRNA.
DR   EMBL; BC074946; AAH74946.1; -; mRNA.
DR   EMBL; BC074947; AAH74947.1; -; mRNA.
DR   EMBL; BC126297; AAI26298.1; -; mRNA.
DR   EMBL; BC126299; AAI26300.1; -; mRNA.
DR   CCDS; CCDS3848.1; -.
DR   PIR; I38848; I38848.
DR   RefSeq; NP_005949.1; NM_005958.4.
DR   PDB; 6ME2; X-ray; 2.80 A; A=12-325.
DR   PDB; 6ME3; X-ray; 2.90 A; A=12-325.
DR   PDB; 6ME4; X-ray; 3.20 A; A=12-325.
DR   PDB; 6ME5; X-ray; 3.20 A; A=12-325.
DR   PDBsum; 6ME2; -.
DR   PDBsum; 6ME3; -.
DR   PDBsum; 6ME4; -.
DR   PDBsum; 6ME5; -.
DR   SMR; P48039; -.
DR   BioGRID; 110639; 231.
DR   CORUM; P48039; -.
DR   ELM; P48039; -.
DR   IntAct; P48039; 223.
DR   MINT; P48039; -.
DR   STRING; 9606.ENSP00000302811; -.
DR   BindingDB; P48039; -.
DR   ChEMBL; CHEMBL1945; -.
DR   DrugBank; DB06594; Agomelatine.
DR   DrugBank; DB01065; Melatonin.
DR   DrugBank; DB00980; Ramelteon.
DR   DrugBank; DB02709; Resveratrol.
DR   DrugBank; DB09071; Tasimelteon.
DR   DrugCentral; P48039; -.
DR   GuidetoPHARMACOLOGY; 287; -.
DR   TCDB; 9.A.14.1.3; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; P48039; 2 sites.
DR   iPTMnet; P48039; -.
DR   BioMuta; MTNR1A; -.
DR   DMDM; 1346544; -.
DR   PaxDb; P48039; -.
DR   PeptideAtlas; P48039; -.
DR   PRIDE; P48039; -.
DR   ProteomicsDB; 55836; -.
DR   Antibodypedia; 29126; 336 antibodies.
DR   DNASU; 4543; -.
DR   Ensembl; ENST00000307161; ENSP00000302811; ENSG00000168412.
DR   GeneID; 4543; -.
DR   KEGG; hsa:4543; -.
DR   UCSC; uc003izd.2; human.
DR   CTD; 4543; -.
DR   DisGeNET; 4543; -.
DR   EuPathDB; HostDB:ENSG00000168412.6; -.
DR   GeneCards; MTNR1A; -.
DR   HGNC; HGNC:7463; MTNR1A.
DR   HPA; ENSG00000168412; Tissue enhanced (brain, intestine, kidney, testis).
DR   MIM; 600665; gene.
DR   neXtProt; NX_P48039; -.
DR   OpenTargets; ENSG00000168412; -.
DR   PharmGKB; PA31267; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00940000160321; -.
DR   HOGENOM; CLU_009579_3_3_1; -.
DR   InParanoid; P48039; -.
DR   KO; K04285; -.
DR   OMA; GYVHCQI; -.
DR   OrthoDB; 1011028at2759; -.
DR   PhylomeDB; P48039; -.
DR   TreeFam; TF331693; -.
DR   PathwayCommons; P48039; -.
DR   Reactome; R-HSA-373076; Class A/1 (Rhodopsin-like receptors).
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   SignaLink; P48039; -.
DR   SIGNOR; P48039; -.
DR   BioGRID-ORCS; 4543; 1 hit in 874 CRISPR screens.
DR   GeneWiki; Melatonin_receptor_1A; -.
DR   GenomeRNAi; 4543; -.
DR   Pharos; P48039; Tclin.
DR   PRO; PR:P48039; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; P48039; protein.
DR   Bgee; ENSG00000168412; Expressed in cerebellum and 38 other tissues.
DR   Genevisible; P48039; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0043235; C:receptor complex; IDA:BHF-UCL.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0042562; F:hormone binding; IPI:BHF-UCL.
DR   GO; GO:0008502; F:melatonin receptor activity; IDA:BHF-UCL.
DR   GO; GO:0097159; F:organic cyclic compound binding; IPI:BHF-UCL.
DR   GO; GO:0007193; P:adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0007623; P:circadian rhythm; IBA:GO_Central.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007187; P:G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; TAS:ProtInc.
DR   GO; GO:0007617; P:mating behavior; TAS:ProtInc.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR002278; Mel_1A/1B_rcpt.
DR   InterPro; IPR000025; Melatonin_rcpt.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01149; MELATONIN1AR.
DR   PRINTS; PR00857; MELATONINR.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Membrane; Polymorphism; Receptor; Reference proteome;
KW   Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..350
FT                   /note="Melatonin receptor type 1A"
FT                   /id="PRO_0000069862"
FT   TOPO_DOM        1..29
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        30..50
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        51..63
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        64..84
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        85..102
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        103..123
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        124..142
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        143..163
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        164..187
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        188..208
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        209..240
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        241..261
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        262..274
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        275..295
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        296..350
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   BINDING         162
FT                   /note="Melatonin"
FT                   /evidence="ECO:0000244|PDB:6ME3,
FT                   ECO:0000269|PubMed:31019306"
FT   BINDING         181
FT                   /note="Melatonin"
FT                   /evidence="ECO:0000244|PDB:6ME3,
FT                   ECO:0000269|PubMed:31019306"
FT   CARBOHYD        4
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        10
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        100..177
FT                   /evidence="ECO:0000244|PDB:6ME2, ECO:0000255|PROSITE-
FT                   ProRule:PRU00521, ECO:0000269|PubMed:31019306"
FT   VARIANT         54
FT                   /note="R -> W (exhibits significantly reduced B(max) and
FT                   slightly enhanced affinity; dbSNP:rs1800885)"
FT                   /evidence="ECO:0000269|PubMed:10471411"
FT                   /id="VAR_009260"
FT   VARIANT         157
FT                   /note="A -> V (similar binding characteristics compared to
FT                   wild-type; dbSNP:rs1800884)"
FT                   /evidence="ECO:0000269|PubMed:10471411"
FT                   /id="VAR_009261"
FT   VARIANT         212
FT                   /note="I -> T (in dbSNP:rs7654853)"
FT                   /id="VAR_049420"
FT   HELIX           24..54
FT                   /evidence="ECO:0000244|PDB:6ME2"
FT   TURN            56..58
FT                   /evidence="ECO:0000244|PDB:6ME2"
FT   HELIX           61..63
FT                   /evidence="ECO:0000244|PDB:6ME2"
FT   HELIX           64..78
FT                   /evidence="ECO:0000244|PDB:6ME2"
FT   HELIX           80..90
FT                   /evidence="ECO:0000244|PDB:6ME2"
FT   HELIX           96..134
FT                   /evidence="ECO:0000244|PDB:6ME2"
FT   HELIX           144..159
FT                   /evidence="ECO:0000244|PDB:6ME2"
FT   HELIX           161..165
FT                   /evidence="ECO:0000244|PDB:6ME2"
FT   STRAND          168..171
FT                   /evidence="ECO:0000244|PDB:6ME2"
FT   TURN            172..175
FT                   /evidence="ECO:0000244|PDB:6ME2"
FT   STRAND          176..179
FT                   /evidence="ECO:0000244|PDB:6ME2"
FT   TURN            181..183
FT                   /evidence="ECO:0000244|PDB:6ME2"
FT   HELIX           185..195
FT                   /evidence="ECO:0000244|PDB:6ME2"
FT   HELIX           197..218
FT                   /evidence="ECO:0000244|PDB:6ME2"
FT   TURN            229..231
FT                   /evidence="ECO:0000244|PDB:6ME2"
FT   HELIX           235..263
FT                   /evidence="ECO:0000244|PDB:6ME2"
FT   HELIX           265..271
FT                   /evidence="ECO:0000244|PDB:6ME2"
FT   HELIX           274..286
FT                   /evidence="ECO:0000244|PDB:6ME2"
FT   HELIX           287..289
FT                   /evidence="ECO:0000244|PDB:6ME2"
FT   HELIX           290..298
FT                   /evidence="ECO:0000244|PDB:6ME2"
FT   HELIX           300..312
FT                   /evidence="ECO:0000244|PDB:6ME2"
SQ   SEQUENCE   350 AA;  39375 MW;  DF7C67111D2386ED CRC64;
     MQGNGSALPN ASQPVLRGDG ARPSWLASAL ACVLIFTIVV DILGNLLVIL SVYRNKKLRN
     AGNIFVVSLA VADLVVAIYP YPLVLMSIFN NGWNLGYLHC QVSGFLMGLS VIGSIFNITG
     IAINRYCYIC HSLKYDKLYS SKNSLCYVLL IWLLTLAAVL PNLRAGTLQY DPRIYSCTFA
     QSVSSAYTIA VVVFHFLVPM IIVIFCYLRI WILVLQVRQR VKPDRKPKLK PQDFRNFVTM
     FVVFVLFAIC WAPLNFIGLA VASDPASMVP RIPEWLFVAS YYMAYFNSCL NAIIYGLLNQ
     NFRKEYRRII VSLCTARVFF VDSSNDVADR VKWKPSPLMT NNNVVKVDSV
//
ID   NK1R_HUMAN              Reviewed;         407 AA.
AC   P25103; A8K150;
DT   01-MAY-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1992, sequence version 1.
DT   07-OCT-2020, entry version 198.
DE   RecName: Full=Substance-P receptor;
DE            Short=SPR;
DE   AltName: Full=NK-1 receptor;
DE            Short=NK-1R;
DE   AltName: Full=Tachykinin receptor 1;
GN   Name=TACR1; Synonyms=NK1R, TAC1R;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1718267; DOI=10.1016/0006-291x(91)91704-g;
RA   Takeda Y., Chou K.B., Takeda J., Sachais B.S., Krause J.E.;
RT   "Molecular cloning, structural characterization and functional expression
RT   of the human substance P receptor.";
RL   Biochem. Biophys. Res. Commun. 179:1232-1240(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=1659396; DOI=10.1016/s0006-291x(05)81181-7;
RA   Hopkins B., Powell S.J., Danks P., Briggs I., Graham A.;
RT   "Isolation and characterisation of the human lung NK-1 receptor cDNA.";
RL   Biochem. Biophys. Res. Commun. 180:1110-1117(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1657150; DOI=10.1021/bi00108a006;
RA   Gerard N.P., Garraway L.A., Eddy R.L. Jr., Shows T.B., Iijima H.,
RA   Paquet J.L., Gerard C.;
RT   "Human substance P receptor (NK-1): organization of the gene, chromosome
RT   localization, and functional expression of cDNA clones.";
RL   Biochemistry 30:10640-10646(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=1312928; DOI=10.1111/j.1432-1033.1992.tb16724.x;
RA   Takahashi K., Tanaka A., Hara M., Nakanishi S.;
RT   "The primary structure and gene organization of human substance P and
RT   neuromedin K receptors.";
RL   Eur. J. Biochem. 204:1025-1033(1992).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RX   PubMed=1310144;
RA   Fong T.M., Anderson S.A., Yu H., Huang R.-R.C., Strader C.D.;
RT   "Differential activation of intracellular effector by two isoforms of human
RT   neurokinin-1 receptor.";
RL   Mol. Pharmacol. 41:24-30(1992).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (NOV-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   LACK OF DETECTION OF ISOFORM 2.
RX   PubMed=11864635; DOI=10.1016/s0014-2999(02)01278-5;
RA   Page N.M., Bell N.J.;
RT   "The human tachykinin NK1 (short form) and tachykinin NK4 receptor: a
RT   reappraisal.";
RL   Eur. J. Pharmacol. 437:27-30(2002).
RN   [12]
RP   BINDING TO ANTAGONIST CP 96345.
RX   PubMed=8384323; DOI=10.1038/362350a0;
RA   Fong T.M., Cascieri M.A., Yu H., Bansai A., Swain C., Strader C.D.;
RT   "Amino-aromatic interaction between histidine 197 of the neurokinin-1
RT   receptor and CP 96345.";
RL   Nature 362:350-353(1993).
RN   [13]
RP   STRUCTURE BY NMR OF 1-364, AND DISULFIDE BOND.
RX   PubMed=20937248; DOI=10.1016/j.bbamem.2010.09.023;
RA   Gayen A., Goswami S.K., Mukhopadhyay C.;
RT   "NMR evidence of GM1-induced conformational change of Substance P using
RT   isotropic bicelles.";
RL   Biochim. Biophys. Acta 1808:127-139(2011).
RN   [14]
RP   VARIANT HIS-192, AND CHARACTERIZATION OF VARIANT HIS-192.
RX   PubMed=15452552; DOI=10.1038/sj.tpj.6500276;
RA   Randolph G.P., Simon J.S., Arreaza M.G., Qiu P., Lachowicz J.E.,
RA   Duffy R.A.;
RT   "Identification of single-nucleotide polymorphisms of the human neurokinin
RT   1 receptor gene and pharmacological characterization of a Y192H variant.";
RL   Pharmacogenomics J. 4:394-402(2004).
CC   -!- FUNCTION: This is a receptor for the tachykinin neuropeptide substance
CC       P. It is probably associated with G proteins that activate a
CC       phosphatidylinositol-calcium second messenger system. The rank order of
CC       affinity of this receptor to tachykinins is: substance P > substance K
CC       > neuromedin-K.
CC   -!- SUBUNIT: Interacts with ARRB1. {ECO:0000250}.
CC   -!- INTERACTION:
CC       P25103; Q9P0B6: CCDC167; NbExp=3; IntAct=EBI-6655287, EBI-9083477;
CC       P25103; PRO_0000033530 [P20366]: TAC1; NbExp=2; IntAct=EBI-6655287, EBI-6655360;
CC       P25103; Q9BVK8: TMEM147; NbExp=3; IntAct=EBI-6655287, EBI-348587;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P25103-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P25103-3; Sequence=VSP_053824;
CC   -!- MISCELLANEOUS: [Isoform 2]: In contrast to Fong et al. data
CC       (PubMed:1310144), isoform 2 is not detected by PCR in any of 24 human
CC       tissues examined including the placenta (PubMed:11864635).
CC       {ECO:0000305|PubMed:11864635, ECO:0000305|PubMed:1310144}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Tachykinin entry;
CC       URL="https://en.wikipedia.org/wiki/Tachykinin";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; S62045; AAB20168.2; -; mRNA.
DR   EMBL; M74290; AAA60601.1; -; mRNA.
DR   EMBL; M81797; AAA59933.1; -; mRNA.
DR   EMBL; M76675; AAA59936.1; -; mRNA.
DR   EMBL; X65177; CAA46292.1; -; Genomic_DNA.
DR   EMBL; X65178; CAA46292.1; JOINED; Genomic_DNA.
DR   EMBL; X65179; CAA46292.1; JOINED; Genomic_DNA.
DR   EMBL; X65180; CAA46292.1; JOINED; Genomic_DNA.
DR   EMBL; X65181; CAA46292.1; JOINED; Genomic_DNA.
DR   EMBL; M84425; AAA36641.1; -; mRNA.
DR   EMBL; M84426; AAA36644.1; -; mRNA.
DR   EMBL; AY462098; AAR23925.1; -; mRNA.
DR   EMBL; AK289765; BAF82454.1; -; mRNA.
DR   EMBL; CH471053; EAW99596.1; -; Genomic_DNA.
DR   EMBL; BC074911; AAH74911.1; -; mRNA.
DR   EMBL; BC074912; AAH74912.1; -; mRNA.
DR   EMBL; AC007400; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS1958.1; -. [P25103-1]
DR   CCDS; CCDS46345.1; -. [P25103-3]
DR   PIR; A41134; JQ1274.
DR   RefSeq; NP_001049.1; NM_001058.3. [P25103-1]
DR   RefSeq; NP_056542.1; NM_015727.2. [P25103-3]
DR   PDB; 2KS9; NMR; -; A=1-364.
DR   PDB; 2KSA; NMR; -; A=1-364.
DR   PDB; 2KSB; NMR; -; A=1-364.
DR   PDB; 6E59; X-ray; 3.40 A; A=1-227, A=238-346.
DR   PDB; 6HLL; X-ray; 3.27 A; A=1-226, A=238-335.
DR   PDB; 6HLO; X-ray; 2.40 A; A=1-226, A=238-335.
DR   PDB; 6HLP; X-ray; 2.20 A; A=1-226, A=238-335.
DR   PDBsum; 2KS9; -.
DR   PDBsum; 2KSA; -.
DR   PDBsum; 2KSB; -.
DR   PDBsum; 6E59; -.
DR   PDBsum; 6HLL; -.
DR   PDBsum; 6HLO; -.
DR   PDBsum; 6HLP; -.
DR   BMRB; P25103; -.
DR   SMR; P25103; -.
DR   BioGRID; 112732; 54.
DR   IntAct; P25103; 46.
DR   STRING; 9606.ENSP00000303522; -.
DR   BindingDB; P25103; -.
DR   ChEMBL; CHEMBL249; -.
DR   DrugBank; DB00673; Aprepitant.
DR   DrugBank; DB05072; AV608.
DR   DrugBank; DB06634; Casopitant.
DR   DrugBank; DB05421; CP-122721.
DR   DrugBank; DB14019; Fosnetupitant.
DR   DrugBank; DB05418; GW 597599.
DR   DrugBank; DB01221; Ketamine.
DR   DrugBank; DB09048; Netupitant.
DR   DrugBank; DB05466; R673.
DR   DrugBank; DB09291; Rolapitant.
DR   DrugBank; DB05790; SR 140333.
DR   DrugBank; DB00193; Tramadol.
DR   DrugBank; DB04894; Vapreotide.
DR   DrugBank; DB11949; Vestipitant.
DR   DrugBank; DB12436; Vofopitant.
DR   DrugCentral; P25103; -.
DR   GuidetoPHARMACOLOGY; 360; -.
DR   GlyGen; P25103; 2 sites.
DR   iPTMnet; P25103; -.
DR   PhosphoSitePlus; P25103; -.
DR   BioMuta; TACR1; -.
DR   DMDM; 128359; -.
DR   PaxDb; P25103; -.
DR   PeptideAtlas; P25103; -.
DR   PRIDE; P25103; -.
DR   ProteomicsDB; 54260; -. [P25103-1]
DR   ABCD; P25103; 1 sequenced antibody.
DR   Antibodypedia; 16803; 553 antibodies.
DR   DNASU; 6869; -.
DR   Ensembl; ENST00000305249; ENSP00000303522; ENSG00000115353. [P25103-1]
DR   Ensembl; ENST00000409848; ENSP00000386448; ENSG00000115353. [P25103-3]
DR   GeneID; 6869; -.
DR   KEGG; hsa:6869; -.
DR   UCSC; uc002sng.3; human. [P25103-1]
DR   CTD; 6869; -.
DR   DisGeNET; 6869; -.
DR   EuPathDB; HostDB:ENSG00000115353.10; -.
DR   GeneCards; TACR1; -.
DR   HGNC; HGNC:11526; TACR1.
DR   HPA; ENSG00000115353; Tissue enhanced (adipose).
DR   MIM; 162323; gene.
DR   neXtProt; NX_P25103; -.
DR   OpenTargets; ENSG00000115353; -.
DR   PharmGKB; PA36302; -.
DR   eggNOG; KOG4219; Eukaryota.
DR   GeneTree; ENSGT00940000153745; -.
DR   HOGENOM; CLU_009579_6_1_1; -.
DR   InParanoid; P25103; -.
DR   KO; K04222; -.
DR   OMA; MIIVVCT; -.
DR   OrthoDB; 715197at2759; -.
DR   PhylomeDB; P25103; -.
DR   TreeFam; TF315303; -.
DR   PathwayCommons; P25103; -.
DR   Reactome; R-HSA-380095; Tachykinin receptors bind tachykinins.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-8856825; Cargo recognition for clathrin-mediated endocytosis.
DR   Reactome; R-HSA-8856828; Clathrin-mediated endocytosis.
DR   SIGNOR; P25103; -.
DR   BioGRID-ORCS; 6869; 3 hits in 871 CRISPR screens.
DR   ChiTaRS; TACR1; human.
DR   EvolutionaryTrace; P25103; -.
DR   GeneWiki; Tachykinin_receptor_1; -.
DR   GenomeRNAi; 6869; -.
DR   Pharos; P25103; Tclin.
DR   PRO; PR:P25103; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; P25103; protein.
DR   Bgee; ENSG00000115353; Expressed in endocervix and 143 other tissues.
DR   Genevisible; P25103; HS.
DR   GO; GO:0044297; C:cell body; IEA:Ensembl.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0036126; C:sperm flagellum; IDA:UniProtKB.
DR   GO; GO:0061827; C:sperm head; IDA:UniProtKB.
DR   GO; GO:0097225; C:sperm midpiece; IDA:UniProtKB.
DR   GO; GO:0016496; F:substance P receptor activity; IMP:UniProtKB.
DR   GO; GO:0004995; F:tachykinin receptor activity; IBA:GO_Central.
DR   GO; GO:0002526; P:acute inflammatory response; IEA:Ensembl.
DR   GO; GO:0002118; P:aggressive behavior; IEA:Ensembl.
DR   GO; GO:0003051; P:angiotensin-mediated drinking behavior; IEA:Ensembl.
DR   GO; GO:0008306; P:associative learning; IEA:Ensembl.
DR   GO; GO:0048266; P:behavioral response to pain; IEA:Ensembl.
DR   GO; GO:0009582; P:detection of abiotic stimulus; TAS:ProtInc.
DR   GO; GO:0042755; P:eating behavior; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006954; P:inflammatory response; TAS:ProtInc.
DR   GO; GO:0007616; P:long-term memory; IEA:Ensembl.
DR   GO; GO:0035106; P:operant conditioning; IEA:Ensembl.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0045760; P:positive regulation of action potential; IEA:Ensembl.
DR   GO; GO:0045777; P:positive regulation of blood pressure; IEA:Ensembl.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IDA:UniProtKB.
DR   GO; GO:0010634; P:positive regulation of epithelial cell migration; IEA:Ensembl.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:1902093; P:positive regulation of flagellated sperm motility; IMP:UniProtKB.
DR   GO; GO:0046887; P:positive regulation of hormone secretion; IEA:Ensembl.
DR   GO; GO:0002687; P:positive regulation of leukocyte migration; IEA:Ensembl.
DR   GO; GO:0050671; P:positive regulation of lymphocyte proliferation; IEA:Ensembl.
DR   GO; GO:0045778; P:positive regulation of ossification; IEA:Ensembl.
DR   GO; GO:0035815; P:positive regulation of renal sodium excretion; IEA:Ensembl.
DR   GO; GO:0046878; P:positive regulation of saliva secretion; IEA:Ensembl.
DR   GO; GO:0051496; P:positive regulation of stress fiber assembly; IEA:Ensembl.
DR   GO; GO:0032224; P:positive regulation of synaptic transmission, cholinergic; IEA:Ensembl.
DR   GO; GO:0032230; P:positive regulation of synaptic transmission, GABAergic; IEA:Ensembl.
DR   GO; GO:0070474; P:positive regulation of uterine smooth muscle contraction; IEA:Ensembl.
DR   GO; GO:0043117; P:positive regulation of vascular permeability; IEA:Ensembl.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; IEA:Ensembl.
DR   GO; GO:0014910; P:regulation of smooth muscle cell migration; IEA:Ensembl.
DR   GO; GO:0048660; P:regulation of smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0010996; P:response to auditory stimulus; IEA:Ensembl.
DR   GO; GO:0051602; P:response to electrical stimulus; IEA:Ensembl.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0009408; P:response to heat; IEA:Ensembl.
DR   GO; GO:0043278; P:response to morphine; IEA:Ensembl.
DR   GO; GO:0035094; P:response to nicotine; IEA:Ensembl.
DR   GO; GO:0010193; P:response to ozone; IEA:Ensembl.
DR   GO; GO:0032570; P:response to progesterone; IEA:Ensembl.
DR   GO; GO:0019233; P:sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0060083; P:smooth muscle contraction involved in micturition; IEA:Ensembl.
DR   GO; GO:0042713; P:sperm ejaculation; IEA:Ensembl.
DR   GO; GO:0007217; P:tachykinin receptor signaling pathway; IDA:BHF-UCL.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR001681; Neurokn_rcpt.
DR   InterPro; IPR000046; NK1_rcpt.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01024; NEUROKININ1R.
DR   PRINTS; PR00244; NEUROKININR.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane; Palmitate;
KW   Polymorphism; Receptor; Reference proteome; Transducer; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..407
FT                   /note="Substance-P receptor"
FT                   /id="PRO_0000069885"
FT   TOPO_DOM        1..31
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        32..54
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        55..64
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        65..86
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        87..106
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        107..128
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        129..148
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        149..169
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        170..194
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        195..219
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        220..248
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        249..270
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        271..283
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        284..308
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        309..407
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   BINDING         197
FT                   /note="Antagonist CP 96345"
FT   LIPID           322
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        14
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        18
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        105..180
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521,
FT                   ECO:0000269|PubMed:20937248"
FT   VAR_SEQ         312..407
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:1310144"
FT                   /id="VSP_053824"
FT   VARIANT         192
FT                   /note="Y -> H (display properties similar to those of the
FT                   wild-type receptor; dbSNP:rs200685841)"
FT                   /evidence="ECO:0000269|PubMed:15452552"
FT                   /id="VAR_026826"
FT   CONFLICT        116
FT                   /note="V -> C (in Ref. 3; AAA59936)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        218
FT                   /note="V -> I (in Ref. 3; AAA59936)"
FT                   /evidence="ECO:0000305"
FT   STRAND          4..8
FT                   /evidence="ECO:0000244|PDB:2KS9"
FT   TURN            18..20
FT                   /evidence="ECO:0000244|PDB:2KS9"
FT   TURN            24..26
FT                   /evidence="ECO:0000244|PDB:2KS9"
FT   HELIX           29..58
FT                   /evidence="ECO:0000244|PDB:6HLP"
FT   HELIX           61..63
FT                   /evidence="ECO:0000244|PDB:6HLP"
FT   HELIX           66..94
FT                   /evidence="ECO:0000244|PDB:6HLP"
FT   HELIX           102..135
FT                   /evidence="ECO:0000244|PDB:6HLP"
FT   HELIX           144..168
FT                   /evidence="ECO:0000244|PDB:6HLP"
FT   STRAND          169..182
FT                   /evidence="ECO:0000244|PDB:6HLP"
FT   HELIX           191..204
FT                   /evidence="ECO:0000244|PDB:6HLP"
FT   HELIX           206..225
FT                   /evidence="ECO:0000244|PDB:6HLP"
FT   STRAND          229..234
FT                   /evidence="ECO:0000244|PDB:2KS9"
FT   HELIX           238..273
FT                   /evidence="ECO:0000244|PDB:6HLP"
FT   STRAND          279..281
FT                   /evidence="ECO:0000244|PDB:2KS9"
FT   HELIX           283..308
FT                   /evidence="ECO:0000244|PDB:6HLP"
FT   HELIX           310..319
FT                   /evidence="ECO:0000244|PDB:6HLP"
FT   TURN            320..322
FT                   /evidence="ECO:0000244|PDB:6HLP"
FT   STRAND          323..325
FT                   /evidence="ECO:0000244|PDB:6HLP"
FT   STRAND          335..340
FT                   /evidence="ECO:0000244|PDB:2KS9"
FT   STRAND          342..344
FT                   /evidence="ECO:0000244|PDB:2KS9"
FT   TURN            355..358
FT                   /evidence="ECO:0000244|PDB:2KS9"
FT   STRAND          359..361
FT                   /evidence="ECO:0000244|PDB:2KS9"
SQ   SEQUENCE   407 AA;  46251 MW;  2AFFD3F61B1A3041 CRC64;
     MDNVLPVDSD LSPNISTNTS EPNQFVQPAW QIVLWAAAYT VIVVTSVVGN VVVMWIILAH
     KRMRTVTNYF LVNLAFAEAS MAAFNTVVNF TYAVHNEWYY GLFYCKFHNF FPIAAVFASI
     YSMTAVAFDR YMAIIHPLQP RLSATATKVV ICVIWVLALL LAFPQGYYST TETMPSRVVC
     MIEWPEHPNK IYEKVYHICV TVLIYFLPLL VIGYAYTVVG ITLWASEIPG DSSDRYHEQV
     SAKRKVVKMM IVVVCTFAIC WLPFHIFFLL PYINPDLYLK KFIQQVYLAI MWLAMSSTMY
     NPIIYCCLND RFRLGFKHAF RCCPFISAGD YEGLEMKSTR YLQTQGSVYK VSRLETTIST
     VVGAHEEEPE DGPKATPSSL DLTSNCSSRS DSKTMTESFS FSSNVLS
//
ID   OPSB_HUMAN              Reviewed;         348 AA.
AC   P03999; Q13877;
DT   23-OCT-1986, integrated into UniProtKB/Swiss-Prot.
DT   23-OCT-1986, sequence version 1.
DT   07-OCT-2020, entry version 192.
DE   RecName: Full=Short-wave-sensitive opsin 1;
DE   AltName: Full=Blue cone photoreceptor pigment;
DE   AltName: Full=Blue-sensitive opsin;
DE            Short=BOP;
GN   Name=OPN1SW; Synonyms=BCP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RC   TISSUE=Retinal cone cell;
RX   PubMed=2937147; DOI=10.1126/science.2937147;
RA   Nathans J., Thomas D., Hogness D.S.;
RT   "Molecular genetics of human color vision: the genes encoding blue, green,
RT   and red pigments.";
RL   Science 232:193-202(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9089077; DOI=10.1007/pl00006157;
RA   Shimmin L.C., Mai P., Li W.H.;
RT   "Sequences and evolution of human and squirrel monkey blue opsin genes.";
RL   J. Mol. Evol. 44:378-382(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT TRITANOPIA SER-264.
RA   Li T., Studencki A., Falk J., Smith V., Pokorny J., Went L., O'Shea R.,
RA   Applebury M.L.;
RT   "A point mutation in the blue cone opsin gene causes tritanopia in two
RT   autosomal dominant tritan pedigrees.";
RL   Submitted (NOV-2001) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 272-310.
RX   PubMed=2565599; DOI=10.1126/science.2565599;
RA   Sarkar G., Sommer S.S.;
RT   "Access to a messenger RNA sequence or its protein product is not limited
RT   by tissue or species specificity.";
RL   Science 244:331-334(1989).
RN   [5]
RP   REVIEW.
RX   PubMed=3303660; DOI=10.1016/0042-6989(86)90115-x;
RA   Applebury M.L., Hargrave P.A.;
RT   "Molecular biology of the visual pigments.";
RL   Vision Res. 26:1881-1895(1986).
RN   [6]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=30168605; DOI=10.1002/lsm.23015;
RA   Castellano-Pellicena I., Uzunbajakava N.E., Mignon C., Raafs B.,
RA   Botchkarev V.A., Thornton M.J.;
RT   "Does blue light restore human epidermal barrier function via activation of
RT   Opsin during cutaneous wound healing?";
RL   Lasers. Surg. Med. 51:370-382(2019).
RN   [7]
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INDUCTION BY ULTRAVIOLET A
RP   LIGHT.
RX   PubMed=31380578; DOI=10.1111/bjd.18410;
RA   Lan Y., Wang Y., Lu H.;
RT   "Opsin 3 is a key regulator of ultraviolet A-induced photoageing in human
RT   dermal fibroblast cells.";
RL   Br. J. Dermatol. 182:1228-1244(2020).
RN   [8]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=31730232; DOI=10.1111/php.13178;
RA   Wang Y., Lan Y., Lu H.;
RT   "Opsin3 Downregulation Induces Apoptosis of Human Epidermal Melanocytes via
RT   Mitochondrial Pathway.";
RL   Photochem. Photobiol. 96:83-93(2020).
RN   [9]
RP   VARIANTS CBT ARG-79 AND PRO-214.
RX   PubMed=1531728;
RA   Weitz C.J., Miyake Y., Shinzato K., Montag E., Zrenner E., Went L.N.,
RA   Nathans J.;
RT   "Human tritanopia associated with two amino acid substitutions in the blue-
RT   sensitive opsin.";
RL   Am. J. Hum. Genet. 50:498-507(1992).
RN   [10]
RP   VARIANT CBT SER-264.
RX   PubMed=1386496;
RA   Weitz C.J., Went L.N., Nathans J.;
RT   "Human tritanopia associated with a third amino acid substitution in the
RT   blue-sensitive visual pigment.";
RL   Am. J. Hum. Genet. 51:444-446(1992).
RN   [11]
RP   VARIANT CBT ILE-190.
RX   PubMed=23022137; DOI=10.1016/j.visres.2012.09.007;
RA   Baraas R.C., Hagen L.A., Dees E.W., Neitz M.;
RT   "Substitution of isoleucine for threonine at position 190 of S-opsin causes
RT   S-cone-function abnormalities.";
RL   Vision Res. 73:1-9(2012).
CC   -!- FUNCTION: Visual pigments are the light-absorbing molecules that
CC       mediate vision. They consist of an apoprotein, opsin, covalently linked
CC       to cis-retinal (Probable). Required for the maintenance of cone outer
CC       segment organization in the ventral retina, but not essential for the
CC       maintenance of functioning cone photoreceptors (By similarity).
CC       Involved in ensuring correct abundance and localization of retinal
CC       membrane proteins (By similarity). May increase spectral sensitivity in
CC       dim light (By similarity). {ECO:0000250|UniProtKB:P51491,
CC       ECO:0000305|PubMed:2937147}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Absorption:
CC         Abs(max)=420 nm;
CC   -!- INTERACTION:
CC       P03999; Q9GZY8-5: MFF; NbExp=3; IntAct=EBI-13385956, EBI-11956541;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:2937147,
CC       ECO:0000269|PubMed:31380578, ECO:0000269|PubMed:31730232}; Multi-pass
CC       membrane protein {ECO:0000255}. Photoreceptor inner segment
CC       {ECO:0000250|UniProtKB:P51491}. Cell projection, cilium, photoreceptor
CC       outer segment {ECO:0000250|UniProtKB:P51491}. Cytoplasm, perinuclear
CC       region {ECO:0000269|PubMed:30168605}.
CC   -!- TISSUE SPECIFICITY: The three color pigments are found in the cone
CC       photoreceptor cells (PubMed:2937147). Expressed throughout the
CC       epidermis and dermis, primarily in the stratum granulosum in the facial
CC       and abdominal skin (at protein level) (PubMed:30168605). Expressed in
CC       dermal fibroblasts (at protein level) (PubMed:31380578). Expressed in
CC       melanocytes (at protein level) (PubMed:31730232).
CC       {ECO:0000269|PubMed:2937147, ECO:0000269|PubMed:30168605,
CC       ECO:0000269|PubMed:31380578, ECO:0000269|PubMed:31730232}.
CC   -!- INDUCTION: Induced by ultraviolet A light in dermal fibroblasts.
CC       {ECO:0000269|PubMed:31380578}.
CC   -!- PTM: Phosphorylated on some or all of the serine and threonine residues
CC       present in the C-terminal region.
CC   -!- DISEASE: Tritan color blindness (CBT) [MIM:190900]: A disorder of
CC       vision characterized by a selective deficiency of blue spectral
CC       sensitivity. {ECO:0000269|PubMed:1386496, ECO:0000269|PubMed:1531728,
CC       ECO:0000269|PubMed:23022137}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family. Opsin
CC       subfamily. {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=Mutations of the color pigment genes; Note=Retina
CC       International's Scientific Newsletter;
CC       URL="https://www.retina-international.org/files/sci-news/cppmut.htm";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M13299; AAB05207.1; -; Genomic_DNA.
DR   EMBL; M13295; AAB05207.1; JOINED; Genomic_DNA.
DR   EMBL; M13296; AAB05207.1; JOINED; Genomic_DNA.
DR   EMBL; M13297; AAB05207.1; JOINED; Genomic_DNA.
DR   EMBL; M13298; AAB05207.1; JOINED; Genomic_DNA.
DR   EMBL; U53874; AAC51334.1; -; Genomic_DNA.
DR   EMBL; L32835; AAL31362.1; -; Genomic_DNA.
DR   EMBL; M26172; AAA35608.1; -; mRNA.
DR   CCDS; CCDS5806.1; -.
DR   PIR; A03156; OOHUB.
DR   RefSeq; NP_001699.1; NM_001708.2.
DR   PDB; 1KPN; Model; -; A=1-348.
DR   PDBsum; 1KPN; -.
DR   BioGRID; 107082; 1.
DR   IntAct; P03999; 1.
DR   STRING; 9606.ENSP00000249389; -.
DR   GlyGen; P03999; 1 site.
DR   iPTMnet; P03999; -.
DR   PhosphoSitePlus; P03999; -.
DR   BioMuta; OPN1SW; -.
DR   DMDM; 129203; -.
DR   MassIVE; P03999; -.
DR   PaxDb; P03999; -.
DR   PeptideAtlas; P03999; -.
DR   PRIDE; P03999; -.
DR   ProteomicsDB; 51629; -.
DR   Antibodypedia; 31899; 68 antibodies.
DR   DNASU; 611; -.
DR   Ensembl; ENST00000249389; ENSP00000249389; ENSG00000128617.
DR   GeneID; 611; -.
DR   KEGG; hsa:611; -.
DR   CTD; 611; -.
DR   DisGeNET; 611; -.
DR   EuPathDB; HostDB:ENSG00000128617.2; -.
DR   GeneCards; OPN1SW; -.
DR   HGNC; HGNC:1012; OPN1SW.
DR   HPA; ENSG00000128617; Group enriched (heart muscle, retina).
DR   MalaCards; OPN1SW; -.
DR   MIM; 190900; phenotype.
DR   MIM; 613522; gene.
DR   neXtProt; NX_P03999; -.
DR   OpenTargets; ENSG00000128617; -.
DR   Orphanet; 88629; Tritanopia.
DR   PharmGKB; PA31938; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00960000186618; -.
DR   HOGENOM; CLU_009579_3_0_1; -.
DR   InParanoid; P03999; -.
DR   KO; K04252; -.
DR   OMA; QFRACIM; -.
DR   OrthoDB; 940057at2759; -.
DR   PhylomeDB; P03999; -.
DR   TreeFam; TF324998; -.
DR   PathwayCommons; P03999; -.
DR   Reactome; R-HSA-2187335; The retinoid cycle in cones (daylight vision).
DR   Reactome; R-HSA-2453864; Retinoid cycle disease events.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-419771; Opsins.
DR   BioGRID-ORCS; 611; 2 hits in 870 CRISPR screens.
DR   GeneWiki; OPN1SW; -.
DR   GenomeRNAi; 611; -.
DR   Pharos; P03999; Tbio.
DR   PRO; PR:P03999; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; P03999; protein.
DR   Bgee; ENSG00000128617; Expressed in lower esophagus and 116 other tissues.
DR   ExpressionAtlas; P03999; baseline and differential.
DR   Genevisible; P03999; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:UniProtKB.
DR   GO; GO:0097381; C:photoreceptor disc membrane; TAS:Reactome.
DR   GO; GO:0001917; C:photoreceptor inner segment; IEA:UniProtKB-SubCell.
DR   GO; GO:0001750; C:photoreceptor outer segment; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0008020; F:G protein-coupled photoreceptor activity; IBA:GO_Central.
DR   GO; GO:0038023; F:signaling receptor activity; TAS:ProtInc.
DR   GO; GO:0071482; P:cellular response to light stimulus; IBA:GO_Central.
DR   GO; GO:0071492; P:cellular response to UV-A; IDA:UniProtKB.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007602; P:phototransduction; IBA:GO_Central.
DR   GO; GO:0018298; P:protein-chromophore linkage; IEA:UniProtKB-KW.
DR   GO; GO:0001523; P:retinoid metabolic process; TAS:Reactome.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0007601; P:visual perception; TAS:ProtInc.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR001760; Opsin.
DR   InterPro; IPR001521; Opsin_blue.
DR   InterPro; IPR027430; Retinal_BS.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00238; OPSIN.
DR   PRINTS; PR00574; OPSINBLUE.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
DR   PROSITE; PS00238; OPSIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Cell projection; Chromophore; Cytoplasm;
KW   Disease mutation; Disulfide bond; G-protein coupled receptor; Glycoprotein;
KW   Membrane; Phosphoprotein; Photoreceptor protein; Receptor;
KW   Reference proteome; Retinal protein; Sensory transduction; Transducer;
KW   Transmembrane; Transmembrane helix; Vision.
FT   CHAIN           1..348
FT                   /note="Short-wave-sensitive opsin 1"
FT                   /id="PRO_0000197762"
FT   TOPO_DOM        1..33
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        34..58
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        59..70
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        71..96
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        97..110
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        111..130
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        131..149
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        150..173
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        174..199
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        200..227
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        228..249
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        250..273
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        274..281
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        282..306
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        307..348
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         293
FT                   /note="N6-(retinylidene)lysine"
FT   CARBOHYD        14
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000305"
FT   DISULFID        107..184
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VARIANT         79
FT                   /note="G -> R (in CBT; dbSNP:rs104894031)"
FT                   /evidence="ECO:0000269|PubMed:1531728"
FT                   /id="VAR_004838"
FT   VARIANT         190
FT                   /note="T -> I (in CBT; dbSNP:rs1190183515)"
FT                   /evidence="ECO:0000269|PubMed:23022137"
FT                   /id="VAR_081835"
FT   VARIANT         214
FT                   /note="S -> P (in CBT; dbSNP:rs104894032)"
FT                   /evidence="ECO:0000269|PubMed:1531728"
FT                   /id="VAR_004839"
FT   VARIANT         264
FT                   /note="P -> S (in CBT; dbSNP:rs104894033)"
FT                   /evidence="ECO:0000269|PubMed:1386496, ECO:0000269|Ref.3"
FT                   /id="VAR_004840"
FT   CONFLICT        308..310
FT                   /note="KQF -> VKL (in Ref. 4)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   348 AA;  39135 MW;  83FAB2E7111CB581 CRC64;
     MRKMSEEEFY LFKNISSVGP WDGPQYHIAP VWAFYLQAAF MGTVFLIGFP LNAMVLVATL
     RYKKLRQPLN YILVNVSFGG FLLCIFSVFP VFVASCNGYF VFGRHVCALE GFLGTVAGLV
     TGWSLAFLAF ERYIVICKPF GNFRFSSKHA LTVVLATWTI GIGVSIPPFF GWSRFIPEGL
     QCSCGPDWYT VGTKYRSESY TWFLFIFCFI VPLSLICFSY TQLLRALKAV AAQQQESATT
     QKAEREVSRM VVVMVGSFCV CYVPYAAFAM YMVNNRNHGL DLRLVTIPSF FSKSACIYNP
     IIYCFMNKQF QACIMKMVCG KAMTDESDTC SSQKTEVSTV SSTQVGPN
//
ID   PAR1_HUMAN              Reviewed;         425 AA.
AC   P25116; Q53XV0; Q96RF7; Q9BUN4;
DT   01-MAY-1992, integrated into UniProtKB/Swiss-Prot.
DT   16-APR-2002, sequence version 2.
DT   07-OCT-2020, entry version 215.
DE   RecName: Full=Proteinase-activated receptor 1;
DE            Short=PAR-1;
DE   AltName: Full=Coagulation factor II receptor;
DE   AltName: Full=Thrombin receptor;
DE   Flags: Precursor;
GN   Name=F2R; Synonyms=CF2R, PAR1, TR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1672265; DOI=10.1016/0092-8674(91)90261-v;
RA   Vu T.-K.H., Hung D.T., Wheaton V.I., Coughlin S.R.;
RT   "Molecular cloning of a functional thrombin receptor reveals a novel
RT   proteolytic mechanism of receptor activation.";
RL   Cell 64:1057-1068(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT VAL-335.
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT VAL-335.
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PHOSPHORYLATION.
RX   PubMed=8955127; DOI=10.1074/jbc.271.51.32874;
RA   Shapiro M.J., Trejo J., Zeng D., Coughlin S.R.;
RT   "Role of the thrombin receptor's cytoplasmic tail in intracellular
RT   trafficking. Distinct determinants for agonist-triggered versus tonic
RT   internalization and intracellular localization.";
RL   J. Biol. Chem. 271:32874-32880(1996).
RN   [6]
RP   FUNCTION.
RX   PubMed=10079109; DOI=10.1172/jci6042;
RA   Kahn M.L., Nakanishi-Matsui M., Shapiro M.J., Ishihara H., Coughlin S.R.;
RT   "Protease-activated receptors 1 and 4 mediate activation of human platelets
RT   by thrombin.";
RL   J. Clin. Invest. 103:879-887(1999).
RN   [7]
RP   ANGIOGENESIS INHIBITION PROPERTIES OF PARSTATIN.
RX   PubMed=18988770; DOI=10.1124/jpet.108.145664;
RA   Zania P., Gourni D., Aplin A.C., Nicosia R.F., Flordellis C.S.,
RA   Maragoudakis M.E., Tsopanoglou N.E.;
RT   "Parstatin, the cleaved peptide on proteinase-activated receptor 1
RT   activation, is a potent inhibitor of angiogenesis.";
RL   J. Pharmacol. Exp. Ther. 328:378-389(2009).
RN   [8]
RP   SIGNAL SEQUENCE CLEAVAGE SITE.
RX   PubMed=22659187; DOI=10.1016/j.febslet.2012.05.042;
RA   Zampatis D.E., Rutz C., Furkert J., Schmidt A., Wustenhagen D., Kubick S.,
RA   Tsopanoglou N.E., Schulein R.;
RT   "The protease-activated receptor 1 possesses a functional and cleavable
RT   signal peptide which is necessary for receptor expression.";
RL   FEBS Lett. 586:2351-2359(2012).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-418, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [10]
RP   VARIANT GLY-166.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions of
RT   human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [11]
RP   ERRATUM OF PUBMED:10391209.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 38-64 IN COMPLEX WITH THROMBIN.
RX   PubMed=8136362; DOI=10.1021/bi00177a018;
RA   Mathews I.I., Padmanabhan K.P., Ganesh V., Tulinsky A., Ishii M., Chen J.,
RA   Turck C.W., Coughlin S.R., Fenton J.W. II;
RT   "Crystallographic structures of thrombin complexed with thrombin receptor
RT   peptides: existence of expected and novel binding modes.";
RL   Biochemistry 33:3266-3279(1994).
CC   -!- FUNCTION: High affinity receptor for activated thrombin coupled to G
CC       proteins that stimulate phosphoinositide hydrolysis. May play a role in
CC       platelets activation and in vascular development.
CC       {ECO:0000269|PubMed:10079109}.
CC   -!- INTERACTION:
CC       P25116; Q03135: CAV1; NbExp=3; IntAct=EBI-2803960, EBI-603614;
CC       P25116; Q9UNN8: PROCR; NbExp=5; IntAct=EBI-2803960, EBI-719705;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Platelets and vascular endothelial cells.
CC   -!- DOMAIN: The cleaved signal peptide may not be degraded and may function
CC       as an intracellular angiogenesis inhibitor peptide known as parstatin.
CC   -!- PTM: A proteolytic cleavage generates a new N-terminus that functions
CC       as a tethered ligand.
CC   -!- PTM: Phosphorylated in the C-terminal tail; probably mediating
CC       desensitization prior to the uncoupling and internalization of the
CC       receptor. {ECO:0000269|PubMed:8955127}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/f2r/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M62424; AAA36743.1; -; mRNA.
DR   EMBL; AF391809; AAK69768.1; -; Genomic_DNA.
DR   EMBL; BT007279; AAP35943.1; -; mRNA.
DR   EMBL; BC002464; AAH02464.1; -; mRNA.
DR   EMBL; BC051909; AAH51909.1; -; mRNA.
DR   CCDS; CCDS4032.1; -.
DR   PIR; A37912; A37912.
DR   RefSeq; NP_001298242.1; NM_001311313.1.
DR   RefSeq; NP_001983.2; NM_001992.4.
DR   PDB; 1NRN; X-ray; 3.10 A; R=38-60.
DR   PDB; 1NRO; X-ray; 3.10 A; R=38-64.
DR   PDB; 1NRP; X-ray; 3.00 A; R=38-60.
DR   PDB; 1NRQ; X-ray; 3.50 A; R=40-60.
DR   PDB; 1NRR; X-ray; 2.40 A; R=43-60.
DR   PDB; 3BEF; X-ray; 2.20 A; C/F=49-57.
DR   PDB; 3HKI; X-ray; 2.20 A; C/F=42-62.
DR   PDB; 3HKJ; X-ray; 2.60 A; C/F=42-62.
DR   PDB; 3LU9; X-ray; 1.80 A; C/F=33-57.
DR   PDB; 3VW7; X-ray; 2.20 A; A=86-395.
DR   PDBsum; 1NRN; -.
DR   PDBsum; 1NRO; -.
DR   PDBsum; 1NRP; -.
DR   PDBsum; 1NRQ; -.
DR   PDBsum; 1NRR; -.
DR   PDBsum; 3BEF; -.
DR   PDBsum; 3HKI; -.
DR   PDBsum; 3HKJ; -.
DR   PDBsum; 3LU9; -.
DR   PDBsum; 3VW7; -.
DR   SMR; P25116; -.
DR   BioGRID; 108448; 22.
DR   DIP; DIP-29703N; -.
DR   IntAct; P25116; 21.
DR   MINT; P25116; -.
DR   STRING; 9606.ENSP00000321326; -.
DR   BindingDB; P25116; -.
DR   ChEMBL; CHEMBL3974; -.
DR   DrugBank; DB05361; SR-123781A.
DR   DrugBank; DB00086; Streptokinase.
DR   DrugBank; DB11300; Thrombin.
DR   DrugBank; DB09030; Vorapaxar.
DR   DrugCentral; P25116; -.
DR   GuidetoPHARMACOLOGY; 347; -.
DR   GlyGen; P25116; 5 sites.
DR   iPTMnet; P25116; -.
DR   PhosphoSitePlus; P25116; -.
DR   SwissPalm; P25116; -.
DR   BioMuta; F2R; -.
DR   DMDM; 20178318; -.
DR   jPOST; P25116; -.
DR   MassIVE; P25116; -.
DR   MaxQB; P25116; -.
DR   PaxDb; P25116; -.
DR   PeptideAtlas; P25116; -.
DR   PRIDE; P25116; -.
DR   ProteomicsDB; 54263; -.
DR   Antibodypedia; 4409; 635 antibodies.
DR   DNASU; 2149; -.
DR   Ensembl; ENST00000319211; ENSP00000321326; ENSG00000181104.
DR   GeneID; 2149; -.
DR   KEGG; hsa:2149; -.
DR   UCSC; uc003ken.5; human.
DR   CTD; 2149; -.
DR   DisGeNET; 2149; -.
DR   EuPathDB; HostDB:ENSG00000181104.6; -.
DR   GeneCards; F2R; -.
DR   HGNC; HGNC:3537; F2R.
DR   HPA; ENSG00000181104; Tissue enhanced (lymphoid).
DR   MIM; 187930; gene.
DR   neXtProt; NX_P25116; -.
DR   OpenTargets; ENSG00000181104; -.
DR   PharmGKB; PA27946; -.
DR   eggNOG; ENOG502QTR0; Eukaryota.
DR   GeneTree; ENSGT00970000193405; -.
DR   HOGENOM; CLU_009579_8_2_1; -.
DR   InParanoid; P25116; -.
DR   KO; K03914; -.
DR   OMA; FGSEMCR; -.
DR   OrthoDB; 763273at2759; -.
DR   PhylomeDB; P25116; -.
DR   TreeFam; TF330775; -.
DR   PathwayCommons; P25116; -.
DR   Reactome; R-HSA-140875; Common Pathway of Fibrin Clot Formation.
DR   Reactome; R-HSA-375276; Peptide ligand-binding receptors.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-456926; Thrombin signalling through proteinase activated receptors (PARs).
DR   SIGNOR; P25116; -.
DR   BioGRID-ORCS; 2149; 11 hits in 871 CRISPR screens.
DR   ChiTaRS; F2R; human.
DR   EvolutionaryTrace; P25116; -.
DR   GeneWiki; Coagulation_factor_II_receptor; -.
DR   GenomeRNAi; 2149; -.
DR   Pharos; P25116; Tclin.
DR   PRO; PR:P25116; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; P25116; protein.
DR   Bgee; ENSG00000181104; Expressed in decidua and 193 other tissues.
DR   ExpressionAtlas; P25116; baseline and differential.
DR   Genevisible; P25116; HS.
DR   GO; GO:0005901; C:caveola; IDA:BHF-UCL.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005769; C:early endosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; TAS:ProtInc.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005770; C:late endosome; IDA:UniProtKB.
DR   GO; GO:0031594; C:neuromuscular junction; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0031094; C:platelet dense tubular network; IDA:BHF-UCL.
DR   GO; GO:0045211; C:postsynaptic membrane; ISS:UniProtKB.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; ISS:UniProtKB.
DR   GO; GO:0001965; F:G-protein alpha-subunit binding; ISS:UniProtKB.
DR   GO; GO:0031681; F:G-protein beta-subunit binding; ISS:UniProtKB.
DR   GO; GO:0005102; F:signaling receptor binding; IPI:BHF-UCL.
DR   GO; GO:0015057; F:thrombin-activated receptor activity; IDA:BHF-UCL.
DR   GO; GO:0006919; P:activation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:BHF-UCL.
DR   GO; GO:0000186; P:activation of MAPKK activity; ISS:UniProtKB.
DR   GO; GO:0009653; P:anatomical structure morphogenesis; TAS:ProtInc.
DR   GO; GO:0007596; P:blood coagulation; TAS:Reactome.
DR   GO; GO:0045217; P:cell-cell junction maintenance; IMP:UniProtKB.
DR   GO; GO:0002248; P:connective tissue replacement involved in inflammatory response wound healing; IDA:BHF-UCL.
DR   GO; GO:0007529; P:establishment of synaptic specificity at neuromuscular junction; ISS:UniProtKB.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0048873; P:homeostasis of number of cells within a tissue; ISS:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; ISS:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:BHF-UCL.
DR   GO; GO:0003105; P:negative regulation of glomerular filtration; ISS:UniProtKB.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; ISS:UniProtKB.
DR   GO; GO:1900134; P:negative regulation of renin secretion into blood stream; ISS:UniProtKB.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0030168; P:platelet activation; IDA:BHF-UCL.
DR   GO; GO:0060155; P:platelet dense granule organization; IC:BHF-UCL.
DR   GO; GO:0030194; P:positive regulation of blood coagulation; IDA:BHF-UCL.
DR   GO; GO:0051928; P:positive regulation of calcium ion transport; ISS:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; ISS:UniProtKB.
DR   GO; GO:0032967; P:positive regulation of collagen biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0043280; P:positive regulation of cysteine-type endopeptidase activity involved in apoptotic process; IDA:BHF-UCL.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; ISS:UniProtKB.
DR   GO; GO:0051482; P:positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway; ISS:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:UniProtKB.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; IMP:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IEP:UniProtKB.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IDA:UniProtKB.
DR   GO; GO:0032757; P:positive regulation of interleukin-8 production; IDA:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:BHF-UCL.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; ISS:UniProtKB.
DR   GO; GO:0046427; P:positive regulation of receptor signaling pathway via JAK-STAT; NAS:BHF-UCL.
DR   GO; GO:0051281; P:positive regulation of release of sequestered calcium ion into cytosol; IDA:BHF-UCL.
DR   GO; GO:0035025; P:positive regulation of Rho protein signal transduction; ISS:UniProtKB.
DR   GO; GO:0045987; P:positive regulation of smooth muscle contraction; ISS:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:BHF-UCL.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; ISS:UniProtKB.
DR   GO; GO:0007205; P:protein kinase C-activating G protein-coupled receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0030193; P:regulation of blood coagulation; IDA:BHF-UCL.
DR   GO; GO:0032651; P:regulation of interleukin-1 beta production; ISS:UniProtKB.
DR   GO; GO:0051930; P:regulation of sensory perception of pain; ISS:UniProtKB.
DR   GO; GO:0051209; P:release of sequestered calcium ion into cytosol; ISS:UniProtKB.
DR   GO; GO:0032496; P:response to lipopolysaccharide; ISS:UniProtKB.
DR   GO; GO:0009611; P:response to wounding; IDA:BHF-UCL.
DR   GO; GO:0099553; P:trans-synaptic signaling by endocannabinoid, modulating synaptic transmission; IEA:Ensembl.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR003912; Protea_act_rcpt.
DR   InterPro; IPR000935; Thrmbn_rcpt.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01428; PROTEASEAR.
DR   PRINTS; PR00908; THROMBINR.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Blood coagulation; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Hemostasis; Membrane;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome; Signal;
KW   Transducer; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..21
FT                   /evidence="ECO:0000269|PubMed:22659187"
FT   PROPEP          22..41
FT                   /id="PRO_0000012740"
FT   CHAIN           42..425
FT                   /note="Proteinase-activated receptor 1"
FT                   /id="PRO_0000012741"
FT   TOPO_DOM        42..102
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        103..128
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        129..137
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        138..157
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        158..176
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        177..198
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        199..218
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        219..239
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        240..268
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        269..288
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        289..311
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        312..334
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        335..350
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        351..374
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        375..425
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        57..60
FT                   /note="Asp/Glu-rich (acidic)"
FT   SITE            41..42
FT                   /note="Cleavage; by thrombin"
FT   MOD_RES         418
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   CARBOHYD        35
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        62
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        75
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        250
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        259
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        175..254
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VARIANT         166
FT                   /note="S -> G (in dbSNP:rs5893)"
FT                   /evidence="ECO:0000269|PubMed:10391209"
FT                   /id="VAR_014167"
FT   VARIANT         187
FT                   /note="Y -> N (in dbSNP:rs2230849)"
FT                   /id="VAR_049432"
FT   VARIANT         257
FT                   /note="V -> L (in dbSNP:rs2227832)"
FT                   /id="VAR_049433"
FT   VARIANT         268
FT                   /note="A -> P (in dbSNP:rs1055103)"
FT                   /id="VAR_060680"
FT   VARIANT         335
FT                   /note="A -> V (in dbSNP:rs17849599)"
FT                   /evidence="ECO:0000269|PubMed:15489334, ECO:0000269|Ref.3"
FT                   /id="VAR_060681"
FT   VARIANT         412
FT                   /note="S -> Y (in dbSNP:rs2227799)"
FT                   /id="VAR_049434"
FT   CONFLICT        238
FT                   /note="L -> V (in Ref. 1; AAA36743)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        364
FT                   /note="C -> S (in Ref. 1; AAA36743)"
FT                   /evidence="ECO:0000305"
FT   STRAND          39..41
FT                   /evidence="ECO:0000244|PDB:3LU9"
FT   TURN            47..50
FT                   /evidence="ECO:0000244|PDB:3LU9"
FT   HELIX           92..96
FT                   /evidence="ECO:0000244|PDB:3VW7"
FT   HELIX           99..102
FT                   /evidence="ECO:0000244|PDB:3VW7"
FT   HELIX           104..130
FT                   /evidence="ECO:0000244|PDB:3VW7"
FT   HELIX           131..133
FT                   /evidence="ECO:0000244|PDB:3VW7"
FT   HELIX           136..152
FT                   /evidence="ECO:0000244|PDB:3VW7"
FT   HELIX           155..163
FT                   /evidence="ECO:0000244|PDB:3VW7"
FT   HELIX           172..205
FT                   /evidence="ECO:0000244|PDB:3VW7"
FT   HELIX           216..238
FT                   /evidence="ECO:0000244|PDB:3VW7"
FT   STRAND          243..246
FT                   /evidence="ECO:0000244|PDB:3VW7"
FT   TURN            247..250
FT                   /evidence="ECO:0000244|PDB:3VW7"
FT   STRAND          251..257
FT                   /evidence="ECO:0000244|PDB:3VW7"
FT   HELIX           265..296
FT                   /evidence="ECO:0000244|PDB:3VW7"
FT   HELIX           305..324
FT                   /evidence="ECO:0000244|PDB:3VW7"
FT   HELIX           327..338
FT                   /evidence="ECO:0000244|PDB:3VW7"
FT   HELIX           347..360
FT                   /evidence="ECO:0000244|PDB:3VW7"
FT   HELIX           363..373
FT                   /evidence="ECO:0000244|PDB:3VW7"
SQ   SEQUENCE   425 AA;  47441 MW;  41B742A99EEC96AB CRC64;
     MGPRRLLLVA ACFSLCGPLL SARTRARRPE SKATNATLDP RSFLLRNPND KYEPFWEDEE
     KNESGLTEYR LVSINKSSPL QKQLPAFISE DASGYLTSSW LTLFVPSVYT GVFVVSLPLN
     IMAIVVFILK MKVKKPAVVY MLHLATADVL FVSVLPFKIS YYFSGSDWQF GSELCRFVTA
     AFYCNMYASI LLMTVISIDR FLAVVYPMQS LSWRTLGRAS FTCLAIWALA IAGVVPLLLK
     EQTIQVPGLN ITTCHDVLNE TLLEGYYAYY FSAFSAVFFF VPLIISTVCY VSIIRCLSSS
     AVANRSKKSR ALFLSAAVFC IFIICFGPTN VLLIAHYSFL SHTSTTEAAY FAYLLCVCVS
     SISCCIDPLI YYYASSECQR YVYSILCCKE SSDPSSYNSS GQLMASKMDT CSSNLNNSIY
     KKLLT
//
ID   PAR4_HUMAN              Reviewed;         385 AA.
AC   Q96RI0; O76067; Q6DK42;
DT   27-MAR-2002, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 3.
DT   12-AUG-2020, entry version 171.
DE   RecName: Full=Proteinase-activated receptor 4;
DE            Short=PAR-4;
DE   AltName: Full=Coagulation factor II receptor-like 3;
DE   AltName: Full=Thrombin receptor-like 3;
DE   Flags: Precursor;
GN   Name=F2RL3; Synonyms=PAR4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT THR-120.
RX   PubMed=9722561; DOI=10.1074/jbc.273.36.23290;
RA   Kahn M.L., Hammes S.R., Botka C., Coughlin S.R.;
RT   "Gene and locus structure and chromosomal localization of the protease-
RT   activated receptor gene family.";
RL   J. Biol. Chem. 273:23290-23296(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT THR-120.
RX   PubMed=9716134; DOI=10.1038/29325;
RA   Kahn M.L., Zheng Y.-W., Huang W., Bigornia V., Zeng D., Moff S.,
RA   Farese R.V. Jr., Tam C., Coughlin S.R.;
RT   "A dual thrombin receptor system for platelet activation.";
RL   Nature 394:690-694(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], MUTAGENESIS OF ARG-47 AND ARG-68, AND VARIANT
RP   THR-120.
RC   TISSUE=Lymphoma;
RX   PubMed=9618465; DOI=10.1073/pnas.95.12.6642;
RA   Xu W.-F., Andersen H., Whitmore T.E., Presnell S.R., Yee D.P., Ching A.,
RA   Gilbert T., Davie E.W., Foster D.C.;
RT   "Cloning and characterization of human protease-activated receptor 4.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:6642-6646(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RA   King M.M., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS VAL-296 AND LEU-310.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUN-2001) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION.
RX   PubMed=10079109; DOI=10.1172/jci6042;
RA   Kahn M.L., Nakanishi-Matsui M., Shapiro M.J., Ishihara H., Coughlin S.R.;
RT   "Protease-activated receptors 1 and 4 mediate activation of human platelets
RT   by thrombin.";
RL   J. Clin. Invest. 103:879-887(1999).
CC   -!- FUNCTION: Receptor for activated thrombin or trypsin coupled to G
CC       proteins that stimulate phosphoinositide hydrolysis. May play a role in
CC       platelets activation. {ECO:0000269|PubMed:10079109}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Widely expressed, with highest levels in lung,
CC       pancreas, thyroid, testis and small intestine. Not expressed in brain,
CC       kidney, spinal cord and peripheral blood leukocytes. Also detected in
CC       platelets.
CC   -!- PTM: A proteolytic cleavage generates a new N-terminus that functions
CC       as a tethered ligand.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/f2rl3/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF080214; AAC28860.1; -; mRNA.
DR   EMBL; AF055917; AAC25699.1; -; mRNA.
DR   EMBL; AY431102; AAR08487.1; -; mRNA.
DR   EMBL; AF384819; AAK61908.1; -; Genomic_DNA.
DR   EMBL; BC074782; AAH74782.2; -; mRNA.
DR   CCDS; CCDS12350.1; -.
DR   RefSeq; NP_003941.2; NM_003950.3.
DR   PDB; 2ZPK; X-ray; 1.80 A; P/Q=46-53.
DR   PDB; 3QDZ; X-ray; 2.80 A; E/F=39-47.
DR   PDBsum; 2ZPK; -.
DR   PDBsum; 3QDZ; -.
DR   SMR; Q96RI0; -.
DR   BioGRID; 114481; 2.
DR   ELM; Q96RI0; -.
DR   STRING; 9606.ENSP00000248076; -.
DR   BindingDB; Q96RI0; -.
DR   ChEMBL; CHEMBL4691; -.
DR   DrugBank; DB11300; Thrombin.
DR   GuidetoPHARMACOLOGY; 350; -.
DR   GlyGen; Q96RI0; 1 site.
DR   iPTMnet; Q96RI0; -.
DR   PhosphoSitePlus; Q96RI0; -.
DR   BioMuta; F2RL3; -.
DR   DMDM; 116242700; -.
DR   jPOST; Q96RI0; -.
DR   MassIVE; Q96RI0; -.
DR   PaxDb; Q96RI0; -.
DR   PeptideAtlas; Q96RI0; -.
DR   PRIDE; Q96RI0; -.
DR   ProteomicsDB; 77962; -.
DR   ABCD; Q96RI0; 2 sequenced antibodies.
DR   Antibodypedia; 14245; 390 antibodies.
DR   Ensembl; ENST00000248076; ENSP00000248076; ENSG00000127533.
DR   GeneID; 9002; -.
DR   KEGG; hsa:9002; -.
DR   UCSC; uc002nfa.4; human.
DR   CTD; 9002; -.
DR   DisGeNET; 9002; -.
DR   EuPathDB; HostDB:ENSG00000127533.3; -.
DR   GeneCards; F2RL3; -.
DR   HGNC; HGNC:3540; F2RL3.
DR   HPA; ENSG00000127533; Tissue enhanced (adipose tissue, breast, lung).
DR   MIM; 602779; gene.
DR   neXtProt; NX_Q96RI0; -.
DR   OpenTargets; ENSG00000127533; -.
DR   PharmGKB; PA27949; -.
DR   eggNOG; ENOG502QU4Y; Eukaryota.
DR   GeneTree; ENSGT00970000193405; -.
DR   HOGENOM; CLU_009579_8_2_1; -.
DR   InParanoid; Q96RI0; -.
DR   KO; K04236; -.
DR   OMA; VYYYVSA; -.
DR   OrthoDB; 995441at2759; -.
DR   PhylomeDB; Q96RI0; -.
DR   TreeFam; TF350010; -.
DR   PathwayCommons; Q96RI0; -.
DR   Reactome; R-HSA-375276; Peptide ligand-binding receptors.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-456926; Thrombin signalling through proteinase activated receptors (PARs).
DR   SIGNOR; Q96RI0; -.
DR   BioGRID-ORCS; 9002; 4 hits in 867 CRISPR screens.
DR   EvolutionaryTrace; Q96RI0; -.
DR   GeneWiki; F2RL3; -.
DR   GenomeRNAi; 9002; -.
DR   Pharos; Q96RI0; Tchem.
DR   PRO; PR:Q96RI0; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; Q96RI0; protein.
DR   Bgee; ENSG00000127533; Expressed in adipose tissue and 101 other tissues.
DR   ExpressionAtlas; Q96RI0; baseline and differential.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0015057; F:thrombin-activated receptor activity; TAS:ProtInc.
DR   GO; GO:0007596; P:blood coagulation; TAS:ProtInc.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0060155; P:platelet dense granule organization; IC:BHF-UCL.
DR   GO; GO:0051482; P:positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway; IBA:GO_Central.
DR   GO; GO:0051281; P:positive regulation of release of sequestered calcium ion into cytosol; IDA:BHF-UCL.
DR   GO; GO:0035025; P:positive regulation of Rho protein signal transduction; IBA:GO_Central.
DR   GO; GO:0009611; P:response to wounding; TAS:ProtInc.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR003944; Prot_act_rcpt_4.
DR   InterPro; IPR003912; Protea_act_rcpt.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01428; PROTEASEAR.
DR   PRINTS; PR01430; PROTEASEAR4.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Blood coagulation; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Hemostasis; Membrane;
KW   Polymorphism; Receptor; Reference proteome; Signal; Transducer;
KW   Transmembrane; Transmembrane helix.
FT   SIGNAL          1..17
FT                   /evidence="ECO:0000255"
FT   PROPEP          18..47
FT                   /note="Removed for receptor activation"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000012762"
FT   CHAIN           48..385
FT                   /note="Proteinase-activated receptor 4"
FT                   /id="PRO_0000012763"
FT   TOPO_DOM        48..82
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        83..103
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        104..108
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        109..129
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        130..151
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        152..172
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        173..192
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        193..213
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        214..247
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        248..268
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        269..283
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        284..304
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        305..319
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        320..343
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        344..385
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        301..305
FT                   /note="Poly-Leu"
FT   SITE            47..48
FT                   /note="Cleavage; by thrombin or trypsin"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        56
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        149..228
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VARIANT         120
FT                   /note="A -> T (in dbSNP:rs773902)"
FT                   /evidence="ECO:0000269|PubMed:9618465,
FT                   ECO:0000269|PubMed:9716134, ECO:0000269|PubMed:9722561"
FT                   /id="VAR_028300"
FT   VARIANT         215
FT                   /note="R -> Q (in dbSNP:rs2230799)"
FT                   /id="VAR_028301"
FT   VARIANT         296
FT                   /note="F -> V (in dbSNP:rs2227346)"
FT                   /evidence="ECO:0000269|Ref.5"
FT                   /id="VAR_012852"
FT   VARIANT         310
FT                   /note="P -> L (in dbSNP:rs2227376)"
FT                   /evidence="ECO:0000269|Ref.5"
FT                   /id="VAR_012853"
FT   MUTAGEN         47
FT                   /note="R->A: No proteolytic cleavage (by thrombin or
FT                   trypsin)."
FT                   /evidence="ECO:0000269|PubMed:9618465"
FT   MUTAGEN         68
FT                   /note="R->A: No effect on receptor activation."
FT                   /evidence="ECO:0000269|PubMed:9618465"
FT   STRAND          44..46
FT                   /evidence="ECO:0000244|PDB:3QDZ"
SQ   SEQUENCE   385 AA;  41133 MW;  FACE32F10D5C561E CRC64;
     MWGRLLLWPL VLGFSLSGGT QTPSVYDESG STGGGDDSTP SILPAPRGYP GQVCANDSDT
     LELPDSSRAL LLGWVPTRLV PALYGLVLVV GLPANGLALW VLATQAPRLP STMLLMNLAA
     ADLLLALALP PRIAYHLRGQ RWPFGEAACR LATAALYGHM YGSVLLLAAV SLDRYLALVH
     PLRARALRGR RLALGLCMAA WLMAAALALP LTLQRQTFRL ARSDRVLCHD ALPLDAQASH
     WQPAFTCLAL LGCFLPLLAM LLCYGATLHT LAASGRRYGH ALRLTAVVLA SAVAFFVPSN
     LLLLLHYSDP SPSAWGNLYG AYVPSLALST LNSCVDPFIY YYVSAEFRDK VRAGLFQRSP
     GDTVASKASA EGGSRGMGTH SSLLQ
//
ID   PTAFR_HUMAN             Reviewed;         342 AA.
AC   P25105; A3KMC8; A8K2H5;
DT   01-MAY-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1992, sequence version 1.
DT   07-OCT-2020, entry version 192.
DE   RecName: Full=Platelet-activating factor receptor;
DE            Short=PAF-R;
DE            Short=PAFr;
GN   Name=PTAFR; Synonyms=PAFR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND TISSUE SPECIFICITY.
RC   TISSUE=Granulocyte;
RX   PubMed=1656963; DOI=10.1016/s0006-291x(05)81261-6;
RA   Ye R.D., Prossnitz E.R., Zou A., Cochrane C.G.;
RT   "Characterization of a human cDNA that encodes a functional receptor for
RT   platelet activating factor.";
RL   Biochem. Biophys. Res. Commun. 180:105-111(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TISSUE SPECIFICITY, AND INDUCTION.
RC   TISSUE=Leukocyte;
RX   PubMed=1657923;
RA   Nakamura M., Honda Z., Izumi T., Sakanaka C., Mutoh H., Minami M., Bito H.,
RA   Seyama Y., Matsumoto T., Noma M., Shimizu T.;
RT   "Molecular cloning and expression of platelet-activating factor receptor
RT   from human leukocytes.";
RL   J. Biol. Chem. 266:20400-20405(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND SUBCELLULAR LOCATION.
RC   TISSUE=Leukocyte;
RX   PubMed=1374385;
RA   Kunz D., Gerard N.P., Gerard C.;
RT   "The human leukocyte platelet-activating factor receptor. cDNA cloning,
RT   cell surface expression, and construction of a novel epitope-bearing
RT   analog.";
RL   J. Biol. Chem. 267:9101-9106(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Fetal liver;
RX   PubMed=1322356; DOI=10.1016/0888-7543(92)90162-l;
RA   Seyfried C.E., Schweickart V.L., Godiska R., Gray P.W.;
RT   "The human platelet-activating factor receptor gene (PTAFR) contains no
RT   introns and maps to chromosome 1.";
RL   Genomics 13:832-834(1992).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND TISSUE SPECIFICITY.
RC   TISSUE=Heart ventricle;
RX   PubMed=1281995; DOI=10.1016/0006-291x(92)92245-s;
RA   Sugimoto T., Tsuchimochi H., McGregor C.G.A., Mutoh H., Shimizu T.,
RA   Kurachi Y.;
RT   "Molecular cloning and characterization of the platelet-activating factor
RT   receptor gene expressed in the human heart.";
RL   Biochem. Biophys. Res. Commun. 189:617-624(1992).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Cervix carcinoma;
RA   Behal R.H., Debuysere M.S., Olson M.S.;
RT   "Nucleotide sequence of platelet-activating-factor receptor derived from
RT   HeLa cell genomic DNA and Rhesus monkey genomic DNA.";
RL   Submitted (DEC-1992) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8383507; DOI=10.1165/ajrcmb/8.3.240;
RA   Chase P.B., Halonen M., Regan J.W.;
RT   "Cloning of a human platelet-activating factor receptor gene: evidence for
RT   an intron in the 5'-untranslated region.";
RL   Am. J. Respir. Cell Mol. Biol. 8:240-244(1993).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta;
RA   Warren C.N., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Umbilical cord blood;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, and Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   INTERACTION WITH ARRB1.
RX   PubMed=16709866; DOI=10.4049/jimmunol.176.11.7039;
RA   McLaughlin N.J., Banerjee A., Kelher M.R., Gamboni-Robertson F., Hamiel C.,
RA   Sheppard F.R., Moore E.E., Silliman C.C.;
RT   "Platelet-activating factor-induced clathrin-mediated endocytosis requires
RT   beta-arrestin-1 recruitment and activation of the p38 MAPK signalosome at
RT   the plasma membrane for actin bundle formation.";
RL   J. Immunol. 176:7039-7050(2006).
RN   [14]
RP   VARIANTS ASP-224 AND SER-338.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions of
RT   human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [15]
RP   ERRATUM OF PUBMED:10391209.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
CC   -!- FUNCTION: Receptor for platelet activating factor, a chemotactic
CC       phospholipid mediator that possesses potent inflammatory, smooth-muscle
CC       contractile and hypotensive activity. Seems to mediate its action via a
CC       G protein that activates a phosphatidylinositol-calcium second
CC       messenger system. {ECO:0000269|PubMed:1281995,
CC       ECO:0000269|PubMed:1374385, ECO:0000269|PubMed:1656963,
CC       ECO:0000269|PubMed:1657923}.
CC   -!- SUBUNIT: Interacts with ARRB1. {ECO:0000269|PubMed:16709866}.
CC   -!- INTERACTION:
CC       P25105; P02686: MBP; NbExp=2; IntAct=EBI-3906092, EBI-947410;
CC       P25105; P04156: PRNP; NbExp=2; IntAct=EBI-3906092, EBI-977302;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:1374385};
CC       Multi-pass membrane protein {ECO:0000269|PubMed:1374385}.
CC   -!- TISSUE SPECIFICITY: Expressed in the placenta, lung, left and right
CC       heart ventricles, heart atrium, leukocytes and differentiated HL-60
CC       granulocytes. {ECO:0000269|PubMed:1281995, ECO:0000269|PubMed:1656963,
CC       ECO:0000269|PubMed:1657923}.
CC   -!- INDUCTION: By CSF2/GM-CSF, IL5/interleukin-5 and n-butyrate.
CC       {ECO:0000269|PubMed:1657923}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M80436; AAA60001.1; -; mRNA.
DR   EMBL; D10202; BAA01050.1; -; mRNA.
DR   EMBL; M76674; AAA60002.1; -; mRNA.
DR   EMBL; M88177; AAA60214.1; -; Genomic_DNA.
DR   EMBL; S52624; AAB24695.2; -; mRNA.
DR   EMBL; L07334; AAA60108.1; -; mRNA.
DR   EMBL; S56396; AAB25755.1; -; Genomic_DNA.
DR   EMBL; AY275466; AAP32298.1; -; mRNA.
DR   EMBL; BT009801; AAP88803.1; -; mRNA.
DR   EMBL; AK290240; BAF82929.1; -; mRNA.
DR   EMBL; CH471059; EAX07711.1; -; Genomic_DNA.
DR   EMBL; BC013816; AAH13816.1; -; mRNA.
DR   EMBL; BC063000; AAH63000.1; -; mRNA.
DR   CCDS; CCDS318.1; -.
DR   PIR; A40191; A40191.
DR   RefSeq; NP_000943.1; NM_000952.4.
DR   RefSeq; NP_001158193.1; NM_001164721.1.
DR   RefSeq; NP_001158194.1; NM_001164722.2.
DR   RefSeq; NP_001158195.1; NM_001164723.2.
DR   PDB; 2B0X; Model; -; A=1-342.
DR   PDBsum; 2B0X; -.
DR   SMR; P25105; -.
DR   BioGRID; 111696; 11.
DR   CORUM; P25105; -.
DR   IntAct; P25105; 15.
DR   MINT; P25105; -.
DR   STRING; 9606.ENSP00000362965; -.
DR   BindingDB; P25105; -.
DR   ChEMBL; CHEMBL250; -.
DR   DrugBank; DB09166; Etizolam.
DR   DrugBank; DB02261; Platelet Activating Factor.
DR   DrugBank; DB11614; Rupatadine.
DR   DrugCentral; P25105; -.
DR   GuidetoPHARMACOLOGY; 334; -.
DR   SwissLipids; SLP:000001565; -.
DR   TCDB; 9.A.14.13.3; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; P25105; 1 site.
DR   iPTMnet; P25105; -.
DR   PhosphoSitePlus; P25105; -.
DR   BioMuta; PTAFR; -.
DR   DMDM; 129557; -.
DR   EPD; P25105; -.
DR   jPOST; P25105; -.
DR   MassIVE; P25105; -.
DR   PaxDb; P25105; -.
DR   PeptideAtlas; P25105; -.
DR   PRIDE; P25105; -.
DR   ProteomicsDB; 54261; -.
DR   ABCD; P25105; 1 sequenced antibody.
DR   Antibodypedia; 30903; 179 antibodies.
DR   DNASU; 5724; -.
DR   Ensembl; ENST00000305392; ENSP00000301974; ENSG00000169403.
DR   Ensembl; ENST00000373857; ENSP00000362965; ENSG00000169403.
DR   Ensembl; ENST00000539896; ENSP00000442658; ENSG00000169403.
DR   GeneID; 5724; -.
DR   KEGG; hsa:5724; -.
DR   UCSC; uc001bpl.4; human.
DR   CTD; 5724; -.
DR   DisGeNET; 5724; -.
DR   EuPathDB; HostDB:ENSG00000169403.11; -.
DR   GeneCards; PTAFR; -.
DR   HGNC; HGNC:9582; PTAFR.
DR   HPA; ENSG00000169403; Tissue enriched (blood).
DR   MIM; 173393; gene.
DR   neXtProt; NX_P25105; -.
DR   OpenTargets; ENSG00000169403; -.
DR   PharmGKB; PA33933; -.
DR   eggNOG; ENOG502QTQI; Eukaryota.
DR   GeneTree; ENSGT00980000198579; -.
DR   HOGENOM; CLU_009579_8_2_1; -.
DR   InParanoid; P25105; -.
DR   KO; K04279; -.
DR   OMA; KCSRQTT; -.
DR   OrthoDB; 800525at2759; -.
DR   PhylomeDB; P25105; -.
DR   TreeFam; TF350009; -.
DR   PathwayCommons; P25105; -.
DR   Reactome; R-HSA-373076; Class A/1 (Rhodopsin-like receptors).
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-6783783; Interleukin-10 signaling.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-877300; Interferon gamma signaling.
DR   SIGNOR; P25105; -.
DR   BioGRID-ORCS; 5724; 5 hits in 884 CRISPR screens.
DR   ChiTaRS; PTAFR; human.
DR   GeneWiki; Platelet-activating_factor_receptor; -.
DR   GenomeRNAi; 5724; -.
DR   Pharos; P25105; Tchem.
DR   PRO; PR:P25105; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P25105; protein.
DR   Bgee; ENSG00000169403; Expressed in blood and 229 other tissues.
DR   Genevisible; P25105; HS.
DR   GO; GO:0016021; C:integral component of membrane; NAS:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0030667; C:secretory granule membrane; TAS:Reactome.
DR   GO; GO:0070821; C:tertiary granule membrane; TAS:Reactome.
DR   GO; GO:0045028; F:G protein-coupled purinergic nucleotide receptor activity; IBA:GO_Central.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; TAS:ProtInc.
DR   GO; GO:0001530; F:lipopolysaccharide binding; IEA:Ensembl.
DR   GO; GO:0001875; F:lipopolysaccharide immune receptor activity; IEA:Ensembl.
DR   GO; GO:0051019; F:mitogen-activated protein kinase binding; IEA:Ensembl.
DR   GO; GO:0005543; F:phospholipid binding; IDA:UniProtKB.
DR   GO; GO:0004992; F:platelet activating factor receptor activity; IDA:UniProtKB.
DR   GO; GO:1904317; P:cellular response to 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine; IEA:Ensembl.
DR   GO; GO:0071320; P:cellular response to cAMP; IEA:Ensembl.
DR   GO; GO:0071398; P:cellular response to fatty acid; IEA:Ensembl.
DR   GO; GO:0071258; P:cellular response to gravity; IEA:Ensembl.
DR   GO; GO:0006935; P:chemotaxis; TAS:ProtInc.
DR   GO; GO:0001816; P:cytokine production; IEA:Ensembl.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0006955; P:immune response; TAS:ProtInc.
DR   GO; GO:0006954; P:inflammatory response; TAS:ProtInc.
DR   GO; GO:0032959; P:inositol trisphosphate biosynthetic process; IEA:Ensembl.
DR   GO; GO:0060333; P:interferon-gamma-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0045776; P:negative regulation of blood pressure; IEA:Ensembl.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0007567; P:parturition; IEA:Ensembl.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; IDA:UniProtKB.
DR   GO; GO:0097755; P:positive regulation of blood vessel diameter; IEA:Ensembl.
DR   GO; GO:1904306; P:positive regulation of gastro-intestinal system smooth muscle contraction; IEA:Ensembl.
DR   GO; GO:0060732; P:positive regulation of inositol phosphate biosynthetic process; IEA:Ensembl.
DR   GO; GO:1903238; P:positive regulation of leukocyte tethering or rolling; IEA:Ensembl.
DR   GO; GO:1904303; P:positive regulation of maternal process involved in parturition; IEA:Ensembl.
DR   GO; GO:0043315; P:positive regulation of neutrophil degranulation; IEA:Ensembl.
DR   GO; GO:0010863; P:positive regulation of phospholipase C activity; IEA:Ensembl.
DR   GO; GO:1904058; P:positive regulation of sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:1904300; P:positive regulation of transcytosis; IEA:Ensembl.
DR   GO; GO:0045727; P:positive regulation of translation; IEA:Ensembl.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; IEA:Ensembl.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; IEA:Ensembl.
DR   GO; GO:1902943; P:positive regulation of voltage-gated chloride channel activity; IEA:Ensembl.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0071548; P:response to dexamethasone; IEA:Ensembl.
DR   GO; GO:0009609; P:response to symbiotic bacterium; IEA:Ensembl.
DR   GO; GO:0045056; P:transcytosis; IEA:Ensembl.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR002282; PAF_rcpt.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01153; PAFRECEPTOR.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Chemotaxis; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Polymorphism; Receptor;
KW   Reference proteome; Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..342
FT                   /note="Platelet-activating factor receptor"
FT                   /id="PRO_0000070092"
FT   TOPO_DOM        1..16
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        17..38
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        39..54
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        55..74
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        75..91
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        92..113
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        114..133
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        134..155
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        156..184
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        185..205
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        206..233
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        234..254
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        255..276
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        277..296
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        297..342
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        169
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        90..173
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VARIANT         224
FT                   /note="A -> D (in dbSNP:rs5938)"
FT                   /evidence="ECO:0000269|PubMed:10391209"
FT                   /id="VAR_011851"
FT   VARIANT         338
FT                   /note="N -> S (in dbSNP:rs5939)"
FT                   /evidence="ECO:0000269|PubMed:10391209"
FT                   /id="VAR_011852"
FT   CONFLICT        28
FT                   /note="L -> P (in Ref. 6; AAA60108)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        66
FT                   /note="F -> L (in Ref. 6; AAA60108)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        95
FT                   /note="C -> R (in Ref. 6; AAA60108)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        227..228
FT                   /note="KR -> TG (in Ref. 4; AAA60214)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        227..228
FT                   /note="KR -> TT (in Ref. 6; AAA60108)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        247
FT                   /note="P -> A (in Ref. 6; AAA60108)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        316
FT                   /note="K -> N (in Ref. 5; AAB24695)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   342 AA;  39203 MW;  890073C9EBA79228 CRC64;
     MEPHDSSHMD SEFRYTLFPI VYSIIFVLGV IANGYVLWVF ARLYPCKKFN EIKIFMVNLT
     MADMLFLITL PLWIVYYQNQ GNWILPKFLC NVAGCLFFIN TYCSVAFLGV ITYNRFQAVT
     RPIKTAQANT RKRGISLSLV IWVAIVGAAS YFLILDSTNT VPDSAGSGNV TRCFEHYEKG
     SVPVLIIHIF IVFSFFLVFL IILFCNLVII RTLLMQPVQQ QRNAEVKRRA LWMVCTVLAV
     FIICFVPHHV VQLPWTLAEL GFQDSKFHQA INDAHQVTLC LLSTNCVLDP VIYCFLTKKF
     RKHLTEKFYS MRSSRKCSRA TTDTVTEVVV PFNQIPGNSL KN
//
ID   LPAR1_HUMAN             Reviewed;         364 AA.
AC   Q92633; B4DK36; O00656; O00722; P78351;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   06-DEC-2002, sequence version 3.
DT   07-OCT-2020, entry version 186.
DE   RecName: Full=Lysophosphatidic acid receptor 1;
DE            Short=LPA receptor 1;
DE            Short=LPA-1;
DE   AltName: Full=Lysophosphatidic acid receptor Edg-2 {ECO:0000303|PubMed:9070858};
GN   Name=LPAR1; Synonyms=EDG2, LPA1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=9070858; DOI=10.1006/bbrc.1997.6150;
RA   An S., Dickens M.A., Bleu T., Hallmark O.G., Goetzl E.J.;
RT   "Molecular cloning of the human Edg2 protein and its identification as a
RT   functional cellular receptor for lysophosphatidic acid.";
RL   Biochem. Biophys. Res. Commun. 231:619-622(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND REVIEW.
RX   PubMed=9069262; DOI=10.1016/s0955-0674(97)80059-2;
RA   Moolenaar W.H., Kranenburg O., Postma F.R., Zondag G.C.M.;
RT   "Lysophosphatidic acid: G-protein signalling and cellular responses.";
RL   Curr. Opin. Cell Biol. 9:168-173(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Hippocampus, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   REVIEW.
RX   PubMed=11093753; DOI=10.1124/mol.58.6.1188;
RA   Contos J.J.A., Ishii I., Chun J.;
RT   "Lysophosphatidic acid receptors.";
RL   Mol. Pharmacol. 58:1188-1196(2000).
RN   [8]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=18066075; DOI=10.1038/nm1685;
RA   Tager A.M., LaCamera P., Shea B.S., Campanella G.S., Selman M., Zhao Z.,
RA   Polosukhin V., Wain J., Karimi-Shah B.A., Kim N.D., Hart W.K., Pardo A.,
RA   Blackwell T.S., Xu Y., Chun J., Luster A.D.;
RT   "The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung
RT   injury by mediating fibroblast recruitment and vascular leak.";
RL   Nat. Med. 14:45-54(2008).
RN   [9]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH RALA AND GRK2.
RX   PubMed=19306925; DOI=10.1016/j.cellsig.2009.03.011;
RA   Aziziyeh A.I., Li T.T., Pape C., Pampillo M., Chidiac P., Possmayer F.,
RA   Babwah A.V., Bhattacharya M.;
RT   "Dual regulation of lysophosphatidic acid (LPA1) receptor signalling by Ral
RT   and GRK.";
RL   Cell. Signal. 21:1207-1217(2009).
RN   [10]
RP   FUNCTION.
RX   PubMed=19656035; DOI=10.1902/jop.2009.080624;
RA   George J., Headen K.V., Ogunleye A.O., Perry G.A., Wilwerding T.M.,
RA   Parrish L.C., McVaney T.P., Mattson J.S., Cerutis D.R.;
RT   "Lysophosphatidic acid signals through specific lysophosphatidic acid
RT   receptor subtypes to control key regenerative responses of human gingival
RT   and periodontal ligament fibroblasts.";
RL   J. Periodontology 80:1338-1347(2009).
RN   [11]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=19733258; DOI=10.1016/j.bbalip.2009.08.011;
RA   Song H.Y., Lee M.J., Kim M.Y., Kim K.H., Lee I.H., Shin S.H., Lee J.S.,
RA   Kim J.H.;
RT   "Lysophosphatidic acid mediates migration of human mesenchymal stem cells
RT   stimulated by synovial fluid of patients with rheumatoid arthritis.";
RL   Biochim. Biophys. Acta 1801:23-30(2010).
RN   [12]
RP   FUNCTION, SUBCELLULAR LOCATION, MUTAGENESIS OF TYR-85; LEU-87 AND
RP   325-ILE-LEU-326, AND GLYCOSYLATION.
RX   PubMed=25025571; DOI=10.1016/j.cellsig.2014.07.005;
RA   Zhao J., Wei J., Bowser R.K., Dong S., Xiao S., Zhao Y.;
RT   "Molecular regulation of lysophosphatidic acid receptor 1 trafficking to
RT   the cell surface.";
RL   Cell. Signal. 26:2406-2411(2014).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-341, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [14]
RP   REVIEW.
RX   PubMed=25732591; DOI=10.1007/s00018-015-1872-8;
RA   Fukushima N., Ishii S., Tsujiuchi T., Kagawa N., Katoh K.;
RT   "Comparative analyses of lysophosphatidic acid receptor-mediated
RT   signaling.";
RL   Cell. Mol. Life Sci. 72:2377-2394(2015).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 2-326 IN COMPLEXES WITH SYNTHETIC
RP   ANTAGONISTS, FUNCTION, SUBCELLULAR LOCATION, TOPOLOGY, AND DISULFIDE BOND.
RX   PubMed=26091040; DOI=10.1016/j.cell.2015.06.002;
RA   Chrencik J.E., Roth C.B., Terakado M., Kurata H., Omi R., Kihara Y.,
RA   Warshaviak D., Nakade S., Asmar-Rovira G., Mileni M., Mizuno H.,
RA   Griffith M.T., Rodgers C., Han G.W., Velasquez J., Chun J., Stevens R.C.,
RA   Hanson M.A.;
RT   "Crystal structure of antagonist bound human lysophosphatidic acid receptor
RT   1.";
RL   Cell 161:1633-1643(2015).
CC   -!- FUNCTION: Receptor for lysophosphatidic acid (LPA) (PubMed:9070858,
CC       PubMed:19306925, PubMed:25025571, PubMed:26091040). Plays a role in the
CC       reorganization of the actin cytoskeleton, cell migration,
CC       differentiation and proliferation, and thereby contributes to the
CC       responses to tissue damage and infectious agents. Activates downstream
CC       signaling cascades via the G(i)/G(o), G(12)/G(13), and G(q) families of
CC       heteromeric G proteins. Signaling inhibits adenylyl cyclase activity
CC       and decreases cellular cAMP levels (PubMed:26091040). Signaling
CC       triggers an increase of cytoplasmic Ca(2+) levels (PubMed:19656035,
CC       PubMed:19733258, PubMed:26091040). Activates RALA; this leads to the
CC       activation of phospholipase C (PLC) and the formation of inositol
CC       1,4,5-trisphosphate (PubMed:19306925). Signaling mediates activation of
CC       down-stream MAP kinases (By similarity). Contributes to the regulation
CC       of cell shape. Promotes Rho-dependent reorganization of the actin
CC       cytoskeleton in neuronal cells and neurite retraction
CC       (PubMed:26091040). Promotes the activation of Rho and the formation of
CC       actin stress fibers (PubMed:26091040). Promotes formation of
CC       lamellipodia at the leading edge of migrating cells via activation of
CC       RAC1 (By similarity). Through its function as lysophosphatidic acid
CC       receptor, plays a role in chemotaxis and cell migration, including
CC       responses to injury and wounding (PubMed:18066075, PubMed:19656035,
CC       PubMed:19733258). Plays a role in triggering inflammation in response
CC       to bacterial lipopolysaccharide (LPS) via its interaction with CD14.
CC       Promotes cell proliferation in response to lysophosphatidic acid.
CC       Required for normal skeleton development. May play a role in osteoblast
CC       differentiation. Required for normal brain development. Required for
CC       normal proliferation, survival and maturation of newly formed neurons
CC       in the adult dentate gyrus. Plays a role in pain perception and in the
CC       initiation of neuropathic pain (By similarity).
CC       {ECO:0000250|UniProtKB:P61793, ECO:0000269|PubMed:18066075,
CC       ECO:0000269|PubMed:19306925, ECO:0000269|PubMed:19656035,
CC       ECO:0000269|PubMed:19733258, ECO:0000269|PubMed:25025571,
CC       ECO:0000269|PubMed:26091040, ECO:0000269|PubMed:9070858,
CC       ECO:0000305|PubMed:11093753, ECO:0000305|PubMed:9069262}.
CC   -!- SUBUNIT: Interacts with RALA and GRK2 (PubMed:19306925). Interacts with
CC       GNAQ and GNA13. Interacts with CD14; the interaction is enhanced by
CC       exposure to bacterial lipopolysaccharide (LPS) (By similarity).
CC       {ECO:0000250|UniProtKB:P61793, ECO:0000269|PubMed:19306925}.
CC   -!- SUBCELLULAR LOCATION: Cell surface {ECO:0000269|PubMed:19306925,
CC       ECO:0000269|PubMed:25025571}. Cell membrane
CC       {ECO:0000269|PubMed:19306925, ECO:0000269|PubMed:25025571,
CC       ECO:0000269|PubMed:26091040, ECO:0000269|PubMed:9070858}; Multi-pass
CC       membrane protein {ECO:0000269|PubMed:19306925,
CC       ECO:0000269|PubMed:26091040}. Endosome {ECO:0000269|PubMed:19306925}.
CC       Note=Prior to LPA treatment found predominantly at the cell surface.
CC       Internalized after LPA treatment. Colocalizes with RALA in endocytic
CC       vesicles after LPA treatment. {ECO:0000269|PubMed:19306925}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q92633-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q92633-2; Sequence=VSP_057046;
CC   -!- TISSUE SPECIFICITY: Expressed in many adult organs, including brain,
CC       heart, colon, small intestine, placenta, prostate, ovary, pancreas,
CC       testes, spleen, skeletal muscle, and kidney. Little or no expression in
CC       liver, lung, thymus, or peripheral blood leukocytes (PubMed:9070858).
CC       Detected in lung fibroblasts from bronchoalveolar fluid from patients
CC       with idiopathic pulmonary fibrosis (PubMed:18066075). Detected in bone
CC       marrow-derived mesenchymal stem cells (PubMed:19733258).
CC       {ECO:0000269|PubMed:18066075, ECO:0000269|PubMed:19733258,
CC       ECO:0000269|PubMed:9070858}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:25025571}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/LPAR1ID40405ch9q31.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U80811; AAC51139.1; -; mRNA.
DR   EMBL; Y09479; CAA70686.1; -; mRNA.
DR   EMBL; Y09479; CAA70687.1; -; mRNA.
DR   EMBL; U78192; AAC00530.1; -; mRNA.
DR   EMBL; AY322546; AAP84359.1; -; mRNA.
DR   EMBL; AK296374; BAG59048.1; -; mRNA.
DR   EMBL; AC007157; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL157881; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL442064; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC030615; AAH30615.1; -; mRNA.
DR   EMBL; BC036034; AAH36034.1; -; mRNA.
DR   CCDS; CCDS6777.1; -. [Q92633-1]
DR   PIR; JC5293; JC5293.
DR   RefSeq; NP_001392.2; NM_001401.3. [Q92633-1]
DR   RefSeq; NP_476500.1; NM_057159.2. [Q92633-1]
DR   RefSeq; XP_005251838.1; XM_005251781.3.
DR   RefSeq; XP_005251839.1; XM_005251782.3. [Q92633-1]
DR   RefSeq; XP_016869872.1; XM_017014383.1.
DR   RefSeq; XP_016869873.1; XM_017014384.1.
DR   RefSeq; XP_016869874.1; XM_017014385.1.
DR   RefSeq; XP_016869875.1; XM_017014386.1.
DR   RefSeq; XP_016869876.1; XM_017014387.1.
DR   RefSeq; XP_016869877.1; XM_017014388.1.
DR   RefSeq; XP_016869878.1; XM_017014389.1.
DR   RefSeq; XP_016869879.1; XM_017014390.1.
DR   RefSeq; XP_016869880.1; XM_017014391.1.
DR   RefSeq; XP_016869881.1; XM_017014392.1.
DR   RefSeq; XP_016869882.1; XM_017014393.1.
DR   RefSeq; XP_016869883.1; XM_017014394.1.
DR   RefSeq; XP_016869884.1; XM_017014395.1.
DR   RefSeq; XP_016869885.1; XM_017014396.1.
DR   RefSeq; XP_016869886.1; XM_017014397.1.
DR   RefSeq; XP_016869887.1; XM_017014398.1.
DR   RefSeq; XP_016869888.1; XM_017014399.1.
DR   RefSeq; XP_016869889.1; XM_017014400.1.
DR   RefSeq; XP_016869890.1; XM_017014401.1.
DR   RefSeq; XP_016869891.1; XM_017014402.1.
DR   RefSeq; XP_016869892.1; XM_017014403.1.
DR   RefSeq; XP_016869893.1; XM_017014404.1. [Q92633-1]
DR   RefSeq; XP_016869894.1; XM_017014405.1.
DR   RefSeq; XP_016869895.1; XM_017014406.1.
DR   RefSeq; XP_016869896.1; XM_017014407.1.
DR   PDB; 4Z34; X-ray; 3.00 A; A=2-232, A=248-326.
DR   PDB; 4Z35; X-ray; 2.90 A; A=2-232, A=248-326.
DR   PDB; 4Z36; X-ray; 2.90 A; A=2-232, A=249-327.
DR   PDBsum; 4Z34; -.
DR   PDBsum; 4Z35; -.
DR   PDBsum; 4Z36; -.
DR   SMR; Q92633; -.
DR   BioGRID; 108226; 156.
DR   IntAct; Q92633; 104.
DR   MINT; Q92633; -.
DR   STRING; 9606.ENSP00000363553; -.
DR   BindingDB; Q92633; -.
DR   ChEMBL; CHEMBL3819; -.
DR   GuidetoPHARMACOLOGY; 272; -.
DR   SwissLipids; SLP:000001567; -.
DR   GlyGen; Q92633; 2 sites.
DR   iPTMnet; Q92633; -.
DR   PhosphoSitePlus; Q92633; -.
DR   SwissPalm; Q92633; -.
DR   BioMuta; LPAR1; -.
DR   DMDM; 26454626; -.
DR   jPOST; Q92633; -.
DR   MassIVE; Q92633; -.
DR   MaxQB; Q92633; -.
DR   PaxDb; Q92633; -.
DR   PeptideAtlas; Q92633; -.
DR   PRIDE; Q92633; -.
DR   ProteomicsDB; 4425; -.
DR   ProteomicsDB; 75389; -. [Q92633-1]
DR   Antibodypedia; 15104; 380 antibodies.
DR   DNASU; 1902; -.
DR   Ensembl; ENST00000358883; ENSP00000351755; ENSG00000198121. [Q92633-1]
DR   Ensembl; ENST00000374430; ENSP00000363552; ENSG00000198121. [Q92633-1]
DR   Ensembl; ENST00000374431; ENSP00000363553; ENSG00000198121. [Q92633-1]
DR   GeneID; 1902; -.
DR   KEGG; hsa:1902; -.
DR   UCSC; uc004bfa.4; human. [Q92633-1]
DR   CTD; 1902; -.
DR   DisGeNET; 1902; -.
DR   EuPathDB; HostDB:ENSG00000198121.13; -.
DR   GeneCards; LPAR1; -.
DR   HGNC; HGNC:3166; LPAR1.
DR   HPA; ENSG00000198121; Tissue enhanced (brain).
DR   MIM; 602282; gene.
DR   neXtProt; NX_Q92633; -.
DR   OpenTargets; ENSG00000198121; -.
DR   PharmGKB; PA162394187; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT01000000214362; -.
DR   InParanoid; Q92633; -.
DR   KO; K04289; -.
DR   OMA; CICDIEH; -.
DR   PhylomeDB; Q92633; -.
DR   TreeFam; TF330052; -.
DR   PathwayCommons; Q92633; -.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-419408; Lysosphingolipid and LPA receptors.
DR   SIGNOR; Q92633; -.
DR   BioGRID-ORCS; 1902; 24 hits in 873 CRISPR screens.
DR   ChiTaRS; LPAR1; human.
DR   GeneWiki; LPAR1; -.
DR   GenomeRNAi; 1902; -.
DR   Pharos; Q92633; Tchem.
DR   PRO; PR:Q92633; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; Q92633; protein.
DR   Bgee; ENSG00000198121; Expressed in medial globus pallidus and 248 other tissues.
DR   ExpressionAtlas; Q92633; baseline and differential.
DR   Genevisible; Q92633; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0043198; C:dendritic shaft; IEA:Ensembl.
DR   GO; GO:0043197; C:dendritic spine; IEA:Ensembl.
DR   GO; GO:0005768; C:endosome; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; ISS:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0001965; F:G-protein alpha-subunit binding; IEA:Ensembl.
DR   GO; GO:0035727; F:lysophosphatidic acid binding; IDA:UniProtKB.
DR   GO; GO:0070915; F:lysophosphatidic acid receptor activity; IDA:UniProtKB.
DR   GO; GO:0030165; F:PDZ domain binding; IEA:Ensembl.
DR   GO; GO:0000187; P:activation of MAPK activity; IEA:Ensembl.
DR   GO; GO:0007202; P:activation of phospholipase C activity; IDA:UniProtKB.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007193; P:adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0032060; P:bleb assembly; IEA:Ensembl.
DR   GO; GO:0060326; P:cell chemotaxis; IMP:UniProtKB.
DR   GO; GO:1904566; P:cellular response to 1-oleoyl-sn-glycerol 3-phosphate; IEA:Ensembl.
DR   GO; GO:0071453; P:cellular response to oxygen levels; IEA:Ensembl.
DR   GO; GO:0021549; P:cerebellum development; IEA:Ensembl.
DR   GO; GO:0022038; P:corpus callosum development; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0042552; P:myelination; IEA:Ensembl.
DR   GO; GO:0043951; P:negative regulation of cAMP-mediated signaling; IEA:Ensembl.
DR   GO; GO:0010977; P:negative regulation of neuron projection development; ISS:UniProtKB.
DR   GO; GO:0022008; P:neurogenesis; IBA:GO_Central.
DR   GO; GO:0014003; P:oligodendrocyte development; IEA:Ensembl.
DR   GO; GO:0021554; P:optic nerve development; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; TAS:ProtInc.
DR   GO; GO:0051482; P:positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway; IMP:UniProtKB.
DR   GO; GO:0060999; P:positive regulation of dendritic spine development; IEA:Ensembl.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IEP:UniProtKB.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; ISS:UniProtKB.
DR   GO; GO:0035025; P:positive regulation of Rho protein signal transduction; ISS:UniProtKB.
DR   GO; GO:0071673; P:positive regulation of smooth muscle cell chemotaxis; IEA:Ensembl.
DR   GO; GO:0051496; P:positive regulation of stress fiber assembly; ISS:UniProtKB.
DR   GO; GO:0008360; P:regulation of cell shape; ISS:UniProtKB.
DR   GO; GO:0019222; P:regulation of metabolic process; IBA:GO_Central.
DR   CDD; cd15344; 7tmA_LPAR1_Edg2; 1.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR004065; LPA_rcpt.
DR   InterPro; IPR002277; LPA_rcpt_EDG2.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01148; EDG2RECEPTOR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01527; LPARECEPTOR.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Disulfide bond;
KW   Endosome; G-protein coupled receptor; Glycoprotein; Lipid-binding;
KW   Membrane; Phosphoprotein; Polymorphism; Receptor; Reference proteome;
KW   Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..364
FT                   /note="Lysophosphatidic acid receptor 1"
FT                   /id="PRO_0000069417"
FT   TOPO_DOM        1..50
FT                   /note="Extracellular"
FT   TRANSMEM        51..75
FT                   /note="Helical; Name=1"
FT   TOPO_DOM        76..83
FT                   /note="Cytoplasmic"
FT   TRANSMEM        84..107
FT                   /note="Helical; Name=2"
FT   TOPO_DOM        108..121
FT                   /note="Extracellular"
FT   TRANSMEM        122..144
FT                   /note="Helical; Name=3"
FT   TOPO_DOM        145..163
FT                   /note="Cytoplasmic"
FT   TRANSMEM        164..184
FT                   /note="Helical; Name=4"
FT   TOPO_DOM        185..204
FT                   /note="Extracellular"
FT   TRANSMEM        205..225
FT                   /note="Helical; Name=5"
FT   TOPO_DOM        226..255
FT                   /note="Cytoplasmic"
FT   TRANSMEM        256..280
FT                   /note="Helical; Name=6"
FT   TOPO_DOM        281..294
FT                   /note="Extracellular"
FT   TRANSMEM        295..315
FT                   /note="Helical; Name=7"
FT   TOPO_DOM        316..364
FT                   /note="Cytoplasmic"
FT   REGION          124..129
FT                   /note="Lysophosphatidic acid binding"
FT                   /evidence="ECO:0000305|PubMed:26091040"
FT   BINDING         39
FT                   /note="Lysophosphatidic acid"
FT                   /evidence="ECO:0000305|PubMed:26091040"
FT   BINDING         210
FT                   /note="Lysophosphatidic acid"
FT                   /evidence="ECO:0000305|PubMed:26091040"
FT   MOD_RES         341
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   MOD_RES         351
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P61793"
FT   CARBOHYD        27
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        35
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        24..190
FT                   /evidence="ECO:0000244|PDB:4Z34, ECO:0000244|PDB:4Z35,
FT                   ECO:0000244|PDB:4Z36"
FT   DISULFID        188..195
FT                   /evidence="ECO:0000244|PDB:4Z34, ECO:0000244|PDB:4Z35,
FT                   ECO:0000244|PDB:4Z36"
FT   DISULFID        284..287
FT                   /evidence="ECO:0000244|PDB:4Z34, ECO:0000244|PDB:4Z35,
FT                   ECO:0000244|PDB:4Z36"
FT   VAR_SEQ         1..15
FT                   /note="MAAISTSIPVISQPQ -> MLLLLIPAHSSVLENE (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_057046"
FT   VARIANT         77
FT                   /note="N -> S (in dbSNP:rs11542862)"
FT                   /id="VAR_049414"
FT   MUTAGEN         85
FT                   /note="Y->A: Impairs localization at the cell membrane."
FT                   /evidence="ECO:0000269|PubMed:25025571"
FT   MUTAGEN         87
FT                   /note="L->A: Impairs localization at the cell membrane."
FT                   /evidence="ECO:0000269|PubMed:25025571"
FT   MUTAGEN         325..326
FT                   /note="IL->AA: Impairs localization at the cell membrane."
FT                   /evidence="ECO:0000269|PubMed:25025571"
FT   CONFLICT        340
FT                   /note="G -> S (in Ref. 1; AAC51139)"
FT                   /evidence="ECO:0000305"
FT   HELIX           30..36
FT                   /evidence="ECO:0000244|PDB:4Z35"
FT   HELIX           47..76
FT                   /evidence="ECO:0000244|PDB:4Z35"
FT   HELIX           78..80
FT                   /evidence="ECO:0000244|PDB:4Z35"
FT   HELIX           83..106
FT                   /evidence="ECO:0000244|PDB:4Z35"
FT   HELIX           110..113
FT                   /evidence="ECO:0000244|PDB:4Z35"
FT   HELIX           118..151
FT                   /evidence="ECO:0000244|PDB:4Z35"
FT   HELIX           158..178
FT                   /evidence="ECO:0000244|PDB:4Z35"
FT   HELIX           181..183
FT                   /evidence="ECO:0000244|PDB:4Z35"
FT   HELIX           192..194
FT                   /evidence="ECO:0000244|PDB:4Z35"
FT   HELIX           204..232
FT                   /evidence="ECO:0000244|PDB:4Z35"
FT   HELIX           248..283
FT                   /evidence="ECO:0000244|PDB:4Z35"
FT   TURN            285..287
FT                   /evidence="ECO:0000244|PDB:4Z35"
FT   HELIX           294..314
FT                   /evidence="ECO:0000244|PDB:4Z35"
FT   HELIX           316..326
FT                   /evidence="ECO:0000244|PDB:4Z35"
SQ   SEQUENCE   364 AA;  41109 MW;  4CA6262FD00DFE74 CRC64;
     MAAISTSIPV ISQPQFTAMN EPQCFYNESI AFFYNRSGKH LATEWNTVSK LVMGLGITVC
     IFIMLANLLV MVAIYVNRRF HFPIYYLMAN LAAADFFAGL AYFYLMFNTG PNTRRLTVST
     WLLRQGLIDT SLTASVANLL AIAIERHITV FRMQLHTRMS NRRVVVVIVV IWTMAIVMGA
     IPSVGWNCIC DIENCSNMAP LYSDSYLVFW AIFNLVTFVV MVVLYAHIFG YVRQRTMRMS
     RHSSGPRRNR DTMMSLLKTV VIVLGAFIIC WTPGLVLLLL DVCCPQCDVL AYEKFFLLLA
     EFNSAMNPII YSYRDKEMSA TFRQILCCQR SENPTGPTEG SDRSASSLNH TILAGVHSND
     HSVV
//
ID   OPRK_HUMAN              Reviewed;         380 AA.
AC   P41145; E5RHC9; Q499G4;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   17-OCT-2006, sequence version 2.
DT   07-OCT-2020, entry version 192.
DE   RecName: Full=Kappa-type opioid receptor;
DE            Short=K-OR-1;
DE            Short=KOR-1;
GN   Name=OPRK1; Synonyms=OPRK;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RC   TISSUE=Placenta;
RX   PubMed=8060324; DOI=10.1006/bbrc.1994.2091;
RA   Mansson E., Bare L.A., Yang D.;
RT   "Isolation of a human kappa opioid receptor cDNA from placenta.";
RL   Biochem. Biophys. Res. Commun. 202:1431-1437(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RC   TISSUE=Placenta;
RX   PubMed=7624359; DOI=10.1073/pnas.92.15.7006;
RA   Simonin F., Gaveriaus-Ruff C., Befort K., Lannes B., Micheletti G.,
RA   Mattei M.-G., Charon G., Bloch B., Kieffer B.;
RT   "Kappa-opioid receptor in humans: cDNA and genomic cloning, chromosomal
RT   assignment, functional expression, pharmacology, and expression pattern in
RT   the central nervous system.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:7006-7010(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=7869844; DOI=10.1016/0024-3205(94)00507-o;
RA   Zhu J., Chen C., Xue J.-C., Kunapuli S., Deriel J.K., Liu-Chen L.-Y.;
RT   "Cloning of a human kappa opioid receptor from the brain.";
RL   Life Sci. 56:PL201-PL207(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M.,
RA   Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L.,
RA   Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S.,
RA   Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A.,
RA   Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III,
RA   Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K.,
RA   Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B.,
RA   O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K.,
RA   Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L.,
RA   Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G.,
RA   Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W.,
RA   Platzer M., Shimizu N., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 136-279 (ISOFORMS 1/2).
RC   TISSUE=Brain;
RX   PubMed=7929306;
RA   Wang J.B., Johnson P.S., Wu J.M., Wang W.F., Uhl G.R.;
RT   "Human kappa opiate receptor second extracellular loop elevates dynorphin's
RT   affinity for human mu/kappa chimeras.";
RL   J. Biol. Chem. 269:25966-25969(1994).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 132-203 (ISOFORMS 1/2).
RA   Grandy D.K.;
RT   "Mapping of the human kappa opioid receptor gene to chromosome 8q11.2-q12:
RT   no evidence for multiple kappa opioid receptor genes.";
RL   Submitted (DEC-1994) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   INTERACTION WITH SLC9A3R1, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12004055; DOI=10.1074/jbc.m200058200;
RA   Li J.-G., Chen C., Liu-Chen L.-Y.;
RT   "Ezrin-radixin-moesin-binding phosphoprotein-50/Na+/H+ exchanger regulatory
RT   factor (EBP50/NHERF) blocks U50,488H-induced down-regulation of the human
RT   kappa opioid receptor by enhancing its recycling rate.";
RL   J. Biol. Chem. 277:27545-27552(2002).
RN   [11]
RP   INTERACTION WITH GABARAPL1.
RX   PubMed=16431922; DOI=10.1074/jbc.m509805200;
RA   Chen C., Li J.-G., Chen Y., Huang P., Wang Y., Liu-Chen L.-Y.;
RT   "GEC1 interacts with the kappa opioid receptor and enhances expression of
RT   the receptor.";
RL   J. Biol. Chem. 281:7983-7993(2006).
RN   [12]
RP   GLYCOSYLATION AT ASN-25 AND ASN-39.
RX   PubMed=17711303; DOI=10.1021/bi700443j;
RA   Li J.G., Chen C., Liu-Chen L.Y.;
RT   "N-glycosylation of the human kappa opioid receptor enhances its stability
RT   but slows its trafficking along the biosynthesis pathway.";
RL   Biochemistry 46:10960-10970(2007).
RN   [13]
RP   REVIEW.
RX   PubMed=20729876; DOI=10.1038/aps.2010.138;
RA   Wang Y.H., Sun J.F., Tao Y.M., Chi Z.Q., Liu J.G.;
RT   "The role of kappa-opioid receptor activation in mediating antinociception
RT   and addiction.";
RL   Acta Pharmacol. Sin. 31:1065-1070(2010).
RN   [14]
RP   REVIEW.
RX   PubMed=20401607; DOI=10.1007/s00213-010-1806-y;
RA   Bruchas M.R., Chavkin C.;
RT   "Kinase cascades and ligand-directed signaling at the kappa opioid
RT   receptor.";
RL   Psychopharmacology 210:137-147(2010).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 43-358 IN COMPLEX WITH ANTAGONIST,
RP   FUNCTION, SUBCELLULAR LOCATION, AND DISULFIDE BOND.
RX   PubMed=22437504; DOI=10.1038/nature10939;
RA   Wu H., Wacker D., Mileni M., Katritch V., Han G.W., Vardy E., Liu W.,
RA   Thompson A.A., Huang X.P., Carroll F.I., Mascarella S.W., Westkaemper R.B.,
RA   Mosier P.D., Roth B.L., Cherezov V., Stevens R.C.;
RT   "Structure of the human kappa-opioid receptor in complex with JDTic.";
RL   Nature 485:327-332(2012).
CC   -!- FUNCTION: G-protein coupled opioid receptor that functions as receptor
CC       for endogenous alpha-neoendorphins and dynorphins, but has low affinity
CC       for beta-endorphins. Also functions as receptor for various synthetic
CC       opioids and for the psychoactive diterpene salvinorin A. Ligand binding
CC       causes a conformation change that triggers signaling via guanine
CC       nucleotide-binding proteins (G proteins) and modulates the activity of
CC       down-stream effectors, such as adenylate cyclase. Signaling leads to
CC       the inhibition of adenylate cyclase activity. Inhibits neurotransmitter
CC       release by reducing calcium ion currents and increasing potassium ion
CC       conductance. Plays a role in the perception of pain. Plays a role in
CC       mediating reduced physical activity upon treatment with synthetic
CC       opioids. Plays a role in the regulation of salivation in response to
CC       synthetic opioids. May play a role in arousal and regulation of
CC       autonomic and neuroendocrine functions. {ECO:0000269|PubMed:12004055,
CC       ECO:0000269|PubMed:22437504, ECO:0000269|PubMed:7624359,
CC       ECO:0000269|PubMed:8060324}.
CC   -!- SUBUNIT: Interacts with SLC9A3R1. Interacts with GABARAPL1.
CC       {ECO:0000269|PubMed:12004055, ECO:0000269|PubMed:16431922,
CC       ECO:0000269|PubMed:22437504}.
CC   -!- INTERACTION:
CC       P41145; P35414: APLNR; NbExp=3; IntAct=EBI-925028, EBI-2875891;
CC       P41145; Q9H0R8: GABARAPL1; NbExp=5; IntAct=EBI-925028, EBI-746969;
CC       P41145; Q16617: NKG7; NbExp=3; IntAct=EBI-925028, EBI-3919611;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:12004055,
CC       ECO:0000269|PubMed:22437504, ECO:0000269|PubMed:7624359,
CC       ECO:0000269|PubMed:8060324}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:12004055, ECO:0000269|PubMed:22437504,
CC       ECO:0000269|PubMed:7624359, ECO:0000269|PubMed:8060324}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P41145-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P41145-2; Sequence=VSP_055313;
CC   -!- TISSUE SPECIFICITY: Detected in brain and placenta.
CC       {ECO:0000269|PubMed:7624359, ECO:0000269|PubMed:8060324}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Kappa opioid receptor entry;
CC       URL="https://en.wikipedia.org/wiki/Kappa_opioid_receptor";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U11053; AAA20985.1; -; mRNA.
DR   EMBL; U17298; AAC50158.1; -; mRNA.
DR   EMBL; L37362; AAA63906.1; -; mRNA.
DR   EMBL; AF498922; AAM21070.1; -; mRNA.
DR   EMBL; AK310233; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AC009646; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC099912; AAH99912.1; -; mRNA.
DR   EMBL; L36130; AAA63646.1; -; mRNA.
DR   EMBL; U16860; AAA56758.1; -; Genomic_DNA.
DR   CCDS; CCDS6152.1; -. [P41145-1]
DR   CCDS; CCDS64895.1; -. [P41145-2]
DR   PIR; JC2338; JC2338.
DR   RefSeq; NP_000903.2; NM_000912.4. [P41145-1]
DR   RefSeq; NP_001269833.1; NM_001282904.1. [P41145-2]
DR   RefSeq; NP_001305426.1; NM_001318497.1.
DR   PDB; 2A0D; Model; -; A=1-380.
DR   PDB; 2IQN; Model; -; A=55-348.
DR   PDB; 4DJH; X-ray; 2.90 A; A/B=43-358.
DR   PDB; 6B73; X-ray; 3.10 A; A/B=54-358.
DR   PDB; 6VI4; X-ray; 3.30 A; A/B=54-358.
DR   PDBsum; 2A0D; -.
DR   PDBsum; 2IQN; -.
DR   PDBsum; 4DJH; -.
DR   PDBsum; 6B73; -.
DR   PDBsum; 6VI4; -.
DR   SMR; P41145; -.
DR   BioGRID; 111031; 11.
DR   IntAct; P41145; 11.
DR   MINT; P41145; -.
DR   STRING; 9606.ENSP00000265572; -.
DR   BindingDB; P41145; -.
DR   ChEMBL; CHEMBL237; -.
DR   DrugBank; DB01571; 3-Methylfentanyl.
DR   DrugBank; DB01439; 3-Methylthiofentanyl.
DR   DrugBank; DB05443; ADL 10-0101.
DR   DrugBank; DB06274; Alvimopan.
DR   DrugBank; DB00321; Amitriptyline.
DR   DrugBank; DB01238; Aripiprazole.
DR   DrugBank; DB05104; Asimadoline.
DR   DrugBank; DB00289; Atomoxetine.
DR   DrugBank; DB00921; Buprenorphine.
DR   DrugBank; DB00611; Butorphanol.
DR   DrugBank; DB09173; Butyrfentanyl.
DR   DrugBank; DB01535; Carfentanil.
DR   DrugBank; DB00318; Codeine.
DR   DrugBank; DB05155; CR665.
DR   DrugBank; DB00514; Dextromethorphan.
DR   DrugBank; DB00647; Dextropropoxyphene.
DR   DrugBank; DB01209; Dezocine.
DR   DrugBank; DB01452; Diamorphine.
DR   DrugBank; DB01565; Dihydromorphine.
DR   DrugBank; DB01548; Diprenorphine.
DR   DrugBank; DB09272; Eluxadoline.
DR   DrugBank; DB01497; Etorphine.
DR   DrugBank; DB00813; Fentanyl.
DR   DrugBank; DB00327; Hydromorphone.
DR   DrugBank; DB01221; Ketamine.
DR   DrugBank; DB06738; Ketobemidone.
DR   DrugBank; DB00555; Lamotrigine.
DR   DrugBank; DB00825; Levomenthol.
DR   DrugBank; DB00854; Levorphanol.
DR   DrugBank; DB00836; Loperamide.
DR   DrugBank; DB14146; Loxicodegol.
DR   DrugBank; DB00454; Meperidine.
DR   DrugBank; DB06800; Methylnaltrexone.
DR   DrugBank; DB06148; Mianserin.
DR   DrugBank; DB00370; Mirtazapine.
DR   DrugBank; DB00295; Morphine.
DR   DrugBank; DB06409; Morphine glucuronide.
DR   DrugBank; DB00844; Nalbuphine.
DR   DrugBank; DB11691; Naldemedine.
DR   DrugBank; DB06230; Nalmefene.
DR   DrugBank; DB01183; Naloxone.
DR   DrugBank; DB00704; Naltrexone.
DR   DrugBank; DB11130; Opium.
DR   DrugBank; DB00497; Oxycodone.
DR   DrugBank; DB00652; Pentazocine.
DR   DrugBank; DB11186; Pentoxyverine.
DR   DrugBank; DB09209; Pholcodine.
DR   DrugBank; DB00396; Progesterone.
DR   DrugBank; DB00899; Remifentanil.
DR   DrugBank; DB00708; Sufentanil.
DR   DrugBank; DB06204; Tapentadol.
DR   DrugBank; DB00193; Tramadol.
DR   DrugBank; DB05046; V1003.
DR   DrugCentral; P41145; -.
DR   GuidetoPHARMACOLOGY; 318; -.
DR   GlyGen; P41145; 2 sites.
DR   iPTMnet; P41145; -.
DR   PhosphoSitePlus; P41145; -.
DR   BioMuta; OPRK1; -.
DR   DMDM; 116242691; -.
DR   MassIVE; P41145; -.
DR   PaxDb; P41145; -.
DR   PeptideAtlas; P41145; -.
DR   PRIDE; P41145; -.
DR   ProteomicsDB; 15940; -.
DR   ProteomicsDB; 55403; -. [P41145-1]
DR   ABCD; P41145; 1 sequenced antibody.
DR   Antibodypedia; 11640; 383 antibodies.
DR   DNASU; 4986; -.
DR   Ensembl; ENST00000265572; ENSP00000265572; ENSG00000082556. [P41145-1]
DR   Ensembl; ENST00000520287; ENSP00000429706; ENSG00000082556. [P41145-1]
DR   Ensembl; ENST00000524278; ENSP00000430923; ENSG00000082556. [P41145-2]
DR   Ensembl; ENST00000612786; ENSP00000483000; ENSG00000082556. [P41145-2]
DR   Ensembl; ENST00000613482; ENSP00000478453; ENSG00000082556. [P41145-1]
DR   GeneID; 4986; -.
DR   KEGG; hsa:4986; -.
DR   UCSC; uc003xrh.2; human. [P41145-1]
DR   CTD; 4986; -.
DR   DisGeNET; 4986; -.
DR   EuPathDB; HostDB:ENSG00000082556.10; -.
DR   GeneCards; OPRK1; -.
DR   HGNC; HGNC:8154; OPRK1.
DR   HPA; ENSG00000082556; Tissue enhanced (brain, prostate).
DR   MIM; 165196; gene.
DR   neXtProt; NX_P41145; -.
DR   OpenTargets; ENSG00000082556; -.
DR   PharmGKB; PA31943; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00940000157341; -.
DR   HOGENOM; CLU_009579_8_1_1; -.
DR   InParanoid; P41145; -.
DR   KO; K04214; -.
DR   OMA; RMDRQST; -.
DR   OrthoDB; 1011272at2759; -.
DR   PhylomeDB; P41145; -.
DR   TreeFam; TF315737; -.
DR   PathwayCommons; P41145; -.
DR   Reactome; R-HSA-375276; Peptide ligand-binding receptors.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-9022699; MECP2 regulates neuronal receptors and channels.
DR   SignaLink; P41145; -.
DR   SIGNOR; P41145; -.
DR   BioGRID-ORCS; 4986; 4 hits in 870 CRISPR screens.
DR   GeneWiki; %CE%9A-opioid_receptor; -.
DR   GenomeRNAi; 4986; -.
DR   Pharos; P41145; Tclin.
DR   PRO; PR:P41145; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   RNAct; P41145; protein.
DR   Bgee; ENSG00000082556; Expressed in chorionic villus and 87 other tissues.
DR   ExpressionAtlas; P41145; baseline and differential.
DR   Genevisible; P41145; HS.
DR   GO; GO:0043679; C:axon terminus; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0016021; C:integral component of membrane; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IMP:UniProtKB.
DR   GO; GO:0099055; C:integral component of postsynaptic membrane; IEA:Ensembl.
DR   GO; GO:0030285; C:integral component of synaptic vesicle membrane; IEA:Ensembl.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0043204; C:perikaryon; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0038048; F:dynorphin receptor activity; IDA:UniProtKB.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0042923; F:neuropeptide binding; IBA:GO_Central.
DR   GO; GO:0004985; F:opioid receptor activity; IDA:UniProtKB.
DR   GO; GO:0042277; F:peptide binding; IBA:GO_Central.
DR   GO; GO:0033612; F:receptor serine/threonine kinase binding; IEA:Ensembl.
DR   GO; GO:0007193; P:adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0031635; P:adenylate cyclase-inhibiting opioid receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0048148; P:behavioral response to cocaine; IEA:Ensembl.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; IEA:Ensembl.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0007268; P:chemical synaptic transmission; TAS:ProtInc.
DR   GO; GO:1990708; P:conditioned place preference; IEA:Ensembl.
DR   GO; GO:0051607; P:defense response to virus; IDA:UniProtKB.
DR   GO; GO:0042755; P:eating behavior; IEA:Ensembl.
DR   GO; GO:0044849; P:estrous cycle; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006955; P:immune response; IDA:UniProtKB.
DR   GO; GO:0007626; P:locomotory behavior; ISS:UniProtKB.
DR   GO; GO:0042711; P:maternal behavior; IEA:Ensembl.
DR   GO; GO:0033685; P:negative regulation of luteinizing hormone secretion; IEA:Ensembl.
DR   GO; GO:0007218; P:neuropeptide signaling pathway; IBA:GO_Central.
DR   GO; GO:0038003; P:opioid receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0033603; P:positive regulation of dopamine secretion; IEA:Ensembl.
DR   GO; GO:1904000; P:positive regulation of eating behavior; IEA:Ensembl.
DR   GO; GO:0040017; P:positive regulation of locomotion; IEA:Ensembl.
DR   GO; GO:1900745; P:positive regulation of p38MAPK cascade; IEA:Ensembl.
DR   GO; GO:1901381; P:positive regulation of potassium ion transmembrane transport; IEA:Ensembl.
DR   GO; GO:0046877; P:regulation of saliva secretion; ISS:UniProtKB.
DR   GO; GO:0051930; P:regulation of sensory perception of pain; IEA:Ensembl.
DR   GO; GO:1903937; P:response to acrylamide; IEA:Ensembl.
DR   GO; GO:0043627; P:response to estrogen; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0032868; P:response to insulin; IEA:Ensembl.
DR   GO; GO:0043278; P:response to morphine; IEA:Ensembl.
DR   GO; GO:0009314; P:response to radiation; IEA:Ensembl.
DR   GO; GO:0007600; P:sensory perception; TAS:ProtInc.
DR   GO; GO:0019233; P:sensory perception of pain; ISS:UniProtKB.
DR   GO; GO:0050951; P:sensory perception of temperature stimulus; IEA:Ensembl.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR000452; Kappa_opi_rcpt.
DR   InterPro; IPR001418; Opioid_rcpt.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00532; KAPPAOPIOIDR.
DR   PRINTS; PR00384; OPIOIDR.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Behavior; Cell membrane;
KW   Disulfide bond; G-protein coupled receptor; Glycoprotein; Lipoprotein;
KW   Membrane; Palmitate; Polymorphism; Receptor; Reference proteome;
KW   Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..380
FT                   /note="Kappa-type opioid receptor"
FT                   /id="PRO_0000069967"
FT   TOPO_DOM        1..57
FT                   /note="Extracellular"
FT   TRANSMEM        58..85
FT                   /note="Helical; Name=1"
FT   TOPO_DOM        86..95
FT                   /note="Cytoplasmic"
FT   TRANSMEM        96..119
FT                   /note="Helical; Name=2"
FT   TOPO_DOM        120..132
FT                   /note="Extracellular"
FT   TRANSMEM        133..154
FT                   /note="Helical; Name=3"
FT   TOPO_DOM        155..173
FT                   /note="Cytoplasmic"
FT   TRANSMEM        174..196
FT                   /note="Helical; Name=4"
FT   TOPO_DOM        197..222
FT                   /note="Extracellular"
FT   TRANSMEM        223..247
FT                   /note="Helical; Name=5"
FT   TOPO_DOM        248..274
FT                   /note="Cytoplasmic"
FT   TRANSMEM        275..296
FT                   /note="Helical; Name=6"
FT   TOPO_DOM        297..311
FT                   /note="Extracellular"
FT   TRANSMEM        312..333
FT                   /note="Helical; Name=7"
FT   TOPO_DOM        334..380
FT                   /note="Cytoplasmic"
FT   LIPID           345
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        25
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:17711303"
FT   CARBOHYD        39
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:17711303"
FT   DISULFID        131..210
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521,
FT                   ECO:0000269|PubMed:22437504"
FT   VAR_SEQ         1..89
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_055313"
FT   VARIANT         374
FT                   /note="D -> N (in dbSNP:rs9282808)"
FT                   /id="VAR_028067"
FT   CONFLICT        2
FT                   /note="D -> E (in Ref. 1; AAA20985 and 4; AAM21070)"
FT                   /evidence="ECO:0000305"
FT   HELIX           57..86
FT                   /evidence="ECO:0000244|PDB:4DJH"
FT   HELIX           88..90
FT                   /evidence="ECO:0000244|PDB:4DJH"
FT   HELIX           93..109
FT                   /evidence="ECO:0000244|PDB:4DJH"
FT   HELIX           112..121
FT                   /evidence="ECO:0000244|PDB:4DJH"
FT   HELIX           127..159
FT                   /evidence="ECO:0000244|PDB:4DJH"
FT   TURN            163..166
FT                   /evidence="ECO:0000244|PDB:4DJH"
FT   STRAND          167..169
FT                   /evidence="ECO:0000244|PDB:4DJH"
FT   HELIX           170..196
FT                   /evidence="ECO:0000244|PDB:4DJH"
FT   STRAND          197..201
FT                   /evidence="ECO:0000244|PDB:4DJH"
FT   STRAND          203..206
FT                   /evidence="ECO:0000244|PDB:4DJH"
FT   STRAND          208..212
FT                   /evidence="ECO:0000244|PDB:4DJH"
FT   STRAND          215..217
FT                   /evidence="ECO:0000244|PDB:4DJH"
FT   HELIX           219..233
FT                   /evidence="ECO:0000244|PDB:4DJH"
FT   HELIX           236..259
FT                   /evidence="ECO:0000244|PDB:4DJH"
FT   HELIX           267..299
FT                   /evidence="ECO:0000244|PDB:4DJH"
FT   HELIX           309..333
FT                   /evidence="ECO:0000244|PDB:4DJH"
FT   HELIX           335..345
FT                   /evidence="ECO:0000244|PDB:4DJH"
SQ   SEQUENCE   380 AA;  42645 MW;  3DA6E9F90FB48825 CRC64;
     MDSPIQIFRG EPGPTCAPSA CLPPNSSAWF PGWAEPDSNG SAGSEDAQLE PAHISPAIPV
     IITAVYSVVF VVGLVGNSLV MFVIIRYTKM KTATNIYIFN LALADALVTT TMPFQSTVYL
     MNSWPFGDVL CKIVISIDYY NMFTSIFTLT MMSVDRYIAV CHPVKALDFR TPLKAKIINI
     CIWLLSSSVG ISAIVLGGTK VREDVDVIEC SLQFPDDDYS WWDLFMKICV FIFAFVIPVL
     IIIVCYTLMI LRLKSVRLLS GSREKDRNLR RITRLVLVVV AVFVVCWTPI HIFILVEALG
     STSHSTAALS SYYFCIALGY TNSSLNPILY AFLDENFKRC FRDFCFPLKM RMERQSTSRV
     RNTVQDPAYL RDIDGMNKPV
//
ID   ACM2_HUMAN              Reviewed;         466 AA.
AC   P08172; Q4VBK6; Q9P1X9;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1988, sequence version 1.
DT   07-OCT-2020, entry version 204.
DE   RecName: Full=Muscarinic acetylcholine receptor M2;
GN   Name=CHRM2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3037705; DOI=10.1126/science.3037705;
RA   Bonner T.I., Buckley N.J., Young A.C., Brann M.R.;
RT   "Identification of a family of muscarinic acetylcholine receptor genes.";
RL   Science 237:527-532(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=3443095; DOI=10.1002/j.1460-2075.1987.tb02733.x;
RA   Peralta E.G., Ashkenazi A., Winslow J.W., Smith D.H., Ramachandran J.,
RA   Capon D.J.;
RT   "Distinct primary structures, ligand-binding properties and tissue-specific
RT   expression of four human muscarinic acetylcholine receptors.";
RL   EMBO J. 6:3923-3929(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 27-466.
RX   PubMed=15014171; DOI=10.1093/molbev/msh100;
RA   Kitano T., Liu Y.-H., Ueda S., Saitou N.;
RT   "Human-specific amino acid changes found in 103 protein-coding genes.";
RL   Mol. Biol. Evol. 21:936-944(2004).
RN   [6]
RP   INTERACTION WITH ARRB1 AND ARRB2.
RX   PubMed=7822302; DOI=10.1074/jbc.270.2.720;
RA   Gurevich V.V., Dion S.B., Onorato J.J., Ptasienski J., Kim C.M.,
RA   Sterne-Marr R., Hosey M.M., Benovic J.L.;
RT   "Arrestin interactions with G protein-coupled receptors. Direct binding
RT   studies of wild type and mutant arrestins with rhodopsin, beta 2-
RT   adrenergic, and m2 muscarinic cholinergic receptors.";
RL   J. Biol. Chem. 270:720-731(1995).
RN   [7]
RP   INDUCTION, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=16548883; DOI=10.1111/j.1462-5822.2005.00644.x;
RA   Leong W.F., Chow V.T.;
RT   "Transcriptomic and proteomic analyses of rhabdomyosarcoma cells reveal
RT   differential cellular gene expression in response to enterovirus 71
RT   infection.";
RL   Cell. Microbiol. 8:565-580(2006).
RN   [8]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO ALCOHOLISM AND MAJOR DEPRESSIVE DISORDER.
RX   PubMed=15229186; DOI=10.1093/hmg/ddh194;
RA   Wang J.C., Hinrichs A.L., Stock H., Budde J., Allen R., Bertelsen S.,
RA   Kwon J.M., Wu W., Dick D.M., Rice J., Jones K., Nurnberger J.I. Jr.,
RA   Tischfield J., Porjesz B., Edenberg H.J., Hesselbrock V., Crowe R.,
RA   Schuckit M., Begleiter H., Reich T., Goate A.M., Bierut L.J.;
RT   "Evidence of common and specific genetic effects: association of the
RT   muscarinic acetylcholine receptor M2 (CHRM2) gene with alcohol dependence
RT   and major depressive syndrome.";
RL   Hum. Mol. Genet. 13:1903-1911(2004).
RN   [9]
RP   INTERACTION WITH RACK1.
RX   PubMed=20976005; DOI=10.1371/journal.pone.0013517;
RA   Reiner C.L., McCullar J.S., Kow R.L., Le J.H., Goodlett D.R.,
RA   Nathanson N.M.;
RT   "RACK1 associates with muscarinic receptors and regulates M(2) receptor
RT   trafficking.";
RL   PLoS ONE 5:E13517-E13517(2010).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) IN COMPLEX WITH THE ANTAGONIST
RP   3-QUINUCLIDINYLBENZILATE, SUBCELLULAR LOCATION, TOPOLOGY, AND DISULFIDE
RP   BOND.
RX   PubMed=22278061; DOI=10.1038/nature10753;
RA   Haga K., Kruse A.C., Asada H., Yurugi-Kobayashi T., Shiroishi M., Zhang C.,
RA   Weis W.I., Okada T., Kobilka B.K., Haga T., Kobayashi T.;
RT   "Structure of the human M2 muscarinic acetylcholine receptor bound to an
RT   antagonist.";
RL   Nature 482:547-551(2012).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (3.50 ANGSTROMS) IN COMPLEXES WITH THE AGONIST
RP   IPEROXO AND THE ALLOSTERIC EFFECTOR LY2119620, FUNCTION, SUBCELLULAR
RP   LOCATION, TOPOLOGY, DISULFIDE BOND, MOTIF, AND MUTAGENESIS OF ASN-58;
RP   ASP-103; TYR-206 AND ASN-404.
RX   PubMed=24256733; DOI=10.1038/nature12735;
RA   Kruse A.C., Ring A.M., Manglik A., Hu J., Hu K., Eitel K., Hubner H.,
RA   Pardon E., Valant C., Sexton P.M., Christopoulos A., Felder C.C.,
RA   Gmeiner P., Steyaert J., Weis W.I., Garcia K.C., Wess J., Kobilka B.K.;
RT   "Activation and allosteric modulation of a muscarinic acetylcholine
RT   receptor.";
RL   Nature 504:101-106(2013).
CC   -!- FUNCTION: The muscarinic acetylcholine receptor mediates various
CC       cellular responses, including inhibition of adenylate cyclase,
CC       breakdown of phosphoinositides and modulation of potassium channels
CC       through the action of G proteins. Primary transducing effect is
CC       adenylate cyclase inhibition. Signaling promotes phospholipase C
CC       activity, leading to the release of inositol trisphosphate (IP3); this
CC       then triggers calcium ion release into the cytosol.
CC       {ECO:0000269|PubMed:24256733, ECO:0000269|PubMed:3443095}.
CC   -!- SUBUNIT: Interacts with ARRB1 and ARRB2. Interacts with RACK1; the
CC       interaction regulates CHRM2 internalization.
CC       {ECO:0000269|PubMed:20976005, ECO:0000269|PubMed:22278061,
CC       ECO:0000269|PubMed:7822302}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:22278061,
CC       ECO:0000269|PubMed:24256733, ECO:0000269|PubMed:3443095}; Multi-pass
CC       membrane protein {ECO:0000269|PubMed:22278061,
CC       ECO:0000269|PubMed:24256733}. Cell junction, synapse, postsynaptic cell
CC       membrane {ECO:0000305}; Multi-pass membrane protein {ECO:0000305}.
CC       Note=Phosphorylation in response to agonist binding promotes receptor
CC       internalization. {ECO:0000250|UniProtKB:P06199}.
CC   -!- INDUCTION: Up-regulated in response to enterovirus 71 (EV71) infection.
CC       {ECO:0000269|PubMed:16548883}.
CC   -!- PTM: Phosphorylated in response to agonist treatment. {ECO:0000250}.
CC   -!- POLYMORPHISM: Genetic variations in CHRM2 can influence susceptibility
CC       to alcoholism [MIM:103780]. {ECO:0000305|PubMed:15229186}.
CC   -!- DISEASE: Major depressive disorder (MDD) [MIM:608516]: A common
CC       psychiatric disorder. It is a complex trait characterized by one or
CC       more major depressive episodes without a history of manic, mixed, or
CC       hypomanic episodes. A major depressive episode is characterized by at
CC       least 2 weeks during which there is a new onset or clear worsening of
CC       either depressed mood or loss of interest or pleasure in nearly all
CC       activities. Four additional symptoms must also be present including
CC       changes in appetite, weight, sleep, and psychomotor activity; decreased
CC       energy; feelings of worthlessness or guilt; difficulty thinking,
CC       concentrating, or making decisions; or recurrent thoughts of death or
CC       suicidal ideation, plans, or attempts. The episode must be accompanied
CC       by distress or impairment in social, occupational, or other important
CC       areas of functioning. {ECO:0000269|PubMed:15229186}. Note=Disease
CC       susceptibility is associated with variations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       Muscarinic acetylcholine receptor subfamily. CHRM2 sub-subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M16404; AAA51570.1; -; Genomic_DNA.
DR   EMBL; X15264; CAA33335.1; -; Genomic_DNA.
DR   EMBL; AF498916; AAM18939.1; -; mRNA.
DR   EMBL; BC095547; AAH95547.1; -; mRNA.
DR   EMBL; BC106741; AAI06742.1; -; mRNA.
DR   EMBL; BC106742; AAI06743.1; -; mRNA.
DR   EMBL; AB041391; BAA94476.1; -; Genomic_DNA.
DR   CCDS; CCDS5843.1; -.
DR   PIR; S10126; S10126.
DR   RefSeq; NP_000730.1; NM_000739.2.
DR   RefSeq; NP_001006627.1; NM_001006626.1.
DR   RefSeq; NP_001006628.1; NM_001006627.1.
DR   RefSeq; NP_001006629.1; NM_001006628.1.
DR   RefSeq; NP_001006630.1; NM_001006629.1.
DR   RefSeq; NP_001006631.1; NM_001006630.1.
DR   RefSeq; NP_001006632.1; NM_001006631.1.
DR   RefSeq; NP_001006633.1; NM_001006632.1.
DR   RefSeq; XP_011514071.1; XM_011515769.2.
DR   PDB; 1LUB; Model; -; A=1-50.
DR   PDB; 3UON; X-ray; 3.00 A; A=1-217, A=377-466.
DR   PDB; 4MQS; X-ray; 3.50 A; A=1-466.
DR   PDB; 4MQT; X-ray; 3.70 A; A=1-466.
DR   PDB; 5YC8; X-ray; 2.50 A; A=10-466.
DR   PDB; 5ZK3; X-ray; 2.60 A; A=10-466.
DR   PDB; 5ZK8; X-ray; 3.00 A; A=10-466.
DR   PDB; 5ZKB; X-ray; 2.95 A; A=10-466.
DR   PDB; 5ZKC; X-ray; 2.30 A; A=10-466.
DR   PDB; 6OIK; EM; 3.60 A; R=3-466.
DR   PDB; 6U1N; EM; 4.00 A; R=2-466.
DR   PDBsum; 1LUB; -.
DR   PDBsum; 3UON; -.
DR   PDBsum; 4MQS; -.
DR   PDBsum; 4MQT; -.
DR   PDBsum; 5YC8; -.
DR   PDBsum; 5ZK3; -.
DR   PDBsum; 5ZK8; -.
DR   PDBsum; 5ZKB; -.
DR   PDBsum; 5ZKC; -.
DR   PDBsum; 6OIK; -.
DR   PDBsum; 6U1N; -.
DR   SMR; P08172; -.
DR   BioGRID; 107551; 5.
DR   DIP; DIP-56282N; -.
DR   IntAct; P08172; 23.
DR   MINT; P08172; -.
DR   STRING; 9606.ENSP00000399745; -.
DR   BindingDB; P08172; -.
DR   ChEMBL; CHEMBL211; -.
DR   DrugBank; DB03128; Acetylcholine.
DR   DrugBank; DB08897; Aclidinium.
DR   DrugBank; DB05752; ALKS 27.
DR   DrugBank; DB00321; Amitriptyline.
DR   DrugBank; DB00543; Amoxapine.
DR   DrugBank; DB00517; Anisotropine methylbromide.
DR   DrugBank; DB01238; Aripiprazole.
DR   DrugBank; DB14185; Aripiprazole lauroxil.
DR   DrugBank; DB00572; Atropine.
DR   DrugBank; DB00767; Benzquinamide.
DR   DrugBank; DB01019; Bethanechol.
DR   DrugBank; DB00835; Brompheniramine.
DR   DrugBank; DB09300; Butylscopolamine.
DR   DrugBank; DB00411; Carbamoylcholine.
DR   DrugBank; DB01239; Chlorprothixene.
DR   DrugBank; DB00568; Cinnarizine.
DR   DrugBank; DB00363; Clozapine.
DR   DrugBank; DB00907; Cocaine.
DR   DrugBank; DB00785; Cryptenamine.
DR   DrugBank; DB00434; Cyproheptadine.
DR   DrugBank; DB00496; Darifenacin.
DR   DrugBank; DB01151; Desipramine.
DR   DrugBank; DB00804; Dicyclomine.
DR   DrugBank; DB08801; Dimetindene.
DR   DrugBank; DB01075; Diphenhydramine.
DR   DrugBank; DB01231; Diphenidol.
DR   DrugBank; DB00280; Disopyramide.
DR   DrugBank; DB09167; Dosulepin.
DR   DrugBank; DB01135; Doxacurium.
DR   DrugBank; DB01142; Doxepin.
DR   DrugBank; DB09194; Etoperidone.
DR   DrugBank; DB06702; Fesoterodine.
DR   DrugBank; DB01148; Flavoxate.
DR   DrugBank; DB00483; Gallamine triethiodide.
DR   DrugBank; DB00986; Glycopyrronium.
DR   DrugBank; DB06787; Hexocyclium.
DR   DrugBank; DB11181; Homatropine.
DR   DrugBank; DB00725; Homatropine methylbromide.
DR   DrugBank; DB00424; Hyoscyamine.
DR   DrugBank; DB09262; Imidafenacin.
DR   DrugBank; DB00458; Imipramine.
DR   DrugBank; DB00332; Ipratropium.
DR   DrugBank; DB01221; Ketamine.
DR   DrugBank; DB00408; Loxapine.
DR   DrugBank; DB00934; Maprotiline.
DR   DrugBank; DB00454; Meperidine.
DR   DrugBank; DB01403; Methotrimeprazine.
DR   DrugBank; DB00462; Methscopolamine bromide.
DR   DrugBank; DB00340; Metixene.
DR   DrugBank; DB01336; Metocurine.
DR   DrugBank; DB01226; Mivacurium.
DR   DrugBank; DB00622; Nicardipine.
DR   DrugBank; DB00540; Nortriptyline.
DR   DrugBank; DB00334; Olanzapine.
DR   DrugBank; DB01062; Oxybutynin.
DR   DrugBank; DB00383; Oxyphencyclimine.
DR   DrugBank; DB01337; Pancuronium.
DR   DrugBank; DB00715; Paroxetine.
DR   DrugBank; DB01085; Pilocarpine.
DR   DrugBank; DB01338; Pipecuronium.
DR   DrugBank; DB06153; Pizotifen.
DR   DrugBank; DB00387; Procyclidine.
DR   DrugBank; DB00392; Profenamine.
DR   DrugBank; DB00420; Promazine.
DR   DrugBank; DB01069; Promethazine.
DR   DrugBank; DB00777; Propiomazine.
DR   DrugBank; DB12278; Propiverine.
DR   DrugBank; DB01224; Quetiapine.
DR   DrugBank; DB04834; Rapacuronium.
DR   DrugBank; DB11855; Revefenacin.
DR   DrugBank; DB13581; Rociverine.
DR   DrugBank; DB00728; Rocuronium.
DR   DrugBank; DB00747; Scopolamine.
DR   DrugBank; DB01591; Solifenacin.
DR   DrugBank; DB00202; Succinylcholine.
DR   DrugBank; DB00342; Terfenadine.
DR   DrugBank; DB11235; Thonzylamine.
DR   DrugBank; DB01409; Tiotropium.
DR   DrugBank; DB01036; Tolterodine.
DR   DrugBank; DB00505; Tridihexethyl.
DR   DrugBank; DB00508; Triflupromazine.
DR   DrugBank; DB00376; Trihexyphenidyl.
DR   DrugBank; DB09089; Trimebutine.
DR   DrugBank; DB00726; Trimipramine.
DR   DrugBank; DB00809; Tropicamide.
DR   DrugBank; DB09076; Umeclidinium.
DR   DrugBank; DB00246; Ziprasidone.
DR   DrugCentral; P08172; -.
DR   GuidetoPHARMACOLOGY; 14; -.
DR   GlyGen; P08172; 4 sites.
DR   iPTMnet; P08172; -.
DR   PhosphoSitePlus; P08172; -.
DR   SwissPalm; P08172; -.
DR   BioMuta; CHRM2; -.
DR   DMDM; 113122; -.
DR   MassIVE; P08172; -.
DR   PaxDb; P08172; -.
DR   PeptideAtlas; P08172; -.
DR   PRIDE; P08172; -.
DR   ProteomicsDB; 52076; -.
DR   ABCD; P08172; 3 sequenced antibodies.
DR   Antibodypedia; 18171; 547 antibodies.
DR   DNASU; 1129; -.
DR   Ensembl; ENST00000320658; ENSP00000319984; ENSG00000181072.
DR   Ensembl; ENST00000401861; ENSP00000384401; ENSG00000181072.
DR   Ensembl; ENST00000445907; ENSP00000399745; ENSG00000181072.
DR   Ensembl; ENST00000453373; ENSP00000415386; ENSG00000181072.
DR   GeneID; 1129; -.
DR   KEGG; hsa:1129; -.
DR   UCSC; uc003vtg.2; human.
DR   CTD; 1129; -.
DR   DisGeNET; 1129; -.
DR   EuPathDB; HostDB:ENSG00000181072.11; -.
DR   GeneCards; CHRM2; -.
DR   HGNC; HGNC:1951; CHRM2.
DR   HPA; ENSG00000181072; Tissue enhanced (gallbladder, heart muscle, smooth muscle).
DR   MIM; 103780; phenotype.
DR   MIM; 118493; gene.
DR   MIM; 608516; phenotype.
DR   neXtProt; NX_P08172; -.
DR   OpenTargets; ENSG00000181072; -.
DR   PharmGKB; PA111; -.
DR   eggNOG; KOG4220; Eukaryota.
DR   GeneTree; ENSGT00940000158940; -.
DR   HOGENOM; CLU_009579_11_2_1; -.
DR   InParanoid; P08172; -.
DR   KO; K04130; -.
DR   OMA; NSKLTCI; -.
DR   OrthoDB; 1025450at2759; -.
DR   PhylomeDB; P08172; -.
DR   TreeFam; TF320495; -.
DR   PathwayCommons; P08172; -.
DR   Reactome; R-HSA-390648; Muscarinic acetylcholine receptors.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-8856825; Cargo recognition for clathrin-mediated endocytosis.
DR   Reactome; R-HSA-8856828; Clathrin-mediated endocytosis.
DR   SignaLink; P08172; -.
DR   SIGNOR; P08172; -.
DR   BioGRID-ORCS; 1129; 5 hits in 867 CRISPR screens.
DR   ChiTaRS; CHRM2; human.
DR   GeneWiki; Muscarinic_acetylcholine_receptor_M2; -.
DR   GenomeRNAi; 1129; -.
DR   Pharos; P08172; Tclin.
DR   PRO; PR:P08172; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; P08172; protein.
DR   Bgee; ENSG00000181072; Expressed in heart and 82 other tissues.
DR   ExpressionAtlas; P08172; baseline and differential.
DR   Genevisible; P08172; HS.
DR   GO; GO:0032279; C:asymmetric synapse; IEA:Ensembl.
DR   GO; GO:0043679; C:axon terminus; IEA:Ensembl.
DR   GO; GO:0030665; C:clathrin-coated vesicle membrane; TAS:Reactome.
DR   GO; GO:0030425; C:dendrite; IBA:GO_Central.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0016021; C:integral component of membrane; IDA:CAFA.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0099055; C:integral component of postsynaptic membrane; IEA:Ensembl.
DR   GO; GO:0099056; C:integral component of presynaptic membrane; IEA:Ensembl.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:LIFEdb.
DR   GO; GO:0032280; C:symmetric synapse; IEA:Ensembl.
DR   GO; GO:0045202; C:synapse; IBA:GO_Central.
DR   GO; GO:1990763; F:arrestin family protein binding; IPI:CAFA.
DR   GO; GO:0016907; F:G protein-coupled acetylcholine receptor activity; IDA:UniProtKB.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0004993; F:G protein-coupled serotonin receptor activity; IBA:GO_Central.
DR   GO; GO:0030594; F:neurotransmitter receptor activity; IBA:GO_Central.
DR   GO; GO:0007197; P:adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007188; P:adenylate cyclase-modulating G protein-coupled receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0007268; P:chemical synaptic transmission; IBA:GO_Central.
DR   GO; GO:0007213; P:G protein-coupled acetylcholine receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007187; P:G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; IBA:GO_Central.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0007399; P:nervous system development; TAS:ProtInc.
DR   GO; GO:0007207; P:phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0008016; P:regulation of heart contraction; TAS:ProtInc.
DR   GO; GO:0006940; P:regulation of smooth muscle contraction; IBA:GO_Central.
DR   GO; GO:0009615; P:response to virus; IEP:UniProtKB.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR001065; Musac_Ach_M2_rcpt.
DR   InterPro; IPR000995; Musac_Ach_rcpt.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00243; MUSCARINICR.
DR   PRINTS; PR00539; MUSCRINICM2R.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell junction; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Phosphoprotein;
KW   Postsynaptic cell membrane; Receptor; Reference proteome; Synapse;
KW   Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..466
FT                   /note="Muscarinic acetylcholine receptor M2"
FT                   /id="PRO_0000069021"
FT   TOPO_DOM        1..22
FT                   /note="Extracellular"
FT   TRANSMEM        23..45
FT                   /note="Helical; Name=1"
FT   TOPO_DOM        46..59
FT                   /note="Cytoplasmic"
FT   TRANSMEM        60..80
FT                   /note="Helical; Name=2"
FT   TOPO_DOM        81..97
FT                   /note="Extracellular"
FT   TRANSMEM        98..119
FT                   /note="Helical; Name=3"
FT   TOPO_DOM        120..139
FT                   /note="Cytoplasmic"
FT   TRANSMEM        140..162
FT                   /note="Helical; Name=4"
FT   TOPO_DOM        163..184
FT                   /note="Extracellular"
FT   TRANSMEM        185..209
FT                   /note="Helical; Name=5"
FT   TOPO_DOM        210..387
FT                   /note="Cytoplasmic"
FT   TRANSMEM        388..410
FT                   /note="Helical; Name=6"
FT   TOPO_DOM        411..418
FT                   /note="Extracellular"
FT   TRANSMEM        419..442
FT                   /note="Helical; Name=7"
FT   TOPO_DOM        443..466
FT                   /note="Cytoplasmic"
FT   REGION          103..107
FT                   /note="Agonist binding"
FT                   /evidence="ECO:0000305"
FT   REGION          403..404
FT                   /note="Agonist binding"
FT                   /evidence="ECO:0000305"
FT   REGION          426..430
FT                   /note="Agonist binding"
FT                   /evidence="ECO:0000305"
FT   MOTIF           120..122
FT                   /note="Important for signaling"
FT   MOTIF           436..440
FT                   /note="Important for signaling"
FT   MOD_RES         232
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9ERZ4"
FT   MOD_RES         446
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         450
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         465
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        2
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        3
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        6
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        9
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        96..176
FT   DISULFID        413..416
FT   MUTAGEN         58
FT                   /note="N->A: Nearly abolishes signaling via downstream
FT                   effectors."
FT                   /evidence="ECO:0000269|PubMed:24256733"
FT   MUTAGEN         103
FT                   /note="D->E: Reduced affinity for acetylcholine. Abolishes
FT                   signaling via downstream effectors."
FT                   /evidence="ECO:0000269|PubMed:24256733"
FT   MUTAGEN         206
FT                   /note="Y->F: Abolishes signaling via downstream effectors."
FT                   /evidence="ECO:0000269|PubMed:24256733"
FT   MUTAGEN         404
FT                   /note="N->Q: Reduced affinity for acetylcholine. Reduces
FT                   signaling via downstream effectors."
FT                   /evidence="ECO:0000269|PubMed:24256733"
FT   HELIX           17..50
FT                   /evidence="ECO:0000244|PDB:5ZKC"
FT   HELIX           52..54
FT                   /evidence="ECO:0000244|PDB:5ZKC"
FT   HELIX           57..74
FT                   /evidence="ECO:0000244|PDB:5ZKC"
FT   HELIX           76..86
FT                   /evidence="ECO:0000244|PDB:5ZKC"
FT   HELIX           93..126
FT                   /evidence="ECO:0000244|PDB:5ZKC"
FT   TURN            128..131
FT                   /evidence="ECO:0000244|PDB:5ZKC"
FT   HELIX           132..134
FT                   /evidence="ECO:0000244|PDB:5ZKC"
FT   HELIX           137..166
FT                   /evidence="ECO:0000244|PDB:5ZKC"
FT   HELIX           179..182
FT                   /evidence="ECO:0000244|PDB:5ZKC"
FT   HELIX           184..194
FT                   /evidence="ECO:0000244|PDB:5ZKC"
FT   HELIX           196..213
FT                   /evidence="ECO:0000244|PDB:5ZKC"
FT   HELIX           382..410
FT                   /evidence="ECO:0000244|PDB:5ZKC"
FT   HELIX           414..416
FT                   /evidence="ECO:0000244|PDB:5YC8"
FT   HELIX           419..440
FT                   /evidence="ECO:0000244|PDB:5ZKC"
FT   HELIX           441..443
FT                   /evidence="ECO:0000244|PDB:5ZKC"
FT   HELIX           445..455
FT                   /evidence="ECO:0000244|PDB:5ZKC"
SQ   SEQUENCE   466 AA;  51715 MW;  2FC2FD7748C22BEC CRC64;
     MNNSTNSSNN SLALTSPYKT FEVVFIVLVA GSLSLVTIIG NILVMVSIKV NRHLQTVNNY
     FLFSLACADL IIGVFSMNLY TLYTVIGYWP LGPVVCDLWL ALDYVVSNAS VMNLLIISFD
     RYFCVTKPLT YPVKRTTKMA GMMIAAAWVL SFILWAPAIL FWQFIVGVRT VEDGECYIQF
     FSNAAVTFGT AIAAFYLPVI IMTVLYWHIS RASKSRIKKD KKEPVANQDP VSPSLVQGRI
     VKPNNNNMPS SDDGLEHNKI QNGKAPRDPV TENCVQGEEK ESSNDSTSVS AVASNMRDDE
     ITQDENTVST SLGHSKDENS KQTCIRIGTK TPKSDSCTPT NTTVEVVGSS GQNGDEKQNI
     VARKIVKMTK QPAKKKPPPS REKKVTRTIL AILLAFIITW APYNVMVLIN TFCAPCIPNT
     VWTIGYWLCY INSTINPACY ALCNATFKKT FKHLLMCHYK NIGATR
//
ID   PTH1R_HUMAN             Reviewed;         593 AA.
AC   Q03431; Q2M1U3;
DT   01-OCT-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1993, sequence version 1.
DT   07-OCT-2020, entry version 211.
DE   RecName: Full=Parathyroid hormone/parathyroid hormone-related peptide receptor;
DE   AltName: Full=PTH/PTHrP type I receptor;
DE            Short=PTH/PTHr receptor;
DE   AltName: Full=Parathyroid hormone 1 receptor;
DE            Short=PTH1 receptor;
DE   Flags: Precursor;
GN   Name=PTH1R; Synonyms=PTHR, PTHR1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Kidney;
RX   PubMed=8386612; DOI=10.1210/endo.132.5.8386612;
RA   Schipani E., Karga H., Karaplis A.C., Potts J.T. Jr., Kronenberg H.M.,
RA   Abou-Samra A.-B., Segre G.V., Jueppner H.;
RT   "Identical complementary deoxyribonucleic acids encode a human renal and
RT   bone parathyroid hormone (PTH)/PTH-related peptide receptor.";
RL   Endocrinology 132:2157-2165(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, INTERACTION WITH PTH, SUBCELLULAR
RP   LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Kidney;
RX   PubMed=8397094; DOI=10.1016/0922-4106(93)90092-n;
RA   Schneider H., Feyen J.-H., Rao Movva N.;
RT   "Cloning and functional expression of a human parathyroid hormone
RT   receptor.";
RL   Eur. J. Pharmacol. 246:149-155(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7745008; DOI=10.1210/jcem.80.5.7745008;
RA   Schipani E., Weinstein L.S., Bergwitz C., Iida-Klein A., Kong X.F.,
RA   Stuhrmann M., Kruse K., Whyte M.P., Murray T., Schmidtke J., Dop C.,
RA   Brickman A.S., Crawford J.D., Potts J.T. Jr., Kronenberg H.M.,
RA   Abou-Samra A.-B., Segre G.V., Jueppner H.;
RT   "Pseudohypoparathyroidism type Ib is not caused by mutations in the coding
RT   exons of the human parathyroid hormone (PTH)/PTH-related peptide receptor
RT   gene.";
RL   J. Clin. Endocrinol. Metab. 80:1611-1621(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Kidney;
RA   Levine M.A.;
RT   "Characterization of cDNA and genomic DNA encoding the human PTH/PTHrP
RT   receptor.";
RL   Submitted (NOV-1994) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lung;
RA   King M.M., Aronstam R.S., Sharma S.V.;
RT   "Isolation of cDNA coding for parathyroid hormone receptor 1 (PTHR1).";
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Cerebellum;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   DISULFIDE BONDS IN EXTRACELLULAR DOMAIN, AND INTERACTION WITH PTH.
RX   PubMed=10913300; DOI=10.1021/bi0001426;
RA   Grauschopf U., Lilie H., Honold K., Wozny M., Reusch D., Esswein A.,
RA   Schafer W., Rucknagel K.P., Rudolph R.;
RT   "The N-terminal fragment of human parathyroid hormone receptor 1
RT   constitutes a hormone binding domain and reveals a distinct disulfide
RT   pattern.";
RL   Biochemistry 39:8878-8887(2000).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-551, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [9]
RP   STRUCTURE BY NMR OF 168-198.
RX   PubMed=9737850; DOI=10.1021/bi981265h;
RA   Pellegrini M., Bisello A., Rosenblatt M., Chorev M., Mierke D.F.;
RT   "Binding domain of human parathyroid hormone receptor: from conformation to
RT   function.";
RL   Biochemistry 37:12737-12743(1998).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 29-187 IN COMPLEX WITH PTH, AND
RP   DISULFIDE BONDS.
RX   PubMed=18375760; DOI=10.1073/pnas.0801027105;
RA   Pioszak A.A., Xu H.E.;
RT   "Molecular recognition of parathyroid hormone by its G protein-coupled
RT   receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:5034-5039(2008).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 474-481.
RX   PubMed=18611381; DOI=10.1016/j.str.2008.04.010;
RA   Johnston C.A., Kimple A.J., Giguere P.M., Siderovski D.P.;
RT   "Structure of the parathyroid hormone receptor C terminus bound to the G-
RT   protein dimer Gbeta1gamma2.";
RL   Structure 16:1086-1094(2008).
RN   [12]
RP   ERRATUM OF PUBMED:18611381, AND RETRACTION NOTICE OF PUBMED:18611381.
RX   DOI=10.1016/j.str.2011.07.010;
RA   Johnston C.A., Kimple A.J., Giguere P.M., Siderovski D.P.;
RL   Structure 0:0-0(2011).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.94 ANGSTROMS) OF 29-187 IN COMPLEX WITH PTHLH,
RP   SUBUNIT, AND DISULFIDE BONDS.
RX   PubMed=19674967; DOI=10.1074/jbc.m109.022905;
RA   Pioszak A.A., Parker N.R., Gardella T.J., Xu H.E.;
RT   "Structural basis for parathyroid hormone-related protein binding to the
RT   parathyroid hormone receptor and design of conformation-selective
RT   peptides.";
RL   J. Biol. Chem. 284:28382-28391(2009).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (3.24 ANGSTROMS) OF 29-187, FUNCTION, SUBUNIT,
RP   SUBCELLULAR LOCATION, MUTAGENESIS OF ILE-135 AND ASP-137, AND DISULFIDE
RP   BONDS.
RX   PubMed=20172855; DOI=10.1074/jbc.m109.093138;
RA   Pioszak A.A., Harikumar K.G., Parker N.R., Miller L.J., Xu H.E.;
RT   "Dimeric arrangement of the parathyroid hormone receptor and a structural
RT   mechanism for ligand-induced dissociation.";
RL   J. Biol. Chem. 285:12435-12444(2010).
RN   [15]
RP   VARIANT MCDJ ARG-223.
RX   PubMed=7701349; DOI=10.1126/science.7701349;
RA   Schipani E., Kruse K., Jueppner H.;
RT   "A constitutively active mutant PTH-PTHrP receptor in Jansen-type
RT   metaphyseal chondrodysplasia.";
RL   Science 268:98-100(1995).
RN   [16]
RP   VARIANTS MCDJ ARG-223 AND PRO-410.
RX   PubMed=8703170; DOI=10.1056/nejm199609053351004;
RA   Schipani E., Langman C.B., Parfitt A.M., Jensen G.S., Kikuchi S.,
RA   Kooh S.W., Cole W.G., Jueppner H.;
RT   "Constitutively activated receptors for parathyroid hormone and parathyroid
RT   hormone-related peptide in Jansen's metaphyseal chondrodysplasia.";
RL   N. Engl. J. Med. 335:708-714(1996).
RN   [17]
RP   CHARACTERIZATION OF VARIANTS MCDJ ARG-223 AND PRO-410.
RX   PubMed=9178745; DOI=10.1210/mend.11.7.9934;
RA   Schipani E., Jensen G.S., Pincus J., Nissenson R.A., Gardella T.J.,
RA   Jueppner H.;
RT   "Constitutive activation of the cyclic adenosine 3',5'-monophosphate
RT   signaling pathway by parathyroid hormone (PTH)/PTH-related peptide
RT   receptors mutated at the two loci for Jansen's metaphyseal
RT   chondrodysplasia.";
RL   Mol. Endocrinol. 11:851-858(1997).
RN   [18]
RP   VARIANT BOCD LEU-132.
RX   PubMed=9745456; DOI=10.1210/jcem.83.9.5243;
RA   Zhang P., Jobert A.-S., Couvineau A., Silve C.;
RT   "A homozygous inactivating mutation in the parathyroid hormone/parathyroid
RT   hormone-related peptide receptor causing Blomstrand chondrodysplasia.";
RL   J. Clin. Endocrinol. Metab. 83:3365-3368(1998).
RN   [19]
RP   VARIANT MCDJ ARG-458.
RX   PubMed=10487664; DOI=10.1210/jcem.84.9.6000;
RA   Schipani E., Langman C.B., Hunzelman J., Le Merrer M., Loke K.Y.,
RA   Dillon M.J., Silve C., Jueppner H.;
RT   "A novel parathyroid hormone (PTH)/PTH-related peptide receptor mutation in
RT   Jansen's metaphyseal chondrodysplasia.";
RL   J. Clin. Endocrinol. Metab. 84:3052-3057(1999).
RN   [20]
RP   VARIANT ENCHOM CYS-150.
RX   PubMed=11850620; DOI=10.1038/ng844;
RA   Hopyan S., Gokgoz N., Poon R., Gensure R.C., Yu C., Cole W.G., Bell R.S.,
RA   Jueppner H., Andrulis I.L., Wunder J.S., Alman B.A.;
RT   "A mutant PTH/PTHrP type I receptor in enchondromatosis.";
RL   Nat. Genet. 30:306-310(2002).
RN   [21]
RP   DISCUSSION OF THE ASSOCIATION OF CYS-150 WITH ENCHOM.
RX   PubMed=15523647; DOI=10.1002/humu.20095;
RA   Rozeman L.B., Sangiorgi L., Briaire-de Bruijn I.H., Mainil-Varlet P.,
RA   Bertoni F., Cleton-Jansen A.-M., Hogendoorn P.C.W., Bovee J.V.M.G.;
RT   "Enchondromatosis (Ollier disease, Maffucci syndrome) is not caused by the
RT   PTHR1 mutation p.R150C.";
RL   Hum. Mutat. 24:466-473(2004).
RN   [22]
RP   VARIANT MCDJ ARG-410, AND CHARACTERIZATION OF VARIANT MCDJ ARG-410.
RX   PubMed=15240651; DOI=10.1210/jc.2004-0036;
RA   Bastepe M., Raas-Rothschild A., Silver J., Weissman I., Wientroub S.,
RA   Jueppner H., Gillis D.;
RT   "A form of Jansen's metaphyseal chondrodysplasia with limited metabolic and
RT   skeletal abnormalities is caused by a novel activating parathyroid hormone
RT   (PTH)/PTH-related peptide receptor mutation.";
RL   J. Clin. Endocrinol. Metab. 89:3595-3600(2004).
RN   [23]
RP   INVOLVEMENT IN EISD.
RX   PubMed=15525660; DOI=10.1093/hmg/ddi001;
RA   Duchatelet S., Ostergaard E., Cortes D., Lemainque A., Julier C.;
RT   "Recessive mutations in PTHR1 cause contrasting skeletal dysplasias in
RT   Eiken and Blomstrand syndromes.";
RL   Hum. Mol. Genet. 14:1-5(2005).
RN   [24]
RP   INVOLVEMENT IN PRIMARY FAILURE OF TOOTH ERUPTION.
RX   PubMed=19061984; DOI=10.1016/j.ajhg.2008.11.006;
RA   Decker E., Stellzig-Eisenhauer A., Fiebig B.S., Rau C., Kress W., Saar K.,
RA   Rueschendorf F., Hubner N., Grimm T., Weber B.H.F.;
RT   "PTHR1 loss-of-function mutations in familial, nonsyndromic primary failure
RT   of tooth eruption.";
RL   Am. J. Hum. Genet. 83:781-786(2008).
RN   [25]
RP   VARIANT MCDJ ARG-223, CHARACTERIZATION OF VARIANT MCDJ ARG-223,
RP   GLYCOSYLATION, FUNCTION, AND SUBUNIT.
RX   PubMed=27160269; DOI=10.1007/s10266-016-0247-4;
RA   Shimomura-Kuroki J., Farooq M., Sekimoto T., Amizuka N., Shimomura Y.;
RT   "Characterization of a PTH1R missense mutation responsible for Jansen type
RT   metaphyseal chondrodysplasia.";
RL   Odontology 105:150-154(2017).
CC   -!- FUNCTION: Receptor for parathyroid hormone and for parathyroid hormone-
CC       related peptide. The activity of this receptor is mediated by G
CC       proteins which activate adenylyl cyclase and also a
CC       phosphatidylinositol-calcium second messenger system.
CC       {ECO:0000269|PubMed:20172855, ECO:0000269|PubMed:27160269,
CC       ECO:0000269|PubMed:8397094}.
CC   -!- SUBUNIT: Interacts (via N-terminal extracellular domain) with PTHLH and
CC       PTH (PubMed:8397094, PubMed:10913300, PubMed:18375760,
CC       PubMed:19674967). Homodimer in the absence of bound ligand. Peptide
CC       hormone binding leads to dissociation of the homodimer
CC       (PubMed:19674967, PubMed:20172855). {ECO:0000269|PubMed:10913300,
CC       ECO:0000269|PubMed:18375760, ECO:0000269|PubMed:19674967,
CC       ECO:0000269|PubMed:20172855, ECO:0000269|PubMed:27160269,
CC       ECO:0000269|PubMed:8397094}.
CC   -!- INTERACTION:
CC       Q03431; P35222: CTNNB1; NbExp=4; IntAct=EBI-2860297, EBI-491549;
CC       Q03431; O95872: GPANK1; NbExp=3; IntAct=EBI-2860297, EBI-751540;
CC       Q03431; Q96NT3-2: GUCD1; NbExp=3; IntAct=EBI-2860297, EBI-11978177;
CC       Q03431; P49639: HOXA1; NbExp=3; IntAct=EBI-2860297, EBI-740785;
CC       Q03431; Q13064: MKRN3; NbExp=3; IntAct=EBI-2860297, EBI-2340269;
CC       Q03431; P01270: PTH; NbExp=6; IntAct=EBI-2860297, EBI-716817;
CC       Q03431; P12272: PTHLH; NbExp=4; IntAct=EBI-2860297, EBI-2372758;
CC       Q03431; Q92922: SMARCC1; NbExp=3; IntAct=EBI-2860297, EBI-355653;
CC       Q03431; O75716: STK16; NbExp=3; IntAct=EBI-2860297, EBI-749295;
CC       Q03431; Q8WW24: TEKT4; NbExp=3; IntAct=EBI-2860297, EBI-750487;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:20172855,
CC       ECO:0000269|PubMed:8397094}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:20172855}.
CC   -!- TISSUE SPECIFICITY: Expressed in most tissues. Most abundant in kidney,
CC       bone and liver. {ECO:0000269|PubMed:8397094}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:27160269}.
CC   -!- DISEASE: Metaphyseal chondrodysplasia, Jansen type (MCDJ) [MIM:156400]:
CC       A rare autosomal dominant disorder characterized by a short-limbed
CC       dwarfism associated with hypercalcemia and normal or low serum
CC       concentrations of the two parathyroid hormones.
CC       {ECO:0000269|PubMed:10487664, ECO:0000269|PubMed:15240651,
CC       ECO:0000269|PubMed:27160269, ECO:0000269|PubMed:7701349,
CC       ECO:0000269|PubMed:8703170, ECO:0000269|PubMed:9178745}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Chondrodysplasia Blomstrand type (BOCD) [MIM:215045]: Severe
CC       skeletal dysplasia. {ECO:0000269|PubMed:9745456}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Enchondromatosis multiple (ENCHOM) [MIM:166000]: A condition
CC       characterized by multiple formation of enchondromas, benign neoplasms
CC       derived from mesodermal cells that form cartilage. Enchondromas remain
CC       within the substance of a cartilage or bone. Clinical problems caused
CC       by enchondromas include skeletal deformity and the potential for
CC       malignant change to osteosarcoma. {ECO:0000269|PubMed:11850620}.
CC       Note=The disease may be caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Eiken skeletal dysplasia (EISD) [MIM:600002]: A rare skeletal
CC       dysplasia characterized by severely retarded ossification, principally
CC       of the epiphyses, pelvis, hands and feet, as well as by abnormal
CC       modeling of the bones in hands and feet, abnormal persistence of
CC       cartilage in the pelvis and mild growth retardation.
CC       {ECO:0000269|PubMed:15525660}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Primary failure of tooth eruption (PFE) [MIM:125350]: Rare
CC       condition that has high penetrance and variable expressivity and in
CC       which tooth retention occurs without evidence of any obvious mechanical
CC       interference. Instead, malfunction of the eruptive mechanism itself
CC       appears to cause nonankylosed permanent teeth to fail to erupt,
CC       although the eruption pathway has been cleared by bone resorption.
CC       {ECO:0000269|PubMed:19061984}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 2 family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L04308; AAA36525.1; -; mRNA.
DR   EMBL; X68596; CAA48589.1; -; mRNA.
DR   EMBL; U22409; AAB60657.1; -; Genomic_DNA.
DR   EMBL; U22401; AAB60657.1; JOINED; Genomic_DNA.
DR   EMBL; U22402; AAB60657.1; JOINED; Genomic_DNA.
DR   EMBL; U22403; AAB60657.1; JOINED; Genomic_DNA.
DR   EMBL; U22404; AAB60657.1; JOINED; Genomic_DNA.
DR   EMBL; U22405; AAB60657.1; JOINED; Genomic_DNA.
DR   EMBL; U22406; AAB60657.1; JOINED; Genomic_DNA.
DR   EMBL; U22407; AAB60657.1; JOINED; Genomic_DNA.
DR   EMBL; U22408; AAB60657.1; JOINED; Genomic_DNA.
DR   EMBL; U17418; AAA56774.1; -; mRNA.
DR   EMBL; AY449732; AAR18076.1; -; mRNA.
DR   EMBL; BC112221; AAI12222.1; -; mRNA.
DR   EMBL; BC112247; AAI12248.1; -; mRNA.
DR   CCDS; CCDS2747.1; -.
DR   PIR; I38139; A49191.
DR   RefSeq; NP_000307.1; NM_000316.2.
DR   RefSeq; NP_001171673.1; NM_001184744.1.
DR   RefSeq; XP_016862422.1; XM_017006933.1.
DR   PDB; 1BL1; NMR; -; A=168-197.
DR   PDB; 1ET2; Model; -; S=168-469.
DR   PDB; 1ET3; Model; -; S=168-469.
DR   PDB; 3C4M; X-ray; 1.95 A; A/B=29-187.
DR   PDB; 3H3G; X-ray; 1.94 A; A=29-187.
DR   PDB; 3L2J; X-ray; 3.24 A; A/B=29-187.
DR   PDB; 4Z8J; X-ray; 0.95 A; B=586-593.
DR   PDB; 5EMB; X-ray; 0.85 A; B=586-593.
DR   PDB; 6NBF; EM; 3.00 A; R=27-502.
DR   PDB; 6NBH; EM; 3.50 A; R=27-502.
DR   PDB; 6NBI; EM; 4.00 A; R=27-502.
DR   PDBsum; 1BL1; -.
DR   PDBsum; 1ET2; -.
DR   PDBsum; 1ET3; -.
DR   PDBsum; 3C4M; -.
DR   PDBsum; 3H3G; -.
DR   PDBsum; 3L2J; -.
DR   PDBsum; 4Z8J; -.
DR   PDBsum; 5EMB; -.
DR   PDBsum; 6NBF; -.
DR   PDBsum; 6NBH; -.
DR   PDBsum; 6NBI; -.
DR   SMR; Q03431; -.
DR   BioGRID; 111717; 60.
DR   CORUM; Q03431; -.
DR   IntAct; Q03431; 37.
DR   MINT; Q03431; -.
DR   STRING; 9606.ENSP00000321999; -.
DR   BindingDB; Q03431; -.
DR   ChEMBL; CHEMBL1793; -.
DR   DrugBank; DB05084; Abaloparatide.
DR   DrugBank; DB05829; Parathyroid hormone.
DR   DrugBank; DB06285; Teriparatide.
DR   DrugCentral; Q03431; -.
DR   GuidetoPHARMACOLOGY; 331; -.
DR   TCDB; 9.A.14.4.11; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; Q03431; 4 sites.
DR   iPTMnet; Q03431; -.
DR   PhosphoSitePlus; Q03431; -.
DR   BioMuta; PTH1R; -.
DR   DMDM; 417555; -.
DR   REPRODUCTION-2DPAGE; Q03431; -.
DR   MassIVE; Q03431; -.
DR   PaxDb; Q03431; -.
DR   PeptideAtlas; Q03431; -.
DR   PRIDE; Q03431; -.
DR   ProteomicsDB; 58212; -.
DR   TopDownProteomics; Q03431; -.
DR   ABCD; Q03431; 23 sequenced antibodies.
DR   Antibodypedia; 1960; 401 antibodies.
DR   DNASU; 5745; -.
DR   Ensembl; ENST00000313049; ENSP00000321999; ENSG00000160801.
DR   Ensembl; ENST00000418619; ENSP00000411424; ENSG00000160801.
DR   Ensembl; ENST00000430002; ENSP00000413774; ENSG00000160801.
DR   Ensembl; ENST00000449590; ENSP00000402723; ENSG00000160801.
DR   GeneID; 5745; -.
DR   KEGG; hsa:5745; -.
DR   UCSC; uc003cqm.4; human.
DR   CTD; 5745; -.
DR   DisGeNET; 5745; -.
DR   EuPathDB; HostDB:ENSG00000160801.13; -.
DR   GeneCards; PTH1R; -.
DR   HGNC; HGNC:9608; PTH1R.
DR   HPA; ENSG00000160801; Tissue enriched (kidney).
DR   MalaCards; PTH1R; -.
DR   MIM; 125350; phenotype.
DR   MIM; 156400; phenotype.
DR   MIM; 166000; phenotype.
DR   MIM; 168468; gene.
DR   MIM; 215045; phenotype.
DR   MIM; 600002; phenotype.
DR   neXtProt; NX_Q03431; -.
DR   OpenTargets; ENSG00000160801; -.
DR   Orphanet; 50945; Blomstrand lethal chondrodysplasia.
DR   Orphanet; 79106; Eiken syndrome.
DR   Orphanet; 33067; Metaphyseal chondrodysplasia, Jansen type.
DR   Orphanet; 296; Ollier disease.
DR   Orphanet; 412206; Primary failure of tooth eruption.
DR   PharmGKB; PA33953; -.
DR   eggNOG; KOG4564; Eukaryota.
DR   GeneTree; ENSGT00940000158574; -.
DR   InParanoid; Q03431; -.
DR   KO; K04585; -.
DR   OMA; SGTLWQI; -.
DR   OrthoDB; 651627at2759; -.
DR   PhylomeDB; Q03431; -.
DR   TreeFam; TF315710; -.
DR   PathwayCommons; Q03431; -.
DR   Reactome; R-HSA-373080; Class B/2 (Secretin family receptors).
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-9660821; ADORA2B mediated anti-inflammatory cytokines production.
DR   SignaLink; Q03431; -.
DR   SIGNOR; Q03431; -.
DR   BioGRID-ORCS; 5745; 8 hits in 879 CRISPR screens.
DR   ChiTaRS; PTH1R; human.
DR   EvolutionaryTrace; Q03431; -.
DR   GeneWiki; Parathyroid_hormone_1_receptor; -.
DR   GenomeRNAi; 5745; -.
DR   Pharos; Q03431; Tclin.
DR   PRO; PR:Q03431; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q03431; protein.
DR   Bgee; ENSG00000160801; Expressed in adult mammalian kidney and 185 other tissues.
DR   ExpressionAtlas; Q03431; baseline and differential.
DR   Genevisible; Q03431; HS.
DR   GO; GO:0016324; C:apical plasma membrane; ISS:BHF-UCL.
DR   GO; GO:0016323; C:basolateral plasma membrane; ISS:BHF-UCL.
DR   GO; GO:0031526; C:brush border membrane; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0043235; C:receptor complex; ISS:BHF-UCL.
DR   GO; GO:0008528; F:G protein-coupled peptide receptor activity; IBA:GO_Central.
DR   GO; GO:0004991; F:parathyroid hormone receptor activity; IDA:UniProtKB.
DR   GO; GO:0017046; F:peptide hormone binding; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0043621; F:protein self-association; IDA:UniProtKB.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007188; P:adenylate cyclase-modulating G protein-coupled receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0030282; P:bone mineralization; IEA:Ensembl.
DR   GO; GO:0045453; P:bone resorption; IEA:Ensembl.
DR   GO; GO:0048469; P:cell maturation; IEA:Ensembl.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IEA:InterPro.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IBA:GO_Central.
DR   GO; GO:0002062; P:chondrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007187; P:G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; TAS:ProtInc.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0002076; P:osteoblast development; IEA:Ensembl.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; IC:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IEA:Ensembl.
DR   GO; GO:0060732; P:positive regulation of inositol phosphate biosynthetic process; ISS:BHF-UCL.
DR   GO; GO:0001501; P:skeletal system development; TAS:ProtInc.
DR   Gene3D; 4.10.1240.10; -; 1.
DR   InterPro; IPR017981; GPCR_2-like.
DR   InterPro; IPR036445; GPCR_2_extracell_dom_sf.
DR   InterPro; IPR001879; GPCR_2_extracellular_dom.
DR   InterPro; IPR002170; GPCR_2_parathyroid_rcpt.
DR   InterPro; IPR000832; GPCR_2_secretin-like.
DR   InterPro; IPR017983; GPCR_2_secretin-like_CS.
DR   PANTHER; PTHR45620:SF27; PTHR45620:SF27; 1.
DR   Pfam; PF00002; 7tm_2; 1.
DR   Pfam; PF02793; HRM; 1.
DR   PRINTS; PR00249; GPCRSECRETIN.
DR   PRINTS; PR00393; PTRHORMONER.
DR   SMART; SM00008; HormR; 1.
DR   SUPFAM; SSF111418; SSF111418; 1.
DR   PROSITE; PS00649; G_PROTEIN_RECEP_F2_1; 1.
DR   PROSITE; PS00650; G_PROTEIN_RECEP_F2_2; 1.
DR   PROSITE; PS50227; G_PROTEIN_RECEP_F2_3; 1.
DR   PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disease mutation; Disulfide bond; Dwarfism;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Phosphoprotein;
KW   Receptor; Reference proteome; Signal; Transducer; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL          1..26
FT                   /evidence="ECO:0000255"
FT   CHAIN           27..593
FT                   /note="Parathyroid hormone/parathyroid hormone-related
FT                   peptide receptor"
FT                   /id="PRO_0000012845"
FT   TOPO_DOM        27..188
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        189..212
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        213..219
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        220..239
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        240..282
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        283..306
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        307..320
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        321..342
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        343..361
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        362..382
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        383..409
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        410..428
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        429..440
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        441..463
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        464..593
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   MOTIF           474..477
FT                   /note="Important for interaction with G proteins"
FT   MOD_RES         551
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   CARBOHYD        151
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        161
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        166
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        176
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        48..117
FT                   /evidence="ECO:0000244|PDB:3C4M, ECO:0000244|PDB:3H3G,
FT                   ECO:0000244|PDB:3L2J, ECO:0000269|PubMed:10913300,
FT                   ECO:0000269|PubMed:18375760, ECO:0000269|PubMed:19674967"
FT   DISULFID        108..148
FT                   /evidence="ECO:0000244|PDB:3C4M, ECO:0000244|PDB:3H3G,
FT                   ECO:0000244|PDB:3L2J, ECO:0000269|PubMed:10913300,
FT                   ECO:0000269|PubMed:18375760, ECO:0000269|PubMed:19674967"
FT   DISULFID        131..170
FT                   /evidence="ECO:0000244|PDB:3C4M, ECO:0000244|PDB:3H3G,
FT                   ECO:0000244|PDB:3L2J, ECO:0000269|PubMed:10913300,
FT                   ECO:0000269|PubMed:18375760, ECO:0000269|PubMed:19674967"
FT   VARIANT         132
FT                   /note="P -> L (in BOCD; dbSNP:rs121434599)"
FT                   /evidence="ECO:0000269|PubMed:9745456"
FT                   /id="VAR_016062"
FT   VARIANT         150
FT                   /note="R -> C (in ENCHOM; Ollier type; unknown pathological
FT                   significance; dbSNP:rs121434601)"
FT                   /evidence="ECO:0000269|PubMed:11850620"
FT                   /id="VAR_016063"
FT   VARIANT         223
FT                   /note="H -> R (in MCDJ; constitutively activated;
FT                   constitutively increases adenylate cyclase-activating G-
FT                   protein coupled receptor signaling pathway; decreases the
FT                   degree of N-glycosylation; does not affect
FT                   homodimerization; dbSNP:rs121434597)"
FT                   /evidence="ECO:0000269|PubMed:27160269,
FT                   ECO:0000269|PubMed:7701349, ECO:0000269|PubMed:8703170,
FT                   ECO:0000269|PubMed:9178745"
FT                   /id="VAR_003582"
FT   VARIANT         410
FT                   /note="T -> P (in MCDJ; constitutively activated;
FT                   dbSNP:rs121434598)"
FT                   /evidence="ECO:0000269|PubMed:8703170,
FT                   ECO:0000269|PubMed:9178745"
FT                   /id="VAR_003583"
FT   VARIANT         410
FT                   /note="T -> R (in MCDJ; leads to agonist-independent cAMP
FT                   formation which is less pronounced than that observed with
FT                   the Pro-410 mutant; dbSNP:rs121434602)"
FT                   /evidence="ECO:0000269|PubMed:15240651"
FT                   /id="VAR_038811"
FT   VARIANT         458
FT                   /note="I -> R (in MCDJ; dbSNP:rs121434600)"
FT                   /evidence="ECO:0000269|PubMed:10487664"
FT                   /id="VAR_016064"
FT   MUTAGEN         135
FT                   /note="I->K: Abolishes hormone binding and
FT                   homodimerization."
FT                   /evidence="ECO:0000269|PubMed:20172855"
FT   MUTAGEN         137
FT                   /note="D->A: Abolishes hormone binding. No effect on
FT                   homodimerization."
FT                   /evidence="ECO:0000269|PubMed:20172855"
FT   CONFLICT        471
FT                   /note="K -> N (in Ref. 2)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        473
FT                   /note="S -> C (in Ref. 2)"
FT                   /evidence="ECO:0000305"
FT   HELIX           34..55
FT                   /evidence="ECO:0000244|PDB:3H3G"
FT   STRAND          126..130
FT                   /evidence="ECO:0000244|PDB:3H3G"
FT   STRAND          143..148
FT                   /evidence="ECO:0000244|PDB:3H3G"
FT   STRAND          152..154
FT                   /evidence="ECO:0000244|PDB:3C4M"
FT   STRAND          160..163
FT                   /evidence="ECO:0000244|PDB:3H3G"
FT   TURN            168..173
FT                   /evidence="ECO:0000244|PDB:3H3G"
FT   HELIX           181..200
FT                   /evidence="ECO:0000244|PDB:6NBF"
FT   TURN            201..203
FT                   /evidence="ECO:0000244|PDB:6NBF"
FT   HELIX           204..211
FT                   /evidence="ECO:0000244|PDB:6NBF"
FT   HELIX           219..245
FT                   /evidence="ECO:0000244|PDB:6NBF"
FT   HELIX           274..277
FT                   /evidence="ECO:0000244|PDB:6NBH"
FT   HELIX           279..311
FT                   /evidence="ECO:0000244|PDB:6NBF"
FT   HELIX           317..345
FT                   /evidence="ECO:0000244|PDB:6NBF"
FT   HELIX           358..360
FT                   /evidence="ECO:0000244|PDB:6NBF"
FT   HELIX           361..368
FT                   /evidence="ECO:0000244|PDB:6NBF"
FT   TURN            369..371
FT                   /evidence="ECO:0000244|PDB:6NBF"
FT   HELIX           372..390
FT                   /evidence="ECO:0000244|PDB:6NBF"
FT   HELIX           400..411
FT                   /evidence="ECO:0000244|PDB:6NBF"
FT   TURN            412..418
FT                   /evidence="ECO:0000244|PDB:6NBF"
FT   HELIX           420..423
FT                   /evidence="ECO:0000244|PDB:6NBF"
FT   STRAND          424..426
FT                   /evidence="ECO:0000244|PDB:6NBF"
FT   STRAND          432..434
FT                   /evidence="ECO:0000244|PDB:6NBF"
FT   HELIX           435..459
FT                   /evidence="ECO:0000244|PDB:6NBF"
FT   HELIX           464..480
FT                   /evidence="ECO:0000244|PDB:6NBF"
FT   STRAND          588..592
FT                   /evidence="ECO:0000244|PDB:5EMB"
SQ   SEQUENCE   593 AA;  66361 MW;  DA1400640A6C7F2B CRC64;
     MGTARIAPGL ALLLCCPVLS SAYALVDADD VMTKEEQIFL LHRAQAQCEK RLKEVLQRPA
     SIMESDKGWT SASTSGKPRK DKASGKLYPE SEEDKEAPTG SRYRGRPCLP EWDHILCWPL
     GAPGEVVAVP CPDYIYDFNH KGHAYRRCDR NGSWELVPGH NRTWANYSEC VKFLTNETRE
     REVFDRLGMI YTVGYSVSLA SLTVAVLILA YFRRLHCTRN YIHMHLFLSF MLRAVSIFVK
     DAVLYSGATL DEAERLTEEE LRAIAQAPPP PATAAAGYAG CRVAVTFFLY FLATNYYWIL
     VEGLYLHSLI FMAFFSEKKY LWGFTVFGWG LPAVFVAVWV SVRATLANTG CWDLSSGNKK
     WIIQVPILAS IVLNFILFIN IVRVLATKLR ETNAGRCDTR QQYRKLLKST LVLMPLFGVH
     YIVFMATPYT EVSGTLWQVQ MHYEMLFNSF QGFFVAIIYC FCNGEVQAEI KKSWSRWTLA
     LDFKRKARSG SSSYSYGPMV SHTSVTNVGP RVGLGLPLSP RLLPTATTNG HPQLPGHAKP
     GTPALETLET TPPAMAAPKD DGFLNGSCSG LDEEASGPER PPALLQEEWE TVM
//
ID   P2RY6_HUMAN             Reviewed;         328 AA.
AC   Q15077; Q15754;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   07-OCT-2020, entry version 177.
DE   RecName: Full=P2Y purinoceptor 6;
DE            Short=P2Y6;
GN   Name=P2RY6; ORFNames=PP2891;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8670200; DOI=10.1006/bbrc.1996.0739;
RA   Communi D., Parmentier M., Boeynaems J.-M.;
RT   "Cloning, functional expression and tissue distribution of the human P2Y6
RT   receptor.";
RL   Biochem. Biophys. Res. Commun. 222:303-308(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9286708; DOI=10.1006/geno.1997.4841;
RA   Somers G.R., Hammet F., Woollatt E., Richards R.I., Southey M.C.,
RA   Venter D.J.;
RT   "Chromosomal localization of the human P2y6 purinoceptor gene and
RT   phylogenetic analysis of the P2y purinoceptor family.";
RL   Genomics 44:127-130(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   PubMed=9268704; DOI=10.1006/bbrc.1997.7135;
RA   Maier R., Glatz A., Mosbacher J., Bilbe G.;
RT   "Cloning of P2Y6 cDNAs and identification of a pseudogene: comparison of
RT   P2Y receptor subtype expression in bone and brain tissues.";
RL   Biochem. Biophys. Res. Commun. 237:297-302(1997).
RN   [4]
RP   ERRATUM OF PUBMED:9268704.
RX   PubMed=9412455; DOI=10.1006/bbrc.1997.7653;
RA   Maier R., Glatz A., Mosbacher J., Bilbe G.;
RL   Biochem. Biophys. Res. Commun. 240:298-302(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15498874; DOI=10.1073/pnas.0404089101;
RA   Wan D., Gong Y., Qin W., Zhang P., Li J., Wei L., Zhou X., Li H., Qiu X.,
RA   Zhong F., He L., Yu J., Yao G., Jiang H., Qian L., Yu Y., Shu H., Chen X.,
RA   Xu H., Guo M., Pan Z., Chen Y., Ge C., Yang S., Gu J.;
RT   "Large-scale cDNA transfection screening for genes related to cancer
RT   development and progression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:15724-15729(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- FUNCTION: Receptor for extracellular UDP > UTP > ATP. The activity of
CC       this receptor is mediated by G proteins which activate a
CC       phosphatidylinositol-calcium second messenger system.
CC   -!- INTERACTION:
CC       Q15077; P55060: CSE1L; NbExp=2; IntAct=EBI-10235794, EBI-286709;
CC       Q15077; P49639: HOXA1; NbExp=5; IntAct=EBI-10235794, EBI-740785;
CC       Q15077; Q14974: KPNB1; NbExp=4; IntAct=EBI-10235794, EBI-286758;
CC       Q15077; Q07627: KRTAP1-1; NbExp=3; IntAct=EBI-10235794, EBI-11959885;
CC       Q15077; P60409: KRTAP10-7; NbExp=3; IntAct=EBI-10235794, EBI-10172290;
CC       Q15077; P60410: KRTAP10-8; NbExp=3; IntAct=EBI-10235794, EBI-10171774;
CC       Q15077; P60328: KRTAP12-3; NbExp=3; IntAct=EBI-10235794, EBI-11953334;
CC       Q15077; Q9BYR9: KRTAP2-4; NbExp=3; IntAct=EBI-10235794, EBI-14065470;
CC       Q15077; Q9BYR6: KRTAP3-3; NbExp=3; IntAct=EBI-10235794, EBI-3957694;
CC       Q15077; P26371: KRTAP5-9; NbExp=3; IntAct=EBI-10235794, EBI-3958099;
CC       Q15077; Q9BYQ4: KRTAP9-2; NbExp=5; IntAct=EBI-10235794, EBI-1044640;
CC       Q15077; Q8NI22: MCFD2; NbExp=3; IntAct=EBI-10235794, EBI-2689785;
CC       Q15077; P0DPK4: NOTCH2NLC; NbExp=3; IntAct=EBI-10235794, EBI-22310682;
CC       Q15077; O15162: PLSCR1; NbExp=3; IntAct=EBI-10235794, EBI-740019;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X97058; CAA65770.1; -; mRNA.
DR   EMBL; U52464; AAB03572.1; -; mRNA.
DR   EMBL; AF007892; AAB80713.1; -; mRNA.
DR   EMBL; AF007891; AAB80712.1; -; mRNA.
DR   EMBL; AF218005; AAG17247.1; -; mRNA.
DR   EMBL; AF498920; AAM18129.1; -; mRNA.
DR   EMBL; BT006771; AAP35417.1; -; mRNA.
DR   EMBL; BC000571; AAH00571.1; -; mRNA.
DR   EMBL; BC009391; AAH09391.1; -; mRNA.
DR   CCDS; CCDS8220.1; -.
DR   PIR; JC4800; JC4800.
DR   RefSeq; NP_001264133.1; NM_001277204.1.
DR   RefSeq; NP_001264134.1; NM_001277205.1.
DR   RefSeq; NP_001264135.1; NM_001277206.1.
DR   RefSeq; NP_001264136.1; NM_001277207.1.
DR   RefSeq; NP_001264137.1; NM_001277208.1.
DR   RefSeq; NP_789766.1; NM_176796.2.
DR   RefSeq; NP_789767.1; NM_176797.2.
DR   RefSeq; NP_789768.1; NM_176798.2.
DR   RefSeq; XP_005274079.1; XM_005274022.3.
DR   RefSeq; XP_006718634.1; XM_006718571.3.
DR   RefSeq; XP_011543379.1; XM_011545077.2.
DR   RefSeq; XP_011543381.1; XM_011545079.2.
DR   PDB; 2B6R; Model; -; A=1-318.
DR   PDBsum; 2B6R; -.
DR   BioGRID; 111070; 382.
DR   IntAct; Q15077; 374.
DR   STRING; 9606.ENSP00000480966; -.
DR   BindingDB; Q15077; -.
DR   ChEMBL; CHEMBL4714; -.
DR   DrugCentral; Q15077; -.
DR   GuidetoPHARMACOLOGY; 326; -.
DR   GlyGen; Q15077; 1 site.
DR   iPTMnet; Q15077; -.
DR   PhosphoSitePlus; Q15077; -.
DR   BioMuta; P2RY6; -.
DR   DMDM; 2495018; -.
DR   jPOST; Q15077; -.
DR   MaxQB; Q15077; -.
DR   PaxDb; Q15077; -.
DR   PeptideAtlas; Q15077; -.
DR   PRIDE; Q15077; -.
DR   ProteomicsDB; 60428; -.
DR   Antibodypedia; 17126; 247 antibodies.
DR   DNASU; 5031; -.
DR   Ensembl; ENST00000349767; ENSP00000309771; ENSG00000171631.
DR   Ensembl; ENST00000393590; ENSP00000377215; ENSG00000171631.
DR   Ensembl; ENST00000393591; ENSP00000377216; ENSG00000171631.
DR   Ensembl; ENST00000393592; ENSP00000377217; ENSG00000171631.
DR   Ensembl; ENST00000538328; ENSP00000442990; ENSG00000171631.
DR   Ensembl; ENST00000540124; ENSP00000442551; ENSG00000171631.
DR   Ensembl; ENST00000540342; ENSP00000443427; ENSG00000171631.
DR   Ensembl; ENST00000542092; ENSP00000445652; ENSG00000171631.
DR   Ensembl; ENST00000618468; ENSP00000480966; ENSG00000171631.
DR   GeneID; 5031; -.
DR   KEGG; hsa:5031; -.
DR   UCSC; uc001otm.5; human.
DR   CTD; 5031; -.
DR   DisGeNET; 5031; -.
DR   EuPathDB; HostDB:ENSG00000171631.14; -.
DR   GeneCards; P2RY6; -.
DR   HGNC; HGNC:8543; P2RY6.
DR   HPA; ENSG00000171631; Group enriched (blood, lymphoid tissue, placenta).
DR   MIM; 602451; gene.
DR   neXtProt; NX_Q15077; -.
DR   OpenTargets; ENSG00000171631; -.
DR   PharmGKB; PA32872; -.
DR   eggNOG; ENOG502QRYJ; Eukaryota.
DR   GeneTree; ENSGT00990000203702; -.
DR   InParanoid; Q15077; -.
DR   KO; K04272; -.
DR   OMA; AWLVCGA; -.
DR   OrthoDB; 925903at2759; -.
DR   PhylomeDB; Q15077; -.
DR   TreeFam; TF330775; -.
DR   PathwayCommons; Q15077; -.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-417957; P2Y receptors.
DR   SIGNOR; Q15077; -.
DR   BioGRID-ORCS; 5031; 12 hits in 865 CRISPR screens.
DR   ChiTaRS; P2RY6; human.
DR   GeneWiki; P2RY6; -.
DR   GenomeRNAi; 5031; -.
DR   Pharos; Q15077; Tchem.
DR   PRO; PR:Q15077; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q15077; protein.
DR   Bgee; ENSG00000171631; Expressed in left coronary artery and 134 other tissues.
DR   ExpressionAtlas; Q15077; baseline and differential.
DR   Genevisible; Q15077; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0016323; C:basolateral plasma membrane; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0001621; F:G protein-coupled ADP receptor activity; IDA:ARUK-UCL.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; TAS:ProtInc.
DR   GO; GO:0045029; F:G protein-coupled UDP receptor activity; IDA:ARUK-UCL.
DR   GO; GO:0045030; F:G protein-coupled UTP receptor activity; IDA:ARUK-UCL.
DR   GO; GO:0007202; P:activation of phospholipase C activity; TAS:ARUK-UCL.
DR   GO; GO:0071380; P:cellular response to prostaglandin E stimulus; IEA:Ensembl.
DR   GO; GO:0071415; P:cellular response to purine-containing compound; IDA:ARUK-UCL.
DR   GO; GO:1905835; P:cellular response to pyrimidine ribonucleotide; IDA:ARUK-UCL.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006909; P:phagocytosis; ISS:ARUK-UCL.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:BHF-UCL.
DR   GO; GO:0031587; P:positive regulation of inositol 1,4,5-trisphosphate-sensitive calcium-release channel activity; ISS:ARUK-UCL.
DR   GO; GO:0032962; P:positive regulation of inositol trisphosphate biosynthetic process; IDA:ARUK-UCL.
DR   GO; GO:0014911; P:positive regulation of smooth muscle cell migration; IEA:Ensembl.
DR   GO; GO:1904707; P:positive regulation of vascular associated smooth muscle cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0030321; P:transepithelial chloride transport; IEA:Ensembl.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR001973; P2Y6_rcpt.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01068; P2Y6PRNOCPTR.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Membrane; Receptor; Reference proteome; Transducer;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..328
FT                   /note="P2Y purinoceptor 6"
FT                   /id="PRO_0000070028"
FT   TOPO_DOM        1..27
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        28..48
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        49..62
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        63..83
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        84..101
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        102..122
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        123..144
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        145..165
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        166..194
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        195..215
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        216..236
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        237..257
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        258..280
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        281..303
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        304..328
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        5
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        99..177
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   CONFLICT        2..3
FT                   /note="Missing (in Ref. 2)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   328 AA;  36429 MW;  AAD6C55A43818107 CRC64;
     MEWDNGTGQA LGLPPTTCVY RENFKQLLLP PVYSAVLAAG LPLNICVITQ ICTSRRALTR
     TAVYTLNLAL ADLLYACSLP LLIYNYAQGD HWPFGDFACR LVRFLFYANL HGSILFLTCI
     SFQRYLGICH PLAPWHKRGG RRAAWLVCVA VWLAVTTQCL PTAIFAATGI QRNRTVCYDL
     SPPALATHYM PYGMALTVIG FLLPFAALLA CYCLLACRLC RQDGPAEPVA QERRGKAARM
     AVVVAAAFAI SFLPFHITKT AYLAVRSTPG VPCTVLEAFA AAYKGTRPFA SANSVLDPIL
     FYFTQKKFRR RPHELLQKLT AKWQRQGR
//
ID   ADRB2_HUMAN             Reviewed;         413 AA.
AC   P07550; B0LPE4; B2R7X2; O14823; O14824; O14825; O14826; Q4JG18; Q53GA6;
AC   Q6GMT4; Q6P4D8; Q8NEQ9; Q96EC3; Q9UCZ0; Q9UCZ1; Q9UCZ2; Q9UCZ3; Q9UH95;
AC   Q9UHA1; Q9UMZ5;
DT   01-APR-1988, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 3.
DT   07-OCT-2020, entry version 233.
DE   RecName: Full=Beta-2 adrenergic receptor;
DE   AltName: Full=Beta-2 adrenoreceptor;
DE            Short=Beta-2 adrenoceptor;
GN   Name=ADRB2; Synonyms=ADRB2R, B2AR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT GLN-27.
RC   TISSUE=Brain;
RX   PubMed=3026848; DOI=10.1016/0014-5793(87)81436-9;
RA   Chung F.-Z., Lentes K.-U., Gocayne J.D., Fitzgerald M.G., Robinson D.A.,
RA   Kerlavage A.R., Fraser C.M., Venter J.C.;
RT   "Cloning and sequence analysis of the human brain beta-adrenergic receptor.
RT   Evolutionary relationship to rodent and avian beta-receptors and porcine
RT   muscarinic receptors.";
RL   FEBS Lett. 211:200-206(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-16 AND GLN-27.
RX   PubMed=3034889;
RA   Kobilka B.K., Frielle T., Dohlman H.G., Bolanowski M.A., Dixon R.A.F.,
RA   Keller P., Caron M.G., Lefkowitz R.J.;
RT   "Delineation of the intronless nature of the genes for the human and
RT   hamster beta 2-adrenergic receptor and their putative promoter regions.";
RL   J. Biol. Chem. 262:7321-7327(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-16 AND GLN-27.
RX   PubMed=3033609; DOI=10.1093/nar/15.8.3636;
RA   Schofield P.R., Rhee L.M., Peralta E.G.;
RT   "Primary structure of the human beta-adrenergic receptor gene.";
RL   Nucleic Acids Res. 15:3636-3636(1987).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ARG-16 AND GLN-27.
RX   PubMed=3025863; DOI=10.1073/pnas.84.1.46;
RA   Kobilka B.K., Dixon R.A.F., Frielle T., Dohlman H.G., Bolanowski M.A.,
RA   Sigal I.S., Yang-Feng T.L., Francke U., Caron M.G., Lefkowitz R.J.;
RT   "cDNA for the human beta 2-adrenergic receptor: a protein with multiple
RT   membrane-spanning domains and encoded by a gene whose chromosomal location
RT   is shared with that of the receptor for platelet-derived growth factor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:46-50(1987).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLN-27.
RX   PubMed=2823249; DOI=10.1073/pnas.84.20.6995;
RA   Emorine L.J., Marullo S., Delavier-Klutchko C., Kaveri S.V.,
RA   Durieu-Trautmann O., Strosberg A.D.;
RT   "Structure of the gene for human beta 2-adrenergic receptor: expression and
RT   promoter characterization.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:6995-6999(1987).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-16; GLN-27; MET-34 AND
RP   ILE-164.
RX   PubMed=8383511; DOI=10.1165/ajrcmb/8.3.334;
RA   Reihsaus E., Innis M., Macintyre N., Liggett S.B.;
RT   "Mutations in the gene encoding for the beta 2-adrenergic receptor in
RT   normal and asthmatic subjects.";
RL   Am. J. Respir. Cell Mol. Biol. 8:334-339(1993).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLN-27; LEU-159; PHE-159
RP   AND ARG-375.
RC   TISSUE=Blood;
RX   PubMed=11246467; DOI=10.1017/s0003480000008009;
RA   Rupert J.L., Monsalve M.V., Devine D.V., Hochachka P.W.;
RT   "Beta2-adrenergic receptor allele frequencies in the Quechua, a high
RT   altitude native population.";
RL   Ann. Hum. Genet. 64:135-143(2000).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ARG-16 AND GLN-27.
RC   TISSUE=Heart;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT GLN-27.
RC   TISSUE=Thyroid;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLN-27 AND CYS-220.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUN-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLN-27.
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ARG-16 AND GLN-27.
RC   TISSUE=Fetal brain, Leukocyte, and Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [15]
RP   MUTAGENESIS OF ASP-79, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=2831218;
RA   Chung F.-Z., Wang C.-D., Potter P.C., Venter J.C., Fraser C.M.;
RT   "Site-directed mutagenesis and continuous expression of human beta-
RT   adrenergic receptors. Identification of a conserved aspartate residue
RT   involved in agonist binding and receptor activation.";
RL   J. Biol. Chem. 263:4052-4055(1988).
RN   [16]
RP   PALMITOYLATION AT CYS-341, AND MUTAGENESIS OF CYS-341.
RX   PubMed=2540197;
RA   O'Dowd B.F., Hnatowich M., Caron M.G., Lefkowitz R.J., Bouvier M.;
RT   "Palmitoylation of the human beta 2-adrenergic receptor. Mutation of Cys341
RT   in the carboxyl tail leads to an uncoupled nonpalmitoylated form of the
RT   receptor.";
RL   J. Biol. Chem. 264:7564-7569(1989).
RN   [17]
RP   MUTAGENESIS OF TYR-141; TYR-350; TYR-354 AND TYR-366, AND PHOSPHORYLATION
RP   AT TYR-141.
RX   PubMed=8521811; DOI=10.1002/j.1460-2075.1995.tb00241.x;
RA   Valiquette M., Parent S., Loisel T.P., Bouvier M.;
RT   "Mutation of tyrosine-141 inhibits insulin-promoted tyrosine
RT   phosphorylation and increased responsiveness of the human beta 2-adrenergic
RT   receptor.";
RL   EMBO J. 14:5542-5549(1995).
RN   [18]
RP   INTERACTION WITH ARRB1 AND ARRB2.
RX   PubMed=7822302; DOI=10.1074/jbc.270.2.720;
RA   Gurevich V.V., Dion S.B., Onorato J.J., Ptasienski J., Kim C.M.,
RA   Sterne-Marr R., Hosey M.M., Benovic J.L.;
RT   "Arrestin interactions with G protein-coupled receptors. Direct binding
RT   studies of wild type and mutant arrestins with rhodopsin, beta 2-
RT   adrenergic, and m2 muscarinic cholinergic receptors.";
RL   J. Biol. Chem. 270:720-731(1995).
RN   [19]
RP   INTERACTION WITH ARRB1.
RX   PubMed=9388255; DOI=10.1074/jbc.272.49.31051;
RA   Lin F.-T., Krueger K.M., Kendall H.E., Daaka Y., Fredericks Z.L.,
RA   Pitcher J.A., Lefkowitz R.J.;
RT   "Clathrin-mediated endocytosis of the beta-adrenergic receptor is regulated
RT   by phosphorylation/dephosphorylation of beta-arrestin1.";
RL   J. Biol. Chem. 272:31051-31057(1997).
RN   [20]
RP   INTERACTION WITH SLC9A3R1.
RX   PubMed=10499588; DOI=10.1038/45816;
RA   Cao T.T., Deacon H.W., Reczek D., Bretscher A., von Zastrow M.;
RT   "A kinase-regulated PDZ-domain interaction controls endocytic sorting of
RT   the beta2-adrenergic receptor.";
RL   Nature 401:286-290(1999).
RN   [21]
RP   INTERACTION WITH SRC AND ARRB1.
RX   PubMed=9924018; DOI=10.1126/science.283.5402.655;
RA   Luttrell L.M., Ferguson S.S.G., Daaka Y., Miller W.E., Maudsley S.,
RA   Della Rocca G.J., Lin F.-T., Kawakatsu H., Owada K., Luttrell D.K.,
RA   Caron M.G., Lefkowitz R.J.;
RT   "Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein
RT   kinase complexes.";
RL   Science 283:655-661(1999).
RN   [22]
RP   EFFECT OF PALMITOYLATION, PHOSPHORYLATION AT SER-345 AND SER-346, AND
RP   MUTAGENESIS OF 345-SER-SER-346.
RX   PubMed=11146000; DOI=10.1046/j.1471-4159.2001.00005.x;
RA   Moffett S., Rousseau G., Lagace M., Bouvier M.;
RT   "The palmitoylation state of the beta(2)-adrenergic receptor regulates the
RT   synergistic action of cyclic AMP-dependent protein kinase and beta-
RT   adrenergic receptor kinase involved in its phosphorylation and
RT   desensitization.";
RL   J. Neurochem. 76:269-279(2001).
RN   [23]
RP   INTERACTION WITH GPRASP1.
RX   PubMed=12142540; DOI=10.1126/science.1073308;
RA   Whistler J.L., Enquist J., Marley A., Fong J., Gladher F., Tsuruda P.,
RA   Murray S.R., Von Zastrow M.;
RT   "Modulation of postendocytic sorting of G protein-coupled receptors.";
RL   Science 297:615-620(2002).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-246, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [25]
RP   UBIQUITINATION, DEUBIQUITINATION BY USP20 AND USP33, AND INTERACTION WITH
RP   USP20 AND USP33.
RX   PubMed=19424180; DOI=10.1038/emboj.2009.128;
RA   Berthouze M., Venkataramanan V., Li Y., Shenoy S.K.;
RT   "The deubiquitinases USP33 and USP20 coordinate beta2 adrenergic receptor
RT   recycling and resensitization.";
RL   EMBO J. 28:1684-1696(2009).
RN   [26]
RP   INTERACTION WITH EGLN3 AND VHL, SUBCELLULAR LOCATION, INDUCTION,
RP   UBIQUITINATION, HYDROXYLATION AT PRO-382 AND PRO-395, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=19584355; DOI=10.1126/scisignal.2000444;
RA   Xie L., Xiao K., Whalen E.J., Forrester M.T., Freeman R.S., Fong G.,
RA   Gygi S.P., Lefkowitz R.J., Stamler J.S.;
RT   "Oxygen-regulated beta(2)-adrenergic receptor hydroxylation by EGLN3 and
RT   ubiquitylation by pVHL.";
RL   Sci. Signal. 2:RA33-RA33(2009).
RN   [27]
RP   UBIQUITINATION, SUBCELLULAR LOCATION, AND INTERACTION WITH ARRDC3.
RX   PubMed=20559325; DOI=10.1038/embor.2010.80;
RA   Nabhan J.F., Pan H., Lu Q.;
RT   "Arrestin domain-containing protein 3 recruits the NEDD4 E3 ligase to
RT   mediate ubiquitination of the beta2-adrenergic receptor.";
RL   EMBO Rep. 11:605-611(2010).
RN   [28]
RP   INTERACTION WITH SNX27.
RX   PubMed=20733053; DOI=10.1083/jcb.201004060;
RA   Lauffer B.E., Melero C., Temkin P., Lei C., Hong W., Kortemme T.,
RA   von Zastrow M.;
RT   "SNX27 mediates PDZ-directed sorting from endosomes to the plasma
RT   membrane.";
RL   J. Cell Biol. 190:565-574(2010).
RN   [29]
RP   INTERACTION WITH SNX27.
RX   PubMed=21602791; DOI=10.1038/ncb2252;
RA   Temkin P., Lauffer B., Jager S., Cimermancic P., Krogan N.J.,
RA   von Zastrow M.;
RT   "SNX27 mediates retromer tubule entry and endosome-to-plasma membrane
RT   trafficking of signalling receptors.";
RL   Nat. Cell Biol. 13:715-721(2011).
RN   [30]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH ARRDC3.
RX   PubMed=25220262; DOI=10.1002/pro.2549;
RA   Qi S., O'Hayre M., Gutkind J.S., Hurley J.H.;
RT   "Insights into beta2-adrenergic receptor binding from structures of the N-
RT   terminal lobe of ARRDC3.";
RL   Protein Sci. 23:1708-1716(2014).
RN   [31]
RP   INTERACTION WITH CNIH4.
RX   PubMed=24405750; DOI=10.1111/tra.12148;
RA   Sauvageau E., Rochdi M.D., Oueslati M., Hamdan F.F., Percherancier Y.,
RA   Simpson J.C., Pepperkok R., Bouvier M.;
RT   "CNIH4 interacts with newly synthesized GPCR and controls their export from
RT   the endoplasmic reticulum.";
RL   Traffic 15:383-400(2014).
RN   [32]
RP   SUBCELLULAR LOCATION, PALMITOYLATION AT CYS-265 AND CYS-341, AND
RP   MUTAGENESIS OF CYS-265 AND CYS-341.
RX   PubMed=27481942; DOI=10.1074/jbc.m116.725762;
RA   Adachi N., Hess D.T., McLaughlin P., Stamler J.S.;
RT   "S-Palmitoylation of a Novel Site in the beta2-Adrenergic Receptor
RT   Associated with a Novel Intracellular Itinerary.";
RL   J. Biol. Chem. 291:20232-20246(2016).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (3.4 ANGSTROMS) OF 1-365 IN COMPLEX WITH CARAZOLOL,
RP   AND TOPOLOGY.
RX   PubMed=17952055; DOI=10.1038/nature06325;
RA   Rasmussen S.G.F., Choi H.-J., Rosenbaum D.M., Kobilka T.S., Thian F.S.,
RA   Edwards P.C., Burghammer M., Ratnala V.R.P., Sanishvili R., Fischetti R.F.,
RA   Schertler G.F.X., Weis W.I., Kobilka B.K.;
RT   "Crystal structure of the human beta2 adrenergic G-protein-coupled
RT   receptor.";
RL   Nature 450:383-387(2007).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 1-365 IN COMPLEX WITH CARAZOLOL
RP   AND CHOLESTEROL, DISULFIDE BONDS, TOPOLOGY, AND PALMITOYLATION AT CYS-341.
RX   PubMed=17962520; DOI=10.1126/science.1150577;
RA   Cherezov V., Rosenbaum D.M., Hanson M.A., Rasmussen S.G.F., Thian F.S.,
RA   Kobilka T.S., Choi H.-J., Kuhn P., Weis W.I., Kobilka B.K., Stevens R.C.;
RT   "High-resolution crystal structure of an engineered human beta2-adrenergic
RT   G protein-coupled receptor.";
RL   Science 318:1258-1265(2007).
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 1-365 IN COMPLEX WITH TIMOLOL AND
RP   CHOLESTEROL, DISULFIDE BONDS, TOPOLOGY, AND PALMITOYLATION AT CYS-341.
RX   PubMed=18547522; DOI=10.1016/j.str.2008.05.001;
RA   Hanson M.A., Cherezov V., Griffith M.T., Roth C.B., Jaakola V.P.,
RA   Chien E.Y., Velasquez J., Kuhn P., Stevens R.C.;
RT   "A specific cholesterol binding site is established by the 2.8 A structure
RT   of the human beta2-adrenergic receptor.";
RL   Structure 16:897-905(2008).
RN   [36]
RP   VARIANTS ARG-16 AND GLN-27, CHARACTERIZATION, FUNCTION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=7915137; DOI=10.1021/bi00198a006;
RA   Green S.A., Turki J., Innis M., Ligget S.B.;
RT   "Amino-terminal polymorphisms of the human beta 2-adrenergic receptor
RT   impart distinct agonist-promoted regulatory properties.";
RL   Biochemistry 33:9414-9419(1994).
RN   [37]
RP   VARIANT ARG-16, AND POLYMORPHISM.
RX   PubMed=7706471; DOI=10.1172/jci117838;
RA   Turki J., Pak J., Green S.A., Martin R.J., Liggett S.B.;
RT   "Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and
RT   nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal
RT   phenotype.";
RL   J. Clin. Invest. 95:1635-1641(1995).
CC   -!- FUNCTION: Beta-adrenergic receptors mediate the catecholamine-induced
CC       activation of adenylate cyclase through the action of G proteins. The
CC       beta-2-adrenergic receptor binds epinephrine with an approximately 30-
CC       fold greater affinity than it does norepinephrine.
CC       {ECO:0000269|PubMed:2831218, ECO:0000269|PubMed:7915137}.
CC   -!- SUBUNIT: Binds SLC9A3R1 and GPRASP1. Interacts with ARRB1 and ARRB2.
CC       Interacts with SRC, USP20 and USP33. Interacts with VHL; the
CC       interaction, which is increased on hydroxylation of ADRB2,
CC       ubiquitinates ADRB2 leading to its degradation. Interacts with EGLN3;
CC       the interaction hydroxylates ADRB2 facilitating VHL-E3 ligase-mediated
CC       ubiquitination. Interacts (via PDZ-binding motif) with SNX27 (via PDZ
CC       domain); the interaction is required when endocytosed to prevent
CC       degradation in lysosomes and promote recycling to the plasma membrane.
CC       Interacts with CNIH4 (PubMed:24405750). Interacts with ARRDC3
CC       (PubMed:20559325, PubMed:25220262). {ECO:0000269|PubMed:10499588,
CC       ECO:0000269|PubMed:12142540, ECO:0000269|PubMed:17952055,
CC       ECO:0000269|PubMed:17962520, ECO:0000269|PubMed:18547522,
CC       ECO:0000269|PubMed:19424180, ECO:0000269|PubMed:19584355,
CC       ECO:0000269|PubMed:20559325, ECO:0000269|PubMed:20733053,
CC       ECO:0000269|PubMed:21602791, ECO:0000269|PubMed:24405750,
CC       ECO:0000269|PubMed:25220262, ECO:0000269|PubMed:7822302,
CC       ECO:0000269|PubMed:9388255, ECO:0000269|PubMed:9924018}.
CC   -!- INTERACTION:
CC       P07550; P30542: ADORA1; NbExp=5; IntAct=EBI-491169, EBI-2903663;
CC       P07550; P07550: ADRB2; NbExp=4; IntAct=EBI-491169, EBI-491169;
CC       P07550; P32121: ARRB2; NbExp=3; IntAct=EBI-491169, EBI-714559;
CC       P07550; Q96B67: ARRDC3; NbExp=6; IntAct=EBI-491169, EBI-2875665;
CC       P07550; P21554: CNR1; NbExp=5; IntAct=EBI-491169, EBI-2909859;
CC       P07550; P61978: HNRNPK; NbExp=2; IntAct=EBI-491169, EBI-304185;
CC       P07550; P28335: HTR2C; NbExp=2; IntAct=EBI-491169, EBI-994141;
CC       P07550; Q5TCQ9: MAGI3; NbExp=9; IntAct=EBI-491169, EBI-310506;
CC       P07550; P02686: MBP; NbExp=2; IntAct=EBI-491169, EBI-947410;
CC       P07550; Q99685: MGLL; NbExp=2; IntAct=EBI-491169, EBI-721306;
CC       P07550; P04156: PRNP; NbExp=2; IntAct=EBI-491169, EBI-977302;
CC       P07550; O14745: SLC9A3R1; NbExp=6; IntAct=EBI-491169, EBI-349787;
CC       P07550; P12931: SRC; NbExp=3; IntAct=EBI-491169, EBI-621482;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:19584355,
CC       ECO:0000269|PubMed:20559325, ECO:0000269|PubMed:25220262,
CC       ECO:0000269|PubMed:2831218, ECO:0000269|PubMed:7915137}; Multi-pass
CC       membrane protein {ECO:0000269|PubMed:19584355}. Early endosome
CC       {ECO:0000269|PubMed:20559325}. Golgi apparatus
CC       {ECO:0000269|PubMed:27481942}. Note=Colocalizes with VHL at the cell
CC       membrane (PubMed:19584355). Activated receptors are internalized into
CC       endosomes prior to their degradation in lysosomes (PubMed:20559325).
CC       Activated receptors are also detected within the Golgi apparatus
CC       (PubMed:27481942). {ECO:0000269|PubMed:19584355,
CC       ECO:0000269|PubMed:20559325, ECO:0000269|PubMed:27481942}.
CC   -!- PTM: Palmitoylated (PubMed:2540197, PubMed:11146000, PubMed:27481942,
CC       PubMed:17962520, PubMed:18547522). Mainly palmitoylated at Cys-341
CC       (PubMed:2540197, PubMed:17962520, PubMed:18547522). Palmitoylation may
CC       reduce accessibility of phosphorylation sites by anchoring the receptor
CC       to the plasma membrane. Agonist stimulation promotes depalmitoylation
CC       and further allows Ser-345 and Ser-346 phosphorylation
CC       (PubMed:11146000). Also undergoes transient, ligand-induced
CC       palmitoylation at Cys-265 probably by ZDHHC9, ZDHHC14 and ZDHHC18
CC       within the Golgi (PubMed:27481942). Palmitoylation at Cys-265 requires
CC       phosphorylation by PKA and receptor internalization and stabilizes the
CC       receptor (PubMed:27481942). Could be depalmitoylated by LYPLA1 at the
CC       plasma membrane (PubMed:27481942). {ECO:0000269|PubMed:11146000,
CC       ECO:0000269|PubMed:17962520, ECO:0000269|PubMed:18547522,
CC       ECO:0000269|PubMed:2540197, ECO:0000269|PubMed:27481942}.
CC   -!- PTM: Phosphorylated by PKA and BARK upon agonist stimulation, which
CC       mediates homologous desensitization of the receptor. PKA-mediated
CC       phosphorylation seems to facilitate phosphorylation by BARK.
CC   -!- PTM: Phosphorylation of Tyr-141 is induced by insulin and leads to
CC       supersensitization of the receptor. {ECO:0000269|PubMed:8521811}.
CC   -!- PTM: Polyubiquitinated. Agonist-induced ubiquitination leads to sort
CC       internalized receptors to the lysosomes for degradation
CC       (PubMed:19424180, PubMed:20559325). Deubiquitination by USP20 and
CC       USP33, leads to ADRB2 recycling and resensitization after prolonged
CC       agonist stimulation. USP20 and USP33 are constitutively associated and
CC       are dissociated immediately after agonist stimulation. Ubiquitination
CC       by the VHL-E3 ligase complex is oxygen-dependent.
CC       {ECO:0000269|PubMed:19424180, ECO:0000269|PubMed:20559325}.
CC   -!- PTM: Hydroxylation by EGLN3 occurs only under normoxia and increases
CC       the interaction with VHL and the subsequent ubiquitination and
CC       degradation of ADRB2. {ECO:0000269|PubMed:19424180,
CC       ECO:0000269|PubMed:19584355}.
CC   -!- POLYMORPHISM: The Gly-16 allele is overrepresented in individuals
CC       affected by nocturnal asthma as compared to controls, and appears to be
CC       an important genetic factor in the expression of this asthmatic
CC       phenotype.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       Adrenergic receptor subfamily. ADRB2 sub-subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD96745.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/adrb2/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X04827; CAA28511.1; -; mRNA.
DR   EMBL; Y00106; CAA68289.1; -; Genomic_DNA.
DR   EMBL; M15169; AAA88015.1; -; mRNA.
DR   EMBL; J02960; AAA88017.1; -; Genomic_DNA.
DR   EMBL; AF022953; AAB82148.1; -; Genomic_DNA.
DR   EMBL; AF022954; AAB82149.1; -; Genomic_DNA.
DR   EMBL; AF022955; AAB82150.1; -; Genomic_DNA.
DR   EMBL; AF022956; AAB82151.1; -; Genomic_DNA.
DR   EMBL; AF169225; AAD48036.1; -; Genomic_DNA.
DR   EMBL; AF202305; AAF17569.1; -; Genomic_DNA.
DR   EMBL; AF203386; AAF20199.1; -; Genomic_DNA.
DR   EMBL; AY136741; AAN01267.1; -; mRNA.
DR   EMBL; AK313151; BAG35969.1; -; mRNA.
DR   EMBL; AK223025; BAD96745.1; ALT_INIT; mRNA.
DR   EMBL; DQ094845; AAY88739.1; -; Genomic_DNA.
DR   EMBL; EU332834; ABY87523.1; -; Genomic_DNA.
DR   EMBL; CH471062; EAW61798.1; -; Genomic_DNA.
DR   EMBL; BC012481; AAH12481.3; -; mRNA.
DR   EMBL; BC063486; AAH63486.2; -; mRNA.
DR   EMBL; BC073856; AAH73856.1; -; mRNA.
DR   CCDS; CCDS4292.1; -.
DR   PIR; A27525; QRHUB2.
DR   RefSeq; NP_000015.1; NM_000024.5.
DR   PDB; 1GQ4; X-ray; 1.90 A; A=409-413.
DR   PDB; 2R4R; X-ray; 3.40 A; A=1-365.
DR   PDB; 2R4S; X-ray; 3.40 A; A=24-365.
DR   PDB; 2RH1; X-ray; 2.40 A; A=1-230, A=263-365.
DR   PDB; 3D4S; X-ray; 2.80 A; A=1-230, A=263-348.
DR   PDB; 3KJ6; X-ray; 3.40 A; A=2-365.
DR   PDB; 3NY8; X-ray; 2.84 A; A=1-230, A=263-348.
DR   PDB; 3NY9; X-ray; 2.84 A; A=1-230, A=263-348.
DR   PDB; 3NYA; X-ray; 3.16 A; A=1-230, A=263-348.
DR   PDB; 3P0G; X-ray; 3.50 A; A=1-230, A=263-365.
DR   PDB; 3PDS; X-ray; 3.50 A; A=25-230, A=264-348.
DR   PDB; 3SN6; X-ray; 3.20 A; R=29-365.
DR   PDB; 4GBR; X-ray; 3.99 A; A=29-365.
DR   PDB; 4LDE; X-ray; 2.79 A; A=29-348.
DR   PDB; 4LDL; X-ray; 3.10 A; A=29-348.
DR   PDB; 4LDO; X-ray; 3.20 A; A=29-348.
DR   PDB; 4QKX; X-ray; 3.30 A; A=29-348.
DR   PDB; 5D5A; X-ray; 2.48 A; A=1-230, A=263-365.
DR   PDB; 5D5B; X-ray; 3.80 A; A=1-230, A=263-365.
DR   PDB; 5D6L; X-ray; 3.20 A; A=1-223, A=264-365.
DR   PDB; 5JQH; X-ray; 3.20 A; A/B=30-348.
DR   PDB; 5X7D; X-ray; 2.70 A; A=1-230, A=264-365.
DR   PDB; 6E67; X-ray; 3.70 A; A/B=1-232, A/B=268-365.
DR   PDB; 6KR8; NMR; -; A=25-350.
DR   PDB; 6MXT; X-ray; 2.96 A; A=29-365.
DR   PDB; 6N48; X-ray; 3.20 A; A=29-348.
DR   PDB; 6NI3; EM; 3.80 A; R=29-341.
DR   PDB; 6OBA; X-ray; 3.10 A; A=1-230, A=264-365.
DR   PDB; 6PRZ; X-ray; 2.80 A; A=1-230, A=264-348.
DR   PDB; 6PS0; X-ray; 3.40 A; A=1-230, A=264-348.
DR   PDB; 6PS1; X-ray; 3.20 A; A=1-230, A=264-348.
DR   PDB; 6PS2; X-ray; 2.40 A; A=1-230, A=264-348.
DR   PDB; 6PS3; X-ray; 2.50 A; A=1-230, A=264-348.
DR   PDB; 6PS4; X-ray; 2.60 A; A=1-230, A=264-348.
DR   PDB; 6PS5; X-ray; 2.90 A; A=1-230, A=264-348.
DR   PDB; 6PS6; X-ray; 2.70 A; A=1-230, A=264-348.
DR   PDBsum; 1GQ4; -.
DR   PDBsum; 2R4R; -.
DR   PDBsum; 2R4S; -.
DR   PDBsum; 2RH1; -.
DR   PDBsum; 3D4S; -.
DR   PDBsum; 3KJ6; -.
DR   PDBsum; 3NY8; -.
DR   PDBsum; 3NY9; -.
DR   PDBsum; 3NYA; -.
DR   PDBsum; 3P0G; -.
DR   PDBsum; 3PDS; -.
DR   PDBsum; 3SN6; -.
DR   PDBsum; 4GBR; -.
DR   PDBsum; 4LDE; -.
DR   PDBsum; 4LDL; -.
DR   PDBsum; 4LDO; -.
DR   PDBsum; 4QKX; -.
DR   PDBsum; 5D5A; -.
DR   PDBsum; 5D5B; -.
DR   PDBsum; 5D6L; -.
DR   PDBsum; 5JQH; -.
DR   PDBsum; 5X7D; -.
DR   PDBsum; 6E67; -.
DR   PDBsum; 6KR8; -.
DR   PDBsum; 6MXT; -.
DR   PDBsum; 6N48; -.
DR   PDBsum; 6NI3; -.
DR   PDBsum; 6OBA; -.
DR   PDBsum; 6PRZ; -.
DR   PDBsum; 6PS0; -.
DR   PDBsum; 6PS1; -.
DR   PDBsum; 6PS2; -.
DR   PDBsum; 6PS3; -.
DR   PDBsum; 6PS4; -.
DR   PDBsum; 6PS5; -.
DR   PDBsum; 6PS6; -.
DR   SMR; P07550; -.
DR   BioGRID; 106663; 251.
DR   CORUM; P07550; -.
DR   DIP; DIP-33948N; -.
DR   ELM; P07550; -.
DR   IntAct; P07550; 92.
DR   MINT; P07550; -.
DR   STRING; 9606.ENSP00000305372; -.
DR   BindingDB; P07550; -.
DR   ChEMBL; CHEMBL210; -.
DR   DrugBank; DB07543; (S)-carazolol.
DR   DrugBank; DB01193; Acebutolol.
DR   DrugBank; DB00866; Alprenolol.
DR   DrugBank; DB01118; Amiodarone.
DR   DrugBank; DB00182; Amphetamine.
DR   DrugBank; DB01102; Arbutamine.
DR   DrugBank; DB01274; Arformoterol.
DR   DrugBank; DB01238; Aripiprazole.
DR   DrugBank; DB09204; Arotinolol.
DR   DrugBank; DB06216; Asenapine.
DR   DrugBank; DB00335; Atenolol.
DR   DrugBank; DB01408; Bambuterol.
DR   DrugBank; DB05590; Bedoradrine.
DR   DrugBank; DB09013; Befunolol.
DR   DrugBank; DB00195; Betaxolol.
DR   DrugBank; DB00217; Bethanidine.
DR   DrugBank; DB01295; Bevantolol.
DR   DrugBank; DB00612; Bisoprolol.
DR   DrugBank; DB00901; Bitolterol.
DR   DrugBank; DB08807; Bopindolol.
DR   DrugBank; DB06726; Bufuralol.
DR   DrugBank; DB08808; Bupranolol.
DR   DrugBank; DB00248; Cabergoline.
DR   DrugBank; DB00521; Carteolol.
DR   DrugBank; DB01136; Carvedilol.
DR   DrugBank; DB04846; Celiprolol.
DR   DrugBank; DB01407; Clenbuterol.
DR   DrugBank; DB01151; Desipramine.
DR   DrugBank; DB11273; Dihydroergocornine.
DR   DrugBank; DB13345; Dihydroergocristine.
DR   DrugBank; DB00449; Dipivefrin.
DR   DrugBank; DB11278; DL-Methylephedrine.
DR   DrugBank; DB00841; Dobutamine.
DR   DrugBank; DB09273; Doxofylline.
DR   DrugBank; DB06262; Droxidopa.
DR   DrugBank; DB01363; Ephedra sinica root.
DR   DrugBank; DB00668; Epinephrine.
DR   DrugBank; DB01049; Ergoloid mesylate.
DR   DrugBank; DB11587; Etafedrine.
DR   DrugBank; DB01288; Fenoterol.
DR   DrugBank; DB00983; Formoterol.
DR   DrugBank; DB05039; Indacaterol.
DR   DrugBank; DB00221; Isoetharine.
DR   DrugBank; DB01064; Isoprenaline.
DR   DrugBank; DB00598; Labetalol.
DR   DrugBank; DB01210; Levobunolol.
DR   DrugBank; DB13139; Levosalbutamol.
DR   DrugBank; DB01365; Mephentermine.
DR   DrugBank; DB01214; Metipranolol.
DR   DrugBank; DB00264; Metoprolol.
DR   DrugBank; DB01203; Nadolol.
DR   DrugBank; DB05849; NCX 950.
DR   DrugBank; DB04861; Nebivolol.
DR   DrugBank; DB00368; Norepinephrine.
DR   DrugBank; DB00540; Nortriptyline.
DR   DrugBank; DB00334; Olanzapine.
DR   DrugBank; DB09080; Olodaterol.
DR   DrugBank; DB00816; Orciprenaline.
DR   DrugBank; DB01580; Oxprenolol.
DR   DrugBank; DB00715; Paroxetine.
DR   DrugBank; DB01359; Penbutolol.
DR   DrugBank; DB00925; Phenoxybenzamine.
DR   DrugBank; DB00397; Phenylpropanolamine.
DR   DrugBank; DB00960; Pindolol.
DR   DrugBank; DB01291; Pirbuterol.
DR   DrugBank; DB01366; Procaterol.
DR   DrugBank; DB01182; Propafenone.
DR   DrugBank; DB00571; Propranolol.
DR   DrugBank; DB06814; Protokylol.
DR   DrugBank; DB00852; Pseudoephedrine.
DR   DrugBank; DB01917; Putrescine.
DR   DrugBank; DB11124; Racepinephrine.
DR   DrugBank; DB00867; Ritodrine.
DR   DrugBank; DB01001; Salbutamol.
DR   DrugBank; DB00938; Salmeterol.
DR   DrugBank; DB00489; Sotalol.
DR   DrugBank; DB03566; Spermidine.
DR   DrugBank; DB00127; Spermine.
DR   DrugBank; DB00871; Terbutaline.
DR   DrugBank; DB00373; Timolol.
DR   DrugBank; DB00726; Trimipramine.
DR   DrugBank; DB12248; Tulobuterol.
DR   DrugBank; DB09082; Vilanterol.
DR   DrugCentral; P07550; -.
DR   GuidetoPHARMACOLOGY; 29; -.
DR   MoonDB; P07550; Predicted.
DR   TCDB; 9.A.14.3.5; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; P07550; 2 sites.
DR   iPTMnet; P07550; -.
DR   PhosphoSitePlus; P07550; -.
DR   SwissPalm; P07550; -.
DR   BioMuta; ADRB2; -.
DR   DMDM; 296439450; -.
DR   EPD; P07550; -.
DR   jPOST; P07550; -.
DR   MassIVE; P07550; -.
DR   PaxDb; P07550; -.
DR   PeptideAtlas; P07550; -.
DR   PRIDE; P07550; -.
DR   ProteomicsDB; 52013; -.
DR   ABCD; P07550; 18 sequenced antibodies.
DR   Antibodypedia; 15959; 1068 antibodies.
DR   DNASU; 154; -.
DR   Ensembl; ENST00000305988; ENSP00000305372; ENSG00000169252.
DR   GeneID; 154; -.
DR   KEGG; hsa:154; -.
DR   CTD; 154; -.
DR   DisGeNET; 154; -.
DR   EuPathDB; HostDB:ENSG00000169252.5; -.
DR   GeneCards; ADRB2; -.
DR   HGNC; HGNC:286; ADRB2.
DR   HPA; ENSG00000169252; Tissue enhanced (blood).
DR   MalaCards; ADRB2; -.
DR   MIM; 109690; gene+phenotype.
DR   neXtProt; NX_P07550; -.
DR   OpenTargets; ENSG00000169252; -.
DR   PharmGKB; PA39; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00940000159538; -.
DR   HOGENOM; CLU_009579_11_0_1; -.
DR   InParanoid; P07550; -.
DR   KO; K04142; -.
DR   OMA; CLREHKA; -.
DR   OrthoDB; 614199at2759; -.
DR   PhylomeDB; P07550; -.
DR   TreeFam; TF316350; -.
DR   PathwayCommons; P07550; -.
DR   Reactome; R-HSA-390696; Adrenoceptors.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-8856825; Cargo recognition for clathrin-mediated endocytosis.
DR   Reactome; R-HSA-8856828; Clathrin-mediated endocytosis.
DR   Reactome; R-HSA-9660821; ADORA2B mediated anti-inflammatory cytokines production.
DR   SignaLink; P07550; -.
DR   SIGNOR; P07550; -.
DR   BioGRID-ORCS; 154; 2 hits in 874 CRISPR screens.
DR   ChiTaRS; ADRB2; human.
DR   EvolutionaryTrace; P07550; -.
DR   GeneWiki; Beta-2_adrenergic_receptor; -.
DR   GenomeRNAi; 154; -.
DR   Pharos; P07550; Tclin.
DR   PRO; PR:P07550; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; P07550; protein.
DR   Bgee; ENSG00000169252; Expressed in squamous epithelium and 197 other tissues.
DR   ExpressionAtlas; P07550; baseline and differential.
DR   Genevisible; P07550; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0030665; C:clathrin-coated vesicle membrane; TAS:Reactome.
DR   GO; GO:0005769; C:early endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005768; C:endosome; TAS:ProtInc.
DR   GO; GO:0010008; C:endosome membrane; TAS:Reactome.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005764; C:lysosome; TAS:ProtInc.
DR   GO; GO:0016020; C:membrane; NAS:ARUK-UCL.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:MGI.
DR   GO; GO:0043235; C:receptor complex; IDA:HGNC-UCL.
DR   GO; GO:0008179; F:adenylate cyclase binding; IEA:Ensembl.
DR   GO; GO:0001540; F:amyloid-beta binding; IDA:ARUK-UCL.
DR   GO; GO:0004941; F:beta2-adrenergic receptor activity; IDA:HGNC-UCL.
DR   GO; GO:0051379; F:epinephrine binding; IBA:GO_Central.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0051380; F:norepinephrine binding; IDA:HGNC-UCL.
DR   GO; GO:0015459; F:potassium channel regulator activity; IDA:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:HGNC-UCL.
DR   GO; GO:0044877; F:protein-containing complex binding; IPI:ARUK-UCL.
DR   GO; GO:0007190; P:activation of adenylate cyclase activity; IDA:HGNC-UCL.
DR   GO; GO:0007171; P:activation of transmembrane receptor protein tyrosine kinase activity; TAS:ProtInc.
DR   GO; GO:0071880; P:adenylate cyclase-activating adrenergic receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007188; P:adenylate cyclase-modulating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0071875; P:adrenergic receptor signaling pathway; IDA:CAFA.
DR   GO; GO:0045453; P:bone resorption; IEA:Ensembl.
DR   GO; GO:0050873; P:brown fat cell differentiation; IEA:Ensembl.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:1904646; P:cellular response to amyloid-beta; IGI:ARUK-UCL.
DR   GO; GO:0002032; P:desensitization of G protein-coupled receptor signaling pathway by arrestin; IDA:HGNC-UCL.
DR   GO; GO:0002024; P:diet induced thermogenesis; IEA:Ensembl.
DR   GO; GO:0008333; P:endosome to lysosome transport; TAS:ProtInc.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0031649; P:heat generation; IEA:Ensembl.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0040015; P:negative regulation of multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0045986; P:negative regulation of smooth muscle contraction; IBA:GO_Central.
DR   GO; GO:0002025; P:norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure; IBA:GO_Central.
DR   GO; GO:2000969; P:positive regulation of AMPA receptor activity; IGI:ARUK-UCL.
DR   GO; GO:1901098; P:positive regulation of autophagosome maturation; IDA:GO_Central.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; IEA:Ensembl.
DR   GO; GO:2000481; P:positive regulation of cAMP-dependent protein kinase activity; TAS:ARUK-UCL.
DR   GO; GO:0120162; P:positive regulation of cold-induced thermogenesis; ISS:YuBioLab.
DR   GO; GO:1904504; P:positive regulation of lipophagy; IDA:GO_Central.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:HGNC-UCL.
DR   GO; GO:0061885; P:positive regulation of mini excitatory postsynaptic potential; IEA:Ensembl.
DR   GO; GO:0010739; P:positive regulation of protein kinase A signaling; IGI:ARUK-UCL.
DR   GO; GO:0071902; P:positive regulation of protein serine/threonine kinase activity; IGI:ARUK-UCL.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; IMP:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0016579; P:protein deubiquitination; TAS:Reactome.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; IDA:HGNC-UCL.
DR   GO; GO:0002028; P:regulation of sodium ion transport; IEA:Ensembl.
DR   GO; GO:0009409; P:response to cold; IEA:Ensembl.
DR   GO; GO:1990911; P:response to psychosocial stress; TAS:ARUK-UCL.
DR   InterPro; IPR002233; ADR_fam.
DR   InterPro; IPR000332; ADRB2_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   PANTHER; PTHR24248:SF21; PTHR24248:SF21; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01103; ADRENERGICR.
DR   PRINTS; PR00562; ADRENRGCB2AR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; Endosome;
KW   G-protein coupled receptor; Glycoprotein; Golgi apparatus; Hydroxylation;
KW   Lipoprotein; Membrane; Palmitate; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Transducer; Transmembrane; Transmembrane helix;
KW   Ubl conjugation.
FT   CHAIN           1..413
FT                   /note="Beta-2 adrenergic receptor"
FT                   /id="PRO_0000069130"
FT   TOPO_DOM        1..34
FT                   /note="Extracellular"
FT   TRANSMEM        35..58
FT                   /note="Helical; Name=1"
FT   TOPO_DOM        59..71
FT                   /note="Cytoplasmic"
FT   TRANSMEM        72..95
FT                   /note="Helical; Name=2"
FT   TOPO_DOM        96..106
FT                   /note="Extracellular"
FT   TRANSMEM        107..129
FT                   /note="Helical; Name=3"
FT   TOPO_DOM        130..150
FT                   /note="Cytoplasmic"
FT   TRANSMEM        151..174
FT                   /note="Helical; Name=4"
FT   TOPO_DOM        175..196
FT                   /note="Extracellular"
FT   TRANSMEM        197..220
FT                   /note="Helical; Name=5"
FT   TOPO_DOM        221..274
FT                   /note="Cytoplasmic"
FT   TRANSMEM        275..298
FT                   /note="Helical; Name=6"
FT   TOPO_DOM        299..305
FT                   /note="Extracellular"
FT   TRANSMEM        306..329
FT                   /note="Helical; Name=7"
FT   TOPO_DOM        330..413
FT                   /note="Cytoplasmic"
FT   REGION          193..207
FT                   /note="Agonist and antagonist binding"
FT   REGION          286..293
FT                   /note="Agonist and antagonist binding"
FT   REGION          312..316
FT                   /note="Agonist and antagonist binding"
FT   MOTIF           410..413
FT                   /note="PDZ-binding"
FT   BINDING         113
FT                   /note="Agonist or antagonist"
FT   BINDING         118
FT                   /note="Agonist or antagonist"
FT   MOD_RES         141
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000269|PubMed:8521811"
FT   MOD_RES         246
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:17525332"
FT   MOD_RES         261
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         262
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         345
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:11146000"
FT   MOD_RES         346
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000269|PubMed:11146000"
FT   MOD_RES         355
FT                   /note="Phosphoserine; by BARK"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         356
FT                   /note="Phosphoserine; by BARK"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         382
FT                   /note="4-hydroxyproline"
FT                   /evidence="ECO:0000269|PubMed:19584355"
FT   MOD_RES         395
FT                   /note="4-hydroxyproline"
FT                   /evidence="ECO:0000269|PubMed:19584355"
FT   LIPID           265
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:27481942"
FT   LIPID           341
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:17962520,
FT                   ECO:0000269|PubMed:18547522, ECO:0000269|PubMed:2540197,
FT                   ECO:0000269|PubMed:27481942"
FT   CARBOHYD        6
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000305"
FT   CARBOHYD        15
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000305"
FT   DISULFID        106..191
FT   DISULFID        184..190
FT   VARIANT         15
FT                   /note="N -> S (in dbSNP:rs33973603)"
FT                   /id="VAR_049373"
FT   VARIANT         16
FT                   /note="G -> R (common polymorphism; dbSNP:rs1042713)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:3025863, ECO:0000269|PubMed:3033609,
FT                   ECO:0000269|PubMed:3034889, ECO:0000269|PubMed:7706471,
FT                   ECO:0000269|PubMed:7915137, ECO:0000269|PubMed:8383511,
FT                   ECO:0000269|Ref.8"
FT                   /id="VAR_003452"
FT   VARIANT         27
FT                   /note="E -> Q (in dbSNP:rs1042714)"
FT                   /evidence="ECO:0000269|PubMed:11246467,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:2823249,
FT                   ECO:0000269|PubMed:3025863, ECO:0000269|PubMed:3026848,
FT                   ECO:0000269|PubMed:3033609, ECO:0000269|PubMed:3034889,
FT                   ECO:0000269|PubMed:7915137, ECO:0000269|PubMed:8383511,
FT                   ECO:0000269|Ref.10, ECO:0000269|Ref.11, ECO:0000269|Ref.12,
FT                   ECO:0000269|Ref.8"
FT                   /id="VAR_003453"
FT   VARIANT         34
FT                   /note="V -> M (in dbSNP:rs990810566)"
FT                   /evidence="ECO:0000269|PubMed:8383511"
FT                   /id="VAR_003454"
FT   VARIANT         159
FT                   /note="I -> F"
FT                   /evidence="ECO:0000269|PubMed:11246467"
FT                   /id="VAR_009125"
FT   VARIANT         159
FT                   /note="I -> L"
FT                   /evidence="ECO:0000269|PubMed:11246467"
FT                   /id="VAR_009124"
FT   VARIANT         164
FT                   /note="T -> I (in dbSNP:rs1800888)"
FT                   /evidence="ECO:0000269|PubMed:8383511"
FT                   /id="VAR_003455"
FT   VARIANT         220
FT                   /note="S -> C (in dbSNP:rs3729943)"
FT                   /evidence="ECO:0000269|Ref.11"
FT                   /id="VAR_025101"
FT   VARIANT         375
FT                   /note="K -> R (in dbSNP:rs771585355)"
FT                   /evidence="ECO:0000269|PubMed:11246467"
FT                   /id="VAR_009394"
FT   MUTAGEN         79
FT                   /note="D->N: Affects binding of catecholamines, and
FT                   produces an uncoupling between the receptor and stimulatory
FT                   G proteins."
FT                   /evidence="ECO:0000269|PubMed:2831218"
FT   MUTAGEN         141
FT                   /note="Y->F: Abolishes insulin-induced tyrosine
FT                   phosphorylation and insulin-induced receptor
FT                   supersensitization."
FT                   /evidence="ECO:0000269|PubMed:8521811"
FT   MUTAGEN         265
FT                   /note="C->A: Loss of ligand-induced palmitoylation."
FT                   /evidence="ECO:0000269|PubMed:27481942"
FT   MUTAGEN         341
FT                   /note="C->A: Loss of basal palmitoylation."
FT                   /evidence="ECO:0000269|PubMed:27481942"
FT   MUTAGEN         341
FT                   /note="C->G: Uncoupled receptor."
FT                   /evidence="ECO:0000269|PubMed:2540197"
FT   MUTAGEN         345..346
FT                   /note="SS->AA: Delayed agonist-promoted desensitization."
FT                   /evidence="ECO:0000269|PubMed:11146000"
FT   MUTAGEN         350
FT                   /note="Y->A: Does not affect insulin-induced tyrosine
FT                   phosphorylation or insulin-induced receptor
FT                   supersensitization."
FT                   /evidence="ECO:0000269|PubMed:8521811"
FT   MUTAGEN         354
FT                   /note="Y->A: Does not affect insulin-induced tyrosine
FT                   phosphorylation or insulin-induced receptor
FT                   supersensitization."
FT                   /evidence="ECO:0000269|PubMed:8521811"
FT   MUTAGEN         366
FT                   /note="Y->F: Does not affect insulin-induced tyrosine
FT                   phosphorylation or insulin-induced receptor
FT                   supersensitization."
FT                   /evidence="ECO:0000269|PubMed:8521811"
FT   CONFLICT        71
FT                   /note="F -> L (in Ref. 9; BAG35969)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        216
FT                   /note="V -> A (in Ref. 8; AAN01267)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        261
FT                   /note="S -> P (in Ref. 10; BAD96745)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        402
FT                   /note="Q -> P (in Ref. 14; AAH12481)"
FT                   /evidence="ECO:0000305"
FT   STRAND          25..27
FT                   /evidence="ECO:0000244|PDB:3P0G"
FT   HELIX           31..60
FT                   /evidence="ECO:0000244|PDB:2RH1"
FT   HELIX           62..64
FT                   /evidence="ECO:0000244|PDB:2RH1"
FT   HELIX           67..85
FT                   /evidence="ECO:0000244|PDB:2RH1"
FT   HELIX           87..96
FT                   /evidence="ECO:0000244|PDB:2RH1"
FT   HELIX           102..136
FT                   /evidence="ECO:0000244|PDB:2RH1"
FT   STRAND          137..139
FT                   /evidence="ECO:0000244|PDB:2RH1"
FT   STRAND          140..142
FT                   /evidence="ECO:0000244|PDB:6PS2"
FT   HELIX           147..170
FT                   /evidence="ECO:0000244|PDB:2RH1"
FT   TURN            171..174
FT                   /evidence="ECO:0000244|PDB:2RH1"
FT   HELIX           179..186
FT                   /evidence="ECO:0000244|PDB:2RH1"
FT   STRAND          187..189
FT                   /evidence="ECO:0000244|PDB:3SN6"
FT   HELIX           197..207
FT                   /evidence="ECO:0000244|PDB:2RH1"
FT   HELIX           209..229
FT                   /evidence="ECO:0000244|PDB:2RH1"
FT   TURN            235..239
FT                   /evidence="ECO:0000244|PDB:2R4R"
FT   HELIX           267..298
FT                   /evidence="ECO:0000244|PDB:2RH1"
FT   STRAND          299..303
FT                   /evidence="ECO:0000244|PDB:6PS4"
FT   HELIX           305..317
FT                   /evidence="ECO:0000244|PDB:2RH1"
FT   HELIX           318..320
FT                   /evidence="ECO:0000244|PDB:2RH1"
FT   HELIX           322..325
FT                   /evidence="ECO:0000244|PDB:2RH1"
FT   HELIX           326..328
FT                   /evidence="ECO:0000244|PDB:2RH1"
FT   HELIX           330..339
FT                   /evidence="ECO:0000244|PDB:2RH1"
FT   TURN            340..342
FT                   /evidence="ECO:0000244|PDB:5JQH"
FT   TURN            345..347
FT                   /evidence="ECO:0000244|PDB:2R4R"
SQ   SEQUENCE   413 AA;  46459 MW;  408C22731C6EDFBE CRC64;
     MGQPGNGSAF LLAPNGSHAP DHDVTQERDE VWVVGMGIVM SLIVLAIVFG NVLVITAIAK
     FERLQTVTNY FITSLACADL VMGLAVVPFG AAHILMKMWT FGNFWCEFWT SIDVLCVTAS
     IETLCVIAVD RYFAITSPFK YQSLLTKNKA RVIILMVWIV SGLTSFLPIQ MHWYRATHQE
     AINCYANETC CDFFTNQAYA IASSIVSFYV PLVIMVFVYS RVFQEAKRQL QKIDKSEGRF
     HVQNLSQVEQ DGRTGHGLRR SSKFCLKEHK ALKTLGIIMG TFTLCWLPFF IVNIVHVIQD
     NLIRKEVYIL LNWIGYVNSG FNPLIYCRSP DFRIAFQELL CLRRSSLKAY GNGYSSNGNT
     GEQSGYHVEQ EKENKLLCED LPGTEDFVGH QGTVPSDNID SQGRNCSTND SLL
//
ID   AGRE2_HUMAN             Reviewed;         823 AA.
AC   Q9UHX3; B4DQ96; E7ESD7; E9PBR1; E9PEL6; E9PFQ5; E9PG91; Q8NG96; Q9Y4B1;
DT   01-MAR-2004, integrated into UniProtKB/Swiss-Prot.
DT   13-JUN-2006, sequence version 2.
DT   07-OCT-2020, entry version 189.
DE   RecName: Full=Adhesion G protein-coupled receptor E2 {ECO:0000303|PubMed:25713288};
DE   AltName: Full=EGF-like module receptor 2;
DE   AltName: Full=EGF-like module-containing mucin-like hormone receptor-like 2;
DE   AltName: CD_antigen=CD312;
DE   Flags: Precursor;
GN   Name=ADGRE2 {ECO:0000312|HGNC:HGNC:3337}; Synonyms=EMR2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, ALTERNATIVE
RP   SPLICING (ISOFORMS 2; 3; 4 AND 5), AND VARIANT PHE-614.
RX   PubMed=10903844; DOI=10.1006/geno.2000.6238;
RA   Lin H.-H., Stacey M., Hamann J., Gordon S., McKnight A.J.;
RT   "Human EMR2, a novel EGF-TM7 molecule on chromosome 19p13.1, is closely
RT   related to CD97.";
RL   Genomics 67:188-200(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Suwa M., Sato T., Okouchi I., Arita M., Futami K., Matsumoto S.,
RA   Tsutsumi S., Aburatani H., Asai K., Akiyama Y.;
RT   "Genome-wide discovery and analysis of human seven transmembrane helix
RT   receptor genes.";
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 6), AND VARIANT PHE-614.
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT PHE-614.
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [5]
RP   PROTEIN SEQUENCE OF 518-527, PROTEOLYTIC PROCESSING, AND MUTAGENESIS OF
RP   SER-518.
RX   PubMed=12860403; DOI=10.1016/s0014-5793(03)00695-1;
RA   Chang G.-W., Stacey M., Kwakkenbos M.J., Hamann J., Gordon S., Lin H.-H.;
RT   "Proteolytic cleavage of the EMR2 receptor requires both the extracellular
RT   stalk and the GPS motif.";
RL   FEBS Lett. 547:145-150(2003).
RN   [6]
RP   CHARACTERIZATION, AND TISSUE SPECIFICITY.
RX   PubMed=11994511;
RA   Kwakkenbos M.J., Chang G.-W., Lin H.-H., Pouwels W., de Jong E.C.,
RA   van Lier R.A.W., Gordon S., Hamann J.;
RT   "The human EGF-TM7 family member EMR2 is a heterodimeric receptor expressed
RT   on myeloid cells.";
RL   J. Leukoc. Biol. 71:854-862(2002).
RN   [7]
RP   FUNCTION, AND INTERACTION WITH CHONDROITIN SULFATE.
RX   PubMed=12829604; DOI=10.1182/blood-2002-11-3540;
RA   Stacey M., Chang G.-W., Davies J.Q., Kwakkenbos M.J., Sanderson R.D.,
RA   Hamann J., Gordon S., Lin H.-H.;
RT   "The epidermal growth factor-like domains of the human EMR2 receptor
RT   mediate cell attachment through chondroitin sulfate glycosaminoglycans.";
RL   Blood 102:2916-2924(2003).
RN   [8]
RP   AUTOPROTEOLYTIC CLEAVAGE, AND SUBUNIT.
RX   PubMed=15150276; DOI=10.1074/jbc.m402974200;
RA   Lin H.H., Chang G.W., Davies J.Q., Stacey M., Harris J., Gordon S.;
RT   "Autocatalytic cleavage of the EMR2 receptor occurs at a conserved G
RT   protein-coupled receptor proteolytic site motif.";
RL   J. Biol. Chem. 279:31823-31832(2004).
RN   [9]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=17928360; DOI=10.1096/fj.07-9435com;
RA   Yona S., Lin H.H., Dri P., Davies J.Q., Hayhoe R.P., Lewis S.M.,
RA   Heinsbroek S.E., Brown K.A., Perretti M., Hamann J., Treacher D.F.,
RA   Gordon S., Stacey M.;
RT   "Ligation of the adhesion-GPCR EMR2 regulates human neutrophil function.";
RL   FASEB J. 22:741-751(2008).
RN   [10]
RP   FUNCTION.
RX   PubMed=22575658; DOI=10.1016/j.febslet.2012.03.014;
RA   Gupte J., Swaminath G., Danao J., Tian H., Li Y., Wu X.;
RT   "Signaling property study of adhesion G-protein-coupled receptors.";
RL   FEBS Lett. 586:1214-1219(2012).
RN   [11]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=22310662; DOI=10.1128/mcb.06557-11;
RA   Huang Y.S., Chiang N.Y., Hu C.H., Hsiao C.C., Cheng K.F., Tsai W.P.,
RA   Yona S., Stacey M., Gordon S., Chang G.W., Lin H.H.;
RT   "Activation of myeloid cell-specific adhesion class G protein-coupled
RT   receptor EMR2 via ligation-induced translocation and interaction of
RT   receptor subunits in lipid raft microdomains.";
RL   Mol. Cell. Biol. 32:1408-1420(2012).
RN   [12]
RP   NOMENCLATURE.
RX   PubMed=25713288; DOI=10.1124/pr.114.009647;
RA   Hamann J., Aust G., Arac D., Engel F.B., Formstone C., Fredriksson R.,
RA   Hall R.A., Harty B.L., Kirchhoff C., Knapp B., Krishnan A., Liebscher I.,
RA   Lin H.H., Martinelli D.C., Monk K.R., Peeters M.C., Piao X., Promel S.,
RA   Schoneberg T., Schwartz T.W., Singer K., Stacey M., Ushkaryov Y.A.,
RA   Vallon M., Wolfrum U., Wright M.W., Xu L., Langenhan T., Schioth H.B.;
RT   "International union of basic and clinical pharmacology. XCIV. Adhesion G
RT   protein-coupled receptors.";
RL   Pharmacol. Rev. 67:338-367(2015).
RN   [13]
RP   INVOLVEMENT IN VBU, FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY,
RP   VARIANT VBU TYR-492, AND CHARACTERIZATION OF VARIANT VBU TYR-492.
RX   PubMed=26841242; DOI=10.1056/nejmoa1500611;
RA   Boyden S.E., Desai A., Cruse G., Young M.L., Bolan H.C., Scott L.M.,
RA   Eisch A.R., Long R.D., Lee C.C., Satorius C.L., Pakstis A.J., Olivera A.,
RA   Mullikin J.C., Chouery E., Megarbane A., Medlej-Hashim M., Kidd K.K.,
RA   Kastner D.L., Metcalfe D.D., Komarow H.D.;
RT   "Vibratory urticaria associated with a missense variant in ADGRE2.";
RL   N. Engl. J. Med. 374:656-663(2016).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 25-260, INTERACTION WITH CD55,
RP   CALCIUM-BINDING, AND DISULFIDE BONDS.
RX   PubMed=17449467; DOI=10.1074/jbc.m702588200;
RA   Abbott R.J., Spendlove I., Roversi P., Fitzgibbon H., Knott V., Teriete P.,
RA   McDonnell J.M., Handford P.A., Lea S.M.;
RT   "Structural and functional characterization of a novel T cell receptor co-
RT   regulatory protein complex, CD97-CD55.";
RL   J. Biol. Chem. 282:22023-22032(2007).
CC   -!- FUNCTION: Cell surface receptor that binds to the chondroitin sulfate
CC       moiety of glycosaminoglycan chains and promotes cell attachment.
CC       Promotes granulocyte chemotaxis, degranulation and adhesion. In
CC       macrophages, promotes the release of inflammatory cytokines, including
CC       IL8 and TNF. Signals probably through G-proteins. Is a regulator of
CC       mast cell degranulation (PubMed:26841242).
CC       {ECO:0000269|PubMed:12829604, ECO:0000269|PubMed:17928360,
CC       ECO:0000269|PubMed:22310662, ECO:0000269|PubMed:22575658,
CC       ECO:0000269|PubMed:26841242}.
CC   -!- SUBUNIT: Forms a heterodimer, consisting of a large extracellular
CC       region non-covalently linked to a seven-transmembrane moiety. Interacts
CC       with chondroitin sulfate; the interaction with chondroitin sulfate is
CC       calcium-dependent. Interacts with CD55. {ECO:0000269|PubMed:12829604,
CC       ECO:0000269|PubMed:15150276, ECO:0000269|PubMed:17449467}.
CC   -!- INTERACTION:
CC       Q9UHX3; Q13520: AQP6; NbExp=3; IntAct=EBI-11277970, EBI-13059134;
CC       Q9UHX3; Q13323: BIK; NbExp=3; IntAct=EBI-11277970, EBI-700794;
CC       Q9UHX3; Q8WV48: CCDC107; NbExp=3; IntAct=EBI-11277970, EBI-947033;
CC       Q9UHX3; Q03591: CFHR1; NbExp=5; IntAct=EBI-11277970, EBI-3935840;
CC       Q9UHX3; Q96BA8: CREB3L1; NbExp=3; IntAct=EBI-11277970, EBI-6942903;
CC       Q9UHX3; Q9GZR5: ELOVL4; NbExp=3; IntAct=EBI-11277970, EBI-18535450;
CC       Q9UHX3; A1L3X0: ELOVL7; NbExp=3; IntAct=EBI-11277970, EBI-10285373;
CC       Q9UHX3; Q5JX71: FAM209A; NbExp=3; IntAct=EBI-11277970, EBI-18304435;
CC       Q9UHX3; Q7Z5P4: HSD17B13; NbExp=3; IntAct=EBI-11277970, EBI-18053395;
CC       Q9UHX3; P43628: KIR2DL3; NbExp=3; IntAct=EBI-11277970, EBI-8632435;
CC       Q9UHX3; O60337: MARCHF6; NbExp=3; IntAct=EBI-11277970, EBI-2684600;
CC       Q9UHX3; Q6N075: MFSD5; NbExp=3; IntAct=EBI-11277970, EBI-3920969;
CC       Q9UHX3; Q8N4V1: MMGT1; NbExp=3; IntAct=EBI-11277970, EBI-6163737;
CC       Q9UHX3; Q96E29: MTERF3; NbExp=3; IntAct=EBI-11277970, EBI-7825321;
CC       Q9UHX3; Q9NR31: SAR1A; NbExp=3; IntAct=EBI-11277970, EBI-3920694;
CC       Q9UHX3; Q8TBB6: SLC7A14; NbExp=3; IntAct=EBI-11277970, EBI-5235586;
CC       Q9UHX3; Q96MV1: TLCD4; NbExp=3; IntAct=EBI-11277970, EBI-12947623;
CC       Q9UHX3; Q96HE8: TMEM80; NbExp=3; IntAct=EBI-11277970, EBI-11742770;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:22310662,
CC       ECO:0000269|PubMed:26841242}; Multi-pass membrane protein. Cell
CC       projection, ruffle membrane {ECO:0000269|PubMed:17928360}; Multi-pass
CC       membrane protein. Note=Localized at the leading edge of migrating
CC       cells. {ECO:0000269|PubMed:17928360}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC         Comment=A number of isoforms are probably produced. A soluble form
CC         due to a frameshift which introduced a stop codon immediately before
CC         the first TM domain is also detected.;
CC       Name=1;
CC         IsoId=Q9UHX3-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9UHX3-2; Sequence=VSP_041367;
CC       Name=3;
CC         IsoId=Q9UHX3-3; Sequence=VSP_041366;
CC       Name=4;
CC         IsoId=Q9UHX3-4; Sequence=VSP_041365;
CC       Name=5;
CC         IsoId=Q9UHX3-5; Sequence=VSP_041364;
CC       Name=6;
CC         IsoId=Q9UHX3-6; Sequence=VSP_047535;
CC   -!- TISSUE SPECIFICITY: Expression is restricted to myeloid cells. Highest
CC       expression was found in peripheral blood leukocytes, followed by spleen
CC       and lymph nodes, with intermediate to low levels in thymus, bone
CC       marrow, fetal liver, placenta, and lung, and no expression in heart,
CC       brain, skeletal muscle, kidney, or pancreas. Expression is also
CC       detected in monocyte/macrophage and Jurkat cell lines but not in other
CC       cell lines tested. High expression in mast cells (PubMed:26841242).
CC       {ECO:0000269|PubMed:10903844, ECO:0000269|PubMed:11994511,
CC       ECO:0000269|PubMed:26841242}.
CC   -!- DOMAIN: The GPS domain is necessary, but not sufficient for receptor
CC       cleavage, which require the entire extracellular stalk.
CC       {ECO:0000269|PubMed:12860403}.
CC   -!- DOMAIN: Binding to chondroitin sulfate is mediated by the fourth EGF
CC       domain.
CC   -!- PTM: Autoproteolytically cleaved into 2 subunits, an extracellular
CC       alpha subunit and a seven-transmembrane beta subunit.
CC       {ECO:0000269|PubMed:12860403}.
CC   -!- DISEASE: Vibratory urticaria (VBU) [MIM:125630]: An autosomal dominant
CC       disorder characterized by localized hives and systemic manifestations
CC       in response to dermal vibration, with coincident degranulation of mast
CC       cells and increased histamine levels in serum.
CC       {ECO:0000269|PubMed:26841242}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Has no murine ortholog. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 2 family.
CC       Adhesion G-protein coupled receptor (ADGR) subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAC06146.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF114491; AAF21974.1; -; mRNA.
DR   EMBL; AB065931; BAC06146.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AK298700; BAG60858.1; -; mRNA.
DR   EMBL; AC004262; AAC05172.1; -; Genomic_DNA.
DR   EMBL; AC005327; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC090427; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS32935.1; -. [Q9UHX3-1]
DR   CCDS; CCDS59361.1; -. [Q9UHX3-6]
DR   RefSeq; NP_001257981.1; NM_001271052.1. [Q9UHX3-6]
DR   RefSeq; NP_038475.2; NM_013447.3. [Q9UHX3-1]
DR   PDB; 2BO2; X-ray; 2.60 A; A/B=25-260.
DR   PDB; 2BOU; X-ray; 1.90 A; A=25-118, A=212-260.
DR   PDB; 2BOX; X-ray; 2.50 A; A=25-260.
DR   PDBsum; 2BO2; -.
DR   PDBsum; 2BOU; -.
DR   PDBsum; 2BOX; -.
DR   SMR; Q9UHX3; -.
DR   BioGRID; 119041; 21.
DR   IntAct; Q9UHX3; 19.
DR   STRING; 9606.ENSP00000319883; -.
DR   MEROPS; P02.001; -.
DR   GlyConnect; 993; 2 N-Linked glycans (2 sites).
DR   GlyGen; Q9UHX3; 8 sites.
DR   iPTMnet; Q9UHX3; -.
DR   PhosphoSitePlus; Q9UHX3; -.
DR   BioMuta; ADGRE2; -.
DR   DMDM; 108935835; -.
DR   jPOST; Q9UHX3; -.
DR   MassIVE; Q9UHX3; -.
DR   PaxDb; Q9UHX3; -.
DR   PeptideAtlas; Q9UHX3; -.
DR   PRIDE; Q9UHX3; -.
DR   ProteomicsDB; 17966; -.
DR   ProteomicsDB; 84434; -. [Q9UHX3-1]
DR   ProteomicsDB; 84435; -. [Q9UHX3-2]
DR   ProteomicsDB; 84436; -. [Q9UHX3-3]
DR   ProteomicsDB; 84437; -. [Q9UHX3-4]
DR   ProteomicsDB; 84438; -. [Q9UHX3-5]
DR   Antibodypedia; 13808; 458 antibodies.
DR   Ensembl; ENST00000315576; ENSP00000319883; ENSG00000127507. [Q9UHX3-1]
DR   Ensembl; ENST00000392965; ENSP00000376692; ENSG00000127507. [Q9UHX3-6]
DR   Ensembl; ENST00000594076; ENSP00000472735; ENSG00000127507. [Q9UHX3-4]
DR   Ensembl; ENST00000594294; ENSP00000470725; ENSG00000127507. [Q9UHX3-3]
DR   Ensembl; ENST00000595839; ENSP00000469277; ENSG00000127507. [Q9UHX3-5]
DR   Ensembl; ENST00000596991; ENSP00000472280; ENSG00000127507. [Q9UHX3-2]
DR   GeneID; 30817; -.
DR   KEGG; hsa:30817; -.
DR   UCSC; uc002mzp.3; human. [Q9UHX3-1]
DR   CTD; 30817; -.
DR   DisGeNET; 30817; -.
DR   EuPathDB; HostDB:ENSG00000127507.17; -.
DR   GeneCards; ADGRE2; -.
DR   HGNC; HGNC:3337; ADGRE2.
DR   HPA; ENSG00000127507; Tissue enhanced (blood, lymphoid tissue).
DR   MalaCards; ADGRE2; -.
DR   MIM; 125630; phenotype.
DR   MIM; 606100; gene.
DR   neXtProt; NX_Q9UHX3; -.
DR   OpenTargets; ENSG00000127507; -.
DR   Orphanet; 493342; Vibratory urticaria.
DR   PharmGKB; PA27774; -.
DR   eggNOG; KOG4193; Eukaryota.
DR   GeneTree; ENSGT00940000162597; -.
DR   HOGENOM; CLU_002753_3_7_1; -.
DR   InParanoid; Q9UHX3; -.
DR   KO; K08443; -.
DR   OrthoDB; 210309at2759; -.
DR   PhylomeDB; Q9UHX3; -.
DR   TreeFam; TF316380; -.
DR   PathwayCommons; Q9UHX3; -.
DR   Reactome; R-HSA-373080; Class B/2 (Secretin family receptors).
DR   BioGRID-ORCS; 30817; 4 hits in 869 CRISPR screens.
DR   ChiTaRS; ADGRE2; human.
DR   EvolutionaryTrace; Q9UHX3; -.
DR   GeneWiki; EMR2; -.
DR   GenomeRNAi; 30817; -.
DR   Pharos; Q9UHX3; Tbio.
DR   PRO; PR:Q9UHX3; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; Q9UHX3; protein.
DR   Bgee; ENSG00000127507; Expressed in blood and 140 other tissues.
DR   ExpressionAtlas; Q9UHX3; baseline and differential.
DR   Genevisible; Q9UHX3; HS.
DR   GO; GO:0016021; C:integral component of membrane; TAS:GDB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0031256; C:leading edge membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0032587; C:ruffle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0035374; F:chondroitin sulfate binding; IMP:UniProtKB.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007155; P:cell adhesion; IMP:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IMP:UniProtKB.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IEA:InterPro.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:GDB.
DR   GO; GO:0071621; P:granulocyte chemotaxis; IMP:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0043304; P:regulation of mast cell degranulation; IMP:UniProtKB.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR017981; GPCR_2-like.
DR   InterPro; IPR003056; GPCR_2_ADGRE2_ADGRE5.
DR   InterPro; IPR000832; GPCR_2_secretin-like.
DR   InterPro; IPR017983; GPCR_2_secretin-like_CS.
DR   InterPro; IPR000203; GPS.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   Pfam; PF00002; 7tm_2; 1.
DR   Pfam; PF07645; EGF_CA; 4.
DR   Pfam; PF01825; GPS; 1.
DR   PRINTS; PR01278; CD97PROTEIN.
DR   PRINTS; PR00249; GPCRSECRETIN.
DR   SMART; SM00181; EGF; 5.
DR   SMART; SM00179; EGF_CA; 4.
DR   SMART; SM00303; GPS; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS00010; ASX_HYDROXYL; 4.
DR   PROSITE; PS50026; EGF_3; 4.
DR   PROSITE; PS01187; EGF_CA; 4.
DR   PROSITE; PS00650; G_PROTEIN_RECEP_F2_2; 1.
DR   PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1.
DR   PROSITE; PS50221; GPS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Autocatalytic cleavage; Calcium;
KW   Cell adhesion; Cell membrane; Cell projection; Direct protein sequencing;
KW   Disease mutation; Disulfide bond; EGF-like domain;
KW   G-protein coupled receptor; Glycoprotein; Inflammatory response; Membrane;
KW   Polymorphism; Receptor; Reference proteome; Repeat; Signal; Transducer;
KW   Transmembrane; Transmembrane helix.
FT   SIGNAL          1..23
FT                   /evidence="ECO:0000255"
FT   CHAIN           24..823
FT                   /note="Adhesion G protein-coupled receptor E2"
FT                   /id="PRO_0000012875"
FT   TOPO_DOM        24..540
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        541..561
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        562..569
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        570..590
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        591..605
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        606..626
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        627..644
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        645..665
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        666..683
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        684..704
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        705..735
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        736..756
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        757..760
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        761..781
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        782..823
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   DOMAIN          25..66
FT                   /note="EGF-like 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          67..118
FT                   /note="EGF-like 2; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          119..162
FT                   /note="EGF-like 3; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          163..211
FT                   /note="EGF-like 4; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          212..260
FT                   /note="EGF-like 5; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          479..529
FT                   /note="GPS"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00098"
FT   SITE            517..518
FT                   /note="Cleavage; by autolysis"
FT                   /evidence="ECO:0000269|PubMed:15150276"
FT   CARBOHYD        41
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        111
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        206
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        298
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        347
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        354
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        456
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        460
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        29..39
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076,
FT                   ECO:0000269|PubMed:17449467"
FT   DISULFID        33..45
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076,
FT                   ECO:0000269|PubMed:17449467"
FT   DISULFID        47..65
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076,
FT                   ECO:0000269|PubMed:17449467"
FT   DISULFID        71..85
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076,
FT                   ECO:0000269|PubMed:17449467"
FT   DISULFID        79..94
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076,
FT                   ECO:0000269|PubMed:17449467"
FT   DISULFID        96..117
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076,
FT                   ECO:0000269|PubMed:17449467"
FT   DISULFID        123..136
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076,
FT                   ECO:0000269|PubMed:17449467"
FT   DISULFID        130..145
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076,
FT                   ECO:0000269|PubMed:17449467"
FT   DISULFID        147..161
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        167..180
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        174..189
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        191..210
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        216..229
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        223..238
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        240..259
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   VAR_SEQ         119..260
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_041364"
FT   VAR_SEQ         119..211
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_041365"
FT   VAR_SEQ         163..211
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_041366"
FT   VAR_SEQ         397..407
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_041367"
FT   VAR_SEQ         473..530
FT                   /note="Missing (in isoform 6)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_047535"
FT   VARIANT         314
FT                   /note="A -> V (in dbSNP:rs35612307)"
FT                   /id="VAR_061229"
FT   VARIANT         492
FT                   /note="C -> Y (in VBU; affects the regulation of mast cells
FT                   degranulation; results in increased vibration-induced mast
FT                   cells degranulation; no effect on localization to plasma
FT                   membrane; dbSNP:rs199718602)"
FT                   /evidence="ECO:0000269|PubMed:26841242"
FT                   /id="VAR_078578"
FT   VARIANT         605
FT                   /note="T -> I (in dbSNP:rs4410209)"
FT                   /id="VAR_026719"
FT   VARIANT         614
FT                   /note="L -> F (in dbSNP:rs2524383)"
FT                   /evidence="ECO:0000269|PubMed:10903844,
FT                   ECO:0000269|PubMed:14702039, ECO:0000269|PubMed:15057824"
FT                   /id="VAR_026720"
FT   VARIANT         665
FT                   /note="S -> F (in dbSNP:rs3752187)"
FT                   /id="VAR_026721"
FT   VARIANT         720
FT                   /note="E -> D (in dbSNP:rs57865820)"
FT                   /id="VAR_061230"
FT   MUTAGEN         518
FT                   /note="S->A: Abolishes cleavage."
FT                   /evidence="ECO:0000269|PubMed:12860403"
FT   CONFLICT        531
FT                   /note="Missing (in Ref. 4; AAC05172)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        823
FT                   /note="N -> R (in Ref. 2; BAC06146)"
FT                   /evidence="ECO:0000305"
FT   STRAND          37..43
FT                   /evidence="ECO:0000244|PDB:2BOU"
FT   STRAND          45..47
FT                   /evidence="ECO:0000244|PDB:2BOU"
FT   STRAND          54..58
FT                   /evidence="ECO:0000244|PDB:2BOU"
FT   HELIX           70..72
FT                   /evidence="ECO:0000244|PDB:2BOU"
FT   STRAND          74..76
FT                   /evidence="ECO:0000244|PDB:2BO2"
FT   STRAND          83..87
FT                   /evidence="ECO:0000244|PDB:2BOU"
FT   STRAND          92..96
FT                   /evidence="ECO:0000244|PDB:2BOU"
FT   STRAND          100..102
FT                   /evidence="ECO:0000244|PDB:2BOU"
FT   STRAND          109..111
FT                   /evidence="ECO:0000244|PDB:2BOU"
FT   HELIX           112..114
FT                   /evidence="ECO:0000244|PDB:2BOU"
FT   STRAND          117..119
FT                   /evidence="ECO:0000244|PDB:2BOU"
FT   TURN            217..219
FT                   /evidence="ECO:0000244|PDB:2BOU"
FT   STRAND          227..231
FT                   /evidence="ECO:0000244|PDB:2BOU"
FT   STRAND          236..239
FT                   /evidence="ECO:0000244|PDB:2BOU"
FT   STRAND          242..244
FT                   /evidence="ECO:0000244|PDB:2BOU"
FT   STRAND          248..250
FT                   /evidence="ECO:0000244|PDB:2BO2"
FT   STRAND          252..254
FT                   /evidence="ECO:0000244|PDB:2BOU"
SQ   SEQUENCE   823 AA;  90472 MW;  4D38C30A07B46FF4 CRC64;
     MGGRVFLVFL AFCVWLTLPG AETQDSRGCA RWCPQDSSCV NATACRCNPG FSSFSEIITT
     PMETCDDINE CATLSKVSCG KFSDCWNTEG SYDCVCSPGY EPVSGAKTFK NESENTCQDV
     DECQQNPRLC KSYGTCVNTL GSYTCQCLPG FKLKPEDPKL CTDVNECTSG QNPCHSSTHC
     LNNVGSYQCR CRPGWQPIPG SPNGPNNTVC EDVDECSSGQ HQCDSSTVCF NTVGSYSCRC
     RPGWKPRHGI PNNQKDTVCE DMTFSTWTPP PGVHSQTLSR FFDKVQDLGR DYKPGLANNT
     IQSILQALDE LLEAPGDLET LPRLQQHCVA SHLLDGLEDV LRGLSKNLSN GLLNFSYPAG
     TELSLEVQKQ VDRSVTLRQN QAVMQLDWNQ AQKSGDPGPS VVGLVSIPGM GKLLAEAPLV
     LEPEKQMLLH ETHQGLLQDG SPILLSDVIS AFLSNNDTQN LSSPVTFTFS HRSVIPRQKV
     LCVFWEHGQN GCGHWATTGC STIGTRDTST ICRCTHLSSF AVLMAHYDVQ EEDPVLTVIT
     YMGLSVSLLC LLLAALTFLL CKAIQNTSTS LHLQLSLCLF LAHLLFLVAI DQTGHKVLCS
     IIAGTLHYLY LATLTWMLLE ALYLFLTARN LTVVNYSSIN RFMKKLMFPV GYGVPAVTVA
     ISAASRPHLY GTPSRCWLQP EKGFIWGFLG PVCAIFSVNL VLFLVTLWIL KNRLSSLNSE
     VSTLRNTRML AFKATAQLFI LGCTWCLGIL QVGPAARVMA YLFTIINSLQ GVFIFLVYCL
     LSQQVREQYG KWSKGIRKLK TESEMHTLSS SAKADTSKPS TVN
//
ID   NPY2R_HUMAN             Reviewed;         381 AA.
AC   P49146; Q13281; Q13457; Q4W5G7; Q6AZZ6; Q9UE67;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 1.
DT   07-OCT-2020, entry version 173.
DE   RecName: Full=Neuropeptide Y receptor type 2;
DE            Short=NPY2-R;
DE   AltName: Full=NPY-Y2 receptor;
DE            Short=Y2 receptor;
GN   Name=NPY2R;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Hippocampus;
RX   PubMed=7592910; DOI=10.1074/jbc.270.45.26758;
RA   Gerald C., Walker M.W., Vaysse P.J.-J., He C., Branchek T.A.,
RA   Weinshank R.L.;
RT   "Expression cloning and pharmacological characterization of a human
RT   hippocampal neuropeptide Y/peptide YY Y2 receptor subtype.";
RL   J. Biol. Chem. 270:26758-26761(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   PubMed=8632753;
RA   Gehlert D.R., Beavers L.S., Johnson D., Gackenheimer S.L., Schober D.A.,
RA   Gadski R.A.;
RT   "Expression cloning of a human brain neuropeptide Y Y2 receptor.";
RL   Mol. Pharmacol. 49:224-228(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7559383; DOI=10.1074/jbc.270.39.22661;
RA   Rose P.M., Fernandes P., Lynch J.S., Frazier S.T., Fisher S.M.,
RA   Kodukula K., Kienzle B., Seethala R.;
RT   "Cloning and functional expression of a cDNA encoding a human type 2
RT   neuropeptide Y receptor.";
RL   J. Biol. Chem. 270:22661-22664(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8643460; DOI=10.1073/pnas.93.10.4661;
RA   Yan H., Yang J., Marasco J., Yamaguchi K., Brenner S., Collins F.,
RA   Karbon W.;
RT   "Cloning and functional expression of cDNAs encoding human and rat
RT   pancreatic polypeptide receptors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:4661-4665(1996).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8975716; DOI=10.1006/geno.1996.0642;
RA   Ammar D.A., Eadie D.M., Wong D.J., Ma Y.-Y., Kolakowski L.F. Jr.,
RA   Yang-Feng T.L., Thompson D.A.;
RT   "Characterization of the human type 2 neuropeptide Y receptor gene (NPY2R)
RT   and localization to the chromosome 4q region containing the type 1
RT   neuropeptide Y receptor gene.";
RL   Genomics 38:392-398(1996).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Zastawny R.L.;
RT   "Human neuropeptide Y Y2 receptor gene.";
RL   Submitted (OCT-1996) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- FUNCTION: Receptor for neuropeptide Y and peptide YY. The rank order of
CC       affinity of this receptor for pancreatic polypeptides is PYY > NPY >
CC       PYY (3-36) > NPY (2-36) > [Ile-31, Gln-34] PP > [Leu-31, Pro-34] NPY >
CC       PP, [Pro-34] PYY and NPY free acid.
CC   -!- INTERACTION:
CC       P49146; P10082: PYY; NbExp=2; IntAct=EBI-6655721, EBI-6655667;
CC       P49146; A5PKU2: TUSC5; NbExp=3; IntAct=EBI-6655721, EBI-11988865;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: High levels in amygdala, corpus callosum,
CC       hippocampus and subthalamic nucleus. Also detectable in caudate
CC       nucleus, hypothalamus and substantia nigra.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U36269; AAC50281.1; -; mRNA.
DR   EMBL; U42766; AAB04120.1; -; mRNA.
DR   EMBL; U32500; AAA93170.1; -; mRNA.
DR   EMBL; U42389; AAB07760.1; -; mRNA.
DR   EMBL; U50146; AAC51115.1; -; Genomic_DNA.
DR   EMBL; U76254; AAD00248.1; -; Genomic_DNA.
DR   EMBL; AY236540; AAO92062.1; -; Genomic_DNA.
DR   EMBL; AC104407; AAY40940.1; -; Genomic_DNA.
DR   EMBL; CH471056; EAX04901.1; -; Genomic_DNA.
DR   EMBL; BC075053; AAH75053.2; -; mRNA.
DR   EMBL; BC075052; AAH75052.2; -; mRNA.
DR   CCDS; CCDS3791.1; -.
DR   PIR; I39187; I39187.
DR   RefSeq; NP_000901.1; NM_000910.3.
DR   RefSeq; XP_005263090.1; XM_005263033.4.
DR   RefSeq; XP_005263091.1; XM_005263034.4.
DR   PDB; 2IK3; Model; -; @=1-381.
DR   PDBsum; 2IK3; -.
DR   BMRB; P49146; -.
DR   BioGRID; 110947; 63.
DR   IntAct; P49146; 57.
DR   STRING; 9606.ENSP00000332591; -.
DR   BindingDB; P49146; -.
DR   ChEMBL; CHEMBL4018; -.
DR   DrugBank; DB00847; Cysteamine.
DR   DrugBank; DB05045; Obinepitide.
DR   DrugBank; DB05004; Peptide YY (3-36).
DR   DrugCentral; P49146; -.
DR   GuidetoPHARMACOLOGY; 306; -.
DR   GlyGen; P49146; 1 site.
DR   iPTMnet; P49146; -.
DR   PhosphoSitePlus; P49146; -.
DR   BioMuta; NPY2R; -.
DR   DMDM; 1352610; -.
DR   EPD; P49146; -.
DR   jPOST; P49146; -.
DR   PaxDb; P49146; -.
DR   PeptideAtlas; P49146; -.
DR   PRIDE; P49146; -.
DR   ProteomicsDB; 55966; -.
DR   Antibodypedia; 2964; 307 antibodies.
DR   Ensembl; ENST00000329476; ENSP00000332591; ENSG00000185149.
DR   Ensembl; ENST00000506608; ENSP00000426366; ENSG00000185149.
DR   GeneID; 4887; -.
DR   KEGG; hsa:4887; -.
DR   UCSC; uc003ioq.3; human.
DR   CTD; 4887; -.
DR   DisGeNET; 4887; -.
DR   EuPathDB; HostDB:ENSG00000185149.5; -.
DR   GeneCards; NPY2R; -.
DR   HGNC; HGNC:7957; NPY2R.
DR   HPA; ENSG00000185149; Tissue enhanced (brain, breast).
DR   MIM; 162642; gene.
DR   neXtProt; NX_P49146; -.
DR   OpenTargets; ENSG00000185149; -.
DR   PharmGKB; PA31741; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00940000155973; -.
DR   HOGENOM; CLU_009579_6_1_1; -.
DR   InParanoid; P49146; -.
DR   KO; K04205; -.
DR   OMA; AYTRIWT; -.
DR   OrthoDB; 746515at2759; -.
DR   PhylomeDB; P49146; -.
DR   TreeFam; TF315303; -.
DR   PathwayCommons; P49146; -.
DR   Reactome; R-HSA-375276; Peptide ligand-binding receptors.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   SIGNOR; P49146; -.
DR   BioGRID-ORCS; 4887; 2 hits in 871 CRISPR screens.
DR   ChiTaRS; NPY2R; human.
DR   GeneWiki; Neuropeptide_Y_receptor_Y2; -.
DR   GenomeRNAi; 4887; -.
DR   Pharos; P49146; Tchem.
DR   PRO; PR:P49146; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; P49146; protein.
DR   Bgee; ENSG00000185149; Expressed in Ammon's horn and 97 other tissues.
DR   Genevisible; P49146; HS.
DR   GO; GO:0005929; C:cilium; IDA:MGI.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0097730; C:non-motile cilium; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005246; F:calcium channel regulator activity; TAS:ProtInc.
DR   GO; GO:0004983; F:neuropeptide Y receptor activity; TAS:ProtInc.
DR   GO; GO:0001601; F:peptide YY receptor activity; IEA:Ensembl.
DR   GO; GO:0038023; F:signaling receptor activity; TAS:ProtInc.
DR   GO; GO:0007193; P:adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0001662; P:behavioral fear response; IEA:Ensembl.
DR   GO; GO:0003214; P:cardiac left ventricle morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007626; P:locomotory behavior; TAS:ProtInc.
DR   GO; GO:0043951; P:negative regulation of cAMP-mediated signaling; IEA:Ensembl.
DR   GO; GO:0090394; P:negative regulation of excitatory postsynaptic potential; IEA:Ensembl.
DR   GO; GO:2000252; P:negative regulation of feeding behavior; IEA:Ensembl.
DR   GO; GO:0051048; P:negative regulation of secretion; IEA:Ensembl.
DR   GO; GO:0051967; P:negative regulation of synaptic transmission, glutamatergic; IEA:Ensembl.
DR   GO; GO:0007263; P:nitric oxide mediated signal transduction; IEA:Ensembl.
DR   GO; GO:0003151; P:outflow tract morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0010811; P:positive regulation of cell-substrate adhesion; IEA:Ensembl.
DR   GO; GO:0046010; P:positive regulation of circadian sleep/wake cycle, non-REM sleep; IEA:Ensembl.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IEA:Ensembl.
DR   GO; GO:0033603; P:positive regulation of dopamine secretion; IEA:Ensembl.
DR   GO; GO:0002793; P:positive regulation of peptide secretion; IEA:Ensembl.
DR   GO; GO:0045987; P:positive regulation of smooth muscle contraction; IEA:Ensembl.
DR   GO; GO:0051930; P:regulation of sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0046903; P:secretion; IEA:Ensembl.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR001358; NPY2_rcpt.
DR   InterPro; IPR000611; NPY_rcpt.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01014; NRPEPTIDEY2R.
DR   PRINTS; PR01012; NRPEPTIDEYR.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Lipoprotein; Membrane; Palmitate; Receptor;
KW   Reference proteome; Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..381
FT                   /note="Neuropeptide Y receptor type 2"
FT                   /id="PRO_0000069928"
FT   TOPO_DOM        1..51
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        52..72
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        73..86
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        87..107
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        108..124
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        125..145
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        146..165
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        166..186
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        187..216
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        217..237
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        238..268
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        269..289
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        290..304
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        305..325
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        326..381
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   LIPID           342
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        11
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        123..203
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   CONFLICT        134
FT                   /note="V -> A (in Ref. 3; AAA93170)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        172
FT                   /note="A -> G (in Ref. 4)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        174
FT                   /note="G -> R (in Ref. 4)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        202
FT                   /note="A -> P (in Ref. 4; AAB07760)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        209
FT                   /note="G -> A (in Ref. 4; AAB07760)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        248
FT                   /note="N -> S (in Ref. 6; AAD00248)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        311
FT                   /note="H -> Y (in Ref. 6; AAD00248)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   381 AA;  42731 MW;  7D018C0169597BC7 CRC64;
     MGPIGAEADE NQTVEEMKVE QYGPQTTPRG ELVPDPEPEL IDSTKLIEVQ VVLILAYCSI
     ILLGVIGNSL VIHVVIKFKS MRTVTNFFIA NLAVADLLVN TLCLPFTLTY TLMGEWKMGP
     VLCHLVPYAQ GLAVQVSTIT LTVIALDRHR CIVYHLESKI SKRISFLIIG LAWGISALLA
     SPLAIFREYS LIEIIPDFEI VACTEKWPGE EKSIYGTVYS LSSLLILYVL PLGIISFSYT
     RIWSKLKNHV SPGAANDHYH QRRQKTTKML VCVVVVFAVS WLPLHAFQLA VDIDSQVLDL
     KEYKLIFTVF HIIAMCSTFA NPLLYGWMNS NYRKAFLSAF RCEQRLDAIH SEVSVTFKAK
     KNLEVRKNSG PNDSFTEATN V
//
ID   NPY1R_HUMAN             Reviewed;         384 AA.
AC   P25929; B2R6H5;
DT   01-MAY-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1992, sequence version 1.
DT   07-OCT-2020, entry version 185.
DE   RecName: Full=Neuropeptide Y receptor type 1;
DE            Short=NPY1-R;
GN   Name=NPY1R; Synonyms=NPYR, NPYY1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   PubMed=1317848;
RA   Larhammar D., Blomqvist A.G., Yee F., Jazin E.E., Yoo H., Wahlestedt C.R.;
RT   "Cloning and functional expression of a human neuropeptide Y/peptide YY
RT   receptor of the Y1 type.";
RL   J. Biol. Chem. 267:10935-10938(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RX   PubMed=1321422; DOI=10.1073/pnas.89.13.5794;
RA   Herzog H., Hort Y.J., Ball H.J., Hayes G., Shine J., Selbie L.A.;
RT   "Cloned human neuropeptide Y receptor couples to two different second
RT   messenger systems.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:5794-5798(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Blood;
RX   PubMed=8095935;
RA   Herzog H., Baumgartner M., Vivero C., Selbie L.A., Auer B., Shine J.;
RT   "Genomic organization, localization, and allelic differences in the gene
RT   for the human neuropeptide Y Y1 receptor.";
RL   J. Biol. Chem. 268:6703-6707(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (FEB-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Pancreas, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- FUNCTION: Receptor for neuropeptide Y and peptide YY. The rank order of
CC       affinity of this receptor for pancreatic polypeptides is NPY > [Pro-34]
CC       PYY, PYY and [Leu-31, Pro-34] NPY > NPY (2-36) > [Ile-31, Gln-34] PP
CC       and PYY (3-36) > PP > NPY free acid.
CC   -!- INTERACTION:
CC       P25929; P10082: PYY; NbExp=2; IntAct=EBI-372227, EBI-6655667;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/NPY1RID44260ch4q32.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M88461; AAA73215.1; -; mRNA.
DR   EMBL; M84755; AAA59920.1; -; mRNA.
DR   EMBL; L07614; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; L07615; AAA59947.1; -; mRNA.
DR   EMBL; AY548168; AAS55647.1; -; mRNA.
DR   EMBL; AK312578; BAG35472.1; -; mRNA.
DR   EMBL; CH471056; EAX04841.1; -; Genomic_DNA.
DR   EMBL; BC036657; AAH36657.1; -; mRNA.
DR   EMBL; BC071720; AAH71720.1; -; mRNA.
DR   CCDS; CCDS34089.1; -.
DR   PIR; A45490; A45490.
DR   RefSeq; NP_000900.1; NM_000909.5.
DR   RefSeq; XP_005263088.1; XM_005263031.3.
DR   RefSeq; XP_011530312.1; XM_011532010.2.
DR   PDB; 2F1U; Model; -; A=38-67, B=74-103, C=110-142, D=153-175, E=208-233, F=258-288, G=300-320.
DR   PDB; 2IIL; Model; -; @=1-384.
DR   PDB; 5ZBQ; X-ray; 2.70 A; A=2-358.
DR   PDBsum; 2F1U; -.
DR   PDBsum; 2IIL; -.
DR   PDBsum; 5ZBQ; -.
DR   BMRB; P25929; -.
DR   SMR; P25929; -.
DR   BioGRID; 110946; 3.
DR   IntAct; P25929; 5.
DR   STRING; 9606.ENSP00000354652; -.
DR   BindingDB; P25929; -.
DR   ChEMBL; CHEMBL4777; -.
DR   DrugBank; DB05004; Peptide YY (3-36).
DR   GuidetoPHARMACOLOGY; 305; -.
DR   GlyGen; P25929; 3 sites.
DR   iPTMnet; P25929; -.
DR   PhosphoSitePlus; P25929; -.
DR   BioMuta; NPY1R; -.
DR   DMDM; 128997; -.
DR   jPOST; P25929; -.
DR   MassIVE; P25929; -.
DR   PaxDb; P25929; -.
DR   PeptideAtlas; P25929; -.
DR   PRIDE; P25929; -.
DR   ProteomicsDB; 54300; -.
DR   Antibodypedia; 16963; 414 antibodies.
DR   DNASU; 4886; -.
DR   Ensembl; ENST00000296533; ENSP00000354652; ENSG00000164128.
DR   GeneID; 4886; -.
DR   KEGG; hsa:4886; -.
DR   UCSC; uc003iqm.3; human.
DR   CTD; 4886; -.
DR   DisGeNET; 4886; -.
DR   EuPathDB; HostDB:ENSG00000164128.6; -.
DR   GeneCards; NPY1R; -.
DR   HGNC; HGNC:7956; NPY1R.
DR   HPA; ENSG00000164128; Tissue enhanced (lymphoid).
DR   MIM; 162641; gene.
DR   neXtProt; NX_P25929; -.
DR   OpenTargets; ENSG00000164128; -.
DR   PharmGKB; PA258; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00940000160268; -.
DR   HOGENOM; CLU_009579_6_1_1; -.
DR   InParanoid; P25929; -.
DR   KO; K04204; -.
DR   OMA; WNHEILP; -.
DR   OrthoDB; 609835at2759; -.
DR   PhylomeDB; P25929; -.
DR   TreeFam; TF315303; -.
DR   PathwayCommons; P25929; -.
DR   Reactome; R-HSA-375276; Peptide ligand-binding receptors.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   SIGNOR; P25929; -.
DR   BioGRID-ORCS; 4886; 9 hits in 866 CRISPR screens.
DR   ChiTaRS; NPY1R; human.
DR   GeneWiki; Neuropeptide_Y_receptor_Y1; -.
DR   GenomeRNAi; 4886; -.
DR   Pharos; P25929; Tchem.
DR   PRO; PR:P25929; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; P25929; protein.
DR   Bgee; ENSG00000164128; Expressed in spleen and 170 other tissues.
DR   ExpressionAtlas; P25929; baseline and differential.
DR   Genevisible; P25929; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0004983; F:neuropeptide Y receptor activity; TAS:ProtInc.
DR   GO; GO:0001602; F:pancreatic polypeptide receptor activity; IBA:GO_Central.
DR   GO; GO:0001601; F:peptide YY receptor activity; IEA:Ensembl.
DR   GO; GO:0007193; P:adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0007631; P:feeding behavior; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007187; P:G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; TAS:ProtInc.
DR   GO; GO:0006006; P:glucose metabolic process; IEA:Ensembl.
DR   GO; GO:0007626; P:locomotory behavior; IEA:Ensembl.
DR   GO; GO:0003151; P:outflow tract morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0008217; P:regulation of blood pressure; IEA:Ensembl.
DR   GO; GO:0040014; P:regulation of multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0019233; P:sensory perception of pain; IEA:Ensembl.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR000351; NPY1_rcpt.
DR   InterPro; IPR000611; NPY_rcpt.
DR   PANTHER; PTHR24235:SF24; PTHR24235:SF24; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01013; NRPEPTIDEY1R.
DR   PRINTS; PR01012; NRPEPTIDEYR.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Lipoprotein; Membrane; Palmitate; Phosphoprotein;
KW   Polymorphism; Receptor; Reference proteome; Transducer; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..384
FT                   /note="Neuropeptide Y receptor type 1"
FT                   /id="PRO_0000069920"
FT   TOPO_DOM        1..44
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        45..65
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        66..76
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        77..97
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        98..116
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        117..137
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        138..154
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        155..175
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        176..211
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        212..232
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        233..260
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        261..281
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        282..299
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        300..320
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        321..384
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         368
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P21555"
FT   LIPID           338
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        2
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        11
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        17
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        113..198
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VARIANT         374
FT                   /note="K -> T (in dbSNP:rs5578)"
FT                   /id="VAR_014681"
FT   CONFLICT        96
FT                   /note="F -> L (in Ref. 2; AAA59920)"
FT                   /evidence="ECO:0000305"
FT   HELIX           22..24
FT                   /evidence="ECO:0000244|PDB:5ZBQ"
FT   HELIX           37..67
FT                   /evidence="ECO:0000244|PDB:5ZBQ"
FT   HELIX           74..92
FT                   /evidence="ECO:0000244|PDB:5ZBQ"
FT   HELIX           94..103
FT                   /evidence="ECO:0000244|PDB:5ZBQ"
FT   HELIX           110..142
FT                   /evidence="ECO:0000244|PDB:5ZBQ"
FT   TURN            145..147
FT                   /evidence="ECO:0000244|PDB:5ZBQ"
FT   HELIX           152..176
FT                   /evidence="ECO:0000244|PDB:5ZBQ"
FT   STRAND          177..180
FT                   /evidence="ECO:0000244|PDB:5ZBQ"
FT   HELIX           182..184
FT                   /evidence="ECO:0000244|PDB:5ZBQ"
FT   STRAND          197..200
FT                   /evidence="ECO:0000244|PDB:5ZBQ"
FT   HELIX           205..219
FT                   /evidence="ECO:0000244|PDB:5ZBQ"
FT   HELIX           221..240
FT                   /evidence="ECO:0000244|PDB:5ZBQ"
FT   HELIX           259..288
FT                   /evidence="ECO:0000244|PDB:5ZBQ"
FT   STRAND          292..294
FT                   /evidence="ECO:0000244|PDB:5ZBQ"
FT   HELIX           296..321
FT                   /evidence="ECO:0000244|PDB:5ZBQ"
FT   HELIX           325..334
FT                   /evidence="ECO:0000244|PDB:5ZBQ"
SQ   SEQUENCE   384 AA;  44392 MW;  582B0DDB04490316 CRC64;
     MNSTLFSQVE NHSVHSNFSE KNAQLLAFEN DDCHLPLAMI FTLALAYGAV IILGVSGNLA
     LIIIILKQKE MRNVTNILIV NLSFSDLLVA IMCLPFTFVY TLMDHWVFGE AMCKLNPFVQ
     CVSITVSIFS LVLIAVERHQ LIINPRGWRP NNRHAYVGIA VIWVLAVASS LPFLIYQVMT
     DEPFQNVTLD AYKDKYVCFD QFPSDSHRLS YTTLLLVLQY FGPLCFIFIC YFKIYIRLKR
     RNNMMDKMRD NKYRSSETKR INIMLLSIVV AFAVCWLPLT IFNTVFDWNH QIIATCNHNL
     LFLLCHLTAM ISTCVNPIFY GFLNKNFQRD LQFFFNFCDF RSRDDDYETI AMSTMHTDVS
     KTSLKQASPV AFKKINNNDD NEKI
//
ID   OPRD_HUMAN              Reviewed;         372 AA.
AC   P41143; B5B0B8;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   02-NOV-2010, sequence version 4.
DT   07-OCT-2020, entry version 182.
DE   RecName: Full=Delta-type opioid receptor;
DE            Short=D-OR-1;
DE            Short=DOR-1;
GN   Name=OPRD1; Synonyms=OPRD;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, AND VARIANT
RP   PHE-27.
RC   TISSUE=Brain cortex, and Corpus striatum;
RX   PubMed=8201839; DOI=10.1016/0024-3205(94)90138-4;
RA   Knapp R.J., Malatynska E., Fang L., Li X., Babin E., Nguyen M., Santoro G.,
RA   Varga E.V., Hruby V.J., Roeske W.R., Yamamura H.I.;
RT   "Identification of a human delta opioid receptor: cloning and expression.";
RL   Life Sci. 54:PL463-PL469(1994).
RN   [2]
RP   SEQUENCE REVISION TO 40-41; 348 AND 370.
RA   Knapp R.J.;
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=7808419;
RA   Simonin F., Befort K., Gaveriaux-Ruff C., Matthes H., Nappey V., Lannes B.,
RA   Micheletti G., Kieffer B.;
RT   "The human delta-opioid receptor: genomic organization, cDNA cloning,
RT   functional expression, and distribution in human brain.";
RL   Mol. Pharmacol. 46:1015-1021(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT PHE-27.
RC   TISSUE=Kidney;
RA   Kaighin V.A., Martin A.L., Aronstam R.S.;
RT   "Isolation of cDNA coding for human opioid receptor, delta 1 (OPRD1).";
RL   Submitted (JUL-2008) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6]
RP   INTERACTION WITH GPRASP1.
RX   PubMed=12142540; DOI=10.1126/science.1073308;
RA   Whistler J.L., Enquist J., Marley A., Fong J., Gladher F., Tsuruda P.,
RA   Murray S.R., Von Zastrow M.;
RT   "Modulation of postendocytic sorting of G protein-coupled receptors.";
RL   Science 297:615-620(2002).
RN   [7]
RP   INTERACTION WITH GPRASP1.
RX   PubMed=15086532; DOI=10.1111/j.1471-4159.2004.02411.x;
RA   Simonin F., Karcher P., Boeuf J.J.-M., Matifas A., Kieffer B.L.;
RT   "Identification of a novel family of G protein-coupled receptor associated
RT   sorting proteins.";
RL   J. Neurochem. 89:766-775(2004).
RN   [8]
RP   FUNCTION, SUBCELLULAR LOCATION, GLYCOSYLATION, SUBUNIT, AND
RP   CHARACTERIZATION OF VARIANT PHE-27.
RX   PubMed=22184124; DOI=10.1074/jbc.m111.305656;
RA   Leskela T.T., Lackman J.J., Vierimaa M.M., Kobayashi H., Bouvier M.,
RA   Petaja-Repo U.E.;
RT   "Cys-27 variant of human delta-opioid receptor modulates maturation and
RT   cell surface delivery of Phe-27 variant via heteromerization.";
RL   J. Biol. Chem. 287:5008-5020(2012).
RN   [9]
RP   TISSUE SPECIFICITY.
RX   PubMed=22417668; DOI=10.1016/j.rbmo.2012.02.007;
RA   Agirregoitia E., Peralta L., Mendoza R., Exposito A., Ereno E.D.,
RA   Matorras R., Agirregoitia N.;
RT   "Expression and localization of opioid receptors during the maturation of
RT   human oocytes.";
RL   Reprod. BioMed. Online 24:550-557(2012).
RN   [10]
RP   VARIANT PHE-27.
RX   PubMed=10982041; DOI=10.1007/s004390000340;
RA   Gelernter J., Kranzler H.R.;
RT   "Variant detection at the delta opioid receptor (OPRD1) locus and
RT   population genetics of a novel variant affecting protein sequence.";
RL   Hum. Genet. 107:86-88(2000).
RN   [11]
RP   3D-STRUCTURE MODELING.
RX   PubMed=12847517; DOI=10.1038/nsb950;
RA   Decaillot F.M., Befort K., Filliol D., Yue S., Walker P., Kieffer B.L.;
RT   "Opioid receptor random mutagenesis reveals a mechanism for G protein-
RT   coupled receptor activation.";
RL   Nat. Struct. Biol. 10:629-636(2003).
CC   -!- FUNCTION: G-protein coupled receptor that functions as receptor for
CC       endogenous enkephalins and for a subset of other opioids. Ligand
CC       binding causes a conformation change that triggers signaling via
CC       guanine nucleotide-binding proteins (G proteins) and modulates the
CC       activity of down-stream effectors, such as adenylate cyclase. Signaling
CC       leads to the inhibition of adenylate cyclase activity. Inhibits
CC       neurotransmitter release by reducing calcium ion currents and
CC       increasing potassium ion conductance. Plays a role in the perception of
CC       pain and in opiate-mediated analgesia. Plays a role in developing
CC       analgesic tolerance to morphine. {ECO:0000269|PubMed:22184124,
CC       ECO:0000269|PubMed:7808419, ECO:0000269|PubMed:8201839}.
CC   -!- SUBUNIT: May form homooligomers. Forms a heterodimer with OPRM1 (By
CC       similarity). Interacts with GPRASP1 (PubMed:12142540, PubMed:15086532).
CC       Interacts with RTP4; the interaction promotes cell surface localization
CC       of the OPRD1-OPRM1 heterodimer (By similarity).
CC       {ECO:0000250|UniProtKB:P32300, ECO:0000269|PubMed:12142540,
CC       ECO:0000269|PubMed:15086532, ECO:0000269|PubMed:22184124}.
CC   -!- INTERACTION:
CC       P41143; P16615: ATP2A2; NbExp=3; IntAct=EBI-2624456, EBI-358933;
CC       P41143; P27824: CANX; NbExp=2; IntAct=EBI-2624456, EBI-355947;
CC       P41143; Q4LDR2: CTXN3; NbExp=3; IntAct=EBI-2624456, EBI-12019274;
CC       P41143; Q5JY77: GPRASP1; NbExp=2; IntAct=EBI-2624456, EBI-2514717;
CC       P41143; Q9NS64: RPRM; NbExp=3; IntAct=EBI-2624456, EBI-1052363;
CC       P41143; Q9Y666-2: SLC12A7; NbExp=3; IntAct=EBI-2624456, EBI-12854384;
CC       P41143; Q9UKG4: SLC13A4; NbExp=3; IntAct=EBI-2624456, EBI-12808018;
CC       P41143; Q0VAQ4: SMAGP; NbExp=3; IntAct=EBI-2624456, EBI-10226799;
CC       P41143; Q96Q45-2: TMEM237; NbExp=3; IntAct=EBI-2624456, EBI-10982110;
CC       P41143; P11607: ATP2A2; Xeno; NbExp=2; IntAct=EBI-2624456, EBI-8004986;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:22184124,
CC       ECO:0000269|PubMed:7808419, ECO:0000269|PubMed:8201839}; Multi-pass
CC       membrane protein {ECO:0000269|PubMed:22184124,
CC       ECO:0000269|PubMed:7808419, ECO:0000269|PubMed:8201839}.
CC   -!- TISSUE SPECIFICITY: Detected in oocytes (at protein level). Detected in
CC       brain cortex, hypothalamus, hippocampus and olfactory bulb. Detected in
CC       oocytes. {ECO:0000269|PubMed:22417668, ECO:0000269|PubMed:7808419}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:22184124}.
CC   -!- PTM: Ubiquitinated. A basal ubiquitination seems not to be related to
CC       degradation. Ubiquitination is increased upon formation of OPRM1:OPRD1
CC       oligomers leading to proteasomal degradation; the ubiquitination is
CC       diminished by RTP4. {ECO:0000250|UniProtKB:P32300}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Delta opioid receptor entry;
CC       URL="https://en.wikipedia.org/wiki/Delta_opioid_receptor";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U07882; AAA18789.2; -; mRNA.
DR   EMBL; U10504; AAA83426.1; -; mRNA.
DR   EMBL; EU883570; ACG60644.1; -; mRNA.
DR   EMBL; AL009181; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS329.1; -.
DR   PIR; I38532; I38532.
DR   RefSeq; NP_000902.3; NM_000911.3.
DR   PDB; 1OZC; Model; -; A=1-372.
DR   PDB; 2IQM; Model; -; A=45-336.
DR   PDB; 4N6H; X-ray; 1.80 A; A=36-338.
DR   PDB; 4RWA; X-ray; 3.28 A; A/B=39-338.
DR   PDB; 4RWD; X-ray; 2.70 A; A/B=39-338.
DR   PDB; 6PT2; X-ray; 2.80 A; A/B=41-338.
DR   PDB; 6PT3; X-ray; 3.30 A; A/B=41-338.
DR   PDBsum; 1OZC; -.
DR   PDBsum; 2IQM; -.
DR   PDBsum; 4N6H; -.
DR   PDBsum; 4RWA; -.
DR   PDBsum; 4RWD; -.
DR   PDBsum; 6PT2; -.
DR   PDBsum; 6PT3; -.
DR   SMR; P41143; -.
DR   BioGRID; 111030; 23.
DR   ELM; P41143; -.
DR   IntAct; P41143; 10.
DR   MINT; P41143; -.
DR   STRING; 9606.ENSP00000234961; -.
DR   BindingDB; P41143; -.
DR   ChEMBL; CHEMBL236; -.
DR   DrugBank; DB01571; 3-Methylfentanyl.
DR   DrugBank; DB01439; 3-Methylthiofentanyl.
DR   DrugBank; DB05050; ADL5859.
DR   DrugBank; DB06274; Alvimopan.
DR   DrugBank; DB00321; Amitriptyline.
DR   DrugBank; DB01238; Aripiprazole.
DR   DrugBank; DB00921; Buprenorphine.
DR   DrugBank; DB00611; Butorphanol.
DR   DrugBank; DB09173; Butyrfentanyl.
DR   DrugBank; DB09061; Cannabidiol.
DR   DrugBank; DB01535; Carfentanil.
DR   DrugBank; DB00318; Codeine.
DR   DrugBank; DB00514; Dextromethorphan.
DR   DrugBank; DB00647; Dextropropoxyphene.
DR   DrugBank; DB01452; Diamorphine.
DR   DrugBank; DB01565; Dihydromorphine.
DR   DrugBank; DB01444; Dimethylthiambutene.
DR   DrugBank; DB01081; Diphenoxylate.
DR   DrugBank; DB01548; Diprenorphine.
DR   DrugBank; DB09272; Eluxadoline.
DR   DrugBank; DB01497; Etorphine.
DR   DrugBank; DB00813; Fentanyl.
DR   DrugBank; DB00956; Hydrocodone.
DR   DrugBank; DB00327; Hydromorphone.
DR   DrugBank; DB01221; Ketamine.
DR   DrugBank; DB06738; Ketobemidone.
DR   DrugBank; DB00854; Levorphanol.
DR   DrugBank; DB00836; Loperamide.
DR   DrugBank; DB14146; Loxicodegol.
DR   DrugBank; DB14009; Medical Cannabis.
DR   DrugBank; DB00333; Methadone.
DR   DrugBank; DB00295; Morphine.
DR   DrugBank; DB06409; Morphine glucuronide.
DR   DrugBank; DB14011; Nabiximols.
DR   DrugBank; DB00844; Nalbuphine.
DR   DrugBank; DB11691; Naldemedine.
DR   DrugBank; DB06230; Nalmefene.
DR   DrugBank; DB01183; Naloxone.
DR   DrugBank; DB00704; Naltrexone.
DR   DrugBank; DB11130; Opium.
DR   DrugBank; DB00497; Oxycodone.
DR   DrugBank; DB01192; Oxymorphone.
DR   DrugBank; DB09209; Pholcodine.
DR   DrugBank; DB00899; Remifentanil.
DR   DrugBank; DB00708; Sufentanil.
DR   DrugBank; DB06204; Tapentadol.
DR   DrugBank; DB00193; Tramadol.
DR   DrugCentral; P41143; -.
DR   GuidetoPHARMACOLOGY; 317; -.
DR   GlyGen; P41143; 2 sites.
DR   iPTMnet; P41143; -.
DR   PhosphoSitePlus; P41143; -.
DR   BioMuta; OPRD1; -.
DR   DMDM; 311033488; -.
DR   jPOST; P41143; -.
DR   PaxDb; P41143; -.
DR   PeptideAtlas; P41143; -.
DR   PRIDE; P41143; -.
DR   ProteomicsDB; 55402; -.
DR   Antibodypedia; 2932; 423 antibodies.
DR   DNASU; 4985; -.
DR   Ensembl; ENST00000234961; ENSP00000234961; ENSG00000116329.
DR   GeneID; 4985; -.
DR   KEGG; hsa:4985; -.
DR   UCSC; uc001brf.2; human.
DR   CTD; 4985; -.
DR   DisGeNET; 4985; -.
DR   EuPathDB; HostDB:ENSG00000116329.10; -.
DR   GeneCards; OPRD1; -.
DR   HGNC; HGNC:8153; OPRD1.
DR   HPA; ENSG00000116329; Tissue enhanced (brain).
DR   MIM; 165195; gene.
DR   neXtProt; NX_P41143; -.
DR   OpenTargets; ENSG00000116329; -.
DR   PharmGKB; PA31942; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00940000157669; -.
DR   HOGENOM; CLU_009579_8_1_1; -.
DR   InParanoid; P41143; -.
DR   KO; K04213; -.
DR   OMA; HPVKALG; -.
DR   OrthoDB; 1011272at2759; -.
DR   PhylomeDB; P41143; -.
DR   TreeFam; TF315737; -.
DR   PathwayCommons; P41143; -.
DR   Reactome; R-HSA-375276; Peptide ligand-binding receptors.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-6785807; Interleukin-4 and Interleukin-13 signaling.
DR   SignaLink; P41143; -.
DR   SIGNOR; P41143; -.
DR   BioGRID-ORCS; 4985; 1 hit in 871 CRISPR screens.
DR   ChiTaRS; OPRD1; human.
DR   GeneWiki; %CE%94-opioid_receptor; -.
DR   GenomeRNAi; 4985; -.
DR   Pharos; P41143; Tclin.
DR   PRO; PR:P41143; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P41143; protein.
DR   Bgee; ENSG00000116329; Expressed in endothelial cell and 49 other tissues.
DR   ExpressionAtlas; P41143; baseline and differential.
DR   Genevisible; P41143; HS.
DR   GO; GO:0043679; C:axon terminus; IEA:Ensembl.
DR   GO; GO:0032590; C:dendrite membrane; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0099061; C:integral component of postsynaptic density membrane; IEA:Ensembl.
DR   GO; GO:0030285; C:integral component of synaptic vesicle membrane; IEA:Ensembl.
DR   GO; GO:0031226; C:intrinsic component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IEA:Ensembl.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0038046; F:enkephalin receptor activity; IMP:UniProtKB.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0042923; F:neuropeptide binding; IBA:GO_Central.
DR   GO; GO:0004985; F:opioid receptor activity; IDA:UniProtKB.
DR   GO; GO:0042277; F:peptide binding; IBA:GO_Central.
DR   GO; GO:0033612; F:receptor serine/threonine kinase binding; IEA:Ensembl.
DR   GO; GO:0007193; P:adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0008344; P:adult locomotory behavior; IEA:Ensembl.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0071456; P:cellular response to hypoxia; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0097237; P:cellular response to toxic substance; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0042755; P:eating behavior; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007187; P:G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; TAS:ProtInc.
DR   GO; GO:0006955; P:immune response; TAS:ProtInc.
DR   GO; GO:0010629; P:negative regulation of gene expression; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0031333; P:negative regulation of protein-containing complex assembly; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0007218; P:neuropeptide signaling pathway; IBA:GO_Central.
DR   GO; GO:0038003; P:opioid receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0032793; P:positive regulation of CREB transcription factor activity; IC:ParkinsonsUK-UCL.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0051924; P:regulation of calcium ion transport; IEA:Ensembl.
DR   GO; GO:0051881; P:regulation of mitochondrial membrane potential; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0051930; P:regulation of sensory perception of pain; IEA:Ensembl.
DR   InterPro; IPR000321; Delta_opi_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR001418; Opioid_rcpt.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00525; DELTAOPIOIDR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00384; OPIOIDR.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Lipoprotein; Membrane; Palmitate; Polymorphism; Receptor;
KW   Reference proteome; Transducer; Transmembrane; Transmembrane helix;
KW   Ubl conjugation.
FT   CHAIN           1..372
FT                   /note="Delta-type opioid receptor"
FT                   /id="PRO_0000069962"
FT   TOPO_DOM        1..47
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        48..75
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        76..85
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        86..110
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        111..122
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        123..144
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        145..163
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        164..186
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        187..206
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        207..238
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        239..261
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        262..284
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        285..299
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        300..321
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        322..372
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   LIPID           333
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        18
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        33
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        121..198
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VARIANT         27
FT                   /note="C -> F (improved maturation and increased expression
FT                   at the cell surface; dbSNP:rs1042114)"
FT                   /evidence="ECO:0000269|PubMed:10982041,
FT                   ECO:0000269|PubMed:22184124, ECO:0000269|PubMed:8201839,
FT                   ECO:0000269|Ref.4"
FT                   /id="VAR_012083"
FT   HELIX           40..76
FT                   /evidence="ECO:0000244|PDB:4N6H"
FT   HELIX           78..80
FT                   /evidence="ECO:0000244|PDB:4N6H"
FT   HELIX           83..100
FT                   /evidence="ECO:0000244|PDB:4N6H"
FT   HELIX           102..111
FT                   /evidence="ECO:0000244|PDB:4N6H"
FT   HELIX           118..151
FT                   /evidence="ECO:0000244|PDB:4N6H"
FT   TURN            153..155
FT                   /evidence="ECO:0000244|PDB:4N6H"
FT   HELIX           156..159
FT                   /evidence="ECO:0000244|PDB:4N6H"
FT   HELIX           162..186
FT                   /evidence="ECO:0000244|PDB:4N6H"
FT   STRAND          187..192
FT                   /evidence="ECO:0000244|PDB:4N6H"
FT   STRAND          195..200
FT                   /evidence="ECO:0000244|PDB:4N6H"
FT   STRAND          203..205
FT                   /evidence="ECO:0000244|PDB:4N6H"
FT   HELIX           206..220
FT                   /evidence="ECO:0000244|PDB:4N6H"
FT   HELIX           223..242
FT                   /evidence="ECO:0000244|PDB:4N6H"
FT   STRAND          246..249
FT                   /evidence="ECO:0000244|PDB:4N6H"
FT   HELIX           250..286
FT                   /evidence="ECO:0000244|PDB:4N6H"
FT   HELIX           294..321
FT                   /evidence="ECO:0000244|PDB:4N6H"
FT   HELIX           323..334
FT                   /evidence="ECO:0000244|PDB:4N6H"
SQ   SEQUENCE   372 AA;  40369 MW;  9D483FC39BA2BAE4 CRC64;
     MEPAPSAGAE LQPPLFANAS DAYPSACPSA GANASGPPGA RSASSLALAI AITALYSAVC
     AVGLLGNVLV MFGIVRYTKM KTATNIYIFN LALADALATS TLPFQSAKYL METWPFGELL
     CKAVLSIDYY NMFTSIFTLT MMSVDRYIAV CHPVKALDFR TPAKAKLINI CIWVLASGVG
     VPIMVMAVTR PRDGAVVCML QFPSPSWYWD TVTKICVFLF AFVVPILIIT VCYGLMLLRL
     RSVRLLSGSK EKDRSLRRIT RMVLVVVGAF VVCWAPIHIF VIVWTLVDID RRDPLVVAAL
     HLCIALGYAN SSLNPVLYAF LDENFKRCFR QLCRKPCGRP DPSSFSRARE ATARERVTAC
     TPSDGPGGGA AA
//
ID   P2Y12_HUMAN             Reviewed;         342 AA.
AC   Q9H244; D3DNJ5; Q546J7;
DT   27-MAY-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2001, sequence version 1.
DT   07-OCT-2020, entry version 173.
DE   RecName: Full=P2Y purinoceptor 12;
DE            Short=P2Y12;
DE   AltName: Full=ADP-glucose receptor;
DE            Short=ADPG-R;
DE   AltName: Full=P2T(AC);
DE   AltName: Full=P2Y(AC);
DE   AltName: Full=P2Y(cyc);
DE   AltName: Full=P2Y12 platelet ADP receptor;
DE            Short=P2Y(ADP);
DE   AltName: Full=SP1999;
GN   Name=P2RY12; Synonyms=HORK3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, AND INVOLVEMENT IN BDPLT8.
RX   PubMed=11196645; DOI=10.1038/35051599;
RA   Hollopeter G., Jantzen H.-M., Vincent D., Li G., England L.,
RA   Ramakrishnan V., Yang R.-B., Nurden P., Nurden A., Julius D.J.,
RA   Conley P.B.;
RT   "Identification of the platelet ADP receptor targeted by antithrombotic
RT   drugs.";
RL   Nature 409:202-207(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND TISSUE SPECIFICITY.
RC   TISSUE=Hypothalamus;
RX   PubMed=11104774; DOI=10.1074/jbc.m009718200;
RA   Zhang F.L., Luo L., Gustafson E., Lachowicz J., Smith M., Qiao X.,
RA   Liu Y.-H., Chen G., Pramanik B., Laz T.M., Palmer K., Bayne M.,
RA   Monsma F.J. Jr.;
RT   "ADP is the cognate ligand for the orphan G protein-coupled receptor
RT   SP1999.";
RL   J. Biol. Chem. 276:8608-8615(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=11502873;
RA   Takasaki J., Kamohara M., Saito T., Matsumoto M., Matsumoto S., Ohishi T.,
RA   Soga T., Matsushime H., Furuichi K.;
RT   "Molecular cloning of the platelet P2T(AC) ADP receptor: pharmacological
RT   comparison with another ADP receptor, the P2Y1 receptor.";
RL   Mol. Pharmacol. 60:432-439(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Reinscheid R.K., Nothacker H.-P., Wang Z., Zeng J., Ehlert F.J.,
RA   Civelli O.;
RT   "ADP-glucose activates a G-protein coupled receptor and inhibits smooth
RT   muscle contractions.";
RL   Submitted (OCT-2000) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Blood;
RA   Bruess M., von Kugelgen I., Bonisch H.;
RT   "Cloning and characterization of a human platelet ADP-receptor.";
RL   Submitted (AUG-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12044878; DOI=10.1016/s0014-5793(02)02775-8;
RA   Takeda S., Kadowaki S., Haga T., Takaesu H., Mitaku S.;
RT   "Identification of G protein-coupled receptor genes from the human genome
RT   sequence.";
RL   FEBS Lett. 520:97-101(2002).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   X-RAY CRYSTALLOGRAPHY (2.62 ANGSTROMS) IN COMPLEX WITH THE AGONIST AZD1283,
RP   FUNCTION, DISULFIDE BOND, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-80;
RP   SER-156; ASN-159; LYS-280 AND GLU-281.
RX   PubMed=24670650; DOI=10.1038/nature13083;
RA   Zhang K., Zhang J., Gao Z.G., Zhang D., Zhu L., Han G.W., Moss S.M.,
RA   Paoletta S., Kiselev E., Lu W., Fenalti G., Zhang W., Mueller C.E.,
RA   Yang H., Jiang H., Cherezov V., Katritch V., Jacobson K.A., Stevens R.C.,
RA   Wu B., Zhao Q.;
RT   "Structure of the human P2Y12 receptor in complex with an antithrombotic
RT   drug.";
RL   Nature 509:115-118(2014).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 2-342 IN COMPLEX WITH THE ADP
RP   ANALOG 2-(METHYLSULFANYL)ADENOSINE 5'-(TRIHYDROGEN DIPHOSPHATE), FUNCTION,
RP   SUBCELLULAR LOCATION, DISULFIDE BOND, AND MUTAGENESIS OF SER-83; CYS-97;
RP   CYS-175; ARG-256 AND LYS-280.
RX   PubMed=24784220; DOI=10.1038/nature13288;
RA   Zhang J., Zhang K., Gao Z.G., Paoletta S., Zhang D., Han G.W., Li T.,
RA   Ma L., Zhang W., Mueller C.E., Yang H., Jiang H., Cherezov V., Katritch V.,
RA   Jacobson K.A., Stevens R.C., Wu B., Zhao Q.;
RT   "Agonist-bound structure of the human P2Y12 receptor.";
RL   Nature 509:119-122(2014).
RN   [12]
RP   VARIANTS BDPLT8 GLN-256 AND TRP-265, INVOLVEMENT IN BDPLT8, FUNCTION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=12578987; DOI=10.1073/pnas.0437879100;
RA   Cattaneo M., Zighetti M.L., Lombardi R., Martinez C., Lecchi A.,
RA   Conley P.B., Ware J., Ruggeri Z.M.;
RT   "Molecular bases of defective signal transduction in the platelet P2Y12
RT   receptor of a patient with congenital bleeding.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:1978-1983(2003).
RN   [13]
RP   VARIANT BDPLT8 GLN-187.
RX   PubMed=25428217; DOI=10.1182/blood-2013-07-517896;
RA   Lecchi A., Razzari C., Paoletta S., Dupuis A., Nakamura L., Ohlmann P.,
RA   Gachet C., Jacobson K.A., Zieger B., Cattaneo M.;
RT   "Identification of a new dysfunctional platelet P2Y12 receptor variant
RT   associated with bleeding diathesis.";
RL   Blood 125:1006-1013(2015).
CC   -!- FUNCTION: Receptor for ADP and ATP coupled to G-proteins that inhibit
CC       the adenylyl cyclase second messenger system. Not activated by UDP and
CC       UTP. Required for normal platelet aggregation and blood coagulation.
CC       {ECO:0000269|PubMed:11104774, ECO:0000269|PubMed:11196645,
CC       ECO:0000269|PubMed:11502873, ECO:0000269|PubMed:12578987,
CC       ECO:0000269|PubMed:24670650, ECO:0000269|PubMed:24784220}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:11196645,
CC       ECO:0000269|PubMed:12578987, ECO:0000269|PubMed:24670650,
CC       ECO:0000269|PubMed:24784220}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:11196645, ECO:0000269|PubMed:12578987,
CC       ECO:0000269|PubMed:24670650, ECO:0000269|PubMed:24784220}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in the platelets, lower levels in
CC       the brain. Lowest levels in the lung, appendix, pituitary and adrenal
CC       gland. Expressed in the spinal cord and in the fetal brain.
CC       {ECO:0000269|PubMed:11104774, ECO:0000269|PubMed:11196645,
CC       ECO:0000269|PubMed:11502873}.
CC   -!- DOMAIN: The transmembrane domain is composed of seven transmembrane
CC       helices; most of these are not strictly perpendicular to the plane of
CC       the membrane, but are tilted and/or kinked. Agonist binding promotes a
CC       conformation change in the extracellular loops that leads to an inward
CC       movement of the transmembrane helices. Antagonists such as AZD1283 can
CC       bind to an overlapping site, but block the inward movement of the
CC       transmembrane helices (PubMed:24670650, PubMed:24784220).
CC       {ECO:0000269|PubMed:24670650, ECO:0000269|PubMed:24784220}.
CC   -!- DISEASE: Bleeding disorder, platelet-type 8 (BDPLT8) [MIM:609821]: A
CC       condition characterized by mild to moderate mucocutaneous bleeding, and
CC       excessive bleeding after surgery or trauma. The defect is due to severe
CC       impairment of platelet response to ADP resulting in defective platelet
CC       aggregation. {ECO:0000269|PubMed:11196645, ECO:0000269|PubMed:12578987,
CC       ECO:0000269|PubMed:25428217}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF313449; AAG48944.1; -; mRNA.
DR   EMBL; AF321815; AAK00948.1; -; mRNA.
DR   EMBL; AB052684; BAB60824.1; -; mRNA.
DR   EMBL; AF310685; AAL32292.1; -; Genomic_DNA.
DR   EMBL; AJ320495; CAC87144.1; -; mRNA.
DR   EMBL; AB083596; BAB89309.1; -; Genomic_DNA.
DR   EMBL; AY136754; AAN01280.1; -; mRNA.
DR   EMBL; CH471052; EAW78803.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW78804.1; -; Genomic_DNA.
DR   EMBL; BC017898; AAH17898.1; -; mRNA.
DR   CCDS; CCDS3159.1; -.
DR   RefSeq; NP_073625.1; NM_022788.4.
DR   RefSeq; NP_795345.1; NM_176876.2.
DR   RefSeq; XP_016862558.1; XM_017007069.1.
DR   PDB; 1T78; Model; -; A=1-337.
DR   PDB; 1VZ1; Model; -; A=1-337.
DR   PDB; 1Y9C; Model; -; A=1-342.
DR   PDB; 4NTJ; X-ray; 2.62 A; A=2-342.
DR   PDB; 4PXZ; X-ray; 2.50 A; A=2-342.
DR   PDB; 4PY0; X-ray; 3.10 A; A=2-342.
DR   PDBsum; 1T78; -.
DR   PDBsum; 1VZ1; -.
DR   PDBsum; 1Y9C; -.
DR   PDBsum; 4NTJ; -.
DR   PDBsum; 4PXZ; -.
DR   PDBsum; 4PY0; -.
DR   SMR; Q9H244; -.
DR   BioGRID; 122309; 62.
DR   DIP; DIP-61226N; -.
DR   IntAct; Q9H244; 47.
DR   STRING; 9606.ENSP00000307259; -.
DR   BindingDB; Q9H244; -.
DR   ChEMBL; CHEMBL2001; -.
DR   DrugBank; DB06441; Cangrelor.
DR   DrugBank; DB00758; Clopidogrel.
DR   DrugBank; DB06350; Elinogrel.
DR   DrugBank; DB01240; Epoprostenol.
DR   DrugBank; DB06209; Prasugrel.
DR   DrugBank; DB01069; Promethazine.
DR   DrugBank; DB05553; Regrelor.
DR   DrugBank; DB08816; Ticagrelor.
DR   DrugBank; DB00208; Ticlopidine.
DR   DrugBank; DB00374; Treprostinil.
DR   DrugCentral; Q9H244; -.
DR   GuidetoPHARMACOLOGY; 328; -.
DR   TCDB; 9.A.14.13.31; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; Q9H244; 2 sites.
DR   iPTMnet; Q9H244; -.
DR   PhosphoSitePlus; Q9H244; -.
DR   BioMuta; P2RY12; -.
DR   DMDM; 21263835; -.
DR   jPOST; Q9H244; -.
DR   MassIVE; Q9H244; -.
DR   PaxDb; Q9H244; -.
DR   PeptideAtlas; Q9H244; -.
DR   PRIDE; Q9H244; -.
DR   ProteomicsDB; 80487; -.
DR   Antibodypedia; 2951; 194 antibodies.
DR   DNASU; 64805; -.
DR   Ensembl; ENST00000302632; ENSP00000307259; ENSG00000169313.
DR   GeneID; 64805; -.
DR   KEGG; hsa:64805; -.
DR   UCSC; uc003eyx.3; human.
DR   CTD; 64805; -.
DR   DisGeNET; 64805; -.
DR   EuPathDB; HostDB:ENSG00000169313.9; -.
DR   GeneCards; P2RY12; -.
DR   HGNC; HGNC:18124; P2RY12.
DR   HPA; ENSG00000169313; Tissue enhanced (brain).
DR   MalaCards; P2RY12; -.
DR   MIM; 600515; gene.
DR   MIM; 609821; phenotype.
DR   neXtProt; NX_Q9H244; -.
DR   OpenTargets; ENSG00000169313; -.
DR   Orphanet; 36355; Bleeding disorder due to P2Y12 defect.
DR   Orphanet; 240935; Resistance to clopidogrel.
DR   PharmGKB; PA134971947; -.
DR   eggNOG; ENOG502QUS2; Eukaryota.
DR   GeneTree; ENSGT00950000182658; -.
DR   HOGENOM; CLU_009579_8_2_1; -.
DR   InParanoid; Q9H244; -.
DR   KO; K04298; -.
DR   OMA; YKSYKRT; -.
DR   OrthoDB; 15873at2759; -.
DR   PhylomeDB; Q9H244; -.
DR   TreeFam; TF330969; -.
DR   PathwayCommons; Q9H244; -.
DR   Reactome; R-HSA-392170; ADP signalling through P2Y purinoceptor 12.
DR   Reactome; R-HSA-417957; P2Y receptors.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   SIGNOR; Q9H244; -.
DR   BioGRID-ORCS; 64805; 1 hit in 873 CRISPR screens.
DR   ChiTaRS; P2RY12; human.
DR   GeneWiki; P2Y12; -.
DR   GenomeRNAi; 64805; -.
DR   Pharos; Q9H244; Tclin.
DR   PRO; PR:Q9H244; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q9H244; protein.
DR   Bgee; ENSG00000169313; Expressed in substantia nigra and 175 other tissues.
DR   Genevisible; Q9H244; HS.
DR   GO; GO:0009925; C:basal plasma membrane; IEA:Ensembl.
DR   GO; GO:0005901; C:caveola; IEA:Ensembl.
DR   GO; GO:0044298; C:cell body membrane; IEA:Ensembl.
DR   GO; GO:0031253; C:cell projection membrane; IEA:Ensembl.
DR   GO; GO:0009986; C:cell surface; HDA:UniProtKB.
DR   GO; GO:0009897; C:external side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0031224; C:intrinsic component of membrane; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0001609; F:G protein-coupled adenosine receptor activity; IEA:Ensembl.
DR   GO; GO:0001621; F:G protein-coupled ADP receptor activity; IDA:UniProtKB.
DR   GO; GO:0045028; F:G protein-coupled purinergic nucleotide receptor activity; IBA:GO_Central.
DR   GO; GO:0005085; F:guanyl-nucleotide exchange factor activity; TAS:Reactome.
DR   GO; GO:0007202; P:activation of phospholipase C activity; TAS:ARUK-UCL.
DR   GO; GO:0007193; P:adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0070588; P:calcium ion transmembrane transport; IEA:Ensembl.
DR   GO; GO:0019722; P:calcium-mediated signaling; ISS:ARUK-UCL.
DR   GO; GO:0035585; P:calcium-mediated signaling using extracellular calcium source; ISS:ARUK-UCL.
DR   GO; GO:0030030; P:cell projection organization; ISS:ARUK-UCL.
DR   GO; GO:0071318; P:cellular response to ATP; ISS:ARUK-UCL.
DR   GO; GO:0021808; P:cytosolic calcium signaling involved in initiation of cell movement in glial-mediated radial cell migration; ISS:ARUK-UCL.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007599; P:hemostasis; NAS:UniProtKB.
DR   GO; GO:0030032; P:lamellipodium assembly; ISS:ARUK-UCL.
DR   GO; GO:1904124; P:microglial cell migration; TAS:ARUK-UCL.
DR   GO; GO:0045596; P:negative regulation of cell differentiation; IEA:Ensembl.
DR   GO; GO:0010700; P:negative regulation of norepinephrine secretion; IEA:Ensembl.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; ISS:ARUK-UCL.
DR   GO; GO:0070527; P:platelet aggregation; IMP:UniProtKB.
DR   GO; GO:0033630; P:positive regulation of cell adhesion mediated by integrin; ISS:ARUK-UCL.
DR   GO; GO:0050921; P:positive regulation of chemotaxis; ISS:ARUK-UCL.
DR   GO; GO:0033626; P:positive regulation of integrin activation by cell surface receptor linked signal transduction; ISS:ARUK-UCL.
DR   GO; GO:0043270; P:positive regulation of ion transport; IEA:Ensembl.
DR   GO; GO:1904141; P:positive regulation of microglial cell migration; ISS:ARUK-UCL.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; TAS:ARUK-UCL.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; ISS:ARUK-UCL.
DR   GO; GO:1900029; P:positive regulation of ruffle assembly; ISS:ARUK-UCL.
DR   GO; GO:0071805; P:potassium ion transmembrane transport; IEA:Ensembl.
DR   GO; GO:0043491; P:protein kinase B signaling; IEA:Ensembl.
DR   GO; GO:0051924; P:regulation of calcium ion transport; IEA:Ensembl.
DR   GO; GO:0050920; P:regulation of chemotaxis; ISS:ARUK-UCL.
DR   GO; GO:1904139; P:regulation of microglial cell migration; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0048678; P:response to axon injury; ISS:ARUK-UCL.
DR   GO; GO:0006930; P:substrate-dependent cell migration, cell extension; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0150063; P:visual system development; IEA:Ensembl.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR005394; P2Y12_rcpt.
DR   PANTHER; PTHR24233:SF0; PTHR24233:SF0; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01569; P2Y12PRNCPTR.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Blood coagulation; Cell membrane; Disease mutation;
KW   Disulfide bond; G-protein coupled receptor; Glycoprotein; Hemostasis;
KW   Membrane; Phosphoprotein; Polymorphism; Receptor; Reference proteome;
KW   Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..342
FT                   /note="P2Y purinoceptor 12"
FT                   /id="PRO_0000070036"
FT   TOPO_DOM        1..27
FT                   /note="Extracellular"
FT   TRANSMEM        28..50
FT                   /note="Helical; Name=1"
FT   TOPO_DOM        51..61
FT                   /note="Cytoplasmic"
FT   TRANSMEM        62..82
FT                   /note="Helical; Name=2"
FT   TOPO_DOM        83..97
FT                   /note="Extracellular"
FT   TRANSMEM        98..118
FT                   /note="Helical; Name=3"
FT   TOPO_DOM        119..142
FT                   /note="Cytoplasmic"
FT   TRANSMEM        143..162
FT                   /note="Helical; Name=4"
FT   TOPO_DOM        163..185
FT                   /note="Extracellular"
FT   TRANSMEM        186..207
FT                   /note="Helical; Name=5"
FT   TOPO_DOM        208..233
FT                   /note="Cytoplasmic"
FT   TRANSMEM        234..259
FT                   /note="Helical; Name=6"
FT   TOPO_DOM        260..278
FT                   /note="Extracellular"
FT   TRANSMEM        279..298
FT                   /note="Helical; Name=7"
FT   TOPO_DOM        299..342
FT                   /note="Cytoplasmic"
FT   NP_BIND         156..159
FT                   /note="ADP"
FT   NP_BIND         175..179
FT                   /note="ADP"
FT   NP_BIND         256..259
FT                   /note="ADP"
FT   BINDING         93
FT                   /note="ADP"
FT   BINDING         97
FT                   /note="ADP; via carbonyl oxygen"
FT   BINDING         105
FT                   /note="ADP"
FT   BINDING         187
FT                   /note="ADP"
FT   BINDING         191
FT                   /note="ADP"
FT   BINDING         263
FT                   /note="ADP"
FT   BINDING         280
FT                   /note="ADP"
FT   MOD_RES         55
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9EPX4"
FT   MOD_RES         57
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9EPX4"
FT   CARBOHYD        6
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        13
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        17..270
FT   DISULFID        97..175
FT   VARIANT         187
FT                   /note="H -> Q (in BDPLT8)"
FT                   /evidence="ECO:0000269|PubMed:25428217"
FT                   /id="VAR_072802"
FT   VARIANT         256
FT                   /note="R -> Q (in BDPLT8; dbSNP:rs121917885)"
FT                   /evidence="ECO:0000269|PubMed:12578987"
FT                   /id="VAR_025383"
FT   VARIANT         265
FT                   /note="R -> W (in BDPLT8; dbSNP:rs121917886)"
FT                   /evidence="ECO:0000269|PubMed:12578987"
FT                   /id="VAR_025384"
FT   VARIANT         330
FT                   /note="E -> G (in dbSNP:rs16846673)"
FT                   /id="VAR_049431"
FT   MUTAGEN         80
FT                   /note="K->A: Abolishes ADP binding."
FT                   /evidence="ECO:0000269|PubMed:24670650"
FT   MUTAGEN         83
FT                   /note="S->A: No effect on ADP binding."
FT                   /evidence="ECO:0000269|PubMed:24784220"
FT   MUTAGEN         97
FT                   /note="C->A: Abolishes ADP binding."
FT                   /evidence="ECO:0000269|PubMed:24784220"
FT   MUTAGEN         156
FT                   /note="S->A: Slightly decreases affinity for ADP."
FT                   /evidence="ECO:0000269|PubMed:24670650"
FT   MUTAGEN         159
FT                   /note="N->A: Slightly decreases affinity for ADP."
FT                   /evidence="ECO:0000269|PubMed:24670650"
FT   MUTAGEN         175
FT                   /note="C->A: Abolishes ADP binding."
FT                   /evidence="ECO:0000269|PubMed:24784220"
FT   MUTAGEN         256
FT                   /note="R->A: Decreases affinity for ADP."
FT                   /evidence="ECO:0000269|PubMed:24784220"
FT   MUTAGEN         280
FT                   /note="K->A: Abolishes ADP binding."
FT                   /evidence="ECO:0000269|PubMed:24670650,
FT                   ECO:0000269|PubMed:24784220"
FT   MUTAGEN         281
FT                   /note="E->A: Abolishes ADP binding."
FT                   /evidence="ECO:0000269|PubMed:24670650"
FT   HELIX           24..50
FT                   /evidence="ECO:0000244|PDB:4PXZ"
FT   HELIX           58..74
FT                   /evidence="ECO:0000244|PDB:4PXZ"
FT   HELIX           77..85
FT                   /evidence="ECO:0000244|PDB:4PXZ"
FT   STRAND          86..88
FT                   /evidence="ECO:0000244|PDB:4PXZ"
FT   HELIX           91..98
FT                   /evidence="ECO:0000244|PDB:4PXZ"
FT   HELIX           100..127
FT                   /evidence="ECO:0000244|PDB:4PXZ"
FT   HELIX           136..161
FT                   /evidence="ECO:0000244|PDB:4PXZ"
FT   HELIX           175..178
FT                   /evidence="ECO:0000244|PDB:4PXZ"
FT   HELIX           181..226
FT                   /evidence="ECO:0000244|PDB:4PXZ"
FT   HELIX           231..233
FT                   /evidence="ECO:0000244|PDB:4PXZ"
FT   HELIX           236..248
FT                   /evidence="ECO:0000244|PDB:4PXZ"
FT   HELIX           250..264
FT                   /evidence="ECO:0000244|PDB:4PXZ"
FT   HELIX           270..293
FT                   /evidence="ECO:0000244|PDB:4PXZ"
FT   HELIX           296..299
FT                   /evidence="ECO:0000244|PDB:4PXZ"
FT   TURN            302..304
FT                   /evidence="ECO:0000244|PDB:4PXZ"
SQ   SEQUENCE   342 AA;  39439 MW;  8553D2746C89176D CRC64;
     MQAVDNLTSA PGNTSLCTRD YKITQVLFPL LYTVLFFVGL ITNGLAMRIF FQIRSKSNFI
     IFLKNTVISD LLMILTFPFK ILSDAKLGTG PLRTFVCQVT SVIFYFTMYI SISFLGLITI
     DRYQKTTRPF KTSNPKNLLG AKILSVVIWA FMFLLSLPNM ILTNRQPRDK NVKKCSFLKS
     EFGLVWHEIV NYICQVIFWI NFLIVIVCYT LITKELYRSY VRTRGVGKVP RKKVNVKVFI
     IIAVFFICFV PFHFARIPYT LSQTRDVFDC TAENTLFYVK ESTLWLTSLN ACLDPFIYFF
     LCKSFRNSLI SMLKCPNSAT SLSQDNRKKE QDGGDPNEET PM
//
ID   OX1R_HUMAN              Reviewed;         425 AA.
AC   O43613; A8K3A6; Q9HBV6;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   22-JUL-2008, sequence version 2.
DT   07-OCT-2020, entry version 169.
DE   RecName: Full=Orexin receptor type 1;
DE            Short=Ox-1-R;
DE            Short=Ox1-R;
DE            Short=Ox1R;
DE   AltName: Full=Hypocretin receptor type 1;
GN   Name=HCRTR1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=9491897; DOI=10.1016/s0092-8674(00)80949-6;
RA   Sakurai T., Amemiya A., Ishii M., Matsuzaki I., Chemelli R.M., Tanaka H.,
RA   Williams S.C., Richardson J.A., Kozlowski G.P., Wilson S., Arch J.R.S.,
RA   Buckingham R.E., Haynes A.C., Carr S.A., Annan R.S., McNulty D.E.,
RA   Liu W.-S., Terrett J.A., Elshourbagy N.A., Bergsma D.J., Yanagisawa M.;
RT   "Orexins and orexin receptors: a family of hypothalamic neuropeptides and G
RT   protein-coupled receptors that regulate feeding behavior.";
RL   Cell 92:573-585(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=10973318; DOI=10.1038/79690;
RA   Peyron C., Faraco J., Rogers W., Ripley B., Overeem S., Charnay Y.,
RA   Nevsimalova S., Aldrich M., Reynolds D., Albin R., Li R., Hungs M.,
RA   Pedrazzoli M., Padigaru M., Kucherlapati M., Fan J., Maki R., Lammers G.J.,
RA   Bouras C., Kucherlapati R., Nishino S., Mignot E.;
RT   "A mutation in a case of early onset narcolepsy and a generalized absence
RT   of hypocretin peptides in human narcoleptic brains.";
RL   Nat. Med. 6:991-997(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-167; GLN-279; HIS-281
RP   AND VAL-408.
RX   PubMed=11723285; DOI=10.1212/wnl.57.10.1896;
RA   Olafsdottir B.R., Rye D.B., Scammell T.E., Matheson J.K., Stefansson K.,
RA   Gulcher J.R.;
RT   "Polymorphisms in hypocretin/orexin pathway genes and narcolepsy.";
RL   Neurology 57:1896-1899(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Yeager M., Welch R., Haque K., Bergen A.;
RT   "Genomic sequence of the hypocretin (orexin) receptor 1 (HCRTR1).";
RL   Submitted (DEC-2001) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT VAL-408.
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   REVIEW.
RX   PubMed=11340621; DOI=10.1002/bies.1058;
RA   Hungs M., Mignot E.;
RT   "Hypocretin/orexin, sleep and narcolepsy.";
RL   Bioessays 23:397-408(2001).
RN   [10]
RP   REVIEW.
RX   PubMed=11283317; DOI=10.1146/annurev.neuro.24.1.429;
RA   Willie J.T., Chemelli R.M., Sinton C.M., Yanagisawa M.;
RT   "To eat or to sleep? Orexin in the regulation of feeding and wakefulness.";
RL   Annu. Rev. Neurosci. 24:429-458(2001).
RN   [11] {ECO:0000244|PDB:4ZJ8, ECO:0000244|PDB:4ZJC}
RP   X-RAY CRYSTALLOGRAPHY (2.75 ANGSTROMS) OF 1-246 AND 288-380 IN COMPLEXES
RP   WITH THE ANTAGONISTS SUVOREXANT AND SB-674042, DISULFIDE BONDS, FUNCTION,
RP   SUBCELLULAR LOCATION, TOPOLOGY, MUTAGENESIS OF 26-ASP--TYR-41; TRP-36 AND
RP   ASN-318, AND DOMAIN.
RX   PubMed=26950369; DOI=10.1038/nsmb.3183;
RA   Yin J., Babaoglu K., Brautigam C.A., Clark L., Shao Z., Scheuermann T.H.,
RA   Harrell C.M., Gotter A.L., Roecker A.J., Winrow C.J., Renger J.J.,
RA   Coleman P.J., Rosenbaum D.M.;
RT   "Structure and ligand-binding mechanism of the human OX1 and OX2 orexin
RT   receptors.";
RL   Nat. Struct. Mol. Biol. 23:293-299(2016).
CC   -!- FUNCTION: Moderately selective excitatory receptor for orexin-A and,
CC       with a lower affinity, for orexin-B neuropeptide (PubMed:9491897,
CC       PubMed:26950369). Triggers an increase in cytoplasmic Ca(2+) levels in
CC       response to orexin-A binding (PubMed:9491897, PubMed:26950369).
CC       {ECO:0000269|PubMed:26950369, ECO:0000269|PubMed:9491897}.
CC   -!- INTERACTION:
CC       O43613; Q92847-1: GHSR; NbExp=3; IntAct=EBI-21914411, EBI-21459171;
CC       O43613; P48357: LEPR; NbExp=4; IntAct=EBI-21914411, EBI-518596;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:26950369,
CC       ECO:0000269|PubMed:9491897}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:26950369}.
CC   -!- DOMAIN: The N-terminal region is required for orexin signaling.
CC       {ECO:0000269|PubMed:26950369}.
CC   -!- MISCELLANEOUS: The antagonists suvorexant and SB-674042 bind at the
CC       cognate neuropeptide binding site that is situated between the
CC       transmembrane helices and accessible from the extracellular side of the
CC       membrane. {ECO:0000269|PubMed:26950369}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF041243; AAC39601.1; -; mRNA.
DR   EMBL; AF202084; AAG28020.1; -; Genomic_DNA.
DR   EMBL; AF202078; AAG28020.1; JOINED; Genomic_DNA.
DR   EMBL; AF202079; AAG28020.1; JOINED; Genomic_DNA.
DR   EMBL; AF202080; AAG28020.1; JOINED; Genomic_DNA.
DR   EMBL; AF202081; AAG28020.1; JOINED; Genomic_DNA.
DR   EMBL; AF202082; AAG28020.1; JOINED; Genomic_DNA.
DR   EMBL; AF202083; AAG28020.1; JOINED; Genomic_DNA.
DR   EMBL; AY062030; AAL47214.1; -; Genomic_DNA.
DR   EMBL; AY070269; AAL50221.1; -; Genomic_DNA.
DR   EMBL; AK290521; BAF83210.1; -; mRNA.
DR   EMBL; AC114488; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471059; EAX07602.1; -; Genomic_DNA.
DR   EMBL; BC074796; AAH74796.1; -; mRNA.
DR   CCDS; CCDS344.1; -.
DR   RefSeq; NP_001516.2; NM_001525.2.
DR   RefSeq; XP_016856594.1; XM_017001105.1.
DR   RefSeq; XP_016856595.1; XM_017001106.1.
DR   PDB; 4ZJ8; X-ray; 2.75 A; A=1-246, A=288-380.
DR   PDB; 4ZJC; X-ray; 2.83 A; A=1-246, A=288-380.
DR   PDB; 6TO7; X-ray; 2.26 A; A/B=28-380.
DR   PDB; 6TOD; X-ray; 2.11 A; A/B=28-380.
DR   PDB; 6TOS; X-ray; 2.13 A; A/B=28-380.
DR   PDB; 6TOT; X-ray; 2.22 A; A/B=28-380.
DR   PDB; 6TP3; X-ray; 3.04 A; A/B=28-380.
DR   PDB; 6TP4; X-ray; 3.01 A; A/B=28-380.
DR   PDB; 6TP6; X-ray; 2.34 A; A/B=28-380.
DR   PDB; 6TQ4; X-ray; 2.30 A; A/B=28-380.
DR   PDB; 6TQ6; X-ray; 2.55 A; A/B=28-380.
DR   PDB; 6TQ7; X-ray; 2.66 A; A/B=28-380.
DR   PDB; 6TQ9; X-ray; 2.65 A; A/B=28-381.
DR   PDB; 6V9S; X-ray; 3.50 A; A=1-246, A=288-380.
DR   PDBsum; 4ZJ8; -.
DR   PDBsum; 4ZJC; -.
DR   PDBsum; 6TO7; -.
DR   PDBsum; 6TOD; -.
DR   PDBsum; 6TOS; -.
DR   PDBsum; 6TOT; -.
DR   PDBsum; 6TP3; -.
DR   PDBsum; 6TP4; -.
DR   PDBsum; 6TP6; -.
DR   PDBsum; 6TQ4; -.
DR   PDBsum; 6TQ6; -.
DR   PDBsum; 6TQ7; -.
DR   PDBsum; 6TQ9; -.
DR   PDBsum; 6V9S; -.
DR   SMR; O43613; -.
DR   BioGRID; 109311; 6.
DR   ELM; O43613; -.
DR   IntAct; O43613; 2.
DR   STRING; 9606.ENSP00000384387; -.
DR   BindingDB; O43613; -.
DR   ChEMBL; CHEMBL5113; -.
DR   DrugBank; DB11951; Lemborexant.
DR   DrugBank; DB09034; Suvorexant.
DR   DrugCentral; O43613; -.
DR   GuidetoPHARMACOLOGY; 321; -.
DR   GlyGen; O43613; 1 site.
DR   iPTMnet; O43613; -.
DR   PhosphoSitePlus; O43613; -.
DR   BioMuta; HCRTR1; -.
DR   PaxDb; O43613; -.
DR   PRIDE; O43613; -.
DR   ProteomicsDB; 49081; -.
DR   Antibodypedia; 2934; 399 antibodies.
DR   Ensembl; ENST00000373706; ENSP00000362810; ENSG00000121764.
DR   Ensembl; ENST00000403528; ENSP00000384387; ENSG00000121764.
DR   GeneID; 3061; -.
DR   KEGG; hsa:3061; -.
DR   UCSC; uc001btd.3; human.
DR   CTD; 3061; -.
DR   DisGeNET; 3061; -.
DR   EuPathDB; HostDB:ENSG00000121764.11; -.
DR   GeneCards; HCRTR1; -.
DR   HGNC; HGNC:4848; HCRTR1.
DR   HPA; ENSG00000121764; Tissue enhanced (brain).
DR   MIM; 602392; gene.
DR   neXtProt; NX_O43613; -.
DR   OpenTargets; ENSG00000121764; -.
DR   PharmGKB; PA29222; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT01000000214421; -.
DR   HOGENOM; CLU_009579_6_3_1; -.
DR   InParanoid; O43613; -.
DR   KO; K04238; -.
DR   OMA; LMEPSAT; -.
DR   OrthoDB; 981089at2759; -.
DR   PhylomeDB; O43613; -.
DR   TreeFam; TF315303; -.
DR   PathwayCommons; O43613; -.
DR   Reactome; R-HSA-389397; Orexin and neuropeptides FF and QRFP bind to their respective receptors.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   SIGNOR; O43613; -.
DR   BioGRID-ORCS; 3061; 139 hits in 864 CRISPR screens.
DR   ChiTaRS; HCRTR1; human.
DR   GeneWiki; Hypocretin_(orexin)_receptor_1; -.
DR   GenomeRNAi; 3061; -.
DR   Pharos; O43613; Tclin.
DR   PRO; PR:O43613; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; O43613; protein.
DR   Bgee; ENSG00000121764; Expressed in cortical plate and 90 other tissues.
DR   ExpressionAtlas; O43613; baseline and differential.
DR   Genevisible; O43613; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0045202; C:synapse; IEA:GOC.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0016499; F:orexin receptor activity; IDA:UniProtKB.
DR   GO; GO:0017046; F:peptide hormone binding; IEA:Ensembl.
DR   GO; GO:0007268; P:chemical synaptic transmission; TAS:ProtInc.
DR   GO; GO:0007631; P:feeding behavior; TAS:ProtInc.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007218; P:neuropeptide signaling pathway; IDA:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:0051480; P:regulation of cytosolic calcium ion concentration; IDA:UniProtKB.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR000204; Orexin_rcpt.
DR   InterPro; IPR004059; Orexin_rcpt_1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01521; OREXIN1R.
DR   PRINTS; PR01064; OREXINR.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Membrane; Polymorphism; Receptor; Reference proteome;
KW   Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..425
FT                   /note="Orexin receptor type 1"
FT                   /id="PRO_0000069984"
FT   TOPO_DOM        1..46
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:26950369"
FT   TRANSMEM        47..67
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000269|PubMed:26950369"
FT   TOPO_DOM        68..82
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:26950369"
FT   TRANSMEM        83..105
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000269|PubMed:26950369"
FT   TOPO_DOM        106..119
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:26950369"
FT   TRANSMEM        120..140
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000269|PubMed:26950369"
FT   TOPO_DOM        141..160
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:26950369"
FT   TRANSMEM        161..182
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000269|PubMed:26950369"
FT   TOPO_DOM        183..213
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:26950369"
FT   TRANSMEM        214..235
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000269|PubMed:26950369"
FT   TOPO_DOM        236..298
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:26950369"
FT   TRANSMEM        299..321
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000269|PubMed:26950369"
FT   TOPO_DOM        322..336
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:26950369"
FT   TRANSMEM        337..360
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000269|PubMed:26950369"
FT   TOPO_DOM        361..425
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:26950369"
FT   REGION          26..41
FT                   /note="Required for response to orexin-A"
FT                   /evidence="ECO:0000269|PubMed:26950369"
FT   BINDING         318
FT                   /note="Agonist"
FT                   /evidence="ECO:0000244|PDB:4ZJ8,
FT                   ECO:0000305|PubMed:26950369"
FT   SITE            36
FT                   /note="Important for responses to orexin"
FT                   /evidence="ECO:0000269|PubMed:26950369"
FT   CARBOHYD        194
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        119..202
FT                   /evidence="ECO:0000244|PDB:4ZJ8, ECO:0000244|PDB:4ZJC"
FT   VARIANT         167
FT                   /note="G -> S (in dbSNP:rs144603792)"
FT                   /evidence="ECO:0000269|PubMed:11723285"
FT                   /id="VAR_044505"
FT   VARIANT         279
FT                   /note="R -> Q (in dbSNP:rs7516785)"
FT                   /evidence="ECO:0000269|PubMed:11723285"
FT                   /id="VAR_033480"
FT   VARIANT         281
FT                   /note="R -> H (in dbSNP:rs41439244)"
FT                   /evidence="ECO:0000269|PubMed:11723285"
FT                   /id="VAR_044506"
FT   VARIANT         408
FT                   /note="I -> V (in dbSNP:rs2271933)"
FT                   /evidence="ECO:0000269|PubMed:11723285,
FT                   ECO:0000269|PubMed:14702039"
FT                   /id="VAR_022063"
FT   MUTAGEN         26..41
FT                   /note="Missing: Abolishes response to orexin-A."
FT                   /evidence="ECO:0000269|PubMed:26950369"
FT   MUTAGEN         36
FT                   /note="W->A: Strongly impairs response to orexin-A."
FT                   /evidence="ECO:0000269|PubMed:26950369"
FT   MUTAGEN         318
FT                   /note="N->A: Strongly impairs response to orexin-A."
FT                   /evidence="ECO:0000269|PubMed:26950369"
FT   CONFLICT        280
FT                   /note="A -> G (in Ref. 1; AAC39601)"
FT                   /evidence="ECO:0000305"
FT   HELIX           30..38
FT                   /evidence="ECO:0000244|PDB:6TOD"
FT   HELIX           40..43
FT                   /evidence="ECO:0000244|PDB:6TOD"
FT   HELIX           46..73
FT                   /evidence="ECO:0000244|PDB:6TOD"
FT   HELIX           75..77
FT                   /evidence="ECO:0000244|PDB:6TOD"
FT   HELIX           80..109
FT                   /evidence="ECO:0000244|PDB:6TOD"
FT   STRAND          110..112
FT                   /evidence="ECO:0000244|PDB:6TP6"
FT   HELIX           115..149
FT                   /evidence="ECO:0000244|PDB:6TOD"
FT   HELIX           151..153
FT                   /evidence="ECO:0000244|PDB:4ZJ8"
FT   HELIX           158..175
FT                   /evidence="ECO:0000244|PDB:6TOD"
FT   HELIX           177..182
FT                   /evidence="ECO:0000244|PDB:6TOD"
FT   STRAND          183..189
FT                   /evidence="ECO:0000244|PDB:6TOD"
FT   HELIX           190..192
FT                   /evidence="ECO:0000244|PDB:6TOD"
FT   TURN            193..195
FT                   /evidence="ECO:0000244|PDB:6TOD"
FT   STRAND          200..204
FT                   /evidence="ECO:0000244|PDB:6TOD"
FT   STRAND          207..210
FT                   /evidence="ECO:0000244|PDB:6TOD"
FT   HELIX           211..223
FT                   /evidence="ECO:0000244|PDB:6TOD"
FT   HELIX           225..242
FT                   /evidence="ECO:0000244|PDB:6TOD"
FT   HELIX           287..322
FT                   /evidence="ECO:0000244|PDB:6TOD"
FT   HELIX           330..332
FT                   /evidence="ECO:0000244|PDB:6TOD"
FT   HELIX           333..361
FT                   /evidence="ECO:0000244|PDB:6TOD"
FT   HELIX           363..374
FT                   /evidence="ECO:0000244|PDB:6TOD"
SQ   SEQUENCE   425 AA;  47536 MW;  B650B37F3A2CA096 CRC64;
     MEPSATPGAQ MGVPPGSREP SPVPPDYEDE FLRYLWRDYL YPKQYEWVLI AAYVAVFVVA
     LVGNTLVCLA VWRNHHMRTV TNYFIVNLSL ADVLVTAICL PASLLVDITE SWLFGHALCK
     VIPYLQAVSV SVAVLTLSFI ALDRWYAICH PLLFKSTARR ARGSILGIWA VSLAIMVPQA
     AVMECSSVLP ELANRTRLFS VCDERWADDL YPKIYHSCFF IVTYLAPLGL MAMAYFQIFR
     KLWGRQIPGT TSALVRNWKR PSDQLGDLEQ GLSGEPQPRA RAFLAEVKQM RARRKTAKML
     MVVLLVFALC YLPISVLNVL KRVFGMFRQA SDREAVYACF TFSHWLVYAN SAANPIIYNF
     LSGKFREQFK AAFSCCLPGL GPCGSLKAPS PRSSASHKSL SLQSRCSISK ISEHVVLTSV
     TTVLP
//
ID   LSHR_HUMAN              Reviewed;         699 AA.
AC   P22888; Q14751; Q15996; Q9UEW9;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   15-DEC-2009, sequence version 4.
DT   12-AUG-2020, entry version 218.
DE   RecName: Full=Lutropin-choriogonadotropic hormone receptor;
DE            Short=LH/CG-R;
DE   AltName: Full=Luteinizing hormone receptor;
DE            Short=LHR;
DE            Short=LSH-R;
DE   Flags: Precursor;
GN   Name=LHCGR; Synonyms=LCGR, LGR2, LHRHR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT SER-312.
RC   TISSUE=Ovary;
RX   PubMed=2244890; DOI=10.1016/0006-291x(90)91552-4;
RA   Minegish T., Nakamura K., Takakura Y., Miyamoto K., Hasegawa Y., Ibuki Y.,
RA   Igarashi M.;
RT   "Cloning and sequencing of human LH/hCG receptor cDNA.";
RL   Biochem. Biophys. Res. Commun. 172:1049-1054(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Ovary;
RX   PubMed=1922095; DOI=10.1210/mend-5-6-759;
RA   Jia X.-C., Oikawa M., Bo M., Tanaka T., Ny T., Boime I., Hsueh A.J.W.;
RT   "Expression of human luteinizing hormone (LH) receptor: interaction with LH
RT   and chorionic gonadotropin from human but not equine, rat, and ovine
RT   species.";
RL   Mol. Endocrinol. 5:759-768(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Thyroid;
RX   PubMed=2293030; DOI=10.1210/mend-4-8-1264;
RA   Frazier A.L., Robbins L.S., Stork P.J., Sprengel R., Segaloff D.L.,
RA   Cone R.D.;
RT   "Isolation of TSH and LH/CG receptor cDNAs from human thyroid: regulation
RT   by tissue specific splicing.";
RL   Mol. Endocrinol. 4:1264-1276(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LEU-GLN-18 INS AND SER-312.
RX   PubMed=7556872; DOI=10.1016/0303-7207(95)03557-n;
RA   Atger M., Misrahi M., Sar S., Leflem L., Dessen P., Milgrom E.;
RT   "Structure of the human luteinizing hormone-choriogonadotropin receptor
RT   gene: unusual promoter and 5' non-coding regions.";
RL   Mol. Cell. Endocrinol. 111:113-123(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-54, AND VARIANT LEU-GLN-18 INS.
RX   PubMed=9858858; DOI=10.1159/000022840;
RA   Tsai-Morris C.-H., Geng Y., Buczko E., Dehejia A., Dufau M.L.;
RT   "Genomic distribution and gonadal mRNA expression of two human luteinizing
RT   hormone receptor exon 1 sequences in random populations.";
RL   Hum. Hered. 49:48-51(1999).
RN   [7]
RP   FUNCTION, SUBCELLULAR LOCATION, SULFATION AT TYR-331, AND MUTAGENESIS OF
RP   TYR-331 AND TYR-333.
RX   PubMed=11847099; DOI=10.1093/emboj/21.4.504;
RA   Costagliola S., Panneels V., Bonomi M., Koch J., Many M.C., Smits G.,
RA   Vassart G.;
RT   "Tyrosine sulfation is required for agonist recognition by glycoprotein
RT   hormone receptors.";
RL   EMBO J. 21:504-513(2002).
RN   [8]
RP   PALMITOYLATION AT CYS-643 AND CYS-644, AND MUTAGENESIS OF CYS-643 AND
RP   CYS-644.
RX   PubMed=15539429; DOI=10.1210/me.2004-0335;
RA   Munshi U.M., Clouser C.L., Peegel H., Menon K.M.;
RT   "Evidence that palmitoylation of carboxyl terminus cysteine residues of the
RT   human luteinizing hormone receptor regulates postendocytic processing.";
RL   Mol. Endocrinol. 19:749-758(2005).
RN   [9]
RP   3D-STRUCTURE MODELING OF 51-232.
RX   PubMed=8747461; DOI=10.1016/s0969-2126(01)00272-6;
RA   Jiang X., Dreano M., Buckler D.R., Cheng S., Ythier A., Wu H.,
RA   Hendrickson W.A., el Tayar N.;
RT   "Structural predictions for the ligand-binding region of glycoprotein
RT   hormone receptors and the nature of hormone-receptor interactions.";
RL   Structure 3:1341-1353(1995).
RN   [10]
RP   VARIANTS FMPP PRO-368 AND VAL-568, AND CHARACTERIZATION OF VARIANT FMPP
RP   PRO-368.
RX   PubMed=11134146; DOI=10.1210/jcem.85.12.7071;
RA   Latronico A.C., Shinozaki H., Guerra G. Jr., Pereira M.A.A.,
RA   Lemos Marini S.H.V., Baptista M.T.M., Arnhold I.J.P., Fanelli F.,
RA   Mendonca B.B., Segaloff D.L.;
RT   "Gonadotropin-independent precocious puberty due to luteinizing hormone
RT   receptor mutations in Brazilian boys: a novel constitutively activating
RT   mutation in the first transmembrane helix.";
RL   J. Clin. Endocrinol. Metab. 85:4799-4805(2000).
RN   [11]
RP   VARIANT FMPP GLY-564.
RX   PubMed=11391350; DOI=10.1067/mpd.2001.114477;
RA   Leschek E.W., Chan W.-Y., Diamond D.A., Kaefer M., Jones J., Barnes K.M.,
RA   Cutler G.B. Jr.;
RT   "Nodular Leydig cell hyperplasia in a boy with familial male-limited
RT   precocious puberty.";
RL   J. Pediatr. 138:949-951(2001).
RN   [12]
RP   VARIANTS LHR SER-343 AND ARG-543, AND CHARACTERIZATION OF VARIANTS LHR
RP   SER-343 AND ARG-543.
RX   PubMed=12050206; DOI=10.1210/jcem.87.6.8523;
RA   Martens J.W.M., Lumbroso S., Verhoef-Post M., Georget V., Richter-Unruh A.,
RA   Szarras-Czapnik M., Romer T.E., Brunner H.G., Themmen A.P.N., Sultan C.;
RT   "Mutant luteinizing hormone receptors in a compound heterozygous patient
RT   with complete Leydig cell hypoplasia: abnormal processing causes signaling
RT   deficiency.";
RL   J. Clin. Endocrinol. Metab. 87:2506-2513(2002).
RN   [13]
RP   ASSOCIATION OF VARIANT LEU-GLN-18 INS WITH AGE OF BREAST CANCER ONSET.
RX   PubMed=12679452; DOI=10.1210/jc.2002-021585;
RA   Powell B.L., Piersma D., Kevenaar M.E., van Staveren I.L., Themmen A.P.N.,
RA   Iacopetta B.J., Berns E.M.J.J.;
RT   "Luteinizing hormone signaling and breast cancer: polymorphisms and age of
RT   onset.";
RL   J. Clin. Endocrinol. Metab. 88:1653-1657(2003).
RN   [14]
RP   VARIANT FMPP GLY-578.
RX   PubMed=7692306; DOI=10.1038/365652a0;
RA   Shenker A., Laue L., Kosugi S., Merendino J.J. Jr., Minegishi T.,
RA   Cutler G.B. Jr.;
RT   "A constitutively activating mutation of the luteinizing hormone receptor
RT   in familial male precocious puberty.";
RL   Nature 365:652-654(1993).
RN   [15]
RP   VARIANTS FMPP ILE-571 AND GLY-578.
RX   PubMed=8281137; DOI=10.1093/hmg/2.11.1779;
RA   Kremer H., Mariman E., Otten B.J., Moll G.W. Jr., Stoelinga G.B.A.,
RA   Wit J.M., Jansen M., Drop S.L., Faas B., Ropers H.-H., Brunner H.G.;
RT   "Cosegregation of missense mutations of the luteinizing hormone receptor
RT   gene with familial male-limited precocious puberty.";
RL   Hum. Mol. Genet. 2:1779-1783(1993).
RN   [16]
RP   VARIANT FMPP ILE-577.
RX   PubMed=7757065; DOI=10.1093/hmg/4.2.183;
RA   Kosugi S., van Dop C., Geffner M.E., Rabl W., Carel J.-C., Chaussain J.-L.,
RA   Mori T., Merendino J.J. Jr., Shenker A.;
RT   "Characterization of heterogeneous mutations causing constitutive
RT   activation of the luteinizing hormone receptor in familial male precocious
RT   puberty.";
RL   Hum. Mol. Genet. 4:183-188(1995).
RN   [17]
RP   VARIANT FMPP VAL-572.
RX   PubMed=7714085; DOI=10.1210/jcem.80.4.7714085;
RA   Yano K., Saji M., Hidaka A., Moriya N., Okuno A., Kohn L.D.,
RA   Cutler G.B. Jr.;
RT   "A new constitutively activating point mutation in the luteinizing
RT   hormone/choriogonadotropin receptor gene in cases of male-limited
RT   precocious puberty.";
RL   J. Clin. Endocrinol. Metab. 80:1162-1168(1995).
RN   [18]
RP   VARIANT FMPP VAL-568.
RX   PubMed=7629248; DOI=10.1210/jcem.80.8.7629248;
RA   Latronico A.C., Anasti J., Arnhold I.J., Mendonca B.B., Domenice S.,
RA   Albano M.C., Zachman K., Wajchenberg B.L., Tsigos C.;
RT   "A novel mutation of the luteinizing hormone receptor gene causing male
RT   gonadotropin-independent precocious puberty.";
RL   J. Clin. Endocrinol. Metab. 80:2490-2494(1995).
RN   [19]
RP   VARIANT LHR PRO-593.
RX   PubMed=7719343; DOI=10.1038/ng0295-160;
RA   Kremer H., Kraaij R., Toledo S.P.A., Post M., Fridman J.B., Hayashida C.Y.,
RA   van Reen M., Milgrom E., Ropers H.-H., Mariman E., Themmen A.P.N.,
RA   Brunner H.G.;
RT   "Male pseudohermaphroditism due to a homozygous missense mutation of the
RT   luteinizing hormone receptor gene.";
RL   Nat. Genet. 9:160-164(1995).
RN   [20]
RP   VARIANT FMPP ILE-577.
RX   PubMed=8829636;
RX   DOI=10.1002/(sici)1098-1004(1996)7:2<164::aid-humu13>3.0.co;2-0;
RA   Cocco S., Meloni A., Marini M.G., Cao A., Moi P.;
RT   "A missense (T577I) mutation in the luteinizing hormone receptor gene
RT   associated with familial male-limited precocious puberty.";
RL   Hum. Mutat. 7:164-166(1996).
RN   [21]
RP   VARIANT FMPP THR-398.
RX   PubMed=8929952; DOI=10.1136/jmg.33.2.143;
RA   Evans B.A.J., Bowen D.J., Smith P.J., Clayton P.E., Gregory J.W.;
RT   "A new point mutation in the luteinising hormone receptor gene in familial
RT   and sporadic male limited precocious puberty: genotype does not always
RT   correlate with phenotype.";
RL   J. Med. Genet. 33:143-147(1996).
RN   [22]
RP   VARIANT LHR TYR-616.
RX   PubMed=8559204; DOI=10.1056/nejm199602223340805;
RA   Latronico A.C., Anasti J., Arnhold I.J.P., Rapaport R., Mendonca B.B.,
RA   Bloise W., Castro M., Tsigos C., Chrousos G.P.;
RT   "Testicular and ovarian resistance to luteinizing hormone caused by
RT   inactivating mutations of the luteinizing hormone-receptor gene.";
RL   N. Engl. J. Med. 334:507-512(1996).
RN   [23]
RP   VARIANT LHR ARG-131.
RX   PubMed=9215288; DOI=10.1210/jcem.82.7.4039;
RA   Misrahi M., Meduri G., Pissard S., Bouvattier C., Beau I., Loosfelt H.,
RA   Jolivet A., Rappaport R., Milgrom E., Bougneres P.;
RT   "Comparison of immunocytochemical and molecular features with the phenotype
RT   in a case of incomplete male pseudohermaphroditism associated with a
RT   mutation of the luteinizing hormone receptor.";
RL   J. Clin. Endocrinol. Metab. 82:2159-2165(1997).
RN   [24]
RP   VARIANTS LEU-GLN-18 INS; SER-284 AND ASN-306.
RX   PubMed=10215412;
RX   DOI=10.1002/(sici)1098-1004(1998)11:4<333::aid-humu19>3.0.co;2-d;
RA   Wu S.-M., Jose M., Hallermeier K., Rennert O.M., Chan W.-Y.;
RT   "Polymorphisms in the coding exons of the human luteinizing hormone
RT   receptor gene.";
RL   Hum. Mutat. 11:333-334(1998).
RN   [25]
RP   VARIANT FMPP VAL-373.
RX   PubMed=9467560; DOI=10.1210/jcem.83.2.4579;
RA   Gromoll J., Partsch C.-J., Simoni M., Nordhoff V., Sippell W.G.,
RA   Nieschlag E., Saxena B.B.;
RT   "A mutation in the first transmembrane domain of the lutropin receptor
RT   causes male precocious puberty.";
RL   J. Clin. Endocrinol. Metab. 83:476-480(1998).
RN   [26]
RP   VARIANT LHR LYS-354.
RX   PubMed=9626144; DOI=10.1210/jcem.83.6.4855;
RA   Stavrou S.S., Zhu Y.S., Cai L.Q., Katz M.D., Herrera C., Defillo-Ricart M.,
RA   Imperato-Mcginley J.;
RT   "A novel mutation of the human luteinizing hormone receptor in 46XY and
RT   46XX sisters.";
RL   J. Clin. Endocrinol. Metab. 83:2091-2098(1998).
RN   [27]
RP   VARIANT FMPP ARG-457.
RX   PubMed=9661624; DOI=10.1210/jcem.83.7.4968;
RA   Latronico A.C., Abell A.N., Arnhold I.J., Liu X., Lins T.S., Brito V.N.,
RA   Billerbeck A.E., Segaloff D.L., Mendonca B.B.;
RT   "A unique constitutively activating mutation in third transmembrane helix
RT   of luteinizing hormone receptor causes sporadic male gonadotropin-
RT   independent precocious puberty.";
RL   J. Clin. Endocrinol. Metab. 83:2435-2440(1998).
RN   [28]
RP   VARIANT LEU-GLN-18 INS.
RX   PubMed=9851790; DOI=10.1210/jcem.83.12.5325;
RA   Rodien P., Cetani F., Costagliola S., Tonacchera M., Duprez L.,
RA   Minegishi T., Govaerts C., Vassart G.;
RT   "Evidences for an allelic variant of the human LC/CG receptor rather than a
RT   gene duplication: functional comparison of wild-type and variant
RT   receptors.";
RL   J. Clin. Endocrinol. Metab. 83:4431-4434(1998).
RN   [29]
RP   VARIANT LHR 608-LEU-VAL-609 DEL.
RX   PubMed=9514160; DOI=10.1210/mend.12.3.0077;
RA   Latronico A.C., Chai Y., Arnhold I.J.P., Liu X., Mendonca B.B.,
RA   Segaloff D.L.;
RT   "A homozygous microdeletion in helix 7 of the luteinizing hormone receptor
RT   associated with familial testicular and ovarian resistance is due to both
RT   decreased cell surface expression and impaired effector activation by the
RT   cell surface receptor.";
RL   Mol. Endocrinol. 12:442-450(1998).
RN   [30]
RP   VARIANT LHR LYS-625.
RX   PubMed=9626653; DOI=10.1210/mend.12.6.0124;
RA   Martens J.W., Verhoef-Post M., Abelin N., Ezabella M., Toledo S.P.,
RA   Brunner H.G., Themmen A.P.;
RT   "A homozygous mutation in the luteinizing hormone receptor causes partial
RT   Leydig cell hypoplasia: correlation between receptor activity and
RT   phenotype.";
RL   Mol. Endocrinol. 12:775-784(1998).
RN   [31]
RP   VARIANT LEYDIG CELL TUMOR HIS-578.
RX   PubMed=10580072; DOI=10.1056/nejm199912023412304;
RA   Liu G., Duranteau L., Carel J.-C., Monroe J., Doyle D.A., Shenker A.;
RT   "Leydig-cell tumors caused by an activating mutation of the gene encoding
RT   the luteinizing hormone receptor.";
RL   N. Engl. J. Med. 341:1731-1736(1999).
RN   [32]
RP   VARIANT LHR PRO-502, AND CHARACTERIZATION OF VARIANT LCH PRO-502.
RX   PubMed=15372531; DOI=10.1002/ajmg.a.20681;
RA   Leung M.Y.-K., Al-Muslim O., Wu S.-M., Aziz A., Inam S., Awadh M.,
RA   Rennert O.M., Chan W.-Y.;
RT   "A novel missense homozygous inactivating mutation in the fourth
RT   transmembrane helix of the luteinizing hormone receptor in Leydig cell
RT   hypoplasia.";
RL   Am. J. Med. Genet. A 130:146-153(2004).
RN   [33]
RP   VARIANT LHR PHE-144, AND CHARACTERIZATION OF VARIANT LCH PHE-144.
RX   PubMed=15472221; DOI=10.1210/jc.2004-0298;
RA   Richter-Unruh A., Verhoef-Post M., Malak S., Homoki J., Hauffa B.P.,
RA   Themmen A.P.N.;
RT   "Leydig cell hypoplasia: absent luteinizing hormone receptor cell surface
RT   expression caused by a novel homozygous mutation in the extracellular
RT   domain.";
RL   J. Clin. Endocrinol. Metab. 89:5161-5167(2004).
RN   [34]
RP   VARIANT [LARGE SCALE ANALYSIS] ASN-564.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [35]
RP   VARIANT LHR THR-152, AND CHARACTERIZATION OF VARIANT LHR THR-152.
RX   PubMed=19551906; DOI=10.1002/humu.21072;
RA   Qiao J., Han B., Liu B.-L., Chen X., Ru Y., Cheng K.-X., Chen F.-G.,
RA   Zhao S.-X., Liang J., Lu Y.-L., Tang J.-F., Wu Y.-X., Wu W.-L., Chen J.-L.,
RA   Chen M.-D., Song H.-D.;
RT   "A splice site mutation combined with a novel missense mutation of LHCGR
RT   cause male pseudohermaphroditism.";
RL   Hum. Mutat. 30:E855-E865(2009).
CC   -!- FUNCTION: Receptor for lutropin-choriogonadotropic hormone
CC       (PubMed:11847099). The activity of this receptor is mediated by G
CC       proteins which activate adenylate cyclase (PubMed:11847099).
CC       {ECO:0000269|PubMed:11847099}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:11847099};
CC       Multi-pass membrane protein {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=Long;
CC         IsoId=P22888-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=P22888-2; Sequence=VSP_001962;
CC   -!- TISSUE SPECIFICITY: Gonadal and thyroid cells.
CC   -!- PTM: Sulfated. {ECO:0000269|PubMed:11847099}.
CC   -!- DISEASE: Familial male precocious puberty (FMPP) [MIM:176410]: In FMPP
CC       the receptor is constitutively activated. {ECO:0000269|PubMed:11134146,
CC       ECO:0000269|PubMed:11391350, ECO:0000269|PubMed:7629248,
CC       ECO:0000269|PubMed:7692306, ECO:0000269|PubMed:7714085,
CC       ECO:0000269|PubMed:7757065, ECO:0000269|PubMed:8281137,
CC       ECO:0000269|PubMed:8829636, ECO:0000269|PubMed:8929952,
CC       ECO:0000269|PubMed:9467560, ECO:0000269|PubMed:9661624}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Luteinizing hormone resistance (LHR) [MIM:238320]: An
CC       autosomal recessive disorder characterized by unresponsiveness to
CC       luteinizing hormone, defective sexual development in males, and
CC       defective follicular development and ovulation, amenorrhea and
CC       infertility in females. Two forms of the disorder have been defined in
CC       males. Type 1 is a severe form characterized by complete 46,XY male
CC       pseudohermaphroditism, low testosterone and high luteinizing hormone
CC       levels, total lack of responsiveness to luteinizing and chorionic
CC       gonadotropin hormones, lack of breast development, and absent
CC       development of secondary male sex characteristics. Type 2, a milder
CC       form, displays a broader range of phenotypic expression ranging from
CC       micropenis to severe hypospadias. {ECO:0000269|PubMed:12050206,
CC       ECO:0000269|PubMed:15372531, ECO:0000269|PubMed:15472221,
CC       ECO:0000269|PubMed:19551906, ECO:0000269|PubMed:7719343,
CC       ECO:0000269|PubMed:8559204, ECO:0000269|PubMed:9215288,
CC       ECO:0000269|PubMed:9514160, ECO:0000269|PubMed:9626144,
CC       ECO:0000269|PubMed:9626653}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       FSH/LSH/TSH subfamily. {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/LHRID288.html";
CC   -!- WEB RESOURCE: Name=Sequence-structure-function-analysis of glycoprotein
CC       hormone receptors;
CC       URL="http://www.ssfa-gphr.de/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M63108; AAA59515.1; -; mRNA.
DR   EMBL; S57793; AAB19917.2; -; mRNA.
DR   EMBL; M73746; AAA70231.1; -; mRNA.
DR   EMBL; X84753; CAA59234.1; -; Genomic_DNA.
DR   EMBL; X84754; CAA59234.1; JOINED; Genomic_DNA.
DR   EMBL; X84755; CAA59234.1; JOINED; Genomic_DNA.
DR   EMBL; X84756; CAA59234.1; JOINED; Genomic_DNA.
DR   EMBL; X84757; CAA59234.1; JOINED; Genomic_DNA.
DR   EMBL; X84758; CAA59234.1; JOINED; Genomic_DNA.
DR   EMBL; X84759; CAA59234.1; JOINED; Genomic_DNA.
DR   EMBL; X84760; CAA59234.1; JOINED; Genomic_DNA.
DR   EMBL; X84761; CAA59234.1; JOINED; Genomic_DNA.
DR   EMBL; X84762; CAA59234.1; JOINED; Genomic_DNA.
DR   EMBL; X84763; CAA59234.1; JOINED; Genomic_DNA.
DR   EMBL; AC073082; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC087816; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF082076; AAC98291.1; -; Genomic_DNA.
DR   EMBL; AF024642; AAB88417.1; -; Genomic_DNA.
DR   CCDS; CCDS1842.1; -. [P22888-1]
DR   PIR; A36243; QRHUUT.
DR   RefSeq; NP_000224.2; NM_000233.3. [P22888-1]
DR   PDB; 1LUT; Model; -; A=51-232.
DR   PDB; 1XUL; Model; -; C=51-232.
DR   PDBsum; 1LUT; -.
DR   PDBsum; 1XUL; -.
DR   BioGRID; 110161; 4.
DR   CORUM; P22888; -.
DR   MINT; P22888; -.
DR   STRING; 9606.ENSP00000294954; -.
DR   BindingDB; P22888; -.
DR   ChEMBL; CHEMBL1854; -.
DR   DrugBank; DB06719; Buserelin.
DR   DrugBank; DB00050; Cetrorelix.
DR   DrugBank; DB00097; Choriogonadotropin alfa.
DR   DrugBank; DB09126; Chorionic Gonadotropin (Human).
DR   DrugBank; DB00014; Goserelin.
DR   DrugBank; DB00044; Lutropin alfa.
DR   DrugBank; DB00032; Menotropins.
DR   DrugCentral; P22888; -.
DR   GuidetoPHARMACOLOGY; 254; -.
DR   GlyGen; P22888; 6 sites.
DR   iPTMnet; P22888; -.
DR   PhosphoSitePlus; P22888; -.
DR   SwissPalm; P22888; -.
DR   BioMuta; LHCGR; -.
DR   DMDM; 281185513; -.
DR   PaxDb; P22888; -.
DR   PeptideAtlas; P22888; -.
DR   PRIDE; P22888; -.
DR   ProteomicsDB; 54043; -. [P22888-1]
DR   ProteomicsDB; 54044; -. [P22888-2]
DR   Antibodypedia; 4073; 593 antibodies.
DR   DNASU; 3973; -.
DR   Ensembl; ENST00000294954; ENSP00000294954; ENSG00000138039. [P22888-1]
DR   GeneID; 3973; -.
DR   KEGG; hsa:3973; -.
DR   UCSC; uc002rwu.5; human. [P22888-1]
DR   CTD; 3973; -.
DR   DisGeNET; 3973; -.
DR   EuPathDB; HostDB:ENSG00000138039.14; -.
DR   GeneCards; LHCGR; -.
DR   HGNC; HGNC:6585; LHCGR.
DR   HPA; ENSG00000138039; Tissue enhanced (brain, testis).
DR   MalaCards; LHCGR; -.
DR   MIM; 152790; gene+phenotype.
DR   MIM; 176410; phenotype.
DR   MIM; 238320; phenotype.
DR   neXtProt; NX_P22888; -.
DR   OpenTargets; ENSG00000138039; -.
DR   Orphanet; 3000; Familial male-limited precocious puberty.
DR   Orphanet; 96265; Leydig cell hypoplasia due to complete LH resistance.
DR   Orphanet; 96266; Leydig cell hypoplasia due to partial LH resistance.
DR   Orphanet; 619; NON RARE IN EUROPE: Primary ovarian failure.
DR   PharmGKB; PA30357; -.
DR   eggNOG; KOG2087; Eukaryota.
DR   GeneTree; ENSGT00940000157364; -.
DR   InParanoid; P22888; -.
DR   KO; K04248; -.
DR   OMA; CEDILGY; -.
DR   OrthoDB; 257031at2759; -.
DR   PhylomeDB; P22888; -.
DR   TreeFam; TF316814; -.
DR   PathwayCommons; P22888; -.
DR   Reactome; R-HSA-375281; Hormone ligand-binding receptors.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-9660821; ADORA2B mediated anti-inflammatory cytokines production.
DR   SignaLink; P22888; -.
DR   SIGNOR; P22888; -.
DR   BioGRID-ORCS; 3973; 1 hit in 873 CRISPR screens.
DR   ChiTaRS; LHCGR; human.
DR   GeneWiki; Luteinizing_hormone/choriogonadotropin_receptor; -.
DR   GenomeRNAi; 3973; -.
DR   Pharos; P22888; Tclin.
DR   PRO; PR:P22888; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; P22888; protein.
DR   Bgee; ENSG00000138039; Expressed in lower esophagus muscularis layer and 88 other tissues.
DR   ExpressionAtlas; P22888; baseline and differential.
DR   Genevisible; P22888; HS.
DR   GO; GO:0005768; C:endosome; TAS:ProtInc.
DR   GO; GO:0005887; C:integral component of plasma membrane; ISS:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0038106; F:choriogonadotropin hormone binding; ISS:BHF-UCL.
DR   GO; GO:0035472; F:choriogonadotropin hormone receptor activity; ISS:BHF-UCL.
DR   GO; GO:0008528; F:G protein-coupled peptide receptor activity; IBA:GO_Central.
DR   GO; GO:0004964; F:luteinizing hormone receptor activity; IMP:UniProtKB.
DR   GO; GO:0007190; P:activation of adenylate cyclase activity; ISS:BHF-UCL.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0071371; P:cellular response to gonadotropin stimulus; ISS:BHF-UCL.
DR   GO; GO:0071373; P:cellular response to luteinizing hormone stimulus; IMP:UniProtKB.
DR   GO; GO:0050890; P:cognition; IMP:UniProtKB.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007187; P:G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; TAS:ProtInc.
DR   GO; GO:0009755; P:hormone-mediated signaling pathway; IBA:GO_Central.
DR   GO; GO:0042700; P:luteinizing hormone signaling pathway; IMP:UniProtKB.
DR   GO; GO:0030539; P:male genitalia development; TAS:ProtInc.
DR   GO; GO:0008584; P:male gonad development; IBA:GO_Central.
DR   GO; GO:0001541; P:ovarian follicle development; IBA:GO_Central.
DR   GO; GO:0022602; P:ovulation cycle process; IBA:GO_Central.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0032962; P:positive regulation of inositol trisphosphate biosynthetic process; ISS:BHF-UCL.
DR   Gene3D; 3.80.10.10; -; 1.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR002131; Gphrmn_rcpt_fam.
DR   InterPro; IPR026906; LRR_5.
DR   InterPro; IPR032675; LRR_dom_sf.
DR   InterPro; IPR002273; LSH_rcpt.
DR   Pfam; PF00001; 7tm_1; 1.
DR   Pfam; PF13306; LRR_5; 2.
DR   PRINTS; PR00373; GLYCHORMONER.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01144; LSHRECEPTOR.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Disease mutation;
KW   Disulfide bond; G-protein coupled receptor; Glycoprotein;
KW   Leucine-rich repeat; Lipoprotein; Membrane; Palmitate; Polymorphism;
KW   Receptor; Reference proteome; Repeat; Signal; Sulfation; Transducer;
KW   Transmembrane; Transmembrane helix.
FT   SIGNAL          1..26
FT                   /evidence="ECO:0000255"
FT   CHAIN           27..699
FT                   /note="Lutropin-choriogonadotropic hormone receptor"
FT                   /id="PRO_0000012780"
FT   TOPO_DOM        27..363
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        364..385
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        386..395
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        396..416
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        417..439
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        440..462
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        463..482
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        483..505
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        506..525
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        526..549
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        550..570
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        571..594
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        595..605
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        606..627
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        628..699
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          27..66
FT                   /note="LRRNT"
FT   REPEAT          96..115
FT                   /note="LRR 1"
FT   REPEAT          124..145
FT                   /note="LRR 2"
FT   REPEAT          149..171
FT                   /note="LRR 3"
FT   REPEAT          175..196
FT                   /note="LRR 4"
FT   REPEAT          198..220
FT                   /note="LRR 5"
FT   REPEAT          223..244
FT                   /note="LRR 6"
FT   MOD_RES         331
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000305|PubMed:11847099"
FT   LIPID           643
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:15539429"
FT   LIPID           644
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:15539429"
FT   CARBOHYD        99
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        174
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        195
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        291
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        299
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        313
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        439..514
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VAR_SEQ         227..289
FT                   /note="Missing (in isoform Short)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_001962"
FT   VARIANT         18
FT                   /note="Q -> QLQ (may be associated with earlier age of
FT                   onset of breast cancer and poor prognosis)"
FT                   /evidence="ECO:0000269|PubMed:9851790,
FT                   ECO:0000269|PubMed:9858858"
FT                   /id="VAR_003549"
FT   VARIANT         131
FT                   /note="C -> R (in LHR; Leydig cell hypoplasia type 2;
FT                   dbSNP:rs121912527)"
FT                   /evidence="ECO:0000269|PubMed:9215288"
FT                   /id="VAR_010154"
FT   VARIANT         144
FT                   /note="V -> F (in LHR; Leydig cell hypoplasia type 1;
FT                   exhibits a marked impairment of human chorionic
FT                   gonadotropin binding; shows the absence of the glycosylated
FT                   cell surface form; the mutant receptor is retained in the
FT                   endoplasmic reticulum; mutant receptors do not migrate to
FT                   the cell surface; dbSNP:rs121912539)"
FT                   /evidence="ECO:0000269|PubMed:15472221"
FT                   /id="VAR_062336"
FT   VARIANT         152
FT                   /note="I -> T (in LHR; reveals a marked impairment of human
FT                   chorionic gonadotropin binding and signal transduction)"
FT                   /evidence="ECO:0000269|PubMed:19551906"
FT                   /id="VAR_062337"
FT   VARIANT         284
FT                   /note="N -> S"
FT                   /evidence="ECO:0000269|PubMed:10215412"
FT                   /id="VAR_003550"
FT   VARIANT         291
FT                   /note="N -> S (in dbSNP:rs12470652)"
FT                   /id="VAR_055922"
FT   VARIANT         306
FT                   /note="S -> N"
FT                   /evidence="ECO:0000269|PubMed:10215412"
FT                   /id="VAR_003551"
FT   VARIANT         312
FT                   /note="N -> S (in dbSNP:rs2293275)"
FT                   /evidence="ECO:0000269|PubMed:2244890,
FT                   ECO:0000269|PubMed:7556872"
FT                   /id="VAR_060737"
FT   VARIANT         343
FT                   /note="C -> S (in LHR; Leydig cell hypoplasia type 1;
FT                   completely devoided of hormone-induced cAMP reporter gene
FT                   activation; although initial translocation to the
FT                   endoplasmic reticulum is normal translocation is halted or
FT                   misrouted and the mutant does not reach the cell surface
FT                   and cannot bind hormone; dbSNP:rs121912536)"
FT                   /evidence="ECO:0000269|PubMed:12050206"
FT                   /id="VAR_010155"
FT   VARIANT         354
FT                   /note="E -> K (in LHR; Leydig cell hypoplasia type 1;
FT                   dbSNP:rs121912529)"
FT                   /evidence="ECO:0000269|PubMed:9626144"
FT                   /id="VAR_003552"
FT   VARIANT         368
FT                   /note="L -> P (in FMPP; cells expressing the mutation
FT                   display up to a 12-fold increase in basal cAMP production
FT                   compared with cells expressing the same number of cell
FT                   surface wild-type receptor indicating constitutive
FT                   activation of the mutant receptor; dbSNP:rs121912533)"
FT                   /evidence="ECO:0000269|PubMed:11134146"
FT                   /id="VAR_062338"
FT   VARIANT         373
FT                   /note="A -> V (in FMPP; dbSNP:rs121912528)"
FT                   /evidence="ECO:0000269|PubMed:9467560"
FT                   /id="VAR_003553"
FT   VARIANT         398
FT                   /note="M -> T (in FMPP; dbSNP:rs121912526)"
FT                   /evidence="ECO:0000269|PubMed:8929952"
FT                   /id="VAR_003554"
FT   VARIANT         457
FT                   /note="L -> R (in FMPP; dbSNP:rs121912535)"
FT                   /evidence="ECO:0000269|PubMed:9661624"
FT                   /id="VAR_010156"
FT   VARIANT         502
FT                   /note="L -> P (in LHR; Leydig cell hypoplasia type 1; shows
FT                   reduced cAMP production and ligand binding; receptor
FT                   trafficking is not affected by the mutation;
FT                   dbSNP:rs121912538)"
FT                   /evidence="ECO:0000269|PubMed:15372531"
FT                   /id="VAR_062339"
FT   VARIANT         542
FT                   /note="I -> L (in FMPP; dbSNP:rs121912531)"
FT                   /id="VAR_010157"
FT   VARIANT         543
FT                   /note="C -> R (in LHR; Leydig cell hypoplasia type 1;
FT                   completely devoided of hormone-induced cAMP reporter gene
FT                   activation; although initial translocation to the
FT                   endoplasmic reticulum is normal translocation is halted or
FT                   misrouted and the mutant does not reach the cell surface
FT                   and cannot bind hormone; dbSNP:rs121912537)"
FT                   /evidence="ECO:0000269|PubMed:12050206"
FT                   /id="VAR_010158"
FT   VARIANT         564
FT                   /note="D -> G (in FMPP; dbSNP:rs121912540)"
FT                   /evidence="ECO:0000269|PubMed:11391350"
FT                   /id="VAR_010159"
FT   VARIANT         564
FT                   /note="D -> N (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035764"
FT   VARIANT         568
FT                   /note="A -> V (in FMPP; dbSNP:rs121912534)"
FT                   /evidence="ECO:0000269|PubMed:11134146,
FT                   ECO:0000269|PubMed:7629248"
FT                   /id="VAR_003555"
FT   VARIANT         571
FT                   /note="M -> I (in FMPP; dbSNP:rs121912519)"
FT                   /evidence="ECO:0000269|PubMed:8281137"
FT                   /id="VAR_003556"
FT   VARIANT         572
FT                   /note="A -> V (in FMPP; dbSNP:rs121912522)"
FT                   /evidence="ECO:0000269|PubMed:7714085"
FT                   /id="VAR_003557"
FT   VARIANT         575
FT                   /note="I -> L (in FMPP)"
FT                   /id="VAR_010160"
FT   VARIANT         577
FT                   /note="T -> I (in FMPP; dbSNP:rs121912521)"
FT                   /evidence="ECO:0000269|PubMed:7757065,
FT                   ECO:0000269|PubMed:8829636"
FT                   /id="VAR_003558"
FT   VARIANT         578
FT                   /note="D -> E (in FMPP)"
FT                   /id="VAR_010161"
FT   VARIANT         578
FT                   /note="D -> G (in FMPP; dbSNP:rs121912518)"
FT                   /evidence="ECO:0000269|PubMed:7692306,
FT                   ECO:0000269|PubMed:8281137"
FT                   /id="VAR_003559"
FT   VARIANT         578
FT                   /note="D -> H (in Leydig cell tumor; somatic mutation;
FT                   causes receptor activation and precocious puberty;
FT                   dbSNP:rs121912532)"
FT                   /evidence="ECO:0000269|PubMed:10580072"
FT                   /id="VAR_010162"
FT   VARIANT         578
FT                   /note="D -> Y (in FMPP; dbSNP:rs121912532)"
FT                   /id="VAR_010163"
FT   VARIANT         581
FT                   /note="C -> R (in FMPP)"
FT                   /id="VAR_010164"
FT   VARIANT         593
FT                   /note="A -> P (in LHR; Leydig cell hypoplasia type 1;
FT                   abolishes signal transduction; dbSNP:rs121912520)"
FT                   /evidence="ECO:0000269|PubMed:7719343"
FT                   /id="VAR_003560"
FT   VARIANT         608..609
FT                   /note="Missing (in LHR; Leydig cell hypoplasia type 1)"
FT                   /evidence="ECO:0000269|PubMed:9514160"
FT                   /id="VAR_003561"
FT   VARIANT         616
FT                   /note="S -> Y (in LHR; Leydig cell hypoplasia type 1;
FT                   micropenis; dbSNP:rs121912525)"
FT                   /evidence="ECO:0000269|PubMed:8559204"
FT                   /id="VAR_003562"
FT   VARIANT         625
FT                   /note="I -> K (in LHR; Leydig cell hypoplasia type 2;
FT                   dbSNP:rs121912530)"
FT                   /evidence="ECO:0000269|PubMed:9626653"
FT                   /id="VAR_003563"
FT   MUTAGEN         331
FT                   /note="Y->F: Reduces intracellular cAMP accumulation."
FT                   /evidence="ECO:0000269|PubMed:11847099"
FT   MUTAGEN         333
FT                   /note="Y->F: No change in intracellular cAMP accumulation."
FT                   /evidence="ECO:0000269|PubMed:11847099"
FT   MUTAGEN         643
FT                   /note="C->G: Loss of palmitoylation."
FT                   /evidence="ECO:0000269|PubMed:15539429"
FT   MUTAGEN         644
FT                   /note="C->G: Loss of palmitoylation."
FT                   /evidence="ECO:0000269|PubMed:15539429"
FT   CONFLICT        7
FT                   /note="A -> P (in Ref. 3; AAA70231)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        19
FT                   /note="P -> A (in Ref. 3; AAA70231)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        27..28
FT                   /note="EA -> R (in Ref. 3; AAA70231)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        44..51
FT                   /note="CPGPTAGL -> APAPRPS (in Ref. 3; AAA70231)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        68
FT                   /note="A -> S (in Ref. 3; AAA70231)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        124
FT                   /note="R -> G (in Ref. 1; AAA59515 and 4; CAA59234)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        262..263
FT                   /note="RE -> KQ (in Ref. 3; AAA70231)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        270
FT                   /note="E -> R (in Ref. 3; AAA70231)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        274
FT                   /note="T -> H (in Ref. 3; AAA70231)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        290
FT                   /note="Q -> L (in Ref. 3; AAA70231)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        311..323
FT                   /note="Missing (in Ref. 3; AAA70231)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        448
FT                   /note="F -> L (in Ref. 3; AAA70231)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        540
FT                   /note="F -> L (in Ref. 3; AAA70231)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        649
FT                   /note="E -> DP (in Ref. 3; AAA70231)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   699 AA;  78643 MW;  2E3D93F4621BA842 CRC64;
     MKQRFSALQL LKLLLLLQPP LPRALREALC PEPCNCVPDG ALRCPGPTAG LTRLSLAYLP
     VKVIPSQAFR GLNEVIKIEI SQIDSLERIE ANAFDNLLNL SEILIQNTKN LRYIEPGAFI
     NLPRLKYLSI CNTGIRKFPD VTKVFSSESN FILEICDNLH ITTIPGNAFQ GMNNESVTLK
     LYGNGFEEVQ SHAFNGTTLT SLELKENVHL EKMHNGAFRG ATGPKTLDIS STKLQALPSY
     GLESIQRLIA TSSYSLKKLP SRETFVNLLE ATLTYPSHCC AFRNLPTKEQ NFSHSISENF
     SKQCESTVRK VNNKTLYSSM LAESELSGWD YEYGFCLPKT PRCAPEPDAF NPCEDIMGYD
     FLRVLIWLIN ILAIMGNMTV LFVLLTSRYK LTVPRFLMCN LSFADFCMGL YLLLIASVDS
     QTKGQYYNHA IDWQTGSGCS TAGFFTVFAS ELSVYTLTVI TLERWHTITY AIHLDQKLRL
     RHAILIMLGG WLFSSLIAML PLVGVSNYMK VSICFPMDVE TTLSQVYILT ILILNVVAFF
     IICACYIKIY FAVRNPELMA TNKDTKIAKK MAILIFTDFT CMAPISFFAI SAAFKVPLIT
     VTNSKVLLVL FYPINSCANP FLYAIFTKTF QRDFFLLLSK FGCCKRRAEL YRRKDFSAYT
     SNCKNGFTGS NKPSQSTLKL STLHCQGTAL LDKTRYTEC
//
ID   GIPR_HUMAN              Reviewed;         466 AA.
AC   P48546; B7WP14; B7ZKQ0; Q14401; Q16400; Q52M04; Q9UPI1;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 1.
DT   12-AUG-2020, entry version 174.
DE   RecName: Full=Gastric inhibitory polypeptide receptor;
DE            Short=GIP-R;
DE   AltName: Full=Glucose-dependent insulinotropic polypeptide receptor;
DE   Flags: Precursor;
GN   Name=GIPR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Usdin T.B., Gruber C., Modi W., Bonner T.I.;
RT   "The human GIP receptor: gene structure, functional expression of its cDNA,
RT   and chromosomal location.";
RL   Submitted (OCT-1995) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=7589426; DOI=10.1016/0014-5793(95)01006-z;
RA   Volz A., Goke R., Lankat-Buttgereit B., Fehmann H.C., Bode H.P., Goke B.;
RT   "Molecular cloning, functional expression, and signal transduction of the
RT   GIP-receptor cloned from a human insulinoma.";
RL   FEBS Lett. 373:23-29(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Pancreas;
RX   PubMed=7556958; DOI=10.2337/diab.44.10.1202;
RA   Gremlich S., Porret A., Hani E.H., Cherif D., Vionnet N., Froguel P.,
RA   Thorens B.;
RT   "Cloning, functional expression, and chromosomal localization of the human
RT   pancreatic islet glucose-dependent insulinotropic polypeptide receptor.";
RL   Diabetes 44:1202-1208(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RX   PubMed=8575774; DOI=10.1006/geno.1995.9937;
RA   Yamada Y., Hayami T., Nakamura K., Kaisaki P.J., Someya Y., Wang C.Z.,
RA   Seino S., Seino Y.;
RT   "Human gastric inhibitory polypeptide receptor: cloning of the gene (GIPR)
RT   and cDNA.";
RL   Genomics 29:773-776(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   GLYCOSYLATION AT ASN-62 AND ASN-77, AND SUBUNIT.
RX   PubMed=22412906; DOI=10.1371/journal.pone.0032675;
RA   Whitaker G.M., Lynn F.C., McIntosh C.H., Accili E.A.;
RT   "Regulation of GIP and GLP1 receptor cell surface expression by N-
RT   glycosylation and receptor heteromerization.";
RL   PLoS ONE 7:E32675-E32675(2012).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 24-138 IN COMPLEX WITH GIP, AND
RP   DISULFIDE BONDS.
RX   PubMed=17715056; DOI=10.1073/pnas.0706404104;
RA   Parthier C., Kleinschmidt M., Neumann P., Rudolph R., Manhart S.,
RA   Schlenzig D., Fanghanel J., Rahfeld J.-U., Demuth H.-U., Stubbs M.T.;
RT   "Crystal structure of the incretin-bound extracellular domain of a G
RT   protein-coupled receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:13942-13947(2007).
CC   -!- FUNCTION: This is a receptor for GIP. The activity of this receptor is
CC       mediated by G proteins which activate adenylyl cyclase.
CC   -!- SUBUNIT: May form homodimers and heterodimers with GLP1R.
CC       {ECO:0000269|PubMed:17715056, ECO:0000269|PubMed:22412906}.
CC   -!- INTERACTION:
CC       P48546; P01275: GCG; NbExp=2; IntAct=EBI-15653881, EBI-7629173;
CC       P48546; P09681: GIP; NbExp=3; IntAct=EBI-15653881, EBI-8588553;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P48546-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P48546-2; Sequence=VSP_053867, VSP_053868;
CC       Name=3;
CC         IsoId=P48546-3; Sequence=VSP_053866;
CC   -!- PTM: N-glycosylation is required for cell surface expression and
CC       lengthens receptor half-life by preventing degradation in the ER.
CC       {ECO:0000269|PubMed:22412906}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 2 family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA57426.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U39231; AAA84418.1; -; mRNA.
DR   EMBL; S79852; AAB35419.2; -; mRNA.
DR   EMBL; X81832; CAA57426.1; ALT_FRAME; mRNA.
DR   EMBL; D49559; BAA08503.1; -; Genomic_DNA.
DR   EMBL; AC006132; AAC97984.1; -; Genomic_DNA.
DR   EMBL; AC007191; AAD22674.1; -; Genomic_DNA.
DR   EMBL; BC093723; AAH93723.1; -; mRNA.
DR   EMBL; BC101673; AAI01674.1; -; mRNA.
DR   EMBL; BC143300; AAI43301.1; -; mRNA.
DR   CCDS; CCDS12671.1; -. [P48546-1]
DR   CCDS; CCDS82367.1; -. [P48546-3]
DR   PIR; G02234; G02234.
DR   PIR; I37411; I37411.
DR   PIR; S66676; S66676.
DR   RefSeq; NP_000155.1; NM_000164.3. [P48546-1]
DR   RefSeq; NP_001295347.1; NM_001308418.1. [P48546-3]
DR   PDB; 2QKH; X-ray; 1.90 A; A=24-138.
DR   PDB; 4HJ0; X-ray; 3.00 A; A/B=24-138.
DR   PDB; 6DKJ; X-ray; 1.95 A; C/D=22-138.
DR   PDBsum; 2QKH; -.
DR   PDBsum; 4HJ0; -.
DR   PDBsum; 6DKJ; -.
DR   SMR; P48546; -.
DR   BioGRID; 108963; 1.
DR   DIP; DIP-46468N; -.
DR   IntAct; P48546; 2.
DR   STRING; 9606.ENSP00000467494; -.
DR   BindingDB; P48546; -.
DR   ChEMBL; CHEMBL4383; -.
DR   GuidetoPHARMACOLOGY; 248; -.
DR   TCDB; 9.A.14.4.5; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; P48546; 2 sites.
DR   iPTMnet; P48546; -.
DR   PhosphoSitePlus; P48546; -.
DR   BioMuta; GIPR; -.
DR   DMDM; 1346133; -.
DR   PaxDb; P48546; -.
DR   PeptideAtlas; P48546; -.
DR   PRIDE; P48546; -.
DR   ProteomicsDB; 55901; -. [P48546-1]
DR   ProteomicsDB; 55902; -. [P48546-2]
DR   ProteomicsDB; 6283; -.
DR   ABCD; P48546; 2 sequenced antibodies.
DR   Antibodypedia; 17982; 599 antibodies.
DR   Ensembl; ENST00000263281; ENSP00000263281; ENSG00000010310. [P48546-2]
DR   Ensembl; ENST00000304207; ENSP00000305321; ENSG00000010310. [P48546-3]
DR   Ensembl; ENST00000590918; ENSP00000467494; ENSG00000010310. [P48546-1]
DR   GeneID; 2696; -.
DR   KEGG; hsa:2696; -.
DR   UCSC; uc002pct.2; human. [P48546-1]
DR   CTD; 2696; -.
DR   DisGeNET; 2696; -.
DR   EuPathDB; HostDB:ENSG00000010310.8; -.
DR   GeneCards; GIPR; -.
DR   HGNC; HGNC:4271; GIPR.
DR   HPA; ENSG00000010310; Tissue enhanced (brain, stomach).
DR   MIM; 137241; gene.
DR   neXtProt; NX_P48546; -.
DR   OpenTargets; ENSG00000010310; -.
DR   PharmGKB; PA28682; -.
DR   eggNOG; KOG4564; Eukaryota.
DR   GeneTree; ENSGT00940000161988; -.
DR   HOGENOM; CLU_002753_4_0_1; -.
DR   InParanoid; P48546; -.
DR   KO; K04580; -.
DR   OMA; DHSQCED; -.
DR   OrthoDB; 651627at2759; -.
DR   PhylomeDB; P48546; -.
DR   PathwayCommons; P48546; -.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-420092; Glucagon-type ligand receptors.
DR   Reactome; R-HSA-9660821; ADORA2B mediated anti-inflammatory cytokines production.
DR   SIGNOR; P48546; -.
DR   BioGRID-ORCS; 2696; 12 hits in 872 CRISPR screens.
DR   ChiTaRS; GIPR; human.
DR   EvolutionaryTrace; P48546; -.
DR   GeneWiki; Gastric_inhibitory_polypeptide_receptor; -.
DR   GenomeRNAi; 2696; -.
DR   Pharos; P48546; Tchem.
DR   PRO; PR:P48546; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; P48546; protein.
DR   Bgee; ENSG00000010310; Expressed in right uterine tube and 146 other tissues.
DR   ExpressionAtlas; P48546; baseline and differential.
DR   Genevisible; P48546; HS.
DR   GO; GO:0016021; C:integral component of membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0008528; F:G protein-coupled peptide receptor activity; IBA:GO_Central.
DR   GO; GO:0016519; F:gastric inhibitory peptide receptor activity; IBA:GO_Central.
DR   GO; GO:0017046; F:peptide hormone binding; IBA:GO_Central.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; TAS:ProtInc.
DR   GO; GO:0007190; P:activation of adenylate cyclase activity; TAS:ProtInc.
DR   GO; GO:0007188; P:adenylate cyclase-modulating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0002029; P:desensitization of G protein-coupled receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0031018; P:endocrine pancreas development; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006091; P:generation of precursor metabolites and energy; TAS:ProtInc.
DR   GO; GO:0043950; P:positive regulation of cAMP-mediated signaling; IEA:Ensembl.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IEA:Ensembl.
DR   GO; GO:0032024; P:positive regulation of insulin secretion; IEA:Ensembl.
DR   GO; GO:0050796; P:regulation of insulin secretion; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0048678; P:response to axon injury; IEA:Ensembl.
DR   GO; GO:0051592; P:response to calcium ion; IEA:Ensembl.
DR   GO; GO:0070542; P:response to fatty acid; IEA:Ensembl.
DR   GO; GO:0009749; P:response to glucose; IEA:Ensembl.
DR   GO; GO:0007584; P:response to nutrient; TAS:ProtInc.
DR   Gene3D; 4.10.1240.10; -; 1.
DR   InterPro; IPR017981; GPCR_2-like.
DR   InterPro; IPR036445; GPCR_2_extracell_dom_sf.
DR   InterPro; IPR001879; GPCR_2_extracellular_dom.
DR   InterPro; IPR001749; GPCR_2_GIP_rcpt.
DR   InterPro; IPR000832; GPCR_2_secretin-like.
DR   InterPro; IPR017983; GPCR_2_secretin-like_CS.
DR   Pfam; PF00002; 7tm_2; 1.
DR   Pfam; PF02793; HRM; 1.
DR   PRINTS; PR01129; GIPRECEPTOR.
DR   PRINTS; PR00249; GPCRSECRETIN.
DR   SMART; SM00008; HormR; 1.
DR   SUPFAM; SSF111418; SSF111418; 1.
DR   PROSITE; PS00649; G_PROTEIN_RECEP_F2_1; 1.
DR   PROSITE; PS00650; G_PROTEIN_RECEP_F2_2; 1.
DR   PROSITE; PS50227; G_PROTEIN_RECEP_F2_3; 1.
DR   PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Polymorphism; Receptor;
KW   Reference proteome; Signal; Transducer; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..21
FT                   /evidence="ECO:0000255"
FT   CHAIN           22..466
FT                   /note="Gastric inhibitory polypeptide receptor"
FT                   /id="PRO_0000012825"
FT   TOPO_DOM        22..138
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        139..161
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        162..169
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        170..189
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        190..217
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        218..242
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        243..254
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        255..278
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        279..293
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        294..319
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        320..341
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        342..362
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        363..377
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        378..398
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        399..466
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        62
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:22412906"
FT   CARBOHYD        77
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:22412906"
FT   DISULFID        46..70
FT                   /evidence="ECO:0000269|PubMed:17715056"
FT   DISULFID        61..103
FT                   /evidence="ECO:0000269|PubMed:17715056"
FT   DISULFID        84..118
FT                   /evidence="ECO:0000269|PubMed:17715056"
FT   VAR_SEQ         58..93
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_053866"
FT   VAR_SEQ         400..419
FT                   /note="QSEIRRGWHHCRLRRSLGEE -> GRDPAAAPALWRQRGVRRRL (in
FT                   isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:7556958"
FT                   /id="VSP_053867"
FT   VAR_SEQ         420..466
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:7556958"
FT                   /id="VSP_053868"
FT   VARIANT         136
FT                   /note="R -> W (in dbSNP:rs13306402)"
FT                   /id="VAR_029333"
FT   VARIANT         207
FT                   /note="A -> V (in dbSNP:rs1800436)"
FT                   /id="VAR_011808"
FT   VARIANT         262
FT                   /note="L -> V (in dbSNP:rs5392)"
FT                   /id="VAR_011809"
FT   VARIANT         354
FT                   /note="E -> Q (in dbSNP:rs1800437)"
FT                   /id="VAR_011810"
FT   CONFLICT        12
FT                   /note="R -> G (in Ref. 2; AAB35419)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        104
FT                   /note="G -> R (in Ref. 2; AAB35419)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        117
FT                   /note="Missing (in Ref. 3; CAA57426)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        337
FT                   /note="L -> V (in Ref. 2; AAB35419)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        367..371
FT                   /note="GALRF -> APCV (in Ref. 3; CAA57426)"
FT                   /evidence="ECO:0000305"
FT   HELIX           32..52
FT                   /evidence="ECO:0000244|PDB:2QKH"
FT   STRAND          67..71
FT                   /evidence="ECO:0000244|PDB:4HJ0"
FT   STRAND          78..83
FT                   /evidence="ECO:0000244|PDB:2QKH"
FT   STRAND          86..88
FT                   /evidence="ECO:0000244|PDB:4HJ0"
FT   HELIX           91..94
FT                   /evidence="ECO:0000244|PDB:2QKH"
FT   STRAND          98..103
FT                   /evidence="ECO:0000244|PDB:2QKH"
FT   STRAND          105..107
FT                   /evidence="ECO:0000244|PDB:4HJ0"
FT   STRAND          109..114
FT                   /evidence="ECO:0000244|PDB:6DKJ"
FT   HELIX           116..118
FT                   /evidence="ECO:0000244|PDB:2QKH"
FT   HELIX           125..128
FT                   /evidence="ECO:0000244|PDB:6DKJ"
SQ   SEQUENCE   466 AA;  53157 MW;  CA5CF86BA0E32383 CRC64;
     MTTSPILQLL LRLSLCGLLL QRAETGSKGQ TAGELYQRWE RYRRECQETL AAAEPPSGLA
     CNGSFDMYVC WDYAAPNATA RASCPWYLPW HHHVAAGFVL RQCGSDGQWG LWRDHTQCEN
     PEKNEAFLDQ RLILERLQVM YTVGYSLSLA TLLLALLILS LFRRLHCTRN YIHINLFTSF
     MLRAAAILSR DRLLPRPGPY LGDQALALWN QALAACRTAQ IVTQYCVGAN YTWLLVEGVY
     LHSLLVLVGG SEEGHFRYYL LLGWGAPALF VIPWVIVRYL YENTQCWERN EVKAIWWIIR
     TPILMTILIN FLIFIRILGI LLSKLRTRQM RCRDYRLRLA RSTLTLVPLL GVHEVVFAPV
     TEEQARGALR FAKLGFEIFL SSFQGFLVSV LYCFINKEVQ SEIRRGWHHC RLRRSLGEEQ
     RQLPERAFRA LPSGSGPGEV PTSRGLSSGT LPGPGNEASR ELESYC
//
ID   AGRE5_HUMAN             Reviewed;         835 AA.
AC   P48960; A8K7Z4; B2RBJ9; O00718; O76101; Q8NG72; Q8TBQ7;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   21-MAR-2006, sequence version 4.
DT   07-OCT-2020, entry version 204.
DE   RecName: Full=Adhesion G protein-coupled receptor E5 {ECO:0000312|HGNC:HGNC:1711};
DE   AltName: Full=Leukocyte antigen CD97 {ECO:0000303|PubMed:7636245};
DE   AltName: CD_antigen=CD97;
DE   Contains:
DE     RecName: Full=Adhesion G protein-coupled receptor E5 subunit alpha;
DE   Contains:
DE     RecName: Full=Adhesion G protein-coupled receptor E5 subunit beta;
DE   Flags: Precursor;
GN   Name=ADGRE5 {ECO:0000312|HGNC:HGNC:1711};
GN   Synonyms=CD97 {ECO:0000312|HGNC:HGNC:1711};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=7636245;
RA   Hamann J., Eichler W., Hamann D., Kerstens H.M.J., Poddighe P.J.,
RA   Hoovers J.M.N., Hartmann J.M., Strauss M., van Lier R.A.W.;
RT   "Expression cloning and chromosomal mapping of the leukocyte activation
RT   antigen CD97, a new seven-span transmembrane molecule of the secretion
RT   receptor superfamily with an unusual extracellular domain.";
RL   J. Immunol. 155:1942-1950(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RC   TISSUE=Foreskin;
RX   PubMed=8786105; DOI=10.1006/geno.1996.0092;
RA   Hamann J., Hartmann E., van Lier R.A.W.;
RT   "Structure of the human CD97 gene: exon shuffling has generated a new type
RT   of seven-span transmembrane molecule related to the secretin receptor
RT   superfamily.";
RL   Genomics 32:144-147(1996).
RN   [3]
RP   SEQUENCE REVISION.
RA   Hamann J.;
RL   Submitted (OCT-1997) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3).
RX   PubMed=8955192;
RA   Gray J.X., Haino M., Roth M.J., Maguire J.E., Jensen P.N., Yarme A.,
RA   Stetler-Stevenson M.-A., Siebenlist U., Kelly K.;
RT   "CD97 is a processed, seven-transmembrane, heterodimeric receptor
RT   associated with inflammation.";
RL   J. Immunol. 157:5438-5447(1996).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Suwa M., Sato T., Okouchi I., Arita M., Futami K., Matsumoto S.,
RA   Tsutsumi S., Aburatani H., Asai K., Akiyama Y.;
RT   "Genome-wide discovery and analysis of human seven transmembrane helix
RT   receptor genes.";
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Placenta, and Synovium;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Colon adenocarcinoma;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   INTERACTION WITH DAF.
RX   PubMed=11297558; DOI=10.1074/jbc.m101770200;
RA   Lin H.-H., Stacey M., Saxby C., Knott V., Chaudhry Y., Evans D., Gordon S.,
RA   McKnight A.J., Handford P., Lea S.;
RT   "Molecular analysis of the epidermal growth factor-like short consensus
RT   repeat domain-mediated protein-protein interactions: dissection of the
RT   CD97-CD55 complex.";
RL   J. Biol. Chem. 276:24160-24169(2001).
RN   [11]
RP   INTERACTION WITH CHONDROITIN SULFATE.
RX   PubMed=12829604; DOI=10.1182/blood-2002-11-3540;
RA   Stacey M., Chang G.-W., Davies J.Q., Kwakkenbos M.J., Sanderson R.D.,
RA   Hamann J., Gordon S., Lin H.-H.;
RT   "The epidermal growth factor-like domains of the human EMR2 receptor
RT   mediate cell attachment through chondroitin sulfate glycosaminoglycans.";
RL   Blood 102:2916-2924(2003).
RN   [12]
RP   REVIEW.
RX   PubMed=14647991; DOI=10.1007/s00251-003-0625-2;
RA   Kwakkenbos M.J., Kop E.N., Stacey M., Matmati M., Gordon S., Lin H.H.,
RA   Hamann J.;
RT   "The EGF-TM7 family: a postgenomic view.";
RL   Immunogenetics 55:655-666(2004).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-453.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [16]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-371.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-linked
RT   cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-831 AND SER-833, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-815; THR-816; SER-818;
RP   THR-825 AND SER-831, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
CC   -!- FUNCTION: Receptor potentially involved in both adhesion and signaling
CC       processes early after leukocyte activation. Plays an essential role in
CC       leukocyte migration. {ECO:0000250|UniProtKB:Q9Z0M6}.
CC   -!- SUBUNIT: Forms a heterodimer, consisting of a large extracellular
CC       region (alpha subunit) non-covalently linked to a seven-transmembrane
CC       moiety (beta subunit). Interacts with complement decay-accelerating
CC       factor (DAF). The largest isoform (isoform 1) interacts with
CC       chondroitin sulfate. {ECO:0000269|PubMed:11297558,
CC       ECO:0000269|PubMed:12829604}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:Q9Z0M6};
CC       Multi-pass membrane protein {ECO:0000255}.
CC   -!- SUBCELLULAR LOCATION: [Adhesion G protein-coupled receptor E5 subunit
CC       alpha]: Secreted, extracellular space {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=EGF(1,2,3,4,5);
CC         IsoId=P48960-1; Sequence=Displayed;
CC       Name=2; Synonyms=EGF(1,2,5);
CC         IsoId=P48960-2; Sequence=VSP_009411;
CC       Name=3; Synonyms=EGF(1,2,3,5);
CC         IsoId=P48960-3; Sequence=VSP_009412;
CC   -!- TISSUE SPECIFICITY: Broadly expressed, found on most hematopoietic
CC       cells, including activated lymphocytes, monocytes, macrophages,
CC       dendritic cells, and granulocytes. Expressed also abundantly by smooth
CC       muscle cells. Expressed in thyroid, colorectal, gastric, esophageal and
CC       pancreatic carcinomas too. Expression are increased under inflammatory
CC       conditions in the CNS of multiple sclerosis and in synovial tissue of
CC       patients with rheumatoid arthritis. Increased expression of CD97 in the
CC       synovium is accompanied by detectable levels of soluble CD97 in the
CC       synovial fluid.
CC   -!- INDUCTION: Rapid up-regulation during lymphocyte activation.
CC   -!- DOMAIN: The first two EGF domains mediate the interaction with DAF. A
CC       third tandemly arranged EGF domain is necessary for the structural
CC       integrity of the binding region.
CC   -!- DOMAIN: Binding to chondroitin sulfate is mediated by the fourth EGF
CC       domain.
CC   -!- PTM: Proteolytically cleaved into 2 subunits, an extracellular alpha
CC       subunit and a seven-transmembrane subunit. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 2 family. LN-TM7
CC       subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC27673.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=BAC06178.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CD97ID996ch19p13.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X84700; CAA59173.1; -; mRNA.
DR   EMBL; X94630; CAA64333.1; -; Genomic_DNA.
DR   EMBL; X94631; CAA64333.1; JOINED; Genomic_DNA.
DR   EMBL; X94632; CAA64333.1; JOINED; Genomic_DNA.
DR   EMBL; X94633; CAA64333.1; JOINED; Genomic_DNA.
DR   EMBL; Z99830; CAA64333.1; JOINED; Genomic_DNA.
DR   EMBL; Z99831; CAA64333.1; JOINED; Genomic_DNA.
DR   EMBL; X94634; CAA64333.1; JOINED; Genomic_DNA.
DR   EMBL; X94635; CAA64333.1; JOINED; Genomic_DNA.
DR   EMBL; X94636; CAA64333.1; JOINED; Genomic_DNA.
DR   EMBL; X94637; CAA64333.1; JOINED; Genomic_DNA.
DR   EMBL; X94638; CAA64333.1; JOINED; Genomic_DNA.
DR   EMBL; X94639; CAA64333.1; JOINED; Genomic_DNA.
DR   EMBL; X94640; CAA64333.1; JOINED; Genomic_DNA.
DR   EMBL; X94641; CAA64333.1; JOINED; Genomic_DNA.
DR   EMBL; X94642; CAA64333.1; JOINED; Genomic_DNA.
DR   EMBL; X94643; CAA64333.1; JOINED; Genomic_DNA.
DR   EMBL; X94644; CAA64333.1; JOINED; Genomic_DNA.
DR   EMBL; X94645; CAA64333.1; JOINED; Genomic_DNA.
DR   EMBL; X94646; CAA64333.1; JOINED; Genomic_DNA.
DR   EMBL; X94647; CAA64333.1; JOINED; Genomic_DNA.
DR   EMBL; U76764; AAB36682.1; -; mRNA.
DR   EMBL; AB065966; BAC06178.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AC005327; AAC27673.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AK292159; BAF84848.1; -; mRNA.
DR   EMBL; AK314697; BAG37246.1; -; mRNA.
DR   EMBL; CH471106; EAW84412.1; -; Genomic_DNA.
DR   EMBL; CH471106; EAW84413.1; -; Genomic_DNA.
DR   EMBL; BC026690; AAH26690.1; -; mRNA.
DR   CCDS; CCDS32929.1; -. [P48960-1]
DR   CCDS; CCDS32930.1; -. [P48960-3]
DR   CCDS; CCDS32931.1; -. [P48960-2]
DR   PIR; I37225; I37225.
DR   RefSeq; NP_001020331.1; NM_001025160.2. [P48960-3]
DR   RefSeq; NP_001775.2; NM_001784.4. [P48960-2]
DR   RefSeq; NP_510966.1; NM_078481.3. [P48960-1]
DR   RefSeq; XP_016883036.1; XM_017027547.1.
DR   PDB; 2BOU; X-ray; 1.90 A; A=22-32.
DR   PDBsum; 2BOU; -.
DR   SMR; P48960; -.
DR   BioGRID; 107414; 62.
DR   DIP; DIP-52292N; -.
DR   IntAct; P48960; 60.
DR   STRING; 9606.ENSP00000242786; -.
DR   MEROPS; P02.002; -.
DR   TCDB; 9.A.14.6.2; the g-protein-coupled receptor (gpcr) family.
DR   GlyConnect; 1090; 10 N-Linked glycans (3 sites).
DR   GlyGen; P48960; 11 sites, 2 O-linked glycans (1 site).
DR   iPTMnet; P48960; -.
DR   PhosphoSitePlus; P48960; -.
DR   SwissPalm; P48960; -.
DR   BioMuta; ADGRE5; -.
DR   DMDM; 90110013; -.
DR   EPD; P48960; -.
DR   jPOST; P48960; -.
DR   MassIVE; P48960; -.
DR   MaxQB; P48960; -.
DR   PaxDb; P48960; -.
DR   PeptideAtlas; P48960; -.
DR   PRIDE; P48960; -.
DR   ProteomicsDB; 55949; -. [P48960-1]
DR   ProteomicsDB; 55950; -. [P48960-2]
DR   ProteomicsDB; 55951; -. [P48960-3]
DR   TopDownProteomics; P48960-2; -. [P48960-2]
DR   Antibodypedia; 2852; 851 antibodies.
DR   DNASU; 976; -.
DR   Ensembl; ENST00000242786; ENSP00000242786; ENSG00000123146. [P48960-1]
DR   Ensembl; ENST00000357355; ENSP00000349918; ENSG00000123146. [P48960-3]
DR   Ensembl; ENST00000358600; ENSP00000351413; ENSG00000123146. [P48960-2]
DR   GeneID; 976; -.
DR   KEGG; hsa:976; -.
DR   UCSC; uc002myl.4; human. [P48960-1]
DR   CTD; 976; -.
DR   DisGeNET; 976; -.
DR   EuPathDB; HostDB:ENSG00000123146.19; -.
DR   GeneCards; ADGRE5; -.
DR   HGNC; HGNC:1711; ADGRE5.
DR   HPA; ENSG00000123146; Tissue enhanced (blood).
DR   MIM; 601211; gene.
DR   neXtProt; NX_P48960; -.
DR   OpenTargets; ENSG00000123146; -.
DR   PharmGKB; PA26248; -.
DR   eggNOG; KOG4193; Eukaryota.
DR   GeneTree; ENSGT00940000160578; -.
DR   HOGENOM; CLU_002753_3_7_1; -.
DR   InParanoid; P48960; -.
DR   KO; K08446; -.
DR   OMA; ARMLLNW; -.
DR   OrthoDB; 210309at2759; -.
DR   PhylomeDB; P48960; -.
DR   TreeFam; TF316380; -.
DR   PathwayCommons; P48960; -.
DR   Reactome; R-HSA-373080; Class B/2 (Secretin family receptors).
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SIGNOR; P48960; -.
DR   BioGRID-ORCS; 976; 1 hit in 867 CRISPR screens.
DR   ChiTaRS; ADGRE5; human.
DR   GeneWiki; CD97; -.
DR   GenomeRNAi; 976; -.
DR   Pharos; P48960; Tbio.
DR   PRO; PR:P48960; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; P48960; protein.
DR   Bgee; ENSG00000123146; Expressed in blood and 190 other tissues.
DR   ExpressionAtlas; P48960; baseline and differential.
DR   Genevisible; P48960; HS.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0030667; C:secretory granule membrane; TAS:Reactome.
DR   GO; GO:0005509; F:calcium ion binding; IEA:InterPro.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; TAS:ProtInc.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007155; P:cell adhesion; TAS:ProtInc.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0007267; P:cell-cell signaling; TAS:ProtInc.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0006955; P:immune response; TAS:ProtInc.
DR   GO; GO:0006954; P:inflammatory response; TAS:ProtInc.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   InterPro; IPR001881; EGF-like_Ca-bd_dom.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR000152; EGF-type_Asp/Asn_hydroxyl_site.
DR   InterPro; IPR018097; EGF_Ca-bd_CS.
DR   InterPro; IPR017981; GPCR_2-like.
DR   InterPro; IPR003056; GPCR_2_ADGRE2_ADGRE5.
DR   InterPro; IPR000832; GPCR_2_secretin-like.
DR   InterPro; IPR017983; GPCR_2_secretin-like_CS.
DR   InterPro; IPR000203; GPS.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   Pfam; PF00002; 7tm_2; 1.
DR   Pfam; PF07645; EGF_CA; 4.
DR   Pfam; PF01825; GPS; 1.
DR   PRINTS; PR01278; CD97PROTEIN.
DR   PRINTS; PR00249; GPCRSECRETIN.
DR   SMART; SM00181; EGF; 5.
DR   SMART; SM00179; EGF_CA; 4.
DR   SMART; SM00303; GPS; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS00010; ASX_HYDROXYL; 4.
DR   PROSITE; PS50026; EGF_3; 4.
DR   PROSITE; PS01187; EGF_CA; 4.
DR   PROSITE; PS00650; G_PROTEIN_RECEP_F2_2; 1.
DR   PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1.
DR   PROSITE; PS50221; GPS; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Cell adhesion; Cell membrane;
KW   Disulfide bond; EGF-like domain; G-protein coupled receptor; Glycoprotein;
KW   Membrane; Phosphoprotein; Polymorphism; Receptor; Reference proteome;
KW   Repeat; Secreted; Signal; Transducer; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..20
FT                   /evidence="ECO:0000255"
FT   CHAIN           21..835
FT                   /note="Adhesion G protein-coupled receptor E5"
FT                   /id="PRO_0000012868"
FT   CHAIN           21..530
FT                   /note="Adhesion G protein-coupled receptor E5 subunit
FT                   alpha"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000296235"
FT   CHAIN           531..835
FT                   /note="Adhesion G protein-coupled receptor E5 subunit beta"
FT                   /evidence="ECO:0000250"
FT                   /id="PRO_0000296236"
FT   TOPO_DOM        21..552
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        553..572
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        573..581
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        582..601
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        602..620
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        621..642
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        643..653
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        654..674
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        675..691
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        692..712
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        713..739
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        740..760
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        761..766
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        767..789
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        790..835
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          22..63
FT                   /note="EGF-like 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          64..115
FT                   /note="EGF-like 2; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          116..159
FT                   /note="EGF-like 3; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          160..208
FT                   /note="EGF-like 4; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          209..257
FT                   /note="EGF-like 5; calcium-binding"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DOMAIN          492..542
FT                   /note="GPS"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00098"
FT   SITE            530..531
FT                   /note="Cleavage"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         815
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         816
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         818
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         825
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         831
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:20068231,
FT                   ECO:0000244|PubMed:23186163"
FT   MOD_RES         833
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:20068231"
FT   CARBOHYD        33
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        38
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        108
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        203
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        371
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19349973"
FT   CARBOHYD        406
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        413
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        453
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19159218"
FT   CARBOHYD        520
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        26..36
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        30..42
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        44..62
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        68..82
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        76..91
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        93..114
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        120..133
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        127..142
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        144..158
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        164..177
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        171..186
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        188..207
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        213..226
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        220..235
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   DISULFID        237..256
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00076"
FT   VAR_SEQ         116..208
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:7636245,
FT                   ECO:0000303|PubMed:8955192"
FT                   /id="VSP_009411"
FT   VAR_SEQ         160..208
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:8955192"
FT                   /id="VSP_009412"
FT   VARIANT         367
FT                   /note="R -> Q (in dbSNP:rs2230748)"
FT                   /id="VAR_017760"
FT   CONFLICT        103
FT                   /note="A -> T (in Ref. 4; AAB36682)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        512
FT                   /note="G -> V (in Ref. 1 and 2)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        534
FT                   /note="A -> T (in Ref. 1 and 2)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   835 AA;  91869 MW;  06DDDE9178BC494B CRC64;
     MGGRVFLAFC VWLTLPGAET QDSRGCARWC PQNSSCVNAT ACRCNPGFSS FSEIITTPTE
     TCDDINECAT PSKVSCGKFS DCWNTEGSYD CVCSPGYEPV SGAKTFKNES ENTCQDVDEC
     QQNPRLCKSY GTCVNTLGSY TCQCLPGFKF IPEDPKVCTD VNECTSGQNP CHSSTHCLNN
     VGSYQCRCRP GWQPIPGSPN GPNNTVCEDV DECSSGQHQC DSSTVCFNTV GSYSCRCRPG
     WKPRHGIPNN QKDTVCEDMT FSTWTPPPGV HSQTLSRFFD KVQDLGRDSK TSSAEVTIQN
     VIKLVDELME APGDVEALAP PVRHLIATQL LSNLEDIMRI LAKSLPKGPF TYISPSNTEL
     TLMIQERGDK NVTMGQSSAR MKLNWAVAAG AEDPGPAVAG ILSIQNMTTL LANASLNLHS
     KKQAELEEIY ESSIRGVQLR RLSAVNSIFL SHNNTKELNS PILFAFSHLE SSDGEAGRDP
     PAKDVMPGPR QELLCAFWKS DSDRGGHWAT EGCQVLGSKN GSTTCQCSHL SSFAILMAHY
     DVEDWKLTLI TRVGLALSLF CLLLCILTFL LVRPIQGSRT TIHLHLCICL FVGSTIFLAG
     IENEGGQVGL RCRLVAGLLH YCFLAAFCWM SLEGLELYFL VVRVFQGQGL STRWLCLIGY
     GVPLLIVGVS AAIYSKGYGR PRYCWLDFEQ GFLWSFLGPV TFIILCNAVI FVTTVWKLTQ
     KFSEINPDMK KLKKARALTI TAIAQLFLLG CTWVFGLFIF DDRSLVLTYV FTILNCLQGA
     FLYLLHCLLN KKVREEYRKW ACLVAGGSKY SEFTSTTSGT GHNQTRALRA SESGI
//
ID   MTR1B_HUMAN             Reviewed;         362 AA.
AC   P49286;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 1.
DT   12-AUG-2020, entry version 166.
DE   RecName: Full=Melatonin receptor type 1B;
DE            Short=Mel-1B-R;
DE            Short=Mel1b receptor;
GN   Name=MTNR1B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RX   PubMed=7568007; DOI=10.1073/pnas.92.19.8734;
RA   Reppert S.M., Godson C., Mahle C.D., Weaver D.R., Slaugenhaupt S.A.,
RA   Gusella J.F.;
RT   "Molecular characterization of a second melatonin receptor expressed in
RT   human retina and brain: the Mel1b melatonin receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:8734-8738(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLU-24 AND PHE-66.
RX   PubMed=10696804; DOI=10.1016/s0304-3940(99)00981-7;
RA   Ebisawa T., Uchiyama M., Kajimura N., Kamei Y., Shibui K., Kim K., Kudo Y.,
RA   Iwase T., Sugishita M., Jodoi T., Ikeda M., Ozeki Y., Watanabe T.,
RA   Sekimoto M., Katoh M., Yamada N., Toyoshima R., Okawa M., Takahashi K.,
RA   Yamauchi T.;
RT   "Genetic polymorphisms of human melatonin 1b receptor gene in circadian
RT   rhythm sleep disorders and controls.";
RL   Neurosci. Lett. 280:29-32(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Retina;
RA   King M.M., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INTERACTION WITH GPR61; GPR62 AND GPR135.
RX   PubMed=28827538; DOI=10.1038/s41598-017-08996-7;
RA   Oishi A., Karamitri A., Gerbier R., Lahuna O., Ahmad R., Jockers R.;
RT   "Orphan GPR61, GPR62 and GPR135 receptors and the melatonin MT2 receptor
RT   reciprocally modulate their signaling functions.";
RL   Sci. Rep. 7:8990-8990(2017).
RN   [6]
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 35-340 IN COMPLEX WITH MELATONIN
RP   ANALOG, AND DISULFIDE BOND.
RX   PubMed=31019305; DOI=10.1038/s41586-019-1144-0;
RA   Johansson L.C., Stauch B., McCorvy J.D., Han G.W., Patel N., Huang X.P.,
RA   Batyuk A., Gati C., Slocum S.T., Li C., Grandner J.M., Hao S.,
RA   Olsen R.H.J., Tribo A.R., Zaare S., Zhu L., Zatsepin N.A., Weierstall U.,
RA   Yous S., Stevens R.C., Liu W., Roth B.L., Katritch V., Cherezov V.;
RT   "XFEL structures of the human MT2 melatonin receptor reveal the basis of
RT   subtype selectivity.";
RL   Nature 569:289-292(2019).
CC   -!- FUNCTION: High affinity receptor for melatonin. Likely to mediate the
CC       reproductive and circadian actions of melatonin. The activity of this
CC       receptor is mediated by pertussis toxin sensitive G proteins that
CC       inhibit adenylate cyclase activity.
CC   -!- SUBUNIT: Interacts with GPR61, GPR62 and GPR135 (PubMed:28827538).
CC       {ECO:0000269|PubMed:28827538}.
CC   -!- INTERACTION:
CC       P49286; P28335: HTR2C; NbExp=3; IntAct=EBI-1188341, EBI-994141;
CC       P49286; P48039: MTNR1A; NbExp=2; IntAct=EBI-1188341, EBI-1188238;
CC       P49286; O76081: RGS20; NbExp=2; IntAct=EBI-1188341, EBI-1052678;
CC       P49286; Q14669: TRIP12; NbExp=3; IntAct=EBI-1188341, EBI-308443;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Expressed in retina and less in brain and
CC       hippocampus. {ECO:0000269|PubMed:7568007}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Melatonin receptor entry;
CC       URL="https://en.wikipedia.org/wiki/Melatonin_receptor";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U25341; AAC50612.1; -; mRNA.
DR   EMBL; AB033598; BAA92315.1; -; Genomic_DNA.
DR   EMBL; AY521019; AAS00461.1; -; mRNA.
DR   EMBL; BC069163; AAH69163.1; -; mRNA.
DR   CCDS; CCDS8290.1; -.
DR   PIR; I38990; I38990.
DR   RefSeq; NP_005950.1; NM_005959.3.
DR   RefSeq; XP_011541141.1; XM_011542839.2.
DR   PDB; 6ME6; X-ray; 2.80 A; A/B=35-340.
DR   PDB; 6ME7; X-ray; 3.20 A; A/B=35-340.
DR   PDB; 6ME8; X-ray; 3.10 A; A/B=35-340.
DR   PDB; 6ME9; X-ray; 3.30 A; A/B=35-340.
DR   PDBsum; 6ME6; -.
DR   PDBsum; 6ME7; -.
DR   PDBsum; 6ME8; -.
DR   PDBsum; 6ME9; -.
DR   SMR; P49286; -.
DR   BioGRID; 110640; 197.
DR   CORUM; P49286; -.
DR   IntAct; P49286; 204.
DR   MINT; P49286; -.
DR   STRING; 9606.ENSP00000257068; -.
DR   BindingDB; P49286; -.
DR   ChEMBL; CHEMBL1946; -.
DR   DrugBank; DB06594; Agomelatine.
DR   DrugBank; DB01065; Melatonin.
DR   DrugBank; DB00980; Ramelteon.
DR   DrugBank; DB02709; Resveratrol.
DR   DrugBank; DB09071; Tasimelteon.
DR   DrugCentral; P49286; -.
DR   GuidetoPHARMACOLOGY; 288; -.
DR   GlyGen; P49286; 1 site.
DR   BioMuta; MTNR1B; -.
DR   DMDM; 1346548; -.
DR   PaxDb; P49286; -.
DR   PRIDE; P49286; -.
DR   ProteomicsDB; 55983; -.
DR   Antibodypedia; 17799; 321 antibodies.
DR   Ensembl; ENST00000257068; ENSP00000257068; ENSG00000134640.
DR   GeneID; 4544; -.
DR   KEGG; hsa:4544; -.
DR   UCSC; uc001pdk.2; human.
DR   CTD; 4544; -.
DR   DisGeNET; 4544; -.
DR   EuPathDB; HostDB:ENSG00000134640.2; -.
DR   GeneCards; MTNR1B; -.
DR   HGNC; HGNC:7464; MTNR1B.
DR   HPA; ENSG00000134640; Tissue enhanced (brain, lymphoid tissue, placenta, testis).
DR   MalaCards; MTNR1B; -.
DR   MIM; 600804; gene.
DR   neXtProt; NX_P49286; -.
DR   OpenTargets; ENSG00000134640; -.
DR   PharmGKB; PA31268; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00940000162341; -.
DR   HOGENOM; CLU_009579_3_3_1; -.
DR   InParanoid; P49286; -.
DR   KO; K04286; -.
DR   OMA; EVHCKAS; -.
DR   OrthoDB; 1011028at2759; -.
DR   PhylomeDB; P49286; -.
DR   TreeFam; TF331693; -.
DR   PathwayCommons; P49286; -.
DR   Reactome; R-HSA-373076; Class A/1 (Rhodopsin-like receptors).
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   SignaLink; P49286; -.
DR   SIGNOR; P49286; -.
DR   BioGRID-ORCS; 4544; 3 hits in 869 CRISPR screens.
DR   GeneWiki; Melatonin_receptor_1B; -.
DR   GenomeRNAi; 4544; -.
DR   Pharos; P49286; Tclin.
DR   PRO; PR:P49286; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; P49286; protein.
DR   Bgee; ENSG00000134640; Expressed in islet of Langerhans and 36 other tissues.
DR   ExpressionAtlas; P49286; baseline and differential.
DR   Genevisible; P49286; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0045202; C:synapse; IEA:GOC.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0008502; F:melatonin receptor activity; TAS:ProtInc.
DR   GO; GO:0043010; P:camera-type eye development; IEA:Ensembl.
DR   GO; GO:0007268; P:chemical synaptic transmission; TAS:ProtInc.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007187; P:G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; TAS:ProtInc.
DR   GO; GO:0042593; P:glucose homeostasis; IMP:BHF-UCL.
DR   GO; GO:0010754; P:negative regulation of cGMP-mediated signaling; IEA:Ensembl.
DR   GO; GO:0051481; P:negative regulation of cytosolic calcium ion concentration; IEA:Ensembl.
DR   GO; GO:1902260; P:negative regulation of delayed rectifier potassium channel activity; IEA:Ensembl.
DR   GO; GO:0046676; P:negative regulation of insulin secretion; IEA:Ensembl.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0051970; P:negative regulation of transmission of nerve impulse; IEA:Ensembl.
DR   GO; GO:0097755; P:positive regulation of blood vessel diameter; IEA:Ensembl.
DR   GO; GO:0046010; P:positive regulation of circadian sleep/wake cycle, non-REM sleep; IEA:Ensembl.
DR   GO; GO:0051971; P:positive regulation of transmission of nerve impulse; IEA:Ensembl.
DR   GO; GO:0050796; P:regulation of insulin secretion; IMP:BHF-UCL.
DR   GO; GO:0098908; P:regulation of neuronal action potential; IEA:Ensembl.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR002278; Mel_1A/1B_rcpt.
DR   InterPro; IPR000025; Melatonin_rcpt.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01149; MELATONIN1AR.
DR   PRINTS; PR00857; MELATONINR.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Membrane; Polymorphism; Receptor; Reference proteome;
KW   Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..362
FT                   /note="Melatonin receptor type 1B"
FT                   /id="PRO_0000069870"
FT   TOPO_DOM        1..42
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        43..63
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        64..76
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        77..97
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        98..115
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        116..136
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        137..155
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        156..176
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        177..200
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        201..221
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        222..253
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        254..274
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        275..287
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        288..308
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        309..362
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   BINDING         175
FT                   /note="Melatonin"
FT                   /evidence="ECO:0000244|PDB:6ME6,
FT                   ECO:0000269|PubMed:31019305"
FT   BINDING         194
FT                   /note="Melatonin"
FT                   /evidence="ECO:0000244|PDB:6ME6,
FT                   ECO:0000269|PubMed:31019305"
FT   CARBOHYD        4
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        113..190
FT                   /evidence="ECO:0000244|PDB:6ME6, ECO:0000255|PROSITE-
FT                   ProRule:PRU00521, ECO:0000269|PubMed:31019305"
FT   VARIANT         24
FT                   /note="G -> E (in dbSNP:rs8192552)"
FT                   /evidence="ECO:0000269|PubMed:10696804"
FT                   /id="VAR_009262"
FT   VARIANT         66
FT                   /note="L -> F (in dbSNP:rs370338802)"
FT                   /evidence="ECO:0000269|PubMed:10696804"
FT                   /id="VAR_009263"
FT   VARIANT         231
FT                   /note="R -> H (in dbSNP:rs8192553)"
FT                   /id="VAR_049421"
FT   HELIX           39..67
FT                   /evidence="ECO:0000244|PDB:6ME6"
FT   HELIX           69..72
FT                   /evidence="ECO:0000244|PDB:6ME6"
FT   TURN            73..76
FT                   /evidence="ECO:0000244|PDB:6ME6"
FT   HELIX           77..91
FT                   /evidence="ECO:0000244|PDB:6ME6"
FT   HELIX           93..102
FT                   /evidence="ECO:0000244|PDB:6ME6"
FT   HELIX           111..143
FT                   /evidence="ECO:0000244|PDB:6ME6"
FT   HELIX           145..150
FT                   /evidence="ECO:0000244|PDB:6ME6"
FT   HELIX           156..172
FT                   /evidence="ECO:0000244|PDB:6ME6"
FT   HELIX           175..178
FT                   /evidence="ECO:0000244|PDB:6ME6"
FT   STRAND          181..184
FT                   /evidence="ECO:0000244|PDB:6ME6"
FT   HELIX           185..187
FT                   /evidence="ECO:0000244|PDB:6ME6"
FT   STRAND          189..192
FT                   /evidence="ECO:0000244|PDB:6ME6"
FT   STRAND          194..196
FT                   /evidence="ECO:0000244|PDB:6ME6"
FT   HELIX           198..207
FT                   /evidence="ECO:0000244|PDB:6ME6"
FT   HELIX           210..229
FT                   /evidence="ECO:0000244|PDB:6ME6"
FT   HELIX           246..276
FT                   /evidence="ECO:0000244|PDB:6ME6"
FT   TURN            278..280
FT                   /evidence="ECO:0000244|PDB:6ME6"
FT   HELIX           281..284
FT                   /evidence="ECO:0000244|PDB:6ME8"
FT   HELIX           287..299
FT                   /evidence="ECO:0000244|PDB:6ME6"
FT   TURN            300..303
FT                   /evidence="ECO:0000244|PDB:6ME6"
FT   HELIX           304..311
FT                   /evidence="ECO:0000244|PDB:6ME6"
FT   HELIX           313..327
FT                   /evidence="ECO:0000244|PDB:6ME6"
SQ   SEQUENCE   362 AA;  40188 MW;  EECD78649DD79121 CRC64;
     MSENGSFANC CEAGGWAVRP GWSGAGSARP SRTPRPPWVA PALSAVLIVT TAVDVVGNLL
     VILSVLRNRK LRNAGNLFLV SLALADLVVA FYPYPLILVA IFYDGWALGE EHCKASAFVM
     GLSVIGSVFN ITAIAINRYC YICHSMAYHR IYRRWHTPLH ICLIWLLTVV ALLPNFFVGS
     LEYDPRIYSC TFIQTASTQY TAAVVVIHFL LPIAVVSFCY LRIWVLVLQA RRKAKPESRL
     CLKPSDLRSF LTMFVVFVIF AICWAPLNCI GLAVAINPQE MAPQIPEGLF VTSYLLAYFN
     SCLNAIVYGL LNQNFRREYK RILLALWNPR HCIQDASKGS HAEGLQSPAP PIIGVQHQAD
     AL
//
ID   AGTR2_HUMAN             Reviewed;         363 AA.
AC   P50052; B2R9V1; Q13016; Q6FGY7;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   12-AUG-2020, entry version 182.
DE   RecName: Full=Type-2 angiotensin II receptor;
DE   AltName: Full=Angiotensin II type-2 receptor;
DE            Short=AT2;
GN   Name=AGTR2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Liver;
RX   PubMed=7733925; DOI=10.1006/bbrc.1995.1537;
RA   Martin M.M., Elton T.S.;
RT   "The sequence and genomic organization of the human type 2 angiotensin II
RT   receptor.";
RL   Biochem. Biophys. Res. Commun. 209:554-562(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Placenta;
RX   PubMed=7790004; DOI=10.1016/0888-7543(95)80072-t;
RA   Chassagne C., Beatty B.G., Meloche S.;
RT   "Assignment of the human angiotensin II type 2 receptor gene (AGTR2) to
RT   chromosome Xq22-q23 by fluorescence in situ hybridization.";
RL   Genomics 25:601-603(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Blood;
RX   PubMed=7945336; DOI=10.1006/bbrc.1994.2402;
RA   Koike G., Horiuchi M., Yamada T., Szpirer C., Jacob H.J., Dzau V.J.;
RT   "Human type 2 angiotensin II receptor gene: cloned, mapped to the X
RT   chromosome, and its mRNA is expressed in the human lung.";
RL   Biochem. Biophys. Res. Commun. 203:1842-1850(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Placenta;
RX   PubMed=8185599; DOI=10.1006/bbrc.1994.1613;
RA   Tsuzuki S., Ichiki T., Nakakubo H., Kitami Y., Guo D.F., Shirai H.,
RA   Inagami T.;
RT   "Molecular cloning and expression of the gene encoding human angiotensin II
RT   type 2 receptor.";
RL   Biochem. Biophys. Res. Commun. 200:1449-1454(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lung;
RX   PubMed=7999093; DOI=10.1006/bbrc.1994.2714;
RA   Martin M.M., Su B., Elton T.S.;
RT   "Molecular cloning of the human angiotensin II type 2 receptor cDNA.";
RL   Biochem. Biophys. Res. Commun. 205:645-651(1994).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Placenta;
RX   PubMed=7719706;
RA   Lazard D., Briend-Sutren M.M., Villageois P., Mattei M.-G., Strosberg A.D.,
RA   Nahmias C.;
RT   "Molecular characterization and chromosome localization of a human
RT   angiotensin II AT2 receptor gene highly expressed in fetal tissues.";
RL   Recept. Channels 2:271-280(1994).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Zhang M., Ma H., Wang B., Zhao Y.;
RT   "Sequence of the AGTR2 gene in Cantonese.";
RL   Submitted (JAN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "Isolation of complete coding sequence for angiotensin II receptor, type 2
RT   (AGTR2).";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S., Neubert P.,
RA   Kstrang K., Schatten R., Shen B., Henze S., Mar W., Korn B., Zuo D., Hu Y.,
RA   LaBaer J.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Rieder M.J., da Ponte S.H., Kuldanek S.A., Rajkumar N., Smith J.D.,
RA   Toth E.J., Nickerson D.A.;
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [15]
RP   NUCLEOTIDE SEQUENCE OF 1-22.
RC   TISSUE=Blood;
RA   Katsuya T., Dzau V.J.;
RL   Submitted (JAN-1996) to the EMBL/GenBank/DDBJ databases.
RN   [16]
RP   NUCLEOTIDE SEQUENCE OF 1-16.
RC   TISSUE=Uterus;
RA   Warnecke C.H., Holzmeister J., Regitz-Zagrosek V., Fleck E.;
RL   Submitted (JUN-1995) to the EMBL/GenBank/DDBJ databases.
RN   [17]
RP   TISSUE SPECIFICITY, VARIANTS VAL-21; LYS-248; GLN-324 AND VAL-337, AND
RP   POSSIBLE ASSOCIATION OF VARIANTS VAL-21; GLN-324 AND VAL-337 WITH X-LINKED
RP   MENTAL RETARDATION.
RX   PubMed=12089445; DOI=10.1126/science.1072191;
RA   Vervoort V.S., Beachem M.A., Edwards P.S., Ladd S., Miller K.E.,
RA   de Mollerat X., Clarkson K., DuPont B., Schwartz C.E., Stevenson R.E.,
RA   Boyd E., Srivastava A.K.;
RT   "AGTR2 mutations in X-linked mental retardation.";
RL   Science 296:2401-2403(2002).
RN   [18]
RP   INTERACTION WITH MTUS1, AND FUNCTION.
RX   PubMed=15123706; DOI=10.1074/jbc.m403880200;
RA   Nouet S., Amzallag N., Li J.-M., Louis S., Seitz I., Cui T.-X.,
RA   Alleaume A.-M., Di Benedetto M., Boden C., Masson M., Strosberg A.D.,
RA   Horiuchi M., Couraud P.-O., Nahmias C.;
RT   "Trans-inactivation of receptor tyrosine kinases by novel angiotensin II
RT   AT2 receptor-interacting protein, ATIP.";
RL   J. Biol. Chem. 279:28989-28997(2004).
RN   [19]
RP   LACK OF ASSOCIATION VARIANTS VAL-21; GLN-324 AND VAL-337 WITH X-LINKED
RP   MENTAL RETARDATION.
RX   PubMed=23871722; DOI=10.1016/j.ajhg.2013.06.013;
RA   Piton A., Redin C., Mandel J.L.;
RT   "XLID-causing mutations and associated genes challenged in light of data
RT   from large-scale human exome sequencing.";
RL   Am. J. Hum. Genet. 93:368-383(2013).
CC   -!- FUNCTION: Receptor for angiotensin II. Cooperates with MTUS1 to inhibit
CC       ERK2 activation and cell proliferation. {ECO:0000269|PubMed:15123706}.
CC   -!- SUBUNIT: Interacts with MTUS1. {ECO:0000269|PubMed:15123706}.
CC   -!- INTERACTION:
CC       P50052; PRO_0000032459 [P01019]: AGT; NbExp=2; IntAct=EBI-1748067, EBI-2927577;
CC       P50052; P35625: TIMP3; NbExp=7; IntAct=EBI-1748067, EBI-1748085;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: In adult, highly expressed in myometrium with lower
CC       levels in adrenal gland and fallopian tube. Expressed in the
CC       cerebellum. Very highly expressed in fetal kidney and intestine.
CC       {ECO:0000269|PubMed:12089445}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- CAUTION: Although AGTR2 has been reported to be involved in X-linked
CC       mental retardation (PubMed:12089445), its pathological role is
CC       questionable (PubMed:23871722). {ECO:0000305|PubMed:12089445,
CC       ECO:0000305|PubMed:23871722}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U20860; AAA85851.1; -; Genomic_DNA.
DR   EMBL; L34579; AAA98990.1; -; Genomic_DNA.
DR   EMBL; U10273; AAA61794.1; -; Genomic_DNA.
DR   EMBL; U15592; AAA50762.1; -; Genomic_DNA.
DR   EMBL; U16957; AAA67753.1; -; mRNA.
DR   EMBL; U27478; AAA84900.1; -; Genomic_DNA.
DR   EMBL; AY536522; AAS45437.1; -; Genomic_DNA.
DR   EMBL; AY322542; AAP84355.1; -; Genomic_DNA.
DR   EMBL; AY324607; AAP72969.1; -; Genomic_DNA.
DR   EMBL; CR541969; CAG46767.1; -; mRNA.
DR   EMBL; AK313927; BAG36648.1; -; mRNA.
DR   EMBL; AL732602; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471234; EAW51502.1; -; Genomic_DNA.
DR   EMBL; BC095504; AAH95504.1; -; mRNA.
DR   EMBL; X87723; CAA61022.1; -; mRNA.
DR   CCDS; CCDS14569.1; -.
DR   PIR; JC2543; JC2543.
DR   RefSeq; NP_000677.2; NM_000686.4.
DR   RefSeq; XP_011535835.1; XM_011537533.1.
DR   PDB; 5UNF; X-ray; 2.80 A; A/B=35-335.
DR   PDB; 5UNG; X-ray; 2.80 A; B=35-335.
DR   PDB; 5UNH; X-ray; 2.90 A; A/B=35-335.
DR   PDB; 6JOD; X-ray; 3.20 A; A=35-346.
DR   PDBsum; 5UNF; -.
DR   PDBsum; 5UNG; -.
DR   PDBsum; 5UNH; -.
DR   PDBsum; 6JOD; -.
DR   SMR; P50052; -.
DR   BioGRID; 106692; 8.
DR   IntAct; P50052; 3.
DR   STRING; 9606.ENSP00000360973; -.
DR   BindingDB; P50052; -.
DR   ChEMBL; CHEMBL4607; -.
DR   DrugBank; DB05739; CYT006-AngQb.
DR   DrugBank; DB01349; Tasosartan.
DR   DrugCentral; P50052; -.
DR   GuidetoPHARMACOLOGY; 35; -.
DR   GlyGen; P50052; 5 sites.
DR   iPTMnet; P50052; -.
DR   PhosphoSitePlus; P50052; -.
DR   BioMuta; AGTR2; -.
DR   DMDM; 1703214; -.
DR   PaxDb; P50052; -.
DR   PRIDE; P50052; -.
DR   ProteomicsDB; 56191; -.
DR   ABCD; P50052; 1 sequenced antibody.
DR   Antibodypedia; 29644; 259 antibodies.
DR   DNASU; 186; -.
DR   Ensembl; ENST00000371906; ENSP00000360973; ENSG00000180772.
DR   GeneID; 186; -.
DR   KEGG; hsa:186; -.
DR   UCSC; uc004eqh.5; human.
DR   CTD; 186; -.
DR   DisGeNET; 186; -.
DR   EuPathDB; HostDB:ENSG00000180772.6; -.
DR   GeneCards; AGTR2; -.
DR   HGNC; HGNC:338; AGTR2.
DR   HPA; ENSG00000180772; Tissue enhanced (endometrium, lung, smooth muscle).
DR   MalaCards; AGTR2; -.
DR   MIM; 300034; gene.
DR   neXtProt; NX_P50052; -.
DR   OpenTargets; ENSG00000180772; -.
DR   Orphanet; 777; X-linked non-syndromic intellectual disability.
DR   PharmGKB; PA44; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT01000000214406; -.
DR   HOGENOM; CLU_009579_8_3_1; -.
DR   InParanoid; P50052; -.
DR   KO; K04167; -.
DR   OMA; LYCFIGN; -.
DR   OrthoDB; 685818at2759; -.
DR   PhylomeDB; P50052; -.
DR   TreeFam; TF330024; -.
DR   PathwayCommons; P50052; -.
DR   Reactome; R-HSA-375276; Peptide ligand-binding receptors.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   SIGNOR; P50052; -.
DR   BioGRID-ORCS; 186; 5 hits in 499 CRISPR screens.
DR   GeneWiki; Angiotensin_II_receptor_type_2; -.
DR   GenomeRNAi; 186; -.
DR   Pharos; P50052; Tchem.
DR   PRO; PR:P50052; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; P50052; protein.
DR   Bgee; ENSG00000180772; Expressed in kidney and 63 other tissues.
DR   Genevisible; P50052; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0004945; F:angiotensin type II receptor activity; IPI:BHF-UCL.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0048019; F:receptor antagonist activity; TAS:BHF-UCL.
DR   GO; GO:0008134; F:transcription factor binding; IEA:Ensembl.
DR   GO; GO:0035932; P:aldosterone secretion; IEA:Ensembl.
DR   GO; GO:0002033; P:angiotensin-mediated vasodilation involved in regulation of systemic arterial blood pressure; IEA:Ensembl.
DR   GO; GO:0001974; P:blood vessel remodeling; TAS:BHF-UCL.
DR   GO; GO:0007420; P:brain development; NAS:BHF-UCL.
DR   GO; GO:0002035; P:brain renin-angiotensin system; IEA:Ensembl.
DR   GO; GO:0061049; P:cell growth involved in cardiac muscle cell development; IEA:Ensembl.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0071549; P:cellular response to dexamethasone stimulus; IEA:Ensembl.
DR   GO; GO:0006883; P:cellular sodium ion homeostasis; IEA:Ensembl.
DR   GO; GO:0021695; P:cerebellar cortex development; IEA:Ensembl.
DR   GO; GO:0042416; P:dopamine biosynthetic process; IEA:Ensembl.
DR   GO; GO:0035640; P:exploration behavior; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007199; P:G protein-coupled receptor signaling pathway coupled to cGMP nucleotide second messenger; ISS:BHF-UCL.
DR   GO; GO:0006954; P:inflammatory response; IBA:GO_Central.
DR   GO; GO:0035556; P:intracellular signal transduction; ISS:BHF-UCL.
DR   GO; GO:0043537; P:negative regulation of blood vessel endothelial cell migration; NAS:BHF-UCL.
DR   GO; GO:0030308; P:negative regulation of cell growth; TAS:BHF-UCL.
DR   GO; GO:0048147; P:negative regulation of fibroblast proliferation; IEA:Ensembl.
DR   GO; GO:0010459; P:negative regulation of heart rate; ISS:BHF-UCL.
DR   GO; GO:0032304; P:negative regulation of icosanoid secretion; IEA:Ensembl.
DR   GO; GO:0051387; P:negative regulation of neurotrophin TRK receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0010700; P:negative regulation of norepinephrine secretion; IEA:Ensembl.
DR   GO; GO:0007263; P:nitric oxide mediated signal transduction; TAS:BHF-UCL.
DR   GO; GO:0097755; P:positive regulation of blood vessel diameter; IBA:GO_Central.
DR   GO; GO:0090190; P:positive regulation of branching involved in ureteric bud morphogenesis; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0050715; P:positive regulation of cytokine secretion; IEA:Ensembl.
DR   GO; GO:2001238; P:positive regulation of extrinsic apoptotic signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0072300; P:positive regulation of metanephric glomerulus development; IEA:Ensembl.
DR   GO; GO:0045429; P:positive regulation of nitric oxide biosynthetic process; IC:BHF-UCL.
DR   GO; GO:0051000; P:positive regulation of nitric-oxide synthase activity; ISS:BHF-UCL.
DR   GO; GO:0032516; P:positive regulation of phosphoprotein phosphatase activity; IDA:BHF-UCL.
DR   GO; GO:0035815; P:positive regulation of renal sodium excretion; IEA:Ensembl.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IEA:Ensembl.
DR   GO; GO:0008217; P:regulation of blood pressure; TAS:ProtInc.
DR   GO; GO:0035566; P:regulation of metanephros size; IEA:Ensembl.
DR   GO; GO:0042306; P:regulation of protein import into nucleus; IEA:Ensembl.
DR   GO; GO:0001991; P:regulation of systemic arterial blood pressure by circulatory renin-angiotensin; ISS:BHF-UCL.
DR   GO; GO:0002018; P:renin-angiotensin regulation of aldosterone production; IEA:Ensembl.
DR   GO; GO:0042311; P:vasodilation; IDA:BHF-UCL.
DR   InterPro; IPR000147; ATII_AT2_rcpt.
DR   InterPro; IPR000248; ATII_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00241; ANGIOTENSINR.
DR   PRINTS; PR00636; ANGIOTENSN2R.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Membrane; Polymorphism; Receptor; Reference proteome;
KW   Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..363
FT                   /note="Type-2 angiotensin II receptor"
FT                   /id="PRO_0000069167"
FT   TOPO_DOM        1..45
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        46..71
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        72..80
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        81..102
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        103..119
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        120..140
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        141..160
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        161..179
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        180..208
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        209..234
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        235..256
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        257..278
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        279..297
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        298..318
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        319..363
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        4
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        13
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        24
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        29
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        34
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        35..290
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   DISULFID        117..195
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VARIANT         21
FT                   /note="G -> V (rare variant found in patients with X-linked
FT                   mental retardation; unknown pathological significance;
FT                   dbSNP:rs121917810)"
FT                   /evidence="ECO:0000269|PubMed:12089445,
FT                   ECO:0000269|PubMed:23871722"
FT                   /id="VAR_065946"
FT   VARIANT         231
FT                   /note="Y -> H (in dbSNP:rs3729977)"
FT                   /id="VAR_049374"
FT   VARIANT         248
FT                   /note="R -> K (in dbSNP:rs5191)"
FT                   /evidence="ECO:0000269|PubMed:12089445"
FT                   /id="VAR_011849"
FT   VARIANT         268
FT                   /note="C -> W (in dbSNP:rs1042860)"
FT                   /id="VAR_011850"
FT   VARIANT         324
FT                   /note="R -> Q (rare variant found in patients with X-linked
FT                   mental retardation; unknown pathological significance;
FT                   dbSNP:rs35474657)"
FT                   /evidence="ECO:0000269|PubMed:12089445,
FT                   ECO:0000269|PubMed:23871722"
FT                   /id="VAR_065947"
FT   VARIANT         337
FT                   /note="I -> V (rare variant found in patients with X-linked
FT                   mental retardation; unknown pathological significance;
FT                   dbSNP:rs121917811)"
FT                   /evidence="ECO:0000269|PubMed:12089445"
FT                   /id="VAR_065948"
FT   CONFLICT        269
FT                   /note="W -> C (in Ref. 5)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        272
FT                   /note="F -> L (in Ref. 4; AAA50762)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        323
FT                   /note="N -> G (in Ref. 4; AAA50762)"
FT                   /evidence="ECO:0000305"
FT   TURN            39..42
FT                   /evidence="ECO:0000244|PDB:5UNF"
FT   HELIX           46..71
FT                   /evidence="ECO:0000244|PDB:5UNF"
FT   HELIX           79..94
FT                   /evidence="ECO:0000244|PDB:5UNF"
FT   HELIX           97..105
FT                   /evidence="ECO:0000244|PDB:5UNF"
FT   TURN            106..108
FT                   /evidence="ECO:0000244|PDB:6JOD"
FT   HELIX           113..147
FT                   /evidence="ECO:0000244|PDB:5UNF"
FT   HELIX           149..151
FT                   /evidence="ECO:0000244|PDB:5UNG"
FT   STRAND          153..155
FT                   /evidence="ECO:0000244|PDB:6JOD"
FT   HELIX           159..174
FT                   /evidence="ECO:0000244|PDB:5UNF"
FT   HELIX           176..181
FT                   /evidence="ECO:0000244|PDB:5UNF"
FT   STRAND          182..186
FT                   /evidence="ECO:0000244|PDB:5UNF"
FT   TURN            188..190
FT                   /evidence="ECO:0000244|PDB:5UNF"
FT   STRAND          193..197
FT                   /evidence="ECO:0000244|PDB:5UNF"
FT   HELIX           201..203
FT                   /evidence="ECO:0000244|PDB:5UNF"
FT   HELIX           205..219
FT                   /evidence="ECO:0000244|PDB:5UNF"
FT   HELIX           221..240
FT                   /evidence="ECO:0000244|PDB:5UNF"
FT   HELIX           246..283
FT                   /evidence="ECO:0000244|PDB:5UNF"
FT   HELIX           290..318
FT                   /evidence="ECO:0000244|PDB:5UNF"
FT   TURN            319..321
FT                   /evidence="ECO:0000244|PDB:5UNF"
FT   HELIX           322..333
FT                   /evidence="ECO:0000244|PDB:5UNF"
FT   HELIX           335..339
FT                   /evidence="ECO:0000244|PDB:6JOD"
SQ   SEQUENCE   363 AA;  41184 MW;  FDD7D4E6F9B43E60 CRC64;
     MKGNSTLATT SKNITSGLHF GLVNISGNNE STLNCSQKPS DKHLDAIPIL YYIIFVIGFL
     VNIVVVTLFC CQKGPKKVSS IYIFNLAVAD LLLLATLPLW ATYYSYRYDW LFGPVMCKVF
     GSFLTLNMFA SIFFITCMSV DRYQSVIYPF LSQRRNPWQA SYIVPLVWCM ACLSSLPTFY
     FRDVRTIEYL GVNACIMAFP PEKYAQWSAG IALMKNILGF IIPLIFIATC YFGIRKHLLK
     TNSYGKNRIT RDQVLKMAAA VVLAFIICWL PFHVLTFLDA LAWMGVINSC EVIAVIDLAL
     PFAILLGFTN SCVNPFLYCF VGNRFQQKLR SVFRVPITWL QGKRESMSCR KSSSLREMET
     FVS
//
ID   PAR2_HUMAN              Reviewed;         397 AA.
AC   P55085; Q13317; Q13346; Q53XJ8;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   07-OCT-2020, entry version 190.
DE   RecName: Full=Proteinase-activated receptor 2;
DE            Short=PAR-2;
DE   AltName: Full=Coagulation factor II receptor-like 1;
DE   AltName: Full=G-protein coupled receptor 11;
DE   AltName: Full=Thrombin receptor-like 1;
DE   Contains:
DE     RecName: Full=Proteinase-activated receptor 2, alternate cleaved 1;
DE   Contains:
DE     RecName: Full=Proteinase-activated receptor 2, alternate cleaved 2;
DE   Flags: Precursor;
GN   Name=F2RL1; Synonyms=GPR11, PAR2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND TISSUE SPECIFICITY.
RX   PubMed=7556175; DOI=10.1111/j.1432-1033.1995.tb20784.x;
RA   Nystedt S., Emilsson K., Larsson A.-K., Stroembeck B., Sundelin J.;
RT   "Molecular cloning and functional expression of the gene encoding the human
RT   proteinase-activated receptor 2.";
RL   Eur. J. Biochem. 232:84-89(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Kidney;
RX   PubMed=8615752; DOI=10.1042/bj3141009;
RA   Boehm S.K., Kong W., Broemme D., Smeekens S.P., Anderson D.C.,
RA   Connolly A.J., Kahn M.L., Nelken N.A., Coughlin S.R., Payan D.G.,
RA   Bunnett N.W.;
RT   "Molecular cloning, expression and potential functions of the human
RT   proteinase-activated receptor-2.";
RL   Biochem. J. 314:1009-1016(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND INTERACTION WITH COPS5.
RX   PubMed=16410250; DOI=10.1074/jbc.m510784200;
RA   Luo W., Wang Y., Hanck T., Stricker R., Reiser G.;
RT   "Jab1, a novel protease-activated receptor-2 (PAR-2)-interacting protein,
RT   is involved in PAR-2-induced activation of activator protein-1.";
RL   J. Biol. Chem. 281:7927-7936(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS PHE-21; GLN-270 AND
RP   ALA-291.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Ovary, and Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 29-397.
RX   PubMed=8784787; DOI=10.1007/bf03401632;
RA   Kahn M.L., Ishii K., Kuo W.L., Piper M., Connolly A.J., Shi Y.P., Wu R.,
RA   Lin C.C., Coughlin S.R.;
RT   "Conserved structure and adjacent location of the thrombin receptor and
RT   protease-activated receptor 2 genes define a protease-activated receptor
RT   gene cluster.";
RL   Mol. Med. 2:349-357(1996).
RN   [9]
RP   ACTIVATION BY MAST CELL TRYPTASE.
RX   PubMed=9020112; DOI=10.1074/jbc.272.7.4043;
RA   Molino M., Barnathan E.S., Numerof R., Clark J., Dreyer M., Cumashi A.,
RA   Hoxie J.A., Schechter N., Woolkalis M., Brass L.F.;
RT   "Interactions of mast cell tryptase with thrombin receptors and PAR-2.";
RL   J. Biol. Chem. 272:4043-4049(1997).
RN   [10]
RP   FUNCTION IN EPITHELIAL BARRIER PROTECTION.
RX   PubMed=10086357; DOI=10.1038/18223;
RA   Cocks T.M., Fong B., Chow J.M., Anderson G.P., Frauman A.G., Goldie R.G.,
RA   Henry P.J., Carr M.J., Hamilton J.R., Moffatt J.D.;
RT   "A protective role for protease-activated receptors in the airways.";
RL   Nature 398:156-160(1999).
RN   [11]
RP   TRANSACTIVATION BY F2R.
RX   PubMed=10788464; DOI=10.1074/jbc.275.18.13502;
RA   O'Brien P.J., Prevost N., Molino M., Hollinger M.K., Woolkalis M.J.,
RA   Woulfe D.S., Brass L.F.;
RT   "Thrombin responses in human endothelial cells. Contributions from
RT   receptors other than PAR1 include the transactivation of PAR2 by thrombin-
RT   cleaved PAR1.";
RL   J. Biol. Chem. 275:13502-13509(2000).
RN   [12]
RP   FUNCTION, AND MUTAGENESIS OF SER-363 AND THR-366.
RX   PubMed=10725339; DOI=10.1083/jcb.148.6.1267;
RA   DeFea K.A., Zalevsky J., Thoma M.S., Dery O., Mullins R.D., Bunnett N.W.;
RT   "beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is
RT   required for intracellular targeting of activated ERK1/2.";
RL   J. Cell Biol. 148:1267-1281(2000).
RN   [13]
RP   ACTIVATION BY ST14.
RX   PubMed=10831593; DOI=10.1074/jbc.m002941200;
RA   Takeuchi T., Harris J.L., Huang W., Yan K.W., Coughlin S.R., Craik C.S.;
RT   "Cellular localization of membrane-type serine protease 1 and
RT   identification of protease-activated receptor-2 and single-chain urokinase-
RT   type plasminogen activator as substrates.";
RL   J. Biol. Chem. 275:26333-26342(2000).
RN   [14]
RP   ACTIVATION BY COAGULATION FACTORS VII AND XA.
RX   PubMed=10805786; DOI=10.1073/pnas.97.10.5255;
RA   Camerer E., Huang W., Coughlin S.R.;
RT   "Tissue factor- and factor X-dependent activation of protease-activated
RT   receptor 2 by factor VIIa.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:5255-5260(2000).
RN   [15]
RP   FUNCTION, AND ACTIVATION BY GINGIPAINS.
RX   PubMed=11447194; DOI=10.1128/iai.69.8.5121-5130.2001;
RA   Lourbakos A., Potempa J., Travis J., D'Andrea M.R., Andrade-Gordon P.,
RA   Santulli R., Mackie E.J., Pike R.N.;
RT   "Arginine-specific protease from Porphyromonas gingivalis activates
RT   protease-activated receptors on human oral epithelial cells and induces
RT   interleukin-6 secretion.";
RL   Infect. Immun. 69:5121-5130(2001).
RN   [16]
RP   FUNCTION IN JNK AND NF-KAPPA-B PATHWAYS.
RX   PubMed=11413129; DOI=10.1074/jbc.m100377200;
RA   Kanke T., Macfarlane S.R., Seatter M.J., Davenport E., Paul A.,
RA   McKenzie R.C., Plevin R.;
RT   "Proteinase-activated receptor-2-mediated activation of stress-activated
RT   protein kinases and inhibitory kappa B kinases in NCTC 2544
RT   keratinocytes.";
RL   J. Biol. Chem. 276:31657-31666(2001).
RN   [17]
RP   FUNCTION, AND ACTIVATION BY DUST MITE ALLERGENS.
RX   PubMed=11441110; DOI=10.4049/jimmunol.167.2.1014;
RA   Sun G., Stacey M.A., Schmidt M., Mori L., Mattoli S.;
RT   "Interaction of mite allergens Der p3 and Der p9 with protease-activated
RT   receptor-2 expressed by lung epithelial cells.";
RL   J. Immunol. 167:1014-1021(2001).
RN   [18]
RP   FUNCTION IN INFLAMMATORY RESPONSE.
RX   PubMed=11714832; DOI=10.4049/jimmunol.167.11.6615;
RA   Miike S., McWilliam A.S., Kita H.;
RT   "Trypsin induces activation and inflammatory mediator release from human
RT   eosinophils through protease-activated receptor-2.";
RL   J. Immunol. 167:6615-6622(2001).
RN   [19]
RP   GLYCOSYLATION AT ASN-30 AND ASN-222, AND MUTAGENESIS OF ASN-30 AND ASN-222.
RX   PubMed=12171601; DOI=10.1042/bj20020706;
RA   Compton S.J., Sandhu S., Wijesuriya S.J., Hollenberg M.D.;
RT   "Glycosylation of human proteinase-activated receptor-2 (hPAR2): role in
RT   cell surface expression and signalling.";
RL   Biochem. J. 368:495-505(2002).
RN   [20]
RP   POSSIBLE INVOLVEMENT IN ALLERGIC DERMATITIS.
RX   PubMed=11859856; DOI=10.1254/jjp.88.77;
RA   Kawagoe J., Takizawa T., Matsumoto J., Tamiya M., Meek S.E., Smith A.J.,
RA   Hunter G.D., Plevin R., Saito N., Kanke T., Fujii M., Wada Y.;
RT   "Effect of protease-activated receptor-2 deficiency on allergic dermatitis
RT   in the mouse ear.";
RL   Jpn. J. Pharmacol. 88:77-84(2002).
RN   [21]
RP   DEACTIVATION BY NEUTROPHIL ELASTASE AND CATHEPSIN G.
RX   PubMed=12594060; DOI=10.1165/rcmb.4908;
RA   Dulon S., Cande C., Bunnett N.W., Hollenberg M.D., Chignard M., Pidard D.;
RT   "Proteinase-activated receptor-2 and human lung epithelial cells: disarming
RT   by neutrophil serine proteinases.";
RL   Am. J. Respir. Cell Mol. Biol. 28:339-346(2003).
RN   [22]
RP   POSSIBLE INVOLVEMENT IN SKIN DISEASES.
RX   PubMed=14519665; DOI=10.1096/fj.02-1112com;
RA   Seeliger S., Derian C.K., Vergnolle N., Bunnett N.W., Nawroth R.,
RA   Schmelz M., Von Der Weid P.Y., Buddenkotte J., Sunderkotter C., Metze D.,
RA   Andrade-Gordon P., Harms E., Vestweber D., Luger T.A., Steinhoff M.;
RT   "Proinflammatory role of proteinase-activated receptor-2 in humans and mice
RT   during cutaneous inflammation in vivo.";
RL   FASEB J. 17:1871-1885(2003).
RN   [23]
RP   FUNCTION.
RX   PubMed=12832443; DOI=10.1189/jlb.0702351;
RA   Bolton S.J., McNulty C.A., Thomas R.J., Hewitt C.R., Wardlaw A.J.;
RT   "Expression of and functional responses to protease-activated receptors on
RT   human eosinophils.";
RL   J. Leukoc. Biol. 74:60-68(2003).
RN   [24]
RP   MUTAGENESIS OF 355-ALA--SER-363.
RX   PubMed=14607272; DOI=10.1016/s0898-6568(03)00095-0;
RA   Seatter M.J., Drummond R., Kanke T., Macfarlane S.R., Hollenberg M.D.,
RA   Plevin R.;
RT   "The role of the C-terminal tail in protease-activated receptor-2-mediated
RT   Ca2+ signalling, proline-rich tyrosine kinase-2 activation, and mitogen-
RT   activated protein kinase activity.";
RL   Cell. Signal. 16:21-29(2004).
RN   [25]
RP   FUNCTION.
RX   PubMed=15155775; DOI=10.1189/jlb.0503221;
RA   Shpacovitch V.M., Varga G., Strey A., Gunzer M., Mooren F., Buddenkotte J.,
RA   Vergnolle N., Sommerhoff C.P., Grabbe S., Gerke V., Homey B.,
RA   Hollenberg M., Luger T.A., Steinhoff M.;
RT   "Agonists of proteinase-activated receptor-2 modulate human neutrophil
RT   cytokine secretion, expression of cell adhesion molecules, and migration
RT   within 3-D collagen lattices.";
RL   J. Leukoc. Biol. 76:388-398(2004).
RN   [26]
RP   UBIQUITINATION BY CBL.
RX   PubMed=15708858; DOI=10.1074/jbc.m500109200;
RA   Jacob C., Cottrell G.S., Gehringer D., Schmidlin F., Grady E.F.,
RA   Bunnett N.W.;
RT   "c-Cbl mediates ubiquitination, degradation, and down-regulation of human
RT   protease-activated receptor 2.";
RL   J. Biol. Chem. 280:16076-16087(2005).
RN   [27]
RP   FUNCTION IN ENDOTHELIAL BARRIER PROTECTION.
RX   PubMed=16359518; DOI=10.1111/j.1538-7836.2005.01610.x;
RA   Feistritzer C., Lenta R., Riewald M.;
RT   "Protease-activated receptors-1 and -2 can mediate endothelial barrier
RT   protection: role in factor Xa signaling.";
RL   J. Thromb. Haemost. 3:2798-2805(2005).
RN   [28]
RP   POSSIBLE INVOLVEMENT IN COLITIS.
RX   PubMed=15919826; DOI=10.1073/pnas.0409535102;
RA   Hansen K.K., Sherman P.M., Cellars L., Andrade-Gordon P., Pan Z.,
RA   Baruch A., Wallace J.L., Hollenberg M.D., Vergnolle N.;
RT   "A major role for proteolytic activity and proteinase-activated receptor-2
RT   in the pathogenesis of infectious colitis.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:8363-8368(2005).
RN   [29]
RP   POSSIBLE INVOLVEMENT IN BRONCHIAL EOSINOPHILIC INFLAMMATION.
RX   PubMed=15879675; DOI=10.1254/jphs.scz050138;
RA   Takizawa T., Tamiya M., Hara T., Matsumoto J., Saito N., Kanke T.,
RA   Kawagoe J., Hattori Y.;
RT   "Abrogation of bronchial eosinophilic inflammation and attenuated eotaxin
RT   content in protease-activated receptor 2-deficient mice.";
RL   J. Pharmacol. Sci. 98:99-102(2005).
RN   [30]
RP   FUNCTION IN EPITHELIAL BARRIER DISRUPTION.
RX   PubMed=16714334; DOI=10.1152/ajplung.00046.2006;
RA   Winter M.C., Shasby S.S., Ries D.R., Shasby D.M.;
RT   "PAR2 activation interrupts E-cadherin adhesion and compromises the airway
RT   epithelial barrier: protective effect of beta-agonists.";
RL   Am. J. Physiol. 291:L628-L635(2006).
RN   [31]
RP   FUNCTION, AND ACTIVATION BY PRTN3.
RX   PubMed=16478888; DOI=10.1182/blood-2005-05-1875;
RA   Csernok E., Ai M., Gross W.L., Wicklein D., Petersen A., Lindner B.,
RA   Lamprecht P., Holle J.U., Hellmich B.;
RT   "Wegener autoantigen induces maturation of dendritic cells and licenses
RT   them for Th1 priming via the protease-activated receptor-2 pathway.";
RL   Blood 107:4440-4448(2006).
RN   [32]
RP   POSSIBLE INVOLVEMENT IN ENCEPHALOMYELITIS AND MULTIPLE SCLEROSIS.
RX   PubMed=16476770; DOI=10.1084/jem.20052148;
RA   Noorbakhsh F., Tsutsui S., Vergnolle N., Boven L.A., Shariat N.,
RA   Vodjgani M., Warren K.G., Andrade-Gordon P., Hollenberg M.D., Power C.;
RT   "Proteinase-activated receptor 2 modulates neuroinflammation in
RT   experimental autoimmune encephalomyelitis and multiple sclerosis.";
RL   J. Exp. Med. 203:425-435(2006).
RN   [33]
RP   FUNCTION IN ACTIN FILAMENT SEVERING.
RX   PubMed=17500066; DOI=10.1074/jbc.m701391200;
RA   Zoudilova M., Kumar P., Ge L., Wang P., Bokoch G.M., DeFea K.A.;
RT   "Beta-arrestin-dependent regulation of the cofilin pathway downstream of
RT   protease-activated receptor-2.";
RL   J. Biol. Chem. 282:20634-20646(2007).
RN   [34]
RP   INTERACTION WITH TMED2.
RX   PubMed=17693410; DOI=10.1074/jbc.m703205200;
RA   Luo W., Wang Y., Reiser G.;
RT   "p24A, a type I transmembrane protein, controls ARF1-dependent
RT   resensitization of protease-activated receptor-2 by influence on receptor
RT   trafficking.";
RL   J. Biol. Chem. 282:30246-30255(2007).
RN   [35]
RP   FUNCTION, AND ACTIVATION BY MOLD ALLERGENS.
RX   PubMed=17404307; DOI=10.4049/jimmunol.178.8.5237;
RA   Chiu L.L., Perng D.W., Yu C.H., Su S.N., Chow L.P.;
RT   "Mold allergen, pen C 13, induces IL-8 expression in human airway
RT   epithelial cells by activating protease-activated receptor 1 and 2.";
RL   J. Immunol. 178:5237-5244(2007).
RN   [36]
RP   FUNCTION, AND ACTIVATION BY BACTERIAL CHITINASE.
RX   PubMed=18474671; DOI=10.1165/rcmb.2007-0410oc;
RA   Hong J.H., Hong J.Y., Park B., Lee S.I., Seo J.T., Kim K.E., Sohn M.H.,
RA   Shin D.M.;
RT   "Chitinase activates protease-activated receptor-2 in human airway
RT   epithelial cells.";
RL   Am. J. Respir. Cell Mol. Biol. 39:530-535(2008).
RN   [37]
RP   FUNCTION.
RX   PubMed=18424071; DOI=10.1016/j.cellsig.2008.02.015;
RA   Goon Goh F., Sloss C.M., Cunningham M.R., Nilsson M., Cadalbert L.,
RA   Plevin R.;
RT   "G-protein-dependent and -independent pathways regulate proteinase-
RT   activated receptor-2 mediated p65 NFkappaB serine 536 phosphorylation in
RT   human keratinocytes.";
RL   Cell. Signal. 20:1267-1274(2008).
RN   [38]
RP   FUNCTION, AND INTERACTION WITH TLR4.
RX   PubMed=18622013; DOI=10.1074/jbc.m804800200;
RA   Rallabhandi P., Nhu Q.M., Toshchakov V.Y., Piao W., Medvedev A.E.,
RA   Hollenberg M.D., Fasano A., Vogel S.N.;
RT   "Analysis of proteinase-activated receptor 2 and TLR4 signal transduction:
RT   a novel paradigm for receptor cooperativity.";
RL   J. Biol. Chem. 283:24314-24325(2008).
RN   [39]
RP   FUNCTION IN ANTIVIRAL RESPONSE.
RX   PubMed=18453611; DOI=10.4049/jimmunol.180.10.6903;
RA   Feld M., Shpacovitch V.M., Ehrhardt C., Kerkhoff C., Hollenberg M.D.,
RA   Vergnolle N., Ludwig S., Steinhoff M.;
RT   "Agonists of proteinase-activated receptor-2 enhance IFN-gamma-inducible
RT   effects on human monocytes: role in influenza A infection.";
RL   J. Immunol. 180:6903-6910(2008).
RN   [40]
RP   DEUBIQUITINATION.
RX   PubMed=19684015; DOI=10.1074/jbc.m109.025692;
RA   Hasdemir B., Murphy J.E., Cottrell G.S., Bunnett N.W.;
RT   "Endosomal deubiquitinating enzymes control ubiquitination and down-
RT   regulation of protease-activated receptor 2.";
RL   J. Biol. Chem. 284:28453-28466(2009).
RN   [41]
RP   PHOSPHORYLATION.
RX   PubMed=19815543; DOI=10.1074/jbc.m109.048942;
RA   Ricks T.K., Trejo J.;
RT   "Phosphorylation of protease-activated receptor-2 differentially regulates
RT   desensitization and internalization.";
RL   J. Biol. Chem. 284:34444-34457(2009).
RN   [42]
RP   FUNCTION IN ANTIVIRAL RESPONSE.
RX   PubMed=19494303; DOI=10.4049/jimmunol.0803743;
RA   Khoufache K., LeBouder F., Morello E., Laurent F., Riffault S.,
RA   Andrade-Gordon P., Boullier S., Rousset P., Vergnolle N., Riteau B.;
RT   "Protective role for protease-activated receptor-2 against influenza virus
RT   pathogenesis via an IFN-gamma-dependent pathway.";
RL   J. Immunol. 182:7795-7802(2009).
RN   [43]
RP   FUNCTION, AND ACTIVATION BY TRYPSIN AND FUNGAL ASPARTATE PROTEASE.
RX   PubMed=19864598; DOI=10.4049/jimmunol.0901220;
RA   Matsuwaki Y., Wada K., White T.A., Benson L.M., Charlesworth M.C.,
RA   Checkel J.L., Inoue Y., Hotta K., Ponikau J.U., Lawrence C.B., Kita H.;
RT   "Recognition of fungal protease activities induces cellular activation and
RT   eosinophil-derived neurotoxin release in human eosinophils.";
RL   J. Immunol. 183:6708-6716(2009).
RN   [44]
RP   POSSIBLE INVOLVEMENT IN ARTHRITIS.
RX   PubMed=20584806; DOI=10.1136/ard.2010.130336;
RA   Ferrell W.R., Kelso E.B., Lockhart J.C., Plevin R., McInnes I.B.;
RT   "Protease-activated receptor 2: a novel pathogenic pathway in a murine
RT   model of osteoarthritis.";
RL   Ann. Rheum. Dis. 69:2051-2054(2010).
RN   [45]
RP   FUNCTION IN JNK PATHWAY.
RX   PubMed=19781631; DOI=10.1016/j.cellsig.2009.09.028;
RA   McIntosh K., Cunningham M.R., Cadalbert L., Lockhart J., Boyd G.,
RA   Ferrell W.R., Plevin R.;
RT   "Proteinase-activated receptor-2 mediated inhibition of TNFalpha-stimulated
RT   JNK activation - a novel paradigm for G(q/11) linked GPCRs.";
RL   Cell. Signal. 22:265-273(2010).
RN   [46]
RP   FUNCTION IN ENDOTHELIAL BARRIER PROTECTION.
RX   PubMed=20826780; DOI=10.1074/jbc.m110.163642;
RA   Bae J.S., Yang L., Rezaie A.R.;
RT   "Factor X/Xa elicits protective signaling responses in endothelial cells
RT   directly via PAR-2 and indirectly via endothelial protein C receptor-
RT   dependent recruitment of PAR-1.";
RL   J. Biol. Chem. 285:34803-34812(2010).
RN   [47]
RP   POSSIBLE INVOLVEMENT IN PERIODONTITIS.
RX   PubMed=20530726; DOI=10.1177/0022034510373765;
RA   Holzhausen M., Cortelli J.R., da Silva V.A., Franco G.C., Cortelli S.C.,
RA   Vergnolle N.;
RT   "Protease-activated receptor-2 (PAR(2)) in human periodontitis.";
RL   J. Dent. Res. 89:948-953(2010).
RN   [48]
RP   FUNCTION.
RX   PubMed=19865078; DOI=10.1038/mi.2009.120;
RA   Nhu Q.M., Shirey K., Teijaro J.R., Farber D.L., Netzel-Arnett S.,
RA   Antalis T.M., Fasano A., Vogel S.N.;
RT   "Novel signaling interactions between proteinase-activated receptor 2 and
RT   Toll-like receptors in vitro and in vivo.";
RL   Mucosal Immunol. 3:29-39(2010).
RN   [49]
RP   FUNCTION IN ANTIMICROBIAL RESPONSE.
RX   PubMed=21501162; DOI=10.1111/j.1365-2567.2011.03443.x;
RA   Shpacovitch V.M., Feld M., Holzinger D., Kido M., Hollenberg M.D.,
RA   Levi-Schaffer F., Vergnolle N., Ludwig S., Roth J., Luger T., Steinhoff M.;
RT   "Role of proteinase-activated receptor-2 in anti-bacterial and
RT   immunomodulatory effects of interferon-gamma on human neutrophils and
RT   monocytes.";
RL   Immunology 133:329-339(2011).
RN   [50]
RP   PALMITOYLATION AT CYS-361.
RX   PubMed=21627585; DOI=10.1042/bj20101958;
RA   Botham A., Guo X., Xiao Y.P., Morice A.H., Compton S.J., Sadofsky L.R.;
RT   "Palmitoylation of human proteinase-activated receptor-2 differentially
RT   regulates receptor triggered ERK1/2 activation, calcium signalling, and
RT   endocytosis.";
RL   Biochem. J. 438:359-367(2011).
RN   [51]
RP   FUNCTION, TISSUE SPECIFICITY, AND PROTEOLYTIC CLEAVAGE.
RX   PubMed=23202369; DOI=10.1161/atvbaha.112.300474;
RA   Kuckleburg C.J., Newman P.J.;
RT   "Neutrophil proteinase 3 acts on protease-activated receptor-2 to enhance
RT   vascular endothelial cell barrier function.";
RL   Arterioscler. Thromb. Vasc. Biol. 33:275-284(2013).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 59-269 AND 276-377, FUNCTION,
RP   DISULFIDE BOND, TOPOLOGY, AND MUTAGENESIS OF HIS-135; PHE-154; GLY-157;
RP   TYR-210; ASN-222; HIS-227; ASP-228 AND ILE-327.
RX   PubMed=28445455; DOI=10.1038/nature22309;
RA   Cheng R.K.Y., Fiez-Vandal C., Schlenker O., Edman K., Aggeler B.,
RA   Brown D.G., Brown G.A., Cooke R.M., Dumelin C.E., Dore A.S.,
RA   Geschwindner S., Grebner C., Hermansson N.O., Jazayeri A., Johansson P.,
RA   Leong L., Prihandoko R., Rappas M., Soutter H., Snijder A., Sundstrom L.,
RA   Tehan B., Thornton P., Troast D., Wiggin G., Zhukov A., Marshall F.H.,
RA   Dekker N.;
RT   "Structural insight into allosteric modulation of protease-activated
RT   receptor 2.";
RL   Nature 545:112-115(2017).
CC   -!- FUNCTION: Receptor for trypsin and trypsin-like enzymes coupled to G
CC       proteins (PubMed:28445455). Its function is mediated through the
CC       activation of several signaling pathways including phospholipase C
CC       (PLC), intracellular calcium, mitogen-activated protein kinase (MAPK),
CC       I-kappaB kinase/NF-kappaB and Rho (PubMed:28445455). Can also be
CC       transactivated by cleaved F2R/PAR1. Involved in modulation of
CC       inflammatory responses and regulation of innate and adaptive immunity,
CC       and acts as a sensor for proteolytic enzymes generated during
CC       infection. Generally is promoting inflammation. Can signal
CC       synergistically with TLR4 and probably TLR2 in inflammatory responses
CC       and modulates TLR3 signaling. Has a protective role in establishing the
CC       endothelial barrier; the activity involves coagulation factor X.
CC       Regulates endothelial cell barrier integrity during neutrophil
CC       extravasation, probably following proteolytic cleavage by PRTN3
CC       (PubMed:23202369). Proposed to have a bronchoprotective role in airway
CC       epithelium, but also shown to compromise the airway epithelial barrier
CC       by interrupting E-cadherin adhesion (PubMed:10086357). Involved in the
CC       regulation of vascular tone; activation results in hypotension
CC       presumably mediated by vasodilation. Associates with a subset of G
CC       proteins alpha subunits such as GNAQ, GNA11, GNA14, GNA12 and GNA13,
CC       but probably not with G(o) alpha, G(i) subunit alpha-1 and G(i) subunit
CC       alpha-2. However, according to PubMed:21627585 can signal through G(i)
CC       subunit alpha. Believed to be a class B receptor which internalizes as
CC       a complex with arrestin and traffic with it to endosomal vesicles,
CC       presumably as desensitized receptor, for extended periods of time.
CC       Mediates inhibition of TNF-alpha stimulated JNK phosphorylation via
CC       coupling to GNAQ and GNA11; the function involves dissociation of RIPK1
CC       and TRADD from TNFR1. Mediates phosphorylation of nuclear factor NF-
CC       kappa-B RELA subunit at 'Ser-536'; the function involves IKBKB and is
CC       predominantly independent of G proteins. Involved in cellular
CC       migration. Involved in cytoskeletal rearrangement and chemotaxis
CC       through beta-arrestin-promoted scaffolds; the function is independent
CC       of GNAQ and GNA11 and involves promotion of cofilin dephosphorylation
CC       and actin filament severing. Induces redistribution of COPS5 from the
CC       plasma membrane to the cytosol and activation of the JNK cascade is
CC       mediated by COPS5. Involved in the recruitment of leukocytes to the
CC       sites of inflammation and is the major PAR receptor capable of
CC       modulating eosinophil function such as proinflammatory cytokine
CC       secretion, superoxide production and degranulation. During inflammation
CC       promotes dendritic cell maturation, trafficking to the lymph nodes and
CC       subsequent T-cell activation. Involved in antimicrobial response of
CC       innate immune cells; activation enhances phagocytosis of Gram-positive
CC       and killing of Gram-negative bacteria. Acts synergistically with
CC       interferon-gamma in enhancing antiviral responses. Implicated in a
CC       number of acute and chronic inflammatory diseases such as of the
CC       joints, lungs, brain, gastrointestinal tract, periodontium, skin, and
CC       vascular systems, and in autoimmune disorders.
CC       {ECO:0000269|PubMed:10086357, ECO:0000269|PubMed:10725339,
CC       ECO:0000269|PubMed:11413129, ECO:0000269|PubMed:11441110,
CC       ECO:0000269|PubMed:11447194, ECO:0000269|PubMed:11714832,
CC       ECO:0000269|PubMed:12832443, ECO:0000269|PubMed:15155775,
CC       ECO:0000269|PubMed:16359518, ECO:0000269|PubMed:16410250,
CC       ECO:0000269|PubMed:16478888, ECO:0000269|PubMed:16714334,
CC       ECO:0000269|PubMed:17404307, ECO:0000269|PubMed:17500066,
CC       ECO:0000269|PubMed:18424071, ECO:0000269|PubMed:18453611,
CC       ECO:0000269|PubMed:18474671, ECO:0000269|PubMed:18622013,
CC       ECO:0000269|PubMed:19494303, ECO:0000269|PubMed:19781631,
CC       ECO:0000269|PubMed:19864598, ECO:0000269|PubMed:19865078,
CC       ECO:0000269|PubMed:20826780, ECO:0000269|PubMed:21501162,
CC       ECO:0000269|PubMed:23202369, ECO:0000269|PubMed:28445455}.
CC   -!- SUBUNIT: Interacts with TLR4, COPS5 and TMED2. Interacts with GNAQ,
CC       GNA11, GNA12, GNA13 and GNA14 (By similarity). {ECO:0000250}.
CC   -!- INTERACTION:
CC       P55085; P16615: ATP2A2; NbExp=2; IntAct=EBI-4303189, EBI-358933;
CC       P55085; P22681: CBL; NbExp=3; IntAct=EBI-4303189, EBI-518228;
CC       P55085; Q92905: COPS5; NbExp=8; IntAct=EBI-4303189, EBI-594661;
CC       P55085; Q14868: EPR-1; NbExp=4; IntAct=EBI-4303189, EBI-4309771;
CC       P55085; P13726: F3; NbExp=2; IntAct=EBI-4303189, EBI-1040727;
CC       P55085; P0DMV9: HSPA1B; NbExp=2; IntAct=EBI-4303189, EBI-14100688;
CC       P55085; P04156: PRNP; NbExp=3; IntAct=EBI-4303189, EBI-977302;
CC       P55085; Q15363: TMED2; NbExp=6; IntAct=EBI-4303189, EBI-998485;
CC       P55085; P29066: Arrb1; Xeno; NbExp=6; IntAct=EBI-4303189, EBI-4303019;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Widely expressed in tissues with especially high
CC       levels in pancreas, liver, kidney, small intestine, and colon
CC       (PubMed:7556175, PubMed:8615752). Moderate expression is detected in
CC       many organs, but none in brain or skeletal muscle (PubMed:7556175,
CC       PubMed:8615752). Expressed in endothelial cells (PubMed:23202369).
CC       {ECO:0000269|PubMed:23202369, ECO:0000269|PubMed:7556175,
CC       ECO:0000269|PubMed:8615752}.
CC   -!- PTM: A proteolytic cleavage generates a new N-terminus that functions
CC       as a tethered ligand (PubMed:10831593, PubMed:19864598, PubMed:9020112,
CC       PubMed:10805786, PubMed:16478888). Activating serine proteases include
CC       trypsin, mast cell tryptase, coagulation factors VII and Xa,
CC       myeloblastin/PRTN3 and membrane-type serine protease 1/ST14
CC       (PubMed:10831593, PubMed:19864598, PubMed:9020112, PubMed:10805786,
CC       PubMed:16478888, PubMed:23202369). Subsequent cleavage by serine
CC       proteases, including neutrophil elastase and cathepsin G, leads to
CC       receptor deactivation (PubMed:12594060). At least in part, implicated
CC       proteases are also shown to activate the receptor; the glycosylation
CC       status of the receptor is thought to contribute to the difference
CC       (PubMed:12171601). In addition to conventional trypsin-like proteases
CC       activated by other proteases and glycosidases derived from bacteria,
CC       fungi and insects (PubMed:11447194, PubMed:11441110, PubMed:17404307,
CC       PubMed:18474671, PubMed:19864598). Activated by serine protease
CC       allergens such as dust mite Der p3 and Der p9 and mold Pen c13
CC       (PubMed:11441110, PubMed:17404307). Activated by P.gingivalis arginine-
CC       specific (trypsin-like) cysteine proteinases called gingipains
CC       (PubMed:11447194). Activated by S.griseus exogenous chitinase
CC       (PubMed:18474671). Activated by A.alternata aspartate protease; the
CC       cleavage generates non-conventional processed forms (PubMed:19864598).
CC       {ECO:0000269|PubMed:10805786, ECO:0000269|PubMed:10831593,
CC       ECO:0000269|PubMed:11441110, ECO:0000269|PubMed:11447194,
CC       ECO:0000269|PubMed:12171601, ECO:0000269|PubMed:12594060,
CC       ECO:0000269|PubMed:16478888, ECO:0000269|PubMed:17404307,
CC       ECO:0000269|PubMed:18474671, ECO:0000269|PubMed:19864598,
CC       ECO:0000269|PubMed:23202369, ECO:0000269|PubMed:9020112}.
CC   -!- PTM: N-glycosylated and sialylated. {ECO:0000269|PubMed:12171601}.
CC   -!- PTM: Multiple phosphorylated on serine and threonine residues in the
CC       cytoplasmic region upon receptor activation; required for receptor
CC       desensitization and recruitment of beta-arrestin.
CC       {ECO:0000269|PubMed:19815543}.
CC   -!- PTM: Monoubiquitinated by CBL at the plasma membrane and in early
CC       endosomes; not required for receptor endocytosis but for translocation
CC       to late endosomes or lysosomes. Deubiquitination involves STAMBP and
CC       USP8; required for lysosomal trafficking and receptor degradation.
CC   -!- MISCELLANEOUS: Synthetic PAR agonist peptides (APs) that mimic the
CC       first six amino acids of the newly formed N-terminus activate the
CC       native, uncleaved receptor nonenzymatically by binding directly to the
CC       corresponding second extracellular loop to mediate signaling.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Protease-activated receptor entry;
CC       URL="https://en.wikipedia.org/wiki/Protease-activated_receptor";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/f2rl1/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Z49993; CAA90290.1; -; Genomic_DNA.
DR   EMBL; Z49994; CAA90290.1; JOINED; Genomic_DNA.
DR   EMBL; U34038; AAB47871.1; -; mRNA.
DR   EMBL; AY336105; AAP97012.1; -; mRNA.
DR   EMBL; AF400075; AAK77914.1; -; Genomic_DNA.
DR   EMBL; BT009856; AAP88858.1; -; mRNA.
DR   EMBL; CH471084; EAW95782.1; -; Genomic_DNA.
DR   EMBL; BC012453; AAH12453.1; -; mRNA.
DR   EMBL; BC018130; AAH18130.1; -; mRNA.
DR   EMBL; U36753; AAA90957.1; -; Genomic_DNA.
DR   CCDS; CCDS4033.1; -.
DR   PIR; S66518; S66518.
DR   RefSeq; NP_005233.3; NM_005242.5.
DR   PDB; 5NDD; X-ray; 2.80 A; A=59-269, A=276-377.
DR   PDB; 5NDZ; X-ray; 3.60 A; A=59-269, A=276-377.
DR   PDB; 5NJ6; X-ray; 4.00 A; A=55-269, A=276-377.
DR   PDBsum; 5NDD; -.
DR   PDBsum; 5NDZ; -.
DR   PDBsum; 5NJ6; -.
DR   SMR; P55085; -.
DR   BioGRID; 108449; 15.
DR   DIP; DIP-42044N; -.
DR   IntAct; P55085; 77.
DR   MINT; P55085; -.
DR   STRING; 9606.ENSP00000296677; -.
DR   BindingDB; P55085; -.
DR   ChEMBL; CHEMBL5963; -.
DR   GuidetoPHARMACOLOGY; 348; -.
DR   TCDB; 9.A.14.13.12; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; P55085; 2 sites.
DR   iPTMnet; P55085; -.
DR   PhosphoSitePlus; P55085; -.
DR   SwissPalm; P55085; -.
DR   BioMuta; F2RL1; -.
DR   DMDM; 1709580; -.
DR   jPOST; P55085; -.
DR   MassIVE; P55085; -.
DR   MaxQB; P55085; -.
DR   PaxDb; P55085; -.
DR   PeptideAtlas; P55085; -.
DR   PRIDE; P55085; -.
DR   ProteomicsDB; 56787; -.
DR   ABCD; P55085; 81 sequenced antibodies.
DR   Antibodypedia; 4569; 307 antibodies.
DR   DNASU; 2150; -.
DR   Ensembl; ENST00000296677; ENSP00000296677; ENSG00000164251.
DR   GeneID; 2150; -.
DR   KEGG; hsa:2150; -.
DR   UCSC; uc003keo.4; human.
DR   CTD; 2150; -.
DR   DisGeNET; 2150; -.
DR   EuPathDB; HostDB:ENSG00000164251.4; -.
DR   GeneCards; F2RL1; -.
DR   HGNC; HGNC:3538; F2RL1.
DR   HPA; ENSG00000164251; Tissue enhanced (intestine).
DR   MIM; 600933; gene.
DR   neXtProt; NX_P55085; -.
DR   PharmGKB; PA27947; -.
DR   eggNOG; ENOG502QR8S; Eukaryota.
DR   HOGENOM; CLU_009579_8_2_1; -.
DR   InParanoid; P55085; -.
DR   KO; K04234; -.
DR   OrthoDB; 892946at2759; -.
DR   PhylomeDB; P55085; -.
DR   TreeFam; TF330775; -.
DR   PathwayCommons; P55085; -.
DR   Reactome; R-HSA-375276; Peptide ligand-binding receptors.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   SIGNOR; P55085; -.
DR   BioGRID-ORCS; 2150; 6 hits in 882 CRISPR screens.
DR   ChiTaRS; F2RL1; human.
DR   GeneWiki; Protease_activated_receptor_2; -.
DR   GenomeRNAi; 2150; -.
DR   Pharos; P55085; Tchem.
DR   PRO; PR:P55085; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; P55085; protein.
DR   Bgee; ENSG00000164251; Expressed in colonic mucosa and 188 other tissues.
DR   ExpressionAtlas; P55085; baseline and differential.
DR   Genevisible; P55085; HS.
DR   GO; GO:0005769; C:early endosome; IDA:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; TAS:ProtInc.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0031143; C:pseudopodium; ISS:UniProtKB.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IMP:UniProtKB.
DR   GO; GO:0001965; F:G-protein alpha-subunit binding; ISS:UniProtKB.
DR   GO; GO:0031681; F:G-protein beta-subunit binding; ISS:UniProtKB.
DR   GO; GO:0038023; F:signaling receptor activity; TAS:ProtInc.
DR   GO; GO:0005102; F:signaling receptor binding; TAS:ProtInc.
DR   GO; GO:0015057; F:thrombin-activated receptor activity; IEA:InterPro.
DR   GO; GO:0007596; P:blood coagulation; IEA:InterPro.
DR   GO; GO:0045217; P:cell-cell junction maintenance; IMP:UniProtKB.
DR   GO; GO:0090195; P:chemokine secretion; IDA:UniProtKB.
DR   GO; GO:0051607; P:defense response to virus; IDA:UniProtKB.
DR   GO; GO:0061028; P:establishment of endothelial barrier; IDA:UniProtKB.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0032609; P:interferon-gamma production; ISS:UniProtKB.
DR   GO; GO:0032611; P:interleukin-1 beta production; IDA:UniProtKB.
DR   GO; GO:0032613; P:interleukin-10 production; IDA:UniProtKB.
DR   GO; GO:0050900; P:leukocyte migration; IDA:UniProtKB.
DR   GO; GO:0070661; P:leukocyte proliferation; ISS:UniProtKB.
DR   GO; GO:0097029; P:mature conventional dendritic cell differentiation; IDA:UniProtKB.
DR   GO; GO:0090198; P:negative regulation of chemokine secretion; IDA:UniProtKB.
DR   GO; GO:0046329; P:negative regulation of JNK cascade; IDA:UniProtKB.
DR   GO; GO:0034140; P:negative regulation of toll-like receptor 3 signaling pathway; IMP:UniProtKB.
DR   GO; GO:0010804; P:negative regulation of tumor necrosis factor-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0042119; P:neutrophil activation; IDA:UniProtKB.
DR   GO; GO:0030836; P:positive regulation of actin filament depolymerization; IDA:UniProtKB.
DR   GO; GO:0097755; P:positive regulation of blood vessel diameter; ISS:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; ISS:UniProtKB.
DR   GO; GO:0050921; P:positive regulation of chemotaxis; ISS:UniProtKB.
DR   GO; GO:0002720; P:positive regulation of cytokine production involved in immune response; IDA:UniProtKB.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IDA:UniProtKB.
DR   GO; GO:0051482; P:positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway; IBA:GO_Central.
DR   GO; GO:0043311; P:positive regulation of eosinophil degranulation; IDA:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0003104; P:positive regulation of glomerular filtration; ISS:UniProtKB.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; IMP:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IDA:UniProtKB.
DR   GO; GO:0032755; P:positive regulation of interleukin-6 production; IDA:UniProtKB.
DR   GO; GO:0032757; P:positive regulation of interleukin-8 production; IDA:UniProtKB.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IDA:UniProtKB.
DR   GO; GO:0002690; P:positive regulation of leukocyte chemotaxis; IDA:BHF-UCL.
DR   GO; GO:0070963; P:positive regulation of neutrophil mediated killing of gram-negative bacterium; IDA:UniProtKB.
DR   GO; GO:0060100; P:positive regulation of phagocytosis, engulfment; IDA:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; ISS:UniProtKB.
DR   GO; GO:0050927; P:positive regulation of positive chemotaxis; IDA:BHF-UCL.
DR   GO; GO:0031274; P:positive regulation of pseudopodium assembly; ISS:UniProtKB.
DR   GO; GO:1900135; P:positive regulation of renin secretion into blood stream; ISS:UniProtKB.
DR   GO; GO:0035025; P:positive regulation of Rho protein signal transduction; IMP:UniProtKB.
DR   GO; GO:0032930; P:positive regulation of superoxide anion generation; IDA:UniProtKB.
DR   GO; GO:0034137; P:positive regulation of toll-like receptor 2 signaling pathway; IMP:UniProtKB.
DR   GO; GO:0034141; P:positive regulation of toll-like receptor 3 signaling pathway; IMP:UniProtKB.
DR   GO; GO:0034145; P:positive regulation of toll-like receptor 4 signaling pathway; IDA:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0030193; P:regulation of blood coagulation; IDA:BHF-UCL.
DR   GO; GO:2000341; P:regulation of chemokine (C-X-C motif) ligand 2 production; IDA:UniProtKB.
DR   GO; GO:0043122; P:regulation of I-kappaB kinase/NF-kappaB signaling; IDA:UniProtKB.
DR   GO; GO:0046328; P:regulation of JNK cascade; IDA:UniProtKB.
DR   GO; GO:0002286; P:T cell activation involved in immune response; ISS:UniProtKB.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR002281; Pro_rcpt_2.
DR   InterPro; IPR003912; Protea_act_rcpt.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01428; PROTEASEAR.
DR   PRINTS; PR01152; PROTEASEAR2.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Immunity; Inflammatory response; Innate immunity;
KW   Lipoprotein; Membrane; Palmitate; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Signal; Transducer; Transmembrane; Transmembrane helix;
KW   Ubl conjugation.
FT   SIGNAL          1..25
FT                   /evidence="ECO:0000255"
FT   PROPEP          26..36
FT                   /note="Removed for receptor activation"
FT                   /id="PRO_0000012750"
FT   CHAIN           37..397
FT                   /note="Proteinase-activated receptor 2"
FT                   /id="PRO_0000412954"
FT   CHAIN           38..397
FT                   /note="Proteinase-activated receptor 2, alternate cleaved
FT                   1"
FT                   /id="PRO_0000412956"
FT   CHAIN           39..397
FT                   /note="Proteinase-activated receptor 2, alternate cleaved
FT                   2"
FT                   /id="PRO_0000012751"
FT   TOPO_DOM        37..71
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:28445455"
FT   TRANSMEM        72..101
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000269|PubMed:28445455"
FT   TOPO_DOM        102..108
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:28445455"
FT   TRANSMEM        109..137
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000269|PubMed:28445455"
FT   TOPO_DOM        138..149
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:28445455"
FT   TRANSMEM        150..177
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000269|PubMed:28445455"
FT   TOPO_DOM        178..183
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:28445455"
FT   TRANSMEM        184..211
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000269|PubMed:28445455"
FT   TOPO_DOM        212..235
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:28445455"
FT   TRANSMEM        236..269
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000269|PubMed:28445455"
FT   TOPO_DOM        270..277
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:28445455"
FT   TRANSMEM        278..317
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000269|PubMed:28445455"
FT   TOPO_DOM        318..323
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:28445455"
FT   TRANSMEM        324..347
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000269|PubMed:28445455"
FT   TOPO_DOM        348..397
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:28445455"
FT   COMPBIAS        383..390
FT                   /note="Poly-Ser"
FT   SITE            36..37
FT                   /note="Cleavage; by trypsin"
FT   LIPID           361
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:21627585"
FT   CARBOHYD        30
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:12171601"
FT   CARBOHYD        222
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:12171601"
FT   DISULFID        148..226
FT                   /evidence="ECO:0000244|PDB:5NDD, ECO:0000244|PDB:5NDZ,
FT                   ECO:0000244|PDB:5NJ6, ECO:0000255|PROSITE-ProRule:PRU00521,
FT                   ECO:0000269|PubMed:28445455"
FT   VARIANT         21
FT                   /note="S -> F (in dbSNP:rs2243072)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_012846"
FT   VARIANT         30
FT                   /note="N -> S (in dbSNP:rs616235)"
FT                   /id="VAR_049435"
FT   VARIANT         270
FT                   /note="R -> Q (in dbSNP:rs2243062)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_012847"
FT   VARIANT         291
FT                   /note="T -> A (in dbSNP:rs2243083)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_012848"
FT   MUTAGEN         30
FT                   /note="N->A: Decreases cell surface expression; when
FT                   associate with A-222."
FT                   /evidence="ECO:0000269|PubMed:12171601"
FT   MUTAGEN         30
FT                   /note="N->A: Increase of sensitivity towards tryptase."
FT                   /evidence="ECO:0000269|PubMed:12171601"
FT   MUTAGEN         135
FT                   /note="H->Y: Slight reduction in ligand-mediated receptor
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:28445455"
FT   MUTAGEN         154
FT                   /note="F->A: Severe reduction in ligand-mediated receptor
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:28445455"
FT   MUTAGEN         157
FT                   /note="G->C,M: Severe reduction in ligand-mediated receptor
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:28445455"
FT   MUTAGEN         210
FT                   /note="Y->L: No defect in ligand-mediated receptor
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:28445455"
FT   MUTAGEN         222
FT                   /note="N->A: Decreases cell surface expression; when
FT                   associated with A-30. Loss of sensitivity towards all
FT                   tested proteases."
FT                   /evidence="ECO:0000269|PubMed:12171601"
FT   MUTAGEN         222
FT                   /note="N->Q: No defect in ligand-mediated receptor
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:28445455"
FT   MUTAGEN         227
FT                   /note="H->A: No defect in ligand-mediated receptor
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:28445455"
FT   MUTAGEN         227
FT                   /note="H->Q: Slight reduction in ligand-mediated receptor
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:28445455"
FT   MUTAGEN         228
FT                   /note="D->A,N: Severe reduction in ligand-mediated receptor
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:28445455"
FT   MUTAGEN         327
FT                   /note="I->L: Slight reduction in ligand-mediated receptor
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:28445455"
FT   MUTAGEN         355..363
FT                   /note="Missing: Abolishes signaling through accumulation of
FT                   intracellular calcium and phosphoinositide; no effect in
FT                   signaling through MAPK."
FT                   /evidence="ECO:0000269|PubMed:14607272"
FT   MUTAGEN         361
FT                   /note="C->A: Loss of palmitoylation; increases surface
FT                   expression and internalization following trypsin
FT                   activation, decreases sensitivity and intracellular calcium
FT                   signaling, increases ERK activation through G(i) subunit
FT                   alpha."
FT   MUTAGEN         363
FT                   /note="S->A: Reduces receptor desensitization and
FT                   internalization, activates ERK1/2; when associated with A-
FT                   366."
FT                   /evidence="ECO:0000269|PubMed:10725339"
FT   MUTAGEN         366
FT                   /note="T->A: Reduces receptor desensitization and
FT                   internalization, activates ERK1/2; when associated with A-
FT                   363."
FT                   /evidence="ECO:0000269|PubMed:10725339"
FT   CONFLICT        138
FT                   /note="G -> A (in Ref. 2; AAB47871)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        291
FT                   /note="T -> S (in Ref. 7; AAH18130)"
FT                   /evidence="ECO:0000305"
FT   HELIX           63..68
FT                   /evidence="ECO:0000244|PDB:5NDD"
FT   HELIX           72..75
FT                   /evidence="ECO:0000244|PDB:5NDD"
FT   HELIX           77..102
FT                   /evidence="ECO:0000244|PDB:5NDD"
FT   HELIX           109..125
FT                   /evidence="ECO:0000244|PDB:5NDD"
FT   HELIX           128..136
FT                   /evidence="ECO:0000244|PDB:5NDD"
FT   HELIX           145..178
FT                   /evidence="ECO:0000244|PDB:5NDD"
FT   HELIX           186..205
FT                   /evidence="ECO:0000244|PDB:5NDD"
FT   HELIX           207..210
FT                   /evidence="ECO:0000244|PDB:5NDD"
FT   STRAND          215..218
FT                   /evidence="ECO:0000244|PDB:5NDD"
FT   TURN            219..222
FT                   /evidence="ECO:0000244|PDB:5NDD"
FT   STRAND          223..229
FT                   /evidence="ECO:0000244|PDB:5NDD"
FT   HELIX           233..235
FT                   /evidence="ECO:0000244|PDB:5NDD"
FT   HELIX           236..249
FT                   /evidence="ECO:0000244|PDB:5NDD"
FT   HELIX           252..269
FT                   /evidence="ECO:0000244|PDB:5NDD"
FT   HELIX           279..298
FT                   /evidence="ECO:0000244|PDB:5NDD"
FT   HELIX           301..316
FT                   /evidence="ECO:0000244|PDB:5NDD"
FT   HELIX           323..332
FT                   /evidence="ECO:0000244|PDB:5NDD"
FT   HELIX           333..335
FT                   /evidence="ECO:0000244|PDB:5NDD"
FT   HELIX           336..347
FT                   /evidence="ECO:0000244|PDB:5NDD"
FT   HELIX           349..358
FT                   /evidence="ECO:0000244|PDB:5NDD"
SQ   SEQUENCE   397 AA;  44126 MW;  F1A4E1D5AB9B362B CRC64;
     MRSPSAAWLL GAAILLAASL SCSGTIQGTN RSSKGRSLIG KVDGTSHVTG KGVTVETVFS
     VDEFSASVLT GKLTTVFLPI VYTIVFVVGL PSNGMALWVF LFRTKKKHPA VIYMANLALA
     DLLSVIWFPL KIAYHIHGNN WIYGEALCNV LIGFFYGNMY CSILFMTCLS VQRYWVIVNP
     MGHSRKKANI AIGISLAIWL LILLVTIPLY VVKQTIFIPA LNITTCHDVL PEQLLVGDMF
     NYFLSLAIGV FLFPAFLTAS AYVLMIRMLR SSAMDENSEK KRKRAIKLIV TVLAMYLICF
     TPSNLLLVVH YFLIKSQGQS HVYALYIVAL CLSTLNSCID PFVYYFVSHD FRDHAKNALL
     CRSVRTVKQM QVSLTSKKHS RKSSSYSSSS TTVKTSY
//
ID   LGR4_HUMAN              Reviewed;         951 AA.
AC   Q9BXB1; A6NCH3; G5E9B3; Q8N537; Q9NYD1;
DT   20-JUN-2002, integrated into UniProtKB/Swiss-Prot.
DT   22-JUL-2008, sequence version 2.
DT   07-OCT-2020, entry version 166.
DE   RecName: Full=Leucine-rich repeat-containing G-protein coupled receptor 4;
DE   AltName: Full=G-protein coupled receptor 48;
DE   Flags: Precursor;
GN   Name=LGR4; Synonyms=GPR48;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1), AND VARIANTS GLY-215
RP   AND SER-233.
RC   TISSUE=Pancreas;
RX   PubMed=11401528; DOI=10.1006/bbrc.2001.4625;
RA   Loh E.D., Broussard S.R., Kolakowski L.F. Jr.;
RT   "Molecular characterization of a novel glycoprotein hormone G-protein-
RT   coupled receptor.";
RL   Biochem. Biophys. Res. Commun. 282:757-764(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION, AND INTERACTION WITH RSPO1; RSPO2; RSPO3 AND RSPO4.
RX   PubMed=21909076; DOI=10.1038/embor.2011.175;
RA   Glinka A., Dolde C., Kirsch N., Huang Y.L., Kazanskaya O., Ingelfinger D.,
RA   Boutros M., Cruciat C.M., Niehrs C.;
RT   "LGR4 and LGR5 are R-spondin receptors mediating Wnt/beta-catenin and
RT   Wnt/PCP signalling.";
RL   EMBO Rep. 12:1055-1061(2011).
RN   [6]
RP   FUNCTION, AND INTERACTION WITH RSPO1; RSPO2; RSPO3 AND RSPO4.
RX   PubMed=21727895; DOI=10.1038/nature10337;
RA   de Lau W., Barker N., Low T.Y., Koo B.K., Li V.S., Teunissen H., Kujala P.,
RA   Haegebarth A., Peters P.J., van de Wetering M., Stange D.E., van Es J.E.,
RA   Guardavaccaro D., Schasfoort R.B., Mohri Y., Nishimori K., Mohammed S.,
RA   Heck A.J., Clevers H.;
RT   "Lgr5 homologues associate with Wnt receptors and mediate R-spondin
RT   signalling.";
RL   Nature 476:293-297(2011).
RN   [7]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH RSPO1; RSPO2; RSPO3
RP   AND RSPO4.
RX   PubMed=21693646; DOI=10.1073/pnas.1106083108;
RA   Carmon K.S., Gong X., Lin Q., Thomas A., Liu Q.;
RT   "R-spondins function as ligands of the orphan receptors LGR4 and LGR5 to
RT   regulate Wnt/beta-catenin signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:11452-11457(2011).
RN   [8]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH RSPO1.
RX   PubMed=22815884; DOI=10.1371/journal.pone.0040976;
RA   Ruffner H., Sprunger J., Charlat O., Leighton-Davies J., Grosshans B.,
RA   Salathe A., Zietzling S., Beck V., Therier M., Isken A., Xie Y., Zhang Y.,
RA   Hao H., Shi X., Liu D., Song Q., Clay I., Hintzen G., Tchorz J.,
RA   Bouchez L.C., Michaud G., Finan P., Myer V.E., Bouwmeester T., Porter J.,
RA   Hild M., Bassilana F., Parker C.N., Cong F.;
RT   "R-Spondin potentiates Wnt/beta-catenin signaling through orphan receptors
RT   LGR4 and LGR5.";
RL   PLoS ONE 7:E40976-E40976(2012).
RN   [9]
RP   FUNCTION.
RX   PubMed=23444378; DOI=10.1242/jcs.123471;
RA   Deng C., Reddy P., Cheng Y., Luo C.W., Hsiao C.L., Hsueh A.J.;
RT   "Multi-functional norrin is a ligand for the LGR4 receptor.";
RL   J. Cell Sci. 126:2060-2068(2013).
RN   [10]
RP   POLYMORPHISM, INVOLVEMENT IN OSTEOP, AND INVOLVEMENT IN BMND17.
RX   PubMed=23644456; DOI=10.1038/nature12124;
RA   Styrkarsdottir U., Thorleifsson G., Sulem P., Gudbjartsson D.F.,
RA   Sigurdsson A., Jonasdottir A., Jonasdottir A., Oddsson A., Helgason A.,
RA   Magnusson O.T., Walters G.B., Frigge M.L., Helgadottir H.T.,
RA   Johannsdottir H., Bergsteinsdottir K., Ogmundsdottir M.H., Center J.R.,
RA   Nguyen T.V., Eisman J.A., Christiansen C., Steingrimsson E., Jonasson J.G.,
RA   Tryggvadottir L., Eyjolfsson G.I., Theodors A., Jonsson T., Ingvarsson T.,
RA   Olafsson I., Rafnar T., Kong A., Sigurdsson G., Masson G.,
RA   Thorsteinsdottir U., Stefansson K.;
RT   "Nonsense mutation in the LGR4 gene is associated with several human
RT   diseases and other traits.";
RL   Nature 497:517-520(2013).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-920, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 26-527 IN COMPLEX WITH RSPO1,
RP   FUNCTION, GLYCOSYLATION AT ASN-68 AND ASN-199, AND DISULFIDE BONDS.
RX   PubMed=23756652; DOI=10.1101/gad.219360.113;
RA   Wang D., Huang B., Zhang S., Yu X., Wu W., Wang X.;
RT   "Structural basis for R-spondin recognition by LGR4/5/6 receptors.";
RL   Genes Dev. 27:1339-1344(2013).
CC   -!- FUNCTION: Receptor for R-spondins that potentiates the canonical Wnt
CC       signaling pathway and is involved in the formation of various organs.
CC       Upon binding to R-spondins (RSPO1, RSPO2, RSPO3 or RSPO4), associates
CC       with phosphorylated LRP6 and frizzled receptors that are activated by
CC       extracellular Wnt receptors, triggering the canonical Wnt signaling
CC       pathway to increase expression of target genes. In contrast to
CC       classical G-protein coupled receptors, does not activate heterotrimeric
CC       G-proteins to transduce the signal. Its function as activator of the
CC       Wnt signaling pathway is required for the development of various
CC       organs, including liver, kidney, intestine, bone, reproductive tract
CC       and eye. May also act as a receptor for norrin (NDP), such results
CC       however require additional confirmation in vivo. Required during
CC       spermatogenesis to activate the Wnt signaling pathway in peritubular
CC       myoid cells. Required for the maintenance of intestinal stem cells and
CC       Paneth cell differentiation in postnatal intestinal crypts. Acts as a
CC       regulator of bone formation and remodeling. Involved in kidney
CC       development; required for maintaining the ureteric bud in an
CC       undifferentiated state. Involved in the development of the anterior
CC       segment of the eye. Required during erythropoiesis. Also acts as a
CC       negative regulator of innate immunity by inhibiting TLR2/TLR4
CC       associated pattern-recognition and proinflammatory cytokine production.
CC       Plays an important role in regulating the circadian rhythms of plasma
CC       lipids, partially through regulating the rhythmic expression of MTTP
CC       (By similarity). {ECO:0000250|UniProtKB:A2ARI4,
CC       ECO:0000269|PubMed:21693646, ECO:0000269|PubMed:21727895,
CC       ECO:0000269|PubMed:21909076, ECO:0000269|PubMed:22815884,
CC       ECO:0000269|PubMed:23444378, ECO:0000269|PubMed:23756652}.
CC   -!- INTERACTION:
CC       Q9BXB1; Q9ULT6: ZNRF3; NbExp=2; IntAct=EBI-10965764, EBI-949772;
CC       Q9BXB1-2; Q9P0N8: MARCHF2; NbExp=3; IntAct=EBI-17443382, EBI-10317612;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:21693646,
CC       ECO:0000269|PubMed:22815884}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:21693646, ECO:0000269|PubMed:22815884}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9BXB1-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9BXB1-2; Sequence=VSP_047136;
CC   -!- TISSUE SPECIFICITY: Expressed in multiple steroidogenic tissues:
CC       placenta, ovary, testis and adrenal. Expressed also in spinal cord,
CC       thyroid, stomach, trachea, heart, pancreas, kidney, prostate and
CC       spleen.
CC   -!- POLYMORPHISM: Genetic variations in LGR4 define the bone mineral
CC       density quantitative trait locus 17 (BMND17) [MIM:615311]. Variance in
CC       bone mineral density influences bone mass, contributes to size
CC       determination in the general population, and is a susceptibility factor
CC       for osteoporotic fractures. {ECO:0000269|PubMed:23644456}.
CC   -!- DISEASE: Osteoporosis (OSTEOP) [MIM:166710]: A systemic skeletal
CC       disorder characterized by decreased bone mass and deterioration of bone
CC       microarchitecture without alteration in the composition of bone. The
CC       result is fragile bones and an increased risk of fractures, even after
CC       minimal trauma. Osteoporosis is a chronic condition of multifactorial
CC       etiology and is usually clinically silent until a fracture occurs.
CC       {ECO:0000269|PubMed:23644456}. Note=Disease susceptibility may be
CC       associated with variations affecting the gene represented in this
CC       entry. A LGR4 nonsense mutation creating a stop codon after position
CC       126 (c.376C>T) is strongly associated with low bone mineral density and
CC       osteoporotic fractures (PubMed:23644456). This mutation probably causes
CC       degradation of the transcript by nonsense-mediated decay (NMD). The
CC       c.376C>T mutation is also associated with electrolyte imbalance, late
CC       onset of menarche and reduced testosterone levels, as well as an
CC       increased risk of squamous cell carcinoma of the skin and biliary tract
CC       cancer (PubMed:23644456). {ECO:0000269|PubMed:23644456}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF346711; AAK31153.1; -; Genomic_DNA.
DR   EMBL; AF346709; AAK31153.1; JOINED; Genomic_DNA.
DR   EMBL; AF346710; AAK31153.1; JOINED; Genomic_DNA.
DR   EMBL; AF257182; AAF68989.1; -; mRNA.
DR   EMBL; AC090597; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC100771; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471064; EAW68285.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW68286.1; -; Genomic_DNA.
DR   EMBL; BC033039; AAH33039.1; -; mRNA.
DR   CCDS; CCDS31449.1; -. [Q9BXB1-1]
DR   CCDS; CCDS86187.1; -. [Q9BXB1-2]
DR   RefSeq; NP_001333361.1; NM_001346432.1. [Q9BXB1-2]
DR   RefSeq; NP_060960.2; NM_018490.3. [Q9BXB1-1]
DR   PDB; 4KT1; X-ray; 2.50 A; A=26-527.
DR   PDB; 4QXE; X-ray; 2.20 A; A=27-396.
DR   PDB; 4QXF; X-ray; 2.25 A; A/B=27-252.
DR   PDBsum; 4KT1; -.
DR   PDBsum; 4QXE; -.
DR   PDBsum; 4QXF; -.
DR   SMR; Q9BXB1; -.
DR   BioGRID; 120644; 219.
DR   CORUM; Q9BXB1; -.
DR   DIP; DIP-59894N; -.
DR   IntAct; Q9BXB1; 23.
DR   STRING; 9606.ENSP00000368516; -.
DR   GuidetoPHARMACOLOGY; 147; -.
DR   GlyGen; Q9BXB1; 6 sites.
DR   iPTMnet; Q9BXB1; -.
DR   PhosphoSitePlus; Q9BXB1; -.
DR   BioMuta; LGR4; -.
DR   DMDM; 212286375; -.
DR   EPD; Q9BXB1; -.
DR   jPOST; Q9BXB1; -.
DR   MassIVE; Q9BXB1; -.
DR   MaxQB; Q9BXB1; -.
DR   PaxDb; Q9BXB1; -.
DR   PeptideAtlas; Q9BXB1; -.
DR   PRIDE; Q9BXB1; -.
DR   ProteomicsDB; 33888; -.
DR   ProteomicsDB; 79397; -. [Q9BXB1-1]
DR   ABCD; Q9BXB1; 2 sequenced antibodies.
DR   Antibodypedia; 12720; 409 antibodies.
DR   DNASU; 55366; -.
DR   Ensembl; ENST00000379214; ENSP00000368516; ENSG00000205213. [Q9BXB1-1]
DR   Ensembl; ENST00000389858; ENSP00000374508; ENSG00000205213. [Q9BXB1-2]
DR   GeneID; 55366; -.
DR   KEGG; hsa:55366; -.
DR   UCSC; uc001mrj.5; human. [Q9BXB1-1]
DR   CTD; 55366; -.
DR   DisGeNET; 55366; -.
DR   EuPathDB; HostDB:ENSG00000205213.13; -.
DR   GeneCards; LGR4; -.
DR   HGNC; HGNC:13299; LGR4.
DR   HPA; ENSG00000205213; Low tissue specificity.
DR   MalaCards; LGR4; -.
DR   MIM; 166710; phenotype.
DR   MIM; 606666; gene.
DR   MIM; 615311; phenotype.
DR   neXtProt; NX_Q9BXB1; -.
DR   OpenTargets; ENSG00000205213; -.
DR   PharmGKB; PA28893; -.
DR   eggNOG; KOG0619; Eukaryota.
DR   eggNOG; KOG2087; Eukaryota.
DR   GeneTree; ENSGT00940000157925; -.
DR   HOGENOM; CLU_006843_0_0_1; -.
DR   InParanoid; Q9BXB1; -.
DR   KO; K04309; -.
DR   OMA; LFHGGEY; -.
DR   OrthoDB; 1095345at2759; -.
DR   PhylomeDB; Q9BXB1; -.
DR   TreeFam; TF316814; -.
DR   PathwayCommons; Q9BXB1; -.
DR   Reactome; R-HSA-4641263; Regulation of FZD by ubiquitination.
DR   SIGNOR; Q9BXB1; -.
DR   BioGRID-ORCS; 55366; 9 hits in 876 CRISPR screens.
DR   ChiTaRS; LGR4; human.
DR   GeneWiki; LGR4; -.
DR   GenomeRNAi; 55366; -.
DR   Pharos; Q9BXB1; Tbio.
DR   PRO; PR:Q9BXB1; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q9BXB1; protein.
DR   Bgee; ENSG00000205213; Expressed in stomach and 232 other tissues.
DR   ExpressionAtlas; Q9BXB1; baseline and differential.
DR   Genevisible; Q9BXB1; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0008528; F:G protein-coupled peptide receptor activity; IBA:GO_Central.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; TAS:ProtInc.
DR   GO; GO:0016500; F:protein-hormone receptor activity; IEA:InterPro.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; IDA:UniProtKB.
DR   GO; GO:0007190; P:activation of adenylate cyclase activity; IBA:GO_Central.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0030282; P:bone mineralization; ISS:UniProtKB.
DR   GO; GO:0046849; P:bone remodeling; ISS:UniProtKB.
DR   GO; GO:0061290; P:canonical Wnt signaling pathway involved in metanephric kidney development; IEA:Ensembl.
DR   GO; GO:0072202; P:cell differentiation involved in metanephros development; IEA:Ensembl.
DR   GO; GO:0032922; P:circadian regulation of gene expression; ISS:UniProtKB.
DR   GO; GO:0048565; P:digestive tract development; IEA:Ensembl.
DR   GO; GO:2001013; P:epithelial cell proliferation involved in renal tubule morphogenesis; IEA:Ensembl.
DR   GO; GO:0001942; P:hair follicle development; IEA:Ensembl.
DR   GO; GO:0009755; P:hormone-mediated signaling pathway; IBA:GO_Central.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0036335; P:intestinal stem cell homeostasis; IEA:Ensembl.
DR   GO; GO:0030539; P:male genitalia development; IEA:Ensembl.
DR   GO; GO:0072224; P:metanephric glomerulus development; IEA:Ensembl.
DR   GO; GO:0072282; P:metanephric nephron tubule morphogenesis; IEA:Ensembl.
DR   GO; GO:0120163; P:negative regulation of cold-induced thermogenesis; ISS:YuBioLab.
DR   GO; GO:0050710; P:negative regulation of cytokine secretion; ISS:UniProtKB.
DR   GO; GO:0034122; P:negative regulation of toll-like receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IEA:Ensembl.
DR   GO; GO:0001649; P:osteoblast differentiation; ISS:UniProtKB.
DR   GO; GO:0090190; P:positive regulation of branching involved in ureteric bud morphogenesis; IEA:Ensembl.
DR   GO; GO:0090263; P:positive regulation of canonical Wnt signaling pathway; IDA:UniProtKB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IEA:Ensembl.
DR   GO; GO:0007283; P:spermatogenesis; ISS:UniProtKB.
DR   Gene3D; 3.80.10.10; -; 1.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR002131; Gphrmn_rcpt_fam.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR003591; Leu-rich_rpt_typical-subtyp.
DR   InterPro; IPR032675; LRR_dom_sf.
DR   InterPro; IPR000372; LRRNT.
DR   Pfam; PF00001; 7tm_1; 1.
DR   Pfam; PF13855; LRR_8; 4.
DR   Pfam; PF01462; LRRNT; 1.
DR   PRINTS; PR00373; GLYCHORMONER.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM00369; LRR_TYP; 15.
DR   SMART; SM00013; LRRNT; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
DR   PROSITE; PS51450; LRR; 15.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Biological rhythms; Cell membrane;
KW   Developmental protein; Differentiation; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Immunity; Innate immunity;
KW   Leucine-rich repeat; Membrane; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Repeat; Signal; Spermatogenesis; Transducer;
KW   Transmembrane; Transmembrane helix; Wnt signaling pathway.
FT   SIGNAL          1..24
FT                   /evidence="ECO:0000255"
FT   CHAIN           25..951
FT                   /note="Leucine-rich repeat-containing G-protein coupled
FT                   receptor 4"
FT                   /id="PRO_0000012792"
FT   TOPO_DOM        25..544
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        545..565
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        566..575
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        576..596
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        597..620
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        621..641
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        642..661
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        662..682
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        683..703
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        704..724
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        725..756
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        757..777
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        778..783
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        784..804
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        805..951
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          25..57
FT                   /note="LRRNT"
FT   REPEAT          58..79
FT                   /note="LRR 1"
FT   REPEAT          82..103
FT                   /note="LRR 2"
FT   REPEAT          106..127
FT                   /note="LRR 3"
FT   REPEAT          130..151
FT                   /note="LRR 4"
FT   REPEAT          154..177
FT                   /note="LRR 5"
FT   REPEAT          178..199
FT                   /note="LRR 6"
FT   REPEAT          202..223
FT                   /note="LRR 7"
FT   REPEAT          226..247
FT                   /note="LRR 8"
FT   REPEAT          249..270
FT                   /note="LRR 9"
FT   REPEAT          273..294
FT                   /note="LRR 10"
FT   REPEAT          320..341
FT                   /note="LRR 11"
FT   REPEAT          344..365
FT                   /note="LRR 12"
FT   REPEAT          366..387
FT                   /note="LRR 13"
FT   REPEAT          390..411
FT                   /note="LRR 14"
FT   REPEAT          414..435
FT                   /note="LRR 15"
FT   MOD_RES         920
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   CARBOHYD        68
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:23756652"
FT   CARBOHYD        199
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:23756652"
FT   CARBOHYD        294
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        314
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        505
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        29..35
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521,
FT                   ECO:0000269|PubMed:23756652"
FT   DISULFID        33..43
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521,
FT                   ECO:0000269|PubMed:23756652"
FT   DISULFID        339..364
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521,
FT                   ECO:0000269|PubMed:23756652"
FT   DISULFID        470..522
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521,
FT                   ECO:0000269|PubMed:23756652"
FT   DISULFID        471..476
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521,
FT                   ECO:0000269|PubMed:23756652"
FT   DISULFID        618..693
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VAR_SEQ         62..85
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_047136"
FT   VARIANT         215
FT                   /note="S -> G (in dbSNP:rs2448010)"
FT                   /evidence="ECO:0000269|PubMed:11401528"
FT                   /id="VAR_044528"
FT   VARIANT         233
FT                   /note="N -> S (in dbSNP:rs2472617)"
FT                   /evidence="ECO:0000269|PubMed:11401528"
FT                   /id="VAR_044529"
FT   VARIANT         480
FT                   /note="A -> V (in dbSNP:rs12284579)"
FT                   /id="VAR_044530"
FT   VARIANT         684
FT                   /note="R -> G (in dbSNP:rs7125959)"
FT                   /id="VAR_044531"
FT   VARIANT         709
FT                   /note="T -> M (in dbSNP:rs34717439)"
FT                   /id="VAR_044532"
FT   VARIANT         844
FT                   /note="D -> G (in dbSNP:rs34804482)"
FT                   /id="VAR_044533"
FT   CONFLICT        22
FT                   /note="S -> G (in Ref. 4; AAH33039)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        172
FT                   /note="P -> H (in Ref. 4; AAH33039)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        247
FT                   /note="L -> R (in Ref. 1; AAF68989/AAK31153)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        292
FT                   /note="F -> S (in Ref. 1; AAF68989)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        433
FT                   /note="L -> P (in Ref. 1; AAF68989)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        668
FT                   /note="L -> S (in Ref. 1; AAF68989)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        681
FT                   /note="L -> I (in Ref. 4; AAH33039)"
FT                   /evidence="ECO:0000305"
FT   STRAND          39..42
FT                   /evidence="ECO:0000244|PDB:4QXE"
FT   STRAND          61..63
FT                   /evidence="ECO:0000244|PDB:4QXE"
FT   TURN            74..79
FT                   /evidence="ECO:0000244|PDB:4QXE"
FT   STRAND          85..87
FT                   /evidence="ECO:0000244|PDB:4QXE"
FT   TURN            98..103
FT                   /evidence="ECO:0000244|PDB:4QXE"
FT   STRAND          109..111
FT                   /evidence="ECO:0000244|PDB:4QXE"
FT   TURN            122..127
FT                   /evidence="ECO:0000244|PDB:4QXE"
FT   STRAND          133..135
FT                   /evidence="ECO:0000244|PDB:4QXE"
FT   TURN            146..151
FT                   /evidence="ECO:0000244|PDB:4QXE"
FT   STRAND          157..159
FT                   /evidence="ECO:0000244|PDB:4QXE"
FT   HELIX           170..173
FT                   /evidence="ECO:0000244|PDB:4QXE"
FT   STRAND          181..183
FT                   /evidence="ECO:0000244|PDB:4QXE"
FT   TURN            194..199
FT                   /evidence="ECO:0000244|PDB:4QXE"
FT   STRAND          205..207
FT                   /evidence="ECO:0000244|PDB:4QXE"
FT   TURN            218..223
FT                   /evidence="ECO:0000244|PDB:4QXE"
FT   STRAND          229..231
FT                   /evidence="ECO:0000244|PDB:4QXE"
FT   HELIX           242..246
FT                   /evidence="ECO:0000244|PDB:4QXE"
FT   STRAND          252..254
FT                   /evidence="ECO:0000244|PDB:4QXE"
FT   TURN            265..270
FT                   /evidence="ECO:0000244|PDB:4QXE"
FT   STRAND          276..278
FT                   /evidence="ECO:0000244|PDB:4QXE"
FT   TURN            289..294
FT                   /evidence="ECO:0000244|PDB:4QXE"
FT   STRAND          300..304
FT                   /evidence="ECO:0000244|PDB:4QXE"
FT   STRAND          323..329
FT                   /evidence="ECO:0000244|PDB:4QXE"
FT   HELIX           338..341
FT                   /evidence="ECO:0000244|PDB:4QXE"
FT   TURN            342..344
FT                   /evidence="ECO:0000244|PDB:4QXE"
FT   STRAND          347..349
FT                   /evidence="ECO:0000244|PDB:4QXE"
FT   STRAND          369..371
FT                   /evidence="ECO:0000244|PDB:4QXE"
FT   TURN            382..387
FT                   /evidence="ECO:0000244|PDB:4KT1"
FT   STRAND          393..395
FT                   /evidence="ECO:0000244|PDB:4QXE"
FT   TURN            406..411
FT                   /evidence="ECO:0000244|PDB:4KT1"
FT   STRAND          417..419
FT                   /evidence="ECO:0000244|PDB:4KT1"
FT   STRAND          437..440
FT                   /evidence="ECO:0000244|PDB:4KT1"
FT   HELIX           453..456
FT                   /evidence="ECO:0000244|PDB:4KT1"
FT   STRAND          461..463
FT                   /evidence="ECO:0000244|PDB:4KT1"
FT   HELIX           467..470
FT                   /evidence="ECO:0000244|PDB:4KT1"
FT   TURN            471..473
FT                   /evidence="ECO:0000244|PDB:4KT1"
FT   STRAND          521..523
FT                   /evidence="ECO:0000244|PDB:4KT1"
SQ   SEQUENCE   951 AA;  104475 MW;  42D48AE5F0BEB6B1 CRC64;
     MPGPLGLLCF LALGLLGSAG PSGAAPPLCA APCSCDGDRR VDCSGKGLTA VPEGLSAFTQ
     ALDISMNNIT QLPEDAFKNF PFLEELQLAG NDLSFIHPKA LSGLKELKVL TLQNNQLKTV
     PSEAIRGLSA LQSLRLDANH ITSVPEDSFE GLVQLRHLWL DDNSLTEVPV HPLSNLPTLQ
     ALTLALNKIS SIPDFAFTNL SSLVVLHLHN NKIRSLSQHC FDGLDNLETL DLNYNNLGEF
     PQAIKALPSL KELGFHSNSI SVIPDGAFDG NPLLRTIHLY DNPLSFVGNS AFHNLSDLHS
     LVIRGASMVQ QFPNLTGTVH LESLTLTGTK ISSIPNNLCQ EQKMLRTLDL SYNNIRDLPS
     FNGCHALEEI SLQRNQIYQI KEGTFQGLIS LRILDLSRNL IHEIHSRAFA TLGPITNLDV
     SFNELTSFPT EGLNGLNQLK LVGNFKLKEA LAAKDFVNLR SLSVPYAYQC CAFWGCDSYA
     NLNTEDNSLQ DHSVAQEKGT ADAANVTSTL ENEEHSQIII HCTPSTGAFK PCEYLLGSWM
     IRLTVWFIFL VALFFNLLVI LTTFASCTSL PSSKLFIGLI SVSNLFMGIY TGILTFLDAV
     SWGRFAEFGI WWETGSGCKV AGFLAVFSSE SAIFLLMLAT VERSLSAKDI MKNGKSNHLK
     QFRVAALLAF LGATVAGCFP LFHRGEYSAS PLCLPFPTGE TPSLGFTVTL VLLNSLAFLL
     MAVIYTKLYC NLEKEDLSEN SQSSMIKHVA WLIFTNCIFF CPVAFFSFAP LITAISISPE
     IMKSVTLIFF PLPACLNPVL YVFFNPKFKE DWKLLKRRVT KKSGSVSVSI SSQGGCLEQD
     FYYDCGMYSH LQGNLTVCDC CESFLLTKPV SCKHLIKSHS CPALAVASCQ RPEGYWSDCG
     TQSAHSDYAD EEDSFVSDSS DQVQACGRAC FYQSRGFPLV RYAYNLPRVK D
//
ID   P2RY1_HUMAN             Reviewed;         373 AA.
AC   P47900;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 1.
DT   07-OCT-2020, entry version 185.
DE   RecName: Full=P2Y purinoceptor 1;
DE            Short=P2Y1;
DE   AltName: Full=ADP receptor {ECO:0000303|PubMed:9038354};
DE   AltName: Full=Purinergic receptor;
GN   Name=P2RY1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   PubMed=8666290; DOI=10.1016/0378-1119(96)00027-3;
RA   Leon C., Vial C., Cazenave J.-P., Gachet C.;
RT   "Cloning and sequencing of a human cDNA encoding endothelial P2Y1
RT   purinoceptor.";
RL   Gene 171:295-297(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8579591; DOI=10.1006/bbrc.1996.0139;
RA   Ayyanathan K., Tania W., Harbansjit S., Raghbir A.S., Barnard E.A.,
RA   Kunapuli S.P.;
RT   "Cloning and chromosomal localization of the human P2Y1 purinoceptor.";
RL   Biochem. Biophys. Res. Commun. 218:783-788(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8630005; DOI=10.1006/bbrc.1996.0640;
RA   Janssens R., Communi D., Pirotton S., Samson M., Parmentier M.,
RA   Boeynaems J.-M.;
RT   "Cloning and tissue distribution of the human P2Y1 receptor.";
RL   Biochem. Biophys. Res. Commun. 221:588-593(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Blood;
RA   Leon C., Vial C., Weber J., Cazenave J.-P., Gacher C.;
RL   Submitted (JUN-1998) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 95-373, FUNCTION, AND ACTIVITY REGULATION.
RC   TISSUE=Platelet;
RX   PubMed=9442040; DOI=10.1074/jbc.273.4.2030;
RA   Jin J., Daniel J.L., Kunapuli S.P.;
RT   "Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor
RT   mediates ADP-induced intracellular calcium mobilization and shape change in
RT   platelets.";
RL   J. Biol. Chem. 273:2030-2034(1998).
RN   [8]
RP   FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=9038354; DOI=10.1016/s0014-5793(97)00022-7;
RA   Leon C., Hechler B., Vial C., Leray C., Cazenave J.P., Gachet C.;
RT   "The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in
RT   platelets and megakaryoblastic cells.";
RL   FEBS Lett. 403:26-30(1997).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [10] {ECO:0000244|PDB:4XNV, ECO:0000244|PDB:4XNW}
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 2-247 AND 253-373 IN COMPLEXES
RP   WITH ATP ANALOG MRS2500 AND SYNTHETIC ANTAGONIST BPTU, SUBCELLULAR
RP   LOCATION, TOPOLOGY, DISULFIDE BONDS, AND MUTAGENESIS OF LEU-44; TYR-110;
RP   TYR-203; THR-205; ASN-283 AND TYR-306.
RX   PubMed=25822790; DOI=10.1038/nature14287;
RA   Zhang D., Gao Z.G., Zhang K., Kiselev E., Crane S., Wang J., Paoletta S.,
RA   Yi C., Ma L., Zhang W., Han G.W., Liu H., Cherezov V., Katritch V.,
RA   Jiang H., Stevens R.C., Jacobson K.A., Zhao Q., Wu B.;
RT   "Two disparate ligand-binding sites in the human P2Y1 receptor.";
RL   Nature 520:317-321(2015).
CC   -!- FUNCTION: Receptor for extracellular adenine nucleotides such as ADP
CC       (PubMed:9442040, PubMed:9038354, PubMed:25822790). In platelets,
CC       binding to ADP leads to mobilization of intracellular calcium ions via
CC       activation of phospholipase C, a change in platelet shape, and
CC       ultimately platelet aggregation (PubMed:9442040).
CC       {ECO:0000269|PubMed:25822790, ECO:0000269|PubMed:9038354,
CC       ECO:0000269|PubMed:9442040}.
CC   -!- ACTIVITY REGULATION: ATP functions as antagonist and inhibits ADP-
CC       induced mobilization of Ca(2+) (PubMed:9038354). The P2Y1 receptor-
CC       specific antagonists A3P5PS, A3P5P and A2P5P inhibit downstream
CC       signaling mediated by mobilization of Ca(2+) from intracellular stores,
CC       and platelet shape changes in response to extracellular ADP
CC       (PubMed:9442040). {ECO:0000269|PubMed:9038354,
CC       ECO:0000269|PubMed:9442040}.
CC   -!- INTERACTION:
CC       P47900; O14745: SLC9A3R1; NbExp=2; IntAct=EBI-8677223, EBI-349787;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:25822790};
CC       Multi-pass membrane protein {ECO:0000269|PubMed:25822790}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Z49205; CAA89066.1; -; mRNA.
DR   EMBL; U42030; AAA97873.1; -; mRNA.
DR   EMBL; U42029; AAA97872.1; -; mRNA.
DR   EMBL; S81950; AAB47091.1; -; Genomic_DNA.
DR   EMBL; AJ006945; CAA07339.1; -; Genomic_DNA.
DR   EMBL; AY136752; AAN01278.1; -; mRNA.
DR   EMBL; BC074784; AAH74784.1; -; mRNA.
DR   EMBL; BC074785; AAH74785.1; -; mRNA.
DR   EMBL; AF018284; AAB94556.1; -; mRNA.
DR   CCDS; CCDS3169.1; -.
DR   PIR; JC4737; JC4737.
DR   RefSeq; NP_002554.1; NM_002563.4.
DR   PDB; 1Y36; Model; -; A=1-373.
DR   PDB; 4XNV; X-ray; 2.20 A; A=2-247, A=253-373.
DR   PDB; 4XNW; X-ray; 2.70 A; A/C=2-247, A/C=253-373.
DR   PDBsum; 1Y36; -.
DR   PDBsum; 4XNV; -.
DR   PDBsum; 4XNW; -.
DR   SMR; P47900; -.
DR   BioGRID; 111067; 12.
DR   IntAct; P47900; 8.
DR   MINT; P47900; -.
DR   STRING; 9606.ENSP00000304767; -.
DR   BindingDB; P47900; -.
DR   ChEMBL; CHEMBL4315; -.
DR   DrugBank; DB01069; Promethazine.
DR   DrugCentral; P47900; -.
DR   GuidetoPHARMACOLOGY; 323; -.
DR   TCDB; 9.A.14.13.22; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; P47900; 4 sites.
DR   iPTMnet; P47900; -.
DR   PhosphoSitePlus; P47900; -.
DR   BioMuta; P2RY1; -.
DR   DMDM; 1352692; -.
DR   MassIVE; P47900; -.
DR   PaxDb; P47900; -.
DR   PeptideAtlas; P47900; -.
DR   PRIDE; P47900; -.
DR   ProteomicsDB; 55818; -.
DR   TopDownProteomics; P47900; -.
DR   Antibodypedia; 2952; 378 antibodies.
DR   Ensembl; ENST00000305097; ENSP00000304767; ENSG00000169860.
DR   GeneID; 5028; -.
DR   KEGG; hsa:5028; -.
DR   UCSC; uc003ezq.4; human.
DR   CTD; 5028; -.
DR   DisGeNET; 5028; -.
DR   EuPathDB; HostDB:ENSG00000169860.6; -.
DR   GeneCards; P2RY1; -.
DR   HGNC; HGNC:8539; P2RY1.
DR   HPA; ENSG00000169860; Tissue enhanced (brain, placenta).
DR   MIM; 601167; gene.
DR   neXtProt; NX_P47900; -.
DR   OpenTargets; ENSG00000169860; -.
DR   PharmGKB; PA32868; -.
DR   eggNOG; ENOG502QWPV; Eukaryota.
DR   GeneTree; ENSGT00960000186584; -.
DR   HOGENOM; CLU_009579_8_2_1; -.
DR   InParanoid; P47900; -.
DR   KO; K04270; -.
DR   OMA; FHVMKTL; -.
DR   OrthoDB; 730191at2759; -.
DR   PhylomeDB; P47900; -.
DR   TreeFam; TF350009; -.
DR   PathwayCommons; P47900; -.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-417957; P2Y receptors.
DR   Reactome; R-HSA-418592; ADP signalling through P2Y purinoceptor 1.
DR   SIGNOR; P47900; -.
DR   BioGRID-ORCS; 5028; 6 hits in 874 CRISPR screens.
DR   ChiTaRS; P2RY1; human.
DR   GeneWiki; P2RY1; -.
DR   GenomeRNAi; 5028; -.
DR   Pharos; P47900; Tchem.
DR   PRO; PR:P47900; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; P47900; protein.
DR   Bgee; ENSG00000169860; Expressed in gingival epithelium and 199 other tissues.
DR   Genevisible; P47900; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0016323; C:basolateral plasma membrane; IEA:Ensembl.
DR   GO; GO:0044297; C:cell body; ISS:BHF-UCL.
DR   GO; GO:0009986; C:cell surface; HDA:UniProtKB.
DR   GO; GO:0005929; C:cilium; IDA:MGI.
DR   GO; GO:0030425; C:dendrite; ISS:BHF-UCL.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0099059; C:integral component of presynaptic active zone membrane; IEA:Ensembl.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; ISS:BHF-UCL.
DR   GO; GO:0014069; C:postsynaptic density; ISS:BHF-UCL.
DR   GO; GO:0045211; C:postsynaptic membrane; ISS:BHF-UCL.
DR   GO; GO:0031686; F:A1 adenosine receptor binding; IEA:Ensembl.
DR   GO; GO:0043531; F:ADP binding; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IMP:UniProtKB.
DR   GO; GO:0001621; F:G protein-coupled ADP receptor activity; IMP:UniProtKB.
DR   GO; GO:0045031; F:G protein-coupled ATP receptor activity; ISS:BHF-UCL.
DR   GO; GO:0045028; F:G protein-coupled purinergic nucleotide receptor activity; ISS:BHF-UCL.
DR   GO; GO:0046982; F:protein heterodimerization activity; IEA:Ensembl.
DR   GO; GO:0097110; F:scaffold protein binding; ISS:BHF-UCL.
DR   GO; GO:0038023; F:signaling receptor activity; TAS:ProtInc.
DR   GO; GO:0007193; P:adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0071318; P:cellular response to ATP; TAS:ARUK-UCL.
DR   GO; GO:0071415; P:cellular response to purine-containing compound; IMP:UniProtKB.
DR   GO; GO:0042755; P:eating behavior; IEA:Ensembl.
DR   GO; GO:0001973; P:G protein-coupled adenosine receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0008347; P:glial cell migration; IEA:Ensembl.
DR   GO; GO:0051100; P:negative regulation of binding; IEA:Ensembl.
DR   GO; GO:0010700; P:negative regulation of norepinephrine secretion; IEA:Ensembl.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0030168; P:platelet activation; IEA:InterPro.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; ISS:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:BHF-UCL.
DR   GO; GO:0046887; P:positive regulation of hormone secretion; IEA:Ensembl.
DR   GO; GO:0032962; P:positive regulation of inositol trisphosphate biosynthetic process; IEA:Ensembl.
DR   GO; GO:0043270; P:positive regulation of ion transport; IEA:Ensembl.
DR   GO; GO:0060406; P:positive regulation of penile erection; IEA:Ensembl.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; ISS:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0072659; P:protein localization to plasma membrane; ISS:BHF-UCL.
DR   GO; GO:0097746; P:regulation of blood vessel diameter; IEA:Ensembl.
DR   GO; GO:0008360; P:regulation of cell shape; IMP:UniProtKB.
DR   GO; GO:0010469; P:regulation of signaling receptor activity; IEA:Ensembl.
DR   GO; GO:0090075; P:relaxation of muscle; IEA:InterPro.
DR   GO; GO:0070848; P:response to growth factor; IEA:Ensembl.
DR   GO; GO:0009612; P:response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0019233; P:sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0023019; P:signal transduction involved in regulation of gene expression; ISS:BHF-UCL.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR000142; P2Y1_rcpt.
DR   PANTHER; PTHR24231:SF2; PTHR24231:SF2; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00595; P2Y1PRNOCPTR.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Blood coagulation; Cell membrane;
KW   Disulfide bond; G-protein coupled receptor; Glycoprotein; Hemostasis;
KW   Membrane; Nucleotide-binding; Receptor; Reference proteome; Transducer;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..373
FT                   /note="P2Y purinoceptor 1"
FT                   /id="PRO_0000070006"
FT   TOPO_DOM        1..51
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:25822790"
FT   TRANSMEM        52..74
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000269|PubMed:25822790"
FT   TOPO_DOM        75..87
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:25822790"
FT   TRANSMEM        88..109
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000269|PubMed:25822790"
FT   TOPO_DOM        110..125
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:25822790"
FT   TRANSMEM        126..147
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000269|PubMed:25822790"
FT   TOPO_DOM        148..166
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:25822790"
FT   TRANSMEM        167..188
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000269|PubMed:25822790"
FT   TOPO_DOM        189..214
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:25822790"
FT   TRANSMEM        215..237
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000269|PubMed:25822790"
FT   TOPO_DOM        238..260
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:25822790"
FT   TRANSMEM        261..284
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000269|PubMed:25822790"
FT   TOPO_DOM        285..303
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:25822790"
FT   TRANSMEM        304..325
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000269|PubMed:25822790"
FT   TOPO_DOM        326..373
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:25822790"
FT   NP_BIND         203..205
FT                   /note="ADP"
FT                   /evidence="ECO:0000244|PDB:4XNW,
FT                   ECO:0000305|PubMed:25822790"
FT   NP_BIND         283..287
FT                   /note="ADP"
FT                   /evidence="ECO:0000244|PDB:4XNW,
FT                   ECO:0000305|PubMed:25822790"
FT   NP_BIND         303..306
FT                   /note="ADP"
FT                   /evidence="ECO:0000244|PDB:4XNW,
FT                   ECO:0000305|PubMed:25822790"
FT   BINDING         46
FT                   /note="ADP"
FT                   /evidence="ECO:0000244|PDB:4XNW,
FT                   ECO:0000305|PubMed:25822790"
FT   BINDING         310
FT                   /note="ADP"
FT                   /evidence="ECO:0000244|PDB:4XNW,
FT                   ECO:0000305|PubMed:25822790"
FT   CARBOHYD        11
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        27
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        113
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        197
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        42..296
FT                   /evidence="ECO:0000244|PDB:4XNV, ECO:0000244|PDB:4XNW,
FT                   ECO:0000269|PubMed:25822790"
FT   DISULFID        124..202
FT                   /evidence="ECO:0000244|PDB:4XNV, ECO:0000244|PDB:4XNW,
FT                   ECO:0000255|PROSITE-ProRule:PRU00521,
FT                   ECO:0000269|PubMed:25822790"
FT   MUTAGEN         44
FT                   /note="L->A: Loss of ADP analog binding."
FT                   /evidence="ECO:0000269|PubMed:25822790"
FT   MUTAGEN         110
FT                   /note="Y->F: Loss of ADP analog binding."
FT                   /evidence="ECO:0000269|PubMed:25822790"
FT   MUTAGEN         203
FT                   /note="Y->A: Loss of ADP analog binding."
FT                   /evidence="ECO:0000269|PubMed:25822790"
FT   MUTAGEN         205
FT                   /note="T->A: Loss of ADP analog binding."
FT                   /evidence="ECO:0000269|PubMed:25822790"
FT   MUTAGEN         283
FT                   /note="N->A: Loss of ADP analog binding."
FT                   /evidence="ECO:0000269|PubMed:25822790"
FT   MUTAGEN         306
FT                   /note="Y->F: Strongly decreased affinity for ADP analog."
FT                   /evidence="ECO:0000269|PubMed:25822790"
FT   CONFLICT        138
FT                   /note="Missing (in Ref. 1; CAA89066)"
FT                   /evidence="ECO:0000305"
FT   HELIX           50..78
FT                   /evidence="ECO:0000244|PDB:4XNV"
FT   HELIX           85..112
FT                   /evidence="ECO:0000244|PDB:4XNV"
FT   TURN            113..115
FT                   /evidence="ECO:0000244|PDB:4XNV"
FT   HELIX           121..154
FT                   /evidence="ECO:0000244|PDB:4XNV"
FT   TURN            156..158
FT                   /evidence="ECO:0000244|PDB:4XNW"
FT   HELIX           161..183
FT                   /evidence="ECO:0000244|PDB:4XNV"
FT   HELIX           186..189
FT                   /evidence="ECO:0000244|PDB:4XNV"
FT   STRAND          191..194
FT                   /evidence="ECO:0000244|PDB:4XNV"
FT   STRAND          200..205
FT                   /evidence="ECO:0000244|PDB:4XNV"
FT   TURN            208..210
FT                   /evidence="ECO:0000244|PDB:4XNV"
FT   HELIX           211..225
FT                   /evidence="ECO:0000244|PDB:4XNV"
FT   HELIX           227..245
FT                   /evidence="ECO:0000244|PDB:4XNV"
FT   HELIX           253..271
FT                   /evidence="ECO:0000244|PDB:4XNV"
FT   HELIX           273..289
FT                   /evidence="ECO:0000244|PDB:4XNV"
FT   HELIX           293..295
FT                   /evidence="ECO:0000244|PDB:4XNV"
FT   HELIX           296..319
FT                   /evidence="ECO:0000244|PDB:4XNV"
FT   HELIX           321..326
FT                   /evidence="ECO:0000244|PDB:4XNV"
SQ   SEQUENCE   373 AA;  42072 MW;  4DC7C668B4145392 CRC64;
     MTEVLWPAVP NGTDAAFLAG PGSSWGNSTV ASTAAVSSSF KCALTKTGFQ FYYLPAVYIL
     VFIIGFLGNS VAIWMFVFHM KPWSGISVYM FNLALADFLY VLTLPALIFY YFNKTDWIFG
     DAMCKLQRFI FHVNLYGSIL FLTCISAHRY SGVVYPLKSL GRLKKKNAIC ISVLVWLIVV
     VAISPILFYS GTGVRKNKTI TCYDTTSDEY LRSYFIYSMC TTVAMFCVPL VLILGCYGLI
     VRALIYKDLD NSPLRRKSIY LVIIVLTVFA VSYIPFHVMK TMNLRARLDF QTPAMCAFND
     RVYATYQVTR GLASLNSCVD PILYFLAGDT FRRRLSRATR KASRRSEANL QSKSEDMTLN
     ILPEFKQNGD TSL
//
ID   NTR1_HUMAN              Reviewed;         418 AA.
AC   P30989; Q9H4H1; Q9H4T5;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   29-MAR-2005, sequence version 2.
DT   12-AUG-2020, entry version 186.
DE   RecName: Full=Neurotensin receptor type 1;
DE            Short=NT-R-1;
DE            Short=NTR1;
DE   AltName: Full=High-affinity levocabastine-insensitive neurotensin receptor;
DE   AltName: Full=NTRH;
GN   Name=NTSR1; Synonyms=NTRR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=8381365; DOI=10.1016/0014-5793(93)81509-x;
RA   Vita N., Laurent P., Lefort S., Chalon P., Dumont X., Kaghad M., Gully D.,
RA   le Fur G., Ferrara P., Caput D.;
RT   "Cloning and expression of a complementary DNA encoding a high affinity
RT   human neurotensin receptor.";
RL   FEBS Lett. 317:139-142(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D.,
RA   Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G.,
RA   Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E.,
RA   Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D.,
RA   Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M.,
RA   Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D.,
RA   Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M.,
RA   Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A.,
RA   Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L.,
RA   Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L.,
RA   Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [4]
RP   TISSUE SPECIFICITY.
RX   PubMed=20048080; DOI=10.1158/0008-5472.can-09-1252;
RA   Swift S.L., Burns J.E., Maitland N.J.;
RT   "Altered expression of neurotensin receptors is associated with the
RT   differentiation state of prostate cancer.";
RL   Cancer Res. 70:347-356(2010).
RN   [5]
RP   FUNCTION, INTERACTION WITH GNA11, PALMITOYLATION AT CYS-381 AND CYS-383,
RP   SUBCELLULAR LOCATION, GLYCOSYLATION, AND MUTAGENESIS OF CYS-381 AND
RP   CYS-383.
RX   PubMed=21725197; DOI=10.4161/cbt.12.5.15984;
RA   Heakal Y., Woll M.P., Fox T., Seaton K., Levenson R., Kester M.;
RT   "Neurotensin receptor-1 inducible palmitoylation is required for efficient
RT   receptor-mediated mitogenic-signaling within structured membrane
RT   microdomains.";
RL   Cancer Biol. Ther. 12:427-435(2011).
RN   [6]
RP   STRUCTURE BY NMR OF 321-344 IN COMPLEX WITH NTS, AND FUNCTION.
RX   PubMed=23140271; DOI=10.1080/07391102.2012.736776;
RA   Da Costa G., Bondon A., Coutant J., Curmi P., Monti J.P.;
RT   "Intermolecular interactions between the neurotensin and the third
RT   extracellular loop of human neurotensin 1 receptor.";
RL   J. Biomol. Struct. Dyn. 31:1381-1392(2013).
CC   -!- FUNCTION: G-protein coupled receptor for the tridecapeptide neurotensin
CC       (NTS) (PubMed:8381365, PubMed:21725197, PubMed:23140271). Signaling is
CC       effected via G proteins that activate a phosphatidylinositol-calcium
CC       second messenger system. Signaling leads to the activation of
CC       downstream MAP kinases and protects cells against apoptosis
CC       (PubMed:21725197). {ECO:0000269|PubMed:21725197,
CC       ECO:0000269|PubMed:23140271, ECO:0000269|PubMed:8381365}.
CC   -!- SUBUNIT: Interacts (palmitoylated form) with GNA11.
CC       {ECO:0000269|PubMed:21725197, ECO:0000269|PubMed:23140271}.
CC   -!- INTERACTION:
CC       P30989; P14416: DRD2; NbExp=5; IntAct=EBI-6655774, EBI-2928178;
CC       P30989; P30990: NTS; NbExp=2; IntAct=EBI-6655774, EBI-6655799;
CC       P30989; PRO_0000019524 [P30990]: NTS; NbExp=2; IntAct=EBI-6655774, EBI-6655817;
CC       P30989; P30989: NTSR1; NbExp=2; IntAct=EBI-6655774, EBI-6655774;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:8381365};
CC       Multi-pass membrane protein {ECO:0000305}. Membrane raft
CC       {ECO:0000269|PubMed:21725197}. Note=Palmitoylation is required for
CC       localization at CAV1-enriched membrane rafts.
CC       {ECO:0000269|PubMed:21725197}.
CC   -!- TISSUE SPECIFICITY: Expressed in prostate (at protein level). Detected
CC       in colon and peripheral blood mononuclear cells. Detected at very low
CC       levels in brain. {ECO:0000269|PubMed:20048080,
CC       ECO:0000269|PubMed:8381365}.
CC   -!- DOMAIN: The ligand binding pocket consists mainly of extracellular
CC       loops ECL2 and ECL3, as well as transmembrane regions TM6 and TM7.
CC       {ECO:0000250|UniProtKB:P20789}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:21725197}.
CC   -!- PTM: Palmitoylated; this is required for normal localization at
CC       membrane rafts and normal GNA11-mediated activation of down-stream
CC       signaling cascades. The palmitoylation level increases in response to
CC       neurotensin treatment. {ECO:0000269|PubMed:21725197}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       Neurotensin receptor subfamily. NTSR1 sub-subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Neurotensin receptor entry;
CC       URL="https://en.wikipedia.org/wiki/Neurotensin_receptor";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X70070; CAA49675.1; -; mRNA.
DR   EMBL; AY429106; AAR07901.1; -; mRNA.
DR   EMBL; AL035669; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL357033; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS13502.1; -.
DR   PIR; S29506; S29506.
DR   RefSeq; NP_002522.2; NM_002531.2.
DR   PDB; 2LYW; NMR; -; A=321-344.
DR   PDB; 6OS9; EM; 3.00 A; R=20-418.
DR   PDB; 6OSA; EM; 3.00 A; R=20-418.
DR   PDB; 6PWC; EM; 4.90 A; R=49-418.
DR   PDB; 6UP7; EM; 4.20 A; R=50-383.
DR   PDBsum; 2LYW; -.
DR   PDBsum; 6OS9; -.
DR   PDBsum; 6OSA; -.
DR   PDBsum; 6PWC; -.
DR   PDBsum; 6UP7; -.
DR   SMR; P30989; -.
DR   BioGRID; 110977; 2.
DR   DIP; DIP-60977N; -.
DR   IntAct; P30989; 3.
DR   STRING; 9606.ENSP00000359532; -.
DR   BindingDB; P30989; -.
DR   ChEMBL; CHEMBL4123; -.
DR   GuidetoPHARMACOLOGY; 309; -.
DR   TCDB; 9.A.14.1.14; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; P30989; 3 sites.
DR   iPTMnet; P30989; -.
DR   PhosphoSitePlus; P30989; -.
DR   SwissPalm; P30989; -.
DR   BioMuta; NTSR1; -.
DR   DMDM; 62297312; -.
DR   jPOST; P30989; -.
DR   MassIVE; P30989; -.
DR   MaxQB; P30989; -.
DR   PaxDb; P30989; -.
DR   PeptideAtlas; P30989; -.
DR   PRIDE; P30989; -.
DR   ProteomicsDB; 54755; -.
DR   Antibodypedia; 1519; 312 antibodies.
DR   DNASU; 4923; -.
DR   Ensembl; ENST00000370501; ENSP00000359532; ENSG00000101188.
DR   GeneID; 4923; -.
DR   KEGG; hsa:4923; -.
DR   UCSC; uc002ydf.3; human.
DR   CTD; 4923; -.
DR   DisGeNET; 4923; -.
DR   EuPathDB; HostDB:ENSG00000101188.4; -.
DR   GeneCards; NTSR1; -.
DR   HGNC; HGNC:8039; NTSR1.
DR   HPA; ENSG00000101188; Tissue enhanced (brain, intestine).
DR   MIM; 162651; gene.
DR   neXtProt; NX_P30989; -.
DR   OpenTargets; ENSG00000101188; -.
DR   PharmGKB; PA31821; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00990000203538; -.
DR   HOGENOM; CLU_009579_6_5_1; -.
DR   InParanoid; P30989; -.
DR   KO; K04211; -.
DR   OMA; TVGDQHS; -.
DR   OrthoDB; 890529at2759; -.
DR   PhylomeDB; P30989; -.
DR   TreeFam; TF337167; -.
DR   PathwayCommons; P30989; -.
DR   Reactome; R-HSA-375276; Peptide ligand-binding receptors.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   SIGNOR; P30989; -.
DR   BioGRID-ORCS; 4923; 9 hits in 870 CRISPR screens.
DR   GeneWiki; Neurotensin_receptor_1; -.
DR   GenomeRNAi; 4923; -.
DR   Pharos; P30989; Tchem.
DR   PRO; PR:P30989; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   RNAct; P30989; protein.
DR   Bgee; ENSG00000101188; Expressed in muscle layer of sigmoid colon and 75 other tissues.
DR   Genevisible; P30989; HS.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0043198; C:dendritic shaft; IEA:Ensembl.
DR   GO; GO:0043197; C:dendritic spine; IEA:Ensembl.
DR   GO; GO:0005783; C:endoplasmic reticulum; TAS:ProtInc.
DR   GO; GO:0005794; C:Golgi apparatus; TAS:ProtInc.
DR   GO; GO:0005887; C:integral component of plasma membrane; IMP:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0043204; C:perikaryon; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0032280; C:symmetric synapse; IEA:Ensembl.
DR   GO; GO:0043195; C:terminal bouton; IEA:Ensembl.
DR   GO; GO:0016492; F:G protein-coupled neurotensin receptor activity; IDA:UniProtKB.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; TAS:ProtInc.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0047485; F:protein N-terminus binding; IEA:Ensembl.
DR   GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl.
DR   GO; GO:0008344; P:adult locomotory behavior; IEA:Ensembl.
DR   GO; GO:0007268; P:chemical synaptic transmission; TAS:ProtInc.
DR   GO; GO:0070779; P:D-aspartate import across plasma membrane; IEA:Ensembl.
DR   GO; GO:0050965; P:detection of temperature stimulus involved in sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0071545; P:inositol phosphate catabolic process; IEA:Ensembl.
DR   GO; GO:0098712; P:L-glutamate import across plasma membrane; IEA:Ensembl.
DR   GO; GO:0007612; P:learning; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0051280; P:negative regulation of release of sequestered calcium ion into cytosol; IEA:Ensembl.
DR   GO; GO:0003085; P:negative regulation of systemic arterial blood pressure; IEA:Ensembl.
DR   GO; GO:0007218; P:neuropeptide signaling pathway; IDA:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0090238; P:positive regulation of arachidonic acid secretion; IEA:Ensembl.
DR   GO; GO:2001259; P:positive regulation of cation channel activity; IEA:Ensembl.
DR   GO; GO:0014054; P:positive regulation of gamma-aminobutyric acid secretion; IEA:Ensembl.
DR   GO; GO:0014049; P:positive regulation of glutamate secretion; IEA:Ensembl.
DR   GO; GO:0097151; P:positive regulation of inhibitory postsynaptic potential; IEA:Ensembl.
DR   GO; GO:0060732; P:positive regulation of inositol phosphate biosynthetic process; IEA:Ensembl.
DR   GO; GO:0051281; P:positive regulation of release of sequestered calcium ion into cytosol; IEA:Ensembl.
DR   GO; GO:0098900; P:regulation of action potential; IEA:Ensembl.
DR   GO; GO:0003254; P:regulation of membrane depolarization; IEA:Ensembl.
DR   GO; GO:0043576; P:regulation of respiratory gaseous exchange; IEA:Ensembl.
DR   GO; GO:0051930; P:regulation of sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0033993; P:response to lipid; IEA:Ensembl.
DR   GO; GO:0001659; P:temperature homeostasis; IEA:Ensembl.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR003985; NT1_rcpt.
DR   InterPro; IPR003984; NT_rcpt.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01479; NEUROTENSINR.
DR   PRINTS; PR01480; NEUROTENSN1R.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Lipoprotein; Membrane; Palmitate; Polymorphism; Receptor;
KW   Reference proteome; Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..418
FT                   /note="Neurotensin receptor type 1"
FT                   /id="PRO_0000069946"
FT   TOPO_DOM        1..67
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250|UniProtKB:P20789"
FT   TRANSMEM        68..88
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000250|UniProtKB:P20789"
FT   TOPO_DOM        89..102
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:P20789"
FT   TRANSMEM        103..122
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000250|UniProtKB:P20789"
FT   TOPO_DOM        123..142
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250|UniProtKB:P20789"
FT   TRANSMEM        143..164
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000250|UniProtKB:P20789"
FT   TOPO_DOM        165..184
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:P20789"
FT   TRANSMEM        185..205
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000250|UniProtKB:P20789"
FT   TOPO_DOM        206..234
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250|UniProtKB:P20789"
FT   TRANSMEM        235..259
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000250|UniProtKB:P20789"
FT   TOPO_DOM        260..303
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:P20789"
FT   TRANSMEM        304..325
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000250|UniProtKB:P20789"
FT   TOPO_DOM        326..343
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250|UniProtKB:P20789"
FT   TRANSMEM        344..364
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000250|UniProtKB:P20789"
FT   TOPO_DOM        365..418
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250|UniProtKB:P20789"
FT   REGION          321..344
FT                   /note="Neurotensin binding"
FT                   /evidence="ECO:0000250"
FT   LIPID           381
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000305|PubMed:21725197"
FT   LIPID           383
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000305|PubMed:21725197"
FT   CARBOHYD        4
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        37
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        41
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        141..224
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VARIANT         72
FT                   /note="A -> V (in dbSNP:rs11698783)"
FT                   /id="VAR_059328"
FT   VARIANT         275
FT                   /note="Q -> H (in dbSNP:rs35373650)"
FT                   /id="VAR_049424"
FT   VARIANT         304
FT                   /note="V -> I (in dbSNP:rs2273075)"
FT                   /id="VAR_020071"
FT   MUTAGEN         381
FT                   /note="C->S: Abolishes palmitoylation; when associated with
FT                   S-383."
FT                   /evidence="ECO:0000269|PubMed:21725197"
FT   MUTAGEN         383
FT                   /note="C->S: Abolishes palmitoylation; when associated with
FT                   S-381."
FT                   /evidence="ECO:0000269|PubMed:21725197"
FT   CONFLICT        200
FT                   /note="A -> T (in Ref. 1; CAA49675)"
FT                   /evidence="ECO:0000305"
FT   HELIX           52..54
FT                   /evidence="ECO:0000244|PDB:6OS9"
FT   HELIX           60..90
FT                   /evidence="ECO:0000244|PDB:6OS9"
FT   HELIX           98..127
FT                   /evidence="ECO:0000244|PDB:6OS9"
FT   TURN            131..133
FT                   /evidence="ECO:0000244|PDB:6OSA"
FT   HELIX           137..171
FT                   /evidence="ECO:0000244|PDB:6OS9"
FT   HELIX           173..179
FT                   /evidence="ECO:0000244|PDB:6OS9"
FT   HELIX           182..198
FT                   /evidence="ECO:0000244|PDB:6OS9"
FT   TURN            199..201
FT                   /evidence="ECO:0000244|PDB:6OS9"
FT   HELIX           202..205
FT                   /evidence="ECO:0000244|PDB:6OS9"
FT   STRAND          209..211
FT                   /evidence="ECO:0000244|PDB:6OS9"
FT   STRAND          213..216
FT                   /evidence="ECO:0000244|PDB:6OS9"
FT   STRAND          222..224
FT                   /evidence="ECO:0000244|PDB:6OS9"
FT   HELIX           230..244
FT                   /evidence="ECO:0000244|PDB:6OS9"
FT   HELIX           246..271
FT                   /evidence="ECO:0000244|PDB:6OS9"
FT   HELIX           296..328
FT                   /evidence="ECO:0000244|PDB:6OS9"
FT   TURN            331..333
FT                   /evidence="ECO:0000244|PDB:6OS9"
FT   HELIX           336..365
FT                   /evidence="ECO:0000244|PDB:6OS9"
FT   HELIX           366..368
FT                   /evidence="ECO:0000244|PDB:6OS9"
FT   HELIX           371..374
FT                   /evidence="ECO:0000244|PDB:6OS9"
SQ   SEQUENCE   418 AA;  46259 MW;  471AD1C49D29C2C8 CRC64;
     MRLNSSAPGT PGTPAADPFQ RAQAGLEEAL LAPGFGNASG NASERVLAAP SSELDVNTDI
     YSKVLVTAVY LALFVVGTVG NTVTAFTLAR KKSLQSLQST VHYHLGSLAL SDLLTLLLAM
     PVELYNFIWV HHPWAFGDAG CRGYYFLRDA CTYATALNVA SLSVERYLAI CHPFKAKTLM
     SRSRTKKFIS AIWLASALLA VPMLFTMGEQ NRSADGQHAG GLVCTPTIHT ATVKVVIQVN
     TFMSFIFPMV VISVLNTIIA NKLTVMVRQA AEQGQVCTVG GEHSTFSMAI EPGRVQALRH
     GVRVLRAVVI AFVVCWLPYH VRRLMFCYIS DEQWTPFLYD FYHYFYMVTN ALFYVSSTIN
     PILYNLVSAN FRHIFLATLA CLCPVWRRRR KRPAFSRKAD SVSSNHTLSS NATRETLY
//
ID   5HT2B_HUMAN             Reviewed;         481 AA.
AC   P41595; B2R9D5; Q53TI1; Q62221; Q6P523;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   12-AUG-2020, entry version 193.
DE   RecName: Full=5-hydroxytryptamine receptor 2B;
DE            Short=5-HT-2B;
DE            Short=5-HT2B;
DE   AltName: Full=Serotonin receptor 2B;
GN   Name=HTR2B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=8143856; DOI=10.1016/0014-5793(94)80590-3;
RA   Schmuck K., Ullmer C., Engels P., Luebbert H.;
RT   "Cloning and functional characterization of the human 5-HT2B serotonin
RT   receptor.";
RL   FEBS Lett. 342:85-90(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=7926008; DOI=10.1016/0014-5793(94)00968-6;
RA   Choi D.S., Birraux G., Launay J.-M., Maroteaux L.;
RT   "The human serotonin 5-HT2B receptor: pharmacological link between 5-HT2
RT   and 5-HT1D receptors.";
RL   FEBS Lett. 352:393-399(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Uterus;
RX   PubMed=8078486;
RA   Kursar J.D., Nelson D.L., Wainscott D.B., Baez M.;
RT   "Molecular cloning, functional expression, and mRNA tissue distribution of
RT   the human 5-hydroxytryptamine2B receptor.";
RL   Mol. Pharmacol. 46:227-234(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=10722792; DOI=10.1006/mcpr.1999.0281;
RA   Kim S.J., Veenstra-VanderWeele J., Hanna G.L., Gonen D., Leventhal B.L.,
RA   Cook E.H. Jr.;
RT   "Mutation screening of human 5-HT(2B) receptor gene in early-onset
RT   obsessive-compulsive disorder.";
RL   Mol. Cell. Probes 14:47-52(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Colon;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=8882600; DOI=10.1111/j.1476-5381.1996.tb16700.x;
RA   Ullmer C., Boddeke H.G., Schmuck K., Lubbert H.;
RT   "5-HT2B receptor-mediated calcium release from ryanodine-sensitive
RT   intracellular stores in human pulmonary artery endothelial cells.";
RL   Br. J. Pharmacol. 117:1081-1088(1996).
RN   [11]
RP   INTERACTION WITH MPDZ.
RX   PubMed=11150294; DOI=10.1074/jbc.m008089200;
RA   Becamel C., Figge A., Poliak S., Dumuis A., Peles E., Bockaert J.,
RA   Luebbert H., Ullmer C.;
RT   "Interaction of serotonin 5-hydroxytryptamine type 2C receptors with PDZ10
RT   of the multi-PDZ domain protein MUPP1.";
RL   J. Biol. Chem. 276:12974-12982(2001).
RN   [12]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12970106; DOI=10.1038/sj.bjp.0705437;
RA   Schaerlinger B., Hickel P., Etienne N., Guesnier L., Maroteaux L.;
RT   "Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and
RT   their possible relevance to antimigraine efficacy.";
RL   Br. J. Pharmacol. 140:277-284(2003).
RN   [13]
RP   REVIEW.
RX   PubMed=18476671; DOI=10.1021/cr078224o;
RA   Nichols D.E., Nichols C.D.;
RT   "Serotonin receptors.";
RL   Chem. Rev. 108:1614-1641(2008).
RN   [14]
RP   FUNCTION.
RX   PubMed=18703043; DOI=10.1016/j.ejphar.2008.07.040;
RA   Cussac D., Boutet-Robinet E., Ailhaud M.C., Newman-Tancredi A.,
RA   Martel J.C., Danty N., Rauly-Lestienne I.;
RT   "Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and
RT   5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in
RT   CHO cells.";
RL   Eur. J. Pharmacol. 594:32-38(2008).
RN   [15]
RP   FUNCTION, INVOLVEMENT IN IMPULSIVE BEHAVIOR, TISSUE SPECIFICITY,
RP   POLYMORPHISM, AND VARIANTS GLU-45; LEU-173 AND TRP-388.
RX   PubMed=21179162; DOI=10.1038/nature09629;
RA   Bevilacqua L., Doly S., Kaprio J., Yuan Q., Tikkanen R., Paunio T.,
RA   Zhou Z., Wedenoja J., Maroteaux L., Diaz S., Belmer A., Hodgkinson C.A.,
RA   Dell'osso L., Suvisaari J., Coccaro E., Rose R.J., Peltonen L.,
RA   Virkkunen M., Goldman D.;
RT   "A population-specific HTR2B stop codon predisposes to severe
RT   impulsivity.";
RL   Nature 468:1061-1066(2010).
RN   [16]
RP   REVIEW.
RX   PubMed=20945968; DOI=10.33549/physiolres.931903;
RA   Pytliak M., Vargova V., Mechirova V., Felsoci M.;
RT   "Serotonin receptors - from molecular biology to clinical applications.";
RL   Physiol. Res. 60:15-25(2011).
RN   [17]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF LEU-132; ASP-135;
RP   VAL-136; SER-139; THR-140; VAL-208; LEU-209; LYS-211; PHE-217; MET-218;
RP   ALA-225; TRP-337; PHE-340; ASN-344; LEU-347; VAL-348; LEU-362; GLU-363;
RP   VAL-366 AND TYR-370.
RX   PubMed=23519210; DOI=10.1126/science.1232807;
RA   Wang C., Jiang Y., Ma J., Wu H., Wacker D., Katritch V., Han G.W., Liu W.,
RA   Huang X.P., Vardy E., McCorvy J.D., Gao X., Zhou X.E., Melcher K.,
RA   Zhang C., Bai F., Yang H., Yang L., Jiang H., Roth B.L., Cherezov V.,
RA   Stevens R.C., Xu H.E.;
RT   "Structural basis for molecular recognition at serotonin receptors.";
RL   Science 340:610-614(2013).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 36-248 AND 314-405 IN COMPLEX WITH
RP   THE AGONIST ERGOTAMINE, FUNCTION, ROLE IN ARRESTIN-MEDIATED SIGNALING AND
RP   CALCIUM RELEASE, SUBCELLULAR LOCATION, MEMBRANE TOPOLOGY, AND DISULFIDE
RP   BONDS.
RX   PubMed=23519215; DOI=10.1126/science.1232808;
RA   Wacker D., Wang C., Katritch V., Han G.W., Huang X.P., Vardy E.,
RA   McCorvy J.D., Jiang Y., Chu M., Siu F.Y., Liu W., Xu H.E., Cherezov V.,
RA   Roth B.L., Stevens R.C.;
RT   "Structural features for functional selectivity at serotonin receptors.";
RL   Science 340:615-619(2013).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 36-248 AND 314-405 IN COMPLEX
RP   WITH ERGOTAMINE, FUNCTION, DISULFIDE BONDS, AND TOPOLOGY.
RX   PubMed=24357322; DOI=10.1126/science.1244142;
RA   Liu W., Wacker D., Gati C., Han G.W., James D., Wang D., Nelson G.,
RA   Weierstall U., Katritch V., Barty A., Zatsepin N.A., Li D.,
RA   Messerschmidt M., Boutet S., Williams G.J., Koglin J.E., Seibert M.M.,
RA   Wang C., Shah S.T., Basu S., Fromme R., Kupitz C., Rendek K.N.,
RA   Grotjohann I., Fromme P., Kirian R.A., Beyerlein K.R., White T.A.,
RA   Chapman H.N., Caffrey M., Spence J.C., Stevens R.C., Cherezov V.;
RT   "Serial femtosecond crystallography of G protein-coupled receptors.";
RL   Science 342:1521-1524(2013).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 41-248 AND 314-400 IN COMPLEX
RP   WITH LYSERGIC ACID DIETHYLAMIDE, FUNCTION, DISULFIDE BONDS, SUBCELLULAR
RP   LOCATION, TOPOLOGY, AND MUTAGENESIS OF LEU-209.
RX   PubMed=28129538; DOI=10.1016/j.cell.2016.12.033;
RA   Wacker D., Wang S., McCorvy J.D., Betz R.M., Venkatakrishnan A.J.,
RA   Levit A., Lansu K., Schools Z.L., Che T., Nichols D.E., Shoichet B.K.,
RA   Dror R.O., Roth B.L.;
RT   "Crystal structure of an LSD-bound human serotonin receptor.";
RL   Cell 168:377-389(2017).
CC   -!- FUNCTION: G-protein coupled receptor for 5-hydroxytryptamine
CC       (serotonin) (PubMed:8143856, PubMed:7926008, PubMed:8078486,
CC       PubMed:8882600, PubMed:18703043, PubMed:23519210). Also functions as a
CC       receptor for various ergot alkaloid derivatives and psychoactive
CC       substances (PubMed:8143856, PubMed:7926008, PubMed:8078486,
CC       PubMed:12970106, PubMed:18703043, PubMed:23519210, PubMed:23519215,
CC       PubMed:24357322, PubMed:28129538). Ligand binding causes a conformation
CC       change that triggers signaling via guanine nucleotide-binding proteins
CC       (G proteins) and modulates the activity of down-stream effectors
CC       (PubMed:8143856, PubMed:8078486, PubMed:8882600, PubMed:23519215,
CC       PubMed:28129538). Beta-arrestin family members inhibit signaling via G
CC       proteins and mediate activation of alternative signaling pathways
CC       (PubMed:23519215, PubMed:28129538). Signaling activates a
CC       phosphatidylinositol-calcium second messenger system that modulates the
CC       activity of phosphatidylinositol 3-kinase and down-stream signaling
CC       cascades and promotes the release of Ca(2+) ions from intracellular
CC       stores (PubMed:8143856, PubMed:8078486, PubMed:8882600,
CC       PubMed:18703043, PubMed:23519215, PubMed:28129538). Plays a role in the
CC       regulation of dopamine and 5-hydroxytryptamine release, 5-
CC       hydroxytryptamine uptake and in the regulation of extracellular
CC       dopamine and 5-hydroxytryptamine levels, and thereby affects neural
CC       activity. May play a role in the perception of pain (By similarity).
CC       Plays a role in the regulation of behavior, including impulsive
CC       behavior (PubMed:21179162). Required for normal proliferation of
CC       embryonic cardiac myocytes and normal heart development. Protects
CC       cardiomyocytes against apoptosis. Plays a role in the adaptation of
CC       pulmonary arteries to chronic hypoxia. Plays a role in
CC       vasoconstriction. Required for normal osteoblast function and
CC       proliferation, and for maintaining normal bone density. Required for
CC       normal proliferation of the interstitial cells of Cajal in the
CC       intestine (By similarity). {ECO:0000250|UniProtKB:P30994,
CC       ECO:0000250|UniProtKB:Q02152, ECO:0000269|PubMed:12970106,
CC       ECO:0000269|PubMed:18703043, ECO:0000269|PubMed:21179162,
CC       ECO:0000269|PubMed:23519210, ECO:0000269|PubMed:23519215,
CC       ECO:0000269|PubMed:24357322, ECO:0000269|PubMed:28129538,
CC       ECO:0000269|PubMed:7926008, ECO:0000269|PubMed:8078486,
CC       ECO:0000269|PubMed:8143856, ECO:0000269|PubMed:8882600}.
CC   -!- SUBUNIT: Interacts (via C-terminus) with MPDZ.
CC       {ECO:0000269|PubMed:11150294}.
CC   -!- INTERACTION:
CC       P41595; P28223: HTR2A; NbExp=3; IntAct=EBI-7474947, EBI-6656333;
CC       P41595; P28335: HTR2C; NbExp=4; IntAct=EBI-7474947, EBI-994141;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:12970106,
CC       ECO:0000269|PubMed:23519210, ECO:0000269|PubMed:23519215,
CC       ECO:0000269|PubMed:28129538, ECO:0000269|PubMed:7926008,
CC       ECO:0000269|PubMed:8078486, ECO:0000269|PubMed:8143856}; Multi-pass
CC       membrane protein {ECO:0000269|PubMed:23519215,
CC       ECO:0000269|PubMed:24357322, ECO:0000269|PubMed:28129538}. Cell
CC       junction, synapse, synaptosome {ECO:0000250|UniProtKB:Q02152}.
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Detected in liver, kidney, heart,
CC       pulmonary artery, and intestine. Detected at lower levels in blood,
CC       placenta and brain, especially in cerebellum, occipital cortex and
CC       frontal cortex. {ECO:0000269|PubMed:21179162,
CC       ECO:0000269|PubMed:7926008, ECO:0000269|PubMed:8078486,
CC       ECO:0000269|PubMed:8143856, ECO:0000269|PubMed:8882600}.
CC   -!- DOMAIN: Ligands are bound in a hydrophobic pocket formed by the
CC       transmembrane helices. {ECO:0000269|PubMed:23519215,
CC       ECO:0000269|PubMed:24357322, ECO:0000269|PubMed:28129538}.
CC   -!- POLYMORPHISM: A variation at a single nucleotide base, which results in
CC       an erroneous stop codon and affects Gln-20, triggers non-sense mediated
CC       RNA decay, such that no HTR2B-receptor protein is expressed. It is
CC       associated with impulsive behavior and co-segregates with disorders
CC       characterized by impulsivity. However, the presence of this variant is
CC       not in itself sufficient to cause impulsive behavior: male sex,
CC       testosterone level, alcohol and stress exposure are other factors
CC       playing important roles. {ECO:0000269|PubMed:21179162}.
CC   -!- MISCELLANEOUS: Binds lysergic acid diethylamine (LSD) in the
CC       orthosteric pocket, but is not the principal LSD receptor in the brain.
CC       Bound LSD dissociates extremely slowly, with a residence time of about
CC       46 minutes at 37 degrees Celsius. {ECO:0000269|PubMed:28129538}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=On the spur of a whim
CC       - Issue 127 of March 2011;
CC       URL="https://web.expasy.org/spotlight/back_issues/127";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X77307; CAA54513.1; -; mRNA.
DR   EMBL; Z36748; CAA85319.1; -; mRNA.
DR   EMBL; AF156160; AAD39259.1; -; Genomic_DNA.
DR   EMBL; AF156158; AAD39259.1; JOINED; Genomic_DNA.
DR   EMBL; AF156159; AAD39259.1; JOINED; Genomic_DNA.
DR   EMBL; AY136751; AAN01277.1; -; mRNA.
DR   EMBL; AC009407; AAX93128.1; -; Genomic_DNA.
DR   EMBL; AK313741; BAG36482.1; -; mRNA.
DR   EMBL; CH471063; EAW70949.1; -; Genomic_DNA.
DR   EMBL; BC063123; AAH63123.1; -; mRNA.
DR   CCDS; CCDS2483.1; -.
DR   PIR; S43687; S43687.
DR   PIR; S49442; S49442.
DR   RefSeq; NP_000858.3; NM_000867.4.
DR   RefSeq; NP_001307687.1; NM_001320758.1.
DR   PDB; 4IB4; X-ray; 2.70 A; A=36-248, A=314-405.
DR   PDB; 4NC3; X-ray; 2.80 A; A=36-248, A=314-405.
DR   PDB; 5TUD; X-ray; 3.00 A; A/D=36-248, A/D=314-405.
DR   PDB; 5TVN; X-ray; 2.90 A; A=41-248, A=313-400.
DR   PDB; 6DRX; X-ray; 3.10 A; A=36-248, A=314-404.
DR   PDB; 6DRY; X-ray; 2.92 A; A=36-248, A=313-404.
DR   PDB; 6DRZ; X-ray; 3.10 A; A=36-248, A=313-404.
DR   PDB; 6DS0; X-ray; 3.19 A; A=36-248, A=314-404.
DR   PDBsum; 4IB4; -.
DR   PDBsum; 4NC3; -.
DR   PDBsum; 5TUD; -.
DR   PDBsum; 5TVN; -.
DR   PDBsum; 6DRX; -.
DR   PDBsum; 6DRY; -.
DR   PDBsum; 6DRZ; -.
DR   PDBsum; 6DS0; -.
DR   SMR; P41595; -.
DR   BioGRID; 109589; 3.
DR   IntAct; P41595; 27.
DR   MINT; P41595; -.
DR   STRING; 9606.ENSP00000258400; -.
DR   BindingDB; P41595; -.
DR   ChEMBL; CHEMBL1833; -.
DR   DrugBank; DB00543; Amoxapine.
DR   DrugBank; DB00714; Apomorphine.
DR   DrugBank; DB01238; Aripiprazole.
DR   DrugBank; DB06216; Asenapine.
DR   DrugBank; DB01200; Bromocriptine.
DR   DrugBank; DB00248; Cabergoline.
DR   DrugBank; DB06016; Cariprazine.
DR   DrugBank; DB00477; Chlorpromazine.
DR   DrugBank; DB01239; Chlorprothixene.
DR   DrugBank; DB01242; Clomipramine.
DR   DrugBank; DB00924; Cyclobenzaprine.
DR   DrugBank; DB11273; Dihydroergocornine.
DR   DrugBank; DB13345; Dihydroergocristine.
DR   DrugBank; DB00320; Dihydroergotamine.
DR   DrugBank; DB01142; Doxepin.
DR   DrugBank; DB00216; Eletriptan.
DR   DrugBank; DB05492; Epicept NP-1.
DR   DrugBank; DB01049; Ergoloid mesylate.
DR   DrugBank; DB00696; Ergotamine.
DR   DrugBank; DB06678; Esmirtazapine.
DR   DrugBank; DB00574; Fenfluramine.
DR   DrugBank; DB12141; Gilteritinib.
DR   DrugBank; DB01221; Ketamine.
DR   DrugBank; DB00589; Lisuride.
DR   DrugBank; DB04829; Lysergic acid diethylamide.
DR   DrugBank; DB00353; Methylergometrine.
DR   DrugBank; DB00247; Methysergide.
DR   DrugBank; DB06148; Mianserin.
DR   DrugBank; DB01454; Midomafetamine.
DR   DrugBank; DB00805; Minaprine.
DR   DrugBank; DB06229; Ocaperidone.
DR   DrugBank; DB05461; OPC-28326.
DR   DrugBank; DB00715; Paroxetine.
DR   DrugBank; DB01186; Pergolide.
DR   DrugBank; DB09286; Pipamperone.
DR   DrugBank; DB06153; Pizotifen.
DR   DrugBank; DB05607; PRX-08066.
DR   DrugBank; DB09304; Setiptiline.
DR   DrugBank; DB01079; Tegaserod.
DR   DrugBank; DB13025; Tiapride.
DR   DrugBank; DB00508; Triflupromazine.
DR   DrugBank; DB01392; Yohimbine.
DR   DrugCentral; P41595; -.
DR   GuidetoPHARMACOLOGY; 7; -.
DR   TCDB; 9.A.14.3.7; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; P41595; 1 site.
DR   iPTMnet; P41595; -.
DR   PhosphoSitePlus; P41595; -.
DR   BioMuta; HTR2B; -.
DR   DMDM; 1168220; -.
DR   MassIVE; P41595; -.
DR   PaxDb; P41595; -.
DR   PRIDE; P41595; -.
DR   ProteomicsDB; 55473; -.
DR   ABCD; P41595; 1 sequenced antibody.
DR   Antibodypedia; 2921; 384 antibodies.
DR   DNASU; 3357; -.
DR   Ensembl; ENST00000258400; ENSP00000258400; ENSG00000135914.
DR   GeneID; 3357; -.
DR   KEGG; hsa:3357; -.
DR   UCSC; uc002vro.4; human.
DR   CTD; 3357; -.
DR   DisGeNET; 3357; -.
DR   EuPathDB; HostDB:ENSG00000135914.5; -.
DR   GeneCards; HTR2B; -.
DR   HGNC; HGNC:5294; HTR2B.
DR   HPA; ENSG00000135914; Tissue enhanced (placenta).
DR   MIM; 601122; gene.
DR   neXtProt; NX_P41595; -.
DR   OpenTargets; ENSG00000135914; -.
DR   PharmGKB; PA29554; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00960000186619; -.
DR   HOGENOM; CLU_009579_11_3_1; -.
DR   InParanoid; P41595; -.
DR   KO; K04157; -.
DR   OMA; YITCNYQ; -.
DR   OrthoDB; 962038at2759; -.
DR   PhylomeDB; P41595; -.
DR   TreeFam; TF316350; -.
DR   PathwayCommons; P41595; -.
DR   Reactome; R-HSA-390666; Serotonin receptors.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   SIGNOR; P41595; -.
DR   BioGRID-ORCS; 3357; 6 hits in 871 CRISPR screens.
DR   GeneWiki; 5-HT2B_receptor; -.
DR   GenomeRNAi; 3357; -.
DR   Pharos; P41595; Tclin.
DR   PRO; PR:P41595; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; P41595; protein.
DR   Bgee; ENSG00000135914; Expressed in decidua and 139 other tissues.
DR   Genevisible; P41595; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0030425; C:dendrite; IBA:GO_Central.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0045202; C:synapse; IEA:UniProtKB-KW.
DR   GO; GO:0008144; F:drug binding; IDA:UniProtKB.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0004993; F:G protein-coupled serotonin receptor activity; IDA:UniProtKB.
DR   GO; GO:0001965; F:G-protein alpha-subunit binding; IMP:UniProtKB.
DR   GO; GO:0005096; F:GTPase activator activity; ISS:UniProtKB.
DR   GO; GO:0030594; F:neurotransmitter receptor activity; IBA:GO_Central.
DR   GO; GO:0051378; F:serotonin binding; IDA:UniProtKB.
DR   GO; GO:0007202; P:activation of phospholipase C activity; IDA:UniProtKB.
DR   GO; GO:0007610; P:behavior; IEA:UniProtKB-KW.
DR   GO; GO:0019722; P:calcium-mediated signaling; IMP:UniProtKB.
DR   GO; GO:0003300; P:cardiac muscle hypertrophy; ISS:UniProtKB.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IDA:UniProtKB.
DR   GO; GO:0071502; P:cellular response to temperature stimulus; ISS:UniProtKB.
DR   GO; GO:0019934; P:cGMP-mediated signaling; IDA:UniProtKB.
DR   GO; GO:0007268; P:chemical synaptic transmission; IBA:GO_Central.
DR   GO; GO:0048598; P:embryonic morphogenesis; ISS:UniProtKB.
DR   GO; GO:0070371; P:ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0002031; P:G protein-coupled receptor internalization; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0007187; P:G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; IBA:GO_Central.
DR   GO; GO:0003007; P:heart morphogenesis; ISS:UniProtKB.
DR   GO; GO:0014827; P:intestine smooth muscle contraction; IMP:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISS:UniProtKB.
DR   GO; GO:0010507; P:negative regulation of autophagy; IMP:UniProtKB.
DR   GO; GO:0060548; P:negative regulation of cell death; IMP:UniProtKB.
DR   GO; GO:0014033; P:neural crest cell differentiation; ISS:UniProtKB.
DR   GO; GO:0001755; P:neural crest cell migration; ISS:UniProtKB.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; IDA:UniProtKB.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0016310; P:phosphorylation; IMP:UniProtKB.
DR   GO; GO:0051781; P:positive regulation of cell division; ISS:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:0001819; P:positive regulation of cytokine production; IDA:UniProtKB.
DR   GO; GO:0050715; P:positive regulation of cytokine secretion; ISS:UniProtKB.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0043123; P:positive regulation of I-kappaB kinase/NF-kappaB signaling; IEP:UniProtKB.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0051000; P:positive regulation of nitric-oxide synthase activity; IDA:UniProtKB.
DR   GO; GO:0010513; P:positive regulation of phosphatidylinositol biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0070528; P:protein kinase C signaling; IMP:UniProtKB.
DR   GO; GO:0007205; P:protein kinase C-activating G protein-coupled receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0050795; P:regulation of behavior; IMP:UniProtKB.
DR   GO; GO:0051209; P:release of sequestered calcium ion into cytosol; IDA:UniProtKB.
DR   GO; GO:0042493; P:response to drug; IDA:UniProtKB.
DR   GO; GO:0007210; P:serotonin receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0042310; P:vasoconstriction; IMP:UniProtKB.
DR   InterPro; IPR000482; 5HT2B_rcpt.
DR   InterPro; IPR002231; 5HT_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   PANTHER; PTHR24247:SF31; PTHR24247:SF31; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00651; 5HT2BRECEPTR.
DR   PRINTS; PR01101; 5HTRECEPTOR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Behavior; Cell junction; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane; Palmitate;
KW   Polymorphism; Receptor; Reference proteome; Synapse; Synaptosome;
KW   Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..481
FT                   /note="5-hydroxytryptamine receptor 2B"
FT                   /id="PRO_0000068953"
FT   TOPO_DOM        1..56
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:23519215,
FT                   ECO:0000269|PubMed:24357322, ECO:0000269|PubMed:28129538"
FT   TRANSMEM        57..79
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000269|PubMed:23519215,
FT                   ECO:0000269|PubMed:24357322, ECO:0000269|PubMed:28129538"
FT   TOPO_DOM        80..90
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:23519215,
FT                   ECO:0000269|PubMed:24357322, ECO:0000269|PubMed:28129538"
FT   TRANSMEM        91..113
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000269|PubMed:23519215,
FT                   ECO:0000269|PubMed:24357322, ECO:0000269|PubMed:28129538"
FT   TOPO_DOM        114..129
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:23519215,
FT                   ECO:0000269|PubMed:24357322, ECO:0000269|PubMed:28129538"
FT   TRANSMEM        130..151
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000269|PubMed:23519215,
FT                   ECO:0000269|PubMed:24357322, ECO:0000269|PubMed:28129538"
FT   TOPO_DOM        152..171
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:23519215,
FT                   ECO:0000269|PubMed:24357322, ECO:0000269|PubMed:28129538"
FT   TRANSMEM        172..192
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000269|PubMed:23519215,
FT                   ECO:0000269|PubMed:24357322, ECO:0000269|PubMed:28129538"
FT   TOPO_DOM        193..216
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:23519215,
FT                   ECO:0000269|PubMed:24357322, ECO:0000269|PubMed:28129538"
FT   TRANSMEM        217..239
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000269|PubMed:23519215,
FT                   ECO:0000269|PubMed:24357322, ECO:0000269|PubMed:28129538"
FT   TOPO_DOM        240..324
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:23519215,
FT                   ECO:0000269|PubMed:24357322, ECO:0000269|PubMed:28129538"
FT   TRANSMEM        325..345
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000269|PubMed:23519215,
FT                   ECO:0000269|PubMed:24357322, ECO:0000269|PubMed:28129538"
FT   TOPO_DOM        346..360
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:23519215,
FT                   ECO:0000269|PubMed:24357322, ECO:0000269|PubMed:28129538"
FT   TRANSMEM        361..382
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000269|PubMed:23519215,
FT                   ECO:0000269|PubMed:24357322, ECO:0000269|PubMed:28129538"
FT   TOPO_DOM        383..481
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:23519215,
FT                   ECO:0000269|PubMed:24357322, ECO:0000269|PubMed:28129538"
FT   REGION          135..140
FT                   /note="Agonist binding"
FT                   /evidence="ECO:0000244|PDB:4IB4, ECO:0000244|PDB:4NC3,
FT                   ECO:0000244|PDB:5TVN, ECO:0000269|PubMed:23519215,
FT                   ECO:0000269|PubMed:24357322, ECO:0000269|PubMed:28129538"
FT   REGION          337..341
FT                   /note="Agonist binding"
FT                   /evidence="ECO:0000244|PDB:4IB4, ECO:0000244|PDB:4NC3,
FT                   ECO:0000244|PDB:5TVN, ECO:0000269|PubMed:23519215,
FT                   ECO:0000269|PubMed:24357322, ECO:0000269|PubMed:28129538"
FT   MOTIF           152..154
FT                   /note="DRY motif; important for ligand-induced conformation
FT                   changes"
FT                   /evidence="ECO:0000305|PubMed:23519215,
FT                   ECO:0000305|PubMed:28129538"
FT   MOTIF           212..215
FT                   /note="[DE]RFG motif; may stabilize a conformation that
FT                   preferentially activates signaling via beta-arrestin family
FT                   members"
FT                   /evidence="ECO:0000305|PubMed:23519215,
FT                   ECO:0000305|PubMed:28129538"
FT   MOTIF           376..380
FT                   /note="NPxxY motif; important for ligand-induced
FT                   conformation changes and signaling"
FT                   /evidence="ECO:0000305|PubMed:23519215,
FT                   ECO:0000305|PubMed:28129538"
FT   MOTIF           479..481
FT                   /note="PDZ-binding"
FT                   /evidence="ECO:0000269|PubMed:11150294"
FT   SITE            209
FT                   /note="Hydrophobic barrier that decreases the speed of
FT                   ligand binding and dissociation"
FT                   /evidence="ECO:0000269|PubMed:28129538"
FT   LIPID           397
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        30
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        128..207
FT                   /evidence="ECO:0000244|PDB:4IB4, ECO:0000244|PDB:4NC3,
FT                   ECO:0000244|PDB:5TVN, ECO:0000255|PROSITE-ProRule:PRU00521,
FT                   ECO:0000269|PubMed:23519215, ECO:0000269|PubMed:24357322,
FT                   ECO:0000269|PubMed:28129538"
FT   DISULFID        350..353
FT                   /evidence="ECO:0000244|PDB:4IB4, ECO:0000244|PDB:4NC3,
FT                   ECO:0000244|PDB:5TVN, ECO:0000255|PROSITE-ProRule:PRU00521,
FT                   ECO:0000269|PubMed:23519215, ECO:0000269|PubMed:24357322,
FT                   ECO:0000269|PubMed:28129538"
FT   VARIANT         45
FT                   /note="Q -> E (in dbSNP:rs78484969)"
FT                   /evidence="ECO:0000269|PubMed:21179162"
FT                   /id="VAR_064574"
FT   VARIANT         173
FT                   /note="F -> L (in dbSNP:rs77570025)"
FT                   /evidence="ECO:0000269|PubMed:21179162"
FT                   /id="VAR_064575"
FT   VARIANT         388
FT                   /note="R -> W (in dbSNP:rs77982984)"
FT                   /evidence="ECO:0000269|PubMed:21179162"
FT                   /id="VAR_064576"
FT   VARIANT         421
FT                   /note="M -> V (in dbSNP:rs6736017)"
FT                   /id="VAR_055907"
FT   MUTAGEN         132
FT                   /note="L->A: No effect on agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         135
FT                   /note="D->A: Abolishes agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         136
FT                   /note="V->A: Slightly decreases agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         139
FT                   /note="S->A: Slightly decreases agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         140
FT                   /note="T->A: Slightly decreases agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         208
FT                   /note="V->A: No effect on agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         209
FT                   /note="L->A: No effect on agonist binding. Strongly
FT                   increases dissociation of bound lysergic acid diethylamine,
FT                   without affecting binding affinity. Reduces signaling via
FT                   arrestins, but has no effect on signaling via the
FT                   phosphatidylinositol-calcium second messenger system."
FT                   /evidence="ECO:0000269|PubMed:23519210,
FT                   ECO:0000269|PubMed:28129538"
FT   MUTAGEN         211
FT                   /note="K->A: Impairs protein folding and stability.
FT                   Strongly reduced cell surface expression."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         217
FT                   /note="F->A: Slightly decreases agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         218
FT                   /note="M->A: No effect on agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         225
FT                   /note="A->S: No effect on agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         337
FT                   /note="W->A: Slightly decreases agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         340
FT                   /note="F->A: Slightly decreases agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         344
FT                   /note="N->A: Slightly decreases agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         347
FT                   /note="L->A: No effect on agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         348
FT                   /note="V->A: No effect on agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         362
FT                   /note="L->A: No effect on agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         363
FT                   /note="E->A: No effect on agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         366
FT                   /note="V->A: No effect on agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         370
FT                   /note="Y->A: Slightly decreases agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   CONFLICT        452
FT                   /note="T -> P (in Ref. 2; CAA85319)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        477
FT                   /note="Q -> R (in Ref. 9; AAH63123)"
FT                   /evidence="ECO:0000305"
FT   HELIX           40..49
FT                   /evidence="ECO:0000244|PDB:6DRZ"
FT   HELIX           54..63
FT                   /evidence="ECO:0000244|PDB:4IB4"
FT   HELIX           65..81
FT                   /evidence="ECO:0000244|PDB:4IB4"
FT   HELIX           83..85
FT                   /evidence="ECO:0000244|PDB:4IB4"
FT   HELIX           88..106
FT                   /evidence="ECO:0000244|PDB:4IB4"
FT   HELIX           108..111
FT                   /evidence="ECO:0000244|PDB:4IB4"
FT   HELIX           113..116
FT                   /evidence="ECO:0000244|PDB:4IB4"
FT   HELIX           127..158
FT                   /evidence="ECO:0000244|PDB:4IB4"
FT   STRAND          159..161
FT                   /evidence="ECO:0000244|PDB:6DRX"
FT   HELIX           165..187
FT                   /evidence="ECO:0000244|PDB:4IB4"
FT   HELIX           189..193
FT                   /evidence="ECO:0000244|PDB:4IB4"
FT   STRAND          195..198
FT                   /evidence="ECO:0000244|PDB:5TUD"
FT   HELIX           202..204
FT                   /evidence="ECO:0000244|PDB:5TUD"
FT   HELIX           211..225
FT                   /evidence="ECO:0000244|PDB:4IB4"
FT   HELIX           227..248
FT                   /evidence="ECO:0000244|PDB:4IB4"
FT   HELIX           314..349
FT                   /evidence="ECO:0000244|PDB:4IB4"
FT   STRAND          351..353
FT                   /evidence="ECO:0000244|PDB:4IB4"
FT   HELIX           355..381
FT                   /evidence="ECO:0000244|PDB:4IB4"
FT   HELIX           385..394
FT                   /evidence="ECO:0000244|PDB:4IB4"
FT   TURN            395..397
FT                   /evidence="ECO:0000244|PDB:4IB4"
SQ   SEQUENCE   481 AA;  54298 MW;  CDA4447ECDBA3B46 CRC64;
     MALSYRVSEL QSTIPEHILQ STFVHVISSN WSGLQTESIP EEMKQIVEEQ GNKLHWAALL
     ILMVIIPTIG GNTLVILAVS LEKKLQYATN YFLMSLAVAD LLVGLFVMPI ALLTIMFEAM
     WPLPLVLCPA WLFLDVLFST ASIMHLCAIS VDRYIAIKKP IQANQYNSRA TAFIKITVVW
     LISIGIAIPV PIKGIETDVD NPNNITCVLT KERFGDFMLF GSLAAFFTPL AIMIVTYFLT
     IHALQKKAYL VKNKPPQRLT WLTVSTVFQR DETPCSSPEK VAMLDGSRKD KALPNSGDET
     LMRRTSTIGK KSVQTISNEQ RASKVLGIVF FLFLLMWCPF FITNITLVLC DSCNQTTLQM
     LLEIFVWIGY VSSGVNPLVY TLFNKTFRDA FGRYITCNYR ATKSVKTLRK RSSKIYFRNP
     MAENSKFFKK HGIRNGINPA MYQSPMRLRS STIQSSSIIL LDTLLLTENE GDKTEEQVSY
     V
//
ID   PACR_HUMAN              Reviewed;         468 AA.
AC   P41586; A8K1Y1; B7ZLA7; B8ZZK3; Q17S10;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   07-OCT-2020, entry version 187.
DE   RecName: Full=Pituitary adenylate cyclase-activating polypeptide type I receptor;
DE            Short=PACAP type I receptor;
DE            Short=PACAP-R-1;
DE            Short=PACAP-R1;
DE   Flags: Precursor;
GN   Name=ADCYAP1R1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM N).
RC   TISSUE=Pituitary;
RX   PubMed=7902709; DOI=10.1006/bbrc.1993.2423;
RA   Ogi K., Miyamoto Y., Masuda Y., Habata Y., Hosoya M., Ohtaki T., Masuo Y.,
RA   Onda H., Fujino M.;
RT   "Molecular cloning and functional expression of a cDNA encoding a human
RT   pituitary adenylate cyclase activating polypeptide receptor.";
RL   Biochem. Biophys. Res. Commun. 196:1511-1521(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Suwa M., Sato T., Okouchi I., Arita M., Futami K., Matsumoto S.,
RA   Tsutsumi S., Aburatani H., Asai K., Akiyama Y.;
RT   "Genome-wide discovery and analysis of human seven transmembrane helix
RT   receptor genes.";
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM N).
RC   TISSUE=Brain;
RA   King M., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (AUG-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM N).
RC   TISSUE=Hippocampus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM N-HOP1).
RC   TISSUE=Brain, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 418-468.
RC   TISSUE=Placenta;
RX   PubMed=7851900; DOI=10.1006/geno.1994.1560;
RA   Stoffel M., Espinosa R., Trabb J.B., le Beau M.M., Bell G.I.;
RT   "Human type I pituitary adenylate cyclase activating polypeptide receptor
RT   (ADCYAP1R): localization to chromosome band 7p14 and integration into the
RT   cytogenetic, physical and genetic map of chromosome 7.";
RL   Genomics 23:697-699(1994).
RN   [9]
RP   ALTERNATIVE SPLICING.
RX   PubMed=10583729; DOI=10.1046/j.1365-2826.1999.00411.x;
RA   Dautzenberg F.M., Mevenkamp G., Wille S., Hauger R.L.;
RT   "N-terminal splice variants of the type I PACAP receptor: isolation,
RT   characterization and ligand binding/selectivity determinants.";
RL   J. Neuroendocrinol. 11:941-949(1999).
RN   [10]
RP   STRUCTURE BY NMR OF 22-143 IN COMPLEX WITH ADCYAP1, MUTAGENESIS OF VAL-114;
RP   GLU-125; PRO-128; GLU-138 AND TYR-139, AND DISULFIDE BONDS.
RX   PubMed=17470806; DOI=10.1073/pnas.0611397104;
RA   Sun C., Song D., Davis-Taber R.A., Barrett L.W., Scott V.E.,
RA   Richardson P.L., Pereda-Lopez A., Uchic M.E., Solomon L.R., Lake M.R.,
RA   Walter K.A., Hajduk P.J., Olejniczak E.T.;
RT   "Solution structure and mutational analysis of pituitary adenylate cyclase-
RT   activating polypeptide binding to the extracellular domain of PAC1-RS.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:7875-7880(2007).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 26-140, MUTAGENESIS OF GLU-125,
RP   AND DISULFIDE BONDS.
RX   PubMed=21625560; DOI=10.1371/journal.pone.0019682;
RA   Kumar S., Pioszak A., Zhang C., Swaminathan K., Xu H.E.;
RT   "Crystal structure of the PAC1R extracellular domain unifies a consensus
RT   fold for hormone recognition by class B G-protein coupled receptors.";
RL   PLoS ONE 6:E19682-E19682(2011).
CC   -!- FUNCTION: This is a receptor for PACAP-27 and PACAP-38. The activity of
CC       this receptor is mediated by G proteins which activate adenylyl
CC       cyclase. May regulate the release of adrenocorticotropin, luteinizing
CC       hormone, growth hormone, prolactin, epinephrine, and catecholamine. May
CC       play a role in spermatogenesis and sperm motility. Causes smooth muscle
CC       relaxation and secretion in the gastrointestinal tract.
CC   -!- SUBUNIT: Interacts (via N-terminal extracellular domain) with ADCYAP1.
CC       {ECO:0000269|PubMed:17470806}.
CC   -!- INTERACTION:
CC       P41586-2; Q96MV8: ZDHHC15; NbExp=3; IntAct=EBI-17241711, EBI-12837904;
CC       P41586-3; P18509: ADCYAP1; NbExp=2; IntAct=EBI-15635217, EBI-8588930;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=N;
CC         IsoId=P41586-1; Sequence=Displayed;
CC       Name=N-HOP1;
CC         IsoId=P41586-2; Sequence=VSP_042671;
CC       Name=S;
CC         IsoId=P41586-3; Sequence=VSP_042670;
CC       Name=S-HOP1;
CC         IsoId=P41586-4; Sequence=VSP_042670, VSP_042671;
CC       Name=VS;
CC         IsoId=P41586-5; Sequence=VSP_042669, VSP_042670;
CC   -!- TISSUE SPECIFICITY: Most abundant in the brain, low expression in the
CC       lung, liver, thymus, spleen, pancreas and placenta.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 2 family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA04466.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D17516; BAA04466.1; ALT_INIT; mRNA.
DR   EMBL; AB065700; BAC05923.1; -; Genomic_DNA.
DR   EMBL; AY366498; AAQ72806.1; -; mRNA.
DR   EMBL; AK290046; BAF82735.1; -; mRNA.
DR   EMBL; AC006466; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC117116; AAI17117.1; -; mRNA.
DR   EMBL; BC136267; AAI36268.1; -; mRNA.
DR   EMBL; BC143679; AAI43680.1; -; mRNA.
DR   EMBL; CH471073; EAW93978.1; -; Genomic_DNA.
DR   EMBL; U09216; AAA19323.1; -; Genomic_DNA.
DR   CCDS; CCDS5433.1; -. [P41586-1]
DR   CCDS; CCDS56480.1; -. [P41586-2]
DR   CCDS; CCDS56481.1; -. [P41586-3]
DR   PIR; JN0902; JN0902.
DR   RefSeq; NP_001109.2; NM_001118.4. [P41586-1]
DR   RefSeq; NP_001186564.1; NM_001199635.1. [P41586-2]
DR   RefSeq; NP_001186565.1; NM_001199636.1.
DR   RefSeq; NP_001186566.1; NM_001199637.1. [P41586-3]
DR   RefSeq; XP_005249675.1; XM_005249618.4. [P41586-5]
DR   RefSeq; XP_016867226.1; XM_017011737.1. [P41586-4]
DR   PDB; 2JOD; NMR; -; A=22-143.
DR   PDB; 3N94; X-ray; 1.80 A; A=26-140.
DR   PDB; 6LPB; EM; 3.90 A; R=21-417.
DR   PDB; 6M1H; EM; 3.60 A; A=23-438.
DR   PDB; 6M1I; EM; 3.50 A; A=23-438.
DR   PDB; 6P9Y; EM; 3.01 A; R=19-468.
DR   PDBsum; 2JOD; -.
DR   PDBsum; 3N94; -.
DR   PDBsum; 6LPB; -.
DR   PDBsum; 6M1H; -.
DR   PDBsum; 6M1I; -.
DR   PDBsum; 6P9Y; -.
DR   SMR; P41586; -.
DR   BioGRID; 106630; 3.
DR   DIP; DIP-42467N; -.
DR   IntAct; P41586; 2.
DR   MINT; P41586; -.
DR   STRING; 9606.ENSP00000483721; -.
DR   BindingDB; P41586; -.
DR   ChEMBL; CHEMBL5399; -.
DR   GuidetoPHARMACOLOGY; 370; -.
DR   TCDB; 9.A.14.4.8; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; P41586; 5 sites.
DR   iPTMnet; P41586; -.
DR   PhosphoSitePlus; P41586; -.
DR   BioMuta; ADCYAP1R1; -.
DR   DMDM; 1171986; -.
DR   MassIVE; P41586; -.
DR   MaxQB; P41586; -.
DR   PeptideAtlas; P41586; -.
DR   PRIDE; P41586; -.
DR   ProteomicsDB; 55465; -. [P41586-1]
DR   ProteomicsDB; 55466; -. [P41586-2]
DR   ProteomicsDB; 55467; -. [P41586-3]
DR   ProteomicsDB; 55468; -. [P41586-4]
DR   ProteomicsDB; 55469; -. [P41586-5]
DR   ABCD; P41586; 41 sequenced antibodies.
DR   Antibodypedia; 4280; 280 antibodies.
DR   DNASU; 117; -.
DR   Ensembl; ENST00000304166; ENSP00000306620; ENSG00000078549. [P41586-1]
DR   Ensembl; ENST00000396211; ENSP00000379514; ENSG00000078549. [P41586-2]
DR   Ensembl; ENST00000409363; ENSP00000387335; ENSG00000078549. [P41586-3]
DR   Ensembl; ENST00000614107; ENSP00000483721; ENSG00000078549. [P41586-2]
DR   GeneID; 117; -.
DR   KEGG; hsa:117; -.
DR   UCSC; uc003tca.3; human. [P41586-1]
DR   CTD; 117; -.
DR   DisGeNET; 117; -.
DR   EuPathDB; HostDB:ENSG00000078549.14; -.
DR   GeneCards; ADCYAP1R1; -.
DR   HGNC; HGNC:242; ADCYAP1R1.
DR   HPA; ENSG00000078549; Tissue enhanced (brain, fallopian tube).
DR   MIM; 102981; gene.
DR   neXtProt; NX_P41586; -.
DR   OpenTargets; ENSG00000078549; -.
DR   PharmGKB; PA24565; -.
DR   eggNOG; KOG4564; Eukaryota.
DR   GeneTree; ENSGT00940000157362; -.
DR   HOGENOM; CLU_002753_4_4_1; -.
DR   InParanoid; P41586; -.
DR   KO; K04587; -.
DR   OrthoDB; 651627at2759; -.
DR   PhylomeDB; P41586; -.
DR   TreeFam; TF315710; -.
DR   PathwayCommons; P41586; -.
DR   Reactome; R-HSA-187024; NGF-independant TRKA activation.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-420092; Glucagon-type ligand receptors.
DR   Reactome; R-HSA-9660821; ADORA2B mediated anti-inflammatory cytokines production.
DR   SIGNOR; P41586; -.
DR   BioGRID-ORCS; 117; 4 hits in 866 CRISPR screens.
DR   ChiTaRS; ADCYAP1R1; human.
DR   EvolutionaryTrace; P41586; -.
DR   GeneWiki; ADCYAP1R1; -.
DR   GenomeRNAi; 117; -.
DR   Pharos; P41586; Tchem.
DR   PRO; PR:P41586; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; P41586; protein.
DR   Bgee; ENSG00000078549; Expressed in nucleus accumbens and 142 other tissues.
DR   ExpressionAtlas; P41586; baseline and differential.
DR   Genevisible; P41586; HS.
DR   GO; GO:0005923; C:bicellular tight junction; IEA:Ensembl.
DR   GO; GO:0005901; C:caveola; IEA:Ensembl.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0005768; C:endosome; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005791; C:rough endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0008179; F:adenylate cyclase binding; IEA:Ensembl.
DR   GO; GO:0030306; F:ADP-ribosylation factor binding; IEA:Ensembl.
DR   GO; GO:0008528; F:G protein-coupled peptide receptor activity; IBA:GO_Central.
DR   GO; GO:0042923; F:neuropeptide binding; IEA:Ensembl.
DR   GO; GO:0017046; F:peptide hormone binding; IBA:GO_Central.
DR   GO; GO:0038023; F:signaling receptor activity; TAS:ProtInc.
DR   GO; GO:0004999; F:vasoactive intestinal polypeptide receptor activity; IEA:InterPro.
DR   GO; GO:0007202; P:activation of phospholipase C activity; IEA:Ensembl.
DR   GO; GO:0007188; P:adenylate cyclase-modulating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0019933; P:cAMP-mediated signaling; IEA:Ensembl.
DR   GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0046545; P:development of primary female sexual characteristics; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0033555; P:multicellular organismal response to stress; IEA:Ensembl.
DR   GO; GO:0060548; P:negative regulation of cell death; IEA:Ensembl.
DR   GO; GO:0010524; P:positive regulation of calcium ion transport into cytosol; IEA:Ensembl.
DR   GO; GO:0043950; P:positive regulation of cAMP-mediated signaling; IEA:Ensembl.
DR   GO; GO:0060732; P:positive regulation of inositol phosphate biosynthetic process; IEA:Ensembl.
DR   GO; GO:0051057; P:positive regulation of small GTPase mediated signal transduction; IEA:Ensembl.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0007283; P:spermatogenesis; IEA:UniProtKB-KW.
DR   Gene3D; 4.10.1240.10; -; 1.
DR   InterPro; IPR017981; GPCR_2-like.
DR   InterPro; IPR036445; GPCR_2_extracell_dom_sf.
DR   InterPro; IPR001879; GPCR_2_extracellular_dom.
DR   InterPro; IPR002285; GPCR_2_PACAP_1_rcpt.
DR   InterPro; IPR000832; GPCR_2_secretin-like.
DR   InterPro; IPR017983; GPCR_2_secretin-like_CS.
DR   Pfam; PF00002; 7tm_2; 1.
DR   Pfam; PF02793; HRM; 1.
DR   PRINTS; PR00249; GPCRSECRETIN.
DR   PRINTS; PR01156; PACAPRECEPTR.
DR   SMART; SM00008; HormR; 1.
DR   SUPFAM; SSF111418; SSF111418; 1.
DR   PROSITE; PS00649; G_PROTEIN_RECEP_F2_1; 1.
DR   PROSITE; PS00650; G_PROTEIN_RECEP_F2_2; 1.
DR   PROSITE; PS50227; G_PROTEIN_RECEP_F2_3; 1.
DR   PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Developmental protein;
KW   Differentiation; Disulfide bond; G-protein coupled receptor; Glycoprotein;
KW   Membrane; Phosphoprotein; Receptor; Reference proteome; Signal;
KW   Spermatogenesis; Transducer; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..20
FT                   /evidence="ECO:0000255"
FT   CHAIN           21..468
FT                   /note="Pituitary adenylate cyclase-activating polypeptide
FT                   type I receptor"
FT                   /id="PRO_0000012841"
FT   TOPO_DOM        21..155
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        156..178
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        179..186
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        187..205
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        206..227
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        228..253
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        254..268
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        269..291
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        292..309
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        310..332
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        333..350
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        351..371
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        372..385
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        386..405
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        406..468
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REGION          125..139
FT                   /note="Important for ligand binding and specificity"
FT   MOD_RES         434
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P70205"
FT   MOD_RES         447
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P70205"
FT   CARBOHYD        48
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        60
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        117
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        300
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        375
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        34..63
FT   DISULFID        54..118
FT   DISULFID        77..134
FT   VAR_SEQ         53..88
FT                   /note="Missing (in isoform VS)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_042669"
FT   VAR_SEQ         89..109
FT                   /note="Missing (in isoform S, isoform S-HOP1 and isoform
FT                   VS)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_042670"
FT   VAR_SEQ         348
FT                   /note="Y -> YFSCVQKCYCKPQRAQQHSCKMSELSTIT (in isoform N-
FT                   HOP1 and isoform S-HOP1)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_042671"
FT   MUTAGEN         114
FT                   /note="V->A: Reduced affinity for ADCYAP1."
FT                   /evidence="ECO:0000269|PubMed:17470806"
FT   MUTAGEN         125
FT                   /note="E->R: Reduced affinity for ADCYAP1."
FT                   /evidence="ECO:0000269|PubMed:17470806,
FT                   ECO:0000269|PubMed:21625560"
FT   MUTAGEN         128
FT                   /note="P->A: Reduced affinity for ADCYAP1."
FT                   /evidence="ECO:0000269|PubMed:17470806"
FT   MUTAGEN         138
FT                   /note="E->R: Reduced affinity for ADCYAP1."
FT                   /evidence="ECO:0000269|PubMed:17470806"
FT   MUTAGEN         139
FT                   /note="Y->A: Strongly reduced affinity for ADCYAP1."
FT                   /evidence="ECO:0000269|PubMed:17470806"
FT   HELIX           26..47
FT                   /evidence="ECO:0000244|PDB:3N94"
FT   TURN            48..50
FT                   /evidence="ECO:0000244|PDB:2JOD"
FT   STRAND          72..76
FT                   /evidence="ECO:0000244|PDB:3N94"
FT   HELIX           79..83
FT                   /evidence="ECO:0000244|PDB:3N94"
FT   STRAND          113..119
FT                   /evidence="ECO:0000244|PDB:3N94"
FT   HELIX           130..134
FT                   /evidence="ECO:0000244|PDB:3N94"
FT   HELIX           150..163
FT                   /evidence="ECO:0000244|PDB:6P9Y"
FT   HELIX           166..177
FT                   /evidence="ECO:0000244|PDB:6P9Y"
FT   HELIX           186..210
FT                   /evidence="ECO:0000244|PDB:6P9Y"
FT   HELIX           224..255
FT                   /evidence="ECO:0000244|PDB:6P9Y"
FT   HELIX           265..273
FT                   /evidence="ECO:0000244|PDB:6P9Y"
FT   HELIX           276..288
FT                   /evidence="ECO:0000244|PDB:6P9Y"
FT   TURN            289..291
FT                   /evidence="ECO:0000244|PDB:6P9Y"
FT   HELIX           303..336
FT                   /evidence="ECO:0000244|PDB:6P9Y"
FT   HELIX           347..362
FT                   /evidence="ECO:0000244|PDB:6P9Y"
FT   HELIX           364..366
FT                   /evidence="ECO:0000244|PDB:6P9Y"
FT   TURN            367..371
FT                   /evidence="ECO:0000244|PDB:6P9Y"
FT   TURN            374..376
FT                   /evidence="ECO:0000244|PDB:6P9Y"
FT   HELIX           379..385
FT                   /evidence="ECO:0000244|PDB:6P9Y"
FT   TURN            386..391
FT                   /evidence="ECO:0000244|PDB:6P9Y"
FT   HELIX           392..400
FT                   /evidence="ECO:0000244|PDB:6P9Y"
FT   HELIX           405..416
FT                   /evidence="ECO:0000244|PDB:6P9Y"
FT   CONFLICT        P41586-2:350
FT                   /note="Missing (in Ref. 7; AAI43680)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   468 AA;  53314 MW;  BB515B84E9F28977 CRC64;
     MAGVVHVSLA ALLLLPMAPA MHSDCIFKKE QAMCLEKIQR ANELMGFNDS SPGCPGMWDN
     ITCWKPAHVG EMVLVSCPEL FRIFNPDQVW ETETIGESDF GDSNSLDLSD MGVVSRNCTE
     DGWSEPFPHY FDACGFDEYE SETGDQDYYY LSVKALYTVG YSTSLVTLTT AMVILCRFRK
     LHCTRNFIHM NLFVSFMLRA ISVFIKDWIL YAEQDSNHCF ISTVECKAVM VFFHYCVVSN
     YFWLFIEGLY LFTLLVETFF PERRYFYWYT IIGWGTPTVC VTVWATLRLY FDDTGCWDMN
     DSTALWWVIK GPVVGSIMVN FVLFIGIIVI LVQKLQSPDM GGNESSIYLR LARSTLLLIP
     LFGIHYTVFA FSPENVSKRE RLVFELGLGS FQGFVVAVLY CFLNGEVQAE IKRKWRSWKV
     NRYFAVDFKH RHPSLASSGV NGGTQLSILS KSSSQIRMSG LPADNLAT
//
ID   5HT4R_HUMAN             Reviewed;         388 AA.
AC   Q13639; C4WYH4; Q546Q1; Q684M0; Q712M9; Q96KH9; Q96KI0; Q9H199; Q9NY73;
AC   Q9UBM6; Q9UBT4; Q9UE22; Q9UE23; Q9UQR6;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2001, sequence version 2.
DT   07-OCT-2020, entry version 190.
DE   RecName: Full=5-hydroxytryptamine receptor 4;
DE            Short=5-HT-4;
DE            Short=5-HT4;
DE   AltName: Full=Serotonin receptor 4;
GN   Name=HTR4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5-HT4(A); 5-HT4(B); 5-HT4(C) AND
RP   5-HT4(D)).
RC   TISSUE=Intestine;
RX   PubMed=9603189; DOI=10.1046/j.1471-4159.1998.70062252.x;
RA   Blondel O., Gastineau M., Dahmoune Y., Langlois M., Fischmeister R.;
RT   "Cloning, expression, and pharmacology of four human 5-hydroxytryptamine 4
RT   receptor isoforms produced by alternative splicing in the carboxyl
RT   terminus.";
RL   J. Neurochem. 70:2252-2261(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5-HT4(A) AND 5-HT4(B)).
RC   TISSUE=Brain;
RA   Van den Wyngaert I., Gommeren W., Jurzak M., Verhasselt P., Gordon R.,
RA   Leysen J., Luyten W., Bender E.;
RT   "Cloning and expression of 5-HT4 receptor species and splice variants.";
RL   Submitted (JUN-1997) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5-HT4(A)).
RC   TISSUE=Heart;
RX   PubMed=9351641; DOI=10.1097/00001756-199710200-00002;
RA   Claeysen S., Faye P., Sebben M., Lemaire S., Bockaert J., Dumuis A.;
RT   "Cloning and expression of human 5-HT4S receptors. Effect of receptor
RT   density on their coupling to adenylyl cyclase.";
RL   NeuroReport 8:3189-3195(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5-HT4(B)).
RA   Syversveen T., Bach T., Kvingedal A.M., Krobert K.A., Kaumann A.J.,
RA   Levy F.O.;
RT   "Molecular cloning of the human serotonin receptor 5-HT4(b) and
RT   pharmacological comparison with the cloned human 5-HT4(a) receptor.";
RL   Submitted (DEC-1998) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5-HT4(E)).
RC   TISSUE=Brain;
RX   PubMed=10220570;
RA   Claeysen S., Sebben M., Becamel C., Bockaert J., Dumuis A.;
RT   "Novel brain-specific 5-HT4 receptor splice variants show marked
RT   constitutive activity: role of the C-terminal intracellular domain.";
RL   Mol. Pharmacol. 55:910-920(1999).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5-HT4(A); 5-HT4(B); 5-HT4(E) AND
RP   5-HT4(G)).
RC   TISSUE=Brain, and Hippocampus;
RX   PubMed=11750916; DOI=10.1016/s0028-3908(01)00154-x;
RA   Vilaro M.T., Domenech T., Palacios J.M., Mengod G.;
RT   "Cloning and characterization of a novel human 5-HT4 receptor variant that
RT   lacks the alternatively spliced carboxy terminal exon. RT-PCR distribution
RT   in human brain and periphery of multiple 5-HT4 receptor variants.";
RL   Neuropharmacology 42:60-73(2002).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5-HT4(E) AND 5-HT4(I)), AND TISSUE
RP   SPECIFICITY.
RX   PubMed=15118808; DOI=10.1007/s00210-004-0919-4;
RA   Brattelid T., Kvingedal A.M., Krobert K.A., Andressen K.W., Bach T.,
RA   Hystad M.E., Kaumann A.J., Levy F.O.;
RT   "Cloning, pharmacological characterisation and tissue distribution of a
RT   novel 5-HT4 receptor splice variant, 5-HT4(i).";
RL   Naunyn Schmiedebergs Arch. Pharmacol. 369:616-628(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5-HT4C1).
RC   TISSUE=Small intestine;
RA   Reid A.M., Kelsell R.E., Houp J.A., Kelly F.M., Medhurst A.D., Cox H.M.,
RA   Calver A.R.;
RT   "Cloning, expression and characterisation of a novel rat 5-HT4 receptor
RT   splice variant (5-HT4c1).";
RL   Submitted (MAY-2007) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Grigoriev I., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Israni S., Jett J., Kadner K., Kimball H., Kobayashi A.,
RA   Lopez F., Lou Y., Martinez D., Medina C., Morgan J., Nandkeshwar R.,
RA   Noonan J.P., Pitluck S., Pollard M., Predki P., Priest J., Ramirez L.,
RA   Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A., Thayer N.,
RA   Tice H., Tsai M., Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J.,
RA   Dickson M., Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A.,
RA   Rokhsar D.S., Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5-HT4(B)).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 10-388 (ISOFORM 5-HT4(F)).
RX   PubMed=10646498; DOI=10.1046/j.1471-4159.2000.740478.x;
RA   Bender E., Pindon A., van Oers I., Zhang Y.B., Gommeren W., Verhasselt P.,
RA   Jurzak M., Leysen J., Luyten W.;
RT   "Structure of the human serotonin 5-HT4 receptor gene and cloning of a
RT   novel 5-HT4 splice variant.";
RL   J. Neurochem. 74:478-489(2000).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 112-255.
RC   TISSUE=Brain;
RX   PubMed=7656980; DOI=10.1016/0014-5793(95)00828-w;
RA   Ullmer C., Schmuck K., Kalkman H.O., Luebbert H.;
RT   "Expression of serotonin receptor mRNAs in blood vessels.";
RL   FEBS Lett. 370:215-221(1995).
RN   [14]
RP   INTERACTION WITH GRK5, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=19661922; DOI=10.1038/emboj.2009.215;
RA   Barthet G., Carrat G., Cassier E., Barker B., Gaven F., Pillot M.,
RA   Framery B., Pellissier L.P., Augier J., Kang D.S., Claeysen S., Reiter E.,
RA   Baneres J.L., Benovic J.L., Marin P., Bockaert J., Dumuis A.;
RT   "Beta-arrestin1 phosphorylation by GRK5 regulates G protein-independent 5-
RT   HT4 receptor signalling.";
RL   EMBO J. 28:2706-2718(2009).
RN   [15]
RP   VARIANT LEU-27.
RX   PubMed=22197934; DOI=10.1038/ng.1027;
RA   Rademakers R., Baker M., Nicholson A.M., Rutherford N.J., Finch N.,
RA   Soto-Ortolaza A., Lash J., Wider C., Wojtas A., DeJesus-Hernandez M.,
RA   Adamson J., Kouri N., Sundal C., Shuster E.A., Aasly J., MacKenzie J.,
RA   Roeber S., Kretzschmar H.A., Boeve B.F., Knopman D.S., Petersen R.C.,
RA   Cairns N.J., Ghetti B., Spina S., Garbern J., Tselis A.C., Uitti R.,
RA   Das P., Van Gerpen J.A., Meschia J.F., Levy S., Broderick D.F.,
RA   Graff-Radford N., Ross O.A., Miller B.B., Swerdlow R.H., Dickson D.W.,
RA   Wszolek Z.K.;
RT   "Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause
RT   hereditary diffuse leukoencephalopathy with spheroids.";
RL   Nat. Genet. 44:200-205(2012).
CC   -!- FUNCTION: This is one of the several different receptors for 5-
CC       hydroxytryptamine (serotonin), a biogenic hormone that functions as a
CC       neurotransmitter, a hormone, and a mitogen. The activity of this
CC       receptor is mediated by G proteins that stimulate adenylate cyclase.
CC   -!- SUBUNIT: Isoform 5-HT4(A) interacts with MAGI2, MPP3, SLC9A3R1 and
CC       SNX27 isoforms 1 and 2. Isoform 5-HT4(E) interacts with PATJ, NOS1 and
CC       SEC23A. Isoform 5-HT4(A) forms a complex including SLC9A3R1 and EZR (By
CC       similarity). Interacts (via C-terminus 330-346 AA) with GRK5; this
CC       interaction is promoted by 5-HT (serotonin). {ECO:0000250,
CC       ECO:0000269|PubMed:19661922}.
CC   -!- INTERACTION:
CC       Q13639; O15354: GPR37; NbExp=5; IntAct=EBI-6656425, EBI-15639515;
CC       Q13639; O60269: GPRIN2; NbExp=2; IntAct=EBI-6656425, EBI-740397;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC       Endosome. Note=Interaction with SNX27 mediates recruitment to early
CC       endosomes, while interaction with SLC9A3R1 and EZR might target the
CC       protein to specialized subcellular regions, such as microvilli.
CC       {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=9;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=5-HT4(B);
CC         IsoId=Q13639-1; Sequence=Displayed;
CC       Name=5-HT4(A); Synonyms=5-HT4S;
CC         IsoId=Q13639-2; Sequence=VSP_001849;
CC       Name=5-HT4(C);
CC         IsoId=Q13639-3; Sequence=VSP_001848;
CC       Name=5-HT4(D);
CC         IsoId=Q13639-4; Sequence=VSP_001847;
CC       Name=5-HT4(E); Synonyms=H5-HT4(g);
CC         IsoId=Q13639-5; Sequence=VSP_001846;
CC       Name=5-HT4(F);
CC         IsoId=Q13639-6; Sequence=VSP_001845;
CC       Name=5-HT4(G);
CC         IsoId=Q13639-7; Sequence=VSP_001850;
CC       Name=5-HT4(I);
CC         IsoId=Q13639-8; Sequence=VSP_043316;
CC       Name=5-HT4c1;
CC         IsoId=Q13639-9; Sequence=VSP_047862;
CC   -!- TISSUE SPECIFICITY: Isoform 5-HT4(A) is expressed in ileum, brain, and
CC       atrium, but not in the ventricle. {ECO:0000269|PubMed:15118808}.
CC   -!- MISCELLANEOUS: [Isoform 5-HT4(E)]: Mainly expressed in atria and
CC       cardiac ventricle. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 5-HT4(I)]: Expressed in all cardiovascular
CC       tissues analyzed. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Y08756; CAA70002.1; -; mRNA.
DR   EMBL; Y12505; CAA73107.1; -; mRNA.
DR   EMBL; Y12506; CAA73108.1; -; mRNA.
DR   EMBL; Y12507; CAA73109.1; -; mRNA.
DR   EMBL; Y10437; CAA71462.1; -; mRNA.
DR   EMBL; Y13584; CAA73911.1; -; mRNA.
DR   EMBL; Y09586; CAA70774.1; -; mRNA.
DR   EMBL; AJ131724; CAC20411.1; -; mRNA.
DR   EMBL; AJ011371; CAA09600.1; -; mRNA.
DR   EMBL; AJ278979; CAC22248.1; -; mRNA.
DR   EMBL; AJ278980; CAC22249.1; -; mRNA.
DR   EMBL; AJ278981; CAC22250.1; -; mRNA.
DR   EMBL; AJ278982; CAC22251.1; -; mRNA.
DR   EMBL; AJ131725; CAC79533.1; -; mRNA.
DR   EMBL; AJ131726; CAC79538.1; -; mRNA.
DR   EMBL; AJ633645; CAG17627.1; -; mRNA.
DR   EMBL; AM712912; CAN84676.1; -; mRNA.
DR   EMBL; AC008627; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC011390; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC091971; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC114939; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471062; EAW61800.1; -; Genomic_DNA.
DR   EMBL; CH471062; EAW61801.1; -; Genomic_DNA.
DR   EMBL; CH471062; EAW61804.1; -; Genomic_DNA.
DR   EMBL; BC074755; AAH74755.1; -; mRNA.
DR   EMBL; BC095497; AAH95497.1; -; mRNA.
DR   EMBL; AJ243213; CAB71316.1; -; Genomic_DNA.
DR   EMBL; Z48150; CAA88167.1; -; mRNA.
DR   CCDS; CCDS34270.1; -. [Q13639-2]
DR   CCDS; CCDS34271.1; -. [Q13639-5]
DR   CCDS; CCDS34272.1; -. [Q13639-8]
DR   CCDS; CCDS34273.2; -. [Q13639-3]
DR   CCDS; CCDS4291.1; -. [Q13639-1]
DR   CCDS; CCDS75353.1; -. [Q13639-9]
DR   PIR; S66493; S66493.
DR   RefSeq; NP_000861.1; NM_000870.6. [Q13639-1]
DR   RefSeq; NP_001035259.1; NM_001040169.2. [Q13639-2]
DR   RefSeq; NP_001035262.2; NM_001040172.2. [Q13639-3]
DR   RefSeq; NP_001035263.1; NM_001040173.2. [Q13639-8]
DR   RefSeq; NP_001273339.1; NM_001286410.1. [Q13639-9]
DR   RefSeq; NP_955525.1; NM_199453.3. [Q13639-5]
DR   PDB; 5EM9; X-ray; 1.60 A; B=264-268.
DR   PDBsum; 5EM9; -.
DR   SMR; Q13639; -.
DR   IntAct; Q13639; 17.
DR   MINT; Q13639; -.
DR   STRING; 9606.ENSP00000353915; -.
DR   BindingDB; Q13639; -.
DR   ChEMBL; CHEMBL1875; -.
DR   DrugBank; DB08810; Cinitapride.
DR   DrugBank; DB00604; Cisapride.
DR   DrugBank; DB11273; Dihydroergocornine.
DR   DrugBank; DB13345; Dihydroergocristine.
DR   DrugBank; DB01049; Ergoloid mesylate.
DR   DrugBank; DB12141; Gilteritinib.
DR   DrugBank; DB01233; Metoclopramide.
DR   DrugBank; DB05542; Naronapride.
DR   DrugBank; DB00904; Ondansetron.
DR   DrugBank; DB00715; Paroxetine.
DR   DrugBank; DB04873; Piboserod.
DR   DrugBank; DB06480; Prucalopride.
DR   DrugBank; DB04917; Renzapride.
DR   DrugBank; DB09304; Setiptiline.
DR   DrugBank; DB05905; TD-2749.
DR   DrugBank; DB01079; Tegaserod.
DR   DrugBank; DB13025; Tiapride.
DR   DrugBank; DB06422; Ticalopride.
DR   DrugBank; DB12702; Velusetrag.
DR   DrugCentral; Q13639; -.
DR   GuidetoPHARMACOLOGY; 9; -.
DR   GlyGen; Q13639; 1 site.
DR   iPTMnet; Q13639; -.
DR   PhosphoSitePlus; Q13639; -.
DR   SwissPalm; Q13639; -.
DR   BioMuta; HTR4; -.
DR   DMDM; 12644029; -.
DR   PeptideAtlas; Q13639; -.
DR   PRIDE; Q13639; -.
DR   ProteomicsDB; 59633; -. [Q13639-1]
DR   ProteomicsDB; 59634; -. [Q13639-2]
DR   ProteomicsDB; 59635; -. [Q13639-3]
DR   ProteomicsDB; 59636; -. [Q13639-4]
DR   ProteomicsDB; 59637; -. [Q13639-5]
DR   ProteomicsDB; 59638; -. [Q13639-6]
DR   ProteomicsDB; 59639; -. [Q13639-7]
DR   ProteomicsDB; 59640; -. [Q13639-8]
DR   ProteomicsDB; 7599; -.
DR   Antibodypedia; 15936; 431 antibodies.
DR   Ensembl; ENST00000360693; ENSP00000353915; ENSG00000164270. [Q13639-8]
DR   Ensembl; ENST00000362016; ENSP00000355037; ENSG00000164270. [Q13639-8]
DR   Ensembl; ENST00000377888; ENSP00000367120; ENSG00000164270. [Q13639-1]
DR   Ensembl; ENST00000517929; ENSP00000435904; ENSG00000164270. [Q13639-3]
DR   Ensembl; ENST00000520514; ENSP00000427913; ENSG00000164270. [Q13639-9]
DR   Ensembl; ENST00000521530; ENSP00000428320; ENSG00000164270. [Q13639-2]
DR   Ensembl; ENST00000521735; ENSP00000430979; ENSG00000164270. [Q13639-5]
DR   Ensembl; ENST00000522588; ENSP00000430874; ENSG00000164270. [Q13639-5]
DR   Ensembl; ENST00000631296; ENSP00000485747; ENSG00000164270. [Q13639-1]
DR   GeneID; 3360; -.
DR   KEGG; hsa:3360; -.
DR   UCSC; uc003lpn.5; human. [Q13639-1]
DR   CTD; 3360; -.
DR   DisGeNET; 3360; -.
DR   EuPathDB; HostDB:ENSG00000164270.17; -.
DR   GeneCards; HTR4; -.
DR   HGNC; HGNC:5299; HTR4.
DR   HPA; ENSG00000164270; Group enriched (brain, heart muscle, intestine, pituitary gland).
DR   MIM; 602164; gene.
DR   neXtProt; NX_Q13639; -.
DR   OpenTargets; ENSG00000164270; -.
DR   PharmGKB; PA29557; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00940000155983; -.
DR   HOGENOM; CLU_009579_11_0_1; -.
DR   InParanoid; Q13639; -.
DR   KO; K04160; -.
DR   OMA; FVDYTVP; -.
DR   OrthoDB; 750855at2759; -.
DR   PhylomeDB; Q13639; -.
DR   TreeFam; TF316350; -.
DR   PathwayCommons; Q13639; -.
DR   Reactome; R-HSA-390666; Serotonin receptors.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-9660821; ADORA2B mediated anti-inflammatory cytokines production.
DR   SIGNOR; Q13639; -.
DR   BioGRID-ORCS; 3360; 4 hits in 870 CRISPR screens.
DR   ChiTaRS; HTR4; human.
DR   GeneWiki; 5-HT4_receptor; -.
DR   GenomeRNAi; 3360; -.
DR   Pharos; Q13639; Tclin.
DR   PRO; PR:Q13639; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   RNAct; Q13639; protein.
DR   Bgee; ENSG00000164270; Expressed in epithelium of bronchus and 217 other tissues.
DR   ExpressionAtlas; Q13639; baseline and differential.
DR   Genevisible; Q13639; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0030425; C:dendrite; IBA:GO_Central.
DR   GO; GO:0005768; C:endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0016020; C:membrane; IDA:MGI.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0045202; C:synapse; IEA:GOC.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0004993; F:G protein-coupled serotonin receptor activity; IDA:MGI.
DR   GO; GO:0030594; F:neurotransmitter receptor activity; IBA:GO_Central.
DR   GO; GO:0051378; F:serotonin binding; IBA:GO_Central.
DR   GO; GO:0007198; P:adenylate cyclase-inhibiting serotonin receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007268; P:chemical synaptic transmission; IBA:GO_Central.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007187; P:G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; IBA:GO_Central.
DR   GO; GO:0032098; P:regulation of appetite; IEA:InterPro.
DR   InterPro; IPR001520; 5HT4_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01059; 5HT4RECEPTR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Disulfide bond;
KW   Endosome; G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane;
KW   Palmitate; Polymorphism; Receptor; Reference proteome; Transducer;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..388
FT                   /note="5-hydroxytryptamine receptor 4"
FT                   /id="PRO_0000068965"
FT   TOPO_DOM        1..19
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        20..40
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        41..58
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        59..79
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        80..93
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        94..116
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        117..137
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        138..158
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        159..192
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        193..213
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        214..260
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        261..281
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        282..294
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        295..315
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        316..388
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   LIPID           329
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        7
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        93..184
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VAR_SEQ         169
FT                   /note="L -> LERSLNQGLGQDFHA (in isoform 5-HT4(F))"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_001845"
FT   VAR_SEQ         359..388
FT                   /note="RDAVECGGQWESQCHPPATSPLVAAQPSDT -> SSGTETDRRNFGIRKRRL
FT                   TKPS (in isoform 5-HT4(D))"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_001847"
FT   VAR_SEQ         359..388
FT                   /note="RDAVECGGQWESQCHPPATSPLVAAQPSDT -> SGCSPVSSFLLLFCNRPV
FT                   PV (in isoform 5-HT4(E))"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_001846"
FT   VAR_SEQ         359..388
FT                   /note="RDAVECGGQWESQCHPPATSPLVAAQPSDT -> SSGTETDRKKLWNKEEKI
FT                   DQTIQMPKRKRKKKASLSYEDLILLGRKSCFREGK (in isoform 5-HT4c1)"
FT                   /evidence="ECO:0000303|Ref.8"
FT                   /id="VSP_047862"
FT   VAR_SEQ         359
FT                   /note="R -> RTDFLFDRDILARYWTKPARAGPFSGTLSIRCLTARKPVLG (in
FT                   isoform 5-HT4(I))"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_043316"
FT   VAR_SEQ         360..388
FT                   /note="DAVECGGQWESQCHPPATSPLVAAQPSDT -> YTVLHRGHHQELEKLPIHN
FT                   DPESLESCF (in isoform 5-HT4(A))"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_001849"
FT   VAR_SEQ         360..388
FT                   /note="DAVECGGQWESQCHPPATSPLVAAQPSDT -> F (in isoform 5-
FT                   HT4(C))"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_001848"
FT   VAR_SEQ         360..388
FT                   /note="Missing (in isoform 5-HT4(G))"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_001850"
FT   VARIANT         27
FT                   /note="S -> L (in a patient with diffuse
FT                   leukoencephalopathy with spheroids; unknown pathological
FT                   significance; dbSNP:rs199508638)"
FT                   /evidence="ECO:0000269|PubMed:22197934"
FT                   /id="VAR_067412"
FT   VARIANT         372
FT                   /note="C -> Y (in dbSNP:rs34826744)"
FT                   /id="VAR_049364"
FT   STRAND          264..268
FT                   /evidence="ECO:0000244|PDB:5EM9"
SQ   SEQUENCE   388 AA;  43761 MW;  7FCFEC60E7BDF560 CRC64;
     MDKLDANVSS EEGFGSVEKV VLLTFLSTVI LMAILGNLLV MVAVCWDRQL RKIKTNYFIV
     SLAFADLLVS VLVMPFGAIE LVQDIWIYGE VFCLVRTSLD VLLTTASIFH LCCISLDRYY
     AICCQPLVYR NKMTPLRIAL MLGGCWVIPT FISFLPIMQG WNNIGIIDLI EKRKFNQNSN
     STYCVFMVNK PYAITCSVVA FYIPFLLMVL AYYRIYVTAK EHAHQIQMLQ RAGASSESRP
     QSADQHSTHR MRTETKAAKT LCIIMGCFCL CWAPFFVTNI VDPFIDYTVP GQVWTAFLWL
     GYINSGLNPF LYAFLNKSFR RAFLIILCCD DERYRRPSIL GQTVPCSTTT INGSTHVLRD
     AVECGGQWES QCHPPATSPL VAAQPSDT
//
ID   ADRB1_HUMAN             Reviewed;         477 AA.
AC   P08588; B0LPE2; Q5T5Y4; Q9UKG7; Q9UKG8;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   07-JUN-2004, sequence version 2.
DT   07-OCT-2020, entry version 207.
DE   RecName: Full=Beta-1 adrenergic receptor {ECO:0000305};
DE   AltName: Full=Beta-1 adrenoreceptor;
DE            Short=Beta-1 adrenoceptor;
GN   Name=ADRB1 {ECO:0000312|HGNC:HGNC:285}; Synonyms=ADRB1R, B1AR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   PubMed=2825170; DOI=10.1073/pnas.84.22.7920;
RA   Frielle T., Collins S., Daniel K.W., Caron M.G., Lefkowitz R.J.,
RA   Kobilka B.K.;
RT   "Cloning of the cDNA for the human beta 1-adrenergic receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:7920-7924(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLY-49 AND GLY-389.
RX   PubMed=10477438;
RX   DOI=10.1002/(sici)1098-1004(1999)14:3<271::aid-humu14>3.0.co;2-q;
RA   Moore J.D., Mason D.A., Green S.A., Hsu J., Liggett S.B.;
RT   "Racial differences in the frequencies of cardiac beta(1)-adrenergic
RT   receptor polymorphisms: analysis of c145A>G and c1165G>C.";
RL   Hum. Mutat. 14:271-271(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS GLY-49; GLY-389 AND
RP   LEU-389.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (MAR-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT GLY-389.
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [6]
RP   FUNCTION, INTERACTION WITH RAPGEF2, AND MUTAGENESIS OF SER-475 AND VAL-477.
RX   PubMed=12391161; DOI=10.1128/mcb.22.22.7942-7952.2002;
RA   Pak Y., Pham N., Rotin D.;
RT   "Direct binding of the beta1 adrenergic receptor to the cyclic AMP-
RT   dependent guanine nucleotide exchange factor CNrasGEF leads to Ras
RT   activation.";
RL   Mol. Cell. Biol. 22:7942-7952(2002).
RN   [7]
RP   INTERACTION WITH GOPC AND DLG4, MUTAGENESIS OF GLU-474; SER-475; LYS-476
RP   AND VAL-477, AND SUBCELLULAR LOCATION.
RX   PubMed=15358775; DOI=10.1074/jbc.m404876200;
RA   He J., Bellini M., Xu J., Castleberry A.M., Hall R.A.;
RT   "Interaction with cystic fibrosis transmembrane conductance regulator-
RT   associated ligand (CAL) inhibits beta1-adrenergic receptor surface
RT   expression.";
RL   J. Biol. Chem. 279:50190-50196(2004).
RN   [8]
RP   SUBCELLULAR LOCATION.
RX   PubMed=21540189; DOI=10.1074/jbc.m111.224071;
RA   Cheng S.B., Quinn J.A., Graeber C.T., Filardo E.J.;
RT   "Down-modulation of the G-protein-coupled estrogen receptor, GPER, from the
RT   cell surface occurs via a trans-Golgi-proteasome pathway.";
RL   J. Biol. Chem. 286:22441-22455(2011).
RN   [9]
RP   VARIANT GLY-389.
RX   PubMed=10212248; DOI=10.1074/jbc.274.18.12670;
RA   Mason D.A., Moore J.D., Green S.A., Liggett S.B.;
RT   "A gain-of-function polymorphism in a G-protein coupling domain of the
RT   human beta1-adrenergic receptor.";
RL   J. Biol. Chem. 274:12670-12674(1999).
RN   [10]
RP   VARIANT GLY-49.
RX   PubMed=11052857; DOI=10.1053/euhj.1999.1994;
RA   Borjesson M., Magnusson Y., Hjalmarson A., Andersson B.;
RT   "A novel polymorphism in the gene coding for the beta(1)-adrenergic
RT   receptor associated with survival in patients with heart failure.";
RL   Eur. Heart J. 21:1853-1858(2000).
RN   [11]
RP   VARIANT GLY-49, AND POLYMORPHISM.
RX   PubMed=11854867; DOI=10.1086/339621;
RA   Ranade K., Jorgenson E., Sheu W.H.-H., Pei D., Hsiung C.A., Chiang F.-T.,
RA   Chen Y.-D.I., Pratt R., Olshen R.A., Curb D., Cox D.R., Botstein D.,
RA   Risch N.;
RT   "A polymorphism in the beta1 adrenergic receptor is associated with resting
RT   heart rate.";
RL   Am. J. Hum. Genet. 70:935-942(2002).
RN   [12]
RP   VARIANT VAL-187, CHARACTERIZATION OF VARIANT VAL-187, FUNCTION, AND
RP   POLYMORPHISM.
RX   PubMed=31473062; DOI=10.1016/j.neuron.2019.07.026;
RA   Shi G., Xing L., Wu D., Bhattacharyya B.J., Jones C.R., McMahon T.,
RA   Chong S.Y.C., Chen J.A., Coppola G., Geschwind D., Krystal A., Ptacek L.J.,
RA   Fu Y.H.;
RT   "A rare mutation of beta1-adrenergic receptor affects sleep/wake
RT   behaviors.";
RL   Neuron 0:0-0(2019).
CC   -!- FUNCTION: Beta-adrenergic receptors mediate the catecholamine-induced
CC       activation of adenylate cyclase through the action of G proteins. This
CC       receptor binds epinephrine and norepinephrine with approximately equal
CC       affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated
CC       signaling. Involved in the regulation of sleep/wake behaviors
CC       (PubMed:31473062). {ECO:0000269|PubMed:12391161,
CC       ECO:0000269|PubMed:31473062}.
CC   -!- SUBUNIT: Interacts (via C-terminus PDZ motif) with RAPGEF2; the
CC       interaction is direct. Interacts with GOPC, MAGI3 and DLG4.
CC       {ECO:0000269|PubMed:12391161, ECO:0000269|PubMed:15358775}.
CC   -!- INTERACTION:
CC       P08588; P30542: ADORA1; NbExp=5; IntAct=EBI-991009, EBI-2903663;
CC       P08588; P21917: DRD4; NbExp=2; IntAct=EBI-991009, EBI-8592297;
CC       P08588; Q86UL8: MAGI2; NbExp=3; IntAct=EBI-991009, EBI-311035;
CC       P08588; Q5TCQ9: MAGI3; NbExp=5; IntAct=EBI-991009, EBI-310506;
CC       P08588; P31016: Dlg4; Xeno; NbExp=2; IntAct=EBI-991009, EBI-375655;
CC       P08588; P14270: Pde4d; Xeno; NbExp=2; IntAct=EBI-991009, EBI-8333209;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:P18090};
CC       Multi-pass membrane protein {ECO:0000250|UniProtKB:P18090}. Early
CC       endosome. Note=Colocalizes with RAPGEF2 at the plasma membrane (By
CC       similarity). Localized at the plasma membrane. Found in the Golgi upon
CC       GOPC overexpression. {ECO:0000250}.
CC   -!- DOMAIN: The PDZ domain-binding motif mediates competitive interactions
CC       with GOPC, MAGI3 and DLG4 and plays a role in subcellular location of
CC       the receptor.
CC   -!- PTM: Homologous desensitization of the receptor is mediated by its
CC       phosphorylation by beta-adrenergic receptor kinase.
CC   -!- POLYMORPHISM: Genetic variations in ADRB1 are associated with inter-
CC       individual variability in the resting heart rate. This quantitative
CC       trait has been significantly correlated with cardiovascular morbidity
CC       and mortality [MIM:607276]. {ECO:0000269|PubMed:11854867}.
CC   -!- POLYMORPHISM: Genetic variations in ADRB1 are associated with the
CC       familial natural short sleep 2 (FNSS2) phenotype, an autosomal dominant
CC       trait [MIM:618591]. Individuals with this trait require less sleep in
CC       any 24-hour period than is typical for their age group.
CC       {ECO:0000269|PubMed:31473062}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       Adrenergic receptor subfamily. ADRB1 sub-subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/adrb1/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; J03019; AAA51667.1; -; mRNA.
DR   EMBL; AF169006; AAD53696.1; -; Genomic_DNA.
DR   EMBL; AF169007; AAD53697.1; -; Genomic_DNA.
DR   EMBL; AY567837; AAS66983.1; -; Genomic_DNA.
DR   EMBL; EU332832; ABY87521.1; -; Genomic_DNA.
DR   EMBL; AL355543; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS7586.1; -.
DR   PIR; A39911; QRHUB1.
DR   RefSeq; NP_000675.1; NM_000684.2.
DR   PDB; 2LSQ; NMR; -; A=197-221.
DR   PDBsum; 2LSQ; -.
DR   SMR; P08588; -.
DR   BioGRID; 106662; 9.
DR   CORUM; P08588; -.
DR   DIP; DIP-36294N; -.
DR   IntAct; P08588; 14.
DR   MINT; P08588; -.
DR   STRING; 9606.ENSP00000358301; -.
DR   BindingDB; P08588; -.
DR   ChEMBL; CHEMBL213; -.
DR   DrugBank; DB08558; 2-HYDROXYMETHYL-6-OCTYLSULFANYL-TETRAHYDRO-PYRAN-3,4,5-TRIOL.
DR   DrugBank; DB08347; 4-{[(2S)-3-(tert-butylamino)-2-hydroxypropyl]oxy}-3H-indole-2-carbonitrile.
DR   DrugBank; DB01193; Acebutolol.
DR   DrugBank; DB00866; Alprenolol.
DR   DrugBank; DB01118; Amiodarone.
DR   DrugBank; DB00182; Amphetamine.
DR   DrugBank; DB01102; Arbutamine.
DR   DrugBank; DB01238; Aripiprazole.
DR   DrugBank; DB09204; Arotinolol.
DR   DrugBank; DB06216; Asenapine.
DR   DrugBank; DB00335; Atenolol.
DR   DrugBank; DB09013; Befunolol.
DR   DrugBank; DB00195; Betaxolol.
DR   DrugBank; DB00217; Bethanidine.
DR   DrugBank; DB01295; Bevantolol.
DR   DrugBank; DB00612; Bisoprolol.
DR   DrugBank; DB08807; Bopindolol.
DR   DrugBank; DB06726; Bufuralol.
DR   DrugBank; DB08808; Bupranolol.
DR   DrugBank; DB00248; Cabergoline.
DR   DrugBank; DB00521; Carteolol.
DR   DrugBank; DB01136; Carvedilol.
DR   DrugBank; DB04846; Celiprolol.
DR   DrugBank; DB01407; Clenbuterol.
DR   DrugBank; DB01151; Desipramine.
DR   DrugBank; DB11273; Dihydroergocornine.
DR   DrugBank; DB13345; Dihydroergocristine.
DR   DrugBank; DB11278; DL-Methylephedrine.
DR   DrugBank; DB00841; Dobutamine.
DR   DrugBank; DB04855; Dronedarone.
DR   DrugBank; DB06262; Droxidopa.
DR   DrugBank; DB01363; Ephedra sinica root.
DR   DrugBank; DB00668; Epinephrine.
DR   DrugBank; DB01049; Ergoloid mesylate.
DR   DrugBank; DB00187; Esmolol.
DR   DrugBank; DB01288; Fenoterol.
DR   DrugBank; DB00983; Formoterol.
DR   DrugBank; DB00221; Isoetharine.
DR   DrugBank; DB01064; Isoprenaline.
DR   DrugBank; DB00598; Labetalol.
DR   DrugBank; DB00555; Lamotrigine.
DR   DrugBank; DB09351; Levobetaxolol.
DR   DrugBank; DB01210; Levobunolol.
DR   DrugBank; DB00408; Loxapine.
DR   DrugBank; DB01365; Mephentermine.
DR   DrugBank; DB01214; Metipranolol.
DR   DrugBank; DB00264; Metoprolol.
DR   DrugBank; DB01203; Nadolol.
DR   DrugBank; DB04861; Nebivolol.
DR   DrugBank; DB00368; Norepinephrine.
DR   DrugBank; DB00540; Nortriptyline.
DR   DrugBank; DB00334; Olanzapine.
DR   DrugBank; DB01580; Oxprenolol.
DR   DrugBank; DB00715; Paroxetine.
DR   DrugBank; DB01359; Penbutolol.
DR   DrugBank; DB00397; Phenylpropanolamine.
DR   DrugBank; DB00960; Pindolol.
DR   DrugBank; DB01291; Pirbuterol.
DR   DrugBank; DB01297; Practolol.
DR   DrugBank; DB01182; Propafenone.
DR   DrugBank; DB00571; Propranolol.
DR   DrugBank; DB00852; Pseudoephedrine.
DR   DrugBank; DB01917; Putrescine.
DR   DrugBank; DB11124; Racepinephrine.
DR   DrugBank; DB00243; Ranolazine.
DR   DrugBank; DB01001; Salbutamol.
DR   DrugBank; DB00938; Salmeterol.
DR   DrugBank; DB00489; Sotalol.
DR   DrugBank; DB03566; Spermidine.
DR   DrugBank; DB00127; Spermine.
DR   DrugBank; DB00871; Terbutaline.
DR   DrugBank; DB00373; Timolol.
DR   DrugBank; DB00726; Trimipramine.
DR   DrugBank; DB09068; Vortioxetine.
DR   DrugBank; DB13781; Xamoterol.
DR   DrugCentral; P08588; -.
DR   GuidetoPHARMACOLOGY; 28; -.
DR   TCDB; 9.A.14.3.11; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; P08588; 1 site.
DR   iPTMnet; P08588; -.
DR   PhosphoSitePlus; P08588; -.
DR   SwissPalm; P08588; -.
DR   BioMuta; ADRB1; -.
DR   DMDM; 48429211; -.
DR   jPOST; P08588; -.
DR   PaxDb; P08588; -.
DR   PeptideAtlas; P08588; -.
DR   PRIDE; P08588; -.
DR   ProteomicsDB; 52133; -.
DR   ABCD; P08588; 1 sequenced antibody.
DR   Antibodypedia; 31906; 265 antibodies.
DR   Ensembl; ENST00000369295; ENSP00000358301; ENSG00000043591.
DR   GeneID; 153; -.
DR   KEGG; hsa:153; -.
DR   UCSC; uc001lba.4; human.
DR   CTD; 153; -.
DR   DisGeNET; 153; -.
DR   EuPathDB; HostDB:ENSG00000043591.5; -.
DR   GeneCards; ADRB1; -.
DR   HGNC; HGNC:285; ADRB1.
DR   HPA; ENSG00000043591; Tissue enhanced (heart muscle, placenta).
DR   MalaCards; ADRB1; -.
DR   MIM; 109630; gene.
DR   MIM; 607276; phenotype.
DR   neXtProt; NX_P08588; -.
DR   PharmGKB; PA38; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   HOGENOM; CLU_009579_11_0_1; -.
DR   InParanoid; P08588; -.
DR   KO; K04141; -.
DR   OrthoDB; 750855at2759; -.
DR   PhylomeDB; P08588; -.
DR   TreeFam; TF316350; -.
DR   PathwayCommons; P08588; -.
DR   Reactome; R-HSA-390696; Adrenoceptors.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-9660821; ADORA2B mediated anti-inflammatory cytokines production.
DR   SignaLink; P08588; -.
DR   SIGNOR; P08588; -.
DR   BioGRID-ORCS; 153; 5 hits in 871 CRISPR screens.
DR   GeneWiki; Beta-1_adrenergic_receptor; -.
DR   GenomeRNAi; 153; -.
DR   Pharos; P08588; Tclin.
DR   PRO; PR:P08588; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; P08588; protein.
DR   Bgee; ENSG00000043591; Expressed in myocardium and 161 other tissues.
DR   Genevisible; P08588; HS.
DR   GO; GO:0005769; C:early endosome; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0098685; C:Schaffer collateral - CA1 synapse; IEA:Ensembl.
DR   GO; GO:0031694; F:alpha-2A adrenergic receptor binding; IPI:BHF-UCL.
DR   GO; GO:0004939; F:beta-adrenergic receptor activity; TAS:ProtInc.
DR   GO; GO:0004940; F:beta1-adrenergic receptor activity; IBA:GO_Central.
DR   GO; GO:0051379; F:epinephrine binding; IBA:GO_Central.
DR   GO; GO:0099579; F:G protein-coupled neurotransmitter receptor activity involved in regulation of postsynaptic membrane potential; IEA:Ensembl.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0051380; F:norepinephrine binding; IBA:GO_Central.
DR   GO; GO:0030165; F:PDZ domain binding; IPI:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0005088; F:Ras guanyl-nucleotide exchange factor activity; IDA:UniProtKB.
DR   GO; GO:0007190; P:activation of adenylate cyclase activity; TAS:ProtInc.
DR   GO; GO:0071880; P:adenylate cyclase-activating adrenergic receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007188; P:adenylate cyclase-modulating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0050873; P:brown fat cell differentiation; IEA:Ensembl.
DR   GO; GO:0002024; P:diet induced thermogenesis; IEA:Ensembl.
DR   GO; GO:0042596; P:fear response; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0031649; P:heat generation; IEA:Ensembl.
DR   GO; GO:0040015; P:negative regulation of multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0002025; P:norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure; IBA:GO_Central.
DR   GO; GO:0120162; P:positive regulation of cold-induced thermogenesis; ISS:YuBioLab.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; IDA:UniProtKB.
DR   GO; GO:0001996; P:positive regulation of heart rate by epinephrine-norepinephrine; IBA:GO_Central.
DR   GO; GO:0001997; P:positive regulation of the force of heart contraction by epinephrine-norepinephrine; IEA:Ensembl.
DR   GO; GO:0045187; P:regulation of circadian sleep/wake cycle, sleep; IMP:UniProtKB.
DR   GO; GO:0009409; P:response to cold; IEA:Ensembl.
DR   InterPro; IPR002233; ADR_fam.
DR   InterPro; IPR000507; ADRB1_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01103; ADRENERGICR.
DR   PRINTS; PR00561; ADRENRGCB1AR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; Endosome;
KW   G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane; Palmitate;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome; Transducer;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..477
FT                   /note="Beta-1 adrenergic receptor"
FT                   /id="PRO_0000069118"
FT   TOPO_DOM        1..55
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        56..84
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        85..93
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        94..120
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        121..132
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        133..154
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        155..172
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        173..196
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        197..222
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        223..248
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        249..319
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        320..349
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        350..354
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        355..377
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        378..477
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   REGION          218..232
FT                   /note="Agonist and antagonist binding"
FT                   /evidence="ECO:0000250"
FT   REGION          337..344
FT                   /note="Agonist and antagonist binding"
FT                   /evidence="ECO:0000250"
FT   REGION          363..367
FT                   /note="Agonist and antagonist binding"
FT                   /evidence="ECO:0000250"
FT   MOTIF           474..477
FT                   /note="PDZ-Binding"
FT   BINDING         138
FT                   /note="Agonist or antagonist"
FT                   /evidence="ECO:0000250"
FT   BINDING         143
FT                   /note="Agonist or antagonist"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         312
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         412
FT                   /note="Phosphoserine; by PKA"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         428
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P18090"
FT   LIPID           392
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        15
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000305"
FT   DISULFID        131..216
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   DISULFID        209..215
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VARIANT         26
FT                   /note="A -> V (in dbSNP:rs34844626)"
FT                   /id="VAR_055909"
FT   VARIANT         29
FT                   /note="A -> T (in dbSNP:rs35720093)"
FT                   /id="VAR_055910"
FT   VARIANT         31
FT                   /note="R -> Q (in dbSNP:rs35230616)"
FT                   /id="VAR_055911"
FT   VARIANT         49
FT                   /note="S -> G (common variant associated with low mean
FT                   resting heart rate; associated with decreased mortality
FT                   risk in patients with congestive heart failure;
FT                   dbSNP:rs1801252)"
FT                   /evidence="ECO:0000269|PubMed:10477438,
FT                   ECO:0000269|PubMed:11052857, ECO:0000269|PubMed:11854867,
FT                   ECO:0000269|Ref.3"
FT                   /id="VAR_009879"
FT   VARIANT         187
FT                   /note="A -> V (rare variant associated with short sleep;
FT                   results in decreased adenylate cyclase-activating
FT                   adrenergic receptor signaling; decreased protein stability;
FT                   dbSNP:rs776439595)"
FT                   /evidence="ECO:0000269|PubMed:31473062"
FT                   /id="VAR_082587"
FT   VARIANT         389
FT                   /note="R -> G (reduced binding to G proteins;
FT                   dbSNP:rs1801253)"
FT                   /evidence="ECO:0000269|PubMed:10212248,
FT                   ECO:0000269|PubMed:10477438, ECO:0000269|PubMed:15164054,
FT                   ECO:0000269|Ref.3"
FT                   /id="VAR_009880"
FT   VARIANT         389
FT                   /note="R -> L (in dbSNP:rs17875445)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_018742"
FT   VARIANT         399
FT                   /note="R -> H (in dbSNP:rs36052953)"
FT                   /id="VAR_055912"
FT   VARIANT         405
FT                   /note="H -> Y (in dbSNP:rs35705839)"
FT                   /id="VAR_055913"
FT   MUTAGEN         474
FT                   /note="E->A,D: Loss of interaction with GOPC."
FT                   /evidence="ECO:0000269|PubMed:15358775"
FT   MUTAGEN         474
FT                   /note="E->K: Loss of interaction with GOPC; when associated
FT                   with A-477."
FT                   /evidence="ECO:0000269|PubMed:15358775"
FT   MUTAGEN         475
FT                   /note="S->A: Loss of interaction with GOPC. Loss of
FT                   interaction with RAPGEF2. Abolishes agonist-induced Ras
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:12391161,
FT                   ECO:0000269|PubMed:15358775"
FT   MUTAGEN         475
FT                   /note="S->D: Loss of interaction with RAPGEF2."
FT                   /evidence="ECO:0000269|PubMed:12391161,
FT                   ECO:0000269|PubMed:15358775"
FT   MUTAGEN         475
FT                   /note="S->T: Partial loss of interaction with GOPC."
FT                   /evidence="ECO:0000269|PubMed:12391161,
FT                   ECO:0000269|PubMed:15358775"
FT   MUTAGEN         476
FT                   /note="K->A: Partial loss of interaction with GOPC."
FT                   /evidence="ECO:0000269|PubMed:15358775"
FT   MUTAGEN         477
FT                   /note="V->A,F,L,I,M: Loss of interaction with GOPC."
FT                   /evidence="ECO:0000269|PubMed:12391161,
FT                   ECO:0000269|PubMed:15358775"
FT   MUTAGEN         477
FT                   /note="V->A: Loss of interaction with RAPGEF2. Abolishes
FT                   agonist-induced Ras activation."
FT                   /evidence="ECO:0000269|PubMed:12391161,
FT                   ECO:0000269|PubMed:15358775"
FT   HELIX           205..208
FT                   /evidence="ECO:0000244|PDB:2LSQ"
FT   HELIX           209..211
FT                   /evidence="ECO:0000244|PDB:2LSQ"
FT   HELIX           213..215
FT                   /evidence="ECO:0000244|PDB:2LSQ"
SQ   SEQUENCE   477 AA;  51323 MW;  0950F2684E4721B8 CRC64;
     MGAGVLVLGA SEPGNLSSAA PLPDGAATAA RLLVPASPPA SLLPPASESP EPLSQQWTAG
     MGLLMALIVL LIVAGNVLVI VAIAKTPRLQ TLTNLFIMSL ASADLVMGLL VVPFGATIVV
     WGRWEYGSFF CELWTSVDVL CVTASIETLC VIALDRYLAI TSPFRYQSLL TRARARGLVC
     TVWAISALVS FLPILMHWWR AESDEARRCY NDPKCCDFVT NRAYAIASSV VSFYVPLCIM
     AFVYLRVFRE AQKQVKKIDS CERRFLGGPA RPPSPSPSPV PAPAPPPGPP RPAAAAATAP
     LANGRAGKRR PSRLVALREQ KALKTLGIIM GVFTLCWLPF FLANVVKAFH RELVPDRLFV
     FFNWLGYANS AFNPIIYCRS PDFRKAFQRL LCCARRAARR RHATHGDRPR ASGCLARPGP
     PPSPGAASDD DDDDVVGATP PARLLEPWAG CNGGAAADSD SSLDEPCRPG FASESKV
//
ID   OPRX_HUMAN              Reviewed;         370 AA.
AC   P41146; Q8TD34; Q8WYH9; Q9H4K4;
DT   01-FEB-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1995, sequence version 1.
DT   12-AUG-2020, entry version 195.
DE   RecName: Full=Nociceptin receptor;
DE   AltName: Full=Kappa-type 3 opioid receptor;
DE            Short=KOR-3;
DE   AltName: Full=Orphanin FQ receptor;
GN   Name=OPRL1; Synonyms=OOR, ORL1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND SUBCELLULAR LOCATION.
RC   TISSUE=Brain stem;
RX   PubMed=8137918; DOI=10.1016/0014-5793(94)80235-1;
RA   Mollereau C., Parmentier M., Mailleux P., Butour J.-L., Moisand C.,
RA   Chalon P., Caput D., Vassart G., Meunier C.;
RT   "ORL1, a novel member of the opioid receptor family. Cloning, functional
RT   expression and localization.";
RL   FEBS Lett. 341:33-38(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Lee P.H., Zhu J., Liu-Chen L., Chang K.;
RL   Submitted (JAN-1996) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RX   PubMed=11238602; DOI=10.4049/jimmunol.166.6.3650;
RA   Serhan C.N., Fierro I.M., Chiang N., Pouliot M.;
RT   "Nociceptin stimulates neutrophil chemotaxis and recruitment: Inhibition by
RT   aspirin-triggered-15-Epi-lipoxin A4.";
RL   J. Immunol. 166:3650-3654(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Pan Y.-X., Xu J., Pasternak G.W.;
RT   "Identification and characterization of a splice variant of human kappa3-
RT   related opioid receptor (KOR-3D) gene.";
RL   Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RA   Warren C.N., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (MAR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M., Beasley O.P.,
RA   Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J., Buck D., Burrill W.D.,
RA   Butler A.P., Carder C., Carter N.P., Chapman J.C., Clamp M., Clark G.,
RA   Clark L.N., Clark S.Y., Clee C.M., Clegg S., Cobley V.E., Collier R.E.,
RA   Connor R.E., Corby N.R., Coulson A., Coville G.J., Deadman R., Dhami P.D.,
RA   Dunn M., Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H., Rice C.M.,
RA   Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S., Skuce C.D.,
RA   Smith M.L., Soderlund C., Steward C.A., Sulston J.E., Swann R.M.,
RA   Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A., Tracey A.,
RA   Tromans A.C., Vaudin M., Wall M., Wallis J.M., Whitehead S.L.,
RA   Whittaker P., Willey D.L., Williams L., Williams S.A., Wilming L.,
RA   Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-333 (ISOFORM 1), TISSUE SPECIFICITY, AND
RP   INDUCTION.
RC   TISSUE=Lymphocyte;
RX   PubMed=7500847; DOI=10.1016/0169-328x(95)00096-b;
RA   Wick M.J., Minnerath S.R., Roy S., Ramakrishnan S., Loh H.H.;
RT   "Expression of alternate forms of brain opioid 'orphan' receptor mRNA in
RT   activated human peripheral blood lymphocytes and lymphocytic cell lines.";
RL   Brain Res. Mol. Brain Res. 32:342-347(1995).
RN   [10]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12568343; DOI=10.1007/s000180200016;
RA   Spampinato S., Di Toro R., Alessandri M., Murari G.;
RT   "Agonist-induced internalization and desensitization of the human
RT   nociceptin receptor expressed in CHO cells.";
RL   Cell. Mol. Life Sci. 59:2172-2183(2002).
RN   [11]
RP   FUNCTION, MUTAGENESIS OF SER-337; SER-346; SER-351 AND SER-363,
RP   PHOSPHORYLATION AT SER-363, AND SUBCELLULAR LOCATION.
RX   PubMed=23086955; DOI=10.1074/jbc.m112.405696;
RA   Zhang N.R., Planer W., Siuda E.R., Zhao H.C., Stickler L., Chang S.D.,
RA   Baird M.A., Cao Y.Q., Bruchas M.R.;
RT   "Serine 363 is required for nociceptin/orphanin FQ opioid receptor (NOPR)
RT   desensitization, internalization, and arrestin signaling.";
RL   J. Biol. Chem. 287:42019-42030(2012).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (3.01 ANGSTROMS) OF 43-339, FUNCTION, SUBCELLULAR
RP   LOCATION, TOPOLOGY, MUTAGENESIS OF GLN-107; ASP-110; ASP-130; TYR-131;
RP   GLN-280 AND TYR-309, AND DISULFIDE BOND.
RX   PubMed=22596163; DOI=10.1038/nature11085;
RA   Thompson A.A., Liu W., Chun E., Katritch V., Wu H., Vardy E., Huang X.P.,
RA   Trapella C., Guerrini R., Calo G., Roth B.L., Cherezov V., Stevens R.C.;
RT   "Structure of the nociceptin/orphanin FQ receptor in complex with a peptide
RT   mimetic.";
RL   Nature 485:395-399(2012).
CC   -!- FUNCTION: G-protein coupled opioid receptor that functions as receptor
CC       for the endogenous neuropeptide nociceptin. Ligand binding causes a
CC       conformation change that triggers signaling via guanine nucleotide-
CC       binding proteins (G proteins) and modulates the activity of down-stream
CC       effectors. Signaling via G proteins mediates inhibition of adenylate
CC       cyclase activity and calcium channel activity. Arrestins modulate
CC       signaling via G proteins and mediate the activation of alternative
CC       signaling pathways that lead to the activation of MAP kinases. Plays a
CC       role in modulating nociception and the perception of pain. Plays a role
CC       in the regulation of locomotor activity by the neuropeptide nociceptin.
CC       {ECO:0000269|PubMed:11238602, ECO:0000269|PubMed:12568343,
CC       ECO:0000269|PubMed:22596163, ECO:0000269|PubMed:23086955,
CC       ECO:0000269|PubMed:8137918}.
CC   -!- INTERACTION:
CC       P41146; Q6ZMG9: CERS6; NbExp=2; IntAct=EBI-2624699, EBI-20794243;
CC       P41146; PRO_0000008327 [Q13519]: PNOC; NbExp=2; IntAct=EBI-2624699, EBI-6656256;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC       Cytoplasmic vesicle. Note=Ligand binding leads to receptor
CC       internalization into cytoplasmic vesicles, decreasing the amount of
CC       available receptor at the cell surface. Internalization requires
CC       phosphorylation at Ser-363. Can recycle to the cell membrane.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P41146-1; Sequence=Displayed;
CC       Name=2; Synonyms=KOR-3D;
CC         IsoId=P41146-2; Sequence=VSP_001897;
CC   -!- TISSUE SPECIFICITY: Detected in blood leukocytes.
CC       {ECO:0000269|PubMed:7500847}.
CC   -!- INDUCTION: By phytohemagglutinin (PHA). {ECO:0000269|PubMed:7500847}.
CC   -!- PTM: Phosphorylation at Ser-363 requires GRK3.
CC       {ECO:0000269|PubMed:23086955}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X77130; CAA54386.1; -; mRNA.
DR   EMBL; U30185; AAA84913.1; -; mRNA.
DR   EMBL; AF348323; AAK11714.1; -; mRNA.
DR   EMBL; AF126470; AAL54890.1; -; mRNA.
DR   EMBL; AY268428; AAP23195.1; -; mRNA.
DR   EMBL; CR542061; CAG46858.1; -; mRNA.
DR   EMBL; AL121581; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL590548; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC038433; AAH38433.1; -; mRNA.
DR   EMBL; L40949; AAA96251.1; -; mRNA.
DR   CCDS; CCDS13556.1; -. [P41146-1]
DR   PIR; S43087; S43087.
DR   RefSeq; NP_000904.1; NM_000913.5. [P41146-1]
DR   RefSeq; NP_001186948.1; NM_001200019.1. [P41146-1]
DR   RefSeq; NP_001305782.1; NM_001318853.1.
DR   RefSeq; NP_001305783.1; NM_001318854.1. [P41146-2]
DR   RefSeq; NP_001305784.1; NM_001318855.1.
DR   RefSeq; NP_872588.1; NM_182647.3. [P41146-1]
DR   RefSeq; XP_016883343.1; XM_017027854.1. [P41146-1]
DR   RefSeq; XP_016883344.1; XM_017027855.1. [P41146-2]
DR   PDB; 4EA3; X-ray; 3.01 A; A/B=43-339.
DR   PDB; 5DHG; X-ray; 3.00 A; A/B=43-339.
DR   PDB; 5DHH; X-ray; 3.00 A; A/B=43-339.
DR   PDBsum; 4EA3; -.
DR   PDBsum; 5DHG; -.
DR   PDBsum; 5DHH; -.
DR   SMR; P41146; -.
DR   BioGRID; 111032; 4.
DR   IntAct; P41146; 7.
DR   MINT; P41146; -.
DR   STRING; 9606.ENSP00000336764; -.
DR   BindingDB; P41146; -.
DR   ChEMBL; CHEMBL2014; -.
DR   DrugBank; DB00921; Buprenorphine.
DR   DrugBank; DB05492; Epicept NP-1.
DR   DrugBank; DB01497; Etorphine.
DR   DrugCentral; P41146; -.
DR   GuidetoPHARMACOLOGY; 320; -.
DR   GlyGen; P41146; 3 sites.
DR   iPTMnet; P41146; -.
DR   PhosphoSitePlus; P41146; -.
DR   BioMuta; OPRL1; -.
DR   DMDM; 730230; -.
DR   PaxDb; P41146; -.
DR   PRIDE; P41146; -.
DR   ProteomicsDB; 55404; -. [P41146-1]
DR   ProteomicsDB; 55405; -. [P41146-2]
DR   Antibodypedia; 29994; 218 antibodies.
DR   DNASU; 4987; -.
DR   Ensembl; ENST00000336866; ENSP00000336843; ENSG00000125510. [P41146-1]
DR   Ensembl; ENST00000349451; ENSP00000336764; ENSG00000125510. [P41146-1]
DR   Ensembl; ENST00000355631; ENSP00000347848; ENSG00000125510. [P41146-1]
DR   GeneID; 4987; -.
DR   KEGG; hsa:4987; -.
DR   UCSC; uc002yic.4; human. [P41146-1]
DR   CTD; 4987; -.
DR   DisGeNET; 4987; -.
DR   EuPathDB; HostDB:ENSG00000125510.15; -.
DR   GeneCards; OPRL1; -.
DR   HGNC; HGNC:8155; OPRL1.
DR   HPA; ENSG00000125510; Tissue enhanced (blood, brain).
DR   MIM; 602548; gene.
DR   neXtProt; NX_P41146; -.
DR   OpenTargets; ENSG00000125510; -.
DR   PharmGKB; PA31944; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00940000160661; -.
DR   HOGENOM; CLU_009579_8_1_1; -.
DR   InParanoid; P41146; -.
DR   KO; K04216; -.
DR   OMA; VNICIWA; -.
DR   OrthoDB; 1011272at2759; -.
DR   PhylomeDB; P41146; -.
DR   TreeFam; TF315737; -.
DR   PathwayCommons; P41146; -.
DR   Reactome; R-HSA-375276; Peptide ligand-binding receptors.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   SIGNOR; P41146; -.
DR   BioGRID-ORCS; 4987; 5 hits in 868 CRISPR screens.
DR   ChiTaRS; OPRL1; human.
DR   GeneWiki; Nociceptin_receptor; -.
DR   GenomeRNAi; 4987; -.
DR   Pharos; P41146; Tchem.
DR   PRO; PR:P41146; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   RNAct; P41146; protein.
DR   Bgee; ENSG00000125510; Expressed in blood and 119 other tissues.
DR   Genevisible; P41146; HS.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IEA:UniProtKB-KW.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IMP:UniProtKB.
DR   GO; GO:0042923; F:neuropeptide binding; IBA:GO_Central.
DR   GO; GO:0001626; F:nociceptin receptor activity; IDA:UniProtKB.
DR   GO; GO:0042277; F:peptide binding; IBA:GO_Central.
DR   GO; GO:0008022; F:protein C-terminus binding; IEA:Ensembl.
DR   GO; GO:0007193; P:adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:1990708; P:conditioned place preference; IEA:Ensembl.
DR   GO; GO:0042755; P:eating behavior; IEA:Ensembl.
DR   GO; GO:0044849; P:estrous cycle; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0106072; P:negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0045776; P:negative regulation of blood pressure; IEA:Ensembl.
DR   GO; GO:1901386; P:negative regulation of voltage-gated calcium channel activity; IEA:Ensembl.
DR   GO; GO:0007218; P:neuropeptide signaling pathway; IBA:GO_Central.
DR   GO; GO:0038003; P:opioid receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0051482; P:positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway; IPI:UniProtKB.
DR   GO; GO:0060454; P:positive regulation of gastric acid secretion; IEA:Ensembl.
DR   GO; GO:1904058; P:positive regulation of sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0035810; P:positive regulation of urine volume; IEA:Ensembl.
DR   GO; GO:1904059; P:regulation of locomotor rhythm; IEA:Ensembl.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0007600; P:sensory perception; TAS:ProtInc.
DR   GO; GO:0019233; P:sensory perception of pain; ISS:UniProtKB.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR001418; Opioid_rcpt.
DR   InterPro; IPR001420; X_opioid_rcpt.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00384; OPIOIDR.
DR   PRINTS; PR00547; XOPIOIDR.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Behavior; Cell membrane;
KW   Cytoplasmic vesicle; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Lipoprotein; Membrane; Palmitate; Phosphoprotein; Receptor;
KW   Reference proteome; Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..370
FT                   /note="Nociceptin receptor"
FT                   /id="PRO_0000069980"
FT   TOPO_DOM        1..48
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:22596163"
FT   TRANSMEM        49..74
FT                   /note="Helical; Name=1"
FT   TOPO_DOM        75..87
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:22596163"
FT   TRANSMEM        88..109
FT                   /note="Helical; Name=2"
FT   TOPO_DOM        110..124
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:22596163"
FT   TRANSMEM        125..146
FT                   /note="Helical; Name=3"
FT   TOPO_DOM        147..165
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:22596163"
FT   TRANSMEM        166..188
FT                   /note="Helical; Name=4"
FT   TOPO_DOM        189..211
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:22596163"
FT   TRANSMEM        212..236
FT                   /note="Helical; Name=5"
FT   TOPO_DOM        237..264
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:22596163"
FT   TRANSMEM        265..285
FT                   /note="Helical; Name=6"
FT   TOPO_DOM        286..300
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:22596163"
FT   TRANSMEM        301..322
FT                   /note="Helical; Name=7"
FT   TOPO_DOM        323..370
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:22596163"
FT   SITE            110
FT                   /note="Important for G protein-mediated signaling"
FT   SITE            130
FT                   /note="Important for G protein-mediated signaling"
FT   MOD_RES         363
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000305|PubMed:23086955"
FT   LIPID           334
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        21
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        28
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        39
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        123..200
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521,
FT                   ECO:0000269|PubMed:22596163"
FT   VAR_SEQ         74..78
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.4"
FT                   /id="VSP_001897"
FT   MUTAGEN         107
FT                   /note="Q->A: Impairs G protein-mediated inhibition of
FT                   adenylate cyclase."
FT                   /evidence="ECO:0000269|PubMed:22596163"
FT   MUTAGEN         110
FT                   /note="D->A: Abolishes G protein-mediated inhibition of
FT                   adenylate cyclase. No effect on antagonist-mediated
FT                   inhibition of G protein-mediated signaling."
FT                   /evidence="ECO:0000269|PubMed:22596163"
FT   MUTAGEN         130
FT                   /note="D->A: Abolishes G protein-mediated inhibition of
FT                   adenylate cyclase. Abolishes antagonist-mediated inhibition
FT                   of G protein-mediated signaling."
FT                   /evidence="ECO:0000269|PubMed:22596163"
FT   MUTAGEN         131
FT                   /note="Y->A: Impairs G protein-mediated inhibition of
FT                   adenylate cyclase."
FT                   /evidence="ECO:0000269|PubMed:22596163"
FT   MUTAGEN         280
FT                   /note="Q->A: Impairs G protein-mediated inhibition of
FT                   adenylate cyclase."
FT                   /evidence="ECO:0000269|PubMed:22596163"
FT   MUTAGEN         309
FT                   /note="Y->A: Mildly impairs G protein-mediated inhibition
FT                   of adenylate cyclase. Abolishes antagonist-mediated
FT                   inhibition of G protein-mediated signaling."
FT                   /evidence="ECO:0000269|PubMed:22596163"
FT   MUTAGEN         337
FT                   /note="S->A: No effect on ligand-mediated internalization;
FT                   when associated with A-346 and A-351."
FT                   /evidence="ECO:0000269|PubMed:23086955"
FT   MUTAGEN         346
FT                   /note="S->A: No effect on ligand-mediated internalization;
FT                   when associated with A-337 and A-351."
FT                   /evidence="ECO:0000269|PubMed:23086955"
FT   MUTAGEN         351
FT                   /note="S->A: No effect on ligand-mediated internalization;
FT                   when associated with A-337 and A-346."
FT                   /evidence="ECO:0000269|PubMed:23086955"
FT   MUTAGEN         363
FT                   /note="S->A: Impairs ligand-mediated internalization."
FT                   /evidence="ECO:0000269|PubMed:23086955"
FT   HELIX           48..77
FT                   /evidence="ECO:0000244|PDB:5DHG"
FT   HELIX           85..113
FT                   /evidence="ECO:0000244|PDB:5DHG"
FT   HELIX           119..153
FT                   /evidence="ECO:0000244|PDB:5DHG"
FT   HELIX           157..160
FT                   /evidence="ECO:0000244|PDB:5DHG"
FT   HELIX           164..188
FT                   /evidence="ECO:0000244|PDB:5DHG"
FT   STRAND          189..192
FT                   /evidence="ECO:0000244|PDB:5DHG"
FT   STRAND          194..197
FT                   /evidence="ECO:0000244|PDB:5DHG"
FT   STRAND          199..202
FT                   /evidence="ECO:0000244|PDB:5DHG"
FT   HELIX           208..223
FT                   /evidence="ECO:0000244|PDB:5DHG"
FT   HELIX           225..242
FT                   /evidence="ECO:0000244|PDB:5DHG"
FT   HELIX           252..287
FT                   /evidence="ECO:0000244|PDB:5DHG"
FT   HELIX           295..322
FT                   /evidence="ECO:0000244|PDB:5DHG"
FT   HELIX           324..330
FT                   /evidence="ECO:0000244|PDB:5DHG"
SQ   SEQUENCE   370 AA;  40693 MW;  613700C0B4D093BA CRC64;
     MEPLFPAPFW EVIYGSHLQG NLSLLSPNHS LLPPHLLLNA SHGAFLPLGL KVTIVGLYLA
     VCVGGLLGNC LVMYVILRHT KMKTATNIYI FNLALADTLV LLTLPFQGTD ILLGFWPFGN
     ALCKTVIAID YYNMFTSTFT LTAMSVDRYV AICHPIRALD VRTSSKAQAV NVAIWALASV
     VGVPVAIMGS AQVEDEEIEC LVEIPTPQDY WGPVFAICIF LFSFIVPVLV ISVCYSLMIR
     RLRGVRLLSG SREKDRNLRR ITRLVLVVVA VFVGCWTPVQ VFVLAQGLGV QPSSETAVAI
     LRFCTALGYV NSCLNPILYA FLDENFKACF RKFCCASALR RDVQVSDRVR SIAKDVALAC
     KTSETVPRPA
//
ID   PD2R2_HUMAN             Reviewed;         395 AA.
AC   Q9Y5Y4; O94765; Q4QRI6;
DT   11-JUL-2001, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 3.
DT   12-AUG-2020, entry version 157.
DE   RecName: Full=Prostaglandin D2 receptor 2;
DE   AltName: Full=Chemoattractant receptor-homologous molecule expressed on Th2 cells;
DE   AltName: Full=G-protein coupled receptor 44;
DE   AltName: CD_antigen=CD294;
GN   Name=PTGDR2; Synonyms=CRTH2, DL1R, GPR44;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ALA-204.
RX   PubMed=10036181; DOI=10.1006/geno.1998.5655;
RA   Marchese A., Sawzdargo M., Nguyen T., Cheng R., Heng H.H.Q., Nowak T.,
RA   Im D.-S., Lynch K.R., George S.R., O'Dowd B.F.;
RT   "Discovery of three novel orphan G-protein-coupled receptors.";
RL   Genomics 56:12-21(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND VARIANT ALA-204.
RC   TISSUE=Blood;
RX   PubMed=9973380;
RA   Nagata K., Tanaka K., Ogawa K., Kemmotsu K., Imai T., Yoshie O., Abe H.,
RA   Tada K., Nakamura M., Sugamura K., Takano S.;
RT   "Selective expression of a novel surface molecule by human Th2 cells in
RT   vivo.";
RL   J. Immunol. 162:1278-1286(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ALA-204.
RC   TISSUE=Placenta;
RA   Methner A., Schroeder S.;
RT   "Tissue expression and chromosomal organization of a novel G protein-
RT   coupled receptor.";
RL   Submitted (MAR-1999) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ALA-204.
RC   TISSUE=Placenta;
RA   King M.M., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (DEC-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ALA-204.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION AS RECEPTOR FOR PGD2.
RX   PubMed=11535533; DOI=10.1182/blood.v98.6.1942;
RA   Monneret G., Gravel S., Diamond M., Rokach J., Powell W.S.;
RT   "Prostaglandin D2 is a potent chemoattractant for human eosinophils that
RT   acts via a novel DP receptor.";
RL   Blood 98:1942-1948(2001).
RN   [8]
RP   TISSUE SPECIFICITY.
RX   PubMed=11168006; DOI=10.1046/j.1365-2249.2001.01422.x;
RA   Tsuda H., Michimata T., Sakai M., Nagata K., Nakamura M., Saito S.;
RT   "A novel surface molecule of Th2- and Tc2-type cells, CRTH2 expression on
RT   human peripheral and decidual CD4+ and CD8+ T cells during the early stage
RT   of pregnancy.";
RL   Clin. Exp. Immunol. 123:105-111(2001).
RN   [9]
RP   FUNCTION AS RECEPTOR FOR PGD2, AND TISSUE SPECIFICITY.
RX   PubMed=11208866; DOI=10.1084/jem.193.2.255;
RA   Hirai H., Tanaka K., Yoshie O., Ogawa K., Kenmotsu K., Takamori Y.,
RA   Ichimasa M., Sugamura K., Nakamura M., Takano S., Nagata K.;
RT   "Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells,
RT   eosinophils, and basophils via seven-transmembrane receptor CRTH2.";
RL   J. Exp. Med. 193:255-261(2001).
RN   [10]
RP   TISSUE SPECIFICITY, AND CHARACTERIZATION.
RX   PubMed=12466225; DOI=10.1038/sj.bjp.0704973;
RA   Sawyer N., Cauchon E., Chateauneuf A., Cruz R.P., Nicholson D.W.,
RA   Metters K.M., O'Neill G.P., Gervais F.G.;
RT   "Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2.";
RL   Br. J. Pharmacol. 137:1163-1172(2002).
RN   [11]
RP   FUNCTION AS PGD2 RECEPTOR, AND FUNCTION IN PI3K SIGNALING.
RX   PubMed=17196174; DOI=10.1016/j.bcp.2006.11.021;
RA   Xue L., Gyles S.L., Barrow A., Pettipher R.;
RT   "Inhibition of PI3K and calcineurin suppresses chemoattractant receptor-
RT   homologous molecule expressed on Th2 cells (CRTH2)-dependent responses of
RT   Th2 lymphocytes to prostaglandin D(2).";
RL   Biochem. Pharmacol. 73:843-853(2007).
RN   [12]
RP   SUBCELLULAR LOCATION, AND PHOSPHORYLATION.
RX   PubMed=17207480; DOI=10.1016/j.ejphar.2006.11.058;
RA   Gallant M.A., Slipetz D., Hamelin E., Rochdi M.D., Talbot S.,
RA   de Brum-Fernandes A.J., Parent J.L.;
RT   "Differential regulation of the signaling and trafficking of the two
RT   prostaglandin D2 receptors, prostanoid DP receptor and CRTH2.";
RL   Eur. J. Pharmacol. 557:115-123(2007).
RN   [13]
RP   MUTAGENESIS OF ASP-330; SER-331; GLU-332; LEU-333 AND THR-347, AND
RP   IDENTIFICATION OF A RECYCLING MOTIF.
RX   PubMed=20035740; DOI=10.1016/j.ejphar.2009.12.022;
RA   Roy S.J., Parent A., Gallant M.A., de Brum-Fernandes A.J., Stankova J.,
RA   Parent J.L.;
RT   "Characterization of C-terminal tail determinants involved in CRTH2
RT   receptor trafficking: identification of a recycling motif.";
RL   Eur. J. Pharmacol. 630:10-18(2010).
CC   -!- FUNCTION: Receptor for prostaglandin D2 (PGD2). Coupled to the G(i)-
CC       protein. Receptor activation may result in pertussis toxin-sensitive
CC       decreases in cAMP levels and Ca(2+) mobilization. PI3K signaling is
CC       also implicated in mediating PTGDR2 effects. PGD2 induced receptor
CC       internalization. CRTH2 internalization can be regulated by diverse
CC       kinases such as, PKC, PKA, GRK2, GPRK5/GRK5 and GRK6. Receptor
CC       activation is responsible, at least in part, in immune regulation and
CC       allergic/inflammation responses. {ECO:0000269|PubMed:11208866,
CC       ECO:0000269|PubMed:11535533, ECO:0000269|PubMed:17196174}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}; Multi-pass membrane
CC       protein {ECO:0000305}. Note=Internalized receptors colocalized with
CC       RAB11A. {ECO:0000269|PubMed:17207480}.
CC   -!- TISSUE SPECIFICITY: Widespread expression. High expression in stomach,
CC       small intestine, heart and thymus. Intermediate expression in colon,
CC       spinal cord and peripheral blood and low expression in brain, skeletal
CC       muscle and spleen. Expressed also on Th2- and Tc2- type cells,
CC       eosinophils and basophils. {ECO:0000269|PubMed:11168006,
CC       ECO:0000269|PubMed:11208866, ECO:0000269|PubMed:12466225,
CC       ECO:0000269|PubMed:9973380}.
CC   -!- DOMAIN: The 330-DSEL-333 motif is involved in the recycling of PTGDR2
CC       to the cell surface after agonist-induced internalization. This motif
CC       seems to be required for GRK2 and GPRK5/GRK5 to promote agonist-induced
CC       internalization. Thr-347 is a major site for PKC-induced
CC       internalization of the receptor.
CC   -!- PTM: Phosphorylated. {ECO:0000269|PubMed:17207480}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD21055.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAD21055.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF118265; AAD21055.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AB008535; BAA74518.1; -; mRNA.
DR   EMBL; AF144308; AAD34539.1; -; mRNA.
DR   EMBL; AY507142; AAR92484.1; -; mRNA.
DR   EMBL; AP000777; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC096841; AAH96841.1; -; mRNA.
DR   CCDS; CCDS7994.1; -.
DR   RefSeq; NP_004769.2; NM_004778.2.
DR   PDB; 6D26; X-ray; 2.80 A; A=1-339.
DR   PDB; 6D27; X-ray; 2.74 A; A=1-339.
DR   PDBsum; 6D26; -.
DR   PDBsum; 6D27; -.
DR   SMR; Q9Y5Y4; -.
DR   BioGRID; 116412; 4.
DR   STRING; 9606.ENSP00000332812; -.
DR   BindingDB; Q9Y5Y4; -.
DR   ChEMBL; CHEMBL5071; -.
DR   DrugBank; DB00770; Alprostadil.
DR   DrugBank; DB12789; Dinoprost.
DR   DrugBank; DB00917; Dinoprostone.
DR   DrugBank; DB01088; Iloprost.
DR   DrugBank; DB00328; Indomethacin.
DR   DrugBank; DB02056; Prostaglandin D2.
DR   DrugBank; DB13036; Ramatroban.
DR   DrugBank; DB00605; Sulindac.
DR   DrugBank; DB04828; Zomepirac.
DR   DrugCentral; Q9Y5Y4; -.
DR   GuidetoPHARMACOLOGY; 339; -.
DR   SwissLipids; SLP:000001575; -.
DR   GlyGen; Q9Y5Y4; 2 sites.
DR   iPTMnet; Q9Y5Y4; -.
DR   PhosphoSitePlus; Q9Y5Y4; -.
DR   BioMuta; PTGDR2; -.
DR   DMDM; 296439334; -.
DR   MassIVE; Q9Y5Y4; -.
DR   PaxDb; Q9Y5Y4; -.
DR   PeptideAtlas; Q9Y5Y4; -.
DR   PRIDE; Q9Y5Y4; -.
DR   ProteomicsDB; 86540; -.
DR   Antibodypedia; 2960; 630 antibodies.
DR   DNASU; 11251; -.
DR   Ensembl; ENST00000332539; ENSP00000332812; ENSG00000183134.
DR   GeneID; 11251; -.
DR   KEGG; hsa:11251; -.
DR   UCSC; uc001nqc.3; human.
DR   CTD; 11251; -.
DR   DisGeNET; 11251; -.
DR   EuPathDB; HostDB:ENSG00000183134.4; -.
DR   GeneCards; PTGDR2; -.
DR   HGNC; HGNC:4502; PTGDR2.
DR   HPA; ENSG00000183134; Tissue enhanced (blood, lymphoid tissue).
DR   MIM; 604837; gene.
DR   neXtProt; NX_Q9Y5Y4; -.
DR   OpenTargets; ENSG00000183134; -.
DR   PharmGKB; PA28891; -.
DR   eggNOG; ENOG502QTYS; Eukaryota.
DR   GeneTree; ENSGT00940000162009; -.
DR   HOGENOM; CLU_009579_8_0_1; -.
DR   InParanoid; Q9Y5Y4; -.
DR   KO; K06715; -.
DR   OMA; FRDTIPR; -.
DR   OrthoDB; 1102944at2759; -.
DR   PhylomeDB; Q9Y5Y4; -.
DR   TreeFam; TF330976; -.
DR   PathwayCommons; Q9Y5Y4; -.
DR   Reactome; R-HSA-391908; Prostanoid ligand receptors.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   BioGRID-ORCS; 11251; 3 hits in 873 CRISPR screens.
DR   GeneWiki; GPR44; -.
DR   GenomeRNAi; 11251; -.
DR   Pharos; Q9Y5Y4; Tchem.
DR   PRO; PR:Q9Y5Y4; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q9Y5Y4; protein.
DR   Bgee; ENSG00000183134; Expressed in mucosa of transverse colon and 92 other tissues.
DR   Genevisible; Q9Y5Y4; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0043005; C:neuron projection; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IDA:UniProtKB.
DR   GO; GO:0042923; F:neuropeptide binding; IBA:GO_Central.
DR   GO; GO:0042277; F:peptide binding; IBA:GO_Central.
DR   GO; GO:0004956; F:prostaglandin D receptor activity; IDA:UniProtKB.
DR   GO; GO:0004958; F:prostaglandin F receptor activity; IEA:Ensembl.
DR   GO; GO:0001785; F:prostaglandin J receptor activity; IEA:Ensembl.
DR   GO; GO:0007193; P:adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0019722; P:calcium-mediated signaling; IDA:UniProtKB.
DR   GO; GO:0006935; P:chemotaxis; IDA:UniProtKB.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0006955; P:immune response; TAS:ProtInc.
DR   GO; GO:2000255; P:negative regulation of male germ cell proliferation; IEA:Ensembl.
DR   GO; GO:0007218; P:neuropeptide signaling pathway; IBA:GO_Central.
DR   GO; GO:0045745; P:positive regulation of G protein-coupled receptor signaling pathway; IEA:Ensembl.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Membrane; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..395
FT                   /note="Prostaglandin D2 receptor 2"
FT                   /id="PRO_0000069572"
FT   TOPO_DOM        1..33
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        34..56
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        57..67
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        68..89
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        90..106
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        107..127
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        128..146
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        147..168
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        169..210
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        211..231
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        232..247
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        248..269
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        270..288
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        289..308
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        309..395
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   MOTIF           330..333
FT                   /note="Involved in the recycling of CRTH2"
FT   MOD_RES         331
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6XKD3"
FT   MOD_RES         345
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9Z2J6"
FT   CARBOHYD        4
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        25
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        104..182
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VARIANT         204
FT                   /note="V -> A (in dbSNP:rs2467642)"
FT                   /evidence="ECO:0000269|PubMed:10036181,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:9973380,
FT                   ECO:0000269|Ref.3, ECO:0000269|Ref.4"
FT                   /id="VAR_063131"
FT   MUTAGEN         330
FT                   /note="D->A: 45% increases internalization of PTGDR2."
FT                   /evidence="ECO:0000269|PubMed:20035740"
FT   MUTAGEN         331
FT                   /note="S->A: 45% increases internalization of PTGDR2."
FT                   /evidence="ECO:0000269|PubMed:20035740"
FT   MUTAGEN         332
FT                   /note="E->A: 45% increases internalization of PTGDR2."
FT                   /evidence="ECO:0000269|PubMed:20035740"
FT   MUTAGEN         333
FT                   /note="L->A: 45% increase in internalization of PTGDR2."
FT                   /evidence="ECO:0000269|PubMed:20035740"
FT   MUTAGEN         347
FT                   /note="T->A: Decreases in PKC-induced internalization of
FT                   PTGDR2."
FT                   /evidence="ECO:0000269|PubMed:20035740"
FT   HELIX           12..17
FT                   /evidence="ECO:0000244|PDB:6D27"
FT   STRAND          22..25
FT                   /evidence="ECO:0000244|PDB:6D26"
FT   HELIX           33..59
FT                   /evidence="ECO:0000244|PDB:6D27"
FT   HELIX           66..92
FT                   /evidence="ECO:0000244|PDB:6D27"
FT   HELIX           102..134
FT                   /evidence="ECO:0000244|PDB:6D27"
FT   HELIX           136..142
FT                   /evidence="ECO:0000244|PDB:6D27"
FT   HELIX           145..162
FT                   /evidence="ECO:0000244|PDB:6D27"
FT   HELIX           164..168
FT                   /evidence="ECO:0000244|PDB:6D27"
FT   STRAND          170..174
FT                   /evidence="ECO:0000244|PDB:6D27"
FT   STRAND          176..178
FT                   /evidence="ECO:0000244|PDB:6D27"
FT   STRAND          180..184
FT                   /evidence="ECO:0000244|PDB:6D27"
FT   HELIX           186..188
FT                   /evidence="ECO:0000244|PDB:6D26"
FT   HELIX           195..213
FT                   /evidence="ECO:0000244|PDB:6D27"
FT   HELIX           216..236
FT                   /evidence="ECO:0000244|PDB:6D27"
FT   HELIX           245..258
FT                   /evidence="ECO:0000244|PDB:6D27"
FT   HELIX           260..271
FT                   /evidence="ECO:0000244|PDB:6D27"
FT   TURN            272..274
FT                   /evidence="ECO:0000244|PDB:6D27"
FT   HELIX           276..278
FT                   /evidence="ECO:0000244|PDB:6D27"
FT   HELIX           279..294
FT                   /evidence="ECO:0000244|PDB:6D27"
FT   HELIX           296..306
FT                   /evidence="ECO:0000244|PDB:6D27"
FT   HELIX           309..326
FT                   /evidence="ECO:0000244|PDB:6D27"
SQ   SEQUENCE   395 AA;  43268 MW;  99A63CBDA418DEC9 CRC64;
     MSANATLKPL CPILEQMSRL QSHSNTSIRY IDHAAVLLHG LASLLGLVEN GVILFVVGCR
     MRQTVVTTWV LHLALSDLLA SASLPFFTYF LAVGHSWELG TTFCKLHSSI FFLNMFASGF
     LLSAISLDRC LQVVRPVWAQ NHRTVAAAHK VCLVLWALAV LNTVPYFVFR DTISRLDGRI
     MCYYNVLLLN PGPDRDATCN SRQVALAVSK FLLAFLVPLA IIASSHAAVS LRLQHRGRRR
     PGRFVRLVAA VVAAFALCWG PYHVFSLLEA RAHANPGLRP LVWRGLPFVT SLAFFNSVAN
     PVLYVLTCPD MLRKLRRSLR TVLESVLVDD SELGGAGSSR RRRTSSTARS ASPLALCSRP
     EEPRGPARLL GWLLGSCAAS PQTGPLNRAL SSTSS
//
ID   OPSG_HUMAN              Reviewed;         364 AA.
AC   P04001;
DT   23-OCT-1986, integrated into UniProtKB/Swiss-Prot.
DT   23-OCT-1986, sequence version 1.
DT   12-AUG-2020, entry version 195.
DE   RecName: Full=Medium-wave-sensitive opsin 1 {ECO:0000305};
DE   AltName: Full=Green cone photoreceptor pigment;
DE   AltName: Full=Green-sensitive opsin;
DE            Short=GOP;
GN   Name=OPN1MW {ECO:0000312|HGNC:HGNC:4206}; Synonyms=GCP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Retinal cone cell;
RX   PubMed=2937147; DOI=10.1126/science.2937147;
RA   Nathans J., Thomas D., Hogness D.S.;
RT   "Molecular genetics of human color vision: the genes encoding blue, green,
RT   and red pigments.";
RL   Science 232:193-202(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [3]
RP   REVIEW.
RX   PubMed=3303660; DOI=10.1016/0042-6989(86)90115-x;
RA   Applebury M.L., Hargrave P.A.;
RT   "Molecular biology of the visual pigments.";
RL   Vision Res. 26:1881-1895(1986).
RN   [4]
RP   SUBUNIT, GLYCOSYLATION AT ASN-34, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=28402104; DOI=10.1021/acs.biochem.7b00165;
RA   Hofmann L., Alexander N.S., Sun W., Zhang J., Orban T., Palczewski K.;
RT   "Hydrogen/deuterium exchange mass spectrometry of human green opsin reveals
RT   a conserved Pro-Pro motif in extracellular loop 2 of monostable visual G
RT   protein-coupled receptors.";
RL   Biochemistry 56:2338-2348(2017).
RN   [5]
RP   VARIANT CBD ARG-203, AND FUNCTION.
RX   PubMed=1302020; DOI=10.1038/ng0792-251;
RA   Winderickx J., Sanocki E., Lindsey D.T., Teller D.Y., Motulsky A.G.,
RA   Deeb S.S.;
RT   "Defective colour vision associated with a missense mutation in the human
RT   green visual pigment gene.";
RL   Nat. Genet. 1:251-256(1992).
RN   [6]
RP   GLYCOSYLATION, AND REGION.
RX   PubMed=30948514; DOI=10.1074/jbc.ra118.006835;
RA   Salom D., Jin H., Gerken T.A., Yu C., Huang L., Palczewski K.;
RT   "Human red and green cone opsins are O-glycosylated at an N-terminal
RT   Ser/Thr-rich domain conserved in vertebrates.";
RL   J. Biol. Chem. 294:8123-8133(2019).
RN   [7]
RP   VARIANT BCM ARG-203.
RX   PubMed=8666378; DOI=10.1006/geno.1995.9998;
RA   Reyniers E., Van Thienen M.N., Meire F., De Boulle K., Devries K.,
RA   Kestelijn P., Willems P.J.;
RT   "Gene conversion between red and defective green opsin gene in blue cone
RT   monochromacy.";
RL   Genomics 29:323-328(1995).
RN   [8]
RP   VARIANTS CBD LYS-94 AND GLN-330, AND FUNCTION.
RX   PubMed=12051694; DOI=10.1016/s0006-291x(02)00458-8;
RA   Ueyama H., Kuwayama S., Imai H., Tanabe S., Oda S., Nishida Y., Wada A.,
RA   Shichida Y., Yamade S.;
RT   "Novel missense mutations in red/green opsin genes in congenital color-
RT   vision deficiencies.";
RL   Biochem. Biophys. Res. Commun. 294:205-209(2002).
RN   [9]
RP   VARIANT COD5 ARG-177, CHARACTERIZATION OF VARIANT COD5 ARG-177, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=20579627; DOI=10.1016/j.ajhg.2010.05.019;
RA   Gardner J.C., Webb T.R., Kanuga N., Robson A.G., Holder G.E., Stockman A.,
RA   Ripamonti C., Ebenezer N.D., Ogun O., Devery S., Wright G.A., Maher E.R.,
RA   Cheetham M.E., Moore A.T., Michaelides M., Hardcastle A.J.;
RT   "X-linked cone dystrophy caused by mutation of the red and green cone
RT   opsins.";
RL   Am. J. Hum. Genet. 87:26-39(2010).
CC   -!- FUNCTION: Visual pigments are the light-absorbing molecules that
CC       mediate vision. They consist of an apoprotein, opsin, covalently linked
CC       to cis-retinal. {ECO:0000305|PubMed:12051694,
CC       ECO:0000305|PubMed:1302020, ECO:0000305|PubMed:2937147}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Absorption:
CC         Abs(max)=530 nm {ECO:0000305|PubMed:2937147};
CC   -!- SUBUNIT: Monomer. Homodimer. Homotetramer.
CC       {ECO:0000269|PubMed:28402104}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:20579627};
CC       Multi-pass membrane protein {ECO:0000255}.
CC   -!- TISSUE SPECIFICITY: The three color pigments are found in the cone
CC       photoreceptor cells. {ECO:0000305|PubMed:2937147}.
CC   -!- PTM: N-glycosylated (PubMed:30948514). O-glycosylated
CC       (PubMed:30948514). {ECO:0000269|PubMed:30948514}.
CC   -!- PTM: Phosphorylated on some or all of the serine and threonine residues
CC       present in the C-terminal region. {ECO:0000305|PubMed:2937147}.
CC   -!- DISEASE: Colorblindness, partial, deutan series (CBD) [MIM:303800]: A
CC       color vision defect characterized by a dichromasy in which red and
CC       green are confused, without loss of luminance or shift or shortening of
CC       the spectrum. Dichromasy is due to the use of only two types of
CC       photoreceptors, blue plus red in deuteranopia and blue plus green in
CC       protanopia. {ECO:0000269|PubMed:12051694, ECO:0000269|PubMed:1302020}.
CC       Note=The disease is caused by mutations affecting the gene represented
CC       in this entry.
CC   -!- DISEASE: Blue cone monochromacy (BCM) [MIM:303700]: A rare X-linked
CC       congenital stationary cone dysfunction syndrome characterized by the
CC       absence of functional long wavelength-sensitive and medium wavelength-
CC       sensitive cones in the retina. Color discrimination is severely
CC       impaired from birth, and vision is derived from the remaining preserved
CC       blue (S) cones and rod photoreceptors. BCM typically presents with
CC       reduced visual acuity, pendular nystagmus, and photophobia. Patients
CC       often have myopia. {ECO:0000269|PubMed:8666378}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Cone dystrophy 5 (COD5) [MIM:303700]: An X-linked cone
CC       dystrophy. Cone dystrophies are retinal dystrophies characterized by
CC       progressive degeneration of the cone photoreceptors with preservation
CC       of rod function, as indicated by electroretinogram. However, some rod
CC       involvement may be present in some cone dystrophies, particularly at
CC       late stage. Affected individuals suffer from photophobia, loss of
CC       visual acuity, color vision and central visual field. Another sign is
CC       the absence of macular lesions for many years. Cone dystrophies are
CC       distinguished from the cone-rod dystrophies in which some loss of
CC       peripheral vision also occurs. {ECO:0000269|PubMed:20579627}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family. Opsin
CC       subfamily. {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- CAUTION: Medium-wave-sensitive opsin genes vary in number among
CC       individuals and, together with a single red pigment gene, reside in a
CC       head-to-tail tandem array within the X chromosome. In the GRCh38
CC       reference genome assembly, there are 3 genes in tandem coding for
CC       identical proteins AC P04001, AC P0DN77 and P0DN78. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Mutations of the color pigment genes; Note=Retina
CC       International's Scientific Newsletter;
CC       URL="https://www.retina-international.org/files/sci-news/cppmut.htm";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; K03494; AAB59503.1; -; Genomic_DNA.
DR   EMBL; M13306; AAB59503.1; JOINED; Genomic_DNA.
DR   EMBL; K03490; AAB59503.1; JOINED; Genomic_DNA.
DR   EMBL; K03491; AAB59503.1; JOINED; Genomic_DNA.
DR   EMBL; K03492; AAB59503.1; JOINED; Genomic_DNA.
DR   EMBL; K03493; AAB59503.1; JOINED; Genomic_DNA.
DR   EMBL; K03497; AAB59525.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; K03495; AAB59525.1; JOINED; Genomic_DNA.
DR   EMBL; K03496; AAB59525.1; JOINED; Genomic_DNA.
DR   EMBL; AC244097; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS14743.1; -.
DR   CCDS; CCDS35447.1; -.
DR   PIR; A03158; OOHUG.
DR   RefSeq; NP_000504.1; NM_000513.2.
DR   RefSeq; NP_001041646.1; NM_001048181.2.
DR   RefSeq; NP_001316996.1; NM_001330067.1.
DR   RefSeq; XP_016855469.1; XM_016999980.1.
DR   PDB; 1KPW; Model; -; A=1-364.
DR   PDBsum; 1KPW; -.
DR   SMR; P04001; -.
DR   GlyGen; P04001; 1 site.
DR   iPTMnet; P04001; -.
DR   PhosphoSitePlus; P04001; -.
DR   BioMuta; OPN1MW; -.
DR   DMDM; 129215; -.
DR   PRIDE; P04001; -.
DR   ProteomicsDB; 51631; -.
DR   Antibodypedia; 75857; 57 antibodies.
DR   DNASU; 2652; -.
DR   Ensembl; ENST00000595290; ENSP00000472316; ENSG00000268221.
DR   GeneID; 101060233; -.
DR   GeneID; 2652; -.
DR   GeneID; 728458; -.
DR   KEGG; hsa:101060233; -.
DR   KEGG; hsa:2652; -.
DR   KEGG; hsa:728458; -.
DR   UCSC; uc004fkb.4; human.
DR   CTD; 101060233; -.
DR   CTD; 2652; -.
DR   CTD; 728458; -.
DR   DisGeNET; 101060233; -.
DR   DisGeNET; 2652; -.
DR   DisGeNET; 728458; -.
DR   EuPathDB; HostDB:ENSG00000166160.9; -.
DR   EuPathDB; HostDB:ENSG00000268221.5; -.
DR   GeneCards; OPN1MW; -.
DR   HGNC; HGNC:4206; OPN1MW.
DR   HPA; ENSG00000268221; Tissue enhanced (lymphoid).
DR   MalaCards; OPN1MW; -.
DR   MIM; 300821; gene.
DR   MIM; 303700; phenotype.
DR   MIM; 303800; phenotype.
DR   neXtProt; NX_P04001; -.
DR   OpenTargets; ENSG00000268221; -.
DR   Orphanet; 16; Blue cone monochromatism.
DR   Orphanet; 1872; Cone rod dystrophy.
DR   Orphanet; 319698; NON RARE IN EUROPE: Partial color blindness, deutan type.
DR   Orphanet; 90001; X-linked cone dysfunction syndrome with myopia.
DR   PharmGKB; PA142671229; -.
DR   HOGENOM; CLU_009579_3_0_1; -.
DR   InParanoid; P04001; -.
DR   KO; K04251; -.
DR   OMA; PANQGIT; -.
DR   OrthoDB; 940057at2759; -.
DR   PhylomeDB; P04001; -.
DR   TreeFam; TF324998; -.
DR   PathwayCommons; P04001; -.
DR   Reactome; R-HSA-2187335; The retinoid cycle in cones (daylight vision).
DR   Reactome; R-HSA-2453864; Retinoid cycle disease events.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-419771; Opsins.
DR   BioGRID-ORCS; 2652; 4 hits in 119 CRISPR screens.
DR   BioGRID-ORCS; 728458; 0 hits in 102 CRISPR screens.
DR   ChiTaRS; OPN1MW; human.
DR   GeneWiki; OPN1MW; -.
DR   Pharos; P04001; Tbio.
DR   PRO; PR:P04001; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; P04001; protein.
DR   Bgee; ENSG00000166160; Expressed in zone of skin and 6 other tissues.
DR   ExpressionAtlas; P04001; baseline.
DR   Genevisible; P04001; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0097381; C:photoreceptor disc membrane; TAS:Reactome.
DR   GO; GO:0001750; C:photoreceptor outer segment; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0008020; F:G protein-coupled photoreceptor activity; IBA:GO_Central.
DR   GO; GO:0042802; F:identical protein binding; IDA:UniProtKB.
DR   GO; GO:0009881; F:photoreceptor activity; IMP:CACAO.
DR   GO; GO:0071482; P:cellular response to light stimulus; IBA:GO_Central.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007602; P:phototransduction; IBA:GO_Central.
DR   GO; GO:0032467; P:positive regulation of cytokinesis; IMP:UniProtKB.
DR   GO; GO:0018298; P:protein-chromophore linkage; IEA:UniProtKB-KW.
DR   GO; GO:0001523; P:retinoid metabolic process; TAS:Reactome.
DR   GO; GO:0007601; P:visual perception; TAS:ProtInc.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR001760; Opsin.
DR   InterPro; IPR000378; Opsin_red/grn.
DR   InterPro; IPR027430; Retinal_BS.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00238; OPSIN.
DR   PRINTS; PR00575; OPSINREDGRN.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
DR   PROSITE; PS00238; OPSIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Chromophore; Disease mutation; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Phosphoprotein;
KW   Photoreceptor protein; Receptor; Reference proteome; Retinal protein;
KW   Sensory transduction; Transducer; Transmembrane; Transmembrane helix;
KW   Vision.
FT   CHAIN           1..364
FT                   /note="Medium-wave-sensitive opsin 1"
FT                   /id="PRO_0000197785"
FT   TOPO_DOM        1..52
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        53..77
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        78..89
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        90..115
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        116..129
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        130..149
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        150..168
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        169..192
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        193..218
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        219..246
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        247..268
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        269..292
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        293..300
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        301..325
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        326..364
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   REGION          17..43
FT                   /note="Required for 11-cis-retinal regeneration"
FT                   /evidence="ECO:0000269|PubMed:30948514"
FT   MOD_RES         312
FT                   /note="N6-(retinylidene)lysine"
FT                   /evidence="ECO:0000305"
FT   CARBOHYD        34
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:28402104"
FT   DISULFID        126..203
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VARIANT         94
FT                   /note="N -> K (in CBD; dbSNP:rs104894915)"
FT                   /evidence="ECO:0000269|PubMed:12051694"
FT                   /id="VAR_064051"
FT   VARIANT         177
FT                   /note="W -> R (in COD5; results in protein misfolding and
FT                   retention in the endoplasmic reticulum; dbSNP:rs267606927)"
FT                   /evidence="ECO:0000269|PubMed:20579627"
FT                   /id="VAR_064052"
FT   VARIANT         203
FT                   /note="C -> R (in CBD and BCM; dbSNP:rs104894914)"
FT                   /evidence="ECO:0000269|PubMed:1302020,
FT                   ECO:0000269|PubMed:8666378"
FT                   /id="VAR_004841"
FT   VARIANT         330
FT                   /note="R -> Q (in CBD; dbSNP:rs104894916)"
FT                   /evidence="ECO:0000269|PubMed:12051694"
FT                   /id="VAR_064053"
SQ   SEQUENCE   364 AA;  40584 MW;  A98D046958C72AE9 CRC64;
     MAQQWSLQRL AGRHPQDSYE DSTQSSIFTY TNSNSTRGPF EGPNYHIAPR WVYHLTSVWM
     IFVVIASVFT NGLVLAATMK FKKLRHPLNW ILVNLAVADL AETVIASTIS VVNQVYGYFV
     LGHPMCVLEG YTVSLCGITG LWSLAIISWE RWMVVCKPFG NVRFDAKLAI VGIAFSWIWA
     AVWTAPPIFG WSRYWPHGLK TSCGPDVFSG SSYPGVQSYM IVLMVTCCIT PLSIIVLCYL
     QVWLAIRAVA KQQKESESTQ KAEKEVTRMV VVMVLAFCFC WGPYAFFACF AAANPGYPFH
     PLMAALPAFF AKSATIYNPV IYVFMNRQFR NCILQLFGKK VDDGSELSSA SKTEVSSVSS
     VSPA
//
ID   OPSD_HUMAN              Reviewed;         348 AA.
AC   P08100; Q16414; Q2M249;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1988, sequence version 1.
DT   07-OCT-2020, entry version 223.
DE   RecName: Full=Rhodopsin;
DE   AltName: Full=Opsin-2;
GN   Name=RHO; Synonyms=OPN2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=6589631; DOI=10.1073/pnas.81.15.4851;
RA   Nathans J., Hogness D.S.;
RT   "Isolation and nucleotide sequence of the gene encoding human rhodopsin.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:4851-4855(1984).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Suwa M., Sato T., Okouchi I., Arita M., Futami K., Matsumoto S.,
RA   Tsutsumi S., Aburatani H., Asai K., Akiyama Y.;
RT   "Genome-wide diskovery and analysis of human seven transmembrane helix
RT   receptor genes.";
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Retina;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-120.
RX   PubMed=8566799; DOI=10.1016/0378-1119(95)00688-5;
RA   Bennett J., Beller B., Sun D., Kariko K.;
RT   "Sequence analysis of the 5.34-kb 5' flanking region of the human
RT   rhodopsin-encoding gene.";
RL   Gene 167:317-320(1995).
RN   [6]
RP   SUBCELLULAR LOCATION.
RX   PubMed=25664179; DOI=10.1186/s13630-015-0013-1;
RA   Chuang J.Z., Hsu Y.C., Sung C.H.;
RT   "Ultrastructural visualization of trans-ciliary rhodopsin cargoes in
RT   mammalian rods.";
RL   Cilia 4:4-4(2015).
RN   [7]
RP   INTERACTION WITH GRK1 AND SAG, FUNCTION, AND MUTAGENESIS OF GLU-113 AND
RP   MET-257.
RX   PubMed=28524165; DOI=10.1038/cr.2017.72;
RA   He Y., Gao X., Goswami D., Hou L., Pal K., Yin Y., Zhao G., Ernst O.P.,
RA   Griffin P., Melcher K., Xu H.E.;
RT   "Molecular assembly of rhodopsin with G protein-coupled receptor kinases.";
RL   Cell Res. 27:728-747(2017).
RN   [8] {ECO:0000244|PDB:4ZWJ}
RP   X-RAY CRYSTALLOGRAPHY (3.30 ANGSTROMS) OF MUTANT GLN-113 AND TYR-257 IN
RP   COMPLEX WITH SAG, INTERACTION WITH SAG AND GNAT1, FUNCTION, SUBCELLULAR
RP   LOCATION, MUTAGENESIS OF GLU-113 AND MET-257, TOPOLOGY, AND DISULFIDE
RP   BONDS.
RX   PubMed=26200343; DOI=10.1038/nature14656;
RA   Kang Y., Zhou X.E., Gao X., He Y., Liu W., Ishchenko A., Barty A.,
RA   White T.A., Yefanov O., Han G.W., Xu Q., de Waal P.W., Ke J., Tan M.H.,
RA   Zhang C., Moeller A., West G.M., Pascal B.D., Van Eps N., Caro L.N.,
RA   Vishnivetskiy S.A., Lee R.J., Suino-Powell K.M., Gu X., Pal K., Ma J.,
RA   Zhi X., Boutet S., Williams G.J., Messerschmidt M., Gati C., Zatsepin N.A.,
RA   Wang D., James D., Basu S., Roy-Chowdhury S., Conrad C.E., Coe J., Liu H.,
RA   Lisova S., Kupitz C., Grotjohann I., Fromme R., Jiang Y., Tan M., Yang H.,
RA   Li J., Wang M., Zheng Z., Li D., Howe N., Zhao Y., Standfuss J.,
RA   Diederichs K., Dong Y., Potter C.S., Carragher B., Caffrey M., Jiang H.,
RA   Chapman H.N., Spence J.C., Fromme P., Weierstall U., Ernst O.P.,
RA   Katritch V., Gurevich V.V., Griffin P.R., Hubbell W.L., Stevens R.C.,
RA   Cherezov V., Melcher K., Xu H.E.;
RT   "Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray
RT   laser.";
RL   Nature 523:561-567(2015).
RN   [9] {ECO:0000244|PDB:5W0P}
RP   X-RAY CRYSTALLOGRAPHY (3.01 ANGSTROMS) IN COMPLEX WITH SAG, FUNCTION,
RP   TOPOLOGY, GLYCOSYLATION AT ASN-15, PHOSPHORYLATION AT SER-334; THR-336 AND
RP   SER-338, DISULFIDE BOND, AND MUTAGENESIS OF 336-THR--THR-340;
RP   336-THR--SER-338 AND SER-343.
RX   PubMed=28753425; DOI=10.1016/j.cell.2017.07.002;
RA   Zhou X.E., He Y., de Waal P.W., Gao X., Kang Y., Van Eps N., Yin Y.,
RA   Pal K., Goswami D., White T.A., Barty A., Latorraca N.R., Chapman H.N.,
RA   Hubbell W.L., Dror R.O., Stevens R.C., Cherezov V., Gurevich V.V.,
RA   Griffin P.R., Ernst O.P., Melcher K., Xu H.E.;
RT   "Identification of Phosphorylation Codes for Arrestin Recruitment by G
RT   Protein-Coupled Receptors.";
RL   Cell 170:457-469(2017).
RN   [10]
RP   REVIEW ON RP4 VARIANTS.
RX   PubMed=8401533; DOI=10.1002/humu.1380020403;
RA   Al-Maghtheh M., Gregory C., Inglehearn C., Hardcastle A., Bhattacharya S.;
RT   "Rhodopsin mutations in autosomal dominant retinitis pigmentosa.";
RL   Hum. Mutat. 2:249-255(1993).
RN   [11]
RP   VARIANTS RP4.
RX   PubMed=2239971;
RA   Farrar G.J., Kenna P., Redmond R., McWilliam P., Bradley D.G.,
RA   Humphries M.M., Sharp E.M., Inglehearn C.F., Bashir R., Jay M., Watty A.,
RA   Ludwig M., Schinzel A., Samanns C., Gal A., Bhattacharya S.S.,
RA   Humphries P.;
RT   "Autosomal dominant retinitis pigmentosa: absence of the rhodopsin
RT   proline-->histidine substitution (codon 23) in pedigrees from Europe.";
RL   Am. J. Hum. Genet. 47:941-945(1990).
RN   [12]
RP   VARIANT RP4 HIS-23.
RX   PubMed=2137202; DOI=10.1038/343364a0;
RA   Dryja T.P., McGee T.L., Reichei E., Hahn L.B., Cowley G.S., Yandell D.W.,
RA   Sandberg M.A., Berson E.L.;
RT   "A point mutation of the rhodopsin gene in one form of retinitis
RT   pigmentosa.";
RL   Nature 343:364-366(1990).
RN   [13]
RP   VARIANTS RP4 HIS-23; ARG-58; LEU-347 AND SER-347, AND FUNCTION.
RX   PubMed=2215617; DOI=10.1056/nejm199011083231903;
RA   Dryja T.P., McGee T.L., Hahn L.B., Cowley G.S., Olsson J.E., Reichel E.,
RA   Sandberg M.A., Berson E.L.;
RT   "Mutations within the rhodopsin gene in patients with autosomal dominant
RT   retinitis pigmentosa.";
RL   N. Engl. J. Med. 323:1302-1307(1990).
RN   [14]
RP   VARIANT RP4 ILE-255 DEL.
RX   PubMed=1985460;
RA   Inglehearn C.F., Bashir R., Lester D.H., Jay M., Bird A.C.,
RA   Bhattacharya S.S.;
RT   "A 3-bp deletion in the rhodopsin gene in a family with autosomal dominant
RT   retinitis pigmentosa.";
RL   Am. J. Hum. Genet. 48:26-30(1991).
RN   [15]
RP   VARIANTS RP4 MET-17; HIS-23; ARG-58; SER-182 AND LEU-267.
RX   PubMed=1897520;
RA   Sheffield V.C., Fishman G.A., Beck J.S., Kimura A.E., Stone E.M.;
RT   "Identification of novel rhodopsin mutations associated with retinitis
RT   pigmentosa by GC-clamped denaturing gradient gel electrophoresis.";
RL   Am. J. Hum. Genet. 49:699-706(1991).
RN   [16]
RP   VARIANT RP4 ARG-347.
RX   PubMed=1840561; DOI=10.1016/0888-7543(91)90159-c;
RA   Gal A., Artlich A., Ludwig M., Niemeyer G., Olek K., Schwinger E.,
RA   Schinzel A.;
RT   "Pro-347-Arg mutation of the rhodopsin gene in autosomal dominant retinitis
RT   pigmentosa.";
RL   Genomics 11:468-470(1991).
RN   [17]
RP   VARIANTS RP4.
RX   PubMed=1862076; DOI=10.1073/pnas.88.15.6481;
RA   Sung C.H., Davenport C.M., Hennessey J.C., Maumenee I.H., Jacobson S.G.,
RA   Heckenlively J.R., Nowakowski R., Fishman G., Gouras P., Nathans J.;
RT   "Rhodopsin mutations in autosomal dominant retinitis pigmentosa.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:6481-6485(1991).
RN   [18]
RP   VARIANTS RP4.
RX   PubMed=1833777; DOI=10.1073/pnas.88.20.9370;
RA   Dryja T.P., Hahn L.B., Cowley G.S., McGee T.L., Berson E.L.;
RT   "Mutation spectrum of the rhodopsin gene among patients with autosomal
RT   dominant retinitis pigmentosa.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:9370-9374(1991).
RN   [19]
RP   VARIANT RP4 ARG-207.
RX   PubMed=1302614; DOI=10.1093/hmg/1.9.769;
RA   Farrar G.J., Findlay J.B.C., Kumar-Singh R., Kenna P., Humphries M.M.,
RA   Sharpe E., Humphries P.;
RT   "Autosomal dominant retinitis pigmentosa: a novel mutation in the rhodopsin
RT   gene in the original 3q linked family.";
RL   Hum. Mol. Genet. 1:769-771(1992).
RN   [20]
RP   VARIANTS RP4 MET-17 AND LEU-347.
RX   PubMed=1391967; DOI=10.1007/bf01899733;
RA   Fujiki K., Hotta Y., Hayakawa M., Sakuma H., Shiono T., Noro M., Sakuma T.,
RA   Tamai M., Hikiji K., Kawaguchi R., Hoshi A., Nakajima A., Kanai A.;
RT   "Point mutations of rhodopsin gene found in Japanese families with
RT   autosomal dominant retinitis pigmentosa (ADRP).";
RL   Jpn. J. Hum. Genet. 37:125-132(1992).
RN   [21]
RP   VARIANTS RP4 ARG-106; GLY-135; SER-140; GLU-188 AND ARG-211, AND VARIANTS
RP   ALA-51; ILE-104 AND MET-209.
RX   PubMed=8317502;
RA   Macke J.P., Davenport C.M., Jacobson S.G., Hennessey J.C.,
RA   Gonzalez-Fernandez F., Conway B.P., Heckenlively J., Palmer R.,
RA   Maumenee I.H., Sieving P., Gouras P., Good W., Nathans J.;
RT   "Identification of novel rhodopsin mutations responsible for retinitis
RT   pigmentosa: implications for the structure and function of rhodopsin.";
RL   Am. J. Hum. Genet. 53:80-89(1993).
RN   [22]
RP   VARIANT RP4 SER-15.
RX   PubMed=8353500; DOI=10.1093/hmg/2.6.813;
RA   Kranich H., Bartkowski S., Denton M.J., Krey S., Dickinson P.,
RA   Duvigneau C., Gal A.;
RT   "Autosomal dominant 'sector' retinitis pigmentosa due to a point mutation
RT   predicting an Asn-15-Ser substitution of rhodopsin.";
RL   Hum. Mol. Genet. 2:813-814(1993).
RN   [23]
RP   VARIANT CSNBAD1 GLU-292.
RX   PubMed=8358437; DOI=10.1038/ng0793-280;
RA   Dryja T.P., Berson E.L., Rao V.R., Oprian D.D.;
RT   "Heterozygous missense mutation in the rhodopsin gene as a cause of
RT   congenital stationary night blindness.";
RL   Nat. Genet. 4:280-283(1993).
RN   [24]
RP   VARIANTS RP4.
RX   PubMed=8088850; DOI=10.1006/geno.1994.1301;
RA   Vaithinathan R., Berson E.L., Dryja T.P.;
RT   "Further screening of the rhodopsin gene in patients with autosomal
RT   dominant retinitis pigmentosa.";
RL   Genomics 21:461-463(1994).
RN   [25]
RP   VARIANT RP4 THR-44.
RX   PubMed=8076945; DOI=10.1007/bf00208284;
RA   Reig C., Antich J., Gean E., Garcia-Sandoval B., Ramos C., Ayuso C.,
RA   Carballo M.;
RT   "Identification of a novel rhodopsin mutation (Met-44-Thr) in a simplex
RT   case of retinitis pigmentosa.";
RL   Hum. Genet. 94:283-286(1994).
RN   [26]
RP   VARIANTS RP4 PHE-110; PRO-131 AND VAL-164.
RX   PubMed=7981701; DOI=10.1093/hmg/3.7.1203;
RA   Fuchs S., Kranich H., Denton M.J., Zrenner E., Bhattacharya S.S.,
RA   Humphries P., Gal A.;
RT   "Three novel rhodopsin mutations (C110F, L131P, A164V) in patients with
RT   autosomal dominant retinitis pigmentosa.";
RL   Hum. Mol. Genet. 3:1203-1203(1994).
RN   [27]
RP   VARIANT RP4 GLN-171.
RX   PubMed=7987326; DOI=10.1093/hmg/3.8.1421;
RA   Antinolo G., Sanchez B., Borrego S., Rueda T., Chaparro P., Cabeza J.C.;
RT   "Identification of a new mutation at codon 171 of rhodopsin gene causing
RT   autosomal dominant retinitis pigmentosa.";
RL   Hum. Mol. Genet. 3:1421-1421(1994).
RN   [28]
RP   VARIANTS RP4 PHE-127; PRO-131; ASN-178; ARG-267 AND ARG-297.
RX   PubMed=7987331; DOI=10.1093/hmg/3.8.1433;
RA   Souied E., Gerber S., Rozet J.-M., Bonneau D., Dufier J.-L., Ghazi I.,
RA   Philip N., Soubrane G., Coscas G., Munnich A.;
RT   "Five novel missense mutations of the rhodopsin gene in autosomal dominant
RT   retinitis pigmentosa.";
RL   Hum. Mol. Genet. 3:1433-1434(1994).
RN   [29]
RP   VARIANTS RP4 ARG-40 AND LYS-216.
RX   PubMed=8081400; DOI=10.1002/humu.1380030417;
RA   Al-Maghtheh M., Inglehearn C., Lunt P., Jay M., Bird A., Bhattacharya S.;
RT   "Two new rhodopsin transversion mutations (L40R; M216K) in families with
RT   autosomal dominant retinitis pigmentosa.";
RL   Hum. Mutat. 3:409-410(1994).
RN   [30]
RP   VARIANT RP4 LEU-345.
RX   PubMed=8045708;
RA   Rosas D.J., Roman A.J., Weissbrod P., Macke J.P., Nathans J.;
RT   "Autosomal dominant retinitis pigmentosa in a large family: a clinical and
RT   molecular genetic study.";
RL   Invest. Ophthalmol. Vis. Sci. 35:3134-3144(1994).
RN   [31]
RP   CHARACTERIZATION OF VARIANT CSNBAD1 ASP-90, AND FUNCTION.
RX   PubMed=8107847; DOI=10.1038/367639a0;
RA   Rao V.R., Cohen G.B., Oprian D.D.;
RT   "Rhodopsin mutation G90D and a molecular mechanism for congenital night
RT   blindness.";
RL   Nature 367:639-642(1994).
RN   [32]
RP   VARIANT ARRP LYS-150.
RX   PubMed=7987385; DOI=10.1038/ng0994-10;
RA   Kumaramanickavel G., Maw M., Denton M.J., John S., Srikumari C.R., Orth U.,
RA   Oehlmann R., Gal A.;
RT   "Missense rhodopsin mutation in a family with recessive RP.";
RL   Nat. Genet. 8:10-11(1994).
RN   [33]
RP   VARIANT RP4 ALA-347.
RX   PubMed=7633434; DOI=10.1093/hmg/4.4.775;
RA   Macke J.P., Hennessey J.C., Nathans J.;
RT   "Rhodopsin mutation proline347-to-alanine in a family with autosomal
RT   dominant retinitis pigmentosa indicates an important role for proline at
RT   position 347.";
RL   Hum. Mol. Genet. 4:775-776(1995).
RN   [34]
RP   VARIANT CSNBAD1 ASP-90, AND FUNCTION.
RX   PubMed=7846071; DOI=10.1073/pnas.92.3.880;
RA   Sieving P.A., Richards J.E., Naarendorp F., Bingham E.L., Scott K.,
RA   Alpern M.;
RT   "Dark-light: model for nightblindness from the human rhodopsin Gly-90-->Asp
RT   mutation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:880-884(1995).
RN   [35]
RP   VARIANT RP4 TRP-135.
RX   PubMed=8554077; DOI=10.1016/s0002-9394(14)70530-6;
RA   Souied E., Soubrane G., Benlian P., Coscas G.J., Gerber S., Munnich A.,
RA   Kaplan J.;
RT   "Retinitis punctata albescens associated with the Arg135Trp mutation in the
RT   rhodopsin gene.";
RL   Am. J. Ophthalmol. 121:19-25(1996).
RN   [36]
RP   VARIANT RP4 ARG-109.
RX   PubMed=9452035; DOI=10.1002/humu.1380110114;
RA   Goliath R., Bardien S., September A., Martin R., Ramesar R., Greenberg J.;
RT   "Rhodopsin mutation G109R in a family with autosomal dominant retinitis
RT   pigmentosa.";
RL   Hum. Mutat. Suppl. 1:S40-S41(1998).
RN   [37]
RP   VARIANT CSNBAD1 ILE-94.
RX   PubMed=9888392;
RX   DOI=10.1002/(sici)1098-1004(1999)13:1<75::aid-humu9>3.0.co;2-4;
RA   Al-Jandal N., Farrar G.J., Kiang A.-S., Humphries M.M., Bannon N.,
RA   Findlay J.B.C., Humphries P., Kenna P.F.;
RT   "A novel mutation within the rhodopsin gene (Thr-94-Ile) causing autosomal
RT   dominant congenital stationary night blindness.";
RL   Hum. Mutat. 13:75-81(1999).
RN   [38]
RP   CHARACTERIZATION OF VARIANT RP4 HIS-23, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12566452; DOI=10.1074/jbc.m300087200;
RA   Noorwez S.M., Kuksa V., Imanishi Y., Zhu L., Filipek S., Palczewski K.,
RA   Kaushal S.;
RT   "Pharmacological chaperone-mediated in vivo folding and stabilization of
RT   the P23H-opsin mutant associated with autosomal dominant retinitis
RT   pigmentosa.";
RL   J. Biol. Chem. 278:14442-14450(2003).
RN   [39]
RP   CHARACTERIZATION OF VARIANT RP4 HIS-23, AND SUBCELLULAR LOCATION.
RX   PubMed=19934218; DOI=10.1242/jcs.055228;
RA   Kosmaoglou M., Kanuga N., Aguila M., Garriga P., Cheetham M.E.;
RT   "A dual role for EDEM1 in the processing of rod opsin.";
RL   J. Cell Sci. 122:4465-4472(2009).
RN   [40]
RP   VARIANT RP4 LYS-150.
RX   PubMed=19960070;
RA   Azam M., Khan M.I., Gal A., Hussain A., Shah S.T., Khan M.S., Sadeque A.,
RA   Bokhari H., Collin R.W., Orth U., van Genderen M.M., den Hollander A.I.,
RA   Cremers F.P., Qamar R.;
RT   "A homozygous p.Glu150Lys mutation in the opsin gene of two Pakistani
RT   families with autosomal recessive retinitis pigmentosa.";
RL   Mol. Vis. 15:2526-2534(2009).
RN   [41]
RP   VARIANTS RP4 TRP-135; SER-180 AND ASN-214.
RX   PubMed=22334370; DOI=10.1002/humu.22045;
RA   Neveling K., Collin R.W., Gilissen C., van Huet R.A., Visser L.,
RA   Kwint M.P., Gijsen S.J., Zonneveld M.N., Wieskamp N., de Ligt J.,
RA   Siemiatkowska A.M., Hoefsloot L.H., Buckley M.F., Kellner U., Branham K.E.,
RA   den Hollander A.I., Hoischen A., Hoyng C., Klevering B.J.,
RA   van den Born L.I., Veltman J.A., Cremers F.P., Scheffer H.;
RT   "Next-generation genetic testing for retinitis pigmentosa.";
RL   Hum. Mutat. 33:963-972(2012).
RN   [42]
RP   VARIANT ILE-104.
RX   PubMed=28837730; DOI=10.1167/iovs.16-20941;
RA   Wang B., Liu Y., Chen S., Wu Y., Lin S., Duan Y., Zheng K., Zhang L.,
RA   Gu X., Hong W., Shao H., Zeng X., Sun B., Duan S.;
RT   "A novel potentially causative variant of NDUFAF7 revealed by mutation
RT   screening in a chinese family with pathologic myopia.";
RL   Invest. Ophthalmol. Vis. Sci. 58:4182-4192(2017).
CC   -!- FUNCTION: Photoreceptor required for image-forming vision at low light
CC       intensity (PubMed:8107847, PubMed:7846071). Required for photoreceptor
CC       cell viability after birth (PubMed:2215617, PubMed:12566452). Light-
CC       induced isomerization of the chromophore 11-cis-retinal to all-trans-
CC       retinal triggers a conformational change that activates signaling via
CC       G-proteins (PubMed:8107847, PubMed:28524165, PubMed:26200343,
CC       PubMed:28753425). Subsequent receptor phosphorylation mediates
CC       displacement of the bound G-protein alpha subunit by the arrestin SAG
CC       and terminates signaling (PubMed:28524165, PubMed:26200343).
CC       {ECO:0000269|PubMed:12566452, ECO:0000269|PubMed:2215617,
CC       ECO:0000269|PubMed:26200343, ECO:0000269|PubMed:28753425,
CC       ECO:0000269|PubMed:7846071, ECO:0000269|PubMed:8107847,
CC       ECO:0000305|PubMed:28524165}.
CC   -!- SUBUNIT: Homodimer (By similarity). May form a complex composed of RHO,
CC       GRK1 and RCVRN in a Ca(2+)-dependent manner; RCVRN prevents the
CC       interaction between GRK1 and RHO (By similarity). Interacts with GRK1
CC       (PubMed:28524165). Interacts (phosphorylated form) with SAG
CC       (PubMed:28524165, PubMed:26200343, PubMed:28753425). Interacts with
CC       GNAT1 (PubMed:26200343). Interacts with GNAT3. SAG and G-proteins
CC       compete for a common binding site (PubMed:26200343). Interacts with
CC       PRCD; the interaction promotes PRCD stability (By similarity).
CC       {ECO:0000250|UniProtKB:P02699, ECO:0000250|UniProtKB:P15409,
CC       ECO:0000269|PubMed:26200343, ECO:0000269|PubMed:28524165,
CC       ECO:0000269|PubMed:28753425}.
CC   -!- INTERACTION:
CC       P08100; P11912: CD79A; NbExp=3; IntAct=EBI-1394177, EBI-7797864;
CC       P08100; O95405: ZFYVE9; NbExp=2; IntAct=EBI-1394177, EBI-296817;
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:12566452,
CC       ECO:0000269|PubMed:19934218, ECO:0000269|PubMed:25664179,
CC       ECO:0000269|PubMed:26200343, ECO:0000269|PubMed:28753425}; Multi-pass
CC       membrane protein {ECO:0000269|PubMed:19934218,
CC       ECO:0000269|PubMed:26200343, ECO:0000269|PubMed:28753425}. Cell
CC       projection, cilium, photoreceptor outer segment
CC       {ECO:0000269|PubMed:25664179}. Note=Synthesized in the inner segment
CC       (IS) of rod photoreceptor cells before vectorial transport to disk
CC       membranes in the rod outer segment (OS) photosensory cilia.
CC       {ECO:0000269|PubMed:25664179}.
CC   -!- TISSUE SPECIFICITY: Rod shaped photoreceptor cells which mediate vision
CC       in dim light.
CC   -!- PTM: Phosphorylated on some or all of the serine and threonine residues
CC       present in the C-terminal region (By similarity). After activation by
CC       light, phosphorylated by GRK1 (in vitro) (PubMed:28524165).
CC       {ECO:0000250|UniProtKB:P02699, ECO:0000269|PubMed:28524165}.
CC   -!- PTM: Contains one covalently linked retinal chromophore. Upon light
CC       absorption, the covalently bound 11-cis-retinal is converted to all-
CC       trans-retinal. After hydrolysis of the Schiff base and release of the
CC       covalently bound all-trans-retinal, active rhodopsin is regenerated by
CC       binding of a fresh molecule of 11-cis-retinal(PubMed:12566452).
CC       {ECO:0000269|PubMed:12566452}.
CC   -!- DISEASE: Retinitis pigmentosa 4 (RP4) [MIM:613731]: A retinal dystrophy
CC       belonging to the group of pigmentary retinopathies. Retinitis
CC       pigmentosa is characterized by retinal pigment deposits visible on
CC       fundus examination and primary loss of rod photoreceptor cells followed
CC       by secondary loss of cone photoreceptors. Patients typically have night
CC       vision blindness and loss of midperipheral visual field. As their
CC       condition progresses, they lose their far peripheral visual field and
CC       eventually central vision as well. {ECO:0000269|PubMed:12566452,
CC       ECO:0000269|PubMed:1302614, ECO:0000269|PubMed:1391967,
CC       ECO:0000269|PubMed:1833777, ECO:0000269|PubMed:1840561,
CC       ECO:0000269|PubMed:1862076, ECO:0000269|PubMed:1897520,
CC       ECO:0000269|PubMed:1985460, ECO:0000269|PubMed:19934218,
CC       ECO:0000269|PubMed:19960070, ECO:0000269|PubMed:2137202,
CC       ECO:0000269|PubMed:2215617, ECO:0000269|PubMed:22334370,
CC       ECO:0000269|PubMed:2239971, ECO:0000269|PubMed:7633434,
CC       ECO:0000269|PubMed:7981701, ECO:0000269|PubMed:7987326,
CC       ECO:0000269|PubMed:7987331, ECO:0000269|PubMed:8045708,
CC       ECO:0000269|PubMed:8076945, ECO:0000269|PubMed:8081400,
CC       ECO:0000269|PubMed:8088850, ECO:0000269|PubMed:8317502,
CC       ECO:0000269|PubMed:8353500, ECO:0000269|PubMed:8554077,
CC       ECO:0000269|PubMed:9452035}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Night blindness, congenital stationary, autosomal dominant 1
CC       (CSNBAD1) [MIM:610445]: A non-progressive retinal disorder
CC       characterized by impaired night vision, often associated with nystagmus
CC       and myopia. {ECO:0000269|PubMed:7846071, ECO:0000269|PubMed:8107847,
CC       ECO:0000269|PubMed:8358437, ECO:0000269|PubMed:9888392}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family. Opsin
CC       subfamily. {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=Mutations of the RHO gene; Note=Retina
CC       International's Scientific Newsletter;
CC       URL="https://www.retina-international.org/files/sci-news/rhomut.htm";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Rhodopsin entry;
CC       URL="https://en.wikipedia.org/wiki/Rhodopsin";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U49742; AAC31763.1; -; Genomic_DNA.
DR   EMBL; AB065668; BAC05894.1; -; Genomic_DNA.
DR   EMBL; BX537381; CAD97623.1; -; mRNA.
DR   EMBL; BC112104; AAI12105.1; -; mRNA.
DR   EMBL; BC112106; AAI12107.1; -; mRNA.
DR   EMBL; U16824; AAA97436.1; -; Genomic_DNA.
DR   EMBL; S81166; AAB35906.1; -; Genomic_DNA.
DR   CCDS; CCDS3063.1; -.
DR   PIR; A41200; OOHU.
DR   RefSeq; NP_000530.1; NM_000539.3.
DR   PDB; 4ZWJ; X-ray; 3.30 A; A/B/C/D=1-348.
DR   PDB; 5DGY; X-ray; 7.70 A; A/B/C/D=1-348.
DR   PDB; 5W0P; X-ray; 3.01 A; A/B/C/D=1-348.
DR   PDB; 6CMO; EM; 4.50 A; R=3-323.
DR   PDBsum; 4ZWJ; -.
DR   PDBsum; 5DGY; -.
DR   PDBsum; 5W0P; -.
DR   PDBsum; 6CMO; -.
DR   SMR; P08100; -.
DR   BioGRID; 111942; 12.
DR   IntAct; P08100; 4.
DR   STRING; 9606.ENSP00000296271; -.
DR   ChEMBL; CHEMBL4296308; -.
DR   DrugBank; DB04233; (Hydroxyethyloxy)Tri(Ethyloxy)Octane.
DR   DrugBank; DB01728; 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine.
DR   DrugBank; DB03152; B-2-Octylglucoside.
DR   DrugBank; DB02451; B-nonylglucoside.
DR   DrugBank; DB04522; Dexfosfoserine.
DR   DrugBank; DB04147; Dodecyldimethylamine N-oxide.
DR   DrugBank; DB01159; Halothane.
DR   DrugBank; DB04079; Heptane-1,2,3-Triol.
DR   DrugBank; DB04450; Heptyl 1-Thiohexopyranoside.
DR   DrugBank; DB03381; Hexadecanal.
DR   DrugBank; DB01646; N-Acetylmethionine.
DR   DrugBank; DB03796; Palmitic Acid.
DR   DrugBank; DB02482; Phosphonothreonine.
DR   TCDB; 9.A.14.1.2; the g-protein-coupled receptor (gpcr) family.
DR   GlyConnect; 525; 12 N-Linked glycans.
DR   GlyGen; P08100; 2 sites.
DR   iPTMnet; P08100; -.
DR   PhosphoSitePlus; P08100; -.
DR   SwissPalm; P08100; -.
DR   UniCarbKB; P08100; -.
DR   BioMuta; RHO; -.
DR   DMDM; 129207; -.
DR   MassIVE; P08100; -.
DR   PaxDb; P08100; -.
DR   PeptideAtlas; P08100; -.
DR   PRIDE; P08100; -.
DR   ProteomicsDB; 52066; -.
DR   Antibodypedia; 17456; 521 antibodies.
DR   DNASU; 6010; -.
DR   Ensembl; ENST00000296271; ENSP00000296271; ENSG00000163914.
DR   GeneID; 6010; -.
DR   KEGG; hsa:6010; -.
DR   UCSC; uc003emt.4; human.
DR   CTD; 6010; -.
DR   DisGeNET; 6010; -.
DR   EuPathDB; HostDB:ENSG00000163914.4; -.
DR   GeneCards; RHO; -.
DR   GeneReviews; RHO; -.
DR   HGNC; HGNC:10012; RHO.
DR   HPA; ENSG00000163914; Tissue enriched (retina).
DR   MalaCards; RHO; -.
DR   MIM; 180380; gene.
DR   MIM; 610445; phenotype.
DR   MIM; 613731; phenotype.
DR   neXtProt; NX_P08100; -.
DR   OpenTargets; ENSG00000163914; -.
DR   Orphanet; 215; Congenital stationary night blindness.
DR   Orphanet; 791; Retinitis pigmentosa.
DR   Orphanet; 52427; Retinitis punctata albescens.
DR   PharmGKB; PA34390; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00960000186618; -.
DR   HOGENOM; CLU_009579_3_0_1; -.
DR   InParanoid; P08100; -.
DR   KO; K04250; -.
DR   OMA; EQPQYYL; -.
DR   OrthoDB; 940057at2759; -.
DR   PhylomeDB; P08100; -.
DR   TreeFam; TF324998; -.
DR   PathwayCommons; P08100; -.
DR   Reactome; R-HSA-2453902; The canonical retinoid cycle in rods (twilight vision).
DR   Reactome; R-HSA-2485179; Activation of the phototransduction cascade.
DR   Reactome; R-HSA-2514859; Inactivation, recovery and regulation of the phototransduction cascade.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-419771; Opsins.
DR   Reactome; R-HSA-5620916; VxPx cargo-targeting to cilium.
DR   SignaLink; P08100; -.
DR   SIGNOR; P08100; -.
DR   BioGRID-ORCS; 6010; 4 hits in 867 CRISPR screens.
DR   ChiTaRS; RHO; human.
DR   GeneWiki; Rhodopsin; -.
DR   GenomeRNAi; 6010; -.
DR   Pharos; P08100; Tbio.
DR   PRO; PR:P08100; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; P08100; protein.
DR   Bgee; ENSG00000163914; Expressed in retina and 92 other tissues.
DR   Genevisible; P08100; HS.
DR   GO; GO:0005911; C:cell-cell junction; IEA:Ensembl.
DR   GO; GO:0060170; C:ciliary membrane; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:MGI.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0030660; C:Golgi-associated vesicle membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; ISS:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0097381; C:photoreceptor disc membrane; IDA:UniProtKB.
DR   GO; GO:0001917; C:photoreceptor inner segment; IDA:MGI.
DR   GO; GO:0060342; C:photoreceptor inner segment membrane; IDA:UniProtKB.
DR   GO; GO:0001750; C:photoreceptor outer segment; IDA:MGI.
DR   GO; GO:0042622; C:photoreceptor outer segment membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005502; F:11-cis retinal binding; ISS:UniProtKB.
DR   GO; GO:0008020; F:G protein-coupled photoreceptor activity; ISS:UniProtKB.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; TAS:ProtInc.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0016038; P:absorption of visible light; ISS:AgBase.
DR   GO; GO:0071482; P:cellular response to light stimulus; IBA:GO_Central.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0045494; P:photoreceptor cell maintenance; IEA:Ensembl.
DR   GO; GO:0007602; P:phototransduction; IBA:GO_Central.
DR   GO; GO:0007603; P:phototransduction, visible light; TAS:ProtInc.
DR   GO; GO:0006468; P:protein phosphorylation; IEA:Ensembl.
DR   GO; GO:0018298; P:protein-chromophore linkage; IEA:UniProtKB-KW.
DR   GO; GO:0022400; P:regulation of rhodopsin mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0060041; P:retina development in camera-type eye; IEA:Ensembl.
DR   GO; GO:0001523; P:retinoid metabolic process; TAS:Reactome.
DR   GO; GO:0016056; P:rhodopsin mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0007601; P:visual perception; IEA:UniProtKB-KW.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR001760; Opsin.
DR   InterPro; IPR027430; Retinal_BS.
DR   InterPro; IPR000732; Rhodopsin.
DR   InterPro; IPR019477; Rhodopsin_N.
DR   Pfam; PF00001; 7tm_1; 1.
DR   Pfam; PF10413; Rhodopsin_N; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00238; OPSIN.
DR   PRINTS; PR00579; RHODOPSIN.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
DR   PROSITE; PS00238; OPSIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Cell projection; Chromophore;
KW   Congenital stationary night blindness; Disease mutation; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane;
KW   Metal-binding; Palmitate; Phosphoprotein; Photoreceptor protein;
KW   Polymorphism; Receptor; Reference proteome; Retinal protein;
KW   Retinitis pigmentosa; Sensory transduction; Transducer; Transmembrane;
KW   Transmembrane helix; Vision; Zinc.
FT   CHAIN           1..348
FT                   /note="Rhodopsin"
FT                   /id="PRO_0000197677"
FT   TOPO_DOM        1..36
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:26200343,
FT                   ECO:0000269|PubMed:28753425"
FT   TRANSMEM        37..61
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000269|PubMed:26200343,
FT                   ECO:0000269|PubMed:28753425"
FT   TOPO_DOM        62..73
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:26200343,
FT                   ECO:0000269|PubMed:28753425"
FT   TRANSMEM        74..96
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000269|PubMed:26200343,
FT                   ECO:0000269|PubMed:28753425"
FT   TOPO_DOM        97..110
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:26200343,
FT                   ECO:0000269|PubMed:28753425"
FT   TRANSMEM        111..133
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000269|PubMed:26200343,
FT                   ECO:0000269|PubMed:28753425"
FT   TOPO_DOM        134..152
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:26200343,
FT                   ECO:0000269|PubMed:28753425"
FT   TRANSMEM        153..173
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000269|PubMed:26200343,
FT                   ECO:0000269|PubMed:28753425"
FT   TOPO_DOM        174..202
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:26200343,
FT                   ECO:0000269|PubMed:28753425"
FT   TRANSMEM        203..224
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000269|PubMed:26200343,
FT                   ECO:0000269|PubMed:28753425"
FT   TOPO_DOM        225..252
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:26200343,
FT                   ECO:0000269|PubMed:28753425"
FT   TRANSMEM        253..274
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000269|PubMed:26200343,
FT                   ECO:0000269|PubMed:28753425"
FT   TOPO_DOM        275..284
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:26200343,
FT                   ECO:0000269|PubMed:28753425"
FT   TRANSMEM        285..309
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000269|PubMed:26200343,
FT                   ECO:0000269|PubMed:28753425"
FT   TOPO_DOM        310..348
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:26200343,
FT                   ECO:0000269|PubMed:28753425"
FT   REGION          330..348
FT                   /note="Interaction with SAG"
FT                   /evidence="ECO:0000269|PubMed:26200343,
FT                   ECO:0000269|PubMed:28753425"
FT   MOTIF           134..136
FT                   /note="'Ionic lock' involved in activated form
FT                   stabilization"
FT                   /evidence="ECO:0000305|PubMed:26200343"
FT   METAL           201
FT                   /note="Zinc"
FT                   /evidence="ECO:0000250|UniProtKB:P02699"
FT   METAL           279
FT                   /note="Zinc"
FT                   /evidence="ECO:0000250|UniProtKB:P02699"
FT   SITE            113
FT                   /note="Plays an important role in the conformation switch
FT                   to the active conformation"
FT                   /evidence="ECO:0000269|PubMed:26200343"
FT   MOD_RES         1
FT                   /note="N-acetylmethionine"
FT                   /evidence="ECO:0000250|UniProtKB:P02699"
FT   MOD_RES         296
FT                   /note="N6-(retinylidene)lysine"
FT                   /evidence="ECO:0000250|UniProtKB:P02699"
FT   MOD_RES         334
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:28753425"
FT   MOD_RES         336
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:28753425"
FT   MOD_RES         338
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:28753425"
FT   MOD_RES         340
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P02699"
FT   MOD_RES         342
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P02699"
FT   MOD_RES         343
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P02699"
FT   LIPID           322
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250|UniProtKB:P02699"
FT   LIPID           323
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250|UniProtKB:P02699"
FT   CARBOHYD        2
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000250|UniProtKB:P02699"
FT   CARBOHYD        15
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:28753425"
FT   DISULFID        110..187
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521,
FT                   ECO:0000269|PubMed:26200343, ECO:0000269|PubMed:28753425"
FT   VARIANT         4
FT                   /note="T -> K (in RP4)"
FT                   /id="VAR_004765"
FT   VARIANT         15
FT                   /note="N -> S (in RP4; dbSNP:rs104893786)"
FT                   /evidence="ECO:0000269|PubMed:8353500"
FT                   /id="VAR_004766"
FT   VARIANT         17
FT                   /note="T -> M (in RP4; dbSNP:rs104893769)"
FT                   /evidence="ECO:0000269|PubMed:1391967,
FT                   ECO:0000269|PubMed:1897520"
FT                   /id="VAR_004767"
FT   VARIANT         23
FT                   /note="P -> H (in RP4; most common variant; impairs protein
FT                   folding; leads to interaction with EDEM1 followed by
FT                   degradation by the ERAD system; dbSNP:rs104893768)"
FT                   /evidence="ECO:0000269|PubMed:12566452,
FT                   ECO:0000269|PubMed:1897520, ECO:0000269|PubMed:19934218,
FT                   ECO:0000269|PubMed:2137202, ECO:0000269|PubMed:2215617"
FT                   /id="VAR_004768"
FT   VARIANT         23
FT                   /note="P -> L (in RP4)"
FT                   /id="VAR_004769"
FT   VARIANT         28
FT                   /note="Q -> H (in RP4)"
FT                   /id="VAR_004770"
FT   VARIANT         40
FT                   /note="L -> R (in RP4)"
FT                   /evidence="ECO:0000269|PubMed:8081400"
FT                   /id="VAR_004771"
FT   VARIANT         44
FT                   /note="M -> T (in RP4; dbSNP:rs774336493)"
FT                   /evidence="ECO:0000269|PubMed:8076945"
FT                   /id="VAR_004772"
FT   VARIANT         45
FT                   /note="F -> L (in RP4; dbSNP:rs104893770)"
FT                   /id="VAR_004773"
FT   VARIANT         46
FT                   /note="L -> R (in RP4)"
FT                   /id="VAR_004774"
FT   VARIANT         51
FT                   /note="G -> A (in dbSNP:rs149079952)"
FT                   /evidence="ECO:0000269|PubMed:8317502"
FT                   /id="VAR_004775"
FT   VARIANT         51
FT                   /note="G -> R (in RP4; dbSNP:rs104893792)"
FT                   /id="VAR_004776"
FT   VARIANT         51
FT                   /note="G -> V (in RP4)"
FT                   /id="VAR_004777"
FT   VARIANT         53
FT                   /note="P -> R (in RP4; dbSNP:rs28933395)"
FT                   /id="VAR_004778"
FT   VARIANT         58
FT                   /note="T -> R (in RP4; dbSNP:rs28933394)"
FT                   /evidence="ECO:0000269|PubMed:1897520,
FT                   ECO:0000269|PubMed:2215617"
FT                   /id="VAR_004779"
FT   VARIANT         68..71
FT                   /note="Missing (in RP4)"
FT                   /id="VAR_004780"
FT   VARIANT         87
FT                   /note="V -> D (in RP4; dbSNP:rs104893771)"
FT                   /id="VAR_004781"
FT   VARIANT         89
FT                   /note="G -> D (in RP4; dbSNP:rs104893772)"
FT                   /id="VAR_004782"
FT   VARIANT         90
FT                   /note="G -> D (in CSNBAD1; constitutive activity in the
FT                   absence of bound retinal; dbSNP:rs104893790)"
FT                   /evidence="ECO:0000269|PubMed:7846071,
FT                   ECO:0000269|PubMed:8107847"
FT                   /id="VAR_004783"
FT   VARIANT         94
FT                   /note="T -> I (in CSNBAD1; dbSNP:rs104893796)"
FT                   /evidence="ECO:0000269|PubMed:9888392"
FT                   /id="VAR_004784"
FT   VARIANT         104
FT                   /note="V -> I (found in patients with pathologic myopia;
FT                   unknown pathological significance; dbSNP:rs144317206)"
FT                   /evidence="ECO:0000269|PubMed:28837730,
FT                   ECO:0000269|PubMed:8317502"
FT                   /id="VAR_004785"
FT   VARIANT         106
FT                   /note="G -> R (in RP4; dbSNP:rs104893773)"
FT                   /evidence="ECO:0000269|PubMed:8317502"
FT                   /id="VAR_004786"
FT   VARIANT         106
FT                   /note="G -> W (in RP4; dbSNP:rs104893773)"
FT                   /id="VAR_004787"
FT   VARIANT         109
FT                   /note="G -> R (in RP4; dbSNP:rs1415160298)"
FT                   /evidence="ECO:0000269|PubMed:9452035"
FT                   /id="VAR_004788"
FT   VARIANT         110
FT                   /note="C -> F (in RP4)"
FT                   /evidence="ECO:0000269|PubMed:7981701"
FT                   /id="VAR_004789"
FT   VARIANT         110
FT                   /note="C -> Y (in RP4; dbSNP:rs104893787)"
FT                   /id="VAR_004790"
FT   VARIANT         114
FT                   /note="G -> D (in RP4; dbSNP:rs104893788)"
FT                   /id="VAR_004791"
FT   VARIANT         125
FT                   /note="L -> R (in RP4)"
FT                   /id="VAR_004792"
FT   VARIANT         127
FT                   /note="S -> F (in RP4)"
FT                   /evidence="ECO:0000269|PubMed:7987331"
FT                   /id="VAR_004793"
FT   VARIANT         131
FT                   /note="L -> P (in RP4; dbSNP:rs1553781140)"
FT                   /evidence="ECO:0000269|PubMed:7981701,
FT                   ECO:0000269|PubMed:7987331"
FT                   /id="VAR_004794"
FT   VARIANT         135
FT                   /note="R -> G (in RP4)"
FT                   /evidence="ECO:0000269|PubMed:8317502"
FT                   /id="VAR_004795"
FT   VARIANT         135
FT                   /note="R -> L (in RP4; dbSNP:rs104893774)"
FT                   /id="VAR_004796"
FT   VARIANT         135
FT                   /note="R -> W (in RP4; dbSNP:rs104893775)"
FT                   /evidence="ECO:0000269|PubMed:22334370,
FT                   ECO:0000269|PubMed:8554077"
FT                   /id="VAR_004797"
FT   VARIANT         140
FT                   /note="C -> S (in RP4)"
FT                   /evidence="ECO:0000269|PubMed:8317502"
FT                   /id="VAR_004798"
FT   VARIANT         150
FT                   /note="E -> K (in RP4; autosomal recessive;
FT                   dbSNP:rs104893791)"
FT                   /evidence="ECO:0000269|PubMed:19960070,
FT                   ECO:0000269|PubMed:7987385"
FT                   /id="VAR_004799"
FT   VARIANT         164
FT                   /note="A -> E (in RP4; dbSNP:rs104893793)"
FT                   /id="VAR_004800"
FT   VARIANT         164
FT                   /note="A -> V (in RP4; dbSNP:rs104893793)"
FT                   /evidence="ECO:0000269|PubMed:7981701"
FT                   /id="VAR_004801"
FT   VARIANT         167
FT                   /note="C -> R (in RP4)"
FT                   /id="VAR_004802"
FT   VARIANT         171
FT                   /note="P -> L (in RP4)"
FT                   /id="VAR_004803"
FT   VARIANT         171
FT                   /note="P -> Q (in RP4)"
FT                   /evidence="ECO:0000269|PubMed:7987326"
FT                   /id="VAR_004804"
FT   VARIANT         171
FT                   /note="P -> S (in RP4; dbSNP:rs104893794)"
FT                   /id="VAR_004805"
FT   VARIANT         178
FT                   /note="Y -> C (in RP4; dbSNP:rs104893776)"
FT                   /id="VAR_004806"
FT   VARIANT         178
FT                   /note="Y -> N (in RP4)"
FT                   /evidence="ECO:0000269|PubMed:7987331"
FT                   /id="VAR_004807"
FT   VARIANT         180
FT                   /note="P -> S (in RP4)"
FT                   /evidence="ECO:0000269|PubMed:22334370"
FT                   /id="VAR_068359"
FT   VARIANT         181
FT                   /note="E -> K (in RP4; dbSNP:rs775557680)"
FT                   /id="VAR_004808"
FT   VARIANT         182
FT                   /note="G -> S (in RP4; dbSNP:rs104893780)"
FT                   /evidence="ECO:0000269|PubMed:1897520"
FT                   /id="VAR_004809"
FT   VARIANT         186
FT                   /note="S -> P (in RP4)"
FT                   /id="VAR_004810"
FT   VARIANT         188
FT                   /note="G -> E (in RP4; dbSNP:rs1424131846)"
FT                   /evidence="ECO:0000269|PubMed:8317502"
FT                   /id="VAR_004811"
FT   VARIANT         188
FT                   /note="G -> R (in RP4; dbSNP:rs527236100)"
FT                   /id="VAR_004812"
FT   VARIANT         190
FT                   /note="D -> G (in RP4; dbSNP:rs104893777)"
FT                   /id="VAR_004814"
FT   VARIANT         190
FT                   /note="D -> N (in RP4; dbSNP:rs104893779)"
FT                   /id="VAR_004813"
FT   VARIANT         190
FT                   /note="D -> Y (in RP4; dbSNP:rs104893779)"
FT                   /id="VAR_004815"
FT   VARIANT         207
FT                   /note="M -> R (in RP4; dbSNP:rs104893782)"
FT                   /evidence="ECO:0000269|PubMed:1302614"
FT                   /id="VAR_004816"
FT   VARIANT         209
FT                   /note="V -> M (found in a patient with retinitis
FT                   pigmentosa; unknown pathological significance;
FT                   dbSNP:rs567288669)"
FT                   /evidence="ECO:0000269|PubMed:8317502"
FT                   /id="VAR_004817"
FT   VARIANT         211
FT                   /note="H -> P (in RP4; dbSNP:rs28933993)"
FT                   /id="VAR_004818"
FT   VARIANT         211
FT                   /note="H -> R (in RP4)"
FT                   /evidence="ECO:0000269|PubMed:8317502"
FT                   /id="VAR_004819"
FT   VARIANT         214
FT                   /note="I -> N (in RP4)"
FT                   /evidence="ECO:0000269|PubMed:22334370"
FT                   /id="VAR_068360"
FT   VARIANT         216
FT                   /note="M -> K (in RP4)"
FT                   /evidence="ECO:0000269|PubMed:8081400"
FT                   /id="VAR_004820"
FT   VARIANT         220
FT                   /note="F -> C (in RP4; dbSNP:rs766161322)"
FT                   /id="VAR_004821"
FT   VARIANT         222
FT                   /note="C -> R (in RP4)"
FT                   /id="VAR_004822"
FT   VARIANT         255
FT                   /note="Missing (in RP4)"
FT                   /evidence="ECO:0000269|PubMed:1985460"
FT                   /id="VAR_004823"
FT   VARIANT         264
FT                   /note="Missing (in RP4)"
FT                   /id="VAR_004824"
FT   VARIANT         267
FT                   /note="P -> L (in RP4; dbSNP:rs104893781)"
FT                   /evidence="ECO:0000269|PubMed:1897520"
FT                   /id="VAR_004825"
FT   VARIANT         267
FT                   /note="P -> R (in RP4)"
FT                   /evidence="ECO:0000269|PubMed:7987331"
FT                   /id="VAR_004826"
FT   VARIANT         292
FT                   /note="A -> E (in CSNBAD1; dbSNP:rs104893789)"
FT                   /evidence="ECO:0000269|PubMed:8358437"
FT                   /id="VAR_004827"
FT   VARIANT         296
FT                   /note="K -> E (in RP4; dbSNP:rs29001653)"
FT                   /id="VAR_004828"
FT   VARIANT         297
FT                   /note="S -> R (in RP4; dbSNP:rs142285818)"
FT                   /evidence="ECO:0000269|PubMed:7987331"
FT                   /id="VAR_004829"
FT   VARIANT         342
FT                   /note="T -> M (in RP4; dbSNP:rs183318466)"
FT                   /id="VAR_004830"
FT   VARIANT         345
FT                   /note="V -> L (in RP4; dbSNP:rs104893795)"
FT                   /evidence="ECO:0000269|PubMed:8045708"
FT                   /id="VAR_004831"
FT   VARIANT         345
FT                   /note="V -> M (in RP4; dbSNP:rs104893795)"
FT                   /id="VAR_004832"
FT   VARIANT         347
FT                   /note="P -> A (in RP4)"
FT                   /evidence="ECO:0000269|PubMed:7633434"
FT                   /id="VAR_004833"
FT   VARIANT         347
FT                   /note="P -> L (in RP4; common variant; dbSNP:rs29001566)"
FT                   /evidence="ECO:0000269|PubMed:1391967,
FT                   ECO:0000269|PubMed:2215617"
FT                   /id="VAR_004834"
FT   VARIANT         347
FT                   /note="P -> Q (in RP4; dbSNP:rs29001566)"
FT                   /id="VAR_004835"
FT   VARIANT         347
FT                   /note="P -> R (in RP4; dbSNP:rs29001566)"
FT                   /evidence="ECO:0000269|PubMed:1840561"
FT                   /id="VAR_004836"
FT   VARIANT         347
FT                   /note="P -> S (in RP4; dbSNP:rs29001637)"
FT                   /evidence="ECO:0000269|PubMed:2215617"
FT                   /id="VAR_004837"
FT   MUTAGEN         113
FT                   /note="E->Q: Induces a conformation change that promotes
FT                   interaction with GRK1 and SAG; when associated with Y-257."
FT                   /evidence="ECO:0000269|PubMed:26200343"
FT   MUTAGEN         257
FT                   /note="M->Y: Induces a conformation change that promotes
FT                   interaction with GRK1 and SAG; when associated with Q-113."
FT                   /evidence="ECO:0000269|PubMed:26200343,
FT                   ECO:0000269|PubMed:28524165"
FT   MUTAGEN         336..340
FT                   /note="TVSKT->AVAKA: Loss of phosphorylation sites and
FT                   decreased interaction with SAG."
FT                   /evidence="ECO:0000269|PubMed:28753425"
FT   MUTAGEN         336..338
FT                   /note="TVS->AVA: Loss of phosphorylation sites and
FT                   decreased interaction with SAG; when associated with A-
FT                   343."
FT                   /evidence="ECO:0000269|PubMed:28753425"
FT   MUTAGEN         343
FT                   /note="S->A: Loss of phosphorylation sites and decreased
FT                   interaction with SAG; when associated with 336-A--A-338."
FT                   /evidence="ECO:0000269|PubMed:28753425"
FT   STRAND          2..5
FT                   /evidence="ECO:0000244|PDB:5W0P"
FT   STRAND          10..13
FT                   /evidence="ECO:0000244|PDB:5W0P"
FT   STRAND          16..18
FT                   /evidence="ECO:0000244|PDB:5W0P"
FT   TURN            23..25
FT                   /evidence="ECO:0000244|PDB:5W0P"
FT   TURN            29..31
FT                   /evidence="ECO:0000244|PDB:4ZWJ"
FT   HELIX           35..64
FT                   /evidence="ECO:0000244|PDB:5W0P"
FT   HELIX           66..68
FT                   /evidence="ECO:0000244|PDB:5W0P"
FT   TURN            71..73
FT                   /evidence="ECO:0000244|PDB:5W0P"
FT   HELIX           74..88
FT                   /evidence="ECO:0000244|PDB:5W0P"
FT   HELIX           90..100
FT                   /evidence="ECO:0000244|PDB:5W0P"
FT   HELIX           106..140
FT                   /evidence="ECO:0000244|PDB:5W0P"
FT   HELIX           143..147
FT                   /evidence="ECO:0000244|PDB:5W0P"
FT   HELIX           150..168
FT                   /evidence="ECO:0000244|PDB:5W0P"
FT   HELIX           170..173
FT                   /evidence="ECO:0000244|PDB:5W0P"
FT   STRAND          174..176
FT                   /evidence="ECO:0000244|PDB:4ZWJ"
FT   STRAND          178..181
FT                   /evidence="ECO:0000244|PDB:5W0P"
FT   TURN            182..185
FT                   /evidence="ECO:0000244|PDB:5W0P"
FT   STRAND          186..189
FT                   /evidence="ECO:0000244|PDB:5W0P"
FT   STRAND          191..193
FT                   /evidence="ECO:0000244|PDB:5W0P"
FT   TURN            196..199
FT                   /evidence="ECO:0000244|PDB:5W0P"
FT   HELIX           200..209
FT                   /evidence="ECO:0000244|PDB:5W0P"
FT   TURN            210..212
FT                   /evidence="ECO:0000244|PDB:5W0P"
FT   HELIX           213..236
FT                   /evidence="ECO:0000244|PDB:5W0P"
FT   HELIX           241..277
FT                   /evidence="ECO:0000244|PDB:5W0P"
FT   HELIX           285..306
FT                   /evidence="ECO:0000244|PDB:5W0P"
FT   TURN            307..309
FT                   /evidence="ECO:0000244|PDB:5W0P"
FT   HELIX           311..321
FT                   /evidence="ECO:0000244|PDB:5W0P"
FT   TURN            322..324
FT                   /evidence="ECO:0000244|PDB:4ZWJ"
FT   TURN            331..333
FT                   /evidence="ECO:0000244|PDB:5W0P"
FT   STRAND          339..341
FT                   /evidence="ECO:0000244|PDB:5W0P"
SQ   SEQUENCE   348 AA;  38893 MW;  6F4F6FCBA34265B2 CRC64;
     MNGTEGPNFY VPFSNATGVV RSPFEYPQYY LAEPWQFSML AAYMFLLIVL GFPINFLTLY
     VTVQHKKLRT PLNYILLNLA VADLFMVLGG FTSTLYTSLH GYFVFGPTGC NLEGFFATLG
     GEIALWSLVV LAIERYVVVC KPMSNFRFGE NHAIMGVAFT WVMALACAAP PLAGWSRYIP
     EGLQCSCGID YYTLKPEVNN ESFVIYMFVV HFTIPMIIIF FCYGQLVFTV KEAAAQQQES
     ATTQKAEKEV TRMVIIMVIA FLICWVPYAS VAFYIFTHQG SNFGPIFMTI PAFFAKSAAI
     YNPVIYIMMN KQFRNCMLTT ICCGKNPLGD DEASATVSKT ETSQVAPA
//
ID   FSHR_HUMAN              Reviewed;         695 AA.
AC   P23945; A0A0A0MSC5; A8K947; G5CBS7; G5E967; J3KQ00; Q05AH0; Q16225; Q4QRJ3;
AC   Q4ZFZ2; Q53RW2;
DT   01-MAR-1992, integrated into UniProtKB/Swiss-Prot.
DT   02-NOV-2010, sequence version 3.
DT   12-AUG-2020, entry version 219.
DE   RecName: Full=Follicle-stimulating hormone receptor;
DE            Short=FSH-R;
DE   AltName: Full=Follitropin receptor;
DE   Flags: Precursor;
GN   Name=FSHR; Synonyms=LGR1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), AND VARIANT SER-680.
RC   TISSUE=Ovary;
RX   PubMed=1709010; DOI=10.1016/0006-291x(91)91682-3;
RA   Minegish T., Nakamura K., Takakura Y., Ibuki Y., Igarashi M.;
RT   "Cloning and sequencing of human FSH receptor cDNA.";
RL   Biochem. Biophys. Res. Commun. 175:1125-1130(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), AND VARIANT THR-307.
RX   PubMed=1322283; DOI=10.1210/endo.131.2.1322283;
RA   Tilly J.L., Aihara T., Nishimori K., Jia X.-C., Billig H., Kowalski K.I.,
RA   Perlas E.A., Hsueh A.J.;
RT   "Expression of recombinant human follicle-stimulating hormone receptor:
RT   species-specific ligand binding, signal transduction, and identification of
RT   multiple ovarian messenger ribonucleic acid transcripts.";
RL   Endocrinology 131:799-806(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), AND VARIANT THR-307.
RC   TISSUE=Testis;
RX   PubMed=1301382; DOI=10.1016/0303-7207(92)90220-z;
RA   Kelton C.A., Cheng S.V., Nugent N.P., Schweickhardt R.L., Rosenthal J.L.,
RA   Overton S.A., Wands G.D., Kuzeja J.B., Luchette C.A., Chappel S.C.;
RT   "The cloning of the human follicle stimulating hormone receptor and its
RT   expression in COS-7, CHO, and Y-1 cells.";
RL   Mol. Cell. Endocrinol. 89:141-151(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG).
RC   TISSUE=Adipose tissue;
RA   Liu X., Huang H., Sheng J.;
RT   "FSHR expression in adipose tissue.";
RL   Submitted (MAY-2011) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG), AND VARIANT THR-307.
RC   TISSUE=Testis;
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG), AND VARIANT THR-307.
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT SER-680.
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT SER-680.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS LONG AND 3), AND VARIANTS
RP   THR-307 AND SER-680.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-342 (ISOFORM SHORT), AND VARIANT THR-307.
RC   TISSUE=Testis;
RX   PubMed=1359889; DOI=10.1016/0006-291x(92)91341-m;
RA   Gromoll J., Gudermann T., Nieschlag E.;
RT   "Molecular cloning of a truncated isoform of the human follicle stimulating
RT   hormone receptor.";
RL   Biochem. Biophys. Res. Commun. 188:1077-1083(1992).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-51.
RX   PubMed=7926278; DOI=10.1016/0303-7207(94)90102-3;
RA   Gromoll J., Dankbar B., Gudermann T.;
RT   "Characterization of the 5' flanking region of the human follicle-
RT   stimulating hormone receptor gene.";
RL   Mol. Cell. Endocrinol. 102:93-102(1994).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 286-695, AND VARIANTS THR-307 AND
RP   SER-680.
RX   PubMed=7916967; DOI=10.1677/jme.0.0120265;
RA   Gromoll J., Ried T., Holtgreve-Grez H., Nieschlag E., Gudermann T.;
RT   "Localization of the human FSH receptor to chromosome 2p21 using a genomic
RT   probe comprising exon 10.";
RL   J. Mol. Endocrinol. 12:265-271(1994).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, SULFATION AT TYR-335, AND MUTAGENESIS OF
RP   TYR-330 AND TYR-335.
RX   PubMed=11847099; DOI=10.1093/emboj/21.4.504;
RA   Costagliola S., Panneels V., Bonomi M., Koch J., Many M.C., Smits G.,
RA   Vassart G.;
RT   "Tyrosine sulfation is required for agonist recognition by glycoprotein
RT   hormone receptors.";
RL   EMBO J. 21:504-513(2002).
RN   [14]
RP   ALTERNATIVE SPLICING (ISOFORM 4).
RX   PubMed=11872202; DOI=10.1016/s0015-0282(01)03221-6;
RA   Song G.J., Park Y.S., Lee Y.S., Lee C.C., Kang I.S.;
RT   "Alternatively spliced variants of the follicle-stimulating hormone
RT   receptor gene in the testis of infertile men.";
RL   Fertil. Steril. 77:499-504(2002).
RN   [15]
RP   INTERACTION WITH APPL2.
RX   PubMed=17030088; DOI=10.1016/j.mce.2006.08.014;
RA   Nechamen C.A., Thomas R.M., Dias J.A.;
RT   "APPL1, APPL2, Akt2 and FOXO1a interact with FSHR in a potential signaling
RT   complex.";
RL   Mol. Cell. Endocrinol. 260:93-99(2007).
RN   [16]
RP   3D-STRUCTURE MODELING OF 49-228.
RX   PubMed=8747461; DOI=10.1016/s0969-2126(01)00272-6;
RA   Jiang X., Dreano M., Buckler D.R., Cheng S., Ythier A., Wu H.,
RA   Hendrickson W.A., el Tayar N.;
RT   "Structural predictions for the ligand-binding region of glycoprotein
RT   hormone receptors and the nature of hormone-receptor interactions.";
RL   Structure 3:1341-1353(1995).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.92 ANGSTROMS) OF 17-268 IN COMPLEX WITH FSHA AND
RP   FSHB, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-191.
RX   PubMed=15662415; DOI=10.1038/nature03206;
RA   Fan Q.R., Hendrickson W.A.;
RT   "Structure of human follicle-stimulating hormone in complex with its
RT   receptor.";
RL   Nature 433:269-277(2005).
RN   [18] {ECO:0000244|PDB:4MQW}
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 16-366 OF HOMOTRIMER IN COMPLEX
RP   WITH CGA AND FSHB, FUNCTION, SUBCELLULAR LOCATION, GLYCOSYLATION AT
RP   ASN-191, AND DISULFIDE BONDS.
RX   PubMed=24692546; DOI=10.1074/jbc.m114.549592;
RA   Jiang X., Fischer D., Chen X., McKenna S.D., Liu H., Sriraman V., Yu H.N.,
RA   Goutopoulos A., Arkinstall S., He X.;
RT   "Evidence for follicle-stimulating hormone receptor as a functional
RT   trimer.";
RL   J. Biol. Chem. 289:14273-14282(2014).
RN   [19]
RP   VARIANT ODG1 VAL-189.
RX   PubMed=7553856; DOI=10.1016/0092-8674(95)90275-9;
RA   Aittomaeki K., Lucena J.L.D., Pakarinen P., Sistonen P., Tapanainen J.,
RA   Gromoll J., Kaskikari R., Sankila E.-M., Lehvaslaiho H., Engel A.R.,
RA   Nieschlag E., Huhtaniemi I., de la Chapelle A.;
RT   "Mutation in the follicle-stimulating hormone receptor gene causes
RT   hereditary hypergonadotropic ovarian failure.";
RL   Cell 82:959-968(1995).
RN   [20]
RP   VARIANT OVARIAN SEX CORD TUMOR SER-591.
RX   PubMed=9100567; DOI=10.1210/jcem.82.4.3870;
RA   Kotlar T.J., Young R.H., Albanese C., Crowley W.F. Jr., Scully R.E.,
RA   Jameson J.L.;
RT   "A mutation in the follicle-stimulating hormone receptor occurs frequently
RT   in human ovarian sex cord tumors.";
RL   J. Clin. Endocrinol. Metab. 82:1020-1026(1997).
RN   [21]
RP   VARIANT FSHR ACTIVATION GLY-567, AND CHARACTERIZATION OF VARIANT FSHR
RP   ACTIVATION GLY-567.
RX   PubMed=8636335; DOI=10.1210/jcem.81.4.8636335;
RA   Gromoll J., Simoni M., Nieschlag E.;
RT   "An activating mutation of the follicle-stimulating hormone receptor
RT   autonomously sustains spermatogenesis in a hypophysectomized man.";
RL   J. Clin. Endocrinol. Metab. 81:1367-1370(1996).
RN   [22]
RP   VARIANT ODG1 VAL-189.
RX   PubMed=9851774; DOI=10.1210/jcem.83.12.5306;
RA   Jiang M., Aittomaeki K., Nilsson C., Pakarinen P., Iitia A., Torresani T.,
RA   Simonsen H., Goh V., Pettersson K., de la Chapelle A., Huhtaniemi I.;
RT   "The frequency of an inactivating point mutation (566C-->T) of the human
RT   follicle-stimulating hormone receptor gene in four populations using
RT   allele-specific hybridization and time-resolved fluorometry.";
RL   J. Clin. Endocrinol. Metab. 83:4338-4343(1998).
RN   [23]
RP   VARIANTS ODG1 THR-160 AND CYS-573.
RX   PubMed=9769327; DOI=10.1172/jci3795;
RA   Beau I., Touraine P., Meduri G., Gougeon A., Desroches A., Matuchansky C.,
RA   Milgrom E., Kuttenn F., Misrahi M.;
RT   "A novel phenotype related to partial loss of function mutations of the
RT   follicle stimulating hormone receptor.";
RL   J. Clin. Invest. 102:1352-1359(1998).
RN   [24]
RP   VARIANTS ODG1 VAL-224 AND VAL-601, AND CHARACTERIZATION OF VARIANTS ODG1
RP   VAL-224; CYS-573 AND VAL-601.
RX   PubMed=10551778; DOI=10.1210/mend.13.11.0370;
RA   Touraine P., Beau I., Gougeon A., Meduri G., Desroches A., Pichard C.,
RA   Detoeuf M., Paniel B., Prieur M., Zorn J.-R., Milgrom E., Kuttenn F.,
RA   Misrahi M.;
RT   "New natural inactivating mutations of the follicle-stimulating hormone
RT   receptor: correlations between receptor function and phenotype.";
RL   Mol. Endocrinol. 13:1844-1854(1999).
RN   [25]
RP   VARIANTS THR-307; ARG-524 AND SER-680.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions of
RT   human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [26]
RP   ERRATUM OF PUBMED:10391209.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [27]
RP   VARIANTS THR-307 AND SER-680.
RX   PubMed=12059813; DOI=10.1046/j.1439-0272.2002.00493.x;
RA   Asatiani K., Gromoll J., Eckardstein S.V., Zitzmann M., Nieschlag E.,
RA   Simoni M.;
RT   "Distribution and function of FSH receptor genetic variants in normal
RT   men.";
RL   Andrologia 34:172-176(2002).
RN   [28]
RP   VARIANT ODG1 THR-419, AND CHARACTERIZATION OF VARIANT ODG1 THR-419.
RX   PubMed=11889179; DOI=10.1210/jcem.87.3.8319;
RA   Doherty E., Pakarinen P., Tiitinen A., Kiilavuori A., Huhtaniemi I.,
RA   Forrest S., Aittomaeki K.;
RT   "A novel mutation in the FSH receptor inhibiting signal transduction and
RT   causing primary ovarian failure.";
RL   J. Clin. Endocrinol. Metab. 87:1151-1155(2002).
RN   [29]
RP   VARIANT ODG1 ARG-348.
RX   PubMed=12571157; DOI=10.1093/humrep/deg046;
RA   Allen L.A., Achermann J.C., Pakarinen P., Kotlar T.J., Huhtaniemi I.T.,
RA   Jameson J.L., Cheetham T.D., Ball S.G.;
RT   "A novel loss of function mutation in exon 10 of the FSH receptor gene
RT   causing hypergonadotrophic hypogonadism: clinical and molecular
RT   characteristics.";
RL   Hum. Reprod. 18:251-256(2003).
RN   [30]
RP   VARIANT ODG1 THR-519, AND CHARACTERIZATION OF VARIANT ODG1 THR-519.
RX   PubMed=12915623; DOI=10.1210/jc.2003-030217;
RA   Meduri G., Touraine P., Beau I., Lahuna O., Desroches A.,
RA   Vacher-Lavenu M.C., Kuttenn F., Misrahi M.;
RT   "Delayed puberty and primary amenorrhea associated with a novel mutation of
RT   the human follicle-stimulating hormone receptor: clinical, histological,
RT   and molecular studies.";
RL   J. Clin. Endocrinol. Metab. 88:3491-3498(2003).
RN   [31]
RP   VARIANT OHSS ILE-449.
RX   PubMed=12930927; DOI=10.1056/nejmoa030065;
RA   Vasseur C., Rodien P., Beau I., Desroches A., Gerard C., de Poncheville L.,
RA   Chaplot S., Savagner F., Croue A., Mathieu E., Lahlou N., Descamps P.,
RA   Misrahi M.;
RT   "A chorionic gonadotropin-sensitive mutation in the follicle-stimulating
RT   hormone receptor as a cause of familial gestational spontaneous ovarian
RT   hyperstimulation syndrome.";
RL   N. Engl. J. Med. 349:753-759(2003).
RN   [32]
RP   VARIANT OHSS ASN-567.
RX   PubMed=12930928; DOI=10.1056/nejmoa030064;
RA   Smits G., Olatunbosun O., Delbaere A., Pierson R., Vassart G.,
RA   Costagliola S.;
RT   "Ovarian hyperstimulation syndrome due to a mutation in the follicle-
RT   stimulating hormone receptor.";
RL   N. Engl. J. Med. 349:760-766(2003).
RN   [33]
RP   VARIANT OHSS ALA-449, AND CHARACTERIZATION OF VARIANT OHSS ALA-449.
RX   PubMed=15080154; DOI=10.1210/jc.2003-031910;
RA   Montanelli L., Delbaere A., Di Carlo C., Nappi C., Smits G., Vassart G.,
RA   Costagliola S.;
RT   "A mutation in the follicle-stimulating hormone receptor as a cause of
RT   familial spontaneous ovarian hyperstimulation syndrome.";
RL   J. Clin. Endocrinol. Metab. 89:1255-1258(2004).
RN   [34]
RP   VARIANT OHSS THR-545, AND CHARACTERIZATION OF VARIANT OHSS THR-545.
RX   PubMed=16278261; DOI=10.1210/jc.2005-1580;
RA   De Leener A., Montanelli L., Van Durme J., Chae H., Smits G., Vassart G.,
RA   Costagliola S.;
RT   "Presence and absence of follicle-stimulating hormone receptor mutations
RT   provide some insights into spontaneous ovarian hyperstimulation syndrome
RT   physiopathology.";
RL   J. Clin. Endocrinol. Metab. 91:555-562(2006).
RN   [35]
RP   VARIANT OHSS TYR-128, AND CHARACTERIZATION OF VARIANT OHSS TYR-128.
RX   PubMed=17721928; DOI=10.1002/humu.20604;
RA   De Leener A., Caltabiano G., Erkan S., Idil M., Vassart G., Pardo L.,
RA   Costagliola S.;
RT   "Identification of the first germline mutation in the extracellular domain
RT   of the follitropin receptor responsible for spontaneous ovarian
RT   hyperstimulation syndrome.";
RL   Hum. Mutat. 29:91-98(2008).
RN   [36]
RP   VARIANT OHSS ILE-512, CHARACTERIZATION OF VARIANT OHSS ILE-512, AND
RP   FUNCTION.
RX   PubMed=24058690; DOI=10.1371/journal.pone.0075478;
RA   Uchida S., Uchida H., Maruyama T., Kajitani T., Oda H., Miyazaki K.,
RA   Kagami M., Yoshimura Y.;
RT   "Molecular analysis of a mutated FSH receptor detected in a patient with
RT   spontaneous ovarian hyperstimulation syndrome.";
RL   PLoS ONE 8:E75478-E75478(2013).
RN   [37]
RP   VARIANTS OHSS ALA-514 AND VAL-575, AND CHARACTERIZATION OF VARIANTS OHSS
RP   ALA-514 AND VAL-575.
RX   PubMed=25581598; DOI=10.1210/jc.2014-3662;
RA   Desai S.S., Achrekar S.K., Sahasrabuddhe K.A., Meharji P.K., Desai S.K.,
RA   Mangoli V.S., Mahale S.D.;
RT   "Functional characterization of two naturally occurring mutations
RT   (Val514Ala and Ala575Val) in follicle-stimulating hormone receptor.";
RL   J. Clin. Endocrinol. Metab. 100:E638-E645(2015).
CC   -!- FUNCTION: G protein-coupled receptor for follitropin, the follicle-
CC       stimulating hormone (PubMed:11847099, PubMed:24058690,
CC       PubMed:24692546). Through cAMP production activates the downstream
CC       PI3K-AKT and ERK1/ERK2 signaling pathways (PubMed:24058690).
CC       {ECO:0000269|PubMed:11847099, ECO:0000269|PubMed:24058690,
CC       ECO:0000269|PubMed:24692546}.
CC   -!- SUBUNIT: Homotrimer. Functions as a homotrimer binding the FSH hormone
CC       heterodimer composed of CGA and FSHB (PubMed:24692546). Interacts with
CC       ARRB2 (By similarity). Interacts with APPL2; interaction is independent
CC       of follicle stimulating hormone stimulation (PubMed:17030088).
CC       {ECO:0000250|UniProtKB:P20395, ECO:0000269|PubMed:17030088,
CC       ECO:0000269|PubMed:24692546}.
CC   -!- INTERACTION:
CC       P23945; P27348: YWHAQ; NbExp=4; IntAct=EBI-848239, EBI-359854;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:11847099,
CC       ECO:0000269|PubMed:24692546}; Multi-pass membrane protein
CC       {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=Long; Synonyms=R1;
CC         IsoId=P23945-1; Sequence=Displayed;
CC       Name=Short; Synonyms=E9Del;
CC         IsoId=P23945-2; Sequence=VSP_001953;
CC       Name=3; Synonyms=E6Del;
CC         IsoId=P23945-3; Sequence=VSP_043181;
CC       Name=4; Synonyms=E8'Inc;
CC         IsoId=P23945-4; Sequence=VSP_053411;
CC   -!- TISSUE SPECIFICITY: Sertoli cells and ovarian granulosa cells.
CC   -!- PTM: Sulfated. {ECO:0000269|PubMed:11847099}.
CC   -!- PTM: N-glycosylated; indirectly required for FSH-binding, possibly via
CC       a conformational change that allows high affinity binding of hormone.
CC       {ECO:0000250|UniProtKB:P20395}.
CC   -!- DISEASE: Ovarian dysgenesis 1 (ODG1) [MIM:233300]: An autosomal
CC       recessive disease characterized by primary amenorrhea, variable
CC       development of secondary sex characteristics, poorly developed streak
CC       ovaries, and high serum levels of follicle-stimulating hormone (FSH)
CC       and luteinizing hormone (LH). {ECO:0000269|PubMed:10551778,
CC       ECO:0000269|PubMed:11889179, ECO:0000269|PubMed:12571157,
CC       ECO:0000269|PubMed:12915623, ECO:0000269|PubMed:7553856,
CC       ECO:0000269|PubMed:9769327, ECO:0000269|PubMed:9851774}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Ovarian hyperstimulation syndrome (OHSS) [MIM:608115]:
CC       Disorder which occurs either spontaneously or most often as an
CC       iatrogenic complication of ovarian stimulation treatments for in vitro
CC       fertilization. The clinical manifestations vary from abdominal
CC       distention and discomfort to potentially life-threatening, massive
CC       ovarian enlargement and capillary leak with fluid sequestration.
CC       Pathologic features of this syndrome include the presence of multiple
CC       serous and hemorrhagic follicular cysts lined by luteinized cells, a
CC       condition called hyperreactio luteinalis. {ECO:0000269|PubMed:12930927,
CC       ECO:0000269|PubMed:12930928, ECO:0000269|PubMed:15080154,
CC       ECO:0000269|PubMed:16278261, ECO:0000269|PubMed:17721928,
CC       ECO:0000269|PubMed:24058690, ECO:0000269|PubMed:25581598}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       FSH/LSH/TSH subfamily. {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=FSHR";
CC   -!- WEB RESOURCE: Name=Sequence-structure-function-analysis of glycoprotein
CC       hormone receptors;
CC       URL="http://www.ssfa-gphr.de/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M65085; AAA52477.1; -; mRNA.
DR   EMBL; M95489; AAA52478.1; -; mRNA.
DR   EMBL; S59900; AAB26480.1; -; mRNA.
DR   EMBL; JN003607; AEI86722.1; -; mRNA.
DR   EMBL; AY429104; AAR07899.1; -; mRNA.
DR   EMBL; AK292562; BAF85251.1; -; mRNA.
DR   EMBL; AC007189; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC079394; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC092533; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471053; EAX00188.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAX00189.1; -; Genomic_DNA.
DR   EMBL; BC096831; AAH96831.1; -; mRNA.
DR   EMBL; BC118548; AAI18549.1; -; mRNA.
DR   EMBL; BC125270; AAI25271.1; -; mRNA.
DR   EMBL; X68044; CAA48179.1; -; mRNA.
DR   EMBL; S73199; AAB32071.1; -; Genomic_DNA.
DR   EMBL; S73526; AAB32225.1; -; Genomic_DNA.
DR   CCDS; CCDS1843.1; -. [P23945-1]
DR   CCDS; CCDS1844.2; -. [P23945-3]
DR   PIR; I57661; QRHUFT.
DR   RefSeq; NP_000136.2; NM_000145.3.
DR   RefSeq; NP_852111.2; NM_181446.2.
DR   PDB; 1XUN; Model; -; A=49-228.
DR   PDB; 1XWD; X-ray; 2.92 A; C/F=17-268.
DR   PDB; 4AY9; X-ray; 2.50 A; X/Y/Z=17-366.
DR   PDB; 4MQW; X-ray; 2.90 A; X/Y/Z=16-366.
DR   PDBsum; 1XUN; -.
DR   PDBsum; 1XWD; -.
DR   PDBsum; 4AY9; -.
DR   PDBsum; 4MQW; -.
DR   SMR; P23945; -.
DR   BioGRID; 108770; 35.
DR   DIP; DIP-35605N; -.
DR   IntAct; P23945; 20.
DR   MINT; P23945; -.
DR   STRING; 9606.ENSP00000384708; -.
DR   BindingDB; P23945; -.
DR   ChEMBL; CHEMBL2024; -.
DR   DrugBank; DB00097; Choriogonadotropin alfa.
DR   DrugBank; DB09066; Corifollitropin alfa.
DR   DrugBank; DB00066; Follitropin.
DR   DrugBank; DB00032; Menotropins.
DR   DrugBank; DB04786; Suramin.
DR   DrugBank; DB00094; Urofollitropin.
DR   DrugCentral; P23945; -.
DR   GuidetoPHARMACOLOGY; 253; -.
DR   TCDB; 9.A.14.1.5; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; P23945; 4 sites.
DR   iPTMnet; P23945; -.
DR   PhosphoSitePlus; P23945; -.
DR   BioMuta; FSHR; -.
DR   DMDM; 311033420; -.
DR   PaxDb; P23945; -.
DR   PeptideAtlas; P23945; -.
DR   PRIDE; P23945; -.
DR   ProteomicsDB; 33847; -.
DR   ProteomicsDB; 54168; -. [P23945-1]
DR   ProteomicsDB; 54169; -. [P23945-2]
DR   ProteomicsDB; 54170; -. [P23945-3]
DR   Antibodypedia; 15300; 675 antibodies.
DR   Ensembl; ENST00000304421; ENSP00000306780; ENSG00000170820.
DR   GeneID; 2492; -.
DR   KEGG; hsa:2492; -.
DR   UCSC; uc002rww.4; human.
DR   UCSC; uc010fbn.4; human. [P23945-1]
DR   CTD; 2492; -.
DR   DisGeNET; 2492; -.
DR   EuPathDB; HostDB:ENSG00000170820.11; -.
DR   GeneCards; FSHR; -.
DR   HGNC; HGNC:3969; FSHR.
DR   HPA; ENSG00000170820; Tissue enhanced (gallbladder, ovary, testis).
DR   MalaCards; FSHR; -.
DR   MIM; 136435; gene.
DR   MIM; 233300; phenotype.
DR   MIM; 608115; phenotype.
DR   neXtProt; NX_P23945; -.
DR   Orphanet; 243; 46,XX gonadal dysgenesis.
DR   Orphanet; 619; NON RARE IN EUROPE: Primary ovarian failure.
DR   Orphanet; 64739; Ovarian hyperstimulation syndrome.
DR   PharmGKB; PA28386; -.
DR   eggNOG; KOG2087; Eukaryota.
DR   HOGENOM; CLU_006130_1_1_1; -.
DR   InParanoid; P23945; -.
DR   KO; K04247; -.
DR   OrthoDB; 257031at2759; -.
DR   PhylomeDB; P23945; -.
DR   TreeFam; TF316814; -.
DR   PathwayCommons; P23945; -.
DR   Reactome; R-HSA-375281; Hormone ligand-binding receptors.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-9660821; ADORA2B mediated anti-inflammatory cytokines production.
DR   SignaLink; P23945; -.
DR   SIGNOR; P23945; -.
DR   BioGRID-ORCS; 2492; 2 hits in 870 CRISPR screens.
DR   ChiTaRS; FSHR; human.
DR   EvolutionaryTrace; P23945; -.
DR   GeneWiki; Follicle-stimulating_hormone_receptor; -.
DR   GenomeRNAi; 2492; -.
DR   Pharos; P23945; Tclin.
DR   PRO; PR:P23945; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; P23945; protein.
DR   Bgee; ENSG00000170820; Expressed in testis and 68 other tissues.
DR   ExpressionAtlas; P23945; baseline and differential.
DR   Genevisible; P23945; HS.
DR   GO; GO:0016021; C:integral component of membrane; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IDA:UniProtKB.
DR   GO; GO:0004963; F:follicle-stimulating hormone receptor activity; IDA:UniProtKB.
DR   GO; GO:0008528; F:G protein-coupled peptide receptor activity; IBA:GO_Central.
DR   GO; GO:0007190; P:activation of adenylate cyclase activity; IBA:GO_Central.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0071372; P:cellular response to follicle-stimulating hormone stimulus; IMP:UniProtKB.
DR   GO; GO:0007292; P:female gamete generation; TAS:ProtInc.
DR   GO; GO:0008585; P:female gonad development; TAS:ProtInc.
DR   GO; GO:0042699; P:follicle-stimulating hormone signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0008406; P:gonad development; TAS:ProtInc.
DR   GO; GO:0009755; P:hormone-mediated signaling pathway; IBA:GO_Central.
DR   GO; GO:0008584; P:male gonad development; IEP:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IMP:UniProtKB.
DR   GO; GO:0010738; P:regulation of protein kinase A signaling; IMP:UniProtKB.
DR   GO; GO:0007283; P:spermatogenesis; TAS:ProtInc.
DR   InterPro; IPR002272; FSH_rcpt.
DR   InterPro; IPR024635; GnHR_TM.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR002131; Gphrmn_rcpt_fam.
DR   InterPro; IPR026906; LRR_5.
DR   InterPro; IPR000372; LRRNT.
DR   PANTHER; PTHR24372:SF5; PTHR24372:SF5; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   Pfam; PF12369; GnHR_trans; 1.
DR   Pfam; PF13306; LRR_5; 2.
DR   Pfam; PF01462; LRRNT; 1.
DR   PRINTS; PR01143; FSHRECEPTOR.
DR   PRINTS; PR00373; GLYCHORMONER.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM00013; LRRNT; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Disease mutation;
KW   Disulfide bond; G-protein coupled receptor; Glycoprotein;
KW   Leucine-rich repeat; Membrane; Polymorphism; Receptor; Reference proteome;
KW   Repeat; Signal; Sulfation; Transducer; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..17
FT                   /evidence="ECO:0000255"
FT   CHAIN           18..695
FT                   /note="Follicle-stimulating hormone receptor"
FT                   /id="PRO_0000012771"
FT   TOPO_DOM        18..366
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        367..387
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        388..398
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        399..421
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        422..443
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        444..465
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        466..485
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        486..508
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        509..528
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        529..550
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        551..573
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        574..597
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        598..608
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        609..630
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        631..695
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          18..46
FT                   /note="LRRNT"
FT   REPEAT          49..72
FT                   /note="LRR 1"
FT   REPEAT          73..97
FT                   /note="LRR 2"
FT   REPEAT          98..118
FT                   /note="LRR 3"
FT   REPEAT          119..143
FT                   /note="LRR 4"
FT   REPEAT          144..169
FT                   /note="LRR 5"
FT   REPEAT          170..192
FT                   /note="LRR 6"
FT   REPEAT          193..216
FT                   /note="LRR 7"
FT   REPEAT          217..240
FT                   /note="LRR 8"
FT   REPEAT          241..259
FT                   /note="LRR 9"
FT   MOD_RES         335
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000305|PubMed:11847099"
FT   CARBOHYD        191
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000244|PDB:4MQW,
FT                   ECO:0000269|PubMed:15662415, ECO:0000269|PubMed:24692546"
FT   CARBOHYD        199
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        293
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        318
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        18..25
FT                   /evidence="ECO:0000244|PDB:4MQW, ECO:0000255|PROSITE-
FT                   ProRule:PRU00521, ECO:0000269|PubMed:15662415,
FT                   ECO:0000269|PubMed:24692546"
FT   DISULFID        23..32
FT                   /evidence="ECO:0000244|PDB:4MQW, ECO:0000255|PROSITE-
FT                   ProRule:PRU00521, ECO:0000269|PubMed:15662415,
FT                   ECO:0000269|PubMed:24692546"
FT   DISULFID        275..346
FT                   /evidence="ECO:0000244|PDB:4MQW,
FT                   ECO:0000269|PubMed:24692546"
FT   DISULFID        276..356
FT                   /evidence="ECO:0000244|PDB:4MQW,
FT                   ECO:0000269|PubMed:24692546"
FT   DISULFID        276..292
FT                   /evidence="ECO:0000244|PDB:4MQW,
FT                   ECO:0000269|PubMed:24692546"
FT   DISULFID        292..338
FT                   /evidence="ECO:0000244|PDB:4MQW,
FT                   ECO:0000269|PubMed:24692546"
FT   DISULFID        442..517
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VAR_SEQ         149..174
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_043181"
FT   VAR_SEQ         223
FT                   /note="L -> LNRRTRTPTEPNVLLAKYPSGQGVLEEPESLSSSI (in isoform
FT                   4)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_053411"
FT   VAR_SEQ         224..285
FT                   /note="Missing (in isoform Short)"
FT                   /evidence="ECO:0000303|PubMed:1359889"
FT                   /id="VSP_001953"
FT   VARIANT         128
FT                   /note="S -> Y (in OHSS; displays increase in affinity and
FT                   sensitivity toward hCG and does not show any constitutive
FT                   activity nor promiscuous activation by TSH;
FT                   dbSNP:rs121909665)"
FT                   /evidence="ECO:0000269|PubMed:17721928"
FT                   /id="VAR_039279"
FT   VARIANT         160
FT                   /note="I -> T (in ODG1; impairs cell surface expression)"
FT                   /evidence="ECO:0000269|PubMed:9769327"
FT                   /id="VAR_018045"
FT   VARIANT         189
FT                   /note="A -> V (in ODG1; very frequent in the Finnish
FT                   population)"
FT                   /evidence="ECO:0000269|PubMed:7553856,
FT                   ECO:0000269|PubMed:9851774"
FT                   /id="VAR_018046"
FT   VARIANT         224
FT                   /note="D -> V (in ODG1; FSH binding is barely detectable;
FT                   impaired targeting to the cell membrane; adenylate cyclase
FT                   stimulation by FSH is 4 +-2% residual activity)"
FT                   /evidence="ECO:0000269|PubMed:10551778"
FT                   /id="VAR_039280"
FT   VARIANT         307
FT                   /note="A -> T (in dbSNP:rs6165)"
FT                   /evidence="ECO:0000269|PubMed:10391209,
FT                   ECO:0000269|PubMed:12059813, ECO:0000269|PubMed:1301382,
FT                   ECO:0000269|PubMed:1322283, ECO:0000269|PubMed:1359889,
FT                   ECO:0000269|PubMed:14702039, ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:7916967, ECO:0000269|Ref.5"
FT                   /id="VAR_013903"
FT   VARIANT         348
FT                   /note="P -> R (in ODG1)"
FT                   /evidence="ECO:0000269|PubMed:12571157"
FT                   /id="VAR_039281"
FT   VARIANT         419
FT                   /note="A -> T (in ODG1)"
FT                   /evidence="ECO:0000269|PubMed:11889179"
FT                   /id="VAR_018047"
FT   VARIANT         449
FT                   /note="T -> A (in OHSS; increase of receptor sensitivity to
FT                   both hCG and TSH together with an increase in basal
FT                   activity)"
FT                   /evidence="ECO:0000269|PubMed:15080154"
FT                   /id="VAR_039282"
FT   VARIANT         449
FT                   /note="T -> I (in OHSS; dbSNP:rs28928870)"
FT                   /evidence="ECO:0000269|PubMed:12930927"
FT                   /id="VAR_017244"
FT   VARIANT         512
FT                   /note="M -> I (in OHSS; inhibits activation of PI3K/AKT
FT                   signaling pathway; reduces cAMP production; no effect on
FT                   ERK1/2 signaling pathway activation)"
FT                   /evidence="ECO:0000269|PubMed:24058690"
FT                   /id="VAR_074535"
FT   VARIANT         514
FT                   /note="V -> A (in OHSS; increases cell surface expression;
FT                   no effect on hormone binding; increases signaling
FT                   activity)"
FT                   /evidence="ECO:0000269|PubMed:25581598"
FT                   /id="VAR_074536"
FT   VARIANT         519
FT                   /note="P -> T (in ODG1; totally impairs adenylate cyclase
FT                   stimulation in vitro; alters the cell surface targeting of
FT                   the receptor which remains trapped intracellularly)"
FT                   /evidence="ECO:0000269|PubMed:12915623"
FT                   /id="VAR_039283"
FT   VARIANT         524
FT                   /note="S -> R (in dbSNP:rs6167)"
FT                   /evidence="ECO:0000269|PubMed:10391209"
FT                   /id="VAR_013904"
FT   VARIANT         545
FT                   /note="I -> T (in OHSS; displays promiscuous activation by
FT                   both hCG and TSH together with detectable constitutive
FT                   activity)"
FT                   /evidence="ECO:0000269|PubMed:16278261"
FT                   /id="VAR_039284"
FT   VARIANT         567
FT                   /note="D -> G (activating mutation resulting in 1.5-fold
FT                   increase in basal cAMP production compared to the wild-type
FT                   receptor)"
FT                   /evidence="ECO:0000269|PubMed:8636335"
FT                   /id="VAR_039285"
FT   VARIANT         567
FT                   /note="D -> N (in OHSS; dbSNP:rs28928871)"
FT                   /evidence="ECO:0000269|PubMed:12930928"
FT                   /id="VAR_017245"
FT   VARIANT         573
FT                   /note="R -> C (in ODG1; alters signal transduction of the
FT                   receptor; adenylate cyclase stimulation by FSH is 24 +-4%
FT                   residual activity)"
FT                   /evidence="ECO:0000269|PubMed:10551778,
FT                   ECO:0000269|PubMed:9769327"
FT                   /id="VAR_018048"
FT   VARIANT         575
FT                   /note="A -> V (in OHSS; decreases cell surface expression;
FT                   no effect on hormone binding; increases levels of
FT                   internalized hormone receptor complex; cAMP levels are
FT                   similar to basal levels even at high doses of FSH
FT                   stimulation indicating reduced signaling)"
FT                   /evidence="ECO:0000269|PubMed:25581598"
FT                   /id="VAR_074537"
FT   VARIANT         591
FT                   /note="F -> S (in ovarian sex cord tumor; loss of
FT                   function)"
FT                   /evidence="ECO:0000269|PubMed:9100567"
FT                   /id="VAR_018049"
FT   VARIANT         601
FT                   /note="L -> V (in ODG1; binds FSH with a similar affinity
FT                   than the wild-type receptor; adenylate cyclase stimulation
FT                   by FSH is 12 +-3% residual activity)"
FT                   /evidence="ECO:0000269|PubMed:10551778"
FT                   /id="VAR_039286"
FT   VARIANT         680
FT                   /note="N -> S (associated with longer menstrual cycles;
FT                   dbSNP:rs6166)"
FT                   /evidence="ECO:0000269|PubMed:10391209,
FT                   ECO:0000269|PubMed:12059813, ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:15815621, ECO:0000269|PubMed:1709010,
FT                   ECO:0000269|PubMed:7916967, ECO:0000269|Ref.8"
FT                   /id="VAR_013905"
FT   MUTAGEN         330
FT                   /note="Y->F: No change in intracellular cAMP accumulation."
FT                   /evidence="ECO:0000269|PubMed:11847099"
FT   MUTAGEN         335
FT                   /note="Y->F: Reduces intracellular cAMP accumulation."
FT                   /evidence="ECO:0000269|PubMed:11847099"
FT   CONFLICT        13
FT                   /note="S -> R (in Ref. 10; CAA48179)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        112
FT                   /note="N -> T (in Ref. 1; AAA52477)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        197..198
FT                   /note="EL -> AV (in Ref. 1; AAA52477)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        295
FT                   /note="S -> P (in Ref. 10; CAA48179)"
FT                   /evidence="ECO:0000305"
FT   STRAND          21..26
FT                   /evidence="ECO:0000244|PDB:4AY9"
FT   STRAND          29..34
FT                   /evidence="ECO:0000244|PDB:4AY9"
FT   STRAND          49..55
FT                   /evidence="ECO:0000244|PDB:4AY9"
FT   STRAND          59..61
FT                   /evidence="ECO:0000244|PDB:4AY9"
FT   TURN            63..68
FT                   /evidence="ECO:0000244|PDB:1XWD"
FT   STRAND          74..78
FT                   /evidence="ECO:0000244|PDB:4AY9"
FT   TURN            88..90
FT                   /evidence="ECO:0000244|PDB:4MQW"
FT   STRAND          99..105
FT                   /evidence="ECO:0000244|PDB:4AY9"
FT   STRAND          115..117
FT                   /evidence="ECO:0000244|PDB:1XWD"
FT   STRAND          124..130
FT                   /evidence="ECO:0000244|PDB:4AY9"
FT   STRAND          143..145
FT                   /evidence="ECO:0000244|PDB:4AY9"
FT   STRAND          147..153
FT                   /evidence="ECO:0000244|PDB:4AY9"
FT   STRAND          168..171
FT                   /evidence="ECO:0000244|PDB:4AY9"
FT   STRAND          173..176
FT                   /evidence="ECO:0000244|PDB:4AY9"
FT   TURN            187..192
FT                   /evidence="ECO:0000244|PDB:4MQW"
FT   STRAND          193..199
FT                   /evidence="ECO:0000244|PDB:4AY9"
FT   TURN            211..216
FT                   /evidence="ECO:0000244|PDB:4AY9"
FT   STRAND          221..224
FT                   /evidence="ECO:0000244|PDB:4AY9"
FT   STRAND          235..237
FT                   /evidence="ECO:0000244|PDB:4AY9"
FT   STRAND          243..245
FT                   /evidence="ECO:0000244|PDB:4AY9"
FT   TURN            258..260
FT                   /evidence="ECO:0000244|PDB:4AY9"
FT   STRAND          266..268
FT                   /evidence="ECO:0000244|PDB:4AY9"
FT   HELIX           272..280
FT                   /evidence="ECO:0000244|PDB:4AY9"
FT   STRAND          345..348
FT                   /evidence="ECO:0000244|PDB:4AY9"
FT   STRAND          351..353
FT                   /evidence="ECO:0000244|PDB:4MQW"
SQ   SEQUENCE   695 AA;  78265 MW;  766BC421014CD5A4 CRC64;
     MALLLVSLLA FLSLGSGCHH RICHCSNRVF LCQESKVTEI PSDLPRNAIE LRFVLTKLRV
     IQKGAFSGFG DLEKIEISQN DVLEVIEADV FSNLPKLHEI RIEKANNLLY INPEAFQNLP
     NLQYLLISNT GIKHLPDVHK IHSLQKVLLD IQDNINIHTI ERNSFVGLSF ESVILWLNKN
     GIQEIHNCAF NGTQLDELNL SDNNNLEELP NDVFHGASGP VILDISRTRI HSLPSYGLEN
     LKKLRARSTY NLKKLPTLEK LVALMEASLT YPSHCCAFAN WRRQISELHP ICNKSILRQE
     VDYMTQARGQ RSSLAEDNES SYSRGFDMTY TEFDYDLCNE VVDVTCSPKP DAFNPCEDIM
     GYNILRVLIW FISILAITGN IIVLVILTTS QYKLTVPRFL MCNLAFADLC IGIYLLLIAS
     VDIHTKSQYH NYAIDWQTGA GCDAAGFFTV FASELSVYTL TAITLERWHT ITHAMQLDCK
     VQLRHAASVM VMGWIFAFAA ALFPIFGISS YMKVSICLPM DIDSPLSQLY VMSLLVLNVL
     AFVVICGCYI HIYLTVRNPN IVSSSSDTRI AKRMAMLIFT DFLCMAPISF FAISASLKVP
     LITVSKAKIL LVLFHPINSC ANPFLYAIFT KNFRRDFFIL LSKCGCYEMQ AQIYRTETSS
     TVHNTHPRNG HCSSAPRVTN GSTYILVPLS HLAQN
//
ID   FZD2_HUMAN              Reviewed;         565 AA.
AC   Q14332; Q0VG82;
DT   05-DEC-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   07-OCT-2020, entry version 184.
DE   RecName: Full=Frizzled-2;
DE            Short=Fz-2;
DE            Short=hFz2;
DE   AltName: Full=FzE2;
DE   Flags: Precursor;
GN   Name=FZD2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Ovary;
RX   PubMed=7558010; DOI=10.1006/geno.1995.1060;
RA   Zhao Z., Lee C.C., Baldini A., Caskey C.T.;
RT   "A human homologue of the Drosophila polarity gene frizzled has been
RT   identified and mapped to 17q21.1.";
RL   Genomics 27:370-373(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Fetal lung;
RX   PubMed=9813155; DOI=10.1006/bbrc.1998.9607;
RA   Sagara N., Toda G., Hirai M., Terada M., Katoh M.;
RT   "Molecular cloning, differential expression, and chromosomal localization
RT   of human frizzled-1, frizzled-2, and frizzled-7.";
RL   Biochem. Biophys. Res. Commun. 252:117-122(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 282-343.
RC   TISSUE=Esophageal carcinoma;
RX   PubMed=9707618; DOI=10.1073/pnas.95.17.10164;
RA   Tanaka S., Akiyoshi T., Mori M., Wands J.R., Sugimachi K.;
RT   "A novel frizzled gene identified in human esophageal carcinoma mediates
RT   APC/beta-catenin signals.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:10164-10169(1998).
RN   [5]
RP   FUNCTION, INVOLVEMENT IN OMOD2, VARIANT OMOD2 548-TRP--VAL-565 DEL, AND
RP   CHARACTERIZATION OF VARIANT OMOD2 548-TRP--VAL-565 DEL.
RX   PubMed=25759469; DOI=10.1093/hmg/ddv088;
RA   Saal H.M., Prows C.A., Guerreiro I., Donlin M., Knudson L., Sund K.L.,
RA   Chang C.F., Brugmann S.A., Stottmann R.W.;
RT   "A mutation in FRIZZLED2 impairs Wnt signaling and causes autosomal
RT   dominant omodysplasia.";
RL   Hum. Mol. Genet. 24:3399-3409(2015).
RN   [6]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH C.DIFFICILE TCDB
RP   (MICROBIAL INFECTION).
RX   PubMed=27680706; DOI=10.1038/nature19799;
RA   Tao L., Zhang J., Meraner P., Tovaglieri A., Wu X., Gerhard R., Zhang X.,
RA   Stallcup W.B., Miao J., He X., Hurdle J.G., Breault D.T., Brass A.L.,
RA   Dong M.;
RT   "Frizzled proteins are colonic epithelial receptors for C. difficile toxin
RT   B.";
RL   Nature 538:350-355(2016).
RN   [7]
RP   INTERACTION WITH C.DIFFICILE TCDB (MICROBIAL INFECTION).
RX   PubMed=31233493; DOI=10.1371/journal.pbio.3000311;
RA   Simeon R., Jiang M., Chamoun-Emanuelli A.M., Yu H., Zhang Y., Meng R.,
RA   Peng Z., Jakana J., Zhang J., Feng H., Chen Z.;
RT   "Selection and characterization of ultrahigh potency designed ankyrin
RT   repeat protein inhibitors of C. difficile toxin B.";
RL   PLoS Biol. 17:e3000311-e3000311(2019).
RN   [8] {ECO:0000244|PDB:6C0B}
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 34-156 IN COMPLEX WITH
RP   C.DIFFICILE TCDB, DISULFIDE BONDS, GLYCOSYLATION AT ASN-53, FUNCTION
RP   (MICROBIAL INFECTION), AND MUTAGENESIS OF TYR-77 AND LYS-127.
RX   PubMed=29748286; DOI=10.1126/science.aar1999;
RA   Chen P., Tao L., Wang T., Zhang J., He A., Lam K.H., Liu Z., He X.,
RA   Perry K., Dong M., Jin R.;
RT   "Structural basis for recognition of frizzled proteins by Clostridium
RT   difficile toxin B.";
RL   Science 360:664-669(2018).
RN   [9]
RP   VARIANT OMOD2 VAL-434.
RX   PubMed=29230162; DOI=10.1159/000479721;
RA   Tuerkmen S., Spielmann M., Guenes N., Knaus A., Floettmann R., Mundlos S.,
RA   Tueysuez B.;
RT   "A novel de novo FZD2 mutation in a patient with autosomal dominant
RT   omodysplasia.";
RL   Mol. Syndromol. 8:318-324(2017).
RN   [10]
RP   VARIANT OMOD2 547-SER--VAL-565 DEL.
RX   PubMed=29383834; DOI=10.1002/ajmg.a.38623;
RA   Nagasaki K., Nishimura G., Kikuchi T., Nyuzuki H., Sasaki S., Ogawa Y.,
RA   Saitoh A.;
RT   "Nonsense mutations in FZD2 cause autosomal-dominant omodysplasia: Robinow
RT   syndrome-like phenotypes.";
RL   Am. J. Med. Genet. A 176:739-742(2018).
RN   [11]
RP   INVOLVEMENT IN ROBINOW-LIKE SYNDROME, AND VARIANTS LEU-142;
RP   377-TRP--VAL-565 DEL; SER-434 AND VAL-434.
RX   PubMed=29276006; DOI=10.1016/j.ajhg.2017.10.002;
RG   Baylor-Hopkins Center for Mendelian Genomics;
RA   White J.J., Mazzeu J.F., Coban-Akdemir Z., Bayram Y., Bahrambeigi V.,
RA   Hoischen A., van Bon B.W.M., Gezdirici A., Gulec E.Y., Ramond F.,
RA   Touraine R., Thevenon J., Shinawi M., Beaver E., Heeley J., Hoover-Fong J.,
RA   Durmaz C.D., Karabulut H.G., Marzioglu-Ozdemir E., Cayir A., Duz M.B.,
RA   Seven M., Price S., Ferreira B.M., Vianna-Morgante A.M., Ellard S.,
RA   Parrish A., Stals K., Flores-Daboub J., Jhangiani S.N., Gibbs R.A.,
RA   Brunner H.G., Sutton V.R., Lupski J.R., Carvalho C.M.B.;
RT   "WNT signaling perturbations underlie the genetic heterogeneity of Robinow
RT   syndrome.";
RL   Am. J. Hum. Genet. 102:27-43(2018).
RN   [12]
RP   VARIANTS OMOD2 VAL-434 AND 548-TRP--VAL-565 DEL.
RX   PubMed=30455931; DOI=10.1002/ccr3.1818;
RA   Warren H.E., Louie R.J., Friez M.J., Frias J.L., Leroy J.G., Spranger J.W.,
RA   Skinner S.A., Champaigne N.L.;
RT   "Two unrelated patients with autosomal dominant omodysplasia and FRIZZLED2
RT   mutations.";
RL   Clin. Case Rep. 6:2252-2255(2018).
CC   -!- FUNCTION: Receptor for Wnt proteins. Most of frizzled receptors are
CC       coupled to the beta-catenin canonical signaling pathway, which leads to
CC       the activation of disheveled proteins, inhibition of GSK-3 kinase,
CC       nuclear accumulation of beta-catenin and activation of Wnt target genes
CC       (PubMed:25759469). A second signaling pathway involving PKC and calcium
CC       fluxes has been seen for some family members, but it is not yet clear
CC       if it represents a distinct pathway or if it can be integrated in the
CC       canonical pathway, as PKC seems to be required for Wnt-mediated
CC       inactivation of GSK-3 kinase. Both pathways seem to involve
CC       interactions with G-proteins. May be involved in transduction and
CC       intercellular transmission of polarity information during tissue
CC       morphogenesis and/or in differentiated tissues.
CC       {ECO:0000269|PubMed:25759469}.
CC   -!- FUNCTION: (Microbial infection) Acts as a receptor for C.difficile
CC       toxin TcdB in the colonic epithelium (PubMed:27680706,
CC       PubMed:29748286). TcdB occupies the binding site for Wnt-adducted
CC       palmitoleate in frizzled receptors and TcdB-binding prevents Wnt-
CC       binding and downstream Wnt signaling (PubMed:29748286).
CC       {ECO:0000269|PubMed:27680706, ECO:0000269|PubMed:29748286}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with C.difficile toxin TcdB;
CC       frizzled receptors constitute the major host receptors for TcdB in the
CC       colonic epithelium. {ECO:0000269|PubMed:27680706,
CC       ECO:0000269|PubMed:29748286, ECO:0000269|PubMed:31233493}.
CC   -!- INTERACTION:
CC       Q14332; P39688: Fyn; Xeno; NbExp=4; IntAct=EBI-6254477, EBI-524514;
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein. Cell
CC       membrane {ECO:0000250}; Multi-pass membrane protein {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Widely expressed. In the adult, mainly found in
CC       heart, placenta, skeletal muscle, lung, kidney, pancreas, prostate,
CC       testis, ovary and colon. In the fetus, expressed in brain, lung and
CC       kidney. Low levels in fetal liver.
CC   -!- DOMAIN: Lys-Thr-X-X-X-Trp motif interacts with the PDZ domain of Dvl
CC       (Disheveled) family members and is involved in the activation of the
CC       Wnt/beta-catenin signaling pathway. {ECO:0000250}.
CC   -!- DOMAIN: The FZ domain is involved in binding with Wnt ligands.
CC       {ECO:0000250}.
CC   -!- PTM: Ubiquitinated by ZNRF3, leading to its degradation by the
CC       proteasome. {ECO:0000250}.
CC   -!- DISEASE: Omodysplasia 2 (OMOD2) [MIM:164745]: A rare autosomal dominant
CC       skeletal dysplasia characterized by short humeri, radial head
CC       dislocation, short first metacarpals, facial dysmorphism and
CC       genitourinary anomalies. {ECO:0000269|PubMed:25759469,
CC       ECO:0000269|PubMed:29230162, ECO:0000269|PubMed:29383834,
CC       ECO:0000269|PubMed:30455931}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Note=Defects in FZD2 have been found in patients with Robinow
CC       syndrome-like features including short-limb dwarfism, broad thumbs and
CC       craniofacial abnormalities. {ECO:0000269|PubMed:29276006}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor Fz/Smo family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L37882; AAB46397.1; -; mRNA.
DR   EMBL; AB017364; BAA34667.1; -; mRNA.
DR   EMBL; BC113402; AAI13403.1; -; mRNA.
DR   EMBL; BC113404; AAI13405.1; -; mRNA.
DR   CCDS; CCDS11484.1; -.
DR   PIR; JE0338; JE0338.
DR   RefSeq; NP_001457.1; NM_001466.3.
DR   PDB; 6C0B; X-ray; 2.50 A; B=34-156.
DR   PDBsum; 6C0B; -.
DR   SMR; Q14332; -.
DR   BioGRID; 108811; 42.
DR   IntAct; Q14332; 15.
DR   MINT; Q14332; -.
DR   STRING; 9606.ENSP00000323901; -.
DR   ChEMBL; CHEMBL3559686; -.
DR   GuidetoPHARMACOLOGY; 230; -.
DR   GlyGen; Q14332; 4 sites, 2 O-linked glycans (2 sites).
DR   iPTMnet; Q14332; -.
DR   PhosphoSitePlus; Q14332; -.
DR   BioMuta; FZD2; -.
DR   DMDM; 17433019; -.
DR   EPD; Q14332; -.
DR   jPOST; Q14332; -.
DR   MassIVE; Q14332; -.
DR   MaxQB; Q14332; -.
DR   PaxDb; Q14332; -.
DR   PeptideAtlas; Q14332; -.
DR   PRIDE; Q14332; -.
DR   ProteomicsDB; 59968; -.
DR   ABCD; Q14332; 36 sequenced antibodies.
DR   Antibodypedia; 17503; 347 antibodies.
DR   Ensembl; ENST00000315323; ENSP00000323901; ENSG00000180340.
DR   GeneID; 2535; -.
DR   KEGG; hsa:2535; -.
DR   UCSC; uc002igx.3; human.
DR   CTD; 2535; -.
DR   DisGeNET; 2535; -.
DR   EuPathDB; HostDB:ENSG00000180340.6; -.
DR   GeneCards; FZD2; -.
DR   HGNC; HGNC:4040; FZD2.
DR   HPA; ENSG00000180340; Low tissue specificity.
DR   MalaCards; FZD2; -.
DR   MIM; 164745; phenotype.
DR   MIM; 600667; gene.
DR   neXtProt; NX_Q14332; -.
DR   OpenTargets; ENSG00000180340; -.
DR   Orphanet; 93328; Autosomal dominant omodysplasia.
DR   Orphanet; 3107; Autosomal dominant Robinow syndrome.
DR   PharmGKB; PA28457; -.
DR   eggNOG; KOG3577; Eukaryota.
DR   GeneTree; ENSGT00940000161812; -.
DR   HOGENOM; CLU_007873_2_1_1; -.
DR   InParanoid; Q14332; -.
DR   KO; K02235; -.
DR   OMA; LAIPCPM; -.
DR   OrthoDB; 330751at2759; -.
DR   PhylomeDB; Q14332; -.
DR   TreeFam; TF317907; -.
DR   PathwayCommons; Q14332; -.
DR   Reactome; R-HSA-201681; TCF dependent signaling in response to WNT.
DR   Reactome; R-HSA-373080; Class B/2 (Secretin family receptors).
DR   Reactome; R-HSA-4086398; Ca2+ pathway.
DR   Reactome; R-HSA-4608870; Asymmetric localization of PCP proteins.
DR   Reactome; R-HSA-4641262; Disassembly of the destruction complex and recruitment of AXIN to the membrane.
DR   Reactome; R-HSA-5140745; WNT5A-dependent internalization of FZD2, FZD5 and ROR2.
DR   SIGNOR; Q14332; -.
DR   BioGRID-ORCS; 2535; 1 hit in 867 CRISPR screens.
DR   ChiTaRS; FZD2; human.
DR   GeneWiki; FZD2; -.
DR   GenomeRNAi; 2535; -.
DR   Pharos; Q14332; Tbio.
DR   PRO; PR:Q14332; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; Q14332; protein.
DR   Bgee; ENSG00000180340; Expressed in embryo and 170 other tissues.
DR   Genevisible; Q14332; HS.
DR   GO; GO:0030669; C:clathrin-coated endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0005925; C:focal adhesion; HDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0030165; F:PDZ domain binding; IPI:UniProtKB.
DR   GO; GO:0042813; F:Wnt-activated receptor activity; IDA:WormBase.
DR   GO; GO:0017147; F:Wnt-protein binding; IBA:GO_Central.
DR   GO; GO:1904886; P:beta-catenin destruction complex disassembly; TAS:Reactome.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IDA:UniProtKB.
DR   GO; GO:0090103; P:cochlea morphogenesis; IEA:Ensembl.
DR   GO; GO:0030855; P:epithelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0060022; P:hard palate development; IEA:Ensembl.
DR   GO; GO:0060119; P:inner ear receptor cell development; IEA:Ensembl.
DR   GO; GO:0003149; P:membranous septum morphogenesis; IEA:Ensembl.
DR   GO; GO:0003150; P:muscular septum morphogenesis; IEA:Ensembl.
DR   GO; GO:0030182; P:neuron differentiation; ISS:UniProtKB.
DR   GO; GO:0003151; P:outflow tract morphogenesis; IEA:Ensembl.
DR   GO; GO:0090179; P:planar cell polarity pathway involved in neural tube closure; IEA:Ensembl.
DR   GO; GO:0051091; P:positive regulation of DNA-binding transcription factor activity; IDA:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:BHF-UCL.
DR   GO; GO:0007608; P:sensory perception of smell; IEA:Ensembl.
DR   GO; GO:0016055; P:Wnt signaling pathway; IMP:UniProtKB.
DR   GO; GO:0007223; P:Wnt signaling pathway, calcium modulating pathway; TAS:Reactome.
DR   GO; GO:0060071; P:Wnt signaling pathway, planar cell polarity pathway; TAS:Reactome.
DR   CDD; cd07464; CRD_FZ2; 1.
DR   Gene3D; 1.10.2000.10; -; 1.
DR   InterPro; IPR015526; Frizzled/SFRP.
DR   InterPro; IPR000539; Frizzled/Smoothened_TM.
DR   InterPro; IPR020067; Frizzled_dom.
DR   InterPro; IPR036790; Frizzled_dom_sf.
DR   InterPro; IPR041778; FZ2_CRD.
DR   InterPro; IPR026550; FZD2.
DR   InterPro; IPR017981; GPCR_2-like.
DR   PANTHER; PTHR11309; PTHR11309; 1.
DR   PANTHER; PTHR11309:SF34; PTHR11309:SF34; 1.
DR   Pfam; PF01534; Frizzled; 1.
DR   Pfam; PF01392; Fz; 1.
DR   PRINTS; PR00489; FRIZZLED.
DR   SMART; SM00063; FRI; 1.
DR   SMART; SM01330; Frizzled; 1.
DR   SUPFAM; SSF63501; SSF63501; 1.
DR   PROSITE; PS50038; FZ; 1.
DR   PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Developmental protein; Disease mutation;
KW   Disulfide bond; G-protein coupled receptor; Glycoprotein; Membrane;
KW   Receptor; Reference proteome; Signal; Transducer; Transmembrane;
KW   Transmembrane helix; Ubl conjugation; Wnt signaling pathway.
FT   SIGNAL          1..23
FT                   /evidence="ECO:0000255"
FT   CHAIN           24..565
FT                   /note="Frizzled-2"
FT                   /id="PRO_0000012978"
FT   TOPO_DOM        24..247
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        248..268
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        269..279
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        280..300
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        301..327
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        328..348
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        349..370
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        371..391
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        392..414
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        415..435
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        436..461
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        462..482
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        483..519
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        520..540
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        541..565
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          34..153
FT                   /note="FZ"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00090"
FT   MOTIF           543..548
FT                   /note="Lys-Thr-X-X-X-Trp motif, mediates interaction with
FT                   the PDZ domain of Dvl family members"
FT                   /evidence="ECO:0000250"
FT   MOTIF           563..565
FT                   /note="PDZ-binding"
FT   COMPBIAS        181..187
FT                   /note="Poly-Gly"
FT   CARBOHYD        53
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000244|PDB:6C0B,
FT                   ECO:0000269|PubMed:29748286"
FT   CARBOHYD        154
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        39..100
FT                   /evidence="ECO:0000244|PDB:6C0B, ECO:0000255|PROSITE-
FT                   ProRule:PRU00090, ECO:0000269|PubMed:29748286"
FT   DISULFID        47..93
FT                   /evidence="ECO:0000244|PDB:6C0B, ECO:0000255|PROSITE-
FT                   ProRule:PRU00090, ECO:0000269|PubMed:29748286"
FT   DISULFID        84..121
FT                   /evidence="ECO:0000244|PDB:6C0B, ECO:0000255|PROSITE-
FT                   ProRule:PRU00090, ECO:0000269|PubMed:29748286"
FT   DISULFID        110..150
FT                   /evidence="ECO:0000244|PDB:6C0B, ECO:0000255|PROSITE-
FT                   ProRule:PRU00090, ECO:0000269|PubMed:29748286"
FT   DISULFID        114..138
FT                   /evidence="ECO:0000244|PDB:6C0B, ECO:0000255|PROSITE-
FT                   ProRule:PRU00090, ECO:0000269|PubMed:29748286"
FT   VARIANT         142
FT                   /note="P -> L (found in a patient with features of Robinow
FT                   syndrome; unknown pathological significance;
FT                   dbSNP:rs759024435)"
FT                   /evidence="ECO:0000269|PubMed:29276006"
FT                   /id="VAR_083242"
FT   VARIANT         377..565
FT                   /note="Missing (probable disease-associated variant found
FT                   in a patient with features of Robinow syndrome)"
FT                   /evidence="ECO:0000269|PubMed:29276006"
FT                   /id="VAR_083243"
FT   VARIANT         434
FT                   /note="G -> S (probable disease-associated variant found in
FT                   a patient with features of Robinow syndrome;
FT                   dbSNP:rs1223920489)"
FT                   /evidence="ECO:0000269|PubMed:29276006"
FT                   /id="VAR_083244"
FT   VARIANT         434
FT                   /note="G -> V (in OMOD2; also found in a patient with
FT                   features of Robinow syndrome; dbSNP:rs1555657073)"
FT                   /evidence="ECO:0000269|PubMed:29230162,
FT                   ECO:0000269|PubMed:29276006, ECO:0000269|PubMed:30455931"
FT                   /id="VAR_081993"
FT   VARIANT         547..565
FT                   /note="Missing (in OMOD2)"
FT                   /evidence="ECO:0000269|PubMed:29383834"
FT                   /id="VAR_081994"
FT   VARIANT         548..565
FT                   /note="Missing (in OMOD2; decreased Wnt signaling)"
FT                   /evidence="ECO:0000269|PubMed:25759469,
FT                   ECO:0000269|PubMed:30455931"
FT                   /id="VAR_081995"
FT   MUTAGEN         77
FT                   /note="Y->A: Strongly reduced interaction with C.difficile
FT                   toxin TcdB."
FT                   /evidence="ECO:0000269|PubMed:29748286"
FT   MUTAGEN         127
FT                   /note="K->A,E: Strongly reduced interaction with
FT                   C.difficile toxin TcdB."
FT                   /evidence="ECO:0000269|PubMed:29748286"
FT   STRAND          38..41
FT                   /evidence="ECO:0000244|PDB:6C0B"
FT   HELIX           45..47
FT                   /evidence="ECO:0000244|PDB:6C0B"
FT   STRAND          48..51
FT                   /evidence="ECO:0000244|PDB:6C0B"
FT   STRAND          53..58
FT                   /evidence="ECO:0000244|PDB:6C0B"
FT   HELIX           66..74
FT                   /evidence="ECO:0000244|PDB:6C0B"
FT   HELIX           77..81
FT                   /evidence="ECO:0000244|PDB:6C0B"
FT   HELIX           88..96
FT                   /evidence="ECO:0000244|PDB:6C0B"
FT   HELIX           111..127
FT                   /evidence="ECO:0000244|PDB:6C0B"
FT   HELIX           134..136
FT                   /evidence="ECO:0000244|PDB:6C0B"
FT   HELIX           138..140
FT                   /evidence="ECO:0000244|PDB:6C0B"
FT   STRAND          146..148
FT                   /evidence="ECO:0000244|PDB:6C0B"
SQ   SEQUENCE   565 AA;  63554 MW;  AA387876A1DDE063 CRC64;
     MRPRSALPRL LLPLLLLPAA GPAQFHGEKG ISIPDHGFCQ PISIPLCTDI AYNQTIMPNL
     LGHTNQEDAG LEVHQFYPLV KVQCSPELRF FLCSMYAPVC TVLEQAIPPC RSICERARQG
     CEALMNKFGF QWPERLRCEH FPRHGAEQIC VGQNHSEDGA PALLTTAPPP GLQPGAGGTP
     GGPGGGGAPP RYATLEHPFH CPRVLKVPSY LSYKFLGERD CAAPCEPARP DGSMFFSQEE
     TRFARLWILT WSVLCCASTF FTVTTYLVDM QRFRYPERPI IFLSGCYTMV SVAYIAGFVL
     QERVVCNERF SEDGYRTVVQ GTKKEGCTIL FMMLYFFSMA SSIWWVILSL TWFLAAGMKW
     GHEAIEANSQ YFHLAAWAVP AVKTITILAM GQIDGDLLSG VCFVGLNSLD PLRGFVLAPL
     FVYLFIGTSF LLAGFVSLFR IRTIMKHDGT KTEKLERLMV RIGVFSVLYT VPATIVIACY
     FYEQAFREHW ERSWVSQHCK SLAIPCPAHY TPRMSPDFTV YMIKYLMTLI VGITSGFWIW
     SGKTLHSWRK FYTRLTNSRH GETTV
//
ID   FZD4_HUMAN              Reviewed;         537 AA.
AC   Q9ULV1; A8K9Q3; Q14C97; Q6S9E4;
DT   05-DEC-2001, integrated into UniProtKB/Swiss-Prot.
DT   29-MAR-2005, sequence version 2.
DT   07-OCT-2020, entry version 192.
DE   RecName: Full=Frizzled-4;
DE            Short=Fz-4;
DE            Short=hFz4;
DE   AltName: Full=FzE4;
DE   AltName: CD_antigen=CD344;
DE   Flags: Precursor;
GN   Name=FZD4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Fetal lung;
RX   PubMed=10544037; DOI=10.1006/bbrc.1999.1612;
RA   Kirikoshi H., Sagara N., Koike J., Tanaka K., Sekihara H., Hirai M.,
RA   Katoh M.;
RT   "Molecular cloning and characterization of human frizzled-4 on chromosome
RT   11q14-q21.";
RL   Biochem. Biophys. Res. Commun. 264:955-961(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Heart;
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (NOV-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 257-318.
RC   TISSUE=Esophageal carcinoma;
RX   PubMed=9707618; DOI=10.1073/pnas.95.17.10164;
RA   Tanaka S., Akiyoshi T., Mori M., Wands J.R., Sugimachi K.;
RT   "A novel frizzled gene identified in human esophageal carcinoma mediates
RT   APC/beta-catenin signals.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:10164-10169(1998).
RN   [7]
RP   UBIQUITINATION BY ZNRF3.
RX   PubMed=22575959; DOI=10.1038/nature11019;
RA   Hao H.X., Xie Y., Zhang Y., Charlat O., Oster E., Avello M., Lei H.,
RA   Mickanin C., Liu D., Ruffner H., Mao X., Ma Q., Zamponi R., Bouwmeester T.,
RA   Finan P.M., Kirschner M.W., Porter J.A., Serluca F.C., Cong F.;
RT   "ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner.";
RL   Nature 485:195-200(2012).
RN   [8]
RP   INTERACTION WITH GPC3.
RX   PubMed=24496449; DOI=10.1242/jcs.140871;
RA   Capurro M., Martin T., Shi W., Filmus J.;
RT   "Glypican-3 binds to Frizzled and plays a direct role in the stimulation of
RT   canonical Wnt signaling.";
RL   J. Cell Sci. 127:1565-1575(2014).
RN   [9] {ECO:0000244|PDB:6BD4}
RP   X-RAY CRYSTALLOGRAPHY (2.40 ANGSTROMS) OF 178-517, FUNCTION, SUBCELLULAR
RP   LOCATION, TRANSMEMBRANE DOMAINS, DISULFIDE BONDS, CHARACTERIZATION OF
RP   VARIANTS ARG-181 AND TYR-204, AND MUTAGENESIS OF SER-233; TYR-250; ARG-253;
RP   TYR-265; TYR-269; GLU-341; ASP-371; TYR-378; ASN-381; LEU-399; SER-418;
RP   TYR-444; TYR-455; GLU-458; GLU-477; LYS-480; TRP-494 AND TRP-496.
RX   PubMed=30135577; DOI=10.1038/s41586-018-0447-x;
RA   Yang S., Wu Y., Xu T.H., de Waal P.W., He Y., Pu M., Chen Y.,
RA   DeBruine Z.J., Zhang B., Zaidi S.A., Popov P., Guo Y., Han G.W., Lu Y.,
RA   Suino-Powell K., Dong S., Harikumar K.G., Miller L.J., Katritch V.,
RA   Xu H.E., Shui W., Stevens R.C., Melcher K., Zhao S., Xu F.;
RT   "Crystal structure of the Frizzled 4 receptor in a ligand-free state.";
RL   Nature 560:666-670(2018).
RN   [10]
RP   VARIANT EVR1 493-MET-TRP-494 DEL, AND CHARACTERIZATION OF VARIANT EVR1
RP   493-MET-TRP-494 DEL.
RX   PubMed=12172548; DOI=10.1038/ng957;
RA   Robitaille J., MacDonald M.L.E., Kaykas A., Sheldahl L.C., Zeisler J.,
RA   Dube M.-P., Zhang L.-H., Singaraja R.R., Guernsey D.L., Zheng B.,
RA   Siebert L.F., Hoskin-Mott A., Trese M.T., Pimstone S.N., Shastry B.S.,
RA   Moon R.T., Hayden M.R., Goldberg Y.P., Samuels M.E.;
RT   "Mutant frizzled-4 disrupts retinal angiogenesis in familial exudative
RT   vitreoretinopathy.";
RL   Nat. Genet. 32:326-330(2002).
RN   [11]
RP   VARIANTS EVR1 TYR-69; VAL-105; GLN-417 AND ASP-488.
RX   PubMed=14507768; DOI=10.1136/bjo.87.10.1291;
RA   Kondo H., Hayashi H., Oshima K., Tahira T., Hayashi K.;
RT   "Frizzled 4 gene (FZD4) mutations in patients with familial exudative
RT   vitreoretinopathy with variable expressivity.";
RL   Br. J. Ophthalmol. 87:1291-1295(2003).
RN   [12]
RP   VARIANT EVR1 VAL-342.
RX   PubMed=15488808; DOI=10.1016/j.ajo.2004.05.001;
RA   Yoshida S., Arita R., Yoshida A., Tada H., Emori A., Noda Y., Nakao S.,
RA   Fujisawa K., Ishibashi T.;
RT   "Novel mutation in FZD4 gene in a Japanese pedigree with familial exudative
RT   vitreoretinopathy.";
RL   Am. J. Ophthalmol. 138:670-671(2004).
RN   [13]
RP   VARIANTS EVR1 VAL-105 AND VAL-157, AND CHARACTERIZATION OF VARIANTS EVR1
RP   VAL-105; VAL-157 AND 493-MET-TRP-494 DEL.
RX   PubMed=15035989; DOI=10.1016/s0092-8674(04)00216-8;
RA   Xu Q., Wang Y., Dabdoub A., Smallwood P.M., Williams J., Woods C.,
RA   Kelley M.W., Jiang L., Tasman W., Zhang K., Nathans J.;
RT   "Vascular development in the retina and inner ear: control by Norrin and
RT   Frizzled-4, a high-affinity ligand-receptor pair.";
RL   Cell 116:883-895(2004).
RN   [14]
RP   VARIANTS EVR1 ASP-36; THR-105; VAL-157 AND PHE-497, AND VARIANT SER-168.
RX   PubMed=15223780; DOI=10.1167/iovs.03-1044;
RA   Toomes C., Bottomley H.M., Scott S., Mackey D.A., Craig J.E.,
RA   Appukuttan B., Stout J.T., Flaxel C.J., Zhang K., Black G.C.M., Fryer A.,
RA   Downey L.M., Inglehearn C.F.;
RT   "Spectrum and frequency of FZD4 mutations in familial exudative
RT   vitreoretinopathy.";
RL   Invest. Ophthalmol. Vis. Sci. 45:2083-2090(2004).
RN   [15]
RP   VARIANTS EVR1 TYR-69 AND ARG-181.
RX   PubMed=15370539; DOI=10.1080/13816810490514270;
RA   Omoto S., Hayashi T., Kitahara K., Takeuchi T., Ueoka Y.;
RT   "Autosomal dominant familial exudative vitreoretinopathy in two Japanese
RT   families with FZD4 mutations (H69Y and C181R).";
RL   Ophthalmic Genet. 25:81-90(2004).
RN   [16]
RP   VARIANTS EVR1 SER-33 AND VAL-256, AND VARIANT SER-168.
RX   PubMed=15733276; DOI=10.1111/j.1399-0004.2005.00408.x;
RA   MacDonald M.L., Goldberg Y.P., Macfarlane J., Samuels M.E., Trese M.T.,
RA   Shastry B.S.;
RT   "Genetic variants of frizzled-4 gene in familial exudative
RT   vitreoretinopathy and advanced retinopathy of prematurity.";
RL   Clin. Genet. 67:363-366(2005).
RN   [17]
RP   VARIANTS EVR1 TYR-69; VAL-105; CYS-335; VAL-342; GLN-417 AND ASP-488.
RX   PubMed=15981244; DOI=10.1002/humu.20191;
RA   Qin M., Hayashi H., Oshima K., Tahira T., Hayashi K., Kondo H.;
RT   "Complexity of the genotype-phenotype correlation in familial exudative
RT   vitreoretinopathy with mutations in the LRP5 and/or FZD4 genes.";
RL   Hum. Mutat. 26:104-112(2005).
RN   [18]
RP   VARIANTS EVR1 SER-33 AND ARG-204.
RX   PubMed=17093393;
RA   Nallathambi J., Shukla D., Rajendran A., Namperumalsamy P.,
RA   Muthulakshmi R., Sundaresan P.;
RT   "Identification of novel FZD4 mutations in Indian patients with familial
RT   exudative vitreoretinopathy.";
RL   Mol. Vis. 12:1086-1092(2006).
RN   [19]
RP   VARIANT [LARGE SCALE ANALYSIS] THR-436.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [20]
RP   CHARACTERIZATION OF VARIANTS EVR1 VAL-105 AND GLN-417, AND CHARACTERIZATION
RP   OF VARIANT TYR-69.
RX   PubMed=17955262; DOI=10.1007/s00439-007-0438-8;
RA   Qin M., Kondo H., Tahira T., Hayashi K.;
RT   "Moderate reduction of Norrin signaling activity associated with the
RT   causative missense mutations identified in patients with familial exudative
RT   vitreoretinopathy.";
RL   Hum. Genet. 122:615-623(2008).
RN   [21]
RP   VARIANTS EVR1 SER-33; LYS-223 AND PRO-445, AND VARIANT SER-168.
RX   PubMed=19324841; DOI=10.1167/iovs.08-3320;
RA   Boonstra F.N., van Nouhuys C.E., Schuil J., de Wijs I.J.,
RA   van der Donk K.P., Nikopoulos K., Mukhopadhyay A., Scheffer H.,
RA   Tilanus M.A.D., Cremers F.P.M., Hoefsloot L.H.;
RT   "Clinical and molecular evaluation of probands and family members with
RT   familial exudative vitreoretinopathy.";
RL   Invest. Ophthalmol. Vis. Sci. 50:4379-4385(2009).
RN   [22]
RP   VARIANTS EVR1 THR-114 AND 493-MET-TRP-494 DEL.
RX   PubMed=19172507; DOI=10.1080/13816810802464312;
RA   Robitaille J.M., Wallace K., Zheng B., Beis M.J., Samuels M.,
RA   Hoskin-Mott A., Guernsey D.L.;
RT   "Phenotypic overlap of familial exudative vitreoretinopathy (FEVR) with
RT   persistent fetal vasculature (PFV) caused by FZD4 mutations in two distinct
RT   pedigrees.";
RL   Ophthalmic Genet. 30:23-30(2009).
RN   [23]
RP   VARIANTS EVR1 GLN-40; TYR-204 AND ARG-525.
RX   PubMed=20340138; DOI=10.1002/humu.21250;
RA   Nikopoulos K., Venselaar H., Collin R.W.J., Riveiro-Alvarez R.,
RA   Boonstra F.N., Hooymans J.M., Mukhopadhyay A., Shears D., van Bers M.,
RA   de Wijs I.J., van Essen A.J., Sijmons R.H., Tilanus M.A.D.,
RA   van Nouhuys C.E., Ayuso C., Hoefsloot L.H., Cremers F.P.M.;
RT   "Overview of the mutation spectrum in familial exudative vitreoretinopathy
RT   and Norrie disease with identification of 21 novel variants in FZD4, LRP5,
RT   and NDP.";
RL   Hum. Mutat. 31:656-666(2010).
RN   [24]
RP   VARIANTS RETINOPATHY OF PREMATURITY ASN-203 AND GLY-370.
RX   PubMed=20141357; DOI=10.3109/13816810903479834;
RA   Ells A., Guernsey D.L., Wallace K., Zheng B., Vincer M., Allen A.,
RA   Ingram A., DaSilva O., Siebert L., Sheidow T., Beis J., Robitaille J.M.;
RT   "Severe retinopathy of prematurity associated with FZD4 mutations.";
RL   Ophthalmic Genet. 31:37-43(2010).
CC   -!- FUNCTION: Receptor for Wnt proteins (PubMed:30135577). Most frizzled
CC       receptors are coupled to the beta-catenin (CTNNB1) canonical signaling
CC       pathway, which leads to the activation of disheveled proteins,
CC       inhibition of GSK-3 kinase, nuclear accumulation of beta-catenin
CC       (CTNNB1) and activation of Wnt target genes (PubMed:30135577). Plays a
CC       critical role in retinal vascularization by acting as a receptor for
CC       Wnt proteins and norrin (NDP) (By similarity). In retina, it can be
CC       activated by Wnt protein-binding and also by Wnt-independent signaling
CC       via binding of norrin (NDP), promoting in both cases beta-catenin
CC       (CTNNB1) accumulation and stimulation of LEF/TCF-mediated
CC       transcriptional programs (By similarity). A second signaling pathway
CC       involving PKC and calcium fluxes has been seen for some family members,
CC       but it is not yet clear if it represents a distinct pathway or if it
CC       can be integrated in the canonical pathway, as PKC seems to be required
CC       for Wnt-mediated inactivation of GSK-3 kinase. Both pathways seem to
CC       involve interactions with G-proteins. May be involved in transduction
CC       and intercellular transmission of polarity information during tissue
CC       morphogenesis and/or in differentiated tissues.
CC       {ECO:0000250|UniProtKB:Q61088, ECO:0000269|PubMed:30135577}.
CC   -!- SUBUNIT: Interacts with MAGI3 and NDP. Component of a complex, at least
CC       composed of TSPAN12, FZD4 and norrin (NDP). Interacts (via FZ domain)
CC       with TSKU. Interacts with glypican GPC3 (PubMed:24496449).
CC       {ECO:0000250|UniProtKB:Q61088, ECO:0000269|PubMed:24496449}.
CC   -!- INTERACTION:
CC       Q9ULV1; Q00604: NDP; NbExp=4; IntAct=EBI-2466380, EBI-2466352;
CC       Q9ULV1; G3GTH2: I79_000956; Xeno; NbExp=2; IntAct=EBI-2466380, EBI-3504975;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:30135577};
CC       Multi-pass membrane protein {ECO:0000255}.
CC   -!- TISSUE SPECIFICITY: Almost ubiquitous (PubMed:10544037). Largely
CC       expressed in adult heart, skeletal muscle, ovary, and fetal kidney
CC       (PubMed:10544037). Moderate amounts in adult liver, kidney, pancreas,
CC       spleen, and fetal lung, and small amounts in placenta, adult lung,
CC       prostate, testis, colon, fetal brain and liver (PubMed:10544037).
CC       {ECO:0000269|PubMed:10544037}.
CC   -!- DOMAIN: Lys-Thr-X-X-X-Trp motif interacts with the PDZ domain of Dvl
CC       (Disheveled) family members and is involved in the activation of the
CC       Wnt/beta-catenin signaling pathway. {ECO:0000250}.
CC   -!- DOMAIN: The FZ domain is involved in binding with Wnt ligands.
CC       {ECO:0000250}.
CC   -!- PTM: Ubiquitinated by ZNRF3, leading to its degradation by the
CC       proteasome. {ECO:0000269|PubMed:22575959}.
CC   -!- DISEASE: Vitreoretinopathy, exudative 1 (EVR1) [MIM:133780]: A disorder
CC       of the retinal vasculature characterized by an abrupt cessation of
CC       growth of peripheral capillaries, leading to an avascular peripheral
CC       retina. This may lead to compensatory retinal neovascularization, which
CC       is thought to be induced by hypoxia from the initial avascular insult.
CC       New vessels are prone to leakage and rupture causing exudates and
CC       bleeding, followed by scarring, retinal detachment and blindness.
CC       Clinical features can be highly variable, even within the same family.
CC       Patients with mild forms of the disease are asymptomatic, and their
CC       only disease related abnormality is an arc of avascular retina in the
CC       extreme temporal periphery. In many ways the disease resembles
CC       retinopathy of prematurity but there is no evidence of prematurity or
CC       small birth weight in the patient history.
CC       {ECO:0000269|PubMed:12172548, ECO:0000269|PubMed:14507768,
CC       ECO:0000269|PubMed:15035989, ECO:0000269|PubMed:15223780,
CC       ECO:0000269|PubMed:15370539, ECO:0000269|PubMed:15488808,
CC       ECO:0000269|PubMed:15733276, ECO:0000269|PubMed:15981244,
CC       ECO:0000269|PubMed:17093393, ECO:0000269|PubMed:17955262,
CC       ECO:0000269|PubMed:19172507, ECO:0000269|PubMed:19324841,
CC       ECO:0000269|PubMed:20340138}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor Fz/Smo family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB032417; BAA86286.1; -; mRNA.
DR   EMBL; AY462097; AAR23924.1; -; mRNA.
DR   EMBL; AK292768; BAF85457.1; -; mRNA.
DR   EMBL; AP001528; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC114527; AAI14528.1; -; mRNA.
DR   EMBL; BC114622; AAI14623.1; -; mRNA.
DR   CCDS; CCDS8279.1; -.
DR   PIR; JC7127; JC7127.
DR   RefSeq; NP_036325.2; NM_012193.3.
DR   PDB; 5BPB; X-ray; 2.20 A; A/B/C/D=42-179.
DR   PDB; 5BPQ; X-ray; 2.40 A; A/B/C/D=42-179.
DR   PDB; 5BQC; X-ray; 3.00 A; B=42-179.
DR   PDB; 5BQE; X-ray; 2.30 A; C=42-179.
DR   PDB; 5CL1; X-ray; 3.80 A; C/D=38-160.
DR   PDB; 5CM4; X-ray; 2.40 A; A/B=40-164.
DR   PDB; 5UWG; X-ray; 2.56 A; A/B=40-164.
DR   PDB; 6BD4; X-ray; 2.40 A; A=178-517.
DR   PDB; 6NE1; X-ray; 3.01 A; A=42-161.
DR   PDBsum; 5BPB; -.
DR   PDBsum; 5BPQ; -.
DR   PDBsum; 5BQC; -.
DR   PDBsum; 5BQE; -.
DR   PDBsum; 5CL1; -.
DR   PDBsum; 5CM4; -.
DR   PDBsum; 5UWG; -.
DR   PDBsum; 6BD4; -.
DR   PDBsum; 6NE1; -.
DR   SMR; Q9ULV1; -.
DR   BioGRID; 113918; 12.
DR   CORUM; Q9ULV1; -.
DR   IntAct; Q9ULV1; 7.
DR   MINT; Q9ULV1; -.
DR   STRING; 9606.ENSP00000434034; -.
DR   GuidetoPHARMACOLOGY; 232; -.
DR   GlyConnect; 2003; 5 N-Linked glycans (1 site).
DR   GlyGen; Q9ULV1; 2 sites.
DR   iPTMnet; Q9ULV1; -.
DR   PhosphoSitePlus; Q9ULV1; -.
DR   BioMuta; FZD4; -.
DR   DMDM; 62298045; -.
DR   jPOST; Q9ULV1; -.
DR   MassIVE; Q9ULV1; -.
DR   MaxQB; Q9ULV1; -.
DR   PaxDb; Q9ULV1; -.
DR   PeptideAtlas; Q9ULV1; -.
DR   PRIDE; Q9ULV1; -.
DR   ProteomicsDB; 85129; -.
DR   ABCD; Q9ULV1; 21 sequenced antibodies.
DR   Antibodypedia; 17696; 507 antibodies.
DR   Ensembl; ENST00000531380; ENSP00000434034; ENSG00000174804.
DR   GeneID; 8322; -.
DR   KEGG; hsa:8322; -.
DR   UCSC; uc001pce.4; human.
DR   CTD; 8322; -.
DR   DisGeNET; 8322; -.
DR   EuPathDB; HostDB:ENSG00000174804.3; -.
DR   GeneCards; FZD4; -.
DR   GeneReviews; FZD4; -.
DR   HGNC; HGNC:4042; FZD4.
DR   HPA; ENSG00000174804; Tissue enhanced (adipose).
DR   MalaCards; FZD4; -.
DR   MIM; 133780; phenotype.
DR   MIM; 604579; gene.
DR   neXtProt; NX_Q9ULV1; -.
DR   OpenTargets; ENSG00000174804; -.
DR   Orphanet; 891; Familial exudative vitreoretinopathy.
DR   Orphanet; 91495; Persistent hyperplastic primary vitreous.
DR   Orphanet; 90050; Retinopathy of prematurity.
DR   PharmGKB; PA28459; -.
DR   eggNOG; KOG3577; Eukaryota.
DR   GeneTree; ENSGT00940000157141; -.
DR   HOGENOM; CLU_007873_2_1_1; -.
DR   InParanoid; Q9ULV1; -.
DR   KO; K02354; -.
DR   OMA; IRIAMCQ; -.
DR   OrthoDB; 509772at2759; -.
DR   PhylomeDB; Q9ULV1; -.
DR   TreeFam; TF317907; -.
DR   PathwayCommons; Q9ULV1; -.
DR   Reactome; R-HSA-373080; Class B/2 (Secretin family receptors).
DR   Reactome; R-HSA-4086398; Ca2+ pathway.
DR   Reactome; R-HSA-4608870; Asymmetric localization of PCP proteins.
DR   Reactome; R-HSA-4641263; Regulation of FZD by ubiquitination.
DR   Reactome; R-HSA-5099900; WNT5A-dependent internalization of FZD4.
DR   Reactome; R-HSA-5340588; RNF mutants show enhanced WNT signaling and proliferation.
DR   Reactome; R-HSA-8856825; Cargo recognition for clathrin-mediated endocytosis.
DR   Reactome; R-HSA-8856828; Clathrin-mediated endocytosis.
DR   SignaLink; Q9ULV1; -.
DR   SIGNOR; Q9ULV1; -.
DR   BioGRID-ORCS; 8322; 5 hits in 875 CRISPR screens.
DR   ChiTaRS; FZD4; human.
DR   GeneWiki; FZD4; -.
DR   GenomeRNAi; 8322; -.
DR   Pharos; Q9ULV1; Tbio.
DR   PRO; PR:Q9ULV1; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q9ULV1; protein.
DR   Bgee; ENSG00000174804; Expressed in right lung and 221 other tissues.
DR   Genevisible; Q9ULV1; HS.
DR   GO; GO:0009986; C:cell surface; IDA:BHF-UCL.
DR   GO; GO:0005911; C:cell-cell junction; IEA:Ensembl.
DR   GO; GO:0030669; C:clathrin-coated endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0030665; C:clathrin-coated vesicle membrane; TAS:Reactome.
DR   GO; GO:0030425; C:dendrite; ISS:ARUK-UCL.
DR   GO; GO:0005615; C:extracellular space; IBA:GO_Central.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; IC:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0001540; F:amyloid-beta binding; IPI:ARUK-UCL.
DR   GO; GO:0019955; F:cytokine binding; IPI:BHF-UCL.
DR   GO; GO:0004896; F:cytokine receptor activity; IDA:BHF-UCL.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0030165; F:PDZ domain binding; IDA:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0044877; F:protein-containing complex binding; IPI:ARUK-UCL.
DR   GO; GO:0038023; F:signaling receptor activity; ISS:ARUK-UCL.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0042813; F:Wnt-activated receptor activity; IDA:WormBase.
DR   GO; GO:0017147; F:Wnt-protein binding; IBA:GO_Central.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IDA:UniProtKB.
DR   GO; GO:1990830; P:cellular response to leukemia inhibitory factor; IEA:Ensembl.
DR   GO; GO:0071300; P:cellular response to retinoic acid; ISS:UniProtKB.
DR   GO; GO:0061301; P:cerebellum vasculature morphogenesis; IEA:Ensembl.
DR   GO; GO:0035426; P:extracellular matrix-cell signaling; IEA:Ensembl.
DR   GO; GO:0031987; P:locomotion involved in locomotory behavior; IEA:Ensembl.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IBA:GO_Central.
DR   GO; GO:0010812; P:negative regulation of cell-substrate adhesion; IMP:BHF-UCL.
DR   GO; GO:0030182; P:neuron differentiation; ISS:UniProtKB.
DR   GO; GO:0035567; P:non-canonical Wnt signaling pathway; TAS:ARUK-UCL.
DR   GO; GO:0110135; P:Norrin signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0051091; P:positive regulation of DNA-binding transcription factor activity; IDA:BHF-UCL.
DR   GO; GO:0043507; P:positive regulation of JUN kinase activity; IEA:Ensembl.
DR   GO; GO:0150012; P:positive regulation of neuron projection arborization; ISS:ARUK-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:BHF-UCL.
DR   GO; GO:0042701; P:progesterone secretion; IEA:Ensembl.
DR   GO; GO:0030947; P:regulation of vascular endothelial growth factor receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0061299; P:retina vasculature morphogenesis in camera-type eye; IMP:BHF-UCL.
DR   GO; GO:0061304; P:retinal blood vessel morphogenesis; IEA:Ensembl.
DR   GO; GO:0007605; P:sensory perception of sound; IEA:Ensembl.
DR   GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IEA:Ensembl.
DR   GO; GO:0001570; P:vasculogenesis; IEA:Ensembl.
DR   GO; GO:0016055; P:Wnt signaling pathway; ISS:ARUK-UCL.
DR   GO; GO:0007223; P:Wnt signaling pathway, calcium modulating pathway; IDA:BHF-UCL.
DR   GO; GO:0060071; P:Wnt signaling pathway, planar cell polarity pathway; TAS:Reactome.
DR   CDD; cd07448; CRD_FZ4; 1.
DR   Gene3D; 1.10.2000.10; -; 1.
DR   InterPro; IPR015526; Frizzled/SFRP.
DR   InterPro; IPR000539; Frizzled/Smoothened_TM.
DR   InterPro; IPR020067; Frizzled_dom.
DR   InterPro; IPR036790; Frizzled_dom_sf.
DR   InterPro; IPR041765; FZ4_CRD.
DR   InterPro; IPR026551; FZD4.
DR   InterPro; IPR017981; GPCR_2-like.
DR   PANTHER; PTHR11309; PTHR11309; 1.
DR   PANTHER; PTHR11309:SF23; PTHR11309:SF23; 1.
DR   Pfam; PF01534; Frizzled; 1.
DR   Pfam; PF01392; Fz; 1.
DR   PRINTS; PR00489; FRIZZLED.
DR   SMART; SM00063; FRI; 1.
DR   SMART; SM01330; Frizzled; 1.
DR   SUPFAM; SSF63501; SSF63501; 1.
DR   PROSITE; PS50038; FZ; 1.
DR   PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Developmental protein; Disease mutation;
KW   Disulfide bond; G-protein coupled receptor; Glycoprotein; Membrane;
KW   Polymorphism; Receptor; Reference proteome; Signal; Transducer;
KW   Transmembrane; Transmembrane helix; Ubl conjugation; Wnt signaling pathway.
FT   SIGNAL          1..36
FT                   /evidence="ECO:0000255"
FT   CHAIN           37..537
FT                   /note="Frizzled-4"
FT                   /id="PRO_0000012985"
FT   TOPO_DOM        37..212
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   TRANSMEM        213..243
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   TOPO_DOM        244..249
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   TRANSMEM        250..275
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   TOPO_DOM        276..299
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   TRANSMEM        300..333
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   TOPO_DOM        334..336
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   TRANSMEM        337..365
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   TOPO_DOM        366..383
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   TRANSMEM        384..418
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   TOPO_DOM        419..431
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   TRANSMEM        432..460
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   TOPO_DOM        461..473
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   TRANSMEM        474..495
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   TOPO_DOM        496..537
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   DOMAIN          40..161
FT                   /note="FZ"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00090"
FT   MOTIF           499..504
FT                   /note="Lys-Thr-X-X-X-Trp motif, mediates interaction with
FT                   the PDZ domain of Dvl family members"
FT                   /evidence="ECO:0000250"
FT   MOTIF           535..537
FT                   /note="PDZ-binding"
FT   CARBOHYD        59
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        144
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        45..106
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00090"
FT   DISULFID        53..99
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00090"
FT   DISULFID        90..128
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00090"
FT   DISULFID        117..158
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00090"
FT   DISULFID        121..145
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00090"
FT   DISULFID        181..200
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   DISULFID        204..282
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   DISULFID        302..377
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   VARIANT         33
FT                   /note="P -> S (in EVR1; unknown pathological significance;
FT                   dbSNP:rs61735304)"
FT                   /evidence="ECO:0000269|PubMed:15733276,
FT                   ECO:0000269|PubMed:17093393, ECO:0000269|PubMed:19324841"
FT                   /id="VAR_063920"
FT   VARIANT         36
FT                   /note="G -> D (in EVR1; dbSNP:rs80358281)"
FT                   /evidence="ECO:0000269|PubMed:15223780"
FT                   /id="VAR_063921"
FT   VARIANT         40
FT                   /note="E -> Q (in EVR1; dbSNP:rs139401671)"
FT                   /evidence="ECO:0000269|PubMed:20340138"
FT                   /id="VAR_063922"
FT   VARIANT         69
FT                   /note="H -> Y (in EVR1; minor reduction of its wild-type
FT                   activity; dbSNP:rs80358282)"
FT                   /evidence="ECO:0000269|PubMed:14507768,
FT                   ECO:0000269|PubMed:15370539, ECO:0000269|PubMed:15981244,
FT                   ECO:0000269|PubMed:17955262"
FT                   /id="VAR_063923"
FT   VARIANT         105
FT                   /note="M -> T (in EVR1; dbSNP:rs80358285)"
FT                   /evidence="ECO:0000269|PubMed:15223780"
FT                   /id="VAR_063924"
FT   VARIANT         105
FT                   /note="M -> V (in EVR1; loss of function;
FT                   dbSNP:rs80358284)"
FT                   /evidence="ECO:0000269|PubMed:14507768,
FT                   ECO:0000269|PubMed:15035989, ECO:0000269|PubMed:15981244,
FT                   ECO:0000269|PubMed:17955262"
FT                   /id="VAR_038947"
FT   VARIANT         114
FT                   /note="I -> T (in EVR1)"
FT                   /evidence="ECO:0000269|PubMed:19172507"
FT                   /id="VAR_063925"
FT   VARIANT         157
FT                   /note="M -> V (in EVR1; loss of function;
FT                   dbSNP:rs80358286)"
FT                   /evidence="ECO:0000269|PubMed:15035989,
FT                   ECO:0000269|PubMed:15223780"
FT                   /id="VAR_038948"
FT   VARIANT         168
FT                   /note="P -> S (in dbSNP:rs61735303)"
FT                   /evidence="ECO:0000269|PubMed:15223780,
FT                   ECO:0000269|PubMed:15733276, ECO:0000269|PubMed:19324841"
FT                   /id="VAR_063926"
FT   VARIANT         181
FT                   /note="C -> R (in EVR1; increased signaling activity;
FT                   dbSNP:rs80358287)"
FT                   /evidence="ECO:0000269|PubMed:15370539,
FT                   ECO:0000269|PubMed:30135577"
FT                   /id="VAR_063927"
FT   VARIANT         203
FT                   /note="K -> N (in retinopathy of prematurity;
FT                   dbSNP:rs1476724511)"
FT                   /evidence="ECO:0000269|PubMed:20141357"
FT                   /id="VAR_063928"
FT   VARIANT         204
FT                   /note="C -> R (in EVR1; reduced signaling activity in
FT                   presence of WNT3A but no change in presence of NDP/norrin;
FT                   dbSNP:rs80358288)"
FT                   /evidence="ECO:0000269|PubMed:17093393,
FT                   ECO:0000269|PubMed:30135577"
FT                   /id="VAR_063929"
FT   VARIANT         204
FT                   /note="C -> Y (in EVR1; dbSNP:rs1064794064)"
FT                   /evidence="ECO:0000269|PubMed:20340138"
FT                   /id="VAR_063930"
FT   VARIANT         223
FT                   /note="M -> K (in EVR1)"
FT                   /evidence="ECO:0000269|PubMed:19324841"
FT                   /id="VAR_063931"
FT   VARIANT         256
FT                   /note="I -> V (in EVR1; dbSNP:rs104894223)"
FT                   /evidence="ECO:0000269|PubMed:15733276"
FT                   /id="VAR_063932"
FT   VARIANT         335
FT                   /note="W -> C (in EVR1; dbSNP:rs80358292)"
FT                   /evidence="ECO:0000269|PubMed:15981244"
FT                   /id="VAR_063933"
FT   VARIANT         342
FT                   /note="M -> V (in EVR1; dbSNP:rs80358293)"
FT                   /evidence="ECO:0000269|PubMed:15488808,
FT                   ECO:0000269|PubMed:15981244"
FT                   /id="VAR_063934"
FT   VARIANT         370
FT                   /note="A -> G (in retinopathy of prematurity)"
FT                   /evidence="ECO:0000269|PubMed:20141357"
FT                   /id="VAR_063935"
FT   VARIANT         417
FT                   /note="R -> Q (in EVR1; 48% loss of its wild-type activity;
FT                   associated in a EVR4 patient with mutation CYS-444 in LPR5;
FT                   dbSNP:rs80358294)"
FT                   /evidence="ECO:0000269|PubMed:14507768,
FT                   ECO:0000269|PubMed:15981244, ECO:0000269|PubMed:17955262"
FT                   /id="VAR_063936"
FT   VARIANT         436
FT                   /note="K -> T (in a colorectal cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036413"
FT   VARIANT         445
FT                   /note="T -> P (in EVR1; dbSNP:rs80358297)"
FT                   /evidence="ECO:0000269|PubMed:19324841"
FT                   /id="VAR_063937"
FT   VARIANT         488
FT                   /note="G -> D (in EVR1; dbSNP:rs80358298)"
FT                   /evidence="ECO:0000269|PubMed:14507768,
FT                   ECO:0000269|PubMed:15981244"
FT                   /id="VAR_063938"
FT   VARIANT         493..494
FT                   /note="Missing (in EVR1; loss of function)"
FT                   /evidence="ECO:0000269|PubMed:12172548,
FT                   ECO:0000269|PubMed:15035989, ECO:0000269|PubMed:19172507"
FT                   /id="VAR_017777"
FT   VARIANT         497
FT                   /note="S -> F (in EVR1; dbSNP:rs80358300)"
FT                   /evidence="ECO:0000269|PubMed:15223780"
FT                   /id="VAR_063939"
FT   VARIANT         525
FT                   /note="G -> R (in EVR1)"
FT                   /evidence="ECO:0000269|PubMed:20340138"
FT                   /id="VAR_063940"
FT   MUTAGEN         233
FT                   /note="S->A: Increased signaling activity in presence of
FT                   NDP/norrin but not in presence of WNT3A."
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   MUTAGEN         233
FT                   /note="S->F: Slightly increased signaling activity in
FT                   presence of NDP/norrin and reduced signaling in presence of
FT                   WNT3A."
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   MUTAGEN         250
FT                   /note="Y->F: Reduced signaling activity in presence of
FT                   NDP/norrin."
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   MUTAGEN         250
FT                   /note="Y->F: Reduced signaling activity."
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   MUTAGEN         253
FT                   /note="R->C: Reduced signaling activity in presence of
FT                   NDP/norrin."
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   MUTAGEN         265
FT                   /note="Y->A: Slight increase in signaling activity."
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   MUTAGEN         269
FT                   /note="Y->A: Increased signaling activity."
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   MUTAGEN         341
FT                   /note="E->A: Reduced signaling activity in presence of
FT                   NDP/norrin."
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   MUTAGEN         371
FT                   /note="D->A: No effect on signaling activity."
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   MUTAGEN         378
FT                   /note="Y->A: Increased signaling activity."
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   MUTAGEN         381
FT                   /note="N->A: Slight increase in signaling activity."
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   MUTAGEN         399
FT                   /note="L->F: No effect on signaling activity."
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   MUTAGEN         418
FT                   /note="S->N: Increased signaling activity."
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   MUTAGEN         444
FT                   /note="Y->A,F: Reduced signaling activity."
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   MUTAGEN         455
FT                   /note="Y->A: Increased signaling activity in presence of
FT                   WNT3A but not in presence of NDP/norrin."
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   MUTAGEN         458
FT                   /note="E->A: No effect on signaling activity."
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   MUTAGEN         477
FT                   /note="E->A: Increased signaling activity in presence of
FT                   WNT3A but not in presence of NDP/norrin."
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   MUTAGEN         480
FT                   /note="K->A: Increased signaling activity."
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   MUTAGEN         494
FT                   /note="W->L: Reduced signaling activity."
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   MUTAGEN         496
FT                   /note="W->A: Reduced signaling activity."
FT                   /evidence="ECO:0000269|PubMed:30135577"
FT   CONFLICT        481
FT                   /note="I -> T (in Ref. 1; BAA86286)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        500
FT                   /note="T -> S (in Ref. 1; BAA86286)"
FT                   /evidence="ECO:0000305"
FT   STRAND          45..47
FT                   /evidence="ECO:0000244|PDB:5BQC"
FT   HELIX           51..53
FT                   /evidence="ECO:0000244|PDB:5BPB"
FT   STRAND          55..57
FT                   /evidence="ECO:0000244|PDB:5BPB"
FT   STRAND          59..61
FT                   /evidence="ECO:0000244|PDB:5BQC"
FT   HELIX           72..79
FT                   /evidence="ECO:0000244|PDB:5BPB"
FT   HELIX           80..82
FT                   /evidence="ECO:0000244|PDB:5BPB"
FT   HELIX           83..88
FT                   /evidence="ECO:0000244|PDB:5BPB"
FT   HELIX           94..102
FT                   /evidence="ECO:0000244|PDB:5BPB"
FT   STRAND          105..107
FT                   /evidence="ECO:0000244|PDB:5BPB"
FT   STRAND          110..114
FT                   /evidence="ECO:0000244|PDB:5BPB"
FT   HELIX           118..134
FT                   /evidence="ECO:0000244|PDB:5BPB"
FT   HELIX           141..143
FT                   /evidence="ECO:0000244|PDB:5BPB"
FT   HELIX           145..147
FT                   /evidence="ECO:0000244|PDB:5BPB"
FT   STRAND          153..155
FT                   /evidence="ECO:0000244|PDB:5BQC"
FT   TURN            186..190
FT                   /evidence="ECO:0000244|PDB:6BD4"
FT   STRAND          197..201
FT                   /evidence="ECO:0000244|PDB:6BD4"
FT   STRAND          205..211
FT                   /evidence="ECO:0000244|PDB:6BD4"
FT   HELIX           213..243
FT                   /evidence="ECO:0000244|PDB:6BD4"
FT   HELIX           245..247
FT                   /evidence="ECO:0000244|PDB:6BD4"
FT   HELIX           250..252
FT                   /evidence="ECO:0000244|PDB:6BD4"
FT   HELIX           253..275
FT                   /evidence="ECO:0000244|PDB:6BD4"
FT   HELIX           277..281
FT                   /evidence="ECO:0000244|PDB:6BD4"
FT   STRAND          282..289
FT                   /evidence="ECO:0000244|PDB:6BD4"
FT   HELIX           300..330
FT                   /evidence="ECO:0000244|PDB:6BD4"
FT   HELIX           337..341
FT                   /evidence="ECO:0000244|PDB:6BD4"
FT   HELIX           344..365
FT                   /evidence="ECO:0000244|PDB:6BD4"
FT   STRAND          368..370
FT                   /evidence="ECO:0000244|PDB:6BD4"
FT   TURN            372..374
FT                   /evidence="ECO:0000244|PDB:6BD4"
FT   STRAND          377..382
FT                   /evidence="ECO:0000244|PDB:6BD4"
FT   HELIX           384..390
FT                   /evidence="ECO:0000244|PDB:6BD4"
FT   HELIX           392..417
FT                   /evidence="ECO:0000244|PDB:6BD4"
FT   HELIX           432..443
FT                   /evidence="ECO:0000244|PDB:6BD4"
FT   HELIX           445..460
FT                   /evidence="ECO:0000244|PDB:6BD4"
FT   HELIX           462..467
FT                   /evidence="ECO:0000244|PDB:6BD4"
FT   HELIX           474..489
FT                   /evidence="ECO:0000244|PDB:6BD4"
FT   HELIX           492..495
FT                   /evidence="ECO:0000244|PDB:6BD4"
FT   HELIX           498..511
FT                   /evidence="ECO:0000244|PDB:6BD4"
SQ   SEQUENCE   537 AA;  59881 MW;  E0A83ECEC560A381 CRC64;
     MAWRGAGPSV PGAPGGVGLS LGLLLQLLLL LGPARGFGDE EERRCDPIRI SMCQNLGYNV
     TKMPNLVGHE LQTDAELQLT TFTPLIQYGC SSQLQFFLCS VYVPMCTEKI NIPIGPCGGM
     CLSVKRRCEP VLKEFGFAWP ESLNCSKFPP QNDHNHMCME GPGDEEVPLP HKTPIQPGEE
     CHSVGTNSDQ YIWVKRSLNC VLKCGYDAGL YSRSAKEFTD IWMAVWASLC FISTAFTVLT
     FLIDSSRFSY PERPIIFLSM CYNIYSIAYI VRLTVGRERI SCDFEEAAEP VLIQEGLKNT
     GCAIIFLLMY FFGMASSIWW VILTLTWFLA AGLKWGHEAI EMHSSYFHIA AWAIPAVKTI
     VILIMRLVDA DELTGLCYVG NQNLDALTGF VVAPLFTYLV IGTLFIAAGL VALFKIRSNL
     QKDGTKTDKL ERLMVKIGVF SVLYTVPATC VIACYFYEIS NWALFRYSAD DSNMAVEMLK
     IFMSLLVGIT SGMWIWSAKT LHTWQKCSNR LVNSGKVKRE KRGNGWVKPG KGSETVV
//
ID   HRH1_HUMAN              Reviewed;         487 AA.
AC   P35367; A8K047; Q6P9E5;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   12-AUG-2020, entry version 181.
DE   RecName: Full=Histamine H1 receptor;
DE            Short=H1R;
DE            Short=HH1R;
GN   Name=HRH1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8280179; DOI=10.1006/bbrc.1993.2662;
RA   de Backer M.D., Gommeren W., Moereels H., Nobels G., van Gompel P.,
RA   Leysen J.E., Luyten W.H.M.L.;
RT   "Genomic cloning, heterologous expression and pharmacological
RT   characterization of a human histamine H1 receptor.";
RL   Biochem. Biophys. Res. Commun. 197:1601-1608(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8003029; DOI=10.1006/bbrc.1994.1786;
RA   Fukui K., Fujimoto K., Mizuguchi H., Sakamoto K., Horio Y., Takai S.,
RA   Yamada K., Ito S.;
RT   "Molecular cloning of the human histamine H1 receptor gene.";
RL   Biochem. Biophys. Res. Commun. 201:894-901(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7925364; DOI=10.1111/j.1432-1033.1994.00489.x;
RA   Moguilevsky N., Varsalona F., Noyer M., Gillard M., Guillaume J.P.,
RA   Garcia L., Szpirer C., Szpirer J., Bollen A.;
RT   "Stable expression of human H1-histamine-receptor cDNA in Chinese hamster
RT   ovary cells. Pharmacological characterisation of the protein, tissue
RT   distribution of messenger RNA and chromosomal localisation of the gene.";
RL   Eur. J. Biochem. 224:489-495(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lens epithelium;
RA   Rae J.L., Shepard A.R.;
RL   Submitted (SEP-1997) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=15014171; DOI=10.1093/molbev/msh100;
RA   Kitano T., Liu Y.-H., Ueda S., Saitou N.;
RT   "Human-specific amino acid changes found in 103 protein-coding genes.";
RL   Mol. Biol. Evol. 21:936-944(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   PHOSPHORYLATION AT THR-140; THR-142; SER-396 AND SER-398.
RX   PubMed=15328002; DOI=10.1016/j.febslet.2004.07.072;
RA   Horio S., Kato T., Ogawa M., Fujimoto K., Fukui H.;
RT   "Two threonine residues and two serine residues in the second and third
RT   intracellular loops are both involved in histamine H1 receptor
RT   downregulation.";
RL   FEBS Lett. 573:226-230(2004).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-279, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-230, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 20-487 IN COMPLEX WITH ANTAGONIST,
RP   DISULFIDE BOND, SUBCELLULAR LOCATION, AND TOPOLOGY.
RX   PubMed=21697825; DOI=10.1038/nature10236;
RA   Shimamura T., Shiroishi M., Weyand S., Tsujimoto H., Winter G.,
RA   Katritch V., Abagyan R., Cherezov V., Liu W., Han G.W., Kobayashi T.,
RA   Stevens R.C., Iwata S.;
RT   "Structure of the human histamine H1 receptor complex with doxepin.";
RL   Nature 475:65-70(2011).
RN   [15]
RP   VARIANT [LARGE SCALE ANALYSIS] GLU-385.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: In peripheral tissues, the H1 subclass of histamine receptors
CC       mediates the contraction of smooth muscles, increase in capillary
CC       permeability due to contraction of terminal venules, and catecholamine
CC       release from adrenal medulla, as well as mediating neurotransmission in
CC       the central nervous system.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:21697825};
CC       Multi-pass membrane protein {ECO:0000269|PubMed:21697825}.
CC   -!- PTM: Phosphorylation at sites in the second and third cytoplasmic loops
CC       independently contribute to agonist-induced receptor downregulation.
CC       {ECO:0000269|PubMed:15328002}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Z34897; CAA84380.1; -; mRNA.
DR   EMBL; X76786; CAA54182.1; -; Genomic_DNA.
DR   EMBL; D14436; BAA03319.1; -; Genomic_DNA.
DR   EMBL; D28481; BAA05840.1; -; mRNA.
DR   EMBL; AF026261; AAB95156.1; -; mRNA.
DR   EMBL; AB041380; BAA94465.1; -; Genomic_DNA.
DR   EMBL; AY136743; AAN01269.1; -; mRNA.
DR   EMBL; AK289412; BAF82101.1; -; mRNA.
DR   EMBL; CH471055; EAW64092.1; -; Genomic_DNA.
DR   EMBL; BC060802; AAH60802.1; -; mRNA.
DR   CCDS; CCDS2604.1; -.
DR   PIR; JC2495; JC2495.
DR   RefSeq; NP_000852.1; NM_000861.3.
DR   RefSeq; NP_001091681.1; NM_001098211.1.
DR   RefSeq; NP_001091682.1; NM_001098212.1.
DR   RefSeq; NP_001091683.1; NM_001098213.1.
DR   RefSeq; XP_011531954.1; XM_011533652.1.
DR   RefSeq; XP_011531955.1; XM_011533653.2.
DR   RefSeq; XP_016861772.1; XM_017006283.1.
DR   RefSeq; XP_016861773.1; XM_017006284.1.
DR   PDB; 3RZE; X-ray; 3.10 A; A=20-221, A=405-487.
DR   PDBsum; 3RZE; -.
DR   SMR; P35367; -.
DR   BioGRID; 109505; 2.
DR   DIP; DIP-41996N; -.
DR   IntAct; P35367; 15.
DR   MINT; P35367; -.
DR   STRING; 9606.ENSP00000380247; -.
DR   BindingDB; P35367; -.
DR   ChEMBL; CHEMBL231; -.
DR   DrugBank; DB01615; Aceprometazine.
DR   DrugBank; DB09488; Acrivastine.
DR   DrugBank; DB06766; Alcaftadine.
DR   DrugBank; DB01246; Alimemazine.
DR   DrugBank; DB00321; Amitriptyline.
DR   DrugBank; DB00543; Amoxapine.
DR   DrugBank; DB08799; Antazoline.
DR   DrugBank; DB01238; Aripiprazole.
DR   DrugBank; DB14185; Aripiprazole lauroxil.
DR   DrugBank; DB06216; Asenapine.
DR   DrugBank; DB00637; Astemizole.
DR   DrugBank; DB00719; Azatadine.
DR   DrugBank; DB00972; Azelastine.
DR   DrugBank; DB00245; Benzatropine.
DR   DrugBank; DB00767; Benzquinamide.
DR   DrugBank; DB04890; Bepotastine.
DR   DrugBank; DB06698; Betahistine.
DR   DrugBank; DB11591; Bilastine.
DR   DrugBank; DB01237; Bromodiphenhydramine.
DR   DrugBank; DB00835; Brompheniramine.
DR   DrugBank; DB00354; Buclizine.
DR   DrugBank; DB09016; Butriptyline.
DR   DrugBank; DB00748; Carbinoxamine.
DR   DrugBank; DB06016; Cariprazine.
DR   DrugBank; DB00341; Cetirizine.
DR   DrugBank; DB08936; Chlorcyclizine.
DR   DrugBank; DB08800; Chloropyramine.
DR   DrugBank; DB01114; Chlorpheniramine.
DR   DrugBank; DB00477; Chlorpromazine.
DR   DrugBank; DB01239; Chlorprothixene.
DR   DrugBank; DB00568; Cinnarizine.
DR   DrugBank; DB00215; Citalopram.
DR   DrugBank; DB00283; Clemastine.
DR   DrugBank; DB04837; Clofedanol.
DR   DrugBank; DB00363; Clozapine.
DR   DrugBank; DB01176; Cyclizine.
DR   DrugBank; DB00434; Cyproheptadine.
DR   DrugBank; DB01151; Desipramine.
DR   DrugBank; DB00967; Desloratadine.
DR   DrugBank; DB00405; Dexbrompheniramine.
DR   DrugBank; DB09555; Dexchlorpheniramine maleate.
DR   DrugBank; DB00985; Dimenhydrinate.
DR   DrugBank; DB08801; Dimetindene.
DR   DrugBank; DB01075; Diphenhydramine.
DR   DrugBank; DB01146; Diphenylpyraline.
DR   DrugBank; DB09167; Dosulepin.
DR   DrugBank; DB01142; Doxepin.
DR   DrugBank; DB00366; Doxylamine.
DR   DrugBank; DB01084; Emedastine.
DR   DrugBank; DB05492; Epicept NP-1.
DR   DrugBank; DB00751; Epinastine.
DR   DrugBank; DB01175; Escitalopram.
DR   DrugBank; DB06678; Esmirtazapine.
DR   DrugBank; DB00950; Fexofenadine.
DR   DrugBank; DB04841; Flunarizine.
DR   DrugBank; DB00502; Haloperidol.
DR   DrugBank; DB05381; Histamine.
DR   DrugBank; DB05079; HY10275.
DR   DrugBank; DB00557; Hydroxyzine.
DR   DrugBank; DB04946; Iloperidone.
DR   DrugBank; DB00458; Imipramine.
DR   DrugBank; DB08802; Isothipendyl.
DR   DrugBank; DB00920; Ketotifen.
DR   DrugBank; DB00555; Lamotrigine.
DR   DrugBank; DB01106; Levocabastine.
DR   DrugBank; DB06282; Levocetirizine.
DR   DrugBank; DB00455; Loratadine.
DR   DrugBank; DB09195; Lorpiprazole.
DR   DrugBank; DB00408; Loxapine.
DR   DrugBank; DB00934; Maprotiline.
DR   DrugBank; DB00737; Meclizine.
DR   DrugBank; DB06691; Mepyramine.
DR   DrugBank; DB01071; Mequitazine.
DR   DrugBank; DB00902; Methdilazine.
DR   DrugBank; DB01403; Methotrimeprazine.
DR   DrugBank; DB06148; Mianserin.
DR   DrugBank; DB00370; Mirtazapine.
DR   DrugBank; DB00540; Nortriptyline.
DR   DrugBank; DB05080; OBE101.
DR   DrugBank; DB06229; Ocaperidone.
DR   DrugBank; DB00334; Olanzapine.
DR   DrugBank; DB00768; Olopatadine.
DR   DrugBank; DB01173; Orphenadrine.
DR   DrugBank; DB01267; Paliperidone.
DR   DrugBank; DB00715; Paroxetine.
DR   DrugBank; DB08922; Perospirone.
DR   DrugBank; DB01619; Phenindamine.
DR   DrugBank; DB01620; Pheniramine.
DR   DrugBank; DB06153; Pizotifen.
DR   DrugBank; DB00433; Prochlorperazine.
DR   DrugBank; DB00420; Promazine.
DR   DrugBank; DB01069; Promethazine.
DR   DrugBank; DB00777; Propiomazine.
DR   DrugBank; DB01224; Quetiapine.
DR   DrugBank; DB00734; Risperidone.
DR   DrugBank; DB11614; Rupatadine.
DR   DrugBank; DB05345; SO-101.
DR   DrugBank; DB00342; Terfenadine.
DR   DrugBank; DB04905; Tesmilifene.
DR   DrugBank; DB11235; Thonzylamine.
DR   DrugBank; DB00797; Tolazoline.
DR   DrugBank; DB00656; Trazodone.
DR   DrugBank; DB00726; Trimipramine.
DR   DrugBank; DB00792; Tripelennamine.
DR   DrugBank; DB00427; Triprolidine.
DR   DrugBank; DB00246; Ziprasidone.
DR   DrugBank; DB01624; Zuclopenthixol.
DR   DrugCentral; P35367; -.
DR   GuidetoPHARMACOLOGY; 262; -.
DR   GlyGen; P35367; 2 sites.
DR   iPTMnet; P35367; -.
DR   PhosphoSitePlus; P35367; -.
DR   BioMuta; HRH1; -.
DR   DMDM; 547645; -.
DR   EPD; P35367; -.
DR   jPOST; P35367; -.
DR   MassIVE; P35367; -.
DR   MaxQB; P35367; -.
DR   PaxDb; P35367; -.
DR   PeptideAtlas; P35367; -.
DR   PRIDE; P35367; -.
DR   ProteomicsDB; 55036; -.
DR   Antibodypedia; 10679; 522 antibodies.
DR   DNASU; 3269; -.
DR   Ensembl; ENST00000397056; ENSP00000380247; ENSG00000196639.
DR   Ensembl; ENST00000431010; ENSP00000397028; ENSG00000196639.
DR   Ensembl; ENST00000438284; ENSP00000406705; ENSG00000196639.
DR   GeneID; 3269; -.
DR   KEGG; hsa:3269; -.
DR   UCSC; uc003bwb.5; human.
DR   CTD; 3269; -.
DR   DisGeNET; 3269; -.
DR   EuPathDB; HostDB:ENSG00000196639.6; -.
DR   GeneCards; HRH1; -.
DR   HGNC; HGNC:5182; HRH1.
DR   HPA; ENSG00000196639; Low tissue specificity.
DR   MIM; 600167; gene.
DR   neXtProt; NX_P35367; -.
DR   OpenTargets; ENSG00000196639; -.
DR   PharmGKB; PA29456; -.
DR   eggNOG; KOG4220; Eukaryota.
DR   GeneTree; ENSGT00940000160690; -.
DR   HOGENOM; CLU_009579_11_2_1; -.
DR   InParanoid; P35367; -.
DR   KO; K04149; -.
DR   OMA; YRSVRQP; -.
DR   OrthoDB; 1245472at2759; -.
DR   PhylomeDB; P35367; -.
DR   TreeFam; TF333432; -.
DR   PathwayCommons; P35367; -.
DR   Reactome; R-HSA-390650; Histamine receptors.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   SIGNOR; P35367; -.
DR   BioGRID-ORCS; 3269; 3 hits in 875 CRISPR screens.
DR   ChiTaRS; HRH1; human.
DR   GeneWiki; Histamine_H1_receptor; -.
DR   GenomeRNAi; 3269; -.
DR   Pharos; P35367; Tclin.
DR   PRO; PR:P35367; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; P35367; protein.
DR   Bgee; ENSG00000196639; Expressed in layer of synovial tissue and 180 other tissues.
DR   ExpressionAtlas; P35367; baseline and differential.
DR   Genevisible; P35367; HS.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0030425; C:dendrite; IBA:GO_Central.
DR   GO; GO:0005887; C:integral component of plasma membrane; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0045202; C:synapse; IEA:GOC.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0004993; F:G protein-coupled serotonin receptor activity; IBA:GO_Central.
DR   GO; GO:0004969; F:histamine receptor activity; ISS:UniProtKB.
DR   GO; GO:0030594; F:neurotransmitter receptor activity; IBA:GO_Central.
DR   GO; GO:0071420; P:cellular response to histamine; ISS:UniProtKB.
DR   GO; GO:0007268; P:chemical synaptic transmission; IBA:GO_Central.
DR   GO; GO:0048245; P:eosinophil chemotaxis; IEA:InterPro.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0007187; P:G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; IBA:GO_Central.
DR   GO; GO:0006954; P:inflammatory response; TAS:ProtInc.
DR   GO; GO:0048016; P:inositol phosphate-mediated signaling; ISS:BHF-UCL.
DR   GO; GO:0007613; P:memory; IEA:Ensembl.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0032962; P:positive regulation of inositol trisphosphate biosynthetic process; ISS:BHF-UCL.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; IEA:InterPro.
DR   GO; GO:0048167; P:regulation of synaptic plasticity; IEA:Ensembl.
DR   GO; GO:0043114; P:regulation of vascular permeability; IEA:InterPro.
DR   GO; GO:0008542; P:visual learning; IEA:Ensembl.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR000921; Histamine_H1_rcpt.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00530; HISTAMINEH1R.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Membrane; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..487
FT                   /note="Histamine H1 receptor"
FT                   /id="PRO_0000069676"
FT   TOPO_DOM        1..29
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:21697825"
FT   TRANSMEM        30..52
FT                   /note="Helical; Name=1"
FT   TOPO_DOM        53..62
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:21697825"
FT   TRANSMEM        63..83
FT                   /note="Helical; Name=2"
FT   TOPO_DOM        84..101
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:21697825"
FT   TRANSMEM        102..123
FT                   /note="Helical; Name=3"
FT   TOPO_DOM        124..143
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:21697825"
FT   TRANSMEM        144..164
FT                   /note="Helical; Name=4"
FT   TOPO_DOM        165..189
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:21697825"
FT   TRANSMEM        190..210
FT                   /note="Helical; Name=5"
FT   TOPO_DOM        211..416
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:21697825"
FT   TRANSMEM        417..438
FT                   /note="Helical; Name=6"
FT   TOPO_DOM        439..450
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:21697825"
FT   TRANSMEM        451..470
FT                   /note="Helical; Name=7"
FT   TOPO_DOM        471..487
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:21697825"
FT   REGION          107..112
FT                   /note="Important for agonist binding"
FT   REGION          424..428
FT                   /note="Important for agonist binding"
FT   MOD_RES         140
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:15328002"
FT   MOD_RES         142
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:15328002"
FT   MOD_RES         230
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163"
FT   MOD_RES         279
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         344
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P70174"
FT   MOD_RES         347
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P70174"
FT   MOD_RES         380
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P70174"
FT   MOD_RES         396
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:15328002"
FT   MOD_RES         398
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:15328002"
FT   CARBOHYD        5
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        18
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        100..180
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521,
FT                   ECO:0000269|PubMed:21697825"
FT   DISULFID        441..444
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521,
FT                   ECO:0000269|PubMed:21697825"
FT   VARIANT         19
FT                   /note="K -> N (in dbSNP:rs2067466)"
FT                   /id="VAR_049410"
FT   VARIANT         270
FT                   /note="G -> E (in dbSNP:rs7651620)"
FT                   /id="VAR_033476"
FT   VARIANT         385
FT                   /note="D -> E (in a colorectal cancer sample; somatic
FT                   mutation; dbSNP:rs1370695377)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035761"
FT   CONFLICT        308
FT                   /note="V -> E (in Ref. 9; AAH60802)"
FT                   /evidence="ECO:0000305"
FT   HELIX           29..31
FT                   /evidence="ECO:0000244|PDB:3RZE"
FT   HELIX           33..54
FT                   /evidence="ECO:0000244|PDB:3RZE"
FT   HELIX           61..63
FT                   /evidence="ECO:0000244|PDB:3RZE"
FT   HELIX           64..78
FT                   /evidence="ECO:0000244|PDB:3RZE"
FT   HELIX           80..89
FT                   /evidence="ECO:0000244|PDB:3RZE"
FT   STRAND          90..92
FT                   /evidence="ECO:0000244|PDB:3RZE"
FT   HELIX           96..130
FT                   /evidence="ECO:0000244|PDB:3RZE"
FT   TURN            135..138
FT                   /evidence="ECO:0000244|PDB:3RZE"
FT   HELIX           141..155
FT                   /evidence="ECO:0000244|PDB:3RZE"
FT   HELIX           156..158
FT                   /evidence="ECO:0000244|PDB:3RZE"
FT   HELIX           159..163
FT                   /evidence="ECO:0000244|PDB:3RZE"
FT   STRAND          177..180
FT                   /evidence="ECO:0000244|PDB:3RZE"
FT   HELIX           188..198
FT                   /evidence="ECO:0000244|PDB:3RZE"
FT   HELIX           200..216
FT                   /evidence="ECO:0000244|PDB:3RZE"
FT   HELIX           408..441
FT                   /evidence="ECO:0000244|PDB:3RZE"
FT   TURN            447..449
FT                   /evidence="ECO:0000244|PDB:3RZE"
FT   HELIX           450..471
FT                   /evidence="ECO:0000244|PDB:3RZE"
FT   HELIX           473..483
FT                   /evidence="ECO:0000244|PDB:3RZE"
SQ   SEQUENCE   487 AA;  55784 MW;  E5DB418A4C17A985 CRC64;
     MSLPNSSCLL EDKMCEGNKT TMASPQLMPL VVVLSTICLV TVGLNLLVLY AVRSERKLHT
     VGNLYIVSLS VADLIVGAVV MPMNILYLLM SKWSLGRPLC LFWLSMDYVA STASIFSVFI
     LCIDRYRSVQ QPLRYLKYRT KTRASATILG AWFLSFLWVI PILGWNHFMQ QTSVRREDKC
     ETDFYDVTWF KVMTAIINFY LPTLLMLWFY AKIYKAVRQH CQHRELINRS LPSFSEIKLR
     PENPKGDAKK PGKESPWEVL KRKPKDAGGG SVLKSPSQTP KEMKSPVVFS QEDDREVDKL
     YCFPLDIVHM QAAAEGSSRD YVAVNRSHGQ LKTDEQGLNT HGASEISEDQ MLGDSQSFSR
     TDSDTTTETA PGKGKLRSGS NTGLDYIKFT WKRLRSHSRQ YVSGLHMNRE RKAAKQLGFI
     MAAFILCWIP YFIFFMVIAF CKNCCNEHLH MFTIWLGYIN STLNPLIYPL CNENFKKTFK
     RILHIRS
//
ID   GABR1_HUMAN             Reviewed;         961 AA.
AC   Q9UBS5; B0UXY7; O95375; O95468; O95975; O96022; Q5STL4; Q5SUJ8; Q5SUL3;
AC   Q71SG6; Q86W60; Q9UQQ0;
DT   11-JAN-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   07-OCT-2020, entry version 199.
DE   RecName: Full=Gamma-aminobutyric acid type B receptor subunit 1;
DE            Short=GABA-B receptor 1;
DE            Short=GABA-B-R1;
DE            Short=GABA-BR1;
DE            Short=GABABR1;
DE            Short=Gb1;
DE   Flags: Precursor;
GN   Name=GABBR1; Synonyms=GPRC3A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1A AND 1B), FUNCTION, SUBCELLULAR
RP   LOCATION, TISSUE SPECIFICITY, AND DOMAIN.
RC   TISSUE=Cerebellum {ECO:0000303|PubMed:9844003};
RX   PubMed=9844003; DOI=10.1073/pnas.95.25.14991;
RA   Kaupmann K., Schuler V., Mosbacher J., Bischoff S., Bittiger H., Heid J.,
RA   Froestl W., Leonhard S., Pfaff T., Karschin A., Bettler B.;
RT   "Human gamma-aminobutyric acid type B receptors are differentially
RT   expressed and regulate inwardly rectifying K+ channels.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:14991-14996(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1A; 1B AND 1C), FUNCTION, SUBUNIT,
RP   INTERACTION WITH GABBR2, AND SUBCELLULAR LOCATION.
RC   TISSUE=Cerebellum {ECO:0000303|PubMed:9872316};
RX   PubMed=9872316; DOI=10.1038/25354;
RA   White J.H., Wise A., Main M.J., Green A., Fraser N.J., Disney G.H.,
RA   Barnes A.A., Emson P., Foord S.M., Marshall F.H.;
RT   "Heterodimerization is required for the formation of a functional GABA(B)
RT   receptor.";
RL   Nature 396:679-682(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1A).
RC   TISSUE=Brain {ECO:0000303|Ref.3};
RA   Stropp U., Raming K.;
RT   "Human mRNA for GABA-B1a receptor.";
RL   Submitted (OCT-1998) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1A), AND TISSUE SPECIFICITY.
RC   TISSUE=Fetal brain {ECO:0000303|PubMed:9753614};
RX   PubMed=9753614; DOI=10.1006/bbrc.1998.9296;
RA   Grifa A., Totaro A., Rommens J.M., Carella M., Roetto A., Borgato L.,
RA   Zelante L., Gasparini P.;
RT   "GABA (gamma-amino-butyric acid) neurotransmission: identification and fine
RT   mapping of the human GABAB receptor gene.";
RL   Biochem. Biophys. Res. Commun. 250:240-245(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE (ISOFORM 1A).
RX   PubMed=9798068; DOI=10.1016/s0006-3223(98)00244-3;
RA   Goei V.L., Choi J., Ahn J., Bowlus C.L., Raha-Chowdhury R., Gruen J.R.;
RT   "Human gamma-aminobutyric acid B receptor gene: complementary DNA cloning,
RT   expression, chromosomal location, and genomic organization.";
RL   Biol. Psychiatry 44:659-666(1998).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1C).
RC   TISSUE=Cerebellum {ECO:0000303|Ref.6};
RA   Fraser N.J.;
RL   Submitted (OCT-1998) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 1A AND 1B), AND VARIANTS VAL-20
RP   AND SER-489.
RC   TISSUE=Fetal brain {ECO:0000303|PubMed:9933300};
RX   PubMed=9933300; DOI=10.1007/s100480050051;
RA   Peters H.C., Kaemmer G., Volz A., Kaupmann K., Ziegler A., Bettler B.,
RA   Epplen J.T., Sander T., Riess O.;
RT   "Mapping, genomic structure, and polymorphisms of the human GABABR1
RT   receptor gene: evaluation of its involvement in idiopathic generalized
RT   epilepsy.";
RL   Neurogenetics 2:47-54(1998).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1A).
RC   TISSUE=Cerebellum {ECO:0000303|PubMed:9889352};
RX   PubMed=9889352; DOI=10.1016/s0169-328x(98)00316-7;
RA   Makoff A.;
RT   "Molecular cloning of human GABABR1 and its tissue distribution.";
RL   Brain Res. Mol. Brain Res. 64:137-140(1999).
RN   [9]
RP   NUCLEOTIDE SEQUENCE (ISOFORM 1E), FUNCTION, SUBUNIT, INTERACTION WITH
RP   GABBR2, TISSUE SPECIFICITY, AND VARIANT SER-489.
RC   TISSUE=Prostate {ECO:0000303|PubMed:10906333};
RX   PubMed=10906333; DOI=10.1074/jbc.m005333200;
RA   Schwarz D.A., Barry G., Eliasof S.D., Petroski R.E., Conlon P.J.,
RA   Maki R.A.;
RT   "Characterization of gamma-aminobutyric acid receptor GABAB(1e), a GABAB(1)
RT   splice variant encoding a truncated receptor.";
RL   J. Biol. Chem. 275:32174-32181(2000).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT VAL-20.
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1B).
RC   TISSUE=Brain {ECO:0000303|PubMed:15489334};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   SPLICE ISOFORM(S) THAT ARE POTENTIAL NMD TARGET(S).
RX   PubMed=14759258; DOI=10.1186/gb-2004-5-2-r8;
RA   Hillman R.T., Green R.E., Brenner S.E.;
RT   "An unappreciated role for RNA surveillance.";
RL   Genome Biol. 5:R8.1-R8.16(2004).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH GABBR2.
RX   PubMed=10773016;
RA   Sullivan R., Chateauneuf A., Coulombe N., Kolakowski L.F. Jr.,
RA   Johnson M.P., Hebert T.E., Ethier N., Belley M., Metters K., Abramovitz M.,
RA   O'Neill G.P., Ng G.Y.K.;
RT   "Coexpression of full-length gamma-aminobutyric acid(B) (GABA(B)) receptors
RT   with truncated receptors and metabotropic glutamate receptor 4 supports the
RT   GABA(B) heterodimer as the functional receptor.";
RL   J. Pharmacol. Exp. Ther. 293:460-467(2000).
RN   [15]
RP   FUNCTION.
RX   PubMed=10075644; DOI=10.1074/jbc.274.12.7607;
RA   Ng G.Y.K., Clark J., Coulombe N., Ethier N., Hebert T.E., Sullivan R.,
RA   Kargman S., Chateauneuf A., Tsukamoto N., McDonald T., Whiting P.,
RA   Mezey E., Johnson M.P., Liu Q., Kolakowski L.F. Jr., Evans J.F.,
RA   Bonner T.I., O'Neill G.P.;
RT   "Identification of a GABAB receptor subunit, gb2, required for functional
RT   GABAB receptor activity.";
RL   J. Biol. Chem. 274:7607-7610(1999).
RN   [16]
RP   FUNCTION, INTERACTION WITH GABBR2, TISSUE SPECIFICITY, AND DOMAIN.
RX   PubMed=9872744; DOI=10.1126/science.283.5398.74;
RA   Kuner R., Koehr G., Gruenewald S., Eisenhardt G., Bach A., Kornau H.-C.;
RT   "Role of heteromer formation in GABAB receptor function.";
RL   Science 283:74-77(1999).
RN   [17]
RP   INTERACTION WITH JAKMIP1.
RX   PubMed=14718537; DOI=10.1074/jbc.m311737200;
RA   Couve A., Restituito S., Brandon J.M., Charles K.J., Bawagan H.,
RA   Freeman K.B., Pangalos M.N., Calver A.R., Moss S.J.;
RT   "Marlin-1, a novel RNA-binding protein associates with GABA receptors.";
RL   J. Biol. Chem. 279:13934-13943(2004).
RN   [18]
RP   FUNCTION, INTERACTION WITH GABBR2, SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=15617512; DOI=10.1042/bj20041435;
RA   Villemure J.F., Adam L., Bevan N.J., Gearing K., Chenier S., Bouvier M.;
RT   "Subcellular distribution of GABA(B) receptor homo- and hetero-dimers.";
RL   Biochem. J. 388:47-55(2005).
RN   [19]
RP   FUNCTION, AND INTERACTION WITH GABBR2.
RX   PubMed=18165688; DOI=10.1074/jbc.m705202200;
RA   Nomura R., Suzuki Y., Kakizuka A., Jingami H.;
RT   "Direct detection of the interaction between recombinant soluble
RT   extracellular regions in the heterodimeric metabotropic gamma-aminobutyric
RT   acid receptor.";
RL   J. Biol. Chem. 283:4665-4673(2008).
RN   [20]
RP   FUNCTION, PARTIAL PROTEIN SEQUENCE, AGONIST BINDING, MUTAGENESIS OF TYR-230
RP   AND TYR-234, AND INTERACTION WITH GABBR2.
RX   PubMed=22660477; DOI=10.1038/nn.3133;
RA   Geng Y., Xiong D., Mosyak L., Malito D.L., Kniazeff J., Chen Y.,
RA   Burmakina S., Quick M., Bush M., Javitch J.A., Pin J.P., Fan Q.R.;
RT   "Structure and functional interaction of the extracellular domain of human
RT   GABA(B) receptor GBR2.";
RL   Nat. Neurosci. 15:970-978(2012).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 165-576 IN COMPLEXES WITH GABBR2;
RP   AGONISTS AND ANTAGONISTS, FUNCTION, SUBUNIT, DISULFIDE BOND, GLYCOSYLATION
RP   AT ASN-440 AND ASN-482, AND MUTAGENESIS OF TRP-182; HIS-287; TYR-367 AND
RP   TRP-395.
RX   PubMed=24305054; DOI=10.1038/nature12725;
RA   Geng Y., Bush M., Mosyak L., Wang F., Fan Q.R.;
RT   "Structural mechanism of ligand activation in human GABA(B) receptor.";
RL   Nature 504:254-259(2013).
RN   [22]
RP   VARIANTS VAL-20 AND SER-489.
RX   PubMed=10402495;
RX   DOI=10.1002/(sici)1096-8628(19990820)88:4<305::aid-ajmg5>3.0.co;2-x;
RA   Sander T., Peters C., Kaemmer G., Samochowiec J., Zirra M., Mischke D.,
RA   Ziegler A., Kaupmann K., Bettler B., Epplen J.T., Riess O.;
RT   "Association analysis of exonic variants of the gene encoding the GABAB
RT   receptor and idiopathic generalized epilepsy.";
RL   Am. J. Med. Genet. 88:305-310(1999).
CC   -!- FUNCTION: Component of a heterodimeric G-protein coupled receptor for
CC       GABA, formed by GABBR1 and GABBR2 (PubMed:9872316, PubMed:9872744,
CC       PubMed:15617512, PubMed:18165688, PubMed:22660477, PubMed:24305054).
CC       Within the heterodimeric GABA receptor, only GABBR1 seems to bind
CC       agonists, while GABBR2 mediates coupling to G proteins
CC       (PubMed:18165688). Ligand binding causes a conformation change that
CC       triggers signaling via guanine nucleotide-binding proteins (G proteins)
CC       and modulates the activity of down-stream effectors, such as adenylate
CC       cyclase (PubMed:10906333, PubMed:10773016, PubMed:10075644,
CC       PubMed:9872744, PubMed:24305054). Signaling inhibits adenylate cyclase,
CC       stimulates phospholipase A2, activates potassium channels, inactivates
CC       voltage-dependent calcium-channels and modulates inositol phospholipid
CC       hydrolysis (PubMed:10075644). Calcium is required for high affinity
CC       binding to GABA (By similarity). Plays a critical role in the fine-
CC       tuning of inhibitory synaptic transmission (PubMed:9844003). Pre-
CC       synaptic GABA receptor inhibits neurotransmitter release by down-
CC       regulating high-voltage activated calcium channels, whereas
CC       postsynaptic GABA receptor decreases neuronal excitability by
CC       activating a prominent inwardly rectifying potassium (Kir) conductance
CC       that underlies the late inhibitory postsynaptic potentials
CC       (PubMed:9844003, PubMed:9872316, PubMed:10075644, PubMed:9872744,
CC       PubMed:22660477). Not only implicated in synaptic inhibition but also
CC       in hippocampal long-term potentiation, slow wave sleep, muscle
CC       relaxation and antinociception (Probable). Activated by (-)-baclofen,
CC       cgp27492 and blocked by phaclofen (PubMed:9844003, PubMed:9872316,
CC       PubMed:24305054). {ECO:0000250|UniProtKB:Q9Z0U4,
CC       ECO:0000269|PubMed:10075644, ECO:0000269|PubMed:10773016,
CC       ECO:0000269|PubMed:10906333, ECO:0000269|PubMed:15617512,
CC       ECO:0000269|PubMed:18165688, ECO:0000269|PubMed:22660477,
CC       ECO:0000269|PubMed:24305054, ECO:0000269|PubMed:9844003,
CC       ECO:0000269|PubMed:9872316, ECO:0000269|PubMed:9872744, ECO:0000305}.
CC   -!- FUNCTION: Isoform 1E may regulate the formation of functional
CC       GABBR1/GABBR2 heterodimers by competing for GABBR2 binding. This could
CC       explain the observation that certain small molecule ligands exhibit
CC       differential affinity for central versus peripheral sites.
CC   -!- SUBUNIT: Heterodimer of GABBR1 and GABBR2 (PubMed:9872316,
CC       PubMed:10773016, PubMed:9872744, PubMed:15617512, PubMed:18165688,
CC       PubMed:22660477, PubMed:24305054). Homodimers may form, but are
CC       inactive (PubMed:9872316, PubMed:15617512). Isoform 1E (without C-
CC       terminal intracellular domain) is unable to dimerize via a coiled-coil
CC       interaction with GABBR2 (PubMed:10906333). Interacts (via C-terminus)
CC       with ATF4 (via leucine zipper domain) (By similarity). Interacts with
CC       JAKMIP1 (PubMed:14718537). {ECO:0000250|UniProtKB:Q9Z0U4,
CC       ECO:0000269|PubMed:10773016, ECO:0000269|PubMed:10906333,
CC       ECO:0000269|PubMed:14718537, ECO:0000269|PubMed:15617512,
CC       ECO:0000269|PubMed:18165688, ECO:0000269|PubMed:22660477,
CC       ECO:0000269|PubMed:24305054, ECO:0000269|PubMed:9872316,
CC       ECO:0000269|PubMed:9872744}.
CC   -!- INTERACTION:
CC       Q9UBS5; O75899: GABBR2; NbExp=2; IntAct=EBI-724156, EBI-715469;
CC       Q9UBS5; O15354: GPR37; NbExp=2; IntAct=EBI-724156, EBI-15639515;
CC       Q9UBS5; P61244: MAX; NbExp=3; IntAct=EBI-724156, EBI-751711;
CC       Q9UBS5; P16333: NCK1; NbExp=3; IntAct=EBI-724156, EBI-389883;
CC       Q9UBS5; P46459: NSF; NbExp=3; IntAct=EBI-724156, EBI-712251;
CC       Q9UBS5-2; O75899: GABBR2; NbExp=3; IntAct=EBI-16084001, EBI-715469;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:15617512};
CC       Multi-pass membrane protein {ECO:0000305}. Cell junction, synapse,
CC       postsynaptic cell membrane {ECO:0000250|UniProtKB:Q9Z0U4}; Multi-pass
CC       membrane protein {ECO:0000305}. Cell projection, dendrite
CC       {ECO:0000250|UniProtKB:Q9Z0U4}. Note=Colocalizes with ATF4 in
CC       hippocampal neuron dendritic membranes (By similarity). Coexpression of
CC       GABBR1 and GABBR2 is required for GABBR1 maturation and transport to
CC       the plasma membrane (PubMed:15617512). {ECO:0000250|UniProtKB:Q9Z0U4,
CC       ECO:0000269|PubMed:15617512}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 1E]: Secreted {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC         Comment=Isoforms corresponding to the full receptor are essentially
CC         found in the central nervous system (CNS).;
CC       Name=1A;
CC         IsoId=Q9UBS5-1; Sequence=Displayed;
CC       Name=1B;
CC         IsoId=Q9UBS5-2; Sequence=VSP_002037;
CC       Name=1C;
CC         IsoId=Q9UBS5-3; Sequence=VSP_002038;
CC       Name=1D;
CC         IsoId=Q9UBS5-4; Sequence=VSP_002040;
CC       Name=1E; Synonyms=Truncated;
CC         IsoId=Q9UBS5-5; Sequence=VSP_002039;
CC   -!- TISSUE SPECIFICITY: Highly expressed in brain (PubMed:9844003,
CC       PubMed:9753614, PubMed:9872744). Weakly expressed in heart, small
CC       intestine and uterus. Isoform 1A: Mainly expressed in granular cell and
CC       molecular layer (PubMed:9844003). Isoform 1B: Mainly expressed in
CC       Purkinje cells (PubMed:9844003). Isoform 1E: Predominantly expressed in
CC       peripheral tissues as kidney, lung, trachea, colon, small intestine,
CC       stomach, bone marrow, thymus and mammary gland (PubMed:10906333).
CC       {ECO:0000269|PubMed:10906333, ECO:0000269|PubMed:9753614,
CC       ECO:0000269|PubMed:9844003, ECO:0000269|PubMed:9872744}.
CC   -!- DOMAIN: Alpha-helical parts of the C-terminal intracellular region
CC       mediate heterodimeric interaction with GABBR2 (PubMed:9872744). The
CC       linker region between the transmembrane domain 3 (TM3) and the
CC       transmembrane domain 4 (TM4) probably plays a role in the specificity
CC       for G-protein coupling (PubMed:9844003). {ECO:0000305|PubMed:9844003,
CC       ECO:0000305|PubMed:9872744}.
CC   -!- MISCELLANEOUS: [Isoform 1E]: Major isoform in almost all peripheral
CC       tissues, although containing a premature stop codon in the mRNA and
CC       thus being a potential target for nonsense-mediated mRNA decay. May act
CC       as an antagonist of GABA-B receptors, being able to disrupt the normal
CC       association between isoform 1A and GABBR2.
CC       {ECO:0000269|PubMed:10906333}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 3 family. GABA-B
CC       receptor subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AJ225028; CAA12359.1; -; mRNA.
DR   EMBL; AJ225029; CAA12360.1; -; mRNA.
DR   EMBL; AJ012185; CAA09939.1; -; mRNA.
DR   EMBL; AJ012186; CAA09940.1; -; mRNA.
DR   EMBL; AF099148; AAC98508.1; -; mRNA.
DR   EMBL; Y11044; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AJ012187; CAA09941.1; -; mRNA.
DR   EMBL; AJ010170; CAA09031.1; -; Genomic_DNA.
DR   EMBL; AJ010171; CAA09031.1; JOINED; Genomic_DNA.
DR   EMBL; AJ010172; CAA09031.1; JOINED; Genomic_DNA.
DR   EMBL; AJ010173; CAA09031.1; JOINED; Genomic_DNA.
DR   EMBL; AJ010174; CAA09031.1; JOINED; Genomic_DNA.
DR   EMBL; AJ010175; CAA09031.1; JOINED; Genomic_DNA.
DR   EMBL; AJ010176; CAA09031.1; JOINED; Genomic_DNA.
DR   EMBL; AJ010177; CAA09031.1; JOINED; Genomic_DNA.
DR   EMBL; AJ010178; CAA09031.1; JOINED; Genomic_DNA.
DR   EMBL; AJ010179; CAA09031.1; JOINED; Genomic_DNA.
DR   EMBL; AJ010180; CAA09031.1; JOINED; Genomic_DNA.
DR   EMBL; AJ010181; CAA09031.1; JOINED; Genomic_DNA.
DR   EMBL; AJ010182; CAA09031.1; JOINED; Genomic_DNA.
DR   EMBL; AJ010183; CAA09031.1; JOINED; Genomic_DNA.
DR   EMBL; AJ010184; CAA09031.1; JOINED; Genomic_DNA.
DR   EMBL; AJ010185; CAA09031.1; JOINED; Genomic_DNA.
DR   EMBL; AJ010186; CAA09031.1; JOINED; Genomic_DNA.
DR   EMBL; AJ010187; CAA09031.1; JOINED; Genomic_DNA.
DR   EMBL; AJ010188; CAA09031.1; JOINED; Genomic_DNA.
DR   EMBL; AJ010189; CAA09031.1; JOINED; Genomic_DNA.
DR   EMBL; AJ010190; CAA09031.1; JOINED; Genomic_DNA.
DR   EMBL; AJ010191; CAA09031.1; JOINED; Genomic_DNA.
DR   EMBL; AJ012288; CAA09980.1; -; mRNA.
DR   EMBL; AF301005; AAG23962.1; -; mRNA.
DR   EMBL; AL031983; CAA21453.1; -; Genomic_DNA.
DR   EMBL; AL031983; CAA21454.1; -; Genomic_DNA.
DR   EMBL; AL645936; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL662826; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BX000688; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CR388210; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CR759766; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CR759870; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CR788300; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CR936483; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471081; EAX03205.1; -; Genomic_DNA.
DR   EMBL; CH471081; EAX03210.1; -; Genomic_DNA.
DR   EMBL; BC042598; AAH42598.1; -; mRNA.
DR   EMBL; BC050532; AAH50532.2; -; mRNA.
DR   CCDS; CCDS4663.1; -. [Q9UBS5-1]
DR   CCDS; CCDS4664.1; -. [Q9UBS5-3]
DR   CCDS; CCDS4665.1; -. [Q9UBS5-2]
DR   PIR; JE0356; JE0356.
DR   RefSeq; NP_001305982.1; NM_001319053.1.
DR   RefSeq; NP_001461.1; NM_001470.3. [Q9UBS5-1]
DR   RefSeq; NP_068703.1; NM_021903.2. [Q9UBS5-2]
DR   RefSeq; NP_068704.2; NM_021904.3. [Q9UBS5-3]
DR   PDB; 4MQE; X-ray; 2.35 A; A=165-576.
DR   PDB; 4MQF; X-ray; 2.22 A; A=165-576.
DR   PDB; 4MR7; X-ray; 2.15 A; A=165-576.
DR   PDB; 4MR8; X-ray; 2.15 A; A=165-576.
DR   PDB; 4MR9; X-ray; 2.35 A; A=165-576.
DR   PDB; 4MRM; X-ray; 2.86 A; A=165-576.
DR   PDB; 4MS1; X-ray; 2.25 A; A=165-576.
DR   PDB; 4MS3; X-ray; 2.50 A; A=165-576.
DR   PDB; 4MS4; X-ray; 1.90 A; A=165-576.
DR   PDB; 4PAS; X-ray; 1.62 A; A=879-919.
DR   PDB; 6HKC; NMR; -; A=26-98.
DR   PDB; 6UO8; EM; 3.63 A; A=165-919.
DR   PDB; 6UO9; EM; 4.80 A; A=165-919.
DR   PDB; 6UOA; EM; 6.30 A; A=165-919.
DR   PDB; 6VJM; EM; 3.97 A; A=165-919.
DR   PDB; 6W2X; EM; 3.60 A; A=153-961.
DR   PDB; 6W2Y; EM; 3.20 A; A/B=153-961.
DR   PDB; 6WIV; EM; 3.30 A; A=153-919.
DR   PDB; 7C7Q; EM; 3.00 A; A=15-862.
DR   PDB; 7C7S; EM; 2.90 A; A=15-919.
DR   PDBsum; 4MQE; -.
DR   PDBsum; 4MQF; -.
DR   PDBsum; 4MR7; -.
DR   PDBsum; 4MR8; -.
DR   PDBsum; 4MR9; -.
DR   PDBsum; 4MRM; -.
DR   PDBsum; 4MS1; -.
DR   PDBsum; 4MS3; -.
DR   PDBsum; 4MS4; -.
DR   PDBsum; 4PAS; -.
DR   PDBsum; 6HKC; -.
DR   PDBsum; 6UO8; -.
DR   PDBsum; 6UO9; -.
DR   PDBsum; 6UOA; -.
DR   PDBsum; 6VJM; -.
DR   PDBsum; 6W2X; -.
DR   PDBsum; 6W2Y; -.
DR   PDBsum; 6WIV; -.
DR   PDBsum; 7C7Q; -.
DR   PDBsum; 7C7S; -.
DR   SMR; Q9UBS5; -.
DR   BioGRID; 108825; 23.
DR   ComplexPortal; CPX-2955; GABA-B receptor complex.
DR   CORUM; Q9UBS5; -.
DR   DIP; DIP-38394N; -.
DR   IntAct; Q9UBS5; 16.
DR   MINT; Q9UBS5; -.
DR   STRING; 9606.ENSP00000366233; -.
DR   BindingDB; Q9UBS5; -.
DR   ChEMBL; CHEMBL2064; -.
DR   DrugBank; DB08891; Arbaclofen.
DR   DrugBank; DB08892; Arbaclofen Placarbil.
DR   DrugBank; DB00181; Baclofen.
DR   DrugBank; DB02530; gamma-Aminobutyric acid.
DR   DrugBank; DB00837; Progabide.
DR   DrugBank; DB05010; SGS-742.
DR   DrugBank; DB01956; Taurine.
DR   DrugBank; DB06354; Tezampanel.
DR   DrugBank; DB01080; Vigabatrin.
DR   DrugCentral; Q9UBS5; -.
DR   GuidetoPHARMACOLOGY; 240; -.
DR   GlyGen; Q9UBS5; 7 sites.
DR   iPTMnet; Q9UBS5; -.
DR   PhosphoSitePlus; Q9UBS5; -.
DR   BioMuta; GABBR1; -.
DR   DMDM; 12643873; -.
DR   jPOST; Q9UBS5; -.
DR   MassIVE; Q9UBS5; -.
DR   PaxDb; Q9UBS5; -.
DR   PeptideAtlas; Q9UBS5; -.
DR   PRIDE; Q9UBS5; -.
DR   ProteomicsDB; 84047; -. [Q9UBS5-1]
DR   ProteomicsDB; 84048; -. [Q9UBS5-2]
DR   ProteomicsDB; 84049; -. [Q9UBS5-3]
DR   ProteomicsDB; 84050; -. [Q9UBS5-4]
DR   ProteomicsDB; 84051; -. [Q9UBS5-5]
DR   ABCD; Q9UBS5; 1 sequenced antibody.
DR   Antibodypedia; 50418; 530 antibodies.
DR   DNASU; 2550; -.
DR   Ensembl; ENST00000355973; ENSP00000348248; ENSG00000204681. [Q9UBS5-2]
DR   Ensembl; ENST00000376977; ENSP00000366176; ENSG00000204681. [Q9UBS5-5]
DR   Ensembl; ENST00000377012; ENSP00000366211; ENSG00000204681. [Q9UBS5-2]
DR   Ensembl; ENST00000377016; ENSP00000366215; ENSG00000204681. [Q9UBS5-3]
DR   Ensembl; ENST00000377034; ENSP00000366233; ENSG00000204681. [Q9UBS5-1]
DR   Ensembl; ENST00000383537; ENSP00000373029; ENSG00000206466. [Q9UBS5-2]
DR   Ensembl; ENST00000383541; ENSP00000373033; ENSG00000206466. [Q9UBS5-3]
DR   Ensembl; ENST00000383542; ENSP00000373034; ENSG00000206466. [Q9UBS5-1]
DR   Ensembl; ENST00000383543; ENSP00000373035; ENSG00000206466. [Q9UBS5-2]
DR   Ensembl; ENST00000383636; ENSP00000373132; ENSG00000206511. [Q9UBS5-2]
DR   Ensembl; ENST00000383637; ENSP00000373133; ENSG00000206511. [Q9UBS5-3]
DR   Ensembl; ENST00000383638; ENSP00000373134; ENSG00000206511. [Q9UBS5-1]
DR   Ensembl; ENST00000383639; ENSP00000373135; ENSG00000206511. [Q9UBS5-2]
DR   Ensembl; ENST00000414980; ENSP00000406499; ENSG00000232632. [Q9UBS5-2]
DR   Ensembl; ENST00000417759; ENSP00000391572; ENSG00000237112. [Q9UBS5-2]
DR   Ensembl; ENST00000419674; ENSP00000399861; ENSG00000232569. [Q9UBS5-3]
DR   Ensembl; ENST00000423604; ENSP00000388035; ENSG00000232632. [Q9UBS5-1]
DR   Ensembl; ENST00000425097; ENSP00000411286; ENSG00000237112. [Q9UBS5-1]
DR   Ensembl; ENST00000434660; ENSP00000412167; ENSG00000232632. [Q9UBS5-3]
DR   Ensembl; ENST00000438094; ENSP00000406285; ENSG00000232632. [Q9UBS5-2]
DR   Ensembl; ENST00000439457; ENSP00000406066; ENSG00000232569. [Q9UBS5-1]
DR   Ensembl; ENST00000443440; ENSP00000399318; ENSG00000237112. [Q9UBS5-3]
DR   Ensembl; ENST00000446436; ENSP00000394528; ENSG00000237112. [Q9UBS5-2]
DR   Ensembl; ENST00000448754; ENSP00000405709; ENSG00000237051. [Q9UBS5-2]
DR   Ensembl; ENST00000449163; ENSP00000411263; ENSG00000232569. [Q9UBS5-2]
DR   Ensembl; ENST00000452300; ENSP00000408938; ENSG00000232569. [Q9UBS5-2]
DR   Ensembl; ENST00000458612; ENSP00000416903; ENSG00000237051. [Q9UBS5-2]
DR   Ensembl; ENST00000494877; ENSP00000419061; ENSG00000204681. [Q9UBS5-5]
DR   Ensembl; ENST00000546913; ENSP00000448999; ENSG00000232569. [Q9UBS5-1]
DR   Ensembl; ENST00000547410; ENSP00000448531; ENSG00000232569. [Q9UBS5-5]
DR   Ensembl; ENST00000548767; ENSP00000446983; ENSG00000232632. [Q9UBS5-5]
DR   Ensembl; ENST00000551140; ENSP00000448654; ENSG00000237112. [Q9UBS5-5]
DR   Ensembl; ENST00000551423; ENSP00000449342; ENSG00000206511. [Q9UBS5-5]
DR   Ensembl; ENST00000552399; ENSP00000449449; ENSG00000206466. [Q9UBS5-5]
DR   GeneID; 2550; -.
DR   KEGG; hsa:2550; -.
DR   UCSC; uc003nmp.5; human. [Q9UBS5-1]
DR   CTD; 2550; -.
DR   DisGeNET; 2550; -.
DR   EuPathDB; HostDB:ENSG00000204681.10; -.
DR   GeneCards; GABBR1; -.
DR   HGNC; HGNC:4070; GABBR1.
DR   HPA; ENSG00000204681; Tissue enhanced (brain).
DR   MIM; 603540; gene.
DR   neXtProt; NX_Q9UBS5; -.
DR   OpenTargets; ENSG00000204681; -.
DR   PharmGKB; PA28484; -.
DR   eggNOG; KOG1055; Eukaryota.
DR   GeneTree; ENSGT00940000157642; -.
DR   HOGENOM; CLU_005240_2_0_1; -.
DR   InParanoid; Q9UBS5; -.
DR   KO; K04615; -.
DR   OMA; PKICQAR; -.
DR   OrthoDB; 590810at2759; -.
DR   PhylomeDB; Q9UBS5; -.
DR   TreeFam; TF313965; -.
DR   PathwayCommons; Q9UBS5; -.
DR   Reactome; R-HSA-1296041; Activation of G protein gated Potassium channels.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-420499; Class C/3 (Metabotropic glutamate/pheromone receptors).
DR   Reactome; R-HSA-977444; GABA B receptor activation.
DR   Reactome; R-HSA-997272; Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits.
DR   SIGNOR; Q9UBS5; -.
DR   BioGRID-ORCS; 2550; 7 hits in 871 CRISPR screens.
DR   ChiTaRS; GABBR1; human.
DR   GeneWiki; GABBR1; -.
DR   GenomeRNAi; 2550; -.
DR   Pharos; Q9UBS5; Tclin.
DR   PRO; PR:Q9UBS5; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; Q9UBS5; protein.
DR   Bgee; ENSG00000204681; Expressed in paraflocculus and 220 other tissues.
DR   ExpressionAtlas; Q9UBS5; baseline and differential.
DR   Genevisible; Q9UBS5; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0030425; C:dendrite; IEA:UniProtKB-SubCell.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0038039; C:G protein-coupled receptor heterodimeric complex; IPI:UniProtKB.
DR   GO; GO:0098982; C:GABA-ergic synapse; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0045211; C:postsynaptic membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042734; C:presynaptic membrane; IEA:Ensembl.
DR   GO; GO:0098685; C:Schaffer collateral - CA1 synapse; IEA:Ensembl.
DR   GO; GO:0004965; F:G protein-coupled GABA receptor activity; IDA:UniProtKB.
DR   GO; GO:0099579; F:G protein-coupled neurotransmitter receptor activity involved in regulation of postsynaptic membrane potential; IEA:Ensembl.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; IBA:GO_Central.
DR   GO; GO:0007193; P:adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007214; P:gamma-aminobutyric acid signaling pathway; IDA:UniProtKB.
DR   GO; GO:0150099; P:neuron-glial cell signaling; ISS:ARUK-UCL.
DR   CDD; cd00033; CCP; 1.
DR   InterPro; IPR001828; ANF_lig-bd_rcpt.
DR   InterPro; IPR002455; GPCR3_GABA-B.
DR   InterPro; IPR017978; GPCR_3_C.
DR   InterPro; IPR028082; Peripla_BP_I.
DR   InterPro; IPR035976; Sushi/SCR/CCP_sf.
DR   InterPro; IPR000436; Sushi_SCR_CCP_dom.
DR   PANTHER; PTHR10519; PTHR10519; 1.
DR   Pfam; PF00003; 7tm_3; 1.
DR   Pfam; PF01094; ANF_receptor; 1.
DR   Pfam; PF00084; Sushi; 1.
DR   SMART; SM00032; CCP; 2.
DR   SUPFAM; SSF53822; SSF53822; 1.
DR   SUPFAM; SSF57535; SSF57535; 2.
DR   PROSITE; PS50259; G_PROTEIN_RECEP_F3_4; 1.
DR   PROSITE; PS50923; SUSHI; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell junction; Cell membrane;
KW   Cell projection; Coiled coil; Direct protein sequencing; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Phosphoprotein;
KW   Polymorphism; Postsynaptic cell membrane; Receptor; Reference proteome;
KW   Repeat; Secreted; Signal; Sushi; Synapse; Transducer; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL          1..14
FT                   /evidence="ECO:0000255"
FT   CHAIN           15..961
FT                   /note="Gamma-aminobutyric acid type B receptor subunit 1"
FT                   /id="PRO_0000012949"
FT   TOPO_DOM        15..591
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        592..612
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        613..631
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        632..652
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        653..667
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        668..688
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        689..710
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        711..731
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        732..768
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        769..789
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        790..804
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        805..825
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        826..833
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        834..854
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        855..961
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          30..96
FT                   /note="Sushi 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00302"
FT   DOMAIN          98..159
FT                   /note="Sushi 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00302"
FT   REGION          888..916
FT                   /note="Interaction with ATF4"
FT                   /evidence="ECO:0000250"
FT   COILED          869..925
FT                   /evidence="ECO:0000255"
FT   BINDING         247
FT                   /note="Agonist"
FT   BINDING         270
FT                   /note="Agonist"
FT   BINDING         287
FT                   /note="Agonist"
FT   BINDING         367
FT                   /note="Agonist"
FT   BINDING         395
FT                   /note="Agonist"
FT   BINDING         466
FT                   /note="Agonist"
FT   MOD_RES         873
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WV18"
FT   MOD_RES         930
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9WV18"
FT   CARBOHYD        24
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        84
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        409
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        440
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:24305054"
FT   CARBOHYD        482
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:24305054"
FT   CARBOHYD        502
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        514
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        100..145
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00302"
FT   DISULFID        131..157
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00302"
FT   DISULFID        220..246
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00302,
FT                   ECO:0000269|PubMed:24305054"
FT   DISULFID        376..410
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00302,
FT                   ECO:0000269|PubMed:24305054"
FT   VAR_SEQ         1..164
FT                   /note="MLLLLLLAPLFLRPPGAGGAQTPNATSEGCQIIHPPWEGGIRYRGLTRDQVK
FT                   AINFLPVDYEIEYVCRGEREVVGPKVRKCLANGSWTDMDTPSRCVRICSKSYLTLENGK
FT                   VFLTGGDLPALDGARVDFRCDPDFHLVGSSRSICSQGQWSTPKPHCQVNRTPH -> MG
FT                   PGAPFARVGWPLPLLVVMAAGVAPVWASHSPHLPRPHSRVPPHPS (in isoform
FT                   1B)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:9844003, ECO:0000303|PubMed:9872316"
FT                   /id="VSP_002037"
FT   VAR_SEQ         98..159
FT                   /note="Missing (in isoform 1C)"
FT                   /evidence="ECO:0000303|PubMed:9872316, ECO:0000303|Ref.6"
FT                   /id="VSP_002038"
FT   VAR_SEQ         570..961
FT                   /note="GGSPPADQTLVIKTFRFLSQKLFISVSVLSSLGIVLAVVCLSFNIYNSHVRY
FT                   IQNSQPNLNNLTAVGCSLALAAVFPLGLDGYHIGRNQFPFVCQARLWLLGLGFSLGYGS
FT                   MFTKIWWVHTVFTKKEEKKEWRKTLEPWKLYATVGLLVGMDVLTLAIWQIVDPLHRTIE
FT                   TFAKEEPKEDIDVSILPQLEHCSSRKMNTWLGIFYGYKGLLLLLGIFLAYETKSVSTEK
FT                   INDHRAVGMAIYNVAVLCLITAPVTMILSSQQDAAFAFASLAIVFSSYITLVVLFVPKM
FT                   RRLITRGEWQSEAQDTMKTGSSTNNNEEEKSRLLEKENRELEKIIAEKEERVSELRHQL
FT                   QSRQQLRSRRHPPTPPEPSGGLPRGPPEPPDRLSCDGSRVHLLYK -> VISRTHSPT
FT                   (in isoform 1E)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_002039"
FT   VAR_SEQ         905..961
FT                   /note="KEERVSELRHQLQSRQQLRSRRHPPTPPEPSGGLPRGPPEPPDRLSCDGSRV
FT                   HLLYK -> SGGLPRGPPEPPDRLSCDGSRVHLLYK (in isoform 1D)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_002040"
FT   VARIANT         20
FT                   /note="A -> V (in dbSNP:rs1805056)"
FT                   /evidence="ECO:0000269|PubMed:10402495,
FT                   ECO:0000269|PubMed:14574404, ECO:0000269|PubMed:9933300"
FT                   /id="VAR_010146"
FT   VARIANT         489
FT                   /note="G -> S (in dbSNP:rs1805057)"
FT                   /evidence="ECO:0000269|PubMed:10402495,
FT                   ECO:0000269|PubMed:10906333, ECO:0000269|PubMed:9933300"
FT                   /id="VAR_010147"
FT   VARIANT         645
FT                   /note="F -> L (in dbSNP:rs2076489)"
FT                   /id="VAR_049279"
FT   MUTAGEN         182
FT                   /note="W->A: Abolishes signaling via G-proteins. Abolishes
FT                   antagonist binding."
FT                   /evidence="ECO:0000269|PubMed:24305054"
FT   MUTAGEN         230
FT                   /note="Y->A: Slightly decreases signaling via G-proteins."
FT                   /evidence="ECO:0000269|PubMed:22660477"
FT   MUTAGEN         234
FT                   /note="Y->A: Decreases signaling via G-proteins."
FT                   /evidence="ECO:0000269|PubMed:22660477"
FT   MUTAGEN         287
FT                   /note="H->A: Strongly reduces signaling via G-proteins.
FT                   Abolishes antagonist binding."
FT                   /evidence="ECO:0000269|PubMed:24305054"
FT   MUTAGEN         367
FT                   /note="Y->A: Strongly reduces signaling via G-proteins. No
FT                   effect on antagonist binding."
FT                   /evidence="ECO:0000269|PubMed:24305054"
FT   MUTAGEN         395
FT                   /note="W->A: Strongly reduces signaling via G-proteins.
FT                   Strongly reduces antagonist binding."
FT                   /evidence="ECO:0000269|PubMed:24305054"
FT   CONFLICT        2
FT                   /note="L -> M (in Ref. 4; Y11044)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        21
FT                   /note="Q -> H (in Ref. 2; CAA09939/CAA09941)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        93
FT                   /note="P -> L (in Ref. 3; AAC98508)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        127
FT                   /note="V -> A (in Ref. 2; CAA09939)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        322
FT                   /note="Missing (in Ref. 7; CAA09031)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        542
FT                   /note="L -> P (in Ref. 4; Y11044)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        691
FT                   /note="V -> G (in Ref. 4; Y11044)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        905..934
FT                   /note="Missing (in Ref. 7; CAA09031)"
FT                   /evidence="ECO:0000305"
FT   STRAND          37..42
FT                   /evidence="ECO:0000244|PDB:6HKC"
FT   STRAND          51..53
FT                   /evidence="ECO:0000244|PDB:6HKC"
FT   STRAND          62..67
FT                   /evidence="ECO:0000244|PDB:6HKC"
FT   TURN            68..70
FT                   /evidence="ECO:0000244|PDB:6HKC"
FT   STRAND          73..75
FT                   /evidence="ECO:0000244|PDB:6HKC"
FT   STRAND          79..81
FT                   /evidence="ECO:0000244|PDB:6HKC"
FT   STRAND          83..89
FT                   /evidence="ECO:0000244|PDB:6HKC"
FT   STRAND          168..176
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          178..181
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           185..200
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   TURN            203..205
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          209..217
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           222..233
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          234..237
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          240..243
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           247..256
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           257..260
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          263..268
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           272..275
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   TURN            277..279
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          283..287
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           290..292
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           293..303
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          308..316
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           317..332
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          336..345
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           348..356
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          361..365
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           368..381
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          385..387
FT                   /evidence="ECO:0000244|PDB:4MRM"
FT   STRAND          389..393
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           400..402
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           412..419
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          423..427
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           443..453
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           458..460
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   TURN            462..466
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           467..484
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           495..497
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           504..514
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          517..520
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          523..526
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   TURN            529..531
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          536..543
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          546..554
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   TURN            555..558
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   STRAND          559..562
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           569..571
FT                   /evidence="ECO:0000244|PDB:4MS4"
FT   HELIX           885..917
FT                   /evidence="ECO:0000244|PDB:4PAS"
SQ   SEQUENCE   961 AA;  108320 MW;  54E7349CD02B633F CRC64;
     MLLLLLLAPL FLRPPGAGGA QTPNATSEGC QIIHPPWEGG IRYRGLTRDQ VKAINFLPVD
     YEIEYVCRGE REVVGPKVRK CLANGSWTDM DTPSRCVRIC SKSYLTLENG KVFLTGGDLP
     ALDGARVDFR CDPDFHLVGS SRSICSQGQW STPKPHCQVN RTPHSERRAV YIGALFPMSG
     GWPGGQACQP AVEMALEDVN SRRDILPDYE LKLIHHDSKC DPGQATKYLY ELLYNDPIKI
     ILMPGCSSVS TLVAEAARMW NLIVLSYGSS SPALSNRQRF PTFFRTHPSA TLHNPTRVKL
     FEKWGWKKIA TIQQTTEVFT STLDDLEERV KEAGIEITFR QSFFSDPAVP VKNLKRQDAR
     IIVGLFYETE ARKVFCEVYK ERLFGKKYVW FLIGWYADNW FKIYDPSINC TVDEMTEAVE
     GHITTEIVML NPANTRSISN MTSQEFVEKL TKRLKRHPEE TGGFQEAPLA YDAIWALALA
     LNKTSGGGGR SGVRLEDFNY NNQTITDQIY RAMNSSSFEG VSGHVVFDAS GSRMAWTLIE
     QLQGGSYKKI GYYDSTKDDL SWSKTDKWIG GSPPADQTLV IKTFRFLSQK LFISVSVLSS
     LGIVLAVVCL SFNIYNSHVR YIQNSQPNLN NLTAVGCSLA LAAVFPLGLD GYHIGRNQFP
     FVCQARLWLL GLGFSLGYGS MFTKIWWVHT VFTKKEEKKE WRKTLEPWKL YATVGLLVGM
     DVLTLAIWQI VDPLHRTIET FAKEEPKEDI DVSILPQLEH CSSRKMNTWL GIFYGYKGLL
     LLLGIFLAYE TKSVSTEKIN DHRAVGMAIY NVAVLCLITA PVTMILSSQQ DAAFAFASLA
     IVFSSYITLV VLFVPKMRRL ITRGEWQSEA QDTMKTGSST NNNEEEKSRL LEKENRELEK
     IIAEKEERVS ELRHQLQSRQ QLRSRRHPPT PPEPSGGLPR GPPEPPDRLS CDGSRVHLLY
     K
//
ID   GRM7_HUMAN              Reviewed;         915 AA.
AC   Q14831; Q8NFS2; Q8NFS3; Q8NFS4;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 1.
DT   12-AUG-2020, entry version 173.
DE   RecName: Full=Metabotropic glutamate receptor 7;
DE            Short=mGluR7;
DE   Flags: Precursor;
GN   Name=GRM7; Synonyms=GPRC1G, MGLUR7;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=8840028; DOI=10.1016/0169-328x(96)00110-6;
RA   Makoff A., Pilling C., Harrington K., Emson P.;
RT   "Human metabotropic glutamate receptor type 7: molecular cloning and mRNA
RT   distribution in the CNS.";
RL   Brain Res. Mol. Brain Res. 40:165-170(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RX   PubMed=9144652; DOI=10.1016/s0028-3908(96)00176-1;
RA   Flor P.J., Van Der Putten H., Ruegg D., Lukic S., Leonhardt T., Bence M.,
RA   Sansig G., Knoepfel T., Kuhn R.;
RT   "A novel splice variant of a metabotropic glutamate receptor, human
RT   mGluR7b.";
RL   Neuropharmacology 36:153-159(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RX   PubMed=9473604; DOI=10.1016/s0169-328x(97)00277-5;
RA   Wu S., Wright R.A., Rockey P.K., Burgett S.G., Arnold J.S.,
RA   Rosteck P.R. Jr., Johnson B.G., Schoepp D.D., Belagaje R.M.;
RT   "Group III human metabotropic glutamate receptors 4, 7 and 8: molecular
RT   cloning, functional expression, and comparison of pharmacological
RT   properties in RGT cells.";
RL   Brain Res. Mol. Brain Res. 53:88-97(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 3; 4 AND 5), AND TISSUE SPECIFICITY.
RX   PubMed=12052533; DOI=10.1016/s0304-3940(02)00306-3;
RA   Schulz H.L., Stoehr H., Weber B.H.F.;
RT   "Characterization of three novel isoforms of the metabotropic glutamate
RT   receptor 7 (GRM7).";
RL   Neurosci. Lett. 326:37-40(2002).
RN   [5]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 37-513.
RG   Structural genomics consortium (SGC);
RT   "MGluR7 complexed with LY341495.";
RL   Submitted (JUN-2010) to the PDB data bank.
RN   [6]
RP   VARIANT PHE-433.
RX   PubMed=11163549; DOI=10.1016/s0920-9964(99)00235-2;
RA   Bolonna A.A., Kerwin R.W., Munro J., Arranz M.J., Makoff A.J.;
RT   "Polymorphisms in the genes for mGluR types 7 and 8: association studies
RT   with schizophrenia.";
RL   Schizophr. Res. 47:99-103(2001).
CC   -!- FUNCTION: G-protein coupled receptor for glutamate. Ligand binding
CC       causes a conformation change that triggers signaling via guanine
CC       nucleotide-binding proteins (G proteins) and modulates the activity of
CC       down-stream effectors, such as adenylate cyclase. Signaling inhibits
CC       adenylate cyclase activity. {ECO:0000269|PubMed:9473604}.
CC   -!- SUBUNIT: Interacts with PICK1. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1; Synonyms=GRM7_v1, mGluR7a;
CC         IsoId=Q14831-1; Sequence=Displayed;
CC       Name=2; Synonyms=GRM7_v2, mGluR7b;
CC         IsoId=Q14831-2; Sequence=VSP_015735;
CC       Name=3; Synonyms=GRM7_v3;
CC         IsoId=Q14831-3; Sequence=VSP_015732;
CC       Name=4; Synonyms=GRM7_v4;
CC         IsoId=Q14831-4; Sequence=VSP_015733;
CC       Name=5; Synonyms=GRM7_v5;
CC         IsoId=Q14831-5; Sequence=VSP_015734;
CC   -!- TISSUE SPECIFICITY: Expressed in many areas of the brain, especially in
CC       the cerebral cortex, hippocampus, and cerebellum. Expression of GRM7
CC       isoforms in non-neuronal tissues appears to be restricted to isoform 3
CC       and isoform 4. {ECO:0000269|PubMed:12052533,
CC       ECO:0000269|PubMed:8840028}.
CC   -!- MISCELLANEOUS: [Isoform 3]: May be produced at very low levels due to a
CC       premature stop codon in the mRNA, leading to nonsense-mediated mRNA
CC       decay. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 4]: May be produced at very low levels due to a
CC       premature stop codon in the mRNA, leading to nonsense-mediated mRNA
CC       decay. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 3 family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION: [Isoform 3]:
CC       Sequence=AAM47557.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X94552; CAA64245.1; -; mRNA.
DR   EMBL; U92458; AAB51763.1; -; mRNA.
DR   EMBL; AF458052; AAM47557.1; ALT_FRAME; mRNA.
DR   EMBL; AF458053; AAM47558.1; -; mRNA.
DR   EMBL; AF458054; AAM47559.1; -; mRNA.
DR   CCDS; CCDS43042.1; -. [Q14831-1]
DR   RefSeq; NP_000835.1; NM_000844.3. [Q14831-1]
DR   RefSeq; NP_870989.1; NM_181874.2. [Q14831-2]
DR   PDB; 3MQ4; X-ray; 2.80 A; A=37-513.
DR   PDB; 5C5C; X-ray; 1.86 A; A=37-513.
DR   PDBsum; 3MQ4; -.
DR   PDBsum; 5C5C; -.
DR   SMR; Q14831; -.
DR   BioGRID; 109174; 6.
DR   CORUM; Q14831; -.
DR   STRING; 9606.ENSP00000350348; -.
DR   BindingDB; Q14831; -.
DR   ChEMBL; CHEMBL3777; -.
DR   DrugBank; DB00142; Glutamic acid.
DR   DrugCentral; Q14831; -.
DR   GuidetoPHARMACOLOGY; 295; -.
DR   GlyGen; Q14831; 4 sites.
DR   iPTMnet; Q14831; -.
DR   PhosphoSitePlus; Q14831; -.
DR   BioMuta; GRM7; -.
DR   DMDM; 2495078; -.
DR   MassIVE; Q14831; -.
DR   PaxDb; Q14831; -.
DR   PeptideAtlas; Q14831; -.
DR   PRIDE; Q14831; -.
DR   ProteomicsDB; 60197; -. [Q14831-1]
DR   ProteomicsDB; 60198; -. [Q14831-2]
DR   ProteomicsDB; 60199; -. [Q14831-3]
DR   ProteomicsDB; 60200; -. [Q14831-4]
DR   ProteomicsDB; 60201; -. [Q14831-5]
DR   Antibodypedia; 10079; 413 antibodies.
DR   Ensembl; ENST00000357716; ENSP00000350348; ENSG00000196277. [Q14831-1]
DR   Ensembl; ENST00000389335; ENSP00000373986; ENSG00000196277. [Q14831-4]
DR   Ensembl; ENST00000389336; ENSP00000373987; ENSG00000196277. [Q14831-5]
DR   Ensembl; ENST00000467425; ENSP00000419835; ENSG00000196277. [Q14831-2]
DR   Ensembl; ENST00000486284; ENSP00000417536; ENSG00000196277. [Q14831-2]
DR   GeneID; 2917; -.
DR   KEGG; hsa:2917; -.
DR   UCSC; uc003bql.3; human. [Q14831-1]
DR   CTD; 2917; -.
DR   DisGeNET; 2917; -.
DR   EuPathDB; HostDB:ENSG00000196277.15; -.
DR   GeneCards; GRM7; -.
DR   HGNC; HGNC:4599; GRM7.
DR   HPA; ENSG00000196277; Tissue enhanced (brain, parathyroid gland).
DR   MIM; 604101; gene.
DR   neXtProt; NX_Q14831; -.
DR   OpenTargets; ENSG00000196277; -.
DR   PharmGKB; PA28996; -.
DR   eggNOG; KOG1056; Eukaryota.
DR   GeneTree; ENSGT01000000214550; -.
DR   HOGENOM; CLU_005389_0_0_1; -.
DR   InParanoid; Q14831; -.
DR   KO; K04609; -.
DR   OMA; CKLCAYN; -.
DR   PhylomeDB; Q14831; -.
DR   TreeFam; TF313240; -.
DR   PathwayCommons; Q14831; -.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-420499; Class C/3 (Metabotropic glutamate/pheromone receptors).
DR   BioGRID-ORCS; 2917; 4 hits in 871 CRISPR screens.
DR   ChiTaRS; GRM7; human.
DR   EvolutionaryTrace; Q14831; -.
DR   GeneWiki; Metabotropic_glutamate_receptor_7; -.
DR   GenomeRNAi; 2917; -.
DR   Pharos; Q14831; Tchem.
DR   PRO; PR:Q14831; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q14831; protein.
DR   Bgee; ENSG00000196277; Expressed in corpus callosum and 132 other tissues.
DR   ExpressionAtlas; Q14831; baseline and differential.
DR   Genevisible; Q14831; HS.
DR   GO; GO:0032279; C:asymmetric synapse; ISS:UniProtKB.
DR   GO; GO:0030424; C:axon; ISS:UniProtKB.
DR   GO; GO:0005938; C:cell cortex; IDA:UniProtKB.
DR   GO; GO:0030425; C:dendrite; IDA:UniProtKB.
DR   GO; GO:0043198; C:dendritic shaft; ISS:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0045211; C:postsynaptic membrane; ISS:UniProtKB.
DR   GO; GO:0048786; C:presynaptic active zone; ISS:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0010855; F:adenylate cyclase inhibitor activity; IDA:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0016595; F:glutamate binding; IDA:UniProtKB.
DR   GO; GO:0008066; F:glutamate receptor activity; IDA:UniProtKB.
DR   GO; GO:0001642; F:group III metabotropic glutamate receptor activity; IDA:UniProtKB.
DR   GO; GO:0030165; F:PDZ domain binding; NAS:UniProtKB.
DR   GO; GO:0070905; F:serine binding; IDA:UniProtKB.
DR   GO; GO:0007196; P:adenylate cyclase-inhibiting G protein-coupled glutamate receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007193; P:adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007268; P:chemical synaptic transmission; IDA:UniProtKB.
DR   GO; GO:0007216; P:G protein-coupled glutamate receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0014050; P:negative regulation of glutamate secretion; ISS:UniProtKB.
DR   GO; GO:0051966; P:regulation of synaptic transmission, glutamatergic; IBA:GO_Central.
DR   GO; GO:0007605; P:sensory perception of sound; IMP:UniProtKB.
DR   Gene3D; 2.10.50.30; -; 1.
DR   InterPro; IPR001828; ANF_lig-bd_rcpt.
DR   InterPro; IPR000337; GPCR_3.
DR   InterPro; IPR011500; GPCR_3_9-Cys_dom.
DR   InterPro; IPR038550; GPCR_3_9-Cys_sf.
DR   InterPro; IPR017978; GPCR_3_C.
DR   InterPro; IPR017979; GPCR_3_CS.
DR   InterPro; IPR000162; GPCR_3_mtglu_rcpt.
DR   InterPro; IPR001883; GPCR_3_mtglu_rcpt_7.
DR   InterPro; IPR028082; Peripla_BP_I.
DR   Pfam; PF00003; 7tm_3; 1.
DR   Pfam; PF01094; ANF_receptor; 1.
DR   Pfam; PF07562; NCD3G; 1.
DR   PRINTS; PR00248; GPCRMGR.
DR   PRINTS; PR01057; MTABOTROPC7R.
DR   PRINTS; PR00593; MTABOTROPICR.
DR   SUPFAM; SSF53822; SSF53822; 1.
DR   PROSITE; PS00979; G_PROTEIN_RECEP_F3_1; 1.
DR   PROSITE; PS00980; G_PROTEIN_RECEP_F3_2; 1.
DR   PROSITE; PS00981; G_PROTEIN_RECEP_F3_3; 1.
DR   PROSITE; PS50259; G_PROTEIN_RECEP_F3_4; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Phosphoprotein;
KW   Polymorphism; Receptor; Reference proteome; Sensory transduction; Signal;
KW   Transducer; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..34
FT                   /evidence="ECO:0000255"
FT   CHAIN           35..915
FT                   /note="Metabotropic glutamate receptor 7"
FT                   /id="PRO_0000012938"
FT   TOPO_DOM        35..590
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        591..615
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        616..627
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        628..648
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        649..654
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        655..675
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        676..702
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        703..723
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        724..753
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        754..775
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        776..788
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        789..810
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        811..825
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        826..850
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        851..915
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REGION          180..182
FT                   /note="Glutamate binding"
FT                   /evidence="ECO:0000250"
FT   BINDING         159
FT                   /note="Glutamate"
FT                   /evidence="ECO:0000250"
FT   BINDING         230
FT                   /note="Glutamate"
FT                   /evidence="ECO:0000250"
FT   BINDING         314
FT                   /note="Glutamate"
FT                   /evidence="ECO:0000250"
FT   BINDING         407
FT                   /note="Glutamate"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         900
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q68ED2"
FT   CARBOHYD        98
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        458
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        486
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        572
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        67..109
FT                   /evidence="ECO:0000250"
FT   DISULFID        249..541
FT                   /evidence="ECO:0000250"
FT   DISULFID        374..390
FT                   /evidence="ECO:0000250"
FT   DISULFID        430..437
FT                   /evidence="ECO:0000250"
FT   DISULFID        523..542
FT                   /evidence="ECO:0000250"
FT   DISULFID        527..545
FT                   /evidence="ECO:0000250"
FT   DISULFID        548..560
FT                   /evidence="ECO:0000250"
FT   DISULFID        563..576
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         900..915
FT                   /note="SPAAKKKYVSYNNLVI -> NCIPPVRKSVQKSVTWYTIPPTV (in
FT                   isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:9144652"
FT                   /id="VSP_015735"
FT   VAR_SEQ         900..915
FT                   /note="SPAAKKKYVSYNNLVI -> NFFFWLYSGTW (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:12052533"
FT                   /id="VSP_015732"
FT   VAR_SEQ         900..915
FT                   /note="SPAAKKKYVSYNNLVI -> ITSEDLSLHKED (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:12052533"
FT                   /id="VSP_015733"
FT   VAR_SEQ         900..915
FT                   /note="SPAAKKKYVSYNNLVI -> SEKCNCY (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:12052533"
FT                   /id="VSP_015734"
FT   VARIANT         433
FT                   /note="Y -> F (in dbSNP:rs2229902)"
FT                   /evidence="ECO:0000269|PubMed:11163549"
FT                   /id="VAR_003584"
FT   VARIANT         495
FT                   /note="I -> V (in dbSNP:rs7634846)"
FT                   /id="VAR_049276"
FT   VARIANT         745
FT                   /note="G -> E (in dbSNP:rs1485174)"
FT                   /id="VAR_049277"
FT   STRAND          42..45
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   STRAND          48..55
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   STRAND          58..60
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   STRAND          62..64
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   STRAND          66..70
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   TURN            72..75
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   HELIX           76..90
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   STRAND          93..98
FT                   /evidence="ECO:0000244|PDB:3MQ4"
FT   STRAND          101..107
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   HELIX           112..119
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   HELIX           120..123
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   TURN            124..126
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   STRAND          150..154
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   HELIX           159..171
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   STRAND          176..180
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   HELIX           184..187
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   TURN            189..191
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   STRAND          195..199
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   HELIX           202..215
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   STRAND          220..228
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   HELIX           229..245
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   STRAND          249..256
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   HELIX           267..275
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   STRAND          277..279
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   STRAND          282..287
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   HELIX           289..301
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   STRAND          302..304
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   STRAND          308..314
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   STRAND          334..338
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   HELIX           344..351
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   TURN            355..357
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   HELIX           364..371
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   TURN            396..398
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   HELIX           408..429
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   HELIX           438..453
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   STRAND          456..458
FT                   /evidence="ECO:0000244|PDB:3MQ4"
FT   STRAND          462..465
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   STRAND          477..483
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   STRAND          491..504
FT                   /evidence="ECO:0000244|PDB:5C5C"
FT   HELIX           506..508
FT                   /evidence="ECO:0000244|PDB:5C5C"
SQ   SEQUENCE   915 AA;  102251 MW;  CFF94E06BF7F4919 CRC64;
     MVQLRKLLRV LTLMKFPCCV LEVLLCALAA AARGQEMYAP HSIRIEGDVT LGGLFPVHAK
     GPSGVPCGDI KRENGIHRLE AMLYALDQIN SDPNLLPNVT LGARILDTCS RDTYALEQSL
     TFVQALIQKD TSDVRCTNGE PPVFVKPEKV VGVIGASGSS VSIMVANILR LFQIPQISYA
     STAPELSDDR RYDFFSRVVP PDSFQAQAMV DIVKALGWNY VSTLASEGSY GEKGVESFTQ
     ISKEAGGLCI AQSVRIPQER KDRTIDFDRI IKQLLDTPNS RAVVIFANDE DIKQILAAAK
     RADQVGHFLW VGSDSWGSKI NPLHQHEDIA EGAITIQPKR ATVEGFDAYF TSRTLENNRR
     NVWFAEYWEE NFNCKLTISG SKKEDTDRKC TGQERIGKDS NYEQEGKVQF VIDAVYAMAH
     ALHHMNKDLC ADYRGVCPEM EQAGGKKLLK YIRNVNFNGS AGTPVMFNKN GDAPGRYDIF
     QYQTTNTSNP GYRLIGQWTD ELQLNIEDMQ WGKGVREIPA SVCTLPCKPG QRKKTQKGTP
     CCWTCEPCDG YQYQFDEMTC QHCPYDQRPN ENRTGCQDIP IIKLEWHSPW AVIPVFLAML
     GIIATIFVMA TFIRYNDTPI VRASGRELSY VLLTGIFLCY IITFLMIAKP DVAVCSFRRV
     FLGLGMCISY AALLTKTNRI YRIFEQGKKS VTAPRLISPT SQLAITSSLI SVQLLGVFIW
     FGVDPPNIII DYDEHKTMNP EQARGVLKCD ITDLQIICSL GYSILLMVTC TVYAIKTRGV
     PENFNEAKPI GFTMYTTCIV WLAFIPIFFG TAQSAEKLYI QTTTLTISMN LSASVALGML
     YMPKVYIIIF HPELNVQKRK RSFKAVVTAA TMSSRLSHKP SDRPNGEAKT ELCENVDPNS
     PAAKKKYVSY NNLVI
//
ID   GRM5_HUMAN              Reviewed;        1212 AA.
AC   P41594; Q6J164;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 2.
DT   07-OCT-2020, entry version 190.
DE   RecName: Full=Metabotropic glutamate receptor 5;
DE            Short=mGluR5;
DE   Flags: Precursor;
GN   Name=GRM5; Synonyms=GPRC1E, MGLUR5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, AND SUBCELLULAR
RP   LOCATION.
RC   TISSUE=Brain;
RX   PubMed=7908515; DOI=10.1006/bbrc.1994.1349;
RA   Minakami R., Katsuki F., Yamamoto T., Nakamura K., Sugiyama H.;
RT   "Molecular cloning and the functional expression of two isoforms of human
RT   metabotropic glutamate receptor subtype 5.";
RL   Biochem. Biophys. Res. Commun. 199:1136-1143(1994).
RN   [2]
RP   SEQUENCE REVISION.
RA   Katsuki F.;
RL   Submitted (JUL-1996) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RA   Levinthal C., Storjohann L., Hammerland L.G., Hung B.C.P., Krapcho K.J.,
RA   Logan M.A., Smith D.L., Trovato R., Vanwagenen B.C., Stormannn T.M.;
RT   "Molecular cloning and characterization of human metabotropic glutamate
RT   receptor 5d; a splice variant with reduced desensitization properties.";
RL   Abstr. - Soc. Neurosci. 25:976-976(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 860-952 (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=7688218; DOI=10.1006/bbrc.1993.1866;
RA   Minakami R., Katsuki F., Sugiyama H.;
RT   "A variant of metabotropic glutamate receptor subtype 5: an evolutionally
RT   conserved insertion with no termination codon.";
RL   Biochem. Biophys. Res. Commun. 194:622-627(1993).
RN   [6]
RP   INTERACTION WITH NECAB2.
RX   PubMed=19694902; DOI=10.1111/j.1471-4159.2009.06348.x;
RA   Canela L., Fernandez-Duenas V., Albergaria C., Watanabe M., Lluis C.,
RA   Mallol J., Canela E.I., Franco R., Lujan R., Ciruela F.;
RT   "The association of metabotropic glutamate receptor type 5 with the
RT   neuronal Ca2+-binding protein 2 modulates receptor function.";
RL   J. Neurochem. 111:555-567(2009).
RN   [7]
RP   INTERACTION WITH CAMK2A.
RX   PubMed=28130356; DOI=10.1523/jneurosci.2068-16.2017;
RA   Stephenson J.R., Wang X., Perfitt T.L., Parrish W.P., Shonesy B.C.,
RA   Marks C.R., Mortlock D.P., Nakagawa T., Sutcliffe J.S., Colbran R.J.;
RT   "Mutation Disrupts Dendritic Morphology and Synaptic Transmission, and
RT   Causes ASD-Related Behaviors.";
RL   J. Neurosci. 37:2216-2233(2017).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.44 ANGSTROMS) OF 18-505 IN COMPLEX WITH GLUTAMATE,
RP   GLYCOSYLATION AT ASN-445, AND DISULFIDE BONDS.
RG   Structural genomics consortium (SGC);
RT   "Metabotropic glutamate receptor MGluR5 complexed with glutamate.";
RL   Submitted (JUL-2011) to the PDB data bank.
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 569-836 IN COMPLEX WITH
RP   ALLOSTERIC EFFECTOR, FUNCTION, SUBCELLULAR LOCATION, TOPOLOGY, DISULFIDE
RP   BONDS, AND MUTAGENESIS OF SER-613; SER-614; LYS-665 AND GLU-770.
RX   PubMed=25042998; DOI=10.1038/nature13396;
RA   Dore A.S., Okrasa K., Patel J.C., Serrano-Vega M., Bennett K., Cooke R.M.,
RA   Errey J.C., Jazayeri A., Khan S., Tehan B., Weir M., Wiggin G.R.,
RA   Marshall F.H.;
RT   "Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane
RT   domain.";
RL   Nature 511:557-562(2014).
CC   -!- FUNCTION: G-protein coupled receptor for glutamate. Ligand binding
CC       causes a conformation change that triggers signaling via guanine
CC       nucleotide-binding proteins (G proteins) and modulates the activity of
CC       down-stream effectors. Signaling activates a phosphatidylinositol-
CC       calcium second messenger system and generates a calcium-activated
CC       chloride current. Plays an important role in the regulation of synaptic
CC       plasticity and the modulation of the neural network activity.
CC       {ECO:0000269|PubMed:25042998, ECO:0000269|PubMed:7908515}.
CC   -!- SUBUNIT: The PPXXF motif binds HOMER1, HOMER2 and HOMER3. Interacts
CC       with SIAH1, RYR1, RYR2, ITPR1, SHANK1, SHANK3 and TAMALIN. Interacts
CC       with NCDN (By similarity). Isoform 2 interacts with NECAB2
CC       (PubMed:19694902). Interacts with CAMK2A (PubMed:28130356).
CC       {ECO:0000250, ECO:0000269|PubMed:19694902,
CC       ECO:0000269|PubMed:28130356}.
CC   -!- INTERACTION:
CC       P41594; P41594: GRM5; NbExp=3; IntAct=EBI-6595175, EBI-6595175;
CC       P41594-1; Q7Z6G3: NECAB2; NbExp=2; IntAct=EBI-14039683, EBI-950070;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:25042998,
CC       ECO:0000269|PubMed:7908515}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:25042998, ECO:0000269|PubMed:7908515}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=2; Synonyms=5b;
CC         IsoId=P41594-1; Sequence=Displayed;
CC       Name=1; Synonyms=5a;
CC         IsoId=P41594-2; Sequence=VSP_002030;
CC       Name=3; Synonyms=5d;
CC         IsoId=P41594-3; Sequence=VSP_047710;
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 3 family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D28538; BAA05891.1; -; mRNA.
DR   EMBL; D28539; BAA05892.1; -; mRNA.
DR   EMBL; AY608336; AAT37960.1; -; mRNA.
DR   EMBL; AP000626; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP001482; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP001828; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP003120; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP006214; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP006215; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; S64316; AAD13954.1; -; mRNA.
DR   CCDS; CCDS44694.1; -. [P41594-1]
DR   CCDS; CCDS8283.1; -. [P41594-2]
DR   PIR; JC2131; JC2131.
DR   PIR; JC2132; JC2132.
DR   RefSeq; NP_000833.1; NM_000842.4. [P41594-2]
DR   RefSeq; NP_001137303.1; NM_001143831.2. [P41594-1]
DR   RefSeq; XP_006718891.1; XM_006718828.3. [P41594-1]
DR   RefSeq; XP_011541094.1; XM_011542792.1. [P41594-1]
DR   RefSeq; XP_016873116.1; XM_017017627.1. [P41594-2]
DR   PDB; 3LMK; X-ray; 2.44 A; A/B=18-505.
DR   PDB; 4OO9; X-ray; 2.60 A; A=569-836.
DR   PDB; 5CGC; X-ray; 3.10 A; A=569-836.
DR   PDB; 5CGD; X-ray; 2.60 A; A=569-836.
DR   PDB; 6N4X; X-ray; 4.00 A; A/B=20-865.
DR   PDB; 6N4Y; X-ray; 3.26 A; A/B/C/D=21-571.
DR   PDB; 6N50; X-ray; 3.75 A; A/B/C=21-571.
DR   PDB; 6N51; EM; 4.00 A; A/B=23-826.
DR   PDB; 6N52; EM; 4.00 A; A/B=20-839.
DR   PDBsum; 3LMK; -.
DR   PDBsum; 4OO9; -.
DR   PDBsum; 5CGC; -.
DR   PDBsum; 5CGD; -.
DR   PDBsum; 6N4X; -.
DR   PDBsum; 6N4Y; -.
DR   PDBsum; 6N50; -.
DR   PDBsum; 6N51; -.
DR   PDBsum; 6N52; -.
DR   SMR; P41594; -.
DR   BioGRID; 109172; 10.
DR   IntAct; P41594; 5.
DR   STRING; 9606.ENSP00000306138; -.
DR   BindingDB; P41594; -.
DR   ChEMBL; CHEMBL3227; -.
DR   DrugBank; DB00659; Acamprosate.
DR   DrugBank; DB05070; ADX10059.
DR   DrugBank; DB12733; Dipraglurant.
DR   DrugBank; DB06201; Rufinamide.
DR   DrugCentral; P41594; -.
DR   GuidetoPHARMACOLOGY; 293; -.
DR   GlyGen; P41594; 6 sites.
DR   iPTMnet; P41594; -.
DR   PhosphoSitePlus; P41594; -.
DR   BioMuta; GRM5; -.
DR   DMDM; 1709020; -.
DR   jPOST; P41594; -.
DR   MassIVE; P41594; -.
DR   PaxDb; P41594; -.
DR   PeptideAtlas; P41594; -.
DR   PRIDE; P41594; -.
DR   ProteomicsDB; 55471; -. [P41594-1]
DR   ProteomicsDB; 55472; -. [P41594-2]
DR   ProteomicsDB; 66504; -.
DR   ABCD; P41594; 3 sequenced antibodies.
DR   Antibodypedia; 2950; 535 antibodies.
DR   Ensembl; ENST00000305432; ENSP00000305905; ENSG00000168959. [P41594-2]
DR   Ensembl; ENST00000305447; ENSP00000306138; ENSG00000168959. [P41594-1]
DR   Ensembl; ENST00000455756; ENSP00000405690; ENSG00000168959. [P41594-2]
DR   GeneID; 2915; -.
DR   KEGG; hsa:2915; -.
DR   UCSC; uc001pcq.4; human. [P41594-1]
DR   CTD; 2915; -.
DR   DisGeNET; 2915; -.
DR   EuPathDB; HostDB:ENSG00000168959.14; -.
DR   GeneCards; GRM5; -.
DR   HGNC; HGNC:4597; GRM5.
DR   HPA; ENSG00000168959; Tissue enriched (brain).
DR   MIM; 604102; gene.
DR   neXtProt; NX_P41594; -.
DR   OpenTargets; ENSG00000168959; -.
DR   PharmGKB; PA28994; -.
DR   eggNOG; KOG1056; Eukaryota.
DR   GeneTree; ENSGT00950000182807; -.
DR   HOGENOM; CLU_005389_0_1_1; -.
DR   InParanoid; P41594; -.
DR   KO; K04604; -.
DR   OMA; SLCPGYQ; -.
DR   OrthoDB; 107675at2759; -.
DR   PhylomeDB; P41594; -.
DR   TreeFam; TF313240; -.
DR   PathwayCommons; P41594; -.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-420499; Class C/3 (Metabotropic glutamate/pheromone receptors).
DR   Reactome; R-HSA-6794361; Neurexins and neuroligins.
DR   SignaLink; P41594; -.
DR   SIGNOR; P41594; -.
DR   BioGRID-ORCS; 2915; 5 hits in 873 CRISPR screens.
DR   ChiTaRS; GRM5; human.
DR   EvolutionaryTrace; P41594; -.
DR   GenomeRNAi; 2915; -.
DR   Pharos; P41594; Tchem.
DR   PRO; PR:P41594; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; P41594; protein.
DR   Bgee; ENSG00000168959; Expressed in frontal cortex and 124 other tissues.
DR   ExpressionAtlas; P41594; baseline and differential.
DR   Genevisible; P41594; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; IMP:UniProtKB.
DR   GO; GO:0043005; C:neuron projection; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0098839; C:postsynaptic density membrane; IBA:GO_Central.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IMP:UniProtKB.
DR   GO; GO:0099530; F:G protein-coupled receptor activity involved in regulation of postsynaptic membrane potential; IBA:GO_Central.
DR   GO; GO:0008066; F:glutamate receptor activity; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0099583; F:neurotransmitter receptor activity involved in regulation of postsynaptic cytosolic calcium ion concentration; IBA:GO_Central.
DR   GO; GO:0030296; F:protein tyrosine kinase activator activity; TAS:ARUK-UCL.
DR   GO; GO:1990782; F:protein tyrosine kinase binding; ISS:ARUK-UCL.
DR   GO; GO:0035584; P:calcium-mediated signaling using intracellular calcium source; IGI:ARUK-UCL.
DR   GO; GO:1904646; P:cellular response to amyloid-beta; IGI:ARUK-UCL.
DR   GO; GO:0007268; P:chemical synaptic transmission; TAS:ProtInc.
DR   GO; GO:0050890; P:cognition; IMP:UniProtKB.
DR   GO; GO:0007216; P:G protein-coupled glutamate receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007612; P:learning; IEA:Ensembl.
DR   GO; GO:0007611; P:learning or memory; ISS:ARUK-UCL.
DR   GO; GO:0007626; P:locomotory behavior; IEA:Ensembl.
DR   GO; GO:0090647; P:modulation of age-related behavioral decline; ISS:ARUK-UCL.
DR   GO; GO:0007206; P:phospholipase C-activating G protein-coupled glutamate receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0061098; P:positive regulation of protein tyrosine kinase activity; ISS:ARUK-UCL.
DR   GO; GO:1902938; P:regulation of intracellular calcium activated chloride channel activity; IGI:ARUK-UCL.
DR   GO; GO:0048169; P:regulation of long-term neuronal synaptic plasticity; IEA:Ensembl.
DR   GO; GO:0001932; P:regulation of protein phosphorylation; IGI:ARUK-UCL.
DR   GO; GO:0051966; P:regulation of synaptic transmission, glutamatergic; IBA:GO_Central.
DR   GO; GO:0006417; P:regulation of translation; TAS:ARUK-UCL.
DR   GO; GO:0006448; P:regulation of translational elongation; IGI:ARUK-UCL.
DR   GO; GO:0050808; P:synapse organization; ISS:ARUK-UCL.
DR   GO; GO:0099553; P:trans-synaptic signaling by endocannabinoid, modulating synaptic transmission; IBA:GO_Central.
DR   Gene3D; 2.10.50.30; -; 1.
DR   InterPro; IPR001828; ANF_lig-bd_rcpt.
DR   InterPro; IPR000337; GPCR_3.
DR   InterPro; IPR011500; GPCR_3_9-Cys_dom.
DR   InterPro; IPR038550; GPCR_3_9-Cys_sf.
DR   InterPro; IPR017978; GPCR_3_C.
DR   InterPro; IPR017979; GPCR_3_CS.
DR   InterPro; IPR000162; GPCR_3_mtglu_rcpt.
DR   InterPro; IPR000202; GPCR_3_mtglu_rcpt_5.
DR   InterPro; IPR019588; Metabotropic_Glu_rcpt_Homer-bd.
DR   InterPro; IPR028082; Peripla_BP_I.
DR   Pfam; PF00003; 7tm_3; 1.
DR   Pfam; PF01094; ANF_receptor; 1.
DR   Pfam; PF10606; GluR_Homer-bdg; 1.
DR   Pfam; PF07562; NCD3G; 1.
DR   PRINTS; PR00248; GPCRMGR.
DR   PRINTS; PR01055; MTABOTROPC5R.
DR   PRINTS; PR00593; MTABOTROPICR.
DR   SMART; SM01229; GluR_Homer-bdg; 1.
DR   SUPFAM; SSF53822; SSF53822; 1.
DR   PROSITE; PS00979; G_PROTEIN_RECEP_F3_1; 1.
DR   PROSITE; PS00980; G_PROTEIN_RECEP_F3_2; 1.
DR   PROSITE; PS00981; G_PROTEIN_RECEP_F3_3; 1.
DR   PROSITE; PS50259; G_PROTEIN_RECEP_F3_4; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Methylation;
KW   Phosphoprotein; Receptor; Reference proteome; Signal; Transducer;
KW   Transmembrane; Transmembrane helix.
FT   SIGNAL          1..20
FT                   /evidence="ECO:0000255"
FT   CHAIN           21..1212
FT                   /note="Metabotropic glutamate receptor 5"
FT                   /id="PRO_0000012932"
FT   TOPO_DOM        22..580
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:25042998"
FT   TRANSMEM        581..603
FT                   /note="Helical; Name=1"
FT   TOPO_DOM        604..613
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:25042998"
FT   TRANSMEM        614..636
FT                   /note="Helical; Name=2"
FT   TOPO_DOM        637..644
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:25042998"
FT   TRANSMEM        645..667
FT                   /note="Helical; Name=3"
FT   TOPO_DOM        668..693
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:25042998"
FT   TRANSMEM        694..714
FT                   /note="Helical; Name=4"
FT   TOPO_DOM        715..737
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:25042998"
FT   TRANSMEM        738..759
FT                   /note="Helical; Name=5"
FT   TOPO_DOM        760..772
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:25042998"
FT   TRANSMEM        773..795
FT                   /note="Helical; Name=6"
FT   TOPO_DOM        796..798
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:25042998"
FT   TRANSMEM        799..820
FT                   /note="Helical; Name=7"
FT   TOPO_DOM        821..1212
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:25042998"
FT   REGION          173..175
FT                   /note="Glutamate binding"
FT   REGION          805..809
FT                   /note="Allosteric effector binding"
FT   BINDING         64
FT                   /note="Glutamate"
FT                   /evidence="ECO:0000269|Ref.8"
FT   BINDING         152
FT                   /note="Glutamate"
FT                   /evidence="ECO:0000269|Ref.8"
FT   BINDING         223
FT                   /note="Glutamate"
FT                   /evidence="ECO:0000269|Ref.8"
FT   BINDING         305
FT                   /note="Glutamate"
FT                   /evidence="ECO:0000269|Ref.8"
FT   BINDING         396
FT                   /note="Glutamate"
FT                   /evidence="ECO:0000269|Ref.8"
FT   MOD_RES         861
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P31424"
FT   MOD_RES         869
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UVX5"
FT   MOD_RES         925
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UVX5"
FT   MOD_RES         1018
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UVX5"
FT   MOD_RES         1020
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q3UVX5"
FT   CARBOHYD        88
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        210
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        378
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        382
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        445
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|Ref.8"
FT   CARBOHYD        734
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        57..99
FT   DISULFID        241..530
FT                   /evidence="ECO:0000250"
FT   DISULFID        276..278
FT   DISULFID        365..381
FT   DISULFID        419..426
FT   DISULFID        511..531
FT                   /evidence="ECO:0000250"
FT   DISULFID        515..534
FT                   /evidence="ECO:0000250"
FT   DISULFID        537..549
FT                   /evidence="ECO:0000250"
FT   DISULFID        552..565
FT                   /evidence="ECO:0000250"
FT   DISULFID        644..733
FT   VAR_SEQ         877..908
FT                   /note="Missing (in isoform 1)"
FT                   /evidence="ECO:0000303|PubMed:7908515"
FT                   /id="VSP_002030"
FT   VAR_SEQ         896..1165
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.3"
FT                   /id="VSP_047710"
FT   MUTAGEN         613
FT                   /note="S->A,K: Increased constitutive signaling activity."
FT                   /evidence="ECO:0000269|PubMed:25042998"
FT   MUTAGEN         614
FT                   /note="S->D: Decreased constitutive signaling activity."
FT                   /evidence="ECO:0000269|PubMed:25042998"
FT   MUTAGEN         665
FT                   /note="K->A: Increased constitutive signaling activity."
FT                   /evidence="ECO:0000269|PubMed:25042998"
FT   MUTAGEN         770
FT                   /note="E->A: Increased constitutive signaling activity."
FT                   /evidence="ECO:0000269|PubMed:25042998"
FT   STRAND          29..31
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   STRAND          34..41
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   STRAND          49..51
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   TURN            52..55
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   TURN            62..65
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   HELIX           66..81
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   STRAND          83..86
FT                   /evidence="ECO:0000244|PDB:6N4Y"
FT   STRAND          91..97
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   HELIX           102..112
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   STRAND          143..147
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   HELIX           152..162
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   HELIX           163..165
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   STRAND          169..173
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   HELIX           177..180
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   TURN            182..184
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   STRAND          188..192
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   HELIX           195..208
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   STRAND          213..219
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   HELIX           222..235
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   TURN            236..239
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   STRAND          241..248
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   HELIX           254..267
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   TURN            268..270
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   STRAND          273..277
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   HELIX           280..293
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   STRAND          300..303
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   TURN            307..309
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   HELIX           311..314
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   HELIX           318..321
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   STRAND          325..329
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   HELIX           335..342
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   TURN            346..348
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   HELIX           355..363
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   STRAND          378..380
FT                   /evidence="ECO:0000244|PDB:6N4Y"
FT   TURN            387..390
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   HELIX           397..418
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   HELIX           427..429
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   HELIX           434..441
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   STRAND          445..447
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   STRAND          449..451
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   STRAND          453..455
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   STRAND          466..475
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   STRAND          479..488
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   STRAND          491..494
FT                   /evidence="ECO:0000244|PDB:3LMK"
FT   STRAND          522..524
FT                   /evidence="ECO:0000244|PDB:6N4Y"
FT   STRAND          532..534
FT                   /evidence="ECO:0000244|PDB:6N4Y"
FT   STRAND          545..547
FT                   /evidence="ECO:0000244|PDB:6N4Y"
FT   HELIX           569..575
FT                   /evidence="ECO:0000244|PDB:4OO9"
FT   HELIX           579..603
FT                   /evidence="ECO:0000244|PDB:4OO9"
FT   TURN            604..606
FT                   /evidence="ECO:0000244|PDB:4OO9"
FT   HELIX           608..611
FT                   /evidence="ECO:0000244|PDB:4OO9"
FT   HELIX           615..630
FT                   /evidence="ECO:0000244|PDB:4OO9"
FT   HELIX           632..635
FT                   /evidence="ECO:0000244|PDB:4OO9"
FT   HELIX           641..678
FT                   /evidence="ECO:0000244|PDB:4OO9"
FT   HELIX           690..714
FT                   /evidence="ECO:0000244|PDB:4OO9"
FT   HELIX           738..760
FT                   /evidence="ECO:0000244|PDB:4OO9"
FT   TURN            761..763
FT                   /evidence="ECO:0000244|PDB:4OO9"
FT   HELIX           766..793
FT                   /evidence="ECO:0000244|PDB:4OO9"
FT   HELIX           798..817
FT                   /evidence="ECO:0000244|PDB:4OO9"
FT   HELIX           819..827
FT                   /evidence="ECO:0000244|PDB:4OO9"
FT   TURN            829..831
FT                   /evidence="ECO:0000244|PDB:4OO9"
SQ   SEQUENCE   1212 AA;  132469 MW;  A3C73606681C6A25 CRC64;
     MVLLLILSVL LLKEDVRGSA QSSERRVVAH MPGDIIIGAL FSVHHQPTVD KVHERKCGAV
     REQYGIQRVE AMLHTLERIN SDPTLLPNIT LGCEIRDSCW HSAVALEQSI EFIRDSLISS
     EEEEGLVRCV DGSSSSFRSK KPIVGVIGPG SSSVAIQVQN LLQLFNIPQI AYSATSMDLS
     DKTLFKYFMR VVPSDAQQAR AMVDIVKRYN WTYVSAVHTE GNYGESGMEA FKDMSAKEGI
     CIAHSYKIYS NAGEQSFDKL LKKLTSHLPK ARVVACFCEG MTVRGLLMAM RRLGLAGEFL
     LLGSDGWADR YDVTDGYQRE AVGGITIKLQ SPDVKWFDDY YLKLRPETNH RNPWFQEFWQ
     HRFQCRLEGF PQENSKYNKT CNSSLTLKTH HVQDSKMGFV INAIYSMAYG LHNMQMSLCP
     GYAGLCDAMK PIDGRKLLES LMKTNFTGVS GDTILFDENG DSPGRYEIMN FKEMGKDYFD
     YINVGSWDNG ELKMDDDEVW SKKSNIIRSV CSEPCEKGQI KVIRKGEVSC CWTCTPCKEN
     EYVFDEYTCK ACQLGSWPTD DLTGCDLIPV QYLRWGDPEP IAAVVFACLG LLATLFVTVV
     FIIYRDTPVV KSSSRELCYI ILAGICLGYL CTFCLIAKPK QIYCYLQRIG IGLSPAMSYS
     ALVTKTNRIA RILAGSKKKI CTKKPRFMSA CAQLVIAFIL ICIQLGIIVA LFIMEPPDIM
     HDYPSIREVY LICNTTNLGV VTPLGYNGLL ILSCTFYAFK TRNVPANFNE AKYIAFTMYT
     TCIIWLAFVP IYFGSNYKII TMCFSVSLSA TVALGCMFVP KVYIILAKPE RNVRSAFTTS
     TVVRMHVGDG KSSSAASRSS SLVNLWKRRG SSGETLRYKD RRLAQHKSEI ECFTPKGSMG
     NGGRATMSSS NGKSVTWAQN EKSSRGQHLW QRLSIHINKK ENPNQTAVIK PFPKSTESRG
     LGAGAGAGGS AGGVGATGGA GCAGAGPGGP ESPDAGPKAL YDVAEAEEHF PAPARPRSPS
     PISTLSHRAG SASRTDDDVP SLHSEPVARS SSSQGSLMEQ ISSVVTRFTA NISELNSMML
     STAAPSPGVG APLCSSYLIP KEIQLPTTMT TFAEIQPLPA IEVTGGAQPA AGAQAAGDAA
     RESPAAGPEA AAAKPDLEEL VALTPPSPFR DSVDSGSTTP NSPVSESALC IPSSPKYDTL
     IIRDYTQSSS SL
//
ID   GLP1R_HUMAN             Reviewed;         463 AA.
AC   P43220; Q2M229; Q99669;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   02-NOV-2010, sequence version 2.
DT   07-OCT-2020, entry version 194.
DE   RecName: Full=Glucagon-like peptide 1 receptor;
DE            Short=GLP-1 receptor;
DE            Short=GLP-1-R;
DE            Short=GLP-1R;
DE   Flags: Precursor;
GN   Name=GLP1R;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, AND VARIANT
RP   PHE-260.
RC   TISSUE=Pancreatic islet;
RX   PubMed=8405712; DOI=10.2337/diab.42.11.1678;
RA   Thorens B., Porret A., Buehler L., Deng S., Morel P., Widmann C.;
RT   "Cloning and functional expression of the human islet GLP-1 receptor.
RT   Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist
RT   of the receptor.";
RL   Diabetes 42:1678-1682(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT PHE-260.
RC   TISSUE=Pancreas;
RX   PubMed=8404634; DOI=10.1210/endo.133.4.8404634;
RA   Dillon J.S., Tanizawa Y., Wheeler M.B., Leng X., Ligon B.B., Rabin D.U.,
RA   Yoo-Warren H., Permutt M., Boyd A.E.;
RT   "Cloning and functional expression of the human glucagon-like peptide-1
RT   (GLP-1) receptor.";
RL   Endocrinology 133:1907-1910(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, AND VARIANT
RP   PHE-260.
RC   TISSUE=Gastric carcinoma;
RX   PubMed=8216285; DOI=10.1006/bbrc.1993.2226;
RA   Graziano M.P., Hey P.J., Borkowski D., Chicchi G.C., Strader C.D.;
RT   "Cloning and functional expression of a human glucagon-like peptide-1
RT   receptor.";
RL   Biochem. Biophys. Res. Commun. 196:141-146(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND SUBCELLULAR LOCATION.
RC   TISSUE=Insulinoma;
RX   PubMed=7517895; DOI=10.1016/0014-5793(94)00553-2;
RA   van Eyll B., Lankat-Buttgereit B., Bode H.P., Goeke R., Goeke B.;
RT   "Signal transduction of the GLP-1-receptor cloned from a human
RT   insulinoma.";
RL   FEBS Lett. 348:7-13(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT PHE-260.
RC   TISSUE=Pancreas;
RX   PubMed=7843404; DOI=10.1016/0014-5793(94)01430-9;
RA   Wei Y., Mojsov S.;
RT   "Tissue-specific expression of the human receptor for glucagon-like
RT   peptide-I: brain, heart and pancreatic forms have the same deduced amino
RT   acid sequences.";
RL   FEBS Lett. 358:219-224(1995).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Suwa M., Sato T., Okouchi I., Arita M., Futami K., Matsumoto S.,
RA   Tsutsumi S., Aburatani H., Asai K., Akiyama Y.;
RT   "Genome-wide discovery and analysis of human seven transmembrane helix
RT   receptor genes.";
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LEU-7; LYS-20; HIS-44;
RP   GLN-131; SER-168; PHE-260; THR-316; CYS-333 AND GLN-421.
RG   NIEHS SNPs program;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT PHE-260.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-26.
RC   TISSUE=Placenta;
RX   PubMed=9213353; DOI=10.1016/s0196-9781(97)00001-6;
RA   Lankat-Buttgereit B., Goeke B.;
RT   "Cloning and characterization of the 5' flanking sequences (promoter
RT   region) of the human GLP-1 receptor gene.";
RL   Peptides 18:617-624(1997).
RN   [11]
RP   DISULFIDE BOND.
RX   PubMed=20869417; DOI=10.1016/j.peptides.2010.09.015;
RA   Mann R.J., Al-Sabah S., de Maturana R.L., Sinfield J.K., Donnelly D.;
RT   "Functional coupling of Cys-226 and Cys-296 in the glucagon-like peptide-1
RT   (GLP-1) receptor indicates a disulfide bond that is close to the activation
RT   pocket.";
RL   Peptides 31:2289-2293(2010).
RN   [12]
RP   ADP-RIBOSYLATION AT CYS-341 AND ARG-348.
RX   PubMed=21901419; DOI=10.1007/s11033-011-1225-0;
RA   Dezelak M., Bavec A.;
RT   "Glucagon like-peptide-1 receptor is covalently modified by endogenous
RT   mono-ADP-ribosyltransferase.";
RL   Mol. Biol. Rep. 39:4375-4381(2012).
RN   [13]
RP   GLYCOSYLATION AT ASN-63; ASN-82 AND ASN-115, AND SUBUNIT.
RX   PubMed=22412906; DOI=10.1371/journal.pone.0032675;
RA   Whitaker G.M., Lynn F.C., McIntosh C.H., Accili E.A.;
RT   "Regulation of GIP and GLP1 receptor cell surface expression by N-
RT   glycosylation and receptor heteromerization.";
RL   PLoS ONE 7:E32675-E32675(2012).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 24-145 IN COMPLEX WITH ANTAGONIST
RP   EXENDIN-4, AND DISULFIDE BONDS.
RX   PubMed=18287102; DOI=10.1074/jbc.m708740200;
RA   Runge S., Thogersen H., Madsen K., Lau J., Rudolph R.;
RT   "Crystal structure of the ligand-bound glucagon-like peptide-1 receptor
RT   extracellular domain.";
RL   J. Biol. Chem. 283:11340-11347(2008).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 24-145 IN COMPLEX WITH
RP   GLUCAGON-LIKE PEPTIDE-1, FUNCTION, SUBCELLULAR LOCATION, DISULFIDE BONDS,
RP   AND MUTAGENESIS OF LEU-32; TYR-69; TYR-88; LEU-89; PRO-90; ARG-121; GLU-127
RP   AND GLU-128.
RX   PubMed=19861722; DOI=10.1074/jbc.m109.033829;
RA   Underwood C.R., Garibay P., Knudsen L.B., Hastrup S., Peters G.H.,
RA   Rudolph R., Reedtz-Runge S.;
RT   "Crystal structure of glucagon-like peptide-1 in complex with the
RT   extracellular domain of the glucagon-like peptide-1 receptor.";
RL   J. Biol. Chem. 285:723-730(2010).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 24-145, FUNCTION, SUBCELLULAR
RP   LOCATION, AND DISULFIDE BONDS.
RX   PubMed=26308095; DOI=10.1021/acs.jmedchem.5b00726;
RA   Lau J., Bloch P., Schaeffer L., Pettersson I., Spetzler J., Kofoed J.,
RA   Madsen K., Knudsen L.B., McGuire J., Steensgaard D.B., Strauss H.M.,
RA   Gram D.X., Knudsen S.M., Nielsen F.S., Thygesen P., Reedtz-Runge S.,
RA   Kruse T.;
RT   "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue
RT   Semaglutide.";
RL   J. Med. Chem. 58:7370-7380(2015).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 24-145, FUNCTION, SUBCELLULAR
RP   LOCATION, AND DISULFIDE BONDS.
RX   PubMed=27196125; DOI=10.1038/srep26236;
RA   Hennen S., Kodra J.T., Soroka V., Krogh B.O., Wu X., Kaastrup P.,
RA   Oerskov C., Roenn S.G., Schluckebier G., Barbateskovic S., Gandhi P.S.,
RA   Reedtz-Runge S.;
RT   "Structural insight into antibody-mediated antagonism of the Glucagon-like
RT   peptide-1 Receptor.";
RL   Sci. Rep. 6:26236-26236(2016).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 128-431 IN COMPLEXES WITH
RP   ALLOSTERIC MODULATORS, FUNCTION, ACTIVITY REGULATION, SUBCELLULAR LOCATION,
RP   TOPOLOGY, DISULFIDE BOND, AND MUTAGENESIS OF ARG-176; ILE-317; SER-352;
RP   THR-355 AND GLY-361.
RX   PubMed=28514449; DOI=10.1038/nature22378;
RA   Song G., Yang D., Wang Y., de Graaf C., Zhou Q., Jiang S., Liu K., Cai X.,
RA   Dai A., Lin G., Liu D., Wu F., Wu Y., Zhao S., Ye L., Han G.W., Lau J.,
RA   Wu B., Hanson M.A., Liu Z.J., Wang M.W., Stevens R.C.;
RT   "Human GLP-1 receptor transmembrane domain structure in complex with
RT   allosteric modulators.";
RL   Nature 546:312-315(2017).
CC   -!- FUNCTION: G-protein coupled receptor for glucagon-like peptide 1 (GLP-
CC       1) (PubMed:8405712, PubMed:8216285, PubMed:7517895, PubMed:19861722,
CC       PubMed:26308095, PubMed:27196125, PubMed:28514449). Ligand binding
CC       triggers activation of a signaling cascade that leads to the activation
CC       of adenylyl cyclase and increased intracellular cAMP levels
CC       (PubMed:8405712, PubMed:8216285, PubMed:7517895, PubMed:19861722,
CC       PubMed:26308095, PubMed:27196125, PubMed:28514449). Plays a role in
CC       regulating insulin secretion in response to GLP-1 (By similarity).
CC       {ECO:0000250|UniProtKB:O35659, ECO:0000269|PubMed:19861722,
CC       ECO:0000269|PubMed:26308095, ECO:0000269|PubMed:27196125,
CC       ECO:0000269|PubMed:28514449, ECO:0000269|PubMed:7517895,
CC       ECO:0000269|PubMed:8216285, ECO:0000269|PubMed:8405712}.
CC   -!- ACTIVITY REGULATION: The allosteric modulators NNC0640, PF-06372222 and
CC       MK-0893 inhibit the increase of intracellular cAMP levels in response
CC       to GLP-1. {ECO:0000269|PubMed:28514449}.
CC   -!- SUBUNIT: May form homodimers and heterodimers with GIPR.
CC       {ECO:0000269|PubMed:18287102, ECO:0000269|PubMed:22412906}.
CC   -!- INTERACTION:
CC       P43220; A8MQ03: CYSRT1; NbExp=3; IntAct=EBI-7466542, EBI-3867333;
CC       P43220; Q07627: KRTAP1-1; NbExp=3; IntAct=EBI-7466542, EBI-11959885;
CC       P43220; P60409: KRTAP10-7; NbExp=3; IntAct=EBI-7466542, EBI-10172290;
CC       P43220; P60410: KRTAP10-8; NbExp=3; IntAct=EBI-7466542, EBI-10171774;
CC       P43220; P60411: KRTAP10-9; NbExp=3; IntAct=EBI-7466542, EBI-10172052;
CC       P43220; Q9BYP8: KRTAP17-1; NbExp=3; IntAct=EBI-7466542, EBI-11988175;
CC       P43220; P26371: KRTAP5-9; NbExp=3; IntAct=EBI-7466542, EBI-3958099;
CC       P43220; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-7466542, EBI-945833;
CC       P43220; P0DPK4: NOTCH2NLC; NbExp=3; IntAct=EBI-7466542, EBI-22310682;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:19861722,
CC       ECO:0000269|PubMed:26308095, ECO:0000269|PubMed:27196125,
CC       ECO:0000269|PubMed:28514449, ECO:0000269|PubMed:7517895,
CC       ECO:0000269|PubMed:8216285, ECO:0000269|PubMed:8405712}; Multi-pass
CC       membrane protein {ECO:0000269|PubMed:28514449}.
CC   -!- PTM: N-glycosylation enhances cell surface expression and lengthens
CC       receptor half-life by preventing degradation in the ER.
CC       {ECO:0000269|PubMed:22412906}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 2 family.
CC       {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/glp1r/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Glucagon-like peptide 1 entry;
CC       URL="https://en.wikipedia.org/wiki/Glucagon-like_peptide-1";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U01104; AAA03614.1; -; mRNA.
DR   EMBL; U01157; AAA62471.1; -; mRNA.
DR   EMBL; U01156; AAC50050.1; -; mRNA.
DR   EMBL; L23503; AAA17021.1; -; mRNA.
DR   EMBL; U10037; AAA63787.1; -; mRNA.
DR   EMBL; AB065685; BAC05908.1; -; Genomic_DNA.
DR   EMBL; AY439112; AAR05444.1; -; Genomic_DNA.
DR   EMBL; AL035690; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC112126; AAI12127.1; -; mRNA.
DR   EMBL; BC113493; AAI13494.1; -; mRNA.
DR   EMBL; U66062; AAB64013.1; -; Genomic_DNA.
DR   CCDS; CCDS4839.1; -.
DR   PIR; I84494; I84494.
DR   PIR; S71624; S71624.
DR   RefSeq; NP_002053.3; NM_002062.4.
DR   PDB; 3C59; X-ray; 2.30 A; A=24-145.
DR   PDB; 3C5T; X-ray; 2.10 A; A=24-145.
DR   PDB; 3IOL; X-ray; 2.10 A; A=24-145.
DR   PDB; 4ZGM; X-ray; 1.80 A; A=24-145.
DR   PDB; 5E94; X-ray; 2.00 A; G/H=24-145.
DR   PDB; 5NX2; X-ray; 3.70 A; A=24-432.
DR   PDB; 5OTT; X-ray; 1.92 A; A=24-139.
DR   PDB; 5OTU; X-ray; 1.80 A; A/C=24-139.
DR   PDB; 5OTV; X-ray; 2.00 A; A/C=24-139.
DR   PDB; 5OTW; X-ray; 2.10 A; A/C=24-139.
DR   PDB; 5OTX; X-ray; 2.00 A; A/C=24-139.
DR   PDB; 5VEW; X-ray; 2.70 A; A/B=128-257, A/B=261-431.
DR   PDB; 5VEX; X-ray; 3.00 A; A/B=128-257, A/B=261-431.
DR   PDB; 6B3J; EM; 3.30 A; R=24-463.
DR   PDB; 6GB1; X-ray; 2.73 A; A=21-145.
DR   PDB; 6ORV; EM; 3.00 A; RP=24-463.
DR   PDB; 6VCB; EM; 3.30 A; R=24-422.
DR   PDBsum; 3C59; -.
DR   PDBsum; 3C5T; -.
DR   PDBsum; 3IOL; -.
DR   PDBsum; 4ZGM; -.
DR   PDBsum; 5E94; -.
DR   PDBsum; 5NX2; -.
DR   PDBsum; 5OTT; -.
DR   PDBsum; 5OTU; -.
DR   PDBsum; 5OTV; -.
DR   PDBsum; 5OTW; -.
DR   PDBsum; 5OTX; -.
DR   PDBsum; 5VEW; -.
DR   PDBsum; 5VEX; -.
DR   PDBsum; 6B3J; -.
DR   PDBsum; 6GB1; -.
DR   PDBsum; 6ORV; -.
DR   PDBsum; 6VCB; -.
DR   SMR; P43220; -.
DR   BioGRID; 109002; 260.
DR   DIP; DIP-29980N; -.
DR   IntAct; P43220; 11.
DR   MINT; P43220; -.
DR   STRING; 9606.ENSP00000362353; -.
DR   BindingDB; P43220; -.
DR   ChEMBL; CHEMBL1784; -.
DR   DrugBank; DB09043; Albiglutide.
DR   DrugBank; DB09045; Dulaglutide.
DR   DrugBank; DB01276; Exenatide.
DR   DrugBank; DB00040; Glucagon.
DR   DrugBank; DB06655; Liraglutide.
DR   DrugBank; DB09265; Lixisenatide.
DR   DrugBank; DB13928; Semaglutide.
DR   DrugCentral; P43220; -.
DR   GuidetoPHARMACOLOGY; 249; -.
DR   TCDB; 9.A.14.4.6; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; P43220; 3 sites.
DR   iPTMnet; P43220; -.
DR   PhosphoSitePlus; P43220; -.
DR   BioMuta; GLP1R; -.
DR   DMDM; 311033387; -.
DR   PaxDb; P43220; -.
DR   PeptideAtlas; P43220; -.
DR   PRIDE; P43220; -.
DR   ProteomicsDB; 55596; -.
DR   ABCD; P43220; 1 sequenced antibody.
DR   Antibodypedia; 15682; 532 antibodies.
DR   DNASU; 2740; -.
DR   Ensembl; ENST00000373256; ENSP00000362353; ENSG00000112164.
DR   GeneID; 2740; -.
DR   KEGG; hsa:2740; -.
DR   UCSC; uc003ooj.5; human.
DR   CTD; 2740; -.
DR   DisGeNET; 2740; -.
DR   EuPathDB; HostDB:ENSG00000112164.5; -.
DR   GeneCards; GLP1R; -.
DR   HGNC; HGNC:4324; GLP1R.
DR   HPA; ENSG00000112164; Tissue enhanced (pancreas).
DR   MIM; 138032; gene.
DR   neXtProt; NX_P43220; -.
DR   OpenTargets; ENSG00000112164; -.
DR   PharmGKB; PA28725; -.
DR   eggNOG; KOG4564; Eukaryota.
DR   GeneTree; ENSGT00940000161009; -.
DR   HOGENOM; CLU_002753_4_0_1; -.
DR   InParanoid; P43220; -.
DR   KO; K04581; -.
DR   OMA; CRLVFVM; -.
DR   OrthoDB; 651627at2759; -.
DR   PhylomeDB; P43220; -.
DR   TreeFam; TF315710; -.
DR   PathwayCommons; P43220; -.
DR   Reactome; R-HSA-381676; Glucagon-like Peptide-1 (GLP1) regulates insulin secretion.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-420092; Glucagon-type ligand receptors.
DR   Reactome; R-HSA-9660821; ADORA2B mediated anti-inflammatory cytokines production.
DR   SIGNOR; P43220; -.
DR   BioGRID-ORCS; 2740; 5 hits in 873 CRISPR screens.
DR   EvolutionaryTrace; P43220; -.
DR   GeneWiki; Glucagon-like_peptide_1_receptor; -.
DR   GenomeRNAi; 2740; -.
DR   Pharos; P43220; Tclin.
DR   PRO; PR:P43220; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; P43220; protein.
DR   Bgee; ENSG00000112164; Expressed in myocardium and 171 other tissues.
DR   Genevisible; P43220; HS.
DR   GO; GO:0016021; C:integral component of membrane; TAS:ProtInc.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0008528; F:G protein-coupled peptide receptor activity; IBA:GO_Central.
DR   GO; GO:0004967; F:glucagon receptor activity; IEA:InterPro.
DR   GO; GO:0044508; F:glucagon-like peptide 1 receptor activity; IDA:UniProtKB.
DR   GO; GO:0017046; F:peptide hormone binding; IBA:GO_Central.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; TAS:ProtInc.
DR   GO; GO:0007190; P:activation of adenylate cyclase activity; TAS:ProtInc.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007188; P:adenylate cyclase-modulating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0019933; P:cAMP-mediated signaling; IDA:UniProtKB.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IEA:InterPro.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007611; P:learning or memory; IEA:Ensembl.
DR   GO; GO:0045777; P:positive regulation of blood pressure; IBA:GO_Central.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IDA:UniProtKB.
DR   GO; GO:0008016; P:regulation of heart contraction; IEA:Ensembl.
DR   GO; GO:0050796; P:regulation of insulin secretion; TAS:Reactome.
DR   GO; GO:1990911; P:response to psychosocial stress; IEA:Ensembl.
DR   Gene3D; 4.10.1240.10; -; 1.
DR   InterPro; IPR017981; GPCR_2-like.
DR   InterPro; IPR036445; GPCR_2_extracell_dom_sf.
DR   InterPro; IPR001879; GPCR_2_extracellular_dom.
DR   InterPro; IPR003290; GPCR_2_GLP1/glucagon_rcpt.
DR   InterPro; IPR003292; GPCR_2_GLP1_rcpt.
DR   InterPro; IPR000832; GPCR_2_secretin-like.
DR   InterPro; IPR017983; GPCR_2_secretin-like_CS.
DR   PANTHER; PTHR45620:SF25; PTHR45620:SF25; 1.
DR   Pfam; PF00002; 7tm_2; 1.
DR   Pfam; PF02793; HRM; 1.
DR   PRINTS; PR01353; GLUCAGNFAMLY.
DR   PRINTS; PR01355; GLUCAGNLIKER.
DR   PRINTS; PR00249; GPCRSECRETIN.
DR   SMART; SM00008; HormR; 1.
DR   SUPFAM; SSF111418; SSF111418; 1.
DR   PROSITE; PS00649; G_PROTEIN_RECEP_F2_1; 1.
DR   PROSITE; PS00650; G_PROTEIN_RECEP_F2_2; 1.
DR   PROSITE; PS50227; G_PROTEIN_RECEP_F2_3; 1.
DR   PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ADP-ribosylation; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Polymorphism; Receptor;
KW   Reference proteome; Signal; Transducer; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..23
FT                   /evidence="ECO:0000255"
FT   CHAIN           24..463
FT                   /note="Glucagon-like peptide 1 receptor"
FT                   /id="PRO_0000012835"
FT   TOPO_DOM        24..139
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:28514449"
FT   TRANSMEM        140..164
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000269|PubMed:28514449"
FT   TOPO_DOM        165..175
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:28514449"
FT   TRANSMEM        176..201
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000269|PubMed:28514449"
FT   TOPO_DOM        202..227
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:28514449"
FT   TRANSMEM        228..251
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000269|PubMed:28514449"
FT   TOPO_DOM        252..265
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:28514449"
FT   TRANSMEM        266..290
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000269|PubMed:28514449"
FT   TOPO_DOM        291..305
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:28514449"
FT   TRANSMEM        306..328
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000269|PubMed:28514449"
FT   TOPO_DOM        329..348
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:28514449"
FT   TRANSMEM        349..370
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000269|PubMed:28514449"
FT   TOPO_DOM        371..383
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:28514449"
FT   TRANSMEM        384..404
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000269|PubMed:28514449"
FT   TOPO_DOM        405..463
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:28514449"
FT   REGION          352..355
FT                   /note="Important for allosteric inhibitor binding"
FT                   /evidence="ECO:0000269|PubMed:28514449"
FT   SITE            121
FT                   /note="Interaction with the endogenous ligand GLP-1"
FT                   /evidence="ECO:0000269|PubMed:19861722"
FT   SITE            128
FT                   /note="Interaction with the endogenous ligand GLP-1"
FT                   /evidence="ECO:0000269|PubMed:19861722"
FT   MOD_RES         341
FT                   /note="ADP-ribosylcysteine"
FT                   /evidence="ECO:0000269|PubMed:21901419"
FT   MOD_RES         348
FT                   /note="ADP-ribosylarginine"
FT                   /evidence="ECO:0000269|PubMed:21901419"
FT   CARBOHYD        63
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:22412906"
FT   CARBOHYD        82
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:22412906"
FT   CARBOHYD        115
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:22412906"
FT   DISULFID        46..71
FT                   /evidence="ECO:0000244|PDB:3C59, ECO:0000244|PDB:3C5T,
FT                   ECO:0000244|PDB:3IOL, ECO:0000244|PDB:4ZGM,
FT                   ECO:0000244|PDB:5E94, ECO:0000269|PubMed:19861722,
FT                   ECO:0000269|PubMed:26308095, ECO:0000269|PubMed:27196125"
FT   DISULFID        62..104
FT                   /evidence="ECO:0000244|PDB:3C59, ECO:0000244|PDB:3C5T,
FT                   ECO:0000244|PDB:3IOL, ECO:0000244|PDB:4ZGM,
FT                   ECO:0000244|PDB:5E94, ECO:0000269|PubMed:19861722,
FT                   ECO:0000269|PubMed:26308095, ECO:0000269|PubMed:27196125"
FT   DISULFID        85..126
FT                   /evidence="ECO:0000244|PDB:3C59, ECO:0000244|PDB:3C5T,
FT                   ECO:0000244|PDB:3IOL, ECO:0000244|PDB:4ZGM,
FT                   ECO:0000244|PDB:5E94, ECO:0000269|PubMed:19861722,
FT                   ECO:0000269|PubMed:26308095, ECO:0000269|PubMed:27196125"
FT   DISULFID        226..296
FT                   /evidence="ECO:0000244|PDB:3C59, ECO:0000244|PDB:3C5T,
FT                   ECO:0000244|PDB:3IOL, ECO:0000244|PDB:4ZGM,
FT                   ECO:0000244|PDB:5E94, ECO:0000244|PDB:5VEW,
FT                   ECO:0000244|PDB:5VEX, ECO:0000269|PubMed:19861722,
FT                   ECO:0000269|PubMed:26308095, ECO:0000269|PubMed:27196125,
FT                   ECO:0000269|PubMed:28514449"
FT   VARIANT         7
FT                   /note="P -> L (in dbSNP:rs10305420)"
FT                   /evidence="ECO:0000269|Ref.7"
FT                   /id="VAR_018924"
FT   VARIANT         20
FT                   /note="R -> K (in dbSNP:rs10305421)"
FT                   /evidence="ECO:0000269|Ref.7"
FT                   /id="VAR_018925"
FT   VARIANT         44
FT                   /note="R -> H (in dbSNP:rs2295006)"
FT                   /evidence="ECO:0000269|Ref.7"
FT                   /id="VAR_018926"
FT   VARIANT         131
FT                   /note="R -> Q (in dbSNP:rs3765467)"
FT                   /evidence="ECO:0000269|Ref.7"
FT                   /id="VAR_018927"
FT   VARIANT         168
FT                   /note="G -> S (in dbSNP:rs6923761)"
FT                   /evidence="ECO:0000269|Ref.7"
FT                   /id="VAR_018928"
FT   VARIANT         260
FT                   /note="L -> F (in dbSNP:rs1042044)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:7843404, ECO:0000269|PubMed:8216285,
FT                   ECO:0000269|PubMed:8404634, ECO:0000269|PubMed:8405712,
FT                   ECO:0000269|Ref.7"
FT                   /id="VAR_015098"
FT   VARIANT         316
FT                   /note="A -> T (in dbSNP:rs10305492)"
FT                   /evidence="ECO:0000269|Ref.7"
FT                   /id="VAR_018929"
FT   VARIANT         333
FT                   /note="S -> C (in dbSNP:rs10305493)"
FT                   /evidence="ECO:0000269|Ref.7"
FT                   /id="VAR_018930"
FT   VARIANT         421
FT                   /note="R -> Q (in dbSNP:rs10305510)"
FT                   /evidence="ECO:0000269|Ref.7"
FT                   /id="VAR_018931"
FT   MUTAGEN         32
FT                   /note="L->A: No effect on stimulation of cAMP accumulation
FT                   and on GLP-1 binding."
FT                   /evidence="ECO:0000269|PubMed:19861722"
FT   MUTAGEN         69
FT                   /note="Y->A: Abolishes stimulation of cAMP accumulation in
FT                   response to GLP-1."
FT                   /evidence="ECO:0000269|PubMed:19861722"
FT   MUTAGEN         88
FT                   /note="Y->A: Abolishes stimulation of cAMP accumulation in
FT                   response to GLP-1."
FT                   /evidence="ECO:0000269|PubMed:19861722"
FT   MUTAGEN         89
FT                   /note="L->A: Abolishes stimulation of cAMP accumulation in
FT                   response to GLP-1."
FT                   /evidence="ECO:0000269|PubMed:19861722"
FT   MUTAGEN         90
FT                   /note="P->A: Strongly decreased stimulation of cAMP
FT                   accumulation in response to GLP-1."
FT                   /evidence="ECO:0000269|PubMed:19861722"
FT   MUTAGEN         121
FT                   /note="R->A: Strongly decreased stimulation of cAMP
FT                   accumulation in response to GLP-1."
FT                   /evidence="ECO:0000269|PubMed:19861722"
FT   MUTAGEN         127
FT                   /note="E->A: No effect on stimulation of cAMP accumulation
FT                   in response to GLP-1."
FT                   /evidence="ECO:0000269|PubMed:19861722"
FT   MUTAGEN         128
FT                   /note="E->A: Slightly decreases stimulation of cAMP
FT                   accumulation in response to GLP-1."
FT                   /evidence="ECO:0000269|PubMed:19861722"
FT   MUTAGEN         128
FT                   /note="E->Q: No effect on stimulation of cAMP accumulation
FT                   in response to GLP-1."
FT                   /evidence="ECO:0000269|PubMed:19861722"
FT   MUTAGEN         176
FT                   /note="R->Q: Decreases sensitivity to GLP-1."
FT                   /evidence="ECO:0000269|PubMed:28514449"
FT   MUTAGEN         317
FT                   /note="I->C: Causes the formation of an artifactual
FT                   disulfide bond that abolishes signaling in response to GLP-
FT                   1 binding; when associated with C-361."
FT                   /evidence="ECO:0000269|PubMed:28514449"
FT   MUTAGEN         352
FT                   /note="S->A: Abolishes inhibition by negative allosteric
FT                   modulators."
FT                   /evidence="ECO:0000269|PubMed:28514449"
FT   MUTAGEN         355
FT                   /note="T->A: Abolishes inhibition by the negative
FT                   allosteric modulators NNC0640 and PF-06372222, but does not
FT                   abolish inhibition by MK-0893."
FT                   /evidence="ECO:0000269|PubMed:28514449"
FT   MUTAGEN         361
FT                   /note="G->C: Causes the formation of an artifactual
FT                   disulfide bond that abolishes signaling in response to GLP-
FT                   1 binding; when associated with C-317."
FT                   /evidence="ECO:0000269|PubMed:28514449"
FT   CONFLICT        12
FT                   /note="L -> V (in Ref. 1; AAA03614, 4; no nucleotide entry
FT                   and 10; AAB64013)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        136..137
FT                   /note="SP -> WG (in Ref. 1; AAA03614)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        137
FT                   /note="P -> R (in Ref. 4; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        151
FT                   /note="G -> A (in Ref. 1; AAA03614)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        221
FT                   /note="Q -> L (in Ref. 5; AAA63787)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        289
FT                   /note="Y -> I (in Ref. 1; AAA03614)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        316
FT                   /note="A -> G (in Ref. 2; AAA62471/AAC50050)"
FT                   /evidence="ECO:0000305"
FT   HELIX           32..52
FT                   /evidence="ECO:0000244|PDB:4ZGM"
FT   STRAND          57..59
FT                   /evidence="ECO:0000244|PDB:5E94"
FT   STRAND          68..71
FT                   /evidence="ECO:0000244|PDB:6B3J"
FT   STRAND          79..84
FT                   /evidence="ECO:0000244|PDB:4ZGM"
FT   HELIX           92..94
FT                   /evidence="ECO:0000244|PDB:4ZGM"
FT   STRAND          99..104
FT                   /evidence="ECO:0000244|PDB:4ZGM"
FT   STRAND          108..110
FT                   /evidence="ECO:0000244|PDB:4ZGM"
FT   STRAND          116..119
FT                   /evidence="ECO:0000244|PDB:4ZGM"
FT   HELIX           124..126
FT                   /evidence="ECO:0000244|PDB:4ZGM"
FT   HELIX           137..142
FT                   /evidence="ECO:0000244|PDB:5E94"
FT   HELIX           170..172
FT                   /evidence="ECO:0000244|PDB:5VEW"
FT   HELIX           175..199
FT                   /evidence="ECO:0000244|PDB:5VEW"
FT   HELIX           206..210
FT                   /evidence="ECO:0000244|PDB:6B3J"
FT   TURN            220..222
FT                   /evidence="ECO:0000244|PDB:5VEW"
FT   HELIX           224..256
FT                   /evidence="ECO:0000244|PDB:5VEW"
FT   HELIX           263..273
FT                   /evidence="ECO:0000244|PDB:5VEW"
FT   HELIX           275..291
FT                   /evidence="ECO:0000244|PDB:5VEW"
FT   TURN            295..298
FT                   /evidence="ECO:0000244|PDB:5VEW"
FT   TURN            304..306
FT                   /evidence="ECO:0000244|PDB:5VEW"
FT   HELIX           307..336
FT                   /evidence="ECO:0000244|PDB:5VEW"
FT   HELIX           345..366
FT                   /evidence="ECO:0000244|PDB:5VEW"
FT   TURN            367..369
FT                   /evidence="ECO:0000244|PDB:5VEW"
FT   TURN            370..372
FT                   /evidence="ECO:0000244|PDB:6B3J"
FT   HELIX           373..375
FT                   /evidence="ECO:0000244|PDB:6B3J"
FT   HELIX           381..384
FT                   /evidence="ECO:0000244|PDB:5VEW"
FT   HELIX           387..402
FT                   /evidence="ECO:0000244|PDB:5VEW"
FT   TURN            403..405
FT                   /evidence="ECO:0000244|PDB:5VEW"
FT   HELIX           407..421
FT                   /evidence="ECO:0000244|PDB:5VEW"
SQ   SEQUENCE   463 AA;  53026 MW;  EE7C0EAE29931F5D CRC64;
     MAGAPGPLRL ALLLLGMVGR AGPRPQGATV SLWETVQKWR EYRRQCQRSL TEDPPPATDL
     FCNRTFDEYA CWPDGEPGSF VNVSCPWYLP WASSVPQGHV YRFCTAEGLW LQKDNSSLPW
     RDLSECEESK RGERSSPEEQ LLFLYIIYTV GYALSFSALV IASAILLGFR HLHCTRNYIH
     LNLFASFILR ALSVFIKDAA LKWMYSTAAQ QHQWDGLLSY QDSLSCRLVF LLMQYCVAAN
     YYWLLVEGVY LYTLLAFSVL SEQWIFRLYV SIGWGVPLLF VVPWGIVKYL YEDEGCWTRN
     SNMNYWLIIR LPILFAIGVN FLIFVRVICI VVSKLKANLM CKTDIKCRLA KSTLTLIPLL
     GTHEVIFAFV MDEHARGTLR FIKLFTELSF TSFQGLMVAI LYCFVNNEVQ LEFRKSWERW
     RLEHLHIQRD SSMKPLKCPT SSLSSGATAG SSMYTATCQA SCS
//
ID   AA1R_HUMAN              Reviewed;         326 AA.
AC   P30542; A6NFY5; A6NGP4; A8K1L3; B3KXQ4; D2CGD0; Q6FHK3; Q8TAM8;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1993, sequence version 1.
DT   07-OCT-2020, entry version 189.
DE   RecName: Full=Adenosine receptor A1;
GN   Name=ADORA1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Hippocampus;
RX   PubMed=1530647; DOI=10.1016/0006-291x(92)91285-x;
RA   Libert F., van Sande J., Lefort A., Czernilofsky A., Dumont J.E.,
RA   Vassart G., Ensinger H.A., Mendla K.D.;
RT   "Cloning and functional characterization of a human A1 adenosine
RT   receptor.";
RL   Biochem. Biophys. Res. Commun. 187:919-926(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=1339301; DOI=10.1016/0169-328x(92)90248-a;
RA   Townsend-Nicholson A., Shine J.;
RT   "Molecular cloning and characterisation of a human brain A1 adenosine
RT   receptor cDNA.";
RL   Brain Res. Mol. Brain Res. 16:365-370(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Hippocampus;
RX   PubMed=8300646;
RA   Ren H., Stiles G.L.;
RT   "Characterization of the human A1 adenosine receptor gene. Evidence for
RT   alternative splicing.";
RL   J. Biol. Chem. 269:3104-3110(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RA   Salvatore C.A., Luneau C.J., Johnson R.G., Jacobson M.;
RL   Submitted (SEP-1992) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Heart;
RA   Hirabatake Y., Takao K., Hagiwara S., Kasanuki H., Hosoda S., Kokubun S.;
RT   "Complete nucleotide sequence of an adenosine A1-receptor from heart.";
RL   Submitted (JUN-1997) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Feng Y.-H., Cheng H., Qiu R.;
RT   "Identification of a 3TM adenosine receptor subtype 1 variant.";
RL   Submitted (OCT-2006) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain, and Hippocampus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS SER-43;
RP   PRO-50; HIS-105 AND GLN-261.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [14]
RP   VARIANT [LARGE SCALE ANALYSIS] LYS-170.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [15]
RP   VARIANT SER-279, CHARACTERIZATION OF VARIANT SER-279, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=27134041; DOI=10.1002/mds.26627;
RA   Jaberi E., Rohani M., Shahidi G.A., Nafissi S., Arefian E., Soleimani M.,
RA   Moghadam A., Arzenani M.K., Keramatian F., Klotzle B., Fan J.B., Turk C.,
RA   Steemers F., Elahi E.;
RT   "Mutation in ADORA1 identified as likely cause of early-onset parkinsonism
RT   and cognitive dysfunction.";
RL   Mov. Disord. 31:1004-1011(2016).
CC   -!- FUNCTION: Receptor for adenosine. The activity of this receptor is
CC       mediated by G proteins which inhibit adenylyl cyclase.
CC   -!- INTERACTION:
CC       P30542; P29274: ADORA2A; NbExp=4; IntAct=EBI-2903663, EBI-2902702;
CC       P30542; P08588: ADRB1; NbExp=5; IntAct=EBI-2903663, EBI-991009;
CC       P30542; P07550: ADRB2; NbExp=5; IntAct=EBI-2903663, EBI-491169;
CC       P30542; P16473: TSHR; NbExp=2; IntAct=EBI-2903663, EBI-13939599;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:27134041};
CC       Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P30542-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P30542-2; Sequence=VSP_034401, VSP_034402;
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; S45235; AAB23388.1; -; mRNA.
DR   EMBL; S56143; AAB25533.2; -; mRNA.
DR   EMBL; L22214; AAA17544.1; -; mRNA.
DR   EMBL; X68485; CAA48503.1; -; mRNA.
DR   EMBL; AB004662; BAA20433.1; -; mRNA.
DR   EMBL; EF057066; ABO25743.1; -; mRNA.
DR   EMBL; AK127752; BAG54566.1; -; mRNA.
DR   EMBL; AK289928; BAF82617.1; -; mRNA.
DR   EMBL; AY136746; AAN01272.1; -; mRNA.
DR   EMBL; BT019854; AAV38657.1; -; mRNA.
DR   EMBL; CR541749; CAG46549.1; -; mRNA.
DR   EMBL; AC105940; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471067; EAW91465.1; -; Genomic_DNA.
DR   EMBL; BC026340; AAH26340.1; -; mRNA.
DR   CCDS; CCDS1434.1; -. [P30542-1]
DR   PIR; A53005; A53005.
DR   RefSeq; NP_000665.1; NM_000674.2. [P30542-1]
DR   RefSeq; NP_001041695.1; NM_001048230.1. [P30542-1]
DR   PDB; 5N2S; X-ray; 3.30 A; A=4-316.
DR   PDB; 5UEN; X-ray; 3.20 A; A/B=2-211, A/B=228-311.
DR   PDB; 6D9H; EM; 3.60 A; R=2-326.
DR   PDBsum; 5N2S; -.
DR   PDBsum; 5UEN; -.
DR   PDBsum; 6D9H; -.
DR   SMR; P30542; -.
DR   BioGRID; 106646; 8.
DR   IntAct; P30542; 6.
DR   MINT; P30542; -.
DR   STRING; 9606.ENSP00000356205; -.
DR   BindingDB; P30542; -.
DR   ChEMBL; CHEMBL226; -.
DR   DrugBank; DB00640; Adenosine.
DR   DrugBank; DB01223; Aminophylline.
DR   DrugBank; DB00201; Caffeine.
DR   DrugBank; DB09061; Cannabidiol.
DR   DrugBank; DB04932; Defibrotide.
DR   DrugBank; DB00651; Dyphylline.
DR   DrugBank; DB00824; Enprofylline.
DR   DrugBank; DB00996; Gabapentin.
DR   DrugBank; DB11757; Istradefylline.
DR   DrugBank; DB00555; Lamotrigine.
DR   DrugBank; DB06471; Naxifylline.
DR   DrugBank; DB01303; Oxtriphylline.
DR   DrugBank; DB00806; Pentoxifylline.
DR   DrugBank; DB12670; Rolofylline.
DR   DrugBank; DB04954; Tecadenoson.
DR   DrugBank; DB01412; Theobromine.
DR   DrugBank; DB00277; Theophylline.
DR   DrugBank; DB12569; Tonapofylline.
DR   DrugBank; DB00193; Tramadol.
DR   DrugCentral; P30542; -.
DR   GuidetoPHARMACOLOGY; 18; -.
DR   TCDB; 9.A.14.3.4; the g-protein-coupled receptor (gpcr) family.
DR   GlyConnect; 992; 6 N-Linked glycans (1 site).
DR   GlyGen; P30542; 1 site.
DR   iPTMnet; P30542; -.
DR   PhosphoSitePlus; P30542; -.
DR   SwissPalm; P30542; -.
DR   BioMuta; ADORA1; -.
DR   DMDM; 231473; -.
DR   jPOST; P30542; -.
DR   MassIVE; P30542; -.
DR   PaxDb; P30542; -.
DR   PeptideAtlas; P30542; -.
DR   PRIDE; P30542; -.
DR   ProteomicsDB; 54718; -. [P30542-1]
DR   ProteomicsDB; 54719; -. [P30542-2]
DR   Antibodypedia; 20660; 488 antibodies.
DR   DNASU; 134; -.
DR   Ensembl; ENST00000309502; ENSP00000308549; ENSG00000163485. [P30542-1]
DR   Ensembl; ENST00000337894; ENSP00000338435; ENSG00000163485. [P30542-1]
DR   Ensembl; ENST00000367235; ENSP00000356204; ENSG00000163485. [P30542-2]
DR   Ensembl; ENST00000367236; ENSP00000356205; ENSG00000163485. [P30542-1]
DR   Ensembl; ENST00000640524; ENSP00000491900; ENSG00000163485. [P30542-2]
DR   GeneID; 134; -.
DR   KEGG; hsa:134; -.
DR   UCSC; uc001gze.1; human. [P30542-1]
DR   CTD; 134; -.
DR   DisGeNET; 134; -.
DR   EuPathDB; HostDB:ENSG00000163485.15; -.
DR   GeneCards; ADORA1; -.
DR   HGNC; HGNC:262; ADORA1.
DR   HPA; ENSG00000163485; Tissue enhanced (brain).
DR   MIM; 102775; gene.
DR   neXtProt; NX_P30542; -.
DR   OpenTargets; ENSG00000163485; -.
DR   PharmGKB; PA24583; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00990000203639; -.
DR   HOGENOM; CLU_009579_11_5_1; -.
DR   InParanoid; P30542; -.
DR   KO; K04265; -.
DR   OMA; CWTVAFI; -.
DR   OrthoDB; 550297at2759; -.
DR   PhylomeDB; P30542; -.
DR   TreeFam; TF325296; -.
DR   PathwayCommons; P30542; -.
DR   Reactome; R-HSA-417973; Adenosine P1 receptors.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   SIGNOR; P30542; -.
DR   BioGRID-ORCS; 134; 9 hits in 870 CRISPR screens.
DR   ChiTaRS; ADORA1; human.
DR   GeneWiki; Adenosine_A1_receptor; -.
DR   GenomeRNAi; 134; -.
DR   Pharos; P30542; Tclin.
DR   PRO; PR:P30542; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P30542; protein.
DR   Bgee; ENSG00000163485; Expressed in C1 segment of cervical spinal cord and 200 other tissues.
DR   ExpressionAtlas; P30542; baseline and differential.
DR   Genevisible; P30542; HS.
DR   GO; GO:0030673; C:axolemma; IEA:Ensembl.
DR   GO; GO:0016323; C:basolateral plasma membrane; IEA:Ensembl.
DR   GO; GO:0043197; C:dendritic spine; IEA:Ensembl.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0099055; C:integral component of postsynaptic membrane; IEA:Ensembl.
DR   GO; GO:0099056; C:integral component of presynaptic membrane; IEA:Ensembl.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0014069; C:postsynaptic density; IEA:Ensembl.
DR   GO; GO:0048786; C:presynaptic active zone; IEA:Ensembl.
DR   GO; GO:0043195; C:terminal bouton; IEA:Ensembl.
DR   GO; GO:0001609; F:G protein-coupled adenosine receptor activity; IEA:Ensembl.
DR   GO; GO:0001664; F:G protein-coupled receptor binding; IEA:Ensembl.
DR   GO; GO:0031683; F:G-protein beta/gamma-subunit complex binding; IEA:Ensembl.
DR   GO; GO:0031072; F:heat shock protein binding; IEA:Ensembl.
DR   GO; GO:0032795; F:heterotrimeric G-protein binding; IEA:Ensembl.
DR   GO; GO:0046982; F:protein heterodimerization activity; IEA:Ensembl.
DR   GO; GO:0001883; F:purine nucleoside binding; IEA:Ensembl.
DR   GO; GO:0000186; P:activation of MAPKK activity; IEA:Ensembl.
DR   GO; GO:0007193; P:adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0097190; P:apoptotic signaling pathway; TAS:ProtInc.
DR   GO; GO:0007267; P:cell-cell signaling; TAS:ProtInc.
DR   GO; GO:0050890; P:cognition; IEA:Ensembl.
DR   GO; GO:0050965; P:detection of temperature stimulus involved in sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0060079; P:excitatory postsynaptic potential; IEA:Ensembl.
DR   GO; GO:0055089; P:fatty acid homeostasis; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006954; P:inflammatory response; TAS:ProtInc.
DR   GO; GO:0016042; P:lipid catabolic process; IEA:Ensembl.
DR   GO; GO:0002674; P:negative regulation of acute inflammatory response; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0097756; P:negative regulation of blood vessel diameter; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0042323; P:negative regulation of circadian sleep/wake cycle, non-REM sleep; IEA:Ensembl.
DR   GO; GO:0014050; P:negative regulation of glutamate secretion; IEA:Ensembl.
DR   GO; GO:0045822; P:negative regulation of heart contraction; IEA:Ensembl.
DR   GO; GO:0046888; P:negative regulation of hormone secretion; IEA:Ensembl.
DR   GO; GO:0002686; P:negative regulation of leukocyte migration; IEA:Ensembl.
DR   GO; GO:0050995; P:negative regulation of lipid catabolic process; IEA:Ensembl.
DR   GO; GO:1900453; P:negative regulation of long-term synaptic depression; IEA:Ensembl.
DR   GO; GO:1900272; P:negative regulation of long-term synaptic potentiation; IEA:Ensembl.
DR   GO; GO:0070256; P:negative regulation of mucus secretion; IEA:Ensembl.
DR   GO; GO:0032900; P:negative regulation of neurotrophin production; IEA:Ensembl.
DR   GO; GO:0035814; P:negative regulation of renal sodium excretion; IEA:Ensembl.
DR   GO; GO:0032229; P:negative regulation of synaptic transmission, GABAergic; IEA:Ensembl.
DR   GO; GO:0051967; P:negative regulation of synaptic transmission, glutamatergic; IEA:Ensembl.
DR   GO; GO:0003085; P:negative regulation of systemic arterial blood pressure; IEA:Ensembl.
DR   GO; GO:0007399; P:nervous system development; TAS:ProtInc.
DR   GO; GO:0006909; P:phagocytosis; TAS:ProtInc.
DR   GO; GO:0045741; P:positive regulation of epidermal growth factor-activated receptor activity; IEA:Ensembl.
DR   GO; GO:0050996; P:positive regulation of lipid catabolic process; IEA:Ensembl.
DR   GO; GO:1901216; P:positive regulation of neuron death; IEA:Ensembl.
DR   GO; GO:0032244; P:positive regulation of nucleoside transport; IEA:Ensembl.
DR   GO; GO:0002793; P:positive regulation of peptide secretion; IEA:Ensembl.
DR   GO; GO:0043268; P:positive regulation of potassium ion transport; IEA:Ensembl.
DR   GO; GO:0035307; P:positive regulation of protein dephosphorylation; IEA:Ensembl.
DR   GO; GO:0003084; P:positive regulation of systemic arterial blood pressure; IEA:Ensembl.
DR   GO; GO:0006612; P:protein targeting to membrane; IEA:Ensembl.
DR   GO; GO:0086004; P:regulation of cardiac muscle cell contraction; IEA:Ensembl.
DR   GO; GO:0003093; P:regulation of glomerular filtration; IEA:Ensembl.
DR   GO; GO:0099509; P:regulation of presynaptic cytosolic calcium ion concentration; IEA:GOC.
DR   GO; GO:0002087; P:regulation of respiratory gaseous exchange by nervous system process; IEA:Ensembl.
DR   GO; GO:0051930; P:regulation of sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0060087; P:relaxation of vascular associated smooth muscle; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0001659; P:temperature homeostasis; IEA:Ensembl.
DR   GO; GO:0070328; P:triglyceride homeostasis; IEA:Ensembl.
DR   InterPro; IPR001068; Adeno_A1_rcpt.
DR   InterPro; IPR001634; Adenosn_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00552; ADENOSINEA1R.
DR   PRINTS; PR00424; ADENOSINER.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane; Palmitate;
KW   Polymorphism; Receptor; Reference proteome; Transducer; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..326
FT                   /note="Adenosine receptor A1"
FT                   /id="PRO_0000068991"
FT   TOPO_DOM        1..10
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        11..33
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        34..46
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        47..69
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        70..80
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        81..102
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        103..123
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        124..146
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        147..176
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        177..201
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        202..235
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        236..259
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        260..267
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        268..292
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        293..326
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   LIPID           309
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        159
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        80..169
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VAR_SEQ         115..125
FT                   /note="YKMVVTPRRAA -> RISQCMASTKS (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.6"
FT                   /id="VSP_034401"
FT   VAR_SEQ         126..326
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.6"
FT                   /id="VSP_034402"
FT   VARIANT         43
FT                   /note="A -> S (in dbSNP:rs11547175)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_044138"
FT   VARIANT         50
FT                   /note="S -> P (in dbSNP:rs11547174)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_044139"
FT   VARIANT         105
FT                   /note="R -> H (in dbSNP:rs11547176)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_044140"
FT   VARIANT         170
FT                   /note="E -> K (in a colorectal cancer sample; somatic
FT                   mutation; dbSNP:rs899207013)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035754"
FT   VARIANT         261
FT                   /note="P -> Q (in dbSNP:rs17852405)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_044141"
FT   VARIANT         279
FT                   /note="G -> S (found in a family with early-onset autosomal
FT                   recessive parkinsonism and intellectual disability; unknown
FT                   pathological significance; does not affect protein
FT                   abundance; does not affect expression at the cell surface;
FT                   dbSNP:rs748346254)"
FT                   /evidence="ECO:0000269|PubMed:27134041"
FT                   /id="VAR_078549"
FT   CONFLICT        312
FT                   /note="A -> T (in Ref. 7; BAF82617)"
FT                   /evidence="ECO:0000305"
FT   HELIX           7..36
FT                   /evidence="ECO:0000244|PDB:5UEN"
FT   HELIX           38..40
FT                   /evidence="ECO:0000244|PDB:5UEN"
FT   HELIX           43..60
FT                   /evidence="ECO:0000244|PDB:5UEN"
FT   HELIX           62..71
FT                   /evidence="ECO:0000244|PDB:5UEN"
FT   HELIX           77..110
FT                   /evidence="ECO:0000244|PDB:5UEN"
FT   TURN            112..114
FT                   /evidence="ECO:0000244|PDB:5UEN"
FT   HELIX           115..118
FT                   /evidence="ECO:0000244|PDB:5UEN"
FT   HELIX           121..140
FT                   /evidence="ECO:0000244|PDB:5UEN"
FT   HELIX           141..144
FT                   /evidence="ECO:0000244|PDB:5UEN"
FT   HELIX           149..159
FT                   /evidence="ECO:0000244|PDB:5UEN"
FT   HELIX           171..174
FT                   /evidence="ECO:0000244|PDB:5UEN"
FT   HELIX           177..182
FT                   /evidence="ECO:0000244|PDB:5UEN"
FT   HELIX           184..188
FT                   /evidence="ECO:0000244|PDB:5UEN"
FT   HELIX           190..211
FT                   /evidence="ECO:0000244|PDB:5UEN"
FT   HELIX           228..259
FT                   /evidence="ECO:0000244|PDB:5UEN"
FT   HELIX           267..291
FT                   /evidence="ECO:0000244|PDB:5UEN"
FT   HELIX           293..306
FT                   /evidence="ECO:0000244|PDB:5UEN"
SQ   SEQUENCE   326 AA;  36512 MW;  1B555893BCDEC9A6 CRC64;
     MPPSISAFQA AYIGIEVLIA LVSVPGNVLV IWAVKVNQAL RDATFCFIVS LAVADVAVGA
     LVIPLAILIN IGPQTYFHTC LMVACPVLIL TQSSILALLA IAVDRYLRVK IPLRYKMVVT
     PRRAAVAIAG CWILSFVVGL TPMFGWNNLS AVERAWAANG SMGEPVIKCE FEKVISMEYM
     VYFNFFVWVL PPLLLMVLIY LEVFYLIRKQ LNKKVSASSG DPQKYYGKEL KIAKSLALIL
     FLFALSWLPL HILNCITLFC PSCHKPSILT YIAIFLTHGN SAMNPIVYAF RIQKFRVTFL
     KIWNDHFRCQ PAPPIDEDLP EERPDD
//
ID   CXCR4_HUMAN             Reviewed;         352 AA.
AC   P61073; B2R5N0; O60835; P30991; P56438; Q53S69; Q9BXA0; Q9UKN2;
DT   26-APR-2004, integrated into UniProtKB/Swiss-Prot.
DT   26-APR-2004, sequence version 1.
DT   07-OCT-2020, entry version 185.
DE   RecName: Full=C-X-C chemokine receptor type 4;
DE            Short=CXC-R4;
DE            Short=CXCR-4;
DE   AltName: Full=FB22;
DE   AltName: Full=Fusin;
DE   AltName: Full=HM89;
DE   AltName: Full=LCR1;
DE   AltName: Full=Leukocyte-derived seven transmembrane domain receptor;
DE            Short=LESTR {ECO:0000303|PubMed:8276799};
DE   AltName: Full=Lipopolysaccharide-associated protein 3;
DE            Short=LAP-3;
DE            Short=LPS-associated protein 3;
DE   AltName: Full=NPYRL;
DE   AltName: Full=Stromal cell-derived factor 1 receptor;
DE            Short=SDF-1 receptor;
DE   AltName: CD_antigen=CD184;
GN   Name=CXCR4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PRELIMINARY FUNCTION.
RC   TISSUE=Lung;
RX   PubMed=8329116; DOI=10.1089/dna.1993.12.465;
RA   Herzog H., Hort Y.J., Shine J., Selbie L.A.;
RT   "Molecular cloning, characterization, and localization of the human homolog
RT   to the reported bovine NPY Y3 receptor: lack of NPY binding and
RT   activation.";
RL   DNA Cell Biol. 12:465-471(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PRELIMINARY FUNCTION.
RC   TISSUE=Fetal brain;
RX   PubMed=8234909; DOI=10.1016/0167-0115(93)90392-l;
RA   Jazin E.E., Yoo H., Blomqvist A.G., Yee F., Weng G., Walker M.W., Salon J.,
RA   Larhammar D., Wahlestedt C.R.;
RT   "A proposed bovine neuropeptide Y (NPY) receptor cDNA clone, or its human
RT   homologue, confers neither NPY binding sites nor NPY responsiveness on
RT   transfected cells.";
RL   Regul. Pept. 47:247-258(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Fetal spleen;
RX   PubMed=8325644; DOI=10.1006/geno.1993.1251;
RA   Federsppiel B., Melhado I.G., Duncan A.M.V., Delaney A.D., Schappert K.,
RA   Clark-Lewis I., Jirik F.R.;
RT   "Molecular cloning of the cDNA and chromosomal localization of the gene for
RT   a putative seven-transmembrane segment (7-TMS) receptor isolated from human
RT   spleen.";
RL   Genomics 16:707-712(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Monocyte;
RX   PubMed=8276799;
RA   Loetscher M., Geiser T., O'Reilly T., Zwahlen R., Baggiolini M., Moser B.;
RT   "Cloning of a human seven-transmembrane domain receptor, LESTR, that is
RT   highly expressed in leukocytes.";
RL   J. Biol. Chem. 269:232-237(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=7505609; DOI=10.1093/intimm/5.10.1239;
RA   Nomura H., Nielsen B.W., Matsushima K.;
RT   "Molecular cloning of cDNAs encoding a LD78 receptor and putative leukocyte
RT   chemotactic peptide receptors.";
RL   Int. Immunol. 5:1239-1249(1993).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND CHARACTERIZATION OF ITS HIV-1
RP   CORECEPTOR FUNCTION.
RX   PubMed=8629022; DOI=10.1126/science.272.5263.872;
RA   Feng Y., Broder C.C., Kennedy P.E., Berger E.A.;
RT   "HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G
RT   protein-coupled receptor.";
RL   Science 272:872-877(1996).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Peripheral blood leukocyte;
RX   PubMed=9468539; DOI=10.1074/jbc.273.8.4754;
RA   Wegner S.A., Ehrenberg P.K., Chang G., Dayhoff D.E., Sleeker A.L.,
RA   Michael N.L.;
RT   "Genomic organization and functional characterization of the chemokine
RT   receptor CXCR4, a major entry co-receptor for human immunodeficiency virus
RT   type 1.";
RL   J. Biol. Chem. 273:4754-4760(1998).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9599023; DOI=10.1016/s0014-5793(98)00359-7;
RA   Caruz A., Samsom M., Alonso J.M., Alcami J., Baleux F., Virelizier J.-L.,
RA   Parmentier M., Arenzana-Seisdedos F.;
RT   "Genomic organization and promoter characterization of human CXCR4 gene.";
RL   FEBS Lett. 426:271-278(1998).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=10480633; DOI=10.1089/088922299310296;
RA   Xiao L., Weiss S.H., Qari S.H., Rudolph D., Zhao C., Denny T.N., Hodge T.,
RA   Lal R.B.;
RT   "Partial resistance to infection by R5X4 primary HIV type 1 isolates in an
RT   exposed-uninfected individual homozygous for CCR5 32-base pair deletion.";
RL   AIDS Res. Hum. Retroviruses 15:1201-1208(1999).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Peripheral blood lymphocyte;
RX   PubMed=9879064; DOI=10.3109/10799899809047750;
RA   Frodl R., Gierschik P., Moepps B.;
RT   "Genomic organization and expression of the CXCR4 gene in mouse and man:
RT   absence of a splice variant corresponding to mouse CXCR4-B in human
RT   tissues.";
RL   J. Recept. Signal Transduct. 18:321-344(1998).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, AND SUBCELLULAR LOCATION.
RC   TISSUE=Neutrophil;
RX   PubMed=10452968;
RA   Gupta S.K., Pillarisetti K.;
RT   "CXCR4-Lo: molecular cloning and functional expression of a novel human
RT   CXCR4 splice variant.";
RL   J. Immunol. 163:2368-2372(1999).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Fan Z., Li T., Li J., Luo B.;
RL   Submitted (FEB-2001) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Adrenal gland;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RA   Warren C.N., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [16]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   SeattleSNPs variation discovery resource;
RL   Submitted (AUG-2004) to the EMBL/GenBank/DDBJ databases.
RN   [17]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [19]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [20]
RP   FUNCTION.
RX   PubMed=8752280; DOI=10.1038/382829a0;
RA   Bleul C.C., Farzan M., Choe H., Parolin C., Clark-Lewis I., Sodroski J.,
RA   Springer T.A.;
RT   "The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and
RT   blocks HIV-1 entry.";
RL   Nature 382:829-833(1996).
RN   [21]
RP   FUNCTION.
RX   PubMed=8752281; DOI=10.1038/382833a0;
RA   Oberlin E., Amara A., Bachelerie F., Bessia C., Virelizier J.-L.,
RA   Arenzana-Seisdedos F., Schwartz O., Heard J.-M., Clark-Lewis I.,
RA   Legler D.F., Loetscher M., Baggiolini M., Moser B.;
RT   "The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents
RT   infection by T-cell-line-adapted HIV-1.";
RL   Nature 382:833-835(1996).
RN   [22]
RP   ERRATUM OF PUBMED:8752281.
RA   Oberlin E., Amara A., Bachelerie F., Bessia C., Virelizier J.-L.,
RA   Arenzana-Seisdedos F., Schwartz O., Heard J.-M., Clark-Lewis I.,
RA   Legler D.F., Loetscher M., Baggiolini M., Moser B.;
RL   Nature 384:288-288(1996).
RN   [23]
RP   FUNCTION (MICROBIAL INFECTION), AND CHARACTERIZATION AS HIV-1 CORECEPTOR.
RX   PubMed=8849450; DOI=10.1126/science.274.5287.602;
RA   Lapham C.K., Ouyang J., Chandrasekhar B., Nguyen N.Y., Dimitrov D.S.,
RA   Golding H.;
RT   "Evidence for cell-surface association between fusin and the CD4-gp120
RT   complex in human cell lines.";
RL   Science 274:602-605(1996).
RN   [24]
RP   FUNCTION (MICROBIAL INFECTION), AND CHARACTERIZATION AS HIV-2 PRIMARY
RP   RECEPTOR IN SOME ISOLATES.
RX   PubMed=8929542; DOI=10.1016/s0092-8674(00)81393-8;
RA   Endres M.J., Clapham P.R., Marsh M., Ahuja M., Turner J.D., McKnight A.,
RA   Thomas J.F., Stoebenau-Haggarty B., Choe S., Vance P.J., Wells T.N.C.,
RA   Power C.A., Sutterwala S.S., Doms R.W., Landau N.R., Hoxie J.A.;
RT   "CD4-independent infection by HIV-2 is mediated by fusin/CXCR4.";
RL   Cell 87:745-756(1996).
RN   [25]
RP   ANTAGONIST, INTERACTION WITH CXCL12, FUNCTION (MICROBIAL INFECTION), AND
RP   CHARACTERIZATION AS HIV-1 CORECEPTOR.
RX   PubMed=9427609; DOI=10.1038/nm0198-072;
RA   Donzella G.A., Schols D., Lin S.W., Este J.A., Nagashima K.A., Maddon P.J.,
RA   Allaway G.P., Sakmar T.P., Henson G., De Clercq E., Moore J.P.;
RT   "AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-
RT   receptor.";
RL   Nat. Med. 4:72-77(1998).
RN   [26]
RP   SULFATION.
RX   PubMed=10089882; DOI=10.1016/s0092-8674(00)80577-2;
RA   Farzan M., Mirzabekov T., Kolchinsky P., Wyatt R., Cayabyab M.,
RA   Gerard N.P., Gerard C., Sodroski J., Choe H.;
RT   "Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1
RT   entry.";
RL   Cell 96:667-676(1999).
RN   [27]
RP   FUNCTION, AND MUTAGENESIS OF ARG-183; ARG-188 AND ASP-193.
RX   PubMed=10074102;
RA   Brelot A., Heveker N., Adema K., Hosie M.J., Willett B., Alizon M.;
RT   "Effect of mutations in the second extracellular loop of CXCR4 on its
RT   utilization by human and feline immunodeficiency viruses.";
RL   J. Virol. 73:2576-2586(1999).
RN   [28]
RP   DOMAINS, FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH HIV-1 SURFACE
RP   PROTEIN GP120.
RX   PubMed=10074122;
RA   Doranz B.J., Orsini M.J., Turner J.D., Hoffman T.L., Berson J.F.,
RA   Hoxie J.A., Peiper S.C., Brass L.F., Doms R.W.;
RT   "Identification of CXCR4 domains that support coreceptor and chemokine
RT   receptor functions.";
RL   J. Virol. 73:2752-2761(1999).
RN   [29]
RP   INTERACTION WITH ARRB2, AND FUNCTION.
RX   PubMed=10644702; DOI=10.1074/jbc.275.4.2479;
RA   Cheng Z.J., Zhao J., Sun Y., Hu W., Wu Y.L., Cen B., Wu G.-X., Pei G.;
RT   "beta-arrestin differentially regulates the chemokine receptor CXCR4-
RT   mediated signaling and receptor internalization, and this implicates
RT   multiple interaction sites between beta-arrestin and CXCR4.";
RL   J. Biol. Chem. 275:2479-2485(2000).
RN   [30]
RP   FUNCTION, INTERACTION WITH CXCL12, AND MUTAGENESIS OF 2-GLU--SER-9;
RP   4-ILE--ASP-20; TYR-7; 10-ASP--ASP-20; TYR-12; 14-GLU-GLU-15; TYR-21;
RP   ASP-97; ASP-171; ASP-187; ASP-193; ASP-262; GLU-268 AND GLU-288.
RX   PubMed=10825158; DOI=10.1074/jbc.m000776200;
RA   Brelot A., Heveker N., Montes M., Alizon M.;
RT   "Identification of residues of CXCR4 critical for human immunodeficiency
RT   virus coreceptor and chemokine receptor activities.";
RL   J. Biol. Chem. 275:23736-23744(2000).
RN   [31]
RP   GLYCOSYLATION AT ASN-11, FUNCTION (MICROBIAL INFECTION), INTERACTION WITH
RP   HIV-1 ENV, SUBUNIT, AND MUTAGENESIS OF ASN-11; THR-13 AND ASN-176.
RX   PubMed=10756055; DOI=10.1128/jvi.74.9.4404-4413.2000;
RA   Chabot D.J., Chen H., Dimitrov D.S., Broder C.C.;
RT   "N-linked glycosylation of CXCR4 masks coreceptor function for CCR5-
RT   dependent human immunodeficiency virus type 1 isolates.";
RL   J. Virol. 74:4404-4413(2000).
RN   [32]
RP   INDUCTION (MICROBIAL INFECTION), AND INTERACTION WITH HIV-1 TAT.
RX   PubMed=11027346; DOI=10.1073/pnas.97.21.11466;
RA   Xiao H., Neuveut C., Tiffany H.L., Benkirane M., Rich E.A., Murphy P.M.,
RA   Jeang K.-T.;
RT   "Selective CXCR4 antagonism by Tat: implications for in vivo expansion of
RT   coreceptor use by HIV-1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:11466-11471(2000).
RN   [33]
RP   FUNCTION, IDENTIFICATION AS LPS RECEPTOR, INTERACTION WITH GDF5; HSP90AA1
RP   AND HSPA8, AND TISSUE SPECIFICITY.
RX   PubMed=11276205; DOI=10.1038/86342;
RA   Triantafilou K., Triantafilou M., Dedrick R.L.;
RT   "A CD14-independent LPS receptor cluster.";
RL   Nat. Immunol. 2:338-345(2001).
RN   [34]
RP   GLYCOSYLATION AT SER-18, IDENTIFICATION OF PROTEOGLYCAN, INTERACTION WITH
RP   CXCL12, SULFATION AT TYR-21, AND MUTAGENESIS OF TYR-7; THR-8; SER-9;
RP   TYR-12; SER-18 AND TYR-21.
RX   PubMed=12034737; DOI=10.1074/jbc.m203361200;
RA   Farzan M., Babcock G.J., Vasilieva N., Wright P.L., Kiprilov E.,
RA   Mirzabekov T., Choe H.;
RT   "The role of post-translational modifications of the CXCR4 amino terminus
RT   in stromal-derived factor 1 alpha association and HIV-1 entry.";
RL   J. Biol. Chem. 277:29484-29489(2002).
RN   [35]
RP   UBIQUITINATION BY ITCH, AND SUBCELLULAR LOCATION.
RX   PubMed=14602072; DOI=10.1016/s1534-5807(03)00321-6;
RA   Marchese A., Raiborg C., Santini F., Keen J.H., Stenmark H., Benovic J.L.;
RT   "The E3 ubiquitin ligase AIP4 mediates ubiquitination and sorting of the G
RT   protein-coupled receptor CXCR4.";
RL   Dev. Cell 5:709-722(2003).
RN   [36]
RP   INVOLVEMENT IN WHIMS, AND VARIANTS WHIMS 334-ARG--SER-352 DEL AND
RP   343-GLU--SER-352 DEL.
RX   PubMed=12692554; DOI=10.1038/ng1149;
RA   Hernandez P.A., Gorlin R.J., Lukens J.N., Taniuchi S., Bohinjec J.,
RA   Francois F., Klotman M.E., Diaz G.A.;
RT   "Mutations in the chemokine receptor gene CXCR4 are associated with WHIM
RT   syndrome, a combined immunodeficiency disease.";
RL   Nat. Genet. 34:70-74(2003).
RN   [37]
RP   INVOLVEMENT IN WHIMS, AND VARIANT WHIMS 338-SER--SER-352 DEL.
RX   PubMed=15536153; DOI=10.1182/blood-2004-06-2289;
RA   Balabanian K., Lagane B., Pablos J.L., Laurent L., Planchenault T.,
RA   Verola O., Lebbe C., Kerob D., Dupuy A., Hermine O., Nicolas J.F.,
RA   Latger-Cannard V., Bensoussan D., Bordigoni P., Baleux F., Le Deist F.,
RA   Virelizier J.L., Arenzana-Seisdedos F., Bachelerie F.;
RT   "WHIM syndromes with different genetic anomalies are accounted for by
RT   impaired CXCR4 desensitization to CXCL12.";
RL   Blood 105:2449-2457(2005).
RN   [38]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [39]
RP   INTERACTION WITH CD164.
RX   PubMed=17077324; DOI=10.1182/blood-2006-05-023028;
RA   Forde S., Tye B.J., Newey S.E., Roubelakis M., Smythe J., McGuckin C.P.,
RA   Pettengell R., Watt S.M.;
RT   "Endolyn (CD164) modulates the CXCL12-mediated migration of umbilical cord
RT   blood CD133+ cells.";
RL   Blood 109:1825-1833(2007).
RN   [40]
RP   FUNCTION, AND MUTAGENESIS OF ASN-119; ASP-133; ARG-134 AND TYR-135.
RX   PubMed=17197449; DOI=10.1074/jbc.c600270200;
RA   Berchiche Y.A., Chow K.Y., Lagane B., Leduc M., Percherancier Y., Fujii N.,
RA   Tamamura H., Bachelerie F., Heveker N.;
RT   "Direct assessment of CXCR4 mutant conformations reveals complex link
RT   between receptor structure and G(alpha)(i) activation.";
RL   J. Biol. Chem. 282:5111-5115(2007).
RN   [41]
RP   SULFATION AT TYR-7; TYR-12 AND TYR-21, AND INTERACTION WITH CXCL12.
RX   PubMed=18834145; DOI=10.1021/bi800965m;
RA   Seibert C., Veldkamp C.T., Peterson F.C., Chait B.T., Volkman B.F.,
RA   Sakmar T.P.;
RT   "Sequential tyrosine sulfation of CXCR4 by tyrosylprotein
RT   sulfotransferases.";
RL   Biochemistry 47:11251-11262(2008).
RN   [42]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [43]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-319 AND SER-348, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [44]
RP   INTERACTION WITH ITCH, SUBCELLULAR LOCATION, PHOSPHORYLATION AT SER-324 AND
RP   SER-325, AND MUTAGENESIS OF SER-324; SER-325 AND SER-330.
RX   PubMed=19116316; DOI=10.1091/mbc.e08-03-0308;
RA   Bhandari D., Robia S.L., Marchese A.;
RT   "The E3 ubiquitin ligase atrophin interacting protein 4 binds directly to
RT   the chemokine receptor CXCR4 via a novel WW domain-mediated interaction.";
RL   Mol. Biol. Cell 20:1324-1339(2009).
RN   [45]
RP   INTERACTION WITH STAPHYLOCOCCUS AUREUS SUPERANTIGEN-LIKE PROTEIN 10
RP   (MICROBIAL INFECTION).
RX   PubMed=19308288; DOI=10.1593/neo.81508;
RA   Walenkamp A.M., Boer I.G., Bestebroer J., Rozeveld D., Timmer-Bosscha H.,
RA   Hemrika W., van Strijp J.A., de Haas C.J.;
RT   "Staphylococcal superantigen-like 10 inhibits CXCL12-induced human tumor
RT   cell migration.";
RL   Neoplasia 11:333-344(2009).
RN   [46]
RP   PHOSPHORYLATION AT SER-321; SER-324; SER-325; SER-330; SER-339 AND SER-351,
RP   INTERACTION WITH ARRB2 AND ARRC, FUNCTION, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RX   PubMed=20048153; DOI=10.1074/jbc.m109.091173;
RA   Busillo J.M., Armando S., Sengupta R., Meucci O., Bouvier M., Benovic J.L.;
RT   "Site-specific phosphorylation of CXCR4 is dynamically regulated by
RT   multiple kinases and results in differential modulation of CXCR4
RT   signaling.";
RL   J. Biol. Chem. 285:7805-7817(2010).
RN   [47]
RP   FUNCTION, AND INTERACTION WITH UBIQUITIN.
RX   PubMed=20228059; DOI=10.1074/jbc.m110.103408;
RA   Saini V., Marchese A., Majetschak M.;
RT   "CXC chemokine receptor 4 is a cell surface receptor for extracellular
RT   ubiquitin.";
RL   J. Biol. Chem. 285:15566-15576(2010).
RN   [48]
RP   INTERACTION WITH DBN1, AND SUBCELLULAR LOCATION.
RX   PubMed=20215400; DOI=10.1242/jcs.064238;
RA   Perez-Martinez M., Gordon-Alonso M., Cabrero J.R., Barrero-Villar M.,
RA   Rey M., Mittelbrunn M., Lamana A., Morlino G., Calabia C., Yamazaki H.,
RA   Shirao T., Vazquez J., Gonzalez-Amaro R., Veiga E., Sanchez-Madrid F.;
RT   "F-actin-binding protein drebrin regulates CXCR4 recruitment to the immune
RT   synapse.";
RL   J. Cell Sci. 123:1160-1170(2010).
RN   [49]
RP   FUNCTION, AND INTERACTION WITH UBIQUITIN.
RX   PubMed=20505072; DOI=10.1091/mbc.e10-02-0169;
RA   Malik R., Marchese A.;
RT   "Arrestin-2 interacts with the endosomal sorting complex required for
RT   transport machinery to modulate endosomal sorting of CXCR4.";
RL   Mol. Biol. Cell 21:2529-2541(2010).
RN   [50]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [51]
RP   SUBCELLULAR LOCATION.
RX   PubMed=21540189; DOI=10.1074/jbc.m111.224071;
RA   Cheng S.B., Quinn J.A., Graeber C.T., Filardo E.J.;
RT   "Down-modulation of the G-protein-coupled estrogen receptor, GPER, from the
RT   cell surface occurs via a trans-Golgi-proteasome pathway.";
RL   J. Biol. Chem. 286:22441-22455(2011).
RN   [52]
RP   INDUCTION (MICROBIAL INFECTION), AND INTERACTION WITH HHV-5 PROTEIN UL78.
RX   PubMed=22496149; DOI=10.1182/blood-2011-08-372516;
RA   Tadagaki K., Tudor D., Gbahou F., Tschische P., Waldhoer M., Bomsel M.,
RA   Jockers R., Kamal M.;
RT   "Human cytomegalovirus-encoded UL33 and UL78 heteromerize with host CCR5
RT   and CXCR4 impairing their HIV coreceptor activity.";
RL   Blood 119:4908-4918(2012).
RN   [53]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-321; SER-324 AND SER-325, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [54]
RP   INVOLVEMENT IN WALDENSTROEM MACROGLOBULINEMIA, AND VARIANT 338-SER--SER-352
RP   DEL.
RX   PubMed=24366360; DOI=10.1182/blood-2013-09-525808;
RA   Hunter Z.R., Xu L., Yang G., Zhou Y., Liu X., Cao Y., Manning R.J.,
RA   Tripsas C., Patterson C.J., Sheehy P., Treon S.P.;
RT   "The genomic landscape of Waldenstrom macroglobulinemia is characterized by
RT   highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic
RT   deletions associated with B-cell lymphomagenesis.";
RL   Blood 123:1637-1646(2014).
RN   [55]
RP   INVOLVEMENT IN WALDENSTROEM MACROGLOBULINEMIA, AND VARIANTS
RP   333-LYS--SER-352 DEL; 334-ARG--SER-352 DEL AND 338-SER--SER-352 DEL.
RX   PubMed=24553177; DOI=10.1182/blood-2014-01-550905;
RA   Treon S.P., Cao Y., Xu L., Yang G., Liu X., Hunter Z.R.;
RT   "Somatic mutations in MYD88 and CXCR4 are determinants of clinical
RT   presentation and overall survival in Waldenstrom macroglobulinemia.";
RL   Blood 123:2791-2796(2014).
RN   [56]
RP   FUNCTION, AND CHARACTERIZATION OF VARIANT 338-SER--SER-352 DEL.
RX   PubMed=24912431; DOI=10.1038/leu.2014.187;
RA   Cao Y., Hunter Z.R., Liu X., Xu L., Yang G., Chen J., Patterson C.J.,
RA   Tsakmaklis N., Kanan S., Rodig S., Castillo J.J., Treon S.P.;
RT   "The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and
RT   promotes resistance to ibrutinib and other agents used in the treatment of
RT   Waldenstrom's Macroglobulinemia.";
RL   Leukemia 29:169-176(2015).
RN   [57]
RP   FUNCTION, UBIQUITINATION, AND MUTAGENESIS OF LYS-331.
RX   PubMed=28978524; DOI=10.1152/ajpcell.00193.2017;
RA   Lear T., Dunn S.R., McKelvey A.C., Mir A., Evankovich J., Chen B.B.,
RA   Liu Y.;
RT   "RING finger protein 113A regulates C-X-C chemokine receptor type 4
RT   stability and signaling.";
RL   Am. J. Physiol. 313:C584-C592(2017).
RN   [58]
RP   STRUCTURE BY NMR OF 1-38, SULFATION AT TYR-21, IDENTIFICATION BY MASS
RP   SPECTROMETRY, AND INTERACTION WITH CXCL12.
RX   PubMed=16725153; DOI=10.1016/j.jmb.2006.04.052;
RA   Veldkamp C.T., Seibert C., Peterson F.C., Sakmar T.P., Volkman B.F.;
RT   "Recognition of a CXCR4 sulfotyrosine by the chemokine stromal cell-derived
RT   factor-1alpha (SDF-1alpha/CXCL12).";
RL   J. Mol. Biol. 359:1400-1409(2006).
RN   [59]
RP   STRUCTURE BY NMR OF 1-38 OF SULFATED MUTANT ALA-28 IN COMPLEX WITH CXCL12.
RX   PubMed=18799424; DOI=10.1126/scisignal.1160755;
RA   Veldkamp C.T., Seibert C., Peterson F.C., De la Cruz N.B.,
RA   Haugner J.C. III, Basnet H., Sakmar T.P., Volkman B.F.;
RT   "Structural basis of CXCR4 sulfotyrosine recognition by the chemokine SDF-
RT   1/CXCL12.";
RL   Sci. Signal. 1:RA4-RA4(2008).
RN   [60] {ECO:0000244|PDB:3ODU, ECO:0000244|PDB:3OE0, ECO:0000244|PDB:3OE6, ECO:0000244|PDB:3OE8, ECO:0000244|PDB:3OE9}
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 2-325 OF MUTANTS LEU-125 AND
RP   THR-240 IN COMPLEX WITH ANTAGONISTS CVX15 AND IT1T, SUBCELLULAR LOCATION,
RP   TOPOLOGY, HOMODIMERIZATION, AND DISULFIDE BONDS.
RX   PubMed=20929726; DOI=10.1126/science.1194396;
RA   Wu B., Chien E.Y., Mol C.D., Fenalti G., Liu W., Katritch V., Abagyan R.,
RA   Brooun A., Wells P., Bi F.C., Hamel D.J., Kuhn P., Handel T.M.,
RA   Cherezov V., Stevens R.C.;
RT   "Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic
RT   peptide antagonists.";
RL   Science 330:1066-1071(2010).
RN   [61]
RP   X-RAY CRYSTALLOGRAPHY (3.10 ANGSTROMS) OF 2-319 IN COMPLEX WITH HHV-8 VIRUS
RP   ORF K4 PROTEIN, AND INTERACTION WITH HHV-8 VIRUS ORF K4 PROTEIN.
RX   PubMed=25612609; DOI=10.1126/science.1261064;
RA   Qin L., Kufareva I., Holden L.G., Wang C., Zheng Y., Zhao C., Fenalti G.,
RA   Wu H., Han G.W., Cherezov V., Abagyan R., Stevens R.C., Handel T.M.;
RT   "Structural biology. Crystal structure of the chemokine receptor CXCR4 in
RT   complex with a viral chemokine.";
RL   Science 347:1117-1122(2015).
CC   -!- FUNCTION: Receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces
CC       a signal by increasing intracellular calcium ion levels and enhancing
CC       MAPK1/MAPK3 activation (PubMed:10452968, PubMed:28978524,
CC       PubMed:18799424, PubMed:24912431). Involved in the AKT signaling
CC       cascade (PubMed:24912431). Plays a role in regulation of cell
CC       migration, e.g. during wound healing (PubMed:28978524). Acts as a
CC       receptor for extracellular ubiquitin; leading to enhanced intracellular
CC       calcium ions and reduced cellular cAMP levels (PubMed:20228059). Binds
CC       bacterial lipopolysaccharide (LPS) et mediates LPS-induced inflammatory
CC       response, including TNF secretion by monocytes (PubMed:11276205).
CC       Involved in hematopoiesis and in cardiac ventricular septum formation.
CC       Also plays an essential role in vascularization of the gastrointestinal
CC       tract, probably by regulating vascular branching and/or remodeling
CC       processes in endothelial cells. Involved in cerebellar development. In
CC       the CNS, could mediate hippocampal-neuron survival (By similarity).
CC       {ECO:0000250|UniProtKB:P70658, ECO:0000269|PubMed:10074102,
CC       ECO:0000269|PubMed:10452968, ECO:0000269|PubMed:10644702,
CC       ECO:0000269|PubMed:10825158, ECO:0000269|PubMed:11276205,
CC       ECO:0000269|PubMed:17197449, ECO:0000269|PubMed:18799424,
CC       ECO:0000269|PubMed:20048153, ECO:0000269|PubMed:20228059,
CC       ECO:0000269|PubMed:20505072, ECO:0000269|PubMed:24912431,
CC       ECO:0000269|PubMed:28978524, ECO:0000269|PubMed:8752280,
CC       ECO:0000269|PubMed:8752281}.
CC   -!- FUNCTION: (Microbial infection) Acts as a coreceptor (CD4 being the
CC       primary receptor) for human immunodeficiency virus-1/HIV-1 X4 isolates
CC       and as a primary receptor for some HIV-2 isolates. Promotes Env-
CC       mediated fusion of the virus (PubMed:8849450, PubMed:8929542,
CC       PubMed:9427609, PubMed:10074122, PubMed:10756055).
CC       {ECO:0000269|PubMed:10074122, ECO:0000269|PubMed:10756055,
CC       ECO:0000269|PubMed:8849450, ECO:0000269|PubMed:8929542,
CC       ECO:0000269|PubMed:9427609}.
CC   -!- SUBUNIT: Monomer. Can form homodimers (PubMed:20929726). Interacts with
CC       CD164 (PubMed:17077324). Interacts with ARRB2; the interaction is
CC       dependent on the C-terminal phosphorylation of CXCR4 and allows
CC       activation of MAPK1 and MAPK3. Interacts with ARRC; the interaction is
CC       dependent on the C-terminal phosphorylation of CXCR4 and modulates
CC       calcium mobilization (PubMed:20048153). Interacts with RNF113A; the
CC       interaction, enhanced by CXCL12, promotes CXCR4 ubiquitination and
CC       subsequent degradation (PubMed:28978524). Interacts (via the
CC       cytoplasmic C-terminal) with ITCH (via the WW domains I and II); the
CC       interaction, enhanced by CXCL12, promotes CXCR4 ubiquitination and
CC       leads to its degradation. Interacts with extracellular ubiquitin.
CC       Interacts with DBN1; this interaction is enhanced by antigenic
CC       stimulation. Following LPS binding, may form a complex with GDF5,
CC       HSP90AA1 and HSPA8. {ECO:0000269|PubMed:10644702,
CC       ECO:0000269|PubMed:10825158, ECO:0000269|PubMed:11276205,
CC       ECO:0000269|PubMed:12034737, ECO:0000269|PubMed:16725153,
CC       ECO:0000269|PubMed:17077324, ECO:0000269|PubMed:18799424,
CC       ECO:0000269|PubMed:18834145, ECO:0000269|PubMed:19116316,
CC       ECO:0000269|PubMed:20048153, ECO:0000269|PubMed:20215400,
CC       ECO:0000269|PubMed:20228059, ECO:0000269|PubMed:20505072,
CC       ECO:0000269|PubMed:20929726, ECO:0000269|PubMed:28978524}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with HIV-1 surface protein
CC       gp120 and Tat. {ECO:0000269|PubMed:10074122,
CC       ECO:0000269|PubMed:10756055, ECO:0000269|PubMed:11027346,
CC       ECO:0000269|PubMed:25612609}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with HHV-8 protein ORF K4
CC       (PubMed:25612609). {ECO:0000269|PubMed:9427609}.
CC   -!- SUBUNIT: (Microbial infection) May interact with human
CC       cytomegalovirus/HHV-5 protein UL78. {ECO:0000269|PubMed:22496149}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Staphylococcus aureus
CC       protein SSL10. {ECO:0000269|PubMed:19308288}.
CC   -!- INTERACTION:
CC       P61073; P25106: ACKR3; NbExp=18; IntAct=EBI-489411, EBI-1965291;
CC       P61073; P35348: ADRA1A; NbExp=10; IntAct=EBI-489411, EBI-489756;
CC       P61073; P35368: ADRA1B; NbExp=9; IntAct=EBI-489411, EBI-490017;
CC       P61073; P25100: ADRA1D; NbExp=2; IntAct=EBI-489411, EBI-489993;
CC       P61073; P37288: AVPR1A; NbExp=2; IntAct=EBI-489411, EBI-6656842;
CC       P61073; P51681: CCR5; NbExp=4; IntAct=EBI-489411, EBI-489374;
CC       P61073; Q04900: CD164; NbExp=2; IntAct=EBI-489411, EBI-2115896;
CC       P61073; P04233: CD74; NbExp=4; IntAct=EBI-489411, EBI-2622890;
CC       P61073; P49682: CXCR3; NbExp=5; IntAct=EBI-489411, EBI-12836456;
CC       P61073; P61073: CXCR4; NbExp=2; IntAct=EBI-489411, EBI-489411;
CC       P61073; P32302: CXCR5; NbExp=3; IntAct=EBI-489411, EBI-2835269;
CC       P61073; Q16643: DBN1; NbExp=5; IntAct=EBI-489411, EBI-351394;
CC       P61073; P35579: MYH9; NbExp=5; IntAct=EBI-489411, EBI-350338;
CC       P61073; O60603: TLR2; NbExp=3; IntAct=EBI-489411, EBI-973722;
CC       P61073; Q07266-1: Dbn1; Xeno; NbExp=3; IntAct=EBI-489411, EBI-8786792;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10452968,
CC       ECO:0000305|PubMed:20929726}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:20929726}. Cell junction. Early endosome. Late
CC       endosome. Lysosome. Note=In unstimulated cells, diffuse pattern on
CC       plasma membrane. On agonist stimulation, colocalizes with ITCH at the
CC       plasma membrane where it becomes ubiquitinated. In the presence of
CC       antigen, distributes to the immunological synapse forming at the T-
CC       cell-APC contact area, where it localizes at the peripheral and distal
CC       supramolecular activation cluster (SMAC).
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=1;
CC         IsoId=P61073-1, P30991-1;
CC         Sequence=Displayed;
CC       Name=2; Synonyms=CXCR4-LO;
CC         IsoId=P61073-2, P30991-2;
CC         Sequence=VSP_001890;
CC   -!- TISSUE SPECIFICITY: Expressed in numerous tissues, such as peripheral
CC       blood leukocytes, spleen, thymus, spinal cord, heart, placenta, lung,
CC       liver, skeletal muscle, kidney, pancreas, cerebellum, cerebral cortex
CC       and medulla (in microglia as well as in astrocytes), brain
CC       microvascular, coronary artery and umbilical cord endothelial cells.
CC       Isoform 1 is predominant in all tissues tested.
CC       {ECO:0000269|PubMed:11276205}.
CC   -!- INDUCTION: (Microbial infection) May be down-regulated by Human
CC       cytomegalovirus/HHV-5. {ECO:0000269|PubMed:22496149}.
CC   -!- INDUCTION: (Microbial infection) May be down-regulated by HIV-1 tat.
CC       {ECO:0000269|PubMed:11027346}.
CC   -!- DOMAIN: The amino-terminus is critical for ligand binding. Residues in
CC       all four extracellular regions contribute to HIV-1 coreceptor activity.
CC       {ECO:0000269|PubMed:10074122}.
CC   -!- PTM: Phosphorylated on agonist stimulation. Rapidly phosphorylated on
CC       serine and threonine residues in the C-terminal. Phosphorylation at
CC       Ser-324 and Ser-325 leads to recruitment of ITCH, ubiquitination and
CC       protein degradation. {ECO:0000269|PubMed:14602072,
CC       ECO:0000269|PubMed:19116316, ECO:0000269|PubMed:20048153}.
CC   -!- PTM: Ubiquitinated after ligand binding, leading to its degradation
CC       (PubMed:28978524). Ubiquitinated by ITCH at the cell membrane on
CC       agonist stimulation. The ubiquitin-dependent mechanism, endosomal
CC       sorting complex required for transport (ESCRT), then targets CXCR4 for
CC       lysosomal degradation. This process is dependent also on prior
CC       Ser-/Thr-phosphorylation in the C-terminal of CXCR4. Also binding of
CC       ARRB1 to STAM negatively regulates CXCR4 sorting to lysosomes though
CC       modulating ubiquitination of SFR5S. {ECO:0000269|PubMed:14602072,
CC       ECO:0000269|PubMed:28978524}.
CC   -!- PTM: Sulfation on Tyr-21 is required for efficient binding of
CC       CXCL12/SDF-1alpha and promotes its dimerization. Tyr-7 and Tyr-12 are
CC       sulfated in a sequential manner after Tyr-21 is almost fully sulfated,
CC       with the binding affinity for CXCL12/SDF-1alpha increasing with the
CC       number of sulfotyrosines present. Sulfotyrosines Tyr-7 and Tyr-12
CC       occupy clefts on opposing CXCL12 subunits, thus bridging the CXCL12
CC       dimer interface and promoting CXCL12 dimerization.
CC       {ECO:0000269|PubMed:10089882, ECO:0000269|PubMed:12034737,
CC       ECO:0000269|PubMed:16725153, ECO:0000269|PubMed:18834145}.
CC   -!- PTM: O- and N-glycosylated. Asn-11 is the principal site of N-
CC       glycosylation. There appears to be very little or no glycosylation on
CC       Asn-176. N-glycosylation masks coreceptor function in both X4 and R5
CC       laboratory-adapted and primary HIV-1 strains through inhibiting
CC       interaction with their Env glycoproteins. The O-glycosylation
CC       chondroitin sulfate attachment does not affect interaction with
CC       CXCL12/SDF-1alpha nor its coreceptor activity.
CC       {ECO:0000269|PubMed:10756055, ECO:0000269|PubMed:12034737}.
CC   -!- DISEASE: WHIM syndrome (WHIMS) [MIM:193670]: Immunodeficiency disease
CC       characterized by neutropenia, hypogammaglobulinemia and extensive human
CC       papillomavirus (HPV) infection. Despite the peripheral neutropenia,
CC       bone marrow aspirates from affected individuals contain abundant mature
CC       myeloid cells, a condition termed myelokathexis.
CC       {ECO:0000269|PubMed:12692554, ECO:0000269|PubMed:15536153}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Note=CXCR4 mutations play a role in the pathogenesis of
CC       Waldenstroem macroglobulinemia (WM) and influence disease presentation
CC       and outcome, as well as response to therapy. WM is a B-cell lymphoma
CC       characterized by accumulation of malignant lymphoplasmacytic cells in
CC       the bone marrow, lymph nodes and spleen, and hypersecretion of
CC       monoclonal immunoglobulin M (IgM). Excess IgM production results in
CC       serum hyperviscosity, tissue infiltration, and autoimmune-related
CC       pathology. {ECO:0000269|PubMed:24366360, ECO:0000269|PubMed:24553177}.
CC   -!- MISCELLANEOUS: Plerixafor (AMD3100), an antagonist of CXCR4 activity,
CC       blocks HIV-1 entry, interaction with CXCL12 and subsequent CXCR4
CC       signaling.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- CAUTION: Was originally thought to be a receptor for neuropeptide Y
CC       type 3 (NPY3R) (NPY3-R) (PubMed:8329116 and PubMed:8234909). Later
CC       reports showed that it acts as a receptor for the C-X-C chemokine
CC       CXCL12/SDF-1 (PubMed:9427609, PubMed:10825158, PubMed:12034737).
CC       {ECO:0000269|PubMed:10825158, ECO:0000269|PubMed:12034737,
CC       ECO:0000269|PubMed:9427609, ECO:0000305|PubMed:8234909,
CC       ECO:0000305|PubMed:8329116}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA12166.1; Type=Miscellaneous discrepancy; Note=Intron retention.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=CXCR4base; Note=CXCR4 mutation db;
CC       URL="http://structure.bmc.lu.se/idbase/CXCR4base/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=CXC chemokine receptors entry;
CC       URL="https://en.wikipedia.org/wiki/CXC_chemokine_receptors";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=CXCR4 entry;
CC       URL="https://en.wikipedia.org/wiki/CXCR4";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/cxcr4/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L01639; AAA16594.1; -; mRNA.
DR   EMBL; M99293; AAA16617.1; -; mRNA.
DR   EMBL; X71635; CAA50641.1; -; mRNA.
DR   EMBL; L06797; AAA03209.1; -; mRNA.
DR   EMBL; D10924; BAA01722.1; -; mRNA.
DR   EMBL; AF005058; AAB93982.1; -; Genomic_DNA.
DR   EMBL; AF052572; AAC34581.1; -; Genomic_DNA.
DR   EMBL; AJ224869; CAA12166.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AF025375; AAB81970.1; -; mRNA.
DR   EMBL; Y14739; CAA75034.1; -; Genomic_DNA.
DR   EMBL; AF147204; AAF00130.1; -; mRNA.
DR   EMBL; AF348491; AAK29630.1; -; mRNA.
DR   EMBL; AK312244; BAG35177.1; -; mRNA.
DR   EMBL; AY242129; AAO92296.1; -; mRNA.
DR   EMBL; BT006660; AAP35306.1; -; mRNA.
DR   EMBL; AY728138; AAU05775.1; -; Genomic_DNA.
DR   EMBL; AC068492; AAY24044.1; -; Genomic_DNA.
DR   EMBL; CH471058; EAX11616.1; -; Genomic_DNA.
DR   EMBL; BC020968; AAH20968.1; -; mRNA.
DR   CCDS; CCDS33295.1; -. [P61073-2]
DR   CCDS; CCDS46420.1; -.
DR   PIR; A45747; A45747.
DR   RefSeq; NP_001008540.1; NM_001008540.2. [P61073-2]
DR   RefSeq; NP_001334985.1; NM_001348056.1.
DR   RefSeq; NP_001334988.1; NM_001348059.1.
DR   RefSeq; NP_001334989.1; NM_001348060.1.
DR   RefSeq; NP_003458.1; NM_003467.2. [P61073-1]
DR   PDB; 2K03; NMR; -; B/D=1-38.
DR   PDB; 2K04; NMR; -; B/D=1-38.
DR   PDB; 2K05; NMR; -; B/D=1-38.
DR   PDB; 2N55; NMR; -; B=1-38.
DR   PDB; 3ODU; X-ray; 2.50 A; A/B=2-319.
DR   PDB; 3OE0; X-ray; 2.90 A; A=2-319.
DR   PDB; 3OE6; X-ray; 3.20 A; A=2-325.
DR   PDB; 3OE8; X-ray; 3.10 A; A/B/C=2-319.
DR   PDB; 3OE9; X-ray; 3.10 A; A/B=2-319.
DR   PDB; 4RWS; X-ray; 3.10 A; A=2-228, A=231-319.
DR   PDBsum; 2K03; -.
DR   PDBsum; 2K04; -.
DR   PDBsum; 2K05; -.
DR   PDBsum; 2N55; -.
DR   PDBsum; 3ODU; -.
DR   PDBsum; 3OE0; -.
DR   PDBsum; 3OE6; -.
DR   PDBsum; 3OE8; -.
DR   PDBsum; 3OE9; -.
DR   PDBsum; 4RWS; -.
DR   BMRB; P61073; -.
DR   SMR; P61073; -.
DR   BioGRID; 113607; 55.
DR   CORUM; P61073; -.
DR   DIP; DIP-34773N; -.
DR   DIP; DIP-46290N; -.
DR   IntAct; P61073; 40.
DR   MINT; P61073; -.
DR   STRING; 9606.ENSP00000386884; -.
DR   BindingDB; P61073; -.
DR   ChEMBL; CHEMBL2107; -.
DR   DrugBank; DB05501; AMD-070.
DR   DrugBank; DB00452; Framycetin.
DR   DrugBank; DB12698; Ibalizumab.
DR   DrugBank; DB12498; Mogamulizumab.
DR   DrugBank; DB06809; Plerixafor.
DR   DrugCentral; P61073; -.
DR   GuidetoPHARMACOLOGY; 71; -.
DR   TCDB; 9.A.14.13.17; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; P61073; 3 sites.
DR   iPTMnet; P61073; -.
DR   PhosphoSitePlus; P61073; -.
DR   SwissPalm; P61073; -.
DR   BioMuta; CXCR4; -.
DR   DMDM; 46577576; -.
DR   jPOST; P61073; -.
DR   MassIVE; P61073; -.
DR   MaxQB; P61073; -.
DR   PaxDb; P61073; -.
DR   PeptideAtlas; P61073; -.
DR   PRIDE; P61073; -.
DR   ProteomicsDB; 57256; -.
DR   ProteomicsDB; 57257; -. [P61073-2]
DR   ABCD; P61073; 36 sequenced antibodies.
DR   Antibodypedia; 4421; 1729 antibodies.
DR   DNASU; 7852; -.
DR   Ensembl; ENST00000241393; ENSP00000241393; ENSG00000121966. [P61073-1]
DR   Ensembl; ENST00000409817; ENSP00000386884; ENSG00000121966. [P61073-2]
DR   GeneID; 7852; -.
DR   KEGG; hsa:7852; -.
DR   UCSC; uc002tuy.3; human.
DR   CTD; 7852; -.
DR   DisGeNET; 7852; -.
DR   EuPathDB; HostDB:ENSG00000121966.6; -.
DR   GeneCards; CXCR4; -.
DR   HGNC; HGNC:2561; CXCR4.
DR   HPA; ENSG00000121966; Tissue enhanced (bone marrow, lymphoid tissue).
DR   MalaCards; CXCR4; -.
DR   MIM; 162643; gene.
DR   MIM; 193670; phenotype.
DR   neXtProt; NX_P61073; -.
DR   OpenTargets; ENSG00000121966; -.
DR   Orphanet; 51636; WHIM syndrome.
DR   PharmGKB; PA27058; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT01000000214381; -.
DR   HOGENOM; CLU_009579_8_3_1; -.
DR   InParanoid; P61073; -.
DR   KO; K04189; -.
DR   OMA; IVHKWIS; -.
DR   OrthoDB; 773026at2759; -.
DR   PhylomeDB; P61073; -.
DR   TreeFam; TF330966; -.
DR   PathwayCommons; P61073; -.
DR   Reactome; R-HSA-173107; Binding and entry of HIV virion.
DR   Reactome; R-HSA-376176; Signaling by ROBO receptors.
DR   Reactome; R-HSA-380108; Chemokine receptors bind chemokines.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   SignaLink; P61073; -.
DR   SIGNOR; P61073; -.
DR   BioGRID-ORCS; 7852; 1 hit in 875 CRISPR screens.
DR   ChiTaRS; CXCR4; human.
DR   EvolutionaryTrace; P61073; -.
DR   GeneWiki; CXCR4; -.
DR   GenomeRNAi; 7852; -.
DR   Pharos; P61073; Tclin.
DR   PRO; PR:P61073; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; P61073; protein.
DR   Bgee; ENSG00000121966; Expressed in oviduct epithelium and 238 other tissues.
DR   Genevisible; P61073; HS.
DR   GO; GO:0030054; C:cell junction; IEA:UniProtKB-SubCell.
DR   GO; GO:0031252; C:cell leading edge; IDA:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IDA:UniProtKB.
DR   GO; GO:0005769; C:early endosome; IDA:UniProtKB.
DR   GO; GO:0009897; C:external side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005770; C:late endosome; IDA:UniProtKB.
DR   GO; GO:0005764; C:lysosome; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IDA:ARUK-UCL.
DR   GO; GO:0003779; F:actin binding; IDA:UniProtKB.
DR   GO; GO:0019957; F:C-C chemokine binding; IPI:CAFA.
DR   GO; GO:0016493; F:C-C chemokine receptor activity; IBA:GO_Central.
DR   GO; GO:0016494; F:C-X-C chemokine receptor activity; NAS:UniProtKB.
DR   GO; GO:0038147; F:C-X-C motif chemokine 12 receptor activity; IDA:UniProtKB.
DR   GO; GO:0019956; F:chemokine binding; IBA:GO_Central.
DR   GO; GO:0015026; F:coreceptor activity; TAS:ProtInc.
DR   GO; GO:0008144; F:drug binding; IEA:Ensembl.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; TAS:ProtInc.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0032027; F:myosin light chain binding; IDA:UniProtKB.
DR   GO; GO:0043130; F:ubiquitin binding; IDA:UniProtKB.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0001618; F:virus receptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0000187; P:activation of MAPK activity; TAS:ProtInc.
DR   GO; GO:0006915; P:apoptotic process; TAS:ProtInc.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0007420; P:brain development; IBA:GO_Central.
DR   GO; GO:0019722; P:calcium-mediated signaling; IMP:MGI.
DR   GO; GO:0060048; P:cardiac muscle contraction; IEA:Ensembl.
DR   GO; GO:0060326; P:cell chemotaxis; IBA:GO_Central.
DR   GO; GO:0071345; P:cellular response to cytokine stimulus; IDA:UniProtKB.
DR   GO; GO:0035690; P:cellular response to drug; IEA:Ensembl.
DR   GO; GO:0006935; P:chemotaxis; IBA:GO_Central.
DR   GO; GO:0038160; P:CXCL12-activated CXCR4 signaling pathway; IDA:UniProtKB.
DR   GO; GO:0002407; P:dendritic cell chemotaxis; TAS:BHF-UCL.
DR   GO; GO:0050966; P:detection of mechanical stimulus involved in sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0050965; P:detection of temperature stimulus involved in sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0045446; P:endothelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0061154; P:endothelial tube morphogenesis; IEA:Ensembl.
DR   GO; GO:0002064; P:epithelial cell development; IEA:Ensembl.
DR   GO; GO:0019064; P:fusion of virus membrane with host plasma membrane; TAS:Reactome.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0006955; P:immune response; IBA:GO_Central.
DR   GO; GO:0006954; P:inflammatory response; TAS:ProtInc.
DR   GO; GO:0043217; P:myelin maintenance; ISS:BHF-UCL.
DR   GO; GO:0022008; P:neurogenesis; IBA:GO_Central.
DR   GO; GO:0001764; P:neuron migration; IEA:Ensembl.
DR   GO; GO:0008038; P:neuron recognition; IEA:Ensembl.
DR   GO; GO:0050921; P:positive regulation of chemotaxis; IEA:Ensembl.
DR   GO; GO:0120162; P:positive regulation of cold-induced thermogenesis; ISS:YuBioLab.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IBA:GO_Central.
DR   GO; GO:1903861; P:positive regulation of dendrite extension; IEA:Ensembl.
DR   GO; GO:2000448; P:positive regulation of macrophage migration inhibitory factor signaling pathway; IMP:ARUK-UCL.
DR   GO; GO:1905322; P:positive regulation of mesenchymal stem cell migration; IEA:Ensembl.
DR   GO; GO:0048714; P:positive regulation of oligodendrocyte differentiation; ISS:BHF-UCL.
DR   GO; GO:0035470; P:positive regulation of vascular wound healing; IEA:Ensembl.
DR   GO; GO:0051924; P:regulation of calcium ion transport; IEA:Ensembl.
DR   GO; GO:0030155; P:regulation of cell adhesion; IDA:UniProtKB.
DR   GO; GO:0050920; P:regulation of chemotaxis; IMP:UniProtKB.
DR   GO; GO:0043067; P:regulation of programmed cell death; IEA:Ensembl.
DR   GO; GO:0050792; P:regulation of viral process; IEA:Ensembl.
DR   GO; GO:0014823; P:response to activity; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEP:UniProtKB.
DR   GO; GO:0043278; P:response to morphine; IEA:Ensembl.
DR   GO; GO:1990478; P:response to ultrasound; IEA:Ensembl.
DR   GO; GO:0009615; P:response to virus; TAS:ProtInc.
DR   GO; GO:0022029; P:telencephalon cell migration; IEA:Ensembl.
DR   DisProt; DP01249; -.
DR   InterPro; IPR022726; Chemokine_CXCR4_N_dom.
DR   InterPro; IPR000355; Chemokine_rcpt.
DR   InterPro; IPR001277; CXCR4/ACKR2.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   Pfam; PF00001; 7tm_1; 1.
DR   Pfam; PF12109; CXCR4_N; 1.
DR   PRINTS; PR00657; CCCHEMOKINER.
DR   PRINTS; PR00645; CXCCHMKINER4.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell junction; Cell membrane;
KW   Disease mutation; Disulfide bond; Endosome; G-protein coupled receptor;
KW   Glycoprotein; Host cell receptor for virus entry; Host-virus interaction;
KW   Isopeptide bond; Lysosome; Membrane; Phosphoprotein; Proteoglycan;
KW   Receptor; Reference proteome; Sulfation; Transducer; Transmembrane;
KW   Transmembrane helix; Ubl conjugation.
FT   CHAIN           1..352
FT                   /note="C-X-C chemokine receptor type 4"
FT                   /id="PRO_0000069352"
FT   TOPO_DOM        1..38
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:20929726"
FT   TRANSMEM        39..63
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000269|PubMed:20929726"
FT   TOPO_DOM        64..77
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:20929726"
FT   TRANSMEM        78..99
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000269|PubMed:20929726"
FT   TOPO_DOM        100..110
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:20929726"
FT   TRANSMEM        111..130
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000269|PubMed:20929726"
FT   TOPO_DOM        131..154
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:20929726"
FT   TRANSMEM        155..174
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000269|PubMed:20929726"
FT   TOPO_DOM        175..195
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:20929726"
FT   TRANSMEM        196..216
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000269|PubMed:20929726"
FT   TOPO_DOM        217..241
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:20929726"
FT   TRANSMEM        242..261
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000269|PubMed:20929726"
FT   TOPO_DOM        262..282
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:20929726"
FT   TRANSMEM        283..302
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000269|PubMed:20929726"
FT   TOPO_DOM        303..352
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:20929726"
FT   REGION          1..21
FT                   /note="Important for chemokine binding, signaling and HIV-1
FT                   coreceptor activity"
FT                   /evidence="ECO:0000269|PubMed:10825158"
FT   REGION          94..97
FT                   /note="Chemokine binding"
FT                   /evidence="ECO:0000269|PubMed:20929726,
FT                   ECO:0000305|PubMed:10825158"
FT   REGION          113..117
FT                   /note="Chemokine binding"
FT   REGION          135..147
FT                   /note="Involved in dimerization; when bound to chemokine"
FT   REGION          186..190
FT                   /note="Chemokine binding, important for signaling and HIV-1
FT                   coreceptor activity"
FT   REGION          191..210
FT                   /note="Involved in dimerization"
FT   REGION          266..268
FT                   /note="Involved in dimerization"
FT   MOTIF           133..135
FT                   /note="Important for signaling"
FT   BINDING         171
FT                   /note="Chemokine"
FT   BINDING         288
FT                   /note="Chemokine"
FT                   /evidence="ECO:0000269|PubMed:20929726,
FT                   ECO:0000305|PubMed:10825158"
FT   MOD_RES         7
FT                   /note="Sulfotyrosine; partial"
FT                   /evidence="ECO:0000269|PubMed:18834145"
FT   MOD_RES         12
FT                   /note="Sulfotyrosine; partial"
FT                   /evidence="ECO:0000269|PubMed:18834145"
FT   MOD_RES         21
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000269|PubMed:12034737,
FT                   ECO:0000269|PubMed:16725153, ECO:0000269|PubMed:18834145"
FT   MOD_RES         319
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         321
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:23186163,
FT                   ECO:0000269|PubMed:20048153"
FT   MOD_RES         324
FT                   /note="Phosphoserine; by PKC and GRK6"
FT                   /evidence="ECO:0000244|PubMed:23186163,
FT                   ECO:0000269|PubMed:19116316, ECO:0000269|PubMed:20048153"
FT   MOD_RES         325
FT                   /note="Phosphoserine; by PKC and GRK6"
FT                   /evidence="ECO:0000244|PubMed:23186163,
FT                   ECO:0000269|PubMed:19116316, ECO:0000269|PubMed:20048153"
FT   MOD_RES         330
FT                   /note="Phosphoserine; by GRK6"
FT                   /evidence="ECO:0000269|PubMed:20048153"
FT   MOD_RES         339
FT                   /note="Phosphoserine; by GRK6"
FT                   /evidence="ECO:0000269|PubMed:20048153"
FT   MOD_RES         348
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:18669648"
FT   MOD_RES         351
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:20048153"
FT   CARBOHYD        11
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:10756055"
FT   CARBOHYD        18
FT                   /note="O-linked (Xyl...) (chondroitin sulfate) serine"
FT                   /evidence="ECO:0000269|PubMed:12034737"
FT   CARBOHYD        176
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        28..274
FT                   /evidence="ECO:0000244|PDB:3ODU, ECO:0000244|PDB:3OE0,
FT                   ECO:0000244|PDB:3OE8, ECO:0000244|PDB:3OE9,
FT                   ECO:0000244|PDB:4RWS, ECO:0000255|PROSITE-ProRule:PRU00521,
FT                   ECO:0000269|PubMed:20929726"
FT   DISULFID        109..186
FT                   /evidence="ECO:0000244|PDB:3ODU, ECO:0000244|PDB:3OE0,
FT                   ECO:0000244|PDB:3OE6, ECO:0000244|PDB:3OE8,
FT                   ECO:0000244|PDB:3OE9, ECO:0000244|PDB:4RWS,
FT                   ECO:0000255|PROSITE-ProRule:PRU00521,
FT                   ECO:0000269|PubMed:20929726"
FT   CROSSLNK        331
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000305|PubMed:28978524"
FT   VAR_SEQ         1..5
FT                   /note="MEGIS -> MSIPLPLLQ (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10452968"
FT                   /id="VSP_001890"
FT   VARIANT         333..352
FT                   /note="Missing (found in patients with Waldenstroem
FT                   macroglobulinemia; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:24553177"
FT                   /id="VAR_081112"
FT   VARIANT         334..352
FT                   /note="Missing (in WHIMS; also found in patients with
FT                   Waldenstroem macroglobulinemia; somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:12692554,
FT                   ECO:0000269|PubMed:24553177"
FT                   /id="VAR_081113"
FT   VARIANT         338..352
FT                   /note="Missing (in WHIMS; common somatic mutation in
FT                   patients with Waldenstroem macroglobulinemia; results in
FT                   decreased CXCL12-triggered receptor internalization;
FT                   enhanced AKT and MAPK signaling activation; confers
FT                   resistance to ibrutinib-triggered apoptosis)"
FT                   /evidence="ECO:0000269|PubMed:15536153,
FT                   ECO:0000269|PubMed:24366360, ECO:0000269|PubMed:24553177,
FT                   ECO:0000269|PubMed:24912431"
FT                   /id="VAR_081114"
FT   VARIANT         343..352
FT                   /note="Missing (in WHIMS)"
FT                   /evidence="ECO:0000269|PubMed:12692554"
FT                   /id="VAR_081115"
FT   MUTAGEN         2..9
FT                   /note="Missing: Reduced CXCL12 binding. Abolishes
FT                   signaling."
FT                   /evidence="ECO:0000269|PubMed:10825158"
FT   MUTAGEN         4..20
FT                   /note="Missing: Reduced CXCL12 binding. Impaired signaling.
FT                   Reduced coreceptor activity for HIV-1 isolates LAI and
FT                   NDK."
FT                   /evidence="ECO:0000269|PubMed:10825158"
FT   MUTAGEN         7
FT                   /note="Y->A: Reduced coreceptor activity for HIV-1 isolates
FT                   LAI and NDK. Greatly reduced coreceptor activity for HIV-1
FT                   isolates LAI and NDK; when associated with A-12."
FT                   /evidence="ECO:0000269|PubMed:10825158,
FT                   ECO:0000269|PubMed:12034737"
FT   MUTAGEN         7
FT                   /note="Y->F: Sulfate incorporation greatly reduced; when
FT                   associated with F-12 and F-21. Moderate reduction in
FT                   sulfate incorporation; when associated with F-12 and A-18.
FT                   No sulfate incorporation and binding SDF-1alpha greatly
FT                   reduced; when associated with F-12; A-18 and F-21."
FT                   /evidence="ECO:0000269|PubMed:10825158,
FT                   ECO:0000269|PubMed:12034737"
FT   MUTAGEN         8
FT                   /note="T->A: No effect on sulfate incorporation; when
FT                   associated with A-9 and A-13."
FT                   /evidence="ECO:0000269|PubMed:12034737"
FT   MUTAGEN         9
FT                   /note="S->A: No effect on sulfate incorporation; when
FT                   associated with A-8 and A-13."
FT                   /evidence="ECO:0000269|PubMed:12034737"
FT   MUTAGEN         10..20
FT                   /note="Missing: Reduced CXCL12 binding. No effect on
FT                   signaling."
FT                   /evidence="ECO:0000269|PubMed:10825158"
FT   MUTAGEN         11
FT                   /note="N->A: Reduced molecular weight. Enhanced coreceptor
FT                   activity on R5 HIV-1 isolate Envs. Slight further
FT                   enhancement of coreceptor activity; when associated with A-
FT                   13."
FT                   /evidence="ECO:0000269|PubMed:10756055"
FT   MUTAGEN         12
FT                   /note="Y->A: Greatly reduced coreceptor activity for HIV-1
FT                   isolates LAI and NDK; when associated with A-7."
FT                   /evidence="ECO:0000269|PubMed:10825158,
FT                   ECO:0000269|PubMed:12034737"
FT   MUTAGEN         12
FT                   /note="Y->F: Sulfate incorporation greatly reduced; when
FT                   associated with F-7 and F-21. Moderate reduction in sulfate
FT                   incorporation; when associated with F-7 and A-18. No
FT                   sulfate incorporation and binding SDF-1alpha greatly
FT                   reduced; when associated with F-7; A-18 and F-21."
FT                   /evidence="ECO:0000269|PubMed:10825158,
FT                   ECO:0000269|PubMed:12034737"
FT   MUTAGEN         13
FT                   /note="T->A: Enhanced coreceptor activity on R5 HIV-1
FT                   isolate Envs. No effect on sulfate incorporation; when
FT                   associated with A-8 and A-9."
FT                   /evidence="ECO:0000269|PubMed:10756055"
FT   MUTAGEN         14..15
FT                   /note="EE->AA: Reduced CXCL12 binding. Reduced coreceptor
FT                   activity for HIV-1 isolate NDK."
FT                   /evidence="ECO:0000269|PubMed:10825158"
FT   MUTAGEN         18
FT                   /note="S->A: Sulfate incorporation greatly reduced; when
FT                   associated with F-21. Moderate reduction in sulfate
FT                   incorporation; when associated with F-7 and F-12. No
FT                   sulfate incorporation and binding SDF-1alpha greatly
FT                   reduced; when associated with F-7; F-12; and F-21."
FT                   /evidence="ECO:0000269|PubMed:12034737"
FT   MUTAGEN         21
FT                   /note="Y->A: Reduced CXCL12 binding. Reduced coreceptor
FT                   activity for HIV-1 isolates LAI and NDk."
FT                   /evidence="ECO:0000269|PubMed:10825158,
FT                   ECO:0000269|PubMed:12034737"
FT   MUTAGEN         21
FT                   /note="Y->F: Sulfate incorporation greatly reduced; when
FT                   associated with F-7 and F-12. Sulfate incorporation greatly
FT                   reduced; when associated with A-18. No sulfate
FT                   incorporation and binding SDF-1alpha greatly reduced; when
FT                   associated with F-7; F-12 and A-18."
FT                   /evidence="ECO:0000269|PubMed:10825158,
FT                   ECO:0000269|PubMed:12034737"
FT   MUTAGEN         97
FT                   /note="D->N: Reduced CXCL12 binding. Abolishes signaling.
FT                   Markedly reduced coreceptor activity for HIV-1 isolate
FT                   LAI."
FT                   /evidence="ECO:0000269|PubMed:10825158"
FT   MUTAGEN         119
FT                   /note="N->D: No reduction of agonist-induced G-protein
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:17197449"
FT   MUTAGEN         119
FT                   /note="N->K: Loss of agonist-induced G-protein activation."
FT                   /evidence="ECO:0000269|PubMed:17197449"
FT   MUTAGEN         119
FT                   /note="N->S: Constitutive G-protein activation, with
FT                   further activation induced by agonist."
FT                   /evidence="ECO:0000269|PubMed:17197449"
FT   MUTAGEN         125
FT                   /note="L->W: Increased thermostability."
FT   MUTAGEN         133
FT                   /note="D->N: No reduction of agonist-induced G-protein
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:17197449"
FT   MUTAGEN         134
FT                   /note="R->A: Loss of agonist-induced G-protein activation."
FT                   /evidence="ECO:0000269|PubMed:17197449"
FT   MUTAGEN         135
FT                   /note="Y->A: No reduction of agonist-induced G-protein
FT                   activation."
FT                   /evidence="ECO:0000269|PubMed:17197449"
FT   MUTAGEN         171
FT                   /note="D->N: Reduced coreceptor activity for HIV-1 isolate
FT                   NDK."
FT                   /evidence="ECO:0000269|PubMed:10825158"
FT   MUTAGEN         176
FT                   /note="N->A: Enhanced coreceptor activity on R5 HIV-1
FT                   isolate Envs; when associated with A-11."
FT                   /evidence="ECO:0000269|PubMed:10756055"
FT   MUTAGEN         183
FT                   /note="R->A: Reduced coreceptor activity for several HIV-1
FT                   isolates."
FT                   /evidence="ECO:0000269|PubMed:10074102"
FT   MUTAGEN         187
FT                   /note="D->A: Reduced CXCL12 binding. Abolishes signaling."
FT                   /evidence="ECO:0000269|PubMed:10825158"
FT   MUTAGEN         188
FT                   /note="R->A: Reduced coreceptor activity for several HIV-1
FT                   isolates."
FT                   /evidence="ECO:0000269|PubMed:10074102"
FT   MUTAGEN         193
FT                   /note="D->A,S,N: Greatly reduced coreceptor activity for
FT                   HIV-1 isolate NDK. Reduced coreceptor activity for several
FT                   other HIV-1 isolates."
FT                   /evidence="ECO:0000269|PubMed:10074102,
FT                   ECO:0000269|PubMed:10825158"
FT   MUTAGEN         193
FT                   /note="D->R: Abolishes coreceptor activity for HIV-1
FT                   isolate NDK. Reduced coreceptor activity for several other
FT                   HIV-1 isolates."
FT                   /evidence="ECO:0000269|PubMed:10074102,
FT                   ECO:0000269|PubMed:10825158"
FT   MUTAGEN         240
FT                   /note="T->P: Retains ligand-binding affinity but abolishes
FT                   signaling."
FT   MUTAGEN         262
FT                   /note="D->A: Markedly reduced coreceptor activity for HIV-1
FT                   isolate LAI."
FT                   /evidence="ECO:0000269|PubMed:10825158"
FT   MUTAGEN         268
FT                   /note="E->A: Markedly reduced coreceptor activity for HIV-1
FT                   isolate NDK. Less effect for HIV-1 isolate LAI."
FT                   /evidence="ECO:0000269|PubMed:10825158"
FT   MUTAGEN         288
FT                   /note="E->Q: Reduced CXCL12 binding. Impaired signaling.
FT                   Reduced coreceptor activity for HIV-1 isolate LAI. Enhanced
FT                   coreceptor activity for HIV-1 isolate NDK."
FT                   /evidence="ECO:0000269|PubMed:10825158"
FT   MUTAGEN         310
FT                   /note="K->R: No effect on ubiquitination by RNF113A."
FT                   /evidence="ECO:0000269|PubMed:28978524"
FT   MUTAGEN         324
FT                   /note="S->A: Moderate degradation. About 60% reduction in
FT                   binding ITCH and no ubiquitination nor protein degradation;
FT                   when associated with A-325."
FT                   /evidence="ECO:0000269|PubMed:19116316"
FT   MUTAGEN         324
FT                   /note="S->D: Enhanced binding to ITCH. Enhanced binding to
FT                   ITCH and greatly increased protein degradation; when
FT                   associated with D-324."
FT                   /evidence="ECO:0000269|PubMed:19116316"
FT   MUTAGEN         324
FT                   /note="S->D: Enhanced binding to ITCH. Enhanced binding to
FT                   ITCH and greatly increased protein degradation; when
FT                   associated with D-325."
FT                   /evidence="ECO:0000269|PubMed:19116316"
FT   MUTAGEN         325
FT                   /note="S->A: Moderate degradation. About 60% reduction in
FT                   binding ITCH and no ubiquitination nor protein degradation;
FT                   when associated with A-324."
FT                   /evidence="ECO:0000269|PubMed:19116316"
FT   MUTAGEN         330
FT                   /note="S->A: No effect on binding to ITCH."
FT                   /evidence="ECO:0000269|PubMed:19116316"
FT   MUTAGEN         331
FT                   /note="K->R: Loss of ubiquitination by RNF113A."
FT                   /evidence="ECO:0000269|PubMed:28978524"
FT   CONFLICT        242..244
FT                   /note="VIL -> IIP (in Ref. 12; AAK29630)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        278
FT                   /note="N -> S (in Ref. 13; BAG35177)"
FT                   /evidence="ECO:0000305"
FT   STRAND          9..11
FT                   /evidence="ECO:0000244|PDB:2K03"
FT   STRAND          21..23
FT                   /evidence="ECO:0000244|PDB:2K03"
FT   STRAND          32..35
FT                   /evidence="ECO:0000244|PDB:2K05"
FT   HELIX           37..62
FT                   /evidence="ECO:0000244|PDB:3ODU"
FT   TURN            63..66
FT                   /evidence="ECO:0000244|PDB:3ODU"
FT   STRAND          67..69
FT                   /evidence="ECO:0000244|PDB:3OE6"
FT   HELIX           72..88
FT                   /evidence="ECO:0000244|PDB:3ODU"
FT   HELIX           91..99
FT                   /evidence="ECO:0000244|PDB:3ODU"
FT   HELIX           105..139
FT                   /evidence="ECO:0000244|PDB:3ODU"
FT   HELIX           141..143
FT                   /evidence="ECO:0000244|PDB:3OE0"
FT   HELIX           145..153
FT                   /evidence="ECO:0000244|PDB:3ODU"
FT   HELIX           155..159
FT                   /evidence="ECO:0000244|PDB:3ODU"
FT   HELIX           161..166
FT                   /evidence="ECO:0000244|PDB:3ODU"
FT   HELIX           169..174
FT                   /evidence="ECO:0000244|PDB:3ODU"
FT   STRAND          175..179
FT                   /evidence="ECO:0000244|PDB:3ODU"
FT   STRAND          181..188
FT                   /evidence="ECO:0000244|PDB:3ODU"
FT   HELIX           193..207
FT                   /evidence="ECO:0000244|PDB:3ODU"
FT   HELIX           209..225
FT                   /evidence="ECO:0000244|PDB:3ODU"
FT   HELIX           226..228
FT                   /evidence="ECO:0000244|PDB:3ODU"
FT   HELIX           231..266
FT                   /evidence="ECO:0000244|PDB:3ODU"
FT   HELIX           274..291
FT                   /evidence="ECO:0000244|PDB:3ODU"
FT   HELIX           294..301
FT                   /evidence="ECO:0000244|PDB:3ODU"
FT   TURN            302..306
FT                   /evidence="ECO:0000244|PDB:3ODU"
FT   HELIX           313..317
FT                   /evidence="ECO:0000244|PDB:3ODU"
SQ   SEQUENCE   352 AA;  39746 MW;  8C8476A186786B83 CRC64;
     MEGISIYTSD NYTEEMGSGD YDSMKEPCFR EENANFNKIF LPTIYSIIFL TGIVGNGLVI
     LVMGYQKKLR SMTDKYRLHL SVADLLFVIT LPFWAVDAVA NWYFGNFLCK AVHVIYTVNL
     YSSVLILAFI SLDRYLAIVH ATNSQRPRKL LAEKVVYVGV WIPALLLTIP DFIFANVSEA
     DDRYICDRFY PNDLWVVVFQ FQHIMVGLIL PGIVILSCYC IIISKLSHSK GHQKRKALKT
     TVILILAFFA CWLPYYIGIS IDSFILLEII KQGCEFENTV HKWISITEAL AFFHCCLNPI
     LYAFLGAKFK TSAQHALTSV SRGSSLKILS KGKRGGHSSV STESESSSFH SS
//
ID   PE2R3_HUMAN             Reviewed;         390 AA.
AC   P43115; B0AZN4; B1AK19; B5BUP5; O00326; Q12943; Q12944; Q12945; Q147X8;
AC   Q16546; Q5CZ59; Q5CZ61; Q5CZ62; Q5CZ63; Q5CZ64;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   07-OCT-2020, entry version 197.
DE   RecName: Full=Prostaglandin E2 receptor EP3 subtype;
DE            Short=PGE receptor EP3 subtype;
DE            Short=PGE2 receptor EP3 subtype;
DE   AltName: Full=PGE2-R;
DE   AltName: Full=Prostanoid EP3 receptor;
GN   Name=PTGER3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS EP3A; EP3B AND EP3C), FUNCTION, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=8307176; DOI=10.1016/0014-5793(94)80358-7;
RA   Adam M., Boie Y., Rushmore T.H., Mueller G., Bastien L., McKee K.T.,
RA   Metters K.M., Abramovitz M.;
RT   "Cloning and expression of three isoforms of the human EP3 prostanoid
RT   receptor.";
RL   FEBS Lett. 338:170-174(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS EP3A; EP3B; EP3C; EP3D; EP3E AND
RP   EP3F), FUNCTION, AND SUBCELLULAR LOCATION.
RC   TISSUE=Uterus;
RX   PubMed=7883006; DOI=10.1111/j.1432-1033.1995.tb20223.x;
RA   Schmid A., Thierauch K.H., Schleuning W.-D., Dinter H.;
RT   "Splice variants of the human EP3 receptor for prostaglandin E2.";
RL   Eur. J. Biochem. 228:23-30(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM EP3A), FUNCTION, SUBCELLULAR LOCATION,
RP   AND TISSUE SPECIFICITY.
RC   TISSUE=Kidney;
RX   PubMed=8117308; DOI=10.1006/bbrc.1994.1142;
RA   Yang J., Xia M., Goetzl E.J., An S.;
RT   "Cloning and expression of the EP3-subtype of human receptors for
RT   prostaglandin E2.";
RL   Biochem. Biophys. Res. Commun. 198:999-1006(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM EP3A), FUNCTION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=8135729; DOI=10.1042/bj2980263;
RA   Kunapuli S.P., Fen Mao G., Bastepe M., Liu-Chen L.-Y., Li S., Cheung P.P.,
RA   DeRiel J.K., Ashby B.;
RT   "Cloning and expression of a prostaglandin E receptor EP3 subtype from
RT   human erythroleukaemia cells.";
RL   Biochem. J. 298:263-267(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS EP3B; EP3C AND EP3D), FUNCTION, AND
RP   SUBCELLULAR LOCATION.
RC   TISSUE=Uterus;
RX   PubMed=7981210; DOI=10.1021/bi00252a016;
RA   An S., Yang J., So S.W., Zeng L., Goetzl E.J.;
RT   "Isoforms of the EP3 subtype of human prostaglandin E2 receptor transduce
RT   both intracellular calcium and cAMP signals.";
RL   Biochemistry 33:14496-14502(1994).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS EP3A; EP3B; EP3C AND EP3D).
RC   TISSUE=Kidney;
RX   PubMed=7476918;
RA   Kotani M., Tanaka I., Ogawa Y., Usui T., Mori K., Ichikawa A., Narumiya S.,
RA   Yoshimi T., Nakao K.;
RT   "Molecular cloning and expression of multiple isoforms of human
RT   prostaglandin E receptor EP3 subtype generated by alternative messenger RNA
RT   splicing: multiple second messenger systems and tissue-specific
RT   distributions.";
RL   Mol. Pharmacol. 48:869-879(1995).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS EP3A; EP3B; EP3C AND EP3D).
RC   TISSUE=Small intestine;
RX   PubMed=8075855; DOI=10.1111/j.1476-5381.1994.tb13082.x;
RA   Regan J.W., Bailey T.J., Donello J.E., Pierce K.L., Pepperl D.J., Zhang D.,
RA   Kedzie K.M., Fairbairn C.E., Bogardus A.M., Woodward D.F., Gil D.W.;
RT   "Molecular cloning and expression of human EP3 receptors: evidence of three
RT   variants with differing carboxyl termini.";
RL   Br. J. Pharmacol. 112:377-385(1994).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS EP3C; EP3E; EP3-III;
RP   EP3-IV; EP3-V AND EP3E2), AND ALTERNATIVE SPLICING.
RX   PubMed=9073510; DOI=10.1006/geno.1996.4585;
RA   Kotani M., Tanaka I., Ogawa Y., Usui T., Tamura N., Mori K., Narumiya S.,
RA   Yoshimi T., Nakao K.;
RT   "Structural organization of the human prostaglandin EP3 receptor subtype
RT   gene (PTGER3).";
RL   Genomics 40:425-434(1997).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM EP3G).
RC   TISSUE=Placenta;
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM EP3A).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM EP3B).
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H., Maruyama Y.,
RA   Matsuo K., Minami K., Mitsubori M., Mori M., Morishita R., Murase A.,
RA   Nishikawa A., Nishikawa S., Okamoto T., Sakagami N., Sakamoto Y.,
RA   Sasaki Y., Seki T., Sono S., Sugiyama A., Sumiya T., Takayama T.,
RA   Takayama Y., Takeda H., Togashi T., Yahata K., Yamada H., Yanagisawa Y.,
RA   Endo Y., Imamoto F., Kisu Y., Tanaka S., Isogai T., Imai J., Watanabe S.,
RA   Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in vitro-
RT   expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS EP3D AND 12).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [15]
RP   TISSUE SPECIFICITY.
RX   PubMed=18023986; DOI=10.1016/j.plefa.2007.09.005;
RA   Kotelevets L., Foudi N., Louedec L., Couvelard A., Chastre E., Norel X.;
RT   "A new mRNA splice variant coding for the human EP3-I receptor isoform.";
RL   Prostaglandins Leukot. Essent. Fatty Acids 77:195-201(2007).
CC   -!- FUNCTION: Receptor for prostaglandin E2 (PGE2) (PubMed:8307176,
CC       PubMed:7883006, PubMed:8117308, PubMed:8135729, PubMed:7981210). The
CC       activity of this receptor can couple to both the inhibition of
CC       adenylate cyclase mediated by G(i) proteins, and to an elevation of
CC       intracellular calcium (PubMed:7883006, PubMed:8117308, PubMed:8135729,
CC       PubMed:7981210). Required for normal development of fever in response
CC       to pyrinogens, including IL1B, prostaglandin E2 and bacterial
CC       lipopolysaccharide (LPS). Required for normal potentiation of platelet
CC       aggregation by prostaglandin E2, and thus plays a role in the
CC       regulation of blood coagulation. Required for increased HCO3(-)
CC       secretion in the duodenum in response to mucosal acidification, and
CC       thereby contributes to the protection of the mucosa against acid-
CC       induced ulceration. Not required for normal kidney function, normal
CC       urine volume and osmolality (By similarity).
CC       {ECO:0000250|UniProtKB:P30557, ECO:0000269|PubMed:7883006,
CC       ECO:0000269|PubMed:7981210, ECO:0000269|PubMed:8117308,
CC       ECO:0000269|PubMed:8135729, ECO:0000269|PubMed:8307176}.
CC   -!- SUBUNIT: Interacts (via C-terminus) with MKLN1.
CC       {ECO:0000250|UniProtKB:P34980}.
CC   -!- INTERACTION:
CC       P43115-12; Q6UY14-3: ADAMTSL4; NbExp=3; IntAct=EBI-10234038, EBI-10173507;
CC       P43115-12; P32320: CDA; NbExp=3; IntAct=EBI-10234038, EBI-9250559;
CC       P43115-12; O95967: EFEMP2; NbExp=3; IntAct=EBI-10234038, EBI-743414;
CC       P43115-12; Q0VD86: INCA1; NbExp=3; IntAct=EBI-10234038, EBI-6509505;
CC       P43115-12; Q15323: KRT31; NbExp=3; IntAct=EBI-10234038, EBI-948001;
CC       P43115-12; O76015: KRT38; NbExp=3; IntAct=EBI-10234038, EBI-1047263;
CC       P43115-12; Q6A162: KRT40; NbExp=3; IntAct=EBI-10234038, EBI-10171697;
CC       P43115-12; P60409: KRTAP10-7; NbExp=3; IntAct=EBI-10234038, EBI-10172290;
CC       P43115-12; P60410: KRTAP10-8; NbExp=3; IntAct=EBI-10234038, EBI-10171774;
CC       P43115-12; P60411: KRTAP10-9; NbExp=3; IntAct=EBI-10234038, EBI-10172052;
CC       P43115-12; P50222: MEOX2; NbExp=3; IntAct=EBI-10234038, EBI-748397;
CC       P43115-12; Q7Z3S9: NOTCH2NLA; NbExp=3; IntAct=EBI-10234038, EBI-945833;
CC       P43115-12; Q04864: REL; NbExp=3; IntAct=EBI-10234038, EBI-307352;
CC       P43115-12; Q9UGC6: RGS17; NbExp=3; IntAct=EBI-10234038, EBI-3918154;
CC       P43115-12; O76081: RGS20; NbExp=3; IntAct=EBI-10234038, EBI-1052678;
CC       P43115-12; O76081-6: RGS20; NbExp=3; IntAct=EBI-10234038, EBI-10178530;
CC       P43115-12; O43597: SPRY2; NbExp=3; IntAct=EBI-10234038, EBI-742487;
CC       P43115-12; P15884: TCF4; NbExp=3; IntAct=EBI-10234038, EBI-533224;
CC       P43115-12; Q8IWZ5: TRIM42; NbExp=3; IntAct=EBI-10234038, EBI-5235829;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:7883006,
CC       ECO:0000269|PubMed:7981210, ECO:0000269|PubMed:8117308,
CC       ECO:0000269|PubMed:8307176}; Multi-pass membrane protein {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=12;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=EP3A; Synonyms=EP3-I, EP3a1, EP3a2, EP(3-Ic);
CC         IsoId=P43115-1; Sequence=Displayed;
CC       Name=EP3C; Synonyms=EP3-II;
CC         IsoId=P43115-2; Sequence=VSP_001935;
CC       Name=EP3B; Synonyms=EP3-III;
CC         IsoId=P43115-3; Sequence=VSP_001936;
CC       Name=EP3D; Synonyms=EP3-IV;
CC         IsoId=P43115-4; Sequence=VSP_001937;
CC       Name=EP3E;
CC         IsoId=P43115-5; Sequence=VSP_001938;
CC       Name=EP3F;
CC         IsoId=P43115-6; Sequence=VSP_001939;
CC       Name=EP3G;
CC         IsoId=P43115-7; Sequence=VSP_013271;
CC       Name=EP3-III;
CC         IsoId=P43115-8; Sequence=VSP_053774;
CC       Name=EP3-IV;
CC         IsoId=P43115-9; Sequence=VSP_053775;
CC       Name=EP3-V;
CC         IsoId=P43115-10; Sequence=VSP_053776;
CC       Name=EP3E2;
CC         IsoId=P43115-11; Sequence=VSP_053777;
CC       Name=12;
CC         IsoId=P43115-12; Sequence=VSP_058943;
CC   -!- TISSUE SPECIFICITY: Detected in kidney (PubMed:8117308,
CC       PubMed:8135729). Expressed in small intestine, heart, pancreas, gastric
CC       fundic mucosa, mammary artery and pulmonary vessels.
CC       {ECO:0000269|PubMed:18023986, ECO:0000269|PubMed:8117308,
CC       ECO:0000269|PubMed:8135729}.
CC   -!- MISCELLANEOUS: [Isoform EP3C]: Known as EP3D in PubMed:8075855.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform EP3B]: Known as EP3E in PubMed:8075855.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform EP3D]: Known as EP3F in PubMed:8075855.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA58742.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; S69200; AAB29854.1; -; mRNA.
DR   EMBL; L27488; AAC13372.1; -; mRNA.
DR   EMBL; L27489; AAC13373.1; -; mRNA.
DR   EMBL; L27490; AAC13374.1; -; mRNA.
DR   EMBL; X83857; CAA58737.1; -; mRNA.
DR   EMBL; X83858; CAA58738.1; -; mRNA.
DR   EMBL; X83859; CAA58739.1; -; mRNA.
DR   EMBL; X83860; CAA58740.1; -; mRNA.
DR   EMBL; X83861; CAA58741.1; -; mRNA.
DR   EMBL; X83862; CAA58742.1; ALT_FRAME; mRNA.
DR   EMBL; X83863; CAA58743.1; -; mRNA.
DR   EMBL; L26976; AAA60076.1; -; mRNA.
DR   EMBL; S69326; AAB30208.1; -; mRNA.
DR   EMBL; L32660; AAA68191.1; -; mRNA.
DR   EMBL; L32661; AAA68192.1; -; mRNA.
DR   EMBL; L32662; AAA68193.1; -; mRNA.
DR   EMBL; D38297; BAA07416.1; -; mRNA.
DR   EMBL; D38298; BAA07417.1; -; mRNA.
DR   EMBL; D38299; BAA07418.1; -; mRNA.
DR   EMBL; D38300; BAA07419.1; -; mRNA.
DR   EMBL; D38301; BAA07420.1; -; mRNA.
DR   EMBL; U13214; AAA21130.1; -; mRNA.
DR   EMBL; U13215; AAA21131.1; -; mRNA.
DR   EMBL; U13216; AAA21132.1; -; mRNA.
DR   EMBL; U13217; AAA21133.1; -; mRNA.
DR   EMBL; U13218; AAA21134.1; -; mRNA.
DR   EMBL; D86096; BAA19951.1; -; Genomic_DNA.
DR   EMBL; D86096; BAA19952.1; -; Genomic_DNA.
DR   EMBL; D86096; BAA19953.1; -; Genomic_DNA.
DR   EMBL; D86096; BAA19954.1; -; Genomic_DNA.
DR   EMBL; D86096; BAA19956.1; -; Genomic_DNA.
DR   EMBL; D86096; BAA19957.1; -; Genomic_DNA.
DR   EMBL; D86098; BAA19959.1; -; mRNA.
DR   EMBL; AY429108; AAR07903.1; -; mRNA.
DR   EMBL; AK315825; BAF98716.1; -; mRNA.
DR   EMBL; AB451481; BAG70295.1; -; mRNA.
DR   EMBL; AL031429; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL158087; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471059; EAX06439.1; -; Genomic_DNA.
DR   EMBL; CH471059; EAX06446.1; -; Genomic_DNA.
DR   EMBL; BC024229; AAH24229.1; -; mRNA.
DR   EMBL; BC118578; AAI18579.1; -; mRNA.
DR   CCDS; CCDS44160.1; -. [P43115-3]
DR   CCDS; CCDS652.1; -. [P43115-4]
DR   CCDS; CCDS655.1; -. [P43115-5]
DR   CCDS; CCDS656.1; -. [P43115-1]
DR   CCDS; CCDS657.1; -. [P43115-1]
DR   CCDS; CCDS658.1; -. [P43115-2]
DR   PIR; B55995; B55995.
DR   PIR; I38747; I38747.
DR   PIR; I38748; I38748.
DR   PIR; I38750; I38750.
DR   PIR; JC2056; JC2056.
DR   PIR; S43375; S43375.
DR   PIR; S68994; S51313.
DR   PIR; S68995; S51315.
DR   PIR; S68996; S51316.
DR   PIR; S68997; S51317.
DR   PIR; S68998; S51318.
DR   PIR; S68999; S51319.
DR   RefSeq; NP_001119516.1; NM_001126044.1. [P43115-1]
DR   RefSeq; NP_942007.1; NM_198714.1. [P43115-1]
DR   RefSeq; NP_942008.1; NM_198715.2. [P43115-2]
DR   RefSeq; NP_942009.1; NM_198716.1. [P43115-4]
DR   RefSeq; NP_942010.1; NM_198717.1. [P43115-3]
DR   RefSeq; NP_942011.1; NM_198718.1. [P43115-5]
DR   RefSeq; NP_942012.1; NM_198719.1. [P43115-1]
DR   PDB; 6AK3; X-ray; 2.90 A; A/B=43-359.
DR   PDB; 6M9T; X-ray; 2.50 A; A=2-259, A=273-353.
DR   PDBsum; 6AK3; -.
DR   PDBsum; 6M9T; -.
DR   SMR; P43115; -.
DR   BioGRID; 111705; 112.
DR   IntAct; P43115; 78.
DR   STRING; 9606.ENSP00000349003; -.
DR   BindingDB; P43115; -.
DR   ChEMBL; CHEMBL3710; -.
DR   DrugBank; DB00905; Bimatoprost.
DR   DrugBank; DB11113; Castor oil.
DR   DrugBank; DB00917; Dinoprostone.
DR   DrugBank; DB08964; Gemeprost.
DR   DrugBank; DB09211; Limaprost.
DR   DrugBank; DB00929; Misoprostol.
DR   DrugCentral; P43115; -.
DR   GuidetoPHARMACOLOGY; 342; -.
DR   GlyGen; P43115; 2 sites.
DR   iPTMnet; P43115; -.
DR   PhosphoSitePlus; P43115; -.
DR   BioMuta; PTGER3; -.
DR   DMDM; 1172071; -.
DR   PaxDb; P43115; -.
DR   PeptideAtlas; P43115; -.
DR   PRIDE; P43115; -.
DR   ProteomicsDB; 3010; -.
DR   ProteomicsDB; 55580; -. [P43115-1]
DR   ProteomicsDB; 55581; -. [P43115-2]
DR   ProteomicsDB; 55582; -. [P43115-3]
DR   ProteomicsDB; 55583; -. [P43115-4]
DR   ProteomicsDB; 55584; -. [P43115-5]
DR   ProteomicsDB; 55585; -. [P43115-6]
DR   ProteomicsDB; 55586; -. [P43115-7]
DR   ProteomicsDB; 60186; -.
DR   Antibodypedia; 2758; 436 antibodies.
DR   DNASU; 5733; -.
DR   Ensembl; ENST00000306666; ENSP00000302313; ENSG00000050628. [P43115-1]
DR   Ensembl; ENST00000351052; ENSP00000280208; ENSG00000050628. [P43115-1]
DR   Ensembl; ENST00000356595; ENSP00000349003; ENSG00000050628. [P43115-5]
DR   Ensembl; ENST00000370924; ENSP00000359962; ENSG00000050628. [P43115-2]
DR   Ensembl; ENST00000370931; ENSP00000359969; ENSG00000050628. [P43115-1]
DR   Ensembl; ENST00000460330; ENSP00000418073; ENSG00000050628. [P43115-4]
DR   Ensembl; ENST00000479353; ENSP00000421583; ENSG00000050628. [P43115-7]
DR   Ensembl; ENST00000628037; ENSP00000486617; ENSG00000050628. [P43115-3]
DR   GeneID; 5733; -.
DR   KEGG; hsa:5733; -.
DR   UCSC; uc001dfg.2; human. [P43115-1]
DR   CTD; 5733; -.
DR   DisGeNET; 5733; -.
DR   EuPathDB; HostDB:ENSG00000050628.20; -.
DR   GeneCards; PTGER3; -.
DR   HGNC; HGNC:9595; PTGER3.
DR   HPA; ENSG00000050628; Tissue enhanced (breast, endometrium).
DR   MIM; 176806; gene.
DR   neXtProt; NX_P43115; -.
DR   OpenTargets; ENSG00000050628; -.
DR   PharmGKB; PA288; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT01000000214437; -.
DR   InParanoid; P43115; -.
DR   KO; K04260; -.
DR   OMA; PITMMIT; -.
DR   OrthoDB; 972015at2759; -.
DR   PhylomeDB; P43115; -.
DR   TreeFam; TF324982; -.
DR   PathwayCommons; P43115; -.
DR   Reactome; R-HSA-391908; Prostanoid ligand receptors.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   SIGNOR; P43115; -.
DR   BioGRID-ORCS; 5733; 16 hits in 876 CRISPR screens.
DR   ChiTaRS; PTGER3; human.
DR   GenomeRNAi; 5733; -.
DR   Pharos; P43115; Tclin.
DR   PRO; PR:P43115; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P43115; protein.
DR   Bgee; ENSG00000050628; Expressed in body of uterus and 195 other tissues.
DR   ExpressionAtlas; P43115; baseline and differential.
DR   Genevisible; P43115; HS.
DR   GO; GO:0016021; C:integral component of membrane; NAS:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005635; C:nuclear envelope; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0004957; F:prostaglandin E receptor activity; IBA:GO_Central.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0008219; P:cell death; TAS:ProtInc.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006954; P:inflammatory response; IBA:GO_Central.
DR   GO; GO:0014827; P:intestine smooth muscle contraction; IBA:GO_Central.
DR   GO; GO:0060455; P:negative regulation of gastric acid secretion; IBA:GO_Central.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IBA:GO_Central.
DR   GO; GO:0031622; P:positive regulation of fever generation; ISS:BHF-UCL.
DR   InterPro; IPR001481; EP3_rcpt_2.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR008365; Prostanoid_rcpt.
DR   InterPro; IPR001244; Prostglndn_DP_rcpt.
DR   InterPro; IPR000265; Prostglndn_EP3_rcpt.
DR   PANTHER; PTHR11866; PTHR11866; 1.
DR   PANTHER; PTHR11866:SF10; PTHR11866:SF10; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00428; PROSTAGLNDNR.
DR   PRINTS; PR01788; PROSTANOIDR.
DR   PRINTS; PR00584; PRSTNOIDE32R.
DR   PRINTS; PR00582; PRSTNOIDEP3R.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane;
KW   G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane; Palmitate;
KW   Polymorphism; Receptor; Reference proteome; Transducer; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..390
FT                   /note="Prostaglandin E2 receptor EP3 subtype"
FT                   /id="PRO_0000070058"
FT   TOPO_DOM        1..53
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        54..78
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        79..91
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        92..112
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        113..131
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        132..153
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        154..175
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        176..197
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        198..227
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        228..253
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        254..283
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        284..307
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        308..327
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        328..349
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        350..390
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        18
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        36
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         360..390
FT                   /note="IRYHTNNYASSSTSLPCQCSSTLMWSDHLER -> MRKRRLREQFWRPASSG
FT                   SGCQQIRCLMESCSLTQTGVQWSDFRSLQPSPPPLTAIFASWVQVILLPQPPK (in
FT                   isoform 12)"
FT                   /id="VSP_058943"
FT   VAR_SEQ         360..390
FT                   /note="IRYHTNNYASSSTSLPCQCSSTLMWSDHLER -> VANAVSSCSNDGQKGQP
FT                   ISLSNEIIQTEAEEFWGN (in isoform EP3-III)"
FT                   /evidence="ECO:0000303|PubMed:9073510"
FT                   /id="VSP_053774"
FT   VAR_SEQ         360..390
FT                   /note="IRYHTNNYASSSTSLPCQCSSTLMWSDHLER -> VANAVSSCSNDGQKGQP
FT                   ISLSNEIIQTEAMRKRRLREQEEFWGN (in isoform EP3-IV)"
FT                   /evidence="ECO:0000303|PubMed:9073510"
FT                   /id="VSP_053775"
FT   VAR_SEQ         360..390
FT                   /note="IRYHTNNYASSSTSLPCQCSSTLMWSDHLER -> VANAVSSCSNDGQKGQP
FT                   ISLSNEIIQTEAMRKRRLREQEMGPDGRCFCHAWRQVPRTWCSSHDREPCSVQLS (in
FT                   isoform EP3-V)"
FT                   /evidence="ECO:0000303|PubMed:9073510"
FT                   /id="VSP_053776"
FT   VAR_SEQ         360..390
FT                   /note="IRYHTNNYASSSTSLPCQCSSTLMWSDHLER -> EEFWGN (in
FT                   isoform EP3B)"
FT                   /evidence="ECO:0000303|PubMed:19054851,
FT                   ECO:0000303|PubMed:7476918, ECO:0000303|PubMed:7883006,
FT                   ECO:0000303|PubMed:7981210, ECO:0000303|PubMed:8075855,
FT                   ECO:0000303|PubMed:8307176, ECO:0000303|PubMed:9073510"
FT                   /id="VSP_001936"
FT   VAR_SEQ         360..390
FT                   /note="IRYHTNNYASSSTSLPCQCSSTLMWSDHLER -> VANAVSSCSNDGQKGQP
FT                   ISLSNEIIQTEA (in isoform EP3C)"
FT                   /evidence="ECO:0000303|PubMed:7476918,
FT                   ECO:0000303|PubMed:7883006, ECO:0000303|PubMed:7981210,
FT                   ECO:0000303|PubMed:8075855, ECO:0000303|PubMed:8307176,
FT                   ECO:0000303|PubMed:9073510"
FT                   /id="VSP_001935"
FT   VAR_SEQ         360..390
FT                   /note="IRYHTNNYASSSTSLPCQCSSTLMWSDHLER -> MRKRRLREQEEFWGN
FT                   (in isoform EP3D)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:7476918, ECO:0000303|PubMed:7883006,
FT                   ECO:0000303|PubMed:7981210, ECO:0000303|PubMed:8075855,
FT                   ECO:0000303|PubMed:9073510"
FT                   /id="VSP_001937"
FT   VAR_SEQ         360..390
FT                   /note="IRYHTNNYASSSTSLPCQCSSTLMWSDHLER -> MRKRRLREQLICSLQNS
FT                   QIQRATAHCGQVQTYRVLNREEMEVLVSSINVYTRISTVKTE (in isoform
FT                   EP3E)"
FT                   /evidence="ECO:0000303|PubMed:7883006,
FT                   ECO:0000303|PubMed:9073510"
FT                   /id="VSP_001938"
FT   VAR_SEQ         360..390
FT                   /note="IRYHTNNYASSSTSLPCQCSSTLMWSDHLER -> VANAVSSCSNDGQKGQP
FT                   ISLSNEIIQTEAMRKRRLREQLICSLRTLRYRGQLHIVGKYKPIVC (in isoform
FT                   EP3E2)"
FT                   /evidence="ECO:0000303|PubMed:9073510"
FT                   /id="VSP_053777"
FT   VAR_SEQ         360..390
FT                   /note="IRYHTNNYASSSTSLPCQCSSTLMWSDHLER -> MRKRRLREQAPLLPTPT
FT                   VIDPSRFCAQPFRWFLDLSFPAMSSSHPQLPLTLASFKLLREPCSVQLS (in
FT                   isoform EP3F)"
FT                   /evidence="ECO:0000303|PubMed:7883006"
FT                   /id="VSP_001939"
FT   VAR_SEQ         360..390
FT                   /note="IRYHTNNYASSSTSLPCQCSSTLMWSDHLER -> EMGPDGRCFCHAWRQVP
FT                   RTWCSSHDREPCSVQLS (in isoform EP3G)"
FT                   /evidence="ECO:0000303|Ref.9"
FT                   /id="VSP_013271"
FT   VARIANT         169
FT                   /note="M -> L (in dbSNP:rs5670)"
FT                   /id="VAR_014694"
FT   VARIANT         319
FT                   /note="T -> M (in dbSNP:rs13306020)"
FT                   /id="VAR_049436"
FT   VARIANT         366
FT                   /note="N -> S (in dbSNP:rs13306014)"
FT                   /id="VAR_029218"
FT   VARIANT         375
FT                   /note="P -> L (in dbSNP:rs5694)"
FT                   /id="VAR_014695"
FT   CONFLICT        28..29
FT                   /note="ER -> DG (in Ref. 3, 4 and 7)"
FT                   /evidence="ECO:0000305"
FT   TURN            47..49
FT                   /evidence="ECO:0000244|PDB:6M9T"
FT   HELIX           53..77
FT                   /evidence="ECO:0000244|PDB:6M9T"
FT   HELIX           86..115
FT                   /evidence="ECO:0000244|PDB:6M9T"
FT   HELIX           120..123
FT                   /evidence="ECO:0000244|PDB:6M9T"
FT   STRAND          125..127
FT                   /evidence="ECO:0000244|PDB:6M9T"
FT   HELIX           128..160
FT                   /evidence="ECO:0000244|PDB:6M9T"
FT   HELIX           162..167
FT                   /evidence="ECO:0000244|PDB:6M9T"
FT   HELIX           172..189
FT                   /evidence="ECO:0000244|PDB:6M9T"
FT   HELIX           191..194
FT                   /evidence="ECO:0000244|PDB:6M9T"
FT   STRAND          199..202
FT                   /evidence="ECO:0000244|PDB:6M9T"
FT   TURN            203..206
FT                   /evidence="ECO:0000244|PDB:6M9T"
FT   STRAND          207..210
FT                   /evidence="ECO:0000244|PDB:6M9T"
FT   HELIX           225..258
FT                   /evidence="ECO:0000244|PDB:6M9T"
FT   HELIX           276..306
FT                   /evidence="ECO:0000244|PDB:6M9T"
FT   HELIX           324..346
FT                   /evidence="ECO:0000244|PDB:6M9T"
FT   HELIX           348..352
FT                   /evidence="ECO:0000244|PDB:6M9T"
SQ   SEQUENCE   390 AA;  43310 MW;  BC76EAC78FDF5420 CRC64;
     MKETRGYGGD APFCTRLNHS YTGMWAPERS AEARGNLTRP PGSGEDCGSV SVAFPITMLL
     TGFVGNALAM LLVSRSYRRR ESKRKKSFLL CIGWLALTDL VGQLLTTPVV IVVYLSKQRW
     EHIDPSGRLC TFFGLTMTVF GLSSLFIASA MAVERALAIR APHWYASHMK TRATRAVLLG
     VWLAVLAFAL LPVLGVGQYT VQWPGTWCFI STGRGGNGTS SSHNWGNLFF ASAFAFLGLL
     ALTVTFSCNL ATIKALVSRC RAKATASQSS AQWGRITTET AIQLMGIMCV LSVCWSPLLI
     MMLKMIFNQT SVEHCKTHTE KQKECNFFLI AVRLASLNQI LDPWVYLLLR KILLRKFCQI
     RYHTNNYASS STSLPCQCSS TLMWSDHLER
//
ID   OPSR_HUMAN              Reviewed;         364 AA.
AC   P04000;
DT   23-OCT-1986, integrated into UniProtKB/Swiss-Prot.
DT   23-OCT-1986, sequence version 1.
DT   12-AUG-2020, entry version 193.
DE   RecName: Full=Long-wave-sensitive opsin 1;
DE   AltName: Full=Red cone photoreceptor pigment;
DE   AltName: Full=Red-sensitive opsin;
DE            Short=ROP;
GN   Name=OPN1LW; Synonyms=RCP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Retinal cone cell;
RX   PubMed=2937147; DOI=10.1126/science.2937147;
RA   Nathans J., Thomas D., Hogness D.S.;
RT   "Molecular genetics of human color vision: the genes encoding blue, green,
RT   and red pigments.";
RL   Science 232:193-202(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [3]
RP   REVIEW.
RX   PubMed=3303660; DOI=10.1016/0042-6989(86)90115-x;
RA   Applebury M.L., Hargrave P.A.;
RT   "Molecular biology of the visual pigments.";
RL   Vision Res. 26:1881-1895(1986).
RN   [4]
RP   VARIANT ALA-180.
RX   PubMed=1557123; DOI=10.1038/356431a0;
RA   Winderickx J., Lindsey D.T., Sanocki E., Teller D.Y., Motulsky A.G.,
RA   Deeb S.S.;
RT   "Polymorphism in red photopigment underlies variation in colour matching.";
RL   Nature 356:431-433(1992).
RN   [5]
RP   VARIANTS BCM ARG-203 AND LEU-307.
RX   PubMed=8213841;
RA   Nathans J., Maumenee I.H., Zrenner E., Sadowski B., Sharpe L.T.,
RA   Lewis R.A., Hansen E., Rosenberg T., Schwartz M., Heckenlively J.R.;
RT   "Genetic heterogeneity among blue-cone monochromats.";
RL   Am. J. Hum. Genet. 53:987-1000(1993).
RN   [6]
RP   VARIANT BCM ARG-203.
RX   PubMed=8666378; DOI=10.1006/geno.1995.9998;
RA   Reyniers E., Van Thienen M.N., Meire F., De Boulle K., Devries K.,
RA   Kestelijn P., Willems P.J.;
RT   "Gene conversion between red and defective green opsin gene in blue cone
RT   monochromacy.";
RL   Genomics 29:323-328(1995).
RN   [7]
RP   VARIANT CBP GLU-338.
RX   PubMed=12051694; DOI=10.1016/s0006-291x(02)00458-8;
RA   Ueyama H., Kuwayama S., Imai H., Tanabe S., Oda S., Nishida Y., Wada A.,
RA   Shichida Y., Yamade S.;
RT   "Novel missense mutations in red/green opsin genes in congenital color-
RT   vision deficiencies.";
RL   Biochem. Biophys. Res. Commun. 294:205-209(2002).
CC   -!- FUNCTION: Visual pigments are the light-absorbing molecules that
CC       mediate vision. They consist of an apoprotein, opsin, covalently linked
CC       to cis-retinal.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Absorption:
CC         Abs(max)=560 nm;
CC   -!- INTERACTION:
CC       P04000; Q8IXM6: NRM; NbExp=3; IntAct=EBI-13294781, EBI-10262547;
CC       P04000; A5PKU2: TUSC5; NbExp=3; IntAct=EBI-13294781, EBI-11988865;
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: The three color pigments are found in the cone
CC       photoreceptor cells.
CC   -!- PTM: Phosphorylated on some or all of the serine and threonine residues
CC       present in the C-terminal region.
CC   -!- DISEASE: Colorblindness, partial, protan series (CBP) [MIM:303900]: A
CC       color vision defect characterized by a dichromasy in which red and
CC       green are confused, with loss of luminance and shift of brightness and
CC       hue curves toward the short wave end of the spectrum. Dichromasy is due
CC       to the use of only two types of photoreceptors, blue plus red in
CC       deuteranopia and blue plus green in protanopia.
CC       {ECO:0000269|PubMed:12051694}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Blue cone monochromacy (BCM) [MIM:303700]: A rare X-linked
CC       congenital stationary cone dysfunction syndrome characterized by the
CC       absence of functional long wavelength-sensitive and medium wavelength-
CC       sensitive cones in the retina. Color discrimination is severely
CC       impaired from birth, and vision is derived from the remaining preserved
CC       blue (S) cones and rod photoreceptors. BCM typically presents with
CC       reduced visual acuity, pendular nystagmus, and photophobia. Patients
CC       often have myopia. {ECO:0000269|PubMed:8213841,
CC       ECO:0000269|PubMed:8666378}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family. Opsin
CC       subfamily. {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=Mutations of the color pigment genes; Note=Retina
CC       International's Scientific Newsletter;
CC       URL="https://www.retina-international.org/files/sci-news/cppmut.htm";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M13305; AAB59524.1; -; Genomic_DNA.
DR   EMBL; M13300; AAB59524.1; JOINED; Genomic_DNA.
DR   EMBL; M13301; AAB59524.1; JOINED; Genomic_DNA.
DR   EMBL; M13302; AAB59524.1; JOINED; Genomic_DNA.
DR   EMBL; M13303; AAB59524.1; JOINED; Genomic_DNA.
DR   EMBL; M13304; AAB59524.1; JOINED; Genomic_DNA.
DR   EMBL; Z68193; CAA92342.1; -; Genomic_DNA.
DR   CCDS; CCDS14742.1; -.
DR   PIR; A03157; OOHUR.
DR   PDB; 1KPX; Model; -; A=1-364.
DR   PDBsum; 1KPX; -.
DR   IntAct; P04000; 2.
DR   STRING; 9606.ENSP00000358967; -.
DR   ChEMBL; CHEMBL1949482; -.
DR   TCDB; 9.A.14.1.1; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; P04000; 2 sites.
DR   BioMuta; OPN1LW; -.
DR   DMDM; 129219; -.
DR   PaxDb; P04000; -.
DR   PeptideAtlas; P04000; -.
DR   PRIDE; P04000; -.
DR   ProteomicsDB; 51630; -.
DR   Antibodypedia; 64269; 44 antibodies.
DR   DNASU; 5956; -.
DR   Ensembl; ENST00000369951; ENSP00000358967; ENSG00000102076.
DR   UCSC; uc033fax.1; human.
DR   EuPathDB; HostDB:ENSG00000102076.9; -.
DR   GeneCards; OPN1LW; -.
DR   HGNC; HGNC:9936; OPN1LW.
DR   HPA; ENSG00000102076; Tissue enriched (retina).
DR   MalaCards; OPN1LW; -.
DR   MIM; 300822; gene.
DR   MIM; 303700; phenotype.
DR   MIM; 303900; phenotype.
DR   neXtProt; NX_P04000; -.
DR   Orphanet; 16; Blue cone monochromatism.
DR   Orphanet; 1872; Cone rod dystrophy.
DR   Orphanet; 319691; NON RARE IN EUROPE: Partial color blindness, protan type.
DR   Orphanet; 90001; X-linked cone dysfunction syndrome with myopia.
DR   PharmGKB; PA31936; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   HOGENOM; CLU_009579_3_0_1; -.
DR   InParanoid; P04000; -.
DR   OrthoDB; 940057at2759; -.
DR   PhylomeDB; P04000; -.
DR   TreeFam; TF324998; -.
DR   PathwayCommons; P04000; -.
DR   Reactome; R-HSA-2187335; The retinoid cycle in cones (daylight vision).
DR   Reactome; R-HSA-2453864; Retinoid cycle disease events.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-419771; Opsins.
DR   ChiTaRS; OPN1LW; human.
DR   Pharos; P04000; Tbio.
DR   PRO; PR:P04000; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; P04000; protein.
DR   Bgee; ENSG00000102076; Expressed in adrenal gland and 18 other tissues.
DR   ExpressionAtlas; P04000; baseline and differential.
DR   Genevisible; P04000; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0097381; C:photoreceptor disc membrane; TAS:Reactome.
DR   GO; GO:0001750; C:photoreceptor outer segment; IBA:GO_Central.
DR   GO; GO:0008020; F:G protein-coupled photoreceptor activity; IBA:GO_Central.
DR   GO; GO:0009881; F:photoreceptor activity; IMP:CACAO.
DR   GO; GO:0071482; P:cellular response to light stimulus; IBA:GO_Central.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007602; P:phototransduction; IBA:GO_Central.
DR   GO; GO:0032467; P:positive regulation of cytokinesis; IMP:UniProtKB.
DR   GO; GO:0018298; P:protein-chromophore linkage; IEA:UniProtKB-KW.
DR   GO; GO:0001523; P:retinoid metabolic process; TAS:Reactome.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0007601; P:visual perception; TAS:ProtInc.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR001760; Opsin.
DR   InterPro; IPR000378; Opsin_red/grn.
DR   InterPro; IPR027430; Retinal_BS.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00238; OPSIN.
DR   PRINTS; PR00575; OPSINREDGRN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
DR   PROSITE; PS00238; OPSIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Chromophore; Disease mutation; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Phosphoprotein;
KW   Photoreceptor protein; Polymorphism; Receptor; Reference proteome;
KW   Retinal protein; Sensory transduction; Transducer; Transmembrane;
KW   Transmembrane helix; Vision.
FT   CHAIN           1..364
FT                   /note="Long-wave-sensitive opsin 1"
FT                   /id="PRO_0000197802"
FT   TOPO_DOM        1..52
FT                   /note="Extracellular"
FT   TRANSMEM        53..77
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        78..89
FT                   /note="Cytoplasmic"
FT   TRANSMEM        90..115
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        116..129
FT                   /note="Extracellular"
FT   TRANSMEM        130..149
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        150..168
FT                   /note="Cytoplasmic"
FT   TRANSMEM        169..192
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        193..218
FT                   /note="Extracellular"
FT   TRANSMEM        219..246
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        247..268
FT                   /note="Cytoplasmic"
FT   TRANSMEM        269..292
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        293..300
FT                   /note="Extracellular"
FT   TRANSMEM        301..325
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        326..364
FT                   /note="Cytoplasmic"
FT   MOD_RES         312
FT                   /note="N6-(retinylidene)lysine"
FT   CARBOHYD        22
FT                   /note="O-linked (GlcNAc) serine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9BGI7"
FT   CARBOHYD        34
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00498"
FT   DISULFID        126..203
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VARIANT         111
FT                   /note="I -> V (in dbSNP:rs1065421)"
FT                   /id="VAR_012010"
FT   VARIANT         116
FT                   /note="S -> Y (in dbSNP:rs1065422)"
FT                   /id="VAR_012011"
FT   VARIANT         153
FT                   /note="L -> M (in dbSNP:rs713)"
FT                   /id="VAR_012012"
FT   VARIANT         180
FT                   /note="S -> A (in 38% of the population; dbSNP:rs949431)"
FT                   /evidence="ECO:0000269|PubMed:1557123"
FT                   /id="VAR_004842"
FT   VARIANT         203
FT                   /note="C -> R (in BCM; dbSNP:rs121434621)"
FT                   /evidence="ECO:0000269|PubMed:8213841,
FT                   ECO:0000269|PubMed:8666378"
FT                   /id="VAR_009298"
FT   VARIANT         230
FT                   /note="I -> T (in dbSNP:rs148583295)"
FT                   /id="VAR_012014"
FT   VARIANT         274
FT                   /note="I -> V (in dbSNP:rs2315122)"
FT                   /id="VAR_050612"
FT   VARIANT         298
FT                   /note="A -> P (in dbSNP:rs1065440)"
FT                   /id="VAR_012015"
FT   VARIANT         307
FT                   /note="P -> L (in BCM; dbSNP:rs782797093)"
FT                   /evidence="ECO:0000269|PubMed:8213841"
FT                   /id="VAR_009299"
FT   VARIANT         338
FT                   /note="G -> E (in CBP; dbSNP:rs104894913)"
FT                   /evidence="ECO:0000269|PubMed:12051694"
FT                   /id="VAR_064054"
SQ   SEQUENCE   364 AA;  40572 MW;  D9DACDC17BF20DB3 CRC64;
     MAQQWSLQRL AGRHPQDSYE DSTQSSIFTY TNSNSTRGPF EGPNYHIAPR WVYHLTSVWM
     IFVVTASVFT NGLVLAATMK FKKLRHPLNW ILVNLAVADL AETVIASTIS IVNQVSGYFV
     LGHPMCVLEG YTVSLCGITG LWSLAIISWE RWLVVCKPFG NVRFDAKLAI VGIAFSWIWS
     AVWTAPPIFG WSRYWPHGLK TSCGPDVFSG SSYPGVQSYM IVLMVTCCII PLAIIMLCYL
     QVWLAIRAVA KQQKESESTQ KAEKEVTRMV VVMIFAYCVC WGPYTFFACF AAANPGYAFH
     PLMAALPAYF AKSATIYNPV IYVFMNRQFR NCILQLFGKK VDDGSELSSA SKTEVSSVSS
     VSPA
//
ID   OX2R_HUMAN              Reviewed;         444 AA.
AC   O43614; Q5VTM0;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   23-SEP-2008, sequence version 2.
DT   07-OCT-2020, entry version 164.
DE   RecName: Full=Orexin receptor type 2;
DE            Short=Ox-2-R;
DE            Short=Ox2-R;
DE            Short=Ox2R;
DE   AltName: Full=Hypocretin receptor type 2;
GN   Name=HCRTR2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, AND VARIANT
RP   VAL-308.
RX   PubMed=9491897; DOI=10.1016/s0092-8674(00)80949-6;
RA   Sakurai T., Amemiya A., Ishii M., Matsuzaki I., Chemelli R.M., Tanaka H.,
RA   Williams S.C., Richardson J.A., Kozlowski G.P., Wilson S., Arch J.R.S.,
RA   Buckingham R.E., Haynes A.C., Carr S.A., Annan R.S., McNulty D.E.,
RA   Liu W.-S., Terrett J.A., Elshourbagy N.A., Bergsma D.J., Yanagisawa M.;
RT   "Orexins and orexin receptors: a family of hypothalamic neuropeptides and G
RT   protein-coupled receptors that regulate feeding behavior.";
RL   Cell 92:573-585(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS SER-10; THR-11; VAL-293 AND
RP   VAL-308.
RX   PubMed=11723285; DOI=10.1212/wnl.57.10.1896;
RA   Olafsdottir B.R., Rye D.B., Scammell T.E., Matheson J.K., Stefansson K.,
RA   Gulcher J.R.;
RT   "Polymorphisms in hypocretin/orexin pathway genes and narcolepsy.";
RL   Neurology 57:1896-1899(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   REVIEW.
RX   PubMed=11340621; DOI=10.1002/bies.1058;
RA   Hungs M., Mignot E.;
RT   "Hypocretin/orexin, sleep and narcolepsy.";
RL   Bioessays 23:397-408(2001).
RN   [6]
RP   REVIEW.
RX   PubMed=11283317; DOI=10.1146/annurev.neuro.24.1.429;
RA   Willie J.T., Chemelli R.M., Sinton C.M., Yanagisawa M.;
RT   "To eat or to sleep? Orexin in the regulation of feeding and wakefulness.";
RL   Annu. Rev. Neurosci. 24:429-458(2001).
RN   [7]
RP   FUNCTION, SUBCELLULAR LOCATION, TOPOLOGY, MUTAGENESIS OF 33-ASP--HIS-49;
RP   TRP-44 AND ASN-324, AND DOMAIN.
RX   PubMed=26950369; DOI=10.1038/nsmb.3183;
RA   Yin J., Babaoglu K., Brautigam C.A., Clark L., Shao Z., Scheuermann T.H.,
RA   Harrell C.M., Gotter A.L., Roecker A.J., Winrow C.J., Renger J.J.,
RA   Coleman P.J., Rosenbaum D.M.;
RT   "Structure and ligand-binding mechanism of the human OX1 and OX2 orexin
RT   receptors.";
RL   Nat. Struct. Mol. Biol. 23:293-299(2016).
RN   [8] {ECO:0000244|PDB:4S0V}
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 3-254 AND 294-388 IN COMPLEX WITH
RP   THE INHIBITOR SUVOREXANT, TOPOLOGY, SUBCELLULAR LOCATION, AND DISULFIDE
RP   BONDS.
RX   PubMed=25533960; DOI=10.1038/nature14035;
RA   Yin J., Mobarec J.C., Kolb P., Rosenbaum D.M.;
RT   "Crystal structure of the human OX2 orexin receptor bound to the insomnia
RT   drug suvorexant.";
RL   Nature 519:247-250(2015).
CC   -!- FUNCTION: Nonselective, high-affinity receptor for both orexin-A and
CC       orexin-B neuropeptides (PubMed:9491897, PubMed:26950369). Triggers an
CC       increase in cytoplasmic Ca(2+) levels in response to orexin-A binding
CC       (PubMed:9491897, PubMed:26950369). {ECO:0000269|PubMed:26950369,
CC       ECO:0000269|PubMed:9491897}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:26950369,
CC       ECO:0000269|PubMed:9491897, ECO:0000305|PubMed:25533960}; Multi-pass
CC       membrane protein {ECO:0000269|PubMed:25533960}.
CC   -!- DOMAIN: The N-terminal region is required for orexin signaling.
CC       {ECO:0000269|PubMed:26950369}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF041245; AAC39602.1; -; mRNA.
DR   EMBL; AY062031; AAL47215.1; -; Genomic_DNA.
DR   EMBL; AL591718; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL449104; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471081; EAX04440.1; -; Genomic_DNA.
DR   CCDS; CCDS4956.1; -.
DR   RefSeq; NP_001517.2; NM_001526.4.
DR   PDB; 4S0V; X-ray; 2.50 A; A=3-254, A=294-388.
DR   PDB; 5WQC; X-ray; 1.96 A; A=3-254, A=294-386.
DR   PDB; 5WS3; X-ray; 2.30 A; A=3-254, A=294-388.
DR   PDB; 6TPG; X-ray; 2.74 A; A=1-254, A=294-307.
DR   PDB; 6TPJ; X-ray; 2.74 A; A/B=1-254, A/B=294-307.
DR   PDB; 6TPN; X-ray; 2.61 A; A=1-254, A=294-388.
DR   PDBsum; 4S0V; -.
DR   PDBsum; 5WQC; -.
DR   PDBsum; 5WS3; -.
DR   PDBsum; 6TPG; -.
DR   PDBsum; 6TPJ; -.
DR   PDBsum; 6TPN; -.
DR   SMR; O43614; -.
DR   STRING; 9606.ENSP00000477548; -.
DR   BindingDB; O43614; -.
DR   ChEMBL; CHEMBL4792; -.
DR   DrugBank; DB11951; Lemborexant.
DR   DrugBank; DB09034; Suvorexant.
DR   DrugCentral; O43614; -.
DR   GuidetoPHARMACOLOGY; 322; -.
DR   GlyGen; O43614; 3 sites.
DR   iPTMnet; O43614; -.
DR   PhosphoSitePlus; O43614; -.
DR   BioMuta; HCRTR2; -.
DR   EPD; O43614; -.
DR   PaxDb; O43614; -.
DR   PeptideAtlas; O43614; -.
DR   PRIDE; O43614; -.
DR   ProteomicsDB; 49082; -.
DR   Antibodypedia; 17332; 360 antibodies.
DR   DNASU; 3062; -.
DR   Ensembl; ENST00000370862; ENSP00000359899; ENSG00000137252.
DR   Ensembl; ENST00000615358; ENSP00000477548; ENSG00000137252.
DR   GeneID; 3062; -.
DR   KEGG; hsa:3062; -.
DR   CTD; 3062; -.
DR   DisGeNET; 3062; -.
DR   EuPathDB; HostDB:ENSG00000137252.9; -.
DR   GeneCards; HCRTR2; -.
DR   HGNC; HGNC:4849; HCRTR2.
DR   HPA; ENSG00000137252; Tissue enriched (brain).
DR   MIM; 602393; gene.
DR   neXtProt; NX_O43614; -.
DR   OpenTargets; ENSG00000137252; -.
DR   PharmGKB; PA29223; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT01000000214421; -.
DR   HOGENOM; CLU_009579_6_3_1; -.
DR   InParanoid; O43614; -.
DR   KO; K04239; -.
DR   OMA; IRSHHDE; -.
DR   OrthoDB; 981089at2759; -.
DR   PhylomeDB; O43614; -.
DR   TreeFam; TF315303; -.
DR   PathwayCommons; O43614; -.
DR   Reactome; R-HSA-389397; Orexin and neuropeptides FF and QRFP bind to their respective receptors.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   SIGNOR; O43614; -.
DR   BioGRID-ORCS; 3062; 5 hits in 863 CRISPR screens.
DR   ChiTaRS; HCRTR2; human.
DR   GeneWiki; Hypocretin_(orexin)_receptor_2; -.
DR   GenomeRNAi; 3062; -.
DR   Pharos; O43614; Tclin.
DR   PRO; PR:O43614; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; O43614; protein.
DR   Bgee; ENSG00000137252; Expressed in cortical plate and 42 other tissues.
DR   ExpressionAtlas; O43614; baseline and differential.
DR   Genevisible; O43614; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0045202; C:synapse; IEA:GOC.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0008188; F:neuropeptide receptor activity; TAS:ProtInc.
DR   GO; GO:0016499; F:orexin receptor activity; IDA:UniProtKB.
DR   GO; GO:0017046; F:peptide hormone binding; IEA:Ensembl.
DR   GO; GO:0007268; P:chemical synaptic transmission; TAS:ProtInc.
DR   GO; GO:0022410; P:circadian sleep/wake cycle process; IEA:InterPro.
DR   GO; GO:0007631; P:feeding behavior; TAS:ProtInc.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007218; P:neuropeptide signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0010840; P:regulation of circadian sleep/wake cycle, wakefulness; ISS:UniProtKB.
DR   GO; GO:0051480; P:regulation of cytosolic calcium ion concentration; IDA:UniProtKB.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR000204; Orexin_rcpt.
DR   InterPro; IPR004060; Orexin_rcpt_2.
DR   Pfam; PF00001; 7tm_1; 1.
DR   Pfam; PF03827; Orexin_rec2; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01522; OREXIN2R.
DR   PRINTS; PR01064; OREXINR.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Membrane; Polymorphism; Receptor; Reference proteome;
KW   Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..444
FT                   /note="Orexin receptor type 2"
FT                   /id="PRO_0000069989"
FT   TOPO_DOM        1..54
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:25533960,
FT                   ECO:0000305|PubMed:26950369"
FT   TRANSMEM        55..75
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000269|PubMed:25533960"
FT   TOPO_DOM        76..88
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:25533960"
FT   TRANSMEM        89..110
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000269|PubMed:25533960"
FT   TOPO_DOM        111..127
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:25533960"
FT   TRANSMEM        128..150
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000269|PubMed:25533960"
FT   TOPO_DOM        151..170
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:25533960"
FT   TRANSMEM        171..191
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000269|PubMed:25533960"
FT   TOPO_DOM        192..222
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:25533960"
FT   TRANSMEM        223..243
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000269|PubMed:25533960"
FT   TOPO_DOM        244..304
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:25533960"
FT   TRANSMEM        305..326
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000269|PubMed:25533960"
FT   TOPO_DOM        327..342
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:25533960"
FT   TRANSMEM        343..366
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000269|PubMed:25533960"
FT   TOPO_DOM        367..444
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:25533960"
FT   REGION          33..49
FT                   /note="Required for response to orexin-A"
FT                   /evidence="ECO:0000269|PubMed:26950369"
FT   BINDING         324
FT                   /note="Agonist"
FT                   /evidence="ECO:0000269|PubMed:25533960"
FT   SITE            44
FT                   /note="Important for responses to orexin"
FT                   /evidence="ECO:0000269|PubMed:26950369"
FT   CARBOHYD        14
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        22
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        202
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        127..210
FT                   /evidence="ECO:0000244|PDB:4S0V"
FT   VARIANT         10
FT                   /note="P -> S (in dbSNP:rs41271310)"
FT                   /evidence="ECO:0000269|PubMed:11723285"
FT                   /id="VAR_044507"
FT   VARIANT         11
FT                   /note="P -> T (in dbSNP:rs41271312)"
FT                   /evidence="ECO:0000269|PubMed:11723285"
FT                   /id="VAR_044508"
FT   VARIANT         293
FT                   /note="I -> V (in dbSNP:rs74720027)"
FT                   /evidence="ECO:0000269|PubMed:11723285"
FT                   /id="VAR_044509"
FT   VARIANT         308
FT                   /note="I -> V (in dbSNP:rs2653349)"
FT                   /evidence="ECO:0000269|PubMed:11723285,
FT                   ECO:0000269|PubMed:9491897"
FT                   /id="VAR_044510"
FT   MUTAGEN         33..49
FT                   /note="Missing: Abolishes response to orexin-A."
FT                   /evidence="ECO:0000269|PubMed:26950369"
FT   MUTAGEN         44
FT                   /note="W->N: Abolishes response to orexin-A."
FT                   /evidence="ECO:0000269|PubMed:26950369"
FT   MUTAGEN         324
FT                   /note="N->A: Strongly impairs response to orexin-A."
FT                   /evidence="ECO:0000269|PubMed:26950369"
FT   HELIX           40..47
FT                   /evidence="ECO:0000244|PDB:5WQC"
FT   HELIX           54..81
FT                   /evidence="ECO:0000244|PDB:5WQC"
FT   HELIX           83..85
FT                   /evidence="ECO:0000244|PDB:5WQC"
FT   HELIX           88..106
FT                   /evidence="ECO:0000244|PDB:5WQC"
FT   HELIX           108..117
FT                   /evidence="ECO:0000244|PDB:5WQC"
FT   HELIX           123..156
FT                   /evidence="ECO:0000244|PDB:5WQC"
FT   STRAND          158..160
FT                   /evidence="ECO:0000244|PDB:5WQC"
FT   HELIX           166..183
FT                   /evidence="ECO:0000244|PDB:5WQC"
FT   HELIX           185..190
FT                   /evidence="ECO:0000244|PDB:5WQC"
FT   STRAND          191..196
FT                   /evidence="ECO:0000244|PDB:5WQC"
FT   STRAND          199..202
FT                   /evidence="ECO:0000244|PDB:5WS3"
FT   STRAND          207..212
FT                   /evidence="ECO:0000244|PDB:5WQC"
FT   STRAND          215..217
FT                   /evidence="ECO:0000244|PDB:5WQC"
FT   HELIX           218..231
FT                   /evidence="ECO:0000244|PDB:5WQC"
FT   HELIX           233..251
FT                   /evidence="ECO:0000244|PDB:5WQC"
FT   TURN            252..254
FT                   /evidence="ECO:0000244|PDB:6TPN"
FT   HELIX           294..328
FT                   /evidence="ECO:0000244|PDB:5WQC"
FT   TURN            332..335
FT                   /evidence="ECO:0000244|PDB:5WQC"
FT   HELIX           339..367
FT                   /evidence="ECO:0000244|PDB:5WQC"
FT   HELIX           369..381
FT                   /evidence="ECO:0000244|PDB:5WQC"
SQ   SEQUENCE   444 AA;  50694 MW;  C4C9A153D42254C6 CRC64;
     MSGTKLEDSP PCRNWSSASE LNETQEPFLN PTDYDDEEFL RYLWREYLHP KEYEWVLIAG
     YIIVFVVALI GNVLVCVAVW KNHHMRTVTN YFIVNLSLAD VLVTITCLPA TLVVDITETW
     FFGQSLCKVI PYLQTVSVSV SVLTLSCIAL DRWYAICHPL MFKSTAKRAR NSIVIIWIVS
     CIIMIPQAIV MECSTVFPGL ANKTTLFTVC DERWGGEIYP KMYHICFFLV TYMAPLCLMV
     LAYLQIFRKL WCRQIPGTSS VVQRKWKPLQ PVSQPRGPGQ PTKSRMSAVA AEIKQIRARR
     KTARMLMIVL LVFAICYLPI SILNVLKRVF GMFAHTEDRE TVYAWFTFSH WLVYANSAAN
     PIIYNFLSGK FREEFKAAFS CCCLGVHHRQ EDRLTRGRTS TESRKSLTTQ ISNFDNISKL
     SEQVVLTSIS TLPAANGAGP LQNW
//
ID   5HT2C_HUMAN             Reviewed;         458 AA.
AC   P28335; B1AMW4; Q5VUF8; Q9NP28;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-1992, sequence version 1.
DT   07-OCT-2020, entry version 208.
DE   RecName: Full=5-hydroxytryptamine receptor 2C;
DE            Short=5-HT-2C;
DE            Short=5-HT2C;
DE            Short=5-HTR2C;
DE   AltName: Full=5-hydroxytryptamine receptor 1C;
DE            Short=5-HT-1C;
DE            Short=5-HT1C;
DE   AltName: Full=Serotonin receptor 2C;
DE   Flags: Precursor;
GN   Name=HTR2C; Synonyms=HTR1C;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=1722404; DOI=10.1016/0006-291x(91)92105-s;
RA   Saltzman A.G., Morse B., Whitman M.M., Ivanshchenko Y., Jaye M., Felder S.;
RT   "Cloning of the human serotonin 5-HT2 and 5-HT1C receptor subtypes.";
RL   Biochem. Biophys. Res. Commun. 181:1469-1478(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, AND SUBCELLULAR LOCATION.
RC   TISSUE=Hippocampus, and Placenta;
RX   PubMed=7895773; DOI=10.1016/0922-4106(94)90042-6;
RA   Stam N.J., Vanderheyden P., Van Alebeek C., Klomp J., De Boer T.,
RA   Van Delft A.M.L., Olijve W.;
RT   "Genomic organisation and functional expression of the gene encoding the
RT   human serotonin 5-HT2C receptor.";
RL   Eur. J. Pharmacol. 269:339-348(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=8812491; DOI=10.1006/geno.1996.0397;
RA   Xie E., Zhao L., Levine A.J., Shenk T., Chang L.-S.;
RT   "The human serotonin 5-HT2C receptor: complete cDNA, genomic structure, and
RT   alternatively spliced variant.";
RL   Genomics 35:551-561(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND RNA EDITING OF POSITIONS 156;
RP   158 AND 160.
RC   TISSUE=Brain;
RX   PubMed=9928237; DOI=10.1111/j.1749-6632.1998.tb10171.x;
RA   Niswender C.M., Sanders-Bush E., Emeson R.B.;
RT   "Identification and characterization of RNA editing events within the 5-
RT   HT2C receptor.";
RL   Ann. N. Y. Acad. Sci. 861:38-48(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Hippocampus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   INTERACTION WITH MPDZ, DOMAIN, MUTAGENESIS OF SER-456; SER-457 AND VAL-458,
RP   AND GLYCOSYLATION.
RX   PubMed=11150294; DOI=10.1074/jbc.m008089200;
RA   Becamel C., Figge A., Poliak S., Dumuis A., Peles E., Bockaert J.,
RA   Luebbert H., Ullmer C.;
RT   "Interaction of serotonin 5-hydroxytryptamine type 2C receptors with PDZ10
RT   of the multi-PDZ domain protein MUPP1.";
RL   J. Biol. Chem. 276:12974-12982(2001).
RN   [10]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12970106; DOI=10.1038/sj.bjp.0705437;
RA   Schaerlinger B., Hickel P., Etienne N., Guesnier L., Maroteaux L.;
RT   "Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and
RT   their possible relevance to antimigraine efficacy.";
RL   Br. J. Pharmacol. 140:277-284(2003).
RN   [11]
RP   INTERACTION WITH ARRB2, AND MUTAGENESIS OF PRO-159.
RX   PubMed=16319069; DOI=10.1074/jbc.m508074200;
RA   Marion S., Oakley R.H., Kim K.-M., Caron M.G., Barak L.S.;
RT   "A beta-arrestin binding determinant common to the second intracellular
RT   loops of rhodopsin family G protein-coupled receptors.";
RL   J. Biol. Chem. 281:2932-2938(2006).
RN   [12]
RP   REVIEW.
RX   PubMed=18476671; DOI=10.1021/cr078224o;
RA   Nichols D.E., Nichols C.D.;
RT   "Serotonin receptors.";
RL   Chem. Rev. 108:1614-1641(2008).
RN   [13]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=18703043; DOI=10.1016/j.ejphar.2008.07.040;
RA   Cussac D., Boutet-Robinet E., Ailhaud M.C., Newman-Tancredi A.,
RA   Martel J.C., Danty N., Rauly-Lestienne I.;
RT   "Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and
RT   5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in
RT   CHO cells.";
RL   Eur. J. Pharmacol. 594:32-38(2008).
RN   [14]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=19057895; DOI=10.1007/s00210-008-0378-4;
RA   Knauer C.S., Campbell J.E., Chio C.L., Fitzgerald L.W.;
RT   "Pharmacological characterization of mitogen-activated protein kinase
RT   activation by recombinant human 5-HT2C, 5-HT2A, and 5-HT2B receptors.";
RL   Naunyn Schmiedebergs Arch. Pharmacol. 379:461-471(2009).
RN   [15]
RP   REVIEW.
RX   PubMed=20945968; DOI=10.33549/physiolres.931903;
RA   Pytliak M., Vargova V., Mechirova V., Felsoci M.;
RT   "Serotonin receptors - from molecular biology to clinical applications.";
RL   Physiol. Res. 60:15-25(2011).
RN   [16]
RP   SIGNAL SEQUENCE CLEAVAGE SITE, AND VARIANT SER-23.
RX   PubMed=22497996; DOI=10.1016/j.ejphar.2012.03.043;
RA   Jahnsen J.A., Uhlen S.;
RT   "The N-terminal region of the human 5-HT(2)C receptor has as a cleavable
RT   signal peptide.";
RL   Eur. J. Pharmacol. 684:44-50(2012).
RN   [17]
RP   VARIANT SER-23.
RX   PubMed=7557992; DOI=10.1006/geno.1995.1042;
RA   Lappalainen J., Zhang L., Dean M., Oz M., Ozaki N., Yu D., Virkkunen M.,
RA   Weight F., Linnoila M., Goldman D.;
RT   "Identification, expression, and pharmacology of a Cys23-Ser23 substitution
RT   in the human 5-HT2c receptor gene (HTR2C).";
RL   Genomics 27:274-279(1995).
RN   [18]
RP   VARIANT SER-23.
RX   PubMed=10206230;
RX   DOI=10.1002/(sici)1096-8628(19990416)88:2<126::aid-ajmg6>3.0.co;2-m;
RA   Samochowiec J., Smolka M., Winterer G., Rommelspacher H., Schmidt L.G.,
RA   Sander T.;
RT   "Association analysis between a Cys23Ser substitution polymorphism of the
RT   human 5-HT2c receptor gene and neuronal hyperexcitability.";
RL   Am. J. Med. Genet. 88:126-130(1999).
RN   [19]
RP   VARIANT SER-23.
RX   PubMed=10581480;
RX   DOI=10.1002/(sici)1096-8628(19991215)88:6<621::aid-ajmg9>3.0.co;2-h;
RA   Marshall S.E., Bird T.G., Hart K., Welsh K.I.;
RT   "Unified approach to the analysis of genetic variation in serotonergic
RT   pathways.";
RL   Am. J. Med. Genet. 88:621-627(1999).
RN   [20]
RP   VARIANT SER-23.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions of
RT   human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [21]
RP   ERRATUM OF PUBMED:10391209.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
CC   -!- FUNCTION: G-protein coupled receptor for 5-hydroxytryptamine
CC       (serotonin). Also functions as a receptor for various drugs and
CC       psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-
CC       dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid
CC       diethylamide (LSD). Ligand binding causes a conformation change that
CC       triggers signaling via guanine nucleotide-binding proteins (G proteins)
CC       and modulates the activity of down-stream effectors. Beta-arrestin
CC       family members inhibit signaling via G proteins and mediate activation
CC       of alternative signaling pathways. Signaling activates a
CC       phosphatidylinositol-calcium second messenger system that modulates the
CC       activity of phosphatidylinositol 3-kinase and down-stream signaling
CC       cascades and promotes the release of Ca(2+) ions from intracellular
CC       stores. Regulates neuronal activity via the activation of short
CC       transient receptor potential calcium channels in the brain, and thereby
CC       modulates the activation of pro-opiomelacortin neurons and the release
CC       of CRH that then regulates the release of corticosterone. Plays a role
CC       in the regulation of appetite and eating behavior, responses to
CC       anxiogenic stimuli and stress. Plays a role in insulin sensitivity and
CC       glucose homeostasis. {ECO:0000269|PubMed:12970106,
CC       ECO:0000269|PubMed:18703043, ECO:0000269|PubMed:19057895,
CC       ECO:0000269|PubMed:7895773}.
CC   -!- SUBUNIT: Interacts with MPDZ. Interacts with ARRB2.
CC       {ECO:0000269|PubMed:11150294, ECO:0000269|PubMed:16319069}.
CC   -!- INTERACTION:
CC       P28335; P07550: ADRB2; NbExp=2; IntAct=EBI-994141, EBI-491169;
CC       P28335; P08173: CHRM4; NbExp=2; IntAct=EBI-994141, EBI-6655217;
CC       P28335; O95406: CNIH1; NbExp=3; IntAct=EBI-994141, EBI-12172273;
CC       P28335; P54849: EMP1; NbExp=3; IntAct=EBI-994141, EBI-4319440;
CC       P28335; P28223: HTR2A; NbExp=5; IntAct=EBI-994141, EBI-6656333;
CC       P28335; P41595: HTR2B; NbExp=4; IntAct=EBI-994141, EBI-7474947;
CC       P28335; P28335: HTR2C; NbExp=9; IntAct=EBI-994141, EBI-994141;
CC       P28335; P48039: MTNR1A; NbExp=2; IntAct=EBI-994141, EBI-1188238;
CC       P28335; P49286: MTNR1B; NbExp=3; IntAct=EBI-994141, EBI-1188341;
CC       P28335; Q9NUM3: SLC39A9; NbExp=3; IntAct=EBI-994141, EBI-2823239;
CC       P28335; P55061: TMBIM6; NbExp=3; IntAct=EBI-994141, EBI-1045825;
CC       P28335; Q9BVK8: TMEM147; NbExp=4; IntAct=EBI-994141, EBI-348587;
CC       P28335; A0A061IBI8: H671_3g9895; Xeno; NbExp=2; IntAct=EBI-994141, EBI-21399223;
CC       P28335-1; P28223-1: HTR2A; NbExp=3; IntAct=EBI-21299643, EBI-15573967;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:12970106,
CC       ECO:0000269|PubMed:18703043, ECO:0000269|PubMed:19057895,
CC       ECO:0000269|PubMed:7895773}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:12970106, ECO:0000269|PubMed:18703043,
CC       ECO:0000269|PubMed:19057895, ECO:0000269|PubMed:7895773}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P28335-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P28335-2; Sequence=VSP_045171;
CC   -!- TISSUE SPECIFICITY: Detected in brain. {ECO:0000269|PubMed:8812491}.
CC   -!- DOMAIN: The PDZ domain-binding motif is involved in the interaction
CC       with MPDZ. {ECO:0000269|PubMed:11150294}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:11150294}.
CC   -!- RNA EDITING: Modified_positions=156 {ECO:0000269|PubMed:9928237}, 158
CC       {ECO:0000269|PubMed:9928237}, 160 {ECO:0000269|PubMed:9928237};
CC       Note=Partially edited. RNA editing generates receptor isoforms that
CC       differ in their ability to interact with the phospholipase C signaling
CC       cascade in a transfected cell line, suggesting that this RNA processing
CC       event may contribute to the modulation of serotonergic
CC       neurotransmission in the central nervous system.;
CC   -!- POLYMORPHISM: Position 23 is polymorphic; the frequencies in unrelated
CC       Caucasians are 0.87 for Cys and 0.13 for Ser.
CC       {ECO:0000269|PubMed:7557992}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M81778; AAA60317.1; -; mRNA.
DR   EMBL; X80763; CAB59978.1; -; Genomic_DNA.
DR   EMBL; U49516; AAB40898.1; -; mRNA.
DR   EMBL; AF208053; AAF35842.1; -; mRNA.
DR   EMBL; AF498983; AAM21130.1; -; mRNA.
DR   EMBL; AK295753; BAG58583.1; -; mRNA.
DR   EMBL; AC007022; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC007025; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL591402; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL355812; CAI41334.1; -; Genomic_DNA.
DR   EMBL; AC004822; CAI41334.1; JOINED; Genomic_DNA.
DR   EMBL; AL590097; CAI41334.1; JOINED; Genomic_DNA.
DR   EMBL; AC004822; AAC71658.1; -; Genomic_DNA.
DR   EMBL; AL355812; CAI41335.1; -; Genomic_DNA.
DR   EMBL; AL590097; CAI41335.1; JOINED; Genomic_DNA.
DR   EMBL; AC004822; CAI41335.1; JOINED; Genomic_DNA.
DR   EMBL; AL590097; CAH70193.1; -; Genomic_DNA.
DR   EMBL; AC004822; CAH70193.1; JOINED; Genomic_DNA.
DR   EMBL; AL355812; CAH70193.1; JOINED; Genomic_DNA.
DR   EMBL; BC095543; AAH95543.1; -; mRNA.
DR   CCDS; CCDS14564.1; -. [P28335-1]
DR   CCDS; CCDS59174.1; -. [P28335-2]
DR   PIR; JS0616; JS0616.
DR   RefSeq; NP_000859.1; NM_000868.3. [P28335-1]
DR   RefSeq; NP_001243689.1; NM_001256760.2. [P28335-1]
DR   RefSeq; NP_001243690.1; NM_001256761.2. [P28335-2]
DR   PDB; 6BQG; X-ray; 3.00 A; A=40-245, A=301-393.
DR   PDB; 6BQH; X-ray; 2.70 A; A=40-245, A=301-393.
DR   PDBsum; 6BQG; -.
DR   PDBsum; 6BQH; -.
DR   SMR; P28335; -.
DR   BioGRID; 109590; 105.
DR   IntAct; P28335; 119.
DR   MINT; P28335; -.
DR   STRING; 9606.ENSP00000276198; -.
DR   BindingDB; P28335; -.
DR   ChEMBL; CHEMBL225; -.
DR   DrugBank; DB13940; 2,5-Dimethoxy-4-ethylthioamphetamine.
DR   DrugBank; DB01537; 4-Bromo-2,5-dimethoxyphenethylamine.
DR   DrugBank; DB06594; Agomelatine.
DR   DrugBank; DB00321; Amitriptyline.
DR   DrugBank; DB00543; Amoxapine.
DR   DrugBank; DB00714; Apomorphine.
DR   DrugBank; DB01238; Aripiprazole.
DR   DrugBank; DB14185; Aripiprazole lauroxil.
DR   DrugBank; DB06216; Asenapine.
DR   DrugBank; DB01200; Bromocriptine.
DR   DrugBank; DB00248; Cabergoline.
DR   DrugBank; DB09014; Captodiame.
DR   DrugBank; DB00477; Chlorpromazine.
DR   DrugBank; DB01239; Chlorprothixene.
DR   DrugBank; DB01242; Clomipramine.
DR   DrugBank; DB00363; Clozapine.
DR   DrugBank; DB00924; Cyclobenzaprine.
DR   DrugBank; DB00434; Cyproheptadine.
DR   DrugBank; DB04884; Dapoxetine.
DR   DrugBank; DB06512; Deramciclane.
DR   DrugBank; DB01151; Desipramine.
DR   DrugBank; DB01191; Dexfenfluramine.
DR   DrugBank; DB11273; Dihydroergocornine.
DR   DrugBank; DB13345; Dihydroergocristine.
DR   DrugBank; DB06446; Dotarizine.
DR   DrugBank; DB01142; Doxepin.
DR   DrugBank; DB05492; Epicept NP-1.
DR   DrugBank; DB12177; Eplivanserin.
DR   DrugBank; DB01049; Ergoloid mesylate.
DR   DrugBank; DB00696; Ergotamine.
DR   DrugBank; DB01175; Escitalopram.
DR   DrugBank; DB06678; Esmirtazapine.
DR   DrugBank; DB09194; Etoperidone.
DR   DrugBank; DB00574; Fenfluramine.
DR   DrugBank; DB00472; Fluoxetine.
DR   DrugBank; DB00623; Fluphenazine.
DR   DrugBank; DB12141; Gilteritinib.
DR   DrugBank; DB00502; Haloperidol.
DR   DrugBank; DB00458; Imipramine.
DR   DrugBank; DB01221; Ketamine.
DR   DrugBank; DB00589; Lisuride.
DR   DrugBank; DB04948; Lofexidine.
DR   DrugBank; DB04871; Lorcaserin.
DR   DrugBank; DB09195; Lorpiprazole.
DR   DrugBank; DB00408; Loxapine.
DR   DrugBank; DB12110; m-Chlorophenylpiperazine.
DR   DrugBank; DB00934; Maprotiline.
DR   DrugBank; DB01403; Methotrimeprazine.
DR   DrugBank; DB00247; Methysergide.
DR   DrugBank; DB06148; Mianserin.
DR   DrugBank; DB01454; Midomafetamine.
DR   DrugBank; DB00805; Minaprine.
DR   DrugBank; DB00370; Mirtazapine.
DR   DrugBank; DB01149; Nefazodone.
DR   DrugBank; DB00540; Nortriptyline.
DR   DrugBank; DB06229; Ocaperidone.
DR   DrugBank; DB00334; Olanzapine.
DR   DrugBank; DB01267; Paliperidone.
DR   DrugBank; DB00715; Paroxetine.
DR   DrugBank; DB01186; Pergolide.
DR   DrugBank; DB06153; Pizotifen.
DR   DrugBank; DB00420; Promazine.
DR   DrugBank; DB00777; Propiomazine.
DR   DrugBank; DB01224; Quetiapine.
DR   DrugBank; DB00734; Risperidone.
DR   DrugBank; DB12163; Sarpogrelate.
DR   DrugBank; DB06144; Sertindole.
DR   DrugBank; DB09304; Setiptiline.
DR   DrugBank; DB01079; Tegaserod.
DR   DrugBank; DB13025; Tiapride.
DR   DrugBank; DB00193; Tramadol.
DR   DrugBank; DB00656; Trazodone.
DR   DrugBank; DB00726; Trimipramine.
DR   DrugBank; DB01392; Yohimbine.
DR   DrugBank; DB00246; Ziprasidone.
DR   DrugCentral; P28335; -.
DR   GuidetoPHARMACOLOGY; 8; -.
DR   GlyGen; P28335; 1 site.
DR   iPTMnet; P28335; -.
DR   PhosphoSitePlus; P28335; -.
DR   BioMuta; HTR2C; -.
DR   DMDM; 112816; -.
DR   PaxDb; P28335; -.
DR   PeptideAtlas; P28335; -.
DR   PRIDE; P28335; -.
DR   ProteomicsDB; 3230; -.
DR   ProteomicsDB; 54476; -. [P28335-1]
DR   Antibodypedia; 527; 480 antibodies.
DR   Ensembl; ENST00000276198; ENSP00000276198; ENSG00000147246.
DR   Ensembl; ENST00000371950; ENSP00000361018; ENSG00000147246.
DR   Ensembl; ENST00000371951; ENSP00000361019; ENSG00000147246.
DR   GeneID; 3358; -.
DR   KEGG; hsa:3358; -.
DR   UCSC; uc004epu.1; human. [P28335-1]
DR   CTD; 3358; -.
DR   DisGeNET; 3358; -.
DR   EuPathDB; HostDB:ENSG00000147246.9; -.
DR   GeneCards; HTR2C; -.
DR   HGNC; HGNC:5295; HTR2C.
DR   HPA; ENSG00000147246; Tissue enriched (brain).
DR   MIM; 312861; gene.
DR   neXtProt; NX_P28335; -.
DR   PharmGKB; PA194; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   HOGENOM; CLU_009579_11_3_1; -.
DR   InParanoid; P28335; -.
DR   KO; K04157; -.
DR   OrthoDB; 962038at2759; -.
DR   PhylomeDB; P28335; -.
DR   TreeFam; TF316350; -.
DR   PathwayCommons; P28335; -.
DR   Reactome; R-HSA-390666; Serotonin receptors.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   SignaLink; P28335; -.
DR   SIGNOR; P28335; -.
DR   BioGRID-ORCS; 3358; 4 hits in 497 CRISPR screens.
DR   ChiTaRS; HTR2C; human.
DR   GeneWiki; 5-HT2C_receptor; -.
DR   GenomeRNAi; 3358; -.
DR   Pharos; P28335; Tclin.
DR   PRO; PR:P28335; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; P28335; protein.
DR   Bgee; ENSG00000147246; Expressed in choroid plexus epithelium and 74 other tissues.
DR   Genevisible; P28335; HS.
DR   GO; GO:0030425; C:dendrite; IBA:GO_Central.
DR   GO; GO:0005887; C:integral component of plasma membrane; IMP:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0045202; C:synapse; IEA:GOC.
DR   GO; GO:0071886; F:1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding; IDA:UniProtKB.
DR   GO; GO:0008144; F:drug binding; IDA:UniProtKB.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0004993; F:G protein-coupled serotonin receptor activity; IDA:MGI.
DR   GO; GO:0001587; F:Gq/11-coupled serotonin receptor activity; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0030594; F:neurotransmitter receptor activity; IBA:GO_Central.
DR   GO; GO:0051378; F:serotonin binding; IDA:UniProtKB.
DR   GO; GO:0001662; P:behavioral fear response; ISS:UniProtKB.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IDA:UniProtKB.
DR   GO; GO:0019934; P:cGMP-mediated signaling; IDA:UniProtKB.
DR   GO; GO:0007268; P:chemical synaptic transmission; IBA:GO_Central.
DR   GO; GO:0007631; P:feeding behavior; ISS:UniProtKB.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007187; P:G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; IBA:GO_Central.
DR   GO; GO:0007626; P:locomotory behavior; IEA:InterPro.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007208; P:phospholipase C-activating serotonin receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:0051482; P:positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway; ISS:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0045600; P:positive regulation of fat cell differentiation; IEA:Ensembl.
DR   GO; GO:0010513; P:positive regulation of phosphatidylinositol biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0032098; P:regulation of appetite; ISS:UniProtKB.
DR   GO; GO:0043397; P:regulation of corticotropin-releasing hormone secretion; ISS:UniProtKB.
DR   GO; GO:0031644; P:regulation of nervous system process; ISS:UniProtKB.
DR   GO; GO:0051209; P:release of sequestered calcium ion into cytosol; IMP:UniProtKB.
DR   GO; GO:0042493; P:response to drug; IDA:UniProtKB.
DR   GO; GO:0007210; P:serotonin receptor signaling pathway; IMP:UniProtKB.
DR   InterPro; IPR000377; 5HT2C_rcpt.
DR   InterPro; IPR002231; 5HT_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   PANTHER; PTHR24247:SF32; PTHR24247:SF32; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00517; 5HT2CRECEPTR.
DR   PRINTS; PR01101; 5HTRECEPTOR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Behavior; Cell membrane;
KW   Disulfide bond; G-protein coupled receptor; Glycoprotein; Membrane;
KW   Polymorphism; Receptor; Reference proteome; RNA editing; Signal;
KW   Transducer; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..32
FT                   /evidence="ECO:0000269|PubMed:22497996"
FT   CHAIN           33..458
FT                   /note="5-hydroxytryptamine receptor 2C"
FT                   /id="PRO_0000068958"
FT   TOPO_DOM        33..52
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        53..78
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        79..89
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        90..110
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        111..127
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        128..150
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        151..170
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        171..193
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        194..213
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        214..235
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        236..311
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        312..333
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        334..348
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        349..371
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        372..458
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   REGION          134..139
FT                   /note="Agonist binding"
FT                   /evidence="ECO:0000250"
FT   REGION          324..328
FT                   /note="Agonist binding"
FT                   /evidence="ECO:0000250"
FT   MOTIF           151..153
FT                   /note="DRY motif; important for ligand-induced conformation
FT                   changes"
FT                   /evidence="ECO:0000250"
FT   MOTIF           364..368
FT                   /note="NPxxY motif; important for ligand-induced
FT                   conformation changes and signaling"
FT                   /evidence="ECO:0000250"
FT   MOTIF           456..458
FT                   /note="PDZ-binding"
FT   CARBOHYD        39
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000305|PubMed:11150294"
FT   DISULFID        127..207
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   DISULFID        337..341
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VAR_SEQ         153..458
FT                   /note="YVAIRNPIEHSRFNSRTKAIMKIAIVWAISIGVSVPIPVIGLRDEEKVFVNN
FT                   TTCVLNDPNFVLIGSFVAFFIPLTIMVITYCLTIYVLRRQALMLLHGHTEEPPGLSLDF
FT                   LKCCKRNTAEEENSANPNQDQNARRRKKKERRPRGTMQAINNERKASKVLGIVFFVFLI
FT                   MWCPFFITNILSVLCEKSCNQKLMEKLLNVFVWIGYVCSGINPLVYTLFNKIYRRAFSN
FT                   YLRCNYKVEKKPPVRQIPRVAATALSGRELNVNIYRHTNEPVIEKASDNEPGIEMQVEN
FT                   LELPVNPSSVVSERISSV -> CISSYPCDWTEGRRKGVREQHDVRAQRPKFRSYWVLR
FT                   SFLHTADDYGDYVLPDHLRSAPTSFDVTARPHRGTAWTKSGFPEVLQEEYGRGRELCKP
FT                   (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_045171"
FT   VARIANT         23
FT                   /note="C -> S (in dbSNP:rs6318)"
FT                   /evidence="ECO:0000269|PubMed:10206230,
FT                   ECO:0000269|PubMed:10391209, ECO:0000269|PubMed:10581480,
FT                   ECO:0000269|PubMed:22497996, ECO:0000269|PubMed:7557992"
FT                   /id="VAR_003450"
FT   VARIANT         156
FT                   /note="I -> V (in RNA edited version)"
FT                   /id="VAR_010166"
FT   VARIANT         158
FT                   /note="N -> S (in RNA edited version)"
FT                   /id="VAR_010167"
FT   VARIANT         160
FT                   /note="I -> V (in RNA edited version; dbSNP:rs781938388)"
FT                   /id="VAR_010168"
FT   MUTAGEN         159
FT                   /note="P->A: Decreases interaction with ARRB2."
FT                   /evidence="ECO:0000269|PubMed:16319069"
FT   MUTAGEN         456
FT                   /note="S->A: Loss of interaction with MPDZ."
FT                   /evidence="ECO:0000269|PubMed:11150294"
FT   MUTAGEN         456
FT                   /note="S->T: No effect on interaction with MPDZ."
FT                   /evidence="ECO:0000269|PubMed:11150294"
FT   MUTAGEN         457
FT                   /note="S->A: No effect on interaction with MPDZ."
FT                   /evidence="ECO:0000269|PubMed:11150294"
FT   MUTAGEN         458
FT                   /note="V->A: Loss of interaction with MPDZ."
FT                   /evidence="ECO:0000269|PubMed:11150294"
FT   TURN            48..50
FT                   /evidence="ECO:0000244|PDB:6BQG"
FT   HELIX           56..60
FT                   /evidence="ECO:0000244|PDB:6BQH"
FT   HELIX           61..80
FT                   /evidence="ECO:0000244|PDB:6BQH"
FT   HELIX           82..84
FT                   /evidence="ECO:0000244|PDB:6BQH"
FT   HELIX           87..105
FT                   /evidence="ECO:0000244|PDB:6BQH"
FT   HELIX           107..115
FT                   /evidence="ECO:0000244|PDB:6BQH"
FT   TURN            116..118
FT                   /evidence="ECO:0000244|PDB:6BQH"
FT   HELIX           126..154
FT                   /evidence="ECO:0000244|PDB:6BQH"
FT   HELIX           167..186
FT                   /evidence="ECO:0000244|PDB:6BQH"
FT   HELIX           188..195
FT                   /evidence="ECO:0000244|PDB:6BQH"
FT   HELIX           197..199
FT                   /evidence="ECO:0000244|PDB:6BQH"
FT   STRAND          200..202
FT                   /evidence="ECO:0000244|PDB:6BQH"
FT   TURN            203..205
FT                   /evidence="ECO:0000244|PDB:6BQH"
FT   HELIX           212..222
FT                   /evidence="ECO:0000244|PDB:6BQH"
FT   HELIX           224..245
FT                   /evidence="ECO:0000244|PDB:6BQH"
FT   HELIX           301..335
FT                   /evidence="ECO:0000244|PDB:6BQH"
FT   STRAND          338..341
FT                   /evidence="ECO:0000244|PDB:6BQH"
FT   HELIX           343..371
FT                   /evidence="ECO:0000244|PDB:6BQH"
FT   HELIX           373..385
FT                   /evidence="ECO:0000244|PDB:6BQH"
SQ   SEQUENCE   458 AA;  51821 MW;  9E76B3FFD3E09C93 CRC64;
     MVNLRNAVHS FLVHLIGLLV WQCDISVSPV AAIVTDIFNT SDGGRFKFPD GVQNWPALSI
     VIIIIMTIGG NILVIMAVSM EKKLHNATNY FLMSLAIADM LVGLLVMPLS LLAILYDYVW
     PLPRYLCPVW ISLDVLFSTA SIMHLCAISL DRYVAIRNPI EHSRFNSRTK AIMKIAIVWA
     ISIGVSVPIP VIGLRDEEKV FVNNTTCVLN DPNFVLIGSF VAFFIPLTIM VITYCLTIYV
     LRRQALMLLH GHTEEPPGLS LDFLKCCKRN TAEEENSANP NQDQNARRRK KKERRPRGTM
     QAINNERKAS KVLGIVFFVF LIMWCPFFIT NILSVLCEKS CNQKLMEKLL NVFVWIGYVC
     SGINPLVYTL FNKIYRRAFS NYLRCNYKVE KKPPVRQIPR VAATALSGRE LNVNIYRHTN
     EPVIEKASDN EPGIEMQVEN LELPVNPSSV VSERISSV
//
ID   GRM2_HUMAN              Reviewed;         872 AA.
AC   Q14416; B0M0K7; Q14CU5; Q52MC6; Q9H3N6;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   27-SEP-2005, sequence version 2.
DT   07-OCT-2020, entry version 164.
DE   RecName: Full=Metabotropic glutamate receptor 2;
DE            Short=mGluR2;
DE   Flags: Precursor;
GN   Name=GRM2 {ECO:0000312|HGNC:HGNC:4594}; Synonyms=GPRC1B, MGLUR2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RX   PubMed=7620613; DOI=10.1111/j.1460-9568.1995.tb00666.x;
RA   Flor P.J., Lindauer K., Puttner I., Ruegg D., Lukic S., Knopfel T.,
RA   Kuhn R.;
RT   "Molecular cloning, functional expression and pharmacological
RT   characterization of the human metabotropic glutamate receptor type 2.";
RL   Eur. J. Neurosci. 7:622-629(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Yasuyuki F., Akiko J.;
RT   "Structure and polymorphisms of the human metabotropic glutamate receptor
RT   type 2 (hmGluR2) gene: analysis of association with schizophrenia.";
RL   Submitted (JUN-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RA   Bonner T.I., Kauffman D., Nagle J.W.;
RT   "Complete coding sequence of human metabotropic glutamate receptor 2.";
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RA   Kaighin V.A., Martin A.L., Aronstam R.S.;
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain cortex;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   INTERACTION WITH HTR2A, FUNCTION, TISSUE SPECIFICITY, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=18297054; DOI=10.1038/nature06612;
RA   Gonzalez-Maeso J., Ang R.L., Yuen T., Chan P., Weisstaub N.V.,
RA   Lopez-Gimenez J.F., Zhou M., Okawa Y., Callado L.F., Milligan G.,
RA   Gingrich J.A., Filizola M., Meana J.J., Sealfon S.C.;
RT   "Identification of a serotonin/glutamate receptor complex implicated in
RT   psychosis.";
RL   Nature 452:93-97(2008).
RN   [8]
RP   INTERACTION WITH HTR2A, FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   ALA-677; ALA-681 AND ALA-685.
RX   PubMed=23129762; DOI=10.1074/jbc.m112.413161;
RA   Moreno J.L., Muguruza C., Umali A., Mortillo S., Holloway T.,
RA   Pilar-Cuellar F., Mocci G., Seto J., Callado L.F., Neve R.L., Milligan G.,
RA   Sealfon S.C., Lopez-Gimenez J.F., Meana J.J., Benson D.L.,
RA   Gonzalez-Maeso J.;
RT   "Identification of three residues essential for 5-hydroxytryptamine 2A-
RT   metabotropic glutamate 2 (5-HT2A.mGlu2) receptor heteromerization and its
RT   psychoactive behavioral function.";
RL   J. Biol. Chem. 287:44301-44319(2012).
RN   [9]
RP   INTERACTION WITH HTR2A, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=22300836; DOI=10.1016/j.neuropharm.2012.01.010;
RA   Delille H.K., Becker J.M., Burkhardt S., Bleher B., Terstappen G.C.,
RA   Schmidt M., Meyer A.H., Unger L., Marek G.J., Mezler M.;
RT   "Heterocomplex formation of 5-HT2A-mGlu2 and its relevance for cellular
RT   signaling cascades.";
RL   Neuropharmacology 62:2184-2191(2012).
CC   -!- FUNCTION: G-protein coupled receptor for glutamate. Ligand binding
CC       causes a conformation change that triggers signaling via guanine
CC       nucleotide-binding proteins (G proteins) and modulates the activity of
CC       down-stream effectors, such as adenylate cyclase. Signaling inhibits
CC       adenylate cyclase activity. May mediate suppression of
CC       neurotransmission or may be involved in synaptogenesis or synaptic
CC       stabilization. {ECO:0000269|PubMed:18297054,
CC       ECO:0000269|PubMed:22300836, ECO:0000269|PubMed:23129762,
CC       ECO:0000269|PubMed:7620613}.
CC   -!- SUBUNIT: Interacts with TAMALIN (By similarity). Interacts with HTR2A.
CC       {ECO:0000250, ECO:0000269|PubMed:18297054, ECO:0000269|PubMed:22300836,
CC       ECO:0000269|PubMed:23129762}.
CC   -!- INTERACTION:
CC       Q14416; Q5T8D3-2: ACBD5; NbExp=3; IntAct=EBI-10232876, EBI-10961679;
CC       Q14416; Q13520: AQP6; NbExp=3; IntAct=EBI-10232876, EBI-13059134;
CC       Q14416; Q13323: BIK; NbExp=3; IntAct=EBI-10232876, EBI-700794;
CC       Q14416; Q8WV48: CCDC107; NbExp=3; IntAct=EBI-10232876, EBI-947033;
CC       Q14416; P57739: CLDN2; NbExp=3; IntAct=EBI-10232876, EBI-751440;
CC       Q14416; O95484: CLDN9; NbExp=3; IntAct=EBI-10232876, EBI-18341636;
CC       Q14416; Q7Z7G2: CPLX4; NbExp=3; IntAct=EBI-10232876, EBI-18013275;
CC       Q14416; P00387: CYB5R3; NbExp=3; IntAct=EBI-10232876, EBI-1046040;
CC       Q14416; P28223-1: HTR2A; NbExp=4; IntAct=EBI-10232876, EBI-15573967;
CC       Q14416; Q5SR56: MFSD14B; NbExp=3; IntAct=EBI-10232876, EBI-373355;
CC       Q14416; O14880: MGST3; NbExp=3; IntAct=EBI-10232876, EBI-724754;
CC       Q14416; Q8N4V1: MMGT1; NbExp=3; IntAct=EBI-10232876, EBI-6163737;
CC       Q14416; Q58DX5: NAALADL2; NbExp=3; IntAct=EBI-10232876, EBI-10178964;
CC       Q14416; Q13113: PDZK1IP1; NbExp=3; IntAct=EBI-10232876, EBI-716063;
CC       Q14416; Q9NR31: SAR1A; NbExp=3; IntAct=EBI-10232876, EBI-3920694;
CC       Q14416; Q8IWU4: SLC30A8; NbExp=3; IntAct=EBI-10232876, EBI-10262251;
CC       Q14416; Q9H2H9: SLC38A1; NbExp=3; IntAct=EBI-10232876, EBI-9978441;
CC       Q14416; P27105: STOM; NbExp=3; IntAct=EBI-10232876, EBI-1211440;
CC       Q14416; Q8N3G9: TMEM130; NbExp=3; IntAct=EBI-10232876, EBI-19763514;
CC       Q14416; Q96Q45-2: TMEM237; NbExp=3; IntAct=EBI-10232876, EBI-10982110;
CC       Q14416; Q9NWD8: TMEM248; NbExp=3; IntAct=EBI-10232876, EBI-10314986;
CC       Q14416; Q8WUV1: TSPAN18; NbExp=3; IntAct=EBI-10232876, EBI-17670824;
CC       Q14416; Q9UMX0-2: UBQLN1; NbExp=3; IntAct=EBI-10232876, EBI-10173939;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein. Cell
CC       junction, synapse {ECO:0000250}. Cell projection, dendrite
CC       {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Detected in brain cortex (at protein level). Widely
CC       expressed in different regions of the adult brain as well as in fetal
CC       brain. {ECO:0000269|PubMed:18297054}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 3 family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L35318; AAA76855.1; -; mRNA.
DR   EMBL; AB045011; BAB19817.1; -; Genomic_DNA.
DR   EMBL; AY999299; AAY14640.1; -; mRNA.
DR   EMBL; EU432122; ABY87921.1; -; mRNA.
DR   EMBL; CH471055; EAW65150.1; -; Genomic_DNA.
DR   EMBL; BC113615; AAI13616.1; -; mRNA.
DR   EMBL; BC113619; AAI13620.1; -; mRNA.
DR   CCDS; CCDS2834.1; -.
DR   RefSeq; NP_000830.2; NM_000839.3.
DR   RefSeq; XP_016861760.1; XM_017006271.1.
DR   PDB; 4XAQ; X-ray; 2.21 A; A/B=2-493.
DR   PDB; 4XAS; X-ray; 2.35 A; A/B=2-493.
DR   PDB; 5CNI; X-ray; 2.69 A; A/B=2-493.
DR   PDB; 5CNJ; X-ray; 2.65 A; A/B=2-493.
DR   PDB; 5KZN; X-ray; 2.80 A; A=1-562.
DR   PDB; 5KZQ; X-ray; 2.80 A; A=1-562.
DR   PDBsum; 4XAQ; -.
DR   PDBsum; 4XAS; -.
DR   PDBsum; 5CNI; -.
DR   PDBsum; 5CNJ; -.
DR   PDBsum; 5KZN; -.
DR   PDBsum; 5KZQ; -.
DR   SMR; Q14416; -.
DR   BioGRID; 109169; 33.
DR   CORUM; Q14416; -.
DR   DIP; DIP-59826N; -.
DR   IntAct; Q14416; 24.
DR   MINT; Q14416; -.
DR   STRING; 9606.ENSP00000378492; -.
DR   BindingDB; Q14416; -.
DR   ChEMBL; CHEMBL5137; -.
DR   DrugBank; DB05096; LY2140023.
DR   DrugCentral; Q14416; -.
DR   GuidetoPHARMACOLOGY; 290; -.
DR   GlyGen; Q14416; 5 sites.
DR   iPTMnet; Q14416; -.
DR   PhosphoSitePlus; Q14416; -.
DR   BioMuta; GRM2; -.
DR   DMDM; 76803802; -.
DR   MassIVE; Q14416; -.
DR   PaxDb; Q14416; -.
DR   PeptideAtlas; Q14416; -.
DR   PRIDE; Q14416; -.
DR   ProteomicsDB; 59986; -.
DR   Antibodypedia; 14188; 502 antibodies.
DR   DNASU; 2912; -.
DR   Ensembl; ENST00000395052; ENSP00000378492; ENSG00000164082.
DR   GeneID; 2912; -.
DR   KEGG; hsa:2912; -.
DR   UCSC; uc010hlv.4; human.
DR   CTD; 2912; -.
DR   DisGeNET; 2912; -.
DR   EuPathDB; HostDB:ENSG00000164082.14; -.
DR   GeneCards; GRM2; -.
DR   HGNC; HGNC:4594; GRM2.
DR   HPA; ENSG00000164082; Tissue enriched (brain).
DR   MIM; 604099; gene.
DR   neXtProt; NX_Q14416; -.
DR   OpenTargets; ENSG00000164082; -.
DR   PharmGKB; PA28991; -.
DR   eggNOG; KOG1056; Eukaryota.
DR   GeneTree; ENSGT00950000182807; -.
DR   InParanoid; Q14416; -.
DR   KO; K04605; -.
DR   OMA; YCMTFVF; -.
DR   OrthoDB; 1154468at2759; -.
DR   PhylomeDB; Q14416; -.
DR   TreeFam; TF313240; -.
DR   PathwayCommons; Q14416; -.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-420499; Class C/3 (Metabotropic glutamate/pheromone receptors).
DR   SIGNOR; Q14416; -.
DR   BioGRID-ORCS; 2912; 4 hits in 871 CRISPR screens.
DR   GeneWiki; Metabotropic_glutamate_receptor_2; -.
DR   GenomeRNAi; 2912; -.
DR   Pharos; Q14416; Tchem.
DR   PRO; PR:Q14416; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q14416; protein.
DR   Bgee; ENSG00000164082; Expressed in cortical plate and 175 other tissues.
DR   ExpressionAtlas; Q14416; baseline and differential.
DR   Genevisible; Q14416; HS.
DR   GO; GO:0097449; C:astrocyte projection; ISS:ARUK-UCL.
DR   GO; GO:0030424; C:axon; ISS:ARUK-UCL.
DR   GO; GO:0030425; C:dendrite; IEA:UniProtKB-SubCell.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0042734; C:presynaptic membrane; IEA:Ensembl.
DR   GO; GO:0005246; F:calcium channel regulator activity; IEA:Ensembl.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; TAS:UniProtKB.
DR   GO; GO:0008066; F:glutamate receptor activity; IBA:GO_Central.
DR   GO; GO:0001641; F:group II metabotropic glutamate receptor activity; IBA:GO_Central.
DR   GO; GO:0097110; F:scaffold protein binding; ISS:ARUK-UCL.
DR   GO; GO:0007268; P:chemical synaptic transmission; TAS:ProtInc.
DR   GO; GO:0007216; P:G protein-coupled glutamate receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0090461; P:glutamate homeostasis; IEA:Ensembl.
DR   GO; GO:0014047; P:glutamate secretion; IEA:Ensembl.
DR   GO; GO:0007194; P:negative regulation of adenylate cyclase activity; TAS:ProtInc.
DR   GO; GO:0051896; P:regulation of protein kinase B signaling; ISS:ARUK-UCL.
DR   GO; GO:0051966; P:regulation of synaptic transmission, glutamatergic; IBA:GO_Central.
DR   Gene3D; 2.10.50.30; -; 1.
DR   InterPro; IPR001828; ANF_lig-bd_rcpt.
DR   InterPro; IPR000337; GPCR_3.
DR   InterPro; IPR011500; GPCR_3_9-Cys_dom.
DR   InterPro; IPR038550; GPCR_3_9-Cys_sf.
DR   InterPro; IPR017978; GPCR_3_C.
DR   InterPro; IPR017979; GPCR_3_CS.
DR   InterPro; IPR000162; GPCR_3_mtglu_rcpt.
DR   InterPro; IPR001458; GPCR_3_mtglu_rcpt_2.
DR   InterPro; IPR028082; Peripla_BP_I.
DR   Pfam; PF00003; 7tm_3; 1.
DR   Pfam; PF01094; ANF_receptor; 1.
DR   Pfam; PF07562; NCD3G; 1.
DR   PRINTS; PR00248; GPCRMGR.
DR   PRINTS; PR01052; MTABOTROPC2R.
DR   PRINTS; PR00593; MTABOTROPICR.
DR   SUPFAM; SSF53822; SSF53822; 1.
DR   PROSITE; PS00979; G_PROTEIN_RECEP_F3_1; 1.
DR   PROSITE; PS00980; G_PROTEIN_RECEP_F3_2; 1.
DR   PROSITE; PS00981; G_PROTEIN_RECEP_F3_3; 1.
DR   PROSITE; PS50259; G_PROTEIN_RECEP_F3_4; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell junction; Cell membrane; Cell projection;
KW   Disulfide bond; G-protein coupled receptor; Glycoprotein; Membrane;
KW   Receptor; Reference proteome; Signal; Synapse; Transducer; Transmembrane;
KW   Transmembrane helix.
FT   SIGNAL          1..18
FT                   /evidence="ECO:0000255"
FT   CHAIN           19..872
FT                   /note="Metabotropic glutamate receptor 2"
FT                   /id="PRO_0000012925"
FT   TOPO_DOM        19..567
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        568..590
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        591..604
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        605..625
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        626..636
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        637..655
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        656..679
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        680..700
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        701..725
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        726..747
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        748..760
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        761..783
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        784..793
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        794..819
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        820..872
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REGION          166..168
FT                   /note="Glutamate binding"
FT                   /evidence="ECO:0000250"
FT   REGION          677..685
FT                   /note="Important for interaction with HTR2A"
FT   BINDING         145
FT                   /note="Glutamate"
FT                   /evidence="ECO:0000250"
FT   BINDING         216
FT                   /note="Glutamate"
FT                   /evidence="ECO:0000250"
FT   BINDING         295
FT                   /note="Glutamate"
FT                   /evidence="ECO:0000250"
FT   BINDING         377
FT                   /note="Glutamate"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        203
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        286
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        338
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        402
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        547
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        50..92
FT                   /evidence="ECO:0000250"
FT   DISULFID        234..518
FT                   /evidence="ECO:0000250"
FT   DISULFID        355..362
FT                   /evidence="ECO:0000250"
FT   DISULFID        400..407
FT                   /evidence="ECO:0000250"
FT   DISULFID        500..519
FT                   /evidence="ECO:0000250"
FT   DISULFID        504..522
FT                   /evidence="ECO:0000250"
FT   DISULFID        525..537
FT                   /evidence="ECO:0000250"
FT   DISULFID        540..553
FT                   /evidence="ECO:0000250"
FT   MUTAGEN         677
FT                   /note="A->S: Impairs interaction with HTR2A."
FT                   /evidence="ECO:0000269|PubMed:23129762"
FT   MUTAGEN         681
FT                   /note="A->F: Impairs interaction with HTR2A."
FT                   /evidence="ECO:0000269|PubMed:23129762"
FT   MUTAGEN         685
FT                   /note="A->G: Impairs interaction with HTR2A."
FT                   /evidence="ECO:0000269|PubMed:23129762"
FT   CONFLICT        12
FT                   /note="L -> P (in Ref. 1; AAA76855)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        210
FT                   /note="V -> E (in Ref. 1; AAA76855)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        496
FT                   /note="P -> A (in Ref. 1; AAA76855)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        748
FT                   /note="K -> N (in Ref. 1; AAA76855)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        776
FT                   /note="F -> L (in Ref. 1; AAA76855)"
FT                   /evidence="ECO:0000305"
FT   STRAND          26..28
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   STRAND          31..38
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   STRAND          41..43
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   STRAND          49..53
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   TURN            55..58
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   HELIX           59..74
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   STRAND          76..81
FT                   /evidence="ECO:0000244|PDB:4XAS"
FT   STRAND          84..90
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   HELIX           95..106
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   TURN            107..109
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   STRAND          138..140
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   HELIX           145..155
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   HELIX           156..158
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   STRAND          162..166
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   HELIX           170..173
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   TURN            175..177
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   STRAND          181..185
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   HELIX           188..202
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   STRAND          206..214
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   HELIX           217..230
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   STRAND          234..241
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   HELIX           247..258
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   STRAND          260..262
FT                   /evidence="ECO:0000244|PDB:5CNJ"
FT   STRAND          265..269
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   HELIX           272..284
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   STRAND          290..293
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   TURN            295..299
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   HELIX           301..304
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   HELIX           308..311
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   STRAND          315..320
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   HELIX           327..332
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   TURN            336..338
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   HELIX           345..352
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   STRAND          357..359
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   TURN            361..364
FT                   /evidence="ECO:0000244|PDB:5KZQ"
FT   TURN            367..369
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   HELIX           378..399
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   HELIX           408..410
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   HELIX           415..421
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   HELIX           423..425
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   STRAND          427..429
FT                   /evidence="ECO:0000244|PDB:4XAS"
FT   STRAND          440..442
FT                   /evidence="ECO:0000244|PDB:4XAS"
FT   STRAND          453..460
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   STRAND          466..480
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   HELIX           482..484
FT                   /evidence="ECO:0000244|PDB:4XAQ"
FT   TURN            486..490
FT                   /evidence="ECO:0000244|PDB:5KZN"
FT   STRAND          508..511
FT                   /evidence="ECO:0000244|PDB:5KZN"
FT   STRAND          521..524
FT                   /evidence="ECO:0000244|PDB:5KZN"
FT   STRAND          529..533
FT                   /evidence="ECO:0000244|PDB:5KZN"
FT   STRAND          536..539
FT                   /evidence="ECO:0000244|PDB:5KZN"
FT   TURN            548..550
FT                   /evidence="ECO:0000244|PDB:5KZQ"
SQ   SEQUENCE   872 AA;  95568 MW;  801976D034AA8100 CRC64;
     MGSLLALLAL LLLWGAVAEG PAKKVLTLEG DLVLGGLFPV HQKGGPAEDC GPVNEHRGIQ
     RLEAMLFALD RINRDPHLLP GVRLGAHILD SCSKDTHALE QALDFVRASL SRGADGSRHI
     CPDGSYATHG DAPTAITGVI GGSYSDVSIQ VANLLRLFQI PQISYASTSA KLSDKSRYDY
     FARTVPPDFF QAKAMAEILR FFNWTYVSTV ASEGDYGETG IEAFELEARA RNICVATSEK
     VGRAMSRAAF EGVVRALLQK PSARVAVLFT RSEDARELLA ASQRLNASFT WVASDGWGAL
     ESVVAGSEGA AEGAITIELA SYPISDFASY FQSLDPWNNS RNPWFREFWE QRFRCSFRQR
     DCAAHSLRAV PFEQESKIMF VVNAVYAMAH ALHNMHRALC PNTTRLCDAM RPVNGRRLYK
     DFVLNVKFDA PFRPADTHNE VRFDRFGDGI GRYNIFTYLR AGSGRYRYQK VGYWAEGLTL
     DTSLIPWASP SAGPLPASRC SEPCLQNEVK SVQPGEVCCW LCIPCQPYEY RLDEFTCADC
     GLGYWPNASL TGCFELPQEY IRWGDAWAVG PVTIACLGAL ATLFVLGVFV RHNATPVVKA
     SGRELCYILL GGVFLCYCMT FIFIAKPSTA VCTLRRLGLG TAFSVCYSAL LTKTNRIARI
     FGGAREGAQR PRFISPASQV AICLALISGQ LLIVVAWLVV EAPGTGKETA PERREVVTLR
     CNHRDASMLG SLAYNVLLIA LCTLYAFKTR KCPENFNEAK FIGFTMYTTC IIWLAFLPIF
     YVTSSDYRVQ TTTMCVSVSL SGSVVLGCLF APKLHIILFQ PQKNVVSHRA PTSRFGSAAA
     RASSSLGQGS GSQFVPTVCN GREVVDSTTS SL
//
ID   GLR_HUMAN               Reviewed;         477 AA.
AC   P47871; Q2M3M5;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 1.
DT   07-OCT-2020, entry version 172.
DE   RecName: Full=Glucagon receptor;
DE            Short=GL-R;
DE   Flags: Precursor;
GN   Name=GCGR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND SUBCELLULAR LOCATION.
RC   TISSUE=Liver;
RX   PubMed=7507321; DOI=10.1006/bbrc.1994.1046;
RA   Macneil D.J., Occi J.L., Hey P.J., Strader C.D., Graziano M.P.;
RT   "Cloning and expression of a human glucagon receptor.";
RL   Biochem. Biophys. Res. Commun. 198:328-334(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8144028; DOI=10.1016/0378-1119(94)90545-2;
RA   Lok S., Kuijper J.L., Jelinek L.J., Kramer J.M., Whitmore T.E.,
RA   Sprecher C.A., Mathewes S., Grant F.J., Biggs S.H., Rosenberg G.B.;
RT   "The human glucagon receptor encoding gene: structure, cDNA sequence and
RT   chromosomal localization.";
RL   Gene 140:203-209(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 21-54.
RC   TISSUE=Placenta;
RX   PubMed=8020989; DOI=10.1006/geno.1994.1179;
RA   Menzel S., Stoffel M., Espinosa R. III, Fernald A.A., Le Beau M.M.,
RA   Bell G.I.;
RT   "Localization of the glucagon receptor gene to human chromosome band
RT   17q25.";
RL   Genomics 20:327-328(1994).
RN   [5]
RP   FUNCTION, SUBCELLULAR LOCATION, AND PHOSPHORYLATION.
RX   PubMed=9287038; DOI=10.2337/diab.46.9.1400;
RA   Buggy J.J., Heurich R.O., MacDougall M., Kelley K.A., Livingston J.N.,
RA   Yoo-Warren H., Rossomando A.J.;
RT   "Role of the glucagon receptor COOH-terminal domain in glucagon-mediated
RT   signaling and receptor internalization.";
RL   Diabetes 46:1400-1405(1997).
RN   [6]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-456 AND SER-459, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (1.2 ANGSTROMS) OF 412-420 IN COMPLEX WITH CLASS I
RP   MHC.
RX   PubMed=16221670; DOI=10.1074/jbc.m508528200;
RA   Ruckert C., Fiorillo M.T., Loll B., Moretti R., Biesiadka J., Saenger W.,
RA   Ziegler A., Sorrentino R., Uchanska-Ziegler B.;
RT   "Conformational dimorphism of self-peptides and molecular mimicry in a
RT   disease-associated HLA-B27 subtype.";
RL   J. Biol. Chem. 281:2306-2316(2006).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.64 ANGSTROMS) OF 28-123, FUNCTION, MUTAGENESIS OF
RP   TYR-65 AND GLN-113, DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-74 AND
RP   ASN-78.
RX   PubMed=22908259; DOI=10.1073/pnas.1206734109;
RA   Koth C.M., Murray J.M., Mukund S., Madjidi A., Minn A., Clarke H.J.,
RA   Wong T., Chiang V., Luis E., Estevez A., Rondon J., Zhang Y., Hotzel I.,
RA   Allan B.B.;
RT   "Molecular basis for negative regulation of the glucagon receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:14393-14398(2012).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (3.3 ANGSTROMS) OF 123-432, FUNCTION, SUBCELLULAR
RP   LOCATION, DISULFIDE BONDS, MEMBRANE TOPOLOGY, MUTAGENESIS OF TRP-36;
RP   ASP-63; ALA-135; TYR-145; TYR-149; LEU-198; ARG-201; TYR-202; ASP-208;
RP   TRP-215; GLN-232; TYR-233; LYS-286; GLU-290; CYS-294; TRP-295; TRP-304;
RP   LEU-382 AND LEU-386, AND CHARACTERIZATION OF VARIANT SER-86.
RX   PubMed=23863937; DOI=10.1038/nature12393;
RA   Siu F.Y., He M., de Graaf C., Han G.W., Yang D., Zhang Z., Zhou C., Xu Q.,
RA   Wacker D., Joseph J.S., Liu W., Lau J., Cherezov V., Katritch V.,
RA   Wang M.W., Stevens R.C.;
RT   "Structure of the human glucagon class B G-protein-coupled receptor.";
RL   Nature 499:444-449(2013).
RN   [10] {ECO:0000244|PDB:5EE7}
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 136-254; 256-256 AND 259-417 IN
RP   COMPLEX WITH SYNTHETIC ANTAGONIST, FUNCTION, SUBCELLULAR LOCATION, AND
RP   DISULFIDE BONDS.
RX   PubMed=27111510; DOI=10.1038/nature17414;
RA   Jazayeri A., Dore A.S., Lamb D., Krishnamurthy H., Southall S.M.,
RA   Baig A.H., Bortolato A., Koglin M., Robertson N.J., Errey J.C.,
RA   Andrews S.P., Teobald I., Brown A.J., Cooke R.M., Weir M., Marshall F.H.;
RT   "Extra-helical binding site of a glucagon receptor antagonist.";
RL   Nature 533:274-277(2016).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (3.0 ANGSTROMS) OF 27-432 IN COMPLEX WITH THE
RP   SYNTHETIC ANTAGONIST NNC0640, FUNCTION, SUBCELLULAR LOCATION, TOPOLOGY,
RP   GLYCOSYLATION AT ASN-46; ASN-59; ASN-74 AND ASN-78, MUTAGENESIS OF GLN-113;
RP   VAL-130; ASP-209; LEU-210; SER-350 AND THR-353, AND DISULFIDE BONDS.
RX   PubMed=28514451; DOI=10.1038/nature22363;
RA   Zhang H., Qiao A., Yang D., Yang L., Dai A., de Graaf C., Reedtz-Runge S.,
RA   Dharmarajan V., Zhang H., Han G.W., Grant T.D., Sierra R.G., Weierstall U.,
RA   Nelson G., Liu W., Wu Y., Ma L., Cai X., Lin G., Wu X., Geng Z., Dong Y.,
RA   Song G., Griffin P.R., Lau J., Cherezov V., Yang H., Hanson M.A.,
RA   Stevens R.C., Zhao Q., Jiang H., Wang M.W., Wu B.;
RT   "Structure of the full-length glucagon class B G-protein-coupled
RT   receptor.";
RL   Nature 546:259-264(2017).
RN   [12]
RP   VARIANT SER-40.
RX   PubMed=7589886; DOI=10.1007/bf00400589;
RA   Fujisawa T., Ikegami H., Yamato E., Takekawa K., Nakagawa Y., Hamada Y.,
RA   Ueda H., Fukuda M., Ogihara T.;
RT   "A mutation in the glucagon receptor gene (Gly40Ser): heterogeneity in the
RT   association with diabetes mellitus.";
RL   Diabetologia 38:983-985(1995).
RN   [13]
RP   VARIANT SER-86, FUNCTION, SUBCELLULAR LOCATION, AND CHARACTERIZATION OF
RP   VARIANT SER-86.
RX   PubMed=19657311; DOI=10.1097/mpa.0b013e3181b2bb03;
RA   Zhou C., Dhall D., Nissen N.N., Chen C.R., Yu R.;
RT   "Homozygous P86S mutation of the human glucagon receptor is associated with
RT   hyperglucagonemia, alpha cell hyperplasia, and islet cell tumor.";
RL   Pancreas 38:941-946(2009).
CC   -!- FUNCTION: G-protein coupled receptor for glucagon that plays a central
CC       role in the regulation of blood glucose levels and glucose homeostasis.
CC       Regulates the rate of hepatic glucose production by promoting glycogen
CC       hydrolysis and gluconeogenesis. Plays an important role in mediating
CC       the responses to fasting. Ligand binding causes a conformation change
CC       that triggers signaling via guanine nucleotide-binding proteins (G
CC       proteins) and modulates the activity of down-stream effectors, such as
CC       adenylate cyclase. Promotes activation of adenylate cyclase. Besides,
CC       plays a role in signaling via a phosphatidylinositol-calcium second
CC       messenger system. {ECO:0000269|PubMed:19657311,
CC       ECO:0000269|PubMed:22908259, ECO:0000269|PubMed:23863937,
CC       ECO:0000269|PubMed:27111510, ECO:0000269|PubMed:28514451,
CC       ECO:0000269|PubMed:7507321, ECO:0000269|PubMed:9287038}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:19657311,
CC       ECO:0000269|PubMed:23863937, ECO:0000269|PubMed:27111510,
CC       ECO:0000269|PubMed:28514451, ECO:0000269|PubMed:7507321,
CC       ECO:0000269|PubMed:9287038}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:19657311, ECO:0000269|PubMed:23863937,
CC       ECO:0000269|PubMed:27111510, ECO:0000269|PubMed:28514451,
CC       ECO:0000269|PubMed:7507321, ECO:0000269|PubMed:9287038}. Note=Is
CC       rapidly internalized after ligand-binding.
CC       {ECO:0000269|PubMed:9287038}.
CC   -!- PTM: Ligand-binding promotes phosphorylation of serine residues in the
CC       C-terminal cytoplasmic domain. Phosphorylation is important for
CC       receptor endocytosis after ligand-binding.
CC       {ECO:0000269|PubMed:9287038}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 2 family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U03469; AAC52063.1; -; mRNA.
DR   EMBL; L20316; AAA53628.1; -; mRNA.
DR   EMBL; BC104854; AAI04855.1; -; mRNA.
DR   EMBL; BC112041; AAI12042.1; -; mRNA.
DR   EMBL; L24751; AAA35897.1; -; Genomic_DNA.
DR   CCDS; CCDS54177.1; -.
DR   PIR; JC2041; JC2041.
DR   RefSeq; NP_000151.1; NM_000160.4.
DR   RefSeq; XP_006722340.1; XM_006722277.1.
DR   PDB; 2A83; X-ray; 1.40 A; C=412-420.
DR   PDB; 3CZF; X-ray; 1.20 A; C=412-420.
DR   PDB; 4ERS; X-ray; 2.64 A; A=28-123.
DR   PDB; 4L6R; X-ray; 3.30 A; A=123-432.
DR   PDB; 4LF3; X-ray; 2.74 A; C/F=29-123.
DR   PDB; 5EE7; X-ray; 2.50 A; A=136-254, A=259-417.
DR   PDB; 5XEZ; X-ray; 3.00 A; A/B=27-432.
DR   PDB; 6LMK; EM; 3.70 A; R=27-432.
DR   PDB; 6LML; EM; 3.90 A; R=27-432.
DR   PDB; 6WHC; EM; 3.40 A; R=1-477.
DR   PDBsum; 2A83; -.
DR   PDBsum; 3CZF; -.
DR   PDBsum; 4ERS; -.
DR   PDBsum; 4L6R; -.
DR   PDBsum; 4LF3; -.
DR   PDBsum; 5EE7; -.
DR   PDBsum; 5XEZ; -.
DR   PDBsum; 6LMK; -.
DR   PDBsum; 6LML; -.
DR   PDBsum; 6WHC; -.
DR   SMR; P47871; -.
DR   BioGRID; 108912; 3.
DR   IntAct; P47871; 4.
DR   STRING; 9606.ENSP00000383558; -.
DR   BindingDB; P47871; -.
DR   ChEMBL; CHEMBL1985; -.
DR   DrugBank; DB00040; Glucagon.
DR   DrugCentral; P47871; -.
DR   GuidetoPHARMACOLOGY; 251; -.
DR   TCDB; 9.A.14.4.13; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; P47871; 4 sites.
DR   iPTMnet; P47871; -.
DR   PhosphoSitePlus; P47871; -.
DR   BioMuta; GCGR; -.
DR   DMDM; 1346144; -.
DR   MassIVE; P47871; -.
DR   PaxDb; P47871; -.
DR   PeptideAtlas; P47871; -.
DR   PRIDE; P47871; -.
DR   ProteomicsDB; 55805; -.
DR   ABCD; P47871; 93 sequenced antibodies.
DR   Antibodypedia; 4808; 469 antibodies.
DR   Ensembl; ENST00000400723; ENSP00000383558; ENSG00000215644.
DR   Ensembl; ENST00000671794; ENSP00000500297; ENSG00000288269.
DR   GeneID; 2642; -.
DR   KEGG; hsa:2642; -.
DR   UCSC; uc010wuw.2; human.
DR   CTD; 2642; -.
DR   DisGeNET; 2642; -.
DR   EuPathDB; HostDB:ENSG00000215644.9; -.
DR   GeneCards; GCGR; -.
DR   HGNC; HGNC:4192; GCGR.
DR   HPA; ENSG00000215644; Tissue enriched (liver).
DR   MalaCards; GCGR; -.
DR   MIM; 138033; gene.
DR   neXtProt; NX_P47871; -.
DR   OpenTargets; ENSG00000215644; -.
DR   Orphanet; 438274; GCGR-related hyperglucagonemia.
DR   PharmGKB; PA28607; -.
DR   eggNOG; KOG4564; Eukaryota.
DR   GeneTree; ENSGT00940000157969; -.
DR   HOGENOM; CLU_002753_4_0_1; -.
DR   InParanoid; P47871; -.
DR   KO; K04583; -.
DR   OrthoDB; 651627at2759; -.
DR   PhylomeDB; P47871; -.
DR   TreeFam; TF315710; -.
DR   PathwayCommons; P47871; -.
DR   SIGNOR; P47871; -.
DR   BioGRID-ORCS; 2642; 6 hits in 873 CRISPR screens.
DR   EvolutionaryTrace; P47871; -.
DR   GeneWiki; Glucagon_receptor; -.
DR   GenomeRNAi; 2642; -.
DR   Pharos; P47871; Tclin.
DR   PRO; PR:P47871; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; P47871; protein.
DR   Bgee; ENSG00000215644; Expressed in right lobe of liver and 90 other tissues.
DR   ExpressionAtlas; P47871; baseline and differential.
DR   Genevisible; P47871; HS.
DR   GO; GO:0005768; C:endosome; IEA:Ensembl.
DR   GO; GO:0016021; C:integral component of membrane; TAS:ProtInc.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0008528; F:G protein-coupled peptide receptor activity; IBA:GO_Central.
DR   GO; GO:0004967; F:glucagon receptor activity; IDA:UniProtKB.
DR   GO; GO:0005085; F:guanyl-nucleotide exchange factor activity; TAS:Reactome.
DR   GO; GO:0017046; F:peptide hormone binding; IBA:GO_Central.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007188; P:adenylate cyclase-modulating G protein-coupled receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IEA:InterPro.
DR   GO; GO:0071377; P:cellular response to glucagon stimulus; IDA:UniProtKB.
DR   GO; GO:0009267; P:cellular response to starvation; ISS:ARUK-UCL.
DR   GO; GO:0006887; P:exocytosis; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006091; P:generation of precursor metabolites and energy; TAS:ProtInc.
DR   GO; GO:0042593; P:glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0009755; P:hormone-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISS:ARUK-UCL.
DR   GO; GO:0008217; P:regulation of blood pressure; TAS:ProtInc.
DR   GO; GO:0070873; P:regulation of glycogen metabolic process; ISS:UniProtKB.
DR   GO; GO:0007584; P:response to nutrient; TAS:ProtInc.
DR   GO; GO:0042594; P:response to starvation; ISS:UniProtKB.
DR   Gene3D; 4.10.1240.10; -; 1.
DR   InterPro; IPR017981; GPCR_2-like.
DR   InterPro; IPR036445; GPCR_2_extracell_dom_sf.
DR   InterPro; IPR001879; GPCR_2_extracellular_dom.
DR   InterPro; IPR003290; GPCR_2_GLP1/glucagon_rcpt.
DR   InterPro; IPR003291; GPCR_2_glucagon_rcpt.
DR   InterPro; IPR000832; GPCR_2_secretin-like.
DR   InterPro; IPR017983; GPCR_2_secretin-like_CS.
DR   Pfam; PF00002; 7tm_2; 1.
DR   Pfam; PF02793; HRM; 1.
DR   PRINTS; PR01353; GLUCAGNFAMLY.
DR   PRINTS; PR01354; GLUCAGONR.
DR   PRINTS; PR00249; GPCRSECRETIN.
DR   SMART; SM00008; HormR; 1.
DR   SUPFAM; SSF111418; SSF111418; 1.
DR   PROSITE; PS00649; G_PROTEIN_RECEP_F2_1; 1.
DR   PROSITE; PS00650; G_PROTEIN_RECEP_F2_2; 1.
DR   PROSITE; PS50227; G_PROTEIN_RECEP_F2_3; 1.
DR   PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Diabetes mellitus; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Phosphoprotein;
KW   Polymorphism; Receptor; Reference proteome; Signal; Transducer;
KW   Transmembrane; Transmembrane helix.
FT   SIGNAL          1..25
FT                   /evidence="ECO:0000255"
FT   CHAIN           26..477
FT                   /note="Glucagon receptor"
FT                   /id="PRO_0000012832"
FT   TOPO_DOM        26..136
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:23863937,
FT                   ECO:0000269|PubMed:27111510, ECO:0000269|PubMed:28514451"
FT   TRANSMEM        137..161
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000269|PubMed:23863937,
FT                   ECO:0000269|PubMed:27111510, ECO:0000269|PubMed:28514451"
FT   TOPO_DOM        162..173
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:23863937,
FT                   ECO:0000269|PubMed:27111510, ECO:0000269|PubMed:28514451"
FT   TRANSMEM        174..198
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000269|PubMed:23863937,
FT                   ECO:0000269|PubMed:27111510, ECO:0000269|PubMed:28514451"
FT   TOPO_DOM        199..225
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:23863937,
FT                   ECO:0000269|PubMed:27111510, ECO:0000269|PubMed:28514451"
FT   TRANSMEM        226..249
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000269|PubMed:23863937,
FT                   ECO:0000269|PubMed:27111510, ECO:0000269|PubMed:28514451"
FT   TOPO_DOM        250..263
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:23863937,
FT                   ECO:0000269|PubMed:27111510, ECO:0000269|PubMed:28514451"
FT   TRANSMEM        264..285
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000269|PubMed:23863937,
FT                   ECO:0000269|PubMed:27111510, ECO:0000269|PubMed:28514451"
FT   TOPO_DOM        286..303
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:23863937,
FT                   ECO:0000269|PubMed:27111510, ECO:0000269|PubMed:28514451"
FT   TRANSMEM        304..326
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000269|PubMed:23863937,
FT                   ECO:0000269|PubMed:27111510, ECO:0000269|PubMed:28514451"
FT   TOPO_DOM        327..350
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:23863937,
FT                   ECO:0000269|PubMed:27111510, ECO:0000269|PubMed:28514451"
FT   TRANSMEM        351..369
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000269|PubMed:23863937,
FT                   ECO:0000269|PubMed:27111510, ECO:0000269|PubMed:28514451"
FT   TOPO_DOM        370..381
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:23863937,
FT                   ECO:0000269|PubMed:27111510, ECO:0000269|PubMed:28514451"
FT   TRANSMEM        382..402
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000269|PubMed:23863937,
FT                   ECO:0000269|PubMed:27111510, ECO:0000269|PubMed:28514451"
FT   TOPO_DOM        403..477
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:23863937,
FT                   ECO:0000269|PubMed:27111510, ECO:0000269|PubMed:28514451"
FT   REGION          350..353
FT                   /note="Allosteric inhibitor binding"
FT                   /evidence="ECO:0000269|PubMed:27111510,
FT                   ECO:0000269|PubMed:28514451"
FT   MOD_RES         456
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   MOD_RES         459
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:24275569"
FT   CARBOHYD        46
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:28514451"
FT   CARBOHYD        59
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:28514451"
FT   CARBOHYD        74
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000244|PDB:4ERS,
FT                   ECO:0000269|PubMed:22908259, ECO:0000269|PubMed:28514451"
FT   CARBOHYD        78
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000244|PDB:4ERS,
FT                   ECO:0000269|PubMed:22908259, ECO:0000269|PubMed:28514451"
FT   DISULFID        43..67
FT                   /evidence="ECO:0000244|PDB:4ERS, ECO:0000244|PDB:4LF3,
FT                   ECO:0000269|PubMed:22908259, ECO:0000269|PubMed:28514451"
FT   DISULFID        58..100
FT                   /evidence="ECO:0000244|PDB:4ERS, ECO:0000244|PDB:4LF3,
FT                   ECO:0000269|PubMed:22908259, ECO:0000269|PubMed:28514451"
FT   DISULFID        81..121
FT                   /evidence="ECO:0000244|PDB:4ERS, ECO:0000244|PDB:4LF3,
FT                   ECO:0000269|PubMed:22908259, ECO:0000269|PubMed:28514451"
FT   DISULFID        224..294
FT                   /evidence="ECO:0000244|PDB:4L6R, ECO:0000244|PDB:5EE7,
FT                   ECO:0000269|PubMed:23863937, ECO:0000269|PubMed:27111510,
FT                   ECO:0000269|PubMed:28514451"
FT   VARIANT         40
FT                   /note="G -> S (in dbSNP:rs1801483)"
FT                   /evidence="ECO:0000269|PubMed:7589886"
FT                   /id="VAR_003581"
FT   VARIANT         86
FT                   /note="P -> S (abolishes glucagon binding)"
FT                   /evidence="ECO:0000269|PubMed:19657311,
FT                   ECO:0000269|PubMed:23863937"
FT                   /id="VAR_069815"
FT   VARIANT         114
FT                   /note="P -> A (in dbSNP:rs5385)"
FT                   /id="VAR_014837"
FT   VARIANT         303
FT                   /note="F -> C (in dbSNP:rs5387)"
FT                   /id="VAR_033966"
FT   MUTAGEN         36
FT                   /note="W->A: Abolishes glucagon binding."
FT                   /evidence="ECO:0000269|PubMed:23863937"
FT   MUTAGEN         63
FT                   /note="D->A: Abolishes glucagon binding."
FT                   /evidence="ECO:0000269|PubMed:23863937"
FT   MUTAGEN         65
FT                   /note="Y->A: Strongly reduced affinity for glucagon.
FT                   Increased constitutive signaling via G-proteins."
FT                   /evidence="ECO:0000269|PubMed:22908259"
FT   MUTAGEN         113
FT                   /note="Q->A,N: No effect on affinity for glucagon."
FT                   /evidence="ECO:0000269|PubMed:22908259"
FT   MUTAGEN         113
FT                   /note="Q->C: Causes the formation of an artifactual
FT                   disulfide bond that abolishes glucagon binding; when
FT                   associated with C-209."
FT                   /evidence="ECO:0000269|PubMed:28514451"
FT   MUTAGEN         113
FT                   /note="Q->E: Strongly reduced affinity for glucagon."
FT                   /evidence="ECO:0000269|PubMed:22908259"
FT   MUTAGEN         130
FT                   /note="V->C: Causes the formation of an artifactual
FT                   disulfide bond that interferes with glucagon binding; when
FT                   associated with C-210."
FT                   /evidence="ECO:0000269|PubMed:28514451"
FT   MUTAGEN         135
FT                   /note="A->P: Abolishes glucagon binding."
FT                   /evidence="ECO:0000269|PubMed:23863937"
FT   MUTAGEN         145
FT                   /note="Y->A: Abolishes glucagon binding."
FT                   /evidence="ECO:0000269|PubMed:23863937"
FT   MUTAGEN         149
FT                   /note="Y->A: Abolishes expression at cell surface and
FT                   glucagon binding."
FT                   /evidence="ECO:0000269|PubMed:23863937"
FT   MUTAGEN         198
FT                   /note="L->A: Abolishes glucagon binding."
FT                   /evidence="ECO:0000269|PubMed:23863937"
FT   MUTAGEN         201
FT                   /note="R->D: Abolishes glucagon binding."
FT                   /evidence="ECO:0000269|PubMed:23863937"
FT   MUTAGEN         202
FT                   /note="Y->A: Abolishes glucagon binding."
FT                   /evidence="ECO:0000269|PubMed:23863937"
FT   MUTAGEN         208
FT                   /note="D->Q: Abolishes glucagon binding."
FT                   /evidence="ECO:0000269|PubMed:23863937"
FT   MUTAGEN         209
FT                   /note="D->C: Causes the formation of an artifactual
FT                   disulfide bond that abolishes glucagon binding; when
FT                   associated with C-113."
FT                   /evidence="ECO:0000269|PubMed:28514451"
FT   MUTAGEN         210
FT                   /note="L->C: Causes the formation of an artifactual
FT                   disulfide bond that interferes with glucagon binding; when
FT                   associated with C-130."
FT                   /evidence="ECO:0000269|PubMed:28514451"
FT   MUTAGEN         215
FT                   /note="W->L: Abolishes glucagon binding."
FT                   /evidence="ECO:0000269|PubMed:23863937"
FT   MUTAGEN         232
FT                   /note="Q->L: Abolishes expression at cell surface and
FT                   glucagon binding."
FT                   /evidence="ECO:0000269|PubMed:23863937"
FT   MUTAGEN         233
FT                   /note="Y->A: Abolishes glucagon binding. Strongly reduces
FT                   expression at the cell surface."
FT                   /evidence="ECO:0000269|PubMed:23863937"
FT   MUTAGEN         286
FT                   /note="K->L: Abolishes glucagon binding."
FT                   /evidence="ECO:0000269|PubMed:23863937"
FT   MUTAGEN         290
FT                   /note="E->A: Abolishes glucagon binding."
FT                   /evidence="ECO:0000269|PubMed:23863937"
FT   MUTAGEN         294
FT                   /note="C->A,S: Abolishes glucagon binding."
FT                   /evidence="ECO:0000269|PubMed:23863937"
FT   MUTAGEN         295
FT                   /note="W->A,H: Abolishes glucagon binding."
FT                   /evidence="ECO:0000269|PubMed:23863937"
FT   MUTAGEN         304
FT                   /note="W->Q: Abolishes glucagon binding."
FT                   /evidence="ECO:0000269|PubMed:23863937"
FT   MUTAGEN         350
FT                   /note="S->A: Strongly decreases affinity for synthetic
FT                   antagonist."
FT                   /evidence="ECO:0000269|PubMed:28514451"
FT   MUTAGEN         353
FT                   /note="T->A: Loss of synthetic antagonist binding."
FT                   /evidence="ECO:0000269|PubMed:28514451"
FT   MUTAGEN         382
FT                   /note="L->A: Abolishes glucagon binding."
FT                   /evidence="ECO:0000269|PubMed:23863937"
FT   MUTAGEN         386
FT                   /note="L->F: Abolishes glucagon binding."
FT                   /evidence="ECO:0000269|PubMed:23863937"
FT   HELIX           31..49
FT                   /evidence="ECO:0000244|PDB:4ERS"
FT   STRAND          54..58
FT                   /evidence="ECO:0000244|PDB:4ERS"
FT   STRAND          64..68
FT                   /evidence="ECO:0000244|PDB:4LF3"
FT   STRAND          75..80
FT                   /evidence="ECO:0000244|PDB:4ERS"
FT   TURN            86..90
FT                   /evidence="ECO:0000244|PDB:4ERS"
FT   STRAND          95..100
FT                   /evidence="ECO:0000244|PDB:4ERS"
FT   STRAND          104..106
FT                   /evidence="ECO:0000244|PDB:4LF3"
FT   HELIX           119..121
FT                   /evidence="ECO:0000244|PDB:4ERS"
FT   STRAND          127..130
FT                   /evidence="ECO:0000244|PDB:5XEZ"
FT   HELIX           139..165
FT                   /evidence="ECO:0000244|PDB:5EE7"
FT   HELIX           167..169
FT                   /evidence="ECO:0000244|PDB:5EE7"
FT   HELIX           172..198
FT                   /evidence="ECO:0000244|PDB:5EE7"
FT   STRAND          203..206
FT                   /evidence="ECO:0000244|PDB:5XEZ"
FT   HELIX           213..215
FT                   /evidence="ECO:0000244|PDB:5EE7"
FT   HELIX           218..253
FT                   /evidence="ECO:0000244|PDB:5EE7"
FT   HELIX           264..271
FT                   /evidence="ECO:0000244|PDB:5EE7"
FT   HELIX           273..289
FT                   /evidence="ECO:0000244|PDB:5EE7"
FT   STRAND          293..295
FT                   /evidence="ECO:0000244|PDB:4L6R"
FT   HELIX           305..307
FT                   /evidence="ECO:0000244|PDB:5EE7"
FT   HELIX           308..334
FT                   /evidence="ECO:0000244|PDB:5EE7"
FT   HELIX           343..369
FT                   /evidence="ECO:0000244|PDB:5EE7"
FT   HELIX           379..389
FT                   /evidence="ECO:0000244|PDB:5EE7"
FT   HELIX           392..400
FT                   /evidence="ECO:0000244|PDB:5EE7"
FT   TURN            401..403
FT                   /evidence="ECO:0000244|PDB:5EE7"
FT   HELIX           405..417
FT                   /evidence="ECO:0000244|PDB:5EE7"
SQ   SEQUENCE   477 AA;  54009 MW;  ADBB477C6267AE6E CRC64;
     MPPCQPQRPL LLLLLLLACQ PQVPSAQVMD FLFEKWKLYG DQCHHNLSLL PPPTELVCNR
     TFDKYSCWPD TPANTTANIS CPWYLPWHHK VQHRFVFKRC GPDGQWVRGP RGQPWRDASQ
     CQMDGEEIEV QKEVAKMYSS FQVMYTVGYS LSLGALLLAL AILGGLSKLH CTRNAIHANL
     FASFVLKASS VLVIDGLLRT RYSQKIGDDL SVSTWLSDGA VAGCRVAAVF MQYGIVANYC
     WLLVEGLYLH NLLGLATLPE RSFFSLYLGI GWGAPMLFVV PWAVVKCLFE NVQCWTSNDN
     MGFWWILRFP VFLAILINFF IFVRIVQLLV AKLRARQMHH TDYKFRLAKS TLTLIPLLGV
     HEVVFAFVTD EHAQGTLRSA KLFFDLFLSS FQGLLVAVLY CFLNKEVQSE LRRRWHRWRL
     GKVLWEERNT SNHRASSSPG HGPPSKELQF GRGGGSQDSS AETPLAGGLP RLAESPF
//
ID   FZD7_HUMAN              Reviewed;         574 AA.
AC   O75084; O94816; Q53S59; Q96B74;
DT   05-DEC-2001, integrated into UniProtKB/Swiss-Prot.
DT   27-SEP-2004, sequence version 2.
DT   07-OCT-2020, entry version 184.
DE   RecName: Full=Frizzled-7;
DE            Short=Fz-7;
DE            Short=hFz7;
DE   AltName: Full=FzE3;
DE   Flags: Precursor;
GN   Name=FZD7;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND COUPLING TO BETA-CATENIN PATHWAY.
RC   TISSUE=Esophageal carcinoma;
RX   PubMed=9707618; DOI=10.1073/pnas.95.17.10164;
RA   Tanaka S., Akiyoshi T., Mori M., Wands J.R., Sugimachi K.;
RT   "A novel frizzled gene identified in human esophageal carcinoma mediates
RT   APC/beta-catenin signals.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:10164-10169(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Fetal lung;
RX   PubMed=9813155; DOI=10.1006/bbrc.1998.9607;
RA   Sagara N., Toda G., Hirai M., Terada M., Katoh M.;
RT   "Molecular cloning, differential expression, and chromosomal localization
RT   of human frizzled-1, frizzled-2, and frizzled-7.";
RL   Biochem. Biophys. Res. Commun. 252:117-122(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   INTERACTION WITH MYOC.
RX   PubMed=19188438; DOI=10.1128/mcb.01274-08;
RA   Kwon H.S., Lee H.S., Ji Y., Rubin J.S., Tomarev S.I.;
RT   "Myocilin is a modulator of Wnt signaling.";
RL   Mol. Cell. Biol. 29:2139-2154(2009).
RN   [7]
RP   VARIANT SER-24.
RX   PubMed=17224074; DOI=10.1186/bcr1637;
RA   Chanock S.J., Burdett L., Yeager M., Llaca V., Langeroed A., Presswalla S.,
RA   Kaaresen R., Strausberg R.L., Gerhard D.S., Kristensen V., Perou C.M.,
RA   Boerresen-Dale A.-L.;
RT   "Somatic sequence alterations in twenty-one genes selected by expression
RT   profile analysis of breast carcinomas.";
RL   Breast Cancer Res. 9:R5-R5(2007).
RN   [8]
RP   INTERACTION WITH GPC3.
RX   PubMed=24496449; DOI=10.1242/jcs.140871;
RA   Capurro M., Martin T., Shi W., Filmus J.;
RT   "Glypican-3 binds to Frizzled and plays a direct role in the stimulation of
RT   canonical Wnt signaling.";
RL   J. Cell Sci. 127:1565-1575(2014).
RN   [9]
RP   FUNCTION, AND INTERACTION WITH CCDC88C.
RX   PubMed=26126266; DOI=10.7554/elife.07091;
RA   Aznar N., Midde K.K., Dunkel Y., Lopez-Sanchez I., Pavlova Y., Marivin A.,
RA   Barbazan J., Murray F., Nitsche U., Janssen K.P., Willert K., Goel A.,
RA   Abal M., Garcia-Marcos M., Ghosh P.;
RT   "Daple is a novel non-receptor GEF required for trimeric G protein
RT   activation in Wnt signaling.";
RL   Elife 4:E07091-E07091(2015).
RN   [10]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH C.DIFFICILE TCDB
RP   (MICROBIAL INFECTION).
RX   PubMed=27680706; DOI=10.1038/nature19799;
RA   Tao L., Zhang J., Meraner P., Tovaglieri A., Wu X., Gerhard R., Zhang X.,
RA   Stallcup W.B., Miao J., He X., Hurdle J.G., Breault D.T., Brass A.L.,
RA   Dong M.;
RT   "Frizzled proteins are colonic epithelial receptors for C. difficile toxin
RT   B.";
RL   Nature 538:350-355(2016).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF 569-574, SITE, INTERACTION WITH
RP   SYNTENIN, MUTAGENESIS OF LYS-569, AND SUBCELLULAR LOCATION.
RX   PubMed=27386966; DOI=10.1038/ncomms12101;
RA   Egea-Jimenez A.L., Gallardo R., Garcia-Pino A., Ivarsson Y.,
RA   Wawrzyniak A.M., Kashyap R., Loris R., Schymkowitz J., Rousseau F.,
RA   Zimmermann P.;
RT   "Frizzled 7 and PIP2 binding by syntenin PDZ2 domain supports Frizzled 7
RT   trafficking and signalling.";
RL   Nat. Commun. 7:12101-12101(2016).
CC   -!- FUNCTION: Receptor for Wnt proteins. Most frizzled receptors are
CC       coupled to the beta-catenin canonical signaling pathway, which leads to
CC       the activation of disheveled proteins, inhibition of GSK-3 kinase,
CC       nuclear accumulation of beta-catenin and activation of Wnt target
CC       genes. A second signaling pathway involving PKC and calcium fluxes has
CC       been seen for some family members, but it is not yet clear if it
CC       represents a distinct pathway or if it can be integrated in the
CC       canonical pathway, as PKC seems to be required for Wnt-mediated
CC       inactivation of GSK-3 kinase. Both pathways seem to involve
CC       interactions with G-proteins. Activation by WNT8 induces expression of
CC       beta-catenin target genes (By similarity). Following ligand activation,
CC       binds to CCDC88C/DAPLE which displaces DVL1 from FZD7 and leads to
CC       inhibition of canonical Wnt signaling, activation of G-proteins by
CC       CCDC88C and triggering of non-canonical Wnt responses
CC       (PubMed:26126266). May be involved in transduction and intercellular
CC       transmission of polarity information during tissue morphogenesis and/or
CC       in differentiated tissues. {ECO:0000250|UniProtKB:Q61090,
CC       ECO:0000269|PubMed:26126266}.
CC   -!- FUNCTION: (Microbial infection) Acts as a receptor for C.difficile
CC       toxin TcdB in the colonic epithelium. {ECO:0000269|PubMed:27680706}.
CC   -!- SUBUNIT: Interacts with MAGI3 (By similarity). Interacts with DVL1 (By
CC       similarity). Interacts with CCDC88C/DAPLE; the interaction displaces
CC       DVL1 from FZD7, leading to inhibition of canonical Wnt signaling and
CC       triggering of non-canonical Wnt responses (PubMed:26126266). Interacts
CC       with MYOC (PubMed:19188438). Binds to SDCBP; this interaction is
CC       increased by inositol trisphosphate (IP3) (PubMed:27386966). Interacts
CC       with glypican GPC3 (PubMed:24496449). {ECO:0000250|UniProtKB:Q61090,
CC       ECO:0000269|PubMed:19188438, ECO:0000269|PubMed:24496449,
CC       ECO:0000269|PubMed:26126266}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with C.difficile toxin TcdB;
CC       frizzled receptors constitute the major host receptors for TcdB in the
CC       colonic epithelium. {ECO:0000269|PubMed:27680706}.
CC   -!- INTERACTION:
CC       O75084; O43315: AQP9; NbExp=3; IntAct=EBI-746917, EBI-17444777;
CC       O75084; Q9BXK5: BCL2L13; NbExp=3; IntAct=EBI-746917, EBI-747430;
CC       O75084; O15552: FFAR2; NbExp=3; IntAct=EBI-746917, EBI-2833872;
CC       O75084; P37235: HPCAL1; NbExp=3; IntAct=EBI-746917, EBI-749311;
CC       O75084; A8MZ59: LEUTX; NbExp=3; IntAct=EBI-746917, EBI-17490413;
CC       O75084; P10620: MGST1; NbExp=3; IntAct=EBI-746917, EBI-2691601;
CC       O75084; P61601: NCALD; NbExp=3; IntAct=EBI-746917, EBI-749635;
CC       O75084; P62166: NCS1; NbExp=5; IntAct=EBI-746917, EBI-746987;
CC       O75084; P04156: PRNP; NbExp=3; IntAct=EBI-746917, EBI-977302;
CC       O75084; O00560: SDCBP; NbExp=4; IntAct=EBI-746917, EBI-727004;
CC       O75084; O43765: SGTA; NbExp=3; IntAct=EBI-746917, EBI-347996;
CC       O75084; Q96EQ0: SGTB; NbExp=3; IntAct=EBI-746917, EBI-744081;
CC       O75084; O14863: SLC30A4; NbExp=3; IntAct=EBI-746917, EBI-13918058;
CC       O75084; Q9NP94: SLC39A2; NbExp=3; IntAct=EBI-746917, EBI-12898013;
CC       O75084; Q9H2J7: SLC6A15; NbExp=3; IntAct=EBI-746917, EBI-11343466;
CC       O75084; Q96Q45-2: TMEM237; NbExp=3; IntAct=EBI-746917, EBI-10982110;
CC       O75084; Q9UMX0: UBQLN1; NbExp=5; IntAct=EBI-746917, EBI-741480;
CC       O75084; Q9UHD9: UBQLN2; NbExp=3; IntAct=EBI-746917, EBI-947187;
CC       O75084; P56703: WNT3; NbExp=3; IntAct=EBI-746917, EBI-3644922;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:27386966};
CC       Multi-pass membrane protein {ECO:0000269|PubMed:27386966}. Endosome
CC       membrane {ECO:0000269|PubMed:27386966}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:27386966}. Note=Associated to the plasma membrane
CC       in the presence of FZD7 and phosphatidylinositol 4,5-bisphosphate
CC       (PIP2). Localized in recycling endosomes in other conditions.
CC       {ECO:0000269|PubMed:27386966}.
CC   -!- TISSUE SPECIFICITY: High expression in adult skeletal muscle and fetal
CC       kidney, followed by fetal lung, adult heart, brain, and placenta.
CC       Specifically expressed in squamous cell esophageal carcinomas.
CC   -!- DOMAIN: Lys-Thr-X-X-X-Trp motif interacts with the PDZ domain of Dvl
CC       (Disheveled) family members and is involved in the activation of the
CC       Wnt/beta-catenin signaling pathway. {ECO:0000250}.
CC   -!- DOMAIN: The FZ domain is involved in binding with Wnt ligands.
CC       {ECO:0000250}.
CC   -!- PTM: Ubiquitinated by ZNRF3, leading to its degradation by the
CC       proteasome. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor Fz/Smo family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB010881; BAA32424.1; -; mRNA.
DR   EMBL; AB017365; BAA34668.1; -; mRNA.
DR   EMBL; AC069148; AAX93250.1; -; Genomic_DNA.
DR   EMBL; CH471063; EAW70298.1; -; Genomic_DNA.
DR   EMBL; BC015915; AAH15915.1; -; mRNA.
DR   CCDS; CCDS2351.1; -.
DR   PIR; JE0339; JE0339.
DR   RefSeq; NP_003498.1; NM_003507.1.
DR   PDB; 4Z33; X-ray; 2.45 A; C/D=569-574.
DR   PDB; 5T44; X-ray; 1.99 A; A/B=31-168.
DR   PDB; 5URV; X-ray; 2.20 A; A/B=30-168.
DR   PDB; 5WBS; X-ray; 2.88 A; A/B/C/D/E/F/G/H=30-174.
DR   PDB; 6NE2; X-ray; 1.30 A; A=46-163.
DR   PDB; 6NE4; X-ray; 1.65 A; A=46-163.
DR   PDB; 6O3A; X-ray; 2.10 A; E=42-179.
DR   PDB; 6O3B; X-ray; 2.50 A; C/H=42-179.
DR   PDBsum; 4Z33; -.
DR   PDBsum; 5T44; -.
DR   PDBsum; 5URV; -.
DR   PDBsum; 5WBS; -.
DR   PDBsum; 6NE2; -.
DR   PDBsum; 6NE4; -.
DR   PDBsum; 6O3A; -.
DR   PDBsum; 6O3B; -.
DR   SMR; O75084; -.
DR   BioGRID; 113920; 35.
DR   IntAct; O75084; 40.
DR   MINT; O75084; -.
DR   STRING; 9606.ENSP00000286201; -.
DR   ChEMBL; CHEMBL3559688; -.
DR   GuidetoPHARMACOLOGY; 235; -.
DR   GlyGen; O75084; 3 sites, 1 O-linked glycan (1 site).
DR   iPTMnet; O75084; -.
DR   PhosphoSitePlus; O75084; -.
DR   BioMuta; FZD7; -.
DR   EPD; O75084; -.
DR   jPOST; O75084; -.
DR   MassIVE; O75084; -.
DR   MaxQB; O75084; -.
DR   PaxDb; O75084; -.
DR   PeptideAtlas; O75084; -.
DR   PRIDE; O75084; -.
DR   ProteomicsDB; 49751; -.
DR   ABCD; O75084; 44 sequenced antibodies.
DR   Antibodypedia; 19943; 516 antibodies.
DR   DNASU; 8324; -.
DR   Ensembl; ENST00000286201; ENSP00000286201; ENSG00000155760.
DR   GeneID; 8324; -.
DR   KEGG; hsa:8324; -.
DR   UCSC; uc002uyw.2; human.
DR   CTD; 8324; -.
DR   DisGeNET; 8324; -.
DR   EuPathDB; HostDB:ENSG00000155760.2; -.
DR   GeneCards; FZD7; -.
DR   HGNC; HGNC:4045; FZD7.
DR   HPA; ENSG00000155760; Low tissue specificity.
DR   MIM; 603410; gene.
DR   neXtProt; NX_O75084; -.
DR   OpenTargets; ENSG00000155760; -.
DR   PharmGKB; PA28462; -.
DR   eggNOG; KOG3577; Eukaryota.
DR   GeneTree; ENSGT00940000158239; -.
DR   HOGENOM; CLU_007873_2_1_1; -.
DR   InParanoid; O75084; -.
DR   KO; K02432; -.
DR   OMA; SFSCPRQ; -.
DR   OrthoDB; 330751at2759; -.
DR   PhylomeDB; O75084; -.
DR   TreeFam; TF317907; -.
DR   PathwayCommons; O75084; -.
DR   Reactome; R-HSA-373080; Class B/2 (Secretin family receptors).
DR   Reactome; R-HSA-4086400; PCP/CE pathway.
DR   Reactome; R-HSA-4608870; Asymmetric localization of PCP proteins.
DR   Reactome; R-HSA-9673324; WNT5:FZD7-mediated leishmania damping.
DR   SignaLink; O75084; -.
DR   SIGNOR; O75084; -.
DR   BioGRID-ORCS; 8324; 4 hits in 872 CRISPR screens.
DR   ChiTaRS; FZD7; human.
DR   GeneWiki; FZD7; -.
DR   GenomeRNAi; 8324; -.
DR   Pharos; O75084; Tbio.
DR   PRO; PR:O75084; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; O75084; protein.
DR   Bgee; ENSG00000155760; Expressed in thoracic mammary gland and 226 other tissues.
DR   Genevisible; O75084; HS.
DR   GO; GO:0016021; C:integral component of membrane; IBA:GO_Central.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0055038; C:recycling endosome membrane; IDA:UniProtKB.
DR   GO; GO:0005109; F:frizzled binding; IPI:UniProtKB.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0030165; F:PDZ domain binding; IPI:UniProtKB.
DR   GO; GO:0005546; F:phosphatidylinositol-4,5-bisphosphate binding; IDA:UniProtKB.
DR   GO; GO:0042813; F:Wnt-activated receptor activity; IDA:WormBase.
DR   GO; GO:0017147; F:Wnt-protein binding; IPI:BHF-UCL.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IDA:UniProtKB.
DR   GO; GO:0071300; P:cellular response to retinoic acid; ISS:UniProtKB.
DR   GO; GO:0060231; P:mesenchymal to epithelial transition; IMP:BHF-UCL.
DR   GO; GO:2000726; P:negative regulation of cardiac muscle cell differentiation; IGI:BHF-UCL.
DR   GO; GO:0010812; P:negative regulation of cell-substrate adhesion; IMP:BHF-UCL.
DR   GO; GO:0042666; P:negative regulation of ectodermal cell fate specification; IMP:BHF-UCL.
DR   GO; GO:0030182; P:neuron differentiation; ISS:UniProtKB.
DR   GO; GO:0038031; P:non-canonical Wnt signaling pathway via JNK cascade; IMP:BHF-UCL.
DR   GO; GO:0060054; P:positive regulation of epithelial cell proliferation involved in wound healing; IMP:BHF-UCL.
DR   GO; GO:0046330; P:positive regulation of JNK cascade; IC:BHF-UCL.
DR   GO; GO:0042327; P:positive regulation of phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:BHF-UCL.
DR   GO; GO:0060828; P:regulation of canonical Wnt signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IMP:BHF-UCL.
DR   GO; GO:0014834; P:skeletal muscle satellite cell maintenance involved in skeletal muscle regeneration; IEA:Ensembl.
DR   GO; GO:0048103; P:somatic stem cell division; IEA:Ensembl.
DR   GO; GO:0019827; P:stem cell population maintenance; IMP:BHF-UCL.
DR   GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IEA:Ensembl.
DR   GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl.
DR   GO; GO:0060071; P:Wnt signaling pathway, planar cell polarity pathway; TAS:Reactome.
DR   CDD; cd07466; CRD_FZ7; 1.
DR   Gene3D; 1.10.2000.10; -; 1.
DR   InterPro; IPR042742; Frizzled-7_CRD.
DR   InterPro; IPR015526; Frizzled/SFRP.
DR   InterPro; IPR000539; Frizzled/Smoothened_TM.
DR   InterPro; IPR020067; Frizzled_dom.
DR   InterPro; IPR036790; Frizzled_dom_sf.
DR   InterPro; IPR026552; FZD7.
DR   InterPro; IPR017981; GPCR_2-like.
DR   PANTHER; PTHR11309; PTHR11309; 1.
DR   PANTHER; PTHR11309:SF31; PTHR11309:SF31; 1.
DR   Pfam; PF01534; Frizzled; 1.
DR   Pfam; PF01392; Fz; 1.
DR   PRINTS; PR00489; FRIZZLED.
DR   SMART; SM00063; FRI; 1.
DR   SMART; SM01330; Frizzled; 1.
DR   SUPFAM; SSF63501; SSF63501; 1.
DR   PROSITE; PS50038; FZ; 1.
DR   PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Developmental protein; Disulfide bond;
KW   Endosome; G-protein coupled receptor; Glycoprotein; Membrane; Polymorphism;
KW   Receptor; Reference proteome; Signal; Transducer; Transmembrane;
KW   Transmembrane helix; Ubl conjugation; Wnt signaling pathway.
FT   SIGNAL          1..32
FT                   /evidence="ECO:0000255"
FT   CHAIN           33..574
FT                   /note="Frizzled-7"
FT                   /id="PRO_0000012996"
FT   TOPO_DOM        33..256
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        257..277
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        278..288
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        289..309
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        310..336
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        337..357
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        358..379
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        380..400
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        401..423
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        424..444
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        445..470
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        471..491
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        492..528
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        529..549
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        550..574
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          44..163
FT                   /note="FZ"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00090"
FT   MOTIF           552..557
FT                   /note="Lys-Thr-X-X-X-Trp motif, mediates interaction with
FT                   the PDZ domain of Dvl family members"
FT                   /evidence="ECO:0000250"
FT   MOTIF           572..574
FT                   /note="PDZ-binding"
FT   SITE            569
FT                   /note="Essential for SDCBP-mediated plasma membrane
FT                   phosphatidylinositol-4,5-bisphosphate recognition"
FT                   /evidence="ECO:0000269|PubMed:27386966"
FT   CARBOHYD        63
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        164
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        49..110
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00090"
FT   DISULFID        57..103
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00090"
FT   DISULFID        94..131
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00090"
FT   DISULFID        120..160
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00090"
FT   DISULFID        124..148
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00090"
FT   VARIANT         24
FT                   /note="G -> D (in dbSNP:rs35111363)"
FT                   /id="VAR_049292"
FT   VARIANT         24
FT                   /note="G -> S (in dbSNP:rs755615030)"
FT                   /evidence="ECO:0000269|PubMed:17224074"
FT                   /id="VAR_033024"
FT   VARIANT         196
FT                   /note="G -> E (in dbSNP:rs34908164)"
FT                   /id="VAR_033941"
FT   VARIANT         487
FT                   /note="A -> V (in dbSNP:rs35600847)"
FT                   /id="VAR_033942"
FT   MUTAGEN         569
FT                   /note="K->A: Impaired SDCBP-mediated interaction with
FT                   phosphatidylinositol-4,5-bisphosphate."
FT                   /evidence="ECO:0000269|PubMed:27386966"
FT   CONFLICT        8
FT                   /note="A -> V (in Ref. 1; BAA32424)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        15
FT                   /note="L -> F (in Ref. 1; BAA32424)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        201
FT                   /note="R -> K (in Ref. 1; BAA32424)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        308
FT                   /note="L -> F (in Ref. 1; BAA32424)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        408
FT                   /note="S -> N (in Ref. 1; BAA32424)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        415
FT                   /note="L -> F (in Ref. 1; BAA32424)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        433
FT                   /note="L -> F (in Ref. 1; BAA32424)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        447
FT                   /note="L -> F (in Ref. 1; BAA32424)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        534
FT                   /note="Y -> C (in Ref. 1; BAA32424)"
FT                   /evidence="ECO:0000305"
FT   STRAND          45..47
FT                   /evidence="ECO:0000244|PDB:6O3B"
FT   STRAND          48..51
FT                   /evidence="ECO:0000244|PDB:6NE2"
FT   HELIX           55..57
FT                   /evidence="ECO:0000244|PDB:6NE2"
FT   STRAND          58..61
FT                   /evidence="ECO:0000244|PDB:5T44"
FT   STRAND          64..68
FT                   /evidence="ECO:0000244|PDB:6NE2"
FT   HELIX           76..84
FT                   /evidence="ECO:0000244|PDB:6NE2"
FT   HELIX           87..91
FT                   /evidence="ECO:0000244|PDB:6NE2"
FT   HELIX           98..106
FT                   /evidence="ECO:0000244|PDB:6NE2"
FT   STRAND          112..115
FT                   /evidence="ECO:0000244|PDB:6NE2"
FT   HELIX           121..128
FT                   /evidence="ECO:0000244|PDB:6NE2"
FT   HELIX           131..137
FT                   /evidence="ECO:0000244|PDB:6NE2"
FT   HELIX           144..146
FT                   /evidence="ECO:0000244|PDB:6NE2"
FT   HELIX           148..150
FT                   /evidence="ECO:0000244|PDB:6NE2"
FT   TURN            154..156
FT                   /evidence="ECO:0000244|PDB:6NE2"
FT   STRAND          572..574
FT                   /evidence="ECO:0000244|PDB:4Z33"
SQ   SEQUENCE   574 AA;  63620 MW;  801934246B426DF5 CRC64;
     MRDPGAAAPL SSLGLCALVL ALLGALSAGA GAQPYHGEKG ISVPDHGFCQ PISIPLCTDI
     AYNQTILPNL LGHTNQEDAG LEVHQFYPLV KVQCSPELRF FLCSMYAPVC TVLDQAIPPC
     RSLCERARQG CEALMNKFGF QWPERLRCEN FPVHGAGEIC VGQNTSDGSG GPGGGPTAYP
     TAPYLPDLPF TALPPGASDG RGRPAFPFSC PRQLKVPPYL GYRFLGERDC GAPCEPGRAN
     GLMYFKEEER RFARLWVGVW SVLCCASTLF TVLTYLVDMR RFSYPERPII FLSGCYFMVA
     VAHVAGFLLE DRAVCVERFS DDGYRTVAQG TKKEGCTILF MVLYFFGMAS SIWWVILSLT
     WFLAAGMKWG HEAIEANSQY FHLAAWAVPA VKTITILAMG QVDGDLLSGV CYVGLSSVDA
     LRGFVLAPLF VYLFIGTSFL LAGFVSLFRI RTIMKHDGTK TEKLEKLMVR IGVFSVLYTV
     PATIVLACYF YEQAFREHWE RTWLLQTCKS YAVPCPPGHF PPMSPDFTVF MIKYLMTMIV
     GITTGFWIWS GKTLQSWRRF YHRLSHSSKG ETAV
//
ID   GRM3_HUMAN              Reviewed;         879 AA.
AC   Q14832; Q2PNZ6; Q75MV4; Q75N17; Q86YG6; Q8TBH9;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   27-SEP-2005, sequence version 2.
DT   07-OCT-2020, entry version 179.
DE   RecName: Full=Metabotropic glutamate receptor 3;
DE            Short=mGluR3;
DE   Flags: Precursor;
GN   Name=GRM3; Synonyms=GPRC1C, MGLUR3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=8840013; DOI=10.1016/0169-328x(96)00037-x;
RA   Makoff A., Volpe F., Lelchuk R., Harrington K., Emson P.;
RT   "Molecular characterization and localization of human metabotropic
RT   glutamate receptor type 3.";
RL   Brain Res. Mol. Brain Res. 40:55-63(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND ALTERNATIVE SPLICING.
RC   TISSUE=Lymphoblast;
RX   PubMed=16417579; DOI=10.1111/j.1471-4159.2005.03609.x;
RA   Sartorius L.J., Nagappan G., Lipska B.K., Lu B., Sei Y., Ren-Patterson R.,
RA   Li Z., Weinberger D.R., Harrison P.J.;
RT   "Alternative splicing of human metabotropic glutamate receptor 3.";
RL   J. Neurochem. 96:1139-1148(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   X-RAY CRYSTALLOGRAPHY (2.26 ANGSTROMS) OF 26-504 OF MUTANT SER-240, AND
RP   DISULFIDE BONDS.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of metabotropic glutamate receptor 3 precursor in
RT   presence of LY341495 antagonist.";
RL   Submitted (JUL-2011) to the PDB data bank.
CC   -!- FUNCTION: G-protein coupled receptor for glutamate. Ligand binding
CC       causes a conformation change that triggers signaling via guanine
CC       nucleotide-binding proteins (G proteins) and modulates the activity of
CC       down-stream effectors. Signaling inhibits adenylate cyclase activity.
CC       {ECO:0000269|PubMed:8840013}.
CC   -!- SUBUNIT: Interacts with TAMALIN. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:8840013};
CC       Multi-pass membrane protein {ECO:0000269|PubMed:8840013}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q14832-1; Sequence=Displayed;
CC       Name=2; Synonyms=GRM3Delta4;
CC         IsoId=Q14832-2; Sequence=VSP_047679, VSP_047680;
CC   -!- TISSUE SPECIFICITY: Detected in brain cortex, thalamus, subthalamic
CC       nucleus, substantia nigra, hypothalamus, hippocampus, corpus callosum,
CC       caudate nucleus and amygdala. {ECO:0000269|PubMed:8840013}.
CC   -!- MISCELLANEOUS: [Isoform 2]: Appears to be membrane-associated, despite
CC       the absence of the seven-transmembrane domain. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 3 family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD15616.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=ABC47402.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=CAA54796.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X77748; CAA54796.1; ALT_INIT; mRNA.
DR   EMBL; DQ315361; ABC47402.1; ALT_INIT; mRNA.
DR   EMBL; AC004829; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC005009; AAD15616.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AC002081; AAC60379.2; -; Genomic_DNA.
DR   EMBL; BC022496; AAH22496.2; -; mRNA.
DR   EMBL; BC041407; AAH41407.1; -; mRNA.
DR   CCDS; CCDS5600.1; -. [Q14832-1]
DR   CCDS; CCDS87515.1; -. [Q14832-2]
DR   RefSeq; NP_000831.2; NM_000840.2. [Q14832-1]
DR   RefSeq; XP_011514390.1; XM_011516088.1.
DR   PDB; 1S8M; Model; -; A=30-499.
DR   PDB; 3SM9; X-ray; 2.26 A; A=26-504.
DR   PDB; 4XAR; X-ray; 2.26 A; A=2-508.
DR   PDB; 5CNK; X-ray; 3.15 A; A/B/C=2-507.
DR   PDB; 5CNM; X-ray; 2.84 A; A=2-507.
DR   PDB; 6B7H; X-ray; 2.82 A; A=2-507.
DR   PDBsum; 1S8M; -.
DR   PDBsum; 3SM9; -.
DR   PDBsum; 4XAR; -.
DR   PDBsum; 5CNK; -.
DR   PDBsum; 5CNM; -.
DR   PDBsum; 6B7H; -.
DR   SMR; Q14832; -.
DR   BioGRID; 109170; 5.
DR   CORUM; Q14832; -.
DR   IntAct; Q14832; 1.
DR   STRING; 9606.ENSP00000355316; -.
DR   BindingDB; Q14832; -.
DR   ChEMBL; CHEMBL2888; -.
DR   DrugBank; DB05096; LY2140023.
DR   DrugCentral; Q14832; -.
DR   GuidetoPHARMACOLOGY; 291; -.
DR   GlyGen; Q14832; 4 sites.
DR   iPTMnet; Q14832; -.
DR   PhosphoSitePlus; Q14832; -.
DR   BioMuta; GRM3; -.
DR   DMDM; 76803803; -.
DR   MassIVE; Q14832; -.
DR   PaxDb; Q14832; -.
DR   PeptideAtlas; Q14832; -.
DR   PRIDE; Q14832; -.
DR   ProteomicsDB; 60202; -. [Q14832-1]
DR   ProteomicsDB; 61428; -.
DR   Antibodypedia; 15243; 367 antibodies.
DR   DNASU; 2913; -.
DR   Ensembl; ENST00000361669; ENSP00000355316; ENSG00000198822. [Q14832-1]
DR   Ensembl; ENST00000439827; ENSP00000398767; ENSG00000198822. [Q14832-2]
DR   GeneID; 2913; -.
DR   KEGG; hsa:2913; -.
DR   UCSC; uc003uid.4; human. [Q14832-1]
DR   CTD; 2913; -.
DR   DisGeNET; 2913; -.
DR   EuPathDB; HostDB:ENSG00000198822.10; -.
DR   GeneCards; GRM3; -.
DR   HGNC; HGNC:4595; GRM3.
DR   HPA; ENSG00000198822; Tissue enriched (brain).
DR   MIM; 601115; gene.
DR   neXtProt; NX_Q14832; -.
DR   OpenTargets; ENSG00000198822; -.
DR   PharmGKB; PA28992; -.
DR   eggNOG; KOG1056; Eukaryota.
DR   GeneTree; ENSGT00950000182807; -.
DR   HOGENOM; CLU_005389_0_0_1; -.
DR   InParanoid; Q14832; -.
DR   KO; K04606; -.
DR   OMA; CIARIFN; -.
DR   PhylomeDB; Q14832; -.
DR   TreeFam; TF313240; -.
DR   PathwayCommons; Q14832; -.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-420499; Class C/3 (Metabotropic glutamate/pheromone receptors).
DR   SignaLink; Q14832; -.
DR   SIGNOR; Q14832; -.
DR   BioGRID-ORCS; 2913; 3 hits in 870 CRISPR screens.
DR   ChiTaRS; GRM3; human.
DR   GeneWiki; Metabotropic_glutamate_receptor_3; -.
DR   GenomeRNAi; 2913; -.
DR   Pharos; Q14832; Tchem.
DR   PRO; PR:Q14832; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; Q14832; protein.
DR   Bgee; ENSG00000198822; Expressed in caudate nucleus and 112 other tissues.
DR   ExpressionAtlas; Q14832; baseline and differential.
DR   Genevisible; Q14832; HS.
DR   GO; GO:0097449; C:astrocyte projection; ISS:ARUK-UCL.
DR   GO; GO:0030424; C:axon; ISS:ARUK-UCL.
DR   GO; GO:0043197; C:dendritic spine; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0014069; C:postsynaptic density; IEA:Ensembl.
DR   GO; GO:0045211; C:postsynaptic membrane; IEA:Ensembl.
DR   GO; GO:0042734; C:presynaptic membrane; IEA:Ensembl.
DR   GO; GO:0005246; F:calcium channel regulator activity; IEA:Ensembl.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; TAS:UniProtKB.
DR   GO; GO:0008066; F:glutamate receptor activity; IBA:GO_Central.
DR   GO; GO:0001641; F:group II metabotropic glutamate receptor activity; IBA:GO_Central.
DR   GO; GO:0097110; F:scaffold protein binding; ISS:ARUK-UCL.
DR   GO; GO:0007268; P:chemical synaptic transmission; TAS:ProtInc.
DR   GO; GO:0007216; P:G protein-coupled glutamate receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007194; P:negative regulation of adenylate cyclase activity; TAS:ProtInc.
DR   GO; GO:0051966; P:regulation of synaptic transmission, glutamatergic; IBA:GO_Central.
DR   Gene3D; 2.10.50.30; -; 1.
DR   InterPro; IPR001828; ANF_lig-bd_rcpt.
DR   InterPro; IPR000337; GPCR_3.
DR   InterPro; IPR011500; GPCR_3_9-Cys_dom.
DR   InterPro; IPR038550; GPCR_3_9-Cys_sf.
DR   InterPro; IPR017978; GPCR_3_C.
DR   InterPro; IPR017979; GPCR_3_CS.
DR   InterPro; IPR000162; GPCR_3_mtglu_rcpt.
DR   InterPro; IPR001234; GPCR_3_mtglu_rcpt_3.
DR   InterPro; IPR028082; Peripla_BP_I.
DR   Pfam; PF00003; 7tm_3; 1.
DR   Pfam; PF01094; ANF_receptor; 1.
DR   Pfam; PF07562; NCD3G; 1.
DR   PRINTS; PR00248; GPCRMGR.
DR   PRINTS; PR01053; MTABOTROPC3R.
DR   PRINTS; PR00593; MTABOTROPICR.
DR   SUPFAM; SSF53822; SSF53822; 1.
DR   PROSITE; PS00979; G_PROTEIN_RECEP_F3_1; 1.
DR   PROSITE; PS00980; G_PROTEIN_RECEP_F3_2; 1.
DR   PROSITE; PS00981; G_PROTEIN_RECEP_F3_3; 1.
DR   PROSITE; PS50259; G_PROTEIN_RECEP_F3_4; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Polymorphism; Receptor;
KW   Reference proteome; Signal; Transducer; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..22
FT                   /evidence="ECO:0000255"
FT   CHAIN           23..879
FT                   /note="Metabotropic glutamate receptor 3"
FT                   /id="PRO_0000012927"
FT   TOPO_DOM        23..576
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        577..599
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        600..613
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        614..634
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        635..645
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        646..664
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        665..688
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        689..709
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        710..734
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        735..756
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        757..769
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        770..792
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        793..802
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        803..828
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        829..879
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REGION          172..174
FT                   /note="Glutamate binding"
FT                   /evidence="ECO:0000250"
FT   BINDING         151
FT                   /note="Glutamate"
FT                   /evidence="ECO:0000250"
FT   BINDING         222
FT                   /note="Glutamate"
FT                   /evidence="ECO:0000250"
FT   BINDING         301
FT                   /note="Glutamate"
FT                   /evidence="ECO:0000250"
FT   BINDING         389
FT                   /note="Glutamate"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        209
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        292
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        414
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        439
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        57..99
FT                   /evidence="ECO:0000269|Ref.5"
FT   DISULFID        240..527
FT                   /evidence="ECO:0000250"
FT   DISULFID        361..373
FT                   /evidence="ECO:0000269|Ref.5"
FT   DISULFID        412..419
FT                   /evidence="ECO:0000269|Ref.5"
FT   DISULFID        509..528
FT                   /evidence="ECO:0000250"
FT   DISULFID        513..531
FT                   /evidence="ECO:0000250"
FT   DISULFID        534..546
FT                   /evidence="ECO:0000250"
FT   DISULFID        549..562
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         442..537
FT                   /note="APFNPNKDADSIVKFDTFGDGMGRYNVFNFQNVGGKYSYLKVGHWAETLSLD
FT                   VNSIHWSRNSVPTSQCSDPCAPNEMKNMQPGDVCCWICIPCEPY -> GADDNHVHLCQ
FT                   PEWLCGLGLFVCTQGSHHPVSTPEECCHTQTAPQQVQCQWNWDHILSVLCKHVCANGVQ
FT                   WAGSPRLHHLISVIVNCSSVLVFLDC (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:16417579"
FT                   /id="VSP_047679"
FT   VAR_SEQ         538..879
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:16417579"
FT                   /id="VSP_047680"
FT   VARIANT         475
FT                   /note="G -> D (in dbSNP:rs17161026)"
FT                   /id="VAR_049274"
FT   CONFLICT        96
FT                   /note="L -> F (in Ref. 4; AAH41407)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        446
FT                   /note="P -> T (in Ref. 4; AAH22496)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        512
FT                   /note="P -> A (in Ref. 4; AAH22496)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        856
FT                   /note="S -> Y (in Ref. 4; AAH22496)"
FT                   /evidence="ECO:0000305"
FT   STRAND          33..35
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   STRAND          38..45
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   STRAND          48..50
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   STRAND          56..60
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   TURN            62..65
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   HELIX           66..81
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   STRAND          83..86
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   STRAND          91..97
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   HELIX           102..114
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   STRAND          142..146
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   HELIX           151..161
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   HELIX           162..164
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   STRAND          168..172
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   HELIX           176..179
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   TURN            181..186
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   STRAND          187..191
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   HELIX           195..207
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   STRAND          212..220
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   HELIX           221..235
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   TURN            236..238
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   STRAND          240..247
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   HELIX           253..264
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   STRAND          271..275
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   HELIX           278..290
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   STRAND          296..299
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   TURN            301..305
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   HELIX           307..310
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   TURN            314..319
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   STRAND          321..325
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   HELIX           331..338
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   TURN            342..344
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   HELIX           351..359
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   TURN            381..383
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   HELIX           390..411
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   HELIX           420..423
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   HELIX           427..433
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   HELIX           435..437
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   STRAND          438..440
FT                   /evidence="ECO:0000244|PDB:4XAR"
FT   HELIX           450..452
FT                   /evidence="ECO:0000244|PDB:5CNM"
FT   STRAND          453..455
FT                   /evidence="ECO:0000244|PDB:4XAR"
FT   STRAND          466..476
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   STRAND          478..492
FT                   /evidence="ECO:0000244|PDB:3SM9"
FT   HELIX           494..496
FT                   /evidence="ECO:0000244|PDB:3SM9"
SQ   SEQUENCE   879 AA;  98879 MW;  7EB84521676E8304 CRC64;
     MKMLTRLQVL TLALFSKGFL LSLGDHNFLR REIKIEGDLV LGGLFPINEK GTGTEECGRI
     NEDRGIQRLE AMLFAIDEIN KDDYLLPGVK LGVHILDTCS RDTYALEQSL EFVRASLTKV
     DEAEYMCPDG SYAIQENIPL LIAGVIGGSY SSVSIQVANL LRLFQIPQIS YASTSAKLSD
     KSRYDYFART VPPDFYQAKA MAEILRFFNW TYVSTVASEG DYGETGIEAF EQEARLRNIC
     IATAEKVGRS NIRKSYDSVI RELLQKPNAR VVVLFMRSDD SRELIAAASR ANASFTWVAS
     DGWGAQESII KGSEHVAYGA ITLELASQPV RQFDRYFQSL NPYNNHRNPW FRDFWEQKFQ
     CSLQNKRNHR RVCDKHLAID SSNYEQESKI MFVVNAVYAM AHALHKMQRT LCPNTTKLCD
     AMKILDGKKL YKDYLLKINF TAPFNPNKDA DSIVKFDTFG DGMGRYNVFN FQNVGGKYSY
     LKVGHWAETL SLDVNSIHWS RNSVPTSQCS DPCAPNEMKN MQPGDVCCWI CIPCEPYEYL
     ADEFTCMDCG SGQWPTADLT GCYDLPEDYI RWEDAWAIGP VTIACLGFMC TCMVVTVFIK
     HNNTPLVKAS GRELCYILLF GVGLSYCMTF FFIAKPSPVI CALRRLGLGS SFAICYSALL
     TKTNCIARIF DGVKNGAQRP KFISPSSQVF ICLGLILVQI VMVSVWLILE APGTRRYTLA
     EKRETVILKC NVKDSSMLIS LTYDVILVIL CTVYAFKTRK CPENFNEAKF IGFTMYTTCI
     IWLAFLPIFY VTSSDYRVQT TTMCISVSLS GFVVLGCLFA PKVHIILFQP QKNVVTHRLH
     LNRFSVSGTG TTYSQSSAST YVPTVCNGRE VLDSTTSSL
//
ID   FPR2_HUMAN              Reviewed;         351 AA.
AC   P25090; A8K3E2;
DT   01-MAY-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1993, sequence version 2.
DT   07-OCT-2020, entry version 183.
DE   RecName: Full=N-formyl peptide receptor 2;
DE   AltName: Full=FMLP-related receptor I;
DE            Short=FMLP-R-I;
DE   AltName: Full=Formyl peptide receptor-like 1;
DE   AltName: Full=HM63;
DE   AltName: Full=Lipoxin A4 receptor;
DE            Short=LXA4 receptor;
DE   AltName: Full=RFP;
GN   Name=FPR2; Synonyms=FPRH1, FPRL1, LXA4R;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1612600; DOI=10.1016/0888-7543(92)90265-t;
RA   Bao L., Gerard N.P., Eddy R.L. Jr., Shows T.B., Gerard C.;
RT   "Mapping of genes for the human C5a receptor (C5AR), human FMLP receptor
RT   (FPR), and two FMLP receptor homologue orphan receptors (FPRH1, FPRH2) to
RT   chromosome 19.";
RL   Genomics 13:437-440(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Bone marrow;
RX   PubMed=1511907; DOI=10.1016/0378-1119(92)90208-7;
RA   Perez H.D., Holmes R., Kelly E., McClary J., Andrews W.H.;
RT   "Cloning of a cDNA encoding a receptor related to the formyl peptide
RT   receptor of human neutrophils.";
RL   Gene 118:303-304(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RC   TISSUE=Granulocyte;
RX   PubMed=1374236; DOI=10.1016/0006-291x(92)90629-y;
RA   Ye R.D., Cavanagh S.L., Quehenberger O., Prossnitz E.R., Cochrane C.G.;
RT   "Isolation of a cDNA that encodes a novel granulocyte N-formyl peptide
RT   receptor.";
RL   Biochem. Biophys. Res. Commun. 184:582-589(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1373134;
RA   Murphy P.M., Ozcelik T., Kenney R.T., Tiffany H.L., McDermott D.,
RA   Francke U.;
RT   "A structural homologue of the N-formyl peptide receptor. Characterization
RT   and chromosome mapping of a peptide chemoattractant receptor family.";
RL   J. Biol. Chem. 267:7637-7643(1992).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Monocyte;
RX   PubMed=7505609; DOI=10.1093/intimm/5.10.1239;
RA   Nomura H., Nielsen B.W., Matsushima K.;
RT   "Molecular cloning of cDNAs encoding a LD78 receptor and putative leukocyte
RT   chemotactic peptide receptors.";
RL   Int. Immunol. 5:1239-1249(1993).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Maddox J.F., Hachicha M., Takano T., Petasis N.A., Fokin V.V., Serhan C.N.;
RL   Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RX   PubMed=9547339; DOI=10.1084/jem.187.8.1285;
RA   Gronert K., Gewirtz A., Madara J.L., Serhan C.N.;
RT   "Identification of a human enterocyte lipoxin A4 receptor that is regulated
RT   by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis
RT   factor alpha-induced IL-8 release.";
RL   J. Exp. Med. 187:1285-1294(1998).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Heart;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Blood;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   TISSUE SPECIFICITY.
RX   PubMed=9151906; DOI=10.1084/jem.185.9.1693;
RA   Takano T., Fiore S., Maddox J.F., Brady H.R., Petasis N.A., Serhan C.N.;
RT   "Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are
RT   potent inhibitors of acute inflammation: evidence for anti-inflammatory
RT   receptors.";
RL   J. Exp. Med. 185:1693-1704(1997).
RN   [14]
RP   INTERACTION WITH AMYLOID-BETA PROTEIN 42, AND SUBCELLULAR LOCATION.
RX   PubMed=11689470; DOI=10.1096/fj.01-0251com;
RA   Yazawa H., Yu Z.-X., Takeda K., Le Y., Gong W., Ferrans V.J.,
RA   Oppenheim J.J., Li C.C.H., Wang J.M.;
RT   "Beta amyloid peptide (Abeta42) is internalized via the G-protein-coupled
RT   receptor FPRL1 and forms fibrillar aggregates in macrophages.";
RL   FASEB J. 15:2454-2462(2001).
RN   [15]
RP   INTERACTION WITH STAPHYLOCOCCUS AUREUS PROTEIN SSL13 (MICROBIAL INFECTION).
RX   PubMed=30098280; DOI=10.1111/cmi.12941;
RA   Zhao Y., van Kessel K.P.M., de Haas C.J.C., Rogers M.R.C.,
RA   van Strijp J.A.G., Haas P.A.;
RT   "Staphylococcal superantigen-like protein 13 activates neutrophils via
RT   formyl peptide receptor 2.";
RL   Cell. Microbiol. 20:E12941-E12941(2018).
CC   -!- FUNCTION: Low affinity receptor for N-formyl-methionyl peptides, which
CC       are powerful neutrophil chemotactic factors (PubMed:1374236). Binding
CC       of FMLP to the receptor causes activation of neutrophils
CC       (PubMed:1374236). This response is mediated via a G-protein that
CC       activates a phosphatidylinositol-calcium second messenger system
CC       (PubMed:1374236). The activation of LXA4R could result in an anti-
CC       inflammatory outcome counteracting the actions of proinflammatory
CC       signals such as LTB4 (leukotriene B4) (PubMed:9547339). Receptor for
CC       the chemokine-like protein FAM19A5, mediating FAM19A5-stimulated
CC       macrophage chemotaxis and the inhibitory effect on TNFSF11/RANKL-
CC       induced osteoclast differentiation (By similarity).
CC       {ECO:0000250|UniProtKB:O88536, ECO:0000269|PubMed:1374236,
CC       ECO:0000269|PubMed:9547339}.
CC   -!- SUBUNIT: Interacts with Amyloid-beta protein 42, product of APP; the
CC       interaction takes place at the cell surface and the complex is then
CC       rapidly internalized. {ECO:0000269|PubMed:11689470}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Staphylococcus aureus
CC       protein SSL13; this interaction leads to the activation of neutrophils.
CC       {ECO:0000269|PubMed:30098280}.
CC   -!- INTERACTION:
CC       P25090; P05090: APOD; NbExp=3; IntAct=EBI-17291771, EBI-715495;
CC       P25090; Q9H0Q3: FXYD6; NbExp=3; IntAct=EBI-17291771, EBI-713304;
CC       P25090; Q8N386: LRRC25; NbExp=3; IntAct=EBI-17291771, EBI-11304917;
CC       P25090; Q8WWF3: SSMEM1; NbExp=3; IntAct=EBI-17291771, EBI-17280858;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:11689470};
CC       Multi-pass membrane protein. Note=Associates with Amyloid-beta protein
CC       42, product of APP, at the cell surface and the complex is then rapidly
CC       internalized. {ECO:0000269|PubMed:11689470}.
CC   -!- TISSUE SPECIFICITY: Expressed abundantly in the lung and neutrophils.
CC       Also found in the spleen and testis. {ECO:0000269|PubMed:9151906}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M76672; AAA58481.1; -; mRNA.
DR   EMBL; X63819; CAA45319.1; -; mRNA.
DR   EMBL; M88107; AAA60070.1; -; mRNA.
DR   EMBL; M84562; AAA52473.1; -; mRNA.
DR   EMBL; D10922; BAA01720.1; -; mRNA.
DR   EMBL; U81501; AAB51133.1; -; mRNA.
DR   EMBL; AF054013; AAC13684.1; -; mRNA.
DR   EMBL; AY225226; AAO67711.1; -; Genomic_DNA.
DR   EMBL; AK290557; BAF83246.1; -; mRNA.
DR   EMBL; AC018755; AAF87844.1; -; Genomic_DNA.
DR   EMBL; CH471135; EAW72043.1; -; Genomic_DNA.
DR   EMBL; BC029125; AAH29125.1; -; mRNA.
DR   EMBL; BC071722; AAH71722.1; -; mRNA.
DR   CCDS; CCDS12840.1; -.
DR   PIR; B42009; B42009.
DR   RefSeq; NP_001005738.1; NM_001005738.1.
DR   RefSeq; NP_001453.1; NM_001462.3.
DR   RefSeq; XP_006723183.1; XM_006723120.3.
DR   RefSeq; XP_016882031.1; XM_017026542.1.
DR   PDB; 6LW5; X-ray; 2.80 A; A=3-322.
DR   PDB; 6OMM; EM; 3.17 A; R=1-342.
DR   PDBsum; 6LW5; -.
DR   PDBsum; 6OMM; -.
DR   SMR; P25090; -.
DR   BioGRID; 108641; 81.
DR   IntAct; P25090; 75.
DR   STRING; 9606.ENSP00000468897; -.
DR   BindingDB; P25090; -.
DR   ChEMBL; CHEMBL4227; -.
DR   GuidetoPHARMACOLOGY; 223; -.
DR   GlyGen; P25090; 1 site.
DR   iPTMnet; P25090; -.
DR   PhosphoSitePlus; P25090; -.
DR   BioMuta; FPR2; -.
DR   DMDM; 399504; -.
DR   jPOST; P25090; -.
DR   MassIVE; P25090; -.
DR   PaxDb; P25090; -.
DR   PeptideAtlas; P25090; -.
DR   PRIDE; P25090; -.
DR   ProteomicsDB; 54252; -.
DR   TopDownProteomics; P25090; -.
DR   Antibodypedia; 19050; 395 antibodies.
DR   DNASU; 2358; -.
DR   Ensembl; ENST00000340023; ENSP00000340191; ENSG00000171049.
DR   Ensembl; ENST00000598776; ENSP00000468897; ENSG00000171049.
DR   Ensembl; ENST00000598953; ENSP00000468876; ENSG00000171049.
DR   GeneID; 2358; -.
DR   KEGG; hsa:2358; -.
DR   UCSC; uc002pxr.4; human.
DR   CTD; 2358; -.
DR   DisGeNET; 2358; -.
DR   EuPathDB; HostDB:ENSG00000171049.8; -.
DR   GeneCards; FPR2; -.
DR   HGNC; HGNC:3827; FPR2.
DR   HPA; ENSG00000171049; Group enriched (blood, lymphoid tissue).
DR   MIM; 136538; gene.
DR   neXtProt; NX_P25090; -.
DR   OpenTargets; ENSG00000171049; -.
DR   PharmGKB; PA162388901; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00980000198522; -.
DR   HOGENOM; CLU_009579_8_0_1; -.
DR   InParanoid; P25090; -.
DR   KO; K04173; -.
DR   OMA; PNGDTYC; -.
DR   OrthoDB; 910274at2759; -.
DR   PhylomeDB; P25090; -.
DR   TreeFam; TF330976; -.
DR   PathwayCommons; P25090; -.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-444473; Formyl peptide receptors bind formyl peptides and many other ligands.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SIGNOR; P25090; -.
DR   BioGRID-ORCS; 2358; 3 hits in 867 CRISPR screens.
DR   GeneWiki; Formyl_peptide_receptor_2; -.
DR   GenomeRNAi; 2358; -.
DR   Pharos; P25090; Tchem.
DR   PRO; PR:P25090; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; P25090; protein.
DR   Bgee; ENSG00000171049; Expressed in blood and 120 other tissues.
DR   ExpressionAtlas; P25090; baseline and differential.
DR   Genevisible; P25090; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:ARUK-UCL.
DR   GO; GO:0101003; C:ficolin-1-rich granule membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; IDA:ARUK-UCL.
DR   GO; GO:0035579; C:specific granule membrane; TAS:Reactome.
DR   GO; GO:0070821; C:tertiary granule membrane; TAS:Reactome.
DR   GO; GO:0001540; F:amyloid-beta binding; IPI:ARUK-UCL.
DR   GO; GO:0038024; F:cargo receptor activity; ISS:ARUK-UCL.
DR   GO; GO:0004875; F:complement receptor activity; IBA:GO_Central.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0004982; F:N-formyl peptide receptor activity; IBA:GO_Central.
DR   GO; GO:0005124; F:scavenger receptor binding; IPI:ARUK-UCL.
DR   GO; GO:0038023; F:signaling receptor activity; IDA:ARUK-UCL.
DR   GO; GO:0007193; P:adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway; IGI:ARUK-UCL.
DR   GO; GO:0048143; P:astrocyte activation; ISS:ARUK-UCL.
DR   GO; GO:0019722; P:calcium-mediated signaling; IGI:ARUK-UCL.
DR   GO; GO:0007155; P:cell adhesion; TAS:ProtInc.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IDA:ARUK-UCL.
DR   GO; GO:1904646; P:cellular response to amyloid-beta; IDA:ARUK-UCL.
DR   GO; GO:0006935; P:chemotaxis; TAS:ProtInc.
DR   GO; GO:0002430; P:complement receptor mediated signaling pathway; IBA:GO_Central.
DR   GO; GO:0042742; P:defense response to bacterium; IDA:ARUK-UCL.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IGI:ARUK-UCL.
DR   GO; GO:0002768; P:immune response-regulating cell surface receptor signaling pathway; IDA:ARUK-UCL.
DR   GO; GO:0006954; P:inflammatory response; IBA:GO_Central.
DR   GO; GO:0001774; P:microglial cell activation; ISS:ARUK-UCL.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IDA:ARUK-UCL.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0050918; P:positive chemotaxis; ISS:ARUK-UCL.
DR   GO; GO:0061903; P:positive regulation of 1-phosphatidylinositol-3-kinase activity; ISS:ARUK-UCL.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IBA:GO_Central.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IGI:ARUK-UCL.
DR   GO; GO:0045089; P:positive regulation of innate immune response; IDA:ARUK-UCL.
DR   GO; GO:0090026; P:positive regulation of monocyte chemotaxis; IGI:ARUK-UCL.
DR   GO; GO:0050766; P:positive regulation of phagocytosis; IDA:ARUK-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IGI:ARUK-UCL.
DR   GO; GO:0032930; P:positive regulation of superoxide anion generation; ISS:ARUK-UCL.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; ISS:ARUK-UCL.
DR   InterPro; IPR027347; Formyl_pep_2/3_rcpt.
DR   InterPro; IPR000826; Formyl_rcpt-rel.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   PANTHER; PTHR24225; PTHR24225; 1.
DR   PANTHER; PTHR24225:SF16; PTHR24225:SF16; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Chemotaxis; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Receptor;
KW   Reference proteome; Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..351
FT                   /note="N-formyl peptide receptor 2"
FT                   /id="PRO_0000069451"
FT   TOPO_DOM        1..27
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        28..50
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        51..61
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        62..83
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        84..100
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        101..121
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        122..140
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        141..162
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        163..205
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        206..226
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        227..242
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        243..266
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        267..286
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        287..306
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        307..351
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        4
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        98..176
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   CONFLICT        339
FT                   /note="S -> C (in Ref. 1; AAA58481)"
FT                   /evidence="ECO:0000305"
FT   HELIX           3..6
FT                   /evidence="ECO:0000244|PDB:6LW5"
FT   TURN            11..13
FT                   /evidence="ECO:0000244|PDB:6LW5"
FT   HELIX           15..17
FT                   /evidence="ECO:0000244|PDB:6LW5"
FT   HELIX           20..53
FT                   /evidence="ECO:0000244|PDB:6LW5"
FT   HELIX           59..75
FT                   /evidence="ECO:0000244|PDB:6LW5"
FT   HELIX           78..86
FT                   /evidence="ECO:0000244|PDB:6LW5"
FT   HELIX           95..128
FT                   /evidence="ECO:0000244|PDB:6LW5"
FT   HELIX           130..136
FT                   /evidence="ECO:0000244|PDB:6LW5"
FT   HELIX           139..145
FT                   /evidence="ECO:0000244|PDB:6LW5"
FT   HELIX           147..155
FT                   /evidence="ECO:0000244|PDB:6LW5"
FT   HELIX           158..163
FT                   /evidence="ECO:0000244|PDB:6LW5"
FT   STRAND          164..168
FT                   /evidence="ECO:0000244|PDB:6LW5"
FT   STRAND          170..172
FT                   /evidence="ECO:0000244|PDB:6LW5"
FT   STRAND          174..178
FT                   /evidence="ECO:0000244|PDB:6LW5"
FT   HELIX           180..182
FT                   /evidence="ECO:0000244|PDB:6LW5"
FT   HELIX           187..207
FT                   /evidence="ECO:0000244|PDB:6LW5"
FT   TURN            208..210
FT                   /evidence="ECO:0000244|PDB:6LW5"
FT   HELIX           211..230
FT                   /evidence="ECO:0000244|PDB:6LW5"
FT   STRAND          233..235
FT                   /evidence="ECO:0000244|PDB:6LW5"
FT   HELIX           240..266
FT                   /evidence="ECO:0000244|PDB:6LW5"
FT   HELIX           268..273
FT                   /evidence="ECO:0000244|PDB:6LW5"
FT   HELIX           278..282
FT                   /evidence="ECO:0000244|PDB:6LW5"
FT   HELIX           284..302
FT                   /evidence="ECO:0000244|PDB:6LW5"
FT   TURN            303..305
FT                   /evidence="ECO:0000244|PDB:6LW5"
FT   HELIX           307..316
FT                   /evidence="ECO:0000244|PDB:6LW5"
FT   STRAND          317..319
FT                   /evidence="ECO:0000244|PDB:6LW5"
SQ   SEQUENCE   351 AA;  38964 MW;  DC6A1D77AFC0D780 CRC64;
     METNFSTPLN EYEEVSYESA GYTVLRILPL VVLGVTFVLG VLGNGLVIWV AGFRMTRTVT
     TICYLNLALA DFSFTATLPF LIVSMAMGEK WPFGWFLCKL IHIVVDINLF GSVFLIGFIA
     LDRCICVLHP VWAQNHRTVS LAMKVIVGPW ILALVLTLPV FLFLTTVTIP NGDTYCTFNF
     ASWGGTPEER LKVAITMLTA RGIIRFVIGF SLPMSIVAIC YGLIAAKIHK KGMIKSSRPL
     RVLTAVVASF FICWFPFQLV ALLGTVWLKE MLFYGKYKII DILVNPTSSL AFFNSCLNPM
     LYVFVGQDFR ERLIHSLPTS LERALSEDSA PTNDTAANSA SPPAETELQA M
//
ID   FFAR1_HUMAN             Reviewed;         300 AA.
AC   O14842; Q0VAS2; Q4VBL4;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   07-OCT-2020, entry version 157.
DE   RecName: Full=Free fatty acid receptor 1;
DE   AltName: Full=G-protein coupled receptor 40;
GN   Name=FFAR1; Synonyms=GPR40;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9344866; DOI=10.1006/bbrc.1997.7513;
RA   Sawzdargo M., George S.R., Nguyen T., Xu S., Kolakowski L.F. Jr.,
RA   O'Dowd B.F.;
RT   "A cluster of four novel human G protein-coupled receptor genes occurring
RT   in close proximity to CD22 gene on chromosome 19q13.1.";
RL   Biochem. Biophys. Res. Commun. 239:543-547(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT HIS-211.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=12496284; DOI=10.1074/jbc.m211495200;
RA   Briscoe C.P., Tadayyon M., Andrews J.L., Benson W.G., Chambers J.K.,
RA   Eilert M.M., Ellis C., Elshourbagy N.A., Goetz A.S., Minnick D.T.,
RA   Murdock P.R., Sauls H.R. Jr., Shabon U., Spinage L.D., Strum J.C.,
RA   Szekeres P.G., Tan K.B., Way J.M., Ignar D.M., Wilson S., Muir A.I.;
RT   "The orphan G protein-coupled receptor GPR40 is activated by medium and
RT   long-chain fatty acids.";
RL   J. Biol. Chem. 278:11303-11311(2003).
RN   [4]
RP   TISSUE SPECIFICITY.
RX   PubMed=16289108; DOI=10.1016/j.bbrc.2005.10.161;
RA   Tomita T., Masuzaki H., Noguchi M., Iwakura H., Fujikura J., Tanaka T.,
RA   Ebihara K., Kawamura J., Komoto I., Kawaguchi Y., Fujimoto K., Doi R.,
RA   Shimada Y., Hosoda K., Imamura M., Nakao K.;
RT   "GPR40 gene expression in human pancreas and insulinoma.";
RL   Biochem. Biophys. Res. Commun. 338:1788-1790(2005).
RN   [5]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF TYR-12; TYR-91; HIS-137;
RP   ARG-183; TYR-240; ASN-244 AND ARG-258.
RX   PubMed=17699519; DOI=10.1074/jbc.m705077200;
RA   Sum C.S., Tikhonova I.G., Neumann S., Engel S., Raaka B.M., Costanzi S.,
RA   Gershengorn M.C.;
RT   "Identification of residues important for agonist recognition and
RT   activation in GPR40.";
RL   J. Biol. Chem. 282:29248-29255(2007).
RN   [6]
RP   FUNCTION, MUTAGENESIS OF GLU-145 AND GLU-172, AND SITE.
RX   PubMed=19068482; DOI=10.1074/jbc.m806987200;
RA   Sum C.S., Tikhonova I.G., Costanzi S., Gershengorn M.C.;
RT   "Two arginine-glutamate ionic locks near the extracellular surface of FFAR1
RT   gate receptor activation.";
RL   J. Biol. Chem. 284:3529-3536(2009).
RN   [7]
RP   FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=21570468; DOI=10.1016/j.nbd.2011.04.020;
RA   Kruska N., Reiser G.;
RT   "Phytanic acid and pristanic acid, branched-chain fatty acids associated
RT   with Refsum disease and other inherited peroxisomal disorders, mediate
RT   intracellular Ca2+ signaling through activation of free fatty acid receptor
RT   GPR40.";
RL   Neurobiol. Dis. 43:465-472(2011).
RN   [8]
RP   FUNCTION.
RX   PubMed=23809162; DOI=10.1016/j.immuni.2013.05.015;
RA   Yan Y., Jiang W., Spinetti T., Tardivel A., Castillo R., Bourquin C.,
RA   Guarda G., Tian Z., Tschopp J., Zhou R.;
RT   "Omega-3 fatty acids prevent inflammation and metabolic disorder through
RT   inhibition of NLRP3 inflammasome activation.";
RL   Immunity 38:1154-1163(2013).
RN   [9]
RP   FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=24130766; DOI=10.1371/journal.pone.0076280;
RA   Yabuki C., Komatsu H., Tsujihata Y., Maeda R., Ito R., Matsuda-Nagasumi K.,
RA   Sakuma K., Miyawaki K., Kikuchi N., Takeuchi K., Habata Y., Mori M.;
RT   "A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric
RT   modulator of FFAR1.";
RL   PLoS ONE 8:E76280-E76280(2013).
RN   [10]
RP   FUNCTION.
RX   PubMed=24742677; DOI=10.1074/jbc.m114.568683;
RA   Suckow A.T., Polidori D., Yan W., Chon S., Ma J.Y., Leonard J.,
RA   Briscoe C.P.;
RT   "Alteration of the glucagon axis in GPR120 (FFAR4) knockout mice: a role
RT   for GPR120 in glucagon secretion.";
RL   J. Biol. Chem. 289:15751-15763(2014).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.33 ANGSTROMS) OF 1-211 AND 214-300 IN COMPLEX WITH
RP   THE AGONIST TAK-875, AGONIST BINDING SITES, SUBCELLULAR LOCATION, TOPOLOGY,
RP   DISULFIDE BOND, AND MUTAGENESIS OF TYR-91; ARG-183; TYR-240; ASN-244 AND
RP   ARG-258.
RX   PubMed=25043059; DOI=10.1038/nature13494;
RA   Srivastava A., Yano J., Hirozane Y., Kefala G., Gruswitz F., Snell G.,
RA   Lane W., Ivetac A., Aertgeerts K., Nguyen J., Jennings A., Okada K.;
RT   "High-resolution structure of the human GPR40 receptor bound to allosteric
RT   agonist TAK-875.";
RL   Nature 513:124-127(2014).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.76 ANGSTROMS) OF 1-211 AND 214-300, AND
RP   MUTAGENESIS OF TYR-44; TYR-114 AND SER-123.
RX   PubMed=29695780; DOI=10.1038/s41467-017-01240-w;
RA   Ho J.D., Chau B., Rodgers L., Lu F., Wilbur K.L., Otto K.A., Chen Y.,
RA   Song M., Riley J.P., Yang H.C., Reynolds N.A., Kahl S.D., Lewis A.P.,
RA   Groshong C., Madsen R.E., Conners K., Lineswala J.P., Gheyi T.,
RA   Saflor M.D., Lee M.R., Benach J., Baker K.A., Montrose-Rafizadeh C.,
RA   Genin M.J., Miller A.R., Hamdouchi C.;
RT   "Structural basis for GPR40 allosteric agonism and incretin stimulation.";
RL   Nat. Commun. 9:1645-1645(2018).
CC   -!- FUNCTION: G-protein coupled receptor for medium and long chain
CC       saturated and unsaturated fatty acids that plays an important role in
CC       glucose homeostasis. Fatty acid binding increases glucose-stimulated
CC       insulin secretion, and may also enhance the secretion of glucagon-like
CC       peptide 1 (GLP-1). May also play a role in bone homeostasis; receptor
CC       signaling activates pathways that inhibit osteoclast differentiation
CC       (By similarity). Ligand binding leads to a conformation change that
CC       triggers signaling via G-proteins that activate phospholipase C,
CC       leading to an increase of the intracellular calcium concentration.
CC       Seems to act through a G(q) and G(i)-mediated pathway. Mediates the
CC       anti-inflammatory effects of omega-3 polyunsaturated fatty acids
CC       (PUFAs) via inhibition of NLRP3 inflammasome activation.
CC       {ECO:0000250|UniProtKB:Q76JU9, ECO:0000269|PubMed:12496284,
CC       ECO:0000269|PubMed:17699519, ECO:0000269|PubMed:23809162,
CC       ECO:0000269|PubMed:24130766, ECO:0000269|PubMed:24742677}.
CC   -!- ACTIVITY REGULATION: The receptor is strongly activated by gamma-
CC       linolenic acid, while myristate gives a lower response. It is also
CC       activated by phytanic acid and pristanic acid (PubMed:21570468). Is
CC       also activated by synthetic agonists, such as TAK-875 (fasiglifam);
CC       this compound is a partial agonist and potentiates the activity of the
CC       endogenous ligand gamma-linolenic acid (PubMed:24130766).
CC       {ECO:0000269|PubMed:21570468, ECO:0000269|PubMed:24130766}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:17699519,
CC       ECO:0000269|PubMed:25043059}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:25043059}.
CC   -!- TISSUE SPECIFICITY: Detected in brain and pancreas. Detected in
CC       pancreatic beta cells. {ECO:0000269|PubMed:12496284,
CC       ECO:0000269|PubMed:16289108}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF024687; AAB86710.1; -; Genomic_DNA.
DR   EMBL; BC095536; AAH95536.1; -; mRNA.
DR   EMBL; BC120944; AAI20945.1; -; mRNA.
DR   CCDS; CCDS12458.1; -.
DR   PIR; JC5714; JC5714.
DR   RefSeq; NP_005294.1; NM_005303.2.
DR   PDB; 4PHU; X-ray; 2.33 A; A=1-211, A=214-300.
DR   PDB; 5KW2; X-ray; 2.76 A; A=1-211, A=214-300.
DR   PDB; 5TZR; X-ray; 2.20 A; A=1-211, A=214-300.
DR   PDB; 5TZY; X-ray; 3.22 A; A=1-211, A=214-300.
DR   PDBsum; 4PHU; -.
DR   PDBsum; 5KW2; -.
DR   PDBsum; 5TZR; -.
DR   PDBsum; 5TZY; -.
DR   SMR; O14842; -.
DR   STRING; 9606.ENSP00000246553; -.
DR   BindingDB; O14842; -.
DR   ChEMBL; CHEMBL4422; -.
DR   DrugBank; DB00159; Icosapent.
DR   DrugCentral; O14842; -.
DR   GuidetoPHARMACOLOGY; 225; -.
DR   SwissLipids; SLP:000001550; -.
DR   TCDB; 9.A.14.13.30; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; O14842; 1 site.
DR   iPTMnet; O14842; -.
DR   PhosphoSitePlus; O14842; -.
DR   BioMuta; FFAR1; -.
DR   PaxDb; O14842; -.
DR   PRIDE; O14842; -.
DR   ProteomicsDB; 48273; -.
DR   TopDownProteomics; O14842; -.
DR   Antibodypedia; 15908; 321 antibodies.
DR   DNASU; 2864; -.
DR   Ensembl; ENST00000246553; ENSP00000246553; ENSG00000126266.
DR   GeneID; 2864; -.
DR   KEGG; hsa:2864; -.
DR   UCSC; uc002nzc.3; human.
DR   CTD; 2864; -.
DR   DisGeNET; 2864; -.
DR   EuPathDB; HostDB:ENSG00000126266.3; -.
DR   GeneCards; FFAR1; -.
DR   HGNC; HGNC:4498; FFAR1.
DR   HPA; ENSG00000126266; Tissue enhanced (bone marrow, brain, ovary, pancreas).
DR   MIM; 603820; gene.
DR   neXtProt; NX_O14842; -.
DR   OpenTargets; ENSG00000126266; -.
DR   PharmGKB; PA28887; -.
DR   eggNOG; ENOG502QVCS; Eukaryota.
DR   GeneTree; ENSGT00990000203527; -.
DR   HOGENOM; CLU_009579_8_4_1; -.
DR   InParanoid; O14842; -.
DR   KO; K04325; -.
DR   OMA; RRPRYSW; -.
DR   OrthoDB; 1074213at2759; -.
DR   PhylomeDB; O14842; -.
DR   TreeFam; TF350010; -.
DR   PathwayCommons; O14842; -.
DR   Reactome; R-HSA-381771; Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1).
DR   Reactome; R-HSA-400511; Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP).
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-434316; Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion.
DR   Reactome; R-HSA-444209; Free fatty acid receptors.
DR   SIGNOR; O14842; -.
DR   BioGRID-ORCS; 2864; 1 hit in 867 CRISPR screens.
DR   GeneWiki; Free_fatty_acid_receptor_1; -.
DR   GenomeRNAi; 2864; -.
DR   Pharos; O14842; Tchem.
DR   PRO; PR:O14842; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; O14842; protein.
DR   Bgee; ENSG00000126266; Expressed in islet of Langerhans and 56 other tissues.
DR   Genevisible; O14842; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0045125; F:bioactive lipid receptor activity; IDA:UniProtKB.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; TAS:ProtInc.
DR   GO; GO:0008289; F:lipid binding; IEA:UniProtKB-KW.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0042593; P:glucose homeostasis; IEA:Ensembl.
DR   GO; GO:0030073; P:insulin secretion; IEA:Ensembl.
DR   GO; GO:0032691; P:negative regulation of interleukin-1 beta production; IMP:UniProtKB.
DR   GO; GO:0051928; P:positive regulation of calcium ion transport; IDA:UniProtKB.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IDA:UniProtKB.
DR   GO; GO:0032024; P:positive regulation of insulin secretion; IEA:Ensembl.
DR   GO; GO:0070542; P:response to fatty acid; IDA:UniProtKB.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR013312; GPR40-rel_orph.
DR   InterPro; IPR013313; GPR40_recept_FA.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01905; FATTYACIDR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01904; GPR40FAMILY.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Lipid-binding; Membrane; Polymorphism; Receptor;
KW   Reference proteome; Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..300
FT                   /note="Free fatty acid receptor 1"
FT                   /id="PRO_0000069567"
FT   TOPO_DOM        1..8
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255, ECO:0000269|PubMed:25043059"
FT   TRANSMEM        9..31
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255, ECO:0000269|PubMed:25043059"
FT   TOPO_DOM        32..41
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255, ECO:0000269|PubMed:25043059"
FT   TRANSMEM        42..64
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255, ECO:0000269|PubMed:25043059"
FT   TOPO_DOM        65..79
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255, ECO:0000269|PubMed:25043059"
FT   TRANSMEM        80..101
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255, ECO:0000269|PubMed:25043059"
FT   TOPO_DOM        102..121
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255, ECO:0000269|PubMed:25043059"
FT   TRANSMEM        122..142
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255, ECO:0000269|PubMed:25043059"
FT   TOPO_DOM        143..178
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255, ECO:0000269|PubMed:25043059"
FT   TRANSMEM        179..200
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255, ECO:0000269|PubMed:25043059"
FT   TOPO_DOM        201..223
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255, ECO:0000269|PubMed:25043059"
FT   TRANSMEM        224..248
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255, ECO:0000269|PubMed:25043059"
FT   TOPO_DOM        249..256
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255, ECO:0000269|PubMed:25043059"
FT   TRANSMEM        257..279
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255, ECO:0000269|PubMed:25043059"
FT   TOPO_DOM        280..300
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255, ECO:0000269|PubMed:25043059"
FT   REGION          87..91
FT                   /note="Agonist binding"
FT                   /evidence="ECO:0000269|PubMed:25043059"
FT   BINDING         183
FT                   /note="Agonist"
FT                   /evidence="ECO:0000269|PubMed:25043059"
FT   BINDING         240
FT                   /note="Agonist"
FT                   /evidence="ECO:0000269|PubMed:25043059"
FT   BINDING         258
FT                   /note="Agonist"
FT                   /evidence="ECO:0000269|PubMed:25043059"
FT   SITE            145
FT                   /note="Important for receptor activation"
FT                   /evidence="ECO:0000269|PubMed:19068482"
FT   SITE            172
FT                   /note="Important for receptor activation"
FT                   /evidence="ECO:0000269|PubMed:19068482"
FT   CARBOHYD        155
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        79..170
FT                   /evidence="ECO:0000269|PubMed:25043059"
FT   VARIANT         211
FT                   /note="R -> H (in dbSNP:rs2301151)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_020076"
FT   MUTAGEN         12
FT                   /note="Y->A: Reduces cell surface expression and response
FT                   to linolenic acid and synthetic agonists."
FT                   /evidence="ECO:0000269|PubMed:17699519"
FT   MUTAGEN         44
FT                   /note="Y->F: Reduces response to synthetic agonists."
FT                   /evidence="ECO:0000269|PubMed:29695780"
FT   MUTAGEN         91
FT                   /note="Y->A: Reduces response to linolenic acid. Reduces
FT                   response to synthetic agonists."
FT                   /evidence="ECO:0000269|PubMed:17699519,
FT                   ECO:0000269|PubMed:25043059"
FT   MUTAGEN         114
FT                   /note="Y->F: Reduces response to synthetic agonists."
FT                   /evidence="ECO:0000269|PubMed:29695780"
FT   MUTAGEN         123
FT                   /note="S->A: Reduces response to synthetic agonists."
FT                   /evidence="ECO:0000269|PubMed:29695780"
FT   MUTAGEN         137
FT                   /note="H->A: Reduces response to linolenic acid. Reduces
FT                   response to synthetic agonists."
FT                   /evidence="ECO:0000269|PubMed:17699519,
FT                   ECO:0000269|PubMed:25043059"
FT   MUTAGEN         145
FT                   /note="E->A: Constitutive receptor signaling."
FT                   /evidence="ECO:0000269|PubMed:19068482"
FT   MUTAGEN         172
FT                   /note="E->A: Constitutive receptor signaling."
FT                   /evidence="ECO:0000269|PubMed:19068482"
FT   MUTAGEN         183
FT                   /note="R->A: Reduces response to linolenic acid. Strongly
FT                   reduces response to synthetic agonists."
FT                   /evidence="ECO:0000269|PubMed:17699519,
FT                   ECO:0000269|PubMed:25043059"
FT   MUTAGEN         240
FT                   /note="Y->A: Reduces response to linolenic acid. Reduces
FT                   response to synthetic agonists."
FT                   /evidence="ECO:0000269|PubMed:17699519,
FT                   ECO:0000269|PubMed:25043059"
FT   MUTAGEN         244
FT                   /note="N->A: Reduces response to linolenic acid. Reduces
FT                   response to synthetic agonists."
FT                   /evidence="ECO:0000269|PubMed:17699519,
FT                   ECO:0000269|PubMed:25043059"
FT   MUTAGEN         258
FT                   /note="R->A: Strongly reduces response to linolenic acid.
FT                   Strongly reduces response to synthetic agonists."
FT                   /evidence="ECO:0000269|PubMed:17699519,
FT                   ECO:0000269|PubMed:25043059"
FT   MUTAGEN         258
FT                   /note="R->K: Reduces response to linolenic acid. Strongly
FT                   reduces response to synthetic agonists."
FT                   /evidence="ECO:0000269|PubMed:17699519"
FT   CONFLICT        24
FT                   /note="V -> A (in Ref. 2; AAH95536)"
FT                   /evidence="ECO:0000305"
FT   HELIX           5..36
FT                   /evidence="ECO:0000244|PDB:5TZR"
FT   HELIX           40..67
FT                   /evidence="ECO:0000244|PDB:5TZR"
FT   TURN            68..70
FT                   /evidence="ECO:0000244|PDB:5TZR"
FT   HELIX           76..78
FT                   /evidence="ECO:0000244|PDB:5TZR"
FT   HELIX           79..109
FT                   /evidence="ECO:0000244|PDB:5TZR"
FT   HELIX           111..117
FT                   /evidence="ECO:0000244|PDB:5KW2"
FT   HELIX           121..145
FT                   /evidence="ECO:0000244|PDB:5TZR"
FT   STRAND          149..151
FT                   /evidence="ECO:0000244|PDB:5TZR"
FT   STRAND          169..171
FT                   /evidence="ECO:0000244|PDB:5TZR"
FT   HELIX           176..190
FT                   /evidence="ECO:0000244|PDB:5TZR"
FT   HELIX           192..211
FT                   /evidence="ECO:0000244|PDB:5TZR"
FT   HELIX           214..235
FT                   /evidence="ECO:0000244|PDB:5TZR"
FT   HELIX           237..249
FT                   /evidence="ECO:0000244|PDB:5TZR"
FT   HELIX           256..266
FT                   /evidence="ECO:0000244|PDB:5TZR"
FT   HELIX           268..275
FT                   /evidence="ECO:0000244|PDB:5TZR"
SQ   SEQUENCE   300 AA;  31457 MW;  77EF27DACD93E80B CRC64;
     MDLPPQLSFG LYVAAFALGF PLNVLAIRGA TAHARLRLTP SLVYALNLGC SDLLLTVSLP
     LKAVEALASG AWPLPASLCP VFAVAHFFPL YAGGGFLAAL SAGRYLGAAF PLGYQAFRRP
     CYSWGVCAAI WALVLCHLGL VFGLEAPGGW LDHSNTSLGI NTPVNGSPVC LEAWDPASAG
     PARFSLSLLL FFLPLAITAF CYVGCLRALA RSGLTHRRKL RAAWVAGGAL LTLLLCVGPY
     NASNVASFLY PNLGGSWRKL GLITGAWSVV LNPLVTGYLG RGPGLKTVCA ARTQGGKSQK
//
ID   DRD4_HUMAN              Reviewed;         419 AA.
AC   P21917; B0M0J7; Q7Z7Q5; Q8NGM5;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   10-APR-2019, sequence version 3.
DT   12-AUG-2020, entry version 194.
DE   RecName: Full=D(4) dopamine receptor;
DE   AltName: Full=D(2C) dopamine receptor;
DE   AltName: Full=Dopamine D4 receptor;
GN   Name=DRD4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE D4.7), POLYMORPHISM, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=1319557; DOI=10.1038/358149a0;
RA   van Tol H.H., Wu C.M., Guan H.C., Ohara K., Bunzow J.R., Civelli O.,
RA   Kennedy J., Seeman P., Niznik H.B., Jovanovic V.;
RT   "Multiple dopamine D4 receptor variants in the human population.";
RL   Nature 358:149-152(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE D4.2), FUNCTION, AND SUBCELLULAR
RP   LOCATION.
RC   TISSUE=Brain;
RX   PubMed=1840645; DOI=10.1038/350610a0;
RA   van Tol H.H.M., Bunzow J.R., Guan H.-C., Sunahara R.K., Seeman P.,
RA   Niznik H.B., Civelli O.;
RT   "Cloning of the gene for a human dopamine D4 receptor with high affinity
RT   for the antipsychotic clozapine.";
RL   Nature 350:610-614(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE D.4.4).
RA   Suwa M., Sato T., Okouchi I., Arita M., Futami K., Matsumoto S.,
RA   Tsutsumi S., Aburatani H., Asai K., Akiyama Y.;
RT   "Genome-wide discovery and analysis of human seven transmembrane helix
RT   receptor genes.";
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ALLELE D.4.4).
RC   TISSUE=Brain;
RA   Kaighin V.A., Martin A.L., Aronstam R.S.;
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (ALLELE D4.4).
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (ALLELE D.4.4).
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   POLYMORPHISM.
RX   PubMed=8353495; DOI=10.1093/hmg/2.6.767;
RA   Lichter J.B., Barr C.L., Kennedy J.L., Van Tol H.H., Kidd K.K., Livak K.J.;
RT   "A hypervariable segment in the human dopamine receptor D4 (DRD4) gene.";
RL   Hum. Mol. Genet. 2:767-773(1993).
RN   [8]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=7512953;
RA   Chio C.L., Drong R.F., Riley D.T., Gill G.S., Slightom J.L., Huff R.M.;
RT   "D4 dopamine receptor-mediated signaling events determined in transfected
RT   Chinese hamster ovary cells.";
RL   J. Biol. Chem. 269:11813-11819(1994).
RN   [9]
RP   POLYMORPHISM, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=8078498;
RA   Asghari V., Schoots O., van Kats S., Ohara K., Jovanovic V., Guan H.-C.,
RA   Bunzow J.R., Petronis A., Van Tol H.H.M.;
RT   "Dopamine D4 receptor repeat: analysis of different native and mutant forms
RT   of the human and rat genes.";
RL   Mol. Pharmacol. 46:364-373(1994).
RN   [10]
RP   TISSUE SPECIFICITY.
RX   PubMed=7769992; DOI=10.1016/0169-328x(94)00245-a;
RA   Matsumoto M., Hidaka K., Tada S., Tasaki Y., Yamaguchi T.;
RT   "Full-length cDNA cloning and distribution of human dopamine D4 receptor.";
RL   Brain Res. Mol. Brain Res. 29:157-162(1995).
RN   [11]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=7643093; DOI=10.1046/j.1471-4159.1995.65031157.x;
RA   Asghari V., Sanyal S., Buchwaldt S., Paterson A., Jovanovic V.,
RA   Van Tol H.H.;
RT   "Modulation of intracellular cyclic AMP levels by different human dopamine
RT   D4 receptor variants.";
RL   J. Neurochem. 65:1157-1165(1995).
RN   [12]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=9003072; DOI=10.1046/j.1471-4159.1997.68020804.x;
RA   Lanau F., Zenner M.T., Civelli O., Hartman D.S.;
RT   "Epinephrine and norepinephrine act as potent agonists at the recombinant
RT   human dopamine D4 receptor.";
RL   J. Neurochem. 68:804-812(1997).
RN   [13]
RP   INTERACTION WITH GPRASP1.
RX   PubMed=12142540; DOI=10.1126/science.1073308;
RA   Whistler J.L., Enquist J., Marley A., Fong J., Gladher F., Tsuruda P.,
RA   Murray S.R., Von Zastrow M.;
RT   "Modulation of postendocytic sorting of G protein-coupled receptors.";
RL   Science 297:615-620(2002).
RN   [14]
RP   FUNCTION, ACTIVITY REGULATION, SUBCELLULAR LOCATION, AND POLYMORPHISM.
RX   PubMed=16423344; DOI=10.1016/j.ejphar.2005.11.063;
RA   Czermak C., Lehofer M., Liebmann P.M., Traynor J.;
RT   "[35S]GTPgammaS binding at the human dopamine D4 receptor variants hD4.2,
RT   hD4.4 and hD4.7 following stimulation by dopamine, epinephrine and
RT   norepinephrine.";
RL   Eur. J. Pharmacol. 531:20-24(2006).
RN   [15]
RP   UBIQUITINATION, AND INTERACTION WITH KLHL12.
RX   PubMed=18303015; DOI=10.1074/jbc.m708473200;
RA   Rondou P., Haegeman G., Vanhoenacker P., Van Craenenbroeck K.;
RT   "BTB Protein KLHL12 targets the dopamine D4 receptor for ubiquitination by
RT   a Cul3-based E3 ligase.";
RL   J. Biol. Chem. 283:11083-11096(2008).
RN   [16]
RP   POSSIBLE INTERACTION WITH ADORA2A.
RX   PubMed=20836733; DOI=10.3109/10799893.2010.513842;
RA   Woods A.S.;
RT   "The dopamine D(4) receptor, the ultimate disordered protein.";
RL   J. Recept. Signal Transduct. 30:331-336(2010).
RN   [17]
RP   UBIQUITINATION, AND SUBCELLULAR LOCATION.
RX   PubMed=20100572; DOI=10.1016/j.cellsig.2010.01.014;
RA   Rondou P., Skieterska K., Packeu A., Lintermans B., Vanhoenacker P.,
RA   Vauquelin G., Haegeman G., Van Craenenbroeck K.;
RT   "KLHL12-mediated ubiquitination of the dopamine D4 receptor does not target
RT   the receptor for degradation.";
RL   Cell. Signal. 22:900-913(2010).
RN   [18]
RP   HOMOOLIGOMERIZATION, AND INTERACTION WITH DRD2.
RX   PubMed=21184734; DOI=10.1016/j.bbrc.2010.12.083;
RA   Borroto-Escuela D.O., Van Craenenbroeck K., Romero-Fernandez W.,
RA   Guidolin D., Woods A.S., Rivera A., Haegeman G., Agnati L.F.,
RA   Tarakanov A.O., Fuxe K.;
RT   "Dopamine D2 and D4 receptor heteromerization and its allosteric receptor-
RT   receptor interactions.";
RL   Biochem. Biophys. Res. Commun. 404:928-934(2011).
RN   [19]
RP   PALMITOYLATION AT CYS-419, MUTAGENESIS OF CYS-418 AND CYS-419, SUBCELLULAR
RP   LOCATION, AND FUNCTION.
RX   PubMed=27659709; DOI=10.1016/j.bbrc.2016.09.094;
RA   Zhang X., Kim K.M.;
RT   "Palmitoylation of the carboxyl-terminal tail of dopamine D4 receptor is
RT   required for surface expression, endocytosis, and signaling.";
RL   Biochem. Biophys. Res. Commun. 479:398-403(2016).
RN   [20]
RP   3D-STRUCTURE MODELING.
RX   PubMed=1358063; DOI=10.1042/bj2870277;
RA   Livingstone C.D., Strange P.G., Naylor L.H.;
RT   "Molecular modelling of D2-like dopamine receptors.";
RL   Biochem. J. 287:277-282(1992).
RN   [21] {ECO:0000244|PDB:5WIU, ECO:0000244|PDB:5WIV}
RP   X-RAY CRYSTALLOGRAPHY (1.96 ANGSTROMS) OF 1-228 AND 335-419 IN COMPLEX WITH
RP   NEMONAPRIDE, FUNCTION, ACTIVITY REGULATION, SUBCELLULAR LOCATION, TOPOLOGY,
RP   DISULFIDE BONDS, AND MUTAGENESIS OF VAL-382.
RX   PubMed=29051383; DOI=10.1126/science.aan5468;
RA   Wang S., Wacker D., Levit A., Che T., Betz R.M., McCorvy J.D.,
RA   Venkatakrishnan A.J., Huang X.P., Dror R.O., Shoichet B.K., Roth B.L.;
RT   "D4 dopamine receptor high-resolution structures enable the discovery of
RT   selective agonists.";
RL   Science 358:381-386(2017).
RN   [22]
RP   VARIANT GLY-194.
RX   PubMed=7726213; DOI=10.1002/ajmg.1320540419;
RA   Seeman P., Ulpian C., Chouinard G., van Tol H.H.M., Dwosh H.,
RA   Lieberman J.A., Siminovitch K., Liu I.S.C., Waye J., Voruganti P.,
RA   Hudson C., Serjeant G.R., Masibay A.S., Seeman M.V.;
RT   "Dopamine D4 receptor variant, D4-glycine-194, in Africans, but not in
RT   Caucasians: no association with schizophrenia.";
RL   Am. J. Med. Genet. 54:384-390(1994).
CC   -!- FUNCTION: Dopamine receptor responsible for neuronal signaling in the
CC       mesolimbic system of the brain, an area of the brain that regulates
CC       emotion and complex behavior. Activated by dopamine, but also by
CC       epinephrine and norepinephrine, and by numerous synthetic agonists and
CC       drugs (PubMed:9003072, PubMed:16423344, PubMed:27659709,
CC       PubMed:29051383). Agonist binding triggers signaling via G proteins
CC       that inhibit adenylyl cyclase (PubMed:7512953, PubMed:7643093,
CC       PubMed:16423344, PubMed:27659709, PubMed:29051383). Modulates the
CC       circadian rhythm of contrast sensitivity by regulating the rhythmic
CC       expression of NPAS2 in the retinal ganglion cells (By similarity).
CC       {ECO:0000250|UniProtKB:P51436, ECO:0000269|PubMed:16423344,
CC       ECO:0000269|PubMed:1840645, ECO:0000269|PubMed:27659709,
CC       ECO:0000269|PubMed:29051383, ECO:0000269|PubMed:7512953,
CC       ECO:0000269|PubMed:7643093, ECO:0000269|PubMed:8078498,
CC       ECO:0000269|PubMed:9003072}.
CC   -!- ACTIVITY REGULATION: Signaling in response to agonists such as
CC       dopamine, epinephrine and norepinephrine is modulated by Na(+); lower
CC       Na(+) levels result in higher receptor activity (in vitro).
CC       {ECO:0000269|PubMed:16423344, ECO:0000269|PubMed:29051383}.
CC   -!- SUBUNIT: Forms homo- and heterooligomers with DRD2. D4.7 allele
CC       exhibits higher affinity for homodimers compared to DRD2 heterodimers,
CC       while alleles D42. and 4.4 have similar affinities for both. The
CC       interaction with DRD2 may modulate agonist-induced downstream signaling
CC       (PubMed:21184734). Interacts with CLIC6 (By similarity). Interacts with
CC       GPRASP1 (PubMed:12142540). May interact with ADORA2A (PubMed:20836733).
CC       Interacts with KLHL12 (PubMed:18303015). {ECO:0000250|UniProtKB:P30729,
CC       ECO:0000269|PubMed:12142540, ECO:0000269|PubMed:18303015,
CC       ECO:0000269|PubMed:21184734}.
CC   -!- INTERACTION:
CC       P21917; P35368: ADRA1B; NbExp=2; IntAct=EBI-8592297, EBI-490017;
CC       P21917; P08588: ADRB1; NbExp=2; IntAct=EBI-8592297, EBI-991009;
CC       P21917; P14416-1: DRD2; NbExp=4; IntAct=EBI-8592297, EBI-11686358;
CC       P21917; P21917: DRD4; NbExp=5; IntAct=EBI-8592297, EBI-8592297;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:1319557,
CC       ECO:0000269|PubMed:16423344, ECO:0000269|PubMed:1840645,
CC       ECO:0000269|PubMed:20100572, ECO:0000269|PubMed:27659709,
CC       ECO:0000269|PubMed:29051383, ECO:0000269|PubMed:7512953,
CC       ECO:0000269|PubMed:7643093, ECO:0000269|PubMed:8078498,
CC       ECO:0000269|PubMed:9003072}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:20100572, ECO:0000269|PubMed:29051383}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in retina. Detected at much lower
CC       levels in brain, in amygdala, thalamus, hypothalamus, cerebellum and
CC       pituitary. {ECO:0000269|PubMed:7769992}.
CC   -!- PTM: Polyubiquitinated by the BCR(KLHL12) E3 ubiquitin ligase complex:
CC       polyubiquitination does not lead to degradation of DRD4 protein.
CC       {ECO:0000269|PubMed:18303015, ECO:0000269|PubMed:20100572}.
CC   -!- PTM: Palmitoylated. Palmitoylation of the C-terminal Cys is important
CC       for normal expression at the cell membrane.
CC       {ECO:0000269|PubMed:27659709}.
CC   -!- POLYMORPHISM: The number of repeats of 16 amino acids in the third
CC       cytoplasmic loop is highly polymorphic and varies among different
CC       alleles. Alleles corresponding in size to a 2 (D4.2), 3 (D4.3), 4
CC       (D4.4), 5 (D4.5), 6 (D4.6), 7 (D4.7) and 9 (D4.9) repeats have been
CC       described. The sequence shown is that of allele D4.4. The polymorphic
CC       repeat sequence has little influence on DRD4-binding profiles and might
CC       not be essential for G protein interaction.
CC       {ECO:0000269|PubMed:1319557, ECO:0000269|PubMed:16423344,
CC       ECO:0000269|PubMed:8078498, ECO:0000269|PubMed:8353495}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAL58637.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L12398; AAB59386.1; -; mRNA.
DR   EMBL; L12397; AAL58637.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AB065765; BAC05985.1; -; Genomic_DNA.
DR   EMBL; EU432112; ABY87911.1; -; mRNA.
DR   EMBL; AP006284; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471158; EAX02369.1; -; Genomic_DNA.
DR   CCDS; CCDS7710.1; -.
DR   PIR; S15079; DYHUD4.
DR   PIR; S24195; S24195.
DR   RefSeq; NP_000788.2; NM_000797.3.
DR   PDB; 5WIU; X-ray; 1.96 A; A=1-228, A=335-419.
DR   PDB; 5WIV; X-ray; 2.14 A; A=1-228, A=335-419.
DR   PDBsum; 5WIU; -.
DR   PDBsum; 5WIV; -.
DR   SMR; P21917; -.
DR   BioGRID; 108149; 14.
DR   CORUM; P21917; -.
DR   DIP; DIP-59865N; -.
DR   IntAct; P21917; 3.
DR   MINT; P21917; -.
DR   ChEMBL; CHEMBL219; -.
DR   DrugBank; DB00543; Amoxapine.
DR   DrugBank; DB00714; Apomorphine.
DR   DrugBank; DB01238; Aripiprazole.
DR   DrugBank; DB14185; Aripiprazole lauroxil.
DR   DrugBank; DB06216; Asenapine.
DR   DrugBank; DB01200; Bromocriptine.
DR   DrugBank; DB00490; Buspirone.
DR   DrugBank; DB00248; Cabergoline.
DR   DrugBank; DB00477; Chlorpromazine.
DR   DrugBank; DB00363; Clozapine.
DR   DrugBank; DB13345; Dihydroergocristine.
DR   DrugBank; DB00988; Dopamine.
DR   DrugBank; DB11275; Epicriptine.
DR   DrugBank; DB01049; Ergoloid mesylate.
DR   DrugBank; DB04908; Flibanserin.
DR   DrugBank; DB04946; Iloperidone.
DR   DrugBank; DB01235; Levodopa.
DR   DrugBank; DB00589; Lisuride.
DR   DrugBank; DB00408; Loxapine.
DR   DrugBank; DB01403; Methotrimeprazine.
DR   DrugBank; DB00334; Olanzapine.
DR   DrugBank; DB01267; Paliperidone.
DR   DrugBank; DB12061; Pardoprunox.
DR   DrugBank; DB01186; Pergolide.
DR   DrugBank; DB08922; Perospirone.
DR   DrugBank; DB09286; Pipamperone.
DR   DrugBank; DB00413; Pramipexole.
DR   DrugBank; DB00420; Promazine.
DR   DrugBank; DB00777; Propiomazine.
DR   DrugBank; DB01224; Quetiapine.
DR   DrugBank; DB00409; Remoxipride.
DR   DrugBank; DB00268; Ropinirole.
DR   DrugBank; DB05271; Rotigotine.
DR   DrugBank; DB06477; Sumanirole.
DR   DrugBank; DB00372; Thiethylperazine.
DR   DrugBank; DB00246; Ziprasidone.
DR   DrugCentral; P21917; -.
DR   GuidetoPHARMACOLOGY; 217; -.
DR   GlyGen; P21917; 1 site.
DR   iPTMnet; P21917; -.
DR   PhosphoSitePlus; P21917; -.
DR   BioMuta; DRD4; -.
DR   DMDM; 1345939; -.
DR   MassIVE; P21917; -.
DR   PeptideAtlas; P21917; -.
DR   PRIDE; P21917; -.
DR   ProteomicsDB; 53940; -.
DR   Antibodypedia; 22579; 443 antibodies.
DR   DNASU; 1815; -.
DR   Ensembl; ENST00000176183; ENSP00000176183; ENSG00000069696.
DR   Ensembl; ENST00000611962; ENSP00000478431; ENSG00000276825.
DR   GeneID; 1815; -.
DR   KEGG; hsa:1815; -.
DR   UCSC; uc001lqp.3; human.
DR   CTD; 1815; -.
DR   DisGeNET; 1815; -.
DR   EuPathDB; HostDB:ENSG00000069696.6; -.
DR   GeneCards; DRD4; -.
DR   HGNC; HGNC:3025; DRD4.
DR   HPA; ENSG00000069696; Tissue enriched (retina).
DR   MalaCards; DRD4; -.
DR   MIM; 126452; gene.
DR   neXtProt; NX_P21917; -.
DR   OpenTargets; ENSG00000069696; -.
DR   PharmGKB; PA27480; -.
DR   GeneTree; ENSGT00940000160974; -.
DR   HOGENOM; CLU_009579_11_1_1; -.
DR   InParanoid; P21917; -.
DR   KO; K04147; -.
DR   OMA; VVHITQA; -.
DR   OrthoDB; 1215361at2759; -.
DR   PhylomeDB; P21917; -.
DR   TreeFam; TF334382; -.
DR   PathwayCommons; P21917; -.
DR   Reactome; R-HSA-390651; Dopamine receptors.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   SIGNOR; P21917; -.
DR   BioGRID-ORCS; 1815; 4 hits in 866 CRISPR screens.
DR   ChiTaRS; DRD4; human.
DR   GeneWiki; Dopamine_receptor_D4; -.
DR   GenomeRNAi; 1815; -.
DR   Pharos; P21917; Tchem.
DR   PRO; PR:P21917; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; P21917; protein.
DR   Bgee; ENSG00000069696; Expressed in muscle tissue and 106 other tissues.
DR   Genevisible; P21917; HS.
DR   GO; GO:0030425; C:dendrite; IBA:GO_Central.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:SYSCILIA_CCNET.
DR   GO; GO:0098794; C:postsynapse; IEA:GOC.
DR   GO; GO:0035240; F:dopamine binding; IDA:UniProtKB.
DR   GO; GO:0004952; F:dopamine neurotransmitter receptor activity; IDA:BHF-UCL.
DR   GO; GO:0001591; F:dopamine neurotransmitter receptor activity, coupled via Gi/Go; IDA:UniProtKB.
DR   GO; GO:0008144; F:drug binding; IDA:BHF-UCL.
DR   GO; GO:0051379; F:epinephrine binding; IDA:UniProtKB.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0004993; F:G protein-coupled serotonin receptor activity; IBA:GO_Central.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0030594; F:neurotransmitter receptor activity; IBA:GO_Central.
DR   GO; GO:0051380; F:norepinephrine binding; IDA:UniProtKB.
DR   GO; GO:0015459; F:potassium channel regulator activity; NAS:BHF-UCL.
DR   GO; GO:0017124; F:SH3 domain binding; IDA:BHF-UCL.
DR   GO; GO:0000187; P:activation of MAPK activity; IDA:BHF-UCL.
DR   GO; GO:0007195; P:adenylate cyclase-inhibiting dopamine receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0008344; P:adult locomotory behavior; ISS:BHF-UCL.
DR   GO; GO:0050482; P:arachidonic acid secretion; IDA:BHF-UCL.
DR   GO; GO:0001662; P:behavioral fear response; NAS:BHF-UCL.
DR   GO; GO:0048148; P:behavioral response to cocaine; ISS:BHF-UCL.
DR   GO; GO:0048149; P:behavioral response to ethanol; TAS:BHF-UCL.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IC:BHF-UCL.
DR   GO; GO:0007268; P:chemical synaptic transmission; IBA:GO_Central.
DR   GO; GO:0042417; P:dopamine metabolic process; IC:BHF-UCL.
DR   GO; GO:0007212; P:dopamine receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0042596; P:fear response; ISS:BHF-UCL.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007187; P:G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; IBA:GO_Central.
DR   GO; GO:0060080; P:inhibitory postsynaptic potential; ISS:BHF-UCL.
DR   GO; GO:0050709; P:negative regulation of protein secretion; IDA:BHF-UCL.
DR   GO; GO:1901386; P:negative regulation of voltage-gated calcium channel activity; IDA:BHF-UCL.
DR   GO; GO:0051586; P:positive regulation of dopamine uptake involved in synaptic transmission; IC:BHF-UCL.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IDA:BHF-UCL.
DR   GO; GO:0032417; P:positive regulation of sodium:proton antiporter activity; IDA:BHF-UCL.
DR   GO; GO:0042752; P:regulation of circadian rhythm; ISS:UniProtKB.
DR   GO; GO:0042053; P:regulation of dopamine metabolic process; ISS:BHF-UCL.
DR   GO; GO:0099149; P:regulation of postsynaptic neurotransmitter receptor internalization; IEA:Ensembl.
DR   GO; GO:0001975; P:response to amphetamine; ISS:BHF-UCL.
DR   GO; GO:0034776; P:response to histamine; IDA:BHF-UCL.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   GO; GO:0035176; P:social behavior; NAS:BHF-UCL.
DR   InterPro; IPR002185; Dopamine_D4_rcpt.
DR   InterPro; IPR000929; Dopamine_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   PANTHER; PTHR24248:SF143; PTHR24248:SF143; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00569; DOPAMINED4R.
DR   PRINTS; PR00242; DOPAMINER.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Biological rhythms; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane;
KW   Metal-binding; Palmitate; Polymorphism; Receptor; Reference proteome;
KW   Repeat; Sodium; Transducer; Transmembrane; Transmembrane helix;
KW   Ubl conjugation.
FT   CHAIN           1..419
FT                   /note="D(4) dopamine receptor"
FT                   /id="PRO_0000069401"
FT   TOPO_DOM        1..29
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:29051383"
FT   TRANSMEM        30..50
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000269|PubMed:29051383"
FT   TOPO_DOM        51..71
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:29051383"
FT   TRANSMEM        72..92
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000269|PubMed:29051383"
FT   TOPO_DOM        93..110
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:29051383"
FT   TRANSMEM        111..131
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000269|PubMed:29051383"
FT   TOPO_DOM        132..152
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:29051383"
FT   TRANSMEM        153..173
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000269|PubMed:29051383"
FT   TOPO_DOM        174..192
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:29051383"
FT   TRANSMEM        193..213
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000269|PubMed:29051383"
FT   TOPO_DOM        214..346
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:29051383"
FT   TRANSMEM        347..367
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000269|PubMed:29051383"
FT   TOPO_DOM        368..382
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:29051383"
FT   TRANSMEM        383..403
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000269|PubMed:29051383"
FT   TOPO_DOM        404..419
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:29051383"
FT   REPEAT          249..264
FT                   /note="1; approximate"
FT   REPEAT          265..280
FT                   /note="2"
FT   REPEAT          281..296
FT                   /note="3"
FT   REPEAT          297..312
FT                   /note="4; approximate"
FT   REGION          249..312
FT                   /note="4 X 16 AA approximate tandem repeats of [PA]-A-P-G-
FT                   L-P-[PQR]-[DG]-P-C-G-P-D-C-A-P"
FT   METAL           80
FT                   /note="Sodium"
FT                   /evidence="ECO:0000305|PubMed:29051383"
FT   METAL           122
FT                   /note="Sodium"
FT                   /evidence="ECO:0000305|PubMed:29051383"
FT   BINDING         115
FT                   /note="Agonist"
FT                   /evidence="ECO:0000305|PubMed:29051383"
FT   LIPID           419
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:27659709"
FT   CARBOHYD        3
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        108..185
FT                   /evidence="ECO:0000244|PDB:5WIU, ECO:0000244|PDB:5WIV,
FT                   ECO:0000255|PROSITE-ProRule:PRU00521,
FT                   ECO:0000269|PubMed:29051383"
FT   DISULFID        372..375
FT                   /evidence="ECO:0000244|PDB:5WIU, ECO:0000244|PDB:5WIV,
FT                   ECO:0000269|PubMed:29051383"
FT   VARIANT         194
FT                   /note="V -> G (in dbSNP:rs1800443)"
FT                   /evidence="ECO:0000269|PubMed:7726213"
FT                   /id="VAR_003464"
FT   VARIANT         265..296
FT                   /note="Missing (in allele D4.2)"
FT                   /evidence="ECO:0000269|PubMed:1840645"
FT                   /id="VAR_003465"
FT   VARIANT         284
FT                   /note="S -> GLPPDPCGPDCAPPAPGLPQDPCGPDCAPPAPGLPRGPCGPDCAPPA
FT                   PG (in allele D4.7)"
FT                   /evidence="ECO:0000269|PubMed:1319557"
FT                   /id="VAR_081438"
FT   MUTAGEN         382
FT                   /note="V->Y: Increased basal level of G protein-mediated
FT                   signaling."
FT                   /evidence="ECO:0000269|PubMed:29051383"
FT   MUTAGEN         418
FT                   /note="C->G: No effect on palmitoylation."
FT                   /evidence="ECO:0000269|PubMed:27659709"
FT   MUTAGEN         419
FT                   /note="C->G: Loss of palmitoylation."
FT                   /evidence="ECO:0000269|PubMed:27659709"
FT   CONFLICT        237
FT                   /note="R -> F (in Ref. 2; BAC05985)"
FT                   /evidence="ECO:0000305"
FT   HELIX           35..61
FT                   /evidence="ECO:0000244|PDB:5WIU"
FT   HELIX           63..65
FT                   /evidence="ECO:0000244|PDB:5WIU"
FT   HELIX           68..86
FT                   /evidence="ECO:0000244|PDB:5WIU"
FT   HELIX           88..96
FT                   /evidence="ECO:0000244|PDB:5WIU"
FT   TURN            97..99
FT                   /evidence="ECO:0000244|PDB:5WIU"
FT   HELIX           105..138
FT                   /evidence="ECO:0000244|PDB:5WIU"
FT   STRAND          144..147
FT                   /evidence="ECO:0000244|PDB:5WIU"
FT   HELIX           151..171
FT                   /evidence="ECO:0000244|PDB:5WIU"
FT   HELIX           190..200
FT                   /evidence="ECO:0000244|PDB:5WIU"
FT   TURN            201..203
FT                   /evidence="ECO:0000244|PDB:5WIU"
FT   HELIX           204..220
FT                   /evidence="ECO:0000244|PDB:5WIU"
FT   HELIX           340..344
FT                   /evidence="ECO:0000244|PDB:5WIU"
FT   HELIX           347..371
FT                   /evidence="ECO:0000244|PDB:5WIU"
FT   HELIX           379..403
FT                   /evidence="ECO:0000244|PDB:5WIU"
FT   HELIX           405..412
FT                   /evidence="ECO:0000244|PDB:5WIU"
SQ   SEQUENCE   419 AA;  43901 MW;  34CBE8320302008E CRC64;
     MGNRSTADAD GLLAGRGPAA GASAGASAGL AGQGAAALVG GVLLIGAVLA GNSLVCVSVA
     TERALQTPTN SFIVSLAAAD LLLALLVLPL FVYSEVQGGA WLLSPRLCDA LMAMDVMLCT
     ASIFNLCAIS VDRFVAVAVP LRYNRQGGSR RQLLLIGATW LLSAAVAAPV LCGLNDVRGR
     DPAVCRLEDR DYVVYSSVCS FFLPCPLMLL LYWATFRGLQ RWEVARRAKL HGRAPRRPSG
     PGPPSPTPPA PRLPQDPCGP DCAPPAPGLP RGPCGPDCAP AAPSLPQDPC GPDCAPPAPG
     LPPDPCGSNC APPDAVRAAA LPPQTPPQTR RRRRAKITGR ERKAMRVLPV VVGAFLLCWT
     PFFVVHITQA LCPACSVPPR LVSAVTWLGY VNSALNPVIY TVFNAEFRNV FRKALRACC
//
ID   EDNRB_HUMAN             Reviewed;         442 AA.
AC   P24530; A2A2Z8; A8K3T4; O15343; Q59GB1; Q5W0G9; Q8NHM6; Q8NHM7; Q8NHM8;
AC   Q8NHM9; Q9UD23; Q9UQK3;
DT   01-MAR-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-1992, sequence version 1.
DT   12-AUG-2020, entry version 227.
DE   RecName: Full=Endothelin receptor type B {ECO:0000305};
DE            Short=ET-B;
DE            Short=ET-BR;
DE   AltName: Full=Endothelin receptor non-selective type;
DE   Flags: Precursor;
GN   Name=EDNRB {ECO:0000312|HGNC:HGNC:3180}; Synonyms=ETRB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A).
RX   PubMed=1710450; DOI=10.1016/0006-291x(91)91944-8;
RA   Nakamuta M., Takayanagi R., Sakai Y., Sakamoto S., Hagiwara H., Mizuno T.,
RA   Saito Y., Hirose S., Yamamoto M., Nawata H.;
RT   "Cloning and sequence analysis of a cDNA encoding human non-selective type
RT   of endothelin receptor.";
RL   Biochem. Biophys. Res. Commun. 177:34-39(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A).
RX   PubMed=1648908; DOI=10.1016/0006-291x(91)91806-n;
RA   Ogawa Y., Nakao K., Arai H., Nakagawa O., Hosoda K., Suga S., Nakanishi S.,
RA   Imura H.;
RT   "Molecular cloning of a non-isopeptide-selective human endothelin
RT   receptor.";
RL   Biochem. Biophys. Res. Commun. 178:248-255(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A).
RX   PubMed=1713452; DOI=10.1016/0006-291x(91)90158-4;
RA   Sakamoto A., Yanagisawa M., Sakurai T., Takuwa Y., Yanagisawa H.,
RA   Masaki T.;
RT   "Cloning and functional expression of human cDNA for the ETB endothelin
RT   receptor.";
RL   Biochem. Biophys. Res. Commun. 178:656-663(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A).
RC   TISSUE=Lung;
RX   PubMed=1282938; DOI=10.1097/00005344-199204002-00002;
RA   Haendler B., Hechler U., Schleuning W.-D.;
RT   "Molecular cloning of human endothelin (ET) receptors ETA and ETB.";
RL   J. Cardiovasc. Pharmacol. 20:S1-S4(1992).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A).
RX   PubMed=1291713; DOI=10.1253/jcj.56.supplementv_1303;
RA   Arai H., Nakao K., Hosoda K., Ogawa Y., Nakagawa O., Komatsu Y., Imura H.;
RT   "Molecular cloning of human endothelin receptors and their expression in
RT   vascular endothelial cells and smooth muscle cells.";
RL   Jpn. Circ. J. 56:1303-1307(1992).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8429023;
RA   Arai H., Nakao K., Takaya K., Hosoda K., Ogawa Y., Nakanishi S., Imura H.;
RT   "The human endothelin-B receptor gene. Structural organization and
RT   chromosomal assignment.";
RL   J. Biol. Chem. 268:3463-3470(1993).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A).
RX   PubMed=8440682;
RA   Elshourbagy N.A., Korman D.R., Wu H.L., Sylvester D.R., Lee J.A.,
RA   Nuthalaganti P., Bergsma D.J., Kumar C.S., Nambi P.;
RT   "Molecular characterization and regulation of the human endothelin
RT   receptors.";
RL   J. Biol. Chem. 268:3873-3879(1993).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM A), AND FUNCTION.
RC   TISSUE=Prostate;
RX   PubMed=7536888;
RA   Webb M.L., Chao C.-C., Rizzo M., Shapiro R.A., Neubauer M., Liu E.C.K.,
RA   Aversa C.R., Brittain R.J., Treiger B.;
RT   "Cloning and expression of an endothelin receptor subtype B from human
RT   prostate that mediates contraction.";
RL   Mol. Pharmacol. 47:730-737(1995).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM B).
RC   TISSUE=Placenta;
RX   PubMed=8810293; DOI=10.1074/jbc.271.41.25300;
RA   Elshourbagy N.A., Adamou J.E., Gagnon A.W., Wu H.L., Pullen M., Nambi P.;
RT   "Molecular characterization of a novel human endothelin receptor splice
RT   variant.";
RL   J. Biol. Chem. 271:25300-25307(1996).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM C).
RX   PubMed=10072757; DOI=10.1016/s0378-1119(99)00014-1;
RA   Tsutsumi M., Liang G., Jones P.A.;
RT   "Novel endothelin B receptor transcripts with the potential of generating a
RT   new receptor.";
RL   Gene 228:43-49(1999).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM A).
RC   TISSUE=Placenta;
RA   Warren C.N., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM A).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS THR-5 AND ASN-305.
RG   NIEHS SNPs program;
RL   Submitted (FEB-2004) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S.,
RA   Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C.,
RA   Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P.,
RA   Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L.,
RA   Frankish A.G., Frankland J., French L., Garner P., Garnett J.,
RA   Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M.,
RA   Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D.,
RA   Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D.,
RA   Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S.,
RA   Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R.,
RA   Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W.,
RA   Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L.,
RA   Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R.,
RA   Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [16]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [17]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM A).
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [18]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-102; 172-196 AND 200-317.
RX   PubMed=12628594; DOI=10.1016/s0890-8508(03)00003-3;
RA   Zaahl M.G., du Plessis L., Warnich L., Kotze M.J., Moore S.W.;
RT   "Significance of novel endothelin-B receptor gene polymorphisms in
RT   Hirschsprung's disease: predominance of a novel variant (561C/T) in
RT   patients with co-existing Down's syndrome.";
RL   Mol. Cell. Probes 17:49-54(2003).
RN   [19]
RP   TISSUE SPECIFICITY.
RX   PubMed=9284755; DOI=10.1210/jcem.82.9.4209;
RA   Bourgeois C., Robert B., Rebourcet R., Mondon F., Mignot T.-M.,
RA   Duc-Goiran P., Ferre F.;
RT   "Endothelin-1 and ETA receptor expression in vascular smooth muscle cells
RT   from human placenta: a new ETA receptor messenger ribonucleic acid is
RT   generated by alternative splicing of exon 3.";
RL   J. Clin. Endocrinol. Metab. 82:3116-3123(1997).
RN   [20]
RP   PALMITOYLATION AT CYS-402; CYS-403 AND CYS-405, AND MUTAGENESIS OF CYS-402;
RP   CYS-403 AND CYS-405.
RX   PubMed=9261180; DOI=10.1074/jbc.272.34.21589;
RA   Okamoto Y., Ninomiya H., Tanioka M., Sakamoto A., Miwa S., Masaki T.;
RT   "Palmitoylation of human endothelinB. Its critical role in G protein
RT   coupling and a differential requirement for the cytoplasmic tail by G
RT   protein subtypes.";
RL   J. Biol. Chem. 272:21589-21596(1997).
RN   [21]
RP   REVIEW ON VARIANTS.
RX   PubMed=9359036;
RA   Hofstra R.M.W., Osinga J., Buys C.H.C.M.;
RT   "Mutations in Hirschsprung disease: when does a mutation contribute to the
RT   phenotype.";
RL   Eur. J. Hum. Genet. 5:180-185(1997).
RN   [22]
RP   VARIANT HSCR2 CYS-276.
RX   PubMed=8001158; DOI=10.1016/0092-8674(94)90016-7;
RA   Puffenberger E.G., Hosoda K., Washington S.S., Nakao K., Dewit D.,
RA   Yanagisawa M., Chakravarti A.;
RT   "A missense mutation of the endothelin-B receptor gene in multigenic
RT   Hirschsprung's disease.";
RL   Cell 79:1257-1266(1994).
RN   [23]
RP   VARIANT WS4A GLY-183.
RX   PubMed=8634719; DOI=10.1093/hmg/4.12.2407;
RA   Attie T., Till M., Pelet A., Amiel J., Edery P., Boutrand L., Munnich A.,
RA   Lyonnet S.;
RT   "Mutation of the endothelin-receptor B gene in Waardenburg-Hirschsprung
RT   disease.";
RL   Hum. Mol. Genet. 4:2407-2409(1995).
RN   [24]
RP   VARIANT ASN-305.
RX   PubMed=8852659; DOI=10.1093/hmg/5.3.351;
RA   Auricchio A., Casari G., Staiano A., Ballabio A.;
RT   "Endothelin-B receptor mutations in patients with isolated Hirschsprung
RT   disease from a non-inbred population.";
RL   Hum. Mol. Genet. 5:351-354(1996).
RN   [25]
RP   VARIANTS HSCR2 TRP-319 AND LEU-383, AND VARIANT SER-57.
RX   PubMed=8852660; DOI=10.1093/hmg/5.3.355;
RA   Amiel J., Attie T., Jan D., Pelet A., Edery P., Bidaud C., Lacombe D.,
RA   Tam P., Simeoni J., Flori E., Nihoul-Fekete C., Munnich A., Lyonnet S.;
RT   "Heterozygous endothelin receptor B (EDNRB) mutations in isolated
RT   Hirschsprung disease.";
RL   Hum. Mol. Genet. 5:355-357(1996).
RN   [26]
RP   VARIANT HSCR2 ILE-374, AND VARIANT SER-57.
RX   PubMed=8630503; DOI=10.1038/ng0496-445;
RA   Hofstra R.M.W., Tan-Sindhunata G., Wu Y., Kamsteeg E.-J., Stulp R.P.,
RA   van Ravenswaaij-Arts C., Majoor-Krakauer D., Angrist M., Chakravarti A.,
RA   Meijers C., Buys C.H.C.M.;
RT   "A homozygous mutation in the endothelin-3 gene associated with a combined
RT   Waardenburg type 2 and Hirschsprung phenotype (Shah-Waardenburg
RT   syndrome).";
RL   Nat. Genet. 12:445-447(1996).
RN   [27]
RP   VARIANT SER-57.
RX   PubMed=9760196; DOI=10.1007/s004390050797;
RA   Svensson P.J., Anvret M., Molander M.L., Nordenskjold A.;
RT   "Phenotypic variation in a family with mutations in two Hirschsprung-
RT   related genes (RET and endothelin receptor B).";
RL   Hum. Genet. 103:145-148(1998).
RN   [28]
RP   VARIANT ASN-305.
RX   PubMed=10874640;
RA   Brooks A.S., Breuning M.H., Osinga J., vd Smagt J.J., Catsman C.E.,
RA   Buys C.H., Meijers C., Hofstra R.M.;
RT   "A consanguineous family with Hirschsprung disease, microcephaly, and
RT   mental retardation (Goldberg-Shprintzen syndrome).";
RL   J. Med. Genet. 36:485-489(1999).
RN   [29]
RP   CHARACTERIZATION OF VARIANTS HSCR2 TRP-319 AND LEU-383, AND
RP   CHARACTERIZATION OF VARIANT SER-57.
RX   PubMed=11471546; DOI=10.1007/bf03401945;
RA   Fuchs S., Amiel J., Claudel S., Lyonnet S., Corvol P., Pinet F.;
RT   "Functional characterization of three mutations of the endothelin B
RT   receptor gene in patients with Hirschsprung's disease: evidence for
RT   selective loss of Gi coupling.";
RL   Mol. Med. 7:115-124(2001).
RN   [30]
RP   INVOLVEMENT IN ABCD SYNDROME.
RX   PubMed=11891690; DOI=10.1002/ajmg.10172;
RA   Verheij J.B., Kunze J., Osinga J., van Essen A.J., Hofstra R.M.;
RT   "ABCD syndrome is caused by a homozygous mutation in the EDNRB gene.";
RL   Am. J. Med. Genet. 108:223-225(2002).
RN   [31]
RP   VARIANT WS4A LEU-292.
RX   PubMed=12189494; DOI=10.1007/s00439-002-0765-8;
RA   Pingault V., Girard M., Bondurand N., Dorkins H., Van Maldergem L.,
RA   Mowat D., Shimotake T., Verma I., Baumann C., Goossens M.;
RT   "SOX10 mutations in chronic intestinal pseudo-obstruction suggest a complex
RT   physiopathological mechanism.";
RL   Hum. Genet. 111:198-206(2002).
RN   [32]
RP   VARIANTS PHE-17; PRO-17; TYR-137; ARG-156 AND 226-TRP--SER-442 DEL,
RP   INVOLVEMENT IN WAARDENBURG SYNDROME 2, SUBCELLULAR LOCATION,
RP   CHARACTERIZATION OF VARIANTS PHE-17; PRO-17; TYR-137; ARG-156 AND
RP   226-TRP--SER-442 DEL, AND CHARACTERIZATION OF VARIANTS HSCR2 ILE-374 AND
RP   LEU-383.
RX   PubMed=28236341; DOI=10.1002/humu.23206;
RA   Issa S., Bondurand N., Faubert E., Poisson S., Lecerf L., Nitschke P.,
RA   Deggouj N., Loundon N., Jonard L., David A., Sznajer Y., Blanchet P.,
RA   Marlin S., Pingault V.;
RT   "EDNRB mutations cause Waardenburg syndrome type II in the heterozygous
RT   state.";
RL   Hum. Mutat. 38:581-593(2017).
CC   -!- FUNCTION: Non-specific receptor for endothelin 1, 2, and 3. Mediates
CC       its action by association with G proteins that activate a
CC       phosphatidylinositol-calcium second messenger system.
CC       {ECO:0000269|PubMed:7536888}.
CC   -!- INTERACTION:
CC       P24530; P05305: EDN1; NbExp=2; IntAct=EBI-6624656, EBI-715181;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:28236341};
CC       Multi-pass membrane protein. Note=internalized after activation by
CC       endothelins. {ECO:0000269|PubMed:28236341}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=A;
CC         IsoId=P24530-1; Sequence=Displayed;
CC       Name=B;
CC         IsoId=P24530-2; Sequence=VSP_001879;
CC       Name=C; Synonyms=Delta-3;
CC         IsoId=P24530-3; Sequence=VSP_001878;
CC   -!- TISSUE SPECIFICITY: Expressed in placental stem villi vessels, but not
CC       in cultured placental villi smooth muscle cells.
CC       {ECO:0000269|PubMed:9284755}.
CC   -!- PTM: Palmitoylation of Cys-402 was confirmed by the palmitoylation of
CC       Cys-402 in a deletion mutant lacking both Cys-403 and Cys-405.
CC       {ECO:0000269|PubMed:9261180}.
CC   -!- DISEASE: Waardenburg syndrome 4A (WS4A) [MIM:277580]: A disorder
CC       characterized by the association of Waardenburg features
CC       (depigmentation and deafness) with the absence of enteric ganglia in
CC       the distal part of the intestine (Hirschsprung disease).
CC       {ECO:0000269|PubMed:12189494, ECO:0000269|PubMed:8634719}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Hirschsprung disease 2 (HSCR2) [MIM:600155]: A disorder of
CC       neural crest development characterized by absence of enteric ganglia
CC       along a variable length of the intestine. It is the most common cause
CC       of congenital intestinal obstruction. Early symptoms range from
CC       complete acute neonatal obstruction, characterized by vomiting,
CC       abdominal distention and failure to pass stool, to chronic constipation
CC       in the older child. {ECO:0000269|PubMed:11471546,
CC       ECO:0000269|PubMed:28236341, ECO:0000269|PubMed:8001158,
CC       ECO:0000269|PubMed:8630503, ECO:0000269|PubMed:8852660}. Note=The
CC       disease is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: ABCD syndrome (ABCDS) [MIM:600501]: An autosomal recessive
CC       syndrome characterized by albinism, black lock at temporal occipital
CC       region, bilateral deafness, aganglionosis of the large intestine and
CC       total absence of neurocytes and nerve fibers in the small intestine.
CC       {ECO:0000269|PubMed:11891690}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Note=Heterozygous mutations in EDNRB may be responsible for
CC       Waardenburg syndrome 2, an autosomal dominant disorder characterized by
CC       sensorineural deafness and pigmentary disturbances.
CC       {ECO:0000269|PubMed:28236341}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       Endothelin receptor subfamily. EDNRB sub-subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD92435.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/ednrb/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M74921; AAA58465.1; -; mRNA.
DR   EMBL; D90402; BAA14398.1; -; mRNA.
DR   EMBL; S44866; AAB19411.1; -; mRNA.
DR   EMBL; S57283; AAB25531.1; -; mRNA.
DR   EMBL; D13168; BAA02445.1; -; Genomic_DNA.
DR   EMBL; L06623; AAA52342.1; -; mRNA.
DR   EMBL; X99250; CAA67623.1; -; mRNA.
DR   EMBL; AF114165; AAD24541.1; -; mRNA.
DR   EMBL; AY275463; AAP32295.1; -; mRNA.
DR   EMBL; AB209198; BAD92435.1; ALT_INIT; mRNA.
DR   EMBL; AK290699; BAF83388.1; -; mRNA.
DR   EMBL; AY547312; AAS38516.1; -; Genomic_DNA.
DR   EMBL; AL139002; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471093; EAW80573.1; -; Genomic_DNA.
DR   EMBL; CH471093; EAW80575.1; -; Genomic_DNA.
DR   EMBL; BC014472; AAH14472.1; -; mRNA.
DR   EMBL; AJ458188; CAD30645.1; -; Genomic_DNA.
DR   EMBL; AJ458189; CAD30646.1; -; Genomic_DNA.
DR   EMBL; AJ458190; CAD30647.1; -; Genomic_DNA.
DR   EMBL; AJ458191; CAD30648.1; -; Genomic_DNA.
DR   CCDS; CCDS45059.1; -. [P24530-2]
DR   CCDS; CCDS55902.1; -. [P24530-3]
DR   CCDS; CCDS9461.1; -. [P24530-1]
DR   PIR; A46609; JQ1042.
DR   RefSeq; NP_000106.1; NM_000115.4. [P24530-1]
DR   RefSeq; NP_001116131.1; NM_001122659.2. [P24530-1]
DR   RefSeq; NP_001188326.1; NM_001201397.1. [P24530-3]
DR   RefSeq; NP_003982.1; NM_003991.3. [P24530-2]
DR   PDB; 5GLH; X-ray; 2.80 A; A=66-303, A=313-395.
DR   PDB; 5GLI; X-ray; 2.50 A; A=66-303, A=313-395.
DR   PDB; 5X93; X-ray; 2.20 A; A=66-303, A=311-407.
DR   PDB; 5XPR; X-ray; 3.60 A; A=66-303, A=311-407.
DR   PDB; 6IGK; X-ray; 2.00 A; A=66-407.
DR   PDB; 6IGL; X-ray; 2.70 A; A=66-407.
DR   PDBsum; 5GLH; -.
DR   PDBsum; 5GLI; -.
DR   PDBsum; 5X93; -.
DR   PDBsum; 5XPR; -.
DR   PDBsum; 6IGK; -.
DR   PDBsum; 6IGL; -.
DR   SMR; P24530; -.
DR   BioGRID; 108232; 33.
DR   IntAct; P24530; 25.
DR   MINT; P24530; -.
DR   STRING; 9606.ENSP00000366416; -.
DR   BindingDB; P24530; -.
DR   ChEMBL; CHEMBL1785; -.
DR   DrugBank; DB06403; Ambrisentan.
DR   DrugBank; DB00559; Bosentan.
DR   DrugBank; DB06460; Enrasentan.
DR   DrugBank; DB06138; IRL-1620.
DR   DrugBank; DB08932; Macitentan.
DR   DrugBank; DB06268; Sitaxentan.
DR   DrugBank; DB06558; Tezosentan.
DR   DrugCentral; P24530; -.
DR   GuidetoPHARMACOLOGY; 220; -.
DR   GlyGen; P24530; 1 site.
DR   iPTMnet; P24530; -.
DR   PhosphoSitePlus; P24530; -.
DR   SwissPalm; P24530; -.
DR   BioMuta; EDNRB; -.
DR   DMDM; 119622; -.
DR   jPOST; P24530; -.
DR   MassIVE; P24530; -.
DR   MaxQB; P24530; -.
DR   PaxDb; P24530; -.
DR   PeptideAtlas; P24530; -.
DR   PRIDE; P24530; -.
DR   ProteomicsDB; 54211; -. [P24530-1]
DR   ProteomicsDB; 54212; -. [P24530-2]
DR   ProteomicsDB; 54213; -. [P24530-3]
DR   Antibodypedia; 4509; 454 antibodies.
DR   DNASU; 1910; -.
DR   Ensembl; ENST00000377211; ENSP00000366416; ENSG00000136160. [P24530-3]
DR   Ensembl; ENST00000475537; ENSP00000487082; ENSG00000136160. [P24530-1]
DR   Ensembl; ENST00000626030; ENSP00000486202; ENSG00000136160. [P24530-2]
DR   Ensembl; ENST00000646605; ENSP00000494278; ENSG00000136160. [P24530-1]
DR   Ensembl; ENST00000646607; ENSP00000493527; ENSG00000136160. [P24530-1]
DR   Ensembl; ENST00000646948; ENSP00000493895; ENSG00000136160. [P24530-1]
DR   GeneID; 1910; -.
DR   KEGG; hsa:1910; -.
DR   UCSC; uc001vko.3; human. [P24530-1]
DR   CTD; 1910; -.
DR   DisGeNET; 1910; -.
DR   EuPathDB; HostDB:ENSG00000136160.14; -.
DR   GeneCards; EDNRB; -.
DR   GeneReviews; EDNRB; -.
DR   HGNC; HGNC:3180; EDNRB.
DR   HPA; ENSG00000136160; Tissue enhanced (placenta).
DR   MalaCards; EDNRB; -.
DR   MIM; 131244; gene.
DR   MIM; 142623; phenotype.
DR   MIM; 277580; phenotype.
DR   MIM; 600155; phenotype.
DR   MIM; 600501; phenotype.
DR   neXtProt; NX_P24530; -.
DR   OpenTargets; ENSG00000136160; -.
DR   Orphanet; 388; Hirschsprung disease.
DR   Orphanet; 895; Waardenburg syndrome type 2.
DR   Orphanet; 897; Waardenburg-Shah syndrome.
DR   PharmGKB; PA27618; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT01000000214541; -.
DR   HOGENOM; CLU_009579_28_0_1; -.
DR   InParanoid; P24530; -.
DR   KO; K04198; -.
DR   OMA; GFDMITT; -.
DR   PhylomeDB; P24530; -.
DR   TreeFam; TF331292; -.
DR   PathwayCommons; P24530; -.
DR   Reactome; R-HSA-375276; Peptide ligand-binding receptors.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   SignaLink; P24530; -.
DR   SIGNOR; P24530; -.
DR   BioGRID-ORCS; 1910; 3 hits in 876 CRISPR screens.
DR   ChiTaRS; EDNRB; human.
DR   GeneWiki; Endothelin_receptor_type_B; -.
DR   GenomeRNAi; 1910; -.
DR   Pharos; P24530; Tclin.
DR   PRO; PR:P24530; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   RNAct; P24530; protein.
DR   Bgee; ENSG00000136160; Expressed in spinal cord and 229 other tissues.
DR   ExpressionAtlas; P24530; baseline and differential.
DR   Genevisible; P24530; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0045121; C:membrane raft; IEA:Ensembl.
DR   GO; GO:0031965; C:nuclear membrane; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0004962; F:endothelin receptor activity; IDA:BHF-UCL.
DR   GO; GO:0017046; F:peptide hormone binding; IPI:BHF-UCL.
DR   GO; GO:0031702; F:type 1 angiotensin receptor binding; IEA:Ensembl.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0019722; P:calcium-mediated signaling; IMP:UniProtKB.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0019934; P:cGMP-mediated signaling; IEA:Ensembl.
DR   GO; GO:0086100; P:endothelin receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0048484; P:enteric nervous system development; ISS:BHF-UCL.
DR   GO; GO:0035645; P:enteric smooth muscle cell differentiation; ISS:BHF-UCL.
DR   GO; GO:0042045; P:epithelial fluid transport; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0048246; P:macrophage chemotaxis; IMP:BHF-UCL.
DR   GO; GO:0030318; P:melanocyte differentiation; IEA:Ensembl.
DR   GO; GO:0007194; P:negative regulation of adenylate cyclase activity; TAS:ProtInc.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0032269; P:negative regulation of cellular protein metabolic process; IMP:BHF-UCL.
DR   GO; GO:0014043; P:negative regulation of neuron maturation; ISS:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IMP:BHF-UCL.
DR   GO; GO:0007399; P:nervous system development; TAS:ProtInc.
DR   GO; GO:0001755; P:neural crest cell migration; IEA:Ensembl.
DR   GO; GO:0007422; P:peripheral nervous system development; IEA:Ensembl.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IEA:Ensembl.
DR   GO; GO:0060406; P:positive regulation of penile erection; IEA:Ensembl.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IEA:Ensembl.
DR   GO; GO:0035815; P:positive regulation of renal sodium excretion; IEA:Ensembl.
DR   GO; GO:0035810; P:positive regulation of urine volume; IEA:Ensembl.
DR   GO; GO:0007497; P:posterior midgut development; IEA:Ensembl.
DR   GO; GO:0008217; P:regulation of blood pressure; IEA:Ensembl.
DR   GO; GO:0050678; P:regulation of epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0031620; P:regulation of fever generation; IEA:Ensembl.
DR   GO; GO:0006885; P:regulation of pH; IEA:Ensembl.
DR   GO; GO:0051930; P:regulation of sensory perception of pain; IEA:Ensembl.
DR   GO; GO:1990839; P:response to endothelin; IEA:Ensembl.
DR   GO; GO:0014070; P:response to organic cyclic compound; IEA:Ensembl.
DR   GO; GO:0048265; P:response to pain; IEA:Ensembl.
DR   GO; GO:0019233; P:sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0042310; P:vasoconstriction; IMP:BHF-UCL.
DR   GO; GO:0042311; P:vasodilation; IEA:Ensembl.
DR   GO; GO:0014826; P:vein smooth muscle contraction; IMP:BHF-UCL.
DR   InterPro; IPR000499; Endthln_rcpt.
DR   InterPro; IPR001112; ETB_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00571; ENDOTHELINBR.
DR   PRINTS; PR00366; ENDOTHELINR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Albinism; Alternative splicing; Cell membrane; Deafness;
KW   Disease mutation; Disulfide bond; G-protein coupled receptor; Glycoprotein;
KW   Hirschsprung disease; Lipoprotein; Membrane; Palmitate; Phosphoprotein;
KW   Polymorphism; Receptor; Reference proteome; Signal; Transducer;
KW   Transmembrane; Transmembrane helix; Waardenburg syndrome.
FT   SIGNAL          1..26
FT                   /evidence="ECO:0000255"
FT   CHAIN           27..442
FT                   /note="Endothelin receptor type B"
FT                   /id="PRO_0000012729"
FT   TOPO_DOM        27..101
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        102..126
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        127..137
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        138..163
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        164..175
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        176..197
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        198..218
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        219..243
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        244..271
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        272..296
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        297..324
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        325..350
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        351..362
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        363..389
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        390..442
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         305
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P28088"
FT   MOD_RES         419
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P28088"
FT   MOD_RES         439
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P28088"
FT   MOD_RES         440
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P28088"
FT   MOD_RES         441
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P28088"
FT   MOD_RES         442
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P28088"
FT   LIPID           402
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:9261180"
FT   LIPID           403
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000255"
FT   LIPID           405
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        59
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        174..255
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VAR_SEQ         1
FT                   /note="M -> MNKSTCLMAAETPSKRWRLHCLAFSQRFVRAGPACSSREACSSPRAG
FT                   WNPAGFRLPGRWSPFVALHLVCQIREALKLRSGHRTPSGAGSSM (in isoform
FT                   C)"
FT                   /evidence="ECO:0000303|PubMed:10072757"
FT                   /id="VSP_001878"
FT   VAR_SEQ         399..442
FT                   /note="SCLCCWCQSFEEKQSLEEKQSCLKFKANDHGYDNFRSSNKYSSS -> AGPH
FT                   VGNKLVMLFSVNIECDGTVNQNPTMWPERKSNNN (in isoform B)"
FT                   /evidence="ECO:0000303|PubMed:8810293"
FT                   /id="VSP_001879"
FT   VARIANT         5
FT                   /note="P -> T (in dbSNP:rs12720160)"
FT                   /evidence="ECO:0000269|Ref.14"
FT                   /id="VAR_019285"
FT   VARIANT         7
FT                   /note="L -> Q (in dbSNP:rs5345)"
FT                   /id="VAR_014675"
FT   VARIANT         17
FT                   /note="L -> F (polymorphism; no effect on cell membrane
FT                   location; dbSNP:rs5346)"
FT                   /evidence="ECO:0000269|PubMed:28236341"
FT                   /id="VAR_014676"
FT   VARIANT         17
FT                   /note="L -> P (probable disease-associated variant found in
FT                   patients with Waardenburg syndrome 2; loss of cell membrane
FT                   location; new cytoplasmic location)"
FT                   /evidence="ECO:0000269|PubMed:28236341"
FT                   /id="VAR_078312"
FT   VARIANT         57
FT                   /note="G -> S (associated with increased susceptibility for
FT                   Hirschsprung disease; sex-dependent gene dosage effect;
FT                   dbSNP:rs1801710)"
FT                   /evidence="ECO:0000269|PubMed:11471546,
FT                   ECO:0000269|PubMed:8630503, ECO:0000269|PubMed:8852660,
FT                   ECO:0000269|PubMed:9760196"
FT                   /id="VAR_003469"
FT   VARIANT         76
FT                   /note="R -> M (in dbSNP:rs2228271)"
FT                   /id="VAR_024255"
FT   VARIANT         112
FT                   /note="F -> V (in dbSNP:rs5347)"
FT                   /id="VAR_014677"
FT   VARIANT         137
FT                   /note="N -> Y (probable disease-associated variant found in
FT                   patients with Waardenburg syndrome 2; decreased calcium
FT                   release upon endothelin 3 exposure; loss of downstream
FT                   pathway activation upon endothelin 3 exposure; no effect on
FT                   cell membrane location; no effect on internalization upon
FT                   endothelin 3 exposure)"
FT                   /evidence="ECO:0000269|PubMed:28236341"
FT                   /id="VAR_078313"
FT   VARIANT         156
FT                   /note="P -> R (probable disease-associated variant found in
FT                   patients with Waardenburg syndrome 2; loss of cell membrane
FT                   location; new cytoplasmic location)"
FT                   /evidence="ECO:0000269|PubMed:28236341"
FT                   /id="VAR_078314"
FT   VARIANT         183
FT                   /note="A -> G (in WS4A; dbSNP:rs104894388)"
FT                   /evidence="ECO:0000269|PubMed:8634719"
FT                   /id="VAR_003470"
FT   VARIANT         226..442
FT                   /note="Missing (probable disease-associated variant found
FT                   in patients with Waardenburg syndrome 2; loss of cell
FT                   membrane location; new cytoplasmic location)"
FT                   /evidence="ECO:0000269|PubMed:28236341"
FT                   /id="VAR_078315"
FT   VARIANT         244
FT                   /note="T -> M (in dbSNP:rs5350)"
FT                   /id="VAR_014678"
FT   VARIANT         276
FT                   /note="W -> C (in HSCR2; dbSNP:rs104894387)"
FT                   /evidence="ECO:0000269|PubMed:8001158"
FT                   /id="VAR_003471"
FT   VARIANT         292
FT                   /note="F -> L (in WS4A)"
FT                   /evidence="ECO:0000269|PubMed:12189494"
FT                   /id="VAR_015294"
FT   VARIANT         305
FT                   /note="S -> N (in dbSNP:rs5352)"
FT                   /evidence="ECO:0000269|PubMed:8852659, ECO:0000269|Ref.14"
FT                   /id="VAR_003472"
FT   VARIANT         319
FT                   /note="R -> W (in HSCR2; sporadic; dbSNP:rs200363611)"
FT                   /evidence="ECO:0000269|PubMed:11471546,
FT                   ECO:0000269|PubMed:8852660"
FT                   /id="VAR_003473"
FT   VARIANT         374
FT                   /note="M -> I (in HSCR2; decreased calcium release; no
FT                   effect on cell membrane location)"
FT                   /evidence="ECO:0000269|PubMed:28236341,
FT                   ECO:0000269|PubMed:8630503"
FT                   /id="VAR_003474"
FT   VARIANT         383
FT                   /note="P -> L (in HSCR2; familial; loss of cell membrane
FT                   location; new cytoplasmic location)"
FT                   /evidence="ECO:0000269|PubMed:11471546,
FT                   ECO:0000269|PubMed:28236341, ECO:0000269|PubMed:8852660"
FT                   /id="VAR_003475"
FT   MUTAGEN         402
FT                   /note="C->S: Abolishes palmitoylation; when associated with
FT                   S-403 and S-405."
FT                   /evidence="ECO:0000269|PubMed:9261180"
FT   MUTAGEN         403
FT                   /note="C->S: Abolishes palmitoylation; when associated with
FT                   S-402 and S-405."
FT                   /evidence="ECO:0000269|PubMed:9261180"
FT   MUTAGEN         405
FT                   /note="C->S: Abolishes palmitoylation; when associated with
FT                   S-402 and S-403."
FT                   /evidence="ECO:0000269|PubMed:9261180"
FT   CONFLICT        10
FT                   /note="R -> P (in Ref. 3; AAB19411)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        16
FT                   /note="V -> L (in Ref. 8)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        22..24
FT                   /note="SRI -> LGV (in Ref. 8)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        35
FT                   /note="R -> K (in Ref. 8)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        45
FT                   /note="I -> M (in Ref. 12; BAD92435)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        58
FT                   /note="S -> P (in Ref. 13; BAF83388)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        140
FT                   /note="I -> V (in Ref. 8)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        385
FT                   /note="A -> V (in Ref. 13; BAF83388)"
FT                   /evidence="ECO:0000305"
FT   HELIX           98..128
FT                   /evidence="ECO:0000244|PDB:6IGK"
FT   HELIX           130..132
FT                   /evidence="ECO:0000244|PDB:6IGK"
FT   HELIX           135..164
FT                   /evidence="ECO:0000244|PDB:6IGK"
FT   HELIX           170..204
FT                   /evidence="ECO:0000244|PDB:6IGK"
FT   STRAND          206..208
FT                   /evidence="ECO:0000244|PDB:6IGK"
FT   STRAND          212..214
FT                   /evidence="ECO:0000244|PDB:5X93"
FT   HELIX           216..232
FT                   /evidence="ECO:0000244|PDB:6IGK"
FT   HELIX           234..239
FT                   /evidence="ECO:0000244|PDB:6IGK"
FT   STRAND          240..247
FT                   /evidence="ECO:0000244|PDB:6IGK"
FT   STRAND          250..257
FT                   /evidence="ECO:0000244|PDB:6IGK"
FT   HELIX           264..281
FT                   /evidence="ECO:0000244|PDB:6IGK"
FT   HELIX           283..310
FT                   /evidence="ECO:0000244|PDB:6IGK"
FT   HELIX           313..349
FT                   /evidence="ECO:0000244|PDB:6IGK"
FT   STRAND          352..354
FT                   /evidence="ECO:0000244|PDB:5GLI"
FT   TURN            355..357
FT                   /evidence="ECO:0000244|PDB:6IGK"
FT   HELIX           358..389
FT                   /evidence="ECO:0000244|PDB:6IGK"
FT   HELIX           391..401
FT                   /evidence="ECO:0000244|PDB:6IGK"
FT   CONFLICT        P24530-3:79..84
FT                   /note="SGHRTP -> RPPDA (in Ref. 10; AAD24541)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   442 AA;  49644 MW;  CD4F96CF92C7C51E CRC64;
     MQPPPSLCGR ALVALVLACG LSRIWGEERG FPPDRATPLL QTAEIMTPPT KTLWPKGSNA
     SLARSLAPAE VPKGDRTAGS PPRTISPPPC QGPIEIKETF KYINTVVSCL VFVLGIIGNS
     TLLRIIYKNK CMRNGPNILI ASLALGDLLH IVIDIPINVY KLLAEDWPFG AEMCKLVPFI
     QKASVGITVL SLCALSIDRY RAVASWSRIK GIGVPKWTAV EIVLIWVVSV VLAVPEAIGF
     DIITMDYKGS YLRICLLHPV QKTAFMQFYK TAKDWWLFSF YFCLPLAITA FFYTLMTCEM
     LRKKSGMQIA LNDHLKQRRE VAKTVFCLVL VFALCWLPLH LSRILKLTLY NQNDPNRCEL
     LSFLLVLDYI GINMASLNSC INPIALYLVS KRFKNCFKSC LCCWCQSFEE KQSLEEKQSC
     LKFKANDHGY DNFRSSNKYS SS
//
ID   ACKR3_HUMAN             Reviewed;         362 AA.
AC   P25106; A8K6J4; Q53RV4; Q8NE10; Q92938; Q92986;
DT   01-MAY-1992, integrated into UniProtKB/Swiss-Prot.
DT   03-OCT-2006, sequence version 3.
DT   07-OCT-2020, entry version 197.
DE   RecName: Full=Atypical chemokine receptor 3;
DE   AltName: Full=C-X-C chemokine receptor type 7;
DE            Short=CXC-R7;
DE            Short=CXCR-7;
DE   AltName: Full=Chemokine orphan receptor 1;
DE   AltName: Full=G-protein coupled receptor 159;
DE   AltName: Full=G-protein coupled receptor RDC1 homolog;
DE            Short=RDC-1;
GN   Name=ACKR3; Synonyms=CMKOR1, CXCR7, GPR159, RDC1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RX   PubMed=1675791; DOI=10.1073/pnas.88.11.4986;
RA   Sreedharan S.P., Robichon A., Peterson K.E., Goetzl E.J.;
RT   "Cloning and expression of the human vasoactive intestinal peptide
RT   receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:4986-4990(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Oates E.L., Roos B.A., Howard G.A.;
RT   "Coding and 3'-noncoding sequence of human RDC1, an orphan G protein-
RT   coupled receptor.";
RL   Submitted (OCT-1996) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Bi A., Yu L., Zhang Q., Tu Q., Xing Y., Zheng L.;
RT   "Human RDC1 gene.";
RL   Submitted (OCT-1997) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Martin A.L., Kaighin V.A., Aronstam R.S.;
RT   "Isolation of cDNA coding for Homo sapiens chemokine orphan receptor 1
RT   (CMKOR1).";
RL   Submitted (JUN-2006) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   DOUBTS ON THE ORIGINAL FUNCTION.
RX   PubMed=1315461; DOI=10.1016/0165-6147(92)90037-7;
RA   Nagata S., Ishihara T., Robberecht P., Libert F., Parmentier M.,
RA   Christophe J., Vassart G.;
RT   "RDC1 may not be VIP receptor.";
RL   Trends Pharmacol. Sci. 13:102-103(1992).
RN   [10]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=16107333; DOI=10.1074/jbc.m508234200;
RA   Balabanian K., Lagane B., Infantino S., Chow K.Y., Harriague J., Moepps B.,
RA   Arenzana-Seisdedos F., Thelen M., Bachelerie F.;
RT   "The chemokine SDF-1/CXCL12 binds to and signals through the orphan
RT   receptor RDC1 in T lymphocytes.";
RL   J. Biol. Chem. 280:35760-35766(2005).
RN   [11]
RP   FUNCTION.
RX   PubMed=16940167; DOI=10.1084/jem.20052144;
RA   Burns J.M., Summers B.C., Wang Y., Melikian A., Berahovich R., Miao Z.,
RA   Penfold M.E., Sunshine M.J., Littman D.R., Kuo C.J., Wei K., McMaster B.E.,
RA   Wright K., Howard M.C., Schall T.J.;
RT   "A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival,
RT   cell adhesion, and tumor development.";
RL   J. Exp. Med. 203:2201-2213(2006).
RN   [12]
RP   TISSUE SPECIFICITY.
RX   PubMed=16455976; DOI=10.4049/jimmunol.176.4.2197;
RA   Infantino S., Moepps B., Thelen M.;
RT   "Expression and regulation of the orphan receptor RDC1 and its putative
RT   ligand in human dendritic and B cells.";
RL   J. Immunol. 176:2197-2207(2006).
RN   [13]
RP   FUNCTION, AND HETERODIMERIZATION.
RX   PubMed=17804806; DOI=10.1073/pnas.0702229104;
RA   Sierro F., Biben C., Martinez-Munoz L., Mellado M., Ransohoff R.M., Li M.,
RA   Woehl B., Leung H., Groom J., Batten M., Harvey R.P., Martinez-A C.,
RA   Mackay C.R., Mackay F.;
RT   "Disrupted cardiac development but normal hematopoiesis in mice deficient
RT   in the second CXCL12/SDF-1 receptor, CXCR7.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:14759-14764(2007).
RN   [14]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=18653785; DOI=10.1189/jlb.0208088;
RA   Hartmann T.N., Grabovsky V., Pasvolsky R., Shulman Z., Buss E.C.,
RA   Spiegel A., Nagler A., Lapidot T., Thelen M., Alon R.;
RT   "A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid
RT   CXCL12-triggered integrin activation but not in chemokine-triggered
RT   motility of human T lymphocytes and CD34+ cells.";
RL   J. Leukoc. Biol. 84:1130-1140(2008).
RN   [15]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=19380869; DOI=10.1182/blood-2008-12-196618;
RA   Levoye A., Balabanian K., Baleux F., Bachelerie F., Lagane B.;
RT   "CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein
RT   signaling.";
RL   Blood 113:6085-6093(2009).
RN   [16]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=19641136; DOI=10.4049/jimmunol.0900269;
RA   Zabel B.A., Wang Y., Lewen S., Berahovich R.D., Penfold M.E., Zhang P.,
RA   Powers J., Summers B.C., Miao Z., Zhao B., Jalili A.,
RA   Janowska-Wieczorek A., Jaen J.C., Schall T.J.;
RT   "Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-
RT   mediated tumor cell transendothelial migration by CXCR7 ligands.";
RL   J. Immunol. 183:3204-3211(2009).
RN   [17]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=19255243; DOI=10.1124/mol.108.053389;
RA   Kalatskaya I., Berchiche Y.A., Gravel S., Limberg B.J., Rosenbaum J.S.,
RA   Heveker N.;
RT   "AMD3100 is a CXCR7 ligand with allosteric agonist properties.";
RL   Mol. Pharmacol. 75:1240-1247(2009).
RN   [18]
RP   FUNCTION, TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=20388803; DOI=10.1158/0008-5472.can-09-3642;
RA   Hattermann K., Held-Feindt J., Lucius R., Muerkoster S.S., Penfold M.E.,
RA   Schall T.J., Mentlein R.;
RT   "The chemokine receptor CXCR7 is highly expressed in human glioma cells and
RT   mediates antiapoptotic effects.";
RL   Cancer Res. 70:3299-3308(2010).
RN   [19]
RP   REVIEW.
RX   PubMed=20373092; DOI=10.1007/82_2010_19;
RA   Bonecchi R., Savino B., Borroni E.M., Mantovani A., Locati M.;
RT   "Chemokine decoy receptors: structure-function and biological properties.";
RL   Curr. Top. Microbiol. Immunol. 341:15-36(2010).
RN   [20]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=20887389; DOI=10.1111/j.1600-0609.2010.01531.x;
RA   Tarnowski M., Liu R., Wysoczynski M., Ratajczak J., Kucia M.,
RA   Ratajczak M.Z.;
RT   "CXCR7: a new SDF-1-binding receptor in contrast to normal CD34(+)
RT   progenitors is functional and is expressed at higher level in human
RT   malignant hematopoietic cells.";
RL   Eur. J. Haematol. 85:472-483(2010).
RN   [21]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF SER-145 AND THR-147.
RX   PubMed=20161793; DOI=10.1371/journal.pone.0009175;
RA   Naumann U., Cameroni E., Pruenster M., Mahabaleshwar H., Raz E.,
RA   Zerwes H.G., Rot A., Thelen M.;
RT   "CXCR7 functions as a scavenger for CXCL12 and CXCL11.";
RL   PLoS ONE 5:E9175-E9175(2010).
RN   [22]
RP   FUNCTION.
RX   PubMed=20018651; DOI=10.1073/pnas.0912852107;
RA   Rajagopal S., Kim J., Ahn S., Craig S., Lam C.M., Gerard N.P., Gerard C.,
RA   Lefkowitz R.J.;
RT   "Beta-arrestin- but not G protein-mediated signaling by the 'decoy'
RT   receptor CXCR7.";
RL   Proc. Natl. Acad. Sci. U.S.A. 107:628-632(2010).
RN   [23]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=21655198; DOI=10.1371/journal.pone.0020680;
RA   Shimizu S., Brown M., Sengupta R., Penfold M.E., Meucci O.;
RT   "CXCR7 protein expression in human adult brain and differentiated
RT   neurons.";
RL   PLoS ONE 6:E20680-E20680(2011).
RN   [24]
RP   REVIEW.
RX   PubMed=22698181; DOI=10.1016/j.imlet.2012.04.004;
RA   Graham G.J., Locati M., Mantovani A., Rot A., Thelen M.;
RT   "The biochemistry and biology of the atypical chemokine receptors.";
RL   Immunol. Lett. 145:30-38(2012).
RN   [25]
RP   FUNCTION, SUBCELLULAR LOCATION, C-TERMINAL CYTOPLASMIC TAIL, AND
RP   INTERACTION WITH ARRB2.
RX   PubMed=22300987; DOI=10.1016/j.biocel.2012.01.007;
RA   Ray P., Mihalko L.A., Coggins N.L., Moudgil P., Ehrlich A., Luker K.E.,
RA   Luker G.D.;
RT   "Carboxy-terminus of CXCR7 regulates receptor localization and function.";
RL   Int. J. Biochem. Cell Biol. 44:669-678(2012).
RN   [26]
RP   UBIQUITINATION, C-TERMINAL CYTOPLASMIC TAIL, SUBCELLULAR LOCATION, AND
RP   INTERACTION WITH ARRB1 AND ARRB2.
RX   PubMed=22457824; DOI=10.1371/journal.pone.0034192;
RA   Canals M., Scholten D.J., de Munnik S., Han M.K., Smit M.J., Leurs R.;
RT   "Ubiquitination of CXCR7 controls receptor trafficking.";
RL   PLoS ONE 7:E34192-E34192(2012).
RN   [27]
RP   REVIEW.
RX   PubMed=23356288; DOI=10.1042/bst20120246;
RA   Cancellieri C., Vacchini A., Locati M., Bonecchi R., Borroni E.M.;
RT   "Atypical chemokine receptors: from silence to sound.";
RL   Biochem. Soc. Trans. 41:231-236(2013).
RN   [28]
RP   REVIEW.
RX   PubMed=23153575; DOI=10.1016/j.molmed.2012.10.004;
RA   Sanchez-Martin L., Sanchez-Mateos P., Cabanas C.;
RT   "CXCR7 impact on CXCL12 biology and disease.";
RL   Trends Mol. Med. 19:12-22(2013).
CC   -!- FUNCTION: Atypical chemokine receptor that controls chemokine levels
CC       and localization via high-affinity chemokine binding that is uncoupled
CC       from classic ligand-driven signal transduction cascades, resulting
CC       instead in chemokine sequestration, degradation, or transcytosis. Also
CC       known as interceptor (internalizing receptor) or chemokine-scavenging
CC       receptor or chemokine decoy receptor. Acts as a receptor for chemokines
CC       CXCL11 and CXCL12/SDF1. Chemokine binding does not activate G-protein-
CC       mediated signal transduction but instead induces beta-arrestin
CC       recruitment, leading to ligand internalization and activation of MAPK
CC       signaling pathway. Required for regulation of CXCR4 protein levels in
CC       migrating interneurons, thereby adapting their chemokine
CC       responsiveness. In glioma cells, transduces signals via MEK/ERK
CC       pathway, mediating resistance to apoptosis. Promotes cell growth and
CC       survival. Not involved in cell migration, adhesion or proliferation of
CC       normal hematopoietic progenitors but activated by CXCL11 in malignant
CC       hemapoietic cells, leading to phosphorylation of ERK1/2 (MAPK3/MAPK1)
CC       and enhanced cell adhesion and migration. Plays a regulatory role in
CC       CXCR4-mediated activation of cell surface integrins by CXCL12. Required
CC       for heart valve development. Acts as coreceptor with CXCR4 for a
CC       restricted number of HIV isolates. {ECO:0000269|PubMed:16107333,
CC       ECO:0000269|PubMed:16940167, ECO:0000269|PubMed:17804806,
CC       ECO:0000269|PubMed:18653785, ECO:0000269|PubMed:19255243,
CC       ECO:0000269|PubMed:19380869, ECO:0000269|PubMed:19641136,
CC       ECO:0000269|PubMed:20018651, ECO:0000269|PubMed:20161793,
CC       ECO:0000269|PubMed:20388803, ECO:0000269|PubMed:20887389,
CC       ECO:0000269|PubMed:22300987}.
CC   -!- SUBUNIT: Homodimer. Can form heterodimers with CXCR4;
CC       heterodimerization may regulate CXCR4 signaling activity. Interacts
CC       with ARRB1 and ARRB2. {ECO:0000269|PubMed:19255243,
CC       ECO:0000269|PubMed:19380869, ECO:0000269|PubMed:22300987,
CC       ECO:0000269|PubMed:22457824}.
CC   -!- INTERACTION:
CC       P25106; P35348: ADRA1A; NbExp=4; IntAct=EBI-1965291, EBI-489756;
CC       P25106; P35368: ADRA1B; NbExp=5; IntAct=EBI-1965291, EBI-490017;
CC       P25106; P25100: ADRA1D; NbExp=4; IntAct=EBI-1965291, EBI-489993;
CC       P25106; P18089: ADRA2B; NbExp=2; IntAct=EBI-1965291, EBI-9077302;
CC       P25106; P37288: AVPR1A; NbExp=7; IntAct=EBI-1965291, EBI-6656842;
CC       P25106; P61073: CXCR4; NbExp=18; IntAct=EBI-1965291, EBI-489411;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC       Cytoplasm, perinuclear region. Early endosome. Recycling endosome
CC       {ECO:0000250}. Note=Predominantly localizes to endocytic vesicles, and
CC       upon stimulation by the ligand is internalized via clathrin-coated pits
CC       in a beta-arrestin-dependent manner. Once internalized, the ligand
CC       dissociates from the receptor, and is targeted to degradation while the
CC       receptor is recycled back to the cell membrane.
CC   -!- TISSUE SPECIFICITY: Expressed in monocytes, basophils, B-cells,
CC       umbilical vein endothelial cells (HUVEC) and B-lymphoblastoid cells.
CC       Lower expression detected in CD4+ T-lymphocytes and natural killer
CC       cells. In the brain, detected in endothelial cells and capillaries, and
CC       in mature neurons of the frontal cortex and hippocampus. Expressed in
CC       tubular formation in the kidney. Highly expressed in astroglial tumor
CC       endothelial, microglial and glioma cells. Expressed at low levels in
CC       normal CD34+ progenitor cells, but at very high levels in several
CC       myeloid malignant cell lines. Expressed in breast carcinomas but not in
CC       normal breast tissue (at protein level). {ECO:0000269|PubMed:16107333,
CC       ECO:0000269|PubMed:16455976, ECO:0000269|PubMed:19641136,
CC       ECO:0000269|PubMed:20388803, ECO:0000269|PubMed:20887389,
CC       ECO:0000269|PubMed:21655198}.
CC   -!- INDUCTION: Up-regulated during cell differentiation in glioma cells.
CC       {ECO:0000269|PubMed:20388803}.
CC   -!- DOMAIN: The C-terminal cytoplasmic tail, plays a key role in: correct
CC       trafficking to the cell membrane, recruitment of beta-arrestin,
CC       ubiquitination, and in chemokine scavenging and signaling functions.
CC       The Ser/Thr residues and the Lys residues in the C-terminal cytoplasmic
CC       tail are essential for beta-arrestin recruitment and ubiquitination
CC       respectively.
CC   -!- PTM: The Ser/Thr residues in the C-terminal cytoplasmic tail may be
CC       phosphorylated.
CC   -!- PTM: Ubiquitinated at the Lys residues in its C-terminal cytoplasmic
CC       tail and is essential for correct trafficking from and to the cell
CC       membrane. Deubiquitinated by CXCL12-stimulation in a reversible manner.
CC       {ECO:0000269|PubMed:22457824}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       Atypical chemokine receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00521}.
CC   -!- CAUTION: Was originally thought to be the receptor for VIP.
CC       {ECO:0000305|PubMed:1675791}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CMKOR1ID40108ch2q37.html";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=CXC chemokine receptors entry;
CC       URL="https://en.wikipedia.org/wiki/CXC_chemokine_receptors";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M64749; AAA62370.1; -; mRNA.
DR   EMBL; U73141; AAB18130.1; -; Genomic_DNA.
DR   EMBL; U67784; AAB16913.1; -; mRNA.
DR   EMBL; AF030297; AAB94130.1; -; mRNA.
DR   EMBL; DQ822477; ABH01258.1; -; mRNA.
DR   EMBL; AK291659; BAF84348.1; -; mRNA.
DR   EMBL; AC079611; AAX93086.1; -; Genomic_DNA.
DR   EMBL; CH471063; EAW71092.1; -; Genomic_DNA.
DR   EMBL; BC036661; AAH36661.1; -; mRNA.
DR   CCDS; CCDS2516.1; -.
DR   PIR; A39714; A39714.
DR   RefSeq; NP_064707.1; NM_020311.2.
DR   RefSeq; XP_005246154.1; XM_005246097.2.
DR   RefSeq; XP_005246155.1; XM_005246098.3.
DR   RefSeq; XP_016860005.1; XM_017004516.1.
DR   PDB; 6K3F; X-ray; 2.30 A; U/V/W/X/Y/Z=331-345.
DR   PDBsum; 6K3F; -.
DR   BioGRID; 121321; 16.
DR   IntAct; P25106; 24.
DR   STRING; 9606.ENSP00000272928; -.
DR   BindingDB; P25106; -.
DR   ChEMBL; CHEMBL2010631; -.
DR   DrugCentral; P25106; -.
DR   GuidetoPHARMACOLOGY; 80; -.
DR   GlyGen; P25106; 3 sites.
DR   iPTMnet; P25106; -.
DR   PhosphoSitePlus; P25106; -.
DR   BioMuta; ACKR3; -.
DR   DMDM; 115502380; -.
DR   MassIVE; P25106; -.
DR   MaxQB; P25106; -.
DR   PaxDb; P25106; -.
DR   PeptideAtlas; P25106; -.
DR   PRIDE; P25106; -.
DR   ProteomicsDB; 54262; -.
DR   ABCD; P25106; 9 sequenced antibodies.
DR   Antibodypedia; 47699; 796 antibodies.
DR   DNASU; 57007; -.
DR   Ensembl; ENST00000272928; ENSP00000272928; ENSG00000144476.
DR   GeneID; 57007; -.
DR   KEGG; hsa:57007; -.
DR   UCSC; uc002vwd.4; human.
DR   CTD; 57007; -.
DR   DisGeNET; 57007; -.
DR   EuPathDB; HostDB:ENSG00000144476.5; -.
DR   GeneCards; ACKR3; -.
DR   HGNC; HGNC:23692; ACKR3.
DR   HPA; ENSG00000144476; Low tissue specificity.
DR   MIM; 610376; gene.
DR   neXtProt; NX_P25106; -.
DR   OpenTargets; ENSG00000144476; -.
DR   PharmGKB; PA162383053; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT01000000214378; -.
DR   HOGENOM; CLU_009579_8_3_1; -.
DR   InParanoid; P25106; -.
DR   KO; K04304; -.
DR   OMA; VVWVNLQ; -.
DR   OrthoDB; 819032at2759; -.
DR   PhylomeDB; P25106; -.
DR   TreeFam; TF333489; -.
DR   PathwayCommons; P25106; -.
DR   Reactome; R-HSA-380108; Chemokine receptors bind chemokines.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   SignaLink; P25106; -.
DR   SIGNOR; P25106; -.
DR   BioGRID-ORCS; 57007; 5 hits in 853 CRISPR screens.
DR   ChiTaRS; ACKR3; human.
DR   GeneWiki; CXCR7; -.
DR   GenomeRNAi; 57007; -.
DR   Pharos; P25106; Tchem.
DR   PRO; PR:P25106; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; P25106; protein.
DR   Bgee; ENSG00000144476; Expressed in synovial joint and 231 other tissues.
DR   ExpressionAtlas; P25106; baseline and differential.
DR   Genevisible; P25106; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005905; C:clathrin-coated pit; IDA:UniProtKB.
DR   GO; GO:0005769; C:early endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005768; C:endosome; IDA:UniProtKB.
DR   GO; GO:0009897; C:external side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0055037; C:recycling endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0019957; F:C-C chemokine binding; IBA:GO_Central.
DR   GO; GO:0016493; F:C-C chemokine receptor activity; IBA:GO_Central.
DR   GO; GO:0019958; F:C-X-C chemokine binding; IMP:UniProtKB.
DR   GO; GO:0016494; F:C-X-C chemokine receptor activity; IMP:BHF-UCL.
DR   GO; GO:0019956; F:chemokine binding; IBA:GO_Central.
DR   GO; GO:0015026; F:coreceptor activity; IEA:InterPro.
DR   GO; GO:0005044; F:scavenger receptor activity; IMP:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; IEA:InterPro.
DR   GO; GO:0019722; P:calcium-mediated signaling; IBA:GO_Central.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0060326; P:cell chemotaxis; IBA:GO_Central.
DR   GO; GO:0070098; P:chemokine-mediated signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0006935; P:chemotaxis; IBA:GO_Central.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006955; P:immune response; IBA:GO_Central.
DR   GO; GO:1902230; P:negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage; IMP:BHF-UCL.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IBA:GO_Central.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:1905322; P:positive regulation of mesenchymal stem cell migration; IEA:Ensembl.
DR   GO; GO:0031623; P:receptor internalization; IMP:UniProtKB.
DR   GO; GO:0001570; P:vasculogenesis; IEA:InterPro.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   InterPro; IPR001416; ACKR3.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   PANTHER; PTHR10489:SF931; PTHR10489:SF931; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00646; RDC1ORPHANR.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell adhesion; Cell membrane; Cytoplasm;
KW   Developmental protein; Disulfide bond; Endosome;
KW   G-protein coupled receptor; Glycoprotein; Host-virus interaction; Membrane;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome; Transducer;
KW   Transmembrane; Transmembrane helix; Ubl conjugation.
FT   CHAIN           1..362
FT                   /note="Atypical chemokine receptor 3"
FT                   /id="PRO_0000070101"
FT   TOPO_DOM        1..40
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        41..61
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        62..81
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        82..102
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        103..118
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        119..139
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        140..162
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        163..183
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        184..213
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        214..234
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        235..252
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        253..273
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        274..296
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        297..319
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        320..362
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REGION          324..362
FT                   /note="C-terminal cytoplasmic tail"
FT   MOD_RES         347
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P56485"
FT   MOD_RES         350
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P56485"
FT   MOD_RES         355
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P56485"
FT   CARBOHYD        13
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        22
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        39
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        117..196
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VARIANT         219
FT                   /note="L -> W (in dbSNP:rs10183641)"
FT                   /id="VAR_027477"
FT   MUTAGEN         145
FT                   /note="S->A: Does not result in CXCL12-inducible
FT                   chemotaxis, calcium mobilization or ERK activation, and has
FT                   no effect on CXCR7-mediated CXCL12 degradation; when
FT                   associated with V-147."
FT                   /evidence="ECO:0000269|PubMed:20161793"
FT   MUTAGEN         147
FT                   /note="T->V: Does not result in CXCL12-inducible
FT                   chemotaxis, calcium mobilization or ERK activation, and has
FT                   no effect on CXCR7-mediated CXCL12 degradation; when
FT                   associated with A-145."
FT                   /evidence="ECO:0000269|PubMed:20161793"
FT   CONFLICT        9
FT                   /note="S -> A (in Ref. 1; AAA62370)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        130
FT                   /note="G -> S (in Ref. 1; AAA62370, 2; AAB16913 and 3;
FT                   AAB94130)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        131
FT                   /note="S -> G (in Ref. 1; AAA62370)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        228
FT                   /note="I -> V (in Ref. 8; AAH36661)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        360..361
FT                   /note="ST -> NA (in Ref. 1; AAA62370)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   362 AA;  41493 MW;  A863EC1AFB5B158B CRC64;
     MDLHLFDYSE PGNFSDISWP CNSSDCIVVD TVMCPNMPNK SVLLYTLSFI YIFIFVIGMI
     ANSVVVWVNI QAKTTGYDTH CYILNLAIAD LWVVLTIPVW VVSLVQHNQW PMGELTCKVT
     HLIFSINLFG SIFFLTCMSV DRYLSITYFT NTPSSRKKMV RRVVCILVWL LAFCVSLPDT
     YYLKTVTSAS NNETYCRSFY PEHSIKEWLI GMELVSVVLG FAVPFSIIAV FYFLLARAIS
     ASSDQEKHSS RKIIFSYVVV FLVCWLPYHV AVLLDIFSIL HYIPFTCRLE HALFTALHVT
     QCLSLVHCCV NPVLYSFINR NYRYELMKAF IFKYSAKTGL TKLIDASRVS ETEYSALEQS
     TK
//
ID   DRD3_HUMAN              Reviewed;         400 AA.
AC   P35462; A1A4V5; Q4VBM8;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 2.
DT   07-OCT-2020, entry version 198.
DE   RecName: Full=D(3) dopamine receptor;
DE   AltName: Full=Dopamine D3 receptor;
GN   Name=DRD3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2129115;
RA   Giros B., Martres M.-P., Sokoloff P., Schwartz J.-C.;
RT   "Gene cloning of human dopaminergic D3 receptor and identification of its
RT   chromosome.";
RL   C. R. Acad. Sci. III, Sci. Vie 311:501-508(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=8415635; DOI=10.1073/pnas.90.19.8942;
RA   Schmauss C., Haroutunian V., Davis K.L., Davidson M.;
RT   "Selective loss of dopamine D3-type receptor mRNA expression in parietal
RT   and motor cortices of patients with chronic schizophrenia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:8942-8946(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING.
RC   TISSUE=Brain;
RX   PubMed=7961889;
RA   Liu K., Bergson C., Levenson R., Schmauss C.;
RT   "On the origin of mRNA encoding the truncated dopamine D3-type receptor
RT   D3nf and detection of D3nf-like immunoreactivity in human brain.";
RL   J. Biol. Chem. 269:29220-29226(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Fishburn C.S., Park B.-H., Fuchs S.;
RL   Submitted (JUL-1995) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT GLY-9.
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT GLY-9.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   INVOLVEMENT IN SCZD, AND VARIANT GLY-9.
RX   PubMed=1362221; DOI=10.1136/jmg.29.12.858;
RA   Crocq M.A., Mant R., Asherson P., Williams J., Hode Y., Mayerova A.,
RA   Collier D., Lannfelt L., Sokoloff P., Schwartz J.C.;
RT   "Association between schizophrenia and homozygosity at the dopamine D3
RT   receptor gene.";
RL   J. Med. Genet. 29:858-860(1992).
RN   [9]
RP   INVOLVEMENT IN SCZD, AND VARIANT GLY-9.
RX   PubMed=9514583;
RX   DOI=10.1002/(sici)1096-8628(19980207)81:1<24::aid-ajmg5>3.0.co;2-n;
RA   Spurlock G., Williams J., McGuffin P., Aschauer H.N., Lenzinger E.,
RA   Fuchs K., Sieghart W.C., Meszaros K., Fathi N., Laurent C., Mallet J.,
RA   Macciardi F., Pedrini S., Gill M., Hawi Z., Gibson S., Jazin E.E.,
RA   Yang H.T., Adolfsson R., Pato C.N., Dourado A.M., Owen M.J.;
RT   "European multicentre association study of schizophrenia: a study of the
RT   DRD2 Ser311Cys and DRD3 Ser9Gly polymorphisms.";
RL   Am. J. Med. Genet. 81:24-28(1998).
RN   [10]
RP   INTERACTION WITH PALM.
RX   PubMed=16386234; DOI=10.1016/j.abb.2005.10.027;
RA   Basile M., Lin R., Kabbani N., Karpa K., Kilimann M., Simpson I.,
RA   Kester M.;
RT   "Paralemmin interacts with D3 dopamine receptors: implications for membrane
RT   localization and cAMP signaling.";
RL   Arch. Biochem. Biophys. 446:60-68(2006).
RN   [11]
RP   PHOSPHORYLATION BY GRK4, SUBCELLULAR LOCATION, INTERACTION WITH GRK4, AND
RP   FUNCTION.
RX   PubMed=19520868; DOI=10.1074/jbc.m109.003665;
RA   Villar V.A.M., Jones J.E., Armando I., Palmes-Saloma C., Yu P.,
RA   Pascua A.M., Keever L., Arnaldo F.B., Wang Z., Luo Y., Felder R.A.,
RA   Jose P.A.;
RT   "G protein-coupled receptor kinase 4 (GRK4) regulates the phosphorylation
RT   and function of the dopamine D3 receptor.";
RL   J. Biol. Chem. 284:21425-21434(2009).
RN   [12]
RP   INTERACTION WITH FLNA.
RX   PubMed=26460884; DOI=10.1021/acs.biochem.5b00975;
RA   Tirupula K.C., Ithychanda S.S., Mohan M.L., Naga Prasad S.V., Qin J.,
RA   Karnik S.S.;
RT   "G Protein-Coupled Receptors Directly Bind Filamin A with High Affinity and
RT   Promote Filamin Phosphorylation.";
RL   Biochemistry 54:6673-6683(2015).
RN   [13]
RP   PALMITOYLATION.
RX   PubMed=27659709; DOI=10.1016/j.bbrc.2016.09.094;
RA   Zhang X., Kim K.M.;
RT   "Palmitoylation of the carboxyl-terminal tail of dopamine D4 receptor is
RT   required for surface expression, endocytosis, and signaling.";
RL   Biochem. Biophys. Res. Commun. 479:398-403(2016).
RN   [14] {ECO:0000244|PDB:3PBL}
RP   X-RAY CRYSTALLOGRAPHY (2.89 ANGSTROMS) OF 2-221 AND 319-400 IN COMPLEX WITH
RP   THE ANTAGONIST ETICLOPRIDE, DISULFIDE BONDS, AND MEMBRANE TOPOLOGY.
RX   PubMed=21097933; DOI=10.1126/science.1197410;
RA   Chien E.Y., Liu W., Zhao Q., Katritch V., Han G.W., Hanson M.A., Shi L.,
RA   Newman A.H., Javitch J.A., Cherezov V., Stevens R.C.;
RT   "Structure of the human dopamine D3 receptor in complex with a D2/D3
RT   selective antagonist.";
RL   Science 330:1091-1095(2010).
RN   [15]
RP   VARIANT GLY-9.
RA   Lannfelt T., Sokoloff P., Martres M.-P., Pilon C., Giros B., Joensson E.,
RA   Sedvall G., Schwartz J.-C.;
RT   "Amino-acid substitution in the dopamine D3 receptor as useful polymorphism
RT   for investigating psychiatric disorders.";
RL   Psychiatr. Genet. 2:249-256(1992).
RN   [16]
RP   VARIANT GLY-9.
RX   PubMed=9034004;
RX   DOI=10.1002/(sici)1096-8628(19970221)74:1<40::aid-ajmg9>3.0.co;2-z;
RA   Chen C.-H., Liu M.-Y., Wei F.-C., Koong F.-J., Hwu H.-G., Hsiao K.-J.;
RT   "Further evidence of no association between Ser9Gly polymorphism of
RT   dopamine D3 receptor gene and schizophrenia.";
RL   Am. J. Med. Genet. 74:40-43(1997).
RN   [17]
RP   VARIANT GLY-9.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions of
RT   human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [18]
RP   ERRATUM OF PUBMED:10391209.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [19]
RP   VARIANT GLY-9, AND INVOLVEMENT IN SUSCEPTIBILITY TO ETM1.
RX   PubMed=16650084; DOI=10.1111/j.1399-0004.2006.00600.x;
RA   Lucotte G., Lagarde J.-P., Funalot B., Sokoloff P.;
RT   "Linkage with the Ser9Gly DRD3 polymorphism in essential tremor families.";
RL   Clin. Genet. 69:437-440(2006).
RN   [20]
RP   VARIANT GLY-9, CHARACTERIZATION OF VARIANT GLY-9, AND INVOLVEMENT IN
RP   SUSCEPTIBILITY TO ETM1.
RX   PubMed=16809426; DOI=10.1073/pnas.0508189103;
RA   Jeanneteau F., Funalot B., Jankovic J., Deng H., Lagarde J.-P., Lucotte G.,
RA   Sokoloff P.;
RT   "A functional variant of the dopamine D3 receptor is associated with risk
RT   and age-at-onset of essential tremor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:10753-10758(2006).
CC   -!- FUNCTION: Dopamine receptor whose activity is mediated by G proteins
CC       which inhibit adenylyl cyclase. Promotes cell proliferation.
CC       {ECO:0000269|PubMed:19520868}.
CC   -!- SUBUNIT: Interacts with CLIC6 (By similarity). Interacts with GRK4
CC       (PubMed:19520868). Interacts with PALM (PubMed:16386234). Interacts
CC       with FLNA (via filamin repeat 21); increases PKA-mediated
CC       phosphorylation of FLNA (PubMed:26460884).
CC       {ECO:0000250|UniProtKB:P19020, ECO:0000269|PubMed:16386234,
CC       ECO:0000269|PubMed:19520868, ECO:0000269|PubMed:26460884}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:19520868};
CC       Multi-pass membrane protein {ECO:0000269|PubMed:19520868}. Note=Both
CC       membrane-bound and scattered in the cytoplasm during basal conditions.
CC       Receptor stimulation results in the rapid internalization and
CC       sequestration of the receptors at the perinuclear area (5 and 15
CC       minutes), followed by the dispersal of the receptors to the membrane
CC       (30 minutes). DRD3 and GRK4 co-localize in lipid rafts of renal
CC       proximal tubule cells.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=D3;
CC         IsoId=P35462-1; Sequence=Displayed;
CC       Name=3;
CC         IsoId=P35462-3; Sequence=VSP_040570;
CC   -!- TISSUE SPECIFICITY: Brain.
CC   -!- PTM: Phosphorylated by GRK4 (GRK4-alpha and GRK4-gamma).
CC       {ECO:0000269|PubMed:19520868}.
CC   -!- PTM: Palmitoylated. {ECO:0000269|PubMed:27659709}.
CC   -!- DISEASE: Tremor, hereditary essential 1 (ETM1) [MIM:190300]: A common
CC       movement disorder mainly characterized by postural tremor of the arms.
CC       Head, legs, trunk, voice, jaw, and facial muscles also may be involved.
CC       The condition can be aggravated by emotions, hunger, fatigue and
CC       temperature extremes, and may cause a functional disability or even
CC       incapacitation. Inheritance is autosomal dominant.
CC       {ECO:0000269|PubMed:16650084, ECO:0000269|PubMed:16809426}.
CC       Note=Disease susceptibility is associated with variations affecting the
CC       gene represented in this entry.
CC   -!- DISEASE: Schizophrenia (SCZD) [MIM:181500]: A complex, multifactorial
CC       psychotic disorder or group of disorders characterized by disturbances
CC       in the form and content of thought (e.g. delusions, hallucinations), in
CC       mood (e.g. inappropriate affect), in sense of self and relationship to
CC       the external world (e.g. loss of ego boundaries, withdrawal), and in
CC       behavior (e.g bizarre or apparently purposeless behavior). Although it
CC       affects emotions, it is distinguished from mood disorders in which such
CC       disturbances are primary. Similarly, there may be mild impairment of
CC       cognitive function, and it is distinguished from the dementias in which
CC       disturbed cognitive function is considered primary. Some patients
CC       manifest schizophrenic as well as bipolar disorder symptoms and are
CC       often given the diagnosis of schizoaffective disorder.
CC       {ECO:0000269|PubMed:1362221, ECO:0000269|PubMed:9514583}. Note=Disease
CC       susceptibility may be associated with variations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA03543.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=AAA64369.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=DRD3";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L20469; AAA03543.1; ALT_FRAME; mRNA.
DR   EMBL; AH003061; AAA64369.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; U32499; AAA73929.1; -; mRNA.
DR   EMBL; AC092896; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471052; EAW79610.1; -; Genomic_DNA.
DR   EMBL; BC095510; AAH95510.1; -; mRNA.
DR   EMBL; BC128123; AAI28124.1; -; mRNA.
DR   CCDS; CCDS2978.1; -. [P35462-1]
DR   CCDS; CCDS33829.1; -. [P35462-3]
DR   PIR; A48258; A48258.
DR   PIR; A55419; A55419.
DR   PIR; G01977; G01977.
DR   RefSeq; NP_000787.2; NM_000796.5.
DR   RefSeq; NP_001269492.1; NM_001282563.2.
DR   RefSeq; NP_001277738.1; NM_001290809.1.
DR   RefSeq; NP_387512.3; NM_033663.5.
DR   PDB; 3PBL; X-ray; 2.89 A; A/B=2-221, A/B=319-400.
DR   PDBsum; 3PBL; -.
DR   SMR; P35462; -.
DR   BioGRID; 108148; 13.
DR   DIP; DIP-5976N; -.
DR   IntAct; P35462; 6.
DR   STRING; 9606.ENSP00000373169; -.
DR   BindingDB; P35462; -.
DR   ChEMBL; CHEMBL234; -.
DR   DrugBank; DB05766; ACP-104.
DR   DrugBank; DB06288; Amisulpride.
DR   DrugBank; DB00543; Amoxapine.
DR   DrugBank; DB00714; Apomorphine.
DR   DrugBank; DB01238; Aripiprazole.
DR   DrugBank; DB14185; Aripiprazole lauroxil.
DR   DrugBank; DB09207; AS-8112.
DR   DrugBank; DB06216; Asenapine.
DR   DrugBank; DB09223; Blonanserin.
DR   DrugBank; DB01200; Bromocriptine.
DR   DrugBank; DB00490; Buspirone.
DR   DrugBank; DB00248; Cabergoline.
DR   DrugBank; DB09014; Captodiame.
DR   DrugBank; DB06016; Cariprazine.
DR   DrugBank; DB00477; Chlorpromazine.
DR   DrugBank; DB01239; Chlorprothixene.
DR   DrugBank; DB00363; Clozapine.
DR   DrugBank; DB11274; Dihydro-alpha-ergocryptine.
DR   DrugBank; DB13345; Dihydroergocristine.
DR   DrugBank; DB01184; Domperidone.
DR   DrugBank; DB00988; Dopamine.
DR   DrugBank; DB11275; Epicriptine.
DR   DrugBank; DB01049; Ergoloid mesylate.
DR   DrugBank; DB00502; Haloperidol.
DR   DrugBank; DB04946; Iloperidone.
DR   DrugBank; DB01235; Levodopa.
DR   DrugBank; DB00589; Lisuride.
DR   DrugBank; DB00408; Loxapine.
DR   DrugBank; DB01403; Methotrimeprazine.
DR   DrugBank; DB06148; Mianserin.
DR   DrugBank; DB00334; Olanzapine.
DR   DrugBank; DB01267; Paliperidone.
DR   DrugBank; DB12061; Pardoprunox.
DR   DrugBank; DB01186; Pergolide.
DR   DrugBank; DB01100; Pimozide.
DR   DrugBank; DB09286; Pipamperone.
DR   DrugBank; DB12478; Piribedil.
DR   DrugBank; DB00413; Pramipexole.
DR   DrugBank; DB01224; Quetiapine.
DR   DrugBank; DB00409; Remoxipride.
DR   DrugBank; DB00268; Ropinirole.
DR   DrugBank; DB05271; Rotigotine.
DR   DrugBank; DB06454; Sarizotan.
DR   DrugBank; DB00391; Sulpiride.
DR   DrugBank; DB06477; Sumanirole.
DR   DrugBank; DB09289; Tianeptine.
DR   DrugBank; DB13025; Tiapride.
DR   DrugBank; DB01392; Yohimbine.
DR   DrugBank; DB00246; Ziprasidone.
DR   DrugCentral; P35462; -.
DR   GuidetoPHARMACOLOGY; 216; -.
DR   TCDB; 9.A.14.3.9; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; P35462; 4 sites.
DR   iPTMnet; P35462; -.
DR   PhosphoSitePlus; P35462; -.
DR   SwissPalm; P35462; -.
DR   BioMuta; DRD3; -.
DR   DMDM; 1169206; -.
DR   PaxDb; P35462; -.
DR   PeptideAtlas; P35462; -.
DR   PRIDE; P35462; -.
DR   ProteomicsDB; 55066; -. [P35462-1]
DR   ProteomicsDB; 55067; -. [P35462-3]
DR   ABCD; P35462; 1 sequenced antibody.
DR   Antibodypedia; 16482; 260 antibodies.
DR   DNASU; 1814; -.
DR   Ensembl; ENST00000383673; ENSP00000373169; ENSG00000151577.
DR   Ensembl; ENST00000460779; ENSP00000419402; ENSG00000151577.
DR   Ensembl; ENST00000467632; ENSP00000420662; ENSG00000151577.
DR   GeneID; 1814; -.
DR   KEGG; hsa:1814; -.
DR   CTD; 1814; -.
DR   DisGeNET; 1814; -.
DR   EuPathDB; HostDB:ENSG00000151577.12; -.
DR   GeneCards; DRD3; -.
DR   HGNC; HGNC:3024; DRD3.
DR   HPA; ENSG00000151577; Tissue enhanced (blood, brain, testis).
DR   MalaCards; DRD3; -.
DR   MIM; 126451; gene.
DR   MIM; 181500; phenotype.
DR   MIM; 190300; phenotype.
DR   neXtProt; NX_P35462; -.
DR   Orphanet; 862; NON RARE IN EUROPE: Hereditary essential tremor.
DR   PharmGKB; PA27479; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   InParanoid; P35462; -.
DR   KO; K04146; -.
DR   PhylomeDB; P35462; -.
DR   TreeFam; TF334382; -.
DR   PathwayCommons; P35462; -.
DR   Reactome; R-HSA-390651; Dopamine receptors.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   SignaLink; P35462; -.
DR   SIGNOR; P35462; -.
DR   BioGRID-ORCS; 1814; 2 hits in 868 CRISPR screens.
DR   GenomeRNAi; 1814; -.
DR   Pharos; P35462; Tclin.
DR   PRO; PR:P35462; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; P35462; protein.
DR   Bgee; ENSG00000151577; Expressed in nucleus accumbens and 20 other tissues.
DR   ExpressionAtlas; P35462; baseline and differential.
DR   Genevisible; P35462; HS.
DR   GO; GO:0045177; C:apical part of cell; IEA:Ensembl.
DR   GO; GO:0042995; C:cell projection; IEA:Ensembl.
DR   GO; GO:0098691; C:dopaminergic synapse; IEA:Ensembl.
DR   GO; GO:0030139; C:endocytic vesicle; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0031748; F:D1 dopamine receptor binding; IEA:Ensembl.
DR   GO; GO:0035240; F:dopamine binding; IEA:Ensembl.
DR   GO; GO:0001591; F:dopamine neurotransmitter receptor activity, coupled via Gi/Go; IDA:BHF-UCL.
DR   GO; GO:0008144; F:drug binding; IDA:BHF-UCL.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0019904; F:protein domain specific binding; IEA:Ensembl.
DR   GO; GO:0046717; P:acid secretion; ISS:BHF-UCL.
DR   GO; GO:0071880; P:adenylate cyclase-activating adrenergic receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007191; P:adenylate cyclase-activating dopamine receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0007195; P:adenylate cyclase-inhibiting dopamine receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0007188; P:adenylate cyclase-modulating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0050482; P:arachidonic acid secretion; IDA:BHF-UCL.
DR   GO; GO:0006914; P:autophagy; IEA:Ensembl.
DR   GO; GO:0048148; P:behavioral response to cocaine; IEP:BHF-UCL.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IDA:BHF-UCL.
DR   GO; GO:0032922; P:circadian regulation of gene expression; ISS:BHF-UCL.
DR   GO; GO:0042417; P:dopamine metabolic process; IC:BHF-UCL.
DR   GO; GO:0002031; P:G protein-coupled receptor internalization; IDA:BHF-UCL.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0035483; P:gastric emptying; IEA:Ensembl.
DR   GO; GO:0007612; P:learning; NAS:BHF-UCL.
DR   GO; GO:0007611; P:learning or memory; NAS:BHF-UCL.
DR   GO; GO:0007626; P:locomotory behavior; ISS:BHF-UCL.
DR   GO; GO:0050883; P:musculoskeletal movement, spinal reflex action; ISS:BHF-UCL.
DR   GO; GO:0007194; P:negative regulation of adenylate cyclase activity; IBA:GO_Central.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0045776; P:negative regulation of blood pressure; ISS:BHF-UCL.
DR   GO; GO:0051481; P:negative regulation of cytosolic calcium ion concentration; IBA:GO_Central.
DR   GO; GO:0060160; P:negative regulation of dopamine receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0048715; P:negative regulation of oligodendrocyte differentiation; ISS:BHF-UCL.
DR   GO; GO:0051898; P:negative regulation of protein kinase B signaling; ISS:BHF-UCL.
DR   GO; GO:0050709; P:negative regulation of protein secretion; IDA:BHF-UCL.
DR   GO; GO:0032416; P:negative regulation of sodium:proton antiporter activity; IEA:Ensembl.
DR   GO; GO:0051967; P:negative regulation of synaptic transmission, glutamatergic; IBA:GO_Central.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:1901386; P:negative regulation of voltage-gated calcium channel activity; IBA:GO_Central.
DR   GO; GO:0060158; P:phospholipase C-activating dopamine receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0032467; P:positive regulation of cytokinesis; IMP:UniProtKB.
DR   GO; GO:0051482; P:positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway; IBA:GO_Central.
DR   GO; GO:0060161; P:positive regulation of dopamine receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0045840; P:positive regulation of mitotic nuclear division; ISS:BHF-UCL.
DR   GO; GO:0035815; P:positive regulation of renal sodium excretion; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0060134; P:prepulse inhibition; IMP:BHF-UCL.
DR   GO; GO:0002016; P:regulation of blood volume by renin-angiotensin; IEA:Ensembl.
DR   GO; GO:0045187; P:regulation of circadian sleep/wake cycle, sleep; IEA:Ensembl.
DR   GO; GO:0014059; P:regulation of dopamine secretion; ISS:BHF-UCL.
DR   GO; GO:0051584; P:regulation of dopamine uptake involved in synaptic transmission; IC:BHF-UCL.
DR   GO; GO:0019216; P:regulation of lipid metabolic process; IEA:Ensembl.
DR   GO; GO:0090325; P:regulation of locomotion involved in locomotory behavior; IEA:Ensembl.
DR   GO; GO:0040014; P:regulation of multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0043266; P:regulation of potassium ion transport; IBA:GO_Central.
DR   GO; GO:0001975; P:response to amphetamine; IEA:Ensembl.
DR   GO; GO:0042220; P:response to cocaine; IEP:BHF-UCL.
DR   GO; GO:0042493; P:response to drug; ISS:BHF-UCL.
DR   GO; GO:0034776; P:response to histamine; IDA:BHF-UCL.
DR   GO; GO:0043278; P:response to morphine; ISS:BHF-UCL.
DR   GO; GO:0035176; P:social behavior; NAS:BHF-UCL.
DR   GO; GO:0001963; P:synaptic transmission, dopaminergic; IBA:GO_Central.
DR   GO; GO:0008542; P:visual learning; ISS:BHF-UCL.
DR   InterPro; IPR001620; Dopamine_D3_rcpt.
DR   InterPro; IPR000929; Dopamine_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00568; DOPAMINED3R.
DR   PRINTS; PR00242; DOPAMINER.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane; Palmitate;
KW   Polymorphism; Receptor; Reference proteome; Schizophrenia; Transducer;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..400
FT                   /note="D(3) dopamine receptor"
FT                   /id="PRO_0000069397"
FT   TOPO_DOM        1..32
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:21097933"
FT   TRANSMEM        33..55
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000269|PubMed:21097933"
FT   TOPO_DOM        56..65
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:21097933"
FT   TRANSMEM        66..88
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000269|PubMed:21097933"
FT   TOPO_DOM        89..104
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:21097933"
FT   TRANSMEM        105..126
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000269|PubMed:21097933"
FT   TOPO_DOM        127..149
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:21097933"
FT   TRANSMEM        150..170
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000269|PubMed:21097933"
FT   TOPO_DOM        171..187
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:21097933"
FT   TRANSMEM        188..209
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000269|PubMed:21097933"
FT   TOPO_DOM        210..329
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:21097933"
FT   TRANSMEM        330..351
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000269|PubMed:21097933"
FT   TOPO_DOM        352..366
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:21097933"
FT   TRANSMEM        367..386
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000269|PubMed:21097933"
FT   TOPO_DOM        387..400
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:21097933"
FT   REGION          189..196
FT                   /note="Agonist binding"
FT   REGION          342..350
FT                   /note="Agonist binding"
FT   BINDING         110
FT                   /note="Agonist"
FT   CARBOHYD        12
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        19
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        97
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        173
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        103..181
FT                   /evidence="ECO:0000244|PDB:3PBL, ECO:0000255|PROSITE-
FT                   ProRule:PRU00521, ECO:0000269|PubMed:21097933"
FT   DISULFID        355..358
FT                   /evidence="ECO:0000244|PDB:3PBL, ECO:0000255|PROSITE-
FT                   ProRule:PRU00521, ECO:0000269|PubMed:21097933"
FT   VAR_SEQ         287..320
FT                   /note="SPTIAPKLSLEVRKLSNGRLSTSLKLGPLQPRGV -> M (in isoform
FT                   3)"
FT                   /evidence="ECO:0000303|PubMed:8415635"
FT                   /id="VSP_040570"
FT   VARIANT         9
FT                   /note="S -> G (polymorphism; associated with susceptibility
FT                   to essential tremor; risk factor for schizophrenia; gain of
FT                   function; dbSNP:rs6280)"
FT                   /evidence="ECO:0000269|PubMed:10391209,
FT                   ECO:0000269|PubMed:1362221, ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:16641997, ECO:0000269|PubMed:16650084,
FT                   ECO:0000269|PubMed:16809426, ECO:0000269|PubMed:9034004,
FT                   ECO:0000269|PubMed:9514583, ECO:0000269|Ref.15"
FT                   /id="VAR_003463"
FT   CONFLICT        396
FT                   /note="K -> L (in Ref. 7; AAH95510)"
FT                   /evidence="ECO:0000305"
FT   HELIX           35..56
FT                   /evidence="ECO:0000244|PDB:3PBL"
FT   HELIX           63..81
FT                   /evidence="ECO:0000244|PDB:3PBL"
FT   HELIX           83..91
FT                   /evidence="ECO:0000244|PDB:3PBL"
FT   HELIX           100..133
FT                   /evidence="ECO:0000244|PDB:3PBL"
FT   HELIX           135..140
FT                   /evidence="ECO:0000244|PDB:3PBL"
FT   STRAND          143..145
FT                   /evidence="ECO:0000244|PDB:3PBL"
FT   HELIX           147..169
FT                   /evidence="ECO:0000244|PDB:3PBL"
FT   TURN            170..172
FT                   /evidence="ECO:0000244|PDB:3PBL"
FT   HELIX           186..196
FT                   /evidence="ECO:0000244|PDB:3PBL"
FT   HELIX           198..216
FT                   /evidence="ECO:0000244|PDB:3PBL"
FT   HELIX           322..353
FT                   /evidence="ECO:0000244|PDB:3PBL"
FT   HELIX           362..386
FT                   /evidence="ECO:0000244|PDB:3PBL"
FT   HELIX           388..398
FT                   /evidence="ECO:0000244|PDB:3PBL"
SQ   SEQUENCE   400 AA;  44225 MW;  2CDA789D78378DDA CRC64;
     MASLSQLSSH LNYTCGAENS TGASQARPHA YYALSYCALI LAIVFGNGLV CMAVLKERAL
     QTTTNYLVVS LAVADLLVAT LVMPWVVYLE VTGGVWNFSR ICCDVFVTLD VMMCTASILN
     LCAISIDRYT AVVMPVHYQH GTGQSSCRRV ALMITAVWVL AFAVSCPLLF GFNTTGDPTV
     CSISNPDFVI YSSVVSFYLP FGVTVLVYAR IYVVLKQRRR KRILTRQNSQ CNSVRPGFPQ
     QTLSPDPAHL ELKRYYSICQ DTALGGPGFQ ERGGELKREE KTRNSLSPTI APKLSLEVRK
     LSNGRLSTSL KLGPLQPRGV PLREKKATQM VAIVLGAFIV CWLPFFLTHV LNTHCQTCHV
     SPELYSATTW LGYVNSALNP VIYTTFNIEF RKAFLKILSC
//
ID   FZD8_HUMAN              Reviewed;         694 AA.
AC   Q9H461;
DT   05-DEC-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2001, sequence version 1.
DT   07-OCT-2020, entry version 175.
DE   RecName: Full=Frizzled-8;
DE            Short=Fz-8;
DE            Short=hFz8;
DE   Flags: Precursor;
GN   Name=FZD8;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=11295046; DOI=10.3892/ijo.18.5.991;
RA   Saitoh T., Hirai M., Katoh M.;
RT   "Molecular cloning and characterization of human Frizzled-8 gene on
RT   chromosome 10p11.2.";
RL   Int. J. Oncol. 18:991-996(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [3]
RP   INTERACTION WITH LRP5 AND LRP6 IN THE WNT-FZD-LRP5-LRP6 COMPLEX, AND
RP   FUNCTION.
RX   PubMed=11448771; DOI=10.1016/s0960-9822(01)00290-1;
RA   Semenov M.V., Tamai K., Brott B.K., Kuhl M., Sokol S., He X.;
RT   "Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6.";
RL   Curr. Biol. 11:951-961(2001).
RN   [4]
RP   INTERACTION WITH GOPC.
RX   PubMed=16882988; DOI=10.1110/ps.062087506;
RA   Li X., Zhang J., Cao Z., Wu J., Shi Y.;
RT   "Solution structure of GOPC PDZ domain and its interaction with the C-
RT   terminal motif of neuroligin.";
RL   Protein Sci. 15:2149-2158(2006).
RN   [5]
RP   UBIQUITINATION BY ZNRF3.
RX   PubMed=22575959; DOI=10.1038/nature11019;
RA   Hao H.X., Xie Y., Zhang Y., Charlat O., Oster E., Avello M., Lei H.,
RA   Mickanin C., Liu D., Ruffner H., Mao X., Ma Q., Zamponi R., Bouwmeester T.,
RA   Finan P.M., Kirschner M.W., Porter J.A., Serluca F.C., Cong F.;
RT   "ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner.";
RL   Nature 485:195-200(2012).
RN   [6]
RP   INTERACTION WITH GPC3.
RX   PubMed=24496449; DOI=10.1242/jcs.140871;
RA   Capurro M., Martin T., Shi W., Filmus J.;
RT   "Glypican-3 binds to Frizzled and plays a direct role in the stimulation of
RT   canonical Wnt signaling.";
RL   J. Cell Sci. 127:1565-1575(2014).
CC   -!- FUNCTION: Receptor for Wnt proteins. Component of the Wnt-Fzd-LRP5-LRP6
CC       complex that triggers beta-catenin signaling through inducing
CC       aggregation of receptor-ligand complexes into ribosome-sized
CC       signalosomes. The beta-catenin canonical signaling pathway leads to the
CC       activation of disheveled proteins, inhibition of GSK-3 kinase, nuclear
CC       accumulation of beta-catenin and activation of Wnt target genes. A
CC       second signaling pathway involving PKC and calcium fluxes has been seen
CC       for some family members, but it is not yet clear if it represents a
CC       distinct pathway or if it can be integrated in the canonical pathway,
CC       as PKC seems to be required for Wnt-mediated inactivation of GSK-3
CC       kinase. Both pathways seem to involve interactions with G-proteins. May
CC       be involved in transduction and intercellular transmission of polarity
CC       information during tissue morphogenesis and/or in differentiated
CC       tissues. Coreceptor along with RYK of Wnt proteins, such as WNT1.
CC       {ECO:0000269|PubMed:11448771}.
CC   -!- SUBUNIT: Component of a Wnt-signaling complex that contains a WNT
CC       protein, a FZD protein and LRP5 or LRP6. Interacts directly with LRP5
CC       or LRP6; the interaction is promoted by Wnt-binding and signaling and
CC       inhibited by DKK1. Interacts with GPOC, RSPO1 and RSPO3 (By
CC       similarity). Interacts with glypican GPC3 (PubMed:24496449).
CC       {ECO:0000250, ECO:0000269|PubMed:24496449}.
CC   -!- INTERACTION:
CC       Q9H461; P56704: WNT3A; NbExp=2; IntAct=EBI-6254212, EBI-6173037;
CC       Q9H461; P98086: C1qa; Xeno; NbExp=3; IntAct=EBI-6254212, EBI-299840;
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein. Golgi
CC       apparatus {ECO:0000250}. Cell membrane {ECO:0000250}; Multi-pass
CC       membrane protein {ECO:0000250}. Note=Colocalizes with GOPC at the Golgi
CC       apparatus. {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Most abundant in fetal kidney, followed by brain
CC       and lung. In adult tissues, expressed in kidney, heart, pancreas and
CC       skeletal muscle.
CC   -!- DOMAIN: The PDZ-binding motif mediates interaction with GOPC.
CC       {ECO:0000250}.
CC   -!- DOMAIN: Lys-Thr-X-X-X-Trp motif interacts with the PDZ domain of Dvl
CC       (Disheveled) family members and is involved in the activation of the
CC       Wnt/beta-catenin signaling pathway. {ECO:0000250}.
CC   -!- DOMAIN: The FZ domain is involved in binding with Wnt ligands.
CC       {ECO:0000250}.
CC   -!- PTM: Ubiquitinated by ZNRF3, leading to its degradation by the
CC       proteasome. {ECO:0000269|PubMed:22575959}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor Fz/Smo family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB043703; BAB41064.1; -; mRNA.
DR   EMBL; AL121749; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS7192.1; -.
DR   RefSeq; NP_114072.1; NM_031866.2.
DR   PDB; 5UN5; X-ray; 2.99 A; A/B=28-150.
DR   PDB; 5UN6; X-ray; 3.20 A; A/B/C/D=28-150.
DR   PDB; 6NDZ; X-ray; 2.26 A; A/C/E=32-150.
DR   PDBsum; 5UN5; -.
DR   PDBsum; 5UN6; -.
DR   PDBsum; 6NDZ; -.
DR   SMR; Q9H461; -.
DR   BioGRID; 113921; 9.
DR   IntAct; Q9H461; 5.
DR   STRING; 9606.ENSP00000363826; -.
DR   ChEMBL; CHEMBL3559689; -.
DR   GuidetoPHARMACOLOGY; 236; -.
DR   GlyGen; Q9H461; 3 sites.
DR   iPTMnet; Q9H461; -.
DR   PhosphoSitePlus; Q9H461; -.
DR   BioMuta; FZD8; -.
DR   DMDM; 17433053; -.
DR   jPOST; Q9H461; -.
DR   MassIVE; Q9H461; -.
DR   PaxDb; Q9H461; -.
DR   PeptideAtlas; Q9H461; -.
DR   PRIDE; Q9H461; -.
DR   ProteomicsDB; 80787; -.
DR   ABCD; Q9H461; 39 sequenced antibodies.
DR   Antibodypedia; 13314; 314 antibodies.
DR   DNASU; 8325; -.
DR   Ensembl; ENST00000374694; ENSP00000363826; ENSG00000177283.
DR   GeneID; 8325; -.
DR   KEGG; hsa:8325; -.
DR   UCSC; uc001iyz.2; human.
DR   CTD; 8325; -.
DR   DisGeNET; 8325; -.
DR   EuPathDB; HostDB:ENSG00000177283.5; -.
DR   GeneCards; FZD8; -.
DR   HGNC; HGNC:4046; FZD8.
DR   HPA; ENSG00000177283; Low tissue specificity.
DR   MIM; 606146; gene.
DR   neXtProt; NX_Q9H461; -.
DR   OpenTargets; ENSG00000177283; -.
DR   PharmGKB; PA28463; -.
DR   eggNOG; KOG3577; Eukaryota.
DR   GeneTree; ENSGT00940000161191; -.
DR   HOGENOM; CLU_007873_2_0_1; -.
DR   InParanoid; Q9H461; -.
DR   KO; K02375; -.
DR   OMA; HEKVACN; -.
DR   OrthoDB; 509772at2759; -.
DR   PhylomeDB; Q9H461; -.
DR   TreeFam; TF317907; -.
DR   PathwayCommons; Q9H461; -.
DR   Reactome; R-HSA-373080; Class B/2 (Secretin family receptors).
DR   Reactome; R-HSA-4608870; Asymmetric localization of PCP proteins.
DR   Reactome; R-HSA-4641263; Regulation of FZD by ubiquitination.
DR   Reactome; R-HSA-5340588; RNF mutants show enhanced WNT signaling and proliferation.
DR   SignaLink; Q9H461; -.
DR   SIGNOR; Q9H461; -.
DR   BioGRID-ORCS; 8325; 8 hits in 867 CRISPR screens.
DR   GeneWiki; FZD8; -.
DR   GenomeRNAi; 8325; -.
DR   Pharos; Q9H461; Tbio.
DR   PRO; PR:Q9H461; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; Q9H461; protein.
DR   Bgee; ENSG00000177283; Expressed in ventricular zone and 201 other tissues.
DR   Genevisible; Q9H461; HS.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:1990851; C:Wnt-Frizzled-LRP5/6 complex; IEA:Ensembl.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0030165; F:PDZ domain binding; IPI:BHF-UCL.
DR   GO; GO:0005102; F:signaling receptor binding; IEA:Ensembl.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:UniProtKB.
DR   GO; GO:0042813; F:Wnt-activated receptor activity; IDA:WormBase.
DR   GO; GO:0017147; F:Wnt-protein binding; IBA:GO_Central.
DR   GO; GO:0001525; P:angiogenesis; IEA:Ensembl.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IDA:WormBase.
DR   GO; GO:0030182; P:neuron differentiation; ISS:UniProtKB.
DR   GO; GO:0043507; P:positive regulation of JUN kinase activity; IEA:Ensembl.
DR   GO; GO:0033077; P:T cell differentiation in thymus; IEA:Ensembl.
DR   CDD; cd07461; CRD_FZ8; 1.
DR   Gene3D; 1.10.2000.10; -; 1.
DR   InterPro; IPR015526; Frizzled/SFRP.
DR   InterPro; IPR000539; Frizzled/Smoothened_TM.
DR   InterPro; IPR020067; Frizzled_dom.
DR   InterPro; IPR036790; Frizzled_dom_sf.
DR   InterPro; IPR041776; FZ8_CRD.
DR   InterPro; IPR017981; GPCR_2-like.
DR   PANTHER; PTHR11309; PTHR11309; 1.
DR   Pfam; PF01534; Frizzled; 1.
DR   Pfam; PF01392; Fz; 1.
DR   PRINTS; PR00489; FRIZZLED.
DR   SMART; SM00063; FRI; 1.
DR   SMART; SM01330; Frizzled; 1.
DR   SUPFAM; SSF63501; SSF63501; 1.
DR   PROSITE; PS50038; FZ; 1.
DR   PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Developmental protein; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Golgi apparatus; Membrane;
KW   Receptor; Reference proteome; Signal; Transducer; Transmembrane;
KW   Transmembrane helix; Ubl conjugation; Wnt signaling pathway.
FT   SIGNAL          1..27
FT                   /evidence="ECO:0000255"
FT   CHAIN           28..694
FT                   /note="Frizzled-8"
FT                   /id="PRO_0000013000"
FT   TOPO_DOM        28..275
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        276..296
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        297..312
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        313..333
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        334..396
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        397..417
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        418..439
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        440..460
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        461..483
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        484..504
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        505..532
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        533..553
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        554..584
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        585..605
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        606..694
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          30..151
FT                   /note="FZ"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00090"
FT   REGION          71..78
FT                   /note="Palmitate-binding groove"
FT                   /evidence="ECO:0000250"
FT   REGION          95..100
FT                   /note="Wnt-binding"
FT                   /evidence="ECO:0000250"
FT   REGION          147..152
FT                   /note="Wnt-binding"
FT                   /evidence="ECO:0000250"
FT   MOTIF           608..613
FT                   /note="Lys-Thr-X-X-X-Trp motif, mediates interaction with
FT                   the PDZ domain of Dvl family members"
FT                   /evidence="ECO:0000250"
FT   MOTIF           692..694
FT                   /note="PDZ-binding"
FT   COMPBIAS        168..172
FT                   /note="Poly-Pro"
FT   COMPBIAS        194..202
FT                   /note="Poly-Gly"
FT   COMPBIAS        211..216
FT                   /note="Poly-Gly"
FT   COMPBIAS        639..663
FT                   /note="Poly-Gly"
FT   CARBOHYD        49
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        152
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        475
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        35..96
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00090"
FT   DISULFID        43..89
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00090"
FT   DISULFID        80..118
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00090"
FT   DISULFID        107..148
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00090"
FT   DISULFID        111..135
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00090"
FT   STRAND          35..37
FT                   /evidence="ECO:0000244|PDB:5UN6"
FT   HELIX           41..43
FT                   /evidence="ECO:0000244|PDB:6NDZ"
FT   STRAND          50..54
FT                   /evidence="ECO:0000244|PDB:5UN6"
FT   HELIX           62..70
FT                   /evidence="ECO:0000244|PDB:6NDZ"
FT   HELIX           73..78
FT                   /evidence="ECO:0000244|PDB:6NDZ"
FT   HELIX           84..92
FT                   /evidence="ECO:0000244|PDB:6NDZ"
FT   HELIX           108..124
FT                   /evidence="ECO:0000244|PDB:6NDZ"
FT   HELIX           131..133
FT                   /evidence="ECO:0000244|PDB:6NDZ"
FT   STRAND          135..138
FT                   /evidence="ECO:0000244|PDB:6NDZ"
FT   STRAND          144..146
FT                   /evidence="ECO:0000244|PDB:6NDZ"
SQ   SEQUENCE   694 AA;  73300 MW;  E740CBFDA2A233EF CRC64;
     MEWGYLLEVT SLLAALALLQ RSSGAAAASA KELACQEITV PLCKGIGYNY TYMPNQFNHD
     TQDEAGLEVH QFWPLVEIQC SPDLKFFLCS MYTPICLEDY KKPLPPCRSV CERAKAGCAP
     LMRQYGFAWP DRMRCDRLPE QGNPDTLCMD YNRTDLTTAA PSPPRRLPPP PPGEQPPSGS
     GHGRPPGARP PHRGGGRGGG GGDAAAPPAR GGGGGGKARP PGGGAAPCEP GCQCRAPMVS
     VSSERHPLYN RVKTGQIANC ALPCHNPFFS QDERAFTVFW IGLWSVLCFV STFATVSTFL
     IDMERFKYPE RPIIFLSACY LFVSVGYLVR LVAGHEKVAC SGGAPGAGGA GGAGGAAAGA
     GAAGAGAGGP GGRGEYEELG AVEQHVRYET TGPALCTVVF LLVYFFGMAS SIWWVILSLT
     WFLAAGMKWG NEAIAGYSQY FHLAAWLVPS VKSIAVLALS SVDGDPVAGI CYVGNQSLDN
     LRGFVLAPLV IYLFIGTMFL LAGFVSLFRI RSVIKQQDGP TKTHKLEKLM IRLGLFTVLY
     TVPAAVVVAC LFYEQHNRPR WEATHNCPCL RDLQPDQARR PDYAVFMLKY FMCLVVGITS
     GVWVWSGKTL ESWRSLCTRC CWASKGAAVG GGAGATAAGG GGGPGGGGGG GPGGGGGPGG
     GGGSLYSDVS TGLTWRSGTA SSVSYPKQMP LSQV
//
ID   AA3R_HUMAN              Reviewed;         318 AA.
AC   P0DMS8; A2A3P4; P33765; Q6UWU0; Q9BYZ1;
DT   01-APR-2015, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-2015, sequence version 1.
DT   07-OCT-2020, entry version 45.
DE   RecName: Full=Adenosine receptor A3;
GN   Name=ADORA3 {ECO:0000312|HGNC:HGNC:268};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Heart;
RX   PubMed=8399349; DOI=10.1016/0167-4889(93)90077-3;
RA   Sajjadi F.G., Firestein G.S.;
RT   "cDNA cloning and sequence analysis of the human A3 adenosine receptor.";
RL   Biochim. Biophys. Acta 1179:105-107(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RC   TISSUE=Brain;
RX   PubMed=8234299; DOI=10.1073/pnas.90.21.10365;
RA   Salvatore C.A., Jacobson M.A., Taylor H.E., Linden J., Johnson R.G.;
RT   "Molecular cloning and characterization of the human A3 adenosine
RT   receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:10365-10369(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT LEU-248.
RC   TISSUE=Testis;
RA   Meyerehof W., Hamm B., Schoenrock C., Fehr S., Wulfsen I., Richter D.;
RL   Submitted (DEC-1993) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Testis;
RA   Atkinson M.R., Townsend-Nicholson A., Nicholl J.K., Sutherland G.R.,
RA   Schofield P.R.;
RL   Submitted (JUN-1996) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, Lung, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 166-272.
RX   PubMed=11214319; DOI=10.1038/35054550;
RA   Murphy W.J., Eizirik E., Johnson W.E., Zhang Y.-P., Ryder O.A.,
RA   O'Brien S.J.;
RT   "Molecular phylogenetics and the origins of placental mammals.";
RL   Nature 409:614-618(2001).
RN   [9]
RP   FUNCTION, TISSUE SPECIFICITY, AND ALTERNATIVE SPLICING.
RX   PubMed=27886186; DOI=10.1038/ncomms13561;
RA   Iyer S.V., Ranjan A., Elias H.K., Parrales A., Sasaki H., Roy B.C.,
RA   Umar S., Tawfik O.W., Iwakuma T.;
RT   "Genome-wide RNAi screening identifies TMIGD3 isoform1 as a suppressor of
RT   NF-kappaB and osteosarcoma progression.";
RL   Nat. Commun. 7:13561-13561(2016).
RN   [10]
RP   VARIANT [LARGE SCALE ANALYSIS] THR-105.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: [Isoform 2]: Receptor for adenosine. The activity of this
CC       receptor is mediated by G proteins which inhibits adenylyl cyclase
CC       (PubMed:8234299). {ECO:0000269|PubMed:8234299}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250|UniProtKB:Q28309};
CC       Multi-pass membrane protein {ECO:0000255}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=2; Synonyms=A3AR i2 {ECO:0000303|PubMed:27886186}, A3AR
CC       {ECO:0000303|PubMed:27886186};
CC         IsoId=P0DMS8-1; Sequence=Displayed;
CC       Name=1; Synonyms=TMIGD3 i1 {ECO:0000303|PubMed:27886186}, A3AR i1
CC       {ECO:0000303|PubMed:27886186};
CC         IsoId=P0DMS9-2; Sequence=External;
CC       Name=3; Synonyms=TMIGD3 i3, A3AR i3;
CC         IsoId=P0DMS9-1; Sequence=External;
CC   -!- TISSUE SPECIFICITY: Expressed in the lung and bone. Expressed at lower
CC       levels in osteosarcoma tissues (at protein level).
CC       {ECO:0000269|PubMed:27886186}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L20463; AAA16365.1; -; mRNA.
DR   EMBL; L22607; AAA35949.1; -; mRNA.
DR   EMBL; X76981; CAA54288.1; -; mRNA.
DR   EMBL; L77730; AAB02790.1; -; Genomic_DNA.
DR   EMBL; L77729; AAB02790.1; JOINED; Genomic_DNA.
DR   EMBL; AY136749; AAN01275.1; -; mRNA.
DR   EMBL; AL390195; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC029831; AAH29831.1; -; mRNA.
DR   EMBL; AY011231; AAG35155.1; -; Genomic_DNA.
DR   CCDS; CCDS839.1; -. [P0DMS8-1]
DR   PIR; S38511; S38511.
DR   RefSeq; NP_000668.1; NM_000677.3. [P0DMS8-1]
DR   PDB; 1OEA; Model; -; A=1-298.
DR   PDB; 1R7N; Model; -; A=1-318.
DR   PDBsum; 1OEA; -.
DR   PDBsum; 1R7N; -.
DR   SMR; P0DMS8; -.
DR   IntAct; P0DMS8; 6.
DR   BindingDB; P0DMS8; -.
DR   ChEMBL; CHEMBL256; -.
DR   DrugBank; DB00640; Adenosine.
DR   DrugBank; DB01223; Aminophylline.
DR   DrugBank; DB00201; Caffeine.
DR   DrugBank; DB00824; Enprofylline.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB05511; Piclidenoson.
DR   DrugCentral; P0DMS8; -.
DR   GuidetoPHARMACOLOGY; 21; -.
DR   GlyGen; P0DMS8; 3 sites.
DR   iPTMnet; P0DMS8; -.
DR   PhosphoSitePlus; P0DMS8; -.
DR   BioMuta; ADORA3; -.
DR   MassIVE; P0DMS8; -.
DR   PeptideAtlas; P0DMS8; -.
DR   PRIDE; P0DMS8; -.
DR   Antibodypedia; 77173; 126 antibodies.
DR   Ensembl; ENST00000241356; ENSP00000241356; ENSG00000282608. [P0DMS8-1]
DR   GeneID; 140; -.
DR   KEGG; hsa:140; -.
DR   CTD; 140; -.
DR   DisGeNET; 140; -.
DR   EuPathDB; HostDB:ENSG00000282608.1; -.
DR   GeneCards; ADORA3; -.
DR   HGNC; HGNC:268; ADORA3.
DR   HPA; ENSG00000282608; Group enriched (blood, brain).
DR   MIM; 600445; gene.
DR   neXtProt; NX_P0DMS8; -.
DR   OpenTargets; ENSG00000282608; -.
DR   GeneTree; ENSGT00990000203639; -.
DR   HOGENOM; CLU_009579_11_5_1; -.
DR   KO; K04268; -.
DR   OMA; INCITYF; -.
DR   OrthoDB; 550297at2759; -.
DR   PhylomeDB; P0DMS8; -.
DR   PathwayCommons; P0DMS8; -.
DR   Reactome; R-HSA-417973; Adenosine P1 receptors.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   SIGNOR; P0DMS8; -.
DR   BioGRID-ORCS; 140; 2 hits in 869 CRISPR screens.
DR   GenomeRNAi; 140; -.
DR   Pharos; P0DMS8; Tchem.
DR   PRO; PR:P0DMS8; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P0DMS8; protein.
DR   Bgee; ENSG00000282608; Expressed in substantia nigra and 150 other tissues.
DR   ExpressionAtlas; P0DMS8; baseline and differential.
DR   Genevisible; P0DMS8; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0001609; F:G protein-coupled adenosine receptor activity; IEA:InterPro.
DR   GO; GO:0007190; P:activation of adenylate cyclase activity; TAS:ProtInc.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006954; P:inflammatory response; TAS:ProtInc.
DR   GO; GO:0030336; P:negative regulation of cell migration; IMP:UniProtKB.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:UniProtKB.
DR   GO; GO:0032088; P:negative regulation of NF-kappaB transcription factor activity; IMP:UniProtKB.
DR   GO; GO:0008016; P:regulation of heart contraction; TAS:ProtInc.
DR   GO; GO:0009611; P:response to wounding; TAS:ProtInc.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   InterPro; IPR000466; Adeno_A3_rcpt.
DR   InterPro; IPR001634; Adenosn_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00555; ADENOSINEA3R.
DR   PRINTS; PR00424; ADENOSINER.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane; Palmitate;
KW   Polymorphism; Receptor; Reference proteome; Transducer; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..318
FT                   /note="Adenosine receptor A3"
FT                   /id="PRO_0000069010"
FT   TOPO_DOM        1..14
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        15..37
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        38..48
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        49..72
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        73..84
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        85..106
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        107..126
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        127..148
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        149..177
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        178..198
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        199..231
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        232..255
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        256..261
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        262..284
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        285..318
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   LIPID           303
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        3
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        4
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        12
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        83..166
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VARIANT         105
FT                   /note="A -> T (in a colorectal cancer sample; somatic
FT                   mutation; dbSNP:rs746154553)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035755"
FT   VARIANT         248
FT                   /note="I -> L (in dbSNP:rs35511654)"
FT                   /evidence="ECO:0000269|Ref.3"
FT                   /id="VAR_049366"
FT   VARIANT         266
FT                   /note="M -> K (in dbSNP:rs2800889)"
FT                   /id="VAR_049367"
FT   CONFLICT        7
FT                   /note="A -> T (in Ref. 1; AAA16365)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        175
FT                   /note="D -> V (in Ref. 8; AAG35155)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   318 AA;  36185 MW;  690E67986130FC28 CRC64;
     MPNNSTALSL ANVTYITMEI FIGLCAIVGN VLVICVVKLN PSLQTTTFYF IVSLALADIA
     VGVLVMPLAI VVSLGITIHF YSCLFMTCLL LIFTHASIMS LLAIAVDRYL RVKLTVRYKR
     VTTHRRIWLA LGLCWLVSFL VGLTPMFGWN MKLTSEYHRN VTFLSCQFVS VMRMDYMVYF
     SFLTWIFIPL VVMCAIYLDI FYIIRNKLSL NLSNSKETGA FYGREFKTAK SLFLVLFLFA
     LSWLPLSIIN CIIYFNGEVP QLVLYMGILL SHANSMMNPI VYAYKIKKFK ETYLLILKAC
     VVCHPSDSLD TSIEKNSE
//
ID   ACKR1_HUMAN             Reviewed;         336 AA.
AC   Q16570; A8YPG5; O75898; Q16300; Q8WWE3; Q9UJP0; Q9UKZ5; Q9UKZ6; Q9UQE1;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   07-JUN-2005, sequence version 3.
DT   12-AUG-2020, entry version 179.
DE   RecName: Full=Atypical chemokine receptor 1;
DE   AltName: Full=Duffy antigen/chemokine receptor;
DE   AltName: Full=Fy glycoprotein;
DE            Short=GpFy;
DE   AltName: Full=Glycoprotein D;
DE   AltName: Full=Plasmodium vivax receptor;
DE   AltName: CD_antigen=CD234;
GN   Name=ACKR1; Synonyms=DARC, FY, GPD;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PARTIAL PROTEIN SEQUENCE, AND
RP   VARIANT ASP-42.
RC   TISSUE=Bone marrow;
RX   PubMed=8248172; DOI=10.1073/pnas.90.22.10793;
RA   Chaudhuri A., Polyakova J., Zbrzezna V., Williams K., Gulati S., Pogo A.;
RT   "Cloning of glycoprotein D cDNA, which encodes the major subunit of the
RT   Duffy blood group system and the receptor for the Plasmodium vivax malaria
RT   parasite.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:10793-10797(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ASP-42.
RC   TISSUE=Blood;
RX   PubMed=7663520; DOI=10.1038/ng0695-224;
RA   Tournamille C., Colin Y., Cartron J.-P., Le van Kim C.;
RT   "Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid
RT   gene expression in Duffy-negative individuals.";
RL   Nat. Genet. 10:224-228(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Blood;
RX   PubMed=7833467;
RA   Iwamoto S., Omi T., Kajii E., Ikemoto S.;
RT   "Genomic organization of the glycoprotein D gene: Duffy blood group Fya/Fyb
RT   alloantigen system is associated with a polymorphism at the 44-amino acid
RT   residue.";
RL   Blood 85:622-626(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 2), AND VARIANTS ASP-42; CYS-89
RP   AND THR-100.
RC   TISSUE=Blood;
RX   PubMed=9731074;
RA   Tournamille C., Le Van Kim C., Gane P., Le Pennec P.Y., Roubinet F.,
RA   Babinet J., Cartron J.-P., Colin Y.;
RT   "Arg89Cys substitution results in very low membrane expression of the Duffy
RT   antigen/receptor for chemokines in Fy(x) individuals.";
RL   Blood 92:2147-2156(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS ASP-42; CYS-89 AND
RP   THR-100.
RX   PubMed=9886340; DOI=10.1046/j.1365-2141.1998.01083.x;
RA   Olsson M.L., Smythe J.S., Hansson C., Poole J., Mallinson G., Jones J.,
RA   Avent N.D., Daniels G.;
RT   "The Fy(x) phenotype is associated with a missense mutation in the Fy(b)
RT   allele predicting Arg89Cys in the Duffy glycoprotein.";
RL   Br. J. Haematol. 103:1184-1191(1998).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT PHE-326.
RC   TISSUE=Peripheral blood;
RA   Doescher A.;
RT   "New polymorphisms in DARC.";
RL   Submitted (SEP-2007) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT PHE-326.
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-117 (ISOFORMS 1 AND 2).
RX   PubMed=10570183; DOI=10.1073/pnas.96.24.13973;
RA   Zimmerman P.A., Woolley I., Masinde G.L., Miller S.M., McNamara D.T.,
RA   Hazlett F., Mgone C.S., Alpers M.P., Genton B., Boatin B.A., Kazura J.W.;
RT   "Emergence of FY*A(null) in a Plasmodium vivax-endemic region of Papua New
RT   Guinea.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:13973-13977(1999).
RN   [10]
RP   DISULFIDE BONDS, AND GLYCOSYLATION AT ASN-16.
RX   PubMed=12956774; DOI=10.1046/j.1365-2141.2003.04533.x;
RA   Tournamille C., Filipe A., Wasniowska K., Gane P., Lisowska E.,
RA   Cartron J.-P., Colin Y., Le Van Kim C.;
RT   "Structure-function analysis of the extracellular domains of the Duffy
RT   antigen/receptor for chemokines: characterization of antibody and chemokine
RT   binding sites.";
RL   Br. J. Haematol. 122:1014-1023(2003).
RN   [11]
RP   POLYMORPHISM, AND INVOLVEMENT IN RESISTANCE TO MALARIA.
RX   PubMed=17389925; DOI=10.1371/journal.pone.0000336;
RA   Kasehagen L.J., Mueller I., Kiniboro B., Bockarie M.J., Reeder J.C.,
RA   Kazura J.W., Kastens W., McNamara D.T., King C.H., Whalen C.C.,
RA   Zimmerman P.A.;
RT   "Reduced Plasmodium vivax erythrocyte infection in PNG Duffy-negative
RT   heterozygotes.";
RL   PLoS ONE 2:E336-E336(2007).
RN   [12]
RP   REVIEW.
RX   PubMed=20373092; DOI=10.1007/82_2010_19;
RA   Bonecchi R., Savino B., Borroni E.M., Mantovani A., Locati M.;
RT   "Chemokine decoy receptors: structure-function and biological properties.";
RL   Curr. Top. Microbiol. Immunol. 341:15-36(2010).
RN   [13]
RP   REVIEW.
RX   PubMed=22912641; DOI=10.3389/fimmu.2012.00266;
RA   Novitzky-Basso I., Rot A.;
RT   "Duffy antigen receptor for chemokines and its involvement in patterning
RT   and control of inflammatory chemokines.";
RL   Front. Immunol. 3:266-266(2012).
RN   [14]
RP   REVIEW.
RX   PubMed=22698181; DOI=10.1016/j.imlet.2012.04.004;
RA   Graham G.J., Locati M., Mantovani A., Rot A., Thelen M.;
RT   "The biochemistry and biology of the atypical chemokine receptors.";
RL   Immunol. Lett. 145:30-38(2012).
RN   [15]
RP   REVIEW.
RX   PubMed=23356288; DOI=10.1042/bst20120246;
RA   Cancellieri C., Vacchini A., Locati M., Bonecchi R., Borroni E.M.;
RT   "Atypical chemokine receptors: from silence to sound.";
RL   Biochem. Soc. Trans. 41:231-236(2013).
RN   [16]
RP   VARIANT ASP-42.
RC   TISSUE=Peripheral blood;
RX   PubMed=7705836; DOI=10.1007/bf00208965;
RA   Tournamille C., Le van Kim C., Gane P., Cartron J.-P., Colin Y.;
RT   "Molecular basis and PCR-DNA typing of the Fya/fyb blood group
RT   polymorphism.";
RL   Hum. Genet. 95:407-410(1995).
RN   [17]
RP   VARIANT CYS-89.
RX   PubMed=9746760;
RA   Parasol N., Reid M., Rios M., Castilho L., Harari I., Kosower N.S.;
RT   "A novel mutation in the coding sequence of the FY*B allele of the Duffy
RT   chemokine receptor gene is associated with an altered erythrocyte
RT   phenotype.";
RL   Blood 92:2237-2243(1998).
RN   [18]
RP   INVOLVEMENT IN WBCQ1.
RX   PubMed=18179887; DOI=10.1016/j.ajhg.2007.09.003;
RA   Nalls M.A., Wilson J.G., Patterson N.J., Tandon A., Zmuda J.M.,
RA   Huntsman S., Garcia M., Hu D., Li R., Beamer B.A., Patel K.V.,
RA   Akylbekova E.L., Files J.C., Hardy C.L., Buxbaum S.G., Taylor H.A.,
RA   Reich D., Harris T.B., Ziv E.;
RT   "Admixture mapping of white cell count: genetic locus responsible for lower
RT   white blood cell count in the Health ABC and Jackson Heart Studies.";
RL   Am. J. Hum. Genet. 82:81-87(2008).
RN   [19]
RP   ERRATUM OF PUBMED:18179887.
RA   Nalls M.A., Wilson J.G., Patterson N.J., Tandon A., Zmuda J.M.,
RA   Huntsman S., Garcia M., Hu D., Li R., Beamer B.A., Patel K.V.,
RA   Akylbekova E.L., Files J.C., Hardy C.L., Buxbaum S.G., Taylor H.A.,
RA   Reich D., Harris T.B., Ziv E.;
RL   Am. J. Hum. Genet. 82:532-532(2008).
CC   -!- FUNCTION: Atypical chemokine receptor that controls chemokine levels
CC       and localization via high-affinity chemokine binding that is uncoupled
CC       from classic ligand-driven signal transduction cascades, resulting
CC       instead in chemokine sequestration, degradation, or transcytosis. Also
CC       known as interceptor (internalizing receptor) or chemokine-scavenging
CC       receptor or chemokine decoy receptor. Has a promiscuous chemokine-
CC       binding profile, interacting with inflammatory chemokines of both the
CC       CXC and the CC subfamilies but not with homeostatic chemokines. Acts as
CC       a receptor for chemokines including CCL2, CCL5, CCL7, CCL11, CCL13,
CC       CCL14, CCL17, CXCL5, CXCL6, IL8/CXCL8, CXCL11, GRO, RANTES, MCP-1, TARC
CC       and also for the malaria parasites P.vivax and P.knowlesi. May regulate
CC       chemokine bioavailability and, consequently, leukocyte recruitment
CC       through two distinct mechanisms: when expressed in endothelial cells,
CC       it sustains the abluminal to luminal transcytosis of tissue-derived
CC       chemokines and their subsequent presentation to circulating leukocytes;
CC       when expressed in erythrocytes, serves as blood reservoir of cognate
CC       chemokines but also as a chemokine sink, buffering potential surges in
CC       plasma chemokine levels.
CC   -!- INTERACTION:
CC       Q16570-1; P22290: PVDR; Xeno; NbExp=3; IntAct=EBI-15935975, EBI-15935953;
CC       Q16570-2; P51681: CCR5; NbExp=3; IntAct=EBI-21403047, EBI-489374;
CC   -!- SUBCELLULAR LOCATION: Early endosome. Recycling endosome. Membrane;
CC       Multi-pass membrane protein. Note=Predominantly localizes to endocytic
CC       vesicles, and upon stimulation by the ligand is internalized via
CC       caveolae. Once internalized, the ligand dissociates from the receptor,
CC       and is targeted to degradation while the receptor is recycled back to
CC       the cell membrane.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=2;
CC         IsoId=Q16570-1; Sequence=Displayed;
CC       Name=1;
CC         IsoId=Q16570-2; Sequence=VSP_001323;
CC   -!- TISSUE SPECIFICITY: Found in adult kidney, adult spleen, bone marrow
CC       and fetal liver. In particular, it is expressed along postcapillary
CC       venules throughout the body, except in the adult liver. Erythroid cells
CC       and postcapillary venule endothelium are the principle tissues
CC       expressing duffy. Fy(-A-B) individuals do not express duffy in the bone
CC       marrow, however they do, in postcapillary venule endothelium.
CC   -!- POLYMORPHISM: DARC is responsible for the Duffy blood group system (FY)
CC       [MIM:110700]. The molecular basis of the Fy(A)=Fy1/Fy(B)=Fy2 blood
CC       group antigens is a single variation in position 42; Gly-42 corresponds
CC       to Fy(A) and Asp-42 to Fy(B). Individuals that do not produce the Duffy
CC       antigen (FY(A-B-)) are more resistant to infection by the malarial
CC       parasite Plasmodium vivax. This allele is found predominantly in
CC       population of African origin [MIM:611162].
CC   -!- POLYMORPHISM: Genetic variations in DARC define the white blood cell
CC       count quantitative trait locus 1 (WBCQ1) [MIM:611862]. Peripheral white
CC       blood cell count (WBC) is a common clinical measurement, used to
CC       determine evidence of acute inflammation or infection. Peripheral WBC
CC       is the sum of several cell types including neutrophils and lymphocytes,
CC       which are the most common types of WBC, as well as less common cell
CC       types such as eosinophils, basophils, and monocytes. Elevated WBC has
CC       been associated with risk of coronary heart disease, cancer, and all-
CC       cause mortality. White blood cell levels have widespread clinical
CC       applications including assessment of patients undergoing chemotherapy
CC       and evaluation of infection.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       Atypical chemokine receptor subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=dbRBC/BGMUT; Note=Blood group antigen gene mutation
CC       database;
CC       URL="https://www.ncbi.nlm.nih.gov/gv/mhc/xslcgi.cgi?cmd=bgmut/systems_info&system=duffy";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Duffy antigen entry;
CC       URL="https://en.wikipedia.org/wiki/Duffy_antigen";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U01839; AAC50055.1; -; mRNA.
DR   EMBL; X85785; CAA59770.1; -; Genomic_DNA.
DR   EMBL; S76830; AAB33239.1; -; Genomic_DNA.
DR   EMBL; AF055992; AAC72301.1; -; Genomic_DNA.
DR   EMBL; AF030521; AAD20435.1; -; mRNA.
DR   EMBL; AM887935; CAP12644.1; -; Genomic_DNA.
DR   EMBL; AL035403; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC017817; AAH17817.1; -; mRNA.
DR   EMBL; AF100634; AAF02415.1; -; Genomic_DNA.
DR   EMBL; AF100634; AAF02416.1; -; Genomic_DNA.
DR   CCDS; CCDS1183.1; -. [Q16570-1]
DR   CCDS; CCDS44252.1; -. [Q16570-2]
DR   PIR; I52608; I52608.
DR   RefSeq; NP_001116423.1; NM_001122951.2. [Q16570-2]
DR   RefSeq; NP_002027.2; NM_002036.3. [Q16570-1]
DR   PDB; 4NUU; X-ray; 1.95 A; C=16-43.
DR   PDB; 4NUV; X-ray; 2.60 A; C/D=14-43.
DR   PDBsum; 4NUU; -.
DR   PDBsum; 4NUV; -.
DR   SMR; Q16570; -.
DR   BioGRID; 108808; 3.
DR   DIP; DIP-3783N; -.
DR   IntAct; Q16570; 3.
DR   MINT; Q16570; -.
DR   STRING; 9606.ENSP00000357103; -.
DR   ChEMBL; CHEMBL2321626; -.
DR   GlyGen; Q16570; 2 sites.
DR   iPTMnet; Q16570; -.
DR   PhosphoSitePlus; Q16570; -.
DR   BioMuta; ACKR1; -.
DR   DMDM; 67476970; -.
DR   jPOST; Q16570; -.
DR   MassIVE; Q16570; -.
DR   PaxDb; Q16570; -.
DR   PeptideAtlas; Q16570; -.
DR   PRIDE; Q16570; -.
DR   ProteomicsDB; 60923; -. [Q16570-1]
DR   ProteomicsDB; 60924; -. [Q16570-2]
DR   ABCD; Q16570; 1 sequenced antibody.
DR   Antibodypedia; 2945; 517 antibodies.
DR   DNASU; 2532; -.
DR   Ensembl; ENST00000368121; ENSP00000357103; ENSG00000213088. [Q16570-2]
DR   Ensembl; ENST00000368122; ENSP00000357104; ENSG00000213088. [Q16570-1]
DR   Ensembl; ENST00000537147; ENSP00000441985; ENSG00000213088. [Q16570-1]
DR   GeneID; 2532; -.
DR   KEGG; hsa:2532; -.
DR   CTD; 2532; -.
DR   DisGeNET; 2532; -.
DR   EuPathDB; HostDB:ENSG00000213088.9; -.
DR   GeneCards; ACKR1; -.
DR   HGNC; HGNC:4035; ACKR1.
DR   HPA; ENSG00000213088; Tissue enhanced (adipose).
DR   MalaCards; ACKR1; -.
DR   MIM; 110700; phenotype.
DR   MIM; 611162; phenotype.
DR   MIM; 611862; phenotype.
DR   MIM; 613665; gene.
DR   neXtProt; NX_Q16570; -.
DR   OpenTargets; ENSG00000213088; -.
DR   PharmGKB; PA28451; -.
DR   eggNOG; ENOG502SNW7; Eukaryota.
DR   GeneTree; ENSGT00390000006372; -.
DR   HOGENOM; CLU_813693_0_0_1; -.
DR   InParanoid; Q16570; -.
DR   KO; K06574; -.
DR   OMA; WFIFWWP; -.
DR   PhylomeDB; Q16570; -.
DR   TreeFam; TF105419; -.
DR   PathwayCommons; Q16570; -.
DR   Reactome; R-HSA-375276; Peptide ligand-binding receptors.
DR   BioGRID-ORCS; 2532; 3 hits in 861 CRISPR screens.
DR   ChiTaRS; ACKR1; human.
DR   GeneWiki; Duffy_antigen_system; -.
DR   GenomeRNAi; 2532; -.
DR   Pharos; Q16570; Tbio.
DR   PRO; PR:Q16570; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q16570; protein.
DR   Bgee; ENSG00000213088; Expressed in ectocervix and 204 other tissues.
DR   ExpressionAtlas; Q16570; baseline and differential.
DR   Genevisible; Q16570; HS.
DR   GO; GO:0005769; C:early endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0055037; C:recycling endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0019957; F:C-C chemokine binding; IPI:BHF-UCL.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0038023; F:signaling receptor activity; TAS:ProtInc.
DR   GO; GO:0004888; F:transmembrane signaling receptor activity; TAS:ProtInc.
DR   GO; GO:0070098; P:chemokine-mediated signaling pathway; IEA:InterPro.
DR   GO; GO:0006952; P:defense response; NAS:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; IBA:GO_Central.
DR   GO; GO:0032642; P:regulation of chemokine production; IBA:GO_Central.
DR   InterPro; IPR005384; Duffy_chemokine_rcpt.
DR   PANTHER; PTHR14181; PTHR14181; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Blood group antigen;
KW   Direct protein sequencing; Disulfide bond; Endosome;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Polymorphism; Receptor;
KW   Reference proteome; Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..336
FT                   /note="Atypical chemokine receptor 1"
FT                   /id="PRO_0000152585"
FT   TOPO_DOM        1..63
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        64..84
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        85..95
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        96..116
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        117..129
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        130..153
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        154..166
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        167..187
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        188..207
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        208..228
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        229..244
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        245..265
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        266..287
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        288..308
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        309..336
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        16
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:12956774"
FT   CARBOHYD        33
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        51..276
FT                   /evidence="ECO:0000269|PubMed:12956774"
FT   DISULFID        129..195
FT                   /evidence="ECO:0000269|PubMed:12956774"
FT   VAR_SEQ         1..7
FT                   /note="MGNCLHR -> MASSGYVLQ (in isoform 1)"
FT                   /evidence="ECO:0000303|PubMed:8248172,
FT                   ECO:0000303|PubMed:9886340"
FT                   /id="VSP_001323"
FT   VARIANT         42
FT                   /note="G -> D (antigen Fy(b); dbSNP:rs12075)"
FT                   /evidence="ECO:0000269|PubMed:7663520,
FT                   ECO:0000269|PubMed:7705836, ECO:0000269|PubMed:8248172,
FT                   ECO:0000269|PubMed:9731074, ECO:0000269|PubMed:9886340"
FT                   /id="VAR_003480"
FT   VARIANT         89
FT                   /note="R -> C (antigen Fy(x); dbSNP:rs34599082)"
FT                   /evidence="ECO:0000269|PubMed:9731074,
FT                   ECO:0000269|PubMed:9746760, ECO:0000269|PubMed:9886340"
FT                   /id="VAR_015068"
FT   VARIANT         100
FT                   /note="A -> T (in dbSNP:rs13962)"
FT                   /evidence="ECO:0000269|PubMed:9731074,
FT                   ECO:0000269|PubMed:9886340"
FT                   /id="VAR_015069"
FT   VARIANT         203
FT                   /note="L -> Q (in dbSNP:rs3027020)"
FT                   /id="VAR_044116"
FT   VARIANT         326
FT                   /note="S -> F (in dbSNP:rs17851570)"
FT                   /evidence="ECO:0000269|PubMed:15489334, ECO:0000269|Ref.6"
FT                   /id="VAR_044117"
FT   HELIX           22..28
FT                   /evidence="ECO:0000244|PDB:4NUU"
SQ   SEQUENCE   336 AA;  35553 MW;  C3F2A3E71D972E2D CRC64;
     MGNCLHRAEL SPSTENSSQL DFEDVWNSSY GVNDSFPDGD YGANLEAAAP CHSCNLLDDS
     ALPFFILTSV LGILASSTVL FMLFRPLFRW QLCPGWPVLA QLAVGSALFS IVVPVLAPGL
     GSTRSSALCS LGYCVWYGSA FAQALLLGCH ASLGHRLGAG QVPGLTLGLT VGIWGVAALL
     TLPVTLASGA SGGLCTLIYS TELKALQATH TVACLAIFVL LPLGLFGAKG LKKALGMGPG
     PWMNILWAWF IFWWPHGVVL GLDFLVRSKL LLLSTCLAQQ ALDLLLNLAE ALAILHCVAT
     PLLLALFCHQ ATRTLLPSLP LPEGWSSHLD TLGSKS
//
ID   5HT1B_HUMAN             Reviewed;         390 AA.
AC   P28222; Q4VAY7;
DT   01-DEC-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-DEC-1992, sequence version 1.
DT   07-OCT-2020, entry version 188.
DE   RecName: Full=5-hydroxytryptamine receptor 1B;
DE            Short=5-HT-1B;
DE            Short=5-HT1B;
DE   AltName: Full=S12;
DE   AltName: Full=Serotonin 1D beta receptor;
DE            Short=5-HT-1D-beta;
DE   AltName: Full=Serotonin receptor 1B;
GN   Name=HTR1B; Synonyms=HTR1DB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=1315531; DOI=10.1016/0006-291x(92)90654-4;
RA   Hamblin M.W., Metcalf M.A., McGuffin R.W., Karpells S.;
RT   "Molecular cloning and functional characterization of a human 5-HT1B
RT   serotonin receptor: a homologue of the rat 5-HT1B receptor with 5-HT1D-like
RT   pharmacological specificity.";
RL   Biochem. Biophys. Res. Commun. 184:752-759(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=1610347; DOI=10.1016/0006-291x(92)91655-a;
RA   Mochizuki D., Yuyama Y., Tsujita R., Komaki H., Sagai H.;
RT   "Cloning and expression of the human 5-HT1B-type receptor gene.";
RL   Biochem. Biophys. Res. Commun. 185:517-523(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=1348246;
RA   Jin H., Oksenberg D., Ashkenazi A., Peroutka S.J., Duncan A.M.V.,
RA   Rozmahel R., Yang Y., Mengod G., Palacios J.M., O'Dowd B.F.;
RT   "Characterization of the human 5-hydroxytryptamine1B receptor.";
RL   J. Biol. Chem. 267:5735-5738(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=1559993;
RA   Levy F.O., Gudermann T., Perez-Reyes E., Birnbaumer M., Kaumann A.J.,
RA   Birnbaumer L.;
RT   "Molecular cloning of a human serotonin receptor (S12) with a
RT   pharmacological profile resembling that of the 5-HT1D subtype.";
RL   J. Biol. Chem. 267:7553-7562(1992).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND SUBCELLULAR LOCATION.
RC   TISSUE=Placenta;
RX   PubMed=1565658; DOI=10.1073/pnas.89.8.3630;
RA   Weinshank R.L., Zgombick J.M., Macchi M.J., Branchek T.A., Hartig P.R.;
RT   "Human serotonin 1D receptor is encoded by a subfamily of two distinct
RT   genes: 5-HT1D alpha and 5-HT1D beta.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:3630-3634(1992).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=1351684; DOI=10.1073/pnas.89.12.5522;
RA   Demchyshyn L., Sunahara R.K., Miller K., Teitler M., Hoffman B.J.,
RA   Kennedy J.L., Seeman P., van Tol H.H.M., Niznik H.B.;
RT   "A human serotonin 1D receptor variant (5HT1D beta) encoded by an
RT   intronless gene on chromosome 6.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:5522-5526(1992).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=1328844;
RA   Veldman S.A., Bienkowski M.J.;
RT   "Cloning and pharmacological characterization of a novel human 5-
RT   hydroxytryptamine1D receptor subtype.";
RL   Mol. Pharmacol. 42:439-444(1992).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=15014171; DOI=10.1093/molbev/msh100;
RA   Kitano T., Liu Y.-H., Ueda S., Saitou N.;
RT   "Human-specific amino acid changes found in 103 protein-coding genes.";
RL   Mol. Biol. Evol. 21:936-944(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "Isolation of complete coding sequence for 5-hydroxytryptamine (serotonin)
RT   receptor 1B (HTR1B).";
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   PALMITOYLATION, PHOSPHORYLATION, AND FUNCTION.
RX   PubMed=8218242; DOI=10.1021/bi00094a032;
RA   Ng G.Y.K., George S.R., Zastawny R.L., Caron M., Bouvier M., Dennis M.,
RA   O'Dowd B.F.;
RT   "Human serotonin1B receptor expression in Sf9 cells: phosphorylation,
RT   palmitoylation, and adenylyl cyclase inhibition.";
RL   Biochemistry 32:11727-11733(1993).
RN   [13]
RP   FUNCTION, SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=10452531; DOI=10.1016/s0014-5793(99)00918-7;
RA   Xie Z., Lee S.P., O'Dowd B.F., George S.R.;
RT   "Serotonin 5-HT1B and 5-HT1D receptors form homodimers when expressed alone
RT   and heterodimers when co-expressed.";
RL   FEBS Lett. 456:63-67(1999).
RN   [14]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=15853772; DOI=10.1042/cs20050016;
RA   Edvinsson L., Uddman E., Wackenfors A., Davenport A., Longmore J.,
RA   Malmsjo M.;
RT   "Triptan-induced contractile (5-HT1B receptor) responses in human cerebral
RT   and coronary arteries: relationship to clinical effect.";
RL   Clin. Sci. 109:335-342(2005).
RN   [15]
RP   REVIEW.
RX   PubMed=18476671; DOI=10.1021/cr078224o;
RA   Nichols D.E., Nichols C.D.;
RT   "Serotonin receptors.";
RL   Chem. Rev. 108:1614-1641(2008).
RN   [16]
RP   REVIEW.
RX   PubMed=20945968; DOI=10.33549/physiolres.931903;
RA   Pytliak M., Vargova V., Mechirova V., Felsoci M.;
RT   "Serotonin receptors - from molecular biology to clinical applications.";
RL   Physiol. Res. 60:15-25(2011).
RN   [17]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=23519215; DOI=10.1126/science.1232808;
RA   Wacker D., Wang C., Katritch V., Han G.W., Huang X.P., Vardy E.,
RA   McCorvy J.D., Jiang Y., Chu M., Siu F.Y., Liu W., Xu H.E., Cherezov V.,
RA   Roth B.L., Stevens R.C.;
RT   "Structural features for functional selectivity at serotonin receptors.";
RL   Science 340:615-619(2013).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 33-390 IN COMPLEXES WITH
RP   ERGOTAMINE AND DIHYDROERGOTAMINE, FUNCTION, SUBCELLULAR LOCATION, MEMBRANE
RP   TOPOLOGY, DOMAIN, DISULFIDE BOND, AND MUTAGENESIS OF LEU-126; ASP-129;
RP   ILE-130; CYS-133; THR-134; VAL-200; VAL-201; THR-203; THR-209; SER-212;
RP   ALA-216; TRP-327; PHE-330; PHE-331; SER-334; MET-337; PHE-351; ASP-352;
RP   THR-355 AND TYR-359.
RX   PubMed=23519210; DOI=10.1126/science.1232807;
RA   Wang C., Jiang Y., Ma J., Wu H., Wacker D., Katritch V., Han G.W., Liu W.,
RA   Huang X.P., Vardy E., McCorvy J.D., Gao X., Zhou X.E., Melcher K.,
RA   Zhang C., Bai F., Yang H., Yang L., Jiang H., Roth B.L., Cherezov V.,
RA   Stevens R.C., Xu H.E.;
RT   "Structural basis for molecular recognition at serotonin receptors.";
RL   Science 340:610-614(2013).
RN   [19]
RP   VARIANT CYS-124.
RX   PubMed=7802650; DOI=10.1006/bbrc.1994.2792;
RA   Nothen M.M., Erdmann J., Shimron-Abarbanell D., Propping P.;
RT   "Identification of genetic variation in the human serotonin 1D beta
RT   receptor gene.";
RL   Biochem. Biophys. Res. Commun. 205:1194-1200(1994).
CC   -!- FUNCTION: G-protein coupled receptor for 5-hydroxytryptamine
CC       (serotonin). Also functions as a receptor for ergot alkaloid
CC       derivatives, various anxiolytic and antidepressant drugs and other
CC       psychoactive substances, such as lysergic acid diethylamide (LSD).
CC       Ligand binding causes a conformation change that triggers signaling via
CC       guanine nucleotide-binding proteins (G proteins) and modulates the
CC       activity of down-stream effectors, such as adenylate cyclase. Signaling
CC       inhibits adenylate cyclase activity. Arrestin family members inhibit
CC       signaling via G proteins and mediate activation of alternative
CC       signaling pathways. Regulates the release of 5-hydroxytryptamine,
CC       dopamine and acetylcholine in the brain, and thereby affects neural
CC       activity, nociceptive processing, pain perception, mood and behavior.
CC       Besides, plays a role in vasoconstriction of cerebral arteries.
CC       {ECO:0000269|PubMed:10452531, ECO:0000269|PubMed:1315531,
CC       ECO:0000269|PubMed:1328844, ECO:0000269|PubMed:1348246,
CC       ECO:0000269|PubMed:1351684, ECO:0000269|PubMed:1559993,
CC       ECO:0000269|PubMed:1565658, ECO:0000269|PubMed:15853772,
CC       ECO:0000269|PubMed:1610347, ECO:0000269|PubMed:23519210,
CC       ECO:0000269|PubMed:23519215, ECO:0000269|PubMed:8218242}.
CC   -!- SUBUNIT: Homodimer. Heterodimer with HTR1D.
CC       {ECO:0000269|PubMed:10452531}.
CC   -!- INTERACTION:
CC       P28222; P35609: ACTN2; NbExp=3; IntAct=EBI-1056863, EBI-77797;
CC       P28222; Q99750: MDFI; NbExp=7; IntAct=EBI-1056863, EBI-724076;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10452531,
CC       ECO:0000269|PubMed:1315531, ECO:0000269|PubMed:1328844,
CC       ECO:0000269|PubMed:1348246, ECO:0000269|PubMed:1351684,
CC       ECO:0000269|PubMed:1559993, ECO:0000269|PubMed:1565658,
CC       ECO:0000269|PubMed:1610347, ECO:0000269|PubMed:23519210,
CC       ECO:0000269|PubMed:23519215}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:10452531, ECO:0000269|PubMed:1315531,
CC       ECO:0000269|PubMed:1328844, ECO:0000269|PubMed:1348246,
CC       ECO:0000269|PubMed:1351684, ECO:0000269|PubMed:1559993,
CC       ECO:0000269|PubMed:1565658, ECO:0000269|PubMed:1610347,
CC       ECO:0000269|PubMed:23519210, ECO:0000269|PubMed:23519215}.
CC   -!- TISSUE SPECIFICITY: Detected in cerebral artery smooth muscle cells (at
CC       protein level). Detected in brain cortex, striatum, amygdala, medulla,
CC       hippocampus, caudate nucleus and putamen. {ECO:0000269|PubMed:1348246,
CC       ECO:0000269|PubMed:1351684, ECO:0000269|PubMed:15853772}.
CC   -!- DOMAIN: Ligands are bound in a hydrophobic pocket formed by the
CC       transmembrane helices. {ECO:0000269|PubMed:23519210}.
CC   -!- PTM: Phosphorylated. Desensitization of the receptor may be mediated by
CC       its phosphorylation. {ECO:0000269|PubMed:8218242}.
CC   -!- PTM: Palmitoylated. {ECO:0000269|PubMed:8218242}.
CC   -!- MISCELLANEOUS: A residue in the 7th transmembrane region (Thr-355 in
CC       human, 'Asn-351' in mouse and rat) is important for species-specific
CC       sensitivity to various agonists.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M89478; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; D10995; BAA01763.1; -; Genomic_DNA.
DR   EMBL; M83180; AAA36029.1; -; Genomic_DNA.
DR   EMBL; L09732; AAA36030.1; -; Genomic_DNA.
DR   EMBL; M81590; AAA60316.1; -; mRNA.
DR   EMBL; M75128; AAA58675.1; -; Genomic_DNA.
DR   EMBL; AB041370; BAA94455.1; -; Genomic_DNA.
DR   EMBL; AY225227; AAO67712.1; -; Genomic_DNA.
DR   EMBL; AL049595; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC069065; AAH69065.1; -; mRNA.
DR   EMBL; BC096206; AAH96206.1; -; mRNA.
DR   EMBL; BC096207; AAH96207.1; -; mRNA.
DR   EMBL; BC096208; AAH96208.1; -; mRNA.
DR   CCDS; CCDS4986.1; -.
DR   PIR; JN0268; JN0268.
DR   RefSeq; NP_000854.1; NM_000863.2.
DR   PDB; 2G1X; Model; -; A=1-390.
DR   PDB; 4IAQ; X-ray; 2.80 A; A=33-239, A=304-390.
DR   PDB; 4IAR; X-ray; 2.70 A; A=33-239, A=306-390.
DR   PDB; 5V54; X-ray; 3.90 A; A/B=37-390.
DR   PDB; 6G79; EM; 3.78 A; S=34-390.
DR   PDBsum; 2G1X; -.
DR   PDBsum; 4IAQ; -.
DR   PDBsum; 4IAR; -.
DR   PDBsum; 5V54; -.
DR   PDBsum; 6G79; -.
DR   SMR; P28222; -.
DR   BioGRID; 109583; 6.
DR   CORUM; P28222; -.
DR   IntAct; P28222; 7.
DR   STRING; 9606.ENSP00000358963; -.
DR   BindingDB; P28222; -.
DR   ChEMBL; CHEMBL1898; -.
DR   DrugBank; DB00918; Almotriptan.
DR   DrugBank; DB00321; Amitriptyline.
DR   DrugBank; DB00543; Amoxapine.
DR   DrugBank; DB00714; Apomorphine.
DR   DrugBank; DB01238; Aripiprazole.
DR   DrugBank; DB14185; Aripiprazole lauroxil.
DR   DrugBank; DB06216; Asenapine.
DR   DrugBank; DB08807; Bopindolol.
DR   DrugBank; DB01200; Bromocriptine.
DR   DrugBank; DB00248; Cabergoline.
DR   DrugBank; DB00363; Clozapine.
DR   DrugBank; DB04884; Dapoxetine.
DR   DrugBank; DB11273; Dihydroergocornine.
DR   DrugBank; DB13345; Dihydroergocristine.
DR   DrugBank; DB00320; Dihydroergotamine.
DR   DrugBank; DB00216; Eletriptan.
DR   DrugBank; DB01049; Ergoloid mesylate.
DR   DrugBank; DB00696; Ergotamine.
DR   DrugBank; DB00998; Frovatriptan.
DR   DrugBank; DB12141; Gilteritinib.
DR   DrugBank; DB01221; Ketamine.
DR   DrugBank; DB00589; Lisuride.
DR   DrugBank; DB00408; Loxapine.
DR   DrugBank; DB00247; Methysergide.
DR   DrugBank; DB00952; Naratriptan.
DR   DrugBank; DB06096; NXN-188.
DR   DrugBank; DB00334; Olanzapine.
DR   DrugBank; DB00904; Ondansetron.
DR   DrugBank; DB00715; Paroxetine.
DR   DrugBank; DB01359; Penbutolol.
DR   DrugBank; DB01186; Pergolide.
DR   DrugBank; DB00960; Pindolol.
DR   DrugBank; DB06153; Pizotifen.
DR   DrugBank; DB00571; Propranolol.
DR   DrugBank; DB01224; Quetiapine.
DR   DrugBank; DB00953; Rizatriptan.
DR   DrugBank; DB09304; Setiptiline.
DR   DrugBank; DB00669; Sumatriptan.
DR   DrugBank; DB13025; Tiapride.
DR   DrugBank; DB09068; Vortioxetine.
DR   DrugBank; DB01392; Yohimbine.
DR   DrugBank; DB00246; Ziprasidone.
DR   DrugBank; DB00315; Zolmitriptan.
DR   DrugCentral; P28222; -.
DR   GuidetoPHARMACOLOGY; 2; -.
DR   TCDB; 9.A.14.3.6; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; P28222; 3 sites, 1 O-linked glycan (1 site).
DR   iPTMnet; P28222; -.
DR   PhosphoSitePlus; P28222; -.
DR   BioMuta; HTR1B; -.
DR   DMDM; 112821; -.
DR   MassIVE; P28222; -.
DR   PaxDb; P28222; -.
DR   PeptideAtlas; P28222; -.
DR   PRIDE; P28222; -.
DR   ProteomicsDB; 54452; -.
DR   Antibodypedia; 18374; 284 antibodies.
DR   DNASU; 3351; -.
DR   Ensembl; ENST00000369947; ENSP00000358963; ENSG00000135312.
DR   GeneID; 3351; -.
DR   KEGG; hsa:3351; -.
DR   CTD; 3351; -.
DR   DisGeNET; 3351; -.
DR   EuPathDB; HostDB:ENSG00000135312.5; -.
DR   GeneCards; HTR1B; -.
DR   HGNC; HGNC:5287; HTR1B.
DR   HPA; ENSG00000135312; Tissue enhanced (brain, placenta, stomach).
DR   MIM; 182131; gene.
DR   neXtProt; NX_P28222; -.
DR   OpenTargets; ENSG00000135312; -.
DR   PharmGKB; PA29549; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT01000000214615; -.
DR   HOGENOM; CLU_009579_11_1_1; -.
DR   InParanoid; P28222; -.
DR   KO; K04153; -.
DR   OMA; ACWFHMA; -.
DR   OrthoDB; 354230at2759; -.
DR   PhylomeDB; P28222; -.
DR   TreeFam; TF316350; -.
DR   PathwayCommons; P28222; -.
DR   Reactome; R-HSA-390666; Serotonin receptors.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   SIGNOR; P28222; -.
DR   BioGRID-ORCS; 3351; 9 hits in 871 CRISPR screens.
DR   GeneWiki; 5-HT1B_receptor; -.
DR   GenomeRNAi; 3351; -.
DR   Pharos; P28222; Tclin.
DR   PRO; PR:P28222; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; P28222; protein.
DR   Bgee; ENSG00000135312; Expressed in popliteal artery and 94 other tissues.
DR   ExpressionAtlas; P28222; baseline and differential.
DR   Genevisible; P28222; HS.
DR   GO; GO:0044305; C:calyx of Held; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0030425; C:dendrite; IBA:GO_Central.
DR   GO; GO:0005887; C:integral component of plasma membrane; IMP:UniProtKB.
DR   GO; GO:0099056; C:integral component of presynaptic membrane; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0099154; C:serotonergic synapse; IEA:Ensembl.
DR   GO; GO:0008144; F:drug binding; IEA:Ensembl.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0004993; F:G protein-coupled serotonin receptor activity; IDA:UniProtKB.
DR   GO; GO:0030594; F:neurotransmitter receptor activity; IBA:GO_Central.
DR   GO; GO:0051378; F:serotonin binding; IBA:GO_Central.
DR   GO; GO:0099626; F:voltage-gated calcium channel activity involved in regulation of presynaptic cytosolic calcium levels; IEA:Ensembl.
DR   GO; GO:0007193; P:adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007198; P:adenylate cyclase-inhibiting serotonin receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0046849; P:bone remodeling; IEA:Ensembl.
DR   GO; GO:0071312; P:cellular response to alkaloid; IDA:UniProtKB.
DR   GO; GO:0035690; P:cellular response to drug; IDA:UniProtKB.
DR   GO; GO:0071502; P:cellular response to temperature stimulus; IEA:Ensembl.
DR   GO; GO:0007268; P:chemical synaptic transmission; IBA:GO_Central.
DR   GO; GO:0042756; P:drinking behavior; IEA:Ensembl.
DR   GO; GO:0002031; P:G protein-coupled receptor internalization; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007187; P:G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; IBA:GO_Central.
DR   GO; GO:0014053; P:negative regulation of gamma-aminobutyric acid secretion; IEA:Ensembl.
DR   GO; GO:0014063; P:negative regulation of serotonin secretion; ISS:UniProtKB.
DR   GO; GO:0032229; P:negative regulation of synaptic transmission, GABAergic; IEA:Ensembl.
DR   GO; GO:0051967; P:negative regulation of synaptic transmission, glutamatergic; IEA:Ensembl.
DR   GO; GO:1904707; P:positive regulation of vascular associated smooth muscle cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0007205; P:protein kinase C-activating G protein-coupled receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0050795; P:regulation of behavior; IEA:InterPro.
DR   GO; GO:0014059; P:regulation of dopamine secretion; IEA:Ensembl.
DR   GO; GO:0042220; P:response to cocaine; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0051385; P:response to mineralocorticoid; IEA:Ensembl.
DR   GO; GO:0042310; P:vasoconstriction; IEA:InterPro.
DR   InterPro; IPR002147; 5HT1B_rcpt.
DR   InterPro; IPR002231; 5HT_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   PANTHER; PTHR24247:SF16; PTHR24247:SF16; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00513; 5HT1BRECEPTR.
DR   PRINTS; PR01101; 5HTRECEPTOR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Behavior; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane; Palmitate;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome; Transducer;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..390
FT                   /note="5-hydroxytryptamine receptor 1B"
FT                   /id="PRO_0000068916"
FT   TOPO_DOM        1..49
FT                   /note="Extracellular"
FT   TRANSMEM        50..75
FT                   /note="Helical; Name=1"
FT   TOPO_DOM        76..84
FT                   /note="Cytoplasmic"
FT   TRANSMEM        85..110
FT                   /note="Helical; Name=2"
FT   TOPO_DOM        111..123
FT                   /note="Extracellular"
FT   TRANSMEM        124..145
FT                   /note="Helical; Name=3"
FT   TOPO_DOM        146..165
FT                   /note="Cytoplasmic"
FT   TRANSMEM        166..187
FT                   /note="Helical; Name=4"
FT   TOPO_DOM        188..205
FT                   /note="Extracellular"
FT   TRANSMEM        206..228
FT                   /note="Helical; Name=5"
FT   TOPO_DOM        229..315
FT                   /note="Cytoplasmic"
FT   TRANSMEM        316..336
FT                   /note="Helical; Name=6"
FT   TOPO_DOM        337..349
FT                   /note="Extracellular"
FT   TRANSMEM        350..371
FT                   /note="Helical; Name=7"
FT   TOPO_DOM        372..390
FT                   /note="Cytoplasmic"
FT   REGION          125..134
FT                   /note="Agonist binding"
FT   REGION          327..331
FT                   /note="Agonist binding"
FT   MOTIF           146..148
FT                   /note="DRY motif; important for ligand-induced conformation
FT                   changes and signaling"
FT   MOTIF           365..369
FT                   /note="NPxxY motif; important for ligand-induced
FT                   conformation changes and signaling"
FT   SITE            355
FT                   /note="Important for species-specific agonist sensitivity"
FT   LIPID           388
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        24
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        32
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        122..199
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521,
FT                   ECO:0000269|PubMed:23519210"
FT   VARIANT         124
FT                   /note="F -> C (in dbSNP:rs130060)"
FT                   /evidence="ECO:0000269|PubMed:7802650"
FT                   /id="VAR_011715"
FT   VARIANT         219
FT                   /note="F -> L (in dbSNP:rs130061)"
FT                   /id="VAR_011831"
FT   VARIANT         367
FT                   /note="I -> V (in dbSNP:rs130063)"
FT                   /id="VAR_011832"
FT   VARIANT         374
FT                   /note="E -> K (in dbSNP:rs130064)"
FT                   /id="VAR_011833"
FT   MUTAGEN         126
FT                   /note="L->A: No effect on agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         129
FT                   /note="D->A: Abolishes agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         130
FT                   /note="I->A: Abolishes agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         133
FT                   /note="C->A: Abolishes agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         134
FT                   /note="T->A: Slightly decreases agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         200
FT                   /note="V->A: No effect on agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         201
FT                   /note="V->A: No effect on agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         203
FT                   /note="T->A: No effect on agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         209
FT                   /note="T->A: No effect on agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         212
FT                   /note="S->A: No effect on agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         216
FT                   /note="A->S: No effect on agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         327
FT                   /note="W->A: Abolishes agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         330
FT                   /note="F->A: Abolishes agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         331
FT                   /note="F->A: No effect on agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         334
FT                   /note="S->A: No effect on agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         337
FT                   /note="M->A: No effect on agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         351
FT                   /note="F->A: No effect on agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         352
FT                   /note="D->A: No effect on agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         355
FT                   /note="T->A: No effect on agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   MUTAGEN         359
FT                   /note="Y->A: No effect on agonist binding."
FT                   /evidence="ECO:0000269|PubMed:23519210"
FT   HELIX           40..43
FT                   /evidence="ECO:0000244|PDB:4IAR"
FT   HELIX           46..76
FT                   /evidence="ECO:0000244|PDB:4IAR"
FT   HELIX           78..80
FT                   /evidence="ECO:0000244|PDB:4IAR"
FT   HELIX           83..101
FT                   /evidence="ECO:0000244|PDB:4IAR"
FT   HELIX           104..112
FT                   /evidence="ECO:0000244|PDB:4IAR"
FT   HELIX           118..152
FT                   /evidence="ECO:0000244|PDB:4IAR"
FT   HELIX           154..158
FT                   /evidence="ECO:0000244|PDB:4IAR"
FT   HELIX           163..181
FT                   /evidence="ECO:0000244|PDB:4IAR"
FT   HELIX           206..216
FT                   /evidence="ECO:0000244|PDB:4IAR"
FT   HELIX           218..239
FT                   /evidence="ECO:0000244|PDB:4IAR"
FT   HELIX           311..336
FT                   /evidence="ECO:0000244|PDB:4IAR"
FT   HELIX           349..372
FT                   /evidence="ECO:0000244|PDB:4IAR"
FT   HELIX           374..383
FT                   /evidence="ECO:0000244|PDB:4IAR"
SQ   SEQUENCE   390 AA;  43568 MW;  CD874DC7EB44CF12 CRC64;
     MEEPGAQCAP PPPAGSETWV PQANLSSAPS QNCSAKDYIY QDSISLPWKV LLVMLLALIT
     LATTLSNAFV IATVYRTRKL HTPANYLIAS LAVTDLLVSI LVMPISTMYT VTGRWTLGQV
     VCDFWLSSDI TCCTASILHL CVIALDRYWA ITDAVEYSAK RTPKRAAVMI ALVWVFSISI
     SLPPFFWRQA KAEEEVSECV VNTDHILYTV YSTVGAFYFP TLLLIALYGR IYVEARSRIL
     KQTPNRTGKR LTRAQLITDS PGSTSSVTSI NSRVPDVPSE SGSPVYVNQV KVRVSDALLE
     KKKLMAARER KATKTLGIIL GAFIVCWLPF FIISLVMPIC KDACWFHLAI FDFFTWLGYL
     NSLINPIIYT MSNEDFKQAF HKLIRFKCTS
//
ID   DRD2_HUMAN              Reviewed;         443 AA.
AC   P14416; Q9NZR3; Q9UPA9;
DT   01-JAN-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1990, sequence version 2.
DT   07-OCT-2020, entry version 228.
DE   RecName: Full=D(2) dopamine receptor;
DE   AltName: Full=Dopamine D2 receptor;
GN   Name=DRD2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2533064; DOI=10.1089/dna.1.1989.8.683;
RA   Selbie L.A., Hayes G., Shine J.;
RT   "The major dopamine D2 receptor: molecular analysis of the human D2A
RT   subtype.";
RL   DNA 8:683-689(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORMS 1 AND 2), AND TISSUE
RP   SPECIFICITY.
RX   PubMed=2531656;
RA   Dal-Toso R., Sommer B., Ewert M., Herb A., Pritchett D.B., Bach A.,
RA   Shivers B.D., Seeburg P.H.;
RT   "The dopamine D2 receptor: two molecular forms generated by alternative
RT   splicing.";
RL   EMBO J. 8:4025-4034(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Retina;
RX   PubMed=2138729; DOI=10.1093/nar/18.5.1299;
RA   Robakis N.K., Mohamadi M., Fu D.Y., Sambamurti K., Refolo L.M.;
RT   "Human retina D2 receptor cDNAs have multiple polyadenylation sites and
RT   differ from a pituitary clone at the 5' non-coding region.";
RL   Nucleic Acids Res. 18:1299-1299(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=2532362; DOI=10.1073/pnas.86.24.9762;
RA   Grandy D.K., Marchionni M.A., Makam H., Stofko R.E., Alfano M.,
RA   Frothingham L., Fischer J.B., Burke-Howie K.J., Bunzow J.R., Server A.C.,
RA   Civelli O.;
RT   "Cloning of the cDNA and gene for a human D2 dopamine receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 86:9762-9766(1989).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Retina;
RX   PubMed=2137193;
RA   Stormann T.M., Gdula D.C., Weiner D.M., Brann M.R.;
RT   "Molecular cloning and expression of a dopamine D2 receptor from human
RT   retina.";
RL   Mol. Pharmacol. 37:1-6(1990).
RN   [6]
RP   NUCLEOTIDE SEQUENCE (ISOFORM 1).
RX   PubMed=2144985;
RA   Selbie L.A., Hayes G., Shine J.;
RT   "DNA homology screening: isolation and characterization of the human D2A
RT   dopamine receptor subtype.";
RL   Adv. Second Messenger Phosphoprotein Res. 24:9-14(1990).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1363862; DOI=10.1016/0197-0186(92)90071-x;
RA   Araki K., Kuwano R., Morii K., Hayashi S., Minoshima S., Shimizu N.,
RA   Katagiri T., Usui H., Kumanishi T., Takahashi Y.;
RT   "Structure and expression of human and rat D2 dopamine receptor genes.";
RL   Neurochem. Int. 21:91-98(1992).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Retina;
RX   PubMed=1835903; DOI=10.1007/bf00734808;
RA   Dearry A., Falardeau P., Shores C., Caron M.G.;
RT   "D2 dopamine receptors in the human retina: cloning of cDNA and
RT   localization of mRNA.";
RL   Cell. Mol. Neurobiol. 11:437-453(1991).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=8471125; DOI=10.1038/npp.1993.15;
RA   Seeman P., Ohara K., Ulpian C., Seeman M.V., Jellinger K., Tol H.H.,
RA   Niznik H.B.;
RT   "Schizophrenia: normal sequence in the dopamine D2 receptor region that
RT   couples to G-proteins. DNA polymorphisms in D2.";
RL   Neuropsychopharmacology 8:137-142(1993).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RC   TISSUE=Corpus striatum;
RX   PubMed=10719223; DOI=10.1016/s0169-328x(99)00343-5;
RA   Seeman P., Nam D., Ulpian C., Liu I.S.C., Tallerico T.;
RT   "New dopamine receptor, D2(Longer), with unique TG splice site, in human
RT   brain.";
RL   Brain Res. Mol. Brain Res. 76:132-141(2000).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 3).
RA   Suwa M., Sato T., Okouchi I., Arita M., Futami K., Matsumoto S.,
RA   Tsutsumi S., Aburatani H., Asai K., Akiyama Y.;
RT   "Genome-wide discovery and analysis of human seven transmembrane helix
RT   receptor genes.";
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE (ISOFORM 1).
RA   Kidd K.K.;
RL   Submitted (FEB-1998) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [14]
RP   INTERACTION WITH CADPS AND CADPS2.
RX   PubMed=15857609; DOI=10.1016/j.bcp.2005.02.015;
RA   Binda A.V., Kabbani N., Levenson R.;
RT   "Regulation of dense core vesicle release from PC12 cells by interaction
RT   between the D2 dopamine receptor and calcium-dependent activator protein
RT   for secretion (CAPS).";
RL   Biochem. Pharmacol. 69:1451-1461(2005).
RN   [15]
RP   INTERACTION WITH GNAI2.
RX   PubMed=17550964; DOI=10.1242/jcs.005611;
RA   Lopez-Aranda M.F., Acevedo M.J., Gutierrez A., Koulen P., Khan Z.U.;
RT   "Role of a Galphai2 protein splice variant in the formation of an
RT   intracellular dopamine D2 receptor pool.";
RL   J. Cell Sci. 120:2171-2178(2007).
RN   [16]
RP   HOMOOLIGOMERIZATION, AND INTERACTION WITH DRD4.
RX   PubMed=21184734; DOI=10.1016/j.bbrc.2010.12.083;
RA   Borroto-Escuela D.O., Van Craenenbroeck K., Romero-Fernandez W.,
RA   Guidolin D., Woods A.S., Rivera A., Haegeman G., Agnati L.F.,
RA   Tarakanov A.O., Fuxe K.;
RT   "Dopamine D2 and D4 receptor heteromerization and its allosteric receptor-
RT   receptor interactions.";
RL   Biochem. Biophys. Res. Commun. 404:928-934(2011).
RN   [17]
RP   INTERACTION WITH HTR2A, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=21645528; DOI=10.1016/j.neuropharm.2011.05.023;
RA   Albizu L., Holloway T., Gonzalez-Maeso J., Sealfon S.C.;
RT   "Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine
RT   D2 receptors.";
RL   Neuropharmacology 61:770-777(2011).
RN   [18]
RP   RETRACTED PAPER.
RX   PubMed=17264214; DOI=10.1073/pnas.0608599104;
RA   Johnston C.A., Siderovski D.P.;
RT   "Structural basis for nucleotide exchange on G alpha i subunits and
RT   receptor coupling specificity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:2001-2006(2007).
RN   [19]
RP   RETRACTION NOTICE OF PUBMED:17264214.
RX   PubMed=22408789; DOI=10.1073/pnas.1200173109;
RA   Johnston C.A., Siderovski D.P.;
RL   Proc. Natl. Acad. Sci. U.S.A. 109:1808-1808(2012).
RN   [20]
RP   SUBCELLULAR LOCATION, PALMITOYLATION AT CYS-443, AND MUTAGENESIS OF
RP   CYS-126; CYS-244; CYS-253 AND CYS-443.
RX   PubMed=26535572; DOI=10.1371/journal.pone.0140661;
RA   Ebersole B., Petko J., Woll M., Murakami S., Sokolina K., Wong V.,
RA   Stagljar I., Luescher B., Levenson R.;
RT   "Effect of C-Terminal S-Palmitoylation on D2 Dopamine Receptor Trafficking
RT   and Stability.";
RL   PLoS ONE 10:e0140661-e0140661(2015).
RN   [21] {ECO:0000244|PDB:5AER}
RP   X-RAY CRYSTALLOGRAPHY (2.19 ANGSTROMS) OF 430-443 IN COMPLEX WITH NCS1.
RX   PubMed=25979333; DOI=10.1074/jbc.m114.627059;
RA   Pandalaneni S., Karuppiah V., Saleem M., Haynes L.P., Burgoyne R.D.,
RA   Mayans O., Derrick J.P., Lian L.Y.;
RT   "Neuronal Calcium Sensor-1 Binds the D2 Dopamine Receptor and G-protein-
RT   coupled Receptor Kinase 1 (GRK1) Peptides Using Different Modes of
RT   Interactions.";
RL   J. Biol. Chem. 290:18744-18756(2015).
RN   [22] {ECO:0000244|PDB:6CM4}
RP   X-RAY CRYSTALLOGRAPHY (2.87 ANGSTROMS) OF 35-222 AND 363-443 IN COMPLEX
RP   WITH INVERSE AGONIST RISPERIDONE, AND DISULFIDE BONDS.
RX   PubMed=29466326; DOI=10.1038/nature25758;
RA   Wang S., Che T., Levit A., Shoichet B.K., Wacker D., Roth B.L.;
RT   "Structure of the D2 dopamine receptor bound to the atypical antipsychotic
RT   drug risperidone.";
RL   Nature 555:269-273(2018).
RN   [23]
RP   VARIANT CYS-311.
RX   PubMed=7902708; DOI=10.1006/bbrc.1993.2404;
RA   Itokawa M., Arinami T., Futamura N., Hamaguchi H., Toru M.;
RT   "A structural polymorphism of human dopamine D2 receptor,
RT   D2(Ser311->Cys).";
RL   Biochem. Biophys. Res. Commun. 196:1369-1375(1993).
RN   [24]
RP   VARIANT ILE-154.
RX   PubMed=10220438; DOI=10.1073/pnas.96.9.5173;
RA   Klein C., Brin M.F., Kramer P., Sena-Esteves M., de Leon D., Doheny D.,
RA   Bressman S., Fahn S., Breakefield X.O., Ozelius L.J.;
RT   "Association of a missense change in the D2 dopamine receptor with
RT   myoclonus dystonia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:5173-5176(1999).
RN   [25]
RP   INVOLVEMENT IN SUSCEPTIBILITY TO ALCOHOLISM.
RX   PubMed=15389757; DOI=10.1002/ajmg.b.30085;
RA   Johann M., Putzhammer A., Eichhammer P., Wodarz N.;
RT   "Association of the -141C Del variant of the dopamine D2 receptor (DRD2)
RT   with positive family history and suicidality in German alcoholics.";
RL   Am. J. Med. Genet. B Neuropsychiatr. Genet. 132:46-49(2005).
RN   [26]
RP   CHARACTERIZATION OF VARIANT ILE-154.
RX   PubMed=10716258;
RX   DOI=10.1002/1531-8249(200003)47:3<369::aid-ana14>3.0.co;2-9;
RA   Klein C., Gurvich N., Sena-Esteves M., Bressman S., Brin M.F.,
RA   Ebersole B.J., Fink S., Forsgren L., Friedman J., Grimes D., Holmgren G.,
RA   Kyllerman M., Lang A.E., de Leon D., Leung J., Prioleau C., Raymond D.,
RA   Sanner G., Saunders-Pullman R., Vieregge P., Wahlstrom J.,
RA   Breakefield X.O., Kramer P.L., Ozelius L.J., Sealfon S.C.;
RT   "Evaluation of the role of the D2 dopamine receptor in myoclonus
RT   dystonia.";
RL   Ann. Neurol. 47:369-373(2000).
RN   [27]
RP   VARIANT GLU-327.
RX   PubMed=21179162; DOI=10.1038/nature09629;
RA   Bevilacqua L., Doly S., Kaprio J., Yuan Q., Tikkanen R., Paunio T.,
RA   Zhou Z., Wedenoja J., Maroteaux L., Diaz S., Belmer A., Hodgkinson C.A.,
RA   Dell'osso L., Suvisaari J., Coccaro E., Rose R.J., Peltonen L.,
RA   Virkkunen M., Goldman D.;
RT   "A population-specific HTR2B stop codon predisposes to severe
RT   impulsivity.";
RL   Nature 468:1061-1066(2010).
CC   -!- FUNCTION: Dopamine receptor whose activity is mediated by G proteins
CC       which inhibit adenylyl cyclase (PubMed:21645528). Positively regulates
CC       postnatal regression of retinal hyaloid vessels via suppression of
CC       VEGFR2/KDR activity, downstream of OPN5 (By similarity).
CC       {ECO:0000250|UniProtKB:P61168, ECO:0000269|PubMed:21645528}.
CC   -!- SUBUNIT: Forms homo- and heterooligomers with DRD4 (PubMed:21184734).
CC       The interaction with DRD4 may modulate agonist-induced downstream
CC       signaling (PubMed:21184734). Interacts with CADPS and CADPS2
CC       (PubMed:15857609). Interacts with GPRASP1, PPP1R9B and CLIC6 (By
CC       similarity). Interacts with ARRB2 (By similarity). Interacts with HTR2A
CC       (PubMed:21645528). Interacts with GNAI2 isoform sGi2, the interaction
CC       allows the creation of an intracellular pool of DRD2 that can be
CC       released to cell surface upon agonist stimulation (PubMed:17550964).
CC       Interacts with DRD1 (By similarity). Interacts with KCNA2 (By
CC       similarity). {ECO:0000250|UniProtKB:P61168,
CC       ECO:0000250|UniProtKB:P61169}.
CC   -!- INTERACTION:
CC       P14416; P29274: ADORA2A; NbExp=4; IntAct=EBI-2928178, EBI-2902702;
CC       P14416; P14416: DRD2; NbExp=9; IntAct=EBI-2928178, EBI-2928178;
CC       P14416; P63096: GNAI1; NbExp=2; IntAct=EBI-2928178, EBI-618639;
CC       P14416; P30989: NTSR1; NbExp=5; IntAct=EBI-2928178, EBI-6655774;
CC       P14416; Q99720: SIGMAR1; NbExp=5; IntAct=EBI-2928178, EBI-3248663;
CC       P14416; Q01959: SLC6A3; NbExp=4; IntAct=EBI-2928178, EBI-6661445;
CC       P14416; P29066: Arrb1; Xeno; NbExp=3; IntAct=EBI-2928178, EBI-4303019;
CC       P14416-1; P21917: DRD4; NbExp=4; IntAct=EBI-11686358, EBI-8592297;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:21645528,
CC       ECO:0000269|PubMed:26535572}; Multi-pass membrane protein
CC       {ECO:0000255}. Golgi apparatus membrane {ECO:0000269|PubMed:26535572};
CC       Multi-pass membrane protein {ECO:0000255}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=D2(Long), D2A;
CC         IsoId=P14416-1; Sequence=Displayed;
CC       Name=2; Synonyms=D2(Short), D2B;
CC         IsoId=P14416-2; Sequence=VSP_001870;
CC       Name=3; Synonyms=D2(Longer);
CC         IsoId=P14416-3; Sequence=VSP_026455;
CC   -!- TISSUE SPECIFICITY: [Isoform 1]: Expressed in the anterior pituitary
CC       gland. {ECO:0000269|PubMed:2531656}.
CC   -!- TISSUE SPECIFICITY: [Isoform 2]: Expressed in the anterior pituitary
CC       gland. {ECO:0000269|PubMed:2531656}.
CC   -!- PTM: Palmitoylated. Palmitoylation which is required for proper
CC       localization to the plasma membrane and stability of the receptor could
CC       be carried on by ZDHHC4, ZDHHC3 and ZDHHC8.
CC       {ECO:0000269|PubMed:26535572}.
CC   -!- POLYMORPHISM: Genetic variations in DRD2 may determine the genetic
CC       susceptibility to alcoholism [MIM:103780]. Genetic variations in DRD2
CC       might be a protective factor against the development of withdrawal
CC       symptoms but might also be a risk factor in a highly burdened subgroup
CC       of alcoholics with a paternal and grandpaternal history of alcoholism
CC       and might contribute to suicide risk in alcoholics.
CC       {ECO:0000305|PubMed:15389757}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M30625; AAA88024.1; -; mRNA.
DR   EMBL; X51645; CAB56463.1; -; mRNA.
DR   EMBL; X51646; CAB37869.1; -; Genomic_DNA.
DR   EMBL; X51362; CAA35746.1; -; mRNA.
DR   EMBL; M29066; AAA52761.1; -; mRNA.
DR   EMBL; S62137; AAB26819.1; -; mRNA.
DR   EMBL; S69899; AAB20571.1; -; mRNA.
DR   EMBL; S58589; AAB26274.1; -; Genomic_DNA.
DR   EMBL; S58577; AAB26274.1; JOINED; Genomic_DNA.
DR   EMBL; S58584; AAB26274.1; JOINED; Genomic_DNA.
DR   EMBL; S58586; AAB26274.1; JOINED; Genomic_DNA.
DR   EMBL; S58588; AAB26274.1; JOINED; Genomic_DNA.
DR   EMBL; AF176812; AAF61479.1; -; mRNA.
DR   EMBL; AB065860; BAC06078.1; -; Genomic_DNA.
DR   EMBL; AF050737; AAC78779.1; -; Genomic_DNA.
DR   EMBL; BC021195; AAH21195.1; -; mRNA.
DR   CCDS; CCDS8361.1; -. [P14416-1]
DR   CCDS; CCDS8362.1; -. [P14416-2]
DR   PIR; S08417; DYHUD2.
DR   RefSeq; NP_000786.1; NM_000795.3. [P14416-1]
DR   RefSeq; NP_057658.2; NM_016574.3. [P14416-2]
DR   RefSeq; XP_016872785.1; XM_017017296.1. [P14416-1]
DR   PDB; 1I15; Model; -; A=34-58, B=72-97, C=108-129, D=153-172, E=190-210, F=371-396, G=403-426.
DR   PDB; 5AER; X-ray; 2.19 A; B/C=430-443.
DR   PDB; 6CM4; X-ray; 2.87 A; A=35-222, A=363-443.
DR   PDB; 6LUQ; X-ray; 3.10 A; A=35-222, A=367-443.
DR   PDB; 6VMS; EM; 3.80 A; R=29-443.
DR   PDBsum; 1I15; -.
DR   PDBsum; 5AER; -.
DR   PDBsum; 6CM4; -.
DR   PDBsum; 6LUQ; -.
DR   PDBsum; 6VMS; -.
DR   SMR; P14416; -.
DR   BioGRID; 108147; 25.
DR   CORUM; P14416; -.
DR   DIP; DIP-5977N; -.
DR   IntAct; P14416; 74.
DR   MINT; P14416; -.
DR   STRING; 9606.ENSP00000354859; -.
DR   BindingDB; P14416; -.
DR   ChEMBL; CHEMBL217; -.
DR   DrugBank; DB01614; Acepromazine.
DR   DrugBank; DB01063; Acetophenazine.
DR   DrugBank; DB05766; ACP-104.
DR   DrugBank; DB01425; Alizapride.
DR   DrugBank; DB00915; Amantadine.
DR   DrugBank; DB06288; Amisulpride.
DR   DrugBank; DB05964; Amitifadine.
DR   DrugBank; DB00543; Amoxapine.
DR   DrugBank; DB00182; Amphetamine.
DR   DrugBank; DB04599; Aniracetam.
DR   DrugBank; DB00714; Apomorphine.
DR   DrugBank; DB01238; Aripiprazole.
DR   DrugBank; DB14185; Aripiprazole lauroxil.
DR   DrugBank; DB09207; AS-8112.
DR   DrugBank; DB06216; Asenapine.
DR   DrugBank; DB04889; Bicifadine.
DR   DrugBank; DB04888; Bifeprunox.
DR   DrugBank; DB05687; BL-1020.
DR   DrugBank; DB09223; Blonanserin.
DR   DrugBank; DB04857; Brasofensine.
DR   DrugBank; DB09128; Brexpiprazole.
DR   DrugBank; DB01200; Bromocriptine.
DR   DrugBank; DB09018; Bromopride.
DR   DrugBank; DB00490; Buspirone.
DR   DrugBank; DB00248; Cabergoline.
DR   DrugBank; DB06016; Cariprazine.
DR   DrugBank; DB01038; Carphenazine.
DR   DrugBank; DB00477; Chlorpromazine.
DR   DrugBank; DB01239; Chlorprothixene.
DR   DrugBank; DB00568; Cinnarizine.
DR   DrugBank; DB00363; Clozapine.
DR   DrugBank; DB01151; Desipramine.
DR   DrugBank; DB11274; Dihydro-alpha-ergocryptine.
DR   DrugBank; DB13345; Dihydroergocristine.
DR   DrugBank; DB01184; Domperidone.
DR   DrugBank; DB00988; Dopamine.
DR   DrugBank; DB00450; Droperidol.
DR   DrugBank; DB11275; Epicriptine.
DR   DrugBank; DB01049; Ergoloid mesylate.
DR   DrugBank; DB00696; Ergotamine.
DR   DrugBank; DB01175; Escitalopram.
DR   DrugBank; DB09194; Etoperidone.
DR   DrugBank; DB00875; Flupentixol.
DR   DrugBank; DB00623; Fluphenazine.
DR   DrugBank; DB04842; Fluspirilene.
DR   DrugBank; DB00502; Haloperidol.
DR   DrugBank; DB04946; Iloperidone.
DR   DrugBank; DB00458; Imipramine.
DR   DrugBank; DB04924; Itopride.
DR   DrugBank; DB12579; JNJ-37822681.
DR   DrugBank; DB01221; Ketamine.
DR   DrugBank; DB00555; Lamotrigine.
DR   DrugBank; DB01235; Levodopa.
DR   DrugBank; DB00589; Lisuride.
DR   DrugBank; DB00408; Loxapine.
DR   DrugBank; DB06077; Lumateperone.
DR   DrugBank; DB08815; Lurasidone.
DR   DrugBank; DB00934; Maprotiline.
DR   DrugBank; DB09224; Melperone.
DR   DrugBank; DB01043; Memantine.
DR   DrugBank; DB00933; Mesoridazine.
DR   DrugBank; DB01403; Methotrimeprazine.
DR   DrugBank; DB01233; Metoclopramide.
DR   DrugBank; DB06148; Mianserin.
DR   DrugBank; DB00805; Minaprine.
DR   DrugBank; DB01618; Molindone.
DR   DrugBank; DB00540; Nortriptyline.
DR   DrugBank; DB06229; Ocaperidone.
DR   DrugBank; DB00334; Olanzapine.
DR   DrugBank; DB01267; Paliperidone.
DR   DrugBank; DB12061; Pardoprunox.
DR   DrugBank; DB00715; Paroxetine.
DR   DrugBank; DB01186; Pergolide.
DR   DrugBank; DB08922; Perospirone.
DR   DrugBank; DB00850; Perphenazine.
DR   DrugBank; DB05316; Pimavanserin.
DR   DrugBank; DB01100; Pimozide.
DR   DrugBank; DB09286; Pipamperone.
DR   DrugBank; DB01621; Pipotiazine.
DR   DrugBank; DB12478; Piribedil.
DR   DrugBank; DB00413; Pramipexole.
DR   DrugBank; DB00433; Prochlorperazine.
DR   DrugBank; DB00420; Promazine.
DR   DrugBank; DB01069; Promethazine.
DR   DrugBank; DB00777; Propiomazine.
DR   DrugBank; DB01224; Quetiapine.
DR   DrugBank; DB09097; Quinagolide.
DR   DrugBank; DB12518; Raclopride.
DR   DrugBank; DB00409; Remoxipride.
DR   DrugBank; DB00734; Risperidone.
DR   DrugBank; DB01549; Rolicyclidine.
DR   DrugBank; DB00268; Ropinirole.
DR   DrugBank; DB05271; Rotigotine.
DR   DrugBank; DB06454; Sarizotan.
DR   DrugBank; DB06144; Sertindole.
DR   DrugBank; DB00391; Sulpiride.
DR   DrugBank; DB06477; Sumanirole.
DR   DrugBank; DB04844; Tetrabenazine.
DR   DrugBank; DB12093; Tetrahydropalmatine.
DR   DrugBank; DB00372; Thiethylperazine.
DR   DrugBank; DB01622; Thioproperazine.
DR   DrugBank; DB00679; Thioridazine.
DR   DrugBank; DB01623; Thiothixene.
DR   DrugBank; DB13025; Tiapride.
DR   DrugBank; DB00831; Trifluoperazine.
DR   DrugBank; DB00508; Triflupromazine.
DR   DrugBank; DB00726; Trimipramine.
DR   DrugBank; DB06109; YKP-1358.
DR   DrugBank; DB01392; Yohimbine.
DR   DrugBank; DB00246; Ziprasidone.
DR   DrugBank; DB09225; Zotepine.
DR   DrugBank; DB01624; Zuclopenthixol.
DR   DrugCentral; P14416; -.
DR   GuidetoPHARMACOLOGY; 215; -.
DR   TCDB; 9.A.14.3.10; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; P14416; 3 sites.
DR   iPTMnet; P14416; -.
DR   PhosphoSitePlus; P14416; -.
DR   SwissPalm; P14416; -.
DR   BioMuta; DRD2; -.
DR   DMDM; 118206; -.
DR   PaxDb; P14416; -.
DR   PeptideAtlas; P14416; -.
DR   PRIDE; P14416; -.
DR   ProteomicsDB; 53053; -. [P14416-1]
DR   ProteomicsDB; 53054; -. [P14416-2]
DR   ProteomicsDB; 53055; -. [P14416-3]
DR   Antibodypedia; 2801; 360 antibodies.
DR   DNASU; 1813; -.
DR   Ensembl; ENST00000346454; ENSP00000278597; ENSG00000149295. [P14416-2]
DR   Ensembl; ENST00000362072; ENSP00000354859; ENSG00000149295. [P14416-1]
DR   Ensembl; ENST00000538967; ENSP00000438215; ENSG00000149295. [P14416-3]
DR   Ensembl; ENST00000542968; ENSP00000442172; ENSG00000149295. [P14416-1]
DR   GeneID; 1813; -.
DR   KEGG; hsa:1813; -.
DR   UCSC; uc001pnz.4; human. [P14416-1]
DR   CTD; 1813; -.
DR   DisGeNET; 1813; -.
DR   EuPathDB; HostDB:ENSG00000149295.13; -.
DR   GeneCards; DRD2; -.
DR   HGNC; HGNC:3023; DRD2.
DR   HPA; ENSG00000149295; Group enriched (adrenal gland, brain, pituitary gland).
DR   MalaCards; DRD2; -.
DR   MIM; 103780; phenotype.
DR   MIM; 126450; gene.
DR   neXtProt; NX_P14416; -.
DR   OpenTargets; ENSG00000149295; -.
DR   Orphanet; 36899; Myoclonus-dystonia syndrome.
DR   PharmGKB; PA27478; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00940000155539; -.
DR   HOGENOM; CLU_009579_11_1_1; -.
DR   InParanoid; P14416; -.
DR   KO; K04145; -.
DR   OMA; MLFGLNN; -.
DR   PhylomeDB; P14416; -.
DR   TreeFam; TF334382; -.
DR   PathwayCommons; P14416; -.
DR   Reactome; R-HSA-390651; Dopamine receptors.
DR   SignaLink; P14416; -.
DR   SIGNOR; P14416; -.
DR   BioGRID-ORCS; 1813; 4 hits in 878 CRISPR screens.
DR   ChiTaRS; DRD2; human.
DR   EvolutionaryTrace; P14416; -.
DR   GeneWiki; Dopamine_receptor_D2; -.
DR   GenomeRNAi; 1813; -.
DR   Pharos; P14416; Tclin.
DR   PRO; PR:P14416; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; P14416; protein.
DR   Bgee; ENSG00000149295; Expressed in adenohypophysis and 134 other tissues.
DR   ExpressionAtlas; P14416; baseline and differential.
DR   Genevisible; P14416; HS.
DR   GO; GO:0001669; C:acrosomal vesicle; IEA:Ensembl.
DR   GO; GO:0030424; C:axon; ISS:BHF-UCL.
DR   GO; GO:0043679; C:axon terminus; IEA:Ensembl.
DR   GO; GO:0060170; C:ciliary membrane; IDA:SYSCILIA_CCNET.
DR   GO; GO:0005929; C:cilium; IDA:MGI.
DR   GO; GO:0030425; C:dendrite; ISS:BHF-UCL.
DR   GO; GO:0043197; C:dendritic spine; IEA:Ensembl.
DR   GO; GO:0098691; C:dopaminergic synapse; IEA:Ensembl.
DR   GO; GO:0030139; C:endocytic vesicle; IEA:Ensembl.
DR   GO; GO:0098978; C:glutamatergic synapse; IBA:GO_Central.
DR   GO; GO:0000139; C:Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0099056; C:integral component of presynaptic membrane; IBA:GO_Central.
DR   GO; GO:0016328; C:lateral plasma membrane; IEA:Ensembl.
DR   GO; GO:0097730; C:non-motile cilium; IDA:SYSCILIA_CCNET.
DR   GO; GO:0043204; C:perikaryon; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:WormBase.
DR   GO; GO:0014069; C:postsynaptic density; IEA:Ensembl.
DR   GO; GO:0036126; C:sperm flagellum; IEA:Ensembl.
DR   GO; GO:0045202; C:synapse; IEA:GOC.
DR   GO; GO:0030672; C:synaptic vesicle membrane; IEA:Ensembl.
DR   GO; GO:0035240; F:dopamine binding; IEA:Ensembl.
DR   GO; GO:0001591; F:dopamine neurotransmitter receptor activity, coupled via Gi/Go; IDA:BHF-UCL.
DR   GO; GO:0008144; F:drug binding; IDA:BHF-UCL.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0035255; F:ionotropic glutamate receptor binding; IEA:Ensembl.
DR   GO; GO:0015459; F:potassium channel regulator activity; NAS:BHF-UCL.
DR   GO; GO:0044877; F:protein-containing complex binding; IEA:Ensembl.
DR   GO; GO:0046717; P:acid secretion; IEA:Ensembl.
DR   GO; GO:0032147; P:activation of protein kinase activity; IEA:Ensembl.
DR   GO; GO:0021984; P:adenohypophysis development; ISS:BHF-UCL.
DR   GO; GO:0071880; P:adenylate cyclase-activating adrenergic receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007195; P:adenylate cyclase-inhibiting dopamine receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0007188; P:adenylate cyclase-modulating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007628; P:adult walking behavior; ISS:BHF-UCL.
DR   GO; GO:0050482; P:arachidonic acid secretion; IDA:BHF-UCL.
DR   GO; GO:0008306; P:associative learning; ISS:BHF-UCL.
DR   GO; GO:0031223; P:auditory behavior; IEA:Ensembl.
DR   GO; GO:0006914; P:autophagy; IEA:Ensembl.
DR   GO; GO:0007409; P:axonogenesis; ISS:BHF-UCL.
DR   GO; GO:0048148; P:behavioral response to cocaine; ISS:BHF-UCL.
DR   GO; GO:0048149; P:behavioral response to ethanol; ISS:BHF-UCL.
DR   GO; GO:0048755; P:branching morphogenesis of a nerve; ISS:BHF-UCL.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IC:BHF-UCL.
DR   GO; GO:0021853; P:cerebral cortex GABAergic interneuron migration; ISS:BHF-UCL.
DR   GO; GO:0032922; P:circadian regulation of gene expression; ISS:BHF-UCL.
DR   GO; GO:0042417; P:dopamine metabolic process; IC:BHF-UCL.
DR   GO; GO:0042756; P:drinking behavior; IEA:Ensembl.
DR   GO; GO:0060079; P:excitatory postsynaptic potential; NAS:ParkinsonsUK-UCL.
DR   GO; GO:0002031; P:G protein-coupled receptor internalization; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007625; P:grooming behavior; IEA:Ensembl.
DR   GO; GO:1990384; P:hyaloid vascular plexus regression; ISS:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:BHF-UCL.
DR   GO; GO:0007626; P:locomotory behavior; ISS:BHF-UCL.
DR   GO; GO:0007616; P:long-term memory; IEA:Ensembl.
DR   GO; GO:0007194; P:negative regulation of adenylate cyclase activity; IDA:BHF-UCL.
DR   GO; GO:0045776; P:negative regulation of blood pressure; ISS:BHF-UCL.
DR   GO; GO:0060548; P:negative regulation of cell death; IEA:Ensembl.
DR   GO; GO:0030336; P:negative regulation of cell migration; ISS:BHF-UCL.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; ISS:BHF-UCL.
DR   GO; GO:0042321; P:negative regulation of circadian sleep/wake cycle, sleep; IEA:Ensembl.
DR   GO; GO:0051481; P:negative regulation of cytosolic calcium ion concentration; IBA:GO_Central.
DR   GO; GO:0060160; P:negative regulation of dopamine receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0033602; P:negative regulation of dopamine secretion; IEA:Ensembl.
DR   GO; GO:0045824; P:negative regulation of innate immune response; IEA:Ensembl.
DR   GO; GO:0046676; P:negative regulation of insulin secretion; IEA:Ensembl.
DR   GO; GO:0051898; P:negative regulation of protein kinase B signaling; ISS:BHF-UCL.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; IEA:Ensembl.
DR   GO; GO:0050709; P:negative regulation of protein secretion; IDA:BHF-UCL.
DR   GO; GO:0051967; P:negative regulation of synaptic transmission, glutamatergic; ISS:BHF-UCL.
DR   GO; GO:1901386; P:negative regulation of voltage-gated calcium channel activity; IDA:BHF-UCL.
DR   GO; GO:0001976; P:nervous system process involved in regulation of systemic arterial blood pressure; ISS:BHF-UCL.
DR   GO; GO:0007270; P:neuron-neuron synaptic transmission; ISS:BHF-UCL.
DR   GO; GO:0021769; P:orbitofrontal cortex development; IEA:Ensembl.
DR   GO; GO:0030432; P:peristalsis; ISS:BHF-UCL.
DR   GO; GO:0060158; P:phospholipase C-activating dopamine receptor signaling pathway; IGI:MGI.
DR   GO; GO:0043473; P:pigmentation; IEA:Ensembl.
DR   GO; GO:0032467; P:positive regulation of cytokinesis; IMP:UniProtKB.
DR   GO; GO:0051482; P:positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0051586; P:positive regulation of dopamine uptake involved in synaptic transmission; ISS:BHF-UCL.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IEA:Ensembl.
DR   GO; GO:0045745; P:positive regulation of G protein-coupled receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:1900168; P:positive regulation of glial cell-derived neurotrophic factor secretion; IDA:CACAO.
DR   GO; GO:0060124; P:positive regulation of growth hormone secretion; ISS:BHF-UCL.
DR   GO; GO:1900273; P:positive regulation of long-term synaptic potentiation; IEA:Ensembl.
DR   GO; GO:0040018; P:positive regulation of multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0002052; P:positive regulation of neuroblast proliferation; ISS:BHF-UCL.
DR   GO; GO:0002092; P:positive regulation of receptor internalization; IEA:Ensembl.
DR   GO; GO:0035815; P:positive regulation of renal sodium excretion; IEA:Ensembl.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0035810; P:positive regulation of urine volume; IEA:Ensembl.
DR   GO; GO:0099170; P:postsynaptic modulation of chemical synaptic transmission; IEA:Ensembl.
DR   GO; GO:0060134; P:prepulse inhibition; ISS:BHF-UCL.
DR   GO; GO:0008104; P:protein localization; ISS:BHF-UCL.
DR   GO; GO:0014059; P:regulation of dopamine secretion; IBA:GO_Central.
DR   GO; GO:0051584; P:regulation of dopamine uptake involved in synaptic transmission; IC:BHF-UCL.
DR   GO; GO:0002027; P:regulation of heart rate; ISS:BHF-UCL.
DR   GO; GO:0090325; P:regulation of locomotion involved in locomotory behavior; IEA:Ensembl.
DR   GO; GO:0048169; P:regulation of long-term neuronal synaptic plasticity; ISS:BHF-UCL.
DR   GO; GO:0043666; P:regulation of phosphoprotein phosphatase activity; IEA:Ensembl.
DR   GO; GO:0043266; P:regulation of potassium ion transport; ISS:BHF-UCL.
DR   GO; GO:0002028; P:regulation of sodium ion transport; ISS:BHF-UCL.
DR   GO; GO:0051823; P:regulation of synapse structural plasticity; IEA:Ensembl.
DR   GO; GO:0032228; P:regulation of synaptic transmission, GABAergic; ISS:BHF-UCL.
DR   GO; GO:2000300; P:regulation of synaptic vesicle exocytosis; IEA:Ensembl.
DR   GO; GO:0051209; P:release of sequestered calcium ion into cytosol; ISS:BHF-UCL.
DR   GO; GO:0001975; P:response to amphetamine; ISS:BHF-UCL.
DR   GO; GO:0048678; P:response to axon injury; IEA:Ensembl.
DR   GO; GO:0042220; P:response to cocaine; ISS:BHF-UCL.
DR   GO; GO:0042493; P:response to drug; ISS:BHF-UCL.
DR   GO; GO:0034776; P:response to histamine; IDA:BHF-UCL.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0014854; P:response to inactivity; IEA:Ensembl.
DR   GO; GO:0010039; P:response to iron ion; IEA:Ensembl.
DR   GO; GO:0009416; P:response to light stimulus; ISS:BHF-UCL.
DR   GO; GO:0043278; P:response to morphine; ISS:BHF-UCL.
DR   GO; GO:0035094; P:response to nicotine; IEA:Ensembl.
DR   GO; GO:0009636; P:response to toxic substance; IEA:Ensembl.
DR   GO; GO:0007608; P:sensory perception of smell; ISS:BHF-UCL.
DR   GO; GO:0021756; P:striatum development; IEA:Ensembl.
DR   GO; GO:0007416; P:synapse assembly; ISS:BHF-UCL.
DR   GO; GO:0001963; P:synaptic transmission, dopaminergic; IBA:GO_Central.
DR   GO; GO:0001659; P:temperature homeostasis; ISS:BHF-UCL.
DR   GO; GO:0008542; P:visual learning; ISS:BHF-UCL.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:Ensembl.
DR   InterPro; IPR001922; Dopamine_D2_rcpt.
DR   InterPro; IPR000929; Dopamine_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00567; DOPAMINED2R.
DR   PRINTS; PR00242; DOPAMINER.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Disease mutation;
KW   Disulfide bond; G-protein coupled receptor; Glycoprotein; Golgi apparatus;
KW   Lipoprotein; Membrane; Palmitate; Polymorphism; Receptor;
KW   Reference proteome; Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..443
FT                   /note="D(2) dopamine receptor"
FT                   /id="PRO_0000069387"
FT   TOPO_DOM        1..37
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        38..60
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        61..70
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        71..93
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        94..108
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        109..130
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        131..151
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        152..172
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        173..188
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        189..213
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        214..373
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        374..395
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        396..409
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        410..431
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        432..443
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   REGION          190..197
FT                   /note="Agonist binding"
FT                   /evidence="ECO:0000250"
FT   REGION          211..373
FT                   /note="Interaction with PPP1R9B"
FT                   /evidence="ECO:0000250"
FT   REGION          386..394
FT                   /note="Agonist binding"
FT                   /evidence="ECO:0000250"
FT   BINDING         114
FT                   /note="Agonist"
FT                   /evidence="ECO:0000250"
FT   SITE            194
FT                   /note="Important for receptor activation"
FT                   /evidence="ECO:0000250"
FT   SITE            197
FT                   /note="Important for receptor activation"
FT                   /evidence="ECO:0000250"
FT   LIPID           443
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:26535572"
FT   CARBOHYD        5
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        17
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        23
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        107..182
FT                   /evidence="ECO:0000244|PDB:6CM4,
FT                   ECO:0000269|PubMed:29466326"
FT   DISULFID        399..401
FT                   /evidence="ECO:0000244|PDB:6CM4,
FT                   ECO:0000269|PubMed:29466326"
FT   VAR_SEQ         242..270
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:2531656"
FT                   /id="VSP_001870"
FT   VAR_SEQ         270
FT                   /note="V -> VVQ (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:10719223"
FT                   /id="VSP_026455"
FT   VARIANT         154
FT                   /note="V -> I (found in patients with alcohol-responsive
FT                   myoclonus-dystonia; unknown pathological significance; the
FT                   mutation does not affect functional properties;
FT                   dbSNP:rs104894220)"
FT                   /evidence="ECO:0000269|PubMed:10220438,
FT                   ECO:0000269|PubMed:10716258"
FT                   /id="VAR_017143"
FT   VARIANT         310
FT                   /note="P -> S (in dbSNP:rs1800496)"
FT                   /id="VAR_014674"
FT   VARIANT         311
FT                   /note="S -> C (may be associated with a higher risk for
FT                   schizophrenia; dbSNP:rs1801028)"
FT                   /evidence="ECO:0000269|PubMed:7902708"
FT                   /id="VAR_003462"
FT   VARIANT         327
FT                   /note="K -> E (in dbSNP:rs71653614)"
FT                   /evidence="ECO:0000269|PubMed:21179162"
FT                   /id="VAR_064579"
FT   MUTAGEN         126
FT                   /note="C->S: No effect on palmitoylation; no effect on
FT                   localization to the plasma membrane."
FT                   /evidence="ECO:0000269|PubMed:26535572"
FT   MUTAGEN         244
FT                   /note="C->S: No effect on palmitoylation; no effect on
FT                   localization to the plasma membrane."
FT                   /evidence="ECO:0000269|PubMed:26535572"
FT   MUTAGEN         253
FT                   /note="C->S: No effect on palmitoylation; no effect on
FT                   localization to the plasma membrane."
FT                   /evidence="ECO:0000269|PubMed:26535572"
FT   MUTAGEN         443
FT                   /note="Missing: Decreased palmitoylation; decreased
FT                   localization to the plasma membrane; decreased stability."
FT                   /evidence="ECO:0000269|PubMed:26535572"
FT   CONFLICT        40
FT                   /note="L -> R (in Ref. 7; AAB26819)"
FT                   /evidence="ECO:0000305"
FT   HELIX           36..61
FT                   /evidence="ECO:0000244|PDB:6CM4"
FT   HELIX           63..65
FT                   /evidence="ECO:0000244|PDB:6CM4"
FT   HELIX           68..86
FT                   /evidence="ECO:0000244|PDB:6CM4"
FT   HELIX           88..97
FT                   /evidence="ECO:0000244|PDB:6CM4"
FT   HELIX           104..137
FT                   /evidence="ECO:0000244|PDB:6CM4"
FT   HELIX           147..167
FT                   /evidence="ECO:0000244|PDB:6CM4"
FT   HELIX           168..175
FT                   /evidence="ECO:0000244|PDB:6CM4"
FT   HELIX           183..185
FT                   /evidence="ECO:0000244|PDB:6CM4"
FT   HELIX           189..195
FT                   /evidence="ECO:0000244|PDB:6CM4"
FT   TURN            196..198
FT                   /evidence="ECO:0000244|PDB:6CM4"
FT   HELIX           199..222
FT                   /evidence="ECO:0000244|PDB:6CM4"
FT   HELIX           369..398
FT                   /evidence="ECO:0000244|PDB:6CM4"
FT   HELIX           405..417
FT                   /evidence="ECO:0000244|PDB:6CM4"
FT   HELIX           418..420
FT                   /evidence="ECO:0000244|PDB:6CM4"
FT   HELIX           422..429
FT                   /evidence="ECO:0000244|PDB:6CM4"
FT   HELIX           431..442
FT                   /evidence="ECO:0000244|PDB:5AER"
SQ   SEQUENCE   443 AA;  50619 MW;  9BF8EA36C988A2E2 CRC64;
     MDPLNLSWYD DDLERQNWSR PFNGSDGKAD RPHYNYYATL LTLLIAVIVF GNVLVCMAVS
     REKALQTTTN YLIVSLAVAD LLVATLVMPW VVYLEVVGEW KFSRIHCDIF VTLDVMMCTA
     SILNLCAISI DRYTAVAMPM LYNTRYSSKR RVTVMISIVW VLSFTISCPL LFGLNNADQN
     ECIIANPAFV VYSSIVSFYV PFIVTLLVYI KIYIVLRRRR KRVNTKRSSR AFRAHLRAPL
     KGNCTHPEDM KLCTVIMKSN GSFPVNRRRV EAARRAQELE MEMLSSTSPP ERTRYSPIPP
     SHHQLTLPDP SHHGLHSTPD SPAKPEKNGH AKDHPKIAKI FEIQTMPNGK TRTSLKTMSR
     RKLSQQKEKK ATQMLAIVLG VFIICWLPFF ITHILNIHCD CNIPPVLYSA FTWLGYVNSA
     VNPIIYTTFN IEFRKAFLKI LHC
//
ID   RXFP2_HUMAN             Reviewed;         754 AA.
AC   Q8WXD0; B1ALE9; Q3KU23;
DT   06-JUN-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2002, sequence version 1.
DT   07-OCT-2020, entry version 176.
DE   RecName: Full=Relaxin receptor 2;
DE   AltName: Full=G-protein coupled receptor 106;
DE   AltName: Full=G-protein coupled receptor affecting testicular descent;
DE   AltName: Full=Leucine-rich repeat-containing G-protein coupled receptor 8;
DE   AltName: Full=Relaxin family peptide receptor 2;
GN   Name=RXFP2; Synonyms=GPR106, GREAT, LGR8;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND MUTAGENESIS OF ASP-647.
RX   PubMed=11809971; DOI=10.1126/science.1065654;
RA   Hsu S.Y., Nakabayashi K., Nishi S., Kumagai J., Kudo M., Sherwood O.D.,
RA   Hsueh A.J.W.;
RT   "Activation of orphan receptors by the hormone relaxin.";
RL   Science 295:671-674(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT CRYPTO PRO-222, AND VARIANT
RP   VAL-604.
RX   PubMed=12217959; DOI=10.1093/hmg/11.19.2309;
RA   Gorlov I.P., Kamat A., Bogatcheva N.V., Jones E., Lamb D.J., Truong A.,
RA   Bishop C.E., McElreavey K., Agoulnik A.I.;
RT   "Mutations of the GREAT gene cause cryptorchidism.";
RL   Hum. Mol. Genet. 11:2309-2318(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=16051677; DOI=10.1093/molehr/gah205;
RA   Muda M., He C., Martini P.G.V., Ferraro T., Layfield S., Taylor D.,
RA   Chevrier C., Schweickhardt R., Kelton C., Ryan P.L., Bathgate R.A.D.;
RT   "Splice variants of the relaxin and INSL3 receptors reveal unanticipated
RT   molecular complexity.";
RL   Mol. Hum. Reprod. 11:591-600(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057823; DOI=10.1038/nature02379;
RA   Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L.,
RA   Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S.,
RA   Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C.,
RA   Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P.,
RA   Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L.,
RA   Frankish A.G., Frankland J., French L., Garner P., Garnett J.,
RA   Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M.,
RA   Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D.,
RA   Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D.,
RA   Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S.,
RA   Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S.,
RA   Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R.,
RA   Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W.,
RA   Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L.,
RA   Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R.,
RA   Rogers J., Ross M.T.;
RT   "The DNA sequence and analysis of human chromosome 13.";
RL   Nature 428:522-528(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Receptor for relaxin. The activity of this receptor is
CC       mediated by G proteins leading to stimulation of adenylate cyclase and
CC       an increase of cAMP. May also be a receptor for Leydig insulin-like
CC       peptide (INSL3).
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q8WXD0-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8WXD0-2; Sequence=VSP_042831;
CC   -!- TISSUE SPECIFICITY: Expressed mainly in the brain, kidney, muscle,
CC       testis, thyroid, uterus, peripheral blood cells and bone marrow.
CC   -!- DISEASE: Cryptorchidism (CRYPTO) [MIM:219050]: One of the most frequent
CC       congenital abnormalities in humans, involving 2-5% of male births.
CC       Cryptorchidism is associated with increased risk of infertility and
CC       testicular cancer. {ECO:0000269|PubMed:12217959}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- CAUTION: It is uncertain whether Met-1 or Met-18 is the initiator.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF403384; AAL69324.2; -; mRNA.
DR   EMBL; AF453828; AAL73946.1; -; mRNA.
DR   EMBL; AY899851; AAX85199.1; -; mRNA.
DR   EMBL; AL138708; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL159161; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471075; EAX08484.1; -; Genomic_DNA.
DR   CCDS; CCDS53862.1; -. [Q8WXD0-2]
DR   CCDS; CCDS9342.1; -. [Q8WXD0-1]
DR   RefSeq; NP_001159530.1; NM_001166058.1. [Q8WXD0-2]
DR   RefSeq; NP_570718.1; NM_130806.4. [Q8WXD0-1]
DR   PDB; 2M96; NMR; -; A=38-81.
DR   PDBsum; 2M96; -.
DR   BMRB; Q8WXD0; -.
DR   SMR; Q8WXD0; -.
DR   BioGRID; 125757; 1.
DR   STRING; 9606.ENSP00000298386; -.
DR   ChEMBL; CHEMBL1628482; -.
DR   GuidetoPHARMACOLOGY; 352; -.
DR   GlyGen; Q8WXD0; 5 sites.
DR   iPTMnet; Q8WXD0; -.
DR   PhosphoSitePlus; Q8WXD0; -.
DR   BioMuta; RXFP2; -.
DR   DMDM; 21362625; -.
DR   EPD; Q8WXD0; -.
DR   MassIVE; Q8WXD0; -.
DR   PaxDb; Q8WXD0; -.
DR   PeptideAtlas; Q8WXD0; -.
DR   PRIDE; Q8WXD0; -.
DR   ProteomicsDB; 75010; -. [Q8WXD0-1]
DR   ProteomicsDB; 75011; -. [Q8WXD0-2]
DR   Antibodypedia; 22835; 302 antibodies.
DR   DNASU; 122042; -.
DR   Ensembl; ENST00000298386; ENSP00000298386; ENSG00000133105. [Q8WXD0-1]
DR   Ensembl; ENST00000380314; ENSP00000369670; ENSG00000133105. [Q8WXD0-2]
DR   GeneID; 122042; -.
DR   KEGG; hsa:122042; -.
DR   UCSC; uc001utt.4; human. [Q8WXD0-1]
DR   CTD; 122042; -.
DR   DisGeNET; 122042; -.
DR   EuPathDB; HostDB:ENSG00000133105.7; -.
DR   GeneCards; RXFP2; -.
DR   HGNC; HGNC:17318; RXFP2.
DR   HPA; ENSG00000133105; Tissue enhanced (brain, epididymis).
DR   MalaCards; RXFP2; -.
DR   MIM; 219050; phenotype.
DR   MIM; 606655; gene.
DR   neXtProt; NX_Q8WXD0; -.
DR   OpenTargets; ENSG00000133105; -.
DR   PharmGKB; PA134918556; -.
DR   eggNOG; KOG0619; Eukaryota.
DR   eggNOG; KOG2087; Eukaryota.
DR   GeneTree; ENSGT00940000158948; -.
DR   HOGENOM; CLU_006130_2_1_1; -.
DR   InParanoid; Q8WXD0; -.
DR   KO; K04307; -.
DR   OMA; MESLECR; -.
DR   OrthoDB; 559381at2759; -.
DR   PhylomeDB; Q8WXD0; -.
DR   TreeFam; TF326185; -.
DR   PathwayCommons; Q8WXD0; -.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-444821; Relaxin receptors.
DR   Reactome; R-HSA-9660821; ADORA2B mediated anti-inflammatory cytokines production.
DR   SIGNOR; Q8WXD0; -.
DR   BioGRID-ORCS; 122042; 2 hits in 861 CRISPR screens.
DR   ChiTaRS; RXFP2; human.
DR   GeneWiki; Relaxin/insulin-like_family_peptide_receptor_2; -.
DR   GenomeRNAi; 122042; -.
DR   Pharos; Q8WXD0; Tbio.
DR   PRO; PR:Q8WXD0; -.
DR   Proteomes; UP000005640; Chromosome 13.
DR   RNAct; Q8WXD0; protein.
DR   Bgee; ENSG00000133105; Expressed in monocyte and 50 other tissues.
DR   Genevisible; Q8WXD0; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0008528; F:G protein-coupled peptide receptor activity; IBA:GO_Central.
DR   GO; GO:0017046; F:peptide hormone binding; IEA:Ensembl.
DR   GO; GO:0016500; F:protein-hormone receptor activity; IEA:Ensembl.
DR   GO; GO:0007190; P:activation of adenylate cyclase activity; IBA:GO_Central.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007193; P:adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0009755; P:hormone-mediated signaling pathway; IBA:GO_Central.
DR   GO; GO:0008584; P:male gonad development; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0001556; P:oocyte maturation; IEA:Ensembl.
DR   GO; GO:0043950; P:positive regulation of cAMP-mediated signaling; IEA:Ensembl.
DR   CDD; cd00112; LDLa; 1.
DR   Gene3D; 3.80.10.10; -; 2.
DR   Gene3D; 4.10.400.10; -; 1.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR036055; LDL_receptor-like_sf.
DR   InterPro; IPR023415; LDLR_class-A_CS.
DR   InterPro; IPR002172; LDrepeatLR_classA_rpt.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR003591; Leu-rich_rpt_typical-subtyp.
DR   InterPro; IPR032675; LRR_dom_sf.
DR   InterPro; IPR008112; Relaxin_rcpt.
DR   Pfam; PF00001; 7tm_1; 1.
DR   Pfam; PF00057; Ldl_recept_a; 1.
DR   Pfam; PF13855; LRR_8; 3.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01739; RELAXINR.
DR   SMART; SM00192; LDLa; 1.
DR   SMART; SM00369; LRR_TYP; 10.
DR   SUPFAM; SSF57424; SSF57424; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
DR   PROSITE; PS01209; LDLRA_1; 1.
DR   PROSITE; PS50068; LDLRA_2; 1.
DR   PROSITE; PS51450; LRR; 9.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Disease mutation;
KW   Disulfide bond; G-protein coupled receptor; Glycoprotein;
KW   Leucine-rich repeat; Membrane; Polymorphism; Receptor; Reference proteome;
KW   Repeat; Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..754
FT                   /note="Relaxin receptor 2"
FT                   /id="PRO_0000069702"
FT   TOPO_DOM        1..416
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        417..437
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        438..455
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        456..476
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        477..495
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        496..518
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        519..537
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        538..558
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        559..592
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        593..613
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        614..639
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        640..660
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        661..670
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        671..691
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        692..754
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          44..81
FT                   /note="LDL-receptor class A"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00124"
FT   REPEAT          138..159
FT                   /note="LRR 1"
FT   REPEAT          162..183
FT                   /note="LRR 2"
FT   REPEAT          186..207
FT                   /note="LRR 3"
FT   REPEAT          210..231
FT                   /note="LRR 4"
FT   REPEAT          234..255
FT                   /note="LRR 5"
FT   REPEAT          258..279
FT                   /note="LRR 6"
FT   REPEAT          282..303
FT                   /note="LRR 7"
FT   REPEAT          306..327
FT                   /note="LRR 8"
FT   REPEAT          330..351
FT                   /note="LRR 9"
FT   REPEAT          354..375
FT                   /note="LRR 10"
FT   CARBOHYD        54
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        138
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        274
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        335
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        378
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        45..58
FT                   /evidence="ECO:0000250"
FT   DISULFID        52..71
FT                   /evidence="ECO:0000250"
FT   DISULFID        65..80
FT                   /evidence="ECO:0000250"
FT   DISULFID        495..573
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         286..309
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:16051677"
FT                   /id="VSP_042831"
FT   VARIANT         222
FT                   /note="T -> P (in CRYPTO; functionally inactive;
FT                   dbSNP:rs121918303)"
FT                   /evidence="ECO:0000269|PubMed:12217959"
FT                   /id="VAR_015386"
FT   VARIANT         604
FT                   /note="I -> V (in dbSNP:rs17076657)"
FT                   /evidence="ECO:0000269|PubMed:12217959"
FT                   /id="VAR_015387"
FT   MUTAGEN         647
FT                   /note="D->Y: Leads to constitutive increase of basal cAMP."
FT                   /evidence="ECO:0000269|PubMed:11809971"
FT   HELIX           61..63
FT                   /evidence="ECO:0000244|PDB:2M96"
FT   STRAND          70..75
FT                   /evidence="ECO:0000244|PDB:2M96"
SQ   SEQUENCE   754 AA;  86453 MW;  2088ECD204C6A6C5 CRC64;
     MIVFLVFKHL FSLRLITMFF LLHFIVLINV KDFALTQGSM ITPSCQKGYF PCGNLTKCLP
     RAFHCDGKDD CGNGADEENC GDTSGWATIF GTVHGNANSV ALTQECFLKQ YPQCCDCKET
     ELECVNGDLK SVPMISNNVT LLSLKKNKIH SLPDKVFIKY TKLKKIFLQH NCIRHISRKA
     FFGLCNLQIL YLNHNCITTL RPGIFKDLHQ LTWLILDDNP ITRISQRLFT GLNSLFFLSM
     VNNYLEALPK QMCAQMPQLN WVDLEGNRIK YLTNSTFLSC DSLTVLFLPR NQIGFVPEKT
     FSSLKNLGEL DLSSNTITEL SPHLFKDLKL LQKLNLSSNP LMYLHKNQFE SLKQLQSLDL
     ERIEIPNINT RMFQPMKNLS HIYFKNFRYC SYAPHVRICM PLTDGISSFE DLLANNILRI
     FVWVIAFITC FGNLFVIGMR SFIKAENTTH AMSIKILCCA DCLMGVYLFF VGIFDIKYRG
     QYQKYALLWM ESVQCRLMGF LAMLSTEVSV LLLTYLTLEK FLVIVFPFSN IRPGKRQTSV
     ILICIWMAGF LIAVIPFWNK DYFGNFYGKN GVCFPLYYDQ TEDIGSKGYS LGIFLGVNLL
     AFLIIVFSYI TMFCSIQKTA LQTTEVRNCF GREVAVANRF FFIVFSDAIC WIPVFVVKIL
     SLFRVEIPDT MTSWIVIFFL PVNSALNPIL YTLTTNFFKD KLKQLLHKHQ RKSIFKIKKK
     SLSTSIVWIE DSSSLKLGVL NKITLGDSIM KPVS
//
ID   SMO_HUMAN               Reviewed;         787 AA.
AC   Q99835; A4D1K5;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1997, sequence version 1.
DT   07-OCT-2020, entry version 201.
DE   RecName: Full=Smoothened homolog;
DE            Short=SMO;
DE   AltName: Full=Protein Gx;
DE   Flags: Precursor;
GN   Name=SMO; Synonyms=SMOH;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Embryonic lung;
RX   PubMed=8906787; DOI=10.1038/384129a0;
RA   Stone D.M., Hynes M., Armanini M., Swanson T.A., Gu Q., Johnson R.L.,
RA   Scott M.P., Pennica D., Goddard A., Phillips H., Noll M., Hooper J.E.,
RA   de Sauvage F., Rosenthal A.;
RT   "The tumour-suppressor gene patched encodes a candidate receptor for Sonic
RT   hedgehog.";
RL   Nature 384:129-134(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS LEU-535 AND GLN-562.
RX   PubMed=9422511; DOI=10.1038/34201;
RA   Xie J., Murone M., Luoh S.-M., Ryan A., Gu Q., Zhang C., Bonifas J.M.,
RA   Lam C.-W., Hynes M., Goddard A., Rosenthal A., Epstein E.H. Jr.,
RA   de Sauvage F.J.;
RT   "Activating Smoothened mutations in sporadic basal-cell carcinoma.";
RL   Nature 391:90-92(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Jiang N., Zeng Z.Y., Li G.Y.;
RT   "Cloning and identification of Gx gene in NPC.";
RL   Submitted (JAN-1999) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D.,
RA   Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S.,
RA   Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R.,
RA   Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N.,
RA   Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E.,
RA   Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R.,
RA   Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T.,
RA   Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W.,
RA   Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A.,
RA   Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X.,
RA   Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E.,
RA   Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J.,
RA   Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION, AND INTERACTION WITH KIF7.
RX   PubMed=19592253; DOI=10.1016/j.cub.2009.06.046;
RA   Endoh-Yamagami S., Evangelista M., Wilson D., Wen X., Theunissen J.W.,
RA   Phamluong K., Davis M., Scales S.J., Solloway M.J., de Sauvage F.J.,
RA   Peterson A.S.;
RT   "The mammalian Cos2 homolog Kif7 plays an essential role in modulating Hh
RT   signal transduction during development.";
RL   Curr. Biol. 19:1320-1326(2009).
RN   [8]
RP   INTERACTION WITH GAS8.
RX   PubMed=21659505; DOI=10.1074/jbc.m111.234666;
RA   Evron T., Philipp M., Lu J., Meloni A.R., Burkhalter M., Chen W.,
RA   Caron M.G.;
RT   "Growth arrest specific 8 (Gas8) and G protein-coupled receptor kinase 2
RT   (GRK2) cooperate in the control of Smoothened signaling.";
RL   J. Biol. Chem. 286:27676-27686(2011).
RN   [9]
RP   ASSOCIATION WITH THE BBSOME COMPLEX, INTERACTION WITH BBS5 AND BBS7, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=22072986; DOI=10.1371/journal.pgen.1002358;
RA   Seo S., Zhang Q., Bugge K., Breslow D.K., Searby C.C., Nachury M.V.,
RA   Sheffield V.C.;
RT   "A novel protein LZTFL1 regulates ciliary trafficking of the BBSome and
RT   Smoothened.";
RL   PLoS Genet. 7:E1002358-E1002358(2011).
RN   [10]
RP   INVOLVEMENT IN CRJS, AND VARIANT CRJS PHE-412.
RX   PubMed=27236920; DOI=10.1016/j.ajhg.2016.04.007;
RA   Twigg S.R., Hufnagel R.B., Miller K.A., Zhou Y., McGowan S.J., Taylor J.,
RA   Craft J., Taylor J.C., Santoro S.L., Huang T., Hopkin R.J., Brady A.F.,
RA   Clayton-Smith J., Clericuzio C.L., Grange D.K., Groesser L., Hafner C.,
RA   Horn D., Temple I.K., Dobyns W.B., Curry C.J., Jones M.C., Wilkie A.O.;
RT   "A recurrent mosaic mutation in SMO, encoding the hedgehog signal
RT   transducer smoothened, is the major cause of Curry-Jones syndrome.";
RL   Am. J. Hum. Genet. 98:1256-1265(2016).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF 190-555 IN COMPLEX WITH
RP   ANTAGONIST, SUBUNIT, AND DISULFIDE BONDS.
RX   PubMed=23636324; DOI=10.1038/nature12167;
RA   Wang C., Wu H., Katritch V., Han G.W., Huang X.P., Liu W., Siu F.Y.,
RA   Roth B.L., Cherezov V., Stevens R.C.;
RT   "Structure of the human smoothened receptor bound to an antitumour agent.";
RL   Nature 497:338-343(2013).
RN   [12]
RP   VARIANT CRJS PHE-412, VARIANT LEU-535, CHARACTERIZATION OF VARIANT CRJS
RP   PHE-412, AND CHARACTERIZATION OF VARIANT LEU-535.
RX   PubMed=24859340; DOI=10.1038/ng.2986;
RA   Sweeney R.T., McClary A.C., Myers B.R., Biscocho J., Neahring L.,
RA   Kwei K.A., Qu K., Gong X., Ng T., Jones C.D., Varma S., Odegaard J.I.,
RA   Sugiyama T., Koyota S., Rubin B.P., Troxell M.L., Pelham R.J.,
RA   Zehnder J.L., Beachy P.A., Pollack J.R., West R.B.;
RT   "Identification of recurrent SMO and BRAF mutations in ameloblastomas.";
RL   Nat. Genet. 46:722-725(2014).
CC   -!- FUNCTION: G protein-coupled receptor that probably associates with the
CC       patched protein (PTCH) to transduce the hedgehog's proteins signal.
CC       Binding of sonic hedgehog (SHH) to its receptor patched is thought to
CC       prevent normal inhibition by patched of smoothened (SMO). Required for
CC       the accumulation of KIF7, GLI2 and GLI3 in the cilia (PubMed:19592253).
CC       Interacts with DLG5 at the ciliary base to induce the accumulation of
CC       KIF7 and GLI2 at the ciliary tip for GLI2 activation (By similarity).
CC       {ECO:0000250|UniProtKB:P56726, ECO:0000269|PubMed:19592253}.
CC   -!- SUBUNIT: Homodimer (PubMed:23636324). Interacts with ARRB2 (By
CC       similarity). Interacts with KIF7 (PubMed:19592253). Interacts with BBS5
CC       and BBS7; the interactions are indicative for the association of SMO
CC       with the BBsome complex to facilitate ciliary localization of SMO
CC       (PubMed:22072986). Interacts with DLG5 and SDCBP (By similarity).
CC       Interacts with GAS8/DRC4 (PubMed:21659505).
CC       {ECO:0000250|UniProtKB:P56726, ECO:0000269|PubMed:19592253,
CC       ECO:0000269|PubMed:21659505, ECO:0000269|PubMed:22072986,
CC       ECO:0000269|PubMed:23636324}.
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000269|PubMed:22072986}; Multi-
CC       pass membrane protein {ECO:0000269|PubMed:22072986}. Cell projection,
CC       cilium {ECO:0000269|PubMed:22072986}.
CC   -!- DISEASE: Curry-Jones syndrome (CRJS) [MIM:601707]: A multisystem
CC       disorder characterized by patchy skin lesions, polysyndactyly, diverse
CC       cerebral malformations, unicoronal craniosynostosis, iris colobomas,
CC       microphthalmia, and intestinal malrotation with myofibromas or
CC       hamartomas. {ECO:0000269|PubMed:24859340, ECO:0000269|PubMed:27236920}.
CC       Note=The disease is caused by mutations affecting the gene represented
CC       in this entry. 8 individuals have been identified with the disease-
CC       causing mutation Phe-412 and all were mosaic. The mutation could not be
CC       reliably detected in blood, greatest success rates were obtained with
CC       affected tissues obtained by invasive procedures. It is thought that
CC       the mutation has arisen postzygotically early during embryonic
CC       development (PubMed:27236920). This mutation has also been identified
CC       in ameloblastoma, medulloblastoma, meningioma, and basal cell
CC       carcinoma, and has been reported as the oncogenic driver in some of
CC       these tumors (PubMed:24859340). {ECO:0000269|PubMed:24859340,
CC       ECO:0000269|PubMed:27236920}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor Fz/Smo family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U84401; AAB41788.1; -; mRNA.
DR   EMBL; AF114821; AAD17202.1; -; Genomic_DNA.
DR   EMBL; AF114819; AAD17202.1; JOINED; Genomic_DNA.
DR   EMBL; AF114820; AAD17202.1; JOINED; Genomic_DNA.
DR   EMBL; AF120103; AAF31757.1; -; mRNA.
DR   EMBL; AF071494; AAC24863.1; -; mRNA.
DR   EMBL; CH236950; EAL24102.1; -; Genomic_DNA.
DR   EMBL; CH471070; EAW83715.1; -; Genomic_DNA.
DR   EMBL; BC009989; AAH09989.1; -; mRNA.
DR   CCDS; CCDS5811.1; -.
DR   RefSeq; NP_005622.1; NM_005631.4.
DR   PDB; 4JKV; X-ray; 2.45 A; A/B=190-555.
DR   PDB; 4N4W; X-ray; 2.80 A; A=190-555.
DR   PDB; 4O9R; X-ray; 3.20 A; A=190-433, A=441-555.
DR   PDB; 4QIM; X-ray; 2.61 A; A=190-433, A=441-555.
DR   PDB; 4QIN; X-ray; 2.60 A; A=190-433, A=441-555.
DR   PDB; 5L7D; X-ray; 3.20 A; A/B=32-428, A/B=443-555.
DR   PDB; 5L7I; X-ray; 3.30 A; A/B=32-428, A/B=443-555.
DR   PDB; 5V56; X-ray; 2.90 A; A/B=53-437, A/B=444-558.
DR   PDB; 5V57; X-ray; 3.00 A; A/B=58-437, A/B=444-558.
DR   PDB; 6OT0; EM; 3.90 A; R=1-555.
DR   PDBsum; 4JKV; -.
DR   PDBsum; 4N4W; -.
DR   PDBsum; 4O9R; -.
DR   PDBsum; 4QIM; -.
DR   PDBsum; 4QIN; -.
DR   PDBsum; 5L7D; -.
DR   PDBsum; 5L7I; -.
DR   PDBsum; 5V56; -.
DR   PDBsum; 5V57; -.
DR   PDBsum; 6OT0; -.
DR   SMR; Q99835; -.
DR   BioGRID; 112492; 11.
DR   DIP; DIP-34574N; -.
DR   IntAct; Q99835; 34.
DR   MINT; Q99835; -.
DR   STRING; 9606.ENSP00000249373; -.
DR   BindingDB; Q99835; -.
DR   ChEMBL; CHEMBL5971; -.
DR   DrugBank; DB01047; Fluocinonide.
DR   DrugBank; DB11978; Glasdegib.
DR   DrugBank; DB06786; Halcinonide.
DR   DrugBank; DB09143; Sonidegib.
DR   DrugBank; DB08828; Vismodegib.
DR   DrugCentral; Q99835; -.
DR   GuidetoPHARMACOLOGY; 239; -.
DR   TCDB; 9.A.14.16.4; the g-protein-coupled receptor (gpcr) family.
DR   GlyConnect; 2079; 1 N-Linked glycan (1 site).
DR   GlyGen; Q99835; 5 sites, 1 N-linked glycan (1 site), 2 O-linked glycans (2 sites).
DR   iPTMnet; Q99835; -.
DR   PhosphoSitePlus; Q99835; -.
DR   BioMuta; SMO; -.
DR   DMDM; 6226142; -.
DR   EPD; Q99835; -.
DR   jPOST; Q99835; -.
DR   MassIVE; Q99835; -.
DR   PaxDb; Q99835; -.
DR   PeptideAtlas; Q99835; -.
DR   PRIDE; Q99835; -.
DR   ProteomicsDB; 78499; -.
DR   Antibodypedia; 31982; 570 antibodies.
DR   DNASU; 6608; -.
DR   Ensembl; ENST00000249373; ENSP00000249373; ENSG00000128602.
DR   GeneID; 6608; -.
DR   KEGG; hsa:6608; -.
DR   UCSC; uc003vor.4; human.
DR   CTD; 6608; -.
DR   DisGeNET; 6608; -.
DR   EuPathDB; HostDB:ENSG00000128602.9; -.
DR   GeneCards; SMO; -.
DR   HGNC; HGNC:11119; SMO.
DR   HPA; ENSG00000128602; Low tissue specificity.
DR   MalaCards; SMO; -.
DR   MIM; 601500; gene.
DR   MIM; 601707; phenotype.
DR   neXtProt; NX_Q99835; -.
DR   OpenTargets; ENSG00000128602; -.
DR   Orphanet; 1553; Curry-Jones syndrome.
DR   PharmGKB; PA35968; -.
DR   eggNOG; KOG3577; Eukaryota.
DR   GeneTree; ENSGT00940000157206; -.
DR   HOGENOM; CLU_007873_3_1_1; -.
DR   InParanoid; Q99835; -.
DR   KO; K06226; -.
DR   OMA; DMHAYIA; -.
DR   OrthoDB; 385042at2759; -.
DR   PhylomeDB; Q99835; -.
DR   TreeFam; TF106460; -.
DR   PathwayCommons; Q99835; -.
DR   Reactome; R-HSA-373080; Class B/2 (Secretin family receptors).
DR   Reactome; R-HSA-5610787; Hedgehog 'off' state.
DR   Reactome; R-HSA-5620922; BBSome-mediated cargo-targeting to cilium.
DR   Reactome; R-HSA-5632684; Hedgehog 'on' state.
DR   Reactome; R-HSA-5635838; Activation of SMO.
DR   SignaLink; Q99835; -.
DR   SIGNOR; Q99835; -.
DR   BioGRID-ORCS; 6608; 10 hits in 873 CRISPR screens.
DR   ChiTaRS; SMO; human.
DR   GeneWiki; Smoothened; -.
DR   GenomeRNAi; 6608; -.
DR   Pharos; Q99835; Tclin.
DR   PRO; PR:Q99835; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; Q99835; protein.
DR   Bgee; ENSG00000128602; Expressed in stomach and 195 other tissues.
DR   ExpressionAtlas; Q99835; baseline and differential.
DR   Genevisible; Q99835; HS.
DR   GO; GO:0060170; C:ciliary membrane; TAS:Reactome.
DR   GO; GO:0097542; C:ciliary tip; TAS:Reactome.
DR   GO; GO:0005929; C:cilium; IDA:MGI.
DR   GO; GO:0030425; C:dendrite; IBA:GO_Central.
DR   GO; GO:0030666; C:endocytic vesicle membrane; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IBA:GO_Central.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0008144; F:drug binding; IDA:UniProtKB.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0005113; F:patched binding; IPI:BHF-UCL.
DR   GO; GO:0009952; P:anterior/posterior pattern specification; IEA:Ensembl.
DR   GO; GO:0048143; P:astrocyte activation; IEA:Ensembl.
DR   GO; GO:0060413; P:atrial septum morphogenesis; IEA:Ensembl.
DR   GO; GO:0001708; P:cell fate specification; IEA:Ensembl.
DR   GO; GO:0071397; P:cellular response to cholesterol; ISS:BHF-UCL.
DR   GO; GO:0007417; P:central nervous system development; IBA:GO_Central.
DR   GO; GO:0021953; P:central nervous system neuron differentiation; IEA:Ensembl.
DR   GO; GO:0021696; P:cerebellar cortex morphogenesis; IEA:Ensembl.
DR   GO; GO:0021987; P:cerebral cortex development; IEA:Ensembl.
DR   GO; GO:0071679; P:commissural neuron axon guidance; IBA:GO_Central.
DR   GO; GO:0060242; P:contact inhibition; IMP:BHF-UCL.
DR   GO; GO:0021542; P:dentate gyrus development; IEA:Ensembl.
DR   GO; GO:0003140; P:determination of left/right asymmetry in lateral mesoderm; ISS:BHF-UCL.
DR   GO; GO:0021904; P:dorsal/ventral neural tube patterning; IEA:Ensembl.
DR   GO; GO:0060684; P:epithelial-mesenchymal cell signaling; IEA:Ensembl.
DR   GO; GO:0048853; P:forebrain morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0031069; P:hair follicle morphogenesis; IEA:Ensembl.
DR   GO; GO:0001947; P:heart looping; ISS:BHF-UCL.
DR   GO; GO:0048873; P:homeostasis of number of cells within a tissue; IEA:Ensembl.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0070986; P:left/right axis specification; IEA:Ensembl.
DR   GO; GO:0060644; P:mammary gland epithelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0072285; P:mesenchymal to epithelial transition involved in metanephric renal vesicle formation; ISS:UniProtKB.
DR   GO; GO:0007494; P:midgut development; ISS:BHF-UCL.
DR   GO; GO:0035264; P:multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0051451; P:myoblast migration; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0043392; P:negative regulation of DNA binding; ISS:UniProtKB.
DR   GO; GO:0030857; P:negative regulation of epithelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0010629; P:negative regulation of gene expression; ISS:UniProtKB.
DR   GO; GO:0051799; P:negative regulation of hair follicle development; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0001755; P:neural crest cell migration; IEA:Ensembl.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0001649; P:osteoblast differentiation; IEA:Ensembl.
DR   GO; GO:0061113; P:pancreas morphogenesis; IEA:Ensembl.
DR   GO; GO:0090190; P:positive regulation of branching involved in ureteric bud morphogenesis; ISS:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:ARUK-UCL.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:ARUK-UCL.
DR   GO; GO:0007228; P:positive regulation of hh target transcription factor activity; ISS:BHF-UCL.
DR   GO; GO:0002053; P:positive regulation of mesenchymal cell proliferation; IEA:Ensembl.
DR   GO; GO:0040018; P:positive regulation of multicellular organism growth; IEA:Ensembl.
DR   GO; GO:0002052; P:positive regulation of neuroblast proliferation; IEA:Ensembl.
DR   GO; GO:0046622; P:positive regulation of organ growth; IEA:Ensembl.
DR   GO; GO:0042307; P:positive regulation of protein import into nucleus; IEA:Ensembl.
DR   GO; GO:0045880; P:positive regulation of smoothened signaling pathway; IBA:GO_Central.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0034504; P:protein localization to nucleus; IEA:Ensembl.
DR   GO; GO:0050821; P:protein stabilization; IEA:Ensembl.
DR   GO; GO:2000826; P:regulation of heart morphogenesis; ISS:BHF-UCL.
DR   GO; GO:2000036; P:regulation of stem cell population maintenance; IEA:Ensembl.
DR   GO; GO:0048741; P:skeletal muscle fiber development; IEA:Ensembl.
DR   GO; GO:0048745; P:smooth muscle tissue development; IEP:UniProtKB.
DR   GO; GO:0007224; P:smoothened signaling pathway; IMP:UniProtKB.
DR   GO; GO:0021938; P:smoothened signaling pathway involved in regulation of cerebellar granule cell precursor cell proliferation; IEA:Ensembl.
DR   GO; GO:0021910; P:smoothened signaling pathway involved in ventral spinal cord patterning; IEA:Ensembl.
DR   GO; GO:0061053; P:somite development; ISS:BHF-UCL.
DR   GO; GO:0021794; P:thalamus development; IEA:Ensembl.
DR   GO; GO:0003323; P:type B pancreatic cell development; IEA:Ensembl.
DR   GO; GO:0001570; P:vasculogenesis; IEA:Ensembl.
DR   GO; GO:0007371; P:ventral midline determination; ISS:BHF-UCL.
DR   CDD; cd07451; CRD_SMO; 1.
DR   Gene3D; 1.10.2000.10; -; 1.
DR   InterPro; IPR015526; Frizzled/SFRP.
DR   InterPro; IPR000539; Frizzled/Smoothened_TM.
DR   InterPro; IPR020067; Frizzled_dom.
DR   InterPro; IPR036790; Frizzled_dom_sf.
DR   InterPro; IPR017981; GPCR_2-like.
DR   InterPro; IPR026544; SMO.
DR   InterPro; IPR041771; SMO_CRD.
DR   PANTHER; PTHR11309; PTHR11309; 1.
DR   PANTHER; PTHR11309:SF35; PTHR11309:SF35; 1.
DR   Pfam; PF01534; Frizzled; 1.
DR   Pfam; PF01392; Fz; 1.
DR   PRINTS; PR00489; FRIZZLED.
DR   SMART; SM00063; FRI; 1.
DR   SMART; SM01330; Frizzled; 1.
DR   SUPFAM; SSF63501; SSF63501; 1.
DR   PROSITE; PS50038; FZ; 1.
DR   PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell projection; Developmental protein; Disease mutation;
KW   Disulfide bond; G-protein coupled receptor; Glycoprotein; Membrane;
KW   Polymorphism; Receptor; Reference proteome; Signal; Transducer;
KW   Transmembrane; Transmembrane helix.
FT   SIGNAL          1..27
FT                   /evidence="ECO:0000255"
FT   CHAIN           28..787
FT                   /note="Smoothened homolog"
FT                   /id="PRO_0000013015"
FT   TOPO_DOM        28..233
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        234..254
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        255..262
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        263..283
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        284..314
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        315..335
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        336..358
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        359..379
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        380..402
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        403..423
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        424..451
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        452..472
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        473..524
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        525..545
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        546..787
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          65..181
FT                   /note="FZ"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00090"
FT   REGION          538..569
FT                   /note="Interaction with BBS5 and BBS7"
FT                   /evidence="ECO:0000269|PubMed:22072986"
FT   REGION          581..593
FT                   /note="Interaction with DLG5"
FT                   /evidence="ECO:0000250|UniProtKB:P56726"
FT   CARBOHYD        35
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        188
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        309
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        70..134
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00090"
FT   DISULFID        78..127
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00090"
FT   DISULFID        118..154
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00090"
FT   DISULFID        147..169
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00090"
FT   DISULFID        193..213
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00090,
FT                   ECO:0000269|PubMed:23636324"
FT   DISULFID        217..295
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00090,
FT                   ECO:0000269|PubMed:23636324"
FT   DISULFID        314..390
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00090,
FT                   ECO:0000269|PubMed:23636324"
FT   DISULFID        490..507
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00090,
FT                   ECO:0000269|PubMed:23636324"
FT   VARIANT         412
FT                   /note="L -> F (in CRJS; constitutive activation of the
FT                   smoothened signaling pathway; dbSNP:rs879255280)"
FT                   /evidence="ECO:0000269|PubMed:24859340,
FT                   ECO:0000269|PubMed:27236920"
FT                   /id="VAR_077087"
FT   VARIANT         473
FT                   /note="D -> H (in dbSNP:rs17710891)"
FT                   /id="VAR_037891"
FT   VARIANT         535
FT                   /note="W -> L (in basal cell carcinoma and ameloblastoma
FT                   samples; somatic mutation; constitutive activation of the
FT                   smoothened signaling pathway; dbSNP:rs121918347)"
FT                   /evidence="ECO:0000269|PubMed:24859340,
FT                   ECO:0000269|PubMed:9422511"
FT                   /id="VAR_007848"
FT   VARIANT         562
FT                   /note="R -> Q (in basal cell carcinoma samples; somatic
FT                   mutation; dbSNP:rs121918348)"
FT                   /evidence="ECO:0000269|PubMed:9422511"
FT                   /id="VAR_007849"
FT   STRAND          65..67
FT                   /evidence="ECO:0000244|PDB:5V56"
FT   STRAND          76..78
FT                   /evidence="ECO:0000244|PDB:5V56"
FT   STRAND          86..88
FT                   /evidence="ECO:0000244|PDB:5V56"
FT   STRAND          90..92
FT                   /evidence="ECO:0000244|PDB:5V56"
FT   HELIX           99..109
FT                   /evidence="ECO:0000244|PDB:5V56"
FT   HELIX           110..113
FT                   /evidence="ECO:0000244|PDB:5V56"
FT   HELIX           116..130
FT                   /evidence="ECO:0000244|PDB:5V56"
FT   STRAND          136..140
FT                   /evidence="ECO:0000244|PDB:5V56"
FT   HELIX           144..151
FT                   /evidence="ECO:0000244|PDB:5V56"
FT   TURN            152..154
FT                   /evidence="ECO:0000244|PDB:5V56"
FT   HELIX           155..160
FT                   /evidence="ECO:0000244|PDB:5V56"
FT   TURN            165..167
FT                   /evidence="ECO:0000244|PDB:5V56"
FT   TURN            171..173
FT                   /evidence="ECO:0000244|PDB:5V56"
FT   TURN            182..184
FT                   /evidence="ECO:0000244|PDB:5V56"
FT   STRAND          190..192
FT                   /evidence="ECO:0000244|PDB:4JKV"
FT   STRAND          197..199
FT                   /evidence="ECO:0000244|PDB:4JKV"
FT   HELIX           203..205
FT                   /evidence="ECO:0000244|PDB:4JKV"
FT   STRAND          210..218
FT                   /evidence="ECO:0000244|PDB:4JKV"
FT   HELIX           224..254
FT                   /evidence="ECO:0000244|PDB:4JKV"
FT   HELIX           256..259
FT                   /evidence="ECO:0000244|PDB:4JKV"
FT   TURN            262..265
FT                   /evidence="ECO:0000244|PDB:4JKV"
FT   HELIX           266..282
FT                   /evidence="ECO:0000244|PDB:4JKV"
FT   HELIX           283..285
FT                   /evidence="ECO:0000244|PDB:4JKV"
FT   HELIX           289..294
FT                   /evidence="ECO:0000244|PDB:4JKV"
FT   STRAND          299..301
FT                   /evidence="ECO:0000244|PDB:4JKV"
FT   STRAND          304..306
FT                   /evidence="ECO:0000244|PDB:4JKV"
FT   STRAND          308..310
FT                   /evidence="ECO:0000244|PDB:5L7D"
FT   HELIX           313..347
FT                   /evidence="ECO:0000244|PDB:4JKV"
FT   TURN            354..356
FT                   /evidence="ECO:0000244|PDB:4QIM"
FT   HELIX           361..378
FT                   /evidence="ECO:0000244|PDB:4JKV"
FT   STRAND          381..384
FT                   /evidence="ECO:0000244|PDB:4JKV"
FT   TURN            385..388
FT                   /evidence="ECO:0000244|PDB:4JKV"
FT   STRAND          389..395
FT                   /evidence="ECO:0000244|PDB:4JKV"
FT   HELIX           397..403
FT                   /evidence="ECO:0000244|PDB:4JKV"
FT   HELIX           405..432
FT                   /evidence="ECO:0000244|PDB:4JKV"
FT   STRAND          436..442
FT                   /evidence="ECO:0000244|PDB:4JKV"
FT   HELIX           443..492
FT                   /evidence="ECO:0000244|PDB:4JKV"
FT   STRAND          501..503
FT                   /evidence="ECO:0000244|PDB:5V56"
FT   HELIX           515..532
FT                   /evidence="ECO:0000244|PDB:4JKV"
FT   HELIX           533..536
FT                   /evidence="ECO:0000244|PDB:4JKV"
FT   HELIX           539..548
FT                   /evidence="ECO:0000244|PDB:4JKV"
FT   STRAND          554..558
FT                   /evidence="ECO:0000244|PDB:5V57"
SQ   SEQUENCE   787 AA;  86397 MW;  8B4C459B34D13F83 CRC64;
     MAAARPARGP ELPLLGLLLL LLLGDPGRGA ASSGNATGPG PRSAGGSARR SAAVTGPPPP
     LSHCGRAAPC EPLRYNVCLG SVLPYGATST LLAGDSDSQE EAHGKLVLWS GLRNAPRCWA
     VIQPLLCAVY MPKCENDRVE LPSRTLCQAT RGPCAIVERE RGWPDFLRCT PDRFPEGCTN
     EVQNIKFNSS GQCEVPLVRT DNPKSWYEDV EGCGIQCQNP LFTEAEHQDM HSYIAAFGAV
     TGLCTLFTLA TFVADWRNSN RYPAVILFYV NACFFVGSIG WLAQFMDGAR REIVCRADGT
     MRLGEPTSNE TLSCVIIFVI VYYALMAGVV WFVVLTYAWH TSFKALGTTY QPLSGKTSYF
     HLLTWSLPFV LTVAILAVAQ VDGDSVSGIC FVGYKNYRYR AGFVLAPIGL VLIVGGYFLI
     RGVMTLFSIK SNHPGLLSEK AASKINETML RLGIFGFLAF GFVLITFSCH FYDFFNQAEW
     ERSFRDYVLC QANVTIGLPT KQPIPDCEIK NRPSLLVEKI NLFAMFGTGI AMSTWVWTKA
     TLLIWRRTWC RLTGQSDDEP KRIKKSKMIA KAFSKRHELL QNPGQELSFS MHTVSHDGPV
     AGLAFDLNEP SADVSSAWAQ HVTKMVARRG AILPQDISVT PVATPVPPEE QANLWLVEAE
     ISPELQKRLG RKKKRRKRKK EVCPLAPPPE LHPPAPAPST IPRLPQLPRQ KCLVAAGAWG
     AGDSCRQGAW TLVSNPFCPE PSPPQDPFLP SAPAPVAWAH GRRQGLGPIH SRTNLMDTEL
     MDADSDF
//
ID   TSHR_HUMAN              Reviewed;         764 AA.
AC   P16473; A0PJU7; F5GYU5; G3V2A9; Q16503; Q8TB90; Q96GT6; Q9P1V4; Q9ULA3;
AC   Q9UPH3;
DT   01-AUG-1990, integrated into UniProtKB/Swiss-Prot.
DT   29-MAR-2005, sequence version 2.
DT   12-AUG-2020, entry version 237.
DE   RecName: Full=Thyrotropin receptor;
DE   AltName: Full=Thyroid-stimulating hormone receptor;
DE            Short=TSH-R;
DE   Flags: Precursor;
GN   Name=TSHR; Synonyms=LGR3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG).
RX   PubMed=2558651; DOI=10.1016/0006-291x(89)92727-7;
RA   Nagayama Y., Kaufman K.D., Seto P., Rapoport B.;
RT   "Molecular cloning, sequence and functional expression of the cDNA for the
RT   human thyrotropin receptor.";
RL   Biochem. Biophys. Res. Commun. 165:1184-1190(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), AND TISSUE SPECIFICITY.
RC   TISSUE=Thyroid;
RX   PubMed=2610690; DOI=10.1016/0006-291x(89)92736-8;
RA   Libert F., Lefort A., Gerard C., Parmentier M., Perret J., Ludgate M.,
RA   Dumont J.E., Vassart G.;
RT   "Cloning, sequencing and expression of the human thyrotropin (TSH)
RT   receptor: evidence for binding of autoantibodies.";
RL   Biochem. Biophys. Res. Commun. 165:1250-1255(1989).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), AND VARIANT GLU-727.
RX   PubMed=2302212; DOI=10.1016/0006-291x(90)91958-u;
RA   Misrahi M., Loosfelt H., Atger M., Sar S., Guiochon-Mantel A., Milgrom E.;
RT   "Cloning, sequencing and expression of human TSH receptor.";
RL   Biochem. Biophys. Res. Commun. 166:394-403(1990).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG).
RC   TISSUE=Thyroid;
RX   PubMed=2293030; DOI=10.1210/mend-4-8-1264;
RA   Frazier A.L., Robbins L.S., Stork P.J., Sprengel R., Segaloff D.L.,
RA   Cone R.D.;
RT   "Isolation of TSH and LH/CG receptor cDNAs from human thyroid: regulation
RT   by tissue specific splicing.";
RL   Mol. Endocrinol. 4:1264-1276(1990).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT).
RX   PubMed=1530609; DOI=10.1016/0006-291x(92)91315-h;
RA   Graves P.N., Tomer Y., Davies T.F.;
RT   "Cloning and sequencing of a 1.3 KB variant of human thyrotropin receptor
RT   mRNA lacking the transmembrane domain.";
RL   Biochem. Biophys. Res. Commun. 187:1135-1143(1992).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT).
RC   TISSUE=Thyroid;
RX   PubMed=1445355; DOI=10.1016/0006-291x(92)91360-3;
RA   Takeshita A., Nagayama Y., Fujiyama K., Yokoyama N., Namba H.,
RA   Yamashita S., Izumi M., Nagataki S.;
RT   "Molecular cloning and sequencing of an alternatively spliced form of the
RT   human thyrotropin receptor transcript.";
RL   Biochem. Biophys. Res. Commun. 188:1214-1219(1992).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG).
RC   TISSUE=Thyroid;
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT GLU-727.
RX   PubMed=12508121; DOI=10.1038/nature01348;
RA   Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,
RA   Cattolico L., Levy M., Barbe V., De Berardinis V., Ureta-Vidal A.,
RA   Pelletier E., Vico V., Anthouard V., Rowen L., Madan A., Qin S., Sun H.,
RA   Du H., Pepin K., Artiguenave F., Robert C., Cruaud C., Bruels T.,
RA   Jaillon O., Friedlander L., Samson G., Brottier P., Cure S., Segurens B.,
RA   Aniere F., Samain S., Crespeau H., Abbasi N., Aiach N., Boscus D.,
RA   Dickhoff R., Dors M., Dubois I., Friedman C., Gouyvenoux M., James R.,
RA   Madan A., Mairey-Estrada B., Mangenot S., Martins N., Menard M., Oztas S.,
RA   Ratcliffe A., Shaffer T., Trask B., Vacherie B., Bellemere C., Belser C.,
RA   Besnard-Gonnet M., Bartol-Mavel D., Boutard M., Briez-Silla S.,
RA   Combette S., Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C.,
RA   Muselet D., Magdelenat G., Pateau E., Petit E., Sirvain-Trukniewicz P.,
RA   Trybou A., Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,
RA   Dumont C., Guerin T., Haffray S., Hammadi R., Muanga J., Pellouin V.,
RA   Robert D., Wunderle E., Gauguet G., Roy A., Sainte-Marthe L., Verdier J.,
RA   Verdier-Discala C., Hillier L.W., Fulton L., McPherson J., Matsuda F.,
RA   Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W., Quetier F.,
RA   Waterston R., Hood L., Weissenbach J.;
RT   "The DNA sequence and analysis of human chromosome 14.";
RL   Nature 421:601-607(2003).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS SHORT AND 3).
RC   TISSUE=Ovarian adenocarcinoma;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   PROTEIN SEQUENCE OF 66-80; 113-123; 184-210 AND 294-310, AND GLYCOSYLATION
RP   AT ASN-77; ASN-113; ASN-198 AND ASN-302.
RX   PubMed=11502179; DOI=10.1021/bi0107389;
RA   Cornelis S., Uttenweiler-Joseph S., Panneels V., Vassart G.,
RA   Costagliola S.;
RT   "Purification and characterization of a soluble bioactive amino-terminal
RT   extracellular domain of the human thyrotropin receptor.";
RL   Biochemistry 40:9860-9869(2001).
RN   [11]
RP   FUNCTION, GLYCOSYLATION, SUBCELLULAR LOCATION, SULFATION AT TYR-385, TISSUE
RP   SPECIFICITY, AND MUTAGENESIS OF CYS-283; TYR-385 AND TYR-387.
RX   PubMed=11847099; DOI=10.1093/emboj/21.4.504;
RA   Costagliola S., Panneels V., Bonomi M., Koch J., Many M.C., Smits G.,
RA   Vassart G.;
RT   "Tyrosine sulfation is required for agonist recognition by glycoprotein
RT   hormone receptors.";
RL   EMBO J. 21:504-513(2002).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH HETERODIMER GPHA2-GPHB5.
RX   PubMed=12045258; DOI=10.1172/jci14340;
RA   Nakabayashi K., Matsumi H., Bhalla A., Bae J., Mosselman S., Hsu S.Y.,
RA   Hsueh A.J.W.;
RT   "Thyrostimulin, a heterodimer of two new human glycoprotein hormone
RT   subunits, activates the thyroid-stimulating hormone receptor.";
RL   J. Clin. Invest. 109:1445-1452(2002).
RN   [13]
RP   INTERACTION WITH SCRIB.
RX   PubMed=15775968; DOI=10.1038/sj.emboj.7600616;
RA   Lahuna O., Quellari M., Achard C., Nola S., Meduri G., Navarro C.,
RA   Vitale N., Borg J.-P., Misrahi M.;
RT   "Thyrotropin receptor trafficking relies on the hScrib-betaPIX-GIT1-ARF6
RT   pathway.";
RL   EMBO J. 24:1364-1374(2005).
RN   [14]
RP   3D-STRUCTURE MODELING OF 54-236.
RX   PubMed=8747461; DOI=10.1016/s0969-2126(01)00272-6;
RA   Jiang X., Dreano M., Buckler D.R., Cheng S., Ythier A., Wu H.,
RA   Hendrickson W.A., el Tayar N.;
RT   "Structural predictions for the ligand-binding region of glycoprotein
RT   hormone receptors and the nature of hormone-receptor interactions.";
RL   Structure 3:1341-1353(1995).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (2.55 ANGSTROMS) OF 22-260 IN COMPLEX WITH ANTIBODY,
RP   GLYCOSYLATION AT ASN-77; ASN-99; ASN-113; ASN-177 AND ASN-198, AND
RP   N-TERMINAL DISULFIDE BOND.
RX   PubMed=17542669; DOI=10.1089/thy.2007.0034;
RA   Sanders J., Chirgadze D.Y., Sanders P., Baker S., Sullivan A.,
RA   Bhardwaja A., Bolton J., Reeve M., Nakatake N., Evans M., Richards T.,
RA   Powell M., Miguel R.N., Blundell T.L., Furmaniak J., Smith B.R.;
RT   "Crystal structure of the TSH receptor in complex with a thyroid-
RT   stimulating autoantibody.";
RL   Thyroid 17:395-410(2007).
RN   [16]
RP   ANALYSIS OF INVOLVEMENT OF VARIANT GLU-727 IN GRAVES DISEASE.
RX   PubMed=11887032;
RA   Chistiakov D.A., Savost'anov K.V., Turakulov R.I., Petunina N.,
RA   Balabolkin M.I., Nosikov V.V.;
RT   "Further studies of genetic susceptibility to Graves' disease in a Russian
RT   population.";
RL   Med. Sci. Monit. 8:CR180-CR184(2002).
RN   [17]
RP   ANALYSIS OF INVOLVEMENT OF VARIANT GLU-727 IN GRAVES DISEASE.
RX   PubMed=12593721; DOI=10.1089/105072502321085171;
RA   Ban Y., Greenberg D.A., Concepcion E.S., Tomer Y.;
RT   "A germline single nucleotide polymorphism at the intracellular domain of
RT   the human thyrotropin receptor does not have a major effect on the
RT   development of Graves' disease.";
RL   Thyroid 12:1079-1083(2002).
RN   [18]
RP   ANALYSIS OF INVOLVEMENT OF VARIANTS HIS-36; THR-52 AND GLU-727 IN GRAVES
RP   DISEASE.
RX   PubMed=12930595; DOI=10.1089/105072503322238773;
RA   Ho S.-C., Goh S.-S., Khoo D.H.;
RT   "Association of Graves' disease with intragenic polymorphism of the
RT   thyrotropin receptor gene in a cohort of Singapore patients of multi-ethnic
RT   origins.";
RL   Thyroid 13:523-528(2003).
RN   [19]
RP   REVIEW ON VARIANTS.
RX   PubMed=10870027; DOI=10.1530/eje.0.1430025;
RA   Farid N.R., Kascur V., Balazs C.;
RT   "The human thyrotropin receptor is highly mutable: a review of gain-of-
RT   function mutations.";
RL   Eur. J. Endocrinol. 143:25-30(2000).
RN   [20]
RP   VARIANT HIS-36.
RX   PubMed=1955520; DOI=10.1210/jcem-73-6-1374;
RA   Heldin N.-E., Gustavsson B., Westermark K., Westermark B.;
RT   "A somatic point mutation in a putative ligand binding domain of the TSH
RT   receptor in a patient with autoimmune hyperthyroidism.";
RL   J. Clin. Endocrinol. Metab. 73:1374-1376(1991).
RN   [21]
RP   VARIANTS HYPERTHYROIDISM GLY-619 AND ILE-623.
RX   PubMed=8413627; DOI=10.1038/365649a0;
RA   Parma J., Duprez L., van Sande J., Cochaux P., Gervy C., Mockel J.,
RA   Dumont J.E., Vassart G.;
RT   "Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning
RT   thyroid adenomas.";
RL   Nature 365:649-651(1993).
RN   [22]
RP   VARIANT THR-52.
RX   PubMed=7508946; DOI=10.1210/jcem.78.2.7508946;
RA   Bahn R.S., Dutton C.M., Heufelder A.E., Sarkar G.;
RT   "A genomic point mutation in the extracellular domain of the thyrotropin
RT   receptor in patients with Graves' ophthalmopathy.";
RL   J. Clin. Endocrinol. Metab. 78:256-260(1994).
RN   [23]
RP   VARIANTS HYPERTHYROIDISM CYS-631; ILE-632; GLU-633 AND TYR-633.
RX   PubMed=8045989; DOI=10.1210/jcem.79.2.8045989;
RA   Porcellini A., Ciullo I., Laviola L., Amabile G., Fenzi G.,
RA   Avvedimento V.E.;
RT   "Novel mutations of thyrotropin receptor gene in thyroid hyperfunctioning
RT   adenomas. Rapid identification by fine needle aspiration biopsy.";
RL   J. Clin. Endocrinol. Metab. 79:657-661(1994).
RN   [24]
RP   VARIANTS HYPERTHYROIDISM VAL-623 AND ILE-632.
RX   PubMed=7989485; DOI=10.1210/jcem.79.6.7989485;
RA   Paschke R., Tonacchera M., van Sande J., Parma J., Vassart G.;
RT   "Identification and functional characterization of two new somatic
RT   mutations causing constitutive activation of the thyrotropin receptor in
RT   hyperfunctioning autonomous adenomas of the thyroid.";
RL   J. Clin. Endocrinol. Metab. 79:1785-1789(1994).
RN   [25]
RP   VARIANTS HTNA ALA-509 AND TYR-672.
RX   PubMed=7920658; DOI=10.1038/ng0794-396;
RA   Duprez L., Parma J., van Sande J., Allgeier A., Leclere J., Schvartz C.,
RA   Delisle M.-J., Decoulx M., Orgiazzi J., Dumont J.E., Vassart G.;
RT   "Germline mutations in the thyrotropin receptor gene cause non-autoimmune
RT   autosomal dominant hyperthyroidism.";
RL   Nat. Genet. 7:396-401(1994).
RN   [26]
RP   CHARACTERIZATION OF VARIANT HIS-36.
RX   PubMed=7556878; DOI=10.1016/0303-7207(95)03562-l;
RA   Gustavsson B., Eklof C., Westermark K., Westermark B., Heldin N.-E.;
RT   "Functional analysis of a variant of the thyrotropin receptor gene in a
RT   family with Graves' disease.";
RL   Mol. Cell. Endocrinol. 111:167-173(1995).
RN   [27]
RP   VARIANT HTNA LEU-631.
RX   PubMed=7800007; DOI=10.1056/nejm199501193320304;
RA   Kopp P., van Sande J., Parma J., Duprez L., Gerber H., Joss E.,
RA   Jameson J.L., Dumont J.E., Vassart G.;
RT   "Congenital hyperthyroidism caused by a mutation in the thyrotropin-
RT   receptor gene.";
RL   N. Engl. J. Med. 332:150-154(1995).
RN   [28]
RP   VARIANTS CHNG1 ALA-162 AND ASN-167, AND VARIANT THR-52.
RX   PubMed=7528344; DOI=10.1056/nejm199501193320305;
RA   Sunthornthepvarakul T., Gottschalk M.E., Hayashi Y., Refetoff S.;
RT   "Resistance to thyrotropin caused by mutations in the thyrotropin-receptor
RT   gene.";
RL   N. Engl. J. Med. 332:155-160(1995).
RN   [29]
RP   VARIANTS PAPILLARY CANCER ILE-197; GLU-219; ASP-715 AND MET-723, AND
RP   VARIANT GLU-727.
RX   PubMed=7647578; DOI=10.1089/thy.1995.5.97;
RA   Ohno M., Endo T., Ohta K., Gunji K., Onaya T.;
RT   "Point mutations in the thyrotropin receptor in human thyroid tumors.";
RL   Thyroid 5:97-100(1995).
RN   [30]
RP   VARIANT THR-52.
RX   PubMed=7488864; DOI=10.1089/thy.1995.5.255;
RA   Cuddihy R.M., Bryant W.P., Bahn R.S.;
RT   "Normal function in vivo of a homozygotic polymorphism in the human
RT   thyrotropin receptor.";
RL   Thyroid 5:255-257(1995).
RN   [31]
RP   VARIANTS HTNA ARG-505; TYR-650 AND SER-670.
RX   PubMed=8636266; DOI=10.1210/jcem.81.2.8636266;
RA   Tonacchera M., van Sande J., Cetani F., Swillens S., Schvartz C.,
RA   Winiszewski P., Portmann L., Dumont J.E., Vassart G., Parma J.;
RT   "Functional characteristics of three new germline mutations of the
RT   thyrotropin receptor gene causing autosomal dominant toxic thyroid
RT   hyperplasia.";
RL   J. Clin. Endocrinol. Metab. 81:547-554(1996).
RN   [32]
RP   VARIANT HTNA THR-453.
RX   PubMed=8964822; DOI=10.1210/jcem.81.6.8964822;
RA   de Roux N., Polak M., Couet J., Leger J., Czernichow P., Milgrom E.,
RA   Misrahi M.;
RT   "A neomutation of the thyroid-stimulating hormone receptor in a severe
RT   neonatal hyperthyroidism.";
RL   J. Clin. Endocrinol. Metab. 81:2023-2026(1996).
RN   [33]
RP   VARIANTS CHNG1 SER-41; ALA-162; TRP-390; ASN-410 AND LEU-525.
RX   PubMed=8954020; DOI=10.1210/jcem.81.12.8954020;
RA   de Roux N., Misrahi M., Brauner R., Houang M., Carel J.-C., Granier M.,
RA   Le Bouc Y., Ghinea N., Boumedienne A., Toublanc J.E., Milgrom E.;
RT   "Four families with loss of function mutations of the thyrotropin
RT   receptor.";
RL   J. Clin. Endocrinol. Metab. 81:4229-4235(1996).
RN   [34]
RP   VARIANT INSULAR CARCINOMA HIS-633.
RX   PubMed=9062474; DOI=10.1210/jcem.82.3.3838;
RA   Russo D., Tumino S., Arturi F., Vigneri P., Grasso G., Pontecorvi A.,
RA   Filetti S., Belfiore A.;
RT   "Detection of an activating mutation of the thyrotropin receptor in a case
RT   of an autonomously hyperfunctioning thyroid insular carcinoma.";
RL   J. Clin. Endocrinol. Metab. 82:735-738(1997).
RN   [35]
RP   VARIANT CHNG1 GLN-109.
RX   PubMed=9100579; DOI=10.1210/jcem.82.4.3863;
RA   Clifton-Bligh R.J., Gregory J.W., Ludgate M., John R., Persani L.,
RA   Asteria C., Beck-Peccoz P., Chatterjee V.K.K.;
RT   "Two novel mutations in the thyrotropin (TSH) receptor gene in a child with
RT   resistance to TSH.";
RL   J. Clin. Endocrinol. Metab. 82:1094-1100(1997).
RN   [36]
RP   VARIANTS HYPERTHYROIDISM ASN-281; THR-281; THR-453; PHE-486; MET-486;
RP   THR-568; GLY-619; ILE-623; PHE-629; LEU-630; LEU-631; ILE-632; ALA-633;
RP   GLU-633; HIS-633; TYR-633 AND 658-ASN--ILE-661 DEL.
RX   PubMed=9253356; DOI=10.1210/jcem.82.8.4144;
RA   Parma J., Duprez L., van Sande J., Hermans J., Rocmans P., van Vliet G.,
RA   Costagliola S., Rodien P., Dumont J.E., Vassart G.;
RT   "Diversity and prevalence of somatic mutations in the thyrotropin receptor
RT   and Gs alpha genes as a cause of toxic thyroid adenomas.";
RL   J. Clin. Endocrinol. Metab. 82:2695-2701(1997).
RN   [37]
RP   VARIANT CHNG1 TRP-390.
RX   PubMed=9329388; DOI=10.1210/jcem.82.10.4286;
RA   Biebermann H., Schoeneberg T., Krude H., Schultz G., Gudermann T.,
RA   Grueters A.;
RT   "Mutations of the human thyrotropin receptor gene causing thyroid
RT   hypoplasia and persistent congenital hypothyroidism.";
RL   J. Clin. Endocrinol. Metab. 82:3471-3480(1997).
RN   [38]
RP   VARIANT HTNA ASN-505.
RX   PubMed=9360555; DOI=10.1210/jcem.82.11.4378;
RA   Holzapfel H.P., Wonerow P., von Petrykowski W., Henschen M.,
RA   Scherbaum W.A., Paschke R.;
RT   "Sporadic congenital hyperthyroidism due to a spontaneous germline mutation
RT   in the thyrotropin receptor gene.";
RL   J. Clin. Endocrinol. Metab. 82:3879-3884(1997).
RN   [39]
RP   VARIANT HTNA PHE-629.
RX   PubMed=9398746; DOI=10.1210/jcem.82.12.4405;
RA   Fuhrer D., Wonerow P., Willgerodt H., Paschke R.;
RT   "Identification of a new thyrotropin receptor germline mutation (Leu629Phe)
RT   in a family with neonatal onset of autosomal dominant nonautoimmune
RT   hyperthyroidism.";
RL   J. Clin. Endocrinol. Metab. 82:4234-4238(1997).
RN   [40]
RP   VARIANT CHNG1 THR-553.
RX   PubMed=9185526; DOI=10.1172/jci119497;
RA   Abramowicz M.J., Duprez L., Parma J., Vassart G., Heinrichs C.;
RT   "Familial congenital hypothyroidism due to inactivating mutation of the
RT   thyrotropin receptor causing profound hypoplasia of the thyroid gland.";
RL   J. Clin. Invest. 99:3018-3024(1997).
RN   [41]
RP   VARIANT HYPERTHYROIDISM ILE-281.
RX   PubMed=9294132; DOI=10.1172/jci119687;
RA   Kopp P., Muirhead S., Jourdain N., Gu W.X., Jameson J.L., Rodd C.;
RT   "Congenital hyperthyroidism caused by a solitary toxic adenoma harboring a
RT   novel somatic mutation (serine281-->isoleucine) in the extracellular domain
RT   of the thyrotropin receptor.";
RL   J. Clin. Invest. 100:1634-1639(1997).
RN   [42]
RP   VARIANT HTNA ILE-632.
RX   PubMed=9349581; DOI=10.1089/thy.1997.7.765;
RA   Kopp P., Jameson J.L., Roe T.F.;
RT   "Congenital nonautoimmune hyperthyroidism in a nonidentical twin caused by
RT   a sporadic germline mutation in the thyrotropin receptor gene.";
RL   Thyroid 7:765-770(1997).
RN   [43]
RP   VARIANT HTNA ASN-281, AND VARIANT HIS-528.
RX   PubMed=9589634; DOI=10.1210/jcem.83.5.4776;
RA   Grueters A., Schoeneberg T., Biebermann H., Krude H., Krohn H.P.,
RA   Dralle H., Gudermann T.;
RT   "Severe congenital hyperthyroidism caused by a germ-line neo mutation in
RT   the extracellular portion of the thyrotropin receptor.";
RL   J. Clin. Endocrinol. Metab. 83:1431-1436(1998).
RN   [44]
RP   VARIANT HTFG ARG-183.
RX   PubMed=9854118; DOI=10.1056/nejm199812173392505;
RA   Rodien P., Bremont C., Raffin Sanson M.-L., Parma J., van Sande J.,
RA   Costagliola S., Luton J.-P., Vassart G., Duprez L.;
RT   "Familial gestational hyperthyroidism caused by a mutant thyrotropin
RT   receptor hypersensitive to human chorionic gonadotropin.";
RL   N. Engl. J. Med. 339:1823-1826(1998).
RN   [45]
RP   VARIANT HTNA SER-639.
RX   PubMed=10199795; DOI=10.1210/jcem.84.4.5620;
RA   Khoo D.H.C., Parma J., Rajasoorya C., Ho S.C., Vassart G.;
RT   "A germline mutation of the thyrotropin receptor gene associated with
RT   thyrotoxicosis and mitral valve prolapse in a Chinese family.";
RL   J. Clin. Endocrinol. Metab. 84:1459-1462(1999).
RN   [46]
RP   VARIANTS MET-606; GLY-703; GLU-720 AND GLU-727.
RX   PubMed=10487707; DOI=10.1210/jcem.84.9.5966;
RA   Gabriel E.M., Bergert E.R., Grant C.S., van Heerden J.A., Thompson G.B.,
RA   Morris J.C.;
RT   "Germline polymorphism of codon 727 of human thyroid-stimulating hormone
RT   receptor is associated with toxic multinodular goiter.";
RL   J. Clin. Endocrinol. Metab. 84:3328-3335(1999).
RN   [47]
RP   VARIANT THYROID CARCINOMA VAL-677.
RX   PubMed=10037070; DOI=10.1089/thy.1999.9.13;
RA   Russo D., Wong M.G., Costante G., Chiefari E., Treseler P.A., Arturi F.,
RA   Filetti S., Clark O.H.;
RT   "A Val 677 activating mutation of the thyrotropin receptor in a Hurthle
RT   cell thyroid carcinoma associated with thyrotoxicosis.";
RL   Thyroid 9:13-17(1999).
RN   [48]
RP   VARIANT HYPERTHYROIDISM LEU-597.
RX   PubMed=10560955; DOI=10.1089/thy.1999.9.1005;
RA   Esapa C.T., Duprez L., Ludgate M., Mustafa M.S., Kendall-Taylor P.,
RA   Vassart G., Harris P.E.;
RT   "A novel thyrotropin receptor mutation in an infant with severe
RT   thyrotoxicosis.";
RL   Thyroid 9:1005-1010(1999).
RN   [49]
RP   VARIANT HYPERTHYROIDISM ARG-512, AND CHARACTERIZATION OF VARIANT
RP   HYPERTHYROIDISM ARG-512.
RX   PubMed=11022192; DOI=10.1530/eje.0.1430471;
RA   Kosugi S., Hai N., Okamoto H., Sugawa H., Mori T.;
RT   "A novel activating mutation in the thyrotropin receptor gene in an
RT   autonomously functioning thyroid nodule developed by a Japanese patient.";
RL   Eur. J. Endocrinol. 143:471-477(2000).
RN   [50]
RP   VARIANT THR-52.
RX   PubMed=10651846; DOI=10.1046/j.1365-2370.2000.00187.x;
RA   Kaczur V., Takacs M., Szalai C., Falus A., Nagy Z., Berencsi G., Balazs C.;
RT   "Analysis of the genetic variability of the 1st (CCC/ACC, P52T) and the
RT   10th exons (bp 1012-1704) of the TSH receptor gene in Graves' disease.";
RL   Eur. J. Immunogenet. 27:17-23(2000).
RN   [51]
RP   VARIANT CHNG1 ILE-477.
RX   PubMed=10720030; DOI=10.1210/jcem.85.3.6460;
RA   Tonacchera M., Agretti P., Pinchera A., Rosellini V., Perri A.,
RA   Collecchi P., Vitti P., Chiovato L.;
RT   "Congenital hypothyroidism with impaired thyroid response to thyrotropin
RT   (TSH) and absent circulating thyroglobulin: evidence for a new inactivating
RT   mutation of the TSH receptor gene.";
RL   J. Clin. Endocrinol. Metab. 85:1001-1008(2000).
RN   [52]
RP   VARIANTS HTNA ASN-281; MET-486; PHE-486; PHE-629; ALA-632; ILE-632; GLU-633
RP   AND VAL-647.
RX   PubMed=10852462; DOI=10.1210/jcem.85.6.6634;
RA   Tonacchera M., Agretti P., Chiovato L., Rosellini V., Ceccarini G.,
RA   Perri A., Viacava P., Naccarato A.G., Miccoli P., Pinchera A., Vitti P.;
RT   "Activating thyrotropin receptor mutations are present in nonadenomatous
RT   hyperfunctioning nodules of toxic or autonomous multinodular goiter.";
RL   J. Clin. Endocrinol. Metab. 85:2270-2274(2000).
RN   [53]
RP   VARIANT GLU-727.
RX   PubMed=10946859; DOI=10.1210/jcem.85.8.6704;
RA   Muehlberg T., Herrmann K., Joba W., Kirchberger M., Heberling H.-J.,
RA   Heufelder A.E.;
RT   "Lack of association of nonautoimmune hyperfunctioning thyroid disorders
RT   and a germline polymorphism of codon 727 of the human thyrotropin receptor
RT   in a European Caucasian population.";
RL   J. Clin. Endocrinol. Metab. 85:2640-2643(2000).
RN   [54]
RP   VARIANT CHNG1 CYS-310.
RX   PubMed=11095460; DOI=10.1210/jcem.85.11.6985;
RA   Russo D., Betterle C., Arturi F., Chiefari E., Girelli M.E., Filetti S.;
RT   "A novel mutation in the thyrotropin (TSH) receptor gene causing loss of
RT   TSH binding but constitutive receptor activation in a family with
RT   resistance to TSH.";
RL   J. Clin. Endocrinol. Metab. 85:4238-4242(2000).
RN   [55]
RP   VARIANTS HTNA ASN-281; SER-431 AND ILE-632.
RX   PubMed=11127522; DOI=10.1007/s004230000145;
RA   Biebermann H., Schoeneberg T., Krude H., Gudermann T., Grueters A.;
RT   "Constitutively activating TSH-receptor mutations as a molecular cause of
RT   non-autoimmune hyperthyroidism in childhood.";
RL   Langenbecks Arch. Surg. 385:390-392(2000).
RN   [56]
RP   VARIANT HTNA THR-568.
RX   PubMed=11081252; DOI=10.1089/thy.2000.10.859;
RA   Tonacchera M., Agretti P., Rosellini V., Ceccarini G., Perri A.,
RA   Zampolli M., Longhi R., Larizza D., Pinchera A., Vitti P., Chiovato L.;
RT   "Sporadic nonautoimmune congenital hyperthyroidism due to a strong
RT   activating mutation of the thyrotropin receptor gene.";
RL   Thyroid 10:859-863(2000).
RN   [57]
RP   VARIANT FOLLICULAR CARCINOMA PHE-486.
RX   PubMed=11128715; DOI=10.1089/thy.2000.10.1009;
RA   Camacho P., Gordon D., Chiefari E., Yong S., DeJong S., Pitale S.,
RA   Russo D., Filetti S.;
RT   "A Phe 486 thyrotropin receptor mutation in an autonomously functioning
RT   follicular carcinoma that was causing hyperthyroidism.";
RL   Thyroid 10:1009-1012(2000).
RN   [58]
RP   VARIANT HTNA VAL-463.
RX   PubMed=11201847; DOI=10.1089/thy.2000.10.1035;
RA   Fuhrer D., Warner J., Sequeira M., Paschke R., Gregory J.W., Ludgate M.;
RT   "Novel TSHR germline mutation (Met463Val) masquerading as Graves' disease
RT   in a large Welsh kindred with hyperthyroidism.";
RL   Thyroid 10:1035-1041(2000).
RN   [59]
RP   VARIANT HTNA PHE-597, AND CHARACTERIZATION OF VARIANT HTNA PHE-597.
RX   PubMed=11517004; DOI=10.1530/eje.0.1450249;
RA   Alberti L., Proverbio M.C., Costagliola S., Weber G., Beck-Peccoz P.,
RA   Chiumello G., Persani L.;
RT   "A novel germline mutation in the TSH receptor gene causes non-autoimmune
RT   autosomal dominant hyperthyroidism.";
RL   Eur. J. Endocrinol. 145:249-254(2001).
RN   [60]
RP   VARIANT HTNA SER-431, AND CHARACTERIZATION OF VARIANT HTNA SER-431.
RX   PubMed=11549687; DOI=10.1210/jcem.86.9.7888;
RA   Biebermann H., Schoeneberg T., Hess C., Germak J., Gudermann T.,
RA   Grueters A.;
RT   "The first activating TSH receptor mutation in transmembrane domain 1
RT   identified in a family with nonautoimmune hyperthyroidism.";
RL   J. Clin. Endocrinol. Metab. 86:4429-4433(2001).
RN   [61]
RP   VARIANTS ASN-281; ILE-425; THR-453; PHE-486; ASN-505; ARG-512; GLN-512;
RP   THR-568; GLY-619; VAL-623; LEU-631; ALA-632; ILE-632; GLU-633; HIS-633;
RP   TYR-633; ALA-639 AND PHE-656, AND CHARACTERIZATION OF VARIANTS ILE-425 AND
RP   GLN-512.
RX   PubMed=11434721; DOI=10.1007/s001090000170;
RA   Truelzsch B., Krohn K., Wonerow P., Chey S., Holzapfel H.-P., Ackermann F.,
RA   Fuehrer D., Paschke R.;
RT   "Detection of thyroid-stimulating hormone receptor and G(s)alpha mutations:
RT   in 75 toxic thyroid nodules by denaturing gradient gel electrophoresis.";
RL   J. Mol. Med. 78:684-691(2001).
RN   [62]
RP   VARIANTS CHNG1 HIS-450 AND SER-498.
RX   PubMed=11442002; DOI=10.1089/105072501750302859;
RA   Nagashima T., Murakami M., Onigata K., Morimura T., Nagashima K., Mori M.,
RA   Morikawa A.;
RT   "Novel inactivating missense mutations in the thyrotropin receptor gene in
RT   Japanese children with resistance to thyrotropin.";
RL   Thyroid 11:551-559(2001).
RN   [63]
RP   VARIANTS HYPERTHYROIDISM THR-453; MET-486; ARG-512 AND ALA-632.
RX   PubMed=12213664; DOI=10.1530/eje.0.1470287;
RA   Vanvooren V., Uchino S., Duprez L., Costa M.J., Vandekerckhove J.,
RA   Parma J., Vassart G., Dumont J.E., van Sande J., Noguchi S.;
RT   "Oncogenic mutations in the thyrotropin receptor of autonomously
RT   functioning thyroid nodules in the Japanese population.";
RL   Eur. J. Endocrinol. 147:287-291(2002).
RN   [64]
RP   VARIANTS CHNG1 SER-41; ALA-162; PRO-467 AND ARG-600.
RX   PubMed=12050212; DOI=10.1210/jcem.87.6.8536;
RA   Alberti L., Proverbio M.C., Costagliola S., Romoli R., Boldrighini B.,
RA   Vigone M.C., Weber G., Chiumello G., Beck-Peccoz P., Persani L.;
RT   "Germline mutations of TSH receptor gene as cause of nonautoimmune
RT   subclinical hypothyroidism.";
RL   J. Clin. Endocrinol. Metab. 87:2549-2555(2002).
RN   [65]
RP   VARIANT TOXIC THYROID ADENOMA ASN-593, VARIANT GLU-727, CHARACTERIZATION OF
RP   VARIANT TOXIC THYROID ADENOMA ASN-593, AND CHARACTERIZATION OF VARIANT
RP   GLU-727.
RX   PubMed=12589819; DOI=10.1016/s0006-291x(03)00071-8;
RA   Sykiotis G.P., Neumann S., Georgopoulos N.A., Sgourou A.,
RA   Papachatzopoulou A., Markou K.B., Kyriazopoulou V., Paschke R.,
RA   Vagenakis A.G., Papavassiliou A.G.;
RT   "Functional significance of the thyrotropin receptor germline polymorphism
RT   D727E.";
RL   Biochem. Biophys. Res. Commun. 301:1051-1056(2003).
RN   [66]
RP   VARIANTS HIS-36; THR-52 AND GLU-727, AND ASSOCIATION WITH PLASMA TSH LEVEL.
RX   PubMed=12788902; DOI=10.1210/jc.2002-021592;
RA   Peeters R.P., van Toor H., Klootwijk W., de Rijke Y.B., Kuiper G.G.J.M.,
RA   Uitterlinden A.G., Visser T.J.;
RT   "Polymorphisms in thyroid hormone pathway genes are associated with plasma
RT   TSH and iodothyronine levels in healthy subjects.";
RL   J. Clin. Endocrinol. Metab. 88:2880-2888(2003).
RN   [67]
RP   VARIANTS HIS-36 AND THR-52, AND RECEPTOR GENETIC ANALYSIS IN CHILDREN WITH
RP   DOWN'S SYNDROME.
RX   PubMed=14759073; DOI=10.1007/bf03348198;
RA   Tonacchera M., Perri A., De Marco G., Agretti P., Montanelli L.,
RA   Banco M.E., Corrias A., Bellone J., Tosi M.T., Vitti P., Martino E.,
RA   Pinchera A., Chiovato L.;
RT   "TSH receptor and Gs(alpha) genetic analysis in children with Down's
RT   syndrome and subclinical hypothyroidism.";
RL   J. Endocrinol. Invest. 26:997-1000(2003).
RN   [68]
RP   VARIANT CHNG1 THR-553.
RX   PubMed=14725684; DOI=10.1111/j.1365-2265.2004.01967.x;
RA   Park S.-M., Clifton-Bligh R.J., Betts P., Chatterjee V.K.K.;
RT   "Congenital hypothyroidism and apparent athyreosis with compound
RT   heterozygosity or compensated hypothyroidism with probable hemizygosity for
RT   inactivating mutations of the TSH receptor.";
RL   Clin. Endocrinol. (Oxf.) 60:220-227(2004).
RN   [69]
RP   VARIANT HTNA ASN-505.
RX   PubMed=15163335; DOI=10.1111/j.1365-2265.2004.02040.x;
RA   Vaidya B., Campbell V., Tripp J.H., Spyer G., Hattersley A.T., Ellard S.;
RT   "Premature birth and low birth weight associated with nonautoimmune
RT   hyperthyroidism due to an activating thyrotropin receptor gene mutation.";
RL   Clin. Endocrinol. (Oxf.) 60:711-718(2004).
RN   [70]
RP   VARIANTS CHNG1 ALA-162 AND PRO-252, AND CHARACTERIZATION OF VARIANT CHNG1
RP   PRO-252.
RX   PubMed=15531543; DOI=10.1210/jc.2004-1243;
RA   Tonacchera M., Perri A., De Marco G., Agretti P., Banco M.E., Di Cosmo C.,
RA   Grasso L., Vitti P., Chiovato L., Pinchera A.;
RT   "Low prevalence of thyrotropin receptor mutations in a large series of
RT   subjects with sporadic and familial nonautoimmune subclinical
RT   hypothyroidism.";
RL   J. Clin. Endocrinol. Metab. 89:5787-5793(2004).
RN   [71]
RP   VARIANTS CHNG1 ALA-162; ASP-432 AND LEU-449, AND CHARACTERIZATION OF
RP   VARIANTS CHNG1 ASP-432 AND LEU-449.
RX   PubMed=25978107; DOI=10.1210/jc.2014-4511;
RA   Labadi A., Grassi E.S., Gellen B., Kleinau G., Biebermann H., Ruzsa B.,
RA   Gelmini G., Rideg O., Miseta A., Kovacs G.L., Patocs A., Felszeghy E.,
RA   Nagy E.V., Mezosi E., Persani L.;
RT   "Loss-of-function variants in a Hungarian cohort reveal structural insights
RT   on TSH receptor maturation and signaling.";
RL   J. Clin. Endocrinol. Metab. 100:E1039-E1045(2015).
CC   -!- FUNCTION: Receptor for the thyroid-stimulating hormone (TSH) or
CC       thyrotropin (PubMed:11847099, PubMed:12045258). Also acts as a receptor
CC       for the heterodimeric glycoprotein hormone (GPHA2:GPHB5) or
CC       thyrostimulin (PubMed:12045258). The activity of this receptor is
CC       mediated by G proteins which activate adenylate cyclase
CC       (PubMed:11847099). Plays a central role in controlling thyroid cell
CC       metabolism (By similarity). {ECO:0000250|UniProtKB:P21463,
CC       ECO:0000269|PubMed:11847099, ECO:0000269|PubMed:12045258}.
CC   -!- SUBUNIT: Interacts with heterodimer GPHA2:GPHB5; this interaction
CC       stimulates cAMP production (PubMed:12045258). Interacts (via the PDZ-
CC       binding motif) with SCRIB; regulates TSHR trafficking and function
CC       (PubMed:15775968). {ECO:0000269|PubMed:12045258,
CC       ECO:0000269|PubMed:15775968}.
CC   -!- INTERACTION:
CC       P16473; P30542: ADORA1; NbExp=2; IntAct=EBI-13939599, EBI-2903663;
CC       P16473; Q9NPA3: MID1IP1; NbExp=2; IntAct=EBI-13939599, EBI-750096;
CC       P16473; Q14160: SCRIB; NbExp=3; IntAct=EBI-13939599, EBI-357345;
CC       P16473; P21579: SYT1; NbExp=2; IntAct=EBI-13939599, EBI-524909;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:11847099};
CC       Multi-pass membrane protein {ECO:0000305}. Basolateral cell membrane
CC       {ECO:0000269|PubMed:11847099}; Multi-pass membrane protein
CC       {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=Long;
CC         IsoId=P16473-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=P16473-2; Sequence=VSP_001981, VSP_001982;
CC       Name=3;
CC         IsoId=P16473-3; Sequence=VSP_044643, VSP_044644;
CC   -!- TISSUE SPECIFICITY: Expressed in thyroide cells (at protein level)
CC       (PubMed:11847099). Expressed in the thyroid (PubMed:2610690).
CC       {ECO:0000269|PubMed:11847099, ECO:0000269|PubMed:2610690}.
CC   -!- PTM: Glycosylated. {ECO:0000269|PubMed:11847099}.
CC   -!- PTM: Sulfated. Sulfation on Tyr-385 plays a role in thyrotropin
CC       receptor binding and activation. {ECO:0000269|PubMed:11847099}.
CC   -!- POLYMORPHISM: The Asp727Glu polymorphism is associated with Graves
CC       disease in a Russian population. The Glu727 allele and the heterozygous
CC       Asp727Glu genotype are related to higher risk of the disease. The
CC       Asp727Glu polymorphism significantly ameliorates G(s)alpha protein
CC       activation in the presence of the gain-of-function mutation Ala593Asn
CC       although it is functionally inert in the context of the wild-type TSHR.
CC       {ECO:0000269|PubMed:11887032}.
CC   -!- DISEASE: Note=Defects in TSHR are found in patients affected by
CC       hyperthyroidism with different etiologies. Somatic, constitutively
CC       activating TSHR mutations and/or constitutively activating G(s)alpha
CC       mutations have been identified in toxic thyroid nodules (TTNs) that are
CC       the predominant cause of hyperthyroidism in iodine deficient areas.
CC       These mutations lead to TSH independent activation of the cAMP cascade
CC       resulting in thyroid growth and hormone production. TSHR mutations are
CC       found in autonomously functioning thyroid nodules (AFTN), toxic
CC       multinodular goiter (TMNG) and hyperfunctioning thyroid adenomas (HTA).
CC       TMNG encompasses a spectrum of different clinical entities, ranging
CC       from a single hyperfunctioning nodule within an enlarged thyroid, to
CC       multiple hyperfunctioning areas scattered throughout the gland. HTA are
CC       discrete encapsulated neoplasms characterized by TSH-independent
CC       autonomous growth, hypersecretion of thyroid hormones, and TSH
CC       suppression. Defects in TSHR are also a cause of thyroid neoplasms
CC       (papillary and follicular cancers).
CC   -!- DISEASE: Note=Autoantibodies against TSHR are directly responsible for
CC       the pathogenesis and hyperthyroidism of Graves disease. Antibody
CC       interaction with TSHR results in an uncontrolled receptor stimulation.
CC   -!- DISEASE: Hypothyroidism, congenital, non-goitrous, 1 (CHNG1)
CC       [MIM:275200]: A non-autoimmune condition characterized by resistance to
CC       thyroid-stimulating hormone (TSH) leading to increased levels of plasma
CC       TSH and low levels of thyroid hormone. It presents variable severity
CC       depending on the completeness of the defect. Most patients are
CC       euthyroid and asymptomatic, with a normal sized thyroid gland. Only a
CC       subset of patients develop hypothyroidism and present a hypoplastic
CC       thyroid gland. {ECO:0000269|PubMed:10720030,
CC       ECO:0000269|PubMed:11095460, ECO:0000269|PubMed:11442002,
CC       ECO:0000269|PubMed:12050212, ECO:0000269|PubMed:14725684,
CC       ECO:0000269|PubMed:15531543, ECO:0000269|PubMed:25978107,
CC       ECO:0000269|PubMed:7528344, ECO:0000269|PubMed:8954020,
CC       ECO:0000269|PubMed:9100579, ECO:0000269|PubMed:9185526,
CC       ECO:0000269|PubMed:9329388}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Familial gestational hyperthyroidism (HTFG) [MIM:603373]: A
CC       condition characterized by abnormally high levels of serum thyroid
CC       hormones occurring during early pregnancy.
CC       {ECO:0000269|PubMed:9854118}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Hyperthyroidism, non-autoimmune (HTNA) [MIM:609152]: A
CC       condition characterized by abnormally high levels of serum thyroid
CC       hormones, thyroid hyperplasia, goiter and lack of anti-thyroid
CC       antibodies. Typical features of Graves disease such as exophthalmia,
CC       myxedema, antibodies anti-TSH receptor and lymphocytic infiltration of
CC       the thyroid gland are absent. {ECO:0000269|PubMed:10199795,
CC       ECO:0000269|PubMed:10852462, ECO:0000269|PubMed:11081252,
CC       ECO:0000269|PubMed:11127522, ECO:0000269|PubMed:11201847,
CC       ECO:0000269|PubMed:11517004, ECO:0000269|PubMed:11549687,
CC       ECO:0000269|PubMed:15163335, ECO:0000269|PubMed:7800007,
CC       ECO:0000269|PubMed:7920658, ECO:0000269|PubMed:8636266,
CC       ECO:0000269|PubMed:8964822, ECO:0000269|PubMed:9349581,
CC       ECO:0000269|PubMed:9360555, ECO:0000269|PubMed:9398746,
CC       ECO:0000269|PubMed:9589634}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       FSH/LSH/TSH subfamily. {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA70232.1; Type=Frameshift; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=TSH receptor database;
CC       URL="https://endokrinologie.uniklinikum-leipzig.de/tsh/";
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=TSHR";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=TSH receptor entry;
CC       URL="https://en.wikipedia.org/wiki/TSH_receptor";
CC   -!- WEB RESOURCE: Name=Sequence-structure-function-analysis of glycoprotein
CC       hormone receptors;
CC       URL="http://www.ssfa-gphr.de/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/TSHRID290ch14q31.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M31774; AAA36783.1; -; mRNA.
DR   EMBL; M32215; AAA61236.1; -; mRNA.
DR   EMBL; M73747; AAA70232.1; ALT_FRAME; mRNA.
DR   EMBL; S45272; AAB23390.2; -; mRNA.
DR   EMBL; S49816; AAB24246.1; -; mRNA.
DR   EMBL; AY429111; AAR07906.1; -; mRNA.
DR   EMBL; AC007262; AAD31568.1; -; Genomic_DNA.
DR   EMBL; AC010072; AAF09032.1; -; Genomic_DNA.
DR   EMBL; AC010582; AAF26775.1; -; Genomic_DNA.
DR   EMBL; AL136040; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC009237; AAH09237.1; -; mRNA.
DR   EMBL; BC024205; AAH24205.1; -; mRNA.
DR   EMBL; BC063613; AAH63613.1; -; mRNA.
DR   EMBL; BC108653; AAI08654.1; -; mRNA.
DR   EMBL; BC120973; AAI20974.1; -; mRNA.
DR   EMBL; BC127628; AAI27629.1; -; mRNA.
DR   EMBL; BC141970; AAI41971.1; -; mRNA.
DR   CCDS; CCDS32131.1; -. [P16473-2]
DR   CCDS; CCDS55935.1; -. [P16473-3]
DR   CCDS; CCDS9872.1; -. [P16473-1]
DR   PIR; A33789; QRHURH.
DR   PIR; JC1319; JC1319.
DR   PIR; T01787; T01787.
DR   RefSeq; NP_000360.2; NM_000369.2.
DR   RefSeq; NP_001018046.1; NM_001018036.2. [P16473-2]
DR   RefSeq; NP_001136098.1; NM_001142626.2. [P16473-3]
DR   RefSeq; XP_005268096.1; XM_005268039.1. [P16473-2]
DR   RefSeq; XP_006720308.1; XM_006720245.1. [P16473-3]
DR   PDB; 1XUM; Model; -; A=54-236.
DR   PDB; 2XWT; X-ray; 1.90 A; C=22-260.
DR   PDB; 3G04; X-ray; 2.55 A; C=22-260.
DR   PDBsum; 1XUM; -.
DR   PDBsum; 2XWT; -.
DR   PDBsum; 3G04; -.
DR   BioGRID; 113104; 31.
DR   IntAct; P16473; 25.
DR   MINT; P16473; -.
DR   STRING; 9606.ENSP00000441235; -.
DR   BindingDB; P16473; -.
DR   ChEMBL; CHEMBL1963; -.
DR   DrugBank; DB00024; Thyrotropin alfa.
DR   DrugCentral; P16473; -.
DR   GuidetoPHARMACOLOGY; 255; -.
DR   GlyGen; P16473; 6 sites.
DR   iPTMnet; P16473; -.
DR   PhosphoSitePlus; P16473; -.
DR   SwissPalm; P16473; -.
DR   BioMuta; TSHR; -.
DR   DMDM; 62298994; -.
DR   MassIVE; P16473; -.
DR   PaxDb; P16473; -.
DR   PeptideAtlas; P16473; -.
DR   PRIDE; P16473; -.
DR   ProteomicsDB; 24847; -.
DR   ProteomicsDB; 32578; -.
DR   ProteomicsDB; 53374; -. [P16473-1]
DR   ProteomicsDB; 53375; -. [P16473-2]
DR   ABCD; P16473; 5 sequenced antibodies.
DR   Antibodypedia; 4379; 1139 antibodies.
DR   DNASU; 7253; -.
DR   Ensembl; ENST00000342443; ENSP00000340113; ENSG00000165409. [P16473-2]
DR   Ensembl; ENST00000554435; ENSP00000450549; ENSG00000165409. [P16473-3]
DR   GeneID; 7253; -.
DR   KEGG; hsa:7253; -.
DR   UCSC; uc001xvc.4; human. [P16473-1]
DR   CTD; 7253; -.
DR   DisGeNET; 7253; -.
DR   EuPathDB; HostDB:ENSG00000165409.15; -.
DR   GeneCards; TSHR; -.
DR   HGNC; HGNC:12373; TSHR.
DR   HPA; ENSG00000165409; Tissue enriched (thyroid).
DR   MalaCards; TSHR; -.
DR   MIM; 275200; phenotype.
DR   MIM; 603372; gene+phenotype.
DR   MIM; 603373; phenotype.
DR   MIM; 609152; phenotype.
DR   neXtProt; NX_P16473; -.
DR   OpenTargets; ENSG00000165409; -.
DR   Orphanet; 95713; Athyreosis.
DR   Orphanet; 99819; Familial gestational hyperthyroidism.
DR   Orphanet; 424; Familial hyperthyroidism due to mutations in TSH receptor.
DR   Orphanet; 90673; Hypothyroidism due to TSH receptor mutations.
DR   Orphanet; 95720; Thyroid hypoplasia.
DR   PharmGKB; PA37042; -.
DR   eggNOG; KOG2087; Eukaryota.
DR   GeneTree; ENSGT00940000156510; -.
DR   InParanoid; P16473; -.
DR   KO; K04249; -.
DR   PhylomeDB; P16473; -.
DR   TreeFam; TF316814; -.
DR   PathwayCommons; P16473; -.
DR   Reactome; R-HSA-375281; Hormone ligand-binding receptors.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-9660821; ADORA2B mediated anti-inflammatory cytokines production.
DR   SignaLink; P16473; -.
DR   SIGNOR; P16473; -.
DR   BioGRID-ORCS; 7253; 5 hits in 873 CRISPR screens.
DR   ChiTaRS; TSHR; human.
DR   EvolutionaryTrace; P16473; -.
DR   GeneWiki; Thyrotropin_receptor; -.
DR   GenomeRNAi; 7253; -.
DR   Pharos; P16473; Tclin.
DR   PRO; PR:P16473; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   RNAct; P16473; protein.
DR   Bgee; ENSG00000165409; Expressed in left lobe of thyroid gland and 116 other tissues.
DR   ExpressionAtlas; P16473; baseline and differential.
DR   Genevisible; P16473; HS.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:UniProtKB.
DR   GO; GO:0009986; C:cell surface; ISS:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0008528; F:G protein-coupled peptide receptor activity; IBA:GO_Central.
DR   GO; GO:0044877; F:protein-containing complex binding; IDA:UniProtKB.
DR   GO; GO:0038023; F:signaling receptor activity; IMP:UniProtKB.
DR   GO; GO:0004996; F:thyroid-stimulating hormone receptor activity; IMP:UniProtKB.
DR   GO; GO:0007190; P:activation of adenylate cyclase activity; IBA:GO_Central.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0007267; P:cell-cell signaling; TAS:ProtInc.
DR   GO; GO:1904588; P:cellular response to glycoprotein; IMP:UniProtKB.
DR   GO; GO:1905229; P:cellular response to thyrotropin-releasing hormone; IMP:UniProtKB.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007187; P:G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; TAS:ProtInc.
DR   GO; GO:0009755; P:hormone-mediated signaling pathway; IBA:GO_Central.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; TAS:ProtInc.
DR   GO; GO:0120162; P:positive regulation of cold-induced thermogenesis; ISS:YuBioLab.
DR   GO; GO:0038194; P:thyroid-stimulating hormone signaling pathway; IMP:UniProtKB.
DR   Gene3D; 3.80.10.10; -; 1.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR002131; Gphrmn_rcpt_fam.
DR   InterPro; IPR026906; LRR_5.
DR   InterPro; IPR032675; LRR_dom_sf.
DR   InterPro; IPR002274; TSH_rcpt.
DR   PANTHER; PTHR24372:SF0; PTHR24372:SF0; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   Pfam; PF13306; LRR_5; 2.
DR   PRINTS; PR00373; GLYCHORMONER.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01145; TSHRECEPTOR.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane;
KW   Congenital hypothyroidism; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; G-protein coupled receptor; Glycoprotein;
KW   Leucine-rich repeat; Membrane; Polymorphism; Receptor; Reference proteome;
KW   Repeat; Signal; Sulfation; Transducer; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..20
FT   CHAIN           21..764
FT                   /note="Thyrotropin receptor"
FT                   /id="PRO_0000012786"
FT   TOPO_DOM        21..413
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        414..441
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        442..450
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        451..473
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        474..494
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        495..517
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        518..537
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        538..560
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        561..580
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        581..602
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        603..625
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        626..649
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        650..660
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        661..682
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        683..764
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REPEAT          100..124
FT                   /note="LRR 1"
FT   REPEAT          125..150
FT                   /note="LRR 2"
FT   REPEAT          152..174
FT                   /note="LRR 3"
FT   REPEAT          176..199
FT                   /note="LRR 4"
FT   REPEAT          200..223
FT                   /note="LRR 5"
FT   REPEAT          227..248
FT                   /note="LRR 6"
FT   REPEAT          250..271
FT                   /note="LRR 7"
FT   MOTIF           762..764
FT                   /note="PDZ-binding"
FT   MOD_RES         385
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000305|PubMed:11847099"
FT   CARBOHYD        77
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:11502179,
FT                   ECO:0000269|PubMed:17542669"
FT   CARBOHYD        99
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:17542669"
FT   CARBOHYD        113
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:11502179,
FT                   ECO:0000269|PubMed:17542669"
FT   CARBOHYD        177
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:17542669"
FT   CARBOHYD        198
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:11502179,
FT                   ECO:0000269|PubMed:17542669"
FT   CARBOHYD        302
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:11502179"
FT   DISULFID        31..41
FT   DISULFID        494..569
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VAR_SEQ         232..274
FT                   /note="DVSQTSVTALPSKGLEHLKELIARNTWTLKKLPLSLSFLHLTR -> VENVA
FT                   VSGKGFCKSLFSWLYRLPLGRKSLSFETQKAPRSSMPS (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_044643"
FT   VAR_SEQ         232..253
FT                   /note="DVSQTSVTALPSKGLEHLKELI -> LPLGRKSLSFETQKAPRSSMPS (in
FT                   isoform Short)"
FT                   /evidence="ECO:0000303|PubMed:1445355,
FT                   ECO:0000303|PubMed:1530609, ECO:0000303|PubMed:15489334"
FT                   /id="VSP_001981"
FT   VAR_SEQ         254..764
FT                   /note="Missing (in isoform Short)"
FT                   /evidence="ECO:0000303|PubMed:1445355,
FT                   ECO:0000303|PubMed:1530609, ECO:0000303|PubMed:15489334"
FT                   /id="VSP_001982"
FT   VAR_SEQ         275..764
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_044644"
FT   VARIANT         34
FT                   /note="E -> K (in dbSNP:rs45499704)"
FT                   /id="VAR_055925"
FT   VARIANT         36
FT                   /note="D -> H (in a patient with Graves disease;
FT                   dbSNP:rs61747482)"
FT                   /evidence="ECO:0000269|PubMed:12788902,
FT                   ECO:0000269|PubMed:12930595, ECO:0000269|PubMed:14759073,
FT                   ECO:0000269|PubMed:1955520, ECO:0000269|PubMed:7556878"
FT                   /id="VAR_003564"
FT   VARIANT         41
FT                   /note="C -> S (in CHNG1)"
FT                   /evidence="ECO:0000269|PubMed:12050212,
FT                   ECO:0000269|PubMed:8954020"
FT                   /id="VAR_011519"
FT   VARIANT         52
FT                   /note="P -> T (does not contribute to the genetic
FT                   susceptibility to Graves disease; dbSNP:rs2234919)"
FT                   /evidence="ECO:0000269|PubMed:10651846,
FT                   ECO:0000269|PubMed:12788902, ECO:0000269|PubMed:12930595,
FT                   ECO:0000269|PubMed:14759073, ECO:0000269|PubMed:7488864,
FT                   ECO:0000269|PubMed:7508946, ECO:0000269|PubMed:7528344"
FT                   /id="VAR_003565"
FT   VARIANT         109
FT                   /note="R -> Q (in CHNG1)"
FT                   /evidence="ECO:0000269|PubMed:9100579"
FT                   /id="VAR_011520"
FT   VARIANT         162
FT                   /note="P -> A (in CHNG1; dbSNP:rs121908863)"
FT                   /evidence="ECO:0000269|PubMed:12050212,
FT                   ECO:0000269|PubMed:15531543, ECO:0000269|PubMed:25978107,
FT                   ECO:0000269|PubMed:7528344, ECO:0000269|PubMed:8954020"
FT                   /id="VAR_011521"
FT   VARIANT         167
FT                   /note="I -> N (in CHNG1)"
FT                   /evidence="ECO:0000269|PubMed:7528344"
FT                   /id="VAR_011522"
FT   VARIANT         183
FT                   /note="K -> R (in HTFG; enhances receptor response to
FT                   chorionic gonadotropin)"
FT                   /evidence="ECO:0000269|PubMed:9854118"
FT                   /id="VAR_003566"
FT   VARIANT         197
FT                   /note="F -> I (in papillary cancer)"
FT                   /evidence="ECO:0000269|PubMed:7647578"
FT                   /id="VAR_003567"
FT   VARIANT         219
FT                   /note="D -> E (in papillary cancer)"
FT                   /evidence="ECO:0000269|PubMed:7647578"
FT                   /id="VAR_003568"
FT   VARIANT         252
FT                   /note="L -> P (in CHNG1; displays a low expression at the
FT                   cell surface and a reduced response to bovine TSH in terms
FT                   of cAMP production)"
FT                   /evidence="ECO:0000269|PubMed:15531543"
FT                   /id="VAR_021495"
FT   VARIANT         281
FT                   /note="S -> I (in hyperthyroidism; congenital; due to a
FT                   toxic adenoma)"
FT                   /evidence="ECO:0000269|PubMed:9294132"
FT                   /id="VAR_003569"
FT   VARIANT         281
FT                   /note="S -> N (in HTNA; gain of function; found in toxic
FT                   thyroid nodules and hyperfunctioning thyroid adenomas)"
FT                   /evidence="ECO:0000269|PubMed:10852462,
FT                   ECO:0000269|PubMed:11127522, ECO:0000269|PubMed:11434721,
FT                   ECO:0000269|PubMed:9253356, ECO:0000269|PubMed:9589634"
FT                   /id="VAR_003570"
FT   VARIANT         281
FT                   /note="S -> T (in hyperthyroidism; associated with
FT                   hyperfunctioning thyroid adenomas)"
FT                   /evidence="ECO:0000269|PubMed:9253356"
FT                   /id="VAR_011523"
FT   VARIANT         310
FT                   /note="R -> C (in CHNG1)"
FT                   /evidence="ECO:0000269|PubMed:11095460"
FT                   /id="VAR_011524"
FT   VARIANT         390
FT                   /note="C -> W (in CHNG1; persistent hypothyroidism and
FT                   defective thyroid development; abolishes high affinity
FT                   hormone binding)"
FT                   /evidence="ECO:0000269|PubMed:8954020,
FT                   ECO:0000269|PubMed:9329388"
FT                   /id="VAR_011525"
FT   VARIANT         410
FT                   /note="D -> N (in CHNG1; lack of adenylate cyclase
FT                   activation)"
FT                   /evidence="ECO:0000269|PubMed:8954020"
FT                   /id="VAR_011526"
FT   VARIANT         425
FT                   /note="S -> I (found in toxic thyroid nodules; 8 to 9 times
FT                   higher levels of basal cAMP than wild-type TSHR and similar
FT                   response to maximal TSH stimulation)"
FT                   /evidence="ECO:0000269|PubMed:11434721"
FT                   /id="VAR_021496"
FT   VARIANT         431
FT                   /note="G -> S (in HTNA; gain of function; constitutive
FT                   activation of the G(s)/adenylyl cyclase system)"
FT                   /evidence="ECO:0000269|PubMed:11127522,
FT                   ECO:0000269|PubMed:11549687"
FT                   /id="VAR_011527"
FT   VARIANT         432
FT                   /note="N -> D (in CHNG1; abolishes cell membrane location;
FT                   abolishes adenylate cyclase-activating G-protein coupled
FT                   receptor signaling pathway; abolishes phospholipase C-
FT                   activating G-protein coupled receptor signaling pathway)"
FT                   /evidence="ECO:0000269|PubMed:25978107"
FT                   /id="VAR_075585"
FT   VARIANT         449
FT                   /note="P -> L (in CHNG1; no effect on cell membrane
FT                   location; upon TSH stimulation decreases more phospholipase
FT                   C-activating G-protein coupled receptor signaling pathway
FT                   than adenylate cyclase-activating G-protein coupled
FT                   receptor signaling pathway)"
FT                   /evidence="ECO:0000269|PubMed:25978107"
FT                   /id="VAR_075586"
FT   VARIANT         450
FT                   /note="R -> H (in CHNG1)"
FT                   /evidence="ECO:0000269|PubMed:11442002"
FT                   /id="VAR_011528"
FT   VARIANT         453
FT                   /note="M -> T (in HTNA; sporadic; found in toxic thyroid
FT                   nodules and hyperfunctioning thyroid adenomas)"
FT                   /evidence="ECO:0000269|PubMed:11434721,
FT                   ECO:0000269|PubMed:12213664, ECO:0000269|PubMed:8964822,
FT                   ECO:0000269|PubMed:9253356"
FT                   /id="VAR_011529"
FT   VARIANT         463
FT                   /note="M -> V (in HTNA; gain of function)"
FT                   /evidence="ECO:0000269|PubMed:11201847"
FT                   /id="VAR_011530"
FT   VARIANT         467
FT                   /note="L -> P (in CHNG1)"
FT                   /evidence="ECO:0000269|PubMed:12050212"
FT                   /id="VAR_017295"
FT   VARIANT         477
FT                   /note="T -> I (in CHNG1; severe hypothyroidism)"
FT                   /evidence="ECO:0000269|PubMed:10720030"
FT                   /id="VAR_017296"
FT   VARIANT         486
FT                   /note="I -> F (in HTNA; found in thyroid toxic nodules and
FT                   hyperfunctioning thyroid adenomas; also in hyperfunctioning
FT                   follicular carcinoma)"
FT                   /evidence="ECO:0000269|PubMed:10852462,
FT                   ECO:0000269|PubMed:11128715, ECO:0000269|PubMed:11434721,
FT                   ECO:0000269|PubMed:9253356"
FT                   /id="VAR_011531"
FT   VARIANT         486
FT                   /note="I -> M (in HTNA; found in hyperfunctioning thyroid
FT                   adenomas)"
FT                   /evidence="ECO:0000269|PubMed:10852462,
FT                   ECO:0000269|PubMed:12213664, ECO:0000269|PubMed:9253356"
FT                   /id="VAR_011532"
FT   VARIANT         498
FT                   /note="G -> S (in CHNG1)"
FT                   /evidence="ECO:0000269|PubMed:11442002"
FT                   /id="VAR_011533"
FT   VARIANT         505
FT                   /note="S -> N (in HTNA; found in toxic thyroid nodules)"
FT                   /evidence="ECO:0000269|PubMed:11434721,
FT                   ECO:0000269|PubMed:15163335, ECO:0000269|PubMed:9360555"
FT                   /id="VAR_003571"
FT   VARIANT         505
FT                   /note="S -> R (in HTNA; gain of function)"
FT                   /evidence="ECO:0000269|PubMed:8636266"
FT                   /id="VAR_011534"
FT   VARIANT         509
FT                   /note="V -> A (in HTNA; gain of function)"
FT                   /evidence="ECO:0000269|PubMed:7920658"
FT                   /id="VAR_011535"
FT   VARIANT         512
FT                   /note="L -> Q (found in toxic thyroid nodules; 5 times
FT                   higher levels of basal cAMP than wild-type TSHR and
FT                   slightly less response to maximal TSH stimulation)"
FT                   /evidence="ECO:0000269|PubMed:11434721"
FT                   /id="VAR_021497"
FT   VARIANT         512
FT                   /note="L -> R (in hyperthyroidism; associated with
FT                   autonomously functioning thyroid nodules; 3.3-fold increase
FT                   in basal cAMP level)"
FT                   /evidence="ECO:0000269|PubMed:11022192,
FT                   ECO:0000269|PubMed:11434721, ECO:0000269|PubMed:12213664"
FT                   /id="VAR_011536"
FT   VARIANT         525
FT                   /note="F -> L (in CHNG1; impairs adenylate cyclase
FT                   activation)"
FT                   /evidence="ECO:0000269|PubMed:8954020"
FT                   /id="VAR_011537"
FT   VARIANT         528
FT                   /note="R -> H"
FT                   /evidence="ECO:0000269|PubMed:9589634"
FT                   /id="VAR_003572"
FT   VARIANT         553
FT                   /note="A -> T (in CHNG1; severe hypothyroidism)"
FT                   /evidence="ECO:0000269|PubMed:14725684,
FT                   ECO:0000269|PubMed:9185526"
FT                   /id="VAR_011538"
FT   VARIANT         568
FT                   /note="I -> T (in HTNA; found in thyroid toxic nodules and
FT                   hyperfunctioning thyroid adenomas)"
FT                   /evidence="ECO:0000269|PubMed:11081252,
FT                   ECO:0000269|PubMed:11434721, ECO:0000269|PubMed:9253356"
FT                   /id="VAR_011539"
FT   VARIANT         593
FT                   /note="A -> N (in toxic thyroid adenoma; requires 2
FT                   nucleotide substitutions; somatic mutation; constitutively
FT                   activates the cAMP cascade)"
FT                   /evidence="ECO:0000269|PubMed:12589819"
FT                   /id="VAR_021498"
FT   VARIANT         597
FT                   /note="V -> F (in HTNA; 11-fold increase in specific
FT                   constitutive activity associated with reduction in receptor
FT                   protein expression)"
FT                   /evidence="ECO:0000269|PubMed:11517004"
FT                   /id="VAR_021499"
FT   VARIANT         597
FT                   /note="V -> L (in hyperthyroidism; congenital with severe
FT                   thyrotoxicosis)"
FT                   /evidence="ECO:0000269|PubMed:10560955"
FT                   /id="VAR_011540"
FT   VARIANT         600
FT                   /note="C -> R (in CHNG1)"
FT                   /evidence="ECO:0000269|PubMed:12050212"
FT                   /id="VAR_017297"
FT   VARIANT         606
FT                   /note="I -> M"
FT                   /evidence="ECO:0000269|PubMed:10487707"
FT                   /id="VAR_011541"
FT   VARIANT         619
FT                   /note="D -> G (in hyperthyroidism; found in toxic thyroid
FT                   nodules; associated with hyperfunctioning thyroid
FT                   adenomas)"
FT                   /evidence="ECO:0000269|PubMed:11434721,
FT                   ECO:0000269|PubMed:8413627, ECO:0000269|PubMed:9253356"
FT                   /id="VAR_003573"
FT   VARIANT         623
FT                   /note="A -> I (in hyperthyroidism; associated with
FT                   hyperfunctioning thyroid adenomas; gain of function;
FT                   requires 2 nucleotide substitutions)"
FT                   /evidence="ECO:0000269|PubMed:8413627,
FT                   ECO:0000269|PubMed:9253356"
FT                   /id="VAR_003574"
FT   VARIANT         623
FT                   /note="A -> V (in hyperthyroidism; found in toxic thyroid
FT                   nodules; associated with hyperfunctioning thyroid adenomas;
FT                   gain of function)"
FT                   /evidence="ECO:0000269|PubMed:11434721,
FT                   ECO:0000269|PubMed:7989485"
FT                   /id="VAR_011542"
FT   VARIANT         629
FT                   /note="L -> F (in HTNA; also in hyperfunctioning thyroid
FT                   adenomas and non-adenomatous nodules)"
FT                   /evidence="ECO:0000269|PubMed:10852462,
FT                   ECO:0000269|PubMed:9253356, ECO:0000269|PubMed:9398746"
FT                   /id="VAR_003575"
FT   VARIANT         630
FT                   /note="I -> L (in hyperthyroidism; associated with
FT                   hyperfunctioning thyroid adenomas)"
FT                   /evidence="ECO:0000269|PubMed:9253356"
FT                   /id="VAR_011543"
FT   VARIANT         631
FT                   /note="F -> C (in hyperthyroidism; associated with
FT                   hyperfunctioning thyroid adenomas)"
FT                   /evidence="ECO:0000269|PubMed:8045989"
FT                   /id="VAR_011544"
FT   VARIANT         631
FT                   /note="F -> L (in HTNA; gain of function; found in toxic
FT                   thyroid nodules and hyperfunctioning thyroid adenomas)"
FT                   /evidence="ECO:0000269|PubMed:11434721,
FT                   ECO:0000269|PubMed:7800007, ECO:0000269|PubMed:9253356"
FT                   /id="VAR_011545"
FT   VARIANT         632
FT                   /note="T -> A (in HTNA; found in toxic thyroid nodules and
FT                   hyperfunctioning non-adenomatous nodules)"
FT                   /evidence="ECO:0000269|PubMed:10852462,
FT                   ECO:0000269|PubMed:11434721, ECO:0000269|PubMed:12213664"
FT                   /id="VAR_011546"
FT   VARIANT         632
FT                   /note="T -> I (in HTNA; gain of function; found in thyroid
FT                   toxic nodules and hyperfunctioning thyroid adenomas)"
FT                   /evidence="ECO:0000269|PubMed:10852462,
FT                   ECO:0000269|PubMed:11127522, ECO:0000269|PubMed:11434721,
FT                   ECO:0000269|PubMed:7989485, ECO:0000269|PubMed:8045989,
FT                   ECO:0000269|PubMed:9253356, ECO:0000269|PubMed:9349581"
FT                   /id="VAR_011547"
FT   VARIANT         633
FT                   /note="D -> A (in hyperthyroidism; associated with
FT                   hyperfunctioning thyroid adenomas)"
FT                   /evidence="ECO:0000269|PubMed:9253356"
FT                   /id="VAR_011548"
FT   VARIANT         633
FT                   /note="D -> E (in HTNA; found in thyroid toxic nodules and
FT                   hyperfunctioning thyroid adenomas)"
FT                   /evidence="ECO:0000269|PubMed:10852462,
FT                   ECO:0000269|PubMed:11434721, ECO:0000269|PubMed:8045989,
FT                   ECO:0000269|PubMed:9253356"
FT                   /id="VAR_011549"
FT   VARIANT         633
FT                   /note="D -> H (in hyperthyroidism; found in toxic thyroid
FT                   nodules; associated with hyperfunctioning thyroid adenomas;
FT                   also in hyperfunctioning insular carcinoma; with severe
FT                   thyrotoxicosis; gain of function; dbSNP:rs28937584)"
FT                   /evidence="ECO:0000269|PubMed:11434721,
FT                   ECO:0000269|PubMed:9062474, ECO:0000269|PubMed:9253356"
FT                   /id="VAR_011550"
FT   VARIANT         633
FT                   /note="D -> Y (in hyperthyroidism; found in toxic thyroid
FT                   nodules; associated with hyperfunctioning thyroid
FT                   adenomas)"
FT                   /evidence="ECO:0000269|PubMed:11434721,
FT                   ECO:0000269|PubMed:8045989, ECO:0000269|PubMed:9253356"
FT                   /id="VAR_011551"
FT   VARIANT         639
FT                   /note="P -> A (found in toxic thyroid nodules)"
FT                   /evidence="ECO:0000269|PubMed:11434721"
FT                   /id="VAR_021500"
FT   VARIANT         639
FT                   /note="P -> S (in HTNA; gain of function)"
FT                   /evidence="ECO:0000269|PubMed:10199795"
FT                   /id="VAR_011552"
FT   VARIANT         647
FT                   /note="A -> V (in HTNA; found in non-adenomatous
FT                   hyperfunctioning nodules)"
FT                   /evidence="ECO:0000269|PubMed:10852462"
FT                   /id="VAR_011553"
FT   VARIANT         650
FT                   /note="N -> Y (in HTNA; gain of function)"
FT                   /evidence="ECO:0000269|PubMed:8636266"
FT                   /id="VAR_011554"
FT   VARIANT         656
FT                   /note="V -> F (found in toxic thyroid nodules)"
FT                   /evidence="ECO:0000269|PubMed:11434721"
FT                   /id="VAR_021501"
FT   VARIANT         658..661
FT                   /note="Missing (in hyperthyroidism; associated with
FT                   hyperfunctioning thyroid adenomas)"
FT                   /evidence="ECO:0000269|PubMed:9253356"
FT                   /id="VAR_011555"
FT   VARIANT         670
FT                   /note="N -> S (in HTNA; gain of function)"
FT                   /evidence="ECO:0000269|PubMed:8636266"
FT                   /id="VAR_011556"
FT   VARIANT         672
FT                   /note="C -> Y (in HTNA; gain of function)"
FT                   /evidence="ECO:0000269|PubMed:7920658"
FT                   /id="VAR_011557"
FT   VARIANT         677
FT                   /note="L -> V (in thyroid carcinoma; with thyrotoxicosis;
FT                   gain of function)"
FT                   /evidence="ECO:0000269|PubMed:10037070"
FT                   /id="VAR_011558"
FT   VARIANT         703
FT                   /note="A -> G"
FT                   /evidence="ECO:0000269|PubMed:10487707"
FT                   /id="VAR_011559"
FT   VARIANT         715
FT                   /note="N -> D (in papillary cancer)"
FT                   /evidence="ECO:0000269|PubMed:7647578"
FT                   /id="VAR_003576"
FT   VARIANT         720
FT                   /note="Q -> E"
FT                   /evidence="ECO:0000269|PubMed:10487707"
FT                   /id="VAR_011560"
FT   VARIANT         723
FT                   /note="K -> M (in papillary cancer)"
FT                   /evidence="ECO:0000269|PubMed:7647578"
FT                   /id="VAR_003577"
FT   VARIANT         727
FT                   /note="D -> E (may be a predisposing factor in toxic
FT                   multinodular goiter pathogenesis; activation of the cAMP
FT                   cascade does not differ from the wild-type;
FT                   dbSNP:rs1991517)"
FT                   /evidence="ECO:0000269|PubMed:10487707,
FT                   ECO:0000269|PubMed:10946859, ECO:0000269|PubMed:12508121,
FT                   ECO:0000269|PubMed:12589819, ECO:0000269|PubMed:12788902,
FT                   ECO:0000269|PubMed:2302212, ECO:0000269|PubMed:7647578"
FT                   /id="VAR_003578"
FT   MUTAGEN         283
FT                   /note="C->S: Abolishes cell surface expression."
FT                   /evidence="ECO:0000269|PubMed:11847099"
FT   MUTAGEN         385..387
FT                   /note="YDY->EDE: Inhibits intracellular cAMP accumulation."
FT                   /evidence="ECO:0000269|PubMed:11847099"
FT   MUTAGEN         385..387
FT                   /note="YDY->FDF: Abolishes sulfation. Inhibits
FT                   intracellular cAMP accumulation."
FT                   /evidence="ECO:0000269|PubMed:11847099"
FT   MUTAGEN         385
FT                   /note="Y->E: Reduces binding with thyrotropin. Inhibits
FT                   intracellular cAMP accumulation."
FT                   /evidence="ECO:0000269|PubMed:11847099,
FT                   ECO:0000305|PubMed:11847099"
FT   MUTAGEN         385
FT                   /note="Y->F: Reduces sulfation. Reduces binding with
FT                   thyrotropin. Inhibits intracellular cAMP accumulation."
FT                   /evidence="ECO:0000269|PubMed:11847099,
FT                   ECO:0000305|PubMed:11847099"
FT   MUTAGEN         387
FT                   /note="Y->E: No change in intracellular cAMP accumulation."
FT                   /evidence="ECO:0000269|PubMed:11847099"
FT   MUTAGEN         387
FT                   /note="Y->F: Reduces sulfation. No change in intracellular
FT                   cAMP accumulation."
FT                   /evidence="ECO:0000269|PubMed:11847099"
FT   CONFLICT        87
FT                   /note="V -> L (in Ref. 2; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        196..198
FT                   /note="AFN -> DFF (in Ref. 4; AAA70232)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        257
FT                   /note="T -> S (in Ref. 4; AAA70232)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        264
FT                   /note="P -> A (in Ref. 4; AAA70232)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        306..308
FT                   /note="MQS -> IET (in Ref. 4; AAA70232)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        528
FT                   /note="R -> A (in Ref. 4; AAA70232)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        601
FT                   /note="Y -> H (in Ref. 1; AAA36783)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        635
FT                   /note="I -> T (in Ref. 4; AAA70232)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        645
FT                   /note="L -> V (in Ref. 4; AAA70232)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        669
FT                   /note="L -> I (in Ref. 4; AAA70232)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        744
FT                   /note="N -> K (in Ref. 3; AAA61236)"
FT                   /evidence="ECO:0000305"
FT   STRAND          26..28
FT                   /evidence="ECO:0000244|PDB:2XWT"
FT   STRAND          30..33
FT                   /evidence="ECO:0000244|PDB:2XWT"
FT   TURN            35..37
FT                   /evidence="ECO:0000244|PDB:3G04"
FT   STRAND          38..41
FT                   /evidence="ECO:0000244|PDB:2XWT"
FT   STRAND          56..61
FT                   /evidence="ECO:0000244|PDB:2XWT"
FT   STRAND          65..67
FT                   /evidence="ECO:0000244|PDB:2XWT"
FT   TURN            69..74
FT                   /evidence="ECO:0000244|PDB:2XWT"
FT   STRAND          80..84
FT                   /evidence="ECO:0000244|PDB:2XWT"
FT   TURN            94..96
FT                   /evidence="ECO:0000244|PDB:2XWT"
FT   STRAND          97..99
FT                   /evidence="ECO:0000244|PDB:2XWT"
FT   STRAND          105..111
FT                   /evidence="ECO:0000244|PDB:2XWT"
FT   STRAND          121..123
FT                   /evidence="ECO:0000244|PDB:2XWT"
FT   STRAND          130..136
FT                   /evidence="ECO:0000244|PDB:2XWT"
FT   STRAND          152..160
FT                   /evidence="ECO:0000244|PDB:2XWT"
FT   TURN            169..174
FT                   /evidence="ECO:0000244|PDB:2XWT"
FT   STRAND          175..183
FT                   /evidence="ECO:0000244|PDB:2XWT"
FT   STRAND          190..192
FT                   /evidence="ECO:0000244|PDB:3G04"
FT   TURN            194..199
FT                   /evidence="ECO:0000244|PDB:2XWT"
FT   STRAND          201..206
FT                   /evidence="ECO:0000244|PDB:2XWT"
FT   TURN            218..223
FT                   /evidence="ECO:0000244|PDB:2XWT"
FT   STRAND          229..232
FT                   /evidence="ECO:0000244|PDB:2XWT"
FT   STRAND          250..253
FT                   /evidence="ECO:0000244|PDB:2XWT"
FT   CONFLICT        P16473-2:239
FT                   /note="L -> F (in Ref. 6; AAB24246)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        P16473-2:248
FT                   /note="R -> S (in Ref. 5; AAB23390 and 9; AAH09237/
FT                   AAI20974)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        P16473-2:251
FT                   /note="M -> T (in Ref. 5; AAB23390)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        P16473-3:269
FT                   /note="R -> S (in Ref. 9; AAI27629)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   764 AA;  86830 MW;  D2EE9CEBFD64A65F CRC64;
     MRPADLLQLV LLLDLPRDLG GMGCSSPPCE CHQEEDFRVT CKDIQRIPSL PPSTQTLKLI
     ETHLRTIPSH AFSNLPNISR IYVSIDVTLQ QLESHSFYNL SKVTHIEIRN TRNLTYIDPD
     ALKELPLLKF LGIFNTGLKM FPDLTKVYST DIFFILEITD NPYMTSIPVN AFQGLCNETL
     TLKLYNNGFT SVQGYAFNGT KLDAVYLNKN KYLTVIDKDA FGGVYSGPSL LDVSQTSVTA
     LPSKGLEHLK ELIARNTWTL KKLPLSLSFL HLTRADLSYP SHCCAFKNQK KIRGILESLM
     CNESSMQSLR QRKSVNALNS PLHQEYEENL GDSIVGYKEK SKFQDTHNNA HYYVFFEEQE
     DEIIGFGQEL KNPQEETLQA FDSHYDYTIC GDSEDMVCTP KSDEFNPCED IMGYKFLRIV
     VWFVSLLALL GNVFVLLILL TSHYKLNVPR FLMCNLAFAD FCMGMYLLLI ASVDLYTHSE
     YYNHAIDWQT GPGCNTAGFF TVFASELSVY TLTVITLERW YAITFAMRLD RKIRLRHACA
     IMVGGWVCCF LLALLPLVGI SSYAKVSICL PMDTETPLAL AYIVFVLTLN IVAFVIVCCC
     YVKIYITVRN PQYNPGDKDT KIAKRMAVLI FTDFICMAPI SFYALSAILN KPLITVSNSK
     ILLVLFYPLN SCANPFLYAI FTKAFQRDVF ILLSKFGICK RQAQAYRGQR VPPKNSTDIQ
     VQKVTHDMRQ GLHNMEDVYE LIENSHLTPK KQGQISEEYM QTVL
//
ID   S1PR2_HUMAN             Reviewed;         353 AA.
AC   O95136; Q86UN8;
DT   07-NOV-2003, integrated into UniProtKB/Swiss-Prot.
DT   07-NOV-2003, sequence version 2.
DT   12-AUG-2020, entry version 166.
DE   RecName: Full=Sphingosine 1-phosphate receptor 2;
DE            Short=S1P receptor 2;
DE            Short=S1P2;
DE   AltName: Full=Endothelial differentiation G-protein coupled receptor 5;
DE   AltName: Full=Sphingosine 1-phosphate receptor Edg-5;
DE            Short=S1P receptor Edg-5;
GN   Name=S1PR2; Synonyms=EDG5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RC   TISSUE=Fetal brain;
RX   PubMed=10617617; DOI=10.1074/jbc.275.1.288;
RA   An S., Zheng Y., Bleu T.;
RT   "Sphingosine 1-phosphate-induced cell proliferation, survival, and related
RT   signaling events mediated by G protein-coupled receptors Edg3 and Edg5.";
RL   J. Biol. Chem. 275:288-296(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (MAR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   VARIANTS DFNB68 PRO-108 AND CYS-140.
RX   PubMed=26805784; DOI=10.1016/j.ajhg.2015.12.004;
RG   University of Washington Center for Mendelian Genomics;
RA   Santos-Cortez R.L., Faridi R., Rehman A.U., Lee K., Ansar M., Wang X.,
RA   Morell R.J., Isaacson R., Belyantseva I.A., Dai H., Acharya A.,
RA   Qaiser T.A., Muhammad D., Ali R.A., Shams S., Hassan M.J., Shahzad S.,
RA   Raza S.I., Bashir Z.E., Smith J.D., Nickerson D.A., Bamshad M.J.,
RA   Riazuddin S., Ahmad W., Friedman T.B., Leal S.M.;
RT   "Autosomal-recessive hearing impairment due to rare missense variants
RT   within S1PR2.";
RL   Am. J. Hum. Genet. 98:331-338(2016).
RN   [5]
RP   FUNCTION.
RX   PubMed=29453251; DOI=10.1161/circulationaha.117.032398;
RA   Wang Y., Chen D., Zhang Y., Wang P., Zheng C., Zhang S., Yu B., Zhang L.,
RA   Zhao G., Ma B., Cai Z., Xie N., Huang S., Liu Z., Mo X., Guan Y., Wang X.,
RA   Fu Y., Ma D., Wang Y., Kong W.;
RT   "Novel Adipokine, FAM19A5, Inhibits Neointima Formation After Injury
RT   Through Sphingosine-1-Phosphate Receptor 2.";
RL   Circulation 138:48-63(2018).
CC   -!- FUNCTION: Receptor for the lysosphingolipid sphingosine 1-phosphate
CC       (S1P) (PubMed:10617617). S1P is a bioactive lysophospholipid that
CC       elicits diverse physiological effects on most types of cells and
CC       tissues (PubMed:10617617). When expressed in rat HTC4 hepatoma cells,
CC       is capable of mediating S1P-induced cell proliferation and suppression
CC       of apoptosis (PubMed:10617617). Receptor for the chemokine-like protein
CC       FAM19A5 (PubMed:29453251). Mediates the inhibitory effect of FAM19A5 on
CC       vascular smooth muscle cell proliferation and migration (By
CC       similarity). {ECO:0000250|UniProtKB:P47752,
CC       ECO:0000269|PubMed:10617617, ECO:0000269|PubMed:29453251}.
CC   -!- INTERACTION:
CC       O95136; P16144: ITGB4; NbExp=2; IntAct=EBI-10634606, EBI-948678;
CC       O95136; Q9JK11-1: Rtn4; Xeno; NbExp=2; IntAct=EBI-10634606, EBI-919989;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- DISEASE: Deafness, autosomal recessive, 68 (DFNB68) [MIM:610419]: A
CC       form of non-syndromic sensorineural hearing loss. Sensorineural
CC       deafness results from damage to the neural receptors of the inner ear,
CC       the nerve pathways to the brain, or the area of the brain that receives
CC       sound information. {ECO:0000269|PubMed:26805784}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF034780; AAC98919.1; -; mRNA.
DR   EMBL; AY262688; AAP20652.1; -; Genomic_DNA.
DR   EMBL; BC069598; AAH69598.1; -; mRNA.
DR   CCDS; CCDS12229.1; -.
DR   RefSeq; NP_004221.3; NM_004230.3.
DR   PDB; 1ZTI; Model; -; A=1-353.
DR   PDBsum; 1ZTI; -.
DR   SMR; O95136; -.
DR   BioGRID; 114708; 26.
DR   CORUM; O95136; -.
DR   DIP; DIP-60682N; -.
DR   IntAct; O95136; 26.
DR   STRING; 9606.ENSP00000466933; -.
DR   BindingDB; O95136; -.
DR   ChEMBL; CHEMBL2955; -.
DR   GuidetoPHARMACOLOGY; 276; -.
DR   GlyGen; O95136; 1 site.
DR   iPTMnet; O95136; -.
DR   PhosphoSitePlus; O95136; -.
DR   SwissPalm; O95136; -.
DR   BioMuta; S1PR2; -.
DR   jPOST; O95136; -.
DR   MassIVE; O95136; -.
DR   PaxDb; O95136; -.
DR   PeptideAtlas; O95136; -.
DR   PRIDE; O95136; -.
DR   ProteomicsDB; 50657; -.
DR   Antibodypedia; 65016; 299 antibodies.
DR   DNASU; 9294; -.
DR   Ensembl; ENST00000646641; ENSP00000496438; ENSG00000267534.
DR   GeneID; 9294; -.
DR   KEGG; hsa:9294; -.
DR   UCSC; uc002mnl.3; human.
DR   CTD; 9294; -.
DR   DisGeNET; 9294; -.
DR   EuPathDB; HostDB:ENSG00000267534.2; -.
DR   GeneCards; S1PR2; -.
DR   HGNC; HGNC:3169; S1PR2.
DR   HPA; ENSG00000267534; Low tissue specificity.
DR   MalaCards; S1PR2; -.
DR   MIM; 605111; gene.
DR   MIM; 610419; phenotype.
DR   neXtProt; NX_O95136; -.
DR   OpenTargets; ENSG00000267534; -.
DR   Orphanet; 90636; Autosomal recessive non-syndromic sensorineural deafness type DFNB.
DR   PharmGKB; PA162402353; -.
DR   eggNOG; ENOG502QVQY; Eukaryota.
DR   GeneTree; ENSGT00970000193365; -.
DR   HOGENOM; CLU_047979_1_0_1; -.
DR   InParanoid; O95136; -.
DR   KO; K04292; -.
DR   OMA; DYACPVR; -.
DR   OrthoDB; 981486at2759; -.
DR   PhylomeDB; O95136; -.
DR   PathwayCommons; O95136; -.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-419408; Lysosphingolipid and LPA receptors.
DR   SIGNOR; O95136; -.
DR   BioGRID-ORCS; 9294; 3 hits in 871 CRISPR screens.
DR   ChiTaRS; S1PR2; human.
DR   GeneWiki; S1PR2; -.
DR   GenomeRNAi; 9294; -.
DR   Pharos; O95136; Tchem.
DR   PRO; PR:O95136; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; O95136; protein.
DR   Bgee; ENSG00000267534; Expressed in layer of synovial tissue and 194 other tissues.
DR   ExpressionAtlas; O95136; baseline and differential.
DR   Genevisible; O95136; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0001664; F:G protein-coupled receptor binding; IPI:UniProtKB.
DR   GO; GO:0005178; F:integrin binding; IPI:UniProtKB.
DR   GO; GO:0008289; F:lipid binding; TAS:ProtInc.
DR   GO; GO:0038036; F:sphingosine-1-phosphate receptor activity; IMP:UniProtKB.
DR   GO; GO:0031532; P:actin cytoskeleton reorganization; IMP:UniProtKB.
DR   GO; GO:0000187; P:activation of MAPK activity; TAS:ProtInc.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0046847; P:filopodium assembly; IMP:UniProtKB.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0090394; P:negative regulation of excitatory postsynaptic potential; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; TAS:ProtInc.
DR   GO; GO:1903142; P:positive regulation of establishment of endothelial barrier; IMP:UniProtKB.
DR   GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; IMP:UniProtKB.
DR   GO; GO:0019222; P:regulation of metabolic process; IBA:GO_Central.
DR   GO; GO:0003376; P:sphingosine-1-phosphate receptor signaling pathway; IMP:UniProtKB.
DR   InterPro; IPR004063; EDG5_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR004061; S1P_rcpt.
DR   PANTHER; PTHR22750:SF17; PTHR22750:SF17; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01525; EDG5RECEPTOR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01523; S1PRECEPTOR.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Deafness; Disease mutation;
KW   G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane;
KW   Non-syndromic deafness; Palmitate; Receptor; Reference proteome;
KW   Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..353
FT                   /note="Sphingosine 1-phosphate receptor 2"
FT                   /id="PRO_0000069427"
FT   TOPO_DOM        1..34
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        35..59
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        60..66
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        67..95
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        96..109
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        110..128
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        129..147
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        148..173
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        174..189
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        190..210
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        211..233
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        234..255
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        256..271
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        272..292
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        293..353
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   LIPID           305
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        19
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VARIANT         108
FT                   /note="R -> P (in DFNB68; dbSNP:rs869312749)"
FT                   /evidence="ECO:0000269|PubMed:26805784"
FT                   /id="VAR_076391"
FT   VARIANT         140
FT                   /note="Y -> C (in DFNB68; dbSNP:rs869312750)"
FT                   /evidence="ECO:0000269|PubMed:26805784"
FT                   /id="VAR_076392"
FT   CONFLICT        113
FT                   /note="F -> S (in Ref. 1; AAC98919)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        318
FT                   /note="G -> V (in Ref. 1; AAC98919)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   353 AA;  38867 MW;  8E37084284ABF7E8 CRC64;
     MGSLYSEYLN PNKVQEHYNY TKETLETQET TSRQVASAFI VILCCAIVVE NLLVLIAVAR
     NSKFHSAMYL FLGNLAASDL LAGVAFVANT LLSGSVTLRL TPVQWFAREG SAFITLSASV
     FSLLAIAIER HVAIAKVKLY GSDKSCRMLL LIGASWLISL VLGGLPILGW NCLGHLEACS
     TVLPLYAKHY VLCVVTIFSI ILLAIVALYV RIYCVVRSSH ADMAAPQTLA LLKTVTIVLG
     VFIVCWLPAF SILLLDYACP VHSCPILYKA HYFFAVSTLN SLLNPVIYTW RSRDLRREVL
     RPLQCWRPGV GVQGRRRGGT PGHHLLPLRS SSSLERGMHM PTSPTFLEGN TVV
//
ID   VIPR2_HUMAN             Reviewed;         438 AA.
AC   P41587; Q13053; Q15870; Q53Y09; Q6ZN22; Q9UCW0;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 2.
DT   12-AUG-2020, entry version 177.
DE   RecName: Full=Vasoactive intestinal polypeptide receptor 2;
DE            Short=VIP-R-2;
DE   AltName: Full=Helodermin-preferring VIP receptor;
DE   AltName: Full=Pituitary adenylate cyclase-activating polypeptide type III receptor;
DE            Short=PACAP type III receptor;
DE            Short=PACAP-R-3;
DE            Short=PACAP-R3;
DE   AltName: Full=VPAC2;
DE   Flags: Precursor;
GN   Name=VIPR2; Synonyms=VIP2R;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1).
RX   PubMed=7811244; DOI=10.1006/bbrc.1994.2852;
RA   Svoboda M., Tastenoy M., van Rampelbergh J., Goossens J.-F., Neef P.,
RA   Waelbroeck M., Robberecht P.;
RT   "Molecular cloning and functional characterization of a human VIP receptor
RT   from SUP-T1 lymphoblasts.";
RL   Biochem. Biophys. Res. Commun. 205:1617-1624(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8938447; DOI=10.1006/geno.1996.0569;
RA   Mackay M., Fantes J., Scherer S., Boyle S., West K., Tsui L.-C.,
RA   Belloni E., Lutz E., van Heyningen V., Harmar A.J.;
RT   "Chromosomal localization in mouse and human of the vasoactive intestinal
RT   peptide receptor type 2 gene: a possible contributor to the
RT   holoprosencephaly 3 phenotype.";
RL   Genomics 37:345-353(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Adipose tissue;
RX   PubMed=8933357; DOI=10.1046/j.1365-2826.1996.05191.x;
RA   Wei Y., Mojsov S.;
RT   "Tissue specific expression of different human receptor types for pituitary
RT   adenylate cyclase activating polypeptide and vasoactive intestinal
RT   polypeptide: implications for their role in human physiology.";
RL   J. Neuroendocrinol. 8:811-817(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1).
RX   PubMed=10481065; DOI=10.1016/s0014-5793(99)01135-7;
RA   Lutz E.M., Shen S., Mackay M., West K., Harmar A.J.;
RT   "Structure of the human VIP2R gene for vasoactive intestinal peptide type 2
RT   receptor.";
RL   FEBS Lett. 458:197-203(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Heart;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R., Wylie K.,
RA   Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E., Fewell G.A.,
RA   Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H., Sun H.,
RA   Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A., Vanbrunt A.,
RA   Nguyen C., Du F., Lamar B., Courtney L., Kalicki J., Ozersky P.,
RA   Bielicki L., Scott K., Holmes A., Harkins R., Harris A., Strong C.M.,
RA   Hou S., Tomlinson C., Dauphin-Kohlberg S., Kozlowicz-Reilly A., Leonard S.,
RA   Rohlfing T., Rock S.M., Tin-Wollam A.-M., Abbott A., Minx P., Maupin R.,
RA   Strowmatt C., Latreille P., Miller N., Johnson D., Murray J.,
RA   Woessner J.P., Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W.,
RA   Spieth J., Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Bedell J.A.,
RA   Mardis E.R., Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K., Simms E.,
RA   Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S., Baertsch R.A.,
RA   Brent M.R., Keibler E., Flicek P., Bork P., Suyama M., Bailey J.A.,
RA   Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R., Eddy S.R.,
RA   McPherson J.D., Olson M.V., Eichler E.E., Green E.D., Waterston R.H.,
RA   Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D.,
RA   Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S.,
RA   Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R.,
RA   Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N.,
RA   Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E.,
RA   Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R.,
RA   Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T.,
RA   Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W.,
RA   Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A.,
RA   Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X.,
RA   Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E.,
RA   Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J.,
RA   Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 244-318 (ISOFORM 1), FUNCTION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=T-cell;
RX   PubMed=8926282; DOI=10.1007/bf01540969;
RA   Xia M., Sreedharan S.P., Goetzl E.J.;
RT   "Predominant expression of type II vasoactive intestinal peptide receptors
RT   by human T lymphoblastoma cells: transduction of both Ca2+ and cyclic AMP
RT   signals.";
RL   J. Clin. Immunol. 16:21-30(1996).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 26-118, AND DISULFIDE BONDS.
RG   Structural genomics consortium (SGC);
RT   "Crystal structure of the extracellular domain of human vasoactive
RT   intestinal polypeptide receptor 2.";
RL   Submitted (MAR-2010) to the PDB data bank.
CC   -!- FUNCTION: This is a receptor for VIP as well as PACAP-38 and -27, the
CC       activity of this receptor is mediated by G proteins which activate
CC       adenylyl cyclase. Can be coupled to phospholipase C.
CC       {ECO:0000269|PubMed:8926282}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P41587-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P41587-2; Sequence=VSP_056684, VSP_056685;
CC   -!- TISSUE SPECIFICITY: Expressed in CD4+ T-cells, but not in CD8+ T-cells.
CC       Expressed in the T-cell lines Jurkat, Peer, MOLT-4, HSB, YT and SUP-T1,
CC       but not in the T-cell lines HARRIS and HuT 78.
CC       {ECO:0000269|PubMed:8926282}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 2 family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L36566; AAC37569.1; -; mRNA.
DR   EMBL; L40764; AAC41756.1; -; Genomic_DNA.
DR   EMBL; U18810; AAC50872.1; -; mRNA.
DR   EMBL; X95097; CAA64474.1; -; mRNA.
DR   EMBL; Y18423; CAB41899.1; -; Genomic_DNA.
DR   EMBL; Y18424; CAB41899.1; JOINED; Genomic_DNA.
DR   EMBL; Y18425; CAB41899.1; JOINED; Genomic_DNA.
DR   EMBL; Y18426; CAB41899.1; JOINED; Genomic_DNA.
DR   EMBL; Y18427; CAB41899.1; JOINED; Genomic_DNA.
DR   EMBL; Y18428; CAB41899.1; JOINED; Genomic_DNA.
DR   EMBL; Y18429; CAB41899.1; JOINED; Genomic_DNA.
DR   EMBL; Y18430; CAB41899.1; JOINED; Genomic_DNA.
DR   EMBL; Y18431; CAB41899.1; JOINED; Genomic_DNA.
DR   EMBL; BT007118; AAP35782.1; -; mRNA.
DR   EMBL; AK131406; BAD18553.1; -; mRNA.
DR   EMBL; AC004863; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC007269; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AF027390; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH236954; EAL23936.1; -; Genomic_DNA.
DR   EMBL; CH471149; EAX04596.1; -; Genomic_DNA.
DR   EMBL; BC010569; AAH10569.1; -; mRNA.
DR   CCDS; CCDS5950.1; -. [P41587-1]
DR   CCDS; CCDS78295.1; -. [P41587-2]
DR   PIR; G02822; G02822.
DR   RefSeq; NP_001291451.1; NM_001304522.1.
DR   RefSeq; NP_001295188.1; NM_001308259.1. [P41587-2]
DR   RefSeq; NP_003373.2; NM_003382.4. [P41587-1]
DR   PDB; 2X57; X-ray; 2.10 A; A/B/C=26-118.
DR   PDBsum; 2X57; -.
DR   SMR; P41587; -.
DR   BioGRID; 113275; 103.
DR   IntAct; P41587; 96.
DR   MINT; P41587; -.
DR   STRING; 9606.ENSP00000262178; -.
DR   BindingDB; P41587; -.
DR   ChEMBL; CHEMBL4532; -.
DR   GuidetoPHARMACOLOGY; 372; -.
DR   GlyGen; P41587; 3 sites.
DR   iPTMnet; P41587; -.
DR   PhosphoSitePlus; P41587; -.
DR   BioMuta; VIPR2; -.
DR   DMDM; 2506490; -.
DR   MassIVE; P41587; -.
DR   PaxDb; P41587; -.
DR   PeptideAtlas; P41587; -.
DR   PRIDE; P41587; -.
DR   ProteomicsDB; 55470; -. [P41587-1]
DR   ProteomicsDB; 67967; -.
DR   Antibodypedia; 18979; 318 antibodies.
DR   DNASU; 7434; -.
DR   Ensembl; ENST00000262178; ENSP00000262178; ENSG00000106018. [P41587-1]
DR   Ensembl; ENST00000377633; ENSP00000366860; ENSG00000106018. [P41587-2]
DR   GeneID; 7434; -.
DR   KEGG; hsa:7434; -.
DR   UCSC; uc064jts.1; human. [P41587-1]
DR   CTD; 7434; -.
DR   DisGeNET; 7434; -.
DR   EuPathDB; HostDB:ENSG00000106018.13; -.
DR   GeneCards; VIPR2; -.
DR   HGNC; HGNC:12695; VIPR2.
DR   HPA; ENSG00000106018; Low tissue specificity.
DR   MalaCards; VIPR2; -.
DR   MIM; 601970; gene.
DR   neXtProt; NX_P41587; -.
DR   OpenTargets; ENSG00000106018; -.
DR   PharmGKB; PA37314; -.
DR   eggNOG; KOG4564; Eukaryota.
DR   GeneTree; ENSGT00940000158089; -.
DR   HOGENOM; CLU_002753_4_4_1; -.
DR   InParanoid; P41587; -.
DR   KO; K04590; -.
DR   OMA; KACTGVW; -.
DR   OrthoDB; 651627at2759; -.
DR   PhylomeDB; P41587; -.
DR   TreeFam; TF315710; -.
DR   PathwayCommons; P41587; -.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-420092; Glucagon-type ligand receptors.
DR   Reactome; R-HSA-9660821; ADORA2B mediated anti-inflammatory cytokines production.
DR   BioGRID-ORCS; 7434; 2 hits in 870 CRISPR screens.
DR   ChiTaRS; VIPR2; human.
DR   GeneWiki; VIPR2; -.
DR   GenomeRNAi; 7434; -.
DR   Pharos; P41587; Tchem.
DR   PRO; PR:P41587; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; P41587; protein.
DR   Bgee; ENSG00000106018; Expressed in esophagus and 150 other tissues.
DR   ExpressionAtlas; P41587; baseline and differential.
DR   Genevisible; P41587; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0008528; F:G protein-coupled peptide receptor activity; IBA:GO_Central.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; TAS:ProtInc.
DR   GO; GO:0017046; F:peptide hormone binding; IBA:GO_Central.
DR   GO; GO:0004999; F:vasoactive intestinal polypeptide receptor activity; IBA:GO_Central.
DR   GO; GO:0007190; P:activation of adenylate cyclase activity; IEA:Ensembl.
DR   GO; GO:0007188; P:adenylate cyclase-modulating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IEA:InterPro.
DR   GO; GO:0007267; P:cell-cell signaling; TAS:ProtInc.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0048662; P:negative regulation of smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   Gene3D; 4.10.1240.10; -; 1.
DR   InterPro; IPR017981; GPCR_2-like.
DR   InterPro; IPR036445; GPCR_2_extracell_dom_sf.
DR   InterPro; IPR001879; GPCR_2_extracellular_dom.
DR   InterPro; IPR000832; GPCR_2_secretin-like.
DR   InterPro; IPR017983; GPCR_2_secretin-like_CS.
DR   InterPro; IPR001571; GPCR_2_VIP_rcpt.
DR   InterPro; IPR002284; GPCR_2_VIP_rcpt_2.
DR   PANTHER; PTHR45620:SF22; PTHR45620:SF22; 1.
DR   Pfam; PF00002; 7tm_2; 1.
DR   Pfam; PF02793; HRM; 1.
DR   PRINTS; PR00249; GPCRSECRETIN.
DR   PRINTS; PR00491; VASOACTVEIPR.
DR   PRINTS; PR01155; VIP2RECEPTOR.
DR   SMART; SM00008; HormR; 1.
DR   SUPFAM; SSF111418; SSF111418; 1.
DR   PROSITE; PS00649; G_PROTEIN_RECEP_F2_1; 1.
DR   PROSITE; PS00650; G_PROTEIN_RECEP_F2_2; 1.
DR   PROSITE; PS50227; G_PROTEIN_RECEP_F2_3; 1.
DR   PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Polymorphism; Receptor;
KW   Reference proteome; Signal; Transducer; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..23
FT                   /evidence="ECO:0000255"
FT   CHAIN           24..438
FT                   /note="Vasoactive intestinal polypeptide receptor 2"
FT                   /id="PRO_0000012860"
FT   TOPO_DOM        24..126
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        127..151
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        152..158
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        159..178
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        179..203
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        204..227
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        228..240
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        241..262
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        263..279
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        280..303
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        304..328
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        329..348
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        349..360
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        361..380
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        381..438
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        58
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        88
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        92
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        38..61
FT                   /evidence="ECO:0000269|Ref.12"
FT   DISULFID        52..93
FT                   /evidence="ECO:0000269|Ref.12"
FT   DISULFID        75..109
FT                   /evidence="ECO:0000269|Ref.12"
FT   DISULFID        202..271
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         1..103
FT                   /note="MRTLLPPALLTCWLLAPVNSIHPECRFHLEIQEEETKCAELLRSQTEKHKAC
FT                   SGVWDNITCWRPANVGETVTVPCPKVFSNFYSKAGNISKNCTSDGWSETFP -> MPLW
FT                   EAPSDHPANPPATLQGHTSLPGCQEEPARDPQSGLPQITSESSSFSEGSLPSWSSGPAG
FT                   AKLNASHEGIGSSSDGNGDSKAATERVVSAMDTVRRKHPE (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056684"
FT   VAR_SEQ         104..119
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056685"
FT   VARIANT         39
FT                   /note="A -> T (in dbSNP:rs1062609)"
FT                   /id="VAR_011811"
FT   VARIANT         412
FT                   /note="R -> H (in dbSNP:rs1042620)"
FT                   /id="VAR_011812"
FT   CONFLICT        424
FT                   /note="G -> A (in Ref. 1; AAC37569/AAC41756 and 3;
FT                   AAC50872)"
FT                   /evidence="ECO:0000305"
FT   HELIX           26..44
FT                   /evidence="ECO:0000244|PDB:2X57"
FT   TURN            45..47
FT                   /evidence="ECO:0000244|PDB:2X57"
FT   STRAND          55..57
FT                   /evidence="ECO:0000244|PDB:2X57"
FT   STRAND          60..62
FT                   /evidence="ECO:0000244|PDB:2X57"
FT   STRAND          70..74
FT                   /evidence="ECO:0000244|PDB:2X57"
FT   HELIX           77..82
FT                   /evidence="ECO:0000244|PDB:2X57"
FT   STRAND          83..85
FT                   /evidence="ECO:0000244|PDB:2X57"
FT   STRAND          88..94
FT                   /evidence="ECO:0000244|PDB:2X57"
FT   HELIX           105..109
FT                   /evidence="ECO:0000244|PDB:2X57"
SQ   SEQUENCE   438 AA;  49479 MW;  265A43A70BE09699 CRC64;
     MRTLLPPALL TCWLLAPVNS IHPECRFHLE IQEEETKCAE LLRSQTEKHK ACSGVWDNIT
     CWRPANVGET VTVPCPKVFS NFYSKAGNIS KNCTSDGWSE TFPDFVDACG YSDPEDESKI
     TFYILVKAIY TLGYSVSLMS LATGSIILCL FRKLHCTRNY IHLNLFLSFI LRAISVLVKD
     DVLYSSSGTL HCPDQPSSWV GCKLSLVFLQ YCIMANFFWL LVEGLYLHTL LVAMLPPRRC
     FLAYLLIGWG LPTVCIGAWT AARLYLEDTG CWDTNDHSVP WWVIRIPILI SIIVNFVLFI
     SIIRILLQKL TSPDVGGNDQ SQYKRLAKST LLLIPLFGVH YMVFAVFPIS ISSKYQILFE
     LCLGSFQGLV VAVLYCFLNS EVQCELKRKW RSRCPTPSAS RDYRVCGSSF SRNGSEGALQ
     FHRGSRAQSF LQTETSVI
//
ID   RXFP1_HUMAN             Reviewed;         757 AA.
AC   Q9HBX9; B4DHD1; B4DTV2; Q2M215; Q3KU24; Q3KU25; Q3KU26;
DT   06-JUN-2002, integrated into UniProtKB/Swiss-Prot.
DT   04-DEC-2007, sequence version 2.
DT   12-AUG-2020, entry version 177.
DE   RecName: Full=Relaxin receptor 1;
DE   AltName: Full=Leucine-rich repeat-containing G-protein coupled receptor 7;
DE   AltName: Full=Relaxin family peptide receptor 1;
GN   Name=RXFP1; Synonyms=LGR7;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND MUTAGENESIS OF ASP-637.
RX   PubMed=10935549; DOI=10.1210/mend.14.8.0510;
RA   Hsu S.Y., Kudo M., Chen T., Nakabayashi K., Bhalla A., van der Spek P.J.,
RA   van Duin M., Hsueh A.J.W.;
RT   "The three subfamilies of leucine-rich repeat-containing G protein-coupled
RT   receptors (LGR): identification of LGR6 and LGR7 and the signaling
RT   mechanism for LGR7.";
RL   Mol. Endocrinol. 14:1257-1271(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2; 3 AND 4), SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=16051677; DOI=10.1093/molehr/gah205;
RA   Muda M., He C., Martini P.G.V., Ferraro T., Layfield S., Taylor D.,
RA   Chevrier C., Schweickhardt R., Kelton C., Ryan P.L., Bathgate R.A.D.;
RT   "Splice variants of the relaxin and INSL3 receptors reveal unanticipated
RT   molecular complexity.";
RL   Mol. Hum. Reprod. 11:591-600(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2 AND 5).
RC   TISSUE=Brain, and Placenta;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain cortex;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   CHARACTERIZATION.
RX   PubMed=11517286; DOI=10.1093/molehr/7.9.799;
RA   Bartsch O., Bartlick B., Ivell R.;
RT   "Relaxin signalling links tyrosine phosphorylation to phosphodiesterase and
RT   adenylyl cyclase activity.";
RL   Mol. Hum. Reprod. 7:799-809(2001).
RN   [8]
RP   INTERACTION WITH RLN3.
RX   PubMed=12506116; DOI=10.1074/jbc.m212457200;
RA   Sudo S., Kumagai J., Nishi S., Layfield S., Ferraro T., Bathgate R.A.D.,
RA   Hsueh A.J.W.;
RT   "H3 relaxin is a specific ligand for LGR7 and activates the receptor by
RT   interacting with both the ectodomain and the exoloop 2.";
RL   J. Biol. Chem. 278:7855-7862(2003).
RN   [9]
RP   GLYCOSYLATION AT ASN-36; ASN-127; ASN-264; ASN-272; ASN-325 AND ASN-368.
RX   PubMed=18533687; DOI=10.1021/bi800535b;
RA   Yan Y., Scott D.J., Wilkinson T.N., Ji J., Tregear G.W., Bathgate R.A.;
RT   "Identification of the N-linked glycosylation sites of the human relaxin
RT   receptor and effect of glycosylation on receptor function.";
RL   Biochemistry 47:6953-6968(2008).
RN   [10]
RP   INTERACTION WITH C1QTNF8.
RX   PubMed=24014093; DOI=10.1002/path.4257;
RA   Glogowska A., Kunanuvat U., Stetefeld J., Patel T.R., Thanasupawat T.,
RA   Krcek J., Weber E., Wong G.W., Del Bigio M.R., Hoang-Vu C.,
RA   Hombach-Klonisch S., Klonisch T.;
RT   "C1q-tumour necrosis factor-related protein 8 (CTRP8) is a novel
RT   interaction partner of relaxin receptor RXFP1 in human brain cancer
RT   cells.";
RL   J. Pathol. 231:466-479(2013).
RN   [11]
RP   STRUCTURE BY NMR OF 23-63 IN COMPLEX WITH CALCIUM IONS.
RX   PubMed=17148455; DOI=10.1074/jbc.m609526200;
RA   Hopkins E.J., Layfield S., Ferraro T., Bathgate R.A.D., Gooley P.R.;
RT   "The NMR solution structure of the relaxin (RXFP1) receptor lipoprotein
RT   receptor class A module and identification of key residues in the N-
RT   terminal region of the module that mediate receptor activation.";
RL   J. Biol. Chem. 282:4172-4184(2007).
CC   -!- FUNCTION: Receptor for relaxins. The activity of this receptor is
CC       mediated by G proteins leading to stimulation of adenylate cyclase and
CC       an increase of cAMP. Binding of the ligand may also activate a tyrosine
CC       kinase pathway that inhibits the activity of a phosphodiesterase that
CC       degrades cAMP.
CC   -!- SUBUNIT: Interacts with C1QTNF8. {ECO:0000269|PubMed:24014093}.
CC   -!- INTERACTION:
CC       Q9HBX9; P24588: AKAP5; NbExp=2; IntAct=EBI-8088969, EBI-703640;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:16051677};
CC       Multi-pass membrane protein {ECO:0000269|PubMed:16051677}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=Q9HBX9-1; Sequence=Displayed;
CC       Name=2; Synonyms=LGR7.10;
CC         IsoId=Q9HBX9-2; Sequence=VSP_001984;
CC       Name=3; Synonyms=LGR7.1;
CC         IsoId=Q9HBX9-3; Sequence=VSP_029877, VSP_029878;
CC       Name=4; Synonyms=LGR7.2;
CC         IsoId=Q9HBX9-4; Sequence=VSP_029879;
CC       Name=5;
CC         IsoId=Q9HBX9-5; Sequence=VSP_054375, VSP_054376;
CC   -!- TISSUE SPECIFICITY: Expressed in the brain, kidney, testis, placenta,
CC       uterus, ovary, adrenal, prostate, skin and heart. Not detected in
CC       spleen. {ECO:0000269|PubMed:16051677}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF190500; AAG17167.1; -; mRNA.
DR   EMBL; AY899848; AAX85196.1; -; mRNA.
DR   EMBL; AY899849; AAX85197.1; -; mRNA.
DR   EMBL; AY899850; AAX85198.1; -; mRNA.
DR   EMBL; AK295040; BAG58092.1; -; mRNA.
DR   EMBL; AK300379; BAG62114.1; -; mRNA.
DR   EMBL; AC019341; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC107056; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC107219; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC108017; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC121161; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC125489; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471056; EAX04856.1; -; Genomic_DNA.
DR   EMBL; BC112142; AAI12143.1; -; mRNA.
DR   EMBL; BC113617; AAI13618.1; -; mRNA.
DR   CCDS; CCDS43276.1; -. [Q9HBX9-1]
DR   CCDS; CCDS58929.1; -. [Q9HBX9-4]
DR   CCDS; CCDS58930.1; -. [Q9HBX9-2]
DR   RefSeq; NP_001240657.1; NM_001253728.1. [Q9HBX9-2]
DR   RefSeq; NP_001240658.1; NM_001253729.1. [Q9HBX9-4]
DR   RefSeq; NP_067647.2; NM_021634.3. [Q9HBX9-1]
DR   PDB; 2JM4; NMR; -; A=23-63.
DR   PDB; 2M7P; NMR; -; A=28-39.
DR   PDBsum; 2JM4; -.
DR   PDBsum; 2M7P; -.
DR   SMR; Q9HBX9; -.
DR   BioGRID; 121891; 87.
DR   IntAct; Q9HBX9; 5.
DR   MINT; Q9HBX9; -.
DR   STRING; 9606.ENSP00000405841; -.
DR   BindingDB; Q9HBX9; -.
DR   ChEMBL; CHEMBL1293316; -.
DR   GuidetoPHARMACOLOGY; 351; -.
DR   GlyGen; Q9HBX9; 6 sites.
DR   iPTMnet; Q9HBX9; -.
DR   PhosphoSitePlus; Q9HBX9; -.
DR   BioMuta; RXFP1; -.
DR   DMDM; 166209887; -.
DR   MassIVE; Q9HBX9; -.
DR   MaxQB; Q9HBX9; -.
DR   PaxDb; Q9HBX9; -.
DR   PeptideAtlas; Q9HBX9; -.
DR   PRIDE; Q9HBX9; -.
DR   ProteomicsDB; 4211; -.
DR   ProteomicsDB; 81607; -. [Q9HBX9-1]
DR   ProteomicsDB; 81608; -. [Q9HBX9-2]
DR   ProteomicsDB; 81609; -. [Q9HBX9-3]
DR   ProteomicsDB; 81610; -. [Q9HBX9-4]
DR   ABCD; Q9HBX9; 9 sequenced antibodies.
DR   Antibodypedia; 7543; 340 antibodies.
DR   DNASU; 59350; -.
DR   Ensembl; ENST00000307765; ENSP00000303248; ENSG00000171509. [Q9HBX9-1]
DR   Ensembl; ENST00000343542; ENSP00000345889; ENSG00000171509. [Q9HBX9-4]
DR   Ensembl; ENST00000470033; ENSP00000420712; ENSG00000171509. [Q9HBX9-2]
DR   Ensembl; ENST00000471616; ENSP00000434475; ENSG00000171509. [Q9HBX9-3]
DR   GeneID; 59350; -.
DR   KEGG; hsa:59350; -.
DR   UCSC; uc003ipz.4; human. [Q9HBX9-1]
DR   CTD; 59350; -.
DR   DisGeNET; 59350; -.
DR   EuPathDB; HostDB:ENSG00000171509.15; -.
DR   GeneCards; RXFP1; -.
DR   HGNC; HGNC:19718; RXFP1.
DR   HPA; ENSG00000171509; Tissue enhanced (brain, placenta).
DR   MIM; 606654; gene.
DR   neXtProt; NX_Q9HBX9; -.
DR   OpenTargets; ENSG00000171509; -.
DR   PharmGKB; PA134868312; -.
DR   eggNOG; KOG0619; Eukaryota.
DR   eggNOG; KOG2087; Eukaryota.
DR   GeneTree; ENSGT00940000158241; -.
DR   HOGENOM; CLU_1431019_0_0_1; -.
DR   InParanoid; Q9HBX9; -.
DR   KO; K04306; -.
DR   PhylomeDB; Q9HBX9; -.
DR   TreeFam; TF326185; -.
DR   PathwayCommons; Q9HBX9; -.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-444821; Relaxin receptors.
DR   Reactome; R-HSA-9660821; ADORA2B mediated anti-inflammatory cytokines production.
DR   SIGNOR; Q9HBX9; -.
DR   BioGRID-ORCS; 59350; 5 hits in 864 CRISPR screens.
DR   ChiTaRS; RXFP1; human.
DR   EvolutionaryTrace; Q9HBX9; -.
DR   GeneWiki; Relaxin/insulin-like_family_peptide_receptor_1; -.
DR   GenomeRNAi; 59350; -.
DR   Pharos; Q9HBX9; Tchem.
DR   PRO; PR:Q9HBX9; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; Q9HBX9; protein.
DR   Bgee; ENSG00000171509; Expressed in endometrium and 114 other tissues.
DR   ExpressionAtlas; Q9HBX9; baseline and differential.
DR   Genevisible; Q9HBX9; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0008528; F:G protein-coupled peptide receptor activity; IBA:GO_Central.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IDA:MGI.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0007190; P:activation of adenylate cyclase activity; IBA:GO_Central.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0009755; P:hormone-mediated signaling pathway; IBA:GO_Central.
DR   CDD; cd00112; LDLa; 1.
DR   Gene3D; 3.80.10.10; -; 2.
DR   Gene3D; 4.10.400.10; -; 1.
DR   IDEAL; IID00681; -.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR036055; LDL_receptor-like_sf.
DR   InterPro; IPR023415; LDLR_class-A_CS.
DR   InterPro; IPR002172; LDrepeatLR_classA_rpt.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR003591; Leu-rich_rpt_typical-subtyp.
DR   InterPro; IPR032675; LRR_dom_sf.
DR   InterPro; IPR008112; Relaxin_rcpt.
DR   Pfam; PF00001; 7tm_1; 1.
DR   Pfam; PF00057; Ldl_recept_a; 1.
DR   Pfam; PF13855; LRR_8; 2.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01739; RELAXINR.
DR   SMART; SM00192; LDLa; 1.
DR   SMART; SM00369; LRR_TYP; 9.
DR   SUPFAM; SSF57424; SSF57424; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
DR   PROSITE; PS01209; LDLRA_1; 1.
DR   PROSITE; PS50068; LDLRA_2; 1.
DR   PROSITE; PS51450; LRR; 10.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Leucine-rich repeat; Membrane;
KW   Metal-binding; Receptor; Reference proteome; Repeat; Transducer;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..757
FT                   /note="Relaxin receptor 1"
FT                   /id="PRO_0000069700"
FT   TOPO_DOM        1..409
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        410..430
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        431..443
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        444..464
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        465..486
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        487..507
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        508..527
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        528..548
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        549..577
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        578..598
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        599..629
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        630..650
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        651
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        652..672
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        673..757
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          26..63
FT                   /note="LDL-receptor class A"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00124"
FT   DOMAIN          91..127
FT                   /note="LRRNT"
FT   REPEAT          151..172
FT                   /note="LRR 1"
FT   REPEAT          175..196
FT                   /note="LRR 2"
FT   REPEAT          199..220
FT                   /note="LRR 3"
FT   REPEAT          223..244
FT                   /note="LRR 4"
FT   REPEAT          248..269
FT                   /note="LRR 5"
FT   REPEAT          272..293
FT                   /note="LRR 6"
FT   REPEAT          296..317
FT                   /note="LRR 7"
FT   REPEAT          320..341
FT                   /note="LRR 8"
FT   REPEAT          344..365
FT                   /note="LRR 9"
FT   METAL           45
FT                   /note="Calcium; via carbonyl oxygen"
FT   METAL           48
FT                   /note="Calcium"
FT   METAL           50
FT                   /note="Calcium; via carbonyl oxygen"
FT   METAL           52
FT                   /note="Calcium"
FT   METAL           58
FT                   /note="Calcium"
FT   METAL           59
FT                   /note="Calcium"
FT   CARBOHYD        36
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:18533687"
FT   CARBOHYD        127
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:18533687"
FT   CARBOHYD        264
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:18533687"
FT   CARBOHYD        272
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:18533687"
FT   CARBOHYD        325
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:18533687"
FT   CARBOHYD        368
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:18533687"
FT   DISULFID        27..40
FT   DISULFID        34..53
FT   DISULFID        47..62
FT   DISULFID        485..563
FT   VAR_SEQ         1..81
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_054375"
FT   VAR_SEQ         63..96
FT                   /note="GDNNGWSLQFDKYFASYYKMTSQYPFEAETPECL -> V (in isoform
FT                   2)"
FT                   /evidence="ECO:0000303|PubMed:10935549,
FT                   ECO:0000303|PubMed:14702039, ECO:0000303|PubMed:16051677"
FT                   /id="VSP_001984"
FT   VAR_SEQ         180..189
FT                   /note="YLSHNRITFL -> SRAVKDGSEK (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:16051677"
FT                   /id="VSP_029877"
FT   VAR_SEQ         190..757
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:16051677"
FT                   /id="VSP_029878"
FT   VAR_SEQ         252..275
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_054376"
FT   VAR_SEQ         300..348
FT                   /note="LDLGSNKIENLPPLIFKDLKELSQLNLSYNPIQKIQANQFDYLVKLKSL ->
FT                   F (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:16051677"
FT                   /id="VSP_029879"
FT   MUTAGEN         637
FT                   /note="D->Y: Leads to constitutive increase of basal cAMP."
FT                   /evidence="ECO:0000269|PubMed:10935549"
FT   CONFLICT        70
FT                   /note="L -> M (in Ref. 1; AAG17167)"
FT                   /evidence="ECO:0000305"
FT   STRAND          31..33
FT                   /evidence="ECO:0000244|PDB:2JM4"
FT   STRAND          35..38
FT                   /evidence="ECO:0000244|PDB:2JM4"
FT   STRAND          40..42
FT                   /evidence="ECO:0000244|PDB:2JM4"
FT   HELIX           43..45
FT                   /evidence="ECO:0000244|PDB:2JM4"
FT   STRAND          53..55
FT                   /evidence="ECO:0000244|PDB:2JM4"
SQ   SEQUENCE   757 AA;  86975 MW;  B32DD71B1A5D5864 CRC64;
     MTSGSVFFYI LIFGKYFSHG GGQDVKCSLG YFPCGNITKC LPQLLHCNGV DDCGNQADED
     NCGDNNGWSL QFDKYFASYY KMTSQYPFEA ETPECLVGSV PVQCLCQGLE LDCDETNLRA
     VPSVSSNVTA MSLQWNLIRK LPPDCFKNYH DLQKLYLQNN KITSISIYAF RGLNSLTKLY
     LSHNRITFLK PGVFEDLHRL EWLIIEDNHL SRISPPTFYG LNSLILLVLM NNVLTRLPDK
     PLCQHMPRLH WLDLEGNHIH NLRNLTFISC SNLTVLVMRK NKINHLNENT FAPLQKLDEL
     DLGSNKIENL PPLIFKDLKE LSQLNLSYNP IQKIQANQFD YLVKLKSLSL EGIEISNIQQ
     RMFRPLMNLS HIYFKKFQYC GYAPHVRSCK PNTDGISSLE NLLASIIQRV FVWVVSAVTC
     FGNIFVICMR PYIRSENKLY AMSIISLCCA DCLMGIYLFV IGGFDLKFRG EYNKHAQLWM
     ESTHCQLVGS LAILSTEVSV LLLTFLTLEK YICIVYPFRC VRPGKCRTIT VLILIWITGF
     IVAFIPLSNK EFFKNYYGTN GVCFPLHSED TESIGAQIYS VAIFLGINLA AFIIIVFSYG
     SMFYSVHQSA ITATEIRNQV KKEMILAKRF FFIVFTDALC WIPIFVVKFL SLLQVEIPGT
     ITSWVVIFIL PINSALNPIL YTLTTRPFKE MIHRFWYNYR QRKSMDSKGQ KTYAPSFIWV
     EMWPLQEMPP ELMKPDLFTY PCEMSLISQS TRLNSYS
//
ID   TA2R_HUMAN              Reviewed;         343 AA.
AC   P21731; O75228; Q6DK52; Q9UCY1; Q9UCY2;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   05-MAY-2009, sequence version 3.
DT   07-OCT-2020, entry version 210.
DE   RecName: Full=Thromboxane A2 receptor;
DE            Short=TXA2-R;
DE   AltName: Full=Prostanoid TP receptor;
GN   Name=TBXA2R;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Placenta;
RX   PubMed=1825698; DOI=10.1038/349617a0;
RA   Hirata M., Hayashi Y., Ushikubi F., Yokota Y., Kageyama R., Nakanishi S.,
RA   Narumiya S.;
RT   "Cloning and expression of cDNA for a human thromboxane A2 receptor.";
RL   Nature 349:617-620(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Placenta;
RX   PubMed=8227091;
RA   Nuesing R.M., Hirata M., Kakizuka A., Eki T., Ozawa K., Narumiya S.;
RT   "Characterization and chromosomal mapping of the human thromboxane A2
RT   receptor gene.";
RL   J. Biol. Chem. 268:25253-25259(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND ALTERNATIVE SPLICING.
RC   TISSUE=Endothelial cell, and Placenta;
RX   PubMed=8034687;
RA   Raychowdhury M.K., Yukawa M., Collins L.J., McGrail S.H., Kent K.C.,
RA   Ware J.A.;
RT   "Alternative splicing produces a divergent cytoplasmic tail in the human
RT   endothelial thromboxane A2 receptor.";
RL   J. Biol. Chem. 269:19256-19261(1994).
RN   [4]
RP   ERRATUM OF PUBMED:8034687.
RX   PubMed=7896853; DOI=10.1074/jbc.270.12.7011;
RA   Raychowdhury M.K., Yukawa M., Collins L.J., McGrail S.H., Kent K.C.,
RA   Ware J.A.;
RL   J. Biol. Chem. 270:7011-7011(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=7965765;
RA   D'Angelo D.D., Davis M.G., Ali S., Dorn G.W. II;
RT   "Cloning and pharmacologic characterization of a thromboxane A2 receptor
RT   from K562 (human chronic myelogenous leukemia) cells.";
RL   J. Pharmacol. Exp. Ther. 271:1034-1041(1994).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Placenta;
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (OCT-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 329-343 (ISOFORMS 1 AND 2), FUNCTION,
RP   ALTERNATIVE SPLICING, AND CHARACTERIZATION OF VARIANT BDPLT13 LEU-60.
RC   TISSUE=Platelet;
RX   PubMed=8613548; DOI=10.1172/jci118518;
RA   Hirata T., Ushikubi F., Kakizuka A., Okuma M., Narumiya S.;
RT   "Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling
RT   to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation.";
RL   J. Clin. Invest. 97:949-956(1996).
RN   [12]
RP   MUTAGENESIS.
RX   PubMed=8246916;
RA   Funk C.D., Furci L., Moran N., Fitzgerald G.A.;
RT   "Point mutation in the seventh hydrophobic domain of the human thromboxane
RT   A2 receptor allows discrimination between agonist and antagonist binding
RT   sites.";
RL   Mol. Pharmacol. 44:934-939(1993).
RN   [13]
RP   INTERACTION WITH PSMA3.
RX   PubMed=17499743; DOI=10.1016/j.prostaglandins.2006.12.001;
RA   Sasaki M., Sukegawa J., Miyosawa K., Yanagisawa T., Ohkubo S., Nakahata N.;
RT   "Low expression of cell-surface thromboxane A2 receptor beta-isoform
RT   through the negative regulation of its membrane traffic by proteasomes.";
RL   Prostaglandins Other Lipid Mediat. 83:237-249(2007).
RN   [14]
RP   INTERACTION WITH RACK1.
RX   PubMed=18088317; DOI=10.1111/j.1600-0854.2007.00692.x;
RA   Parent A., Laroche G., Hamelin E., Parent J.L.;
RT   "RACK1 regulates the cell surface expression of the G protein-coupled
RT   receptor for thromboxane A(2).";
RL   Traffic 9:394-407(2008).
RN   [15]
RP   INTERACTION WITH RPGRIP1L.
RX   PubMed=19464661; DOI=10.1016/j.prostaglandins.2009.02.001;
RA   Tokue S., Sasaki M., Nakahata N.;
RT   "Thromboxane A2-induced signal transduction is negatively regulated by
RT   KIAA1005 that directly interacts with thromboxane A2 receptor.";
RL   Prostaglandins Other Lipid Mediat. 89:8-15(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-329, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   VARIANT BDPLT13 LEU-60, AND CHARACTERIZATION OF VARIANT BDPLT13 LEU-60.
RX   PubMed=7929844; DOI=10.1172/jci117510;
RA   Hirata T., Kakizuka A., Ushikubi F., Fuse I., Okuma M., Narumiya S.;
RT   "Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly
RT   inherited bleeding disorder.";
RL   J. Clin. Invest. 94:1662-1667(1994).
CC   -!- FUNCTION: Receptor for thromboxane A2 (TXA2), a potent stimulator of
CC       platelet aggregation. The activity of this receptor is mediated by a G-
CC       protein that activates a phosphatidylinositol-calcium second messenger
CC       system. In the kidney, the binding of TXA2 to glomerular TP receptors
CC       causes intense vasoconstriction. Activates phospholipase C. Isoform 1
CC       activates adenylyl cyclase. Isoform 2 inhibits adenylyl cyclase.
CC       {ECO:0000269|PubMed:8613548}.
CC   -!- SUBUNIT: Interacts with RPGRIP1L. Interacts with PSMA3. Interacts with
CC       RACK1; the interaction regulates TBXA2R cell surface expression.
CC       {ECO:0000269|PubMed:17499743, ECO:0000269|PubMed:18088317,
CC       ECO:0000269|PubMed:19464661}.
CC   -!- INTERACTION:
CC       P21731; Q13162: PRDX4; NbExp=3; IntAct=EBI-2625082, EBI-2211957;
CC       P21731-3; Q12791-5: KCNMA1; NbExp=7; IntAct=EBI-15885629, EBI-15861807;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=Alpha;
CC         IsoId=P21731-3; Sequence=Displayed;
CC       Name=2; Synonyms=Beta;
CC         IsoId=P21731-2; Sequence=VSP_001925;
CC   -!- DISEASE: Bleeding disorder, platelet-type 13 (BDPLT13) [MIM:614009]: A
CC       disorder characterized by reduced platelet aggregation and a tendency
CC       to mild mucocutaneous bleeding. {ECO:0000269|PubMed:7929844,
CC       ECO:0000269|PubMed:8613548}. Note=Disease susceptibility is associated
CC       with variations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA58957.1; Type=Frameshift; Evidence={ECO:0000305};
CC   -!- SEQUENCE CAUTION: [Isoform 2]:
CC       Sequence=AAA58957.1; Type=Frameshift; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/tbxa2r/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D38081; BAA07274.1; -; mRNA.
DR   EMBL; D15056; BAA03649.1; -; Genomic_DNA.
DR   EMBL; U11271; AAA58957.1; ALT_FRAME; mRNA.
DR   EMBL; U27325; AAA68608.1; -; mRNA.
DR   EMBL; AY429110; AAR07905.1; -; mRNA.
DR   EMBL; DQ268653; ABB72549.1; -; Genomic_DNA.
DR   EMBL; AC005175; AAC24302.1; -; Genomic_DNA.
DR   EMBL; AC005175; AAC24303.1; -; Genomic_DNA.
DR   EMBL; CH471139; EAW69301.1; -; Genomic_DNA.
DR   EMBL; BC074749; AAH74749.1; -; mRNA.
DR   EMBL; BC074750; AAH74750.1; -; mRNA.
DR   CCDS; CCDS42467.1; -. [P21731-3]
DR   CCDS; CCDS54198.1; -. [P21731-2]
DR   PIR; A49117; A49117.
DR   PIR; A53959; A53959.
DR   PIR; A56194; A56194.
DR   PIR; T02670; T02670.
DR   RefSeq; NP_001051.1; NM_001060.5. [P21731-3]
DR   RefSeq; NP_963998.2; NM_201636.2. [P21731-2]
DR   RefSeq; XP_011526516.1; XM_011528214.2. [P21731-3]
DR   PDB; 1LBN; Model; -; A=100-265.
DR   PDBsum; 1LBN; -.
DR   BMRB; P21731; -.
DR   SMR; P21731; -.
DR   BioGRID; 112777; 63.
DR   DIP; DIP-41465N; -.
DR   IntAct; P21731; 6.
DR   MINT; P21731; -.
DR   STRING; 9606.ENSP00000393333; -.
DR   BindingDB; P21731; -.
DR   ChEMBL; CHEMBL2069; -.
DR   DrugBank; DB09285; Morniflumate.
DR   DrugBank; DB01207; Ridogrel.
DR   DrugBank; DB06739; Seratrodast.
DR   DrugCentral; P21731; -.
DR   GuidetoPHARMACOLOGY; 346; -.
DR   GlyGen; P21731; 2 sites.
DR   iPTMnet; P21731; -.
DR   PhosphoSitePlus; P21731; -.
DR   SwissPalm; P21731; -.
DR   BioMuta; TBXA2R; -.
DR   DMDM; 229463010; -.
DR   jPOST; P21731; -.
DR   MassIVE; P21731; -.
DR   PaxDb; P21731; -.
DR   PeptideAtlas; P21731; -.
DR   PRIDE; P21731; -.
DR   ProteomicsDB; 53894; -. [P21731-3]
DR   ProteomicsDB; 53895; -. [P21731-2]
DR   Antibodypedia; 5899; 178 antibodies.
DR   Ensembl; ENST00000375190; ENSP00000364336; ENSG00000006638. [P21731-3]
DR   Ensembl; ENST00000411851; ENSP00000393333; ENSG00000006638. [P21731-2]
DR   GeneID; 6915; -.
DR   KEGG; hsa:6915; -.
DR   UCSC; uc002lyg.3; human. [P21731-3]
DR   CTD; 6915; -.
DR   DisGeNET; 6915; -.
DR   EuPathDB; HostDB:ENSG00000006638.11; -.
DR   GeneCards; TBXA2R; -.
DR   HGNC; HGNC:11608; TBXA2R.
DR   HPA; ENSG00000006638; Low tissue specificity.
DR   MalaCards; TBXA2R; -.
DR   MIM; 188070; gene.
DR   MIM; 614009; phenotype.
DR   neXtProt; NX_P21731; -.
DR   OpenTargets; ENSG00000006638; -.
DR   Orphanet; 220443; Bleeding diathesis due to thromboxane synthesis deficiency.
DR   PharmGKB; PA348; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT01000000214437; -.
DR   HOGENOM; CLU_045991_3_0_1; -.
DR   InParanoid; P21731; -.
DR   KO; K04264; -.
DR   OMA; LCHFMGV; -.
DR   PhylomeDB; P21731; -.
DR   TreeFam; TF324982; -.
DR   PathwayCommons; P21731; -.
DR   Reactome; R-HSA-391908; Prostanoid ligand receptors.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-416482; G alpha (12/13) signalling events.
DR   Reactome; R-HSA-428930; Thromboxane signalling through TP receptor.
DR   SignaLink; P21731; -.
DR   SIGNOR; P21731; -.
DR   BioGRID-ORCS; 6915; 6 hits in 871 CRISPR screens.
DR   ChiTaRS; TBXA2R; human.
DR   GeneWiki; Thromboxane_receptor; -.
DR   GenomeRNAi; 6915; -.
DR   Pharos; P21731; Tclin.
DR   PRO; PR:P21731; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; P21731; protein.
DR   Bgee; ENSG00000006638; Expressed in metanephric glomerulus and 218 other tissues.
DR   ExpressionAtlas; P21731; baseline and differential.
DR   Genevisible; P21731; HS.
DR   GO; GO:0001669; C:acrosomal vesicle; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0016607; C:nuclear speck; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0005085; F:guanyl-nucleotide exchange factor activity; TAS:Reactome.
DR   GO; GO:0004961; F:thromboxane A2 receptor activity; IBA:GO_Central.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006954; P:inflammatory response; IBA:GO_Central.
DR   GO; GO:0090051; P:negative regulation of cell migration involved in sprouting angiogenesis; IGI:BHF-UCL.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:0030194; P:positive regulation of blood coagulation; IEA:Ensembl.
DR   GO; GO:0045777; P:positive regulation of blood pressure; IBA:GO_Central.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IBA:GO_Central.
DR   GO; GO:0045987; P:positive regulation of smooth muscle contraction; IEA:Ensembl.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; IBA:GO_Central.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0007584; P:response to nutrient; IEA:Ensembl.
DR   GO; GO:0033574; P:response to testosterone; IEA:Ensembl.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR008365; Prostanoid_rcpt.
DR   InterPro; IPR001105; Thbox_rcpt.
DR   PANTHER; PTHR11866; PTHR11866; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01788; PROSTANOIDR.
DR   PRINTS; PR00429; THROMBOXANER.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane;
KW   Direct protein sequencing; Disease mutation; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Phosphoprotein;
KW   Polymorphism; Receptor; Reference proteome; Transducer; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..343
FT                   /note="Thromboxane A2 receptor"
FT                   /id="PRO_0000070138"
FT   TOPO_DOM        1..29
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        30..52
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        53..66
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        67..87
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        88..106
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        107..128
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        129..149
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        150..172
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        173..193
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        194..219
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        220..246
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        247..270
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        271..289
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        290..311
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        312..343
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         329
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:20068231"
FT   MOD_RES         331
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P30987"
FT   CARBOHYD        4
FT                   /note="N-linked (GlcNAc...) asparagine"
FT   CARBOHYD        16
FT                   /note="N-linked (GlcNAc...) asparagine"
FT   DISULFID        105..183
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VAR_SEQ         329..343
FT                   /note="SLSLQPQLTQRSGLQ -> RSLTLWPSLEYSGTISAHCNLRLPGSSDSRASA
FT                   SRAAGITGVSHCARPCMLFDPEFDLLAGVQLLPFEPPTGKALSRKD (in isoform
FT                   2)"
FT                   /evidence="ECO:0000303|PubMed:8034687,
FT                   ECO:0000303|PubMed:8613548"
FT                   /id="VSP_001925"
FT   VARIANT         60
FT                   /note="R -> L (in BDPLT13; does not affect TXA2 binding;
FT                   defective interaction with G proteins; impairs
FT                   phospholipase C and adenylyl cyclase activation; isoform 1;
FT                   has no effect on adenylyl cyclase inhibition; isoform 2;
FT                   dbSNP:rs34377097)"
FT                   /evidence="ECO:0000269|PubMed:7929844,
FT                   ECO:0000269|PubMed:8613548"
FT                   /id="VAR_003515"
FT   VARIANT         68
FT                   /note="C -> S (in dbSNP:rs5743)"
FT                   /id="VAR_014688"
FT   VARIANT         80
FT                   /note="V -> E (in dbSNP:rs5744)"
FT                   /id="VAR_014689"
FT   VARIANT         94
FT                   /note="E -> V (in dbSNP:rs5746)"
FT                   /id="VAR_014690"
FT   VARIANT         160
FT                   /note="A -> T (in dbSNP:rs5749)"
FT                   /id="VAR_014691"
FT   VARIANT         176
FT                   /note="V -> E (in dbSNP:rs5750)"
FT                   /id="VAR_014692"
FT   VARIANT         217
FT                   /note="V -> I (in dbSNP:rs5751)"
FT                   /id="VAR_014693"
FT   MUTAGEN         291
FT                   /note="L->R: Suppresses antagonist binding."
FT                   /evidence="ECO:0000269|PubMed:8246916"
FT   MUTAGEN         295
FT                   /note="R->Q: Reduces antagonist binding."
FT                   /evidence="ECO:0000269|PubMed:8246916"
FT   MUTAGEN         299
FT                   /note="W->L: Reduces antagonist binding."
FT                   /evidence="ECO:0000269|PubMed:8246916"
FT   MUTAGEN         299
FT                   /note="W->R: Reduces antagonist binding."
FT                   /evidence="ECO:0000269|PubMed:8246916"
FT   CONFLICT        263
FT                   /note="V -> W (in Ref. 1; AA sequence)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   343 AA;  37431 MW;  114A7C3F3F0D35F1 CRC64;
     MWPNGSSLGP CFRPTNITLE ERRLIASPWF AASFCVVGLA SNLLALSVLA GARQGGSHTR
     SSFLTFLCGL VLTDFLGLLV TGTIVVSQHA ALFEWHAVDP GCRLCRFMGV VMIFFGLSPL
     LLGAAMASER YLGITRPFSR PAVASQRRAW ATVGLVWAAA LALGLLPLLG VGRYTVQYPG
     SWCFLTLGAE SGDVAFGLLF SMLGGLSVGL SFLLNTVSVA TLCHVYHGQE AAQQRPRDSE
     VEMMAQLLGI MVVASVCWLP LLVFIAQTVL RNPPAMSPAG QLSRTTEKEL LIYLRVATWN
     QILDPWVYIL FRRAVLRRLQ PRLSTRPRSL SLQPQLTQRS GLQ
//
ID   V2R_HUMAN               Reviewed;         371 AA.
AC   P30518; C5HF20; O43192; Q3MJD3; Q9UCV9;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1993, sequence version 1.
DT   07-OCT-2020, entry version 214.
DE   RecName: Full=Vasopressin V2 receptor;
DE            Short=V2R;
DE   AltName: Full=AVPR V2;
DE   AltName: Full=Antidiuretic hormone receptor;
DE   AltName: Full=Renal-type arginine vasopressin receptor;
GN   Name=AVPR2; Synonyms=ADHR, DIR, DIR3, V2R;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1415251;
RA   Seibold A., Brabet P., Rosenthal W., Birnbaumer M.;
RT   "Structure and chromosomal localization of the human antidiuretic hormone
RT   receptor gene.";
RL   Am. J. Hum. Genet. 51:1078-1083(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Kidney;
RX   PubMed=1534149; DOI=10.1038/357333a0;
RA   Birnbaumer M., Seibold A., Gilbert S., Ishido M., Barberis C.,
RA   Antaramian A., Brabet P., Rosenthal W.;
RT   "Molecular cloning of the receptor for human antidiuretic hormone.";
RL   Nature 357:333-335(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7913579;
RA   Wildin R.S., Antush M.J., Bennett R.L., Schoof J.M., Scott C.R.;
RT   "Heterogeneous AVPR2 gene mutations in congenital nephrogenic diabetes
RT   insipidus.";
RL   Am. J. Hum. Genet. 55:266-277(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=8735975; DOI=10.1016/0196-9781(96)00009-5;
RA   Fay M.J., Du J., Yu X., North W.G.;
RT   "Evidence for expression of vasopressin V2 receptor mRNA in human lung.";
RL   Peptides 17:477-481(1996).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Lung carcinoma, and Mammary cancer;
RX   PubMed=9581826;
RA   North W.G., Fay M.J., Longo K.A., Du J.;
RT   "Expression of all known vasopressin receptor subtypes by small cell tumors
RT   implies a multifaceted role for this neuropeptide.";
RL   Cancer Res. 58:1866-1871(1998).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND FUNCTION.
RX   PubMed=19440390; DOI=10.1371/journal.pone.0005573;
RA   Boselt I., Rompler H., Hermsdorf T., Thor D., Busch W., Schulz A.,
RA   Schoneberg T.;
RT   "Involvement of the V2 vasopressin receptor in adaptation to limited water
RT   supply.";
RL   PLoS ONE 4:E5573-E5573(2009).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Kidney;
RA   Warren C.N., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 307-371.
RX   PubMed=8882880; DOI=10.1007/s004390050264;
RA   Oksche A., Moeller A., Dickson J., Rosendahl W., Rascher W., Bichet D.G.,
RA   Rosenthal W.;
RT   "Two novel mutations in the aquaporin-2 and the vasopressin V2 receptor
RT   genes in patients with congenital nephrogenic diabetes insipidus.";
RL   Hum. Genet. 98:587-589(1996).
RN   [11]
RP   PALMITOYLATION AT CYS-341 AND CYS-342, AND MUTAGENESIS OF CYS-341 AND
RP   CYS-342.
RX   PubMed=9224808; DOI=10.1124/mol.52.1.21;
RA   Sadeghi H.M., Innamorati G., Dagarag M., Birnbaumer M.;
RT   "Palmitoylation of the V2 vasopressin receptor.";
RL   Mol. Pharmacol. 52:21-29(1997).
RN   [12]
RP   INTERACTION WITH TMEM147.
RX   PubMed=21056967; DOI=10.1124/mol.110.067363;
RA   Rosemond E., Rossi M., McMillin S.M., Scarselli M., Donaldson J.G.,
RA   Wess J.;
RT   "Regulation of M(3) muscarinic receptor expression and function by
RT   transmembrane protein 147.";
RL   Mol. Pharmacol. 79:251-261(2011).
RN   [13]
RP   INTERACTION WITH ARRDC4, IDENTIFICATION IN A COMPLEX WITH HGS AND ARRDC4,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=23236378; DOI=10.1371/journal.pone.0050557;
RA   Shea F.F., Rowell J.L., Li Y., Chang T.H., Alvarez C.E.;
RT   "Mammalian alpha arrestins link activated seven transmembrane receptors to
RT   Nedd4 family e3 ubiquitin ligases and interact with beta arrestins.";
RL   PLoS ONE 7:E50557-E50557(2012).
RN   [14]
RP   VARIANT XNDI ASP-132.
RX   PubMed=1356229; DOI=10.1038/359233a0;
RA   Rosenthal W., Seibold A., Antaramian A., Lonergan M., Arthus M.-F.,
RA   Hendy G.N., Birnbaumer M., Bichet D.G.;
RT   "Molecular identification of the gene responsible for congenital
RT   nephrogenic diabetes insipidus.";
RL   Nature 359:233-235(1992).
RN   [15]
RP   VARIANTS XNDI CYS-185; CYS-203 AND CYS-205.
RX   PubMed=1303271; DOI=10.1038/ng1092-99;
RA   van den Ouweland A.M.W., Dreesen J.C.F.M., Verdijk M., Knoers N.V.A.M.,
RA   Monnens L.A.H., Rocchi M., van Oost B.A.;
RT   "Mutations in the vasopressin type 2 receptor gene (AVPR2) associated with
RT   nephrogenic diabetes insipidus.";
RL   Nat. Genet. 2:99-102(1992).
RN   [16]
RP   VARIANTS XNDI SER-128; CYS-181; ARG-286 AND 247-ARG--GLY-250 DEL.
RX   PubMed=1303257; DOI=10.1038/ng1092-103;
RA   Pan Y., Metzenberg A., Das S., Jing B., Gitschier J.;
RT   "Mutations in the V2 vasopressin receptor gene are associated with X-linked
RT   nephrogenic diabetes insipidus.";
RL   Nat. Genet. 2:103-106(1992).
RN   [17]
RP   VARIANTS XNDI PRO-143 AND VAL-277 DEL.
RX   PubMed=8267567; DOI=10.1006/bbrc.1993.2578;
RA   Tsukaguchi H., Matsubara H., Aritaki S., Kimura T., Abe S., Inada M.;
RT   "Two novel mutations in the vasopressin V2 receptor gene in unrelated
RT   Japanese kindreds with nephrogenic diabetes insipidus.";
RL   Biochem. Biophys. Res. Commun. 197:1000-1010(1993).
RN   [18]
RP   VARIANT XNDI TRP-113.
RX   PubMed=8479490; DOI=10.1056/nejm199305273282105;
RA   Holtzman E.J., Harris H.W. Jr., Kolakowski L.F. Jr., Guay-Woodford L.M.,
RA   Botelho B., Ausiello D.A.;
RT   "A molecular defect in the vasopressin V2-receptor gene causing nephrogenic
RT   diabetes insipidus.";
RL   N. Engl. J. Med. 328:1534-1537(1993).
RN   [19]
RP   VARIANT XNDI HIS-137.
RX   PubMed=8514744;
RA   Rosenthal W., Antaramian A., Gilbert S., Birnbaumer M.;
RT   "Nephrogenic diabetes insipidus. A V2 vasopressin receptor unable to
RT   stimulate adenylyl cyclase.";
RL   J. Biol. Chem. 268:13030-13033(1993).
RN   [20]
RP   VARIANTS XNDI MET-88; CYS-106; ARG-112; TRP-113; PHE-126; SER-128; HIS-137;
RP   SER-164; LEU-167; CYS-181; CYS-202 AND PRO-285.
RX   PubMed=8037205;
RA   Bichet D.G., Birnbaumer M., Lonergan M., Arthus M.-F., Rosenthal W.,
RA   Goodyer P., Nivet H., Benoit S., Giampietro P., Simonetti S., Fish A.,
RA   Whitley C.B., Jaeger P., Gertner J., New M., Dibona F.J., Kaplan B.S.,
RA   Robertson G.L., Hendy G.N., Fujiwara T.M., Morgan K.;
RT   "Nature and recurrence of AVPR2 mutations in X-linked nephrogenic diabetes
RT   insipidus.";
RL   Am. J. Hum. Genet. 55:278-286(1994).
RN   [21]
RP   VARIANTS XNDI PRO-44 AND THR-167.
RX   PubMed=7999078; DOI=10.1006/bbrc.1994.2700;
RA   Oksche A., Dickson J., Schuelein R., Hansjoerg W.S., Mueller M.,
RA   Rascher W., Birnbaumer M., Rosenthal W.;
RT   "Two novel mutations in the vasopressin V2 receptor gene in patients with
RT   congenital nephrogenic diabetes insipidus.";
RL   Biochem. Biophys. Res. Commun. 205:552-557(1994).
RN   [22]
RP   VARIANTS XNDI CYS-280 AND PRO-292.
RX   PubMed=7987330; DOI=10.1093/hmg/3.8.1429;
RA   Wenkert D., Merendino J.J. Jr., Shenker A., Thambi N., Robertson G.L.,
RA   Moses A.M., Spiegel A.M.;
RT   "Novel mutations in the V2 vasopressin receptor gene of patients with X-
RT   linked nephrogenic diabetes insipidus.";
RL   Hum. Mol. Genet. 3:1429-1430(1994).
RN   [23]
RP   VARIANTS XNDI SER-128; VAL-277 DEL AND LEU-286.
RX   PubMed=7833930; DOI=10.1093/hmg/3.9.1685;
RA   Faa V., Ventruto M.L., Loche S., Bozzola M., Podda R., Cao A.,
RA   Rosatelli M.C.;
RT   "Mutations in the vasopressin V2-receptor gene in three families of Italian
RT   descent with nephrogenic diabetes insipidus.";
RL   Hum. Mol. Genet. 3:1685-1686(1994).
RN   [24]
RP   VARIANT XNDI ARG-80.
RX   PubMed=8045948; DOI=10.1210/jcem.79.2.8045948;
RA   Yuasa H., Ito M., Oiso Y., Kurokawa M., Watanabe T., Oda Y., Ishizuka T.,
RA   Tani N., Ito S., Shibata A., Saito H.;
RT   "Novel mutations in the V2 vasopressin receptor gene in two pedigrees with
RT   congenital nephrogenic diabetes insipidus.";
RL   J. Clin. Endocrinol. Metab. 79:361-365(1994).
RN   [25]
RP   VARIANT XNDI TRP-113.
RX   PubMed=7984150; DOI=10.1210/mend.8.7.7984150;
RA   Birnbaumer M., Gilbert S., Rosenthal W.;
RT   "An extracellular congenital nephrogenic diabetes insipidus mutation of the
RT   vasopressin receptor reduces cell surface expression, affinity for ligand,
RT   and coupling to the Gs/adenylyl cyclase system.";
RL   Mol. Endocrinol. 8:886-894(1994).
RN   [26]
RP   VARIANT XNDI CYS-280.
RX   PubMed=8078903; DOI=10.1073/pnas.91.18.8457;
RA   Friedman E., Bale A.E., Carson E., Boson W.L., Nordenskjoeld M., Ritzen M.,
RA   Ferriera P.C., Jammal A., De Marco L.;
RT   "Nephrogenic diabetes insipidus: an X chromosome-linked dominant
RT   inheritance pattern with a vasopressin type 2 receptor gene that is
RT   structurally normal.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:8457-8461(1994).
RN   [27]
RP   VARIANTS XNDI PRO-143; CYS-202 AND VAL-277 DEL.
RX   PubMed=7560098; DOI=10.1172/jci118252;
RA   Tsukaguchi H., Matsubara H., Taketani S., Mori Y., Seido T., Inada M.;
RT   "Binding-, intracellular transport-, and biosynthesis-defective mutants of
RT   vasopressin type 2 receptor in patients with X-linked nephrogenic diabetes
RT   insipidus.";
RL   J. Clin. Invest. 96:2043-2050(1995).
RN   [28]
RP   VARIANTS XNDI PRO-43; GLU-107 AND SER-322.
RX   PubMed=9402087;
RA   Vargas-Poussou R., Forestier L., Dautzenberg M.D., Niaudet P., Dechaux M.,
RA   Antignac C.;
RT   "Mutations in the vasopressin V2 receptor and aquaporin-2 genes in 12
RT   families with congenital nephrogenic diabetes insipidus.";
RL   J. Am. Soc. Nephrol. 8:1855-1862(1997).
RN   [29]
RP   VARIANTS XNDI HIS-137; VAL-277 DEL AND PRO-309.
RX   PubMed=9452109; DOI=10.1002/humu.1380110188;
RA   Shoji Y., Takahashi T., Suzuki Y., Suzuki T., Komatsu K., Hirono H.,
RA   Shoji Y., Yokoyama T., Kito H., Takada G.;
RT   "Mutational analyses of AVPR2 gene in three Japanese families with X-linked
RT   nephrogenic diabetes insipidus: two recurrent mutations, R137H and
RT   deltaV278, caused by the hypermutability at CpG dinucleotides.";
RL   Hum. Mutat. Suppl. 1:S278-S283(1998).
RN   [30]
RP   VARIANTS XNDI ARG-112; LYS-317 AND SER-323.
RX   PubMed=10694923;
RX   DOI=10.1002/(sici)1098-1004(1998)12:2<137::aid-humu16>3.0.co;2-j;
RA   Szalai C., Triga D., Czinner A.;
RT   "C112R, W323S, N317K mutations in the vasopressin V2 receptor gene in
RT   patients with nephrogenic diabetes insipidus.";
RL   Hum. Mutat. 12:137-138(1998).
RN   [31]
RP   VARIANTS XNDI HIS-137 AND CYS-181.
RX   PubMed=9711877;
RX   DOI=10.1002/(sici)1098-1004(1998)12:3<196::aid-humu7>3.0.co;2-f;
RA   Schoeneberg T., Schulz A., Biebermann H., Grueters A., Grimm T.,
RA   Huebschmann K., Filler G., Gudermann T., Schultz G.;
RT   "V2 vasopressin receptor dysfunction in nephrogenic diabetes insipidus
RT   caused by different molecular mechanisms.";
RL   Hum. Mutat. 12:196-205(1998).
RN   [32]
RP   VARIANTS XNDI LYS-46; VAL-105 AND PHE-130.
RX   PubMed=10770218; DOI=10.1210/jcem.85.4.6507;
RA   Pasel K., Schulz A., Timmermann K., Linnemann K., Hoeltzenbein M.,
RA   Jaaskelainen J., Gruters A., Filler G., Schoneberg T.;
RT   "Functional characterization of the molecular defects causing nephrogenic
RT   diabetes insipidus in eight families.";
RL   J. Clin. Endocrinol. Metab. 85:1703-1710(2000).
RN   [33]
RP   CHARACTERIZATION OF VARIANTS XNDI ASN-204; CYS-205 AND ASP-206.
RX   PubMed=11026555; DOI=10.1016/s0303-7207(00)00236-7;
RA   Postina R., Ufer E., Pfeiffer R., Knoers N.V., Fahrenholz F.;
RT   "Misfolded vasopressin V2 receptors caused by extracellular point mutations
RT   entail congenital nephrogenic diabetes insipidus.";
RL   Mol. Cell. Endocrinol. 164:31-39(2000).
RN   [34]
RP   VARIANT XNDI CYS-104.
RX   PubMed=11232028; DOI=10.1210/jcem.86.1.7165;
RA   Inaba S., Hatakeyama H., Taniguchi N., Miyamori I.;
RT   "The property of a novel V2 receptor mutant in a patient with nephrogenic
RT   diabetes insipidus.";
RL   J. Clin. Endocrinol. Metab. 86:381-385(2001).
RN   [35]
RP   VARIANTS XNDI CYS-106 AND LEU-287.
RX   PubMed=11916004; DOI=10.1007/s100380200002;
RA   Chen C.H., Chen W.Y., Liu H.L., Liu T.T., Tsou A.P., Lin C.Y., Chao T.,
RA   Qi Y., Hsiao K.J.;
RT   "Identification of mutations in the arginine vasopressin receptor 2 gene
RT   causing nephrogenic diabetes insipidus in Chinese patients.";
RL   J. Hum. Genet. 47:66-73(2002).
RN   [36]
RP   VARIANTS NSIAD CYS-137 AND LEU-137.
RX   PubMed=15872203; DOI=10.1056/nejmoa042743;
RA   Feldman B.J., Rosenthal S.M., Vargas G.A., Fenwick R.G., Huang E.A.,
RA   Matsuda-Abedini M., Lustig R.H., Mathias R.S., Portale A.A., Miller W.L.,
RA   Gitelman S.E.;
RT   "Nephrogenic syndrome of inappropriate antidiuresis.";
RL   N. Engl. J. Med. 352:1884-1890(2005).
RN   [37]
RP   VARIANTS XNDI ASP-122 AND HIS-137.
RX   PubMed=16845277; DOI=10.109701.gim.0000223554.46981.7a;
RA   Carroll P., Al-Mojalli H., Al-Abbad A., Al-Hassoun I., Al-Hamed M.,
RA   Al-Amr R., Butt A.I., Meyer B.F.;
RT   "Novel mutations underlying nephrogenic diabetes insipidus in Arab
RT   families.";
RL   Genet. Med. 8:443-447(2006).
RN   [38]
RP   VARIANT [LARGE SCALE ANALYSIS] HIS-247.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Receptor for arginine vasopressin. The activity of this
CC       receptor is mediated by G proteins which activate adenylate cyclase.
CC       Involved in renal water reabsorption. {ECO:0000269|PubMed:19440390}.
CC   -!- SUBUNIT: Interacts with ARRDC4 (PubMed:23236378). Identified in a
CC       complex containing at least ARRDC4, V2R and HGS (PubMed:23236378).
CC       Interacts with TMEM147 (PubMed:21056967). {ECO:0000269|PubMed:21056967,
CC       ECO:0000269|PubMed:23236378}.
CC   -!- INTERACTION:
CC       P30518; Q8NCT1: ARRDC4; NbExp=2; IntAct=EBI-11675746, EBI-11673273;
CC       P30518; P21964: COMT; NbExp=3; IntAct=EBI-11675746, EBI-372265;
CC       P30518; Q8IVJ1: SLC41A1; NbExp=3; IntAct=EBI-11675746, EBI-12266234;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:23236378};
CC       Multi-pass membrane protein {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P30518-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P30518-2; Sequence=VSP_036990, VSP_036991;
CC   -!- TISSUE SPECIFICITY: Kidney.
CC   -!- DISEASE: Nephrogenic syndrome of inappropriate antidiuresis (NSIAD)
CC       [MIM:300539]: Characterized by an inability to excrete a free water
CC       load, with inappropriately concentrated urine and resultant
CC       hyponatremia, hypoosmolarity, and natriuresis.
CC       {ECO:0000269|PubMed:15872203}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Diabetes insipidus, nephrogenic, X-linked (XNDI) [MIM:304800]:
CC       A disorder caused by the inability of the renal collecting ducts to
CC       absorb water in response to arginine vasopressin. Characterized by
CC       excessive water drinking (polydipsia), excessive urine excretion
CC       (polyuria), persistent hypotonic urine, and hypokalemia.
CC       {ECO:0000269|PubMed:10694923, ECO:0000269|PubMed:10770218,
CC       ECO:0000269|PubMed:11026555, ECO:0000269|PubMed:11232028,
CC       ECO:0000269|PubMed:11916004, ECO:0000269|PubMed:1303257,
CC       ECO:0000269|PubMed:1303271, ECO:0000269|PubMed:1356229,
CC       ECO:0000269|PubMed:16845277, ECO:0000269|PubMed:7560098,
CC       ECO:0000269|PubMed:7833930, ECO:0000269|PubMed:7984150,
CC       ECO:0000269|PubMed:7987330, ECO:0000269|PubMed:7999078,
CC       ECO:0000269|PubMed:8037205, ECO:0000269|PubMed:8045948,
CC       ECO:0000269|PubMed:8078903, ECO:0000269|PubMed:8267567,
CC       ECO:0000269|PubMed:8479490, ECO:0000269|PubMed:8514744,
CC       ECO:0000269|PubMed:9402087, ECO:0000269|PubMed:9452109,
CC       ECO:0000269|PubMed:9711877}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       Vasopressin/oxytocin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L22206; AAA03651.1; -; Genomic_DNA.
DR   EMBL; Z11687; CAA77746.1; -; mRNA.
DR   EMBL; U04357; AAC09005.1; -; Genomic_DNA.
DR   EMBL; AF030626; AAB86428.1; -; mRNA.
DR   EMBL; AF101727; AAD16444.1; -; mRNA.
DR   EMBL; AF032388; AAB87678.1; -; mRNA.
DR   EMBL; AY242131; AAO92298.1; -; mRNA.
DR   EMBL; FJ411207; ACR39021.1; -; Genomic_DNA.
DR   EMBL; CH471172; EAW72783.1; -; Genomic_DNA.
DR   EMBL; CH471172; EAW72784.1; -; Genomic_DNA.
DR   EMBL; CH471172; EAW72785.1; -; Genomic_DNA.
DR   EMBL; BC101484; AAI01485.1; -; mRNA.
DR   EMBL; BC112181; AAI12182.1; -; mRNA.
DR   CCDS; CCDS14735.1; -. [P30518-1]
DR   CCDS; CCDS55539.1; -. [P30518-2]
DR   PIR; I51865; I51865.
DR   RefSeq; NP_000045.1; NM_000054.4. [P30518-1]
DR   RefSeq; NP_001139623.1; NM_001146151.1. [P30518-2]
DR   RefSeq; XP_006724891.1; XM_006724828.3.
DR   PDB; 4JQI; X-ray; 2.60 A; V=343-371.
DR   PDB; 6NI2; EM; 4.00 A; V=343-368.
DR   PDB; 6U1N; EM; 4.00 A; R=343-371.
DR   PDBsum; 4JQI; -.
DR   PDBsum; 6NI2; -.
DR   PDBsum; 6U1N; -.
DR   SMR; P30518; -.
DR   BioGRID; 107035; 18.
DR   ELM; P30518; -.
DR   IntAct; P30518; 4.
DR   STRING; 9606.ENSP00000351805; -.
DR   BindingDB; P30518; -.
DR   ChEMBL; CHEMBL1790; -.
DR   DrugBank; DB09059; Atosiban.
DR   DrugBank; DB00872; Conivaptan.
DR   DrugBank; DB00035; Desmopressin.
DR   DrugBank; DB14642; Lypressin.
DR   DrugBank; DB05091; M0002.
DR   DrugBank; DB05838; OPC-51803.
DR   DrugBank; DB02638; Terlipressin.
DR   DrugBank; DB06212; Tolvaptan.
DR   DrugBank; DB00067; Vasopressin.
DR   DrugCentral; P30518; -.
DR   GuidetoPHARMACOLOGY; 368; -.
DR   TCDB; 9.A.14.10.3; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; P30518; 1 site.
DR   iPTMnet; P30518; -.
DR   PhosphoSitePlus; P30518; -.
DR   SwissPalm; P30518; -.
DR   BioMuta; AVPR2; -.
DR   DMDM; 267256; -.
DR   MassIVE; P30518; -.
DR   PaxDb; P30518; -.
DR   PeptideAtlas; P30518; -.
DR   PRIDE; P30518; -.
DR   ProteomicsDB; 54708; -. [P30518-1]
DR   ProteomicsDB; 54709; -. [P30518-2]
DR   TopDownProteomics; P30518-2; -. [P30518-2]
DR   Antibodypedia; 17443; 287 antibodies.
DR   Ensembl; ENST00000337474; ENSP00000338072; ENSG00000126895. [P30518-1]
DR   Ensembl; ENST00000370049; ENSP00000359066; ENSG00000126895. [P30518-2]
DR   Ensembl; ENST00000646375; ENSP00000496396; ENSG00000126895. [P30518-1]
DR   GeneID; 554; -.
DR   KEGG; hsa:554; -.
DR   UCSC; uc004fjh.5; human. [P30518-1]
DR   CTD; 554; -.
DR   DisGeNET; 554; -.
DR   EuPathDB; HostDB:ENSG00000126895.13; -.
DR   GeneCards; AVPR2; -.
DR   GeneReviews; AVPR2; -.
DR   HGNC; HGNC:897; AVPR2.
DR   HPA; ENSG00000126895; Tissue enhanced (adipose).
DR   MalaCards; AVPR2; -.
DR   MIM; 300538; gene.
DR   MIM; 300539; phenotype.
DR   MIM; 304800; phenotype.
DR   neXtProt; NX_P30518; -.
DR   OpenTargets; ENSG00000126895; -.
DR   Orphanet; 223; Nephrogenic diabetes insipidus.
DR   Orphanet; 93606; Nephrogenic syndrome of inappropriate antidiuresis.
DR   PharmGKB; PA25189; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00990000203574; -.
DR   HOGENOM; CLU_009579_15_3_1; -.
DR   InParanoid; P30518; -.
DR   KO; K04228; -.
DR   OMA; PWIYAFF; -.
DR   OrthoDB; 291625at2759; -.
DR   PhylomeDB; P30518; -.
DR   TreeFam; TF106499; -.
DR   PathwayCommons; P30518; -.
DR   Reactome; R-HSA-388479; Vasopressin-like receptors.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-432040; Vasopressin regulates renal water homeostasis via Aquaporins.
DR   Reactome; R-HSA-8856825; Cargo recognition for clathrin-mediated endocytosis.
DR   Reactome; R-HSA-8856828; Clathrin-mediated endocytosis.
DR   Reactome; R-HSA-9036092; Defective AVP does not bind AVPR2 and causes neurohypophyseal diabetes insipidus (NDI).
DR   Reactome; R-HSA-9660821; ADORA2B mediated anti-inflammatory cytokines production.
DR   SignaLink; P30518; -.
DR   SIGNOR; P30518; -.
DR   BioGRID-ORCS; 554; 4 hits in 499 CRISPR screens.
DR   GeneWiki; Arginine_vasopressin_receptor_2; -.
DR   GenomeRNAi; 554; -.
DR   Pharos; P30518; Tclin.
DR   PRO; PR:P30518; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; P30518; protein.
DR   Bgee; ENSG00000126895; Expressed in apex of heart and 129 other tissues.
DR   ExpressionAtlas; P30518; baseline and differential.
DR   Genevisible; P30518; HS.
DR   GO; GO:0030665; C:clathrin-coated vesicle membrane; TAS:Reactome.
DR   GO; GO:0030139; C:endocytic vesicle; IDA:ARUK-UCL.
DR   GO; GO:0005783; C:endoplasmic reticulum; TAS:ProtInc.
DR   GO; GO:0005768; C:endosome; IDA:ARUK-UCL.
DR   GO; GO:0005794; C:Golgi apparatus; TAS:ProtInc.
DR   GO; GO:0016021; C:integral component of membrane; NAS:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IDA:ARUK-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:ARUK-UCL.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0042277; F:peptide binding; IBA:GO_Central.
DR   GO; GO:0005000; F:vasopressin receptor activity; IDA:ARUK-UCL.
DR   GO; GO:0007190; P:activation of adenylate cyclase activity; TAS:ProtInc.
DR   GO; GO:0007188; P:adenylate cyclase-modulating G protein-coupled receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0007588; P:excretion; TAS:ProtInc.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007599; P:hemostasis; TAS:ProtInc.
DR   GO; GO:0007249; P:I-kappaB kinase/NF-kappaB signaling; IEA:Ensembl.
DR   GO; GO:0032609; P:interferon-gamma production; IEA:Ensembl.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:ARUK-UCL.
DR   GO; GO:0035814; P:negative regulation of renal sodium excretion; IEA:Ensembl.
DR   GO; GO:0035811; P:negative regulation of urine volume; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; ISS:UniProtKB.
DR   GO; GO:0031398; P:positive regulation of protein ubiquitination; NAS:BHF-UCL.
DR   GO; GO:0003084; P:positive regulation of systemic arterial blood pressure; IEA:Ensembl.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; IBA:GO_Central.
DR   GO; GO:0001992; P:regulation of systemic arterial blood pressure by vasopressin; IBA:GO_Central.
DR   GO; GO:0003091; P:renal water homeostasis; TAS:Reactome.
DR   GO; GO:0034097; P:response to cytokine; IEA:Ensembl.
DR   GO; GO:0021537; P:telencephalon development; IEA:Ensembl.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR001817; Vasoprsn_rcpt.
DR   InterPro; IPR000161; Vprsn_rcpt_V2.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00896; VASOPRESSINR.
DR   PRINTS; PR00898; VASOPRSNV2R.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Diabetes insipidus;
KW   Disease mutation; G-protein coupled receptor; Glycoprotein; Lipoprotein;
KW   Membrane; Palmitate; Polymorphism; Receptor; Reference proteome;
KW   Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..371
FT                   /note="Vasopressin V2 receptor"
FT                   /id="PRO_0000070208"
FT   TOPO_DOM        1..38
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        39..63
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        64..77
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        78..98
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        99..113
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        114..135
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        136..159
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        160..180
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        181..200
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        201..220
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        221..271
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        272..293
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        294..308
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        309..328
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        329..371
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   LIPID           341
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:9224808"
FT   LIPID           342
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:9224808"
FT   CARBOHYD        22
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         305..309
FT                   /note="APFVL -> GCSRG (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:9581826"
FT                   /id="VSP_036990"
FT   VAR_SEQ         310..371
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:9581826"
FT                   /id="VSP_036991"
FT   VARIANT         7
FT                   /note="T -> S (in dbSNP:rs5196)"
FT                   /id="VAR_003516"
FT   VARIANT         12
FT                   /note="G -> E (in dbSNP:rs2071126)"
FT                   /id="VAR_015296"
FT   VARIANT         42
FT                   /note="A -> V (in dbSNP:rs5198)"
FT                   /id="VAR_011858"
FT   VARIANT         43
FT                   /note="L -> P (in XNDI)"
FT                   /evidence="ECO:0000269|PubMed:9402087"
FT                   /id="VAR_015297"
FT   VARIANT         44
FT                   /note="L -> P (in XNDI)"
FT                   /evidence="ECO:0000269|PubMed:7999078"
FT                   /id="VAR_003517"
FT   VARIANT         46
FT                   /note="I -> K (in XNDI; dbSNP:rs104894759)"
FT                   /evidence="ECO:0000269|PubMed:10770218"
FT                   /id="VAR_015298"
FT   VARIANT         53
FT                   /note="L -> R (in XNDI)"
FT                   /id="VAR_015299"
FT   VARIANT         55
FT                   /note="N -> D (in XNDI)"
FT                   /id="VAR_015300"
FT   VARIANT         55
FT                   /note="N -> H (in XNDI)"
FT                   /id="VAR_015301"
FT   VARIANT         59
FT                   /note="L -> P (in XNDI; dbSNP:rs193922112)"
FT                   /id="VAR_015302"
FT   VARIANT         61
FT                   /note="A -> V"
FT                   /id="VAR_015303"
FT   VARIANT         62..64
FT                   /note="Missing (in XNDI)"
FT                   /id="VAR_003518"
FT   VARIANT         62
FT                   /note="L -> P (in XNDI)"
FT                   /id="VAR_015304"
FT   VARIANT         64
FT                   /note="R -> W (in dbSNP:rs150351033)"
FT                   /id="VAR_003519"
FT   VARIANT         80
FT                   /note="H -> R (in XNDI)"
FT                   /evidence="ECO:0000269|PubMed:8045948"
FT                   /id="VAR_003520"
FT   VARIANT         81
FT                   /note="L -> F (in XNDI)"
FT                   /id="VAR_015305"
FT   VARIANT         83
FT                   /note="L -> P (in XNDI)"
FT                   /id="VAR_015306"
FT   VARIANT         83
FT                   /note="L -> Q (in XNDI)"
FT                   /id="VAR_015307"
FT   VARIANT         84
FT                   /note="A -> D (in XNDI)"
FT                   /id="VAR_015308"
FT   VARIANT         85
FT                   /note="D -> N (in XNDI; dbSNP:rs104894754)"
FT                   /id="VAR_015309"
FT   VARIANT         88
FT                   /note="V -> M (in XNDI)"
FT                   /evidence="ECO:0000269|PubMed:8037205"
FT                   /id="VAR_003521"
FT   VARIANT         92
FT                   /note="Q -> R (in XNDI)"
FT                   /id="VAR_015310"
FT   VARIANT         94
FT                   /note="L -> Q (in XNDI)"
FT                   /id="VAR_015311"
FT   VARIANT         95
FT                   /note="P -> L (in XNDI)"
FT                   /id="VAR_015312"
FT   VARIANT         99
FT                   /note="W -> R (in XNDI)"
FT                   /id="VAR_015313"
FT   VARIANT         104
FT                   /note="R -> C (in XNDI; binding capacity is 10% of wild-
FT                   type, but binding affinity is stronger than wild-type;
FT                   dbSNP:rs104894760)"
FT                   /evidence="ECO:0000269|PubMed:11232028"
FT                   /id="VAR_015314"
FT   VARIANT         105
FT                   /note="F -> V (in XNDI; dbSNP:rs104894758)"
FT                   /evidence="ECO:0000269|PubMed:10770218"
FT                   /id="VAR_015315"
FT   VARIANT         106
FT                   /note="R -> C (in XNDI)"
FT                   /evidence="ECO:0000269|PubMed:11916004,
FT                   ECO:0000269|PubMed:8037205"
FT                   /id="VAR_003522"
FT   VARIANT         107
FT                   /note="G -> E (in XNDI)"
FT                   /evidence="ECO:0000269|PubMed:9402087"
FT                   /id="VAR_015316"
FT   VARIANT         112
FT                   /note="C -> R (in XNDI)"
FT                   /evidence="ECO:0000269|PubMed:10694923,
FT                   ECO:0000269|PubMed:8037205"
FT                   /id="VAR_003523"
FT   VARIANT         112
FT                   /note="C -> Y (in XNDI)"
FT                   /id="VAR_015317"
FT   VARIANT         113
FT                   /note="R -> W (in XNDI; dbSNP:rs28935496)"
FT                   /evidence="ECO:0000269|PubMed:7984150,
FT                   ECO:0000269|PubMed:8037205, ECO:0000269|PubMed:8479490"
FT                   /id="VAR_003524"
FT   VARIANT         122
FT                   /note="G -> D (in XNDI)"
FT                   /evidence="ECO:0000269|PubMed:16845277"
FT                   /id="VAR_062591"
FT   VARIANT         122
FT                   /note="G -> R (in XNDI)"
FT                   /id="VAR_015318"
FT   VARIANT         123
FT                   /note="M -> K (in XNDI)"
FT                   /id="VAR_015319"
FT   VARIANT         126
FT                   /note="S -> F (in XNDI)"
FT                   /evidence="ECO:0000269|PubMed:8037205"
FT                   /id="VAR_003525"
FT   VARIANT         127
FT                   /note="S -> F (in XNDI)"
FT                   /id="VAR_015320"
FT   VARIANT         128
FT                   /note="Y -> S (in XNDI)"
FT                   /evidence="ECO:0000269|PubMed:1303257,
FT                   ECO:0000269|PubMed:7833930, ECO:0000269|PubMed:8037205"
FT                   /id="VAR_003526"
FT   VARIANT         130
FT                   /note="I -> F (in XNDI; dbSNP:rs796052096)"
FT                   /evidence="ECO:0000269|PubMed:10770218"
FT                   /id="VAR_015321"
FT   VARIANT         132
FT                   /note="A -> D (in XNDI; dbSNP:rs104894747)"
FT                   /evidence="ECO:0000269|PubMed:1356229"
FT                   /id="VAR_003527"
FT   VARIANT         135
FT                   /note="L -> P (in XNDI; dbSNP:rs1557100610)"
FT                   /id="VAR_015322"
FT   VARIANT         137
FT                   /note="R -> C (in NSIAD; constitutively active;
FT                   dbSNP:rs104894761)"
FT                   /evidence="ECO:0000269|PubMed:15872203"
FT                   /id="VAR_025901"
FT   VARIANT         137
FT                   /note="R -> H (in XNDI; fails to activate the adenylyl
FT                   cyclase system; dbSNP:rs104894756)"
FT                   /evidence="ECO:0000269|PubMed:16845277,
FT                   ECO:0000269|PubMed:8037205, ECO:0000269|PubMed:8514744,
FT                   ECO:0000269|PubMed:9452109, ECO:0000269|PubMed:9711877"
FT                   /id="VAR_003528"
FT   VARIANT         137
FT                   /note="R -> L (in NSIAD; constitutively active;
FT                   dbSNP:rs104894756)"
FT                   /evidence="ECO:0000269|PubMed:15872203"
FT                   /id="VAR_025902"
FT   VARIANT         139
FT                   /note="R -> S"
FT                   /id="VAR_015323"
FT   VARIANT         143
FT                   /note="R -> P (in XNDI)"
FT                   /evidence="ECO:0000269|PubMed:7560098,
FT                   ECO:0000269|PubMed:8267567"
FT                   /id="VAR_003529"
FT   VARIANT         147
FT                   /note="A -> V (in dbSNP:rs5200)"
FT                   /id="VAR_003530"
FT   VARIANT         163
FT                   /note="A -> P (in XNDI)"
FT                   /id="VAR_015324"
FT   VARIANT         164
FT                   /note="W -> S (in XNDI)"
FT                   /evidence="ECO:0000269|PubMed:8037205"
FT                   /id="VAR_003531"
FT   VARIANT         167
FT                   /note="S -> L (in XNDI)"
FT                   /evidence="ECO:0000269|PubMed:8037205"
FT                   /id="VAR_003532"
FT   VARIANT         167
FT                   /note="S -> T (in XNDI)"
FT                   /evidence="ECO:0000269|PubMed:7999078"
FT                   /id="VAR_003533"
FT   VARIANT         173
FT                   /note="P -> S (in XNDI)"
FT                   /id="VAR_015325"
FT   VARIANT         174
FT                   /note="Q -> L (in XNDI)"
FT                   /id="VAR_015326"
FT   VARIANT         181
FT                   /note="R -> C (in XNDI; dbSNP:rs104894757)"
FT                   /evidence="ECO:0000269|PubMed:1303257,
FT                   ECO:0000269|PubMed:8037205, ECO:0000269|PubMed:9711877"
FT                   /id="VAR_003534"
FT   VARIANT         185
FT                   /note="G -> C (in XNDI; dbSNP:rs104894748)"
FT                   /evidence="ECO:0000269|PubMed:1303271"
FT                   /id="VAR_003535"
FT   VARIANT         191
FT                   /note="D -> G (in XNDI)"
FT                   /id="VAR_015327"
FT   VARIANT         201
FT                   /note="G -> D (in XNDI; dbSNP:rs104894755)"
FT                   /id="VAR_015328"
FT   VARIANT         202
FT                   /note="R -> C (in XNDI; dbSNP:rs782806507)"
FT                   /evidence="ECO:0000269|PubMed:7560098,
FT                   ECO:0000269|PubMed:8037205"
FT                   /id="VAR_003536"
FT   VARIANT         203
FT                   /note="R -> C (in XNDI; dbSNP:rs104894750)"
FT                   /evidence="ECO:0000269|PubMed:1303271"
FT                   /id="VAR_003537"
FT   VARIANT         204
FT                   /note="T -> N (in XNDI)"
FT                   /evidence="ECO:0000269|PubMed:11026555"
FT                   /id="VAR_015329"
FT   VARIANT         205
FT                   /note="Y -> C (in XNDI; dbSNP:rs104894749)"
FT                   /evidence="ECO:0000269|PubMed:11026555,
FT                   ECO:0000269|PubMed:1303271"
FT                   /id="VAR_003538"
FT   VARIANT         206
FT                   /note="V -> D (in XNDI)"
FT                   /evidence="ECO:0000269|PubMed:11026555"
FT                   /id="VAR_015330"
FT   VARIANT         207
FT                   /note="T -> N (in XNDI)"
FT                   /id="VAR_015331"
FT   VARIANT         209
FT                   /note="I -> F (in XNDI)"
FT                   /id="VAR_015332"
FT   VARIANT         214
FT                   /note="F -> S (in XNDI)"
FT                   /id="VAR_015333"
FT   VARIANT         215
FT                   /note="V -> M (in dbSNP:rs112109182)"
FT                   /id="VAR_015334"
FT   VARIANT         217
FT                   /note="P -> T (in XNDI)"
FT                   /id="VAR_015335"
FT   VARIANT         219
FT                   /note="L -> P (in XNDI)"
FT                   /id="VAR_015336"
FT   VARIANT         219
FT                   /note="L -> R (in XNDI)"
FT                   /id="VAR_015337"
FT   VARIANT         247..250
FT                   /note="Missing (in XNDI)"
FT                   /evidence="ECO:0000269|PubMed:1303257"
FT                   /id="VAR_003539"
FT   VARIANT         247
FT                   /note="R -> H (in a breast cancer sample; somatic mutation;
FT                   dbSNP:rs149668713)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035769"
FT   VARIANT         252
FT                   /note="R -> W (in dbSNP:rs61733407)"
FT                   /id="VAR_015338"
FT   VARIANT         272
FT                   /note="M -> K (in XNDI)"
FT                   /id="VAR_015339"
FT   VARIANT         277
FT                   /note="V -> A (in XNDI)"
FT                   /id="VAR_015340"
FT   VARIANT         277
FT                   /note="Missing (in XNDI)"
FT                   /evidence="ECO:0000269|PubMed:7560098,
FT                   ECO:0000269|PubMed:7833930, ECO:0000269|PubMed:8267567,
FT                   ECO:0000269|PubMed:9452109"
FT                   /id="VAR_003540"
FT   VARIANT         280
FT                   /note="Y -> C (in XNDI; dbSNP:rs104894752)"
FT                   /evidence="ECO:0000269|PubMed:7987330,
FT                   ECO:0000269|PubMed:8078903"
FT                   /id="VAR_003541"
FT   VARIANT         282
FT                   /note="L -> P (in XNDI)"
FT                   /id="VAR_015341"
FT   VARIANT         285
FT                   /note="A -> P (in XNDI; dbSNP:rs193922122)"
FT                   /evidence="ECO:0000269|PubMed:8037205"
FT                   /id="VAR_003542"
FT   VARIANT         286
FT                   /note="P -> L (in XNDI; dbSNP:rs1557100917)"
FT                   /evidence="ECO:0000269|PubMed:7833930"
FT                   /id="VAR_003543"
FT   VARIANT         286
FT                   /note="P -> R (in XNDI)"
FT                   /evidence="ECO:0000269|PubMed:1303257"
FT                   /id="VAR_003544"
FT   VARIANT         286
FT                   /note="P -> S (in XNDI)"
FT                   /id="VAR_015342"
FT   VARIANT         287
FT                   /note="F -> L (in XNDI)"
FT                   /evidence="ECO:0000269|PubMed:11916004"
FT                   /id="VAR_015343"
FT   VARIANT         289
FT                   /note="L -> P (in XNDI)"
FT                   /id="VAR_015344"
FT   VARIANT         292
FT                   /note="L -> P (in XNDI)"
FT                   /evidence="ECO:0000269|PubMed:7987330"
FT                   /id="VAR_003545"
FT   VARIANT         294
FT                   /note="A -> P (in XNDI)"
FT                   /id="VAR_015345"
FT   VARIANT         309
FT                   /note="L -> P (in XNDI)"
FT                   /evidence="ECO:0000269|PubMed:9452109"
FT                   /id="VAR_003546"
FT   VARIANT         309
FT                   /note="L -> R (in XNDI)"
FT                   /id="VAR_015346"
FT   VARIANT         315
FT                   /note="S -> R (in XNDI)"
FT                   /id="VAR_015347"
FT   VARIANT         317
FT                   /note="N -> K (in XNDI)"
FT                   /evidence="ECO:0000269|PubMed:10694923"
FT                   /id="VAR_003547"
FT   VARIANT         318
FT                   /note="S -> T"
FT                   /id="VAR_015348"
FT   VARIANT         319
FT                   /note="C -> R (in XNDI)"
FT                   /id="VAR_015349"
FT   VARIANT         321
FT                   /note="N -> D (in XNDI)"
FT                   /id="VAR_015350"
FT   VARIANT         321
FT                   /note="N -> K (in XNDI; dbSNP:rs193922123)"
FT                   /id="VAR_015351"
FT   VARIANT         321
FT                   /note="N -> Y (in XNDI)"
FT                   /id="VAR_015352"
FT   VARIANT         322
FT                   /note="P -> H (in XNDI)"
FT                   /id="VAR_015353"
FT   VARIANT         322
FT                   /note="P -> S (in XNDI)"
FT                   /evidence="ECO:0000269|PubMed:9402087"
FT                   /id="VAR_015354"
FT   VARIANT         323
FT                   /note="W -> R (in XNDI)"
FT                   /id="VAR_015355"
FT   VARIANT         323
FT                   /note="W -> S (in XNDI)"
FT                   /evidence="ECO:0000269|PubMed:10694923"
FT                   /id="VAR_003548"
FT   VARIANT         352
FT                   /note="G -> D (in dbSNP:rs146350208)"
FT                   /id="VAR_015356"
FT   MUTAGEN         341
FT                   /note="C->S: Reduced palmitoylation, reduced cell surface
FT                   localization but coupling to G protein unaffected."
FT                   /evidence="ECO:0000269|PubMed:9224808"
FT   MUTAGEN         342
FT                   /note="C->S: Reduced palmitoylation, reduced cell surface
FT                   localization but coupling to G protein unaffected."
FT                   /evidence="ECO:0000269|PubMed:9224808"
SQ   SEQUENCE   371 AA;  40279 MW;  1F87D20A3C0ECB0D CRC64;
     MLMASTTSAV PGHPSLPSLP SNSSQERPLD TRDPLLARAE LALLSIVFVA VALSNGLVLA
     ALARRGRRGH WAPIHVFIGH LCLADLAVAL FQVLPQLAWK ATDRFRGPDA LCRAVKYLQM
     VGMYASSYMI LAMTLDRHRA ICRPMLAYRH GSGAHWNRPV LVAWAFSLLL SLPQLFIFAQ
     RNVEGGSGVT DCWACFAEPW GRRTYVTWIA LMVFVAPTLG IAACQVLIFR EIHASLVPGP
     SERPGGRRRG RRTGSPGEGA HVSAAVAKTV RMTLVIVVVY VLCWAPFFLV QLWAAWDPEA
     PLEGAPFVLL MLLASLNSCT NPWIYASFSS SVSSELRSLL CCARGRTPPS LGPQDESCTT
     ASSSLAKDTS S
//
ID   V1AR_HUMAN              Reviewed;         418 AA.
AC   P37288;
DT   01-OCT-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1994, sequence version 1.
DT   07-OCT-2020, entry version 182.
DE   RecName: Full=Vasopressin V1a receptor;
DE            Short=V1aR;
DE   AltName: Full=AVPR V1a;
DE   AltName: Full=Antidiuretic hormone receptor 1a;
DE   AltName: Full=Vascular/hepatic-type arginine vasopressin receptor;
GN   Name=AVPR1A; Synonyms=AVPR1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=8106369;
RA   Thibonnier M., Auzan C., Madhun Z., Wilkins P., Berti-Mattera L.,
RA   Clauser E.;
RT   "Molecular cloning, sequencing, and functional expression of a cDNA
RT   encoding the human V1a vasopressin receptor.";
RL   J. Biol. Chem. 269:3304-3310(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=8074728; DOI=10.1006/bbrc.1994.2150;
RA   Hirasawa A., Shibata K., Kotosai K., Tsujimoto G.;
RT   "Cloning, functional expression and tissue distribution of human cDNA for
RT   the vascular-type vasopressin receptor.";
RL   Biochem. Biophys. Res. Commun. 203:72-79(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lung;
RX   PubMed=9357056; DOI=10.1016/s0196-9781(97)00072-7;
RA   North W.G., Fay M.J., Longo K.A., Du J.;
RT   "Functional vasopressin V1 type receptors are present in variant as well as
RT   classical forms of small-cell carcinoma.";
RL   Peptides 18:985-993(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9581826;
RA   North W.G., Fay M.J., Longo K.A., Du J.;
RT   "Expression of all known vasopressin receptor subtypes by small cell tumors
RT   implies a multifaceted role for this neuropeptide.";
RL   Cancer Res. 58:1866-1871(1998).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   ROLE IN SOCIAL BEHAVIOR.
RX   PubMed=12082568; DOI=10.1038/sj.mp.4001125;
RA   Kim S.J., Young L.J., Gonen D., Veenstra-VanderWeele J., Courchesne R.,
RA   Courchesne E., Lord C., Leventhal B.L., Cook E.H. Jr., Insel T.R.;
RT   "Transmission disequilibrium testing of arginine vasopressin receptor 1A
RT   (AVPR1A) polymorphisms in autism.";
RL   Mol. Psychiatry 7:503-507(2002).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 362-418.
RX   PubMed=16511036; DOI=10.1107/s1744309105007293;
RA   Adikesavan N.V., Mahmood S.S., Stanley N., Xu Z., Wu N., Thibonnier M.,
RA   Shoham M.;
RT   "A C-terminal segment of the V1R vasopressin receptor is unstructured in
RT   the crystal structure of its chimera with the maltose-binding protein.";
RL   Acta Crystallogr. F 61:341-345(2005).
CC   -!- FUNCTION: Receptor for arginine vasopressin. The activity of this
CC       receptor is mediated by G proteins which activate a phosphatidyl-
CC       inositol-calcium second messenger system. Has been involved in social
CC       behaviors, including affiliation and attachment.
CC       {ECO:0000269|PubMed:12082568}.
CC   -!- INTERACTION:
CC       P37288; P25106: ACKR3; NbExp=7; IntAct=EBI-6656842, EBI-1965291;
CC       P37288; P61073: CXCR4; NbExp=2; IntAct=EBI-6656842, EBI-489411;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- MISCELLANEOUS: Differences in regional receptor expression in the brain
CC       as well as differences in social behavior may result from a highly
CC       variable repetitive sequence in the 5' flanking region of AVPR1A. One
CC       such allelic variant has been linked to autism.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       Vasopressin/oxytocin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L25615; AAA62271.1; -; mRNA.
DR   EMBL; U19906; AAB19232.1; -; Genomic_DNA.
DR   EMBL; S73899; AAC60638.1; -; mRNA.
DR   EMBL; AF030625; AAC51861.1; -; mRNA.
DR   EMBL; AF101725; AAD17891.1; -; mRNA.
DR   EMBL; AY322550; AAP84363.1; -; mRNA.
DR   EMBL; BC074803; AAH74803.1; -; mRNA.
DR   EMBL; BC074804; AAH74804.1; -; mRNA.
DR   CCDS; CCDS8965.1; -.
DR   PIR; A53046; A53046.
DR   RefSeq; NP_000697.1; NM_000706.4.
DR   PDB; 1YTV; X-ray; 1.80 A; M/N=362-418.
DR   PDBsum; 1YTV; -.
DR   BioGRID; 107033; 3.
DR   IntAct; P37288; 4.
DR   STRING; 9606.ENSP00000299178; -.
DR   BindingDB; P37288; -.
DR   ChEMBL; CHEMBL1889; -.
DR   DrugBank; DB09059; Atosiban.
DR   DrugBank; DB00872; Conivaptan.
DR   DrugBank; DB00035; Desmopressin.
DR   DrugBank; DB00093; Felypressin.
DR   DrugBank; DB14642; Lypressin.
DR   DrugBank; DB05452; PH-284.
DR   DrugBank; DB13929; Relcovaptan.
DR   DrugBank; DB02638; Terlipressin.
DR   DrugBank; DB06212; Tolvaptan.
DR   DrugBank; DB00067; Vasopressin.
DR   DrugCentral; P37288; -.
DR   GuidetoPHARMACOLOGY; 366; -.
DR   GlyGen; P37288; 2 sites.
DR   iPTMnet; P37288; -.
DR   PhosphoSitePlus; P37288; -.
DR   BioMuta; AVPR1A; -.
DR   DMDM; 586197; -.
DR   PaxDb; P37288; -.
DR   PeptideAtlas; P37288; -.
DR   PRIDE; P37288; -.
DR   ProteomicsDB; 55276; -.
DR   Antibodypedia; 29106; 282 antibodies.
DR   Ensembl; ENST00000299178; ENSP00000299178; ENSG00000166148.
DR   GeneID; 552; -.
DR   KEGG; hsa:552; -.
DR   CTD; 552; -.
DR   DisGeNET; 552; -.
DR   EuPathDB; HostDB:ENSG00000166148.3; -.
DR   GeneCards; AVPR1A; -.
DR   HGNC; HGNC:895; AVPR1A.
DR   HPA; ENSG00000166148; Tissue enhanced (adrenal gland, liver).
DR   MIM; 600821; gene.
DR   neXtProt; NX_P37288; -.
DR   OpenTargets; ENSG00000166148; -.
DR   PharmGKB; PA25187; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00950000182665; -.
DR   HOGENOM; CLU_009579_15_3_1; -.
DR   InParanoid; P37288; -.
DR   KO; K04226; -.
DR   OMA; RFRGPDW; -.
DR   OrthoDB; 890925at2759; -.
DR   PhylomeDB; P37288; -.
DR   TreeFam; TF106499; -.
DR   PathwayCommons; P37288; -.
DR   Reactome; R-HSA-388479; Vasopressin-like receptors.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-5619099; Defective AVP does not bind AVPR1A,B and causes neurohypophyseal diabetes insipidus (NDI).
DR   SIGNOR; P37288; -.
DR   BioGRID-ORCS; 552; 40 hits in 870 CRISPR screens.
DR   ChiTaRS; AVPR1A; human.
DR   EvolutionaryTrace; P37288; -.
DR   GeneWiki; Arginine_vasopressin_receptor_1A; -.
DR   GenomeRNAi; 552; -.
DR   Pharos; P37288; Tclin.
DR   PRO; PR:P37288; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; P37288; protein.
DR   Bgee; ENSG00000166148; Expressed in adrenal gland and 168 other tissues.
DR   ExpressionAtlas; P37288; baseline and differential.
DR   Genevisible; P37288; HS.
DR   GO; GO:0030139; C:endocytic vesicle; IDA:ARUK-UCL.
DR   GO; GO:0005768; C:endosome; IDA:ARUK-UCL.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:ARUK-UCL.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0042277; F:peptide binding; IBA:GO_Central.
DR   GO; GO:0017046; F:peptide hormone binding; IEA:Ensembl.
DR   GO; GO:0005080; F:protein kinase C binding; TAS:ProtInc.
DR   GO; GO:0031894; F:V1A vasopressin receptor binding; IEA:Ensembl.
DR   GO; GO:0005000; F:vasopressin receptor activity; IDA:ARUK-UCL.
DR   GO; GO:0007202; P:activation of phospholipase C activity; TAS:ProtInc.
DR   GO; GO:0008015; P:blood circulation; TAS:ProtInc.
DR   GO; GO:0019722; P:calcium-mediated signaling; IEA:Ensembl.
DR   GO; GO:0042631; P:cellular response to water deprivation; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0006091; P:generation of precursor metabolites and energy; TAS:ProtInc.
DR   GO; GO:0007625; P:grooming behavior; IEA:Ensembl.
DR   GO; GO:0002125; P:maternal aggressive behavior; IEA:Ensembl.
DR   GO; GO:0042711; P:maternal behavior; IEA:Ensembl.
DR   GO; GO:0014902; P:myotube differentiation; IEA:Ensembl.
DR   GO; GO:0007621; P:negative regulation of female receptivity; IEA:Ensembl.
DR   GO; GO:0051970; P:negative regulation of transmission of nerve impulse; IEA:Ensembl.
DR   GO; GO:0043084; P:penile erection; IEA:Ensembl.
DR   GO; GO:0030307; P:positive regulation of cell growth; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:ARUK-UCL.
DR   GO; GO:0032849; P:positive regulation of cellular pH reduction; IEA:Ensembl.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; TAS:ProtInc.
DR   GO; GO:0014049; P:positive regulation of glutamate secretion; IEA:Ensembl.
DR   GO; GO:0010460; P:positive regulation of heart rate; IEA:Ensembl.
DR   GO; GO:0031394; P:positive regulation of prostaglandin biosynthetic process; IEA:Ensembl.
DR   GO; GO:0035815; P:positive regulation of renal sodium excretion; IEA:Ensembl.
DR   GO; GO:0003084; P:positive regulation of systemic arterial blood pressure; IEA:Ensembl.
DR   GO; GO:0045907; P:positive regulation of vasoconstriction; IBA:GO_Central.
DR   GO; GO:0001992; P:regulation of systemic arterial blood pressure by vasopressin; IBA:GO_Central.
DR   GO; GO:0051412; P:response to corticosterone; IEA:Ensembl.
DR   GO; GO:0035176; P:social behavior; IEA:Ensembl.
DR   GO; GO:0042713; P:sperm ejaculation; IEA:Ensembl.
DR   GO; GO:0021537; P:telencephalon development; IEA:Ensembl.
DR   GO; GO:0150104; P:transport across blood-brain barrier; NAS:ARUK-UCL.
DR   InterPro; IPR015076; DUF1856.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR001817; Vasoprsn_rcpt.
DR   InterPro; IPR001224; Vprs_V1A_rcpt.
DR   Pfam; PF00001; 7tm_1; 1.
DR   Pfam; PF08983; DUF1856; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00896; VASOPRESSINR.
DR   PRINTS; PR00752; VASOPRSNV1AR.
DR   SMART; SM01164; DUF1856; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Lipoprotein; Membrane; Palmitate; Phosphoprotein;
KW   Polymorphism; Receptor; Reference proteome; Transducer; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..418
FT                   /note="Vasopressin V1a receptor"
FT                   /id="PRO_0000070197"
FT   TOPO_DOM        1..52
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        53..76
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        77..88
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        89..110
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        111..125
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        126..147
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        148..168
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        169..190
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        191..218
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        219..239
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        240..293
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        294..313
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        314..331
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        332..351
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        352..418
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         404
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q62463"
FT   LIPID           365
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250"
FT   LIPID           366
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        27
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        196
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        124..203
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VARIANT         6
FT                   /note="G -> S (in dbSNP:rs2228154)"
FT                   /id="VAR_022065"
SQ   SEQUENCE   418 AA;  46800 MW;  477D4260EC826561 CRC64;
     MRLSAGPDAG PSGNSSPWWP LATGAGNTSR EAEALGEGNG PPRDVRNEEL AKLEIAVLAV
     TFAVAVLGNS SVLLALHRTP RKTSRMHLFI RHLSLADLAV AFFQVLPQMC WDITYRFRGP
     DWLCRVVKHL QVFGMFASAY MLVVMTADRY IAVCHPLKTL QQPARRSRLM IAAAWVLSFV
     LSTPQYFVFS MIEVNNVTKA RDCWATFIQP WGSRAYVTWM TGGIFVAPVV ILGTCYGFIC
     YNIWCNVRGK TASRQSKGAE QAGVAFQKGF LLAPCVSSVK SISRAKIRTV KMTFVIVTAY
     IVCWAPFFII QMWSVWDPMS VWTESENPTI TITALLGSLN SCCNPWIYMF FSGHLLQDCV
     QSFPCCQNMK EKFNKEDTDS MSRRQTFYSN NRSPTNSTGM WKDSPKSSKS IKFIPVST
//
ID   VIPR1_HUMAN             Reviewed;         457 AA.
AC   P32241; A5JUT9; B3KPV1; B4DEB5; B4DGI4; F5H1F5; G3V0I1; Q15871; Q6P2M6;
DT   01-OCT-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1993, sequence version 1.
DT   07-OCT-2020, entry version 190.
DE   RecName: Full=Vasoactive intestinal polypeptide receptor 1;
DE            Short=VIP-R-1;
DE   AltName: Full=Pituitary adenylate cyclase-activating polypeptide type II receptor;
DE            Short=PACAP type II receptor;
DE            Short=PACAP-R-2;
DE            Short=PACAP-R2;
DE   AltName: Full=VPAC1;
DE   Flags: Precursor;
GN   Name=VIPR1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM SHORT).
RC   TISSUE=Intestine;
RX   PubMed=8390245; DOI=10.1006/bbrc.1993.1658;
RA   Sreedharan S.P., Patel D.R., Huang J.-X., Goetzl E.J.;
RT   "Cloning and functional expression of a human neuroendocrine vasoactive
RT   intestinal peptide receptor.";
RL   Biochem. Biophys. Res. Commun. 193:546-553(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS SHORT AND LONG), AND ALTERNATIVE
RP   SPLICING.
RC   TISSUE=Intestine;
RX   PubMed=8179610; DOI=10.1006/bbrc.1994.1517;
RA   Couvineau A., Rouyer-Fessard C., Darmoul D., Maoret J.J., Carrero I.,
RA   Ogier-Denis E., Laburthe M.;
RT   "Human intestinal VIP receptor: cloning and functional expression of two
RT   cDNA encoding proteins with different N-terminal domains.";
RL   Biochem. Biophys. Res. Commun. 200:769-776(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Suwa M., Sato T., Okouchi I., Arita M., Futami K., Matsumoto S.,
RA   Tsutsumi S., Aburatani H., Asai K., Akiyama Y.;
RT   "Genome-wide discovery and analysis of human seven transmembrane helix
RT   receptor genes.";
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT).
RC   TISSUE=Lung;
RA   Martin A.L., Kaighin V.A., Aronstam R.S.;
RL   Submitted (APR-2007) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS SHORT; 3; 4 AND 5).
RC   TISSUE=Brain, Cerebellum, Lung, and Prostate;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM SHORT), AND VARIANT
RP   MET-341.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 33-457.
RC   TISSUE=Liver;
RX   PubMed=7917790; DOI=10.1016/0898-6568(94)90037-x;
RA   Gagnon A.W., Aiyar N., Elshourbagy N.A.;
RT   "Molecular cloning and functional characterization of a human liver
RT   vasoactive intestinal peptide receptor.";
RL   Cell. Signal. 6:321-333(1994).
RN   [10]
RP   INTERACTION WITH VIP.
RX   PubMed=7818527; DOI=10.1006/bbrc.1995.1034;
RA   Couvineau A., Gaudin P., Maoret J.J., Rouyer-Fessard C., Nicole P.,
RA   Laburthe M.;
RT   "Highly conserved aspartate 68, tryptophan 73 and glycine 109 in the N-
RT   terminal extracellular domain of the human VIP receptor are essential for
RT   its ability to bind VIP.";
RL   Biochem. Biophys. Res. Commun. 206:246-252(1995).
RN   [11]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=8926282; DOI=10.1007/bf01540969;
RA   Xia M., Sreedharan S.P., Goetzl E.J.;
RT   "Predominant expression of type II vasoactive intestinal peptide receptors
RT   by human T lymphoblastoma cells: transduction of both Ca2+ and cyclic AMP
RT   signals.";
RL   J. Clin. Immunol. 16:21-30(1996).
RN   [12]
RP   DISULFIDE BOND.
RX   PubMed=9928020; DOI=10.1111/j.1749-6632.1998.tb11186.x;
RA   Knudsen S.M., Tams J.W., Wulff B.S., Fahrenkrug J.;
RT   "Importance of conserved cysteines in the extracellular loops of human
RT   PACAP/VIP1 receptor for ligand binding and stimulation of cAMP
RT   production.";
RL   Ann. N. Y. Acad. Sci. 865:259-265(1998).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.47 ANGSTROMS) OF 400-408 IN COMPLEX WITH MHC.
RX   PubMed=14734527; DOI=10.1084/jem.20031690;
RA   Hulsmeyer M., Fiorillo M.T., Bettosini F., Sorrentino R., Saenger W.,
RA   Ziegler A., Uchanska-Ziegler B.;
RT   "Dual, HLA-B27 subtype-dependent conformation of a self-peptide.";
RL   J. Exp. Med. 199:271-281(2004).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.86 ANGSTROMS) OF 400-408 IN COMPLEX WITH MHC.
RX   PubMed=18650441; DOI=10.1074/jbc.m802818200;
RA   Beltrami A., Rossmann M., Fiorillo M.T., Paladini F., Sorrentino R.,
RA   Saenger W., Kumar P., Ziegler A., Uchanska-Ziegler B.;
RT   "Citrullination-dependent differential presentation of a self-peptide by
RT   HLA-B27 subtypes.";
RL   J. Biol. Chem. 283:27189-27199(2008).
CC   -!- FUNCTION: This is a receptor for VIP. The activity of this receptor is
CC       mediated by G proteins which activate adenylyl cyclase. The affinity is
CC       VIP = PACAP-27 > PACAP-38. {ECO:0000269|PubMed:8926282}.
CC   -!- INTERACTION:
CC       P32241; Q9NQX1-2: PRDM5; NbExp=3; IntAct=EBI-3917984, EBI-12859340;
CC       P32241; PRO_0000011460 [P01282]: VIP; NbExp=2; IntAct=EBI-3917984, EBI-6656819;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=Short; Synonyms=hIVR8;
CC         IsoId=P32241-1; Sequence=Displayed;
CC       Name=Long; Synonyms=hIVR5;
CC         IsoId=P32241-2; Sequence=VSP_002010;
CC       Name=3;
CC         IsoId=P32241-3; Sequence=VSP_045143;
CC       Name=4;
CC         IsoId=P32241-4; Sequence=VSP_047271, VSP_047273;
CC       Name=5;
CC         IsoId=P32241-5; Sequence=VSP_047272;
CC   -!- TISSUE SPECIFICITY: In lung, HT-29 colonic epithelial cells, Raji B-
CC       lymphoblasts. Lesser extent in brain, heart, kidney, liver and
CC       placenta. Not expressed in CD4+ or CD8+ T-cells. Expressed in the T-
CC       cell lines HARRIS, HuT 78, Jurkat and SUP-T1, but not in the T-cell
CC       lines Peer, MOLT-4, HSB and YT. {ECO:0000269|PubMed:8926282}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 2 family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L13288; AAA36805.1; -; mRNA.
DR   EMBL; U11087; AAB60362.1; -; Genomic_DNA.
DR   EMBL; U11079; AAB60362.1; JOINED; Genomic_DNA.
DR   EMBL; U11080; AAB60362.1; JOINED; Genomic_DNA.
DR   EMBL; U11081; AAB60362.1; JOINED; Genomic_DNA.
DR   EMBL; U11083; AAB60362.1; JOINED; Genomic_DNA.
DR   EMBL; U11084; AAB60362.1; JOINED; Genomic_DNA.
DR   EMBL; U11085; AAB60362.1; JOINED; Genomic_DNA.
DR   EMBL; U11086; AAB60362.1; JOINED; Genomic_DNA.
DR   EMBL; X75299; CAA53046.1; -; mRNA.
DR   EMBL; X77777; CAA54814.1; -; mRNA.
DR   EMBL; AB065669; BAC05895.1; -; Genomic_DNA.
DR   EMBL; EF577396; ABQ52416.1; -; mRNA.
DR   EMBL; AK314334; BAG36980.1; -; mRNA.
DR   EMBL; AK293548; BAG57026.1; -; mRNA.
DR   EMBL; AK294609; BAG57795.1; -; mRNA.
DR   EMBL; AK056819; BAG51813.1; -; mRNA.
DR   EMBL; AC092047; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471055; EAW64649.1; -; Genomic_DNA.
DR   EMBL; CH471055; EAW64650.1; -; Genomic_DNA.
DR   EMBL; BC064424; AAH64424.1; -; mRNA.
DR   EMBL; L20295; AAA36802.1; -; mRNA.
DR   CCDS; CCDS2698.1; -. [P32241-1]
DR   CCDS; CCDS58827.1; -. [P32241-4]
DR   CCDS; CCDS58828.1; -. [P32241-5]
DR   CCDS; CCDS58829.1; -. [P32241-3]
DR   PIR; JC2194; JC2194.
DR   PIR; JC2195; JC2195.
DR   RefSeq; NP_001238811.1; NM_001251882.1. [P32241-5]
DR   RefSeq; NP_001238812.1; NM_001251883.1. [P32241-3]
DR   RefSeq; NP_001238813.1; NM_001251884.1. [P32241-4]
DR   RefSeq; NP_001238814.1; NM_001251885.1.
DR   RefSeq; NP_004615.2; NM_004624.3. [P32241-1]
DR   PDB; 1OF2; X-ray; 2.20 A; C=400-408.
DR   PDB; 1OGT; X-ray; 1.47 A; C=400-408.
DR   PDB; 3B3I; X-ray; 1.86 A; C=400-408.
DR   PDB; 3B6S; X-ray; 1.80 A; C=400-408.
DR   PDB; 3DTX; X-ray; 2.10 A; C=400-408.
DR   PDB; 3HCV; X-ray; 1.95 A; C=400-408.
DR   PDB; 5DEF; X-ray; 1.60 A; C=400-408.
DR   PDB; 5DEG; X-ray; 1.83 A; C=400-408.
DR   PDB; 5IB1; X-ray; 1.91 A; C=400-408.
DR   PDB; 5IB2; X-ray; 1.44 A; C=400-408.
DR   PDB; 5IB3; X-ray; 1.91 A; C=400-408.
DR   PDB; 5IB4; X-ray; 1.95 A; C=400-408.
DR   PDB; 5IB5; X-ray; 2.49 A; C/F=400-408.
DR   PDBsum; 1OF2; -.
DR   PDBsum; 1OGT; -.
DR   PDBsum; 3B3I; -.
DR   PDBsum; 3B6S; -.
DR   PDBsum; 3DTX; -.
DR   PDBsum; 3HCV; -.
DR   PDBsum; 5DEF; -.
DR   PDBsum; 5DEG; -.
DR   PDBsum; 5IB1; -.
DR   PDBsum; 5IB2; -.
DR   PDBsum; 5IB3; -.
DR   PDBsum; 5IB4; -.
DR   PDBsum; 5IB5; -.
DR   SMR; P32241; -.
DR   BioGRID; 113274; 36.
DR   IntAct; P32241; 27.
DR   MINT; P32241; -.
DR   STRING; 9606.ENSP00000327246; -.
DR   BindingDB; P32241; -.
DR   ChEMBL; CHEMBL5144; -.
DR   DrugCentral; P32241; -.
DR   GuidetoPHARMACOLOGY; 371; -.
DR   TCDB; 9.A.14.4.9; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; P32241; 4 sites.
DR   iPTMnet; P32241; -.
DR   PhosphoSitePlus; P32241; -.
DR   SwissPalm; P32241; -.
DR   BioMuta; VIPR1; -.
DR   DMDM; 418253; -.
DR   jPOST; P32241; -.
DR   MassIVE; P32241; -.
DR   PaxDb; P32241; -.
DR   PeptideAtlas; P32241; -.
DR   PRIDE; P32241; -.
DR   ProteomicsDB; 25640; -.
DR   ProteomicsDB; 32204; -.
DR   ProteomicsDB; 3938; -.
DR   ProteomicsDB; 54848; -. [P32241-1]
DR   ProteomicsDB; 54849; -. [P32241-2]
DR   ABCD; P32241; 2 sequenced antibodies.
DR   Antibodypedia; 12331; 437 antibodies.
DR   DNASU; 7433; -.
DR   Ensembl; ENST00000325123; ENSP00000327246; ENSG00000114812. [P32241-1]
DR   Ensembl; ENST00000433647; ENSP00000394950; ENSG00000114812. [P32241-5]
DR   Ensembl; ENST00000438259; ENSP00000415371; ENSG00000114812. [P32241-3]
DR   Ensembl; ENST00000543411; ENSP00000445701; ENSG00000114812. [P32241-4]
DR   GeneID; 7433; -.
DR   KEGG; hsa:7433; -.
DR   UCSC; uc003clf.3; human. [P32241-1]
DR   CTD; 7433; -.
DR   DisGeNET; 7433; -.
DR   EuPathDB; HostDB:ENSG00000114812.12; -.
DR   GeneCards; VIPR1; -.
DR   HGNC; HGNC:12694; VIPR1.
DR   HPA; ENSG00000114812; Tissue enhanced (lung).
DR   MIM; 192321; gene.
DR   neXtProt; NX_P32241; -.
DR   OpenTargets; ENSG00000114812; -.
DR   PharmGKB; PA37313; -.
DR   eggNOG; KOG4564; Eukaryota.
DR   GeneTree; ENSGT00940000156402; -.
DR   HOGENOM; CLU_1124194_0_0_1; -.
DR   InParanoid; P32241; -.
DR   KO; K04589; -.
DR   OMA; NQTSGCR; -.
DR   OrthoDB; 651627at2759; -.
DR   PhylomeDB; P32241; -.
DR   TreeFam; TF315710; -.
DR   PathwayCommons; P32241; -.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-420092; Glucagon-type ligand receptors.
DR   Reactome; R-HSA-9660821; ADORA2B mediated anti-inflammatory cytokines production.
DR   SIGNOR; P32241; -.
DR   BioGRID-ORCS; 7433; 2 hits in 876 CRISPR screens.
DR   ChiTaRS; VIPR1; human.
DR   EvolutionaryTrace; P32241; -.
DR   GeneWiki; VIPR1; -.
DR   GenomeRNAi; 7433; -.
DR   Pharos; P32241; Tchem.
DR   PRO; PR:P32241; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; P32241; protein.
DR   Bgee; ENSG00000114812; Expressed in right lung and 168 other tissues.
DR   ExpressionAtlas; P32241; baseline and differential.
DR   Genevisible; P32241; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0008528; F:G protein-coupled peptide receptor activity; IBA:GO_Central.
DR   GO; GO:0017046; F:peptide hormone binding; IPI:GO_Central.
DR   GO; GO:0004999; F:vasoactive intestinal polypeptide receptor activity; IDA:GO_Central.
DR   GO; GO:0007188; P:adenylate cyclase-modulating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IEA:InterPro.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007187; P:G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; IDA:GO_Central.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; TAS:ProtInc.
DR   Gene3D; 4.10.1240.10; -; 1.
DR   InterPro; IPR017981; GPCR_2-like.
DR   InterPro; IPR036445; GPCR_2_extracell_dom_sf.
DR   InterPro; IPR001879; GPCR_2_extracellular_dom.
DR   InterPro; IPR000832; GPCR_2_secretin-like.
DR   InterPro; IPR017983; GPCR_2_secretin-like_CS.
DR   InterPro; IPR001571; GPCR_2_VIP_rcpt.
DR   InterPro; IPR001771; GPCR_2_VIP_rcpt_1.
DR   Pfam; PF00002; 7tm_2; 1.
DR   Pfam; PF02793; HRM; 1.
DR   PRINTS; PR00249; GPCRSECRETIN.
DR   PRINTS; PR00491; VASOACTVEIPR.
DR   PRINTS; PR01154; VIP1RECEPTOR.
DR   SMART; SM00008; HormR; 1.
DR   SUPFAM; SSF111418; SSF111418; 1.
DR   PROSITE; PS00649; G_PROTEIN_RECEP_F2_1; 1.
DR   PROSITE; PS00650; G_PROTEIN_RECEP_F2_2; 1.
DR   PROSITE; PS50227; G_PROTEIN_RECEP_F2_3; 1.
DR   PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Polymorphism; Receptor;
KW   Reference proteome; Signal; Transducer; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..30
FT                   /evidence="ECO:0000255"
FT   CHAIN           31..457
FT                   /note="Vasoactive intestinal polypeptide receptor 1"
FT                   /id="PRO_0000012855"
FT   TOPO_DOM        31..142
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        143..167
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        168..174
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        175..194
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        195..216
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        217..240
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        241..254
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        255..276
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        277..292
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        293..316
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        317..341
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        342..361
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        362..373
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        374..393
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        394..457
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        58
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        69
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        100
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        290
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        50..72
FT                   /evidence="ECO:0000250"
FT   DISULFID        63..105
FT                   /evidence="ECO:0000250"
FT   DISULFID        86..122
FT                   /evidence="ECO:0000250"
FT   DISULFID        215..285
FT                   /evidence="ECO:0000269|PubMed:9928020"
FT   VAR_SEQ         1..263
FT                   /note="MRPPSPLPARWLCVLAGALAWALGPAGGQAARLQEECDYVQMIEVQHKQCLE
FT                   EAQLENETIGCSKMWDNLTCWPATPRGQVVVLACPLIFKLFSSIQGRNVSRSCTDEGWT
FT                   HLEPGPYPIACGLDDKAASLDEQQTMFYGSVKTGYTIGYGLSLATLLVATAILSLFRKL
FT                   HCTRNYIHMHLFISFILRAAAVFIKDLALFDSGESDQCSEGSVGCKAAMVFFQYCVMAN
FT                   FFWLLVEGLYLYTLLAVSFFSERKYFWGYILIGW -> MTRQRVWMRWAVRQPWSFSNI
FT                   VSWLTSSGCWWRASTCTPCLPSPSSLSGSTSG (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_045143"
FT   VAR_SEQ         1..61
FT                   /note="MRPPSPLPARWLCVLAGALAWALGPAGGQAARLQEECDYVQMIEVQHKQCLE
FT                   EAQLENETI -> MRAGRRPRLGPWAG (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_047271"
FT   VAR_SEQ         1..41
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_047272"
FT   VAR_SEQ         1..32
FT                   /note="MRPPSPLPARWLCVLAGALAWALGPAGGQAAR -> MPPPPLLSLRRLGGGW
FT                   SAVTRLVVAAAGARSRGGRGGSRGAGGGGRGGVARRRRLELRAARSLLGSS (in
FT                   isoform Long)"
FT                   /evidence="ECO:0000303|PubMed:8179610"
FT                   /id="VSP_002010"
FT   VAR_SEQ         134
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_047273"
FT   VARIANT         341
FT                   /note="R -> M (in dbSNP:rs17855906)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_055041"
FT   VARIANT         445
FT                   /note="R -> L (in dbSNP:rs3733055)"
FT                   /id="VAR_020021"
FT   CONFLICT        80
FT                   /note="Q -> R (in Ref. 5; BAG57795)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        284
FT                   /note="G -> GLLR (in Ref. 2; CAA54814/CAA53046)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        320
FT                   /note="L -> F (in Ref. 5; BAG51813)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        369
FT                   /note="K -> R (in Ref. 5; BAG57795)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   457 AA;  51547 MW;  DAA40CF5BEC47D7D CRC64;
     MRPPSPLPAR WLCVLAGALA WALGPAGGQA ARLQEECDYV QMIEVQHKQC LEEAQLENET
     IGCSKMWDNL TCWPATPRGQ VVVLACPLIF KLFSSIQGRN VSRSCTDEGW THLEPGPYPI
     ACGLDDKAAS LDEQQTMFYG SVKTGYTIGY GLSLATLLVA TAILSLFRKL HCTRNYIHMH
     LFISFILRAA AVFIKDLALF DSGESDQCSE GSVGCKAAMV FFQYCVMANF FWLLVEGLYL
     YTLLAVSFFS ERKYFWGYIL IGWGVPSTFT MVWTIARIHF EDYGCWDTIN SSLWWIIKGP
     ILTSILVNFI LFICIIRILL QKLRPPDIRK SDSSPYSRLA RSTLLLIPLF GVHYIMFAFF
     PDNFKPEVKM VFELVVGSFQ GFVVAILYCF LNGEVQAELR RKWRRWHLQG VLGWNPKYRH
     PSGGSNGATC STQVSMLTRV SPGARRSSSF QAEVSLV
//
ID   ADRB3_HUMAN             Reviewed;         408 AA.
AC   P13945; Q4JFT4;
DT   01-JAN-1990, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1994, sequence version 3.
DT   07-OCT-2020, entry version 207.
DE   RecName: Full=Beta-3 adrenergic receptor;
DE   AltName: Full=Beta-3 adrenoreceptor;
DE            Short=Beta-3 adrenoceptor;
GN   Name=ADRB3; Synonyms=ADRB3R, B3AR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2570461; DOI=10.1126/science.2570461;
RA   Emorine L.J., Marullo S., Briend-Sutren M.-M., Patey G., Tate K.,
RA   Delavier-Klutchko C., Strosberg A.D.;
RT   "Molecular characterization of the human beta 3-adrenergic receptor.";
RL   Science 245:1118-1121(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND SEQUENCE REVISION.
RX   PubMed=8389293; DOI=10.1111/j.1432-1033.1993.tb17861.x;
RA   van Spronsen A., Nahmias C., Krief S., Briend-Sutren M.-M., Strosberg A.D.,
RA   Emorine L.J.;
RT   "The promoter and intron/exon structure of the human and mouse beta 3-
RT   adrenergic-receptor genes.";
RL   Eur. J. Biochem. 213:1117-1124(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8389717; DOI=10.1016/0014-5793(93)81377-c;
RA   Lelias J.M., Kaghad M., Rodriguez M., Chalon P., Bonnin J., Dupre I.,
RA   Delpech B., Bensaid M., Lefur G., Ferrara P., Caput D.;
RT   "Molecular cloning of a human beta 3-adrenergic receptor cDNA.";
RL   FEBS Lett. 324:127-130(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Placenta;
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (NOV-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-64 AND CYS-353.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUN-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 392-408.
RX   PubMed=1336117;
RA   Granneman J.G., Lahners K.N., Rao D.D.;
RT   "Rodent and human beta 3-adrenergic receptor genes contain an intron within
RT   the protein-coding block.";
RL   Mol. Pharmacol. 42:964-970(1992).
RN   [8]
RP   INTERACTION WITH ARRDC3.
RX   PubMed=21982743; DOI=10.1016/j.cmet.2011.08.011;
RA   Patwari P., Emilsson V., Schadt E.E., Chutkow W.A., Lee S., Marsili A.,
RA   Zhang Y., Dobrin R., Cohen D.E., Larsen P.R., Zavacki A.M., Fong L.G.,
RA   Young S.G., Lee R.T.;
RT   "The arrestin domain-containing 3 protein regulates body mass and energy
RT   expenditure.";
RL   Cell Metab. 14:671-683(2011).
RN   [9]
RP   VARIANT ARG-64.
RX   PubMed=7609752; DOI=10.1056/nejm199508103330605;
RA   Clement K., Vaisse C., Manning B.S.J., Basdevant A., Guy-Grand B., Ruiz J.,
RA   Silver K.D., Shuldiner A.R., Froguel P., Strosberg A.D.;
RT   "Genetic variation in the beta 3-adrenergic receptor and an increased
RT   capacity to gain weight in patients with morbid obesity.";
RL   N. Engl. J. Med. 333:352-354(1995).
RN   [10]
RP   VARIANT ARG-64.
RX   PubMed=8721782; DOI=10.1007/bf00418352;
RA   Fujisawa T., Ikegami H., Yamato E., Takekawa K., Nakagawa Y., Hamada Y.,
RA   Oga T., Ueda H., Shintani M., Fukuda M., Ogihara T.;
RT   "Association of Trp64Arg mutation of the beta3-adrenergic-receptor with
RT   NIDDM and body weight gain.";
RL   Diabetologia 39:349-352(1996).
RN   [11]
RP   VARIANT ARG-64.
RX   PubMed=8641219; DOI=10.1210/endo.137.6.8641219;
RA   Candelore M.R., Deng L., Tota L.M., Kelly L.J., Cascieri M.A.,
RA   Strader C.D.;
RT   "Pharmacological characterization of a recently described human beta 3-
RT   adrenergic receptor mutant.";
RL   Endocrinology 137:2638-2641(1996).
RN   [12]
RP   VARIANTS ARG-64 AND MET-265.
RX   PubMed=10391210; DOI=10.1038/10297;
RA   Halushka M.K., Fan J.-B., Bentley K., Hsie L., Shen N., Weder A.,
RA   Cooper R., Lipshutz R., Chakravarti A.;
RT   "Patterns of single-nucleotide polymorphisms in candidate genes for blood-
RT   pressure homeostasis.";
RL   Nat. Genet. 22:239-247(1999).
CC   -!- FUNCTION: Beta-adrenergic receptors mediate the catecholamine-induced
CC       activation of adenylate cyclase through the action of G proteins. Beta-
CC       3 is involved in the regulation of lipolysis and thermogenesis.
CC   -!- SUBUNIT: Interacts with ARRDC3. {ECO:0000269|PubMed:21982743}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Expressed mainly in adipose tissues.
CC   -!- POLYMORPHISM: The variant Arg-64 seems to be associated with weight
CC       gain (obesity) and is also associated with susceptibility to non-
CC       insulin-dependent diabetes mellitus (NIDDM).
CC       {ECO:0000269|PubMed:8721782, ECO:0000305|PubMed:7609752}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       Adrenergic receptor subfamily. ADRB3 sub-subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/adrb3/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M29932; AAA35550.1; ALT_TERM; Genomic_DNA.
DR   EMBL; X72861; CAA51383.1; -; Genomic_DNA.
DR   EMBL; X70811; CAA50141.1; -; mRNA.
DR   EMBL; X70812; CAA50142.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; X70812; CAA50143.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AY487247; AAR37414.1; -; mRNA.
DR   EMBL; DQ104441; AAY88743.1; -; Genomic_DNA.
DR   EMBL; BC075017; AAH75017.1; -; mRNA.
DR   EMBL; S53291; AAB24837.1; -; mRNA.
DR   CCDS; CCDS6099.1; -.
DR   PIR; I57941; I57941.
DR   PIR; S33751; QRHUBE.
DR   RefSeq; NP_000016.1; NM_000025.2.
DR   PDB; 2CDW; Model; -; A=1-408.
DR   PDBsum; 2CDW; -.
DR   BioGRID; 106664; 2.
DR   DIP; DIP-61451N; -.
DR   IntAct; P13945; 6.
DR   STRING; 9606.ENSP00000343782; -.
DR   BindingDB; P13945; -.
DR   ChEMBL; CHEMBL246; -.
DR   DrugBank; DB00866; Alprenolol.
DR   DrugBank; DB05395; Amibegron.
DR   DrugBank; DB01118; Amiodarone.
DR   DrugBank; DB00182; Amphetamine.
DR   DrugBank; DB01102; Arbutamine.
DR   DrugBank; DB00217; Bethanidine.
DR   DrugBank; DB08807; Bopindolol.
DR   DrugBank; DB06726; Bufuralol.
DR   DrugBank; DB08808; Bupranolol.
DR   DrugBank; DB04846; Celiprolol.
DR   DrugBank; DB01407; Clenbuterol.
DR   DrugBank; DB11273; Dihydroergocornine.
DR   DrugBank; DB13345; Dihydroergocristine.
DR   DrugBank; DB11278; DL-Methylephedrine.
DR   DrugBank; DB06262; Droxidopa.
DR   DrugBank; DB01363; Ephedra sinica root.
DR   DrugBank; DB01049; Ergoloid mesylate.
DR   DrugBank; DB01288; Fenoterol.
DR   DrugBank; DB00983; Formoterol.
DR   DrugBank; DB01064; Isoprenaline.
DR   DrugBank; DB01365; Mephentermine.
DR   DrugBank; DB08893; Mirabegron.
DR   DrugBank; DB04861; Nebivolol.
DR   DrugBank; DB00368; Norepinephrine.
DR   DrugBank; DB00540; Nortriptyline.
DR   DrugBank; DB00334; Olanzapine.
DR   DrugBank; DB01580; Oxprenolol.
DR   DrugBank; DB00715; Paroxetine.
DR   DrugBank; DB00960; Pindolol.
DR   DrugBank; DB00571; Propranolol.
DR   DrugBank; DB11124; Racepinephrine.
DR   DrugBank; DB01001; Salbutamol.
DR   DrugBank; DB00938; Salmeterol.
DR   DrugBank; DB06190; Solabegron.
DR   DrugBank; DB00871; Terbutaline.
DR   DrugBank; DB00726; Trimipramine.
DR   DrugCentral; P13945; -.
DR   GuidetoPHARMACOLOGY; 30; -.
DR   GlyGen; P13945; 2 sites.
DR   PhosphoSitePlus; P13945; -.
DR   SwissPalm; P13945; -.
DR   BioMuta; ADRB3; -.
DR   DMDM; 461604; -.
DR   PaxDb; P13945; -.
DR   PRIDE; P13945; -.
DR   ProteomicsDB; 53011; -.
DR   Antibodypedia; 10846; 397 antibodies.
DR   Ensembl; ENST00000345060; ENSP00000343782; ENSG00000188778.
DR   GeneID; 155; -.
DR   KEGG; hsa:155; -.
DR   UCSC; uc003xkr.3; human.
DR   CTD; 155; -.
DR   DisGeNET; 155; -.
DR   EuPathDB; HostDB:ENSG00000188778.4; -.
DR   GeneCards; ADRB3; -.
DR   HGNC; HGNC:288; ADRB3.
DR   HPA; ENSG00000188778; Tissue enhanced (gallbladder, ovary, smooth muscle).
DR   MalaCards; ADRB3; -.
DR   MIM; 109691; gene.
DR   neXtProt; NX_P13945; -.
DR   OpenTargets; ENSG00000188778; -.
DR   PharmGKB; PA24598; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00940000158663; -.
DR   HOGENOM; CLU_009579_11_0_1; -.
DR   InParanoid; P13945; -.
DR   KO; K04143; -.
DR   OMA; APIMSKW; -.
DR   OrthoDB; 614199at2759; -.
DR   PhylomeDB; P13945; -.
DR   TreeFam; TF316350; -.
DR   PathwayCommons; P13945; -.
DR   Reactome; R-HSA-390696; Adrenoceptors.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-9660821; ADORA2B mediated anti-inflammatory cytokines production.
DR   SIGNOR; P13945; -.
DR   BioGRID-ORCS; 155; 3 hits in 877 CRISPR screens.
DR   GeneWiki; Beta-3_adrenergic_receptor; -.
DR   GenomeRNAi; 155; -.
DR   Pharos; P13945; Tclin.
DR   PRO; PR:P13945; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   RNAct; P13945; protein.
DR   Bgee; ENSG00000188778; Expressed in right ovary and 58 other tissues.
DR   ExpressionAtlas; P13945; baseline and differential.
DR   Genevisible; P13945; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IDA:HGNC-UCL.
DR   GO; GO:0004939; F:beta-adrenergic receptor activity; IDA:HGNC-UCL.
DR   GO; GO:0015052; F:beta3-adrenergic receptor activity; IMP:HGNC-UCL.
DR   GO; GO:0051379; F:epinephrine binding; IBA:GO_Central.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:HGNC-UCL.
DR   GO; GO:0007190; P:activation of adenylate cyclase activity; IDA:HGNC-UCL.
DR   GO; GO:0071880; P:adenylate cyclase-activating adrenergic receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007188; P:adenylate cyclase-modulating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0005975; P:carbohydrate metabolic process; TAS:ProtInc.
DR   GO; GO:0006112; P:energy reserve metabolic process; TAS:ProtInc.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007187; P:G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; TAS:ProtInc.
DR   GO; GO:0006091; P:generation of precursor metabolites and energy; TAS:ProtInc.
DR   GO; GO:0002025; P:norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressure; IBA:GO_Central.
DR   GO; GO:0120162; P:positive regulation of cold-induced thermogenesis; ISS:YuBioLab.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:HGNC-UCL.
DR   InterPro; IPR002233; ADR_fam.
DR   InterPro; IPR000681; ADRB3_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01103; ADRENERGICR.
DR   PRINTS; PR00563; ADRENRGCB3AR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Diabetes mellitus; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane; Obesity;
KW   Palmitate; Polymorphism; Receptor; Reference proteome; Transducer;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..408
FT                   /note="Beta-3 adrenergic receptor"
FT                   /id="PRO_0000069143"
FT   TOPO_DOM        1..36
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        37..63
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        64..72
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        73..91
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        92..111
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        112..133
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        134..155
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        156..178
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        179..203
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        204..225
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        226..292
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        293..314
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        315..326
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        327..347
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        348..408
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   REGION          198..212
FT                   /note="Agonist and antagonist binding"
FT                   /evidence="ECO:0000250"
FT   REGION          305..312
FT                   /note="Agonist and antagonist binding"
FT                   /evidence="ECO:0000250"
FT   REGION          332..336
FT                   /note="Agonist and antagonist binding"
FT                   /evidence="ECO:0000250"
FT   BINDING         117
FT                   /note="Agonist or antagonist"
FT                   /evidence="ECO:0000250"
FT   BINDING         122
FT                   /note="Agonist or antagonist"
FT                   /evidence="ECO:0000250"
FT   LIPID           361
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        8
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        26
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        110..196
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   DISULFID        189..195
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VARIANT         64
FT                   /note="W -> R (in dbSNP:rs4994)"
FT                   /evidence="ECO:0000269|PubMed:10391210,
FT                   ECO:0000269|PubMed:7609752, ECO:0000269|PubMed:8641219,
FT                   ECO:0000269|PubMed:8721782, ECO:0000269|Ref.5"
FT                   /id="VAR_003456"
FT   VARIANT         249
FT                   /note="E -> K (in dbSNP:rs28364012)"
FT                   /id="VAR_029205"
FT   VARIANT         265
FT                   /note="T -> M (in dbSNP:rs4995)"
FT                   /evidence="ECO:0000269|PubMed:10391210"
FT                   /id="VAR_014166"
FT   VARIANT         353
FT                   /note="R -> C (in dbSNP:rs36031925)"
FT                   /evidence="ECO:0000269|Ref.5"
FT                   /id="VAR_025102"
SQ   SEQUENCE   408 AA;  43519 MW;  E98BD6C130DD977B CRC64;
     MAPWPHENSS LAPWPDLPTL APNTANTSGL PGVPWEAALA GALLALAVLA TVGGNLLVIV
     AIAWTPRLQT MTNVFVTSLA AADLVMGLLV VPPAATLALT GHWPLGATGC ELWTSVDVLC
     VTASIETLCA LAVDRYLAVT NPLRYGALVT KRCARTAVVL VWVVSAAVSF APIMSQWWRV
     GADAEAQRCH SNPRCCAFAS NMPYVLLSSS VSFYLPLLVM LFVYARVFVV ATRQLRLLRG
     ELGRFPPEES PPAPSRSLAP APVGTCAPPE GVPACGRRPA RLLPLREHRA LCTLGLIMGT
     FTLCWLPFFL ANVLRALGGP SLVPGPAFLA LNWLGYANSA FNPLIYCRSP DFRSAFRRLL
     CRCGRRLPPE PCAAARPALF PSGVPAARSS PAQPRLCQRL DGASWGVS
//
ID   CLTR1_HUMAN             Reviewed;         337 AA.
AC   Q9Y271; B2R954; D3DTE4; Q5JS94; Q8IV19;
DT   11-FEB-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1999, sequence version 1.
DT   07-OCT-2020, entry version 164.
DE   RecName: Full=Cysteinyl leukotriene receptor 1;
DE            Short=CysLTR1;
DE   AltName: Full=Cysteinyl leukotriene D4 receptor;
DE            Short=LTD4 receptor;
DE   AltName: Full=G-protein coupled receptor HG55;
DE   AltName: Full=HMTMF81;
GN   Name=CYSLTR1; Synonyms=CYSLT1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Tonsil;
RX   PubMed=10391245; DOI=10.1038/21658;
RA   Lynch K.R., O'Neill G.P., Liu Q., Im D.-S., Sawyer N., Metters K.M.,
RA   Coulombe N., Abramovitz M., Figueroa D.J., Zeng Z., Connolly B.M., Bai C.,
RA   Austin C.P., Chateauneuf A., Stocco R., Greig G.M., Kargman S., Hooks S.B.,
RA   Hosfield E., Williams D.L. Jr., Ford-Hutchinson A.W., Caskey C.T.,
RA   Evans J.F.;
RT   "Characterization of the human cysteinyl leukotriene CysLT1 receptor.";
RL   Nature 399:789-793(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Leukocyte, Peripheral blood monocyte, and Spleen;
RX   PubMed=10462554; DOI=10.1124/mol.56.3.657;
RA   Sarau H.M., Ames R.S., Chambers J., Ellis C., Elshourbagy N., Foley J.J.,
RA   Schmidt D.B., Muccitelli R.M., Jenkins O., Murdock P.R., Herrity N.C.,
RA   Halsey W., Sathe G., Muir A.I., Nuthulaganti P., Dytko G.M., Buckley P.T.,
RA   Wilson S., Bergsma D.J., Hay D.W.P.;
RT   "Identification, molecular cloning, expression, and characterization of a
RT   cysteinyl leukotriene receptor.";
RL   Mol. Pharmacol. 56:657-663(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Warren C.N., Aronstam R.S., Sharma S.V.;
RT   "Isolation of complete coding sequence for cysteinyl leukotriene receptor 1
RT   (CYSLTR1).";
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Uterus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L.,
RA   Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C.,
RA   Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A.,
RA   Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P.,
RA   Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D.,
RA   Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D.,
RA   Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L.,
RA   Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P.,
RA   Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G.,
RA   Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J.,
RA   Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D.,
RA   Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L.,
RA   Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z.,
RA   Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O.,
RA   Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H.,
RA   Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T.,
RA   Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L.,
RA   Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R.,
RA   Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y.,
RA   Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K.,
RA   Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J.,
RA   Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L.,
RA   Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S.,
RA   Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A.,
RA   Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L.,
RA   Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S.,
RA   Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C.,
RA   Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S.,
RA   Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V.,
RA   Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K.,
RA   Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B.,
RA   Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C.,
RA   d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q.,
RA   Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N.,
RA   Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A.,
RA   Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J.,
RA   Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A.,
RA   Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L.,
RA   Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S.,
RA   Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- FUNCTION: Receptor for cysteinyl leukotrienes mediating
CC       bronchoconstriction of individuals with and without asthma. Stimulation
CC       by LTD4 results in the contraction and proliferation of smooth muscle,
CC       edema, eosinophil migration and damage to the mucus layer in the lung.
CC       This response is mediated via a G-protein that activates a
CC       phosphatidylinositol-calcium second messenger system. The rank order of
CC       affinities for the leukotrienes is LTD4 >> LTE4 = LTC4 >> LTB4.
CC   -!- INTERACTION:
CC       Q9Y271; Q9NS75: CYSLTR2; NbExp=2; IntAct=EBI-9347754, EBI-3843579;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Widely expressed, with highest levels in spleen and
CC       peripheral blood leukocytes. Lower expression in several tissues, such
CC       as lung (mostly in smooth muscle bundles and alveolar macrophages),
CC       placenta, small intestine, pancreas, colon and heart.
CC   -!- MISCELLANEOUS: Selective antagonists, such as montelukast (Singulair),
CC       zafirlukast (Accolate) and pranlukast (Onon), are used in the treatment
CC       of the asthma crisis.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF119711; AAD42285.1; -; mRNA.
DR   EMBL; AF133266; AAD42778.1; -; mRNA.
DR   EMBL; AY242130; AAO92297.1; -; Genomic_DNA.
DR   EMBL; AK313643; BAG36401.1; -; mRNA.
DR   EMBL; AL445202; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471104; EAW98598.1; -; Genomic_DNA.
DR   EMBL; CH471104; EAW98599.1; -; Genomic_DNA.
DR   EMBL; BC035750; AAH35750.1; -; mRNA.
DR   CCDS; CCDS14439.1; -.
DR   RefSeq; NP_001269115.1; NM_001282186.1.
DR   RefSeq; NP_001269116.1; NM_001282187.1.
DR   RefSeq; NP_001269117.1; NM_001282188.1.
DR   RefSeq; NP_006630.1; NM_006639.3.
DR   PDB; 6RZ4; X-ray; 2.70 A; A=1-311.
DR   PDB; 6RZ5; X-ray; 2.53 A; A/B=1-311.
DR   PDBsum; 6RZ4; -.
DR   PDBsum; 6RZ5; -.
DR   SMR; Q9Y271; -.
DR   BioGRID; 116014; 1.
DR   IntAct; Q9Y271; 1.
DR   STRING; 9606.ENSP00000478492; -.
DR   BindingDB; Q9Y271; -.
DR   ChEMBL; CHEMBL1798; -.
DR   DrugBank; DB00587; Cinalukast.
DR   DrugBank; DB08855; Leukotriene C4.
DR   DrugBank; DB11858; Leukotriene D4.
DR   DrugBank; DB00471; Montelukast.
DR   DrugBank; DB00716; Nedocromil.
DR   DrugBank; DB01411; Pranlukast.
DR   DrugBank; DB00549; Zafirlukast.
DR   DrugCentral; Q9Y271; -.
DR   GuidetoPHARMACOLOGY; 269; -.
DR   SwissLipids; SLP:000001582; -.
DR   TCDB; 9.A.14.13.2; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; Q9Y271; 4 sites.
DR   iPTMnet; Q9Y271; -.
DR   PhosphoSitePlus; Q9Y271; -.
DR   BioMuta; CYSLTR1; -.
DR   DMDM; 20138087; -.
DR   jPOST; Q9Y271; -.
DR   PaxDb; Q9Y271; -.
DR   PeptideAtlas; Q9Y271; -.
DR   PRIDE; Q9Y271; -.
DR   ProteomicsDB; 85673; -.
DR   Antibodypedia; 548; 308 antibodies.
DR   DNASU; 10800; -.
DR   Ensembl; ENST00000373304; ENSP00000362401; ENSG00000173198.
DR   Ensembl; ENST00000614798; ENSP00000478492; ENSG00000173198.
DR   GeneID; 10800; -.
DR   KEGG; hsa:10800; -.
DR   UCSC; uc004edb.5; human.
DR   CTD; 10800; -.
DR   DisGeNET; 10800; -.
DR   EuPathDB; HostDB:ENSG00000173198.5; -.
DR   GeneCards; CYSLTR1; -.
DR   HGNC; HGNC:17451; CYSLTR1.
DR   HPA; ENSG00000173198; Tissue enhanced (blood, esophagus).
DR   MIM; 300201; gene.
DR   neXtProt; NX_Q9Y271; -.
DR   OpenTargets; ENSG00000173198; -.
DR   PharmGKB; PA38453; -.
DR   eggNOG; ENOG502QUJU; Eukaryota.
DR   GeneTree; ENSGT01000000214464; -.
DR   HOGENOM; CLU_009579_8_2_1; -.
DR   InParanoid; Q9Y271; -.
DR   KO; K04322; -.
DR   OMA; PQDNQAK; -.
DR   OrthoDB; 390511at2759; -.
DR   PhylomeDB; Q9Y271; -.
DR   TreeFam; TF350009; -.
DR   PathwayCommons; Q9Y271; -.
DR   Reactome; R-HSA-391906; Leukotriene receptors.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-9664535; LTC4-CYSLTR mediated IL4 production.
DR   Reactome; R-HSA-9679191; Potential therapeutics for SARS.
DR   SIGNOR; Q9Y271; -.
DR   BioGRID-ORCS; 10800; 5 hits in 498 CRISPR screens.
DR   ChiTaRS; CYSLTR1; human.
DR   GeneWiki; Cysteinyl_leukotriene_receptor_1; -.
DR   GenomeRNAi; 10800; -.
DR   Pharos; Q9Y271; Tclin.
DR   PRO; PR:Q9Y271; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; Q9Y271; protein.
DR   Bgee; ENSG00000173198; Expressed in bone marrow and 165 other tissues.
DR   Genevisible; Q9Y271; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0001631; F:cysteinyl leukotriene receptor activity; IBA:GO_Central.
DR   GO; GO:0008528; F:G protein-coupled peptide receptor activity; IBA:GO_Central.
DR   GO; GO:0004974; F:leukotriene receptor activity; TAS:ProtInc.
DR   GO; GO:0006816; P:calcium ion transport; IEA:Ensembl.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0006935; P:chemotaxis; IEA:Ensembl.
DR   GO; GO:0006952; P:defense response; TAS:ProtInc.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0002437; P:inflammatory response to antigenic stimulus; IEA:Ensembl.
DR   GO; GO:0007218; P:neuropeptide signaling pathway; IBA:GO_Central.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; TAS:ProtInc.
DR   GO; GO:0007585; P:respiratory gaseous exchange by respiratory system; TAS:ProtInc.
DR   InterPro; IPR013310; CLT1_recept.
DR   InterPro; IPR004071; Cyst_leuk_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01902; CYSLT1RECPTR.
DR   PRINTS; PR01533; CYSLTRECPTR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Membrane; Receptor; Reference proteome; Transducer;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..337
FT                   /note="Cysteinyl leukotriene receptor 1"
FT                   /id="PRO_0000069299"
FT   TOPO_DOM        1..28
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        29..49
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        50..57
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        58..78
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        79..106
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        107..127
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        128..141
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        142..162
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        163..193
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        194..214
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        215..230
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        231..251
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        252..276
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        277..297
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        298..337
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        6
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        169
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        180
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        262
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        96..173
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   CONFLICT        272
FT                   /note="R -> T (in Ref. 7; AAH35750)"
FT                   /evidence="ECO:0000305"
FT   HELIX           18..49
FT                   /evidence="ECO:0000244|PDB:6RZ5"
FT   HELIX           57..73
FT                   /evidence="ECO:0000244|PDB:6RZ5"
FT   HELIX           76..84
FT                   /evidence="ECO:0000244|PDB:6RZ5"
FT   TURN            85..87
FT                   /evidence="ECO:0000244|PDB:6RZ4"
FT   HELIX           92..126
FT                   /evidence="ECO:0000244|PDB:6RZ5"
FT   TURN            128..130
FT                   /evidence="ECO:0000244|PDB:6RZ4"
FT   HELIX           131..134
FT                   /evidence="ECO:0000244|PDB:6RZ5"
FT   HELIX           137..154
FT                   /evidence="ECO:0000244|PDB:6RZ5"
FT   HELIX           156..158
FT                   /evidence="ECO:0000244|PDB:6RZ5"
FT   HELIX           184..197
FT                   /evidence="ECO:0000244|PDB:6RZ5"
FT   HELIX           199..222
FT                   /evidence="ECO:0000244|PDB:6RZ5"
FT   HELIX           227..244
FT                   /evidence="ECO:0000244|PDB:6RZ5"
FT   HELIX           246..259
FT                   /evidence="ECO:0000244|PDB:6RZ5"
FT   HELIX           267..285
FT                   /evidence="ECO:0000244|PDB:6RZ5"
FT   HELIX           286..289
FT                   /evidence="ECO:0000244|PDB:6RZ5"
FT   HELIX           290..298
FT                   /evidence="ECO:0000244|PDB:6RZ5"
SQ   SEQUENCE   337 AA;  38541 MW;  B9B53940F895F245 CRC64;
     MDETGNLTVS SATCHDTIDD FRNQVYSTLY SMISVVGFFG NGFVLYVLIK TYHKKSAFQV
     YMINLAVADL LCVCTLPLRV VYYVHKGIWL FGDFLCRLST YALYVNLYCS IFFMTAMSFF
     RCIAIVFPVQ NINLVTQKKA RFVCVGIWIF VILTSSPFLM AKPQKDEKNN TKCFEPPQDN
     QTKNHVLVLH YVSLFVGFII PFVIIIVCYT MIILTLLKKS MKKNLSSHKK AIGMIMVVTA
     AFLVSFMPYH IQRTIHLHFL HNETKPCDSV LRMQKSVVIT LSLAASNCCF DPLLYFFSGG
     NFRKRLSTFR KHSLSSVTYV PRKKASLPEK GEEICKV
//
ID   AGRL3_HUMAN             Reviewed;        1447 AA.
AC   Q9HAR2; E9PE04; O94867; Q9NWK5;
DT   10-MAY-2004, integrated into UniProtKB/Swiss-Prot.
DT   10-MAY-2004, sequence version 2.
DT   07-OCT-2020, entry version 157.
DE   RecName: Full=Adhesion G protein-coupled receptor L3 {ECO:0000312|HGNC:HGNC:20974};
DE   AltName: Full=Calcium-independent alpha-latrotoxin receptor 3 {ECO:0000250|UniProtKB:Q9Z173};
DE            Short=CIRL-3 {ECO:0000250|UniProtKB:Q9Z173};
DE   AltName: Full=Latrophilin-3 {ECO:0000312|HGNC:HGNC:20974};
DE   AltName: Full=Lectomedin-3;
DE   Flags: Precursor;
GN   Name=ADGRL3 {ECO:0000312|HGNC:HGNC:20974};
GN   Synonyms=KIAA0768 {ECO:0000312|HGNC:HGNC:20974},
GN   LEC3 {ECO:0000312|HGNC:HGNC:20974}, LPHN3 {ECO:0000312|HGNC:HGNC:20974};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Douangpanya J., Puri K., Hayflick J.;
RL   Submitted (SEP-2000) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 279-707 (ISOFORM 3).
RC   TISSUE=Colon;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 576-1447 (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=9872452; DOI=10.1093/dnares/5.5.277;
RA   Nagase T., Ishikawa K., Suyama M., Kikuno R., Miyajima N., Tanaka A.,
RA   Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XI. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 5:277-286(1998).
RN   [5]
RP   X-RAY CRYSTALLOGRAPHY (3.60 ANGSTROMS) OF 132-392 IN COMPLEX WITH FLRT3 AND
RP   CALCIUM IONS, INTERACTION WITH FLRT3, IDENTIFICATION IN COMPLEXES WITH
RP   FLTR3; UNC5B AND UNC5D, DISULFIDE BOND, FUNCTION, SUBCELLULAR LOCATION,
RP   MUTAGENESIS OF 249-TYR--THR-252 AND ARG-308, AND REGION.
RX   PubMed=26235030; DOI=10.1016/j.str.2015.06.024;
RA   Lu Y.C., Nazarko O.V., Sando R. III, Salzman G.S., Suedhof T.C., Arac D.;
RT   "Structural basis of latrophilin-FLRT-UNC5 interaction in cell adhesion.";
RL   Structure 23:1678-1691(2015).
RN   [6]
RP   VARIANTS SER-247; GLN-465; MET-770 AND VAL-915.
RX   PubMed=21184580; DOI=10.1002/ajmg.b.31141;
RA   Domene S., Stanescu H., Wallis D., Tinloy B., Pineda D.E., Kleta R.,
RA   Arcos-Burgos M., Roessler E., Muenke M.;
RT   "Screening of human LPHN3 for variants with a potential impact on ADHD
RT   susceptibility.";
RL   Am. J. Med. Genet. B Neuropsychiatr. Genet. 156:11-18(2011).
CC   -!- FUNCTION: Plays a role in cell-cell adhesion and neuron guidance via
CC       its interactions with FLRT2 and FLRT3 that are expressed at the surface
CC       of adjacent cells (PubMed:26235030). Plays a role in the development of
CC       glutamatergic synapses in the cortex. Important in determining the
CC       connectivity rates between the principal neurons in the cortex.
CC       {ECO:0000250|UniProtKB:Q80TS3, ECO:0000305|PubMed:26235030}.
CC   -!- SUBUNIT: Interacts (via olfactomedin-like domain) with FLRT3 (via
CC       extracellular domain); the interaction is direct (PubMed:26235030).
CC       Identified in a complex with FLRT3 and UNC5B; does not interact with
CC       UNC5B by itself (PubMed:26235030). Identified in a complex with FLRT3
CC       and UNC5D; does not interact with UNC5D by itself (PubMed:26235030).
CC       Interacts (via olfactomedin-like domain) with FLRT1 (via extracellular
CC       domain). Interacts (via olfactomedin-like domain) with FLRT2 (via
CC       extracellular domain). Interacts (via extracellular domain) with TENM1.
CC       Interacts (via extracellular domain) with TENM3 (By similarity).
CC       {ECO:0000250|UniProtKB:Q80TS3, ECO:0000269|PubMed:26235030}.
CC   -!- INTERACTION:
CC       Q9HAR2; Q9NZU0: FLRT3; NbExp=4; IntAct=EBI-2689295, EBI-1057092;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:26235030};
CC       Multi-pass membrane protein {ECO:0000305}. Cell projection, axon
CC       {ECO:0000250|UniProtKB:Q80TS3}. Cell junction
CC       {ECO:0000250|UniProtKB:Q80TS3}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q9HAR2-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9HAR2-2; Sequence=VSP_010235, VSP_010238, VSP_010239,
CC                                  VSP_010240;
CC       Name=3;
CC         IsoId=Q9HAR2-3; Sequence=VSP_010236, VSP_010237;
CC       Name=4;
CC         IsoId=Q9HAR2-4; Sequence=VSP_010235, VSP_010238;
CC   -!- DOMAIN: The Olfactomedin-like domain is required for the synapse-
CC       promoting function and the interaction with FLRT3. The Olfactomedin-
CC       like and the SUEL-type lectin domains are required for the interaction
CC       with TENM1 (By similarity). {ECO:0000250}.
CC   -!- PTM: Proteolytically cleaved into 2 subunits, an extracellular subunit
CC       and a seven-transmembrane subunit. {ECO:0000250}.
CC   -!- PTM: O-glycosylated (major) and N-glycosylated. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 2 family. LN-TM7
CC       subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA91375.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF307080; AAG27462.1; -; mRNA.
DR   EMBL; AK000781; BAA91375.1; ALT_INIT; mRNA.
DR   EMBL; AC007511; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC020741; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC092643; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC092663; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC092668; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC096723; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC104813; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC108161; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AB018311; BAA34488.1; -; mRNA.
DR   CCDS; CCDS54768.1; -. [Q9HAR2-4]
DR   CCDS; CCDS82926.1; -. [Q9HAR2-2]
DR   RefSeq; NP_001309175.1; NM_001322246.1. [Q9HAR2-2]
DR   RefSeq; NP_001309331.1; NM_001322402.1.
DR   RefSeq; NP_056051.2; NM_015236.5. [Q9HAR2-4]
DR   PDB; 5CMN; X-ray; 3.60 A; E/F/G/H=132-392.
DR   PDB; 6VHH; EM; 2.97 A; B=21-866.
DR   PDBsum; 5CMN; -.
DR   PDBsum; 6VHH; -.
DR   SMR; Q9HAR2; -.
DR   BioGRID; 116882; 10.
DR   CORUM; Q9HAR2; -.
DR   DIP; DIP-56228N; -.
DR   IntAct; Q9HAR2; 10.
DR   STRING; 9606.ENSP00000422533; -.
DR   MEROPS; P02.011; -.
DR   TCDB; 9.A.14.6.8; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; Q9HAR2; 11 sites, 2 O-linked glycans (3 sites).
DR   iPTMnet; Q9HAR2; -.
DR   PhosphoSitePlus; Q9HAR2; -.
DR   SwissPalm; Q9HAR2; -.
DR   BioMuta; ADGRL3; -.
DR   DMDM; 47116772; -.
DR   EPD; Q9HAR2; -.
DR   jPOST; Q9HAR2; -.
DR   MassIVE; Q9HAR2; -.
DR   PaxDb; Q9HAR2; -.
DR   PeptideAtlas; Q9HAR2; -.
DR   PRIDE; Q9HAR2; -.
DR   ProteomicsDB; 19784; -.
DR   ProteomicsDB; 81420; -. [Q9HAR2-1]
DR   ProteomicsDB; 81421; -. [Q9HAR2-2]
DR   ProteomicsDB; 81422; -. [Q9HAR2-3]
DR   Antibodypedia; 2755; 167 antibodies.
DR   Ensembl; ENST00000512091; ENSP00000423388; ENSG00000150471. [Q9HAR2-2]
DR   Ensembl; ENST00000514591; ENSP00000422533; ENSG00000150471. [Q9HAR2-4]
DR   GeneID; 23284; -.
DR   KEGG; hsa:23284; -.
DR   UCSC; uc003hcq.5; human. [Q9HAR2-1]
DR   CTD; 23284; -.
DR   DisGeNET; 23284; -.
DR   EuPathDB; HostDB:ENSG00000150471.15; -.
DR   GeneCards; ADGRL3; -.
DR   HGNC; HGNC:20974; ADGRL3.
DR   HPA; ENSG00000150471; Tissue enhanced (brain, parathyroid gland).
DR   MIM; 616417; gene.
DR   neXtProt; NX_Q9HAR2; -.
DR   OpenTargets; ENSG00000150471; -.
DR   PharmGKB; PA134968284; -.
DR   eggNOG; KOG3545; Eukaryota.
DR   eggNOG; KOG4193; Eukaryota.
DR   eggNOG; KOG4729; Eukaryota.
DR   GeneTree; ENSGT00940000155527; -.
DR   HOGENOM; CLU_002753_0_1_1; -.
DR   InParanoid; Q9HAR2; -.
DR   KO; K04594; -.
DR   PhylomeDB; Q9HAR2; -.
DR   TreeFam; TF351999; -.
DR   PathwayCommons; Q9HAR2; -.
DR   BioGRID-ORCS; 23284; 1 hit in 870 CRISPR screens.
DR   ChiTaRS; ADGRL3; human.
DR   GenomeRNAi; 23284; -.
DR   Pharos; Q9HAR2; Tbio.
DR   PRO; PR:Q9HAR2; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; Q9HAR2; protein.
DR   Bgee; ENSG00000150471; Expressed in adrenal tissue and 216 other tissues.
DR   ExpressionAtlas; Q9HAR2; baseline and differential.
DR   Genevisible; Q9HAR2; HS.
DR   GO; GO:0030424; C:axon; ISS:UniProtKB.
DR   GO; GO:0005911; C:cell-cell junction; ISS:UniProtKB.
DR   GO; GO:0098978; C:glutamatergic synapse; IBA:GO_Central.
DR   GO; GO:0016021; C:integral component of membrane; TAS:GDB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0030246; F:carbohydrate binding; IEA:UniProtKB-KW.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007420; P:brain development; IBA:GO_Central.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IEA:InterPro.
DR   GO; GO:0098742; P:cell-cell adhesion via plasma-membrane adhesion molecules; IDA:UniProtKB.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:GDB.
DR   GO; GO:0031987; P:locomotion involved in locomotory behavior; IEA:Ensembl.
DR   GO; GO:0001764; P:neuron migration; ISS:UniProtKB.
DR   GO; GO:0051965; P:positive regulation of synapse assembly; IEA:Ensembl.
DR   GO; GO:0042220; P:response to cocaine; IEA:Ensembl.
DR   GO; GO:0007416; P:synapse assembly; ISS:UniProtKB.
DR   Gene3D; 2.60.120.740; -; 1.
DR   Gene3D; 4.10.1240.10; -; 1.
DR   InterPro; IPR032471; GAIN_dom_N.
DR   InterPro; IPR017981; GPCR_2-like.
DR   InterPro; IPR036445; GPCR_2_extracell_dom_sf.
DR   InterPro; IPR001879; GPCR_2_extracellular_dom.
DR   InterPro; IPR003924; GPCR_2_latrophilin.
DR   InterPro; IPR003334; GPCR_2_latrophilin_rcpt_C.
DR   InterPro; IPR000832; GPCR_2_secretin-like.
DR   InterPro; IPR017983; GPCR_2_secretin-like_CS.
DR   InterPro; IPR000203; GPS.
DR   InterPro; IPR015630; Latrophilin-3.
DR   InterPro; IPR000922; Lectin_gal-bd_dom.
DR   InterPro; IPR043159; Lectin_gal-bd_sf.
DR   InterPro; IPR003112; Olfac-like_dom.
DR   PANTHER; PTHR12011:SF60; PTHR12011:SF60; 1.
DR   Pfam; PF00002; 7tm_2; 1.
DR   Pfam; PF16489; GAIN; 1.
DR   Pfam; PF02140; Gal_Lectin; 1.
DR   Pfam; PF01825; GPS; 1.
DR   Pfam; PF02354; Latrophilin; 2.
DR   Pfam; PF02191; OLF; 1.
DR   PRINTS; PR00249; GPCRSECRETIN.
DR   PRINTS; PR01444; LATROPHILIN.
DR   SMART; SM00303; GPS; 1.
DR   SMART; SM00008; HormR; 1.
DR   SMART; SM00284; OLF; 1.
DR   PROSITE; PS00650; G_PROTEIN_RECEP_F2_2; 1.
DR   PROSITE; PS50227; G_PROTEIN_RECEP_F2_3; 1.
DR   PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1.
DR   PROSITE; PS50221; GPS; 1.
DR   PROSITE; PS51132; OLF; 1.
DR   PROSITE; PS50228; SUEL_LECTIN; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Cell junction; Cell membrane;
KW   Cell projection; Disulfide bond; G-protein coupled receptor; Glycoprotein;
KW   Lectin; Membrane; Metal-binding; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Signal; Transducer; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..19
FT                   /evidence="ECO:0000255"
FT   CHAIN           20..1447
FT                   /note="Adhesion G protein-coupled receptor L3"
FT                   /id="PRO_0000012913"
FT   TOPO_DOM        20..866
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        867..889
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        890..901
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        902..919
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        920..933
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        934..956
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        957..968
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        969..988
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        989..1007
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        1008..1030
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        1031..1049
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        1050..1072
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        1073..1081
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        1082..1104
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        1105..1447
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          35..124
FT                   /note="SUEL-type lectin"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00260"
FT   DOMAIN          134..393
FT                   /note="Olfactomedin-like"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00446"
FT   DOMAIN          802..853
FT                   /note="GPS"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00098"
FT   REGION          249..279
FT                   /note="Interaction with FLRT3"
FT                   /evidence="ECO:0000269|PubMed:26235030"
FT   METAL           264
FT                   /note="Calcium"
FT                   /evidence="ECO:0000244|PDB:5CMN,
FT                   ECO:0000269|PubMed:26235030"
FT   METAL           312
FT                   /note="Calcium"
FT                   /evidence="ECO:0000244|PDB:5CMN,
FT                   ECO:0000269|PubMed:26235030"
FT   METAL           313
FT                   /note="Calcium; via carbonyl oxygen"
FT                   /evidence="ECO:0000244|PDB:5CMN,
FT                   ECO:0000269|PubMed:26235030"
FT   METAL           367
FT                   /note="Calcium; via carbonyl oxygen"
FT                   /evidence="ECO:0000244|PDB:5CMN,
FT                   ECO:0000269|PubMed:26235030"
FT   SITE            841..842
FT                   /note="Cleavage"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         1164
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q80TS3"
FT   CARBOHYD        93
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        464
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        549
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        746
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        759
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        804
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        830
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1076
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        36..66
FT                   /evidence="ECO:0000244|PDB:5CMN,
FT                   ECO:0000269|PubMed:26235030"
FT   DISULFID        45..123
FT                   /evidence="ECO:0000244|PDB:5CMN,
FT                   ECO:0000269|PubMed:26235030"
FT   DISULFID        78..110
FT                   /evidence="ECO:0000244|PDB:5CMN,
FT                   ECO:0000269|PubMed:26235030"
FT   DISULFID        91..97
FT                   /evidence="ECO:0000244|PDB:5CMN,
FT                   ECO:0000269|PubMed:26235030"
FT   DISULFID        135..317
FT                   /evidence="ECO:0000244|PDB:5CMN, ECO:0000255|PROSITE-
FT                   ProRule:PRU00446, ECO:0000269|PubMed:26235030"
FT   VAR_SEQ         623
FT                   /note="K -> KLQKRERSCRAYVQ (in isoform 2 and isoform 4)"
FT                   /evidence="ECO:0000303|Ref.1"
FT                   /id="VSP_010235"
FT   VAR_SEQ         668..707
FT                   /note="ADNLLKTDIVRENTDNIKLEVARLSTEGNLEDLKFPENMG -> VLQVCLPV
FT                   REQSFLPFFSFFIFFFSFLPFIPLKFRLAKNK (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_010236"
FT   VAR_SEQ         708..1447
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_010237"
FT   VAR_SEQ         1050
FT                   /note="I -> INYEDNRPFI (in isoform 2 and isoform 4)"
FT                   /evidence="ECO:0000303|Ref.1"
FT                   /id="VSP_010238"
FT   VAR_SEQ         1183..1218
FT                   /note="GLLNNARDTSVMDTLPLNGNHGNSYSIASGEYLSNC -> PYRETSMGVKLN
FT                   IAYQIGASEQCQGYKCHGYSTTEW (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.1"
FT                   /id="VSP_010239"
FT   VAR_SEQ         1219..1447
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.1"
FT                   /id="VSP_010240"
FT   VARIANT         247
FT                   /note="A -> S"
FT                   /evidence="ECO:0000269|PubMed:21184580"
FT                   /id="VAR_064477"
FT   VARIANT         465
FT                   /note="R -> Q (in dbSNP:rs35106420)"
FT                   /evidence="ECO:0000269|PubMed:21184580"
FT                   /id="VAR_055934"
FT   VARIANT         770
FT                   /note="T -> M"
FT                   /evidence="ECO:0000269|PubMed:21184580"
FT                   /id="VAR_064478"
FT   VARIANT         915
FT                   /note="L -> V"
FT                   /evidence="ECO:0000269|PubMed:21184580"
FT                   /id="VAR_064479"
FT   MUTAGEN         249..252
FT                   /note="YHDT->AHAA: Strongly reduces FLRT3 binding.
FT                   Abolishes FLRT3 binding; when associated with A-308."
FT                   /evidence="ECO:0000269|PubMed:26235030"
FT   MUTAGEN         308
FT                   /note="R->A: Abolishes FLRT3 binding; when associated with
FT                   249-A--A-252."
FT                   /evidence="ECO:0000269|PubMed:26235030"
SQ   SEQUENCE   1447 AA;  161812 MW;  54B7E7DBE516447A CRC64;
     MWPSQLLIFM MLLAPIIHAF SRAPIPMAVV RRELSCESYP IELRCPGTDV IMIESANYGR
     TDDKICDSDP AQMENIRCYL PDAYKIMSQR CNNRTQCAVV AGPDVFPDPC PGTYKYLEVQ
     YECVPYKVEQ KVFLCPGLLK GVYQSEHLFE SDHQSGAWCK DPLQASDKIY YMPWTPYRTD
     TLTEYSSKDD FIAGRPTTTY KLPHRVDGTG FVVYDGALFF NKERTRNIVK FDLRTRIKSG
     EAIIANANYH DTSPYRWGGK SDIDLAVDEN GLWVIYATEQ NNGKIVISQL NPYTLRIEGT
     WDTAYDKRSA SNAFMICGIL YVVKSVYEDD DNEATGNKID YIYNTDQSKD SLVDVPFPNS
     YQYIAAVDYN PRDNLLYVWN NYHVVKYSLD FGPLDSRSGQ AHHGQVSYIS PPIHLDSELE
     RPSVKDISTT GPLGMGSTTT STTLRTTTLS PGRSTTPSVS GRRNRSTSTP SPAVEVLDDM
     TTHLPSASSQ IPALEESCEA VEAREIMWFK TRQGQIAKQP CPAGTIGVST YLCLAPDGIW
     DPQGPDLSNC SSPWVNHITQ KLKSGETAAN IARELAEQTR NHLNAGDITY SVRAMDQLVG
     LLDVQLRNLT PGGKDSAARS LNKAMVETVN NLLQPQALNA WRDLTTSDQL RAATMLLHTV
     EESAFVLADN LLKTDIVREN TDNIKLEVAR LSTEGNLEDL KFPENMGHGS TIQLSANTLK
     QNGRNGEIRV AFVLYNNLGP YLSTENASMK LGTEALSTNH SVIVNSPVIT AAINKEFSNK
     VYLADPVVFT VKHIKQSEEN FNPNCSFWSY SKRTMTGYWS TQGCRLLTTN KTHTTCSCNH
     LTNFAVLMAH VEVKHSDAVH DLLLDVITWV GILLSLVCLL ICIFTFCFFR GLQSDRNTIH
     KNLCISLFVA ELLFLIGINR TDQPIACAVF AALLHFFFLA AFTWMFLEGV QLYIMLVEVF
     ESEHSRRKYF YLVGYGMPAL IVAVSAAVDY RSYGTDKVCW LRLDTYFIWS FIGPATLIIM
     LNVIFLGIAL YKMFHHTAIL KPESGCLDNI KSWVIGAIAL LCLLGLTWAF GLMYINESTV
     IMAYLFTIFN SLQGMFIFIF HCVLQKKVRK EYGKCLRTHC CSGKSTESSI GSGKTSGSRT
     PGRYSTGSQS RIRRMWNDTV RKQSESSFIT GDINSSASLN REGLLNNARD TSVMDTLPLN
     GNHGNSYSIA SGEYLSNCVQ IIDRGYNHNE TALEKKILKE LTSNYIPSYL NNHERSSEQN
     RNLMNKLVNN LGSGREDDAI VLDDATSFNH EESLGLELIH EESDAPLLPP RVYSTENHQP
     HHYTRRRIPQ DHSESFFPLL TNEHTEDLQS PHRDSLYTSM PTLAGVAATE SVTTSTQTEP
     PPAKCGDAED VYYKSMPNLG SRNHVHQLHT YYQLGRGSSD GFIVPPNKDG TPPEGSSKGP
     AHLVTSL
//
ID   CCR1_HUMAN              Reviewed;         355 AA.
AC   P32246; Q86VA9;
DT   01-OCT-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1993, sequence version 1.
DT   07-OCT-2020, entry version 177.
DE   RecName: Full=C-C chemokine receptor type 1;
DE            Short=C-C CKR-1;
DE            Short=CC-CKR-1;
DE            Short=CCR-1;
DE            Short=CCR1;
DE   AltName: Full=HM145;
DE   AltName: Full=LD78 receptor;
DE   AltName: Full=Macrophage inflammatory protein 1-alpha receptor;
DE            Short=MIP-1alpha-R;
DE   AltName: Full=RANTES-R;
DE   AltName: CD_antigen=CD191;
GN   Name=CCR1; Synonyms=CMKBR1, CMKR1, SCYAR1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7679328; DOI=10.1016/0092-8674(93)90118-a;
RA   Neote K., Digregorio D., Mak J.Y., Horuk R., Schall T.J.;
RT   "Molecular cloning, functional expression, and signaling characteristics of
RT   a C-C chemokine receptor.";
RL   Cell 72:415-425(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7683036; DOI=10.1084/jem.177.5.1421;
RA   Gao J.-L., Kuhns D., Tiffany H.L., McDermott D., Li X., Francke U.,
RA   Murphy P.M.;
RT   "Structure and functional expression of the human macrophage inflammatory
RT   protein 1 alpha/RANTES receptor.";
RL   J. Exp. Med. 177:1421-1427(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Monocyte;
RX   PubMed=7505609; DOI=10.1093/intimm/5.10.1239;
RA   Nomura H., Nielsen B.W., Matsushima K.;
RT   "Molecular cloning of cDNAs encoding a LD78 receptor and putative leukocyte
RT   chemotactic peptide receptors.";
RL   Int. Immunol. 5:1239-1249(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Blood;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   INTERACTION WITH CREB3.
RX   PubMed=15001559; DOI=10.1096/fj.03-0867fje;
RA   Ko J., Jang S.W., Kim Y.S., Kim I.S., Sung H.J., Kim H.-H., Park J.Y.,
RA   Lee Y.H., Kim J., Na D.S.;
RT   "Human LZIP binds to CCR1 and differentially affects the chemotactic
RT   activities of CCR1-dependent chemokines.";
RL   FASEB J. 18:890-892(2004).
RN   [6]
RP   SUBCELLULAR LOCATION, AND INDUCTION.
RX   PubMed=18587271; DOI=10.3858/emm.2008.40.3.332;
RA   Sung H.J., Kim Y.S., Kang H., Ko J.;
RT   "Human LZIP induces monocyte CC chemokine receptor 2 expression leading to
RT   enhancement of monocyte chemoattractant protein 1/CCL2-induced cell
RT   migration.";
RL   Exp. Mol. Med. 40:332-338(2008).
CC   -!- FUNCTION: Receptor for a C-C type chemokine. Binds to MIP-1-alpha, MIP-
CC       1-delta, RANTES, and MCP-3 and, less efficiently, to MIP-1-beta or MCP-
CC       1 and subsequently transduces a signal by increasing the intracellular
CC       calcium ions level. Responsible for affecting stem cell proliferation.
CC   -!- SUBUNIT: Interacts with CREB3. {ECO:0000269|PubMed:15001559}.
CC   -!- INTERACTION:
CC       P32246; P13501: CCL5; NbExp=2; IntAct=EBI-608322, EBI-2848366;
CC       P32246; O43889-2: CREB3; NbExp=7; IntAct=EBI-608322, EBI-625022;
CC       P32246; P02686: MBP; NbExp=2; IntAct=EBI-608322, EBI-947410;
CC       P32246; Q04941: PLP2; NbExp=3; IntAct=EBI-608322, EBI-608347;
CC       P32246; P04156: PRNP; NbExp=2; IntAct=EBI-608322, EBI-977302;
CC       P32246; Q9H3N1: TMX1; NbExp=3; IntAct=EBI-608322, EBI-1051115;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:18587271};
CC       Multi-pass membrane protein {ECO:0000269|PubMed:18587271}.
CC   -!- TISSUE SPECIFICITY: Widely expressed in different hematopoietic cells.
CC   -!- INDUCTION: Up-regulated by CREB3. {ECO:0000269|PubMed:18587271}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=CC chemokine receptors entry;
CC       URL="https://en.wikipedia.org/wiki/CC_chemokine_receptors";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CCR1ID44379ch3p21.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L09230; AAA58408.1; -; mRNA.
DR   EMBL; L10918; AAA36543.1; -; mRNA.
DR   EMBL; D10925; BAA01723.1; -; mRNA.
DR   EMBL; BC051306; AAH51306.2; -; mRNA.
DR   EMBL; BC064991; AAH64991.1; -; mRNA.
DR   CCDS; CCDS2737.1; -.
DR   PIR; A45177; A45177.
DR   RefSeq; NP_001286.1; NM_001295.2.
DR   PDB; 1Y5D; Model; -; A=1-355.
DR   PDBsum; 1Y5D; -.
DR   SMR; P32246; -.
DR   BioGRID; 107635; 20.
DR   DIP; DIP-5832N; -.
DR   IntAct; P32246; 24.
DR   MINT; P32246; -.
DR   STRING; 9606.ENSP00000296140; -.
DR   BindingDB; P32246; -.
DR   ChEMBL; CHEMBL2413; -.
DR   DrugCentral; P32246; -.
DR   GuidetoPHARMACOLOGY; 58; -.
DR   GlyGen; P32246; 1 site.
DR   iPTMnet; P32246; -.
DR   PhosphoSitePlus; P32246; -.
DR   BioMuta; CCR1; -.
DR   DMDM; 416802; -.
DR   MassIVE; P32246; -.
DR   PaxDb; P32246; -.
DR   PeptideAtlas; P32246; -.
DR   PRIDE; P32246; -.
DR   ProteomicsDB; 54854; -.
DR   Antibodypedia; 12727; 524 antibodies.
DR   DNASU; 1230; -.
DR   Ensembl; ENST00000296140; ENSP00000296140; ENSG00000163823.
DR   GeneID; 1230; -.
DR   KEGG; hsa:1230; -.
DR   CTD; 1230; -.
DR   DisGeNET; 1230; -.
DR   EuPathDB; HostDB:ENSG00000163823.3; -.
DR   GeneCards; CCR1; -.
DR   HGNC; HGNC:1602; CCR1.
DR   HPA; ENSG00000163823; Tissue enhanced (blood, lymphoid tissue).
DR   MalaCards; CCR1; -.
DR   MIM; 601159; gene.
DR   neXtProt; NX_P32246; -.
DR   OpenTargets; ENSG00000163823; -.
DR   Orphanet; 117; Behcet disease.
DR   PharmGKB; PA26166; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT01000000214577; -.
DR   HOGENOM; CLU_009579_8_3_1; -.
DR   InParanoid; P32246; -.
DR   KO; K04176; -.
DR   OMA; LMQYKRL; -.
DR   OrthoDB; 900867at2759; -.
DR   PhylomeDB; P32246; -.
DR   TreeFam; TF330966; -.
DR   PathwayCommons; P32246; -.
DR   Reactome; R-HSA-380108; Chemokine receptors bind chemokines.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-6783783; Interleukin-10 signaling.
DR   SIGNOR; P32246; -.
DR   BioGRID-ORCS; 1230; 1 hit in 871 CRISPR screens.
DR   ChiTaRS; CCR1; human.
DR   GeneWiki; CCR1; -.
DR   GenomeRNAi; 1230; -.
DR   Pharos; P32246; Tchem.
DR   PRO; PR:P32246; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; P32246; protein.
DR   Bgee; ENSG00000163823; Expressed in leukocyte and 202 other tissues.
DR   ExpressionAtlas; P32246; baseline and differential.
DR   Genevisible; P32246; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0019957; F:C-C chemokine binding; IPI:UniProtKB.
DR   GO; GO:0016493; F:C-C chemokine receptor activity; IDA:UniProtKB.
DR   GO; GO:0071791; F:chemokine (C-C motif) ligand 5 binding; IPI:UniProtKB.
DR   GO; GO:0035717; F:chemokine (C-C motif) ligand 7 binding; IPI:UniProtKB.
DR   GO; GO:0019956; F:chemokine binding; IBA:GO_Central.
DR   GO; GO:0004950; F:chemokine receptor activity; IDA:UniProtKB.
DR   GO; GO:0004435; F:phosphatidylinositol phospholipase C activity; IDA:UniProtKB.
DR   GO; GO:0006816; P:calcium ion transport; IDA:UniProtKB.
DR   GO; GO:0019722; P:calcium-mediated signaling; IBA:GO_Central.
DR   GO; GO:0007155; P:cell adhesion; TAS:ProtInc.
DR   GO; GO:0060326; P:cell chemotaxis; IBA:GO_Central.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0007267; P:cell-cell signaling; IDA:UniProtKB.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; IDA:UniProtKB.
DR   GO; GO:0070098; P:chemokine-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0006935; P:chemotaxis; IBA:GO_Central.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0002407; P:dendritic cell chemotaxis; TAS:BHF-UCL.
DR   GO; GO:0006887; P:exocytosis; IDA:UniProtKB.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007187; P:G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; TAS:ProtInc.
DR   GO; GO:0006955; P:immune response; IDA:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; IBA:GO_Central.
DR   GO; GO:0030502; P:negative regulation of bone mineralization; IMP:UniProtKB.
DR   GO; GO:0010629; P:negative regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0051928; P:positive regulation of calcium ion transport; IDA:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:CACAO.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IDA:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0090026; P:positive regulation of monocyte chemotaxis; IDA:UniProtKB.
DR   GO; GO:0045672; P:positive regulation of osteoclast differentiation; IMP:UniProtKB.
DR   GO; GO:0009611; P:response to wounding; TAS:ProtInc.
DR   InterPro; IPR002236; Chemokine_CCR1.
DR   InterPro; IPR034321; Chemokine_CCR1_euk.
DR   InterPro; IPR000355; Chemokine_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   PANTHER; PTHR10489:SF711; PTHR10489:SF711; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00657; CCCHEMOKINER.
DR   PRINTS; PR01106; CHEMOKINER1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Membrane; Receptor; Reference proteome; Transducer;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..355
FT                   /note="C-C chemokine receptor type 1"
FT                   /id="PRO_0000069228"
FT   TOPO_DOM        1..34
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        35..60
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        61..64
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        65..91
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        92..107
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        108..129
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        130..146
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        147..171
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        172..197
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        198..223
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        224..239
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        240..264
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        265..281
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        282..305
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        306..355
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        5
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        106..183
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   CONFLICT        337
FT                   /note="E -> D (in Ref. 3; BAA01723)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   355 AA;  41173 MW;  B2C100FFED275985 CRC64;
     METPNTTEDY DTTTEFDYGD ATPCQKVNER AFGAQLLPPL YSLVFVIGLV GNILVVLVLV
     QYKRLKNMTS IYLLNLAISD LLFLFTLPFW IDYKLKDDWV FGDAMCKILS GFYYTGLYSE
     IFFIILLTID RYLAIVHAVF ALRARTVTFG VITSIIIWAL AILASMPGLY FSKTQWEFTH
     HTCSLHFPHE SLREWKLFQA LKLNLFGLVL PLLVMIICYT GIIKILLRRP NEKKSKAVRL
     IFVIMIIFFL FWTPYNLTIL ISVFQDFLFT HECEQSRHLD LAVQVTEVIA YTHCCVNPVI
     YAFVGERFRK YLRQLFHRRV AVHLVKWLPF LSVDRLERVS STSPSTGEHE LSAGF
//
ID   CCR6_HUMAN              Reviewed;         374 AA.
AC   P51684; E1P5C6; P78553; Q92846;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1998, sequence version 2.
DT   07-OCT-2020, entry version 195.
DE   RecName: Full=C-C chemokine receptor type 6;
DE            Short=C-C CKR-6;
DE            Short=CC-CKR-6;
DE            Short=CCR-6;
DE   AltName: Full=Chemokine receptor-like 3;
DE            Short=CKR-L3;
DE   AltName: Full=DRY6;
DE   AltName: Full=G-protein coupled receptor 29;
DE   AltName: Full=GPR-CY4;
DE            Short=GPRCY4;
DE   AltName: Full=LARC receptor;
DE   AltName: CD_antigen=CD196;
GN   Name=CCR6; Synonyms=CKRL3, CMKBR6, GPR29, STRL22;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND FUNCTION.
RX   PubMed=9169459; DOI=10.1074/jbc.272.23.14893;
RA   Baba M., Imai T., Nishimura M., Kakizaki M., Takagi S., Hieshima K.,
RA   Nomiyama H., Yoshie O.;
RT   "Identification of CCR6, the specific receptor for a novel lymphocyte-
RT   directed CC chemokine LARC.";
RL   J. Biol. Chem. 272:14893-14898(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE.
RA   Lautens L.L., Modi W., Bonner T.I.;
RL   Submitted (APR-1996) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND TISSUE SPECIFICITY.
RX   PubMed=8886020; DOI=10.1006/bbrc.1996.1595;
RA   Zaballos A., Varona R., Gutierrez J., Lind P., Marquez G.;
RT   "Molecular cloning and RNA expression of two new human chemokine receptor-
RT   like genes.";
RL   Biochem. Biophys. Res. Commun. 227:846-853(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   McCoy R., Perlmutter D.H.;
RL   Submitted (SEP-1996) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9070937; DOI=10.1006/geno.1996.4544;
RA   Liao F., Lee H.-H., Farber J.M.;
RT   "Cloning of STRL22, a new human gene encoding a G-protein-coupled receptor
RT   related to chemokine receptors and located on chromosome 6q27.";
RL   Genomics 40:175-180(1997).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Warren C.N., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   DISULFIDE BOND, MUTAGENESIS OF CYS-36; CYS-57; CYS-118; CYS-131; CYS-138;
RP   CYS-168; CYS-197; CYS-233; CYS-266; CYS-288; CYS-309; CYS-310; CYS-336 AND
RP   CYS-348, AND SUBCELLULAR LOCATION.
RX   PubMed=12081481; DOI=10.1021/bi025855y;
RA   Ai L.S., Liao F.;
RT   "Mutating the four extracellular cysteines in the chemokine receptor CCR6
RT   reveals their differing roles in receptor trafficking, ligand binding, and
RT   signaling.";
RL   Biochemistry 41:8332-8341(2002).
RN   [11]
RP   FUNCTION, AND BINDING TO CCL20; DEFB4 AND DEFB4A.
RX   PubMed=20068036; DOI=10.1074/jbc.m109.091090;
RA   Roehrl J., Yang D., Oppenheim J.J., Hehlgans T.;
RT   "Specific binding and chemotactic activity of mBD4 and its functional
RT   orthologue hBD2 to CCR6-expressing cells.";
RL   J. Biol. Chem. 285:7028-7034(2010).
RN   [12]
RP   REVIEW, AND FUNCTION.
RX   PubMed=21376174; DOI=10.1016/j.yexcr.2010.12.018;
RA   Ito T., Carson W.F. IV, Cavassani K.A., Connett J.M., Kunkel S.L.;
RT   "CCR6 as a mediator of immunity in the lung and gut.";
RL   Exp. Cell Res. 317:613-619(2011).
RN   [13]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=23765988; DOI=10.1002/jcp.24418;
RA   Caballero-Campo P., Buffone M.G., Benencia F., Conejo-Garcia J.R.,
RA   Rinaudo P.F., Gerton G.L.;
RT   "A role for the chemokine receptor CCR6 in mammalian sperm motility and
RT   chemotaxis.";
RL   J. Cell. Physiol. 229:68-78(2014).
RN   [14]
RP   FUNCTION, TISSUE SPECIFICITY, AND BINDING TO DEFB1.
RX   PubMed=25122636; DOI=10.1126/scitranslmed.3009071;
RA   Diao R., Fok K.L., Chen H., Yu M.K., Duan Y., Chung C.M., Li Z., Wu H.,
RA   Li Z., Zhang H., Ji Z., Zhen W., Ng C.F., Gui Y., Cai Z., Chan H.C.;
RT   "Deficient human beta-defensin 1 underlies male infertility associated with
RT   poor sperm motility and genital tract infection.";
RL   Sci. Transl. Med. 6:249RA108-249RA108(2014).
RN   [15]
RP   REVIEW, AND FUNCTION.
RX   PubMed=25585877; DOI=10.1016/j.cyto.2014.11.029;
RA   Lee A.Y., Phan T.K., Hulett M.D., Koerner H.;
RT   "The relationship between CCR6 and its binding partners: does the CCR6-
RT   CCL20 axis have to be extended?";
RL   Cytokine 72:97-101(2015).
CC   -!- FUNCTION: Receptor for the C-C type chemokine CCL20 (PubMed:9169459).
CC       Binds to CCL20 and subsequently transduces a signal by increasing the
CC       intracellular calcium ion levels (PubMed:20068036). Although CCL20 is
CC       its major ligand it can also act as a receptor for non-chemokine
CC       ligands such as beta-defensins (PubMed:25585877). Binds to defensin
CC       DEFB1 leading to increase in intracellular calcium ions and cAMP
CC       levels. Its binding to DEFB1 is essential for the function of DEFB1 in
CC       regulating sperm motility and bactericidal activity (PubMed:25122636).
CC       Binds to defensins DEFB4 and DEFB4A/B and mediates their chemotactic
CC       effects (PubMed:20068036). The ligand-receptor pair CCL20-CCR6 is
CC       responsible for the chemotaxis of dendritic cells (DC), effector/
CC       memory T-cells and B-cells and plays an important role at skin and
CC       mucosal surfaces under homeostatic and inflammatory conditions, as well
CC       as in pathology, including cancer and various autoimmune diseases.
CC       CCR6-mediated signals are essential for immune responses to microbes in
CC       the intestinal mucosa and in the modulation of inflammatory responses
CC       initiated by tissue insult and trauma (PubMed:21376174). CCR6 is
CC       essential for the recruitment of both the proinflammatory IL17
CC       producing helper T-cells (Th17) and the regulatory T-cells (Treg) to
CC       sites of inflammation. Required for the normal migration of Th17 cells
CC       in Peyers-patches and other related tissue sites of the intestine and
CC       plays a role in regulating effector T-cell balance and distribution in
CC       inflamed intestine. Plays an important role in the coordination of
CC       early thymocyte precursor migration events important for normal
CC       subsequent thymocyte precursor development, but is not required for the
CC       formation of normal thymic natural regulatory T-cells (nTregs).
CC       Required for optimal differentiation of DN2 and DN3 thymocyte
CC       precursors. Essential for B-cell localization in the subepithelial dome
CC       of Peyers-patches and for efficient B-cell isotype switching to IgA in
CC       the Peyers-patches. Essential for appropriate anatomical distribution
CC       of memory B-cells in the spleen and for the secondary recall response
CC       of memory B-cells (By similarity). Positively regulates sperm motility
CC       and chemotaxis via its binding to CCL20 (PubMed:23765988).
CC       {ECO:0000250|UniProtKB:O54689, ECO:0000269|PubMed:20068036,
CC       ECO:0000269|PubMed:23765988, ECO:0000269|PubMed:25122636,
CC       ECO:0000269|PubMed:9169459, ECO:0000303|PubMed:21376174,
CC       ECO:0000303|PubMed:25585877}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:23765988};
CC       Multi-pass membrane protein {ECO:0000255}. Cell surface
CC       {ECO:0000269|PubMed:12081481}.
CC   -!- TISSUE SPECIFICITY: Sperm. Mainly localized in the tail and in the
CC       postacrosomal region but is also found in the midpiece and basal region
CC       in a small percentage of sperm cells. Reduced levels found in the
CC       sperms of asthenozoospermia and leukocytospermia patients (at protein
CC       level). Spleen, lymph nodes, appendix, and fetal liver. Expressed in
CC       lymphocytes, T-cells and B-cells but not in natural killer cells,
CC       monocytes or granulocytes. {ECO:0000269|PubMed:23765988,
CC       ECO:0000269|PubMed:25122636, ECO:0000269|PubMed:8886020}.
CC   -!- INDUCTION: By IL2/interleukin-2.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- CAUTION: It is uncertain whether Met-1 or Met-6 is the initiator.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAB02144.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=CC chemokine receptors entry;
CC       URL="https://en.wikipedia.org/wiki/CC_chemokine_receptors";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U45984; AAB62714.1; -; Genomic_DNA.
DR   EMBL; Z79784; CAB02144.1; ALT_INIT; Genomic_DNA.
DR   EMBL; U60000; AAB06949.1; -; mRNA.
DR   EMBL; U68030; AAC51124.1; -; mRNA.
DR   EMBL; U68032; AAC51125.1; -; Genomic_DNA.
DR   EMBL; AY242126; AAO92293.1; -; mRNA.
DR   EMBL; AL121935; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471051; EAW47506.1; -; Genomic_DNA.
DR   EMBL; CH471051; EAW47507.1; -; Genomic_DNA.
DR   EMBL; BC037960; AAH37960.1; -; mRNA.
DR   CCDS; CCDS5298.1; -.
DR   PIR; JC5068; JC5068.
DR   RefSeq; NP_004358.2; NM_004367.5.
DR   RefSeq; NP_113597.2; NM_031409.3.
DR   PDB; 6WWZ; EM; 3.34 A; R=2-374.
DR   PDBsum; 6WWZ; -.
DR   BioGRID; 107640; 70.
DR   DIP; DIP-5865N; -.
DR   IntAct; P51684; 1.
DR   MINT; P51684; -.
DR   STRING; 9606.ENSP00000383715; -.
DR   BindingDB; P51684; -.
DR   ChEMBL; CHEMBL4423; -.
DR   GuidetoPHARMACOLOGY; 63; -.
DR   GlyGen; P51684; 2 sites.
DR   iPTMnet; P51684; -.
DR   PhosphoSitePlus; P51684; -.
DR   BioMuta; CCR6; -.
DR   DMDM; 2851567; -.
DR   MassIVE; P51684; -.
DR   PaxDb; P51684; -.
DR   PeptideAtlas; P51684; -.
DR   PRIDE; P51684; -.
DR   ProteomicsDB; 56368; -.
DR   Antibodypedia; 2930; 810 antibodies.
DR   DNASU; 1235; -.
DR   Ensembl; ENST00000341935; ENSP00000343952; ENSG00000112486.
DR   Ensembl; ENST00000349984; ENSP00000339393; ENSG00000112486.
DR   Ensembl; ENST00000400926; ENSP00000383715; ENSG00000112486.
DR   Ensembl; ENST00000643861; ENSP00000493637; ENSG00000112486.
DR   GeneID; 1235; -.
DR   KEGG; hsa:1235; -.
DR   UCSC; uc003qvm.5; human.
DR   CTD; 1235; -.
DR   DisGeNET; 1235; -.
DR   EuPathDB; HostDB:ENSG00000112486.14; -.
DR   GeneCards; CCR6; -.
DR   HGNC; HGNC:1607; CCR6.
DR   HPA; ENSG00000112486; Group enriched (blood, intestine, lymphoid tissue).
DR   MalaCards; CCR6; -.
DR   MIM; 601835; gene.
DR   neXtProt; NX_P51684; -.
DR   OpenTargets; ENSG00000112486; -.
DR   Orphanet; 220393; Diffuse cutaneous systemic sclerosis.
DR   Orphanet; 220402; Limited cutaneous systemic sclerosis.
DR   PharmGKB; PA26171; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT01000000214381; -.
DR   HOGENOM; CLU_009579_8_3_1; -.
DR   InParanoid; P51684; -.
DR   KO; K04181; -.
DR   OMA; VFMIFCY; -.
DR   OrthoDB; 981680at2759; -.
DR   PhylomeDB; P51684; -.
DR   TreeFam; TF330966; -.
DR   PathwayCommons; P51684; -.
DR   Reactome; R-HSA-1461957; Beta defensins.
DR   Reactome; R-HSA-380108; Chemokine receptors bind chemokines.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   BioGRID-ORCS; 1235; 6 hits in 872 CRISPR screens.
DR   ChiTaRS; CCR6; human.
DR   GeneWiki; C-C_chemokine_receptor_type_6; -.
DR   GenomeRNAi; 1235; -.
DR   Pharos; P51684; Tchem.
DR   PRO; PR:P51684; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; P51684; protein.
DR   Bgee; ENSG00000112486; Expressed in tonsil and 86 other tissues.
DR   ExpressionAtlas; P51684; baseline and differential.
DR   Genevisible; P51684; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0009897; C:external side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0036126; C:sperm flagellum; IDA:UniProtKB.
DR   GO; GO:0097225; C:sperm midpiece; IDA:UniProtKB.
DR   GO; GO:0097524; C:sperm plasma membrane; IDA:UniProtKB.
DR   GO; GO:0097228; C:sperm principal piece; IDA:UniProtKB.
DR   GO; GO:0019957; F:C-C chemokine binding; IDA:UniProtKB.
DR   GO; GO:0016493; F:C-C chemokine receptor activity; IDA:UniProtKB.
DR   GO; GO:0019956; F:chemokine binding; IBA:GO_Central.
DR   GO; GO:0004950; F:chemokine receptor activity; TAS:ProtInc.
DR   GO; GO:0038023; F:signaling receptor activity; TAS:ProtInc.
DR   GO; GO:0019722; P:calcium-mediated signaling; IMP:UniProtKB.
DR   GO; GO:0060326; P:cell chemotaxis; IDA:UniProtKB.
DR   GO; GO:0006968; P:cellular defense response; TAS:ProtInc.
DR   GO; GO:0006935; P:chemotaxis; IDA:UniProtKB.
DR   GO; GO:0002407; P:dendritic cell chemotaxis; TAS:BHF-UCL.
DR   GO; GO:1904155; P:DN2 thymocyte differentiation; ISS:UniProtKB.
DR   GO; GO:1904156; P:DN3 thymocyte differentiation; ISS:UniProtKB.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006959; P:humoral immune response; TAS:ProtInc.
DR   GO; GO:0006955; P:immune response; IBA:GO_Central.
DR   GO; GO:0048290; P:isotype switching to IgA isotypes; ISS:UniProtKB.
DR   GO; GO:0002523; P:leukocyte migration involved in inflammatory response; ISS:UniProtKB.
DR   GO; GO:0072676; P:lymphocyte migration; ISS:UniProtKB.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IBA:GO_Central.
DR   GO; GO:2000510; P:positive regulation of dendritic cell chemotaxis; IBA:GO_Central.
DR   GO; GO:0010634; P:positive regulation of epithelial cell migration; IEA:Ensembl.
DR   GO; GO:0060474; P:positive regulation of flagellated sperm motility involved in capacitation; IDA:UniProtKB.
DR   GO; GO:2000404; P:regulation of T cell migration; ISS:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0072678; P:T cell migration; ISS:UniProtKB.
DR   GO; GO:0072679; P:thymocyte migration; ISS:UniProtKB.
DR   InterPro; IPR004067; Chemokine_CCR6.
DR   InterPro; IPR000355; Chemokine_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   PANTHER; PTHR10489:SF611; PTHR10489:SF611; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00657; CCCHEMOKINER.
DR   PRINTS; PR01529; CHEMOKINER6.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Membrane; Receptor; Reference proteome; Transducer;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..374
FT                   /note="C-C chemokine receptor type 6"
FT                   /id="PRO_0000069286"
FT   TOPO_DOM        1..47
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        48..74
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        75..83
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        84..104
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        105..119
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        120..141
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        142..159
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        160..180
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        181..211
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        212..238
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        239..254
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        255..279
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        280..303
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        304..321
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        322..374
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        7
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        23
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        118..197
FT                   /evidence="ECO:0000269|PubMed:12081481"
FT   MUTAGEN         36
FT                   /note="C->A: No loss of calcium flux but loss of chemotaxis
FT                   in response to CCL20 stimulation. No effect on cell surface
FT                   expression."
FT                   /evidence="ECO:0000269|PubMed:12081481"
FT   MUTAGEN         36
FT                   /note="C->D,G: Loss of calcium flux and chemotaxis in
FT                   response to CCL20 stimulation. No effect on cell surface
FT                   expression."
FT                   /evidence="ECO:0000269|PubMed:12081481"
FT   MUTAGEN         36
FT                   /note="C->S: No loss of calcium flux but loss of chemotaxis
FT                   in response to CCL20 stimulation, impaired CCL20-binding
FT                   and no effect on cell surface expression; when associated
FT                   with or without S-288. Loss of calcium flux in response to
FT                   CCL20 stimulation and significant reduction in cell surface
FT                   expression; when associated with S-118; S-197 and S-288."
FT                   /evidence="ECO:0000269|PubMed:12081481"
FT   MUTAGEN         57
FT                   /note="C->S: No effect on calcium flux and chemotaxis in
FT                   response to CCL20 stimulation. No effect on cell surface
FT                   expression."
FT                   /evidence="ECO:0000269|PubMed:12081481"
FT   MUTAGEN         118
FT                   /note="C->S: Loss of calcium flux and chemotaxis in
FT                   response to CCL20 stimulation, impaired CCL20-binding and
FT                   significant reduction in cell surface expression; when
FT                   associated with or without S-197. Loss of calcium flux in
FT                   response to CCL20 stimulation and significant reduction in
FT                   cell surface expression; when associated with S-36; S-197
FT                   and S-288."
FT                   /evidence="ECO:0000269|PubMed:12081481"
FT   MUTAGEN         131
FT                   /note="C->S: No effect on calcium flux and chemotaxis in
FT                   response to CCL20 stimulation. No effect on cell surface
FT                   expression."
FT                   /evidence="ECO:0000269|PubMed:12081481"
FT   MUTAGEN         138
FT                   /note="C->S: No effect on calcium flux and chemotaxis in
FT                   response to CCL20 stimulation. No effect on cell surface
FT                   expression."
FT                   /evidence="ECO:0000269|PubMed:12081481"
FT   MUTAGEN         168
FT                   /note="C->S: No effect on calcium flux and chemotaxis in
FT                   response to CCL20 stimulation. No effect on cell surface
FT                   expression."
FT                   /evidence="ECO:0000269|PubMed:12081481"
FT   MUTAGEN         197
FT                   /note="C->S: Loss of calcium flux and chemotaxis in
FT                   response to CCL20 stimulation, impaired CCL20-binding and
FT                   significant reduction in cell surface expression; when
FT                   associated with or without S-118. Loss of calcium flux in
FT                   response to CCL20 stimulation and significant reduction in
FT                   cell surface expression; when associated with S-36; S-118
FT                   and S-288."
FT                   /evidence="ECO:0000269|PubMed:12081481"
FT   MUTAGEN         233
FT                   /note="C->S: No effect on calcium flux and chemotaxis in
FT                   response to CCL20 stimulation. No effect on cell surface
FT                   expression."
FT                   /evidence="ECO:0000269|PubMed:12081481"
FT   MUTAGEN         266
FT                   /note="C->S: No effect on calcium flux and chemotaxis in
FT                   response to CCL20 stimulation. No effect on cell surface
FT                   expression."
FT                   /evidence="ECO:0000269|PubMed:12081481"
FT   MUTAGEN         288
FT                   /note="C->A,G,R: No loss of calcium flux but loss of
FT                   chemotaxis in response to CCL20 stimulation. No effect on
FT                   cell surface expression."
FT                   /evidence="ECO:0000269|PubMed:12081481"
FT   MUTAGEN         288
FT                   /note="C->S: No loss of calcium flux but loss of chemotaxis
FT                   in response to CCL20 stimulation, impaired CCL20-binding
FT                   and no effect on cell surface expression; when associated
FT                   with or without S-36. Loss of calcium flux in response to
FT                   CCL20 stimulation and significant reduction in cell surface
FT                   expression; when associated with S-36; S-118 and S-197."
FT                   /evidence="ECO:0000269|PubMed:12081481"
FT   MUTAGEN         309
FT                   /note="C->S: No effect on calcium flux and chemotaxis in
FT                   response to CCL20 stimulation. No effect on cell surface
FT                   expression."
FT                   /evidence="ECO:0000269|PubMed:12081481"
FT   MUTAGEN         310
FT                   /note="C->S: No effect on calcium flux and chemotaxis in
FT                   response to CCL20 stimulation. No effect on cell surface
FT                   expression."
FT                   /evidence="ECO:0000269|PubMed:12081481"
FT   MUTAGEN         336
FT                   /note="C->S: Reduced calcium flux and chemotaxis in
FT                   response to CCL20 stimulation, and reduced CCL20-binding.
FT                   No effect on cell surface expression."
FT                   /evidence="ECO:0000269|PubMed:12081481"
FT   MUTAGEN         348
FT                   /note="C->S: No effect on calcium flux and chemotaxis in
FT                   response to CCL20 stimulation. No effect on CCL20-binding
FT                   and cell surface expression."
FT                   /evidence="ECO:0000269|PubMed:12081481"
FT   CONFLICT        60
FT                   /note="G -> A (in Ref. 4; AAB06949)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        74
FT                   /note="Y -> N (in Ref. 4; AAB06949)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        86
FT                   /note="L -> V (in Ref. 4; AAB06949)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        164
FT                   /note="S -> T (in Ref. 5; AAC51124/AAC51125)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        182
FT                   /note="T -> S (in Ref. 4; AAB06949)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        192
FT                   /note="Q -> L (in Ref. 4; AAB06949)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        206
FT                   /note="E -> V (in Ref. 4; AAB06949)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        225
FT                   /note="I -> F (in Ref. 4; AAB06949)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        370..374
FT                   /note="SSFTM -> VVLHYVIES (in Ref. 4; AAB06949)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   374 AA;  42494 MW;  D7F963534E990BC4 CRC64;
     MSGESMNFSD VFDSSEDYFV SVNTSYYSVD SEMLLCSLQE VRQFSRLFVP IAYSLICVFG
     LLGNILVVIT FAFYKKARSM TDVYLLNMAI ADILFVLTLP FWAVSHATGA WVFSNATCKL
     LKGIYAINFN CGMLLLTCIS MDRYIAIVQA TKSFRLRSRT LPRSKIICLV VWGLSVIISS
     STFVFNQKYN TQGSDVCEPK YQTVSEPIRW KLLMLGLELL FGFFIPLMFM IFCYTFIVKT
     LVQAQNSKRH KAIRVIIAVV LVFLACQIPH NMVLLVTAAN LGKMNRSCQS EKLIGYTKTV
     TEVLAFLHCC LNPVLYAFIG QKFRNYFLKI LKDLWCVRRK YKSSGFSCAG RYSENISRQT
     SETADNDNAS SFTM
//
ID   CXCR2_HUMAN             Reviewed;         360 AA.
AC   P25025; Q8IUZ1; Q9P2T6; Q9P2T7;
DT   01-MAY-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 2.
DT   07-OCT-2020, entry version 205.
DE   RecName: Full=C-X-C chemokine receptor type 2;
DE            Short=CXC-R2;
DE            Short=CXCR-2;
DE   AltName: Full=CDw128b;
DE   AltName: Full=GRO/MGSA receptor;
DE   AltName: Full=High affinity interleukin-8 receptor B;
DE            Short=IL-8R B;
DE   AltName: Full=IL-8 receptor type 2;
DE   AltName: CD_antigen=CD182;
GN   Name=CXCR2; Synonyms=IL8RB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1891716; DOI=10.1126/science.1891716;
RA   Murphy P.M., Tiffany H.L.;
RT   "Cloning of complementary DNA encoding a functional human interleukin-8
RT   receptor.";
RL   Science 253:1280-1283(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND CHARACTERIZATION.
RX   PubMed=8384312; DOI=10.1016/0161-5890(93)90065-j;
RA   Cerretti D.P., Kozlosky C.J., Vanden Bos T., Nelson N., Gearing D.P.,
RA   Beckmann M.P.;
RT   "Molecular characterization of receptors for human interleukin-8,
RT   GRO/melanoma growth-stimulatory activity and neutrophil activating peptide-
RT   2.";
RL   Mol. Immunol. 30:359-367(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RX   PubMed=7512557;
RA   Sprenger H., Lloyd A.R., Lautens L.L., Bonner T.I., Kelvin D.J.;
RT   "Structure, genomic organization, and expression of the human interleukin-8
RT   receptor B gene.";
RL   J. Biol. Chem. 269:11065-11072(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Placenta;
RX   PubMed=7929358;
RA   Ahuja S.K., Shetty A., Tiffany H.L., Murphy P.M.;
RT   "Comparison of the genomic organization and promoter function for human
RT   interleukin-8 receptors A and B.";
RL   J. Biol. Chem. 269:26381-26389(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   SeattleSNPs variation discovery resource;
RL   Submitted (AUG-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 52-162 AND 191-301, AND VARIANT
RP   CYS-80.
RX   PubMed=11196695; DOI=10.1038/sj.gene.6363682;
RA   Kato H., Tsuchiya N., Tokunaga K.;
RT   "Single nucleotide polymorphisms in the coding regions of human CXC-
RT   chemokine receptors CXCR1, CXCR2 and CXCR3.";
RL   Genes Immun. 1:330-337(2000).
RN   [8]
RP   CHARACTERIZATION.
RX   PubMed=1379593;
RA   Lee J., Horuk R., Rice G.C., Bennett G.L., Camerato T., Wood W.I.;
RT   "Characterization of two high affinity human interleukin-8 receptors.";
RL   J. Biol. Chem. 267:16283-16287(1992).
RN   [9]
RP   PHOSPHORYLATION AT SER-347; SER-351; SER-352 AND SER-353.
RX   PubMed=9079638; DOI=10.1074/jbc.272.13.8207;
RA   Mueller S.G., White J.R., Schraw W.P., Lam V., Richmond A.;
RT   "Ligand-induced desensitization of the human CXC chemokine receptor-2 is
RT   modulated by multiple serine residues in the carboxyl-terminal domain of
RT   the receptor.";
RL   J. Biol. Chem. 272:8207-8214(1997).
RN   [10]
RP   CLEAVAGE BY STAPHYLOCOCCUS AUREUS STAPHOPAIN A (MICROBIAL INFECTION).
RX   PubMed=22850671; DOI=10.1038/emboj.2012.212;
RA   Laarman A.J., Mijnheer G., Mootz J.M., van Rooijen W.J., Ruyken M.,
RA   Malone C.L., Heezius E.C., Ward R., Milligan G., van Strijp J.A.,
RA   de Haas C.J., Horswill A.R., van Kessel K.P., Rooijakkers S.H.;
RT   "Staphylococcus aureus Staphopain A inhibits CXCR2-dependent neutrophil
RT   activation and chemotaxis.";
RL   EMBO J. 31:3607-3619(2012).
CC   -!- FUNCTION: Receptor for interleukin-8 which is a powerful neutrophil
CC       chemotactic factor. Binding of IL-8 to the receptor causes activation
CC       of neutrophils. This response is mediated via a G-protein that
CC       activates a phosphatidylinositol-calcium second messenger system. Binds
CC       to IL-8 with high affinity. Also binds with high affinity to CXCL3,
CC       GRO/MGSA and NAP-2.
CC   -!- INTERACTION:
CC       P25025; Q9HD20-3: ATP13A1; NbExp=3; IntAct=EBI-2835281, EBI-12069500;
CC       P25025; Q8WVX3-2: C4orf3; NbExp=3; IntAct=EBI-2835281, EBI-12003442;
CC       P25025; Q8N7P3: CLDN22; NbExp=3; IntAct=EBI-2835281, EBI-17766761;
CC       P25025; P10145: CXCL8; NbExp=3; IntAct=EBI-2835281, EBI-3917999;
CC       P25025; P54849: EMP1; NbExp=3; IntAct=EBI-2835281, EBI-4319440;
CC       P25025; Q14318: FKBP8; NbExp=3; IntAct=EBI-2835281, EBI-724839;
CC       P25025; P46940: IQGAP1; NbExp=12; IntAct=EBI-2835281, EBI-297509;
CC       P25025; Q05940: SLC18A2; NbExp=3; IntAct=EBI-2835281, EBI-18036244;
CC       P25025; Q9NP94: SLC39A2; NbExp=3; IntAct=EBI-2835281, EBI-12898013;
CC       P25025; Q9NRQ5: SMCO4; NbExp=3; IntAct=EBI-2835281, EBI-8640191;
CC       P25025; Q9BVK8: TMEM147; NbExp=3; IntAct=EBI-2835281, EBI-348587;
CC       P25025; Q96HE8: TMEM80; NbExp=3; IntAct=EBI-2835281, EBI-11742770;
CC       P25025; A5PKU2: TUSC5; NbExp=3; IntAct=EBI-2835281, EBI-11988865;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- PTM: Phosphorylated upon ligand binding; which is required for
CC       desensitization. {ECO:0000269|PubMed:9079638}.
CC   -!- PTM: (Microbial infection) Proteolytically cleaved by Staphylococcus
CC       aureus staphopain A/SspP. This cleavage inhibits CXCR2-dependent
CC       neutrophil activation and chemotaxis. {ECO:0000269|PubMed:22850671}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=CXC chemokine receptors entry;
CC       URL="https://en.wikipedia.org/wiki/CXC_chemokine_receptors";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/il8rb/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M73969; AAA83148.1; -; mRNA.
DR   EMBL; M94582; AAA36108.1; -; mRNA.
DR   EMBL; M99412; AAC14460.1; -; Genomic_DNA.
DR   EMBL; L19593; AAB59437.1; -; mRNA.
DR   EMBL; U11869; AAB60656.1; -; Genomic_DNA.
DR   EMBL; AY714242; AAT97985.1; -; Genomic_DNA.
DR   EMBL; BC037961; AAH37961.2; -; mRNA.
DR   EMBL; AB032733; BAA92295.1; -; Genomic_DNA.
DR   EMBL; AB032734; BAA92296.1; -; Genomic_DNA.
DR   CCDS; CCDS2408.1; -.
DR   PIR; I37898; A53611.
DR   RefSeq; NP_001161770.1; NM_001168298.1.
DR   RefSeq; NP_001548.1; NM_001557.3.
DR   RefSeq; XP_005246587.1; XM_005246530.3.
DR   RefSeq; XP_016859479.1; XM_017003990.1.
DR   RefSeq; XP_016859480.1; XM_017003991.1.
DR   RefSeq; XP_016859481.1; XM_017003992.1.
DR   PDB; 4Q3H; X-ray; 1.44 A; A/B=356-360.
DR   PDB; 5TYT; X-ray; 2.40 A; A/B/C/D=356-360.
DR   PDBsum; 4Q3H; -.
DR   PDBsum; 5TYT; -.
DR   BioGRID; 109793; 20.
DR   CORUM; P25025; -.
DR   DIP; DIP-3782N; -.
DR   IntAct; P25025; 40.
DR   MINT; P25025; -.
DR   STRING; 9606.ENSP00000319635; -.
DR   BindingDB; P25025; -.
DR   ChEMBL; CHEMBL2434; -.
DR   DrugCentral; P25025; -.
DR   GuidetoPHARMACOLOGY; 69; -.
DR   GlyGen; P25025; 1 site.
DR   iPTMnet; P25025; -.
DR   PhosphoSitePlus; P25025; -.
DR   BioMuta; CXCR2; -.
DR   DMDM; 1352454; -.
DR   jPOST; P25025; -.
DR   MassIVE; P25025; -.
DR   PaxDb; P25025; -.
DR   PeptideAtlas; P25025; -.
DR   PRIDE; P25025; -.
DR   ProteomicsDB; 54246; -.
DR   Antibodypedia; 4268; 977 antibodies.
DR   DNASU; 3579; -.
DR   Ensembl; ENST00000318507; ENSP00000319635; ENSG00000180871.
DR   GeneID; 3579; -.
DR   KEGG; hsa:3579; -.
DR   CTD; 3579; -.
DR   DisGeNET; 3579; -.
DR   EuPathDB; HostDB:ENSG00000180871.7; -.
DR   GeneCards; CXCR2; -.
DR   HGNC; HGNC:6027; CXCR2.
DR   HPA; ENSG00000180871; Tissue enriched (blood).
DR   MalaCards; CXCR2; -.
DR   MIM; 146928; gene.
DR   neXtProt; NX_P25025; -.
DR   OpenTargets; ENSG00000180871; -.
DR   Orphanet; 420699; Autosomal recessive severe congenital neutropenia due to CXCR2 deficiency.
DR   PharmGKB; PA29843; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT01000000214381; -.
DR   HOGENOM; CLU_009579_8_3_1; -.
DR   InParanoid; P25025; -.
DR   KO; K05050; -.
DR   OMA; INKHAVV; -.
DR   OrthoDB; 865441at2759; -.
DR   PhylomeDB; P25025; -.
DR   TreeFam; TF330966; -.
DR   PathwayCommons; P25025; -.
DR   Reactome; R-HSA-380108; Chemokine receptors bind chemokines.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SignaLink; P25025; -.
DR   SIGNOR; P25025; -.
DR   BioGRID-ORCS; 3579; 3 hits in 871 CRISPR screens.
DR   ChiTaRS; CXCR2; human.
DR   GenomeRNAi; 3579; -.
DR   Pharos; P25025; Tchem.
DR   PRO; PR:P25025; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; P25025; protein.
DR   Bgee; ENSG00000180871; Expressed in blood and 177 other tissues.
DR   ExpressionAtlas; P25025; baseline and differential.
DR   Genevisible; P25025; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0009897; C:external side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:UniProtKB.
DR   GO; GO:0042629; C:mast cell granule; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0015630; C:microtubule cytoskeleton; IDA:HPA.
DR   GO; GO:0072686; C:mitotic spindle; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0030667; C:secretory granule membrane; TAS:Reactome.
DR   GO; GO:0019957; F:C-C chemokine binding; IBA:GO_Central.
DR   GO; GO:0016493; F:C-C chemokine receptor activity; IBA:GO_Central.
DR   GO; GO:0016494; F:C-X-C chemokine receptor activity; IDA:UniProtKB.
DR   GO; GO:0019956; F:chemokine binding; IBA:GO_Central.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IDA:UniProtKB.
DR   GO; GO:0019959; F:interleukin-8 binding; IPI:UniProtKB.
DR   GO; GO:0004918; F:interleukin-8 receptor activity; IDA:UniProtKB.
DR   GO; GO:0002438; P:acute inflammatory response to antigenic stimulus; IEA:Ensembl.
DR   GO; GO:0019722; P:calcium-mediated signaling; IBA:GO_Central.
DR   GO; GO:0060326; P:cell chemotaxis; IBA:GO_Central.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0006968; P:cellular defense response; IDA:UniProtKB.
DR   GO; GO:0006935; P:chemotaxis; IDA:UniProtKB.
DR   GO; GO:0002407; P:dendritic cell chemotaxis; TAS:BHF-UCL.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006955; P:immune response; IBA:GO_Central.
DR   GO; GO:0006954; P:inflammatory response; TAS:ProtInc.
DR   GO; GO:0038112; P:interleukin-8-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0072173; P:metanephric tubule morphogenesis; IEA:Ensembl.
DR   GO; GO:0030901; P:midbrain development; IEA:Ensembl.
DR   GO; GO:0033030; P:negative regulation of neutrophil apoptotic process; IEA:Ensembl.
DR   GO; GO:0042119; P:neutrophil activation; IDA:UniProtKB.
DR   GO; GO:0030593; P:neutrophil chemotaxis; IDA:UniProtKB.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:0010666; P:positive regulation of cardiac muscle cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IBA:GO_Central.
DR   GO; GO:0090023; P:positive regulation of neutrophil chemotaxis; IEA:Ensembl.
DR   GO; GO:0043117; P:positive regulation of vascular permeability; IEA:Ensembl.
DR   GO; GO:0031623; P:receptor internalization; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   IDEAL; IID00625; -.
DR   InterPro; IPR000057; Chemokine_CXCR2.
DR   InterPro; IPR000174; Chemokine_CXCR_1/2.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00427; INTRLEUKIN8R.
DR   PRINTS; PR00573; INTRLEUKN8BR.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Chemotaxis; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Phosphoprotein;
KW   Polymorphism; Receptor; Reference proteome; Transducer; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..360
FT                   /note="C-X-C chemokine receptor type 2"
FT                   /id="PRO_0000069337"
FT   TOPO_DOM        1..48
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        49..75
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        76..84
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        85..105
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        106..120
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        121..142
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        143..163
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        164..183
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        184..208
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        209..231
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        232..251
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        252..273
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        274..294
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        295..315
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        316..360
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   SITE            35..36
FT                   /note="(Microbial infection) Cleavage; by Staphylococcus
FT                   aureus/SspP"
FT                   /evidence="ECO:0000269|PubMed:22850671"
FT   MOD_RES         347
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000305|PubMed:9079638"
FT   MOD_RES         351
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000305|PubMed:9079638"
FT   MOD_RES         352
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000305|PubMed:9079638"
FT   MOD_RES         353
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000305|PubMed:9079638"
FT   CARBOHYD        22
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        119..196
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VARIANT         80
FT                   /note="R -> C (in dbSNP:rs1805038)"
FT                   /evidence="ECO:0000269|PubMed:11196695"
FT                   /id="VAR_014679"
FT   STRAND          356..359
FT                   /evidence="ECO:0000244|PDB:5TYT"
SQ   SEQUENCE   360 AA;  40759 MW;  564F04A8BCC0A197 CRC64;
     MEDFNMESDS FEDFWKGEDL SNYSYSSTLP PFLLDAAPCE PESLEINKYF VVIIYALVFL
     LSLLGNSLVM LVILYSRVGR SVTDVYLLNL ALADLLFALT LPIWAASKVN GWIFGTFLCK
     VVSLLKEVNF YSGILLLACI SVDRYLAIVH ATRTLTQKRY LVKFICLSIW GLSLLLALPV
     LLFRRTVYSS NVSPACYEDM GNNTANWRML LRILPQSFGF IVPLLIMLFC YGFTLRTLFK
     AHMGQKHRAM RVIFAVVLIF LLCWLPYNLV LLADTLMRTQ VIQETCERRN HIDRALDATE
     ILGILHSCLN PLIYAFIGQK FRHGLLKILA IHGLISKDSL PKDSRPSFVG SSSGHTSTTL
//
ID   CXCR1_HUMAN             Reviewed;         350 AA.
AC   P25024; B2R6Q3; Q2YEF8; Q2YEG4; Q2YEG5; Q2YEG7; Q2YEG8; Q53R18; Q6IN95;
AC   Q8N6T6; Q9P2T8; Q9P2T9; Q9P2U0; Q9P2U1; Q9P2U2;
DT   01-MAY-1992, integrated into UniProtKB/Swiss-Prot.
DT   30-MAY-2006, sequence version 2.
DT   07-OCT-2020, entry version 195.
DE   RecName: Full=C-X-C chemokine receptor type 1;
DE            Short=CXC-R1;
DE            Short=CXCR-1;
DE   AltName: Full=CDw128a;
DE   AltName: Full=High affinity interleukin-8 receptor A;
DE            Short=IL-8R A;
DE   AltName: Full=IL-8 receptor type 1;
DE   AltName: CD_antigen=CD181;
GN   Name=CXCR1; Synonyms=CMKAR1, IL8RA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND VARIANT THR-276.
RX   PubMed=1840701; DOI=10.1126/science.1840701;
RA   Holmes W.E., Lee J., Kuang W.-J., Rice G.C., Wood W.I.;
RT   "Structure and functional expression of a human interleukin-8 receptor.";
RL   Science 253:1278-1280(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND CHARACTERIZATION.
RX   PubMed=8384312; DOI=10.1016/0161-5890(93)90065-j;
RA   Cerretti D.P., Kozlosky C.J., Vanden Bos T., Nelson N., Gearing D.P.,
RA   Beckmann M.P.;
RT   "Molecular characterization of receptors for human interleukin-8,
RT   GRO/melanoma growth-stimulatory activity and neutrophil activating peptide-
RT   2.";
RL   Mol. Immunol. 30:359-367(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8486366; DOI=10.1006/geno.1993.1167;
RA   Mollereau C., Passage E., Mattei M.-G., Vassart G., Parmentier M.;
RT   "The high-affinity interleukin 8 receptor gene (IL8RA) maps to the 2q33-q36
RT   region of the human genome: cloning of a pseudogene (IL8RBP) for the low-
RT   affinity receptor.";
RL   Genomics 16:248-251(1993).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Placenta;
RX   PubMed=7929358;
RA   Ahuja S.K., Shetty A., Tiffany H.L., Murphy P.M.;
RT   "Comparison of the genomic organization and promoter function for human
RT   interleukin-8 receptors A and B.";
RL   J. Biol. Chem. 269:26381-26389(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-31; THR-276 AND
RP   CYS-335.
RX   PubMed=16205979; DOI=10.1007/s00239-005-0039-x;
RA   Liu Y., Yang S., Lin A.A., Cavalli-Sforza L.L., Su B.;
RT   "Molecular evolution of CXCR1, a G protein-coupled receptor involved in
RT   signal transduction of neutrophils.";
RL   J. Mol. Evol. 61:691-696(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Halleck A., Ebert L., Mkoundinya M., Schick M., Eisenstein S., Neubert P.,
RA   Kstrang K., Schatten R., Shen B., Henze S., Mar W., Korn B., Zuo D., Hu Y.,
RA   LaBaer J.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-31; THR-276; CYS-335
RP   AND LEU-342.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ARG-31 AND CYS-335.
RC   TISSUE=Blood;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 223-350, AND VARIANTS THR-276; THR-306
RP   AND CYS-335.
RX   PubMed=11196695; DOI=10.1038/sj.gene.6363682;
RA   Kato H., Tsuchiya N., Tokunaga K.;
RT   "Single nucleotide polymorphisms in the coding regions of human CXC-
RT   chemokine receptors CXCR1, CXCR2 and CXCR3.";
RL   Genes Immun. 1:330-337(2000).
RN   [13]
RP   CHARACTERIZATION.
RX   PubMed=1379593;
RA   Lee J., Horuk R., Rice G.C., Bennett G.L., Camerato T., Wood W.I.;
RT   "Characterization of two high affinity human interleukin-8 receptors.";
RL   J. Biol. Chem. 267:16283-16287(1992).
RN   [14]
RP   STRUCTURE BY NMR OF 9-29 IN COMPLEX WITH IL-8.
RX   PubMed=10368283; DOI=10.1016/s0969-2126(99)80022-7;
RA   Skelton N.J., Quan C., Reilly D., Lowman H.;
RT   "Structure of a CXC chemokine-receptor fragment in complex with
RT   interleukin-8.";
RL   Structure 7:157-168(1999).
CC   -!- FUNCTION: Receptor to interleukin-8, which is a powerful neutrophils
CC       chemotactic factor. Binding of IL-8 to the receptor causes activation
CC       of neutrophils. This response is mediated via a G-protein that activate
CC       a phosphatidylinositol-calcium second messenger system. This receptor
CC       binds to IL-8 with a high affinity and to MGSA (GRO) with a low
CC       affinity.
CC   -!- INTERACTION:
CC       P25024; Q9NY35: CLDND1; NbExp=3; IntAct=EBI-3905522, EBI-4319704;
CC       P25024; Q969F0: FATE1; NbExp=3; IntAct=EBI-3905522, EBI-743099;
CC       P25024; P24593: IGFBP5; NbExp=3; IntAct=EBI-3905522, EBI-720480;
CC       P25024; A5PKU2: TUSC5; NbExp=3; IntAct=EBI-3905522, EBI-11988865;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=CXC chemokine receptors entry;
CC       URL="https://en.wikipedia.org/wiki/CXC_chemokine_receptors";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/il8ra/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L19591; AAB59436.1; -; mRNA.
DR   EMBL; L19592; AAA59160.1; -; Genomic_DNA.
DR   EMBL; M68932; AAA59159.1; -; mRNA.
DR   EMBL; X65858; CAA46688.1; -; Genomic_DNA.
DR   EMBL; U11870; AAA64378.1; -; Genomic_DNA.
DR   EMBL; AY916762; AAY21512.1; -; Genomic_DNA.
DR   EMBL; AY916763; AAY21513.1; -; Genomic_DNA.
DR   EMBL; AY916764; AAY21514.1; -; Genomic_DNA.
DR   EMBL; AY916765; AAY21515.1; -; Genomic_DNA.
DR   EMBL; AY916766; AAY21516.1; -; Genomic_DNA.
DR   EMBL; AY916769; AAY21519.1; -; Genomic_DNA.
DR   EMBL; AY916772; AAY21522.1; -; Genomic_DNA.
DR   EMBL; AY916773; AAY21523.1; -; Genomic_DNA.
DR   EMBL; CR541994; CAG46791.1; -; mRNA.
DR   EMBL; CR542029; CAG46826.1; -; mRNA.
DR   EMBL; AK312668; BAG35550.1; -; mRNA.
DR   EMBL; AY651785; AAT46689.1; -; Genomic_DNA.
DR   EMBL; AC097483; AAX93212.1; -; Genomic_DNA.
DR   EMBL; CH471063; EAW70590.1; -; Genomic_DNA.
DR   EMBL; BC028221; AAH28221.1; -; mRNA.
DR   EMBL; BC072397; AAH72397.1; -; mRNA.
DR   EMBL; AB032728; BAA92290.1; -; Genomic_DNA.
DR   EMBL; AB032729; BAA92291.1; -; Genomic_DNA.
DR   EMBL; AB032730; BAA92292.1; -; Genomic_DNA.
DR   EMBL; AB032731; BAA92293.1; -; Genomic_DNA.
DR   EMBL; AB032732; BAA92294.1; -; Genomic_DNA.
DR   CCDS; CCDS2409.1; -.
DR   PIR; I37449; A39445.
DR   RefSeq; NP_000625.1; NM_000634.2.
DR   PDB; 1ILP; NMR; -; C=9-29.
DR   PDB; 1ILQ; NMR; -; C=9-29.
DR   PDB; 2LNL; NMR; -; A=20-328.
DR   PDBsum; 1ILP; -.
DR   PDBsum; 1ILQ; -.
DR   PDBsum; 2LNL; -.
DR   BMRB; P25024; -.
DR   SMR; P25024; -.
DR   BioGRID; 109791; 9.
DR   DIP; DIP-3779N; -.
DR   IntAct; P25024; 8.
DR   STRING; 9606.ENSP00000295683; -.
DR   BindingDB; P25024; -.
DR   ChEMBL; CHEMBL4029; -.
DR   DrugBank; DB01009; Ketoprofen.
DR   DrugCentral; P25024; -.
DR   GuidetoPHARMACOLOGY; 68; -.
DR   GlyGen; P25024; 2 sites.
DR   iPTMnet; P25024; -.
DR   PhosphoSitePlus; P25024; -.
DR   BioMuta; CXCR1; -.
DR   DMDM; 108936015; -.
DR   MassIVE; P25024; -.
DR   PaxDb; P25024; -.
DR   PeptideAtlas; P25024; -.
DR   PRIDE; P25024; -.
DR   ProteomicsDB; 54245; -.
DR   Antibodypedia; 4267; 599 antibodies.
DR   DNASU; 3577; -.
DR   Ensembl; ENST00000295683; ENSP00000295683; ENSG00000163464.
DR   GeneID; 3577; -.
DR   KEGG; hsa:3577; -.
DR   UCSC; uc002vhc.4; human.
DR   CTD; 3577; -.
DR   DisGeNET; 3577; -.
DR   EuPathDB; HostDB:ENSG00000163464.7; -.
DR   GeneCards; CXCR1; -.
DR   HGNC; HGNC:6026; CXCR1.
DR   HPA; ENSG00000163464; Tissue enriched (blood).
DR   MalaCards; CXCR1; -.
DR   MIM; 146929; gene.
DR   neXtProt; NX_P25024; -.
DR   OpenTargets; ENSG00000163464; -.
DR   PharmGKB; PA29842; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT01000000214381; -.
DR   HOGENOM; CLU_009579_8_3_1; -.
DR   InParanoid; P25024; -.
DR   KO; K04175; -.
DR   OMA; NDTAKWR; -.
DR   OrthoDB; 865441at2759; -.
DR   PhylomeDB; P25024; -.
DR   TreeFam; TF330966; -.
DR   PathwayCommons; P25024; -.
DR   Reactome; R-HSA-380108; Chemokine receptors bind chemokines.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SIGNOR; P25024; -.
DR   BioGRID-ORCS; 3577; 4 hits in 871 CRISPR screens.
DR   ChiTaRS; CXCR1; human.
DR   EvolutionaryTrace; P25024; -.
DR   GeneWiki; Interleukin_8_receptor,_alpha; -.
DR   GenomeRNAi; 3577; -.
DR   Pharos; P25024; Tchem.
DR   PRO; PR:P25024; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; P25024; protein.
DR   Bgee; ENSG00000163464; Expressed in blood and 114 other tissues.
DR   Genevisible; P25024; HS.
DR   GO; GO:0009897; C:external side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0030667; C:secretory granule membrane; TAS:Reactome.
DR   GO; GO:0019957; F:C-C chemokine binding; IBA:GO_Central.
DR   GO; GO:0016493; F:C-C chemokine receptor activity; IBA:GO_Central.
DR   GO; GO:0019956; F:chemokine binding; IBA:GO_Central.
DR   GO; GO:0004950; F:chemokine receptor activity; TAS:ProtInc.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; TAS:ProtInc.
DR   GO; GO:0019959; F:interleukin-8 binding; IPI:UniProtKB.
DR   GO; GO:0004918; F:interleukin-8 receptor activity; IDA:UniProtKB.
DR   GO; GO:0019722; P:calcium-mediated signaling; IBA:GO_Central.
DR   GO; GO:0060326; P:cell chemotaxis; IBA:GO_Central.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0006935; P:chemotaxis; IBA:GO_Central.
DR   GO; GO:0002407; P:dendritic cell chemotaxis; TAS:BHF-UCL.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006955; P:immune response; IBA:GO_Central.
DR   GO; GO:0030593; P:neutrophil chemotaxis; IBA:GO_Central.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IBA:GO_Central.
DR   GO; GO:0031623; P:receptor internalization; IDA:UniProtKB.
DR   InterPro; IPR001355; Chemokine_CXCR1.
DR   InterPro; IPR000174; Chemokine_CXCR_1/2.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00427; INTRLEUKIN8R.
DR   PRINTS; PR00572; INTRLEUKN8AR.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Chemotaxis; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Polymorphism; Receptor;
KW   Reference proteome; Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..350
FT                   /note="C-X-C chemokine receptor type 1"
FT                   /id="PRO_0000069330"
FT   TOPO_DOM        1..39
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        40..66
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        67..75
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        76..96
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        97..111
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        112..133
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        134..154
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        155..174
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        175..199
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        200..220
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        221..242
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        243..264
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        265..285
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        286..308
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        309..350
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        3
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        16
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        110..187
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VARIANT         31
FT                   /note="M -> R (in dbSNP:rs16858811)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:16205979, ECO:0000269|Ref.8"
FT                   /id="VAR_021061"
FT   VARIANT         71
FT                   /note="R -> C (in dbSNP:rs1805038)"
FT                   /id="VAR_016236"
FT   VARIANT         268
FT                   /note="M -> L (in dbSNP:rs9282752)"
FT                   /id="VAR_026525"
FT   VARIANT         276
FT                   /note="S -> T (common polymorphism; dbSNP:rs2234671)"
FT                   /evidence="ECO:0000269|PubMed:11196695,
FT                   ECO:0000269|PubMed:16205979, ECO:0000269|PubMed:1840701,
FT                   ECO:0000269|Ref.8"
FT                   /id="VAR_003479"
FT   VARIANT         306
FT                   /note="A -> T (in dbSNP:rs201583693)"
FT                   /evidence="ECO:0000269|PubMed:11196695"
FT                   /id="VAR_016237"
FT   VARIANT         335
FT                   /note="R -> C (in dbSNP:rs16858808)"
FT                   /evidence="ECO:0000269|PubMed:11196695,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:16205979,
FT                   ECO:0000269|Ref.8"
FT                   /id="VAR_016238"
FT   VARIANT         342
FT                   /note="S -> L (in dbSNP:rs16858806)"
FT                   /evidence="ECO:0000269|Ref.8"
FT                   /id="VAR_021062"
FT   CONFLICT        154
FT                   /note="K -> N (in Ref. 11; AAH72397)"
FT                   /evidence="ECO:0000305"
FT   HELIX           38..66
FT                   /evidence="ECO:0000244|PDB:2LNL"
FT   HELIX           75..100
FT                   /evidence="ECO:0000244|PDB:2LNL"
FT   STRAND          101..103
FT                   /evidence="ECO:0000244|PDB:2LNL"
FT   HELIX           108..138
FT                   /evidence="ECO:0000244|PDB:2LNL"
FT   STRAND          139..141
FT                   /evidence="ECO:0000244|PDB:2LNL"
FT   STRAND          143..146
FT                   /evidence="ECO:0000244|PDB:2LNL"
FT   HELIX           149..173
FT                   /evidence="ECO:0000244|PDB:2LNL"
FT   TURN            195..197
FT                   /evidence="ECO:0000244|PDB:2LNL"
FT   HELIX           201..204
FT                   /evidence="ECO:0000244|PDB:2LNL"
FT   TURN            205..207
FT                   /evidence="ECO:0000244|PDB:2LNL"
FT   HELIX           208..225
FT                   /evidence="ECO:0000244|PDB:2LNL"
FT   TURN            226..228
FT                   /evidence="ECO:0000244|PDB:2LNL"
FT   STRAND          229..231
FT                   /evidence="ECO:0000244|PDB:2LNL"
FT   HELIX           235..238
FT                   /evidence="ECO:0000244|PDB:2LNL"
FT   HELIX           240..267
FT                   /evidence="ECO:0000244|PDB:2LNL"
FT   STRAND          270..272
FT                   /evidence="ECO:0000244|PDB:2LNL"
FT   HELIX           276..282
FT                   /evidence="ECO:0000244|PDB:2LNL"
FT   HELIX           285..293
FT                   /evidence="ECO:0000244|PDB:2LNL"
FT   HELIX           294..298
FT                   /evidence="ECO:0000244|PDB:2LNL"
FT   HELIX           300..308
FT                   /evidence="ECO:0000244|PDB:2LNL"
FT   HELIX           311..322
FT                   /evidence="ECO:0000244|PDB:2LNL"
SQ   SEQUENCE   350 AA;  39791 MW;  2463E868C0EB0DE2 CRC64;
     MSNITDPQMW DFDDLNFTGM PPADEDYSPC MLETETLNKY VVIIAYALVF LLSLLGNSLV
     MLVILYSRVG RSVTDVYLLN LALADLLFAL TLPIWAASKV NGWIFGTFLC KVVSLLKEVN
     FYSGILLLAC ISVDRYLAIV HATRTLTQKR HLVKFVCLGC WGLSMNLSLP FFLFRQAYHP
     NNSSPVCYEV LGNDTAKWRM VLRILPHTFG FIVPLFVMLF CYGFTLRTLF KAHMGQKHRA
     MRVIFAVVLI FLLCWLPYNL VLLADTLMRT QVIQESCERR NNIGRALDAT EILGFLHSCL
     NPIIYAFIGQ NFRHGFLKIL AMHGLVSKEF LARHRVTSYT SSSVNVSSNL
//
ID   ADA2A_HUMAN             Reviewed;         465 AA.
AC   P08913; B0LPF6; Q2I8G2; Q2XN99; Q86TH8; Q9BZK1;
DT   01-NOV-1988, integrated into UniProtKB/Swiss-Prot.
DT   11-DEC-2019, sequence version 4.
DT   07-OCT-2020, entry version 217.
DE   RecName: Full=Alpha-2A adrenergic receptor {ECO:0000305};
DE   AltName: Full=Alpha-2 adrenergic receptor subtype C10;
DE   AltName: Full=Alpha-2A adrenoreceptor;
DE            Short=Alpha-2A adrenoceptor;
DE            Short=Alpha-2AAR;
GN   Name=ADRA2A {ECO:0000312|HGNC:HGNC:281}; Synonyms=ADRA2R, ADRAR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2568356;
RA   Fraser C.M., Arakawa S., McCombie W.R., Venter J.C.;
RT   "Cloning, sequence analysis, and permanent expression of a human alpha 2-
RT   adrenergic receptor in Chinese hamster ovary cells. Evidence for
RT   independent pathways of receptor coupling to adenylate cyclase attenuation
RT   and activation.";
RL   J. Biol. Chem. 264:11754-11761(1989).
RN   [2]
RP   SEQUENCE REVISION TO 333-365.
RX   PubMed=2170371;
RA   Guyer C.A., Horstman D.A., Wilson A.L., Clark J.D., Kragoe E.J. Jr.,
RA   Limbird L.E.;
RT   "Cloning, sequencing, and expression of the gene encoding the porcine alpha
RT   2-adrenergic receptor. Allosteric modulation by Na+, H+, and amiloride
RT   analogs.";
RL   J. Biol. Chem. 265:17307-17317(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=16567612; DOI=10.1073/pnas.0601345103;
RA   Small K.M., Brown K.M., Seman C.A., Theiss C.T., Liggett S.B.;
RT   "Complex haplotypes derived from noncoding polymorphisms of the intronless
RT   alpha-2A-adrenergic gene diversify receptor expression.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:5472-5477(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Mao Z.-M., Tang K., Li B.-M., Jing N.-H.;
RT   "Cloning and expression of human alpha-2A adrenergic receptor in SY5Y
RT   cells.";
RL   Submitted (JUL-2000) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Castellano M., Giacche' M., Rossi F., Rivadossi F., Perani C., Beschi M.,
RA   Agabiti Rosei E.;
RT   "A search for genetic variability in the human alpha-2 adrenergic receptor
RT   on chromosome 10.";
RL   Submitted (AUG-2000) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Liu L., Yuan L.;
RT   "Human alpha-2A adrenergic receptor gene and the genotype of -1296
RT   nucleotide and motionsickness.";
RL   Submitted (APR-2001) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT LYS-266.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (NOV-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=PNS, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 7-465, AND PARTIAL PROTEIN SEQUENCE.
RC   TISSUE=Platelet;
RX   PubMed=2823383; DOI=10.1126/science.2823383;
RA   Kobilka B.K., Matsui H., Kobilka T.S., Yang-Feng T.L., Francke U.,
RA   Caron M.G., Lefkowitz R.J., Regan J.W.;
RT   "Cloning, sequencing, and expression of the gene coding for the human
RT   platelet alpha 2-adrenergic receptor.";
RL   Science 238:650-656(1987).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 16-465, AND VARIANT LYS-266.
RX   PubMed=10948191; DOI=10.1074/jbc.m004550200;
RA   Small K.M., Forbes S.L., Brown K.M., Liggett S.B.;
RT   "An Asn to Lys polymorphism in the third intracellular loop of the human
RT   alpha 2A-adrenergic receptor imparts enhanced agonist-promoted Gi
RT   coupling.";
RL   J. Biol. Chem. 275:38518-38523(2000).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 92-224.
RX   PubMed=1849485; DOI=10.1016/0014-5793(91)80301-i;
RA   Chhajlani V., Rangel N., Uhlen S., Wikberg J.E.S.;
RT   "Identification of an additional gene belonging to the alpha 2 adrenergic
RT   receptor family in the human genome by PCR.";
RL   FEBS Lett. 280:241-244(1991).
RN   [14]
RP   MUTAGENESIS OF PHE-427.
RX   PubMed=1678390;
RA   Suryanarayana S., Daunt D.A., von Zastrow M., Kobilka B.K.;
RT   "A point mutation in the seventh hydrophobic domain of the alpha 2
RT   adrenergic receptor increases its affinity for a family of beta receptor
RT   antagonists.";
RL   J. Biol. Chem. 266:15488-15492(1991).
RN   [15]
RP   MUTAGENESIS OF ASPARTIC ACID AND SERINE RESIDUES.
RX   PubMed=1678850;
RA   Wang C.-D., Buck M.A., Fraser C.M.;
RT   "Site-directed mutagenesis of alpha 2a-adrenergic receptors: Identification
RT   of amino acids involved in ligand binding and receptor activation by
RT   agonists.";
RL   Mol. Pharmacol. 40:168-179(1991).
RN   [16]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=23105096; DOI=10.1074/jbc.m112.410936;
RA   Li C., Fan Y., Lan T.H., Lambert N.A., Wu G.;
RT   "Rab26 modulates the cell surface transport of alpha2-adrenergic receptors
RT   from the Golgi.";
RL   J. Biol. Chem. 287:42784-42794(2012).
RN   [17]
RP   STRUCTURE BY NMR OF 133-164, AND PROBABLE MEMBRANE TOPOLOGY.
RX   PubMed=11888275; DOI=10.1021/bi015811+;
RA   Chung D.A., Zuiderweg E.R.P., Fowler C.B., Soyer O.S., Mosberg H.I.,
RA   Neubig R.R.;
RT   "NMR structure of the second intracellular loop of the alpha 2A adrenergic
RT   receptor: evidence for a novel cytoplasmic helix.";
RL   Biochemistry 41:3596-3604(2002).
CC   -!- FUNCTION: Alpha-2 adrenergic receptors mediate the catecholamine-
CC       induced inhibition of adenylate cyclase through the action of G
CC       proteins. The rank order of potency for agonists of this receptor is
CC       oxymetazoline > clonidine > epinephrine > norepinephrine >
CC       phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-
CC       octopamine. For antagonists, the rank order is yohimbine > phentolamine
CC       = mianserine > chlorpromazine = spiperone = prazosin > propanolol >
CC       alprenolol = pindolol. {ECO:0000269|PubMed:23105096}.
CC   -!- INTERACTION:
CC       P08913; P08913: ADRA2A; NbExp=2; IntAct=EBI-6622671, EBI-6622671;
CC       P08913; P18825: ADRA2C; NbExp=2; IntAct=EBI-6622671, EBI-12015266;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:23105096};
CC       Multi-pass membrane protein {ECO:0000269|PubMed:23105096}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       Adrenergic receptor subfamily. ADRA2A sub-subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- CAUTION: It is uncertain whether Met-1 or Met-16 is the initiator.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA51664.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAA51664.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=AAA51665.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAA51665.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=AAG00447.2; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAH35047.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAH50414.4; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAK26743.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAK51162.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAZ73101.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=ABB72683.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=ABY87535.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/adra2a/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M23533; AAA51665.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; DQ149926; AAZ73101.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AF284095; AAK26743.1; ALT_INIT; mRNA.
DR   EMBL; AF262016; AAG00447.2; ALT_INIT; Genomic_DNA.
DR   EMBL; AY032736; AAK51162.1; ALT_INIT; Genomic_DNA.
DR   EMBL; DQ285607; ABB72683.1; ALT_INIT; Genomic_DNA.
DR   EMBL; EU332846; ABY87535.1; ALT_INIT; Genomic_DNA.
DR   EMBL; AL158163; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC035047; AAH35047.1; ALT_INIT; mRNA.
DR   EMBL; BC050414; AAH50414.4; ALT_INIT; mRNA.
DR   EMBL; M18415; AAA51664.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AF281308; AAF91441.1; -; Genomic_DNA.
DR   EMBL; AF316894; AAK01634.1; -; Genomic_DNA.
DR   CCDS; CCDS7569.2; -.
DR   PIR; A34169; A34169.
DR   RefSeq; NP_000672.3; NM_000681.3.
DR   PDB; 1HLL; NMR; -; A=133-164.
DR   PDB; 1HO9; NMR; -; A=133-164.
DR   PDB; 1HOD; NMR; -; A=133-164.
DR   PDB; 1HOF; NMR; -; A=133-164.
DR   PDB; 6K42; EM; 4.10 A; R=37-44.
DR   PDB; 6KUX; X-ray; 2.70 A; A=35-460.
DR   PDB; 6KUY; X-ray; 3.20 A; A=35-460.
DR   PDBsum; 1HLL; -.
DR   PDBsum; 1HO9; -.
DR   PDBsum; 1HOD; -.
DR   PDBsum; 1HOF; -.
DR   PDBsum; 6K42; -.
DR   PDBsum; 6KUX; -.
DR   PDBsum; 6KUY; -.
DR   BMRB; P08913; -.
DR   SMR; P08913; -.
DR   BioGRID; 106659; 9.
DR   CORUM; P08913; -.
DR   DIP; DIP-61452N; -.
DR   IntAct; P08913; 7.
DR   STRING; 9606.ENSP00000280155; -.
DR   BindingDB; P08913; -.
DR   ChEMBL; CHEMBL1867; -.
DR   DrugBank; DB01472; 4-Methoxyamphetamine.
DR   DrugBank; DB00321; Amitriptyline.
DR   DrugBank; DB00543; Amoxapine.
DR   DrugBank; DB00182; Amphetamine.
DR   DrugBank; DB00714; Apomorphine.
DR   DrugBank; DB00964; Apraclonidine.
DR   DrugBank; DB09229; Aranidipine.
DR   DrugBank; DB01238; Aripiprazole.
DR   DrugBank; DB14185; Aripiprazole lauroxil.
DR   DrugBank; DB06216; Asenapine.
DR   DrugBank; DB00865; Benzphetamine.
DR   DrugBank; DB00217; Bethanidine.
DR   DrugBank; DB00484; Brimonidine.
DR   DrugBank; DB01200; Bromocriptine.
DR   DrugBank; DB00248; Cabergoline.
DR   DrugBank; DB01136; Carvedilol.
DR   DrugBank; DB04846; Celiprolol.
DR   DrugBank; DB00477; Chlorpromazine.
DR   DrugBank; DB09202; Cirazoline.
DR   DrugBank; DB00575; Clonidine.
DR   DrugBank; DB00363; Clozapine.
DR   DrugBank; DB01151; Desipramine.
DR   DrugBank; DB00633; Dexmedetomidine.
DR   DrugBank; DB11273; Dihydroergocornine.
DR   DrugBank; DB13345; Dihydroergocristine.
DR   DrugBank; DB00320; Dihydroergotamine.
DR   DrugBank; DB00449; Dipivefrin.
DR   DrugBank; DB11278; DL-Methylephedrine.
DR   DrugBank; DB09167; Dosulepin.
DR   DrugBank; DB04855; Dronedarone.
DR   DrugBank; DB06262; Droxidopa.
DR   DrugBank; DB01363; Ephedra sinica root.
DR   DrugBank; DB05492; Epicept NP-1.
DR   DrugBank; DB00751; Epinastine.
DR   DrugBank; DB00668; Epinephrine.
DR   DrugBank; DB01049; Ergoloid mesylate.
DR   DrugBank; DB00696; Ergotamine.
DR   DrugBank; DB01175; Escitalopram.
DR   DrugBank; DB06678; Esmirtazapine.
DR   DrugBank; DB09194; Etoperidone.
DR   DrugBank; DB00800; Fenoldopam.
DR   DrugBank; DB06623; Flupirtine.
DR   DrugBank; DB00629; Guanabenz.
DR   DrugBank; DB01018; Guanfacine.
DR   DrugBank; DB00502; Haloperidol.
DR   DrugBank; DB11577; Indigotindisulfonic acid.
DR   DrugBank; DB00555; Lamotrigine.
DR   DrugBank; DB06707; Levonordefrin.
DR   DrugBank; DB00589; Lisuride.
DR   DrugBank; DB04948; Lofexidine.
DR   DrugBank; DB09195; Lorpiprazole.
DR   DrugBank; DB00408; Loxapine.
DR   DrugBank; DB08815; Lurasidone.
DR   DrugBank; DB00934; Maprotiline.
DR   DrugBank; DB01365; Mephentermine.
DR   DrugBank; DB01577; Metamfetamine.
DR   DrugBank; DB01403; Methotrimeprazine.
DR   DrugBank; DB00968; Methyldopa.
DR   DrugBank; DB06148; Mianserin.
DR   DrugBank; DB00370; Mirtazapine.
DR   DrugBank; DB09205; Moxisylyte.
DR   DrugBank; DB09242; Moxonidine.
DR   DrugBank; DB06711; Naphazoline.
DR   DrugBank; DB01149; Nefazodone.
DR   DrugBank; DB00368; Norepinephrine.
DR   DrugBank; DB00540; Nortriptyline.
DR   DrugBank; DB06229; Ocaperidone.
DR   DrugBank; DB00935; Oxymetazoline.
DR   DrugBank; DB01267; Paliperidone.
DR   DrugBank; DB00715; Paroxetine.
DR   DrugBank; DB01186; Pergolide.
DR   DrugBank; DB01608; Periciazine.
DR   DrugBank; DB00925; Phenoxybenzamine.
DR   DrugBank; DB00692; Phentolamine.
DR   DrugBank; DB00397; Phenylpropanolamine.
DR   DrugBank; DB09286; Pipamperone.
DR   DrugBank; DB09244; Pirlindole.
DR   DrugBank; DB06153; Pizotifen.
DR   DrugBank; DB00413; Pramipexole.
DR   DrugBank; DB00457; Prazosin.
DR   DrugBank; DB00433; Prochlorperazine.
DR   DrugBank; DB01069; Promethazine.
DR   DrugBank; DB00852; Pseudoephedrine.
DR   DrugBank; DB01224; Quetiapine.
DR   DrugBank; DB11124; Racepinephrine.
DR   DrugBank; DB11738; Rilmenidine.
DR   DrugBank; DB00268; Ropinirole.
DR   DrugBank; DB09304; Setiptiline.
DR   DrugBank; DB13025; Tiapride.
DR   DrugBank; DB00697; Tizanidine.
DR   DrugBank; DB00797; Tolazoline.
DR   DrugBank; DB00193; Tramadol.
DR   DrugBank; DB00656; Trazodone.
DR   DrugBank; DB00726; Trimipramine.
DR   DrugBank; DB11477; Xylazine.
DR   DrugBank; DB06694; Xylometazoline.
DR   DrugBank; DB01392; Yohimbine.
DR   DrugBank; DB00246; Ziprasidone.
DR   DrugBank; DB01624; Zuclopenthixol.
DR   DrugCentral; P08913; -.
DR   GuidetoPHARMACOLOGY; 25; -.
DR   iPTMnet; P08913; -.
DR   PhosphoSitePlus; P08913; -.
DR   BioMuta; ADRA2A; -.
DR   DMDM; 1351829; -.
DR   jPOST; P08913; -.
DR   MassIVE; P08913; -.
DR   PaxDb; P08913; -.
DR   PeptideAtlas; P08913; -.
DR   PRIDE; P08913; -.
DR   ProteomicsDB; 52176; -.
DR   Antibodypedia; 31769; 324 antibodies.
DR   DNASU; 150; -.
DR   Ensembl; ENST00000280155; ENSP00000280155; ENSG00000150594.
DR   GeneID; 150; -.
DR   KEGG; hsa:150; -.
DR   UCSC; uc001kzo.4; human.
DR   CTD; 150; -.
DR   DisGeNET; 150; -.
DR   EuPathDB; HostDB:ENSG00000150594.6; -.
DR   GeneCards; ADRA2A; -.
DR   HGNC; HGNC:281; ADRA2A.
DR   HPA; ENSG00000150594; Tissue enhanced (gallbladder).
DR   MIM; 104210; gene.
DR   neXtProt; NX_P08913; -.
DR   OpenTargets; ENSG00000150594; -.
DR   PharmGKB; PA35; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00940000161451; -.
DR   HOGENOM; CLU_009579_11_1_1; -.
DR   InParanoid; P08913; -.
DR   KO; K04138; -.
DR   OMA; KWYIISS; -.
DR   OrthoDB; 737211at2759; -.
DR   PhylomeDB; P08913; -.
DR   TreeFam; TF316350; -.
DR   PathwayCommons; P08913; -.
DR   Reactome; R-HSA-390696; Adrenoceptors.
DR   Reactome; R-HSA-392023; Adrenaline signalling through Alpha-2 adrenergic receptor.
DR   Reactome; R-HSA-400042; Adrenaline,noradrenaline inhibits insulin secretion.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-418597; G alpha (z) signalling events.
DR   Reactome; R-HSA-5683826; Surfactant metabolism.
DR   SignaLink; P08913; -.
DR   SIGNOR; P08913; -.
DR   BioGRID-ORCS; 150; 3 hits in 871 CRISPR screens.
DR   ChiTaRS; ADRA2A; human.
DR   EvolutionaryTrace; P08913; -.
DR   GeneWiki; Alpha-2A_adrenergic_receptor; -.
DR   GenomeRNAi; 150; -.
DR   Pharos; P08913; Tclin.
DR   PRO; PR:P08913; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; P08913; protein.
DR   Bgee; ENSG00000150594; Expressed in adipose tissue of abdominal region and 193 other tissues.
DR   Genevisible; P08913; HS.
DR   GO; GO:0016323; C:basolateral plasma membrane; TAS:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0098691; C:dopaminergic synapse; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IDA:BHF-UCL.
DR   GO; GO:0031692; F:alpha-1B adrenergic receptor binding; ISS:BHF-UCL.
DR   GO; GO:0031696; F:alpha-2C adrenergic receptor binding; IPI:BHF-UCL.
DR   GO; GO:0004938; F:alpha2-adrenergic receptor activity; IDA:BHF-UCL.
DR   GO; GO:0051379; F:epinephrine binding; IDA:BHF-UCL.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0032795; F:heterotrimeric G-protein binding; IDA:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0051380; F:norepinephrine binding; IDA:BHF-UCL.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:BHF-UCL.
DR   GO; GO:0019901; F:protein kinase binding; IPI:BHF-UCL.
DR   GO; GO:0031996; F:thioesterase binding; IPI:BHF-UCL.
DR   GO; GO:0030036; P:actin cytoskeleton organization; TAS:ProtInc.
DR   GO; GO:0032147; P:activation of protein kinase activity; IDA:BHF-UCL.
DR   GO; GO:0032148; P:activation of protein kinase B activity; IDA:BHF-UCL.
DR   GO; GO:0071880; P:adenylate cyclase-activating adrenergic receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0071881; P:adenylate cyclase-inhibiting adrenergic receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0007193; P:adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0007188; P:adenylate cyclase-modulating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0071875; P:adrenergic receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0032870; P:cellular response to hormone stimulus; IGI:BHF-UCL.
DR   GO; GO:0042596; P:fear response; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0042593; P:glucose homeostasis; IMP:BHF-UCL.
DR   GO; GO:0050892; P:intestinal absorption; TAS:BHF-UCL.
DR   GO; GO:1901020; P:negative regulation of calcium ion transmembrane transporter activity; ISS:BHF-UCL.
DR   GO; GO:0051926; P:negative regulation of calcium ion transport; ISS:BHF-UCL.
DR   GO; GO:0045955; P:negative regulation of calcium ion-dependent exocytosis; IC:BHF-UCL.
DR   GO; GO:0032811; P:negative regulation of epinephrine secretion; NAS:BHF-UCL.
DR   GO; GO:0046676; P:negative regulation of insulin secretion; IMP:BHF-UCL.
DR   GO; GO:0061179; P:negative regulation of insulin secretion involved in cellular response to glucose stimulus; IMP:BHF-UCL.
DR   GO; GO:0050995; P:negative regulation of lipid catabolic process; IGI:BHF-UCL.
DR   GO; GO:0010700; P:negative regulation of norepinephrine secretion; TAS:BHF-UCL.
DR   GO; GO:0071882; P:phospholipase C-activating adrenergic receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0030168; P:platelet activation; IEA:InterPro.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; TAS:ProtInc.
DR   GO; GO:0001819; P:positive regulation of cytokine production; IDA:BHF-UCL.
DR   GO; GO:0045741; P:positive regulation of epidermal growth factor-activated receptor activity; IDA:BHF-UCL.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:BHF-UCL.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IDA:BHF-UCL.
DR   GO; GO:0051044; P:positive regulation of membrane protein ectodomain proteolysis; IDA:BHF-UCL.
DR   GO; GO:0043268; P:positive regulation of potassium ion transport; ISS:BHF-UCL.
DR   GO; GO:0090303; P:positive regulation of wound healing; IMP:BHF-UCL.
DR   GO; GO:0007265; P:Ras protein signal transduction; TAS:ProtInc.
DR   GO; GO:0035624; P:receptor transactivation; IDA:BHF-UCL.
DR   GO; GO:0050796; P:regulation of insulin secretion; TAS:Reactome.
DR   GO; GO:0006940; P:regulation of smooth muscle contraction; IEA:InterPro.
DR   GO; GO:2000300; P:regulation of synaptic vesicle exocytosis; IEA:Ensembl.
DR   GO; GO:0019229; P:regulation of vasoconstriction; IEA:InterPro.
DR   GO; GO:0007266; P:Rho protein signal transduction; TAS:ProtInc.
DR   InterPro; IPR002233; ADR_fam.
DR   InterPro; IPR001946; ADRA2A_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01103; ADRENERGICR.
DR   PRINTS; PR00558; ADRENRGCA2AR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Direct protein sequencing; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane;
KW   Methylation; Palmitate; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..465
FT                   /note="Alpha-2A adrenergic receptor"
FT                   /id="PRO_0000069080"
FT   TOPO_DOM        1..48
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        49..74
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        75..85
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        86..111
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        112..121
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        122..144
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        145..166
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        167..187
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        188..209
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        210..232
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        233..389
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        390..410
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        411..424
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        425..444
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        445..465
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   SITE            128
FT                   /note="Implicated in ligand binding"
FT   SITE            215
FT                   /note="Implicated in catechol agonist binding and receptor
FT                   activation"
FT   SITE            219
FT                   /note="Implicated in catechol agonist binding and receptor
FT                   activation"
FT   MOD_RES         346
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P22909"
FT   MOD_RES         368
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q01338"
FT   LIPID           457
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        25
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        29
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        121..203
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VARIANT         266
FT                   /note="N -> K (rare polymorphism; frequency in Caucasians
FT                   0.004 and in African-Americans 0.05; 40% increase in
FT                   agonist-promoted Gi coupling; dbSNP:rs1800035)"
FT                   /evidence="ECO:0000269|PubMed:10948191, ECO:0000269|Ref.7"
FT                   /id="VAR_014957"
FT   VARIANT         416
FT                   /note="C -> S (in dbSNP:rs35658213)"
FT                   /id="VAR_055908"
FT   MUTAGEN         94
FT                   /note="D->N: No change in binding affinity. eliminates
FT                   guanine nucleotide-sensitive agonist binding."
FT                   /evidence="ECO:0000269|PubMed:1678850"
FT   MUTAGEN         128
FT                   /note="D->N: No binding to yohimbine. Increase in adenylate
FT                   cyclase activity."
FT                   /evidence="ECO:0000269|PubMed:1678850"
FT   MUTAGEN         145
FT                   /note="D->N: Lower affinity for agonists. Eliminates
FT                   guanine nucleotide-sensitive agonist binding."
FT                   /evidence="ECO:0000269|PubMed:1678850"
FT   MUTAGEN         215
FT                   /note="S->A: Lower affinity for agonists. No change in
FT                   guanine nucleotide-sensitive agonist binding."
FT                   /evidence="ECO:0000269|PubMed:1678850"
FT   MUTAGEN         219
FT                   /note="S->A: Lower affinity for agonists. Reduced guanine
FT                   nucleotide-sensitive agonist binding."
FT                   /evidence="ECO:0000269|PubMed:1678850"
FT   MUTAGEN         427
FT                   /note="F->N: 350-fold reduced affinity for alpha-2
FT                   antagonist yohimbine, 3000-fold increase for beta-
FT                   antagonist alprenolol."
FT                   /evidence="ECO:0000269|PubMed:1678390"
FT   CONFLICT        119
FT                   /note="A -> T (in Ref. 11; AAA51664)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        139
FT                   /note="L -> P (in Ref. 13)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        172
FT                   /note="V -> C (in Ref. 11; AAA51664)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        383
FT                   /note="R -> L (in Ref. 11; AAA51664)"
FT                   /evidence="ECO:0000305"
FT   HELIX           134..143
FT                   /evidence="ECO:0000244|PDB:1HLL"
FT   HELIX           145..154
FT                   /evidence="ECO:0000244|PDB:1HLL"
FT   HELIX           155..157
FT                   /evidence="ECO:0000244|PDB:1HLL"
SQ   SEQUENCE   465 AA;  50647 MW;  585E576149BDB696 CRC64;
     MFRQEQPLAE GSFAPMGSLQ PDAGNASWNG TEAPGGGARA TPYSLQVTLT LVCLAGLLML
     LTVFGNVLVI IAVFTSRALK APQNLFLVSL ASADILVATL VIPFSLANEV MGYWYFGKAW
     CEIYLALDVL FCTSSIVHLC AISLDRYWSI TQAIEYNLKR TPRRIKAIII TVWVISAVIS
     FPPLISIEKK GGGGGPQPAE PRCEINDQKW YVISSCIGSF FAPCLIMILV YVRIYQIAKR
     RTRVPPSRRG PDAVAAPPGG TERRPNGLGP ERSAGPGGAE AEPLPTQLNG APGEPAPAGP
     RDTDALDLEE SSSSDHAERP PGPRRPERGP RGKGKARASQ VKPGDSLPRR GPGATGIGTP
     AAGPGEERVG AAKASRWRGR QNREKRFTFV LAVVIGVFVV CWFPFFFTYT LTAVGCSVPR
     TLFKFFFWFG YCNSSLNPVI YTIFNHDFRR AFKKILCRGD RKRIV
//
ID   C5AR1_HUMAN             Reviewed;         350 AA.
AC   P21730;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   02-NOV-2010, sequence version 2.
DT   07-OCT-2020, entry version 197.
DE   RecName: Full=C5a anaphylatoxin chemotactic receptor 1;
DE   AltName: Full=C5a anaphylatoxin chemotactic receptor;
DE            Short=C5a-R;
DE            Short=C5aR;
DE   AltName: CD_antigen=CD88;
GN   Name=C5AR1; Synonyms=C5AR, C5R1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANTS ASN-2 AND ASN-279.
RX   PubMed=2007135; DOI=10.1021/bi00226a002;
RA   Boulay F., Mery L., Tardif M., Brouchon L., Vignais P.;
RT   "Expression cloning of a receptor for C5a anaphylatoxin on differentiated
RT   HL-60 cells.";
RL   Biochemistry 30:2993-2999(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND VARIANTS ASN-2 AND ASN-279.
RX   PubMed=1847994; DOI=10.1038/349614a0;
RA   Gerard N.P., Gerard C.;
RT   "The chemotactic receptor for human C5a anaphylatoxin.";
RL   Nature 349:614-617(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ASN-2 AND ASN-279.
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ASN-2 AND ASN-279.
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J., Lamerdin J.E.,
RA   Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M., Aerts A.,
RA   Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E., Caenepeel S.,
RA   Carrano A.V., Caoile C., Chan Y.M., Christensen M., Cleland C.A.,
RA   Copeland A., Dalin E., Dehal P., Denys M., Detter J.C., Escobar J.,
RA   Flowers D., Fotopulos D., Garcia C., Georgescu A.M., Glavina T., Gomez M.,
RA   Gonzales E., Groza M., Hammon N., Hawkins T., Haydu L., Ho I., Huang W.,
RA   Israni S., Jett J., Kadner K., Kimball H., Kobayashi A., Larionov V.,
RA   Leem S.-H., Lopez F., Lou Y., Lowry S., Malfatti S., Martinez D.,
RA   McCready P.M., Medina C., Morgan J., Nelson K., Nolan M., Ovcharenko I.,
RA   Pitluck S., Pollard M., Popkie A.P., Predki P., Quan G., Ramirez L.,
RA   Rash S., Retterer J., Rodriguez A., Rogers S., Salamov A., Salazar A.,
RA   She X., Smith D., Slezak T., Solovyev V., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J.,
RA   Dubchak I., Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ASN-2 AND ASN-279.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-3, AND VARIANT ASN-2.
RX   PubMed=8383526; DOI=10.1021/bi00056a007;
RA   Gerard N.P., Bao L., Xiao-Ping H., Eddy R.L. Jr., Shows T.B., Gerard C.;
RT   "Human chemotaxis receptor genes cluster at 19q13.3-13.4. Characterization
RT   of the human C5a receptor gene.";
RL   Biochemistry 32:1243-1250(1993).
RN   [8]
RP   FUNCTION, AND MUTAGENESIS OF 2-ASP--LEU-22; 2-ASP--SER-30; ASP-10; ASP-15;
RP   ASP-16; ASP-18 AND ASP-21.
RX   PubMed=8182049;
RA   DeMartino J.A., Van Riper G., Siciliano S.J., Molineaux C.J.,
RA   Konteatis Z.D., Rosen H., Springer M.S.;
RT   "The amino terminus of the human C5a receptor is required for high affinity
RT   C5a binding and for receptor activation by C5a but not C5a analogs.";
RL   J. Biol. Chem. 269:14446-14450(1994).
RN   [9]
RP   FUNCTION, AND MUTAGENESIS OF GLU-199.
RX   PubMed=7622471; DOI=10.1074/jbc.270.28.16625;
RA   Monk P.N., Barker M.D., Partridge L.J., Pease J.E.;
RT   "Mutation of glutamate 199 of the human C5a receptor defines a binding site
RT   for ligand distinct from the receptor N terminus.";
RL   J. Biol. Chem. 270:16625-16629(1995).
RN   [10]
RP   PHOSPHORYLATION AT SER-314; SER-317; SER-327; SER-332; SER-334 AND SER-338.
RX   PubMed=7642584; DOI=10.1074/jbc.270.32.19166;
RA   Giannini E., Brouchon L., Boulay F.;
RT   "Identification of the major phosphorylation sites in human C5a
RT   anaphylatoxin receptor in vivo.";
RL   J. Biol. Chem. 270:19166-19172(1995).
RN   [11]
RP   FUNCTION AS A RECEPTOR FOR C5A.
RX   PubMed=9553099; DOI=10.1074/jbc.273.17.10411;
RA   Chen Z., Zhang X., Gonnella N.C., Pellas T.C., Boyar W.C., Ni F.;
RT   "Residues 21-30 within the extracellular N-terminal region of the C5a
RT   receptor represent a binding domain for the C5a anaphylatoxin.";
RL   J. Biol. Chem. 273:10411-10419(1998).
RN   [12]
RP   FUNCTION, AND PHOSPHORYLATION AT SER-314; SER-317; SER-327; SER-332;
RP   SER-334 AND SER-338.
RX   PubMed=10636859; DOI=10.1074/jbc.275.3.1656;
RA   Christophe T., Rabiet M.J., Tardif M., Milcent M.D., Boulay F.;
RT   "Human complement 5a (C5a) anaphylatoxin receptor (CD88) phosphorylation
RT   sites and their specific role in receptor phosphorylation and attenuation
RT   of G protein-mediated responses. Desensitization of C5a receptor controls
RT   superoxide production but not receptor sequestration in HL-60 cells.";
RL   J. Biol. Chem. 275:1656-1664(2000).
RN   [13]
RP   SULFATION AT TYR-11 AND TYR-14.
RX   PubMed=11342590; DOI=10.1084/jem.193.9.1059;
RA   Farzan M., Schnitzler C.E., Vasilieva N., Leung D., Kuhn J., Gerard C.,
RA   Gerard N.P., Choe H.;
RT   "Sulfated tyrosines contribute to the formation of the c5a docking site of
RT   the human c5a anaphylatoxin receptor.";
RL   J. Exp. Med. 193:1059-1066(2001).
RN   [14]
RP   INTERACTION WITH ARRB1 AND ARRB2, SUBCELLULAR LOCATION, AND
RP   PHOSPHORYLATION.
RX   PubMed=12464600; DOI=10.1074/jbc.m210120200;
RA   Braun L., Christophe T., Boulay F.;
RT   "Phosphorylation of key serine residues is required for internalization of
RT   the complement 5a (C5a) anaphylatoxin receptor via a beta-arrestin,
RT   dynamin, and clathrin-dependent pathway.";
RL   J. Biol. Chem. 278:4277-4285(2003).
RN   [15]
RP   SUBUNIT, AND MUTAGENESIS OF CYS-144; CYS-157 AND CYS-221.
RX   PubMed=12835319; DOI=10.1074/jbc.m305606200;
RA   Klco J.M., Lassere T.B., Baranski T.J.;
RT   "C5a receptor oligomerization. I. Disulfide trapping reveals oligomers and
RT   potential contact surfaces in a G protein-coupled receptor.";
RL   J. Biol. Chem. 278:35345-35353(2003).
RN   [16]
RP   FUNCTION, AND INTERACTION WITH CHIPS.
RX   PubMed=15153520; DOI=10.4049/jimmunol.172.11.6994;
RA   Postma B., Poppelier M.J.J.G., van Galen J.C., Prossnitz E.R.,
RA   van Strijp J.A.G., de Haas C.J.C., van Kessel K.P.M.;
RT   "Chemotaxis inhibitory protein of Staphylococcus aureus binds specifically
RT   to the C5a and formylated peptide receptor.";
RL   J. Immunol. 172:6994-7001(2004).
RN   [17]
RP   INTERACTION WITH CHIPS, AND MUTAGENESIS OF ASP-10; GLY-12; TYR-14; ASP-15
RP   AND ASP-18.
RX   PubMed=15542591; DOI=10.1074/jbc.m412230200;
RA   Postma B., Kleibeuker W., Poppelier M.J.J.G., Boonstra M.,
RA   van Kessel K.P.M., van Strijp J.A.G., de Haas C.J.C.;
RT   "Residues 10-18 within the C5a receptor N terminus compose a binding domain
RT   for chemotaxis inhibitory protein of Staphylococcus aureus.";
RL   J. Biol. Chem. 280:2020-2027(2005).
RN   [18]
RP   INTERACTION WITH CHIPS, AND MUTAGENESIS OF TYR-11 AND TYR-14.
RX   PubMed=21706042; DOI=10.1038/aps.2011.53;
RA   Liu Z.J., Yang Y.J., Jiang L., Xu Y.C., Wang A.X., Du G.H., Gao J.M.;
RT   "Tyrosine sulfation in N-terminal domain of human C5a receptor is necessary
RT   for binding of chemotaxis inhibitory protein of Staphylococcus aureus.";
RL   Acta Pharmacol. Sin. 32:1038-1044(2011).
RN   [19] {ECO:0000244|PDB:5O9H}
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 31-333, FUNCTION, SUBCELLULAR
RP   LOCATION, TOPOLOGY, AND DISULFIDE BONDS.
RX   PubMed=29300009; DOI=10.1038/nature25025;
RA   Robertson N., Rappas M., Dore A.S., Brown J., Bottegoni G., Koglin M.,
RA   Cansfield J., Jazayeri A., Cooke R.M., Marshall F.H.;
RT   "Structure of the complement C5a receptor bound to the extra-helical
RT   antagonist NDT9513727.";
RL   Nature 553:111-114(2018).
CC   -!- FUNCTION: Receptor for the chemotactic and inflammatory peptide
CC       anaphylatoxin C5a (PubMed:1847994, PubMed:8182049, PubMed:7622471,
CC       PubMed:9553099, PubMed:10636859, PubMed:15153520, PubMed:29300009). The
CC       ligand interacts with at least two sites on the receptor: a high-
CC       affinity site on the extracellular N-terminus, and a second site in the
CC       transmembrane region which activates downstream signaling events
CC       (PubMed:8182049, PubMed:7622471, PubMed:9553099). Receptor activation
CC       stimulates chemotaxis, granule enzyme release, intracellular calcium
CC       release and superoxide anion production (PubMed:10636859,
CC       PubMed:15153520). {ECO:0000269|PubMed:10636859,
CC       ECO:0000269|PubMed:15153520, ECO:0000269|PubMed:1847994,
CC       ECO:0000269|PubMed:29300009, ECO:0000269|PubMed:7622471,
CC       ECO:0000269|PubMed:8182049, ECO:0000269|PubMed:9553099}.
CC   -!- SUBUNIT: Homodimer. May also form higher-order oligomers
CC       (PubMed:12835319). Interacts (when phosphorylated) with ARRB1 and
CC       ARRB2; the interaction is associated with internalization of C5aR
CC       (PubMed:12464600). Interacts (via N-terminal domain) with S.aureus
CC       chemotaxis inhibitory protein (CHIPS); the interaction blocks the
CC       receptor and may thus inhibit the immune response (PubMed:15153520,
CC       PubMed:15542591, PubMed:21706042). {ECO:0000269|PubMed:12464600,
CC       ECO:0000269|PubMed:12835319, ECO:0000269|PubMed:15153520,
CC       ECO:0000269|PubMed:15542591, ECO:0000269|PubMed:21706042,
CC       ECO:0000303|PubMed:12835319}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:12464600,
CC       ECO:0000269|PubMed:29300009}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:29300009}. Cytoplasmic vesicle
CC       {ECO:0000269|PubMed:12464600}. Note=Phosphorylated C5aR colocalizes
CC       with ARRB1 and ARRB2 in cytoplasmic vesicles.
CC       {ECO:0000269|PubMed:12464600}.
CC   -!- PTM: Sulfation plays a critical role in the association of C5aR with
CC       C5a, but no significant role in the ability of the receptor to
CC       transduce a signal and mobilize calcium in response to a small a small
CC       peptide agonist (PubMed:11342590). Sulfation at Tyr-14 is important for
CC       CHIPS binding (PubMed:21706042). {ECO:0000269|PubMed:11342590,
CC       ECO:0000303|PubMed:21706042}.
CC   -!- PTM: Phosphorylated on serine residues in response to C5a binding,
CC       resulting in internalization of the receptor and short-term
CC       desensitization to the ligand. The key residues involved in this
CC       process are Ser-334 and Ser-338. {ECO:0000269|PubMed:10636859,
CC       ECO:0000269|PubMed:12464600}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M62505; AAA62831.1; -; mRNA.
DR   EMBL; X57250; CAA40530.1; -; mRNA.
DR   EMBL; X58674; CAB37830.1; -; Genomic_DNA.
DR   EMBL; AY221091; AAO65969.1; -; Genomic_DNA.
DR   EMBL; BT007358; AAP36022.1; -; mRNA.
DR   EMBL; AC099491; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC008982; AAH08982.1; -; mRNA.
DR   EMBL; S56556; AAD14919.1; -; Genomic_DNA.
DR   EMBL; S56557; AAD14919.1; JOINED; Genomic_DNA.
DR   CCDS; CCDS33063.1; -.
DR   PIR; A37963; A37963.
DR   RefSeq; NP_001727.1; NM_001736.3.
DR   PDB; 5O9H; X-ray; 2.70 A; A/B=31-333.
DR   PDB; 6C1Q; X-ray; 2.90 A; B=30-331.
DR   PDB; 6C1R; X-ray; 2.20 A; B=30-331.
DR   PDBsum; 5O9H; -.
DR   PDBsum; 6C1Q; -.
DR   PDBsum; 6C1R; -.
DR   SMR; P21730; -.
DR   BioGRID; 107189; 6.
DR   IntAct; P21730; 1.
DR   STRING; 9606.ENSP00000347197; -.
DR   BindingDB; P21730; -.
DR   ChEMBL; CHEMBL2373; -.
DR   GuidetoPHARMACOLOGY; 32; -.
DR   TCDB; 9.A.14.13.26; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; P21730; 1 site.
DR   iPTMnet; P21730; -.
DR   PhosphoSitePlus; P21730; -.
DR   BioMuta; C5AR1; -.
DR   DMDM; 311033355; -.
DR   jPOST; P21730; -.
DR   MassIVE; P21730; -.
DR   PaxDb; P21730; -.
DR   PeptideAtlas; P21730; -.
DR   PRIDE; P21730; -.
DR   ProteomicsDB; 53893; -.
DR   ABCD; P21730; 5 sequenced antibodies.
DR   Antibodypedia; 2966; 960 antibodies.
DR   DNASU; 728; -.
DR   Ensembl; ENST00000355085; ENSP00000347197; ENSG00000197405.
DR   GeneID; 728; -.
DR   KEGG; hsa:728; -.
DR   UCSC; uc002pgj.2; human.
DR   CTD; 728; -.
DR   DisGeNET; 728; -.
DR   EuPathDB; HostDB:ENSG00000197405.7; -.
DR   GeneCards; C5AR1; -.
DR   HGNC; HGNC:1338; C5AR1.
DR   HPA; ENSG00000197405; Tissue enhanced (blood).
DR   MIM; 113995; gene.
DR   neXtProt; NX_P21730; -.
DR   OpenTargets; ENSG00000197405; -.
DR   PharmGKB; PA25920; -.
DR   eggNOG; ENOG502R35Z; Eukaryota.
DR   GeneTree; ENSGT00980000198522; -.
DR   HOGENOM; CLU_009579_8_0_1; -.
DR   InParanoid; P21730; -.
DR   KO; K04010; -.
DR   OMA; ACTLVKG; -.
DR   OrthoDB; 978188at2759; -.
DR   PhylomeDB; P21730; -.
DR   TreeFam; TF330976; -.
DR   PathwayCommons; P21730; -.
DR   Reactome; R-HSA-375276; Peptide ligand-binding receptors.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-977606; Regulation of Complement cascade.
DR   SignaLink; P21730; -.
DR   SIGNOR; P21730; -.
DR   BioGRID-ORCS; 728; 3 hits in 866 CRISPR screens.
DR   ChiTaRS; C5AR1; human.
DR   GeneWiki; C5a_receptor; -.
DR   GenomeRNAi; 728; -.
DR   Pharos; P21730; Tchem.
DR   PRO; PR:P21730; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; P21730; protein.
DR   Bgee; ENSG00000197405; Expressed in blood and 188 other tissues.
DR   ExpressionAtlas; P21730; baseline and differential.
DR   Genevisible; P21730; HS.
DR   GO; GO:0045177; C:apical part of cell; IDA:UniProtKB.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:UniProtKB.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0030667; C:secretory granule membrane; TAS:Reactome.
DR   GO; GO:0001856; F:complement component C5a binding; IEA:Ensembl.
DR   GO; GO:0004878; F:complement component C5a receptor activity; IDA:UniProtKB.
DR   GO; GO:0004875; F:complement receptor activity; IBA:GO_Central.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IPI:UniProtKB.
DR   GO; GO:0000187; P:activation of MAPK activity; TAS:ProtInc.
DR   GO; GO:0007202; P:activation of phospholipase C activity; TAS:ProtInc.
DR   GO; GO:0097242; P:amyloid-beta clearance; ISS:ARUK-UCL.
DR   GO; GO:0031100; P:animal organ regeneration; IEA:Ensembl.
DR   GO; GO:0006915; P:apoptotic process; IEA:Ensembl.
DR   GO; GO:0048143; P:astrocyte activation; ISS:ARUK-UCL.
DR   GO; GO:0021534; P:cell proliferation in hindbrain; IEA:Ensembl.
DR   GO; GO:0006968; P:cellular defense response; TAS:ProtInc.
DR   GO; GO:0006935; P:chemotaxis; TAS:ProtInc.
DR   GO; GO:0050890; P:cognition; ISS:ARUK-UCL.
DR   GO; GO:0038178; P:complement component C5a signaling pathway; IDA:UniProtKB.
DR   GO; GO:0002430; P:complement receptor mediated signaling pathway; IBA:GO_Central.
DR   GO; GO:0050830; P:defense response to Gram-positive bacterium; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006955; P:immune response; TAS:ProtInc.
DR   GO; GO:0006954; P:inflammatory response; IBA:GO_Central.
DR   GO; GO:0001774; P:microglial cell activation; ISS:ARUK-UCL.
DR   GO; GO:0042789; P:mRNA transcription by RNA polymerase II; IDA:UniProtKB.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0030593; P:neutrophil chemotaxis; IEA:Ensembl.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IBA:GO_Central.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; IDA:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IDA:UniProtKB.
DR   GO; GO:0010759; P:positive regulation of macrophage chemotaxis; IEA:Ensembl.
DR   GO; GO:0090023; P:positive regulation of neutrophil chemotaxis; IEA:Ensembl.
DR   GO; GO:0010575; P:positive regulation of vascular endothelial growth factor production; IEA:Ensembl.
DR   GO; GO:0099172; P:presynapse organization; ISS:ARUK-UCL.
DR   GO; GO:0030449; P:regulation of complement activation; TAS:Reactome.
DR   GO; GO:1902947; P:regulation of tau-protein kinase activity; ISS:ARUK-UCL.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0032494; P:response to peptidoglycan; IEA:Ensembl.
DR   GO; GO:0007606; P:sensory perception of chemical stimulus; TAS:ProtInc.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   InterPro; IPR001274; Anaphtx_C5AR1/C5AR2.
DR   InterPro; IPR002234; Anphylx_rcpt.
DR   InterPro; IPR000826; Formyl_rcpt-rel.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   PANTHER; PTHR24225; PTHR24225; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01104; ANPHYLATOXNR.
DR   PRINTS; PR00426; C5ANPHYLTXNR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Chemotaxis; Cytoplasmic vesicle;
KW   Disulfide bond; G-protein coupled receptor; Glycoprotein; Membrane;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome; Sulfation;
KW   Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..350
FT                   /note="C5a anaphylatoxin chemotactic receptor 1"
FT                   /id="PRO_0000069209"
FT   TOPO_DOM        1..37
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:29300009"
FT   TRANSMEM        38..64
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000269|PubMed:29300009"
FT   TOPO_DOM        65..69
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:29300009"
FT   TRANSMEM        70..93
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000269|PubMed:29300009"
FT   TOPO_DOM        94..110
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:29300009"
FT   TRANSMEM        111..132
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000269|PubMed:29300009"
FT   TOPO_DOM        133..153
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:29300009"
FT   TRANSMEM        154..174
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000269|PubMed:29300009"
FT   TOPO_DOM        175..200
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:29300009"
FT   TRANSMEM        201..226
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000269|PubMed:29300009"
FT   TOPO_DOM        227..242
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:29300009"
FT   TRANSMEM        243..265
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000269|PubMed:29300009"
FT   TOPO_DOM        266..282
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:29300009"
FT   TRANSMEM        283..303
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000269|PubMed:29300009"
FT   TOPO_DOM        304..350
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:29300009"
FT   REGION          10..18
FT                   /note="Required for CHIPS binding"
FT                   /evidence="ECO:0000269|PubMed:15542591"
FT   REGION          21..30
FT                   /note="Involved in C5a binding"
FT                   /evidence="ECO:0000269|PubMed:9553099"
FT   MOD_RES         11
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000269|PubMed:11342590"
FT   MOD_RES         14
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000269|PubMed:11342590"
FT   MOD_RES         314
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000305|PubMed:7642584"
FT   MOD_RES         317
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:10636859,
FT                   ECO:0000269|PubMed:7642584"
FT   MOD_RES         327
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:10636859,
FT                   ECO:0000269|PubMed:7642584"
FT   MOD_RES         332
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:10636859,
FT                   ECO:0000269|PubMed:7642584"
FT   MOD_RES         334
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:10636859,
FT                   ECO:0000269|PubMed:7642584"
FT   MOD_RES         338
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:10636859,
FT                   ECO:0000269|PubMed:7642584"
FT   CARBOHYD        5
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        109..188
FT                   /evidence="ECO:0000244|PDB:5O9H, ECO:0000255|PROSITE-
FT                   ProRule:PRU00521, ECO:0000269|PubMed:29300009"
FT   VARIANT         2
FT                   /note="D -> N (in dbSNP:rs4467185)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:1847994, ECO:0000269|PubMed:2007135,
FT                   ECO:0000269|PubMed:8383526, ECO:0000269|Ref.3,
FT                   ECO:0000269|Ref.4"
FT                   /id="VAR_049377"
FT   VARIANT         279
FT                   /note="K -> N (in dbSNP:rs11880097)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:1847994, ECO:0000269|PubMed:2007135,
FT                   ECO:0000269|Ref.3, ECO:0000269|Ref.4"
FT                   /id="VAR_049378"
FT   MUTAGEN         2..30
FT                   /note="Missing: Strongly impairs C5a binding (45,000-
FT                   fold)."
FT                   /evidence="ECO:0000269|PubMed:8182049"
FT   MUTAGEN         2..22
FT                   /note="Missing: Impairs C5a binding. Strongly impairs C5a
FT                   binding; when associated with A-27."
FT                   /evidence="ECO:0000269|PubMed:8182049"
FT   MUTAGEN         10
FT                   /note="D->A: Strongly impairs C5a binding; when associated
FT                   with A-15; A-16; A-18 and A-21 (PubMed:8182049). Moderately
FT                   impairs CHIPS binding (PubMed:15542591). Strongly impairs
FT                   CHIPS binding; when associated with A-15 (PubMed:15542591).
FT                   Strongly impairs CHIPS binding; when associated with A-18
FT                   (PubMed:15542591)."
FT                   /evidence="ECO:0000269|PubMed:15542591,
FT                   ECO:0000269|PubMed:8182049"
FT   MUTAGEN         11
FT                   /note="Y->F: Weakly impairs CHIPS binding. Loss of CHIPS
FT                   binding; when associated with F-14."
FT                   /evidence="ECO:0000269|PubMed:21706042"
FT   MUTAGEN         12
FT                   /note="G->A: Moderately impairs CHIPS binding."
FT                   /evidence="ECO:0000269|PubMed:15542591"
FT   MUTAGEN         14
FT                   /note="Y->F: Weakly impairs CHIPS binding
FT                   (PubMed:15542591). Strongly impairs CHIPS binding
FT                   (PubMed:21706042). Loss of CHIPS binding; when associated
FT                   with F-11 (PubMed:21706042)."
FT                   /evidence="ECO:0000269|PubMed:15542591,
FT                   ECO:0000269|PubMed:21706042"
FT   MUTAGEN         15
FT                   /note="D->A: Strongly impairs C5a binding; when associated
FT                   with A-10; A-16; A-18 and A-21 (PubMed:8182049). Moderately
FT                   impairs CHIPS binding (PubMed:15542591). Strongly impairs
FT                   CHIPS binding; when associated with A-10 (PubMed:15542591).
FT                   Strongly impairs CHIPS binding; when associated with A-18
FT                   (PubMed:15542591)."
FT                   /evidence="ECO:0000269|PubMed:15542591,
FT                   ECO:0000269|PubMed:8182049"
FT   MUTAGEN         16
FT                   /note="D->A: Strongly impairs C5a binding; when associated
FT                   with A-10; A-15; A-18 and A-21."
FT                   /evidence="ECO:0000269|PubMed:8182049"
FT   MUTAGEN         18
FT                   /note="D->A: Strongly impairs C5a binding; when associated
FT                   with A-10; A-15; A-16 and A-21 (PubMed:8182049). Impairs
FT                   CHIPS binding (PubMed:15542591). Strongly impairs CHIPS
FT                   binding; when associated with A-10 (PubMed:15542591).
FT                   Strongly impairs CHIPS binding; when associated with A-15
FT                   (PubMed:15542591)."
FT                   /evidence="ECO:0000269|PubMed:15542591,
FT                   ECO:0000269|PubMed:8182049"
FT   MUTAGEN         21
FT                   /note="D->A: Strongly impairs C5a binding; when associated
FT                   with A-10; A-15; A-16 and A-18."
FT                   /evidence="ECO:0000269|PubMed:8182049"
FT   MUTAGEN         27
FT                   /note="D->A: Strongly impairs C5a binding; when associated
FT                   with 2-D--L-22 Del."
FT                   /evidence="ECO:0000269|PubMed:8182049"
FT   MUTAGEN         144
FT                   /note="C->S: Fails to homodimerize."
FT                   /evidence="ECO:0000269|PubMed:12835319"
FT   MUTAGEN         157
FT                   /note="C->S: No effect on homodimer formation."
FT                   /evidence="ECO:0000269|PubMed:12835319"
FT   MUTAGEN         199
FT                   /note="E->Q: Impairs C5a binding (10-fold reduction) and
FT                   C5a-induced 5-HT secretion."
FT                   /evidence="ECO:0000269|PubMed:7622471"
FT   MUTAGEN         221
FT                   /note="C->S: No effect on homodimer formation."
FT                   /evidence="ECO:0000269|PubMed:12835319"
FT   HELIX           35..65
FT                   /evidence="ECO:0000244|PDB:6C1R"
FT   TURN            66..68
FT                   /evidence="ECO:0000244|PDB:6C1R"
FT   HELIX           70..86
FT                   /evidence="ECO:0000244|PDB:6C1R"
FT   HELIX           89..97
FT                   /evidence="ECO:0000244|PDB:6C1R"
FT   TURN            98..100
FT                   /evidence="ECO:0000244|PDB:6C1R"
FT   HELIX           106..111
FT                   /evidence="ECO:0000244|PDB:6C1R"
FT   HELIX           112..114
FT                   /evidence="ECO:0000244|PDB:6C1R"
FT   HELIX           115..139
FT                   /evidence="ECO:0000244|PDB:6C1R"
FT   HELIX           141..146
FT                   /evidence="ECO:0000244|PDB:6C1R"
FT   HELIX           150..173
FT                   /evidence="ECO:0000244|PDB:6C1R"
FT   STRAND          175..180
FT                   /evidence="ECO:0000244|PDB:6C1R"
FT   TURN            181..184
FT                   /evidence="ECO:0000244|PDB:6C1R"
FT   STRAND          185..190
FT                   /evidence="ECO:0000244|PDB:6C1R"
FT   HELIX           196..210
FT                   /evidence="ECO:0000244|PDB:6C1R"
FT   HELIX           212..230
FT                   /evidence="ECO:0000244|PDB:6C1R"
FT   STRAND          233..235
FT                   /evidence="ECO:0000244|PDB:5O9H"
FT   HELIX           238..266
FT                   /evidence="ECO:0000244|PDB:6C1R"
FT   HELIX           273..280
FT                   /evidence="ECO:0000244|PDB:6C1R"
FT   HELIX           282..289
FT                   /evidence="ECO:0000244|PDB:6C1R"
FT   HELIX           292..305
FT                   /evidence="ECO:0000244|PDB:6C1R"
FT   HELIX           315..323
FT                   /evidence="ECO:0000244|PDB:6C1R"
SQ   SEQUENCE   350 AA;  39336 MW;  9334BB39A2C96D3D CRC64;
     MDSFNYTTPD YGHYDDKDTL DLNTPVDKTS NTLRVPDILA LVIFAVVFLV GVLGNALVVW
     VTAFEAKRTI NAIWFLNLAV ADFLSCLALP ILFTSIVQHH HWPFGGAACS ILPSLILLNM
     YASILLLATI SADRFLLVFK PIWCQNFRGA GLAWIACAVA WGLALLLTIP SFLYRVVREE
     YFPPKVLCGV DYSHDKRRER AVAIVRLVLG FLWPLLTLTI CYTFILLRTW SRRATRSTKT
     LKVVVAVVAS FFIFWLPYQV TGIMMSFLEP SSPTFLLLKK LDSLCVSFAY INCCINPIIY
     VVAGQGFQGR LRKSLPSLLR NVLTEESVVR ESKSFTRSTV DTMAQKTQAV
//
ID   CNR2_HUMAN              Reviewed;         360 AA.
AC   P34972; C6ES44; Q4VBK8; Q5JRH7; Q6B0G7; Q6NSY0;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1994, sequence version 1.
DT   07-OCT-2020, entry version 182.
DE   RecName: Full=Cannabinoid receptor 2;
DE            Short=CB-2;
DE            Short=CB2;
DE            Short=hCB2;
DE   AltName: Full=CX5;
GN   Name=CNR2; Synonyms=CB2A, CB2B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7689702; DOI=10.1038/365061a0;
RA   Munro S., Thomas K.L., Abu-Shaar M.;
RT   "Molecular characterization of a peripheral receptor for cannabinoids.";
RL   Nature 365:61-65(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Spleen;
RX   PubMed=19496827; DOI=10.1111/j.1601-183x.2009.00498.x;
RA   Liu Q.-R., Pan C.H., Hishimoto A., Li C.Y., Xi Z.X., Llorente-Berzal A.,
RA   Viveros M.P., Ishiguro H., Arinami T., Onaivi E.S., Uhl G.R.;
RT   "Species differences in cannabinoid receptor 2 (CNR2 gene): identification
RT   of novel human and rodent CB2 isoforms, differential tissue expression and
RT   regulation by cannabinoid receptor ligands.";
RL   Genes Brain Behav. 8:519-530(2009).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RC   TISSUE=Blood;
RA   Bruess M., Boenisch H.;
RT   "Cannabinoid receptors and their genes.";
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Warren C.N., Aronstam R.S., Sharma S.V.;
RT   "Isolation of complete coding sequence for cannabinoid receptor 2 (CNR2).";
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT TYR-316.
RC   TISSUE=Blood;
RA   Saravanan T., Chugh A., Kant R.;
RT   "Amplification and cloning of human cannabinoid receptor 2 gene from
RT   Asiatic origin.";
RL   Submitted (NOV-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS ARG-63 AND TYR-316.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   TISSUE SPECIFICITY.
RX   PubMed=7556170; DOI=10.1111/j.1432-1033.1995.tb20780.x;
RA   Galiegue S., Mary S., Marchand J., Dussossoy D., Carriere D., Carayon P.,
RA   Bouaboula M., Shire D., Le Fur G., Casellas P.;
RT   "Expression of central and peripheral cannabinoid receptors in human immune
RT   tissues and leukocyte subpopulations.";
RL   Eur. J. Biochem. 232:54-61(1995).
RN   [10]
RP   PHOSPHORYLATION AT SER-352, AND SUBCELLULAR LOCATION.
RX   PubMed=10400664; DOI=10.1074/jbc.274.29.20397;
RA   Bouaboula M., Dussossoy D., Casellas P.;
RT   "Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the
RT   inverse agonist SR 144528. Implications for receptor biological
RT   responses.";
RL   J. Biol. Chem. 274:20397-20405(1999).
RN   [11]
RP   FUNCTION, AND MUTAGENESIS OF LYS-109 AND SER-112.
RX   PubMed=10051546;
RA   Tao Q., McAllister S.D., Andreassi J., Nowell K.W., Cabral G.A.,
RA   Hurst D.P., Bachtel K., Ekman M.C., Reggio P.H., Abood M.E.;
RT   "Role of a conserved lysine residue in the peripheral cannabinoid receptor
RT   (CB2): evidence for subtype specificity.";
RL   Mol. Pharmacol. 55:605-613(1999).
RN   [12]
RP   IDENTIFICATION OF 2-ARACHIDONOYLGLYCEROL AS AN ENDOGENOUS LIGAND.
RX   PubMed=10617657; DOI=10.1074/jbc.275.1.605;
RA   Sugiura T., Kondo S., Kishimoto S., Miyashita T., Nakane S., Kodaka T.,
RA   Suhara Y., Takayama H., Waku K.;
RT   "Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or
RT   anandamide is the physiological ligand for the cannabinoid CB2 receptor.
RT   Comparison of the agonistic activities of various cannabinoid receptor
RT   ligands in HL-60 cells.";
RL   J. Biol. Chem. 275:605-612(2000).
RN   [13]
RP   TISSUE SPECIFICITY.
RX   PubMed=12153574; DOI=10.1046/j.1432-1033.2002.03078.x;
RA   Matias I., Pochard P., Orlando P., Salzet M., Pestel J., Di Marzo V.;
RT   "Presence and regulation of the endocannabinoid system in human dendritic
RT   cells.";
RL   Eur. J. Biochem. 269:3771-3778(2002).
RN   [14]
RP   MUTAGENESIS OF LEU-201 AND TYR-207.
RX   PubMed=12417328; DOI=10.1016/s0014-5793(02)03537-8;
RA   Song Z.H., Feng W.;
RT   "Absence of a conserved proline and presence of a conserved tyrosine in the
RT   CB2 cannabinoid receptor are crucial for its function.";
RL   FEBS Lett. 531:290-294(2002).
RN   [15]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ASP-130; ARG-131 AND
RP   ALA-244.
RX   PubMed=12663043; DOI=10.1016/s0006-2952(03)00005-4;
RA   Feng W., Song Z.H.;
RT   "Effects of D3.49A, R3.50A, and A6.34E mutations on ligand binding and
RT   activation of the cannabinoid-2 (CB2) receptor.";
RL   Biochem. Pharmacol. 65:1077-1085(2003).
RN   [16]
RP   FUNCTION.
RX   PubMed=12711605; DOI=10.1074/jbc.m301359200;
RA   Kishimoto S., Gokoh M., Oka S., Muramatsu M., Kajiwara T., Waku K.,
RA   Sugiura T.;
RT   "2-arachidonoylglycerol induces the migration of HL-60 cells differentiated
RT   into macrophage-like cells and human peripheral blood monocytes through the
RT   cannabinoid CB2 receptor-dependent mechanism.";
RL   J. Biol. Chem. 278:24469-24475(2003).
RN   [17]
RP   TISSUE SPECIFICITY.
RX   PubMed=12511587; DOI=10.1172/jci200316116;
RA   Casanova M.L., Blazquez C., Martinez-Palacio J., Villanueva C.,
RA   Fernandez-Acenero M.J., Huffman J.W., Jorcano J.L., Guzman M.;
RT   "Inhibition of skin tumor growth and angiogenesis in vivo by activation of
RT   cannabinoid receptors.";
RL   J. Clin. Invest. 111:43-50(2003).
RN   [18]
RP   TISSUE SPECIFICITY.
RX   PubMed=14657172; DOI=10.1523/jneurosci.23-35-11136.2003;
RA   Benito C., Nunez E., Tolon R.M., Carrier E.J., Rabano A., Hillard C.J.,
RA   Romero J.;
RT   "Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively
RT   overexpressed in neuritic plaque-associated glia in Alzheimer's disease
RT   brains.";
RL   J. Neurosci. 23:11136-11141(2003).
RN   [19]
RP   TISSUE SPECIFICITY.
RX   PubMed=15266552; DOI=10.1002/syn.20050;
RA   Nunez E., Benito C., Pazos M.R., Barbachano A., Fajardo O., Gonzalez S.,
RA   Tolon R.M., Romero J.;
RT   "Cannabinoid CB2 receptors are expressed by perivascular microglial cells
RT   in the human brain: an immunohistochemical study.";
RL   Synapse 53:208-213(2004).
RN   [20]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=18692962; DOI=10.1016/j.pain.2008.06.007;
RA   Anand U., Otto W.R., Sanchez-Herrera D., Facer P., Yiangou Y., Korchev Y.,
RA   Birch R., Benham C., Bountra C., Chessell I.P., Anand P.;
RT   "Cannabinoid receptor CB2 localisation and agonist-mediated inhibition of
RT   capsaicin responses in human sensory neurons.";
RL   Pain 138:667-680(2008).
RN   [21]
RP   INDUCTION BY ENDOCANNABINOID ANANDAMIDE.
RX   PubMed=23955712; DOI=10.1038/nm.3265;
RA   Jourdan T., Godlewski G., Cinar R., Bertola A., Szanda G., Liu J., Tam J.,
RA   Han T., Mukhopadhyay B., Skarulis M.C., Ju C., Aouadi M., Czech M.P.,
RA   Kunos G.;
RT   "Activation of the Nlrp3 inflammasome in infiltrating macrophages by
RT   endocannabinoids mediates beta cell loss in type 2 diabetes.";
RL   Nat. Med. 19:1132-1140(2013).
RN   [22]
RP   STRUCTURE BY NMR OF 240-272.
RX   PubMed=19397896; DOI=10.1016/j.bbrc.2009.04.099;
RA   Tiburu E.K., Tyukhtenko S., Deshmukh L., Vinogradova O., Janero D.R.,
RA   Makriyannis A.;
RT   "Structural biology of human cannabinoid receptor-2 helix 6 in membrane-
RT   mimetic environments.";
RL   Biochem. Biophys. Res. Commun. 384:243-248(2009).
RN   [23]
RP   VARIANTS ARG-63 AND TYR-316.
RX   PubMed=18286196; DOI=10.1371/journal.pone.0001640;
RA   Onaivi E.S., Ishiguro H., Gong J.-P., Patel S., Meozzi P.A., Myers L.,
RA   Perchuk A., Mora Z., Tagliaferro P.A., Gardner E., Brusco A.,
RA   Akinshola B.E., Hope B., Lujilde J., Inada T., Iwasaki S., Macharia D.,
RA   Teasenfitz L., Arinami T., Uhl G.R.;
RT   "Brain neuronal CB2 cannabinoid receptors in drug abuse and depression:
RT   from mice to human subjects.";
RL   PLoS ONE 3:E1640-E1640(2008).
CC   -!- FUNCTION: Heterotrimeric G protein-coupled receptor for endocannabinoid
CC       2-arachidonoylglycerol mediating inhibition of adenylate cyclase. May
CC       function in inflammatory response, nociceptive transmission and bone
CC       homeostasis. {ECO:0000269|PubMed:10051546, ECO:0000269|PubMed:12663043,
CC       ECO:0000269|PubMed:12711605, ECO:0000269|PubMed:18692962}.
CC   -!- INTERACTION:
CC       P34972; Q9UKJ8: ADAM21; NbExp=3; IntAct=EBI-2835940, EBI-12046857;
CC       P34972; Q15848: ADIPOQ; NbExp=3; IntAct=EBI-2835940, EBI-10827839;
CC       P34972; Q9NRZ5: AGPAT4; NbExp=3; IntAct=EBI-2835940, EBI-1754287;
CC       P34972; P13236: CCL4; NbExp=3; IntAct=EBI-2835940, EBI-2873970;
CC       P34972; P21554: CNR1; NbExp=3; IntAct=EBI-2835940, EBI-2909859;
CC       P34972; P21964: COMT; NbExp=3; IntAct=EBI-2835940, EBI-372265;
CC       P34972; Q14802-3: FXYD3; NbExp=3; IntAct=EBI-2835940, EBI-12175685;
CC       P34972; Q8N387: MUC15; NbExp=3; IntAct=EBI-2835940, EBI-17937277;
CC       P34972; Q8IXM6: NRM; NbExp=3; IntAct=EBI-2835940, EBI-10262547;
CC       P34972; Q96AA3: RFT1; NbExp=3; IntAct=EBI-2835940, EBI-6269616;
CC       P34972; Q9Y6D0: SELENOK; NbExp=3; IntAct=EBI-2835940, EBI-9679163;
CC       P34972; Q6ICL7: SLC35E4; NbExp=3; IntAct=EBI-2835940, EBI-12867720;
CC       P34972; Q9NP94: SLC39A2; NbExp=3; IntAct=EBI-2835940, EBI-12898013;
CC       P34972; I3L0A0: TMEM189-UBE2V1; NbExp=3; IntAct=EBI-2835940, EBI-12213001;
CC       P34972; Q96HH6: TMEM19; NbExp=3; IntAct=EBI-2835940, EBI-741829;
CC       P34972; Q969S6: TMEM203; NbExp=3; IntAct=EBI-2835940, EBI-12274070;
CC       P34972; Q9NWH2: TMEM242; NbExp=3; IntAct=EBI-2835940, EBI-10315004;
CC       P34972; Q9H2L4: TMEM60; NbExp=3; IntAct=EBI-2835940, EBI-2852148;
CC       P34972; Q8N2M4: TMEM86A; NbExp=3; IntAct=EBI-2835940, EBI-12015604;
CC       P34972; Q6ZT21: TMPPE; NbExp=3; IntAct=EBI-2835940, EBI-11724433;
CC       P34972; Q5TGU0: TSPO2; NbExp=3; IntAct=EBI-2835940, EBI-12195249;
CC       P34972; Q9Y548: YIPF1; NbExp=3; IntAct=EBI-2835940, EBI-7850136;
CC       P34972; Q9BSR8: YIPF4; NbExp=3; IntAct=EBI-2835940, EBI-751253;
CC       P34972; Q96EC8: YIPF6; NbExp=3; IntAct=EBI-2835940, EBI-751210;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein. Cell
CC       projection, dendrite {ECO:0000250}. Perikaryon {ECO:0000250}.
CC       Note=Localizes to apical dendrite of pyramidal neurons. {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Preferentially expressed in cells of the immune
CC       system with higher expression in B-cells and NK cells (at protein
CC       level). Expressed in skin in suprabasal layers and hair follicles (at
CC       protein level). Highly expressed in tonsil and to a lower extent in
CC       spleen, peripheral blood mononuclear cells, and thymus. PubMed:14657172
CC       could not detect expression in normal brain. Expressed in brain by
CC       perivascular microglial cells and dorsal root ganglion sensory neurons
CC       (at protein level). Two isoforms are produced by alternative promoter
CC       usage and differ only in the 5' UTR: isoform CB2A is observed
CC       predominantly in testis with some expression in brain, while isoform
CC       CB2B is predominant in spleen and leukocytes.
CC       {ECO:0000269|PubMed:12153574, ECO:0000269|PubMed:12511587,
CC       ECO:0000269|PubMed:14657172, ECO:0000269|PubMed:15266552,
CC       ECO:0000269|PubMed:18692962, ECO:0000269|PubMed:19496827,
CC       ECO:0000269|PubMed:7556170}.
CC   -!- INDUCTION: In macrophages, down-regulated by endocannabinoid
CC       anandamide/AEA. {ECO:0000269|PubMed:23955712}.
CC   -!- PTM: Constitutively phosphorylated on Ser-352; phosphorylation
CC       increases cell internalization and desensitizes the receptor.
CC       {ECO:0000269|PubMed:10400664}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X74328; CAA52376.1; -; mRNA.
DR   EMBL; EU517121; ACD31539.1; -; mRNA.
DR   EMBL; AJ430063; CAD22548.1; -; mRNA.
DR   EMBL; AJ430064; CAD22549.1; -; Genomic_DNA.
DR   EMBL; AY242132; AAO92299.1; -; Genomic_DNA.
DR   EMBL; AM156854; CAJ42137.1; -; mRNA.
DR   EMBL; AM156855; CAJ42138.1; -; mRNA.
DR   EMBL; AM156856; CAJ42139.1; -; mRNA.
DR   EMBL; AL590609; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471134; EAW95099.1; -; Genomic_DNA.
DR   EMBL; BC069722; AAH69722.1; -; mRNA.
DR   EMBL; BC074767; AAH74767.1; -; mRNA.
DR   EMBL; BC095545; AAH95545.1; -; mRNA.
DR   CCDS; CCDS245.1; -.
DR   PIR; S36750; S36750.
DR   RefSeq; NP_001832.1; NM_001841.2.
DR   RefSeq; XP_011538931.1; XM_011540629.2.
DR   RefSeq; XP_016855750.1; XM_017000261.1.
DR   PDB; 2KI9; NMR; -; A=240-272.
DR   PDB; 5ZTY; X-ray; 2.80 A; A=21-222, A=235-325.
DR   PDB; 6KPC; X-ray; 3.20 A; A=21-222, A=235-325.
DR   PDB; 6KPF; EM; 2.90 A; R=1-360.
DR   PDB; 6PT0; EM; 3.20 A; R=1-360.
DR   PDBsum; 2KI9; -.
DR   PDBsum; 5ZTY; -.
DR   PDBsum; 6KPC; -.
DR   PDBsum; 6KPF; -.
DR   PDBsum; 6PT0; -.
DR   BMRB; P34972; -.
DR   SMR; P34972; -.
DR   BioGRID; 107669; 23.
DR   IntAct; P34972; 28.
DR   STRING; 9606.ENSP00000363596; -.
DR   BindingDB; P34972; -.
DR   ChEMBL; CHEMBL253; -.
DR   DrugBank; DB09061; Cannabidiol.
DR   DrugBank; DB00470; Dronabinol.
DR   DrugBank; DB06202; Lasofoxifene.
DR   DrugBank; DB14009; Medical Cannabis.
DR   DrugBank; DB00486; Nabilone.
DR   DrugBank; DB14011; Nabiximols.
DR   DrugBank; DB02955; Ricinoleic Acid.
DR   DrugBank; DB11755; Tetrahydrocannabivarin.
DR   DrugCentral; P34972; -.
DR   GuidetoPHARMACOLOGY; 57; -.
DR   SwissLipids; SLP:000001608; -.
DR   TCDB; 9.A.14.2.6; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; P34972; 1 site.
DR   iPTMnet; P34972; -.
DR   PhosphoSitePlus; P34972; -.
DR   BioMuta; CNR2; -.
DR   DMDM; 461697; -.
DR   MassIVE; P34972; -.
DR   MaxQB; P34972; -.
DR   PaxDb; P34972; -.
DR   PeptideAtlas; P34972; -.
DR   PRIDE; P34972; -.
DR   ProteomicsDB; 54964; -.
DR   Antibodypedia; 4047; 474 antibodies.
DR   DNASU; 1269; -.
DR   Ensembl; ENST00000374472; ENSP00000363596; ENSG00000188822.
DR   GeneID; 1269; -.
DR   KEGG; hsa:1269; -.
DR   UCSC; uc001bif.4; human.
DR   CTD; 1269; -.
DR   DisGeNET; 1269; -.
DR   EuPathDB; HostDB:ENSG00000188822.7; -.
DR   GeneCards; CNR2; -.
DR   HGNC; HGNC:2160; CNR2.
DR   HPA; ENSG00000188822; Group enriched (blood, lymphoid tissue).
DR   MIM; 605051; gene.
DR   neXtProt; NX_P34972; -.
DR   OpenTargets; ENSG00000188822; -.
DR   PharmGKB; PA26682; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT01000000214362; -.
DR   HOGENOM; CLU_009579_7_0_1; -.
DR   InParanoid; P34972; -.
DR   KO; K04278; -.
DR   OMA; GWTCCPS; -.
DR   OrthoDB; 822074at2759; -.
DR   PhylomeDB; P34972; -.
DR   TreeFam; TF330052; -.
DR   PathwayCommons; P34972; -.
DR   Reactome; R-HSA-373076; Class A/1 (Rhodopsin-like receptors).
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   SIGNOR; P34972; -.
DR   BioGRID-ORCS; 1269; 1 hit in 872 CRISPR screens.
DR   ChiTaRS; CNR2; human.
DR   EvolutionaryTrace; P34972; -.
DR   GeneWiki; Cannabinoid_receptor_type_2; -.
DR   GenomeRNAi; 1269; -.
DR   Pharos; P34972; Tchem.
DR   PRO; PR:P34972; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P34972; protein.
DR   Bgee; ENSG00000188822; Expressed in tonsil and 54 other tissues.
DR   ExpressionAtlas; P34972; baseline and differential.
DR   Genevisible; P34972; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0030425; C:dendrite; IEA:UniProtKB-SubCell.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:CACAO.
DR   GO; GO:0031234; C:extrinsic component of cytoplasmic side of plasma membrane; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0043204; C:perikaryon; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0004949; F:cannabinoid receptor activity; IBA:GO_Central.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0038171; P:cannabinoid signaling pathway; IBA:GO_Central.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007187; P:G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; TAS:ProtInc.
DR   GO; GO:0006955; P:immune response; TAS:ProtInc.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0030595; P:leukocyte chemotaxis; IEA:Ensembl.
DR   GO; GO:0045759; P:negative regulation of action potential; IEA:Ensembl.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IEA:Ensembl.
DR   GO; GO:0033004; P:negative regulation of mast cell activation; IEA:Ensembl.
DR   GO; GO:0051001; P:negative regulation of nitric-oxide synthase activity; IEA:Ensembl.
DR   GO; GO:0032229; P:negative regulation of synaptic transmission, GABAergic; IEA:Ensembl.
DR   GO; GO:0019222; P:regulation of metabolic process; IBA:GO_Central.
DR   GO; GO:0001975; P:response to amphetamine; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0019233; P:sensory perception of pain; IEA:Ensembl.
DR   InterPro; IPR001551; Canbinoid_rcpt_2.
DR   InterPro; IPR002230; Cnbnoid_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   PANTHER; PTHR22750:SF10; PTHR22750:SF10; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00523; CANABINOID2R.
DR   PRINTS; PR00362; CANNABINOIDR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Cell projection; G-protein coupled receptor;
KW   Glycoprotein; Inflammatory response; Membrane; Phosphoprotein;
KW   Polymorphism; Receptor; Reference proteome; Transducer; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..360
FT                   /note="Cannabinoid receptor 2"
FT                   /id="PRO_0000069323"
FT   TOPO_DOM        1..33
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        34..59
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        60..71
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        72..92
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        93..104
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        105..129
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        130..149
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        150..172
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        173..188
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        189..214
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        215..246
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        247..267
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        268..279
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        280..301
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        302..360
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         335
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P47936"
FT   MOD_RES         336
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P47936"
FT   MOD_RES         338
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:P47936"
FT   MOD_RES         352
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:10400664"
FT   CARBOHYD        11
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VARIANT         63
FT                   /note="Q -> R (high incidence in Japanese depressed
FT                   subjects; dbSNP:rs2501432)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:18286196"
FT                   /id="VAR_054310"
FT   VARIANT         316
FT                   /note="H -> Y (in dbSNP:rs2229579)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:18286196, ECO:0000269|Ref.5"
FT                   /id="VAR_029209"
FT   MUTAGEN         109
FT                   /note="K->A: No effect on agonist binding. Affects
FT                   cannabinoid agonist binding; when associated with G-112."
FT                   /evidence="ECO:0000269|PubMed:10051546"
FT   MUTAGEN         109
FT                   /note="K->R: No effect on agonist binding."
FT                   /evidence="ECO:0000269|PubMed:10051546"
FT   MUTAGEN         112
FT                   /note="S->G: Affects cannabinoid agonist binding; when
FT                   associated with A-109."
FT                   /evidence="ECO:0000269|PubMed:10051546"
FT   MUTAGEN         130
FT                   /note="D->A: Loss of ligand binding. Alters agonist-induced
FT                   inhibitory effect on adenylate cyclase."
FT                   /evidence="ECO:0000269|PubMed:12663043"
FT   MUTAGEN         131
FT                   /note="R->A: No effect on ligand binding. Alters agonist-
FT                   induced inhibitory effect on adenylate cyclase."
FT                   /evidence="ECO:0000269|PubMed:12663043"
FT   MUTAGEN         201
FT                   /note="L->P: Abolishes ligand binding and agonist-induced
FT                   inhibitory effect on adenylate cyclase."
FT                   /evidence="ECO:0000269|PubMed:12417328"
FT   MUTAGEN         207
FT                   /note="Y->A: Abolishes agonist-induced inhibitory effect on
FT                   adenylate cyclase. No effect on ligand binding."
FT                   /evidence="ECO:0000269|PubMed:12417328"
FT   MUTAGEN         244
FT                   /note="A->E: Loss of ligand binding. Alters agonist-induced
FT                   inhibitory effect on adenylate cyclase."
FT                   /evidence="ECO:0000269|PubMed:12663043"
FT   CONFLICT        173
FT                   /note="T -> A (in Ref. 8; AAH95545)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        307
FT                   /note="R -> H (in Ref. 8; AAH69722)"
FT                   /evidence="ECO:0000305"
FT   HELIX           22..24
FT                   /evidence="ECO:0000244|PDB:5ZTY"
FT   HELIX           31..60
FT                   /evidence="ECO:0000244|PDB:5ZTY"
FT   HELIX           62..65
FT                   /evidence="ECO:0000244|PDB:5ZTY"
FT   HELIX           68..94
FT                   /evidence="ECO:0000244|PDB:5ZTY"
FT   TURN            95..97
FT                   /evidence="ECO:0000244|PDB:6KPC"
FT   HELIX           103..136
FT                   /evidence="ECO:0000244|PDB:5ZTY"
FT   HELIX           138..144
FT                   /evidence="ECO:0000244|PDB:5ZTY"
FT   HELIX           147..165
FT                   /evidence="ECO:0000244|PDB:5ZTY"
FT   HELIX           168..170
FT                   /evidence="ECO:0000244|PDB:5ZTY"
FT   STRAND          175..177
FT                   /evidence="ECO:0000244|PDB:5ZTY"
FT   STRAND          181..183
FT                   /evidence="ECO:0000244|PDB:5ZTY"
FT   HELIX           188..219
FT                   /evidence="ECO:0000244|PDB:5ZTY"
FT   HELIX           220..223
FT                   /evidence="ECO:0000244|PDB:6KPF"
FT   TURN            224..226
FT                   /evidence="ECO:0000244|PDB:6KPF"
FT   HELIX           230..233
FT                   /evidence="ECO:0000244|PDB:6PT0"
FT   HELIX           238..270
FT                   /evidence="ECO:0000244|PDB:5ZTY"
FT   HELIX           275..284
FT                   /evidence="ECO:0000244|PDB:5ZTY"
FT   HELIX           287..302
FT                   /evidence="ECO:0000244|PDB:5ZTY"
FT   HELIX           304..318
FT                   /evidence="ECO:0000244|PDB:5ZTY"
SQ   SEQUENCE   360 AA;  39681 MW;  A7ECF68C16E7514B CRC64;
     MEECWVTEIA NGSKDGLDSN PMKDYMILSG PQKTAVAVLC TLLGLLSALE NVAVLYLILS
     SHQLRRKPSY LFIGSLAGAD FLASVVFACS FVNFHVFHGV DSKAVFLLKI GSVTMTFTAS
     VGSLLLTAID RYLCLRYPPS YKALLTRGRA LVTLGIMWVL SALVSYLPLM GWTCCPRPCS
     ELFPLIPNDY LLSWLLFIAF LFSGIIYTYG HVLWKAHQHV ASLSGHQDRQ VPGMARMRLD
     VRLAKTLGLV LAVLLICWFP VLALMAHSLA TTLSDQVKKA FAFCSMLCLI NSMVNPVIYA
     LRSGEIRSSA HHCLAHWKKC VRGLGSEAKE EAPRSSVTET EADGKITPWP DSRDLDLSDC
//
ID   CALRL_HUMAN             Reviewed;         461 AA.
AC   Q16602; A8K6G5; A8KAD3; Q53S02; Q53TS5;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   14-APR-2009, sequence version 2.
DT   07-OCT-2020, entry version 183.
DE   RecName: Full=Calcitonin gene-related peptide type 1 receptor;
DE            Short=CGRP type 1 receptor;
DE   AltName: Full=Calcitonin receptor-like receptor;
DE   Flags: Precursor;
GN   Name=CALCRL; Synonyms=CGRPR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lung;
RX   PubMed=8626685; DOI=10.1074/jbc.271.19.11325;
RA   Aiyar N., Rand K., Elshourbagy N.A., Zeng Z., Adamou J.E., Bergsma D.J.,
RA   Li Y.;
RT   "A cDNA encoding the calcitonin gene-related peptide type 1 receptor.";
RL   J. Biol. Chem. 271:11325-11329(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Cerebellum;
RX   PubMed=7818539; DOI=10.1006/bbrc.1995.1047;
RA   Fluehmann B., Muff R., Hunziker W., Fischer J.A., Born W.;
RT   "A human orphan calcitonin receptor-like structure.";
RL   Biochem. Biophys. Res. Commun. 206:341-347(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Heart;
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT TYR-8.
RC   TISSUE=Placenta, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   PROTEIN SEQUENCE OF 23-37.
RX   PubMed=15340161; DOI=10.1110/ps.04682504;
RA   Zhang Z., Henzel W.J.;
RT   "Signal peptide prediction based on analysis of experimentally verified
RT   cleavage sites.";
RL   Protein Sci. 13:2819-2824(2004).
RN   [7]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH RAMP2, INVOLVEMENT IN
RP   LMPHM8, VARIANT LMPHM8 VAL-205 DEL, AND CHARACTERIZATION OF VARIANT LMPHM8
RP   VAL-205 DEL.
RX   PubMed=30115739; DOI=10.1084/jem.20180528;
RA   Mackie D.I., Al Mutairi F., Davis R.B., Kechele D.O., Nielsen N.R.,
RA   Snyder J.C., Caron M.G., Kliman H.J., Berg J.S., Simms J., Poyner D.R.,
RA   Caron K.M.;
RT   "hCALCRL mutation causes autosomal recessive nonimmune hydrops fetalis with
RT   lymphatic dysplasia.";
RL   J. Exp. Med. 215:2339-2353(2018).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 23-133 IN COMPLEX WITH RAMP1 AND
RP   ANTAGONIST, SUBUNIT, AND DISULFIDE BONDS.
RX   PubMed=20826335; DOI=10.1016/j.str.2010.05.014;
RA   ter Haar E., Koth C.M., Abdul-Manan N., Swenson L., Coll J.T., Lippke J.A.,
RA   Lepre C.A., Garcia-Guzman M., Moore J.M.;
RT   "Crystal structure of the ectodomain complex of the CGRP receptor, a class-
RT   B GPCR, reveals the site of drug antagonism.";
RL   Structure 18:1083-1093(2010).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 23-136 IN COMPLEX WITH RAMP2,
RP   FUNCTION, MUTAGENESIS OF TRP-72; PHE-92 AND TRP-121, AND DISULFIDE BONDS.
RX   PubMed=22102369; DOI=10.1002/pro.2003;
RA   Kusano S., Kukimoto-Niino M., Hino N., Ohsawa N., Okuda K., Sakamoto K.,
RA   Shirouzu M., Shindo T., Yokoyama S.;
RT   "Structural basis for extracellular interactions between calcitonin
RT   receptor-like receptor and receptor activity-modifying protein 2 for
RT   adrenomedullin-specific binding.";
RL   Protein Sci. 21:199-210(2012).
CC   -!- FUNCTION: Receptor for calcitonin-gene-related peptide (CGRP) together
CC       with RAMP1 and receptor for adrenomedullin together with RAMP3 (By
CC       similarity). Receptor for adrenomedullin together with RAMP2
CC       (PubMed:22102369, PubMed:30115739). The activity of this receptor is
CC       mediated by G proteins which activate adenylyl cyclase
CC       (PubMed:22102369, PubMed:30115739). {ECO:0000250,
CC       ECO:0000269|PubMed:22102369, ECO:0000269|PubMed:30115739}.
CC   -!- SUBUNIT: Heterodimer of CALCRL and RAMP3 (By similarity). Heterodimer
CC       of CALCRL and RAMP1 or CALCRL and RAMP2. {ECO:0000250,
CC       ECO:0000269|PubMed:20826335, ECO:0000269|PubMed:22102369,
CC       ECO:0000269|PubMed:30115739}.
CC   -!- INTERACTION:
CC       Q16602; P06881: CALCA; NbExp=2; IntAct=EBI-962878, EBI-962928;
CC       Q16602; O60894: RAMP1; NbExp=3; IntAct=EBI-962878, EBI-962893;
CC       Q16602; O60895: RAMP2; NbExp=6; IntAct=EBI-962878, EBI-9009040;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:30115739};
CC       Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in the lung and heart.
CC   -!- DISEASE: Lymphatic malformation 8 (LMPHM8) [MIM:618773]: A form of
CC       primary lymphedema, a disease characterized by swelling of body parts
CC       due to developmental anomalies and functional defects of the lymphatic
CC       system. Adult patients with lymphedema may suffer from recurrent local
CC       infections. Impaired lymphatic drainage in the fetus can develop into
CC       hydrops fetalis, a severe condition characterized by excessive fluid
CC       accumulation in more than two fetal extra-vascular compartments and
CC       body cavities, placental enlargement and edema, pericardial or pleural
CC       effusion, or ascites. LMPHM8 is an autosomal recessive form
CC       characterized by onset in utero and fetal death due to non-immune
CC       hydrops fetalis. {ECO:0000269|PubMed:30115739}. Note=The disease may be
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 2 family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAF84319.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L76380; AAC41994.1; -; mRNA.
DR   EMBL; U17473; AAA62158.1; -; mRNA.
DR   EMBL; AY389506; AAQ91332.1; -; mRNA.
DR   EMBL; AK291630; BAF84319.1; ALT_INIT; mRNA.
DR   EMBL; AK292998; BAF85687.1; -; mRNA.
DR   EMBL; AC007319; AAY14806.1; -; Genomic_DNA.
DR   EMBL; AC074020; AAY14996.1; -; Genomic_DNA.
DR   CCDS; CCDS2293.1; -.
DR   PIR; JC2477; JC2477.
DR   RefSeq; NP_001258680.1; NM_001271751.1.
DR   RefSeq; NP_005786.1; NM_005795.5.
DR   PDB; 3AQF; X-ray; 2.60 A; B=23-136.
DR   PDB; 3N7P; X-ray; 2.80 A; A/B/C/J=23-133.
DR   PDB; 3N7R; X-ray; 2.90 A; A/B=23-133.
DR   PDB; 3N7S; X-ray; 2.10 A; A/B=23-133.
DR   PDB; 4RWF; X-ray; 1.76 A; A=31-116.
DR   PDB; 4RWG; X-ray; 2.44 A; A/B/C=31-114.
DR   PDB; 5V6Y; X-ray; 2.80 A; A/B/C/D=29-144.
DR   PDB; 6D1U; X-ray; 2.05 A; A/B/C=29-144.
DR   PDB; 6E3Y; EM; 3.30 A; R=22-461.
DR   PDB; 6UMG; X-ray; 2.70 A; C/c=23-133.
DR   PDB; 6UUN; EM; 3.00 A; R=22-461.
DR   PDB; 6UUS; EM; 2.40 A; R=22-461.
DR   PDB; 6UVA; EM; 2.30 A; R=22-461.
DR   PDB; 6ZHO; X-ray; 1.60 A; A=34-144.
DR   PDB; 6ZIS; X-ray; 1.73 A; A=31-139.
DR   PDBsum; 3AQF; -.
DR   PDBsum; 3N7P; -.
DR   PDBsum; 3N7R; -.
DR   PDBsum; 3N7S; -.
DR   PDBsum; 4RWF; -.
DR   PDBsum; 4RWG; -.
DR   PDBsum; 5V6Y; -.
DR   PDBsum; 6D1U; -.
DR   PDBsum; 6E3Y; -.
DR   PDBsum; 6UMG; -.
DR   PDBsum; 6UUN; -.
DR   PDBsum; 6UUS; -.
DR   PDBsum; 6UVA; -.
DR   PDBsum; 6ZHO; -.
DR   PDBsum; 6ZIS; -.
DR   SMR; Q16602; -.
DR   BioGRID; 115498; 5.
DR   ComplexPortal; CPX-2189; CGRP receptor complex.
DR   ComplexPortal; CPX-2191; Adrenomedullin receptor AM1 complex.
DR   ComplexPortal; CPX-3148; Adrenomedullin receptor AM2 complex.
DR   CORUM; Q16602; -.
DR   DIP; DIP-37674N; -.
DR   IntAct; Q16602; 4.
DR   STRING; 9606.ENSP00000386972; -.
DR   BindingDB; Q16602; -.
DR   ChEMBL; CHEMBL3798; -.
DR   DrugBank; DB14039; Erenumab.
DR   DrugBank; DB04869; Olcegepant.
DR   DrugBank; DB12457; Rimegepant.
DR   DrugBank; DB12228; Telcagepant.
DR   DrugBank; DB15328; Ubrogepant.
DR   GuidetoPHARMACOLOGY; 47; -.
DR   TCDB; 9.A.14.4.12; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; Q16602; 4 sites.
DR   iPTMnet; Q16602; -.
DR   PhosphoSitePlus; Q16602; -.
DR   BioMuta; CALCRL; -.
DR   DMDM; 226693507; -.
DR   EPD; Q16602; -.
DR   jPOST; Q16602; -.
DR   MassIVE; Q16602; -.
DR   PaxDb; Q16602; -.
DR   PeptideAtlas; Q16602; -.
DR   PRIDE; Q16602; -.
DR   ProteomicsDB; 60942; -.
DR   ABCD; Q16602; 1 sequenced antibody.
DR   Antibodypedia; 1959; 233 antibodies.
DR   DNASU; 10203; -.
DR   Ensembl; ENST00000392370; ENSP00000376177; ENSG00000064989.
DR   Ensembl; ENST00000409998; ENSP00000386972; ENSG00000064989.
DR   Ensembl; ENST00000410068; ENSP00000387190; ENSG00000064989.
DR   GeneID; 10203; -.
DR   KEGG; hsa:10203; -.
DR   UCSC; uc002upv.6; human.
DR   CTD; 10203; -.
DR   DisGeNET; 10203; -.
DR   EuPathDB; HostDB:ENSG00000064989.12; -.
DR   GeneCards; CALCRL; -.
DR   HGNC; HGNC:16709; CALCRL.
DR   HPA; ENSG00000064989; Tissue enhanced (lung).
DR   MIM; 114190; gene.
DR   MIM; 618773; phenotype.
DR   neXtProt; NX_Q16602; -.
DR   PharmGKB; PA26033; -.
DR   eggNOG; KOG4564; Eukaryota.
DR   HOGENOM; CLU_002753_4_2_1; -.
DR   InParanoid; Q16602; -.
DR   KO; K04577; -.
DR   PhylomeDB; Q16602; -.
DR   TreeFam; TF315710; -.
DR   PathwayCommons; Q16602; -.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   Reactome; R-HSA-419812; Calcitonin-like ligand receptors.
DR   Reactome; R-HSA-9660821; ADORA2B mediated anti-inflammatory cytokines production.
DR   BioGRID-ORCS; 10203; 5 hits in 865 CRISPR screens.
DR   ChiTaRS; CALCRL; human.
DR   EvolutionaryTrace; Q16602; -.
DR   GeneWiki; CALCRL; -.
DR   GenomeRNAi; 10203; -.
DR   Pharos; Q16602; Tchem.
DR   PRO; PR:Q16602; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q16602; protein.
DR   Bgee; ENSG00000064989; Expressed in lung and 198 other tissues.
DR   ExpressionAtlas; Q16602; baseline and differential.
DR   Genevisible; Q16602; HS.
DR   GO; GO:1903143; C:adrenomedullin receptor complex; IDA:UniProtKB.
DR   GO; GO:1990406; C:CGRP receptor complex; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005768; C:endosome; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005764; C:lysosome; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:1990409; F:adrenomedullin binding; IPI:UniProtKB.
DR   GO; GO:0001605; F:adrenomedullin receptor activity; IPI:UniProtKB.
DR   GO; GO:0001635; F:calcitonin gene-related peptide receptor activity; IPI:UniProtKB.
DR   GO; GO:0004948; F:calcitonin receptor activity; IEA:InterPro.
DR   GO; GO:0008528; F:G protein-coupled peptide receptor activity; IBA:GO_Central.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; TAS:ProtInc.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IPI:UniProtKB.
DR   GO; GO:0007188; P:adenylate cyclase-modulating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:1990410; P:adrenomedullin receptor signaling pathway; IPI:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; IDA:UniProtKB.
DR   GO; GO:1990408; P:calcitonin gene-related peptide receptor signaling pathway; IPI:UniProtKB.
DR   GO; GO:0006816; P:calcium ion transport; IDA:UniProtKB.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IEA:InterPro.
DR   GO; GO:0071329; P:cellular response to sucrose stimulus; IDA:UniProtKB.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007187; P:G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; TAS:ProtInc.
DR   GO; GO:0007507; P:heart development; IEA:Ensembl.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IEA:Ensembl.
DR   GO; GO:0045986; P:negative regulation of smooth muscle contraction; IEA:Ensembl.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0015031; P:protein transport; IDA:UniProtKB.
DR   GO; GO:0031623; P:receptor internalization; IDA:UniProtKB.
DR   Gene3D; 4.10.1240.10; -; 1.
DR   InterPro; IPR003287; GCPR_2_calcitonin_rcpt_fam.
DR   InterPro; IPR017981; GPCR_2-like.
DR   InterPro; IPR003289; GPCR_2_CGRP1_rcpt.
DR   InterPro; IPR036445; GPCR_2_extracell_dom_sf.
DR   InterPro; IPR001879; GPCR_2_extracellular_dom.
DR   InterPro; IPR000832; GPCR_2_secretin-like.
DR   InterPro; IPR017983; GPCR_2_secretin-like_CS.
DR   Pfam; PF00002; 7tm_2; 1.
DR   Pfam; PF02793; HRM; 1.
DR   PRINTS; PR01351; CGRPRECEPTOR.
DR   PRINTS; PR01350; CTRFAMILY.
DR   PRINTS; PR00249; GPCRSECRETIN.
DR   SMART; SM00008; HormR; 1.
DR   SUPFAM; SSF111418; SSF111418; 1.
DR   PROSITE; PS00649; G_PROTEIN_RECEP_F2_1; 1.
DR   PROSITE; PS00650; G_PROTEIN_RECEP_F2_2; 1.
DR   PROSITE; PS50227; G_PROTEIN_RECEP_F2_3; 1.
DR   PROSITE; PS50261; G_PROTEIN_RECEP_F2_4; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; G-protein coupled receptor; Glycoprotein; Membrane;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome; Signal;
KW   Transducer; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..22
FT                   /evidence="ECO:0000269|PubMed:15340161"
FT   CHAIN           23..461
FT                   /note="Calcitonin gene-related peptide type 1 receptor"
FT                   /id="PRO_0000012811"
FT   TOPO_DOM        23..146
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        147..166
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        167..173
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        174..193
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        194..213
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        214..236
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        237..253
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        254..273
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        274..289
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        290..313
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        314..336
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        337..354
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        355..366
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        367..388
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        389..461
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         420
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R1W5"
FT   MOD_RES         445
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R1W5"
FT   CARBOHYD        66
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        118
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        123
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        48..74
FT   DISULFID        65..105
FT   DISULFID        88..127
FT   VARIANT         8
FT                   /note="N -> Y (in dbSNP:rs698577)"
FT                   /evidence="ECO:0000269|PubMed:14702039"
FT                   /id="VAR_054822"
FT   VARIANT         16
FT                   /note="F -> L (in dbSNP:rs13391909)"
FT                   /id="VAR_049453"
FT   VARIANT         205
FT                   /note="Missing (in LMPHM8; unknown pathological
FT                   significance; decreased function in adenylate cyclase-
FT                   modulating G protein-coupled receptor signaling pathway;
FT                   decreased interaction with RAMP2; decreased protein levels
FT                   at the cell membrane)"
FT                   /evidence="ECO:0000269|PubMed:30115739"
FT                   /id="VAR_083775"
FT   VARIANT         274
FT                   /note="R -> I (in dbSNP:rs34010553)"
FT                   /id="VAR_049454"
FT   MUTAGEN         72
FT                   /note="W->A: Strongly reduced affinity for adrenomedullin."
FT                   /evidence="ECO:0000269|PubMed:22102369"
FT   MUTAGEN         92
FT                   /note="F->A: Strongly reduced affinity for adrenomedullin."
FT                   /evidence="ECO:0000269|PubMed:22102369"
FT   MUTAGEN         121
FT                   /note="W->A: Strongly reduced affinity for adrenomedullin."
FT                   /evidence="ECO:0000269|PubMed:22102369"
FT   CONFLICT        144
FT                   /note="L -> Q (in Ref. 4; BAF84319)"
FT                   /evidence="ECO:0000305"
FT   STRAND          33..35
FT                   /evidence="ECO:0000244|PDB:3N7P"
FT   HELIX           36..54
FT                   /evidence="ECO:0000244|PDB:4RWF"
FT   STRAND          60..62
FT                   /evidence="ECO:0000244|PDB:4RWF"
FT   STRAND          63..65
FT                   /evidence="ECO:0000244|PDB:3N7S"
FT   STRAND          71..75
FT                   /evidence="ECO:0000244|PDB:6UUS"
FT   STRAND          78..87
FT                   /evidence="ECO:0000244|PDB:4RWF"
FT   STRAND          90..92
FT                   /evidence="ECO:0000244|PDB:6D1U"
FT   STRAND          99..105
FT                   /evidence="ECO:0000244|PDB:4RWF"
FT   TURN            107..109
FT                   /evidence="ECO:0000244|PDB:6UUN"
FT   TURN            115..117
FT                   /evidence="ECO:0000244|PDB:4RWF"
FT   TURN            125..128
FT                   /evidence="ECO:0000244|PDB:4RWF"
FT   HELIX           130..144
FT                   /evidence="ECO:0000244|PDB:6D1U"
FT   HELIX           172..197
FT                   /evidence="ECO:0000244|PDB:6UVA"
FT   TURN            198..200
FT                   /evidence="ECO:0000244|PDB:6UVA"
FT   TURN            202..204
FT                   /evidence="ECO:0000244|PDB:6UVA"
FT   HELIX           205..207
FT                   /evidence="ECO:0000244|PDB:6UVA"
FT   HELIX           211..241
FT                   /evidence="ECO:0000244|PDB:6UVA"
FT   HELIX           253..260
FT                   /evidence="ECO:0000244|PDB:6UVA"
FT   TURN            261..263
FT                   /evidence="ECO:0000244|PDB:6UVA"
FT   HELIX           264..276
FT                   /evidence="ECO:0000244|PDB:6UVA"
FT   HELIX           281..283
FT                   /evidence="ECO:0000244|PDB:6UVA"
FT   HELIX           289..291
FT                   /evidence="ECO:0000244|PDB:6UVA"
FT   HELIX           292..320
FT                   /evidence="ECO:0000244|PDB:6UVA"
FT   HELIX           331..345
FT                   /evidence="ECO:0000244|PDB:6UVA"
FT   HELIX           347..349
FT                   /evidence="ECO:0000244|PDB:6UVA"
FT   STRAND          350..352
FT                   /evidence="ECO:0000244|PDB:6E3Y"
FT   HELIX           364..384
FT                   /evidence="ECO:0000244|PDB:6UVA"
FT   HELIX           389..398
FT                   /evidence="ECO:0000244|PDB:6UVA"
FT   TURN            399..401
FT                   /evidence="ECO:0000244|PDB:6UVA"
SQ   SEQUENCE   461 AA;  52929 MW;  AF98E55E5454767C CRC64;
     MEKKCTLNFL VLLPFFMILV TAELEESPED SIQLGVTRNK IMTAQYECYQ KIMQDPIQQA
     EGVYCNRTWD GWLCWNDVAA GTESMQLCPD YFQDFDPSEK VTKICDQDGN WFRHPASNRT
     WTNYTQCNVN THEKVKTALN LFYLTIIGHG LSIASLLISL GIFFYFKSLS CQRITLHKNL
     FFSFVCNSVV TIIHLTAVAN NQALVATNPV SCKVSQFIHL YLMGCNYFWM LCEGIYLHTL
     IVVAVFAEKQ HLMWYYFLGW GFPLIPACIH AIARSLYYND NCWISSDTHL LYIIHGPICA
     ALLVNLFFLL NIVRVLITKL KVTHQAESNL YMKAVRATLI LVPLLGIEFV LIPWRPEGKI
     AEEVYDYIMH ILMHFQGLLV STIFCFFNGE VQAILRRNWN QYKIQFGNSF SNSEALRSAS
     YTVSTISDGP GYSHDCPSEH LNGKSIHDIE NVLLKPENLY N
//
ID   AGTR1_HUMAN             Reviewed;         359 AA.
AC   P30556; Q13725; Q8TBK4;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-APR-1993, sequence version 1.
DT   12-AUG-2020, entry version 197.
DE   RecName: Full=Type-1 angiotensin II receptor;
DE   AltName: Full=AT1AR;
DE   AltName: Full=AT1BR;
DE   AltName: Full=Angiotensin II type-1 receptor;
DE            Short=AT1;
GN   Name=AGTR1; Synonyms=AGTR1A, AGTR1B, AT2R1, AT2R1B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1378723; DOI=10.1016/s0006-291x(05)80804-6;
RA   Mauzy C.A., Hwang O., Egloff A.M., Wu L.H., Chung F.-Z.;
RT   "Cloning, expression, and characterization of a gene encoding the human
RT   angiotensin II type 1A receptor.";
RL   Biochem. Biophys. Res. Commun. 186:277-284(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Lymphocyte;
RX   PubMed=1543512; DOI=10.1016/0006-291x(92)91600-u;
RA   Furuta H., Guo D.F., Inagami T.;
RT   "Molecular cloning and sequencing of the gene encoding human angiotensin II
RT   type 1 receptor.";
RL   Biochem. Biophys. Res. Commun. 183:8-13(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=1567413; DOI=10.1016/s0006-291x(05)80288-8;
RA   Bergsma D.J., Ellis C., Kumar C., Nuthalaganti P., Kersten H.,
RA   Elshourbagy N.A., Griffin E., Stadel J.M., Aiyar N.;
RT   "Cloning and characterization of a human angiotensin II type 1 receptor.";
RL   Biochem. Biophys. Res. Commun. 183:989-995(1992).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=1550596; DOI=10.1016/0006-291x(92)90570-b;
RA   Takayanagi R., Ohnaka K., Sakai Y., Nakao R., Yanase T., Haji M.,
RA   Inagami T., Furuta H., Gou D.F., Nakamuta M., Nawata H.;
RT   "Molecular cloning, sequence analysis and expression of a cDNA encoding
RT   human type-1 angiotensin II receptor.";
RL   Biochem. Biophys. Res. Commun. 183:910-916(1992).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1508224; DOI=10.1210/mend.6.7.1508224;
RA   Curnow K.M., Pascoe L., White P.C.;
RT   "Genetic analysis of the human type-1 angiotensin II receptor.";
RL   Mol. Endocrinol. 6:1113-1118(1992).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT TRP-289.
RC   TISSUE=Placenta;
RX   PubMed=8135787; DOI=10.1006/bbrc.1994.1252;
RA   Konishi H., Kuroda S., Inada Y., Fujisawa Y.;
RT   "Novel subtype of human angiotensin II type 1 receptor: cDNA cloning and
RT   expression.";
RL   Biochem. Biophys. Res. Commun. 199:467-474(1994).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=7792812; DOI=10.1016/0039-128x(94)00022-5;
RA   Nawata H., Takayanagi R., Ohnaka K., Sakai Y., Imasaki K., Yanase T.,
RA   Ikuyama S., Tanaka S., Ohe K.;
RT   "Type 1 angiotensin II receptors of adrenal tumors.";
RL   Steroids 60:28-34(1995).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RA   Ostermann E., Castanon M.J.;
RT   "Cloning and sequencing of a human cDNA encoding the angiotensin II
RT   receptor type 1.";
RL   Submitted (JUL-1994) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Antonellis A., Rogus J.J., Pezzolesi M.G., Makita Y., Nam M., Doria A.,
RA   Warram J.H., Krolewski A.S.;
RT   "Rapid identification of polymorphisms in genomic DNA: a high density SNP
RT   map of the type I angiotensin II receptor gene locus on chromosome 3q.";
RL   Submitted (MAR-2000) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANTS VAL-222 AND HIS-341.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [12]
RP   INTERACTION WITH MAS1.
RX   PubMed=15809376; DOI=10.1161/01.cir.0000160867.23556.7d;
RA   Kostenis E., Milligan G., Christopoulos A., Sanchez-Ferrer C.F.,
RA   Heringer-Walther S., Sexton P.M., Gembardt F., Kellett E., Martini L.,
RA   Vanderheyden P., Schultheiss H.P., Walther T.;
RT   "G-protein-coupled receptor Mas is a physiological antagonist of the
RT   angiotensin II type 1 receptor.";
RL   Circulation 111:1806-1813(2005).
RN   [13]
RP   GLYCOSYLATION AT ASN-4.
RX   PubMed=19139490; DOI=10.1074/mcp.m800504-mcp200;
RA   Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., Yuan Z.F., Zheng Z.B.,
RA   Song L.N., Han H.H., Liang Y.M., Wang J.L., Cai Y., Zhang Y.K., Deng Y.L.,
RA   Ying W.T., He S.M., Qian X.H.;
RT   "A strategy for precise and large scale identification of core fucosylated
RT   glycoproteins.";
RL   Mol. Cell. Proteomics 8:913-923(2009).
RN   [14]
RP   INTERACTION WITH FLNA.
RX   PubMed=26460884; DOI=10.1021/acs.biochem.5b00975;
RA   Tirupula K.C., Ithychanda S.S., Mohan M.L., Naga Prasad S.V., Qin J.,
RA   Karnik S.S.;
RT   "G Protein-Coupled Receptors Directly Bind Filamin A with High Affinity and
RT   Promote Filamin Phosphorylation.";
RL   Biochemistry 54:6673-6683(2015).
RN   [15]
RP   VARIANT RTD MET-282.
RX   PubMed=16116425; DOI=10.1038/ng1623;
RA   Gribouval O., Gonzales M., Neuhaus T., Aziza J., Bieth E., Laurent N.,
RA   Bouton J.M., Feuillet F., Makni S., Ben Amar H., Laube G., Delezoide A.-L.,
RA   Bouvier R., Dijoud F., Ollagnon-Roman E., Roume J., Joubert M.,
RA   Antignac C., Gubler M.-C.;
RT   "Mutations in genes in the renin-angiotensin system are associated with
RT   autosomal recessive renal tubular dysgenesis.";
RL   Nat. Genet. 37:964-968(2005).
CC   -!- FUNCTION: Receptor for angiotensin II. Mediates its action by
CC       association with G proteins that activate a phosphatidylinositol-
CC       calcium second messenger system.
CC   -!- SUBUNIT: Interacts with MAS1 (Probable) (PubMed:15809376). Interacts
CC       with ARRB1 (By similarity). Interacts with FLNA (via filamin repeat
CC       21); increases PKA-mediated phosphorylation of FLNA (PubMed:26460884).
CC       {ECO:0000250|UniProtKB:P25095, ECO:0000269|PubMed:15809376,
CC       ECO:0000269|PubMed:26460884, ECO:0000305}.
CC   -!- INTERACTION:
CC       P30556; PRO_0000032458 [P01019]: AGT; NbExp=2; IntAct=EBI-6623016, EBI-6622938;
CC       P30556; P35414: APLNR; NbExp=14; IntAct=EBI-6623016, EBI-2875891;
CC       P30556; P05026: ATP1B1; NbExp=2; IntAct=EBI-6623016, EBI-714630;
CC       P30556; Q6ZMG9: CERS6; NbExp=2; IntAct=EBI-6623016, EBI-20794243;
CC       P30556; O75937: DNAJC8; NbExp=2; IntAct=EBI-6623016, EBI-1045911;
CC       P30556; P54368: OAZ1; NbExp=2; IntAct=EBI-6623016, EBI-948441;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Liver, lung, adrenal and adrenocortical adenomas.
CC   -!- PTM: C-terminal Ser or Thr residues may be phosphorylated.
CC   -!- DISEASE: Renal tubular dysgenesis (RTD) [MIM:267430]: Autosomal
CC       recessive severe disorder of renal tubular development characterized by
CC       persistent fetal anuria and perinatal death, probably due to pulmonary
CC       hypoplasia from early-onset oligohydramnios (the Potter phenotype).
CC       {ECO:0000269|PubMed:16116425}. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=SHMPD; Note=The Singapore human mutation and
CC       polymorphism database;
CC       URL="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&genename=AGTR1";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Angiotensin receptor entry;
CC       URL="https://en.wikipedia.org/wiki/Angiotensin_receptor";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M91464; AAA35569.1; -; Genomic_DNA.
DR   EMBL; Z11162; CAA77513.1; -; Genomic_DNA.
DR   EMBL; M87290; AAA35535.1; -; mRNA.
DR   EMBL; S77410; AAB34644.1; -; mRNA.
DR   EMBL; M93394; AAA58370.1; -; mRNA.
DR   EMBL; D13814; BAA02968.1; -; mRNA.
DR   EMBL; X65699; CAA46621.1; -; mRNA.
DR   EMBL; AF245699; AAF70464.1; -; Genomic_DNA.
DR   EMBL; AY221090; AAO65968.1; -; Genomic_DNA.
DR   EMBL; BC022447; AAH22447.1; -; mRNA.
DR   CCDS; CCDS3137.1; -.
DR   PIR; I39418; I39418.
DR   PIR; JC1104; JC1104.
DR   RefSeq; NP_000676.1; NM_000685.4.
DR   RefSeq; NP_004826.5; NM_004835.4.
DR   RefSeq; NP_033611.1; NM_009585.3.
DR   PDB; 1ZV0; Model; -; B=1-359.
DR   PDB; 4YAY; X-ray; 2.90 A; A=2-319.
DR   PDB; 4ZUD; X-ray; 2.80 A; A=2-315.
DR   PDB; 6DO1; X-ray; 2.90 A; A/B=2-319.
DR   PDB; 6OS0; X-ray; 2.90 A; A=2-319.
DR   PDB; 6OS1; X-ray; 2.79 A; A=2-319.
DR   PDB; 6OS2; X-ray; 2.70 A; A=2-319.
DR   PDBsum; 1ZV0; -.
DR   PDBsum; 4YAY; -.
DR   PDBsum; 4ZUD; -.
DR   PDBsum; 6DO1; -.
DR   PDBsum; 6OS0; -.
DR   PDBsum; 6OS1; -.
DR   PDBsum; 6OS2; -.
DR   SMR; P30556; -.
DR   BioGRID; 106691; 31.
DR   IntAct; P30556; 74.
DR   MINT; P30556; -.
DR   STRING; 9606.ENSP00000419422; -.
DR   BindingDB; P30556; -.
DR   ChEMBL; CHEMBL227; -.
DR   DrugBank; DB11842; Angiotensin II.
DR   DrugBank; DB08822; Azilsartan medoxomil.
DR   DrugBank; DB13919; Candesartan.
DR   DrugBank; DB00796; Candesartan cilexetil.
DR   DrugBank; DB05739; CYT006-AngQb.
DR   DrugBank; DB00876; Eprosartan.
DR   DrugBank; DB09279; Fimasartan.
DR   DrugBank; DB01342; Forasartan.
DR   DrugBank; DB01029; Irbesartan.
DR   DrugBank; DB00678; Losartan.
DR   DrugBank; DB00275; Olmesartan.
DR   DrugBank; DB01347; Saprisartan.
DR   DrugBank; DB01349; Tasosartan.
DR   DrugBank; DB00966; Telmisartan.
DR   DrugBank; DB00177; Valsartan.
DR   DrugCentral; P30556; -.
DR   GuidetoPHARMACOLOGY; 34; -.
DR   TCDB; 9.A.14.13.1; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; P30556; 3 sites.
DR   iPTMnet; P30556; -.
DR   PhosphoSitePlus; P30556; -.
DR   BioMuta; AGTR1; -.
DR   DMDM; 231519; -.
DR   jPOST; P30556; -.
DR   MassIVE; P30556; -.
DR   PaxDb; P30556; -.
DR   PeptideAtlas; P30556; -.
DR   PRIDE; P30556; -.
DR   ProteomicsDB; 54721; -.
DR   ABCD; P30556; 3 sequenced antibodies.
DR   Antibodypedia; 1002; 510 antibodies.
DR   DNASU; 185; -.
DR   Ensembl; ENST00000349243; ENSP00000273430; ENSG00000144891.
DR   Ensembl; ENST00000404754; ENSP00000385612; ENSG00000144891.
DR   Ensembl; ENST00000461609; ENSP00000418851; ENSG00000144891.
DR   Ensembl; ENST00000474935; ENSP00000418084; ENSG00000144891.
DR   Ensembl; ENST00000475347; ENSP00000419783; ENSG00000144891.
DR   Ensembl; ENST00000497524; ENSP00000419422; ENSG00000144891.
DR   GeneID; 185; -.
DR   KEGG; hsa:185; -.
DR   CTD; 185; -.
DR   DisGeNET; 185; -.
DR   EuPathDB; HostDB:ENSG00000144891.17; -.
DR   GeneCards; AGTR1; -.
DR   HGNC; HGNC:336; AGTR1.
DR   HPA; ENSG00000144891; Tissue enhanced (liver, placenta).
DR   MalaCards; AGTR1; -.
DR   MIM; 106165; gene.
DR   MIM; 267430; phenotype.
DR   neXtProt; NX_P30556; -.
DR   OpenTargets; ENSG00000144891; -.
DR   Orphanet; 243761; NON RARE IN EUROPE: Essential hypertension.
DR   Orphanet; 97369; Renal tubular dysgenesis of genetic origin.
DR   PharmGKB; PA43; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT01000000214406; -.
DR   HOGENOM; CLU_009579_8_3_1; -.
DR   InParanoid; P30556; -.
DR   KO; K04166; -.
DR   PhylomeDB; P30556; -.
DR   TreeFam; TF330024; -.
DR   PathwayCommons; P30556; -.
DR   Reactome; R-HSA-375276; Peptide ligand-binding receptors.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-8856825; Cargo recognition for clathrin-mediated endocytosis.
DR   Reactome; R-HSA-8856828; Clathrin-mediated endocytosis.
DR   SignaLink; P30556; -.
DR   SIGNOR; P30556; -.
DR   BioGRID-ORCS; 185; 8 hits in 867 CRISPR screens.
DR   ChiTaRS; AGTR1; human.
DR   GeneWiki; Angiotensin_II_receptor_type_1; -.
DR   GenomeRNAi; 185; -.
DR   Pharos; P30556; Tclin.
DR   PRO; PR:P30556; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; P30556; protein.
DR   Bgee; ENSG00000144891; Expressed in placenta and 184 other tissues.
DR   ExpressionAtlas; P30556; baseline and differential.
DR   Genevisible; P30556; HS.
DR   GO; GO:0016021; C:integral component of membrane; NAS:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IC:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0001596; F:angiotensin type I receptor activity; IDA:BHF-UCL.
DR   GO; GO:0004945; F:angiotensin type II receptor activity; IDA:UniProtKB.
DR   GO; GO:0031711; F:bradykinin receptor binding; IPI:BHF-UCL.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0046982; F:protein heterodimerization activity; IPI:BHF-UCL.
DR   GO; GO:0038166; P:angiotensin-activated signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0019722; P:calcium-mediated signaling; IDA:BHF-UCL.
DR   GO; GO:0060326; P:cell chemotaxis; IDA:UniProtKB.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0006954; P:inflammatory response; IBA:GO_Central.
DR   GO; GO:0001822; P:kidney development; IMP:BHF-UCL.
DR   GO; GO:0034374; P:low-density lipoprotein particle remodeling; NAS:BHF-UCL.
DR   GO; GO:0086097; P:phospholipase C-activating angiotensin-activated signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:1903589; P:positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis; IGI:BHF-UCL.
DR   GO; GO:0032270; P:positive regulation of cellular protein metabolic process; IMP:BHF-UCL.
DR   GO; GO:0010873; P:positive regulation of cholesterol esterification; IMP:BHF-UCL.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IDA:BHF-UCL.
DR   GO; GO:0051482; P:positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; TAS:BHF-UCL.
DR   GO; GO:0010744; P:positive regulation of macrophage derived foam cell differentiation; IC:BHF-UCL.
DR   GO; GO:0033864; P:positive regulation of NAD(P)H oxidase activity; TAS:BHF-UCL.
DR   GO; GO:0032430; P:positive regulation of phospholipase A2 activity; IMP:BHF-UCL.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; TAS:BHF-UCL.
DR   GO; GO:0097746; P:regulation of blood vessel diameter; IC:BHF-UCL.
DR   GO; GO:0002034; P:regulation of blood vessel diameter by renin-angiotensin; IC:BHF-UCL.
DR   GO; GO:0001558; P:regulation of cell growth; NAS:BHF-UCL.
DR   GO; GO:0042127; P:regulation of cell population proliferation; NAS:BHF-UCL.
DR   GO; GO:0050727; P:regulation of inflammatory response; IC:BHF-UCL.
DR   GO; GO:0035813; P:regulation of renal sodium excretion; NAS:BHF-UCL.
DR   GO; GO:0003081; P:regulation of systemic arterial blood pressure by renin-angiotensin; IC:BHF-UCL.
DR   GO; GO:0019229; P:regulation of vasoconstriction; IDA:BHF-UCL.
DR   GO; GO:0002018; P:renin-angiotensin regulation of aldosterone production; NAS:BHF-UCL.
DR   GO; GO:0007266; P:Rho protein signal transduction; IDA:UniProtKB.
DR   InterPro; IPR000190; ATII_AT1_rcpt.
DR   InterPro; IPR000248; ATII_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00241; ANGIOTENSINR.
DR   PRINTS; PR00635; ANGIOTENSN1R.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disease mutation; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Lipoprotein; Membrane; Palmitate;
KW   Phosphoprotein; Polymorphism; Receptor; Reference proteome; Transducer;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..359
FT                   /note="Type-1 angiotensin II receptor"
FT                   /id="PRO_0000069153"
FT   TOPO_DOM        1..27
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        28..52
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        53..64
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        65..87
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        88..102
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        103..124
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        125..142
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        143..162
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        163..192
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        193..214
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        215..240
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        241..262
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        263..275
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        276..296
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        297..359
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   LIPID           355
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        4
FT                   /note="N-linked (GlcNAc...) (complex) asparagine"
FT                   /evidence="ECO:0000269|PubMed:19139490"
FT   CARBOHYD        176
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        188
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        101..180
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VARIANT         163
FT                   /note="A -> T (in dbSNP:rs12721226)"
FT                   /id="VAR_029206"
FT   VARIANT         222
FT                   /note="L -> V (in dbSNP:rs17852013)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_070375"
FT   VARIANT         244
FT                   /note="A -> S (in dbSNP:rs12721225)"
FT                   /id="VAR_029207"
FT   VARIANT         282
FT                   /note="T -> M (in RTD; dbSNP:rs104893677)"
FT                   /evidence="ECO:0000269|PubMed:16116425"
FT                   /id="VAR_035086"
FT   VARIANT         289
FT                   /note="C -> W (in dbSNP:rs1064533)"
FT                   /evidence="ECO:0000269|PubMed:8135787"
FT                   /id="VAR_011847"
FT   VARIANT         336
FT                   /note="T -> P (in dbSNP:rs1801021)"
FT                   /id="VAR_011848"
FT   VARIANT         341
FT                   /note="P -> H (in dbSNP:rs17852012)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_070376"
FT   CONFLICT        187
FT                   /note="Q -> R (in Ref. 6; BAA02968)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        204..205
FT                   /note="FL -> SC (in Ref. 6; BAA02968)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        232
FT                   /note="K -> N (in Ref. 6; BAA02968)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        240
FT                   /note="K -> R (in Ref. 6; BAA02968)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        268
FT                   /note="L -> Q (in Ref. 6; BAA02968)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        311..313
FT                   /note="RYF -> KDI (in Ref. 6; BAA02968)"
FT                   /evidence="ECO:0000305"
FT   STRAND          12..14
FT                   /evidence="ECO:0000244|PDB:6OS2"
FT   TURN            19..22
FT                   /evidence="ECO:0000244|PDB:6OS2"
FT   HELIX           25..56
FT                   /evidence="ECO:0000244|PDB:6OS2"
FT   HELIX           62..79
FT                   /evidence="ECO:0000244|PDB:6OS2"
FT   HELIX           81..89
FT                   /evidence="ECO:0000244|PDB:6OS2"
FT   HELIX           97..131
FT                   /evidence="ECO:0000244|PDB:6OS2"
FT   TURN            133..135
FT                   /evidence="ECO:0000244|PDB:6OS2"
FT   TURN            137..139
FT                   /evidence="ECO:0000244|PDB:6OS2"
FT   HELIX           142..159
FT                   /evidence="ECO:0000244|PDB:6OS2"
FT   HELIX           162..165
FT                   /evidence="ECO:0000244|PDB:6OS2"
FT   STRAND          168..172
FT                   /evidence="ECO:0000244|PDB:6OS2"
FT   TURN            173..176
FT                   /evidence="ECO:0000244|PDB:6OS2"
FT   STRAND          177..184
FT                   /evidence="ECO:0000244|PDB:6OS2"
FT   STRAND          186..188
FT                   /evidence="ECO:0000244|PDB:6OS2"
FT   HELIX           191..194
FT                   /evidence="ECO:0000244|PDB:4ZUD"
FT   HELIX           195..201
FT                   /evidence="ECO:0000244|PDB:6OS2"
FT   TURN            202..204
FT                   /evidence="ECO:0000244|PDB:6OS2"
FT   HELIX           205..226
FT                   /evidence="ECO:0000244|PDB:6OS2"
FT   HELIX           238..267
FT                   /evidence="ECO:0000244|PDB:6OS2"
FT   STRAND          269..271
FT                   /evidence="ECO:0000244|PDB:4YAY"
FT   HELIX           274..295
FT                   /evidence="ECO:0000244|PDB:6OS2"
FT   HELIX           298..305
FT                   /evidence="ECO:0000244|PDB:6OS2"
FT   HELIX           307..317
FT                   /evidence="ECO:0000244|PDB:6OS2"
SQ   SEQUENCE   359 AA;  41061 MW;  35FC856F53E911A6 CRC64;
     MILNSSTEDG IKRIQDDCPK AGRHNYIFVM IPTLYSIIFV VGIFGNSLVV IVIYFYMKLK
     TVASVFLLNL ALADLCFLLT LPLWAVYTAM EYRWPFGNYL CKIASASVSF NLYASVFLLT
     CLSIDRYLAI VHPMKSRLRR TMLVAKVTCI IIWLLAGLAS LPAIIHRNVF FIENTNITVC
     AFHYESQNST LPIGLGLTKN ILGFLFPFLI ILTSYTLIWK ALKKAYEIQK NKPRNDDIFK
     IIMAIVLFFF FSWIPHQIFT FLDVLIQLGI IRDCRIADIV DTAMPITICI AYFNNCLNPL
     FYGFLGKKFK RYFLQLLKYI PPKAKSHSNL STKMSTLSYR PSDNVSSSTK KPAPCFEVE
//
ID   CCR2_HUMAN              Reviewed;         374 AA.
AC   P41597; A0AVQ3; B2RMT0; O95950; Q4VBL2;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   12-AUG-2020, entry version 204.
DE   RecName: Full=C-C chemokine receptor type 2;
DE            Short=C-C CKR-2;
DE            Short=CC-CKR-2;
DE            Short=CCR-2;
DE            Short=CCR2;
DE   AltName: Full=Monocyte chemoattractant protein 1 receptor;
DE            Short=MCP-1-R;
DE   AltName: CD_antigen=CD192;
GN   Name=CCR2; Synonyms=CMKBR2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RX   PubMed=8146186; DOI=10.1073/pnas.91.7.2752;
RA   Charo I.F., Myers S.J., Herman A., Franci C., Connolly A.J., Coughlin S.R.;
RT   "Molecular cloning and functional expression of two monocyte
RT   chemoattractant protein 1 receptors reveals alternative splicing of the
RT   carboxyl-terminal tails.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:2752-2756(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RX   PubMed=8048929; DOI=10.1006/bbrc.1994.2049;
RA   Yamagami S., Tokuda Y., Ishii K., Tamaka H., Endo N.;
RT   "cDNA cloning and functional expression of a human monocyte chemoattractant
RT   protein 1 receptor.";
RL   Biochem. Biophys. Res. Commun. 202:1156-1162(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8995400; DOI=10.1074/jbc.272.2.1038;
RA   Wong L.-M., Myers S.J., Tsou C.-L., Gosling J., Arai H., Charo I.F.;
RT   "Organization and differential expression of the human monocyte
RT   chemoattractant protein 1 receptor gene. Evidence for the role of the
RT   carboxyl-terminal tail in receptor trafficking.";
RL   J. Biol. Chem. 272:1038-1045(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ILE-64 AND GLU-355.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (SEP-2002) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Thymus, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS A AND B).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 221-374 (ISOFORM B), ALTERNATIVE SPLICING,
RP   TISSUE SPECIFICITY, AND INDUCTION BY IL2.
RX   PubMed=9058802;
RA   Polentarutti N., Allavena P., Bianchi G., Giardina G., Basile A.,
RA   Sozzani S., Mantovani A., Introna M.;
RT   "IL-2-Regulated Expression of the Monocyte Chemotactic Protein-1 Receptor
RT   (CCR2) in Human NK Cells.";
RL   J. Immunol. 158:2689-2694(1997).
RN   [10]
RP   PHOSPHORYLATION AT TYR-139 BY JAK2.
RX   PubMed=9670957;
RA   Mellado M., Rodriguez-Frade J.M., Aragay A., del Real G., Martin A.M.,
RA   Vila-Coro A.J., Serrano A., Mayor F. Jr., Martinez-A C.;
RT   "The chemokine monocyte chemotactic protein 1 triggers Janus kinase 2
RT   activation and tyrosine phosphorylation of the CCR2B receptor.";
RL   J. Immunol. 161:805-813(1998).
RN   [11]
RP   INTERACTION WITH ARRB1.
RX   PubMed=9501202; DOI=10.1073/pnas.95.6.2985;
RA   Aragay A.M., Mellado M., Frade J.M., Martin A.M., Jimenez-Sainz M.C.,
RA   Martinez-A C., Mayor F. Jr.;
RT   "Monocyte chemoattractant protein-1-induced CCR2B receptor desensitization
RT   mediated by the G protein-coupled receptor kinase 2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:2985-2990(1998).
RN   [12]
RP   FUNCTION (MICROBIAL INFECTION), AND INTERACTION WITH HIV-1 TAT (MICROBIAL
RP   INFECTION).
RX   PubMed=9789057; DOI=10.1073/pnas.95.22.13153;
RA   Albini A., Ferrini S., Benelli R., Sforzini S., Giunciuglio D.,
RA   Aluigi M.G., Proudfoot A.E.I., Alouani S., Wells T.N.C., Mariani G.,
RA   Rabin R.L., Farber J.M., Noonan D.M.;
RT   "HIV-1 Tat protein mimicry of chemokines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:13153-13158(1998).
RN   [13]
RP   SULFATION AT TYR-26, AND GLYCOSYLATION.
RX   PubMed=11046064; DOI=10.4049/jimmunol.165.9.5295;
RA   Preobrazhensky A.A., Dragan S., Kawano T., Gavrilin M.A., Gulina I.V.,
RA   Chakravarty L., Kolattukudy P.E.;
RT   "Monocyte chemotactic protein-1 receptor CCR2B is a glycoprotein that has
RT   tyrosine sulfation in a conserved extracellular N-terminal region.";
RL   J. Immunol. 165:5295-5303(2000).
RN   [14]
RP   FUNCTION, INTERACTION WITH NUP85, AND SUBCELLULAR LOCATION.
RX   PubMed=15995708; DOI=10.1038/ni1222;
RA   Terashima Y., Onai N., Murai M., Enomoto M., Poonpiriya V., Hamada T.,
RA   Motomura K., Suwa M., Ezaki T., Haga T., Kanegasaki S., Matsushima K.;
RT   "Pivotal function for cytoplasmic protein FROUNT in CCR2-mediated monocyte
RT   chemotaxis.";
RL   Nat. Immunol. 6:827-835(2005).
RN   [15]
RP   SUBCELLULAR LOCATION, AND INDUCTION.
RX   PubMed=18587271; DOI=10.3858/emm.2008.40.3.332;
RA   Sung H.J., Kim Y.S., Kang H., Ko J.;
RT   "Human LZIP induces monocyte CC chemokine receptor 2 expression leading to
RT   enhancement of monocyte chemoattractant protein 1/CCL2-induced cell
RT   migration.";
RL   Exp. Mol. Med. 40:332-338(2008).
RN   [16]
RP   FUNCTION, AND SULFATION.
RX   PubMed=23408426; DOI=10.1074/jbc.m112.447359;
RA   Tan J.H., Ludeman J.P., Wedderburn J., Canals M., Hall P., Butler S.J.,
RA   Taleski D., Christopoulos A., Hickey M.J., Payne R.J., Stone M.J.;
RT   "Tyrosine sulfation of chemokine receptor CCR2 enhances interactions with
RT   both monomeric and dimeric forms of the chemokine monocyte chemoattractant
RT   protein-1 (MCP-1).";
RL   J. Biol. Chem. 288:10024-10034(2013).
RN   [17]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH BETA-DEFENSIN
RP   DEFB106A/DEFB106B.
RX   PubMed=23938203; DOI=10.1016/j.jmb.2013.08.001;
RA   De Paula V.S., Gomes N.S., Lima L.G., Miyamoto C.A., Monteiro R.Q.,
RA   Almeida F.C., Valente A.P.;
RT   "Structural basis for the interaction of human beta-defensin 6 and its
RT   putative chemokine receptor CCR2 and breast cancer microvesicles.";
RL   J. Mol. Biol. 425:4479-4495(2013).
RN   [18]
RP   STRUCTURE BY NMR OF 310-325 (ISOFORM B), INTERACTION WITH NUP85, AND
RP   MUTAGENESIS OF ISOFORM B.
RX   PubMed=25283965; DOI=10.1111/febs.13096;
RA   Esaki K., Yoshinaga S., Tsuji T., Toda E., Terashima Y., Saitoh T.,
RA   Kohda D., Kohno T., Osawa M., Ueda T., Shimada I., Matsushima K.,
RA   Terasawa H.;
RT   "Structural basis for the binding of the membrane-proximal C-terminal
RT   region of chemokine receptor CCR2 with the cytosolic regulator FROUNT.";
RL   FEBS J. 281:5552-5566(2014).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.81 ANGSTROMS) OF 2-328 (ISOFORM B), AND DISULFIDE
RP   BOND.
RX   PubMed=27926736; DOI=10.1038/nature20605;
RA   Zheng Y., Qin L., Zacarias N.V., de Vries H., Han G.W., Gustavsson M.,
RA   Dabros M., Zhao C., Cherney R.J., Carter P., Stamos D., Abagyan R.,
RA   Cherezov V., Stevens R.C., Ijzerman A.P., Heitman L.H., Tebben A.,
RA   Kufareva I., Handel T.M.;
RT   "Structure of CC chemokine receptor 2 with orthosteric and allosteric
RT   antagonists.";
RL   Nature 540:458-461(2016).
RN   [20]
RP   VARIANT ILE-64.
RX   PubMed=9252328; DOI=10.1126/science.277.5328.959;
RA   Smith M.W., Dean M., Carrington M., Winkler C., Huttley G.A., Lomb D.A.,
RA   Goedert J.J., O'Brien T.R., Jacobson L.P., Kaslow R., Buchbinder S.,
RA   Vittinghoff E., Vlahov D., Hoots K., Hilgartner M.W., O'Brien S.J.;
RT   "Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection
RT   and disease progression.";
RL   Science 277:959-965(1997).
RN   [21]
RP   VARIANT ILE-64.
RX   PubMed=9662369; DOI=10.1038/nm0798-786;
RA   Mummidi S., Ahuja S.S., Gonzalez E., Anderson S.A., Santiago E.N.,
RA   Stephan K.T., Craig F.E., O'Connell P., Tryon V., Clark R.A., Dolan M.J.,
RA   Ahuja S.K.;
RT   "Genealogy of the CCR5 locus and chemokine system gene variants associated
RT   with altered rates of HIV-1 disease progression.";
RL   Nat. Med. 4:786-793(1998).
CC   -!- FUNCTION: Key functional receptor for CCL2 but can also bind CCL7 and
CC       CCL12 (PubMed:8146186, PubMed:8048929, PubMed:23408426). Its binding
CC       with CCL2 on monocytes and macrophages mediates chemotaxis and
CC       migration induction through the activation of the PI3K cascade, the
CC       small G protein Rac and lamellipodium protrusion (Probable). Also acts
CC       as a receptor for the beta-defensin DEFB106A/DEFB106B
CC       (PubMed:23938203). Regulates the expression of T-cell inflammatory
CC       cytokines and T-cell differentiation, promoting the differentiation of
CC       T-cells into T-helper 17 cells (Th17) during inflammation (By
CC       similarity). Facilitates the export of mature thymocytes by enhancing
CC       directional movement of thymocytes to sphingosine-1-phosphate
CC       stimulation and up-regulation of S1P1R expression; signals through the
CC       JAK-STAT pathway to regulate FOXO1 activity leading to an increased
CC       expression of S1P1R (By similarity). Plays an important role in
CC       mediating peripheral nerve injury-induced neuropathic pain (By
CC       similarity). Increases NMDA-mediated synaptic transmission in both
CC       dopamine D1 and D2 receptor-containing neurons, which may be caused by
CC       MAPK/ERK-dependent phosphorylation of GRIN2B/NMDAR2B (By similarity).
CC       Mediates the recruitment of macrophages and monocytes to the injury
CC       site following brain injury (By similarity).
CC       {ECO:0000250|UniProtKB:P51683, ECO:0000269|PubMed:23408426,
CC       ECO:0000269|PubMed:23938203, ECO:0000269|PubMed:8048929,
CC       ECO:0000269|PubMed:8146186, ECO:0000305|PubMed:15995708}.
CC   -!- FUNCTION: (Microbial infection) Alternative coreceptor with CD4 for
CC       HIV-1 infection. {ECO:0000269|PubMed:9789057}.
CC   -!- SUBUNIT: Interacts with ARRB1 (PubMed:9501202). Interacts (via
CC       extracellular N-terminal region) with beta-defensin DEFB106A/DEFB106B;
CC       this interaction may preferentially require specific tyrosine sulfation
CC       on CCR2 (PubMed:23938203). Interacts with NUP85; the interaction is
CC       required for CCR2 clusters formation on the cell membrane and CCR2
CC       signaling (PubMed:15995708, PubMed:25283965).
CC       {ECO:0000269|PubMed:15995708, ECO:0000269|PubMed:23938203,
CC       ECO:0000269|PubMed:25283965, ECO:0000269|PubMed:9501202}.
CC   -!- SUBUNIT: (Microbial infection) Binds to HIV-1 Tat.
CC       {ECO:0000269|PubMed:9789057}.
CC   -!- INTERACTION:
CC       P41597-2; Q9BW27: NUP85; NbExp=3; IntAct=EBI-14807859, EBI-716392;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:15995708,
CC       ECO:0000269|PubMed:18587271}; Multi-pass membrane protein
CC       {ECO:0000255}. Note=The chemoattractant receptors are distributed
CC       throughout the cell surface; after stimulation with a ligand, such as
CC       CCL2, they are rapidly recruited into microdomain clusters at the cell
CC       membrane. {ECO:0000269|PubMed:15995708}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=A {ECO:0000303|PubMed:9058802};
CC         IsoId=P41597-1; Sequence=Displayed;
CC       Name=B {ECO:0000303|PubMed:9058802};
CC         IsoId=P41597-2; Sequence=VSP_001893;
CC   -!- TISSUE SPECIFICITY: Expressed by monocytes and IL2-activated NK cells.
CC       {ECO:0000269|PubMed:9058802}.
CC   -!- INDUCTION: Up-regulated by CREB3 (PubMed:18587271). In NK cells,
CC       induced by IL2 (PubMed:9058802). {ECO:0000269|PubMed:18587271,
CC       ECO:0000269|PubMed:9058802}.
CC   -!- PTM: N-glycosylated. {ECO:0000269|PubMed:11046064}.
CC   -!- PTM: Sulfation increases the affinity for both monomeric and dimeric
CC       CCL2 with stronger binding to the monomeric form (PubMed:11046064,
CC       PubMed:23408426). Binding of sulfated CCR2 to CCL2 promotes conversion
CC       of CCL2 from dimer to monomer (PubMed:11046064, PubMed:23408426).
CC       {ECO:0000269|PubMed:11046064, ECO:0000269|PubMed:23408426}.
CC   -!- POLYMORPHISM: Variations in CCR2 are associated with relative
CC       resistance to immunodeficiency virus type 1 (resistance to HIV-1)
CC       [MIM:609423]. {ECO:0000269|PubMed:9252328}.
CC   -!- MISCELLANEOUS: [Isoform B]: Mutagenesis of Leu-316 to Thr as well as
CC       Phe-320 to Asp decrease interaction with NUP85.
CC       {ECO:0000269|PubMed:27926736}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=CC chemokine receptors entry;
CC       URL="https://en.wikipedia.org/wiki/CC_chemokine_receptors";
CC   -!- WEB RESOURCE: Name=SeattleSNPs;
CC       URL="http://pga.gs.washington.edu/data/ccr2/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CCR2ID964ch3p21.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U03882; AAA19119.1; -; mRNA.
DR   EMBL; U03905; AAA19120.1; -; mRNA.
DR   EMBL; D29984; BAA06253.1; -; mRNA.
DR   EMBL; U80924; AAC51637.1; -; Genomic_DNA.
DR   EMBL; U80924; AAC51636.1; -; Genomic_DNA.
DR   EMBL; AF545480; AAN16400.1; -; Genomic_DNA.
DR   EMBL; AK292685; BAF85374.1; -; mRNA.
DR   EMBL; AK292920; BAF85609.1; -; mRNA.
DR   EMBL; U95626; AAB57791.1; -; Genomic_DNA.
DR   EMBL; U95626; AAB57792.1; -; Genomic_DNA.
DR   EMBL; CH471055; EAW64760.1; -; Genomic_DNA.
DR   EMBL; BC074751; AAH74751.1; -; mRNA.
DR   EMBL; BC095540; AAH95540.1; -; mRNA.
DR   EMBL; BC126452; AAI26453.1; -; mRNA.
DR   EMBL; BC136396; AAI36397.1; -; mRNA.
DR   EMBL; X95583; CAA64835.1; -; mRNA.
DR   CCDS; CCDS43078.1; -. [P41597-1]
DR   CCDS; CCDS46813.1; -. [P41597-2]
DR   PIR; I38450; I38450.
DR   PIR; JC2443; JC2443.
DR   RefSeq; NP_001116513.2; NM_001123041.2. [P41597-1]
DR   RefSeq; NP_001116868.1; NM_001123396.1. [P41597-2]
DR   RefSeq; XP_011532371.1; XM_011534069.1. [P41597-2]
DR   PDB; 1KAD; Model; -; A=1-343.
DR   PDB; 1KP1; Model; -; A=1-343.
DR   PDB; 2MLO; NMR; -; A=310-318.
DR   PDB; 2MLQ; NMR; -; A=310-318.
DR   PDB; 5T1A; X-ray; 2.81 A; A=2-313.
DR   PDBsum; 1KAD; -.
DR   PDBsum; 1KP1; -.
DR   PDBsum; 2MLO; -.
DR   PDBsum; 2MLQ; -.
DR   PDBsum; 5T1A; -.
DR   SMR; P41597; -.
DR   BioGRID; 609634; 1.
DR   DIP; DIP-5833N; -.
DR   IntAct; P41597; 42.
DR   MINT; P41597; -.
DR   STRING; 9606.ENSP00000292301; -.
DR   BindingDB; P41597; -.
DR   ChEMBL; CHEMBL4015; -.
DR   DrugBank; DB05159; CCX915.
DR   DrugBank; DB05130; INCB3284.
DR   DrugBank; DB12520; Plozalizumab.
DR   DrugCentral; P41597; -.
DR   GuidetoPHARMACOLOGY; 59; -.
DR   GlyGen; P41597; 1 site.
DR   iPTMnet; P41597; -.
DR   PhosphoSitePlus; P41597; -.
DR   BioMuta; CCR2; -.
DR   DMDM; 1168965; -.
DR   jPOST; P41597; -.
DR   MassIVE; P41597; -.
DR   PaxDb; P41597; -.
DR   PeptideAtlas; P41597; -.
DR   PRIDE; P41597; -.
DR   ProteomicsDB; 55474; -. [P41597-1]
DR   ProteomicsDB; 55475; -. [P41597-2]
DR   ABCD; P41597; 1 sequenced antibody.
DR   Antibodypedia; 29661; 875 antibodies.
DR   Ensembl; ENST00000292301; ENSP00000292301; ENSG00000121807. [P41597-1]
DR   Ensembl; ENST00000400888; ENSP00000383681; ENSG00000121807. [P41597-1]
DR   Ensembl; ENST00000445132; ENSP00000399285; ENSG00000121807. [P41597-2]
DR   GeneID; 729230; -.
DR   KEGG; hsa:729230; -.
DR   UCSC; uc003cpm.5; human. [P41597-1]
DR   CTD; 729230; -.
DR   DisGeNET; 729230; -.
DR   EuPathDB; HostDB:ENSG00000121807.5; -.
DR   GeneCards; CCR2; -.
DR   HGNC; HGNC:1603; CCR2.
DR   HPA; ENSG00000121807; Group enriched (blood, lymphoid tissue).
DR   MIM; 601267; gene.
DR   MIM; 609423; phenotype.
DR   neXtProt; NX_P41597; -.
DR   OpenTargets; ENSG00000121807; -.
DR   PharmGKB; PA26167; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT01000000214577; -.
DR   HOGENOM; CLU_009579_8_3_1; -.
DR   InParanoid; P41597; -.
DR   KO; K04177; -.
DR   OMA; CPVFYGE; -.
DR   OrthoDB; 937138at2759; -.
DR   PhylomeDB; P41597; -.
DR   TreeFam; TF330966; -.
DR   PathwayCommons; P41597; -.
DR   Reactome; R-HSA-1461957; Beta defensins.
DR   Reactome; R-HSA-380108; Chemokine receptors bind chemokines.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-6783783; Interleukin-10 signaling.
DR   SIGNOR; P41597; -.
DR   BioGRID-ORCS; 729230; 6 hits in 872 CRISPR screens.
DR   GeneWiki; CCR2; -.
DR   GenomeRNAi; 729230; -.
DR   Pharos; P41597; Tchem.
DR   PRO; PR:P41597; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; P41597; protein.
DR   Bgee; ENSG00000121807; Expressed in monocyte and 133 other tissues.
DR   ExpressionAtlas; P41597; baseline and differential.
DR   Genevisible; P41597; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0005829; C:cytosol; ISS:BHF-UCL.
DR   GO; GO:0030425; C:dendrite; ISS:BHF-UCL.
DR   GO; GO:0009897; C:external side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0016021; C:integral component of membrane; TAS:ProtInc.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0043025; C:neuronal cell body; ISS:BHF-UCL.
DR   GO; GO:0043204; C:perikaryon; ISS:BHF-UCL.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0019957; F:C-C chemokine binding; IBA:GO_Central.
DR   GO; GO:0016493; F:C-C chemokine receptor activity; IBA:GO_Central.
DR   GO; GO:0031727; F:CCR2 chemokine receptor binding; IDA:MGI.
DR   GO; GO:0035716; F:chemokine (C-C motif) ligand 12 binding; IEA:Ensembl.
DR   GO; GO:0035715; F:chemokine (C-C motif) ligand 2 binding; IEA:Ensembl.
DR   GO; GO:0035717; F:chemokine (C-C motif) ligand 7 binding; IEA:Ensembl.
DR   GO; GO:0019956; F:chemokine binding; IBA:GO_Central.
DR   GO; GO:0004950; F:chemokine receptor activity; TAS:ProtInc.
DR   GO; GO:0042802; F:identical protein binding; ISS:BHF-UCL.
DR   GO; GO:0001974; P:blood vessel remodeling; ISS:BHF-UCL.
DR   GO; GO:0019722; P:calcium-mediated signaling; IBA:GO_Central.
DR   GO; GO:0060326; P:cell chemotaxis; IBA:GO_Central.
DR   GO; GO:0006874; P:cellular calcium ion homeostasis; ISS:BHF-UCL.
DR   GO; GO:0006968; P:cellular defense response; TAS:ProtInc.
DR   GO; GO:0019725; P:cellular homeostasis; ISS:BHF-UCL.
DR   GO; GO:0070098; P:chemokine-mediated signaling pathway; ISS:BHF-UCL.
DR   GO; GO:0006935; P:chemotaxis; IBA:GO_Central.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; IDA:MGI.
DR   GO; GO:0002407; P:dendritic cell chemotaxis; TAS:BHF-UCL.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0030097; P:hemopoiesis; IEA:Ensembl.
DR   GO; GO:0048873; P:homeostasis of number of cells within a tissue; IEA:Ensembl.
DR   GO; GO:0006959; P:humoral immune response; IEA:Ensembl.
DR   GO; GO:0006955; P:immune response; IBA:GO_Central.
DR   GO; GO:0006954; P:inflammatory response; IBA:GO_Central.
DR   GO; GO:0090594; P:inflammatory response to wounding; ISS:UniProtKB.
DR   GO; GO:0061756; P:leukocyte adhesion to vascular endothelial cell; IEA:Ensembl.
DR   GO; GO:1905517; P:macrophage migration; ISS:UniProtKB.
DR   GO; GO:0002548; P:monocyte chemotaxis; IEA:Ensembl.
DR   GO; GO:0035696; P:monocyte extravasation; ISS:UniProtKB.
DR   GO; GO:0007194; P:negative regulation of adenylate cyclase activity; TAS:ProtInc.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; ISS:BHF-UCL.
DR   GO; GO:0043310; P:negative regulation of eosinophil degranulation; ISS:BHF-UCL.
DR   GO; GO:0002829; P:negative regulation of type 2 immune response; ISS:BHF-UCL.
DR   GO; GO:0097350; P:neutrophil clearance; IEA:Ensembl.
DR   GO; GO:0046641; P:positive regulation of alpha-beta T cell proliferation; ISS:BHF-UCL.
DR   GO; GO:2000464; P:positive regulation of astrocyte chemotaxis; IDA:BHF-UCL.
DR   GO; GO:2000451; P:positive regulation of CD8-positive, alpha-beta T cell extravasation; ISS:BHF-UCL.
DR   GO; GO:0120162; P:positive regulation of cold-induced thermogenesis; ISS:YuBioLab.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IBA:GO_Central.
DR   GO; GO:2000473; P:positive regulation of hematopoietic stem cell migration; ISS:BHF-UCL.
DR   GO; GO:0090265; P:positive regulation of immune complex clearance by monocytes and macrophages; ISS:BHF-UCL.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; ISS:BHF-UCL.
DR   GO; GO:0032729; P:positive regulation of interferon-gamma production; ISS:BHF-UCL.
DR   GO; GO:0032743; P:positive regulation of interleukin-2 production; ISS:BHF-UCL.
DR   GO; GO:1903238; P:positive regulation of leukocyte tethering or rolling; IEA:Ensembl.
DR   GO; GO:0090026; P:positive regulation of monocyte chemotaxis; IDA:UniProtKB.
DR   GO; GO:2000439; P:positive regulation of monocyte extravasation; ISS:BHF-UCL.
DR   GO; GO:1904783; P:positive regulation of NMDA glutamate receptor activity; ISS:ARUK-UCL.
DR   GO; GO:0051968; P:positive regulation of synaptic transmission, glutamatergic; ISS:UniProtKB.
DR   GO; GO:0050870; P:positive regulation of T cell activation; ISS:BHF-UCL.
DR   GO; GO:0010820; P:positive regulation of T cell chemotaxis; ISS:BHF-UCL.
DR   GO; GO:0002827; P:positive regulation of T-helper 1 type immune response; ISS:BHF-UCL.
DR   GO; GO:2000412; P:positive regulation of thymocyte migration; ISS:UniProtKB.
DR   GO; GO:0042535; P:positive regulation of tumor necrosis factor biosynthetic process; ISS:BHF-UCL.
DR   GO; GO:0007259; P:receptor signaling pathway via JAK-STAT; TAS:ProtInc.
DR   GO; GO:0050727; P:regulation of inflammatory response; ISS:UniProtKB.
DR   GO; GO:0002724; P:regulation of T cell cytokine production; ISS:UniProtKB.
DR   GO; GO:0045580; P:regulation of T cell differentiation; ISS:UniProtKB.
DR   GO; GO:0010574; P:regulation of vascular endothelial growth factor production; ISS:BHF-UCL.
DR   GO; GO:0009611; P:response to wounding; TAS:ProtInc.
DR   GO; GO:0019233; P:sensory perception of pain; ISS:UniProtKB.
DR   GO; GO:0035705; P:T-helper 17 cell chemotaxis; ISS:BHF-UCL.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   InterPro; IPR002237; Chemokine_CCR2.
DR   InterPro; IPR000355; Chemokine_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00657; CCCHEMOKINER.
DR   PRINTS; PR01107; CHEMOKINER2.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Host-virus interaction;
KW   Inflammatory response; Membrane; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Sulfation; Transducer; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..374
FT                   /note="C-C chemokine receptor type 2"
FT                   /id="PRO_0000069232"
FT   TOPO_DOM        1..42
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        43..70
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        71..80
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        81..100
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        101..114
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        115..136
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        137..153
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        154..178
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        179..206
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        207..226
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        227..243
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        244..268
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        269..285
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        286..309
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        310..374
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         26
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000269|PubMed:11046064"
FT   MOD_RES         139
FT                   /note="Phosphotyrosine; by JAK2"
FT                   /evidence="ECO:0000269|PubMed:9670957"
FT   CARBOHYD        14
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        113..190
FT                   /evidence="ECO:0000269|PubMed:27926736"
FT   VAR_SEQ         314..374
FT                   /note="SLFHIALGCRIAPLQKPVCGGPGVRPGKNVKVTTQGLLDGRGKGKSIGRAPE
FT                   ASLQDKEGA -> RYLSVFFRKHITKRFCKQCPVFYRETVDGVTSTNTPSTGEQEVSAG
FT                   L (in isoform B)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:9058802"
FT                   /id="VSP_001893"
FT   VARIANT         45
FT                   /note="L -> V (in dbSNP:rs4987052)"
FT                   /id="VAR_020066"
FT   VARIANT         64
FT                   /note="V -> I (confers relative resistance to infection by
FT                   HIV-1; delay in disease progression in African Americans
FT                   but not in Caucasians; dbSNP:rs1799864)"
FT                   /evidence="ECO:0000269|PubMed:9252328,
FT                   ECO:0000269|PubMed:9662369, ECO:0000269|Ref.4"
FT                   /id="VAR_014339"
FT   VARIANT         355
FT                   /note="G -> E (in dbSNP:rs3918387)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_014340"
FT   HELIX           38..69
FT                   /evidence="ECO:0000244|PDB:5T1A"
FT   HELIX           76..92
FT                   /evidence="ECO:0000244|PDB:5T1A"
FT   HELIX           95..103
FT                   /evidence="ECO:0000244|PDB:5T1A"
FT   HELIX           110..142
FT                   /evidence="ECO:0000244|PDB:5T1A"
FT   HELIX           146..151
FT                   /evidence="ECO:0000244|PDB:5T1A"
FT   HELIX           154..170
FT                   /evidence="ECO:0000244|PDB:5T1A"
FT   HELIX           173..177
FT                   /evidence="ECO:0000244|PDB:5T1A"
FT   STRAND          179..184
FT                   /evidence="ECO:0000244|PDB:5T1A"
FT   STRAND          187..192
FT                   /evidence="ECO:0000244|PDB:5T1A"
FT   HELIX           196..210
FT                   /evidence="ECO:0000244|PDB:5T1A"
FT   HELIX           212..228
FT                   /evidence="ECO:0000244|PDB:5T1A"
FT   HELIX           237..265
FT                   /evidence="ECO:0000244|PDB:5T1A"
FT   TURN            266..268
FT                   /evidence="ECO:0000244|PDB:5T1A"
FT   HELIX           269..272
FT                   /evidence="ECO:0000244|PDB:5T1A"
FT   HELIX           279..295
FT                   /evidence="ECO:0000244|PDB:5T1A"
FT   TURN            296..300
FT                   /evidence="ECO:0000244|PDB:5T1A"
FT   HELIX           301..308
FT                   /evidence="ECO:0000244|PDB:5T1A"
FT   HELIX           310..318
FT                   /evidence="ECO:0000244|PDB:5T1A"
SQ   SEQUENCE   374 AA;  41915 MW;  F865E0D39E74CF0F CRC64;
     MLSTSRSRFI RNTNESGEEV TTFFDYDYGA PCHKFDVKQI GAQLLPPLYS LVFIFGFVGN
     MLVVLILINC KKLKCLTDIY LLNLAISDLL FLITLPLWAH SAANEWVFGN AMCKLFTGLY
     HIGYFGGIFF IILLTIDRYL AIVHAVFALK ARTVTFGVVT SVITWLVAVF ASVPGIIFTK
     CQKEDSVYVC GPYFPRGWNN FHTIMRNILG LVLPLLIMVI CYSGILKTLL RCRNEKKRHR
     AVRVIFTIMI VYFLFWTPYN IVILLNTFQE FFGLSNCEST SQLDQATQVT ETLGMTHCCI
     NPIIYAFVGE KFRSLFHIAL GCRIAPLQKP VCGGPGVRPG KNVKVTTQGL LDGRGKGKSI
     GRAPEASLQD KEGA
//
ID   CCR9_HUMAN              Reviewed;         369 AA.
AC   P51686; Q4VBM3; Q549E0; Q9UQQ6;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   05-SEP-2006, sequence version 2.
DT   12-AUG-2020, entry version 174.
DE   RecName: Full=C-C chemokine receptor type 9;
DE            Short=C-C CKR-9;
DE            Short=CC-CKR-9;
DE            Short=CCR-9;
DE   AltName: Full=G-protein coupled receptor 28;
DE   AltName: Full=GPR-9-6;
DE   AltName: CD_antigen=CDw199;
GN   Name=CCR9; Synonyms=GPR28;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND FUNCTION.
RX   PubMed=10229797;
RA   Zaballos A., Gutierrez J., Varona R., Ardavin C., Marquez G.;
RT   "Identification of the orphan chemokine receptor GPR-9-6 as CCR9, the
RT   receptor for the chemokine TECK.";
RL   J. Immunol. 162:5671-5675(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), TISSUE SPECIFICITY, AND
RP   FUNCTION.
RX   PubMed=10640743; DOI=10.4049/jimmunol.164.3.1293;
RA   Yu C.-R., Peden K.W.C., Zaitseva M.B., Golding H., Farber J.M.;
RT   "CCR9A and CCR9B: two receptors for the chemokine CCL25/TECK/Ck beta-15
RT   that differ in their sensitivities to ligand.";
RL   J. Immunol. 164:1293-1305(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 2).
RA   Lautens L.L., Tiffany H.L., Gao J.-L., Modi W., Murphy P.M., Bonner T.I.;
RT   "Cloning, tissue distribution and chromosomal localization of two potential
RT   G-protein-linked chemokine receptors.";
RL   Submitted (APR-1996) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RA   Warren C.N., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 24-341, SUBCELLULAR LOCATION, AND
RP   DISULFIDE BOND.
RX   PubMed=27926729; DOI=10.1038/nature20606;
RA   Oswald C., Rappas M., Kean J., Dore A.S., Errey J.C., Bennett K.,
RA   Deflorian F., Christopher J.A., Jazayeri A., Mason J.S., Congreve M.,
RA   Cooke R.M., Marshall F.H.;
RT   "Intracellular allosteric antagonism of the CCR9 receptor.";
RL   Nature 540:462-465(2016).
CC   -!- FUNCTION: Receptor for chemokine SCYA25/TECK. Subsequently transduces a
CC       signal by increasing the intracellular calcium ions level.
CC       {ECO:0000269|PubMed:10229797, ECO:0000269|PubMed:10640743}.
CC   -!- FUNCTION: (Microbial infection) Alternative coreceptor with CD4 for
CC       HIV-1 infection.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305|PubMed:27926729};
CC       Multi-pass membrane protein {ECO:0000305|PubMed:27926729}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=CCR9A;
CC         IsoId=P51686-1; Sequence=Displayed;
CC       Name=2; Synonyms=CCR9B;
CC         IsoId=P51686-2; Sequence=VSP_020286;
CC   -!- TISSUE SPECIFICITY: Highly expressed in the thymus and low in lymph
CC       nodes and spleen. {ECO:0000269|PubMed:10229797,
CC       ECO:0000269|PubMed:10640743}.
CC   -!- MISCELLANEOUS: EC50 of SCYA25/TECK for isoform 1 is lower than for
CC       isoform 2.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH95516.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=CC chemokine receptors entry;
CC       URL="https://en.wikipedia.org/wiki/CC_chemokine_receptors";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/CCR9ID44380ch3p21.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AJ132337; CAB43477.1; -; mRNA.
DR   EMBL; AF145439; AAF66699.1; -; mRNA.
DR   EMBL; AF145440; AAF66700.1; -; mRNA.
DR   EMBL; U45982; AAA93319.1; -; Genomic_DNA.
DR   EMBL; AY242127; AAO92294.1; -; Genomic_DNA.
DR   EMBL; BC069678; AAH69678.1; -; mRNA.
DR   EMBL; BC095516; AAH95516.1; ALT_INIT; mRNA.
DR   CCDS; CCDS2732.1; -. [P51686-1]
DR   CCDS; CCDS2733.1; -. [P51686-2]
DR   RefSeq; NP_001243298.1; NM_001256369.1. [P51686-2]
DR   RefSeq; NP_006632.2; NM_006641.3. [P51686-2]
DR   RefSeq; NP_112477.1; NM_031200.2. [P51686-1]
DR   RefSeq; XP_011531614.1; XM_011533312.2. [P51686-1]
DR   PDB; 5LWE; X-ray; 2.80 A; A/B=24-341.
DR   PDBsum; 5LWE; -.
DR   SMR; P51686; -.
DR   DIP; DIP-5884N; -.
DR   IntAct; P51686; 18.
DR   MINT; P51686; -.
DR   STRING; 9606.ENSP00000350256; -.
DR   BindingDB; P51686; -.
DR   ChEMBL; CHEMBL5815; -.
DR   DrugBank; DB15250; Vercirnon.
DR   GuidetoPHARMACOLOGY; 66; -.
DR   GlyGen; P51686; 1 site.
DR   iPTMnet; P51686; -.
DR   PhosphoSitePlus; P51686; -.
DR   BioMuta; CCR9; -.
DR   DMDM; 114152781; -.
DR   PaxDb; P51686; -.
DR   PeptideAtlas; P51686; -.
DR   PRIDE; P51686; -.
DR   ProteomicsDB; 56370; -. [P51686-1]
DR   ProteomicsDB; 56371; -. [P51686-2]
DR   Antibodypedia; 3479; 617 antibodies.
DR   DNASU; 10803; -.
DR   Ensembl; ENST00000355983; ENSP00000348260; ENSG00000173585. [P51686-2]
DR   Ensembl; ENST00000357632; ENSP00000350256; ENSG00000173585. [P51686-1]
DR   Ensembl; ENST00000395963; ENSP00000379292; ENSG00000173585. [P51686-2]
DR   GeneID; 10803; -.
DR   KEGG; hsa:10803; -.
DR   UCSC; uc003coz.3; human. [P51686-1]
DR   CTD; 10803; -.
DR   DisGeNET; 10803; -.
DR   EuPathDB; HostDB:ENSG00000173585.15; -.
DR   GeneCards; CCR9; -.
DR   HGNC; HGNC:1610; CCR9.
DR   HPA; ENSG00000173585; Tissue enriched (lymphoid).
DR   MIM; 604738; gene.
DR   neXtProt; NX_P51686; -.
DR   OpenTargets; ENSG00000173585; -.
DR   PharmGKB; PA26174; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00950000182749; -.
DR   HOGENOM; CLU_009579_8_3_1; -.
DR   InParanoid; P51686; -.
DR   KO; K04184; -.
DR   OMA; TICTMVY; -.
DR   OrthoDB; 800663at2759; -.
DR   PhylomeDB; P51686; -.
DR   TreeFam; TF330966; -.
DR   PathwayCommons; P51686; -.
DR   Reactome; R-HSA-380108; Chemokine receptors bind chemokines.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   SIGNOR; P51686; -.
DR   BioGRID-ORCS; 10803; 0 hits in 868 CRISPR screens.
DR   GeneWiki; CCR9; -.
DR   GenomeRNAi; 10803; -.
DR   Pharos; P51686; Tchem.
DR   PRO; PR:P51686; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; P51686; protein.
DR   Bgee; ENSG00000173585; Expressed in thymus and 95 other tissues.
DR   ExpressionAtlas; P51686; baseline and differential.
DR   Genevisible; P51686; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0009897; C:external side of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0019957; F:C-C chemokine binding; IBA:GO_Central.
DR   GO; GO:0016493; F:C-C chemokine receptor activity; IBA:GO_Central.
DR   GO; GO:0019956; F:chemokine binding; IBA:GO_Central.
DR   GO; GO:0004950; F:chemokine receptor activity; TAS:ProtInc.
DR   GO; GO:0019722; P:calcium-mediated signaling; IBA:GO_Central.
DR   GO; GO:0002305; P:CD8-positive, gamma-delta intraepithelial T cell differentiation; IEA:Ensembl.
DR   GO; GO:0060326; P:cell chemotaxis; IBA:GO_Central.
DR   GO; GO:0006968; P:cellular defense response; TAS:ProtInc.
DR   GO; GO:0006935; P:chemotaxis; IBA:GO_Central.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006955; P:immune response; IBA:GO_Central.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IBA:GO_Central.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   InterPro; IPR004069; Chemokine_CCR9.
DR   InterPro; IPR000355; Chemokine_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00657; CCCHEMOKINER.
DR   PRINTS; PR01531; CHEMOKINER9.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Host-virus interaction; Membrane;
KW   Polymorphism; Receptor; Reference proteome; Transducer; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..369
FT                   /note="C-C chemokine receptor type 9"
FT                   /id="PRO_0000069291"
FT   TOPO_DOM        1..48
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:27926729"
FT   TRANSMEM        49..74
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000269|PubMed:27926729"
FT   TOPO_DOM        75..85
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:27926729"
FT   TRANSMEM        86..109
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000269|PubMed:27926729"
FT   TOPO_DOM        110..120
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:27926729"
FT   TRANSMEM        121..150
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000269|PubMed:27926729"
FT   TOPO_DOM        151..159
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:27926729"
FT   TRANSMEM        160..185
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000269|PubMed:27926729"
FT   TOPO_DOM        186..208
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:27926729"
FT   TRANSMEM        209..243
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000269|PubMed:27926729"
FT   TOPO_DOM        244..248
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:27926729"
FT   TRANSMEM        249..283
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000269|PubMed:27926729"
FT   TOPO_DOM        284..290
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:27926729"
FT   TRANSMEM        291..321
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000269|PubMed:27926729"
FT   TOPO_DOM        322..369
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255, ECO:0000269|PubMed:27926729"
FT   CARBOHYD        32
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        38..289
FT                   /evidence="ECO:0000269|PubMed:27926729"
FT   DISULFID        119..198
FT                   /evidence="ECO:0000244|PDB:5LWE, ECO:0000255|PROSITE-
FT                   ProRule:PRU00521, ECO:0000269|PubMed:27926729"
FT   VAR_SEQ         1..12
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10640743,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|Ref.4"
FT                   /id="VSP_020286"
FT   VARIANT         92
FT                   /note="I -> V (in dbSNP:rs45530037)"
FT                   /id="VAR_029208"
FT   VARIANT         284
FT                   /note="M -> V (in dbSNP:rs12721497)"
FT                   /id="VAR_020068"
FT   HELIX           33..37
FT                   /evidence="ECO:0000244|PDB:5LWE"
FT   HELIX           45..75
FT                   /evidence="ECO:0000244|PDB:5LWE"
FT   HELIX           82..106
FT                   /evidence="ECO:0000244|PDB:5LWE"
FT   HELIX           117..148
FT                   /evidence="ECO:0000244|PDB:5LWE"
FT   HELIX           151..154
FT                   /evidence="ECO:0000244|PDB:5LWE"
FT   HELIX           155..157
FT                   /evidence="ECO:0000244|PDB:5LWE"
FT   HELIX           158..179
FT                   /evidence="ECO:0000244|PDB:5LWE"
FT   HELIX           181..185
FT                   /evidence="ECO:0000244|PDB:5LWE"
FT   HELIX           209..222
FT                   /evidence="ECO:0000244|PDB:5LWE"
FT   HELIX           224..243
FT                   /evidence="ECO:0000244|PDB:5LWE"
FT   HELIX           249..252
FT                   /evidence="ECO:0000244|PDB:5LWE"
FT   HELIX           254..282
FT                   /evidence="ECO:0000244|PDB:5LWE"
FT   HELIX           289..307
FT                   /evidence="ECO:0000244|PDB:5LWE"
FT   HELIX           308..311
FT                   /evidence="ECO:0000244|PDB:5LWE"
FT   HELIX           313..320
FT                   /evidence="ECO:0000244|PDB:5LWE"
FT   HELIX           324..341
FT                   /evidence="ECO:0000244|PDB:5LWE"
SQ   SEQUENCE   369 AA;  42016 MW;  F27CEA0CFB66B44C CRC64;
     MTPTDFTSPI PNMADDYGSE STSSMEDYVN FNFTDFYCEK NNVRQFASHF LPPLYWLVFI
     VGALGNSLVI LVYWYCTRVK TMTDMFLLNL AIADLLFLVT LPFWAIAAAD QWKFQTFMCK
     VVNSMYKMNF YSCVLLIMCI SVDRYIAIAQ AMRAHTWREK RLLYSKMVCF TIWVLAAALC
     IPEILYSQIK EESGIAICTM VYPSDESTKL KSAVLTLKVI LGFFLPFVVM ACCYTIIIHT
     LIQAKKSSKH KALKVTITVL TVFVLSQFPY NCILLVQTID AYAMFISNCA VSTNIDICFQ
     VTQTIAFFHS CLNPVLYVFV GERFRRDLVK TLKNLGCISQ AQWVSFTRRE GSLKLSSMLL
     ETTSGALSL
//
ID   CCR5_HUMAN              Reviewed;         352 AA.
AC   P51681; O14692; O14693; O14695; O14696; O14697; O14698; O14699; O14700;
AC   O14701; O14702; O14703; O14704; O14705; O14706; O14707; O14708; O15538;
AC   Q9UPA4;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 1.
DT   07-OCT-2020, entry version 204.
DE   RecName: Full=C-C chemokine receptor type 5;
DE            Short=C-C CKR-5;
DE            Short=CC-CKR-5;
DE            Short=CCR-5;
DE            Short=CCR5;
DE   AltName: Full=CHEMR13;
DE   AltName: Full=HIV-1 fusion coreceptor;
DE   AltName: CD_antigen=CD195;
GN   Name=CCR5; Synonyms=CMKBR5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=8639485; DOI=10.1021/bi952950g;
RA   Samson M., Labbe O., Mollereau C., Vassart G., Parmentier M.;
RT   "Molecular cloning and functional expression of a new human CC-chemokine
RT   receptor gene.";
RL   Biochemistry 35:3362-3367(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, INTERACTION WITH CCL4 AND CCL5, AND
RP   TISSUE SPECIFICITY.
RC   TISSUE=Macrophage;
RX   PubMed=8663314; DOI=10.1074/jbc.271.29.17161;
RA   Raport C.J., Gosling J., Schweichart V.L., Gray P.W., Charo I.F.;
RT   "Molecular cloning and functional characterization of a novel human CC
RT   chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha.";
RL   J. Biol. Chem. 271:17161-17166(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND INTERACTION WITH CCL3; CCL4 AND
RP   CCL5.
RX   PubMed=8699119; DOI=10.1002/jlb.60.1.147;
RA   Combadiere C., Ahuja S.K., Tiffany H.L., Murphy P.M.;
RT   "Cloning and functional expression of CC CKR5, a human monocyte CC
RT   chemokine receptor selective for MIP-1(alpha), MIP-1(beta), and RANTES.";
RL   J. Leukoc. Biol. 60:147-152(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9343222;
RA   Kuhmann S.E., Platt E.J., Kozak S.L., Kabat D.;
RT   "Polymorphisms in the CCR5 genes of African green monkeys and mice
RT   implicate specific amino acids in infections by simian and human
RT   immunodeficiency viruses.";
RL   J. Virol. 71:8642-8656(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND POLYMORPHISM.
RX   PubMed=9359654; DOI=10.1089/aid.1997.13.1357;
RA   Zhang L., Carruthers C.D., He T., Huang Y., Cao Y., Wang G., Hahn B.,
RA   Ho D.D.;
RT   "HIV type 1 subtypes, coreceptor usage, and CCR5 polymorphism.";
RL   AIDS Res. Hum. Retroviruses 13:1357-1366(1997).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9388201; DOI=10.1074/jbc.272.49.30662;
RA   Mummidi S., Ahuja S.S., McDaniel B.L., Ahuja S.K.;
RT   "The human CC chemokine receptor 5 (CCR5) gene. Multiple transcripts with
RT   5'-end heterogeneity, dual promoter usage, and evidence for polymorphisms
RT   within the regulatory regions and noncoding exons.";
RL   J. Biol. Chem. 272:30662-30671(1997).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT ARG-178.
RX   PubMed=10917742; DOI=10.1016/s1286-4579(99)80002-1;
RA   Magierowska M., Lepage V., Lien T.X., Lan N.T., Guillotel M., Issafras H.,
RA   Reynes J.M., Fleury H.J., Chi N.H., Follezou J.Y., Debre P., Theodorou I.,
RA   Barre-Sinoussi F.;
RT   "Novel variant of the CCR5 gene in a Vietnamese population.";
RL   Microbes Infect. 1:123-124(1999).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   INVOLVEMENT IN RESISTANCE OR SUSCEPTIBILITY TO HIV-1.
RX   PubMed=8756719; DOI=10.1016/s0092-8674(00)80110-5;
RA   Liu R., Paxton W.A., Choe S., Ceradini D., Martin S.R., Horuk R.,
RA   MacDonald M.E., Stuhlmann H., Koup R.A., Landau N.R.;
RT   "Homozygous defect in HIV-1 coreceptor accounts for resistance of some
RT   multiply-exposed individuals to HIV-1 infection.";
RL   Cell 86:367-377(1996).
RN   [12]
RP   FUNCTION AS A HIV-1 CORECEPTOR.
RX   PubMed=8649511; DOI=10.1038/381661a0;
RA   Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M.,
RA   di Marzio P., Marmon S., Sutton R.E., Hill C.M., Davis C.B., Peiper S.C.,
RA   Schall T.J., Littman D.R., Landau N.R.;
RT   "Identification of a major co-receptor for primary isolates of HIV-1.";
RL   Nature 381:661-666(1996).
RN   [13]
RP   FUNCTION AS A HIV-1 CORECEPTOR.
RX   PubMed=8649512; DOI=10.1038/381667a0;
RA   Dragic T., Litwin V., Allaway G.P., Martin S.R., Huang Y., Nagashima K.A.,
RA   Cayanan C., Maddon P.J., Koup R.A., Moore J.P., Paxton W.A.;
RT   "HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-
RT   5.";
RL   Nature 381:667-673(1996).
RN   [14]
RP   INVOLVEMENT IN RESISTANCE OR SUSCEPTIBILITY TO HIV-1.
RX   PubMed=8751444; DOI=10.1038/382722a0;
RA   Samson M., Libert F., Doranz B.J., Rucker J., Liesnard C., Farber C.M.,
RA   Saragosti S., Lapoumeroulie C., Cognaux J., Forceille C., Muyldermans G.,
RA   Verhofstede C., Burtonboy G., Georges M., Imai T., Rana S., Yi Y.,
RA   Smyth R.J., Collman R.G., Doms R.W., Vassart G., Parmentier M.;
RT   "Resistance to HIV-1 infection in caucasian individuals bearing mutant
RT   alleles of the CCR-5 chemokine receptor gene.";
RL   Nature 382:722-725(1996).
RN   [15]
RP   INTERACTION WITH HIV-1 SURFACE PROTEIN GP120, AND FUNCTION (MICROBIAL
RP   INFECTION).
RX   PubMed=9632396; DOI=10.1126/science.280.5371.1949;
RA   Rizzuto C.D., Wyatt R., Hernandez-Ramos N., Sun Y., Kwong P.D.,
RA   Hendrickson W.A., Sodroski J.;
RT   "A conserved HIV gp120 glycoprotein structure involved in chemokine
RT   receptor binding.";
RL   Science 280:1949-1953(1998).
RN   [16]
RP   SULFATION AT TYR-3, GLYCOSYLATION, AND MUTAGENESIS OF TYR-3; TYR-10; TYR-14
RP   AND TYR-15.
RX   PubMed=10089882; DOI=10.1016/s0092-8674(00)80577-2;
RA   Farzan M., Mirzabekov T., Kolchinsky P., Wyatt R., Cayabyab M.,
RA   Gerard N.P., Gerard C., Sodroski J., Choe H.;
RT   "Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1
RT   entry.";
RL   Cell 96:667-676(1999).
RN   [17]
RP   PHOSPHORYLATION AT SER-336; SER-337; SER-342 AND SER-349, MUTAGENESIS OF
RP   SER-336; SER-337; SER-342 AND SER-349, AND INTERACTION WITH GRK2.
RX   PubMed=10085131; DOI=10.1074/jbc.274.13.8875;
RA   Oppermann M., Mack M., Proudfoot A.E., Olbrich H.;
RT   "Differential effects of CC chemokines on CC chemokine receptor 5 (CCR5)
RT   phosphorylation and identification of phosphorylation sites on the CCR5
RT   carboxyl terminus.";
RL   J. Biol. Chem. 274:8875-8885(1999).
RN   [18]
RP   FUNCTION, FUNCTION (MICROBIAL INFECTION), MUTAGENESIS OF CYS-20; CYS-101;
RP   CYS-178 AND CYS-269, SUBCELLULAR LOCATION, AND INTERACTION WITH CCL4.
RX   PubMed=10383387; DOI=10.1074/jbc.274.27.18902;
RA   Blanpain C., Lee B., Vakili J., Doranz B.J., Govaerts C., Migeotte I.,
RA   Sharron M., Dupriez V., Vassart G., Doms R.W., Parmentier M.;
RT   "Extracellular cysteines of CCR5 are required for chemokine binding, but
RT   dispensable for HIV-1 coreceptor activity.";
RL   J. Biol. Chem. 274:18902-18908(1999).
RN   [19]
RP   PALMITOYLATION AT CYS-321; CYS-323 AND CYS-324, SUBCELLULAR LOCATION,
RP   FUNCTION, AND MUTAGENESIS OF CYS-321; CYS-323 AND CYS-324.
RX   PubMed=11323418; DOI=10.1074/jbc.m100583200;
RA   Blanpain C., Wittamer V., Vanderwinden J.-M., Boom A., Renneboog B.,
RA   Lee B., Le Poul E., El Asmar L., Govaerts C., Vassart G., Doms R.W.,
RA   Parmentier M.;
RT   "Palmitoylation of CCR5 is critical for receptor trafficking and efficient
RT   activation of intracellular signaling pathways.";
RL   J. Biol. Chem. 276:23795-23804(2001).
RN   [20]
RP   INTERACTION WITH ARRB2, AND MUTAGENESIS OF SER-336; SER-337; SER-342 AND
RP   SER-349.
RX   PubMed=11448957; DOI=10.1074/jbc.m102782200;
RA   Kraft K., Olbrich H., Majoul I., Mack M., Proudfoot A., Oppermann M.;
RT   "Characterization of sequence determinants within the carboxyl-terminal
RT   domain of chemokine receptor CCR5 that regulate signaling and receptor
RT   internalization.";
RL   J. Biol. Chem. 276:34408-34418(2001).
RN   [21]
RP   SULFATION, GLYCOSYLATION AT SER-6, INTERACTION WITH CCL3; CCL4 AND CCL5,
RP   MUTAGENESIS OF TYR-3; SER-6; SER-7; TYR-10; TYR-14; TYR-15; THR-16 AND
RP   SER-17, AND CHARACTERIZATION OF VARIANT ASP-10.
RX   PubMed=11733580; DOI=10.1084/jem.194.11.1661;
RA   Bannert N., Craig S., Farzan M., Sogah D., Santo N.V., Choe H.,
RA   Sodroski J.;
RT   "Sialylated O-glycans and sulfated tyrosines in the NH2-terminal domain of
RT   CC chemokine receptor 5 contribute to high affinity binding of
RT   chemokines.";
RL   J. Exp. Med. 194:1661-1673(2001).
RN   [22]
RP   INTERACTION WITH PRAF2.
RX   PubMed=15757671; DOI=10.1016/j.febslet.2005.02.037;
RA   Schweneker M., Bachmann A.S., Moelling K.;
RT   "JM4 is a four-transmembrane protein binding to the CCR5 receptor.";
RL   FEBS Lett. 579:1751-1758(2005).
RN   [23]
RP   INTERACTION WITH ARRB1 AND ARRB2.
RX   PubMed=16144840; DOI=10.1074/jbc.m500535200;
RA   Huettenrauch F., Pollok-Kopp B., Oppermann M.;
RT   "G protein-coupled receptor kinases promote phosphorylation and beta-
RT   arrestin-mediated internalization of CCR5 homo- and hetero-oligomers.";
RL   J. Biol. Chem. 280:37503-37515(2005).
RN   [24]
RP   INVOLVEMENT IN WEST NILE VIRUS INFECTION SUSCEPTIBILITY.
RX   PubMed=16418398; DOI=10.1084/jem.20051970;
RA   Glass W.G., McDermott D.H., Lim J.K., Lekhong S., Yu S.F., Frank W.A.,
RA   Pape J., Cheshier R.C., Murphy P.M.;
RT   "CCR5 deficiency increases risk of symptomatic West Nile virus infection.";
RL   J. Exp. Med. 203:35-40(2006).
RN   [25]
RP   INDUCTION (MICROBIAL INFECTION), AND INTERACTION WITH HHV-5 PROTEIN UL78.
RX   PubMed=22496149; DOI=10.1182/blood-2011-08-372516;
RA   Tadagaki K., Tudor D., Gbahou F., Tschische P., Waldhoer M., Bomsel M.,
RA   Jockers R., Kamal M.;
RT   "Human cytomegalovirus-encoded UL33 and UL78 heteromerize with host CCR5
RT   and CXCR4 impairing their HIV coreceptor activity.";
RL   Blood 119:4908-4918(2012).
RN   [26]
RP   INTERACTION WITH CNIH4.
RX   PubMed=24405750; DOI=10.1111/tra.12148;
RA   Sauvageau E., Rochdi M.D., Oueslati M., Hamdan F.F., Percherancier Y.,
RA   Simpson J.C., Pepperkok R., Bouvier M.;
RT   "CNIH4 interacts with newly synthesized GPCR and controls their export from
RT   the endoplasmic reticulum.";
RL   Traffic 15:383-400(2014).
RN   [27]
RP   3D-STRUCTURE MODELING.
RX   PubMed=12496074; DOI=10.1016/s0006-3495(02)75307-1;
RA   Paterlini M.G.;
RT   "Structure modeling of the chemokine receptor CCR5: implications for ligand
RT   binding and selectivity.";
RL   Biophys. J. 83:3012-3031(2002).
RN   [28]
RP   3D-STRUCTURE MODELING.
RX   PubMed=14517611; DOI=10.1007/s00894-003-0154-9;
RA   Liu S., Fan S., Sun Z.;
RT   "Structural and functional characterization of the human CCR5 receptor in
RT   complex with HIV gp120 envelope glycoprotein and CD4 receptor by molecular
RT   modeling studies.";
RL   J. Mol. Model. 9:329-336(2003).
RN   [29]
RP   STRUCTURE BY NMR OF 1-27 IN COMPLEX WITH HIV-1 GP120 AND CD4 MIMIC PEPTIDE,
RP   FUNCTION (MICROBIAL INFECTION), AND SULFATION AT TYR-10 AND TYR-14.
RX   PubMed=21763489; DOI=10.1016/j.jmb.2011.04.023;
RA   Schnur E., Noah E., Ayzenshtat I., Sargsyan H., Inui T., Ding F.X.,
RA   Arshava B., Sagi Y., Kessler N., Levy R., Scherf T., Naider F.,
RA   Anglister J.;
RT   "The conformation and orientation of a 27-residue CCR5 peptide in a ternary
RT   complex with HIV-1 gp120 and a CD4-mimic peptide.";
RL   J. Mol. Biol. 410:778-797(2011).
RN   [30] {ECO:0000244|PDB:4MBS}
RP   X-RAY CRYSTALLOGRAPHY (2.71 ANGSTROMS) OF 2-223 AND 227-352 IN COMPLEX WITH
RP   DRUG, AND DISULFIDE BONDS.
RX   PubMed=24030490; DOI=10.1126/science.1241475;
RA   Tan Q., Zhu Y., Li J., Chen Z., Han G.W., Kufareva I., Li T., Ma L.,
RA   Fenalti G., Li J., Zhang W., Xie X., Yang H., Jiang H., Cherezov V.,
RA   Liu H., Stevens R.C., Zhao Q., Wu B.;
RT   "Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc
RT   complex.";
RL   Science 341:1387-1390(2013).
RN   [31]
RP   VARIANTS GLN-55; LEU-215; GLN-223; VAL-335 AND PHE-339.
RX   PubMed=9207783; DOI=10.1038/ng0797-221;
RA   Ansari-Lari M.A., Liu X.-M., Metzker M.L., Rut A.R., Gibbs R.A.;
RT   "The extent of genetic variation in the CCR5 gene.";
RL   Nat. Genet. 16:221-222(1997).
RN   [32]
RP   VARIANTS LEU-12; SER-20; SER-29; PHE-42; GLN-55; SER-60; VAL-73; GLN-223;
RP   LYS-228 DEL; VAL-301; VAL-335 AND PHE-339, AND ASSOCIATION WITH
RP   SUSCEPTIBILITY TO HIV-1.
RX   PubMed=9399903; DOI=10.1086/301645;
RA   Carrington M., Kissner T., Gerrard B., Ivanov S., O'Brien S.J., Dean M.;
RT   "Novel alleles of the chemokine-receptor gene CCR5.";
RL   Am. J. Hum. Genet. 61:1261-1267(1997).
RN   [33]
RP   CHARACTERIZATION OF VARIANT SER-60.
RX   PubMed=11369664; DOI=10.1182/blood.v97.11.3651;
RA   Tamasauskas D., Powell V., Saksela K., Yazdanbakhsh K.;
RT   "A homologous naturally occurring mutation in Duffy and CCR5 leading to
RT   reduced receptor expression.";
RL   Blood 97:3651-3654(2001).
RN   [34]
RP   INVOLVEMENT IN RESISTANCE TO HIV-1 INFECTION, VARIANT ARG-106, AND
RP   CHARACTERIZATION OF VARIANTS ARG-106 AND ARG-178.
RX   PubMed=17092330; DOI=10.1186/1742-4690-3-81;
RA   Saez-Cirion A., Versmisse P., Truong L.X., Chakrabarti L.A., Carpentier W.,
RA   Barre-Sinoussi F., Scott-Algara D., Pancino G.;
RT   "Persistent resistance to HIV-1 infection in CD4 T cells from exposed
RT   uninfected Vietnamese individuals is mediated by entry and post-entry
RT   blocks.";
RL   Retrovirology 3:81-81(2006).
RN   [35]
RP   INVOLVEMENT IN IDDM22.
RX   PubMed=19073967; DOI=10.1056/nejmoa0807917;
RA   Smyth D.J., Plagnol V., Walker N.M., Cooper J.D., Downes K., Yang J.H.M.,
RA   Howson J.M.M., Stevens H., McManus R., Wijmenga C., Heap G.A., Dubois P.C.,
RA   Clayton D.G., Hunt K.A., van Heel D.A., Todd J.A.;
RT   "Shared and distinct genetic variants in type 1 diabetes and celiac
RT   disease.";
RL   N. Engl. J. Med. 359:2767-2777(2008).
CC   -!- FUNCTION: Receptor for a number of inflammatory CC-chemokines including
CC       CCL3/MIP-1-alpha, CCL4/MIP-1-beta and RANTES and subsequently
CC       transduces a signal by increasing the intracellular calcium ion level.
CC       May play a role in the control of granulocytic lineage proliferation or
CC       differentiation. {ECO:0000269|PubMed:10383387,
CC       ECO:0000269|PubMed:11323418, ECO:0000269|PubMed:8639485,
CC       ECO:0000269|PubMed:8663314, ECO:0000269|PubMed:8699119}.
CC   -!- FUNCTION: (Microbial infection) Acts as a coreceptor (CD4 being the
CC       primary receptor) of human immunodeficiency virus-1/HIV-1.
CC       {ECO:0000269|PubMed:10383387, ECO:0000269|PubMed:21763489,
CC       ECO:0000269|PubMed:8649511, ECO:0000269|PubMed:8649512,
CC       ECO:0000269|PubMed:9632396}.
CC   -!- SUBUNIT: Interacts with PRAF2 (PubMed:15757671). Efficient ligand
CC       binding to CCL3/MIP-1alpha and CCL4/MIP-1beta requires sulfation, O-
CC       glycosylation and sialic acid modifications. Glycosylation on Ser-6 is
CC       required for efficient binding of CCL4 (PubMed:11733580,
CC       PubMed:8663314, PubMed:8699119, PubMed:10383387). Interacts with GRK2
CC       (PubMed:10085131). Interacts with ARRB1 and ARRB2 (PubMed:11448957,
CC       PubMed:16144840). Interacts with CNIH4 (PubMed:24405750).
CC       {ECO:0000269|PubMed:10085131, ECO:0000269|PubMed:10383387,
CC       ECO:0000269|PubMed:11448957, ECO:0000269|PubMed:11733580,
CC       ECO:0000269|PubMed:15757671, ECO:0000269|PubMed:16144840,
CC       ECO:0000269|PubMed:24405750, ECO:0000269|PubMed:8663314,
CC       ECO:0000269|PubMed:8699119}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with HIV-1 surface protein
CC       gp120. {ECO:0000269|PubMed:21763489, ECO:0000269|PubMed:9632396}.
CC   -!- SUBUNIT: (Microbial infection) May interact with human
CC       cytomegalovirus/HHV-5 protein UL78. {ECO:0000269|PubMed:22496149}.
CC   -!- INTERACTION:
CC       P51681; Q16570-2: ACKR1; NbExp=3; IntAct=EBI-489374, EBI-21403047;
CC       P51681; Q92583: CCL17; NbExp=2; IntAct=EBI-489374, EBI-16640146;
CC       P51681; PRO_0000005165 [P13236]: CCL4; NbExp=2; IntAct=EBI-489374, EBI-6625160;
CC       P51681; P13501: CCL5; NbExp=6; IntAct=EBI-489374, EBI-2848366;
CC       P51681; P51681: CCR5; NbExp=3; IntAct=EBI-489374, EBI-489374;
CC       P51681; P01730: CD4; NbExp=3; IntAct=EBI-489374, EBI-353826;
CC       P51681; P61073: CXCR4; NbExp=4; IntAct=EBI-489374, EBI-489411;
CC       P51681; P54849: EMP1; NbExp=3; IntAct=EBI-489374, EBI-4319440;
CC       P51681; O54081: lukE; Xeno; NbExp=2; IntAct=EBI-489374, EBI-16027720;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10383387,
CC       ECO:0000269|PubMed:11323418}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:11323418}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in spleen, thymus, in the myeloid
CC       cell line THP-1, in the promyeloblastic cell line KG-1a and on CD4+ and
CC       CD8+ T-cells. Medium levels in peripheral blood leukocytes and in small
CC       intestine. Low levels in ovary and lung. {ECO:0000269|PubMed:8639485,
CC       ECO:0000269|PubMed:8663314}.
CC   -!- INDUCTION: (Microbial infection) May be down-regulated by human
CC       cytomegalovirus/HHV-5 protein UL78. {ECO:0000269|PubMed:22496149}.
CC   -!- PTM: Sulfated on at least 2 of the N-terminal tyrosines. Sulfation
CC       contributes to the efficiency of HIV-1 entry and is required for
CC       efficient binding of the chemokines, CCL3 and CCL4.
CC       {ECO:0000269|PubMed:10089882, ECO:0000269|PubMed:11733580,
CC       ECO:0000269|PubMed:21763489}.
CC   -!- PTM: O-glycosylated, but not N-glycosylated. Ser-6 appears to be the
CC       major site. Also sialylated glycans present which contribute to
CC       chemokine binding. Thr-16 and Ser-17 may also be glycosylated and, if
CC       so, with small moieties such as a T-antigen.
CC       {ECO:0000269|PubMed:10089882, ECO:0000269|PubMed:11733580}.
CC   -!- PTM: Palmitoylation in the C-terminal is important for cell surface
CC       expression, and to a lesser extent, for HIV entry.
CC       {ECO:0000269|PubMed:11323418}.
CC   -!- PTM: Phosphorylation on serine residues in the C-terminal is stimulated
CC       by binding CC chemokines especially by APO-RANTES.
CC       {ECO:0000269|PubMed:10085131}.
CC   -!- POLYMORPHISM: Variations in CCR5 are associated with resistance or
CC       susceptibility to immunodeficiency virus type 1 (resistance or
CC       susceptibility to HIV-1) [MIM:609423]. Variations in CCR5 gene also
CC       influence the rate of progression to AIDS after infection.
CC       {ECO:0000269|PubMed:17092330, ECO:0000269|PubMed:8751444,
CC       ECO:0000269|PubMed:8756719}.
CC   -!- POLYMORPHISM: Ser-60 variant, a naturally occurring mutation in a
CC       conserved residue in the first intracellular domain of CCR5, results in
CC       reduced amounts of the protein in the membrane and consequently may be
CC       associated with reduced susceptibility to infection by microbes that
CC       depend on these molecules as their receptors.
CC       {ECO:0000269|PubMed:11369664}.
CC   -!- POLYMORPHISM: Variations in CCR5 are associated with susceptibility to
CC       West Nile virus (WNV) infection [MIM:610379].
CC       {ECO:0000269|PubMed:16418398}.
CC   -!- DISEASE: Diabetes mellitus, insulin-dependent, 22 (IDDM22)
CC       [MIM:612522]: A multifactorial disorder of glucose homeostasis that is
CC       characterized by susceptibility to ketoacidosis in the absence of
CC       insulin therapy. Clinical features are polydipsia, polyphagia and
CC       polyuria which result from hyperglycemia-induced osmotic diuresis and
CC       secondary thirst. These derangements result in long-term complications
CC       that affect the eyes, kidneys, nerves, and blood vessels.
CC       {ECO:0000269|PubMed:19073967}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=CC chemokine receptors entry;
CC       URL="https://en.wikipedia.org/wiki/CC_chemokine_receptors";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=CCR5 receptor entry;
CC       URL="https://en.wikipedia.org/wiki/CCR5";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X91492; CAA62796.1; -; Genomic_DNA.
DR   EMBL; U54994; AAC50598.1; -; mRNA.
DR   EMBL; U57840; AAB17071.1; -; mRNA.
DR   EMBL; U83326; AAC51797.1; -; Genomic_DNA.
DR   EMBL; AF011500; AAB65700.1; -; mRNA.
DR   EMBL; AF011501; AAB65701.1; -; mRNA.
DR   EMBL; AF011502; AAB65702.1; -; mRNA.
DR   EMBL; AF011503; AAB65703.1; -; mRNA.
DR   EMBL; AF011505; AAB65705.1; -; mRNA.
DR   EMBL; AF011506; AAB65706.1; -; mRNA.
DR   EMBL; AF011507; AAB65707.1; -; mRNA.
DR   EMBL; AF011508; AAB65708.1; -; mRNA.
DR   EMBL; AF011509; AAB65709.1; -; mRNA.
DR   EMBL; AF011510; AAB65710.1; -; mRNA.
DR   EMBL; AF011511; AAB65711.1; -; mRNA.
DR   EMBL; AF011512; AAB65712.1; -; mRNA.
DR   EMBL; AF011513; AAB65713.1; -; mRNA.
DR   EMBL; AF011514; AAB65714.1; -; mRNA.
DR   EMBL; AF011515; AAB65715.1; -; mRNA.
DR   EMBL; AF011516; AAB65716.1; -; mRNA.
DR   EMBL; AF011517; AAB65717.1; -; mRNA.
DR   EMBL; AF011518; AAB65718.1; -; mRNA.
DR   EMBL; AF011519; AAB65719.1; -; mRNA.
DR   EMBL; AF011520; AAB65720.1; -; mRNA.
DR   EMBL; AF011521; AAB65721.1; -; mRNA.
DR   EMBL; AF011522; AAB65722.1; -; mRNA.
DR   EMBL; AF011523; AAB65723.1; -; mRNA.
DR   EMBL; AF011524; AAB65724.1; -; mRNA.
DR   EMBL; AF011525; AAB65725.1; -; mRNA.
DR   EMBL; AF011526; AAB65726.1; -; mRNA.
DR   EMBL; AF011527; AAB65727.1; -; mRNA.
DR   EMBL; AF011528; AAB65728.1; -; mRNA.
DR   EMBL; AF011529; AAB65729.1; -; mRNA.
DR   EMBL; AF011530; AAB65730.1; -; mRNA.
DR   EMBL; AF011531; AAB65731.1; -; mRNA.
DR   EMBL; AF011532; AAB65732.1; -; mRNA.
DR   EMBL; AF011533; AAB65733.1; -; mRNA.
DR   EMBL; AF011534; AAB65734.1; -; mRNA.
DR   EMBL; AF011535; AAB65735.1; -; mRNA.
DR   EMBL; AF011536; AAB65736.1; -; mRNA.
DR   EMBL; AF011537; AAB65737.1; -; mRNA.
DR   EMBL; AF031237; AAB94735.1; -; Genomic_DNA.
DR   EMBL; AF052539; AAD18131.1; -; Genomic_DNA.
DR   EMBL; AY221093; AAO65971.1; -; Genomic_DNA.
DR   EMBL; U95626; AAB57793.1; -; Genomic_DNA.
DR   EMBL; BC038398; AAH38398.1; -; mRNA.
DR   CCDS; CCDS2739.1; -.
DR   PIR; A43113; A43113.
DR   RefSeq; NP_000570.1; NM_000579.3.
DR   RefSeq; NP_001093638.1; NM_001100168.1.
DR   PDB; 1ND8; Model; -; A=1-352.
DR   PDB; 1NE0; Model; -; A=1-352.
DR   PDB; 1OPN; Model; -; A=1-352.
DR   PDB; 1OPT; Model; -; A=1-352.
DR   PDB; 1OPW; Model; -; A=1-352.
DR   PDB; 2L87; NMR; -; A=1-27.
DR   PDB; 2MZX; NMR; -; A=186-195.
DR   PDB; 2RLL; NMR; -; A=7-15.
DR   PDB; 2RRS; NMR; -; A=157-174.
DR   PDB; 4MBS; X-ray; 2.71 A; A/B=2-352.
DR   PDB; 5UIW; X-ray; 2.20 A; A=2-352.
DR   PDB; 5YD3; X-ray; 1.35 A; B/D/F/H=11-19.
DR   PDB; 5YD4; X-ray; 1.35 A; B/D/F/H=11-19.
DR   PDB; 5YD5; X-ray; 1.96 A; B/D=11-19.
DR   PDB; 5YY4; X-ray; 1.59 A; B=11-19.
DR   PDB; 6FGP; NMR; -; A=1-27.
DR   PDB; 6MEO; EM; 3.90 A; B=1-313.
DR   PDB; 6MET; EM; 4.50 A; B=1-313.
DR   PDBsum; 1ND8; -.
DR   PDBsum; 1NE0; -.
DR   PDBsum; 1OPN; -.
DR   PDBsum; 1OPT; -.
DR   PDBsum; 1OPW; -.
DR   PDBsum; 2L87; -.
DR   PDBsum; 2MZX; -.
DR   PDBsum; 2RLL; -.
DR   PDBsum; 2RRS; -.
DR   PDBsum; 4MBS; -.
DR   PDBsum; 5UIW; -.
DR   PDBsum; 5YD3; -.
DR   PDBsum; 5YD4; -.
DR   PDBsum; 5YD5; -.
DR   PDBsum; 5YY4; -.
DR   PDBsum; 6FGP; -.
DR   PDBsum; 6MEO; -.
DR   PDBsum; 6MET; -.
DR   BMRB; P51681; -.
DR   SMR; P51681; -.
DR   BioGRID; 107639; 18.
DR   DIP; DIP-5866N; -.
DR   IntAct; P51681; 17.
DR   MINT; P51681; -.
DR   STRING; 9606.ENSP00000292303; -.
DR   BindingDB; P51681; -.
DR   ChEMBL; CHEMBL274; -.
DR   DrugBank; DB05501; AMD-070.
DR   DrugBank; DB06497; Aplaviroc.
DR   DrugBank; DB05906; CCR5 mAb.
DR   DrugBank; DB12698; Ibalizumab.
DR   DrugBank; DB12960; INCB-9471.
DR   DrugBank; DB05941; Leronlimab.
DR   DrugBank; DB04835; Maraviroc.
DR   DrugBank; DB06652; Vicriviroc.
DR   DrugCentral; P51681; -.
DR   GuidetoPHARMACOLOGY; 62; -.
DR   GlyGen; P51681; 4 sites.
DR   iPTMnet; P51681; -.
DR   PhosphoSitePlus; P51681; -.
DR   SwissPalm; P51681; -.
DR   BioMuta; CCR5; -.
DR   DMDM; 1705896; -.
DR   jPOST; P51681; -.
DR   MassIVE; P51681; -.
DR   PaxDb; P51681; -.
DR   PeptideAtlas; P51681; -.
DR   PRIDE; P51681; -.
DR   ProteomicsDB; 56367; -.
DR   ABCD; P51681; 37 sequenced antibodies.
DR   Antibodypedia; 29674; 1694 antibodies.
DR   Ensembl; ENST00000292303; ENSP00000292303; ENSG00000160791.
DR   Ensembl; ENST00000445772; ENSP00000404881; ENSG00000160791.
DR   GeneID; 1234; -.
DR   KEGG; hsa:1234; -.
DR   CTD; 1234; -.
DR   DisGeNET; 1234; -.
DR   EuPathDB; HostDB:ENSG00000160791.13; -.
DR   GeneCards; CCR5; -.
DR   HGNC; HGNC:1606; CCR5.
DR   HPA; ENSG00000160791; Tissue enhanced (blood).
DR   MalaCards; CCR5; -.
DR   MIM; 601373; gene.
DR   MIM; 609423; phenotype.
DR   MIM; 610379; phenotype.
DR   MIM; 612522; phenotype.
DR   neXtProt; NX_P51681; -.
DR   OpenTargets; ENSG00000160791; -.
DR   Orphanet; 319269; Susceptibility/resistance to HIV infection.
DR   PharmGKB; PA26170; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT01000000214577; -.
DR   HOGENOM; CLU_009579_8_3_1; -.
DR   InParanoid; P51681; -.
DR   KO; K04180; -.
DR   OMA; HFWKNFQ; -.
DR   OrthoDB; 937138at2759; -.
DR   PhylomeDB; P51681; -.
DR   TreeFam; TF330966; -.
DR   PathwayCommons; P51681; -.
DR   Reactome; R-HSA-173107; Binding and entry of HIV virion.
DR   Reactome; R-HSA-380108; Chemokine receptors bind chemokines.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-6783783; Interleukin-10 signaling.
DR   SignaLink; P51681; -.
DR   SIGNOR; P51681; -.
DR   BioGRID-ORCS; 1234; 6 hits in 873 CRISPR screens.
DR   EvolutionaryTrace; P51681; -.
DR   GeneWiki; CCR5; -.
DR   GenomeRNAi; 1234; -.
DR   Pharos; P51681; Tclin.
DR   PRO; PR:P51681; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; P51681; protein.
DR   Bgee; ENSG00000160791; Expressed in visceral pleura and 172 other tissues.
DR   ExpressionAtlas; P51681; baseline and differential.
DR   Genevisible; P51681; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005768; C:endosome; IDA:UniProtKB.
DR   GO; GO:0009897; C:external side of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0003779; F:actin binding; IDA:UniProtKB.
DR   GO; GO:0019957; F:C-C chemokine binding; IPI:UniProtKB.
DR   GO; GO:0016493; F:C-C chemokine receptor activity; IDA:UniProtKB.
DR   GO; GO:0071791; F:chemokine (C-C motif) ligand 5 binding; IPI:UniProtKB.
DR   GO; GO:0019956; F:chemokine binding; IBA:GO_Central.
DR   GO; GO:0004950; F:chemokine receptor activity; TAS:ProtInc.
DR   GO; GO:0015026; F:coreceptor activity; TAS:ProtInc.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004435; F:phosphatidylinositol phospholipase C activity; TAS:ProtInc.
DR   GO; GO:0001618; F:virus receptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0006816; P:calcium ion transport; IDA:UniProtKB.
DR   GO; GO:0019722; P:calcium-mediated signaling; IDA:UniProtKB.
DR   GO; GO:0060326; P:cell chemotaxis; IBA:GO_Central.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0007267; P:cell-cell signaling; IDA:UniProtKB.
DR   GO; GO:0006968; P:cellular defense response; TAS:ProtInc.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IEP:UniProtKB.
DR   GO; GO:0006935; P:chemotaxis; IBA:GO_Central.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; TAS:Reactome.
DR   GO; GO:0002407; P:dendritic cell chemotaxis; TAS:BHF-UCL.
DR   GO; GO:0019064; P:fusion of virus membrane with host plasma membrane; TAS:Reactome.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0006955; P:immune response; IBA:GO_Central.
DR   GO; GO:0006954; P:inflammatory response; IBA:GO_Central.
DR   GO; GO:0000165; P:MAPK cascade; IEP:UniProtKB.
DR   GO; GO:2000110; P:negative regulation of macrophage apoptotic process; IEA:Ensembl.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; IBA:GO_Central.
DR   GO; GO:0014808; P:release of sequestered calcium ion into cytosol by sarcoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0070723; P:response to cholesterol; IMP:UniProtKB.
DR   GO; GO:0023052; P:signaling; IEP:UniProtKB.
DR   InterPro; IPR002240; Chemokine_CCR5.
DR   InterPro; IPR000355; Chemokine_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00657; CCCHEMOKINER.
DR   PRINTS; PR01110; CHEMOKINER5.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Diabetes mellitus; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein;
KW   Host cell receptor for virus entry; Host-virus interaction; Lipoprotein;
KW   Membrane; Palmitate; Phosphoprotein; Polymorphism; Receptor;
KW   Reference proteome; Sulfation; Transducer; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..352
FT                   /note="C-C chemokine receptor type 5"
FT                   /id="PRO_0000069257"
FT   TOPO_DOM        1..30
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        31..58
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        59..68
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        69..89
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        90..102
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        103..124
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        125..141
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        142..166
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        167..198
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        199..218
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        219..235
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        236..260
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        261..277
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        278..301
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        302..352
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         3
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000269|PubMed:10089882"
FT   MOD_RES         10
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000269|PubMed:21763489"
FT   MOD_RES         14
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000269|PubMed:21763489"
FT   MOD_RES         15
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         336
FT                   /note="Phosphoserine; by BARK1"
FT                   /evidence="ECO:0000269|PubMed:10085131"
FT   MOD_RES         337
FT                   /note="Phosphoserine; by BARK1"
FT                   /evidence="ECO:0000269|PubMed:10085131"
FT   MOD_RES         342
FT                   /note="Phosphoserine; by BARK1"
FT                   /evidence="ECO:0000269|PubMed:10085131"
FT   MOD_RES         349
FT                   /note="Phosphoserine; by BARK1"
FT                   /evidence="ECO:0000269|PubMed:10085131"
FT   LIPID           321
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:11323418"
FT   LIPID           323
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:11323418"
FT   LIPID           324
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:11323418"
FT   CARBOHYD        6
FT                   /note="O-linked (GalNAc...) serine"
FT                   /evidence="ECO:0000269|PubMed:11733580"
FT   CARBOHYD        7
FT                   /note="O-linked (GalNAc...) serine"
FT                   /evidence="ECO:0000305|PubMed:10089882"
FT   CARBOHYD        16
FT                   /note="O-linked (GalNAc...) threonine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        17
FT                   /note="O-linked (GalNAc...) serine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        20..269
FT                   /evidence="ECO:0000244|PDB:4MBS, ECO:0000244|PDB:5UIW"
FT   DISULFID        101..178
FT                   /evidence="ECO:0000244|PDB:4MBS, ECO:0000244|PDB:5UIW,
FT                   ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VARIANT         10
FT                   /note="Y -> D (in INCCR5-71A; results in absent sulfation
FT                   and greatly decreased binding CCL4 and CCL5 when associated
FT                   with D-3, D-10 and D-15; restored most CCL4 binding when
FT                   associated with D-3 and D-15)"
FT                   /evidence="ECO:0000269|PubMed:11733580"
FT                   /id="VAR_003481"
FT   VARIANT         12
FT                   /note="I -> L"
FT                   /evidence="ECO:0000269|PubMed:9399903"
FT                   /id="VAR_024066"
FT   VARIANT         20
FT                   /note="C -> S (in dbSNP:rs145061115)"
FT                   /evidence="ECO:0000269|PubMed:9399903"
FT                   /id="VAR_024067"
FT   VARIANT         29
FT                   /note="A -> S (in dbSNP:rs1800939)"
FT                   /evidence="ECO:0000269|PubMed:9399903"
FT                   /id="VAR_011839"
FT   VARIANT         31
FT                   /note="R -> H (in INCCR5-72A; dbSNP:rs56340326)"
FT                   /id="VAR_003482"
FT   VARIANT         34
FT                   /note="P -> L (in TZCCR5-179)"
FT                   /id="VAR_003483"
FT   VARIANT         42
FT                   /note="I -> F (in dbSNP:rs1475319259)"
FT                   /evidence="ECO:0000269|PubMed:9399903"
FT                   /id="VAR_024068"
FT   VARIANT         55
FT                   /note="L -> Q (in dbSNP:rs1799863)"
FT                   /evidence="ECO:0000269|PubMed:9207783,
FT                   ECO:0000269|PubMed:9399903"
FT                   /id="VAR_011840"
FT   VARIANT         60
FT                   /note="R -> S (associated with susceptibility to HIV-1;
FT                   reduced surface expression and function of CCR5 protein;
FT                   dbSNP:rs1800940)"
FT                   /evidence="ECO:0000269|PubMed:11369664,
FT                   ECO:0000269|PubMed:9399903"
FT                   /id="VAR_011841"
FT   VARIANT         62
FT                   /note="K -> R (in UGCCR5-145B)"
FT                   /id="VAR_003484"
FT   VARIANT         68
FT                   /note="Y -> H (in ZWCCR5-7; dbSNP:rs758090461)"
FT                   /id="VAR_003485"
FT   VARIANT         73
FT                   /note="A -> V (in dbSNP:rs56198941)"
FT                   /evidence="ECO:0000269|PubMed:9399903"
FT                   /id="VAR_024069"
FT   VARIANT         95
FT                   /note="D -> N (in MWCCR5-107; dbSNP:rs149975182)"
FT                   /id="VAR_003486"
FT   VARIANT         97
FT                   /note="G -> E (in INCCR5-467)"
FT                   /id="VAR_003487"
FT   VARIANT         106
FT                   /note="G -> R (rare polymorphism; protects against HIV-1
FT                   infection; CD4+ T-cells from R-106 carriers are less
FT                   susceptible to infection by HIV-1 R5; results in reduced
FT                   CCR5 surface expression; dbSNP:rs183662584)"
FT                   /evidence="ECO:0000269|PubMed:17092330"
FT                   /id="VAR_080410"
FT   VARIANT         122
FT                   /note="L -> P (in ZWCCR5-7)"
FT                   /id="VAR_003488"
FT   VARIANT         158
FT                   /note="F -> S (in UGCCR5-145A)"
FT                   /id="VAR_003489"
FT   VARIANT         176
FT                   /note="Y -> C (in KECCR5-116)"
FT                   /id="VAR_003490"
FT   VARIANT         177
FT                   /note="T -> A (in INCCR5-45C)"
FT                   /id="VAR_003491"
FT   VARIANT         178
FT                   /note="C -> R (rare polymorphism; protects against HIV-1
FT                   infection; CD4+ T-cells from R-178 carriers are less
FT                   susceptible to infection by HIV-1 R5; results in reduced
FT                   CCR5 surface expression; dbSNP:rs199824195)"
FT                   /evidence="ECO:0000269|PubMed:10917742,
FT                   ECO:0000269|PubMed:17092330"
FT                   /id="VAR_012481"
FT   VARIANT         185
FT                   /note="S -> N (in UGCCR5-145A)"
FT                   /id="VAR_003492"
FT   VARIANT         210
FT                   /note="M -> V (in ZWCCR5-7)"
FT                   /id="VAR_003493"
FT   VARIANT         214
FT                   /note="Y -> C (in KECCR5-3B)"
FT                   /id="VAR_003494"
FT   VARIANT         215
FT                   /note="S -> L (in dbSNP:rs1017863136)"
FT                   /evidence="ECO:0000269|PubMed:9207783"
FT                   /id="VAR_024070"
FT   VARIANT         223
FT                   /note="R -> Q (in dbSNP:rs1800452)"
FT                   /evidence="ECO:0000269|PubMed:9207783,
FT                   ECO:0000269|PubMed:9399903"
FT                   /id="VAR_011842"
FT   VARIANT         228
FT                   /note="Missing"
FT                   /evidence="ECO:0000269|PubMed:9399903"
FT                   /id="VAR_024071"
FT   VARIANT         239
FT                   /note="T -> S (in INCCR5-71A)"
FT                   /id="VAR_003495"
FT   VARIANT         246
FT                   /note="L -> P (in UGCCR5-145A; dbSNP:rs143181119)"
FT                   /id="VAR_003496"
FT   VARIANT         288
FT                   /note="T -> M (in INCCR5-72A; dbSNP:rs534088482)"
FT                   /id="VAR_003497"
FT   VARIANT         301
FT                   /note="G -> V (in dbSNP:rs1800943)"
FT                   /evidence="ECO:0000269|PubMed:9399903"
FT                   /id="VAR_011843"
FT   VARIANT         302
FT                   /note="E -> G (in TZCCR5-179)"
FT                   /id="VAR_003498"
FT   VARIANT         303
FT                   /note="K -> E (in THCCR5-5)"
FT                   /id="VAR_003499"
FT   VARIANT         306
FT                   /note="N -> S (in MWCCR5-1567)"
FT                   /id="VAR_003500"
FT   VARIANT         322
FT                   /note="K -> R (in THCCR5-5)"
FT                   /id="VAR_003501"
FT   VARIANT         333
FT                   /note="E -> G (in THCCR5-2)"
FT                   /id="VAR_003502"
FT   VARIANT         335
FT                   /note="A -> V (in MWCCR5-1567, MWCCR5-1568, ZWCCR5-14 and
FT                   ZWCCR5-112; dbSNP:rs1800944)"
FT                   /evidence="ECO:0000269|PubMed:9207783,
FT                   ECO:0000269|PubMed:9399903"
FT                   /id="VAR_003503"
FT   VARIANT         339
FT                   /note="Y -> F (in TZCCR5-181A and MWCCR5-107;
FT                   dbSNP:rs1800945)"
FT                   /evidence="ECO:0000269|PubMed:9207783,
FT                   ECO:0000269|PubMed:9399903"
FT                   /id="VAR_003504"
FT   VARIANT         345
FT                   /note="E -> G (in UGCCR5-145C)"
FT                   /id="VAR_003505"
FT   MUTAGEN         3
FT                   /note="Y->D: No sulfation and greatly decreased binding of
FT                   CCL4 and CCL5; when associated with D-10; D-14 and D-15.
FT                   Restored most CCL4 binding; when associated with D-10 and
FT                   D-15."
FT                   /evidence="ECO:0000269|PubMed:10089882,
FT                   ECO:0000269|PubMed:11733580"
FT   MUTAGEN         3
FT                   /note="Y->F: No sulfation and greatly decreases binding of
FT                   CCL4 and CCL5; when associated with F-10; F-14 and F-15."
FT                   /evidence="ECO:0000269|PubMed:10089882,
FT                   ECO:0000269|PubMed:11733580"
FT   MUTAGEN         6
FT                   /note="S->A: No change in glycosylation status and greatly
FT                   decreased CCL4 binding. Loss of molecular mass of about 2
FT                   kDa as compared to wild type. Dramatically reduced binding
FT                   of CCL4; when associated with A-7; A-16; A-17. Similar
FT                   molecular mass loss. Dramatically reduced binding of CCL4;
FT                   when associated with A-7 only."
FT                   /evidence="ECO:0000269|PubMed:11733580"
FT   MUTAGEN         7
FT                   /note="S->A: No change in glycosylation status and binds
FT                   CCL4 as efficiently as wild type. Loss of molecular mass of
FT                   about 2 kDa as compared to wild type. Dramatically reduced
FT                   binding of CCL4; when associated with A-6; A-16; A-17.
FT                   Similar molecular mass loss. Dramatically reduced binding
FT                   of CCL4; when associated with A-6 only."
FT                   /evidence="ECO:0000269|PubMed:11733580"
FT   MUTAGEN         10
FT                   /note="Y->F: No sulfation and greatly decreases binding of
FT                   CCL4 and CCL5; when associated with F-3; F-14 and F-15.
FT                   Small loss of sulfation; when associated with F-14 and F-
FT                   15."
FT                   /evidence="ECO:0000269|PubMed:10089882,
FT                   ECO:0000269|PubMed:11733580"
FT   MUTAGEN         14
FT                   /note="Y->D: No sulfation and greatly decreased binding of
FT                   CCL4 and CCL5; when associated with D-3; D-10 and D-14. No
FT                   restoration of CCL4 binding; when associated with D-10 and
FT                   D-15."
FT                   /evidence="ECO:0000269|PubMed:10089882,
FT                   ECO:0000269|PubMed:11733580"
FT   MUTAGEN         14
FT                   /note="Y->F: No sulfation and greatly decreases binding of
FT                   CCL4 and CCL5; when associated with F-3; F-10; and F-15.
FT                   Small loss of sulfation; when associated with F-10 and F-
FT                   15."
FT                   /evidence="ECO:0000269|PubMed:10089882,
FT                   ECO:0000269|PubMed:11733580"
FT   MUTAGEN         15
FT                   /note="Y->D: No sulfation and greatly decreased binding of
FT                   CCL4 and CCL5; when associated with D-3; D-10 and D-14.
FT                   Restored most CCL4 binding; when associated with D-3 and D-
FT                   10."
FT                   /evidence="ECO:0000269|PubMed:10089882,
FT                   ECO:0000269|PubMed:11733580"
FT   MUTAGEN         15
FT                   /note="Y->F: No sulfation and greatly decreases binding of
FT                   CCL4 and CCL5; when associated with F-3; F-10 and F-14.
FT                   Small loss of sulfation; when associated with F-10 and F-
FT                   14."
FT                   /evidence="ECO:0000269|PubMed:10089882,
FT                   ECO:0000269|PubMed:11733580"
FT   MUTAGEN         16
FT                   /note="T->A: Similar decrease in molecular mass when
FT                   treated with O-glycosidase as for wild type; when
FT                   associated with A-17."
FT                   /evidence="ECO:0000269|PubMed:11733580"
FT   MUTAGEN         17
FT                   /note="S->A: Similar decrease in molecular mass when
FT                   treated with O-glycosidase as for wild type; when
FT                   associated with A-16."
FT                   /evidence="ECO:0000269|PubMed:11733580"
FT   MUTAGEN         20
FT                   /note="C->A: Decreases to 40% surface expression. No effect
FT                   on conformational integrity. Disrupts binding of CCL4.
FT                   Decreases cell HIV infection."
FT                   /evidence="ECO:0000269|PubMed:10383387"
FT   MUTAGEN         101
FT                   /note="C->A: Decreases to 40% surface expression. Disrupts
FT                   conformational integrity. Disrupts binding of CCL4.
FT                   Decreases HIV cell infection."
FT                   /evidence="ECO:0000269|PubMed:10383387"
FT   MUTAGEN         178
FT                   /note="C->A: Decreases to 40% surface expression. Disrupts
FT                   conformational integrity. Disrupts binding of CCL4.
FT                   Decreases HIV cell infection."
FT                   /evidence="ECO:0000269|PubMed:10383387"
FT   MUTAGEN         269
FT                   /note="C->A: Decreases to 40% surface expression. No effect
FT                   on conformational integrity. Disrupts binding of CCL4.
FT                   Decreases cell HIV infection."
FT                   /evidence="ECO:0000269|PubMed:10383387"
FT   MUTAGEN         321
FT                   /note="C->A: Small reduction in palmitoylation. Cell
FT                   surface expression reduced by 50%. Greatly reduced
FT                   palmitoylation. Cell surface expression greatly reduced;
FT                   when associated with A-323 or A-324. No palmitoylation.
FT                   Cell surface expression greatly reduced. HIV entry reduced
FT                   by 50%; when associated with A-323 and A-324."
FT                   /evidence="ECO:0000269|PubMed:11323418"
FT   MUTAGEN         323
FT                   /note="C->A: Small reduction in palmitoylation. Cell
FT                   surface expression reduced by 50%. Greatly reduced
FT                   palmitoylation. Cell surface expression greatly reduced;
FT                   when associated with A-321 or A-324. No palmitoylation.
FT                   Cell surface expression greatly reduced. HIV entry reduced
FT                   by 50%; when associated with A-321 and A-324."
FT                   /evidence="ECO:0000269|PubMed:11323418"
FT   MUTAGEN         324
FT                   /note="C->A: Small reduction in palmitoylation. Cell
FT                   surface expression reduced by 50%. Greatly reduced
FT                   palmitoylation. Cell surface expression greatly reduced;
FT                   when associated with A-321 or A-323. No palmitoylation.
FT                   Cell surface expression greatly reduced. HIV entry reduced
FT                   by 50%; when associated with A-321 and A-323."
FT                   /evidence="ECO:0000269|PubMed:11323418"
FT   MUTAGEN         336
FT                   /note="S->A: APO-RANTES-stimulated phosphorylation reduced
FT                   by 15%; APO-RANTES-stimulated phosphorylation reduced by
FT                   30-50%; when associated with A-337 or A-342 or A-349; APO-
FT                   RANTES-stimulated phosphorylation reduced by 80%; when
FT                   associated with A-337 and A-342 or A-349; No APO-RANTES-
FT                   stimulated phosphorylation; when associated with A-337; A-
FT                   342 and A349; abolishes interaction with ARRB2; when
FT                   associated with S-337; S-342 and S-349."
FT                   /evidence="ECO:0000269|PubMed:10085131,
FT                   ECO:0000269|PubMed:11448957"
FT   MUTAGEN         337
FT                   /note="S->A: APO-RANTES-stimulated phosphorylation reduced
FT                   by 18%; APO-RANTES-stimulated phosphorylation reduced by
FT                   30-50% on APO-RANTES stimulation; when associated with A-
FT                   336 or A-342 or A-349; APO-RANTES-stimulated
FT                   phosphorylation reduced by 80%; when associated with A-336
FT                   and A-342 or A-349; No APO-RANTES-stimulated
FT                   phosphorylation; when associated with A-336; A-342 and
FT                   A349; abolishes interaction with ARRB2; when associated
FT                   with S-336; S-342 and S-349."
FT                   /evidence="ECO:0000269|PubMed:10085131,
FT                   ECO:0000269|PubMed:11448957"
FT   MUTAGEN         342
FT                   /note="S->A: APO-RANTES-stimulated phosphorylation reduced
FT                   by 42%. Phosphorylation reduced by 50% on APO-RANTES
FT                   stimulation; when associated with A-336 or A-337 or A-349;
FT                   APO-RANTES-stimulated phosphorylation reduced by 80% when
FT                   associated with A-336 and A-337 or A-349; No APO-RANTES-
FT                   stimulated phosphorylation; when associated with A-336; A-
FT                   337 and A349; abolishes interaction with ARRB2; when
FT                   associated with S-336; S-337 and S-349."
FT                   /evidence="ECO:0000269|PubMed:10085131,
FT                   ECO:0000269|PubMed:11448957"
FT   MUTAGEN         349
FT                   /note="S->A: APO-RANTES-stimulated phosphorylation reduced
FT                   by 43%; APO-RANTES-stimulated phosphorylation reduced by
FT                   30-50%; when associated with A-336 or A-337 or A-342; APO-
FT                   RANTES-stimulated phosphorylation reduced by 80%; when
FT                   associated with A-336 and A-337 or A-342; No APO-RANTES-
FT                   stimulated phosphorylation stimulation; when associated
FT                   with A-336; A-337 and A347; abolishes interaction with
FT                   ARRB2; when associated with S-336; S-337 and S-342."
FT                   /evidence="ECO:0000269|PubMed:10085131,
FT                   ECO:0000269|PubMed:11448957"
FT   HELIX           10..13
FT                   /evidence="ECO:0000244|PDB:2L87"
FT   HELIX           14..17
FT                   /evidence="ECO:0000244|PDB:2L87"
FT   TURN            20..22
FT                   /evidence="ECO:0000244|PDB:2L87"
FT   HELIX           23..57
FT                   /evidence="ECO:0000244|PDB:5UIW"
FT   HELIX           64..91
FT                   /evidence="ECO:0000244|PDB:5UIW"
FT   HELIX           97..131
FT                   /evidence="ECO:0000244|PDB:5UIW"
FT   TURN            133..135
FT                   /evidence="ECO:0000244|PDB:5UIW"
FT   HELIX           136..139
FT                   /evidence="ECO:0000244|PDB:5UIW"
FT   HELIX           142..165
FT                   /evidence="ECO:0000244|PDB:5UIW"
FT   STRAND          167..172
FT                   /evidence="ECO:0000244|PDB:5UIW"
FT   STRAND          175..180
FT                   /evidence="ECO:0000244|PDB:5UIW"
FT   HELIX           184..186
FT                   /evidence="ECO:0000244|PDB:5UIW"
FT   HELIX           187..202
FT                   /evidence="ECO:0000244|PDB:5UIW"
FT   HELIX           204..221
FT                   /evidence="ECO:0000244|PDB:5UIW"
FT   HELIX           227..259
FT                   /evidence="ECO:0000244|PDB:5UIW"
FT   TURN            260..265
FT                   /evidence="ECO:0000244|PDB:5UIW"
FT   HELIX           269..288
FT                   /evidence="ECO:0000244|PDB:5UIW"
FT   HELIX           289..291
FT                   /evidence="ECO:0000244|PDB:5UIW"
FT   HELIX           292..299
FT                   /evidence="ECO:0000244|PDB:5UIW"
FT   HELIX           302..313
FT                   /evidence="ECO:0000244|PDB:5UIW"
SQ   SEQUENCE   352 AA;  40524 MW;  88ECE1F38E6D45A7 CRC64;
     MDYQVSSPIY DINYYTSEPC QKINVKQIAA RLLPPLYSLV FIFGFVGNML VILILINCKR
     LKSMTDIYLL NLAISDLFFL LTVPFWAHYA AAQWDFGNTM CQLLTGLYFI GFFSGIFFII
     LLTIDRYLAV VHAVFALKAR TVTFGVVTSV ITWVVAVFAS LPGIIFTRSQ KEGLHYTCSS
     HFPYSQYQFW KNFQTLKIVI LGLVLPLLVM VICYSGILKT LLRCRNEKKR HRAVRLIFTI
     MIVYFLFWAP YNIVLLLNTF QEFFGLNNCS SSNRLDQAMQ VTETLGMTHC CINPIIYAFV
     GEKFRNYLLV FFQKHIAKRF CKCCSIFQQE APERASSVYT RSTGEQEISV GL
//
ID   CNR1_HUMAN              Reviewed;         472 AA.
AC   P21554; B2R9T4; E1P512; Q13949; Q495Z0; Q4PLI4; Q4VBM6; Q5JVL5; Q5UB37;
AC   Q9UNN0;
DT   01-MAY-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1991, sequence version 1.
DT   07-OCT-2020, entry version 209.
DE   RecName: Full=Cannabinoid receptor 1;
DE            Short=CB-R;
DE            Short=CB1;
DE   AltName: Full=CANN6;
GN   Name=CNR1; Synonyms=CNR;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain stem;
RX   PubMed=2263478; DOI=10.1093/nar/18.23.7142;
RA   Gerard C., Mollereau C., Vassart G., Parmentier M.;
RT   "Nucleotide sequence of a human cannabinoid receptor cDNA.";
RL   Nucleic Acids Res. 18:7142-7142(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RC   TISSUE=Brain stem;
RX   PubMed=1718258; DOI=10.1042/bj2790129;
RA   Gerard C., Mollereau C., Vassart G., Parmentier M.;
RT   "Molecular cloning of a human cannabinoid receptor which is also expressed
RT   in testis.";
RL   Biochem. J. 279:129-134(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Lung;
RX   PubMed=7876112; DOI=10.1074/jbc.270.8.3726;
RA   Shire D., Carillon C., Kaghad M., Calandra B., Rinaldi-Carmona M.,
RA   Le Fur G., Caput D., Ferrara P.;
RT   "An amino-terminal variant of the central cannabinoid receptor resulting
RT   from alternative splicing.";
RL   J. Biol. Chem. 270:3726-3731(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), FUNCTION (ISOFORMS 1; 2 AND 3), AND
RP   TISSUE SPECIFICITY.
RC   TISSUE=Fetal brain;
RX   PubMed=15620723; DOI=10.1016/j.febslet.2004.11.085;
RA   Ryberg E., Vu H.K., Larsson N., Groblewski T., Hjorth S., Elebring T.,
RA   Sjoegren S., Greasley P.J.;
RT   "Identification and characterisation of a novel splice variant of the human
RT   CB1 receptor.";
RL   FEBS Lett. 579:259-264(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Hippocampus;
RA   Kathmann M., Schlicker E.;
RL   Submitted (NOV-1998) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Bonner T.I.;
RL   Submitted (NOV-1996) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain tumor;
RA   Kumar S., Gupta S., Sharma G.;
RL   Submitted (MAY-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Hippocampus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH CNRIP1.
RC   TISSUE=Brain;
RX   PubMed=17895407; DOI=10.1124/mol.107.039263;
RA   Niehaus J.L., Liu Y., Wallis K.T., Egertova M., Bhartur S.G.,
RA   Mukhopadhyay S., Shi S., He H., Selley D.E., Howlett A.C., Elphick M.R.,
RA   Lewis D.L.;
RT   "CB1 cannabinoid receptor activity is modulated by the cannabinoid receptor
RT   interacting protein CRIP 1a.";
RL   Mol. Pharmacol. 72:1557-1566(2007).
RN   [14]
RP   FUNCTION, SUBCELLULAR LOCATION, PALMITOYLATION AT CYS-415, AND MUTAGENESIS
RP   OF CYS-415.
RX   PubMed=21895628; DOI=10.1111/j.1476-5381.2011.01658.x;
RA   Oddi S., Dainese E., Sandiford S., Fezza F., Lanuti M., Chiurchiu V.,
RA   Totaro A., Catanzaro G., Barcaroli D., De Laurenzi V., Centonze D.,
RA   Mukhopadhyay S., Selent J., Howlett A.C., Maccarrone M.;
RT   "Effects of palmitoylation of Cys(415) in helix 8 of the CB(1) cannabinoid
RT   receptor on membrane localization and signalling.";
RL   Br. J. Pharmacol. 165:2635-2651(2012).
RN   [15]
RP   INVOLVEMENT IN OBESITY.
RX   PubMed=18177726; DOI=10.1016/j.cmet.2007.11.012;
RA   Addy C., Wright H., Van Laere K., Gantz I., Erondu N., Musser B.J., Lu K.,
RA   Yuan J., Sanabria-Bohorquez S.M., Stoch A., Stevens C., Fong T.M.,
RA   De Lepeleire I., Cilissen C., Cote J., Rosko K., Gendrano I.N. III,
RA   Nguyen A.M., Gumbiner B., Rothenberg P., de Hoon J., Bormans G., Depre M.,
RA   Eng W.S., Ravussin E., Klein S., Blundell J., Herman G.A., Burns H.D.,
RA   Hargreaves R.J., Wagner J., Gottesdiener K., Amatruda J.M.,
RA   Heymsfield S.B.;
RT   "The acyclic CB1R inverse agonist taranabant mediates weight loss by
RT   increasing energy expenditure and decreasing caloric intake.";
RL   Cell Metab. 7:68-78(2008).
RN   [16]
RP   FUNCTION, AND INDUCTION BY ENDOCANNABINOID ANANDAMIDE.
RX   PubMed=23955712; DOI=10.1038/nm.3265;
RA   Jourdan T., Godlewski G., Cinar R., Bertola A., Szanda G., Liu J., Tam J.,
RA   Han T., Mukhopadhyay B., Skarulis M.C., Ju C., Aouadi M., Czech M.P.,
RA   Kunos G.;
RT   "Activation of the Nlrp3 inflammasome in infiltrating macrophages by
RT   endocannabinoids mediates beta cell loss in type 2 diabetes.";
RL   Nat. Med. 19:1132-1140(2013).
RN   [17]
RP   STRUCTURE BY NMR OF 338-346, INTERACTION WITH GNAI1, AND MUTAGENESIS OF
RP   341-LEU-ALA-342.
RX   PubMed=12237474; DOI=10.1110/ps.0218402;
RA   Ulfers A.L., McMurry J.L., Miller A., Wang L., Kendall D.A., Mierke D.F.;
RT   "Cannabinoid receptor-G protein interactions: G(alphai1)-bound structures
RT   of IC3 and a mutant with altered G protein specificity.";
RL   Protein Sci. 11:2526-2531(2002).
RN   [18] {ECO:0000244|PDB:5TGZ}
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 99-306 AND 332-414, FUNCTION, AND
RP   TOPOLOGY.
RX   PubMed=27768894; DOI=10.1016/j.cell.2016.10.004;
RA   Hua T., Vemuri K., Pu M., Qu L., Han G.W., Wu Y., Zhao S., Shui W., Li S.,
RA   Korde A., Laprairie R.B., Stahl E.L., Ho J.H., Zvonok N., Zhou H.,
RA   Kufareva I., Wu B., Zhao Q., Hanson M.A., Bohn L.M., Makriyannis A.,
RA   Stevens R.C., Liu Z.J.;
RT   "Crystal structure of the human cannabinoid receptor CB1.";
RL   Cell 167:750-762(2016).
RN   [19] {ECO:0000244|PDB:5U09}
RP   X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 90-301 AND 334-421 IN COMPLEX
RP   WITH INVERSE AGONIST TARANABANT, MUTAGENESIS OF THR-210, TOPOLOGY, AND
RP   FUNCTION.
RX   PubMed=27851727; DOI=10.1038/nature20613;
RA   Shao Z., Yin J., Chapman K., Grzemska M., Clark L., Wang J.,
RA   Rosenbaum D.M.;
RT   "High-resolution crystal structure of the human CB1 cannabinoid receptor.";
RL   Nature 540:602-606(2016).
CC   -!- FUNCTION: G-protein coupled receptor for endogenous cannabinoids
CC       (eCBs), including N-arachidonoylethanolamide (also called anandamide or
CC       AEA) and 2-arachidonoylglycerol (2-AG), as well as phytocannabinoids,
CC       such as delta(9)-tetrahydrocannabinol (THC) (PubMed:15620723,
CC       PubMed:27768894, PubMed:27851727). Mediates many cannabinoid-induced
CC       effects, acting, among others, on food intake, memory loss,
CC       gastrointestinal motility, catalepsy, ambulatory activity, anxiety,
CC       chronic pain. Signaling typically involves reduction in cyclic AMP
CC       (PubMed:1718258, PubMed:21895628, PubMed:27768894). In the
CC       hypothalamus, may have a dual effect on mitochondrial respiration
CC       depending upon the agonist dose and possibly upon the cell type.
CC       Increases respiration at low doses, while decreases respiration at high
CC       doses. At high doses, CNR1 signal transduction involves G-protein
CC       alpha-i protein activation and subsequent inhibition of mitochondrial
CC       soluble adenylate cyclase, decrease in cyclic AMP concentration,
CC       inhibition of protein kinase A (PKA)-dependent phosphorylation of
CC       specific subunits of the mitochondrial electron transport system,
CC       including NDUFS2. In the hypothalamus, inhibits leptin-induced reactive
CC       oxygen species (ROS) formation and mediates cannabinoid-induced
CC       increase in SREBF1 and FASN gene expression. In response to
CC       cannabinoids, drives the release of orexigenic beta-endorphin, but not
CC       that of melanocyte-stimulating hormone alpha/alpha-MSH, from
CC       hypothalamic POMC neurons, hence promoting food intake. In the
CC       hippocampus, regulates cellular respiration and energy production in
CC       response to cannabinoids. Involved in cannabinoid-dependent
CC       depolarization-induced suppression of inhibition (DSI), a process in
CC       which depolarization of CA1 postsynaptic pyramidal neurons mobilizes
CC       eCBs, which retrogradely activate presynaptic CB1 receptors,
CC       transiently decreasing GABAergic inhibitory neurotransmission. Also
CC       reduces excitatory synaptic transmission (By similarity). In superior
CC       cervical ganglions and cerebral vascular smooth muscle cells, inhibits
CC       voltage-gated Ca(2+) channels in a constitutive, as well as agonist-
CC       dependent manner (PubMed:17895407). In cerebral vascular smooth muscle
CC       cells, cannabinoid-induced inhibition of voltage-gated Ca(2+) channels
CC       leads to vasodilation and decreased vascular tone (By similarity).
CC       Induces leptin production in adipocytes and reduces LRP2-mediated
CC       leptin clearance in the kidney, hence participating in hyperleptinemia.
CC       In adipose tissue, CNR1 signaling leads to increased expression of
CC       SREBF1, ACACA and FASN genes (By similarity). In the liver, activation
CC       by endocannabinoids leads to increased de novo lipogenesis and reduced
CC       fatty acid catabolism, associated with increased expression of
CC       SREBF1/SREBP-1, GCK, ACACA, ACACB and FASN genes. May also affect de
CC       novo cholesterol synthesis and HDL-cholesteryl ether uptake.
CC       Peripherally modulates energy metabolism (By similarity). In high
CC       carbohydrate diet-induced obesity, may decrease the expression of
CC       mitochondrial dihydrolipoyl dehydrogenase/DLD in striated muscles, as
CC       well as that of selected glucose/ pyruvate metabolic enzymes, hence
CC       affecting energy expenditure through mitochondrial metabolism (By
CC       similarity). In response to cannabinoid anandamide, elicits a
CC       proinflammatory response in macrophages, which involves NLRP3
CC       inflammasome activation and IL1B and IL18 secretion (By similarity). In
CC       macrophages infiltrating pancreatic islets, this process may
CC       participate in the progression of type-2 diabetes and associated loss
CC       of pancreatic beta-cells (PubMed:23955712).
CC       {ECO:0000250|UniProtKB:O02777, ECO:0000250|UniProtKB:P47746,
CC       ECO:0000269|PubMed:15620723, ECO:0000269|PubMed:1718258,
CC       ECO:0000269|PubMed:17895407, ECO:0000269|PubMed:21895628,
CC       ECO:0000269|PubMed:23955712, ECO:0000269|PubMed:27768894,
CC       ECO:0000269|PubMed:27851727}.
CC   -!- FUNCTION: [Isoform 1]: Binds both 2-AG and anandamide.
CC       {ECO:0000269|PubMed:15620723}.
CC   -!- FUNCTION: [Isoform 2]: Only binds 2-AG with high affinity. Contrary to
CC       its effect on isoform 1, 2-AG behaves as an inverse agonist on isoform
CC       2 in assays measuring GTP binding to membranes.
CC       {ECO:0000269|PubMed:15620723}.
CC   -!- FUNCTION: [Isoform 3]: Only binds 2-AG with high affinity. Contrary to
CC       its effect on isoform 1, 2-AG behaves as an inverse agonist on isoform
CC       3 in assays measuring GTP binding to membranes.
CC       {ECO:0000269|PubMed:15620723}.
CC   -!- SUBUNIT: Interacts (via C-terminus) with CNRIP1; this interaction
CC       attenuates constitutive, but not agonist-dependent, inhibition of
CC       voltage-gated Ca(2+) channels in neurons (PubMed:17895407). Associates
CC       with G protein alpha subunits, including G(i) alpha-1/GNAI1, G(i)
CC       alpha-3/GNAI3 and G(o) alpha/GNAO1; palmitoylation is important for
CC       interaction with GNAI3 and GNAO1 (PubMed:12237474).
CC       {ECO:0000269|PubMed:12237474, ECO:0000269|PubMed:17895407}.
CC   -!- INTERACTION:
CC       P21554; P29274: ADORA2A; NbExp=8; IntAct=EBI-2909859, EBI-2902702;
CC       P21554; P07550: ADRB2; NbExp=5; IntAct=EBI-2909859, EBI-491169;
CC       P21554; Q9BXU9: CALN1; NbExp=5; IntAct=EBI-2909859, EBI-12187137;
CC       P21554; P21554: CNR1; NbExp=8; IntAct=EBI-2909859, EBI-2909859;
CC       P21554; P34972: CNR2; NbExp=3; IntAct=EBI-2909859, EBI-2835940;
CC       P21554; P63096: GNAI1; NbExp=4; IntAct=EBI-2909859, EBI-618639;
CC       P21554; P63092-1: GNAS; NbExp=2; IntAct=EBI-2909859, EBI-11428973;
CC       P21554; P28223-1: HTR2A; NbExp=2; IntAct=EBI-2909859, EBI-15573967;
CC       P21554; P29066: Arrb1; Xeno; NbExp=4; IntAct=EBI-2909859, EBI-4303019;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:21895628};
CC       Multi-pass membrane protein {ECO:0000269|PubMed:27768894,
CC       ECO:0000269|PubMed:27851727}. Membrane raft
CC       {ECO:0000269|PubMed:21895628}. Mitochondrion outer membrane
CC       {ECO:0000250|UniProtKB:P47746}. Cell projection, axon
CC       {ECO:0000250|UniProtKB:P20272}. Cell junction, synapse, presynapse
CC       {ECO:0000250|UniProtKB:P20272}. Note=Unexpectedly, in the mitochondria,
CC       the C-terminus is located in the mitochondrial intermembrane space, a
CC       compartment topologically considered as extracellular. In canonical
CC       seven-transmembrane G-protein coupled receptors, the C-terminus is
CC       cytosolic (By similarity). Found on presynaptic axon terminals in some
CC       GABAergic neurons in the somatosensory cortex (By similarity).
CC       {ECO:0000250|UniProtKB:P20272, ECO:0000250|UniProtKB:P47746}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=Long;
CC         IsoId=P21554-1; Sequence=Displayed;
CC       Name=2; Synonyms=CB1a {ECO:0000303|PubMed:15620723}, Short;
CC         IsoId=P21554-2; Sequence=VSP_001868;
CC       Name=3; Synonyms=CB1b {ECO:0000303|PubMed:15620723};
CC         IsoId=P21554-3; Sequence=VSP_016529;
CC   -!- TISSUE SPECIFICITY: Widely expressed, with highest levels in fetal and
CC       adult brain. Expression levels of isoform 2 and isoform 3 are much
CC       lower than those of isoform 1. {ECO:0000269|PubMed:15620723}.
CC   -!- INDUCTION: Up-regulated by endocannabinoid anandamide.
CC       {ECO:0000269|PubMed:23955712}.
CC   -!- PTM: Palmitoylation at Cys-415 is important for recruitment at plasma
CC       membrane and lipid rafts and association with G protein alpha subunits.
CC       {ECO:0000269|PubMed:21895628}.
CC   -!- DISEASE: Obesity (OBESITY) [MIM:601665]: A condition characterized by
CC       an increase of body weight beyond the limitation of skeletal and
CC       physical requirements, as the result of excessive accumulation of body
CC       fat. {ECO:0000269|PubMed:18177726}. Note=The protein represented in
CC       this entry may be involved in disease pathogenesis. May contribute to
CC       the development of diet-induced obesity and several obesity-associated
CC       features, such as dyslipidemia and liver steatosis, regulating
CC       peripheral lipogenesis, energy expenditure and feeding behavior. CNR1
CC       inverse agonists have been shown to reduce body weight and improve
CC       metabolic abnormalities in obese subjects, although adverse
CC       neuropsychiatric effects, including anxiety, irritability, and
CC       depressed mood, halted their therapeutic development (PubMed:18177726).
CC       In obese mice, peripherally restricted CNR1 inverse agonists have been
CC       shown to normalize metabolic abnormalities, including insulin
CC       resistance and fatty liver, and to reverse leptin resistance.
CC       {ECO:0000269|PubMed:18177726}.
CC   -!- MISCELLANEOUS: High-fat diet also increases the hepatic levels of CNR1
CC       ligand anandamide, but not that of 2-arachidonoylglycerol.
CC       {ECO:0000250|UniProtKB:P47746}.
CC   -!- MISCELLANEOUS: [Isoform 2]: Dubious isoform. A putative downstream
CC       initiation AUG is used to produce isoform 2 (PubMed:1718258). The use
CC       of the first AUG (same as isoform 1) gives a truncated protein of 36
CC       AA. {ECO:0000305|PubMed:1718258}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X54937; CAA38699.1; -; mRNA.
DR   EMBL; X81120; CAA57018.1; -; mRNA.
DR   EMBL; X81121; CAA57019.1; -; mRNA.
DR   EMBL; AY766182; AAV35030.1; -; mRNA.
DR   EMBL; AF107262; AAD34320.1; -; mRNA.
DR   EMBL; U73304; AAB18200.1; -; Genomic_DNA.
DR   EMBL; DQ067455; AAY68486.1; -; mRNA.
DR   EMBL; AY225225; AAO67710.1; -; Genomic_DNA.
DR   EMBL; AL136096; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AK313908; BAG36631.1; -; mRNA.
DR   EMBL; CH471051; EAW48574.1; -; Genomic_DNA.
DR   EMBL; CH471051; EAW48575.1; -; Genomic_DNA.
DR   EMBL; CH471051; EAW48576.1; -; Genomic_DNA.
DR   EMBL; BC074811; AAH74811.1; -; mRNA.
DR   EMBL; BC074812; AAH74812.1; -; mRNA.
DR   EMBL; BC095513; AAH95513.1; -; mRNA.
DR   EMBL; BC100968; AAI00969.1; -; mRNA.
DR   EMBL; BC100969; AAI00970.1; -; mRNA.
DR   EMBL; BC100970; AAI00971.1; -; mRNA.
DR   EMBL; BC100971; AAI00972.1; -; mRNA.
DR   CCDS; CCDS5015.1; -. [P21554-1]
DR   CCDS; CCDS5016.2; -. [P21554-3]
DR   PIR; S17595; S17595.
DR   RefSeq; NP_001153698.1; NM_001160226.1. [P21554-1]
DR   RefSeq; NP_001153730.1; NM_001160258.1. [P21554-1]
DR   RefSeq; NP_001153731.1; NM_001160259.1. [P21554-1]
DR   RefSeq; NP_057167.2; NM_016083.4. [P21554-1]
DR   RefSeq; NP_149421.2; NM_033181.3. [P21554-3]
DR   RefSeq; XP_006715393.1; XM_006715330.3.
DR   RefSeq; XP_011533726.1; XM_011535424.1.
DR   RefSeq; XP_011533727.1; XM_011535425.1. [P21554-1]
DR   RefSeq; XP_011533728.1; XM_011535426.1.
DR   RefSeq; XP_011533730.1; XM_011535428.1.
DR   RefSeq; XP_016865727.1; XM_017010238.1.
DR   RefSeq; XP_016865728.1; XM_017010239.1.
DR   RefSeq; XP_016865729.1; XM_017010240.1.
DR   PDB; 1LVQ; NMR; -; A=338-346.
DR   PDB; 1LVR; NMR; -; A=338-346.
DR   PDB; 2B0Y; NMR; -; A=400-414.
DR   PDB; 2KOE; NMR; -; A=377-414.
DR   PDB; 2MZ2; NMR; -; A=400-414.
DR   PDB; 2MZ3; NMR; -; A=400-414.
DR   PDB; 2MZA; NMR; -; A=400-414.
DR   PDB; 5TGZ; X-ray; 2.80 A; A=99-306, A=332-414.
DR   PDB; 5U09; X-ray; 2.60 A; A=90-301, A=333-421.
DR   PDB; 5XR8; X-ray; 2.95 A; A=99-306, A=332-414.
DR   PDB; 5XRA; X-ray; 2.80 A; A=99-306, A=332-414.
DR   PDB; 6KPG; EM; 3.00 A; R=71-425.
DR   PDB; 6KQI; X-ray; 3.25 A; A=94-301, A=334-413.
DR   PDB; 6N4B; EM; 3.00 A; R=1-472.
DR   PDBsum; 1LVQ; -.
DR   PDBsum; 1LVR; -.
DR   PDBsum; 2B0Y; -.
DR   PDBsum; 2KOE; -.
DR   PDBsum; 2MZ2; -.
DR   PDBsum; 2MZ3; -.
DR   PDBsum; 2MZA; -.
DR   PDBsum; 5TGZ; -.
DR   PDBsum; 5U09; -.
DR   PDBsum; 5XR8; -.
DR   PDBsum; 5XRA; -.
DR   PDBsum; 6KPG; -.
DR   PDBsum; 6KQI; -.
DR   PDBsum; 6N4B; -.
DR   SMR; P21554; -.
DR   BioGRID; 107668; 7.
DR   DIP; DIP-61575N; -.
DR   IntAct; P21554; 11.
DR   STRING; 9606.ENSP00000358513; -.
DR   BindingDB; P21554; -.
DR   ChEMBL; CHEMBL218; -.
DR   DrugBank; DB05750; AVE-1625.
DR   DrugBank; DB09061; Cannabidiol.
DR   DrugBank; DB00470; Dronabinol.
DR   DrugBank; DB14009; Medical Cannabis.
DR   DrugBank; DB00486; Nabilone.
DR   DrugBank; DB14011; Nabiximols.
DR   DrugBank; DB11745; Otenabant.
DR   DrugBank; DB09288; Propacetamol.
DR   DrugBank; DB02955; Ricinoleic Acid.
DR   DrugBank; DB06155; Rimonabant.
DR   DrugBank; DB05077; SLV319.
DR   DrugBank; DB11755; Tetrahydrocannabivarin.
DR   DrugBank; DB05201; V24343.
DR   DrugCentral; P21554; -.
DR   GuidetoPHARMACOLOGY; 56; -.
DR   SwissLipids; SLP:000001607; -.
DR   TCDB; 9.A.14.2.2; the g-protein-coupled receptor (gpcr) family.
DR   GlyGen; P21554; 2 sites.
DR   iPTMnet; P21554; -.
DR   PhosphoSitePlus; P21554; -.
DR   SwissPalm; P21554; -.
DR   BioMuta; CNR1; -.
DR   DMDM; 115562; -.
DR   MassIVE; P21554; -.
DR   PaxDb; P21554; -.
DR   PeptideAtlas; P21554; -.
DR   PRIDE; P21554; -.
DR   ProteomicsDB; 53875; -. [P21554-1]
DR   ProteomicsDB; 53876; -. [P21554-2]
DR   ProteomicsDB; 53877; -. [P21554-3]
DR   ABCD; P21554; 62 sequenced antibodies.
DR   Antibodypedia; 3355; 561 antibodies.
DR   DNASU; 1268; -.
DR   Ensembl; ENST00000369499; ENSP00000358511; ENSG00000118432. [P21554-1]
DR   Ensembl; ENST00000369501; ENSP00000358513; ENSG00000118432. [P21554-1]
DR   Ensembl; ENST00000428600; ENSP00000412192; ENSG00000118432. [P21554-1]
DR   Ensembl; ENST00000468898; ENSP00000420188; ENSG00000118432. [P21554-3]
DR   Ensembl; ENST00000549890; ENSP00000446819; ENSG00000118432. [P21554-1]
DR   GeneID; 1268; -.
DR   KEGG; hsa:1268; -.
DR   CTD; 1268; -.
DR   DisGeNET; 1268; -.
DR   EuPathDB; HostDB:ENSG00000118432.12; -.
DR   GeneCards; CNR1; -.
DR   HGNC; HGNC:2159; CNR1.
DR   HPA; ENSG00000118432; Tissue enhanced (brain).
DR   MIM; 114610; gene.
DR   MIM; 601665; phenotype.
DR   neXtProt; NX_P21554; -.
DR   OpenTargets; ENSG00000118432; -.
DR   PharmGKB; PA26681; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT01000000214362; -.
DR   HOGENOM; CLU_009579_7_0_1; -.
DR   InParanoid; P21554; -.
DR   KO; K04277; -.
DR   OMA; YMGSNDI; -.
DR   PhylomeDB; P21554; -.
DR   TreeFam; TF330052; -.
DR   PathwayCommons; P21554; -.
DR   Reactome; R-HSA-373076; Class A/1 (Rhodopsin-like receptors).
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   SIGNOR; P21554; -.
DR   BioGRID-ORCS; 1268; 6 hits in 872 CRISPR screens.
DR   ChiTaRS; CNR1; human.
DR   EvolutionaryTrace; P21554; -.
DR   GeneWiki; Cannabinoid_receptor_type_1; -.
DR   GenomeRNAi; 1268; -.
DR   Pharos; P21554; Tclin.
DR   PRO; PR:P21554; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; P21554; protein.
DR   Bgee; ENSG00000118432; Expressed in subventricular zone (outer) (primate) and 174 other tissues.
DR   ExpressionAtlas; P21554; baseline and differential.
DR   Genevisible; P21554; HS.
DR   GO; GO:0015629; C:actin cytoskeleton; IDA:HPA.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0030426; C:growth cone; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0045121; C:membrane raft; IEA:UniProtKB-SubCell.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0042734; C:presynaptic membrane; IEA:Ensembl.
DR   GO; GO:0004949; F:cannabinoid receptor activity; IDA:UniProtKB.
DR   GO; GO:0008144; F:drug binding; IEA:Ensembl.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007188; P:adenylate cyclase-modulating G protein-coupled receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0007413; P:axonal fasciculation; IEA:Ensembl.
DR   GO; GO:0038171; P:cannabinoid signaling pathway; IDA:UniProtKB.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007187; P:G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; TAS:ProtInc.
DR   GO; GO:0042593; P:glucose homeostasis; IEA:Ensembl.
DR   GO; GO:0099703; P:induction of synaptic vesicle exocytosis by positive regulation of presynaptic cytosolic calcium ion concentration; IEA:GOC.
DR   GO; GO:0060135; P:maternal process involved in female pregnancy; IEA:Ensembl.
DR   GO; GO:0007613; P:memory; IEA:Ensembl.
DR   GO; GO:0045759; P:negative regulation of action potential; IEA:Ensembl.
DR   GO; GO:0045776; P:negative regulation of blood pressure; IEA:Ensembl.
DR   GO; GO:0033602; P:negative regulation of dopamine secretion; IEA:Ensembl.
DR   GO; GO:0031999; P:negative regulation of fatty acid beta-oxidation; IEA:Ensembl.
DR   GO; GO:0033004; P:negative regulation of mast cell activation; IEA:Ensembl.
DR   GO; GO:0051001; P:negative regulation of nitric-oxide synthase activity; IEA:Ensembl.
DR   GO; GO:0014063; P:negative regulation of serotonin secretion; IEA:Ensembl.
DR   GO; GO:0002866; P:positive regulation of acute inflammatory response to antigenic stimulus; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0045777; P:positive regulation of blood pressure; IEA:Ensembl.
DR   GO; GO:0031622; P:positive regulation of fever generation; IEA:Ensembl.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IEA:Ensembl.
DR   GO; GO:0060259; P:regulation of feeding behavior; IEA:Ensembl.
DR   GO; GO:0050796; P:regulation of insulin secretion; IEA:Ensembl.
DR   GO; GO:0019222; P:regulation of metabolic process; IBA:GO_Central.
DR   GO; GO:0060405; P:regulation of penile erection; IEA:Ensembl.
DR   GO; GO:0032228; P:regulation of synaptic transmission, GABAergic; IEA:Ensembl.
DR   GO; GO:0051966; P:regulation of synaptic transmission, glutamatergic; IEA:Ensembl.
DR   GO; GO:0042220; P:response to cocaine; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0043278; P:response to morphine; IEA:Ensembl.
DR   GO; GO:0035094; P:response to nicotine; IEA:Ensembl.
DR   GO; GO:0007584; P:response to nutrient; IEA:Ensembl.
DR   GO; GO:0019233; P:sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0099553; P:trans-synaptic signaling by endocannabinoid, modulating synaptic transmission; IEA:Ensembl.
DR   InterPro; IPR000810; Canbinoid_rcpt_1.
DR   InterPro; IPR002230; Cnbnoid_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   PANTHER; PTHR22750:SF47; PTHR22750:SF47; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PIRSF; PIRSF037995; Cnoid_rcpt_1; 1.
DR   PRINTS; PR00522; CANABINOID1R.
DR   PRINTS; PR00362; CANNABINOIDR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell junction; Cell membrane;
KW   Cell projection; G-protein coupled receptor; Glycoprotein; Lipoprotein;
KW   Membrane; Mitochondrion; Mitochondrion outer membrane; Obesity; Palmitate;
KW   Phosphoprotein; Receptor; Reference proteome; Synapse; Transducer;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..472
FT                   /note="Cannabinoid receptor 1"
FT                   /id="PRO_0000069314"
FT   TOPO_DOM        1..116
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:27768894,
FT                   ECO:0000269|PubMed:27851727"
FT   TRANSMEM        117..142
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000269|PubMed:27768894,
FT                   ECO:0000269|PubMed:27851727"
FT   TOPO_DOM        143..154
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:27768894,
FT                   ECO:0000269|PubMed:27851727"
FT   TRANSMEM        155..175
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000269|PubMed:27768894,
FT                   ECO:0000269|PubMed:27851727"
FT   TOPO_DOM        176..187
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:27768894,
FT                   ECO:0000269|PubMed:27851727"
FT   TRANSMEM        188..212
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000269|PubMed:27768894,
FT                   ECO:0000269|PubMed:27851727"
FT   TOPO_DOM        213..232
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:27768894,
FT                   ECO:0000269|PubMed:27851727"
FT   TRANSMEM        233..255
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000269|PubMed:27768894,
FT                   ECO:0000269|PubMed:27851727"
FT   TOPO_DOM        256..273
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:27768894,
FT                   ECO:0000269|PubMed:27851727"
FT   TRANSMEM        274..299
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000269|PubMed:27768894,
FT                   ECO:0000269|PubMed:27851727"
FT   TOPO_DOM        300..344
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:27768894,
FT                   ECO:0000269|PubMed:27851727"
FT   TRANSMEM        345..365
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000269|PubMed:27768894,
FT                   ECO:0000269|PubMed:27851727"
FT   TOPO_DOM        366..377
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000269|PubMed:27768894,
FT                   ECO:0000269|PubMed:27851727"
FT   TRANSMEM        378..399
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000269|PubMed:27768894,
FT                   ECO:0000269|PubMed:27851727"
FT   TOPO_DOM        400..472
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000269|PubMed:27768894,
FT                   ECO:0000269|PubMed:27851727"
FT   REGION          2..23
FT                   /note="Required for mitochondrial localization"
FT                   /evidence="ECO:0000250|UniProtKB:P47746"
FT   MOD_RES         425
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P47746"
FT   MOD_RES         429
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P47746"
FT   LIPID           415
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000269|PubMed:21895628"
FT   CARBOHYD        77
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        83
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         1..89
FT                   /note="MKSILDGLADTTFRTITTDLLYVGSNDIQYEDIKGDMASKLGYFPQKFPLTS
FT                   FRGSPFQEKMTAGDNPQLVPADQVNITEFYNKSLSSF -> MALQIPPSAPSPLTSCTW
FT                   AQMTFSTKTS (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:7876112"
FT                   /id="VSP_001868"
FT   VAR_SEQ         22..54
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15620723"
FT                   /id="VSP_016529"
FT   MUTAGEN         210
FT                   /note="T->A: 7-fold lower affinity for a synthetic agonist,
FT                   CP55940, possibly due the stabilization of an inactive
FT                   conformation."
FT                   /evidence="ECO:0000269|PubMed:27851727"
FT   MUTAGEN         341..342
FT                   /note="LA->AL: Loss of activity, when assayed for GNAI1
FT                   GTPase stimulatory activity."
FT                   /evidence="ECO:0000269|PubMed:12237474"
FT   MUTAGEN         415
FT                   /note="C->A: Loss of palmitoylation, marked loss of
FT                   association with lipid rafts on the plasma membrane and
FT                   loss of activity, when assayed for downstream GTP-binding
FT                   and reduction in cAMP levels."
FT                   /evidence="ECO:0000269|PubMed:21895628"
FT   CONFLICT        94
FT                   /note="E -> G (in Ref. 12; AAH95513)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        103
FT                   /note="M -> I (in Ref. 12; AAH95513)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        149
FT                   /note="C -> R (in Ref. 12; AAH95513)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        200
FT                   /note="F -> L (in Ref. 5; AAD34320)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        216
FT                   /note="I -> V (in Ref. 5; AAD34320)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        246
FT                   /note="V -> A (in Ref. 5; AAD34320)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        298
FT                   /note="L -> P (in Ref. 12; AAH95513)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        332
FT                   /note="P -> S (in Ref. 12; AAI00972)"
FT                   /evidence="ECO:0000305"
FT   HELIX           105..107
FT                   /evidence="ECO:0000244|PDB:5U09"
FT   HELIX           113..143
FT                   /evidence="ECO:0000244|PDB:5U09"
FT   HELIX           145..148
FT                   /evidence="ECO:0000244|PDB:5U09"
FT   HELIX           151..153
FT                   /evidence="ECO:0000244|PDB:5U09"
FT   HELIX           154..178
FT                   /evidence="ECO:0000244|PDB:5U09"
FT   HELIX           186..219
FT                   /evidence="ECO:0000244|PDB:5U09"
FT   TURN            221..223
FT                   /evidence="ECO:0000244|PDB:5U09"
FT   HELIX           224..227
FT                   /evidence="ECO:0000244|PDB:5U09"
FT   HELIX           230..249
FT                   /evidence="ECO:0000244|PDB:5U09"
FT   HELIX           250..253
FT                   /evidence="ECO:0000244|PDB:5U09"
FT   HELIX           257..260
FT                   /evidence="ECO:0000244|PDB:5U09"
FT   STRAND          266..268
FT                   /evidence="ECO:0000244|PDB:5U09"
FT   HELIX           273..300
FT                   /evidence="ECO:0000244|PDB:5U09"
FT   HELIX           302..305
FT                   /evidence="ECO:0000244|PDB:6KPG"
FT   HELIX           307..310
FT                   /evidence="ECO:0000244|PDB:6KPG"
FT   HELIX           334..367
FT                   /evidence="ECO:0000244|PDB:5U09"
FT   HELIX           375..400
FT                   /evidence="ECO:0000244|PDB:5U09"
FT   HELIX           402..409
FT                   /evidence="ECO:0000244|PDB:5U09"
FT   HELIX           411..415
FT                   /evidence="ECO:0000244|PDB:2B0Y"
SQ   SEQUENCE   472 AA;  52858 MW;  1D2E49061D12ABF2 CRC64;
     MKSILDGLAD TTFRTITTDL LYVGSNDIQY EDIKGDMASK LGYFPQKFPL TSFRGSPFQE
     KMTAGDNPQL VPADQVNITE FYNKSLSSFK ENEENIQCGE NFMDIECFMV LNPSQQLAIA
     VLSLTLGTFT VLENLLVLCV ILHSRSLRCR PSYHFIGSLA VADLLGSVIF VYSFIDFHVF
     HRKDSRNVFL FKLGGVTASF TASVGSLFLT AIDRYISIHR PLAYKRIVTR PKAVVAFCLM
     WTIAIVIAVL PLLGWNCEKL QSVCSDIFPH IDETYLMFWI GVTSVLLLFI VYAYMYILWK
     AHSHAVRMIQ RGTQKSIIIH TSEDGKVQVT RPDQARMDIR LAKTLVLILV VLIICWGPLL
     AIMVYDVFGK MNKLIKTVFA FCSMLCLLNS TVNPIIYALR SKDLRHAFRS MFPSCEGTAQ
     PLDNSMGDSD CLHKHANNAA SVHRAAESCI KSTVKIAKVT MSVSTDTSAE AL
//
ID   S1PR4_HUMAN             Reviewed;         384 AA.
AC   O95977; D6W612;
DT   16-FEB-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1999, sequence version 1.
DT   07-OCT-2020, entry version 164.
DE   RecName: Full=Sphingosine 1-phosphate receptor 4;
DE            Short=S1P receptor 4;
DE            Short=S1P4;
DE   AltName: Full=Endothelial differentiation G-protein coupled receptor 6;
DE   AltName: Full=Sphingosine 1-phosphate receptor Edg-6;
DE            Short=S1P receptor Edg-6;
GN   Name=S1PR4; Synonyms=EDG6;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Dendritic cell;
RX   PubMed=9790765; DOI=10.1006/geno.1998.5491;
RA   Graeler M.H., Bernhardt G., Lipp M.;
RT   "EDG6, a novel G protein-coupled receptor related to receptors for
RT   bioactive lysophospholipids, is specifically expressed in lymphoid
RT   tissue.";
RL   Genomics 53:164-169(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Blood;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   FUNCTION.
RX   PubMed=10679247; DOI=10.1006/bbrc.2000.2162;
RA   Yamazaki Y., Kon J., Sato K., Tomura H., Sato M., Yoneya T., Okazaki H.,
RA   Okajima F., Ohta H.;
RT   "Edg-6 as a putative sphingosine 1-phosphate receptor coupling to Ca(2+)
RT   signaling pathway.";
RL   Biochem. Biophys. Res. Commun. 268:583-589(2000).
RN   [6]
RP   FUNCTION.
RX   PubMed=10753843;
RA   Van Brocklyn J.R., Graeler M.H., Bernhardt G., Hobson J.P., Lipp M.,
RA   Spiegel S.;
RT   "Sphingosine-1-phosphate is a ligand for the G protein-coupled receptor
RT   EDG-6.";
RL   Blood 95:2624-2629(2000).
RN   [7]
RP   STRUCTURE BY NMR OF 105-122.
RX   PubMed=17443712; DOI=10.1002/bip.20745;
RA   Pham T.-C.T., Kriwacki R.W., Parrill A.L.;
RT   "Peptide design and structural characterization of a GPCR loop mimetic.";
RL   Biopolymers 86:298-310(2007).
CC   -!- FUNCTION: Receptor for the lysosphingolipid sphingosine 1-phosphate
CC       (S1P). S1P is a bioactive lysophospholipid that elicits diverse
CC       physiological effect on most types of cells and tissues. May be
CC       involved in cell migration processes that are specific for lymphocytes.
CC       {ECO:0000269|PubMed:10679247, ECO:0000269|PubMed:10753843}.
CC   -!- INTERACTION:
CC       O95977; P57678: GEMIN4; NbExp=3; IntAct=EBI-12194739, EBI-356700;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Specifically expressed in fetal and adult lymphoid
CC       and hematopoietic tissue as well as in lung. Considerable level of
CC       expression in adult and fetal spleen as well as adult peripheral
CC       leukocytes and lung. Lower expression in adult thymus, lymph node, bone
CC       marrow, and appendix as well as in fetal liver, thymus, and lung.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AJ000479; CAA04118.1; -; mRNA.
DR   EMBL; AY322537; AAP84350.1; -; Genomic_DNA.
DR   EMBL; CH471139; EAW69336.1; -; Genomic_DNA.
DR   EMBL; CH471139; EAW69337.1; -; Genomic_DNA.
DR   EMBL; BC014970; AAH14970.1; -; mRNA.
DR   CCDS; CCDS12105.1; -.
DR   RefSeq; NP_003766.1; NM_003775.3.
DR   PDB; 2DCO; NMR; -; A=105-118.
DR   PDBsum; 2DCO; -.
DR   SMR; O95977; -.
DR   BioGRID; 114243; 6.
DR   CORUM; O95977; -.
DR   IntAct; O95977; 3.
DR   STRING; 9606.ENSP00000246115; -.
DR   BindingDB; O95977; -.
DR   ChEMBL; CHEMBL3230; -.
DR   DrugBank; DB08868; Fingolimod.
DR   DrugCentral; O95977; -.
DR   GuidetoPHARMACOLOGY; 278; -.
DR   GlyGen; O95977; 2 sites.
DR   iPTMnet; O95977; -.
DR   PhosphoSitePlus; O95977; -.
DR   SwissPalm; O95977; -.
DR   BioMuta; S1PR4; -.
DR   jPOST; O95977; -.
DR   MassIVE; O95977; -.
DR   PaxDb; O95977; -.
DR   PeptideAtlas; O95977; -.
DR   PRIDE; O95977; -.
DR   ProteomicsDB; 51157; -.
DR   Antibodypedia; 10967; 362 antibodies.
DR   DNASU; 8698; -.
DR   Ensembl; ENST00000246115; ENSP00000246115; ENSG00000125910.
DR   GeneID; 8698; -.
DR   KEGG; hsa:8698; -.
DR   UCSC; uc002lxg.4; human.
DR   CTD; 8698; -.
DR   DisGeNET; 8698; -.
DR   EuPathDB; HostDB:ENSG00000125910.5; -.
DR   GeneCards; S1PR4; -.
DR   HGNC; HGNC:3170; S1PR4.
DR   HPA; ENSG00000125910; Group enriched (blood, bone marrow, lymphoid tissue).
DR   MIM; 603751; gene.
DR   neXtProt; NX_O95977; -.
DR   OpenTargets; ENSG00000125910; -.
DR   PharmGKB; PA162402371; -.
DR   eggNOG; ENOG502QQUE; Eukaryota.
DR   GeneTree; ENSGT01000000214392; -.
DR   HOGENOM; CLU_047979_1_1_1; -.
DR   InParanoid; O95977; -.
DR   KO; K04293; -.
DR   OMA; YVCIANI; -.
DR   OrthoDB; 981486at2759; -.
DR   PhylomeDB; O95977; -.
DR   TreeFam; TF330052; -.
DR   PathwayCommons; O95977; -.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   Reactome; R-HSA-419408; Lysosphingolipid and LPA receptors.
DR   SIGNOR; O95977; -.
DR   BioGRID-ORCS; 8698; 9 hits in 868 CRISPR screens.
DR   EvolutionaryTrace; O95977; -.
DR   GeneWiki; S1PR4; -.
DR   GenomeRNAi; 8698; -.
DR   Pharos; O95977; Tclin.
DR   PRO; PR:O95977; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   RNAct; O95977; protein.
DR   Bgee; ENSG00000125910; Expressed in blood and 154 other tissues.
DR   Genevisible; O95977; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005739; C:mitochondrion; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0008289; F:lipid binding; TAS:ProtInc.
DR   GO; GO:0038036; F:sphingosine-1-phosphate receptor activity; IEA:InterPro.
DR   GO; GO:0007202; P:activation of phospholipase C activity; TAS:ProtInc.
DR   GO; GO:0007189; P:adenylate cyclase-activating G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006955; P:immune response; TAS:ProtInc.
DR   GO; GO:0007204; P:positive regulation of cytosolic calcium ion concentration; TAS:ProtInc.
DR   GO; GO:0019222; P:regulation of metabolic process; IBA:GO_Central.
DR   InterPro; IPR004064; EDG6_rcpt.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR004061; S1P_rcpt.
DR   PANTHER; PTHR22750:SF13; PTHR22750:SF13; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR01526; EDG6RECEPTOR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01523; S1PRECEPTOR.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; G-protein coupled receptor; Glycoprotein;
KW   Lipoprotein; Membrane; Palmitate; Polymorphism; Receptor;
KW   Reference proteome; Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..384
FT                   /note="Sphingosine 1-phosphate receptor 4"
FT                   /id="PRO_0000069431"
FT   TOPO_DOM        1..50
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        51..71
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        72..84
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        85..105
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        106..117
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        118..138
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        139..161
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        162..182
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        183..206
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        207..227
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        228..252
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        253..273
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        274..288
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        289..309
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        310..384
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   LIPID           323
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        2
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        30
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VARIANT         365
FT                   /note="R -> L (in dbSNP:rs3746072)"
FT                   /id="VAR_022066"
FT   HELIX           108..111
FT                   /evidence="ECO:0000244|PDB:2DCO"
FT   STRAND          113..116
FT                   /evidence="ECO:0000244|PDB:2DCO"
SQ   SEQUENCE   384 AA;  41623 MW;  369A7BC56AB46A47 CRC64;
     MNATGTPVAP ESCQQLAAGG HSRLIVLHYN HSGRLAGRGG PEDGGLGALR GLSVAASCLV
     VLENLLVLAA ITSHMRSRRW VYYCLVNITL SDLLTGAAYL ANVLLSGART FRLAPAQWFL
     REGLLFTALA ASTFSLLFTA GERFATMVRP VAESGATKTS RVYGFIGLCW LLAALLGMLP
     LLGWNCLCAF DRCSSLLPLY SKRYILFCLV IFAGVLATIM GLYGAIFRLV QASGQKAPRP
     AARRKARRLL KTVLMILLAF LVCWGPLFGL LLADVFGSNL WAQEYLRGMD WILALAVLNS
     AVNPIIYSFR SREVCRAVLS FLCCGCLRLG MRGPGDCLAR AVEAHSGAST TDSSLRPRDS
     FRGSRSLSFR MREPLSSISS VRSI
//
ID   ACM5_HUMAN              Reviewed;         532 AA.
AC   P08912; Q96RG7;
DT   01-NOV-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 2.
DT   12-AUG-2020, entry version 194.
DE   RecName: Full=Muscarinic acetylcholine receptor M5;
GN   Name=CHRM5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3272174; DOI=10.1016/0896-6273(88)90190-0;
RA   Bonner T.I., Young A.C., Brann M.R., Buckley N.J.;
RT   "Cloning and expression of the human and rat m5 muscarinic acetylcholine
RT   receptor genes.";
RL   Neuron 1:403-410(1988).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Lens epithelium;
RA   Rae J.L., Shepard A.R.;
RL   Submitted (SEP-1997) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Brain;
RA   Wang H., Yeomans J.;
RT   "Human muscarinic acetylcholine receptor 5 is localized on 15q13.1 and its
RT   expression in SH-SY5Y cells.";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-526.
RC   TISSUE=Keratinocyte;
RA   Arredondo J., Grando S.A.;
RT   "Cloning cholinergic receptors in human keratinocytes.";
RL   Submitted (MAY-2001) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: The muscarinic acetylcholine receptor mediates various
CC       cellular responses, including inhibition of adenylate cyclase,
CC       breakdown of phosphoinositides and modulation of potassium channels
CC       through the action of G proteins. Primary transducing effect is Pi
CC       turnover.
CC   -!- INTERACTION:
CC       P08912; P20309: CHRM3; NbExp=7; IntAct=EBI-6655256, EBI-2687785;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein. Cell
CC       junction, synapse, postsynaptic cell membrane; Multi-pass membrane
CC       protein.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       Muscarinic acetylcholine receptor subfamily. CHRM5 sub-subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M80333; AAA51569.1; -; Genomic_DNA.
DR   EMBL; AF026263; AAB95158.1; -; mRNA.
DR   EMBL; AB084282; BAB91222.1; -; mRNA.
DR   EMBL; AF498919; AAM18942.1; -; mRNA.
DR   EMBL; AF385591; AAK68116.1; -; mRNA.
DR   CCDS; CCDS10031.1; -.
DR   PIR; JT0530; JT0530.
DR   RefSeq; NP_001307846.1; NM_001320917.1.
DR   RefSeq; NP_036257.1; NM_012125.3.
DR   PDB; 6OL9; X-ray; 2.54 A; A=21-224, A=431-532.
DR   PDBsum; 6OL9; -.
DR   SMR; P08912; -.
DR   BioGRID; 107555; 1.
DR   IntAct; P08912; 30.
DR   MINT; P08912; -.
DR   STRING; 9606.ENSP00000372750; -.
DR   BindingDB; P08912; -.
DR   ChEMBL; CHEMBL2035; -.
DR   DrugBank; DB08897; Aclidinium.
DR   DrugBank; DB05752; ALKS 27.
DR   DrugBank; DB00321; Amitriptyline.
DR   DrugBank; DB00543; Amoxapine.
DR   DrugBank; DB01238; Aripiprazole.
DR   DrugBank; DB14185; Aripiprazole lauroxil.
DR   DrugBank; DB00572; Atropine.
DR   DrugBank; DB00767; Benzquinamide.
DR   DrugBank; DB00835; Brompheniramine.
DR   DrugBank; DB01239; Chlorprothixene.
DR   DrugBank; DB00568; Cinnarizine.
DR   DrugBank; DB00363; Clozapine.
DR   DrugBank; DB00785; Cryptenamine.
DR   DrugBank; DB00496; Darifenacin.
DR   DrugBank; DB01151; Desipramine.
DR   DrugBank; DB09167; Dosulepin.
DR   DrugBank; DB01142; Doxepin.
DR   DrugBank; DB09194; Etoperidone.
DR   DrugBank; DB06702; Fesoterodine.
DR   DrugBank; DB00483; Gallamine triethiodide.
DR   DrugBank; DB11181; Homatropine.
DR   DrugBank; DB00725; Homatropine methylbromide.
DR   DrugBank; DB00458; Imipramine.
DR   DrugBank; DB01221; Ketamine.
DR   DrugBank; DB00408; Loxapine.
DR   DrugBank; DB00934; Maprotiline.
DR   DrugBank; DB00454; Meperidine.
DR   DrugBank; DB01403; Methotrimeprazine.
DR   DrugBank; DB00340; Metixene.
DR   DrugBank; DB00622; Nicardipine.
DR   DrugBank; DB00540; Nortriptyline.
DR   DrugBank; DB00715; Paroxetine.
DR   DrugBank; DB00420; Promazine.
DR   DrugBank; DB01069; Promethazine.
DR   DrugBank; DB00777; Propiomazine.
DR   DrugBank; DB12278; Propiverine.
DR   DrugBank; DB01224; Quetiapine.
DR   DrugBank; DB11855; Revefenacin.
DR   DrugBank; DB13581; Rociverine.
DR   DrugBank; DB00747; Scopolamine.
DR   DrugBank; DB01591; Solifenacin.
DR   DrugBank; DB00342; Terfenadine.
DR   DrugBank; DB11235; Thonzylamine.
DR   DrugBank; DB01409; Tiotropium.
DR   DrugBank; DB01036; Tolterodine.
DR   DrugBank; DB00376; Trihexyphenidyl.
DR   DrugBank; DB00726; Trimipramine.
DR   DrugBank; DB09076; Umeclidinium.
DR   DrugBank; DB00246; Ziprasidone.
DR   DrugCentral; P08912; -.
DR   GuidetoPHARMACOLOGY; 17; -.
DR   GlyGen; P08912; 1 site.
DR   iPTMnet; P08912; -.
DR   PhosphoSitePlus; P08912; -.
DR   BioMuta; CHRM5; -.
DR   DMDM; 543761; -.
DR   PaxDb; P08912; -.
DR   PeptideAtlas; P08912; -.
DR   PRIDE; P08912; -.
DR   ProteomicsDB; 52175; -.
DR   Antibodypedia; 2963; 229 antibodies.
DR   DNASU; 1133; -.
DR   Ensembl; ENST00000383263; ENSP00000372750; ENSG00000184984.
DR   Ensembl; ENST00000557872; ENSP00000453745; ENSG00000184984.
DR   GeneID; 1133; -.
DR   KEGG; hsa:1133; -.
DR   UCSC; uc001zhk.2; human.
DR   CTD; 1133; -.
DR   DisGeNET; 1133; -.
DR   EuPathDB; HostDB:ENSG00000184984.9; -.
DR   GeneCards; CHRM5; -.
DR   HGNC; HGNC:1954; CHRM5.
DR   HPA; ENSG00000184984; Tissue enriched (brain).
DR   MIM; 118496; gene.
DR   neXtProt; NX_P08912; -.
DR   OpenTargets; ENSG00000184984; -.
DR   PharmGKB; PA26486; -.
DR   eggNOG; KOG4220; Eukaryota.
DR   GeneTree; ENSGT00940000158450; -.
DR   HOGENOM; CLU_009579_11_2_1; -.
DR   InParanoid; P08912; -.
DR   KO; K04133; -.
DR   OMA; PPDECQI; -.
DR   OrthoDB; 1245472at2759; -.
DR   PhylomeDB; P08912; -.
DR   TreeFam; TF320495; -.
DR   PathwayCommons; P08912; -.
DR   Reactome; R-HSA-390648; Muscarinic acetylcholine receptors.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   SIGNOR; P08912; -.
DR   BioGRID-ORCS; 1133; 4 hits in 871 CRISPR screens.
DR   GeneWiki; Muscarinic_acetylcholine_receptor_M5; -.
DR   GenomeRNAi; 1133; -.
DR   Pharos; P08912; Tclin.
DR   PRO; PR:P08912; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; P08912; protein.
DR   Bgee; ENSG00000184984; Expressed in C1 segment of cervical spinal cord and 95 other tissues.
DR   ExpressionAtlas; P08912; baseline and differential.
DR   Genevisible; P08912; HS.
DR   GO; GO:0030425; C:dendrite; IBA:GO_Central.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0045211; C:postsynaptic membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0045202; C:synapse; IBA:GO_Central.
DR   GO; GO:0016907; F:G protein-coupled acetylcholine receptor activity; IBA:GO_Central.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0004993; F:G protein-coupled serotonin receptor activity; IBA:GO_Central.
DR   GO; GO:0030594; F:neurotransmitter receptor activity; IBA:GO_Central.
DR   GO; GO:0004435; F:phosphatidylinositol phospholipase C activity; TAS:ProtInc.
DR   GO; GO:0007197; P:adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007268; P:chemical synaptic transmission; IBA:GO_Central.
DR   GO; GO:0015872; P:dopamine transport; IEA:Ensembl.
DR   GO; GO:0007213; P:G protein-coupled acetylcholine receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007187; P:G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; IBA:GO_Central.
DR   GO; GO:0001696; P:gastric acid secretion; IEA:InterPro.
DR   GO; GO:0060304; P:regulation of phosphatidylinositol dephosphorylation; IEA:Ensembl.
DR   GO; GO:0019226; P:transmission of nerve impulse; IEA:Ensembl.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR000502; Musac_Ach_M5_rcpt.
DR   InterPro; IPR000995; Musac_Ach_rcpt.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00243; MUSCARINICR.
DR   PRINTS; PR00542; MUSCRINICM5R.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell junction; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Phosphoprotein;
KW   Postsynaptic cell membrane; Receptor; Reference proteome; Synapse;
KW   Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..532
FT                   /note="Muscarinic acetylcholine receptor M5"
FT                   /id="PRO_0000069042"
FT   TOPO_DOM        1..29
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        30..53
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        54..66
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        67..87
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        88..104
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        105..126
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        127..146
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        147..169
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        170..191
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        192..214
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        215..443
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        444..464
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        465..478
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        479..498
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        499..532
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         501
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         505
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        8
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        103..183
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   CONFLICT        526
FT                   /note="Q -> P (in Ref. 5)"
FT                   /evidence="ECO:0000305"
FT   HELIX           27..57
FT                   /evidence="ECO:0000244|PDB:6OL9"
FT   HELIX           59..61
FT                   /evidence="ECO:0000244|PDB:6OL9"
FT   HELIX           64..81
FT                   /evidence="ECO:0000244|PDB:6OL9"
FT   HELIX           83..93
FT                   /evidence="ECO:0000244|PDB:6OL9"
FT   HELIX           100..133
FT                   /evidence="ECO:0000244|PDB:6OL9"
FT   TURN            135..138
FT                   /evidence="ECO:0000244|PDB:6OL9"
FT   HELIX           139..141
FT                   /evidence="ECO:0000244|PDB:6OL9"
FT   HELIX           144..173
FT                   /evidence="ECO:0000244|PDB:6OL9"
FT   HELIX           187..189
FT                   /evidence="ECO:0000244|PDB:6OL9"
FT   HELIX           191..201
FT                   /evidence="ECO:0000244|PDB:6OL9"
FT   HELIX           203..218
FT                   /evidence="ECO:0000244|PDB:6OL9"
FT   HELIX           431..466
FT                   /evidence="ECO:0000244|PDB:6OL9"
FT   STRAND          468..470
FT                   /evidence="ECO:0000244|PDB:6OL9"
FT   HELIX           474..498
FT                   /evidence="ECO:0000244|PDB:6OL9"
FT   HELIX           500..511
FT                   /evidence="ECO:0000244|PDB:6OL9"
SQ   SEQUENCE   532 AA;  60074 MW;  EE846186F645DD9B CRC64;
     MEGDSYHNAT TVNGTPVNHQ PLERHRLWEV ITIAAVTAVV SLITIVGNVL VMISFKVNSQ
     LKTVNNYYLL SLACADLIIG IFSMNLYTTY ILMGRWALGS LACDLWLALD YVASNASVMN
     LLVISFDRYF SITRPLTYRA KRTPKRAGIM IGLAWLISFI LWAPAILCWQ YLVGKRTVPL
     DECQIQFLSE PTITFGTAIA AFYIPVSVMT ILYCRIYRET EKRTKDLADL QGSDSVTKAE
     KRKPAHRALF RSCLRCPRPT LAQRERNQAS WSSSRRSTST TGKPSQATGP SANWAKAEQL
     TTCSSYPSSE DEDKPATDPV LQVVYKSQGK ESPGEEFSAE ETEETFVKAE TEKSDYDTPN
     YLLSPAAAHR PKSQKCVAYK FRLVVKADGN QETNNGCHKV KIMPCPFPVA KEPSTKGLNP
     NPSHQMTKRK RVVLVKERKA AQTLSAILLA FIITWTPYNI MVLVSTFCDK CVPVTLWHLG
     YWLCYVNSTV NPICYALCNR TFRKTFKMLL LCRWKKKKVE EKLYWQGNSK LP
//
ID   ACM4_HUMAN              Reviewed;         479 AA.
AC   P08173; B2RPP4; Q0VD60; Q4VBK7;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   19-SEP-2002, sequence version 2.
DT   12-AUG-2020, entry version 184.
DE   RecName: Full=Muscarinic acetylcholine receptor M4;
GN   Name=CHRM4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3037705; DOI=10.1126/science.3037705;
RA   Bonner T.I., Buckley N.J., Young A.C., Brann M.R.;
RT   "Identification of a family of muscarinic acetylcholine receptor genes.";
RL   Science 237:527-532(1987).
RN   [2]
RP   SEQUENCE REVISION TO 258 AND 261-266.
RX   PubMed=3272174; DOI=10.1016/0896-6273(88)90190-0;
RA   Bonner T.I., Young A.C., Brann M.R., Buckley N.J.;
RT   "Cloning and expression of the human and rat m5 muscarinic acetylcholine
RT   receptor genes.";
RL   Neuron 1:403-410(1988).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=3443095; DOI=10.1002/j.1460-2075.1987.tb02733.x;
RA   Peralta E.G., Ashkenazi A., Winslow J.W., Smith D.H., Ramachandran J.,
RA   Capon D.J.;
RT   "Distinct primary structures, ligand-binding properties and tissue-specific
RT   expression of four human muscarinic acetylcholine receptors.";
RL   EMBO J. 6:3923-3929(1987).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RA   Puhl H.L. III, Ikeda S.R., Aronstam R.S.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
CC   -!- FUNCTION: The muscarinic acetylcholine receptor mediates various
CC       cellular responses, including inhibition of adenylate cyclase,
CC       breakdown of phosphoinositides and modulation of potassium channels
CC       through the action of G proteins. Primary transducing effect is
CC       inhibition of adenylate cyclase.
CC   -!- INTERACTION:
CC       P08173; P28335: HTR2C; NbExp=2; IntAct=EBI-6655217, EBI-994141;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein. Cell
CC       junction, synapse, postsynaptic cell membrane; Multi-pass membrane
CC       protein.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       Muscarinic acetylcholine receptor subfamily. CHRM4 sub-subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M16405; AAA51571.2; -; Genomic_DNA.
DR   EMBL; X15265; CAA33336.1; -; Genomic_DNA.
DR   EMBL; AF498918; AAM18941.1; -; mRNA.
DR   EMBL; CH471064; EAW68004.1; -; Genomic_DNA.
DR   EMBL; BC095546; AAH95546.1; -; mRNA.
DR   EMBL; BC119775; AAI19776.1; -; mRNA.
DR   EMBL; BC119817; AAI19818.1; -; mRNA.
DR   EMBL; BC137535; AAI37536.1; -; mRNA.
DR   CCDS; CCDS44581.1; -.
DR   PIR; S10127; S10127.
DR   RefSeq; NP_000732.2; NM_000741.3.
DR   PDB; 5DSG; X-ray; 2.60 A; A/B=22-226, A/B=390-478.
DR   PDB; 6D9H; EM; 3.60 A; R=2-23.
DR   PDB; 6KP6; X-ray; 3.00 A; A=22-227, A=390-479.
DR   PDBsum; 5DSG; -.
DR   PDBsum; 6D9H; -.
DR   PDBsum; 6KP6; -.
DR   SMR; P08173; -.
DR   BioGRID; 107554; 74.
DR   DIP; DIP-61455N; -.
DR   IntAct; P08173; 79.
DR   MINT; P08173; -.
DR   STRING; 9606.ENSP00000409378; -.
DR   BindingDB; P08173; -.
DR   ChEMBL; CHEMBL1821; -.
DR   DrugBank; DB03128; Acetylcholine.
DR   DrugBank; DB08897; Aclidinium.
DR   DrugBank; DB05752; ALKS 27.
DR   DrugBank; DB00321; Amitriptyline.
DR   DrugBank; DB00543; Amoxapine.
DR   DrugBank; DB01238; Aripiprazole.
DR   DrugBank; DB14185; Aripiprazole lauroxil.
DR   DrugBank; DB00572; Atropine.
DR   DrugBank; DB00767; Benzquinamide.
DR   DrugBank; DB01019; Bethanechol.
DR   DrugBank; DB00835; Brompheniramine.
DR   DrugBank; DB00411; Carbamoylcholine.
DR   DrugBank; DB01239; Chlorprothixene.
DR   DrugBank; DB00568; Cinnarizine.
DR   DrugBank; DB00363; Clozapine.
DR   DrugBank; DB00785; Cryptenamine.
DR   DrugBank; DB00496; Darifenacin.
DR   DrugBank; DB01151; Desipramine.
DR   DrugBank; DB09167; Dosulepin.
DR   DrugBank; DB01142; Doxepin.
DR   DrugBank; DB09194; Etoperidone.
DR   DrugBank; DB06702; Fesoterodine.
DR   DrugBank; DB06787; Hexocyclium.
DR   DrugBank; DB11181; Homatropine.
DR   DrugBank; DB00725; Homatropine methylbromide.
DR   DrugBank; DB00424; Hyoscyamine.
DR   DrugBank; DB00458; Imipramine.
DR   DrugBank; DB01625; Isopropamide.
DR   DrugBank; DB01221; Ketamine.
DR   DrugBank; DB00408; Loxapine.
DR   DrugBank; DB00934; Maprotiline.
DR   DrugBank; DB00454; Meperidine.
DR   DrugBank; DB01403; Methotrimeprazine.
DR   DrugBank; DB00340; Metixene.
DR   DrugBank; DB00622; Nicardipine.
DR   DrugBank; DB00540; Nortriptyline.
DR   DrugBank; DB00334; Olanzapine.
DR   DrugBank; DB00715; Paroxetine.
DR   DrugBank; DB01085; Pilocarpine.
DR   DrugBank; DB00387; Procyclidine.
DR   DrugBank; DB00420; Promazine.
DR   DrugBank; DB01069; Promethazine.
DR   DrugBank; DB00777; Propiomazine.
DR   DrugBank; DB12278; Propiverine.
DR   DrugBank; DB01224; Quetiapine.
DR   DrugBank; DB11855; Revefenacin.
DR   DrugBank; DB13581; Rociverine.
DR   DrugBank; DB00747; Scopolamine.
DR   DrugBank; DB01591; Solifenacin.
DR   DrugBank; DB00342; Terfenadine.
DR   DrugBank; DB11235; Thonzylamine.
DR   DrugBank; DB01409; Tiotropium.
DR   DrugBank; DB01036; Tolterodine.
DR   DrugBank; DB00376; Trihexyphenidyl.
DR   DrugBank; DB09089; Trimebutine.
DR   DrugBank; DB00726; Trimipramine.
DR   DrugBank; DB00809; Tropicamide.
DR   DrugBank; DB09076; Umeclidinium.
DR   DrugBank; DB00246; Ziprasidone.
DR   DrugCentral; P08173; -.
DR   GuidetoPHARMACOLOGY; 16; -.
DR   GlyGen; P08173; 2 sites.
DR   iPTMnet; P08173; -.
DR   PhosphoSitePlus; P08173; -.
DR   BioMuta; CHRM4; -.
DR   DMDM; 23503039; -.
DR   MassIVE; P08173; -.
DR   PaxDb; P08173; -.
DR   PeptideAtlas; P08173; -.
DR   PRIDE; P08173; -.
DR   ProteomicsDB; 52077; -.
DR   Antibodypedia; 26327; 193 antibodies.
DR   DNASU; 1132; -.
DR   Ensembl; ENST00000433765; ENSP00000409378; ENSG00000180720.
DR   GeneID; 1132; -.
DR   KEGG; hsa:1132; -.
DR   UCSC; uc001nct.2; human.
DR   CTD; 1132; -.
DR   DisGeNET; 1132; -.
DR   EuPathDB; HostDB:ENSG00000180720.7; -.
DR   GeneCards; CHRM4; -.
DR   HGNC; HGNC:1953; CHRM4.
DR   HPA; ENSG00000180720; Tissue enhanced (brain, intestine, lymphoid tissue).
DR   MIM; 118495; gene.
DR   neXtProt; NX_P08173; -.
DR   OpenTargets; ENSG00000180720; -.
DR   PharmGKB; PA26485; -.
DR   eggNOG; KOG4220; Eukaryota.
DR   GeneTree; ENSGT00940000160394; -.
DR   HOGENOM; CLU_009579_11_2_1; -.
DR   InParanoid; P08173; -.
DR   KO; K04132; -.
DR   OMA; GTECVTA; -.
DR   OrthoDB; 1245472at2759; -.
DR   PhylomeDB; P08173; -.
DR   TreeFam; TF320495; -.
DR   PathwayCommons; P08173; -.
DR   Reactome; R-HSA-390648; Muscarinic acetylcholine receptors.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   SIGNOR; P08173; -.
DR   BioGRID-ORCS; 1132; 9 hits in 866 CRISPR screens.
DR   GeneWiki; Muscarinic_acetylcholine_receptor_M4; -.
DR   GenomeRNAi; 1132; -.
DR   Pharos; P08173; Tclin.
DR   PRO; PR:P08173; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; P08173; protein.
DR   Bgee; ENSG00000180720; Expressed in caudate nucleus and 82 other tissues.
DR   Genevisible; P08173; HS.
DR   GO; GO:0030425; C:dendrite; IBA:GO_Central.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0045211; C:postsynaptic membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0045202; C:synapse; IBA:GO_Central.
DR   GO; GO:0016907; F:G protein-coupled acetylcholine receptor activity; IBA:GO_Central.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0004993; F:G protein-coupled serotonin receptor activity; IBA:GO_Central.
DR   GO; GO:0030594; F:neurotransmitter receptor activity; IBA:GO_Central.
DR   GO; GO:0007197; P:adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0007268; P:chemical synaptic transmission; IBA:GO_Central.
DR   GO; GO:0007213; P:G protein-coupled acetylcholine receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007187; P:G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger; IBA:GO_Central.
DR   GO; GO:0040012; P:regulation of locomotion; IEA:InterPro.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR001432; Musac_Ach_M4_rcpt.
DR   InterPro; IPR000995; Musac_Ach_rcpt.
DR   PANTHER; PTHR24248:SF142; PTHR24248:SF142; 1.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00243; MUSCARINICR.
DR   PRINTS; PR00541; MUSCRINICM4R.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell junction; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Phosphoprotein;
KW   Postsynaptic cell membrane; Receptor; Reference proteome; Synapse;
KW   Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..479
FT                   /note="Muscarinic acetylcholine receptor M4"
FT                   /id="PRO_0000069037"
FT   TOPO_DOM        1..31
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        32..54
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        55..68
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        69..89
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        90..106
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        107..128
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        129..148
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        149..171
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        172..193
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        194..216
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        217..401
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        402..422
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        423..436
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000250"
FT   TRANSMEM        437..456
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000250"
FT   TOPO_DOM        457..479
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         459
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         463
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         477
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        8
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        13
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        105..185
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   HELIX           26..59
FT                   /evidence="ECO:0000244|PDB:5DSG"
FT   HELIX           61..63
FT                   /evidence="ECO:0000244|PDB:5DSG"
FT   HELIX           66..83
FT                   /evidence="ECO:0000244|PDB:5DSG"
FT   HELIX           85..95
FT                   /evidence="ECO:0000244|PDB:5DSG"
FT   HELIX           101..135
FT                   /evidence="ECO:0000244|PDB:5DSG"
FT   TURN            137..140
FT                   /evidence="ECO:0000244|PDB:5DSG"
FT   HELIX           141..143
FT                   /evidence="ECO:0000244|PDB:5DSG"
FT   HELIX           146..169
FT                   /evidence="ECO:0000244|PDB:5DSG"
FT   HELIX           171..175
FT                   /evidence="ECO:0000244|PDB:5DSG"
FT   HELIX           188..190
FT                   /evidence="ECO:0000244|PDB:5DSG"
FT   HELIX           193..203
FT                   /evidence="ECO:0000244|PDB:5DSG"
FT   HELIX           205..220
FT                   /evidence="ECO:0000244|PDB:5DSG"
FT   STRAND          223..225
FT                   /evidence="ECO:0000244|PDB:5DSG"
FT   HELIX           226..229
FT                   /evidence="ECO:0000244|PDB:5DSG"
FT   HELIX           232..237
FT                   /evidence="ECO:0000244|PDB:5DSG"
FT   HELIX           397..422
FT                   /evidence="ECO:0000244|PDB:5DSG"
FT   TURN            423..425
FT                   /evidence="ECO:0000244|PDB:5DSG"
FT   HELIX           432..456
FT                   /evidence="ECO:0000244|PDB:5DSG"
FT   HELIX           458..468
FT                   /evidence="ECO:0000244|PDB:5DSG"
SQ   SEQUENCE   479 AA;  53049 MW;  9C1B05B359A64289 CRC64;
     MANFTPVNGS SGNQSVRLVT SSSHNRYETV EMVFIATVTG SLSLVTVVGN ILVMLSIKVN
     RQLQTVNNYF LFSLACADLI IGAFSMNLYT VYIIKGYWPL GAVVCDLWLA LDYVVSNASV
     MNLLIISFDR YFCVTKPLTY PARRTTKMAG LMIAAAWVLS FVLWAPAILF WQFVVGKRTV
     PDNQCFIQFL SNPAVTFGTA IAAFYLPVVI MTVLYIHISL ASRSRVHKHR PEGPKEKKAK
     TLAFLKSPLM KQSVKKPPPG EAAREELRNG KLEEAPPPAL PPPPRPVADK DTSNESSSGS
     ATQNTKERPA TELSTTEATT PAMPAPPLQP RALNPASRWS KIQIVTKQTG NECVTAIEIV
     PATPAGMRPA ANVARKFASI ARNQVRKKRQ MAARERKVTR TIFAILLAFI LTWTPYNVMV
     LVNTFCQSCI PDTVWSIGYW LCYVNSTINP ACYALCNATF KKTFRHLLLC QYRNIGTAR
//
ID   CCKAR_HUMAN             Reviewed;         428 AA.
AC   P32238; B2R9Z5;
DT   01-OCT-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1993, sequence version 1.
DT   07-OCT-2020, entry version 197.
DE   RecName: Full=Cholecystokinin receptor type A;
DE            Short=CCK-A receptor;
DE            Short=CCK-AR;
DE   AltName: Full=Cholecystokinin-1 receptor;
DE            Short=CCK1-R;
GN   Name=CCKAR; Synonyms=CCKRA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Gall bladder;
RX   PubMed=8503909; DOI=10.1006/bbrc.1993.1610;
RA   Ulrich C.D., Ferber I., Holicky E., Hadac E., Buell G., Miller L.J.;
RT   "Molecular cloning and functional expression of the human gallbladder
RT   cholecystokinin A receptor.";
RL   Biochem. Biophys. Res. Commun. 193:204-211(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8343165; DOI=10.1006/bbrc.1993.1894;
RA   Wank S.A., de Weerth A., Pisegna J.R., Huppi K.;
RT   "Molecular cloning, functional expression and chromosomal localization of
RT   the human cholecystokinin type A receptor.";
RL   Biochem. Biophys. Res. Commun. 194:811-818(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=7557108; DOI=10.1016/0016-5085(95)90601-0;
RA   Miller L.J., Holicky E.L., Ulrich C.D., Wieben E.D.;
RT   "Abnormal processing of the human cholecystokinin receptor gene in
RT   association with gallstones and obesity.";
RL   Gastroenterology 109:1375-1380(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Peripheral blood leukocyte;
RX   PubMed=10682840; DOI=10.1016/s0014-5793(00)01080-2;
RA   Funakoshi A., Miyasaka K., Matsumoto H., Yamamori S., Takiguchi S.,
RA   Kataoka K., Takata Y., Matsusue K., Kono A., Shimokata H.;
RT   "Gene structure of human cholecystokinin (CCK) type-A receptor: body fat
RT   content is related to CCK type-A receptor gene promoter polymorphism.";
RL   FEBS Lett. 466:264-266(2000).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Stomach;
RA   Kopatz S.A., Aronstam R.S., Sharma S.V.;
RT   "cDNA clones of human proteins involved in signal transduction sequenced by
RT   the Guthrie cDNA resource center (www.cdna.org).";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   STRUCTURE BY NMR OF 1-47 IN COMPLEX WITH CCK.
RX   PubMed=10555959; DOI=10.1021/bi991272l;
RA   Pellegrini M., Mierke D.F.;
RT   "Molecular complex of cholecystokinin-8 and N-terminus of the
RT   cholecystokinin A receptor by NMR spectroscopy.";
RL   Biochemistry 38:14775-14783(1999).
RN   [10]
RP   STRUCTURE BY NMR OF 329-357 IN COMPLEX WITH CCK.
RX   PubMed=11300760; DOI=10.1021/bi002659n;
RA   Giragossian C., Mierke D.F.;
RT   "Intermolecular interactions between cholecystokinin-8 and the third
RT   extracellular loop of the cholecystokinin A receptor.";
RL   Biochemistry 40:3804-3809(2001).
CC   -!- FUNCTION: Receptor for cholecystokinin. Mediates pancreatic growth and
CC       enzyme secretion, smooth muscle contraction of the gall bladder and
CC       stomach. Has a 1000-fold higher affinity for CCK rather than for
CC       gastrin. It modulates feeding and dopamine-induced behavior in the
CC       central and peripheral nervous system. This receptor mediates its
CC       action by association with G proteins that activate a
CC       phosphatidylinositol-calcium second messenger system.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Cholecystokinin receptor entry;
CC       URL="https://en.wikipedia.org/wiki/Cholecystokinin_receptor";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L13605; AAA35659.1; -; mRNA.
DR   EMBL; L19315; AAA02819.1; -; mRNA.
DR   EMBL; U23430; AAA91123.1; -; Genomic_DNA.
DR   EMBL; U23427; AAA91123.1; JOINED; Genomic_DNA.
DR   EMBL; U23428; AAA91123.1; JOINED; Genomic_DNA.
DR   EMBL; U23429; AAA91123.1; JOINED; Genomic_DNA.
DR   EMBL; D85606; BAA90879.1; -; Genomic_DNA.
DR   EMBL; AY322549; AAP84362.1; -; mRNA.
DR   EMBL; AK313978; BAG36692.1; -; mRNA.
DR   EMBL; CH471069; EAW92850.1; -; Genomic_DNA.
DR   EMBL; BC074987; AAH74987.1; -; mRNA.
DR   CCDS; CCDS3438.1; -.
DR   PIR; JN0692; JN0692.
DR   RefSeq; NP_000721.1; NM_000730.2.
DR   PDB; 1D6G; NMR; -; A=1-47.
DR   PDB; 1HZN; NMR; -; A=329-357.
DR   PDB; 1PB2; Model; -; A=1-381.
DR   PDBsum; 1D6G; -.
DR   PDBsum; 1HZN; -.
DR   PDBsum; 1PB2; -.
DR   SMR; P32238; -.
DR   BioGRID; 107328; 1.
DR   IntAct; P32238; 1.
DR   MINT; P32238; -.
DR   STRING; 9606.ENSP00000295589; -.
DR   BindingDB; P32238; -.
DR   ChEMBL; CHEMBL1901; -.
DR   DrugBank; DB00403; Ceruletide.
DR   DrugBank; DB08862; Cholecystokinin.
DR   DrugBank; DB04856; Dexloxiglumide.
DR   DrugBank; DB04867; Lintitript.
DR   DrugCentral; P32238; -.
DR   GuidetoPHARMACOLOGY; 76; -.
DR   GlyGen; P32238; 3 sites.
DR   iPTMnet; P32238; -.
DR   PhosphoSitePlus; P32238; -.
DR   BioMuta; CCKAR; -.
DR   DMDM; 416772; -.
DR   MaxQB; P32238; -.
DR   PaxDb; P32238; -.
DR   PeptideAtlas; P32238; -.
DR   PRIDE; P32238; -.
DR   ProteomicsDB; 54844; -.
DR   Antibodypedia; 3359; 435 antibodies.
DR   Ensembl; ENST00000295589; ENSP00000295589; ENSG00000163394.
DR   GeneID; 886; -.
DR   KEGG; hsa:886; -.
DR   UCSC; uc003gse.2; human.
DR   CTD; 886; -.
DR   DisGeNET; 886; -.
DR   EuPathDB; HostDB:ENSG00000163394.5; -.
DR   GeneCards; CCKAR; -.
DR   HGNC; HGNC:1570; CCKAR.
DR   HPA; ENSG00000163394; Group enriched (gallbladder, stomach).
DR   MIM; 118444; gene.
DR   neXtProt; NX_P32238; -.
DR   OpenTargets; ENSG00000163394; -.
DR   PharmGKB; PA26142; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00990000203585; -.
DR   HOGENOM; CLU_009579_6_3_1; -.
DR   InParanoid; P32238; -.
DR   KO; K04194; -.
DR   OMA; CYLQPSK; -.
DR   OrthoDB; 1042780at2759; -.
DR   PhylomeDB; P32238; -.
DR   TreeFam; TF315303; -.
DR   PathwayCommons; P32238; -.
DR   Reactome; R-HSA-375276; Peptide ligand-binding receptors.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   SignaLink; P32238; -.
DR   SIGNOR; P32238; -.
DR   BioGRID-ORCS; 886; 2 hits in 867 CRISPR screens.
DR   EvolutionaryTrace; P32238; -.
DR   GeneWiki; Cholecystokinin_A_receptor; -.
DR   GenomeRNAi; 886; -.
DR   Pharos; P32238; Tclin.
DR   PRO; PR:P32238; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; P32238; protein.
DR   Bgee; ENSG00000163394; Expressed in stomach and 49 other tissues.
DR   Genevisible; P32238; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0016020; C:membrane; IDA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0004951; F:cholecystokinin receptor activity; IDA:GO_Central.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IBA:GO_Central.
DR   GO; GO:0017046; F:peptide hormone binding; IPI:GO_Central.
DR   GO; GO:0007409; P:axonogenesis; IEA:Ensembl.
DR   GO; GO:0038188; P:cholecystokinin signaling pathway; IDA:GO_Central.
DR   GO; GO:0030900; P:forebrain development; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0001764; P:neuron migration; IEA:Ensembl.
DR   GO; GO:0007200; P:phospholipase C-activating G protein-coupled receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0046883; P:regulation of hormone secretion; IBA:GO_Central.
DR   Gene3D; 4.10.670.10; -; 1.
DR   InterPro; IPR009126; Cholcskin_rcpt.
DR   InterPro; IPR000596; Cholcy_rcpt_A.
DR   InterPro; IPR015276; CholecystokininA_recpt_N.
DR   InterPro; IPR036472; CholecystokininA_recpt_N_sf.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   Pfam; PF00001; 7tm_1; 1.
DR   Pfam; PF09193; CholecysA-Rec_N; 1.
DR   PRINTS; PR01822; CCYSTOKININR.
DR   PRINTS; PR00524; CCYSTOKNINAR.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   SMART; SM01381; 7TM_GPCR_Srsx; 1.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Lipoprotein; Membrane; Palmitate; Receptor;
KW   Reference proteome; Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..428
FT                   /note="Cholecystokinin receptor type A"
FT                   /id="PRO_0000069223"
FT   TOPO_DOM        1..41
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        42..67
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        68..77
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        78..104
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        105..115
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        116..137
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        138..157
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        158..178
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        179..210
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        211..234
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        235..313
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        314..334
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        335..349
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        350..373
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        374..428
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   LIPID           387
FT                   /note="S-palmitoyl cysteine"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        10
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        24
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        190
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        18..29
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   DISULFID        114..196
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   TURN            5..11
FT                   /evidence="ECO:0000244|PDB:1D6G"
FT   STRAND          13..15
FT                   /evidence="ECO:0000244|PDB:1D6G"
FT   STRAND          21..25
FT                   /evidence="ECO:0000244|PDB:1D6G"
FT   HELIX           39..44
FT                   /evidence="ECO:0000244|PDB:1D6G"
FT   TURN            330..334
FT                   /evidence="ECO:0000244|PDB:1HZN"
FT   HELIX           335..339
FT                   /evidence="ECO:0000244|PDB:1HZN"
FT   STRAND          346..350
FT                   /evidence="ECO:0000244|PDB:1HZN"
FT   HELIX           352..355
FT                   /evidence="ECO:0000244|PDB:1HZN"
SQ   SEQUENCE   428 AA;  47841 MW;  A6E8FABDA805E610 CRC64;
     MDVVDSLLVN GSNITPPCEL GLENETLFCL DQPRPSKEWQ PAVQILLYSL IFLLSVLGNT
     LVITVLIRNK RMRTVTNIFL LSLAVSDLML CLFCMPFNLI PNLLKDFIFG SAVCKTTTYF
     MGTSVSVSTF NLVAISLERY GAICKPLQSR VWQTKSHALK VIAATWCLSF TIMTPYPIYS
     NLVPFTKNNN QTANMCRFLL PNDVMQQSWH TFLLLILFLI PGIVMMVAYG LISLELYQGI
     KFEASQKKSA KERKPSTTSS GKYEDSDGCY LQKTRPPRKL ELRQLSTGSS SRANRIRSNS
     SAANLMAKKR VIRMLIVIVV LFFLCWMPIF SANAWRAYDT ASAERRLSGT PISFILLLSY
     TSSCVNPIIY CFMNKRFRLG FMATFPCCPN PGPPGARGEV GEEEEGGTTG ASLSRFSYSH
     MSASVPPQ
//
ID   UR2R_HUMAN              Reviewed;         389 AA.
AC   Q9UKP6; B2RMV8;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   07-OCT-2020, entry version 155.
DE   RecName: Full=Urotensin-2 receptor;
DE            Short=UR-2-R;
DE   AltName: Full=G-protein coupled receptor 14;
DE   AltName: Full=Urotensin II receptor;
DE            Short=UR-II-R;
GN   Name=UTS2R; Synonyms=GPR14;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=10499587; DOI=10.1038/45809;
RA   Ames R.S., Sarau H.M., Chambers J.K., Willette R.N., Aiyar N.V.,
RA   Romanic A.M., Louden C.S., Foley J.J., Sauermelch C.F., Coatney R.W.,
RA   Ao Z., Disa J., Holmes S.D., Stadel J.M., Martin J.D., Liu W.-S.,
RA   Glover G.I., Wilson S., McNulty D.E., Ellis C.E., Elshourbagy N.A.,
RA   Shabon U., Trill J.J., Hay D.W.P., Ohlstein E.H., Bergsma D.J.,
RA   Douglas S.A.;
RT   "Human urotensin-II is a potent vasoconstrictor and agonist for the orphan
RT   receptor GPR14.";
RL   Nature 401:282-286(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   FUNCTION AS A UROTENSIN-2B RECEPTOR.
RX   PubMed=14550283; DOI=10.1016/j.bbrc.2003.09.102;
RA   Sugo T., Murakami Y., Shimomura Y., Harada M., Abe M., Ishibashi Y.,
RA   Kitada C., Miyajima N., Suzuki N., Mori M., Fujino M.;
RT   "Identification of urotensin II-related peptide as the urotensin II-
RT   immunoreactive molecule in the rat brain.";
RL   Biochem. Biophys. Res. Commun. 310:860-868(2003).
RN   [5]
RP   VARIANT [LARGE SCALE ANALYSIS] ARG-146.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: High affinity receptor for urotensin-2 and urotensin-2B. The
CC       activity of this receptor is mediated by a G-protein that activate a
CC       phosphatidylinositol-calcium second messenger system.
CC       {ECO:0000269|PubMed:14550283}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Most abundant expression in the heart and pancreas.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF140631; AAD55578.1; -; Genomic_DNA.
DR   EMBL; CH471099; EAW89768.1; -; Genomic_DNA.
DR   EMBL; BC136490; AAI36491.1; -; mRNA.
DR   CCDS; CCDS11810.1; -.
DR   RefSeq; NP_061822.1; NM_018949.2.
DR   PDB; 6HVK; NMR; -; A=153-166.
DR   PDB; 6Q8L; NMR; -; A=154-165.
DR   PDBsum; 6HVK; -.
DR   PDBsum; 6Q8L; -.
DR   SMR; Q9UKP6; -.
DR   BioGRID; 109097; 1.
DR   STRING; 9606.ENSP00000323516; -.
DR   BindingDB; Q9UKP6; -.
DR   ChEMBL; CHEMBL3764; -.
DR   GuidetoPHARMACOLOGY; 365; -.
DR   GlyGen; Q9UKP6; 2 sites.
DR   PhosphoSitePlus; Q9UKP6; -.
DR   BioMuta; UTS2R; -.
DR   DMDM; 8928474; -.
DR   MassIVE; Q9UKP6; -.
DR   PaxDb; Q9UKP6; -.
DR   PeptideAtlas; Q9UKP6; -.
DR   PRIDE; Q9UKP6; -.
DR   ProteomicsDB; 84833; -.
DR   Antibodypedia; 19903; 233 antibodies.
DR   Ensembl; ENST00000313135; ENSP00000323516; ENSG00000181408.
DR   GeneID; 2837; -.
DR   KEGG; hsa:2837; -.
DR   UCSC; uc010wvl.3; human.
DR   CTD; 2837; -.
DR   DisGeNET; 2837; -.
DR   EuPathDB; HostDB:ENSG00000181408.3; -.
DR   GeneCards; UTS2R; -.
DR   HGNC; HGNC:4468; UTS2R.
DR   HPA; ENSG00000181408; Tissue enhanced (testis, thyroid gland).
DR   MIM; 600896; gene.
DR   neXtProt; NX_Q9UKP6; -.
DR   OpenTargets; ENSG00000181408; -.
DR   PharmGKB; PA28857; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00940000157017; -.
DR   HOGENOM; CLU_009579_1_0_1; -.
DR   InParanoid; Q9UKP6; -.
DR   KO; K04241; -.
DR   OMA; PMMLAIR; -.
DR   OrthoDB; 1076228at2759; -.
DR   PhylomeDB; Q9UKP6; -.
DR   TreeFam; TF334200; -.
DR   PathwayCommons; Q9UKP6; -.
DR   Reactome; R-HSA-375276; Peptide ligand-binding receptors.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   SIGNOR; Q9UKP6; -.
DR   BioGRID-ORCS; 2837; 2 hits in 868 CRISPR screens.
DR   GeneWiki; Urotensin-II_receptor; -.
DR   GenomeRNAi; 2837; -.
DR   Pharos; Q9UKP6; Tchem.
DR   PRO; PR:Q9UKP6; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; Q9UKP6; protein.
DR   Bgee; ENSG00000181408; Expressed in heart left ventricle and 58 other tissues.
DR   Genevisible; Q9UKP6; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0008528; F:G protein-coupled peptide receptor activity; IBA:GO_Central.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; TAS:ProtInc.
DR   GO; GO:0001604; F:urotensin II receptor activity; IBA:GO_Central.
DR   GO; GO:0008015; P:blood circulation; TAS:ProtInc.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0007218; P:neuropeptide signaling pathway; IBA:GO_Central.
DR   GO; GO:0008217; P:regulation of blood pressure; IEA:InterPro.
DR   GO; GO:0097746; P:regulation of blood vessel diameter; IEA:InterPro.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR000670; Urot_II_rcpt.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR00647; UROTENSIN2R.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Membrane; Polymorphism; Receptor; Reference proteome;
KW   Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..389
FT                   /note="Urotensin-2 receptor"
FT                   /id="PRO_0000070193"
FT   TOPO_DOM        1..54
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        55..77
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        78..87
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        88..113
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        114..124
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        125..146
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        147..167
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        168..186
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        187..209
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        210..232
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        233..258
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        259..284
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        285..297
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        298..318
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        319..389
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        29
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        33
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        123..199
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VARIANT         70
FT                   /note="A -> P (in dbSNP:rs34442190)"
FT                   /id="VAR_049451"
FT   VARIANT         146
FT                   /note="S -> R (in a breast cancer sample; somatic mutation;
FT                   dbSNP:rs770047242)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_035768"
FT   TURN            155..159
FT                   /evidence="ECO:0000244|PDB:6HVK"
SQ   SEQUENCE   389 AA;  42130 MW;  6D6A88DBF78400CE CRC64;
     MALTPESPSS FPGLAATGSS VPEPPGGPNA TLNSSWASPT EPSSLEDLVA TGTIGTLLSA
     MGVVGVVGNA YTLVVTCRSL RAVASMYVYV VNLALADLLY LLSIPFIVAT YVTKEWHFGD
     VGCRVLFGLD FLTMHASIFT LTVMSSERYA AVLRPLDTVQ RPKGYRKLLA LGTWLLALLL
     TLPVMLAMRL VRRGPKSLCL PAWGPRAHRA YLTLLFATSI AGPGLLIGLL YARLARAYRR
     SQRASFKRAR RPGARALRLV LGIVLLFWAC FLPFWLWQLL AQYHQAPLAP RTARIVNYLT
     TCLTYGNSCA NPFLYTLLTR NYRDHLRGRV RGPGSGGGRG PVPSLQPRAR FQRCSGRSLS
     SCSPQPTDSL VLAPAAPARP APEGPRAPA
//
ID   P2Y13_HUMAN             Reviewed;         354 AA.
AC   Q9BPV8; B2R827; Q05C50; Q6DKN4; Q8IUT5; Q8TDU7; Q9BY61;
DT   10-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   08-FEB-2011, sequence version 3.
DT   07-OCT-2020, entry version 167.
DE   RecName: Full=P2Y purinoceptor 13;
DE            Short=P2Y13;
DE   AltName: Full=G-protein coupled receptor 86;
DE   AltName: Full=G-protein coupled receptor 94;
GN   Name=P2RY13; Synonyms=GPR86, GPR94; ORFNames=FKSG77;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING (ISOFORM 2), AND
RP   VARIANT MET-179.
RX   PubMed=11574155; DOI=10.1016/s0378-1119(01)00651-5;
RA   Lee D.K., Nguyen T., Lynch K.R., Cheng R., Vanti W.B., Arkhitko O.,
RA   Lewis T., Evans J.F., George S.R., O'Dowd B.F.;
RT   "Discovery and mapping of ten novel G protein-coupled receptor genes.";
RL   Gene 275:83-91(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, AND VARIANT MET-179.
RC   TISSUE=Spleen;
RX   PubMed=11546776; DOI=10.1074/jbc.m105912200;
RA   Communi D., Gonzalez N.S., Detheux M., Brezillon S., Lannoy V.,
RA   Parmentier M., Boeynaems J.-M.;
RT   "Identification of a novel human ADP receptor coupled to Gi.";
RL   J. Biol. Chem. 276:41479-41485(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANT MET-179.
RC   TISSUE=Amygdala, Caudate nucleus, Fetal brain, and Placenta;
RX   PubMed=11273702; DOI=10.1006/jmbi.2001.4520;
RA   Wittenberger T., Schaller H.C., Hellebrand S.;
RT   "An expressed sequence tag (EST) data mining strategy succeeding in the
RT   discovery of new G-protein coupled receptors.";
RL   J. Mol. Biol. 307:799-813(2001).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANT MET-179.
RC   TISSUE=Heart;
RA   Wang Y.-G., Gong L.;
RT   "Molecular cloning of FKSG77, a novel gene encoding a putative G-protein-
RT   coupled receptor.";
RL   Submitted (FEB-2001) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12044878; DOI=10.1016/s0014-5793(02)02775-8;
RA   Takeda S., Kadowaki S., Haga T., Takaesu H., Mitaku S.;
RT   "Identification of G protein-coupled receptor genes from the human genome
RT   sequence.";
RL   FEBS Lett. 520:97-101(2002).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT MET-179.
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R., Buhay C.J.,
RA   Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R., Gunaratne P.,
RA   Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V., Hume J., Jackson A.,
RA   Khan Z.M., Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Morgan M.B., Nazareth L.V., Scott G.,
RA   Sodergren E., Song X.-Z., Steffen D., Wei S., Wheeler D.A., Wright M.W.,
RA   Worley K.C., Yuan Y., Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M.,
RA   Brown M.J., Chen G., Chen Z., Clendenning J., Clerc-Blankenburg K.P.,
RA   Chen R., Chen Z., Davis C., Delgado O., Dinh H.H., Dong W., Draper H.,
RA   Ernst S., Fu G., Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J.,
RA   Hao B., Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W.,
RA   Jackson L.R., Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B.,
RA   Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O.,
RA   Palmeiri A., Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J., Zhang X.,
RA   Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H., Reinhardt R.,
RA   Naylor S.L., Yang H., Olson M., Weinstock G., Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT MET-179.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT MET-179.
RC   TISSUE=Brain, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 172-354, AND VARIANT MET-179.
RA   Zhang W., Wan T., Cao X.;
RT   "Molecular cloning of a probable G protein-coupled receptor with three
RT   transmembrane domains.";
RL   Submitted (AUG-1999) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Receptor for ADP. Coupled to G(i)-proteins. May play a role
CC       in hematopoiesis and the immune system. {ECO:0000269|PubMed:11546776}.
CC   -!- INTERACTION:
CC       Q9BPV8; P48165: GJA8; NbExp=3; IntAct=EBI-17459480, EBI-17458373;
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9BPV8-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9BPV8-2; Sequence=VSP_036226;
CC   -!- TISSUE SPECIFICITY: Strong expression in spleen and adult brain. Lower
CC       expression in placenta, lung, liver, spinal cord, thymus, small
CC       intestine, uterus, stomach, testis, fetal brain, and adrenal gland. Not
CC       detected in pancreas, heart, kidney, skeletal muscle, ovary or fetal
CC       aorta. Clearly detected in lymph node and bone marrow, weakly detected
CC       in peripheral blood mononuclear cells (PBMC) and in peripheral blood
CC       leukocytes (PBL), but not detected in polymorphonuclear cells (PMN). In
CC       the brain, detected in all brain regions examined.
CC   -!- MISCELLANEOUS: Stimulation by ADP in stably transfected CHO cells
CC       resulted in inhibition of adenylyl cyclase and the phosphorylation of
CC       the MAP kinases MAPK3 and MAPK1 in a pertussis toxin-sensitive way.
CC       Inhibition of adenylyl cyclase and phosphorylation of the MAP kinases
CC       are transduction mechanisms that involve G(i) proteins.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH29363.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC       Sequence=AAH41116.2; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAG36024.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF411113; AAL26484.1; -; Genomic_DNA.
DR   EMBL; AF406692; AAL01038.1; -; mRNA.
DR   EMBL; AF295368; AAK01864.1; -; mRNA.
DR   EMBL; AF345565; AAK29068.1; -; mRNA.
DR   EMBL; AB083597; BAB89310.1; -; Genomic_DNA.
DR   EMBL; AK313208; BAG36024.1; ALT_INIT; mRNA.
DR   EMBL; AC024886; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471052; EAW78805.1; -; Genomic_DNA.
DR   EMBL; BC029363; AAH29363.1; ALT_SEQ; mRNA.
DR   EMBL; BC041116; AAH41116.2; ALT_INIT; mRNA.
DR   EMBL; BC066887; AAH66887.1; -; mRNA.
DR   EMBL; AF178982; AAK18752.1; -; mRNA.
DR   CCDS; CCDS3158.2; -. [Q9BPV8-1]
DR   RefSeq; NP_795713.2; NM_176894.2. [Q9BPV8-1]
DR   PDB; 2B6U; Model; -; A=22-354.
DR   PDBsum; 2B6U; -.
DR   SMR; Q9BPV8; -.
DR   BioGRID; 119802; 1.
DR   IntAct; Q9BPV8; 1.
DR   STRING; 9606.ENSP00000320376; -.
DR   BindingDB; Q9BPV8; -.
DR   ChEMBL; CHEMBL3321651; -.
DR   DrugBank; DB01069; Promethazine.
DR   DrugCentral; Q9BPV8; -.
DR   GuidetoPHARMACOLOGY; 329; -.
DR   GlyGen; Q9BPV8; 3 sites.
DR   iPTMnet; Q9BPV8; -.
DR   PhosphoSitePlus; Q9BPV8; -.
DR   BioMuta; P2RY13; -.
DR   DMDM; 322510112; -.
DR   MassIVE; Q9BPV8; -.
DR   PaxDb; Q9BPV8; -.
DR   PeptideAtlas; Q9BPV8; -.
DR   PRIDE; Q9BPV8; -.
DR   ProteomicsDB; 78575; -. [Q9BPV8-1]
DR   ProteomicsDB; 78576; -. [Q9BPV8-2]
DR   Antibodypedia; 33610; 355 antibodies.
DR   DNASU; 53829; -.
DR   Ensembl; ENST00000325602; ENSP00000320376; ENSG00000181631. [Q9BPV8-1]
DR   GeneID; 53829; -.
DR   KEGG; hsa:53829; -.
DR   UCSC; uc003eyv.3; human. [Q9BPV8-1]
DR   CTD; 53829; -.
DR   DisGeNET; 53829; -.
DR   EuPathDB; HostDB:ENSG00000181631.6; -.
DR   GeneCards; P2RY13; -.
DR   HGNC; HGNC:4537; P2RY13.
DR   HPA; ENSG00000181631; Group enriched (blood, lymphoid tissue).
DR   MIM; 606380; gene.
DR   neXtProt; NX_Q9BPV8; -.
DR   OpenTargets; ENSG00000181631; -.
DR   eggNOG; ENOG502QUS2; Eukaryota.
DR   GeneTree; ENSGT00950000182658; -.
DR   HOGENOM; CLU_009579_8_2_1; -.
DR   InParanoid; Q9BPV8; -.
DR   KO; K08388; -.
DR   OMA; KIIRPFG; -.
DR   OrthoDB; 971778at2759; -.
DR   PhylomeDB; Q9BPV8; -.
DR   TreeFam; TF330969; -.
DR   PathwayCommons; Q9BPV8; -.
DR   Reactome; R-HSA-417957; P2Y receptors.
DR   Reactome; R-HSA-418594; G alpha (i) signalling events.
DR   SIGNOR; Q9BPV8; -.
DR   BioGRID-ORCS; 53829; 7 hits in 871 CRISPR screens.
DR   GeneWiki; P2RY13; -.
DR   GenomeRNAi; 53829; -.
DR   Pharos; Q9BPV8; Tchem.
DR   PRO; PR:Q9BPV8; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q9BPV8; protein.
DR   Bgee; ENSG00000181631; Expressed in blood and 159 other tissues.
DR   Genevisible; Q9BPV8; HS.
DR   GO; GO:0005783; C:endoplasmic reticulum; IEA:Ensembl.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0045028; F:G protein-coupled purinergic nucleotide receptor activity; IBA:GO_Central.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IEA:Ensembl.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007194; P:negative regulation of adenylate cyclase activity; IEA:InterPro.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   InterPro; IPR008109; P2Y13_rcpt.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PRINTS; PR01735; P2Y13PRNCPTR.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Disulfide bond;
KW   G-protein coupled receptor; Glycoprotein; Membrane; Polymorphism; Receptor;
KW   Reference proteome; Transducer; Transmembrane; Transmembrane helix.
FT   CHAIN           1..354
FT                   /note="P2Y purinoceptor 13"
FT                   /id="PRO_0000070040"
FT   TOPO_DOM        1..49
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        50..70
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        71..77
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        78..98
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        99..117
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        118..138
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        139..161
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        162..182
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        183..211
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        212..232
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        233..252
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        253..273
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        274..300
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        301..321
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        322..333
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        23
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        31
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        285
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        116..194
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   VAR_SEQ         1..21
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:11273702,
FT                   ECO:0000303|PubMed:11546776, ECO:0000303|Ref.4"
FT                   /id="VSP_036226"
FT   VARIANT         179
FT                   /note="T -> M (in dbSNP:rs1466684)"
FT                   /evidence="ECO:0000269|PubMed:11273702,
FT                   ECO:0000269|PubMed:11546776, ECO:0000269|PubMed:11574155,
FT                   ECO:0000269|PubMed:14702039, ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|Ref.10, ECO:0000269|Ref.4, ECO:0000269|Ref.8"
FT                   /id="VAR_028299"
SQ   SEQUENCE   354 AA;  40789 MW;  A2CE5F8ED84C4CAF CRC64;
     MTAAIRRQRE LSILPKVTLE AMNTTVMQGF NRSERCPRDT RIVQLVFPAL YTVVFLTGIL
     LNTLALWVFV HIPSSSTFII YLKNTLVADL IMTLMLPFKI LSDSHLAPWQ LRAFVCRFSS
     VIFYETMYVG IVLLGLIAFD RFLKIIRPLR NIFLKKPVFA KTVSIFIWFF LFFISLPNTI
     LSNKEATPSS VKKCASLKGP LGLKWHQMVN NICQFIFWTV FILMLVFYVV IAKKVYDSYR
     KSKSKDRKNN KKLEGKVFVV VAVFFVCFAP FHFARVPYTH SQTNNKTDCR LQNQLFIAKE
     TTLFLAATNI CMDPLIYIFL CKKFTEKLPC MQGRKTTASS QENHSSQTDN ITLG
//
ID   GPR52_HUMAN             Reviewed;         361 AA.
AC   Q9Y2T5; O75654; Q4VBL6; Q6ISM0;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   27-SEP-2005, sequence version 2.
DT   12-AUG-2020, entry version 143.
DE   RecName: Full=G-protein coupled receptor 52 {ECO:0000312|HGNC:HGNC:4508};
GN   Name=GPR52 {ECO:0000303|PubMed:9931487, ECO:0000312|HGNC:HGNC:4508};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9931487; DOI=10.1016/s0169-328x(98)00277-0;
RA   Sawzdargo M., Nguyen T., Lee D.K., Lynch K.R., Cheng R., Heng H.H.Q.,
RA   George S.R., O'Dowd B.F.;
RT   "Identification and cloning of three novel human G protein-coupled receptor
RT   genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human
RT   brain.";
RL   Brain Res. Mol. Brain Res. 64:193-198(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=24587241; DOI=10.1371/journal.pone.0090134;
RA   Komatsu H., Maruyama M., Yao S., Shinohara T., Sakuma K., Imaichi S.,
RA   Chikatsu T., Kuniyeda K., Siu F.K., Peng L.S., Zhuo K., Mun L.S., Han T.M.,
RA   Matsumoto Y., Hashimoto T., Miyajima N., Itoh Y., Ogi K., Habata Y.,
RA   Mori M.;
RT   "Anatomical transcriptome of G protein-coupled receptors leads to the
RT   identification of a novel therapeutic candidate GPR52 for psychiatric
RT   disorders.";
RL   PLoS ONE 9:E90134-E90134(2014).
RN   [5]
RP   FUNCTION.
RX   PubMed=25738228; DOI=10.7554/elife.05449;
RA   Yao Y., Cui X., Al-Ramahi I., Sun X., Li B., Hou J., Difiglia M.,
RA   Palacino J., Wu Z.Y., Ma L., Botas J., Lu B.;
RT   "A striatal-enriched intronic GPCR modulates huntingtin levels and
RT   toxicity.";
RL   Elife 4:0-0(2015).
CC   -!- FUNCTION: Gs-coupled receptor activated by antipsychotics reserpine
CC       leading to an increase in intracellular cAMP and its internalization
CC       (PubMed:24587241). May play a role in locomotor activity through
CC       modulation of dopamine, NMDA and ADORA2A-induced locomotor activity.
CC       These behavioral changes are accompanied by modulation of the dopamine
CC       receptor signaling pathway in striatum (PubMed:24587241). Modulates HTT
CC       level via cAMP-dependent but PKA independent mechanisms throught
CC       activation of RAB39B that translocates HTT to the endoplasmic
CC       reticulum, thus avoiding proteasome degradation (PubMed:25738228).
CC       {ECO:0000269|PubMed:24587241, ECO:0000269|PubMed:25738228}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane; Multi-pass membrane protein.
CC   -!- TISSUE SPECIFICITY: Expressed in brain, especially in striatum.
CC       {ECO:0000269|PubMed:24587241}.
CC   -!- SIMILARITY: Belongs to the G-protein coupled receptor 1 family.
CC       {ECO:0000255|PROSITE-ProRule:PRU00521}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF096784; AAD22409.1; -; Genomic_DNA.
DR   EMBL; AL022171; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC067456; AAH67456.1; -; mRNA.
DR   EMBL; BC067457; AAH67457.1; -; mRNA.
DR   EMBL; BC067458; AAH67458.1; -; mRNA.
DR   EMBL; BC067459; AAH67459.1; -; mRNA.
DR   EMBL; BC067460; AAH67460.1; -; mRNA.
DR   EMBL; BC069460; AAH69460.1; -; mRNA.
DR   EMBL; BC095532; AAH95532.1; -; mRNA.
DR   CCDS; CCDS30941.1; -.
DR   RefSeq; NP_005675.3; NM_005684.4.
DR   PDB; 6LI0; X-ray; 2.20 A; A=17-236, A=261-340.
DR   PDB; 6LI1; X-ray; 2.90 A; A=17-236, A=265-341.
DR   PDB; 6LI2; X-ray; 2.80 A; A=17-235, A=265-340.
DR   PDB; 6LI3; EM; 3.32 A; R=1-340.
DR   PDBsum; 6LI0; -.
DR   PDBsum; 6LI1; -.
DR   PDBsum; 6LI2; -.
DR   PDBsum; 6LI3; -.
DR   SMR; Q9Y2T5; -.
DR   BioGRID; 114707; 31.
DR   IntAct; Q9Y2T5; 14.
DR   STRING; 9606.ENSP00000356658; -.
DR   BindingDB; Q9Y2T5; -.
DR   ChEMBL; CHEMBL3297639; -.
DR   GuidetoPHARMACOLOGY; 108; -.
DR   GlyGen; Q9Y2T5; 3 sites.
DR   iPTMnet; Q9Y2T5; -.
DR   PhosphoSitePlus; Q9Y2T5; -.
DR   BioMuta; GPR52; -.
DR   DMDM; 76803659; -.
DR   MassIVE; Q9Y2T5; -.
DR   PaxDb; Q9Y2T5; -.
DR   PeptideAtlas; Q9Y2T5; -.
DR   PRIDE; Q9Y2T5; -.
DR   ProteomicsDB; 85897; -.
DR   Antibodypedia; 34403; 279 antibodies.
DR   DNASU; 9293; -.
DR   Ensembl; ENST00000367685; ENSP00000356658; ENSG00000203737.
DR   GeneID; 9293; -.
DR   KEGG; hsa:9293; -.
DR   UCSC; uc001gka.2; human.
DR   CTD; 9293; -.
DR   DisGeNET; 9293; -.
DR   EuPathDB; HostDB:ENSG00000203737.3; -.
DR   GeneCards; GPR52; -.
DR   HGNC; HGNC:4508; GPR52.
DR   HPA; ENSG00000203737; Tissue enriched (brain).
DR   MIM; 604106; gene.
DR   neXtProt; NX_Q9Y2T5; -.
DR   OpenTargets; ENSG00000203737; -.
DR   PharmGKB; PA28897; -.
DR   eggNOG; KOG3656; Eukaryota.
DR   GeneTree; ENSGT00940000163422; -.
DR   HOGENOM; CLU_009579_3_3_1; -.
DR   InParanoid; Q9Y2T5; -.
DR   KO; K08407; -.
DR   OMA; HIFRICQ; -.
DR   OrthoDB; 1099557at2759; -.
DR   PhylomeDB; Q9Y2T5; -.
DR   TreeFam; TF332372; -.
DR   PathwayCommons; Q9Y2T5; -.
DR   BioGRID-ORCS; 9293; 3 hits in 864 CRISPR screens.
DR   GenomeRNAi; 9293; -.
DR   Pharos; Q9Y2T5; Tchem.
DR   PRO; PR:Q9Y2T5; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q9Y2T5; protein.
DR   Bgee; ENSG00000203737; Expressed in caudate nucleus and 68 other tissues.
DR   ExpressionAtlas; Q9Y2T5; baseline and differential.
DR   Genevisible; Q9Y2T5; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0008020; F:G protein-coupled photoreceptor activity; IBA:GO_Central.
DR   GO; GO:0004930; F:G protein-coupled receptor activity; IDA:UniProtKB.
DR   GO; GO:0071482; P:cellular response to light stimulus; IBA:GO_Central.
DR   GO; GO:0007186; P:G protein-coupled receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0007626; P:locomotory behavior; ISS:UniProtKB.
DR   GO; GO:0007602; P:phototransduction; IBA:GO_Central.
DR   GO; GO:0042493; P:response to drug; IDA:UniProtKB.
DR   InterPro; IPR000276; GPCR_Rhodpsn.
DR   InterPro; IPR017452; GPCR_Rhodpsn_7TM.
DR   Pfam; PF00001; 7tm_1; 1.
DR   PRINTS; PR00237; GPCRRHODOPSN.
DR   PROSITE; PS00237; G_PROTEIN_RECEP_F1_1; 1.
DR   PROSITE; PS50262; G_PROTEIN_RECEP_F1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cell membrane; Disulfide bond; G-protein coupled receptor;
KW   Glycoprotein; Membrane; Receptor; Reference proteome; Transducer;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..361
FT                   /note="G-protein coupled receptor 52"
FT                   /id="PRO_0000069576"
FT   TOPO_DOM        1..44
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        45..65
FT                   /note="Helical; Name=1"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        66..87
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        88..108
FT                   /note="Helical; Name=2"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        109..116
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        117..137
FT                   /note="Helical; Name=3"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        138..159
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        160..180
FT                   /note="Helical; Name=4"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        181..203
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        204..224
FT                   /note="Helical; Name=5"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        225..265
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        266..286
FT                   /note="Helical; Name=6"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        287..296
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        297..317
FT                   /note="Helical; Name=7"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        318..361
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        2
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        13
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        20
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        114..193
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00521"
FT   CONFLICT        18
FT                   /note="I -> V (in Ref. 3; AAH95532)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        21
FT                   /note="V -> A (in Ref. 1; AAD22409)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        64
FT                   /note="V -> A (in Ref. 1; AAD22409)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        115
FT                   /note="Q -> R (in Ref. 1; AAD22409)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        264
FT                   /note="A -> T (in Ref. 3; AAH95532)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        307
FT                   /note="I -> V (in Ref. 1; AAD22409)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        322
FT                   /note="S -> G (in Ref. 1; AAD22409)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        332
FT                   /note="S -> F (in Ref. 1; AAD22409)"
FT                   /evidence="ECO:0000305"
FT   STRAND          30..34
FT                   /evidence="ECO:0000244|PDB:6LI0"
FT   TURN            36..40
FT                   /evidence="ECO:0000244|PDB:6LI2"
FT   HELIX           41..66
FT                   /evidence="ECO:0000244|PDB:6LI0"
FT   TURN            67..69
FT                   /evidence="ECO:0000244|PDB:6LI0"
FT   TURN            72..75
FT                   /evidence="ECO:0000244|PDB:6LI0"
FT   HELIX           76..103
FT                   /evidence="ECO:0000244|PDB:6LI0"
FT   HELIX           111..144
FT                   /evidence="ECO:0000244|PDB:6LI0"
FT   HELIX           146..152
FT                   /evidence="ECO:0000244|PDB:6LI0"
FT   HELIX           155..172
FT                   /evidence="ECO:0000244|PDB:6LI0"
FT   HELIX           174..177
FT                   /evidence="ECO:0000244|PDB:6LI0"
FT   HELIX           186..189
FT                   /evidence="ECO:0000244|PDB:6LI0"
FT   HELIX           191..196
FT                   /evidence="ECO:0000244|PDB:6LI0"
FT   HELIX           201..210
FT                   /evidence="ECO:0000244|PDB:6LI0"
FT   HELIX           212..226
FT                   /evidence="ECO:0000244|PDB:6LI0"
FT   HELIX           261..289
FT                   /evidence="ECO:0000244|PDB:6LI0"
FT   HELIX           296..307
FT                   /evidence="ECO:0000244|PDB:6LI0"
FT   HELIX           309..320
FT                   /evidence="ECO:0000244|PDB:6LI0"
FT   HELIX           322..337
FT                   /evidence="ECO:0000244|PDB:6LI0"
SQ   SEQUENCE   361 AA;  41354 MW;  4888D58CEBB2D725 CRC64;
     MNESRWTEWR ILNMSSGIVN VSERHSCPLG FGHYSVVDVC IFETVVIVLL TFLIIAGNLT
     VIFVFHCAPL LHHYTTSYFI QTMAYADLFV GVSCLVPTLS LLHYSTGVHE SLTCQVFGYI
     ISVLKSVSMA CLACISVDRY LAITKPLSYN QLVTPCRLRI CIILIWIYSC LIFLPSFFGW
     GKPGYHGDIF EWCATSWLTS AYFTGFIVCL LYAPAAFVVC FTYFHIFKIC RQHTKEINDR
     RARFPSHEVD SSRETGHSPD RRYAMVLFRI TSVFYMLWLP YIIYFLLESS RVLDNPTLSF
     LTTWLAISNS FCNCVIYSLS NSVFRLGLRR LSETMCTSCM CVKDQEAQEP KPRKRANSCS
     I
//
